Resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
interferon	B-Protein
gamma	I-Protein
production	O
and	O
expression	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
in	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
<EOS>	B-X
IL-10	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
block	B-X
the	B-X
antigen-specific	B-X
T-cell	B-X
cytokine	B-X
response	B-X
by	B-X
inhibiting	B-X
the	B-X
CD28	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
peripheral	B-X
blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
were	B-X
able	B-X
to	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
interferon	B-X
gamma	B-X
after	B-X
CD3	B-X
and	B-X
CD28	B-X
costimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
than	B-X
were	B-X
normal	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
although	B-X
their	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
type	B-X
1	B-X
IL-10	B-X
receptor	B-X
was	B-X
increased	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
was	B-X
sustained	B-X
in	B-X
both	B-X
blood	B-X
and	B-X
synovial	B-X
tissue	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
RA	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
augmented	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
.	B-X
Sera	B-X
from	B-X
RA	B-X
patients	B-X
induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
phosphorylation	B-X
in	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
mostly	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-6	B-X
antibody	B-X
.	B-X
Preincubation	B-X
of	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
IL-6	B-X
reduced	B-X
IL-10-mediated	B-X
inhibition	B-X
of	B-X
interferon	B-X
gamma	B-X
production	B-X
.	B-X
Blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
RA	B-X
patients	B-X
contained	B-X
higher	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
but	B-X
lower	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
3	B-X
mRNA	B-X
compared	B-X
with	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
real-time	B-X
PCR	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
RA	B-X
CD4+	B-X
T	B-X
cells	B-X
become	B-X
resistant	B-X
to	B-X
the	B-X
immunosuppressive	B-X
effect	B-X
of	B-X
IL-10	B-X
before	B-X
migration	B-X
into	B-X
synovial	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
impaired	B-X
IL-10	B-X
signaling	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
sustained	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
activation	B-X
and	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
induction	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
has	O
been	O
shown	O
to	O
block	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
response	O
by	O
inhibiting	O
the	O
CD28	B-Protein
signaling	O
pathway	O
.	O
<EOS>	B-X
Induction	B-X
of	B-X
specific	B-X
unresponsiveness	B-X
(	B-X
tolerance/anergy	B-X
)	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
and	B-X
recovery	B-X
by	B-X
cytokines	B-X
from	B-X
the	B-X
tissue	B-X
microenvironment	B-X
represent	B-X
two	B-X
key	B-X
steps	B-X
in	B-X
specific	B-X
immunotherapy	B-X
(	B-X
SIT	B-X
)	B-X
with	B-X
whole	B-X
allergen	B-X
or	B-X
antigenic	B-X
T	B-X
cell	B-X
peptides	B-X
.	B-X
Substance	B-X
P	B-X
(	B-X
SP	B-X
)	B-X
is	B-X
a	B-X
neuropeptide	B-X
that	B-X
functions	B-X
to	B-X
activate	B-X
the	B-X
cellular	B-X
physiological	B-X
responses	B-X
of	B-X
MSCs	B-X
,	B-X
including	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
secretion	B-X
of	B-X
specific	B-X
cytokines	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
potential	B-X
of	B-X
SP	B-X
to	B-X
restore	B-X
the	B-X
weakened	B-X
immune	B-X
modulating	B-X
activity	B-X
of	B-X
MSCs	B-X
resulting	B-X
from	B-X
long-term	B-X
culture	B-X
by	B-X
measuring	B-X
T	B-X
cell	B-X
activity	B-X
and	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
secretion	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Jurkat	B-X
leukemic	B-X
T	B-X
cells	B-X
and	B-X
primary	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
As	B-X
the	B-X
number	B-X
of	B-X
cell	B-X
passages	B-X
increased	B-X
,	B-X
the	B-X
immunosuppressive	B-X
function	B-X
of	B-X
MSCs	B-X
based	B-X
on	B-X
T	B-X
cell	B-X
activity	B-X
decreased	B-X
.	B-X
This	B-X
weakened	B-X
activity	B-X
of	B-X
MSCs	B-X
could	B-X
be	B-X
restored	B-X
by	B-X
SP	B-X
treatment	B-X
and	B-X
nullified	B-X
by	B-X
co-treatment	B-X
of	B-X
an	B-X
NK1	B-X
receptor	B-X
blocker	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
transforming	B-X
growth	B-X
factor	B-X
beta	B-X
1	B-X
(	B-X
TGF-β1	B-X
)	B-X
secretion	B-X
were	B-X
noted	B-X
in	B-X
the	B-X
medium	B-X
of	B-X
SP-treated	B-X
late	B-X
passage	B-X
MSC	B-X
cultures	B-X
,	B-X
but	B-X
IL-10	B-X
levels	B-X
did	B-X
not	B-X
change	B-X
.	B-X
SP-treated	B-X
MSC-conditioned	B-X
medium	B-X
decreased	B-X
T	B-X
cell	B-X
activity	B-X
and	B-X
IL-2/Interferon	B-X
gamma	B-X
(	B-X
IFN-g	B-X
)	B-X
secretion	B-X
in	B-X
T	B-X
cells	B-X
even	B-X
in	B-X
the	B-X
activation	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
CD3/CD28	B-X
antibodies	B-X
,	B-X
both	B-X
of	B-X
which	B-X
were	B-X
successfully	B-X
blocked	B-X
by	B-X
inhibiting	B-X
the	B-X
TGF	B-X
beta	B-X
signaling	B-X
pathway	B-X
.	B-X
This	B-X
stimulatory	B-X
effect	B-X
of	B-X
SP	B-X
on	B-X
late	B-X
passage	B-X
MSCs	B-X
was	B-X
also	B-X
confirmed	B-X
in	B-X
direct	B-X
cell-cell	B-X
contact	B-X
co-culture	B-X
of	B-X
MSCs	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X

We	O
found	O
that	O
peripheral	O
blood	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
were	O
able	O
to	O
produce	O
greater	O
amounts	O
of	O
interferon	B-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
than	O
were	O
normal	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
although	O
their	O
surface	O
expression	O
of	O
the	O
type	B-Protein
1	I-Protein
IL	I-Protein
-	I-Protein
10	I-Protein
receptor	I-Protein
was	O
increased	O
.	O

The	O
phosphorylation	O
of	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
was	O
sustained	O
in	O
both	O
blood	O
and	O
synovial	O
tissue	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
RA	O
,	O
but	O
it	O
was	O
not	O
augmented	O
by	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O
<EOS>	B-X
IL-10	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
block	B-X
the	B-X
antigen-specific	B-X
T-cell	B-X
cytokine	B-X
response	B-X
by	B-X
inhibiting	B-X
the	B-X
CD28	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
peripheral	B-X
blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
were	B-X
able	B-X
to	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
interferon	B-X
gamma	B-X
after	B-X
CD3	B-X
and	B-X
CD28	B-X
costimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
than	B-X
were	B-X
normal	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
although	B-X
their	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
type	B-X
1	B-X
IL-10	B-X
receptor	B-X
was	B-X
increased	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
was	B-X
sustained	B-X
in	B-X
both	B-X
blood	B-X
and	B-X
synovial	B-X
tissue	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
RA	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
augmented	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
.	B-X
Sera	B-X
from	B-X
RA	B-X
patients	B-X
induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
phosphorylation	B-X
in	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
mostly	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-6	B-X
antibody	B-X
.	B-X
Preincubation	B-X
of	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
IL-6	B-X
reduced	B-X
IL-10-mediated	B-X
inhibition	B-X
of	B-X
interferon	B-X
gamma	B-X
production	B-X
.	B-X
Blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
RA	B-X
patients	B-X
contained	B-X
higher	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
but	B-X
lower	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
3	B-X
mRNA	B-X
compared	B-X
with	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
real-time	B-X
PCR	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
RA	B-X
CD4+	B-X
T	B-X
cells	B-X
become	B-X
resistant	B-X
to	B-X
the	B-X
immunosuppressive	B-X
effect	B-X
of	B-X
IL-10	B-X
before	B-X
migration	B-X
into	B-X
synovial	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
impaired	B-X
IL-10	B-X
signaling	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
sustained	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
activation	B-X
and	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
induction	B-X
.	B-X

Sera	O
from	O
RA	O
patients	O
induced	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
phosphorylation	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
which	O
was	O
mostly	O
abolished	O
by	O
neutralizing	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
antibody	O
.	O
<EOS>	B-X
IL-10	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
block	B-X
the	B-X
antigen-specific	B-X
T-cell	B-X
cytokine	B-X
response	B-X
by	B-X
inhibiting	B-X
the	B-X
CD28	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
peripheral	B-X
blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
were	B-X
able	B-X
to	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
interferon	B-X
gamma	B-X
after	B-X
CD3	B-X
and	B-X
CD28	B-X
costimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
than	B-X
were	B-X
normal	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
although	B-X
their	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
type	B-X
1	B-X
IL-10	B-X
receptor	B-X
was	B-X
increased	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
was	B-X
sustained	B-X
in	B-X
both	B-X
blood	B-X
and	B-X
synovial	B-X
tissue	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
RA	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
augmented	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
.	B-X
Sera	B-X
from	B-X
RA	B-X
patients	B-X
induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
phosphorylation	B-X
in	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
mostly	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-6	B-X
antibody	B-X
.	B-X
Preincubation	B-X
of	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
IL-6	B-X
reduced	B-X
IL-10-mediated	B-X
inhibition	B-X
of	B-X
interferon	B-X
gamma	B-X
production	B-X
.	B-X
Blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
RA	B-X
patients	B-X
contained	B-X
higher	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
but	B-X
lower	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
3	B-X
mRNA	B-X
compared	B-X
with	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
real-time	B-X
PCR	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
RA	B-X
CD4+	B-X
T	B-X
cells	B-X
become	B-X
resistant	B-X
to	B-X
the	B-X
immunosuppressive	B-X
effect	B-X
of	B-X
IL-10	B-X
before	B-X
migration	B-X
into	B-X
synovial	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
impaired	B-X
IL-10	B-X
signaling	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
sustained	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
activation	B-X
and	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
induction	B-X
.	B-X

Preincubation	O
of	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
IL	B-Protein
-	I-Protein
6	I-Protein
reduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
interferon	B-Protein
gamma	I-Protein
production	O
.	O
<EOS>	B-X
IL-10	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
block	B-X
the	B-X
antigen-specific	B-X
T-cell	B-X
cytokine	B-X
response	B-X
by	B-X
inhibiting	B-X
the	B-X
CD28	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
peripheral	B-X
blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
were	B-X
able	B-X
to	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
interferon	B-X
gamma	B-X
after	B-X
CD3	B-X
and	B-X
CD28	B-X
costimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
than	B-X
were	B-X
normal	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
although	B-X
their	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
type	B-X
1	B-X
IL-10	B-X
receptor	B-X
was	B-X
increased	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
was	B-X
sustained	B-X
in	B-X
both	B-X
blood	B-X
and	B-X
synovial	B-X
tissue	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
RA	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
augmented	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
.	B-X
Sera	B-X
from	B-X
RA	B-X
patients	B-X
induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
phosphorylation	B-X
in	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
mostly	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-6	B-X
antibody	B-X
.	B-X
Preincubation	B-X
of	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
IL-6	B-X
reduced	B-X
IL-10-mediated	B-X
inhibition	B-X
of	B-X
interferon	B-X
gamma	B-X
production	B-X
.	B-X
Blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
RA	B-X
patients	B-X
contained	B-X
higher	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
but	B-X
lower	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
3	B-X
mRNA	B-X
compared	B-X
with	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
real-time	B-X
PCR	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
RA	B-X
CD4+	B-X
T	B-X
cells	B-X
become	B-X
resistant	B-X
to	B-X
the	B-X
immunosuppressive	B-X
effect	B-X
of	B-X
IL-10	B-X
before	B-X
migration	B-X
into	B-X
synovial	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
impaired	B-X
IL-10	B-X
signaling	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
sustained	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
activation	B-X
and	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
induction	B-X
.	B-X

Blood	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
contained	O
higher	O
levels	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
but	O
lower	O
levels	O
of	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
3	I-Protein
mRNA	O
compared	O
with	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
as	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O
<EOS>	B-X
IL-10	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
block	B-X
the	B-X
antigen-specific	B-X
T-cell	B-X
cytokine	B-X
response	B-X
by	B-X
inhibiting	B-X
the	B-X
CD28	B-X
signaling	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
peripheral	B-X
blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
active	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
were	B-X
able	B-X
to	B-X
produce	B-X
greater	B-X
amounts	B-X
of	B-X
interferon	B-X
gamma	B-X
after	B-X
CD3	B-X
and	B-X
CD28	B-X
costimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
than	B-X
were	B-X
normal	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
although	B-X
their	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
type	B-X
1	B-X
IL-10	B-X
receptor	B-X
was	B-X
increased	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
was	B-X
sustained	B-X
in	B-X
both	B-X
blood	B-X
and	B-X
synovial	B-X
tissue	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
RA	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
augmented	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
ng/ml	B-X
IL-10	B-X
.	B-X
Sera	B-X
from	B-X
RA	B-X
patients	B-X
induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
phosphorylation	B-X
in	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
was	B-X
mostly	B-X
abolished	B-X
by	B-X
neutralizing	B-X
anti-IL-6	B-X
antibody	B-X
.	B-X
Preincubation	B-X
of	B-X
normal	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
IL-6	B-X
reduced	B-X
IL-10-mediated	B-X
inhibition	B-X
of	B-X
interferon	B-X
gamma	B-X
production	B-X
.	B-X
Blood	B-X
CD4+	B-X
T	B-X
cells	B-X
from	B-X
RA	B-X
patients	B-X
contained	B-X
higher	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
but	B-X
lower	B-X
levels	B-X
of	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
3	B-X
mRNA	B-X
compared	B-X
with	B-X
control	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
real-time	B-X
PCR	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
RA	B-X
CD4+	B-X
T	B-X
cells	B-X
become	B-X
resistant	B-X
to	B-X
the	B-X
immunosuppressive	B-X
effect	B-X
of	B-X
IL-10	B-X
before	B-X
migration	B-X
into	B-X
synovial	B-X
tissue	B-X
,	B-X
and	B-X
this	B-X
impaired	B-X
IL-10	B-X
signaling	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
sustained	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
activation	B-X
and	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signaling	B-X
1	B-X
induction	B-X
.	B-X

These	O
results	O
indicate	O
that	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
resistant	O
to	O
the	O
immunosuppressive	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
before	O
migration	O
into	O
synovial	O
tissue	O
,	O
and	O
this	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
may	O
be	O
associated	O
with	O
sustained	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
activation	O
and	O
suppressor	B-Protein
of	I-Protein
cytokine	I-Protein
signaling	I-Protein
1	I-Protein
induction	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
is	O
a	O
key	O
cytokine	O
in	O
regulating	O
inflammatory	O
responses	O
,	O
mainly	O
by	O
inhibiting	O
the	O
production	O
and	O
function	O
of	O
proinflammatory	O
cytokines	O
.	O
<EOS>	B-X
We	B-X
here	B-X
show	B-X
that	B-X
LPS	B-X
induces	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
metabolic	B-X
regulator	B-X
Pyruvate	B-X
Kinase	B-X
M2	B-X
(	B-X
PKM2	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
PKM2	B-X
using	B-X
two	B-X
well-characterized	B-X
small	B-X
molecules	B-X
,	B-X
DASA-58	B-X
and	B-X
TEPP-46	B-X
,	B-X
inhibited	B-X
LPS-induced	B-X
Hif-1α	B-X
and	B-X
IL-1β	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
range	B-X
of	B-X
other	B-X
Hif-1α-dependent	B-X
genes	B-X
.	B-X
Activation	B-X
of	B-X
PKM2	B-X
attenuated	B-X
an	B-X
LPS-induced	B-X
proinflammatory	B-X
M1	B-X
macrophage	B-X
phenotype	B-X
while	B-X
promoting	B-X
traits	B-X
typical	B-X
of	B-X
an	B-X
M2	B-X
macrophage	B-X
.	B-X
We	B-X
show	B-X
that	B-X
LPS-induced	B-X
PKM2	B-X
enters	B-X
into	B-X
a	B-X
complex	B-X
with	B-X
Hif-1α	B-X
,	B-X
which	B-X
can	B-X
directly	B-X
bind	B-X
to	B-X
the	B-X
IL-1β	B-X
promoter	B-X
,	B-X
an	B-X
event	B-X
that	B-X
is	B-X
inhibited	B-X
by	B-X
activation	B-X
of	B-X
PKM2	B-X
.	B-X
Both	B-X
compounds	B-X
inhibited	B-X
LPS-induced	B-X
glycolytic	B-X
reprogramming	B-X
and	B-X
succinate	B-X
production	B-X
.	B-X
Finally	B-X
,	B-X
activation	B-X
of	B-X
PKM2	B-X
by	B-X
TEPP-46	B-X
in	B-X
vivo	B-X
inhibited	B-X
LPS	B-X
and	B-X
Salmonella	B-X
typhimurium-induced	B-X
IL-1β	B-X
production	B-X
,	B-X
while	B-X
boosting	B-X
production	B-X
of	B-X
IL-10	B-X
.	B-X
PKM2	B-X
is	B-X
therefore	B-X
a	B-X
critical	B-X
determinant	B-X
of	B-X
macrophage	B-X
activation	B-X
by	B-X
LPS	B-X
,	B-X
promoting	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
binds	O
to	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
receptor	I-Protein
(	O
IL	B-Protein
-	I-Protein
10R	I-Protein
)	O
complex	O
that	O
is	O
composed	O
of	O
two	O
subunits	O
,	O
the	O
primary	O
ligand	O
-	O
binding	O
component	O
type	B-Protein
1	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
(	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
)	O
and	O
the	O
accessory	O
component	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
[	O
1	O
]	O
.	O

The	O
interaction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
10R	I-Protein
engages	O
the	O
Janus	O
kinase	O
(	O
JAK	O
)	O
family	O
tyrosine	O
kinases	O
Jak1	B-Protein
and	O
Tyk2	B-Protein
,	O
which	O
are	O
constitutively	O
associated	O
with	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
and	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
,	O
respectively	O
[	O
2	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
the	O
latent	O
transcriptional	O
factors	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
(	I-Protein
STAT	I-Protein
)	I-Protein
3	I-Protein
and	O
STAT1	B-Protein
[	O
3	O
]	O
.	O

Upon	O
phosphorylation	O
,	O
STAT1	B-Protein
and	O
STAT3	B-Protein
proteins	O
form	O
homodimers	O
or	O
heterodimers	O
,	O
rapidly	O
translocate	O
into	O
the	O
nucleus	O
,	O
and	O
modulate	O
gene	O
transcription	O
.	O
<EOS>	B-X
The	B-X
high-affinity	B-X
binding	B-X
interactions	B-X
between	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
and	B-X
their	B-X
cognate	B-X
cell	B-X
surface	B-X
receptors	B-X
lead	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
receptor-associated	B-X
Janus	B-X
protein	B-X
tyrosine	B-X
kinases	B-X
(	B-X
Jaks	B-X
)	B-X
and	B-X
subsequent	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
a	B-X
group	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
the	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
(	B-X
Stats	B-X
)	B-X
.	B-X
Upon	B-X
IFN-induced	B-X
activation	B-X
,	B-X
these	B-X
Stat	B-X
proteins	B-X
form	B-X
homodimeric	B-X
and	B-X
heterodimeric	B-X
complexes	B-X
that	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
bind	B-X
specific	B-X
elements	B-X
within	B-X
the	B-X
promoters	B-X
of	B-X
IFN-stimulated	B-X
genes	B-X
(	B-X
ISGs	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
well-studied	B-X
IFN-induced	B-X
ISG	B-X
factor	B-X
3	B-X
(	B-X
ISGF3	B-X
)	B-X
and	B-X
Stat1:1	B-X
complexes	B-X
,	B-X
IFNs	B-X
induce	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
number	B-X
of	B-X
other	B-X
Stat-containing	B-X
complexes	B-X
,	B-X
including	B-X
Stat3:3	B-X
and	B-X
Stat5:5	B-X
homodimers	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Stat2:1	B-X
and	B-X
Stat5	B-X
:	B-X
CrkL	B-X
heterodimers	B-X
,	B-X
that	B-X
also	B-X
mediate	B-X
gene	B-X
transcription	B-X
.	B-X
Moreover	B-X
,	B-X
emerging	B-X
evidence	B-X
suggests	B-X
that	B-X
particular	B-X
amino	B-X
acid	B-X
residues	B-X
within	B-X
the	B-X
individual	B-X
Stat	B-X
proteins	B-X
contribute	B-X
to	B-X
different	B-X
aspects	B-X
of	B-X
Stat	B-X
function	B-X
.	B-X
These	B-X
residues	B-X
modulate	B-X
the	B-X
transcriptional	B-X
activation	B-X
potential	B-X
of	B-X
Stat-containing	B-X
complexes	B-X
and	B-X
thereby	B-X
influence	B-X
the	B-X
expression	B-X
of	B-X
ISGs	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
Stat	B-X
proteins	B-X
function	B-X
in	B-X
a	B-X
multifaceted	B-X
manner	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
proteins	B-X
that	B-X
mediate	B-X
IFN	B-X
responses	B-X
.	B-X

Intriguingly	O
,	O
STAT3	B-Protein
is	O
indispensable	O
for	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
derived	O
anti	O
-	O
inflammatory	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
derived	O
proinflammatory	O
responses	O
[	O
4	O
]	O
.	O

Studies	O
of	O
cell	O
-	O
type	O
-	O
specific	O
STAT3	B-Protein
-	O
deficient	O
mice	O
have	O
shown	O
that	O
STAT3	B-Protein
activation	O
is	O
essential	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
reactions	O
in	O
macrophages	O
and	O
neutrophils	O
[	O
5	O
]	O
,	O
but	O
is	O
responsible	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
mediated	O
prevention	O
of	O
apoptosis	O
in	O
T	O
cells	O
[	O
6	O
]	O
.	O

The	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
)	O
proteins	O
have	O
been	O
identified	O
as	O
a	O
family	O
of	O
endogenous	O
JAK	O
kinase	O
inhibitors	O
that	O
can	O
act	O
in	O
classic	O
feedback	O
inhibition	O
loops	O
,	O
but	O
their	O
roles	O
as	O
the	O
mediators	O
of	O
crosstalk	O
inhibition	O
by	O
opposing	O
cytokine	O
signaling	O
pathways	O
have	O
been	O
clarified	O
[	O
7	O
]	O
.	O

Recent	O
studies	O
indicate	O
that	O
SOCS3	B-Protein
plays	O
a	O
key	O
role	O
in	O
regulating	O
the	O
divergent	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
by	O
specifically	O
blocking	O
STAT3	B-Protein
activation	O
induced	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
that	O
induced	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
8	O
,	O
9	O
]	O
.	O

The	O
synovial	O
membrane	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
characterized	O
by	O
an	O
infiltrate	O
of	O
a	O
variety	O
of	O
inflammatory	O
cells	O
,	O
such	O
as	O
lymphocytes	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
together	O
with	O
proliferation	O
of	O
synovial	O
fibroblast	O
-	O
like	O
cells	O
.	O

Numerous	O
cytokines	O
are	O
overproduced	O
in	O
the	O
inflamed	O
joint	O
,	O
and	O
macrophages	O
and	O
synovial	O
fibroblasts	O
are	O
an	O
important	O
source	O
of	O
proinflammatory	O
cytokines	O
.	O

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
two	O
major	O
macrophage	O
products	O
,	O
are	O
crucial	O
in	O
the	O
process	O
of	O
chronic	O
inflammation	O
and	O
joint	O
destruction	O
,	O
and	O
they	O
give	O
rise	O
to	O
effector	O
components	O
,	O
including	O
other	O
inflammatory	O
cytokines	O
,	O
chemokines	O
,	O
growth	O
factors	O
,	O
matrix	O
proteases	O
,	O
nitric	O
oxide	O
,	O
and	O
reactive	O
oxygen	O
species	O
[	O
10	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
a	O
pleiotropic	B-Protein
cytokine	I-Protein
produced	O
substantially	O
by	O
activated	O
fibroblasts	O
,	O
and	O
its	O
proinflammatory	O
actions	O
include	O
simulating	O
the	O
acute	O
-	O
phase	O
response	O
,	O
B	O
-	O
cell	O
maturation	O
into	O
plasma	O
cells	O
,	O
T	O
-	O
cell	O
functions	O
,	O
and	O
hematopoietic	O
precursor	O
cell	O
differentiation	O
[	O
11	O
]	O
.	O

However	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
cytokine	O
inhibitors	O
are	O
also	O
present	O
in	O
large	O
quantities	O
in	O
RA	O
joints	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
,	O
produced	O
by	O
macrophages	O
and	O
partly	O
by	O
T	O
cells	O
in	O
the	O
synovial	O
tissue	O
(	O
ST	O
)	O
,	O
is	O
best	O
known	O
as	O
a	O
negative	O
regulator	O
for	O
macrophage	O
and	O
Th1	O
cells	O
,	O
but	O
the	O
expression	O
level	O
is	O
insufficient	O
to	O
counterbalance	O
the	O
cascade	O
of	O
proinflammatory	O
events	O
[	O
12	O
]	O
.	O

In	O
addition	O
,	O
the	O
anti	O
-	O
inflammatory	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
appears	O
to	O
be	O
modulated	O
at	O
the	O
level	O
of	O
signal	O
transduction	O
during	O
chronic	O
inflammation	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
is	O
impaired	O
in	O
macrophages	O
upon	O
chronic	O
exposure	O
to	O
proinflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
immune	O
complexes	O
[	O
13	O
,	O
14	O
]	O
.	O

Cell	O
surface	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
is	O
decreased	O
in	O
synovial	O
fluid	O
dendritic	O
cells	O
due	O
to	O
the	O
presence	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
[	O
15	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
may	O
be	O
activated	O
by	O
arthritogenic	O
antigens	O
,	O
in	O
conjunction	O
with	O
CD28	B-Protein
-	O
mediated	O
costimulatory	O
signaling	O
,	O
in	O
RA	O
.	O

The	O
significance	O
of	O
this	O
autoimmune	O
process	O
has	O
been	O
supported	O
by	O
the	O
linkage	O
of	O
the	O
MHC	O
class	O
II	O
antigens	O
HLA	B-Protein
-	I-Protein
DRB1	I-Protein
*	I-Protein
0404	I-Protein
and	O
HLA	B-Protein
-	I-Protein
DRB1	I-Protein
*	I-Protein
0401	I-Protein
with	O
disease	O
susceptibility	O
and	O
severity	O
[	O
16	O
,	O
17	O
]	O
,	O
and	O
by	O
the	O
high	O
-	O
level	O
expression	O
of	O
MHC	O
class	O
II	O
molecules	O
and	O
both	O
CD28	B-Protein
ligands	O
,	O
CD80	B-Protein
and	O
CD86	B-Protein
,	O
in	O
the	O
inflamed	O
ST	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
continuing	O
emergence	O
of	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
even	O
though	O
few	O
in	O
number	O
,	O
may	O
be	O
crucial	O
in	O
sustaining	O
the	O
activation	O
of	O
macrophages	O
and	O
synovial	O
fibroblasts	O
through	O
cell	O
surface	O
signaling	O
by	O
means	O
of	O
cell	O
surface	O
CD69	B-Protein
and	O
CD11	B-Protein
,	O
as	O
well	O
as	O
the	O
release	O
of	O
proinflammatory	O
Th1	O
cytokines	O
such	O
as	O
interferon	B-Protein
gamma	I-Protein
(	B-Protein
IFN	I-Protein
)	I-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
[	O
21	O
,	O
22	O
]	O
.	O

In	O
addition	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
could	O
stimulate	O
B	O
-	O
cell	O
production	O
of	O
autoantibodies	O
such	O
as	O
rheumatoid	O
factor	O
and	O
osteoclast	O
-	O
mediated	O
bone	O
destruction	O
.	O

Their	O
obligatory	O
role	O
in	O
RA	O
synovitis	O
was	O
recently	O
proved	O
by	O
successful	O
treatment	O
of	O
active	O
disease	O
by	O
selective	O
inhibition	O
of	O
T	O
-	O
cell	O
activation	O
with	O
fusion	O
protein	O
of	O
cytotoxic	B-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
associated	I-Protein
antigen	I-Protein
4	I-Protein
(	I-Protein
CD152	I-Protein
)	I-Protein
-	I-Protein
IgG	I-Protein
,	O
which	O
can	O
block	O
the	O
engagement	O
of	O
CD28	B-Protein
on	O
T	O
cells	O
by	O
binding	O
to	O
CD80	B-Protein
and	O
CD86	B-Protein
with	O
high	O
avidity	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
efficiently	O
blocks	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
response	O
by	O
inhibiting	O
the	O
CD28	B-Protein
signaling	O
pathway	O
[	O
24	O
]	O
,	O
as	O
well	O
as	O
indirectly	O
by	O
downregulating	O
the	O
function	O
of	O
antigen	O
-	O
presenting	O
cells	O
.	O

To	O
elucidate	O
the	O
resistance	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
this	O
direct	O
inhibition	O
in	O
RA	O
,	O
we	O
investigated	O
the	O
production	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
the	O
induction	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
the	O
expression	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
.	O

Patients	O
and	O
samples	O
<EOS>	B-X
Patients	B-X
with	B-X
an	B-X
intestinal	B-X
stoma	B-X
experience	B-X
psychological	B-X
difficulties	B-X
,	B-X
including	B-X
disturbances	B-X
in	B-X
self-efficacy	B-X
and	B-X
self-esteem	B-X
.	B-X
Pharmaceutical	B-X
samples	B-X
are	B-X
widely	B-X
used	B-X
for	B-X
promotion	B-X
and	B-X
marketing	B-X
,	B-X
yet	B-X
little	B-X
is	B-X
known	B-X
about	B-X
who	B-X
receives	B-X
samples	B-X
or	B-X
how	B-X
their	B-X
use	B-X
is	B-X
associated	B-X
with	B-X
patient	B-X
's	B-X
prescription	B-X
costs	B-X
.	B-X
Perceptions	B-X
of	B-X
IBD	B-X
within	B-X
patient	B-X
and	B-X
community	B-X
samples	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
observance	B-X
rate	B-X
of	B-X
the	B-X
patient	B-X
rights	B-X
charter	B-X
was	B-X
considered	B-X
and	B-X
the	B-X
patient	B-X
rights	B-X
charter	B-X
in	B-X
the	B-X
samples	B-X
were	B-X
studied	B-X
based	B-X
on	B-X
dependency	B-X
type	B-X
of	B-X
hospitals	B-X
.	B-X

The	O
total	O
patient	O
population	O
consisted	O
of	O
32	O
patients	O
with	O
RA	O
(	O
25	O
women	O
and	O
seven	O
men	O
;	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
age	O
,	O
52	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
4	O
years	O
)	O
diagnosed	O
according	O
to	O
the	O
revised	O
1987	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
formally	O
,	O
the	O
American	O
Rheumatism	O
Association	O
)	O
[	O
25	O
]	O
.	O

All	O
patients	O
were	O
receiving	O
prednisolone	O
(	O
<	O
=	O
7	O
.	O
5	O
mg	O
/	O
day	O
)	O
and	O
disease	O
-	O
modifying	O
antirheumatic	O
drugs	O
.	O
<EOS>	B-X
Pharmacological	B-X
prevention	B-X
against	B-X
relapses	B-X
in	B-X
patients	B-X
with	B-X
neuromyelitis	B-X
optica	B-X
spectrum	B-X
disorder	B-X
(	B-X
NMOSD	B-X
)	B-X
is	B-X
developing	B-X
rapidly	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
rituximab	B-X
,	B-X
an	B-X
anti-CD20	B-X
monoclonal	B-X
antibody	B-X
,	B-X
against	B-X
relapses	B-X
in	B-X
patients	B-X
with	B-X
NMOSD	B-X
.	B-X
Calcineurin	B-X
inhibitors	B-X
are	B-X
an	B-X
established	B-X
first-line	B-X
corticosteroid-sparing	B-X
therapy	B-X
for	B-X
patients	B-X
with	B-X
corticosteroid-dependent	B-X
nephrotic	B-X
syndrome	B-X
(	B-X
CDNS	B-X
)	B-X
,	B-X
whereas	B-X
B-lymphocyte-depleting	B-X
therapy	B-X
is	B-X
mostly	B-X
used	B-X
as	B-X
a	B-X
rescue	B-X
for	B-X
calcineurin	B-X
inhibitor-resistant	B-X
cases	B-X
.	B-X
To	B-X
evaluate	B-X
and	B-X
compare	B-X
benefits	B-X
and	B-X
harms	B-X
of	B-X
three	B-X
biological	B-X
treatments	B-X
with	B-X
different	B-X
modes	B-X
of	B-X
action	B-X
versus	B-X
active	B-X
conventional	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
early	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Clinical	O
parameters	O
in	O
the	O
study	O
patients	O
were	O
as	O
follows	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
:	O
erythrocyte	O
sedimentation	O
rate	O
,	O
55	O
.	O
9	O
+	O
/	O
-	O
35	O
.	O
4	O
mm	O
/	O
hour	O
;	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
level	O
,	O
32	O
.	O
0	O
+	O
/	O
-	O
32	O
.	O
0	O
mg	O
/	O
l	O
;	O
and	O
IgM	O
class	O
rheumatoid	O
factor	O
titer	O
,	O
142	O
+	O
/	O
-	O
158	O
U	O
/	O
ml	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
24	O
patients	O
with	O
active	O
disease	O
,	O
who	O
had	O
multiple	O
tender	O
and	O
/	O
or	O
swollen	O
joints	O
and	O
elevated	O
serum	O
CRP	O
level	O
(	O
>	O
=	O
10	O
mg	O
/	O
l	O
)	O
;	O
and	O
eight	O
patients	O
with	O
inactive	O
disease	O
,	O
who	O
satisfied	O
the	O
American	O
College	O
of	O
Rheumatology	O
preliminary	O
criteria	O
for	O
clinical	O
remission	O
[	O
26	O
]	O
.	O

Sixteen	O
healthy	O
volunteers	O
(	O
11	O
women	O
and	O
five	O
men	O
;	O
age	O
,	O
45	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
2	O
years	O
)	O
served	O
as	O
controls	O
.	O
<EOS>	B-X
Identifying	B-X
whether	B-X
IPF	B-X
in	B-X
a	B-X
patient	B-X
is	B-X
progressive	B-X
or	B-X
stable	B-X
is	B-X
crucial	B-X
for	B-X
treatment	B-X
regimens	B-X
.	B-X
Purpose	B-X
To	B-X
assess	B-X
the	B-X
role	B-X
of	B-X
hyperpolarized	B-X
(	B-X
HP	B-X
)	B-X
xenon	B-X
129	B-X
(	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
supplementary	B-X
motor	B-X
area	B-X
(	B-X
SMA	B-X
)	B-X
activation	B-X
during	B-X
motor	B-X
,	B-X
sensory	B-X
,	B-X
word	B-X
generation	B-X
,	B-X
listening	B-X
comprehension	B-X
,	B-X
and	B-X
working	B-X
memory	B-X
tasks	B-X
by	B-X
using	B-X
functional	B-X
MR	B-X
imaging	B-X
(	B-X
fMRI	B-X
)	B-X
.	B-X
Human	B-X
supplementary	B-X
motor	B-X
area	B-X
(	B-X
SMA	B-X
)	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
roles	B-X
in	B-X
motor	B-X
control	B-X
and	B-X
other	B-X
various	B-X
functions	B-X
such	B-X
as	B-X
sensory	B-X
,	B-X
speech	B-X
expression	B-X
,	B-X
and	B-X
memory	B-X
.	B-X

ST	O
samples	O
were	O
obtained	O
from	O
three	O
RA	O
patients	O
undergoing	O
total	O
knee	O
replacement	O
.	O

All	O
patients	O
gave	O
informed	O
consent	O
.	O
<EOS>	B-X
Informed	B-X
consent	B-X
is	B-X
a	B-X
process	B-X
which	B-X
consists	B-X
of	B-X
informing	B-X
the	B-X
patient	B-X
about	B-X
the	B-X
medical	B-X
interventions	B-X
planned	B-X
to	B-X
be	B-X
applied	B-X
to	B-X
the	B-X
patient	B-X
's	B-X
body	B-X
and	B-X
making	B-X
the	B-X
patient	B-X
active	B-X
in	B-X
the	B-X
decision	B-X
making	B-X
process	B-X
.	B-X
However	B-X
,	B-X
the	B-X
assessment	B-X
of	B-X
the	B-X
vitamin	B-X
D	B-X
status	B-X
of	B-X
depressed	B-X
juvenile	B-X
patients	B-X
,	B-X
or	B-X
supplementation	B-X
of	B-X
vitamin	B-X
D	B-X
is	B-X
currently	B-X
not	B-X
part	B-X
of	B-X
routine	B-X
treatment	B-X
.	B-X
Only	B-X
the	B-X
British	B-X
Society	B-X
of	B-X
Gastroenterology	B-X
has	B-X
published	B-X
consent	B-X
guidelines	B-X
that	B-X
are	B-X
inclusive	B-X
for	B-X
endoscopic	B-X
retrograde	B-X
cholangiopancreatography	B-X
(	B-X
ERCP	B-X
)	B-X
.	B-X
Previous	B-X
research	B-X
has	B-X
shown	B-X
that	B-X
there	B-X
are	B-X
variations	B-X
in	B-X
the	B-X
information	B-X
discussed	B-X
with	B-X
patients	B-X
who	B-X
are	B-X
undergoing	B-X
ERCP	B-X
.	B-X

Isolation	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
<EOS>	B-X
Once	B-X
regarded	B-X
as	B-X
an	B-X
experimental	B-X
artefact	B-X
,	B-X
cytotoxic	B-X
CD4	B-X
The	B-X
pathogenic	B-X
immune	B-X
response	B-X
in	B-X
celiac	B-X
disease	B-X
(	B-X
CeD	B-X
)	B-X
is	B-X
orchestrated	B-X
by	B-X
phenotypically	B-X
distinct	B-X
CD4	B-X
Humoral	B-X
adaptive	B-X
immune	B-X
responses	B-X
trigger	B-X
the	B-X
establishment	B-X
of	B-X
plasma	B-X
B	B-X
cells	B-X
secreting	B-X
antibodies	B-X
of	B-X
various	B-X
isotypes	B-X
that	B-X
bind	B-X
antigen	B-X
specifically	B-X
and	B-X
with	B-X
high	B-X
affinity	B-X
.	B-X
Moreover	B-X
,	B-X
memory	B-X
B	B-X
cells	B-X
will	B-X
be	B-X
generated	B-X
.	B-X
To	B-X
accomplish	B-X
this	B-X
,	B-X
B	B-X
cells	B-X
need	B-X
assistance	B-X
from	B-X
a	B-X
special	B-X
subset	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
so	B-X
called	B-X
follicular	B-X
T	B-X
cells	B-X
that	B-X
differentiate	B-X
from	B-X
naïve	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
course	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
study	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
is	B-X
of	B-X
primordial	B-X
interest	B-X
when	B-X
investigating	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
determinants	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
This	B-X
is	B-X
done	B-X
by	B-X
direct	B-X
analysis	B-X
of	B-X
the	B-X
cells	B-X
isolated	B-X
from	B-X
mice	B-X
following	B-X
an	B-X
immunological	B-X
challenge	B-X
but	B-X
in	B-X
many	B-X
instances	B-X
such	B-X
analyses	B-X
must	B-X
involve	B-X
follow-up	B-X
studies	B-X
in	B-X
cell	B-X
culture	B-X
requiring	B-X
living	B-X
cells	B-X
.	B-X
Especially	B-X
,	B-X
in	B-X
vitro	B-X
experimentation	B-X
necessitates	B-X
isolation	B-X
and	B-X
sorting	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
follicular	B-X
T	B-X
cells	B-X
are	B-X
generally	B-X
difficult	B-X
to	B-X
handle	B-X
because	B-X
they	B-X
are	B-X
prone	B-X
to	B-X
apoptosis	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
evident	B-X
when	B-X
dealing	B-X
with	B-X
follicular	B-X
T	B-X
cells	B-X
residing	B-X
in	B-X
the	B-X
gut	B-X
since	B-X
we	B-X
observed	B-X
that	B-X
isolation	B-X
and	B-X
processing	B-X
from	B-X
murine	B-X
gut	B-X
notoriously	B-X
results	B-X
in	B-X
very	B-X
high	B-X
loss	B-X
rates	B-X
when	B-X
compared	B-X
for	B-X
example	B-X
to	B-X
cells	B-X
obtained	B-X
from	B-X
immunized	B-X
peripheral	B-X
lymph	B-X
nodes	B-X
.	B-X
To	B-X
bypass	B-X
these	B-X
limitations	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
protocol	B-X
that	B-X
allows	B-X
for	B-X
efficient	B-X
isolation	B-X
of	B-X
intact	B-X
follicular	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
protocol	B-X
introduced	B-X
here	B-X
illustrates	B-X
isolation	B-X
and	B-X
handling	B-X
of	B-X
follicular	B-X
T	B-X
cells	B-X
using	B-X
murine	B-X
Peyer	B-X
's	B-X
Patches	B-X
as	B-X
an	B-X
example	B-X
because	B-X
they	B-X
constantly	B-X
harbor	B-X
significant	B-X
amounts	B-X
of	B-X
these	B-X
cells	B-X
.	B-X

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
prepared	O
from	O
heparinized	O
blood	O
samples	O
by	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
density	O
gradients	O
(	O
Pharmacia	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
purified	O
from	O
PBMC	O
by	O
positive	O
selection	O
using	O
anti	O
-	O
CD4	B-Protein
mAb	O
-	O
coated	O
magnetic	O
beads	O
(	O
Miltenyi	O
Biotec	O
,	O
Gladbach	O
,	O
Germany	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
from	O
ST	O
samples	O
,	O
as	O
previously	O
described	O
[	O
27	O
]	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
R5	B-X
isolates	B-X
that	B-X
predominantly	B-X
use	B-X
CCR5	B-X
as	B-X
a	B-X
coreceptor	B-X
are	B-X
frequently	B-X
described	B-X
as	B-X
macrophage	B-X
tropic	B-X
.	B-X
The	B-X
phenotypes	B-X
of	B-X
these	B-X
envelopes	B-X
were	B-X
compared	B-X
to	B-X
those	B-X
conferred	B-X
by	B-X
an	B-X
extended	B-X
panel	B-X
of	B-X
envelopes	B-X
derived	B-X
from	B-X
brain	B-X
and	B-X
lymph	B-X
node	B-X
that	B-X
we	B-X
reported	B-X
previously	B-X
.	B-X
Highly	B-X
macrophage-tropic	B-X
envelopes	B-X
were	B-X
predominate	B-X
in	B-X
brain	B-X
but	B-X
were	B-X
infrequent	B-X
in	B-X
semen	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
lymph	B-X
node	B-X
samples	B-X
.	B-X
We	B-X
also	B-X
confirmed	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
N283	B-X
in	B-X
the	B-X
C2	B-X
CD4	B-X
binding	B-X
site	B-X
of	B-X
gp120	B-X
is	B-X
associated	B-X
with	B-X
HIV-1	B-X
envelopes	B-X
from	B-X
the	B-X
brain	B-X
but	B-X
absent	B-X
from	B-X
macrophage-tropic	B-X
envelopes	B-X
amplified	B-X
from	B-X
blood	B-X
and	B-X
semen	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
compared	B-X
infection	B-X
of	B-X
macrophages	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
conferred	B-X
by	B-X
macrophage-tropic	B-X
and	B-X
non-macrophage-tropic	B-X
envelopes	B-X
in	B-X
the	B-X
context	B-X
of	B-X
full-length	B-X
replication	B-X
competent	B-X
viral	B-X
clones	B-X
.	B-X
Non-macrophage-tropic	B-X
envelopes	B-X
conferred	B-X
low-level	B-X
infection	B-X
of	B-X
macrophages	B-X
yet	B-X
infected	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
PBMCs	B-X
as	B-X
efficiently	B-X
as	B-X
highly	B-X
macrophage-tropic	B-X
brain	B-X
envelopes	B-X
.	B-X

Briefly	O
,	O
fresh	O
ST	O
samples	O
were	O
fragmented	O
and	O
digested	O
with	O
collagenase	O
and	O
DNase	O
for	O
1	O
hour	O
at	O
37degreesC	O
.	O

After	O
removing	O
tissue	O
debris	O
,	O
ST	O
cell	O
suspensions	O
in	O
culture	O
medium	O
(	O
RPMI	O
1640	O
medium	O
;	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
supplemented	O
with	O
25	O
mM	O
HEPES	O
(	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
2	O
%	O
nonessential	O
amino	O
acids	O
,	O
100	O
IU	O
/	O
ml	O
penicillin	O
,	O
and	O
100	O
mg	O
/	O
ml	O
streptomycin	O
;	O
Life	O
Technologies	O
)	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Life	O
Technologies	O
)	O
were	O
incubated	O
at	O
37degreesC	O
in	O
six	O
-	O
well	O
plates	O
(	O
Coster	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
for	O
45	O
min	O
.	O

Non	O
-	O
adherent	O
cells	O
were	O
harvested	O
and	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
purified	O
by	O
positive	O
selection	O
as	O
already	O
described	O
.	O

Culture	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
<EOS>	B-X
Memory	B-X
T	B-X
cells	B-X
are	B-X
crucial	B-X
players	B-X
in	B-X
vertebrate	B-X
adaptive	B-X
immunity	B-X
but	B-X
their	B-X
development	B-X
is	B-X
incompletely	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
method	B-X
to	B-X
produce	B-X
human	B-X
memory-like	B-X
T	B-X
cells	B-X
from	B-X
naive	B-X
human	B-X
T	B-X
cells	B-X
in	B-X
culture	B-X
.	B-X
Using	B-X
commercially	B-X
available	B-X
human	B-X
T-cell	B-X
differentiation	B-X
kits	B-X
,	B-X
both	B-X
purified	B-X
naive	B-X
CD8+	B-X
T	B-X
cells	B-X
and	B-X
purified	B-X
naive	B-X
CD4+	B-X
T	B-X
cells	B-X
were	B-X
activated	B-X
via	B-X
T-cell	B-X
receptor	B-X
signaling	B-X
and	B-X
appropriate	B-X
cytokines	B-X
for	B-X
several	B-X
days	B-X
in	B-X
culture	B-X
.	B-X
All	B-X
the	B-X
T-cell	B-X
activators	B-X
were	B-X
then	B-X
removed	B-X
from	B-X
the	B-X
medium	B-X
and	B-X
the	B-X
cultures	B-X
were	B-X
continued	B-X
in	B-X
hypoxic	B-X
condition	B-X
(	B-X
1	B-X
%	B-X
O2	B-X
atmosphere	B-X
)	B-X
for	B-X
several	B-X
more	B-X
days	B-X
;	B-X
during	B-X
this	B-X
period	B-X
,	B-X
most	B-X
of	B-X
the	B-X
cells	B-X
died	B-X
,	B-X
but	B-X
some	B-X
survived	B-X
in	B-X
a	B-X
quiescent	B-X
state	B-X
for	B-X
a	B-X
month	B-X
.	B-X
The	B-X
survivors	B-X
had	B-X
small	B-X
round	B-X
cell	B-X
bodies	B-X
,	B-X
expressed	B-X
differentiation	B-X
markers	B-X
characteristic	B-X
of	B-X
memory	B-X
T	B-X
cells	B-X
and	B-X
restarted	B-X
proliferation	B-X
when	B-X
the	B-X
T-cell	B-X
activators	B-X
were	B-X
added	B-X
back	B-X
.	B-X
We	B-X
could	B-X
also	B-X
induce	B-X
memory-like	B-X
T	B-X
cells	B-X
from	B-X
naive	B-X
human	B-X
T	B-X
cells	B-X
without	B-X
hypoxia	B-X
,	B-X
if	B-X
we	B-X
froze	B-X
the	B-X
activated	B-X
T	B-X
cells	B-X
or	B-X
prepared	B-X
the	B-X
naive	B-X
T	B-X
cells	B-X
from	B-X
chilled	B-X
filter	B-X
buffy	B-X
coats	B-X
.	B-X

PB	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
populations	O
were	O
resuspended	O
at	O
a	O
density	O
of	O
1	O
x	O
106	O
cells	O
/	O
ml	O
in	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
,	O
and	O
0	O
.	O
5	O
ml	O
cell	O
suspensions	O
were	O
dispensed	O
into	O
the	O
wells	O
of	O
24	O
-	O
well	O
microtiter	O
plates	O
(	O
Coster	O
)	O
coated	O
with	O
1	O
mug	O
/	O
ml	O
anti	O
-	O
CD3	O
mAb	O
(	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
.	O

The	O
cells	O
were	O
incubated	O
with	O
1	O
mug	O
/	O
ml	O
anti	O
-	O
CD28	B-Protein
mAb	O
(	O
Immunotech	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indicated	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Becton	O
Dickinson	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
at	O
37degreesC	O
in	O
a	O
humidified	O
atmosphere	O
containing	O
5	O
%	O
CO2	O
[	O
28	O
]	O
.	O

Culture	O
supernatants	O
were	O
collected	O
36	O
hours	O
later	O
and	O
cell	O
-	O
free	O
samples	O
were	O
stored	O
at	O
-	O
30degreesC	O
until	O
cytokine	O
assay	O
.	O

To	O
examine	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
on	O
T	O
-	O
cell	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
healthy	O
controls	O
were	O
incubated	O
in	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
Becton	O
Dickinson	O
)	O
for	O
36	O
hours	O
.	O

Cells	O
were	O
then	O
stimulated	O
for	O
36	O
hours	O
with	O
anti	O
-	O
CD3	O
mAb	O
and	O
anti	O
-	O
CD28	B-Protein
mAb	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Culture	O
supernatants	O
were	O
measured	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
concentrations	O
.	O
<EOS>	B-X
QuantiFERON®-TB	B-X
Gold	B-X
in-tube	B-X
(	B-X
QFT-GIT	B-X
)	B-X
supernatants	B-X
may	B-X
be	B-X
important	B-X
samples	B-X
for	B-X
use	B-X
in	B-X
assessment	B-X
of	B-X
anti-tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
antibodies	B-X
when	B-X
only	B-X
limited	B-X
volumes	B-X
of	B-X
blood	B-X
can	B-X
be	B-X
collected	B-X
and	B-X
when	B-X
a	B-X
combination	B-X
of	B-X
antibody	B-X
and	B-X
cytokine	B-X
measurements	B-X
are	B-X
required	B-X
.	B-X
However	B-X
,	B-X
few	B-X
studies	B-X
have	B-X
explored	B-X
the	B-X
use	B-X
of	B-X
QFT-GIT	B-X
supernatants	B-X
for	B-X
investigations	B-X
of	B-X
antibody	B-X
responses	B-X
.	B-X
This	B-X
study	B-X
determined	B-X
the	B-X
correlation	B-X
and	B-X
agreement	B-X
between	B-X
anti-CFP-10	B-X
and	B-X
anti-ESAT-6	B-X
antibody	B-X
concentrations	B-X
in	B-X
QFT-GIT	B-X
nil	B-X
supernatant	B-X
and	B-X
serum	B-X
pairs	B-X
from	B-X
68	B-X
TB	B-X
household	B-X
contacts	B-X
.	B-X
We	B-X
also	B-X
explored	B-X
the	B-X
ability	B-X
of	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
M.tb	B-X
)	B-X
specific	B-X
antibodies	B-X
,	B-X
or	B-X
ratios	B-X
of	B-X
antibody	B-X
to	B-X
interferon	B-X
gamma	B-X
(	B-X
IFN-γ	B-X
)	B-X
in	B-X
QFT-GIT	B-X
supernatants	B-X
,	B-X
to	B-X
differentiate	B-X
97	B-X
APTB	B-X
cases	B-X
from	B-X
58	B-X
individuals	B-X
with	B-X
LTBI	B-X
.	B-X
There	B-X
were	B-X
strong	B-X
and	B-X
statistically	B-X
significant	B-X
correlations	B-X
between	B-X
anti-CFP-10	B-X
and	B-X
anti-ESAT-6	B-X
antibodies	B-X
in	B-X
unstimulated	B-X
QFT-GIT	B-X
supernatants	B-X
and	B-X
sera	B-X
(	B-X
r	B-X
=	B-X
0.89	B-X
;	B-X
p	B-X
<	B-X
0.0001	B-X
for	B-X
both	B-X
)	B-X
,	B-X
and	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
antibody	B-X
concentration	B-X
between	B-X
them	B-X
.	B-X
Anti-CFP-10	B-X
antibody/M.tb	B-X
specific	B-X
IFN-γ	B-X
and	B-X
anti-ESAT-6	B-X
antibody/M.tb	B-X
specific	B-X
IFN-γ	B-X
ratios	B-X
had	B-X
sensitivities	B-X
of	B-X
48.5	B-X
%	B-X
&	B-X
54.6	B-X
%	B-X
and	B-X
specificities	B-X
of	B-X
89.7	B-X
%	B-X
and	B-X
75.9	B-X
%	B-X
respectively	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
QFT-GIT	B-X
nil	B-X
supernatants	B-X
may	B-X
be	B-X
used	B-X
in	B-X
the	B-X
place	B-X
of	B-X
sera	B-X
when	B-X
measuring	B-X
antibody	B-X
responses	B-X
,	B-X
reducing	B-X
blood	B-X
volumes	B-X
needed	B-X
for	B-X
such	B-X
investigations	B-X
.	B-X
Antibodies	B-X
in	B-X
QFT-GIT	B-X
nil	B-X
supernatants	B-X
on	B-X
their	B-X
own	B-X
discriminate	B-X
APTB	B-X
from	B-X
LTBI	B-X
with	B-X
high	B-X
sensitivity	B-X
but	B-X
have	B-X
poor	B-X
specificity	B-X
,	B-X
whereas	B-X
the	B-X
reverse	B-X
is	B-X
true	B-X
when	B-X
antibodies	B-X
are	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
M.tb	B-X
specific	B-X
cytokines	B-X
.	B-X

Flow	O
cytometric	O
analysis	O
for	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
<EOS>	B-X
Studies	B-X
have	B-X
indicated	B-X
that	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-10	B-X
has	B-X
a	B-X
pathogenic	B-X
role	B-X
in	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
;	B-X
however	B-X
,	B-X
a	B-X
protective	B-X
effect	B-X
of	B-X
IL-10	B-X
in	B-X
SLE	B-X
was	B-X
also	B-X
observed	B-X
.	B-X
Because	B-X
the	B-X
exact	B-X
mechanism	B-X
of	B-X
IL-10	B-X
signalling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
SLE	B-X
is	B-X
unclear	B-X
,	B-X
this	B-X
study	B-X
sought	B-X
to	B-X
assess	B-X
the	B-X
expression	B-X
and	B-X
signalling	B-X
of	B-X
interleukin-10	B-X
receptor	B-X
(	B-X
IL-10R	B-X
)	B-X
in	B-X
peripheral	B-X
leucocytes	B-X
from	B-X
patients	B-X
with	B-X
SLE	B-X
.	B-X
We	B-X
used	B-X
flow	B-X
cytometry	B-X
to	B-X
examine	B-X
the	B-X
expression	B-X
of	B-X
IL-10R1	B-X
on	B-X
different	B-X
peripheral	B-X
leucocytes	B-X
from	B-X
28	B-X
SLE	B-X
patients	B-X
,	B-X
of	B-X
whom	B-X
14	B-X
had	B-X
lupus	B-X
nephritis	B-X
(	B-X
LN	B-X
)	B-X
and	B-X
14	B-X
were	B-X
healthy	B-X
controls	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
IL-10	B-X
on	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
-3	B-X
and	B-X
STAT-1	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
obtained	B-X
from	B-X
13	B-X
SLE	B-X
patients	B-X
and	B-X
seven	B-X
healthy	B-X
controls	B-X
.	B-X
Plasma	B-X
cytokines	B-X
were	B-X
detected	B-X
by	B-X
flow	B-X
cytometric	B-X
bead	B-X
array	B-X
(	B-X
CBA	B-X
)	B-X
techniques	B-X
.	B-X
Although	B-X
IL-10R1	B-X
expression	B-X
levels	B-X
on	B-X
each	B-X
peripheral	B-X
leucocyte	B-X
subset	B-X
from	B-X
28	B-X
SLE	B-X
patients	B-X
and	B-X
14	B-X
healthy	B-X
controls	B-X
were	B-X
similar	B-X
,	B-X
the	B-X
expression	B-X
levels	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
LN	B-X
patients	B-X
were	B-X
significantly	B-X
lower	B-X
than	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
controls	B-X
and	B-X
SLE	B-X
patients	B-X
without	B-X
nephritis	B-X
(	B-X
P	B-X
<	B-X
0·01	B-X
)	B-X
.	B-X
IL-10R1	B-X
expression	B-X
levels	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
correlated	B-X
negatively	B-X
with	B-X
the	B-X
SLE	B-X
disease	B-X
activity	B-X
index	B-X
(	B-X
P	B-X
<	B-X
0·01	B-X
)	B-X
.	B-X
Plasma	B-X
IL-10	B-X
levels	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
LN	B-X
patients	B-X
than	B-X
controls	B-X
.	B-X
IL-10R1	B-X
expression	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
signalling	B-X
in	B-X
PBMCs	B-X
were	B-X
down-regulated	B-X
in	B-X
LN	B-X
patients	B-X
,	B-X
indicating	B-X
that	B-X
IL-10	B-X
and	B-X
its	B-X
receptor	B-X
may	B-X
have	B-X
a	B-X
special	B-X
role	B-X
in	B-X
LN	B-X
pathogenesis	B-X
.	B-X

A	O
sample	O
of	O
5	O
x	O
105	O
cells	O
of	O
PBMC	O
was	O
resuspended	O
in	O
PBS	O
with	O
1	O
%	O
FCS	O
.	O

PBMC	O
were	O
incubated	O
with	O
saturating	O
concentrations	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
mAb	O
(	O
IgG1	O
;	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
or	O
with	O
isotype	O
-	O
matched	O
control	O
mAb	O
(	O
Immunotech	O
)	O
,	O
followed	O
by	O
incubation	O
with	O
FITC	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG1	O
polyclonal	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
were	O
then	O
incubated	O
with	O
phycoerythrin	O
-	O
conjugated	O
anti	O
-	O
CD4	B-Protein
mAb	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Cells	O
were	O
washed	O
well	O
with	O
1	O
%	O
FCS	O
/	O
PBS	O
between	O
incubations	O
.	O

Analysis	O
was	O
performed	O
on	O
a	O
FACScan	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
)	O
.	O
<EOS>	B-X
This	B-X
unit	B-X
details	B-X
the	B-X
operation	B-X
of	B-X
a	B-X
FACS	B-X
Calibur	B-X
flow	B-X
cytometer	B-X
for	B-X
cell	B-X
analysis	B-X
.	B-X
The	B-X
operation	B-X
of	B-X
the	B-X
Becton	B-X
Dickinson	B-X
FACS	B-X
Calibur	B-X
and	B-X
CELLQuest	B-X
software	B-X
version	B-X
3.0	B-X
is	B-X
described	B-X
,	B-X
but	B-X
the	B-X
unit	B-X
is	B-X
general	B-X
enough	B-X
to	B-X
be	B-X
helpful	B-X
for	B-X
users	B-X
of	B-X
all	B-X
flow	B-X
cytometers	B-X
.	B-X
Use	B-X
of	B-X
the	B-X
standard	B-X
dual-platform	B-X
flow	B-X
cytometric	B-X
method	B-X
for	B-X
determination	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T-lymphocyte	B-X
counts	B-X
,	B-X
which	B-X
needs	B-X
both	B-X
a	B-X
flow	B-X
cytometer	B-X
(	B-X
FCM	B-X
)	B-X
and	B-X
hematological	B-X
analyzer	B-X
,	B-X
would	B-X
inevitably	B-X
lead	B-X
to	B-X
increased	B-X
variability	B-X
.	B-X
The	B-X
performance	B-X
of	B-X
CyFlow	B-X
(	B-X
green	B-X
)	B-X
was	B-X
compared	B-X
with	B-X
those	B-X
of	B-X
two	B-X
reference	B-X
standard	B-X
SP	B-X
microbead-based	B-X
technologies	B-X
of	B-X
the	B-X
three-color	B-X
TruCOUNT	B-X
tube	B-X
with	B-X
the	B-X
FACScan	B-X
FCM	B-X
and	B-X
a	B-X
two-color	B-X
FACSCount	B-X
system	B-X
(	B-X
Becton	B-X
Dickinson	B-X
Biosciences	B-X
)	B-X
.	B-X
Statistical	B-X
analysis	B-X
for	B-X
correlation	B-X
and	B-X
agreement	B-X
were	B-X
performed	B-X
.	B-X
The	B-X
single-parameter	B-X
CyFlow	B-X
(	B-X
green	B-X
)	B-X
volumetric	B-X
technology	B-X
performed	B-X
well	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
performance	B-X
of	B-X
the	B-X
standard	B-X
SP	B-X
bead-based	B-X
FCM	B-X
system	B-X
.	B-X

Immunoassay	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
prospective	B-X
multicentre	B-X
diagnostic	B-X
study	B-X
to	B-X
evaluate	B-X
the	B-X
combined	B-X
interferon-γ	B-X
(	B-X
IFN-γ	B-X
)	B-X
and	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
release	B-X
assay	B-X
for	B-X
detect	B-X
active	B-X
pulmonary	B-X
tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
in	B-X
China	B-X
.	B-X
Our	B-X
data	B-X
showed	B-X
that	B-X
CLU	B-X
up-regulated	B-X
DNA	B-X
synthesis	B-X
and	B-X
expansion	B-X
of	B-X
NK	B-X
cells	B-X
significantly	B-X
in	B-X
response	B-X
to	B-X
a	B-X
suboptimal	B-X
,	B-X
but	B-X
not	B-X
maximal	B-X
,	B-X
dose	B-X
of	B-X
IL-2	B-X
,	B-X
and	B-X
CLU	B-X
alone	B-X
did	B-X
not	B-X
exhibit	B-X
such	B-X
effects	B-X
.	B-X
This	B-X
CLU-mediated	B-X
synergy	B-X
required	B-X
the	B-X
co-presence	B-X
of	B-X
CLU	B-X
at	B-X
the	B-X
onset	B-X
of	B-X
IL-2	B-X
stimulation	B-X
and	B-X
needed	B-X
a	B-X
continuous	B-X
presence	B-X
during	B-X
the	B-X
rest	B-X
of	B-X
the	B-X
culture	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
NK	B-X
cells	B-X
displayed	B-X
elevated	B-X
IFN-γ	B-X
production	B-X
upon	B-X
RMA/S	B-X
tumor	B-X
target	B-X
exposures	B-X
,	B-X
implying	B-X
that	B-X
CLU	B-X
regulates	B-X
not	B-X
only	B-X
NK	B-X
cell	B-X
expansion	B-X
but	B-X
also	B-X
effector	B-X
function	B-X
of	B-X
NK	B-X
cells	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
data	B-X
present	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
CLU	B-X
as	B-X
a	B-X
novel	B-X
regulator	B-X
of	B-X
NK	B-X
cells	B-X
via	B-X
providing	B-X
costimulation	B-X
required	B-X
for	B-X
cell	B-X
proliferation	B-X
and	B-X
IFN-γ	B-X
secretion	B-X
.	B-X

Concentrations	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
culture	O
supernatants	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
measured	O
in	O
duplicate	O
by	O
the	O
quantitative	O
sandwich	O
ELISA	O
using	O
cytokine	O
-	O
specific	O
capture	O
with	O
biotinylated	O
detection	O
mAb	O
and	O
recombinant	O
cytokine	O
proteins	O
(	O
all	O
from	O
Becton	O
Dickinson	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
detection	O
limits	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
were	O
15	O
pg	O
/	O
ml	O
.	O
<EOS>	B-X
Cytokines	B-X
like	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IL-6	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
IL-12p40	B-X
are	B-X
important	B-X
biomarkers	B-X
for	B-X
characterizing	B-X
the	B-X
nature	B-X
and	B-X
strength	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
optimization	B-X
and	B-X
validation	B-X
of	B-X
capture	B-X
ELISAs	B-X
for	B-X
chicken	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
IL-10	B-X
,	B-X
IL-12p40	B-X
,	B-X
and	B-X
IFN-γ	B-X
using	B-X
commercially	B-X
available	B-X
antibodies	B-X
and	B-X
reagents	B-X
.	B-X
We	B-X
then	B-X
verified	B-X
the	B-X
ELISAs	B-X
’	B-X
performance	B-X
and	B-X
established	B-X
that	B-X
the	B-X
lower	B-X
limit	B-X
of	B-X
detection	B-X
(	B-X
LLOD	B-X
)	B-X
for	B-X
all	B-X
cytokines	B-X
was	B-X
below	B-X
32	B-X
pg/mL	B-X
.	B-X
The	B-X
ELISAs	B-X
show	B-X
the	B-X
same	B-X
binding	B-X
characteristics	B-X
for	B-X
recombinant	B-X
and	B-X
native	B-X
cytokines	B-X
(	B-X
parallelism	B-X
was	B-X
<	B-X
15.2	B-X
%	B-X
CV	B-X
)	B-X
.	B-X
Values	B-X
for	B-X
inter-assay	B-X
variation	B-X
were	B-X
consistently	B-X
low	B-X
and	B-X
mostly	B-X
<	B-X
20	B-X
%	B-X
CV	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
optimized	B-X
capture	B-X
ELISAs	B-X
are	B-X
sensitive	B-X
(	B-X
<	B-X
32	B-X
pg/mL	B-X
)	B-X
and	B-X
reliable	B-X
tools	B-X
to	B-X
quantify	B-X
chicken	B-X
cytokines	B-X
.	B-X

Isolation	O
of	O
mRNA	O
and	O
real	O
-	O
time	O
PCR	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
QRT-PCR	B-X
)	B-X
has	B-X
become	B-X
an	B-X
extensively	B-X
applied	B-X
technique	B-X
.	B-X
Nowadays	B-X
,	B-X
it	B-X
is	B-X
broadly	B-X
used	B-X
to	B-X
describe	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
expression	B-X
patterns	B-X
and	B-X
to	B-X
compare	B-X
the	B-X
relative	B-X
levels	B-X
of	B-X
mRNA	B-X
within	B-X
distinct	B-X
biological	B-X
samples	B-X
.	B-X
The	B-X
scope	B-X
of	B-X
the	B-X
QRT-PCR	B-X
technique	B-X
makes	B-X
it	B-X
applicable	B-X
across	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
experimental	B-X
conditions	B-X
and	B-X
allows	B-X
experimental	B-X
comparison	B-X
between	B-X
normal	B-X
and	B-X
abnormal	B-X
tissue	B-X
.	B-X
An	B-X
inherent	B-X
advantage	B-X
of	B-X
QRT-PCR	B-X
is	B-X
the	B-X
large	B-X
dynamic	B-X
range	B-X
,	B-X
remarkable	B-X
sensitivity	B-X
,	B-X
and	B-X
sequence-specificity	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
detailed	B-X
step	B-X
by	B-X
step	B-X
guide	B-X
to	B-X
the	B-X
principles	B-X
underlying	B-X
a	B-X
successful	B-X
QRT-PCR	B-X
experiment	B-X
.	B-X

Total	O
cellular	O
RNA	O
was	O
extracted	O
from	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
RNeasy	O
Mini	O
kit	O
;	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

cDNA	O
was	O
synthesized	O
from	O
total	O
RNA	O
with	O
Molony	O
murine	O
leukemia	O
virus	O
reverse	O
transcriptase	O
(	O
US	O
Biochemical	O
,	O
Cleveland	O
,	O
OH	O
,	O
USA	O
)	O
and	O
oligo	O
-	O
(	O
dT	O
)	O
15	O
primers	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
with	O
the	O
LightCycler	O
Instrument	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
in	O
glass	O
capillaries	O
.	O

The	O
reaction	O
mix	O
containing	O
Taq	B-Protein
DNA	O
polymerase	O
and	O
DNA	O
double	O
-	O
strand	O
-	O
specific	O
SYBR	O
Green	O
I	O
dye	O
(	O
Lightcycler	O
FastStart	O
DNA	O
Master	O
SYBR	O
Green	O
I	O
;	O
Roche	O
Diagnostics	O
)	O
and	O
specific	O
primers	O
were	O
added	O
to	O
cDNA	O
dilutions	O
.	O

The	O
cDNA	O
samples	O
were	O
denatured	O
at	O
95degrees	O
C	O
for	O
10	O
min	O
,	O
and	O
were	O
then	O
amplified	O
for	O
40	O
-	O
50	O
cycles	O
:	O
at	O
95degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
65degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
72degrees	O
C	O
(	O
22	O
s	O
)	O
for	O
beta	B-Protein
-	I-Protein
actin	I-Protein
;	O
at	O
95degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
62degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
at	O
72degrees	O
C	O
(	O
10	O
s	O
)	O
for	O
SOCS1	B-Protein
;	O
and	O
at	O
96degrees	O
C	O
(	O
10	O
s	O
)	O
,	O
at	O
68degrees	O
C	O
(	O
15	O
s	O
)	O
,	O
and	O
at	O
72degrees	O
C	O
(	O
15	O
s	O
)	O
for	O
SOCS3	B-Protein
.	O

Amplification	O
curves	O
of	O
the	O
fluorescence	O
values	O
versus	O
cycle	O
number	O
were	O
obtained	O
,	O
and	O
a	O
melting	O
curve	O
analysis	O
was	O
then	O
performed	O
.	O

The	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
expression	O
were	O
determined	O
by	O
normalizing	O
relative	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
expression	O
.	O

The	O
forward	O
and	O
reverse	O
primers	O
were	O
as	O
follows	O
:	O
for	O
beta	B-Protein
-	I-Protein
actin	I-Protein
,	O
5	O
'	O
-	O
GTGGGGCGCCCCAGGCACCA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
CTCCTTAATGTCACGCACGATTTC	O
-	O
3	O
'	O
;	O
for	O
SOCS1	B-Protein
,	O
5	O
'	O
-	O
AGACCCCTTCTCACCTCTTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCACAGCAGAAAAATAAAGC	O
-	O
3	O
'	O
;	O
and	O
for	O
SOCS3	B-Protein
,	O
5	O
'	O
-	O
CCCGCCGGCACCTTTCTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
AGGGGCCGGCTCAACACC	O
-	O
3	O
'	O
.	O

Western	O
blot	O
analysis	O
<EOS>	B-X
Appropriate	B-X
protein	B-X
extraction	B-X
method	B-X
,	B-X
electrophoresis	B-X
,	B-X
and	B-X
transfer	B-X
of	B-X
proteins	B-X
,	B-X
immunodetection	B-X
of	B-X
blotted	B-X
protein	B-X
by	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
ultimate	B-X
step	B-X
of	B-X
imaging	B-X
and	B-X
analyzing	B-X
the	B-X
data	B-X
is	B-X
nothing	B-X
short	B-X
of	B-X
a	B-X
symphony	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Electrophoresis	B-X
and	B-X
the	B-X
following	B-X
western	B-X
blot	B-X
analysis	B-X
are	B-X
indispensable	B-X
to	B-X
investigate	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
exposed	B-X
to	B-X
nanoparticles	B-X
or	B-X
nanomaterials	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
select	B-X
a	B-X
good	B-X
blocking	B-X
agent	B-X
and	B-X
an	B-X
appropriate	B-X
pair	B-X
of	B-X
primary	B-X
and	B-X
peroxidase-tagged	B-X
secondary	B-X
antibodies	B-X
to	B-X
obtain	B-X
good	B-X
results	B-X
in	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
the	B-X
whole	B-X
process	B-X
of	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
from	B-X
sample	B-X
preparation	B-X
to	B-X
quantitative	B-X
measurement	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
described	B-X
.	B-X

CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
for	O
20	O
min	O
by	O
the	O
indicated	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
in	O
0	O
.	O
5	O
ml	O
culture	O
medium	O
with	O
10	O
%	O
FCS	O
.	O

To	O
examine	O
the	O
effect	O
of	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
on	O
STAT	O
phosphorylation	O
,	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
for	O
20	O
min	O
with	O
30	O
%	O
active	O
RA	O
serum	O
in	O
culture	O
medium	O
with	O
40	O
mug	O
/	O
ml	O
neutralizing	O
goat	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
polyclonal	O
antibody	O
(	O
IgG	O
;	O
Techne	O
,	O
Princeton	O
,	O
NJ	O
,	O
USA	O
)	O
or	O
control	O
goat	O
IgG	O
(	O
Techne	O
)	O
.	O

Whole	O
cell	O
lysates	O
were	O
prepared	O
by	O
placing	O
cells	O
in	O
100	O
mul	O
SDS	O
lysing	O
buffer	O
(	O
62	O
.	O
5	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
2	O
%	O
SDS	O
,	O
10	O
%	O
glycerol	O
,	O
50	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
1	O
%	O
bromphenol	O
blue	O
)	O
.	O

Then	O
20	O
mul	O
protein	O
samples	O
were	O
fractionated	O
on	O
10	O
%	O
SDS	O
-	O
polyacrylamide	O
gels	O
and	O
were	O
transferred	O
to	O
nitrocellulose	O
membranes	O
(	O
Amersham	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
,	O
and	O
the	O
membrane	O
was	O
blocked	O
with	O
5	O
%	O
skim	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
.	O

Tyrosine	O
phosphorylation	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
was	O
detected	O
using	O
commercial	O
available	O
kits	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Briefly	O
,	O
the	O
membrane	O
was	O
incubated	O
with	O
the	O
antibodies	O
(	O
rabbit	O
IgG	O
)	O
anti	O
-	O
STAT1	B-Protein
antibody	O
,	O
anti	O
-	O
phosphorylated	O
tyrosine	O
701	O
of	O
STAT1	B-Protein
antibody	O
,	O
anti	O
-	O
STAT3	B-Protein
antibody	O
,	O
and	O
anti	O
-	O
phosphorylated	O
tyrosine	O
705	O
of	O
STAT3	B-Protein
antibody	O
,	O
diluted	O
as	O
recommended	O
at	O
1	O
/	O
2000	O
with	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
with	O
5	O
%	O
BSA	O
.	O

Antibody	O
binding	O
was	O
detected	O
by	O
horseradish	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	O
IgG	O
antibody	O
diluted	O
at	O
1	O
/	O
4000	O
with	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
20	O
with	O
5	O
%	O
BSA	O
,	O
and	O
was	O
revealed	O
using	O
the	O
chemiluminescence	O
system	O
.	O

Protein	O
bands	O
were	O
quantified	O
by	O
densitometry	O
using	O
NIH	O
-	O
Image	O
analysis	O
,	O
and	O
STAT	B-Protein
phosphorylation	O
was	O
compared	O
with	O
the	O
total	O
amount	O
of	O
STAT	O
protein	O
.	O

IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
stimulated	O
Hela	O
cells	O
were	O
used	O
as	O
a	O
positive	O
control	O
for	O
STAT1	B-Protein
phosophorylation	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
value	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
or	O
box	O
plots	O
.	O
<EOS>	B-X
The	B-X
heterogeneity	B-X
of	B-X
primary	B-X
and	B-X
secondary	B-X
immunodeficiencies	B-X
demands	B-X
for	B-X
the	B-X
development	B-X
of	B-X
a	B-X
comprehensive	B-X
flow	B-X
cytometric	B-X
screening	B-X
system	B-X
,	B-X
based	B-X
on	B-X
reference	B-X
values	B-X
that	B-X
support	B-X
a	B-X
standardized	B-X
immunophenotypic	B-X
characterization	B-X
of	B-X
most	B-X
lymphocyte	B-X
subpopulations	B-X
.	B-X
Reliability	B-X
refers	B-X
to	B-X
the	B-X
reproducibility	B-X
of	B-X
values	B-X
of	B-X
a	B-X
test	B-X
,	B-X
assay	B-X
or	B-X
other	B-X
measurement	B-X
in	B-X
repeated	B-X
trials	B-X
on	B-X
the	B-X
same	B-X
individuals	B-X
.	B-X
The	B-X
main	B-X
measures	B-X
of	B-X
reliability	B-X
are	B-X
within-subject	B-X
random	B-X
variation	B-X
,	B-X
systematic	B-X
change	B-X
in	B-X
the	B-X
mean	B-X
,	B-X
and	B-X
retest	B-X
correlation	B-X
.	B-X
A	B-X
simple	B-X
,	B-X
adaptable	B-X
form	B-X
of	B-X
within-subject	B-X
variation	B-X
is	B-X
the	B-X
typical	B-X
(	B-X
standard	B-X
)	B-X
error	B-X
of	B-X
measurement	B-X
:	B-X
the	B-X
standard	B-X
deviation	B-X
of	B-X
an	B-X
individual	B-X
's	B-X
repeated	B-X
measurements	B-X
.	B-X
For	B-X
many	B-X
measurements	B-X
in	B-X
sports	B-X
medicine	B-X
and	B-X
science	B-X
,	B-X
the	B-X
typical	B-X
error	B-X
is	B-X
best	B-X
expressed	B-X
as	B-X
a	B-X
coefficient	B-X
of	B-X
variation	B-X
(	B-X
percentage	B-X
of	B-X
the	B-X
mean	B-X
)	B-X
.	B-X
Systematic	B-X
changes	B-X
in	B-X
the	B-X
mean	B-X
of	B-X
a	B-X
measure	B-X
between	B-X
consecutive	B-X
trials	B-X
represent	B-X
such	B-X
effects	B-X
as	B-X
learning	B-X
,	B-X
motivation	B-X
or	B-X
fatigue	B-X
;	B-X
these	B-X
changes	B-X
need	B-X
to	B-X
be	B-X
eliminated	B-X
from	B-X
estimates	B-X
of	B-X
within-subject	B-X
variation	B-X
.	B-X
Retest	B-X
correlation	B-X
is	B-X
difficult	B-X
to	B-X
interpret	B-X
,	B-X
mainly	B-X
because	B-X
its	B-X
value	B-X
is	B-X
sensitive	B-X
to	B-X
the	B-X
heterogeneity	B-X
of	B-X
the	B-X
sample	B-X
of	B-X
participants	B-X
.	B-X
A	B-X
wider	B-X
understanding	B-X
of	B-X
reliability	B-X
and	B-X
adoption	B-X
of	B-X
the	B-X
typical	B-X
error	B-X
as	B-X
the	B-X
standard	B-X
measure	B-X
of	B-X
reliability	B-X
would	B-X
improve	B-X
the	B-X
assessment	B-X
of	B-X
tests	B-X
and	B-X
equipment	B-X
in	B-X
our	B-X
disciplines	B-X
.	B-X

The	O
statistical	O
significance	O
of	O
differences	O
between	O
two	O
groups	O
was	O
determined	O
by	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
or	O
the	O
Wilcoxon	O
signed	O
rank	O
test	O
.	O
<EOS>	B-X
Numerical	B-X
data	B-X
that	B-X
are	B-X
normally	B-X
distributed	B-X
can	B-X
be	B-X
analyzed	B-X
with	B-X
parametric	B-X
tests	B-X
,	B-X
that	B-X
is	B-X
,	B-X
tests	B-X
which	B-X
are	B-X
based	B-X
on	B-X
the	B-X
parameters	B-X
that	B-X
define	B-X
a	B-X
normal	B-X
distribution	B-X
curve	B-X
.	B-X
If	B-X
the	B-X
distribution	B-X
is	B-X
uncertain	B-X
,	B-X
the	B-X
data	B-X
can	B-X
be	B-X
plotted	B-X
as	B-X
a	B-X
normal	B-X
probability	B-X
plot	B-X
and	B-X
visually	B-X
inspected	B-X
,	B-X
or	B-X
tested	B-X
for	B-X
normality	B-X
using	B-X
one	B-X
of	B-X
a	B-X
number	B-X
of	B-X
goodness	B-X
of	B-X
fit	B-X
tests	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Kolmogorov-Smirnov	B-X
test	B-X
.	B-X
The	B-X
widely	B-X
used	B-X
Student	B-X
's	B-X
t-test	B-X
has	B-X
three	B-X
variants	B-X
.	B-X
The	B-X
one-sample	B-X
t-test	B-X
is	B-X
used	B-X
to	B-X
assess	B-X
if	B-X
a	B-X
sample	B-X
mean	B-X
(	B-X
as	B-X
an	B-X
estimate	B-X
of	B-X
the	B-X
population	B-X
mean	B-X
)	B-X
differs	B-X
significantly	B-X
from	B-X
a	B-X
given	B-X
population	B-X
mean	B-X
.	B-X
The	B-X
means	B-X
of	B-X
two	B-X
independent	B-X
samples	B-X
may	B-X
be	B-X
compared	B-X
for	B-X
a	B-X
statistically	B-X
significant	B-X
difference	B-X
by	B-X
the	B-X
unpaired	B-X
or	B-X
independent	B-X
samples	B-X
t-test	B-X
.	B-X
If	B-X
the	B-X
data	B-X
sets	B-X
are	B-X
related	B-X
in	B-X
some	B-X
way	B-X
,	B-X
their	B-X
means	B-X
may	B-X
be	B-X
compared	B-X
by	B-X
the	B-X
paired	B-X
or	B-X
dependent	B-X
samples	B-X
t-test	B-X
.	B-X
The	B-X
t-test	B-X
should	B-X
not	B-X
be	B-X
used	B-X
to	B-X
compare	B-X
the	B-X
means	B-X
of	B-X
more	B-X
than	B-X
two	B-X
groups	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
compare	B-X
groups	B-X
in	B-X
pairs	B-X
,	B-X
when	B-X
there	B-X
are	B-X
more	B-X
than	B-X
two	B-X
groups	B-X
,	B-X
this	B-X
will	B-X
increase	B-X
the	B-X
probability	B-X
of	B-X
a	B-X
Type	B-X
I	B-X
error	B-X
.	B-X
It	B-X
is	B-X
to	B-X
be	B-X
noted	B-X
that	B-X
while	B-X
a	B-X
multiple	B-X
group	B-X
comparison	B-X
test	B-X
such	B-X
as	B-X
ANOVA	B-X
can	B-X
point	B-X
to	B-X
a	B-X
significant	B-X
difference	B-X
,	B-X
it	B-X
does	B-X
not	B-X
identify	B-X
exactly	B-X
between	B-X
which	B-X
two	B-X
groups	B-X
the	B-X
difference	B-X
lies	B-X
.	B-X
To	B-X
do	B-X
this	B-X
,	B-X
multiple	B-X
group	B-X
comparison	B-X
needs	B-X
to	B-X
be	B-X
followed	B-X
up	B-X
by	B-X
an	B-X
appropriate	B-X
post	B-X
hoc	B-X
test	B-X
.	B-X
An	B-X
example	B-X
is	B-X
the	B-X
Tukey	B-X
's	B-X
honestly	B-X
significant	B-X
difference	B-X
test	B-X
following	B-X
ANOVA	B-X
.	B-X
If	B-X
the	B-X
assumptions	B-X
for	B-X
parametric	B-X
tests	B-X
are	B-X
not	B-X
met	B-X
,	B-X
there	B-X
are	B-X
nonparametric	B-X
alternatives	B-X
for	B-X
comparing	B-X
data	B-X
sets	B-X
.	B-X
These	B-X
include	B-X
Mann-Whitney	B-X
U-test	B-X
as	B-X
the	B-X
nonparametric	B-X
counterpart	B-X
of	B-X
the	B-X
unpaired	B-X
Student	B-X
's	B-X
t-test	B-X
,	B-X
Wilcoxon	B-X
signed-rank	B-X
test	B-X
as	B-X
the	B-X
counterpart	B-X
of	B-X
the	B-X
paired	B-X
Student	B-X
's	B-X
t-test	B-X
,	B-X
Kruskal-Wallis	B-X
test	B-X
as	B-X
the	B-X
nonparametric	B-X
equivalent	B-X
of	B-X
ANOVA	B-X
and	B-X
the	B-X
Friedman	B-X
's	B-X
test	B-X
as	B-X
the	B-X
counterpart	B-X
of	B-X
repeated	B-X
measures	B-X
ANOVA	B-X
.	B-X

P	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O
<EOS>	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
side	B-X
effects	B-X
of	B-X
application	B-X
of	B-X
the	B-X
Pfizer	B-X
BioNTech	B-X
vaccine	B-X
on	B-X
the	B-X
workers	B-X
at	B-X
a	B-X
Mexican	B-X
hospital	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
considered	B-X
30	B-X
additional	B-X
serum	B-X
samples	B-X
by	B-X
SN	B-X
assay	B-X
against	B-X
the	B-X
dominant	B-X
B.1.617.2	B-X
(	B-X
Delta	B-X
)	B-X
variant	B-X
.	B-X
In	B-X
the	B-X
first	B-X
analysis	B-X
,	B-X
significant	B-X
differences	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
reference	B-X
strain	B-X
(	B-X

Resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
CD28	B-Protein
costimulatory	O
pathway	O
is	O
crucial	O
for	O
effective	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
cytokine	O
production	O
,	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
can	O
directly	O
suppress	O
this	O
response	O
by	O
inhibiting	O
CD28	B-Protein
tyrosine	O
phosphorylation	O
and	O
binding	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
[	O
24	O
]	O
.	O

To	O
evaluate	O
the	O
responsiveness	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
purified	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
three	O
patients	O
with	O
active	O
RA	O
and	O
from	O
three	O
healthy	O
controls	O
were	O
stimulated	O
by	O
immobilized	O
anti	O
-	O
CD3	B-Protein
antibody	O
and	O
anti	O
-	O
CD28	B-Protein
antibody	O
with	O
or	O
without	O
diluted	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
for	O
36	O
hours	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
measured	O
by	O
ELISA	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

1	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
activated	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
mostly	O
inhibited	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

However	O
,	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
able	O
to	O
produce	O
significant	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
the	O
maximal	O
but	O
not	O
complete	O
inhibition	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
obtained	O
at	O
10	O
-	O
100	O
ng	O
/	O
ml	O
.	O

We	O
thus	O
compared	O
the	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
CD3	B-Protein
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
patients	O
with	O
active	O
disease	O
(	O
multiple	O
inflammatory	O
joints	O
,	O
CRP	O
level	O
>	O
=	O
10	O
mg	O
/	O
l	O
)	O
and	O
inactive	O
disease	O
(	O
in	O
remission	O
,	O
CRP	O
level	O
<	O
10	O
mg	O
/	O
l	O
)	O
[	O
26	O
]	O
and	O
in	O
healthy	O
controls	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
without	O
IL	B-Protein
-	I-Protein
10	I-Protein
among	O
these	O
three	O
groups	O
(	O
Fig	O
.	O
2a	O
)	O
,	O
but	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
significantly	O
limited	O
in	O
the	O
active	O
RA	O
group	O
as	O
compared	O
with	O
the	O
inactive	O
RA	O
group	O
and	O
healthy	O
controls	O
(	O
percentage	O
decrease	O
:	O
active	O
RA	O
,	O
2	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
4	O
%	O
;	O
inactive	O
RA	O
,	O
45	O
.	O
6	O
+	O
/	O
-	O
14	O
.	O
4	O
%	O
;	O
controls	O
,	O
65	O
.	O
8	O
+	O
/	O
-	O
7	O
.	O
9	O
%	O
)	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

As	O
a	O
consequence	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
produced	O
higher	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
than	O
did	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

In	O
addition	O
,	O
we	O
compared	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
active	O
RA	O
patients	O
and	O
in	O
healthy	O
controls	O
.	O
<EOS>	B-X
A	B-X
Th1/Th2	B-X
cytokine	B-X
imbalance	B-X
with	B-X
a	B-X
predominance	B-X
of	B-X
Th1	B-X
cytokines	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
of	B-X
pathogenetic	B-X
importance	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
To	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
Th1/Th2	B-X
cytokines	B-X
in	B-X
RA	B-X
,	B-X
we	B-X
used	B-X
intracellular	B-X
cytokine	B-X
flow	B-X
cytometry	B-X
to	B-X
determine	B-X
cytokine	B-X
profiles	B-X
of	B-X
CD4+	B-X
and	B-X
CD8+	B-X
T	B-X
cells	B-X
in	B-X
34	B-X
peripheral	B-X
blood	B-X
(	B-X
PB	B-X
)	B-X
and	B-X
10	B-X
synovial	B-X
fluid	B-X
(	B-X
SF	B-X
)	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
.	B-X
Results	B-X
were	B-X
compared	B-X
with	B-X
10	B-X
PB	B-X
samples	B-X
from	B-X
healthy	B-X
controls	B-X
(	B-X
HC	B-X
)	B-X
and	B-X
5	B-X
SF	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
non-RA	B-X
synovitis	B-X
.	B-X

Similarly	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
was	O
not	O
affected	O
by	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
patients	O
(	O
percentage	O
decrease	O
,	O
-	O
2	O
.	O
1	O
+	O
/	O
-	O
13	O
.	O
8	O
%	O
)	O
,	O
while	O
it	O
was	O
significantly	O
reduced	O
in	O
healthy	O
controls	O
(	O
61	O
.	O
1	O
+	O
/	O
-	O
13	O
.	O
7	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
<EOS>	B-X
Using	B-X
quantitative	B-X
proteomics	B-X
,	B-X
we	B-X
found	B-X
that	B-X
lenalidomide	B-X
causes	B-X
selective	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
two	B-X
lymphoid	B-X
transcription	B-X
factors	B-X
,	B-X
IKZF1	B-X
and	B-X
IKZF3	B-X
,	B-X
by	B-X
the	B-X
CRBN-CRL4	B-X
ubiquitin	B-X
ligase	B-X
.	B-X
IKZF1	B-X
and	B-X
IKZF3	B-X
are	B-X
essential	B-X
transcription	B-X
factors	B-X
in	B-X
multiple	B-X
myeloma	B-X
.	B-X
A	B-X
single	B-X
amino	B-X
acid	B-X
substitution	B-X
of	B-X
IKZF3	B-X
conferred	B-X
resistance	B-X
to	B-X
lenalidomide-induced	B-X
degradation	B-X
and	B-X
rescued	B-X
lenalidomide-induced	B-X
inhibition	B-X
of	B-X
cell	B-X
growth	B-X
.	B-X
Similarly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
lenalidomide-induced	B-X
interleukin-2	B-X
production	B-X
in	B-X
T	B-X
cells	B-X
is	B-X
due	B-X
to	B-X
depletion	B-X
of	B-X
IKZF1	B-X
and	B-X
IKZF3	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
previously	B-X
unknown	B-X
mechanism	B-X
of	B-X
action	B-X
for	B-X
a	B-X
therapeutic	B-X
agent	B-X
:	B-X
alteration	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
an	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
leading	B-X
to	B-X
selective	B-X
degradation	B-X
of	B-X
specific	B-X
targets	B-X
.	B-X

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
less	O
susceptible	O
to	O
the	O
immunoregulatory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
during	O
the	O
active	O
phase	O
.	O

Increased	O
expression	O
of	O
cell	O
surface	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
on	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
functional	O
receptor	O
complex	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
consists	O
of	O
two	O
subunits	O
,	O
the	O
primary	O
ligand	O
-	O
binding	O
component	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
and	O
the	O
accessory	O
component	O
type	B-Protein
2	I-Protein
IL	I-Protein
-	I-Protein
10R	I-Protein
[	O
1	O
]	O
.	O

IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
plays	O
a	O
critical	O
role	O
in	O
cellular	O
responses	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
29	O
]	O
.	O

To	O
examine	O
whether	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
due	O
to	O
limited	O
receptor	O
expression	O
,	O
the	O
cell	O
surface	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
on	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
was	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

3a	O
,	O
3b	O
,	O
the	O
intensity	O
of	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
on	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
significantly	O
increased	O
in	O
RA	O
patients	O
compared	O
with	O
in	O
healthy	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
the	O
intracellular	O
signal	O
transduction	O
pathway	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
impaired	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
of	O
active	O
RA	O
.	O

Defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
phosphorylation	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

The	O
interaction	O
of	O
IL	B-Protein
-	I-Protein
10R	I-Protein
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
the	O
latent	O
transcription	O
factors	O
STAT1	B-Protein
and	O
STAT3	B-Protein
[	O
3	O
]	O
.	O

Macrophage	O
-	O
specific	O
STAT3	B-Protein
-	O
deficient	O
mice	O
demonstrated	O
that	O
STAT3	B-Protein
plays	O
a	O
dominant	O
role	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
responses	O
[	O
5	O
]	O
,	O
which	O
has	O
recently	O
been	O
confirmed	O
in	O
human	O
macrophages	O
by	O
studies	O
of	O
dominant	O
-	O
negative	O
STAT3	B-Protein
overexpression	O
[	O
30	O
]	O
.	O

The	O
induction	O
of	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
was	O
examined	O
using	O
western	O
blotting	O
.	O

STAT3	B-Protein
phosphorylation	O
was	O
dose	O
-	O
dependently	O
induced	O
after	O
IL	B-Protein
-	I-Protein
10	I-Protein
activation	O
for	O
20	O
min	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4a	O
,	O
4b	O
)	O
.	O

In	O
contrast	O
,	O
STAT3	B-Protein
was	O
phosphorylated	O
in	O
freshly	O
isolated	O
PB	O
CD4	B-Protein
+	O
cells	O
from	O
RA	O
patients	O
and	O
this	O
STAT3	B-Protein
phosphorylation	O
was	O
detectable	O
for	O
up	O
to	O
6	O
hours	O
.	O

STAT3	B-Protein
phosphorylation	O
was	O
augmented	O
only	O
when	O
activated	O
by	O
as	O
much	O
as	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Both	O
sustained	O
STAT3	B-Protein
phosphorylation	O
and	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
phosphorylation	O
were	O
found	O
in	O
RA	O
ST	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4c	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT1	B-Protein
phosphorylation	O
was	O
not	O
detected	O
in	O
either	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
or	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
4a	O
)	O
.	O

These	O
results	O
indicate	O
that	O
STAT3	B-Protein
is	O
the	O
major	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
activated	O
STAT	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
may	O
be	O
diminished	O
in	O
active	O
RA	O
,	O
in	O
association	O
with	O
sustained	O
STAT3	B-Protein
phosphorylation	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
-	O
mediated	O
STAT3	B-Protein
phosphorylation	O
and	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
effect	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
dihydroartemisinin	B-X
(	B-X
DHA	B-X
)	B-X
is	B-X
effective	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
malaria	B-X
.	B-X

STAT3	B-Protein
is	O
activated	O
by	O
many	O
cytokines	O
and	O
growth	O
factors	O
such	O
as	O
the	O
IL	O
-	O
6	O
family	O
of	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
11	I-Protein
,	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
,	O
and	O
oncostatin	B-Protein
M	I-Protein
)	O
,	O
platelet	B-Protein
-	I-Protein
derived	I-Protein
growth	I-Protein
factor	I-Protein
,	O
and	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
,	O
in	O
addition	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
4	O
]	O
,	O
but	O
previous	O
studies	O
have	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
major	O
factor	O
in	O
RA	O
synovial	O
fluid	O
that	O
induces	O
constitutive	O
activation	O
of	O
STAT3	B-Protein
in	O
mononuclear	O
cells	O
[	O
31	O
]	O
.	O

Since	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
also	O
abundant	O
in	O
sera	O
of	O
active	O
RA	O
patients	O
,	O
frequently	O
detected	O
at	O
>	O
1	O
ng	O
/	O
ml	O
[	O
27	O
]	O
,	O
we	O
examined	O
whether	O
persistent	O
exposure	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
blood	O
circulation	O
was	O
responsible	O
for	O
their	O
sustained	O
STAT3	B-Protein
activation	O
and	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
in	O
active	O
RA	O
.	O

Both	O
STAT1	B-Protein
and	O
STAT3	B-Protein
phosphorylation	O
was	O
activated	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
observations	O
[	O
4	O
]	O
.	O

Normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
thus	O
incubated	O
for	O
20	O
min	O
with	O
culture	O
medium	O
containing	O
30	O
%	O
serum	O
from	O
active	O
RA	O
patients	O
and	O
neutralizing	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
antibody	O
or	O
control	O
antibody	O
,	O
and	O
STAT	O
phosphorylation	O
was	O
examined	O
by	O
western	O
blot	O
analysis	O
.	O
<EOS>	B-X
Cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSCs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
various	B-X
stages	B-X
of	B-X
cancer	B-X
development	B-X
and	B-X
therapy	B-X
refractoriness	B-X
.	B-X
8-Hydroxydaidzein	B-X
(	B-X
8-OHD	B-X
)	B-X
has	B-X
revealed	B-X
anti-cancer	B-X
activity	B-X
in	B-X
different	B-X
tumors	B-X
.	B-X
Accordingly	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
effects	B-X
of	B-X
8-OHD	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
breast	B-X
cancer	B-X
stem-like	B-X
cells	B-X
(	B-X
BCSCs	B-X
)	B-X
.	B-X
CD44H	B-X
is	B-X
a	B-X
transmembrane	B-X
molecule	B-X
important	B-X
for	B-X
cell-cell	B-X
and	B-X
cell-extracellular	B-X
matrix	B-X
interactions	B-X
.	B-X
In	B-X
monocytes	B-X
,	B-X
CD44H	B-X
is	B-X
implicated	B-X
in	B-X
phagocytosis	B-X
of	B-X
particles	B-X
coated	B-X
by	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
.	B-X
Tumour	B-X
derived	B-X
microvesicles	B-X
(	B-X
TMVs	B-X
)	B-X
,	B-X
which	B-X
are	B-X
small	B-X
membrane	B-X
fragments	B-X
derived	B-X
from	B-X
tumour	B-X
cells	B-X
can	B-X
carry	B-X
fragments	B-X
of	B-X
HA	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
whether	B-X
monocyte	B-X
's	B-X
CD44H	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
engulfment	B-X
of	B-X
pancreatic	B-X
adenocarcinoma-derived	B-X
microvesicles	B-X
and	B-X
in	B-X
the	B-X
production	B-X
of	B-X
chemokines	B-X
induced	B-X
by	B-X
TMVs	B-X
.	B-X

RA	O
serum	O
was	O
able	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-Protein
but	O
not	O
STAT1	B-Protein
,	O
and	O
this	O
STAT3	B-Protein
activation	O
was	O
mostly	O
abolished	O
by	O
neutralization	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
activity	O
(	O
Fig	O
.	O
5a	O
)	O
.	O

These	O
results	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
dominant	O
STAT3	B-Protein
-	O
activating	O
factor	O
contained	O
in	O
sera	O
of	O
active	O
RA	O
patients	O
.	O

The	O
lack	O
of	O
STAT1	B-Protein
activation	O
by	O
RA	O
serum	O
suggests	O
that	O
much	O
higher	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
may	O
be	O
required	O
for	O
STAT1	B-Protein
activation	O
as	O
compared	O
with	O
STAT3	B-Protein
activation	O
,	O
or	O
that	O
inhibitors	O
of	O
STAT1	B-Protein
signaling	O
may	O
be	O
present	O
in	O
RA	O
serum	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
whether	B-X
the	B-X
anti-Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
effect	B-X
of	B-X
curcumin	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
regulation	B-X
of	B-X
B	B-X
cell-activating	B-X
factor	B-X
belonging	B-X
to	B-X
the	B-X
TNF	B-X
family	B-X
(	B-X
BAFF	B-X
)	B-X
production	B-X
.	B-X

We	O
next	O
examined	O
whether	O
IL	B-Protein
-	I-Protein
6	I-Protein
could	O
suppress	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
to	O
inhibit	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

After	O
preincubation	O
with	O
or	O
without	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
for	O
36	O
hours	O
,	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
stimulated	O
by	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
10	I-Protein
for	O
36	O
hours	O
,	O
and	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
was	O
measured	O
by	O
ELISA	O
.	O
<EOS>	B-X
Preincubation	B-X
of	B-X
the	B-X
group	B-X
I	B-X
intron	B-X
Ca.LSU	B-X
from	B-X
Candida	B-X
albicans	B-X
at	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
divalent	B-X
cations	B-X
results	B-X
in	B-X
partial	B-X
folding	B-X
of	B-X
this	B-X
intron	B-X
.	B-X
This	B-X
is	B-X
indicated	B-X
by	B-X
increased	B-X
resistance	B-X
to	B-X
T1	B-X
ribonuclease	B-X
cleavage	B-X
of	B-X
many	B-X
G	B-X
residues	B-X
in	B-X
most	B-X
local	B-X
helices	B-X
,	B-X
including	B-X
P4-P6	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
non-local	B-X
helix	B-X
P7	B-X
,	B-X
where	B-X
the	B-X
G	B-X
binding	B-X
site	B-X
is	B-X
located	B-X
.	B-X
These	B-X
changes	B-X
correlate	B-X
with	B-X
increased	B-X
gel	B-X
mobility	B-X
and	B-X
activation	B-X
of	B-X
catalysis	B-X
by	B-X
precursor	B-X
RNA	B-X
containing	B-X
this	B-X
intron	B-X
after	B-X
preincubation	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
divalent	B-X
cations	B-X
or	B-X
spermidine	B-X
during	B-X
preincubation	B-X
results	B-X
in	B-X
formation	B-X
of	B-X
the	B-X
predicted	B-X
helices	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
protection	B-X
of	B-X
additional	B-X
G	B-X
residues	B-X
.	B-X
However	B-X
,	B-X
addition	B-X
of	B-X
these	B-X
cations	B-X
during	B-X
preincubation	B-X
of	B-X
the	B-X
precursor	B-X
RNA	B-X
alters	B-X
its	B-X
gel	B-X
mobility	B-X
and	B-X
eliminates	B-X
the	B-X
preincubation	B-X
activation	B-X
of	B-X
precursor	B-X
RNA	B-X
seen	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cations	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
divalent	B-X
cations	B-X
or	B-X
spermidine	B-X
,	B-X
Ca.LSU	B-X
folds	B-X
into	B-X
a	B-X
more	B-X
ordered	B-X
,	B-X
stable	B-X
but	B-X
misfolded	B-X
conformation	B-X
that	B-X
is	B-X
less	B-X
able	B-X
to	B-X
convert	B-X
into	B-X
the	B-X
catalytically	B-X
active	B-X
form	B-X
than	B-X
the	B-X
ribozyme	B-X
preincubated	B-X
without	B-X
cations	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
,	B-X
like	B-X
the	B-X
group	B-X
I	B-X
intron	B-X
of	B-X
Tetrahymena	B-X
,	B-X
multiple	B-X
folding	B-X
pathways	B-X
exist	B-X
for	B-X
Ca.LSU	B-X
.	B-X
However	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
role	B-X
cations	B-X
play	B-X
in	B-X
the	B-X
multiple	B-X
folding	B-X
pathways	B-X
leading	B-X
to	B-X
the	B-X
catalytically	B-X
active	B-X
form	B-X
may	B-X
differ	B-X
between	B-X
folding	B-X
of	B-X
these	B-X
two	B-X
group	B-X
I	B-X
introns	B-X
.	B-X

IL	B-Protein
-	I-Protein
6	I-Protein
pretreatment	O
of	O
normal	O
cells	O
reduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
(	O
Fig	O
.	O
5b	O
)	O
,	O
indicating	O
that	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
could	O
modulate	O
T	O
-	O
cell	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
persistent	O
exposure	O
to	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
may	O
have	O
a	O
role	O
in	O
both	O
the	O
induction	O
of	O
STAT3	B-Protein
activation	O
and	O
the	O
resistance	O
to	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

High	O
expression	O
of	O
SOCS1	B-Protein
mRNA	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O

IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
two	O
potent	O
inhibitors	O
of	O
JAKs	O
(	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
proteins	O
)	O
that	O
not	O
only	O
act	O
as	O
mediators	O
of	O
negative	O
feedback	O
inhibition	O
,	O
but	O
also	O
play	O
a	O
major	O
role	O
in	O
crosstalk	O
inhibition	O
by	O
opposing	O
other	O
cytokine	O
-	O
signaling	O
pathways	O
[	O
7	O
]	O
.	O

SOCS3	B-Protein
has	O
recently	O
been	O
shown	O
to	O
specifically	O
inhibit	O
STAT3	B-Protein
activation	O
induced	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
thereby	O
regulating	O
the	O
divergent	O
action	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
8	O
,	O
9	O
]	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
show	B-X
that	B-X
LPS	B-X
and	B-X
TNFalpha	B-X
are	B-X
potent	B-X
inhibitors	B-X
of	B-X
IL-6-mediated	B-X
STAT3	B-X
activation	B-X
in	B-X
human	B-X
monocyte	B-X
derived	B-X
macrophages	B-X
,	B-X
rat	B-X
liver	B-X
macrophages	B-X
and	B-X
RAW	B-X
264.7	B-X
mouse	B-X
macrophages	B-X
but	B-X
not	B-X
in	B-X
human	B-X
hepatoma	B-X
cells	B-X
(	B-X
HepG2	B-X
)	B-X
or	B-X
in	B-X
rat	B-X
hepatocytes	B-X
.	B-X
Accordingly	B-X
,	B-X
LPS	B-X
and	B-X
TNFalpha	B-X
were	B-X
found	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
SOCS3	B-X
mRNA	B-X
in	B-X
each	B-X
of	B-X
the	B-X
investigated	B-X
type	B-X
of	B-X
macrophages	B-X
but	B-X
not	B-X
in	B-X
HepG2	B-X
cells	B-X
.	B-X
Using	B-X
a	B-X
specific	B-X
inhibitor	B-X
,	B-X
evidence	B-X
is	B-X
presented	B-X
that	B-X
the	B-X
p38	B-X
MAP	B-X
kinase	B-X
might	B-X
be	B-X
involved	B-X
,	B-X
especially	B-X
for	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
TNFalpha	B-X
.	B-X
IL	B-X
(	B-X
interleukin	B-X
)	B-X
-6	B-X
exerts	B-X
pro-	B-X
as	B-X
well	B-X
as	B-X
anti-inflammatory	B-X
activities	B-X
.	B-X
Beside	B-X
many	B-X
other	B-X
activities	B-X
,	B-X
IL-6	B-X
is	B-X
the	B-X
major	B-X
inducer	B-X
of	B-X
acute	B-X
phase	B-X
proteins	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
differentiation	B-X
factor	B-X
for	B-X
blood	B-X
cells	B-X
,	B-X
as	B-X
migration	B-X
factor	B-X
for	B-X
T-cells	B-X
and	B-X
is	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
the	B-X
chemokine	B-X
MCP-1	B-X
(	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
)	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
IL-6	B-X
signal	B-X
transduction	B-X
through	B-X
the	B-X
IL-6-induced	B-X
feedback	B-X
inhibitors	B-X
SOCS	B-X
(	B-X
suppressor	B-X
of	B-X
cytokine	B-X
signalling	B-X
)	B-X
1	B-X
and	B-X
SOCS3	B-X
or	B-X
the	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
SHP-2	B-X
(	B-X
Src	B-X
homology	B-X
2	B-X
domain-containing	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
2	B-X
)	B-X
and	B-X
TcPTP	B-X
(	B-X
T-cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
)	B-X
.	B-X
Studies	B-X
on	B-X
the	B-X
cross-talk	B-X
between	B-X
pro-inflammatory	B-X
mediators	B-X
(	B-X
IL-1	B-X
,	B-X
tumour	B-X
necrosis	B-X
factor	B-X
,	B-X
lipopolysaccharide	B-X
)	B-X
and	B-X
IL-6	B-X
elucidated	B-X
further	B-X
regulatory	B-X
mechanisms	B-X
.	B-X
Less	B-X
is	B-X
known	B-X
about	B-X
the	B-X
regulation	B-X
of	B-X
IL-6	B-X
signal	B-X
transduction	B-X
by	B-X
hormone/cytokine	B-X
signalling	B-X
through	B-X
G-protein-coupled	B-X
receptors	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
the	B-X
inhibitory	B-X
activity	B-X
of	B-X
PGE	B-X
(	B-X
1	B-X
)	B-X
(	B-X
prostaglandin	B-X
E	B-X
(	B-X
1	B-X
)	B-X
)	B-X
on	B-X
IL-6-induced	B-X
MCP-1	B-X
expression	B-X
and	B-X
have	B-X
elucidated	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanism	B-X
.	B-X
Surprisingly	B-X
,	B-X
PGE	B-X
(	B-X
1	B-X
)	B-X
does	B-X
not	B-X
affect	B-X
IL-6-induced	B-X
STAT	B-X
(	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
)	B-X
3	B-X
activation	B-X
,	B-X
but	B-X
does	B-X
affect	B-X
ERK	B-X
(	B-X
extracellular-signal-regulated	B-X
kinase	B-X
)	B-X
1/2	B-X
activation	B-X
which	B-X
is	B-X
crucial	B-X
for	B-X
IL-6-dependent	B-X
expression	B-X
of	B-X
MCP-1	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
discovered	B-X
a	B-X
specific	B-X
cross-talk	B-X
between	B-X
the	B-X
adenylate	B-X
cyclase	B-X
cascade	B-X
and	B-X
the	B-X
IL-6-induced	B-X
MAPK	B-X
(	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
)	B-X
cascade	B-X
and	B-X
have	B-X
investigated	B-X
its	B-X
impact	B-X
on	B-X
IL-6-dependent	B-X
gene	B-X
expression	B-X
.	B-X

On	O
the	O
contrary	O
,	O
SOCS1	B-Protein
is	O
able	O
to	O
partially	O
inhibit	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
and	O
cellular	O
responses	O
,	O
as	O
well	O
as	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
STAT1	B-Protein
activation	O
[	O
32	O
]	O
.	O

To	O
determine	O
whether	O
SOCSs	O
were	O
involved	O
in	O
the	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
the	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
expression	O
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
and	O
from	O
healthy	O
controls	O
were	O
compared	O
by	O
semiquantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
contained	O
higher	O
levels	O
of	O
SOCS1	B-Protein
but	O
lower	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
than	O
did	O
control	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
6a	O
)	O
.	O

Constitutive	O
expression	O
of	O
SOCS1	B-Protein
mRNA	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
comparable	O
with	O
the	O
expression	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
stimulated	O
by	O
10	O
ng	O
/	O
ml	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
Fig	O
.	O
6b	O
)	O
,	O
supporting	O
its	O
functional	O
significance	O
.	O

Defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
activation	O
therefore	O
appears	O
to	O
be	O
due	O
at	O
least	O
in	O
part	O
to	O
an	O
abundance	O
of	O
SOCS1	B-Protein
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
orchestrate	O
the	O
Th1	O
-	O
type	O
cell	O
-	O
mediated	O
immune	O
response	O
in	O
RA	O
[	O
22	O
]	O
.	O

Activated	O
CD4	B-Protein
+	O
T	O
cells	O
stimulate	O
macrophages	O
,	O
synovial	O
fibroblasts	O
,	O
B	O
cells	O
,	O
and	O
osteoclasts	O
through	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
and	O
Th1	O
cytokines	O
,	O
thereby	O
contributing	O
to	O
both	O
the	O
chronic	O
inflammation	O
and	O
the	O
joint	O
destruction	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
require	O
two	O
signals	O
to	O
be	O
activated	O
;	O
antigen	O
receptor	O
occupancy	O
and	O
CD28	B-Protein
-	O
mediated	O
costimulation	O
.	O
<EOS>	B-X
Activated	B-X
CD4	B-X
T	B-X
cells	B-X
proliferate	B-X
rapidly	B-X
and	B-X
remodel	B-X
epigenetically	B-X
before	B-X
exiting	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
engaging	B-X
acquired	B-X
effector	B-X
functions	B-X
.	B-X
Metabolic	B-X
reprogramming	B-X
from	B-X
the	B-X
naive	B-X
state	B-X
is	B-X
required	B-X
throughout	B-X
these	B-X
phases	B-X
of	B-X
activation	B-X
While	B-X
stimulator	B-X
of	B-X
interferon	B-X
genes	B-X
(	B-X
STING	B-X
)	B-X
activation	B-X
in	B-X
innate	B-X
immune	B-X
cells	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
can	B-X
result	B-X
in	B-X
CD8	B-X
T	B-X
cell-dependent	B-X
antitumor	B-X
immunity	B-X
,	B-X
whether	B-X
STING	B-X
signaling	B-X
affects	B-X
CD4	B-X
T-cell	B-X
responses	B-X
remains	B-X
elusive	B-X
.	B-X
Tumor	B-X
progression	B-X
is	B-X
facilitated	B-X
by	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
and	B-X
restricted	B-X
by	B-X
effector	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
document	B-X
parallel	B-X
regulation	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
by	B-X
programmed	B-X
death-1	B-X
(	B-X
PD-1	B-X
,	B-X
PDCD1	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
identify	B-X
an	B-X
additional	B-X
role	B-X
of	B-X
CTL	B-X
antigen-4	B-X
(	B-X
CTLA-4	B-X
)	B-X
inhibitory	B-X
receptor	B-X
in	B-X
further	B-X
promoting	B-X
dysfunction	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
effector	B-X
cells	B-X
in	B-X
tumor	B-X
models	B-X
(	B-X
CT26	B-X
colon	B-X
carcinoma	B-X
and	B-X
ID8-VEGF	B-X
ovarian	B-X
carcinoma	B-X
)	B-X
.	B-X
Blockade	B-X
of	B-X
both	B-X
PD-1	B-X
and	B-X
CTLA-4	B-X
resulted	B-X
in	B-X
reversal	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
TIL	B-X
dysfunction	B-X
and	B-X
led	B-X
to	B-X
tumor	B-X
rejection	B-X
in	B-X
two	B-X
thirds	B-X
of	B-X
mice	B-X
.	B-X
Double	B-X
blockade	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
proliferation	B-X
of	B-X
antigen-specific	B-X
effector	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
antigen-specific	B-X
cytokine	B-X
release	B-X
,	B-X
inhibition	B-X
of	B-X
suppressive	B-X
functions	B-X
of	B-X
Tregs	B-X
,	B-X
and	B-X
upregulation	B-X
of	B-X
key	B-X
signaling	B-X
molecules	B-X
critical	B-X
for	B-X
T-cell	B-X
function	B-X
.	B-X
When	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
GVAX	B-X
vaccination	B-X
(	B-X
consisting	B-X
of	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor-expressing	B-X
irradiated	B-X
tumor	B-X
cells	B-X
)	B-X
,	B-X
inhibitory	B-X
pathway	B-X
blockade	B-X
induced	B-X
rejection	B-X
of	B-X
CT26	B-X
tumors	B-X
in	B-X
100	B-X
%	B-X
of	B-X
mice	B-X
and	B-X
ID8-VEGF	B-X
tumors	B-X
in	B-X
75	B-X
%	B-X
of	B-X
mice	B-X
.	B-X
Our	B-X
study	B-X
indicates	B-X
that	B-X
PD-1	B-X
signaling	B-X
in	B-X
tumors	B-X
is	B-X
required	B-X
for	B-X
both	B-X
suppressing	B-X
effector	B-X
T	B-X
cells	B-X
and	B-X
maintaining	B-X
tumor	B-X
Tregs	B-X
,	B-X
and	B-X
that	B-X
PD-1/PD-L1	B-X
pathway	B-X
(	B-X
CD274	B-X
)	B-X
blockade	B-X
augments	B-X
tumor	B-X
inhibition	B-X
by	B-X
increasing	B-X
effector	B-X
T-cell	B-X
activity	B-X
,	B-X
thereby	B-X
attenuating	B-X
Treg	B-X
suppression	B-X
.	B-X

In	O
the	O
ST	O
lesion	O
,	O
the	O
CD28	B-Protein
ligands	O
,	O
both	O
CD80	B-Protein
and	O
CD86	B-Protein
,	O
together	O
with	O
MHC	O
class	O
II	O
antigens	O
,	O
are	O
substantially	O
expressed	O
by	O
antigen	O
-	O
presenting	O
cells	O
such	O
as	O
macrophages	O
and	O
dendritic	O
cells	O
[	O
18	O
-	O
20	O
]	O
.	O

The	O
significance	O
of	O
CD28	B-Protein
engagement	O
in	O
the	O
T	O
-	O
cell	O
-	O
mediated	O
disease	O
process	O
has	O
recently	O
been	O
proven	O
by	O
the	O
clinical	O
efficacy	O
of	O
its	O
blocker	O
cytotoxic	B-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
associated	I-Protein
antigen	I-Protein
4	I-Protein
(	I-Protein
CD152	I-Protein
)	I-Protein
-	I-Protein
IgG	I-Protein
in	O
RA	O
patients	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
plays	O
a	O
predominant	O
role	O
in	O
limiting	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
function	O
of	O
both	O
macrophages	O
and	O
Th1	O
cells	O
[	O
1	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibits	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
CD28	B-Protein
molecule	O
and	O
the	O
subsequent	O
phosphatidylinositol	O
3	O
-	O
kinase	O
binding	O
in	O
T	O
cells	O
,	O
and	O
thereby	O
directly	O
acts	O
on	O
T	O
cells	O
[	O
24	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
RA	O
,	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
are	O
able	O
to	O
produce	O
higher	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
CD3	O
and	O
CD28	B-Protein
costimulation	O
than	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

Despite	O
high	O
-	O
level	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
and	O
constitutive	O
STAT3	B-Protein
activation	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-Protein
is	O
suppressed	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
in	O
contrast	O
to	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
where	O
STAT3	B-Protein
phosphorylation	O
is	O
dose	O
-	O
dependently	O
inducible	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
from	O
RA	O
patients	O
induces	O
STAT3	B-Protein
but	O
not	O
STAT1	B-Protein
phosphorylation	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
and	O
exogenous	O
IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
differences	B-X
in	B-X
the	B-X
strength	B-X
of	B-X
inhibition	B-X
of	B-X
IL-6/STAT3	B-X
signalling	B-X
induced	B-X
by	B-X
subcutaneously	B-X
(	B-X
sc	B-X
)	B-X
administered	B-X
tocilizumab	B-X
(	B-X
TCZ	B-X
)	B-X
and	B-X
sarilumab	B-X
(	B-X
SAR	B-X
)	B-X
.	B-X
IL-19	B-X
is	B-X
a	B-X
novel	B-X
cytokine	B-X
of	B-X
the	B-X
IL-10	B-X
family	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
examine	B-X
whether	B-X
IL-19	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
RA	B-X
.	B-X
A	B-X
previously	B-X
identified	B-X
signal	B-X
transduction	B-X
and	B-X
activator	B-X
of	B-X
transcription-3	B-X
(	B-X
STAT3	B-X
)	B-X
target-enriched	B-X
gene	B-X
signature	B-X
in	B-X
circulating	B-X
CD4+	B-X
T	B-X
cells	B-X
of	B-X
patients	B-X
with	B-X
early	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
was	B-X
prominent	B-X
in	B-X
autoantibody-negative	B-X
individuals	B-X
.	B-X
Here	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6-mediated	B-X
STAT	B-X
signalling	B-X
was	B-X
investigated	B-X
in	B-X
circulating	B-X
lymphocytes	B-X
of	B-X
an	B-X
independent	B-X
early	B-X
arthritis	B-X
patient	B-X
cohort	B-X
,	B-X
seeking	B-X
further	B-X
insight	B-X
into	B-X
RA	B-X
pathogenesis	B-X
and	B-X
biomarkers	B-X
of	B-X
potential	B-X
clinical	B-X
utility	B-X
.	B-X

RA	O
CD4	B-Protein
+	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
SOCS1	B-Protein
but	O
contain	O
lower	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
in	O
comparison	O
with	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
become	O
resistant	O
to	O
the	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
before	O
migration	O
into	O
the	O
inflamed	O
ST	O
,	O
and	O
suggest	O
that	O
this	O
resistance	O
may	O
be	O
attributable	O
to	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
,	O
in	O
association	O
with	O
sustained	O
STAT3	B-Protein
phosphorylation	O
and	O
SOCS1	B-Protein
induction	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
inhibition	O
of	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
cytokine	O
production	O
is	O
principally	O
dependent	O
on	O
its	O
inhibition	O
of	O
macrophage	O
antigen	O
-	O
presenting	O
cell	O
function	O
[	O
1	O
]	O
.	O

However	O
,	O
this	O
indirect	O
inhibitory	O
effect	O
is	O
thought	O
to	O
be	O
restricted	O
at	O
the	O
site	O
of	O
T	O
-	O
cell	O
activation	O
in	O
RA	O
,	O
because	O
macrophages	O
in	O
the	O
ST	O
express	O
high	O
levels	O
of	O
cytokines	O
,	O
CD80	B-Protein
and	O
CD86	B-Protein
molecules	O
,	O
and	O
MHC	O
class	O
II	O
antigens	O
[	O
10	O
,	O
18	O
-	O
20	O
]	O
.	O

More	O
recently	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
has	O
been	O
shown	O
to	O
induce	O
the	O
antigen	O
-	O
specific	O
T	O
-	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
CD28	B-Protein
tyrosine	O
phosphorylation	O
[	O
33	O
]	O
.	O

This	O
direct	O
effect	O
also	O
may	O
be	O
limited	O
in	O
active	O
RA	O
patients	O
,	O
because	O
their	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
showed	O
a	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
CD28	B-Protein
-	O
costimulated	O
production	O
of	O
both	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Numerous	O
cytokines	O
,	O
both	O
proinflammatory	O
and	O
anti	O
-	O
inflammatory	O
,	O
have	O
been	O
detected	O
in	O
the	O
ST	O
of	O
RA	O
,	O
and	O
the	O
balance	O
between	O
these	O
opposing	O
cytokine	O
activities	O
regulates	O
disease	O
severity	O
[	O
10	O
]	O
.	O

Endogenous	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
produced	O
mainly	O
by	O
macrophages	O
and	O
T	O
cells	O
,	O
inhibits	O
proinflammatory	O
cytokine	O
production	O
by	O
ST	O
cells	O
[	O
12	O
]	O
.	O

However	O
,	O
this	O
regulatory	O
activity	O
seems	O
to	O
be	O
restricted	O
during	O
chronic	O
inflammation	O
.	O
<EOS>	B-X
Autoimmune	B-X
aspects	B-X
in	B-X
T2DM	B-X
are	B-X
not	B-X
solely	B-X
restricted	B-X
to	B-X
autoantibodies	B-X
and	B-X
thus	B-X
LADA	B-X
.	B-X
They	B-X
include	B-X
the	B-X
self-reactive	B-X
T	B-X
cells	B-X
or	B-X
defects	B-X
in	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
,	B-X
which	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
autoantibody-negative	B-X
T2DM	B-X
patients	B-X
as	B-X
well	B-X
.	B-X
One	B-X
contributor	B-X
to	B-X
the	B-X
autoimmune	B-X
activation	B-X
in	B-X
T2DM	B-X
seems	B-X
to	B-X
be	B-X
the	B-X
chronic	B-X
inflammatory	B-X
state	B-X
,	B-X
characteristic	B-X
of	B-X
this	B-X
disease	B-X
.	B-X
Upon	B-X
inflammation-induced	B-X
tissue	B-X
destruction	B-X
,	B-X
cryptic	B-X
'self	B-X
'	B-X
antigens	B-X
can	B-X
trigger	B-X
an	B-X
autoimmune	B-X
response	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
accelerates	B-X
β-cell	B-X
death	B-X
.	B-X
However	B-X
,	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
inflammation	B-X
overlaps	B-X
with	B-X
autoimmunity	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Our	B-X
review	B-X
focuses	B-X
on	B-X
autoimmune	B-X
involvement	B-X
in	B-X
T2DM	B-X
,	B-X
with	B-X
an	B-X
emphasis	B-X
on	B-X
LADA	B-X
and	B-X
the	B-X
humoral	B-X
immune	B-X
response	B-X
,	B-X
on	B-X
the	B-X
involvement	B-X
of	B-X
chronic	B-X
inflammation	B-X
in	B-X
autoimmunity	B-X
,	B-X
and	B-X
specifically	B-X
the	B-X
role	B-X
of	B-X
B	B-X
and	B-X
T	B-X
cells	B-X
as	B-X
links	B-X
between	B-X
inflammatory	B-X
and	B-X
autoimmune	B-X
reactions	B-X
.	B-X

The	O
activation	O
of	O
both	O
the	O
extracellular	O
stimulus	O
-	O
regulated	O
kinase	O
and	O
p38	O
kinase	O
pathways	O
,	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
inhibits	O
the	O
Jak1	B-Protein
-	O
STAT3	B-Protein
signaling	O
pathway	O
shared	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
adhered	O
macrophages	O
[	O
13	O
]	O
.	O

More	O
importantly	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
is	O
mostly	O
undetectable	O
in	O
RA	O
synovial	O
macrophages	O
.	O

This	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
is	O
probably	O
induced	O
by	O
chronic	O
exposure	O
to	O
immune	O
complexes	O
in	O
vivo	O
,	O
because	O
both	O
cell	O
surface	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
Jak1	B-Protein
activation	O
are	O
suppressed	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
primed	O
macrophages	O
by	O
a	O
protein	O
kinase	O
C	O
-	O
dependent	O
pathway	O
following	O
ligation	O
of	O
the	O
IgG	O
Fc	O
gamma	O
receptor	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
dendritic	O
cells	O
from	O
RA	O
synovial	O
fluids	O
are	O
resistant	O
to	O
the	O
immunoregulatory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
due	O
to	O
decreased	O
transport	O
of	O
intracellular	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
in	O
the	O
presence	O
of	O
proinflammatory	O
cytokine	O
stimuli	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
[	O
15	O
]	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
resistance	O
of	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
associated	O
with	O
defective	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
,	O
but	O
not	O
with	O
IL	B-Protein
-	I-Protein
10R1	I-Protein
expression	O
.	O

Inhibitory	O
effects	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
these	O
inflammatory	O
cell	O
types	O
are	O
therefore	O
differentially	O
modulated	O
at	O
the	O
signal	O
transduction	O
level	O
under	O
the	O
inflammatory	O
environment	O
in	O
RA	O
.	O

In	O
association	O
with	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
,	O
STAT3	B-Protein
was	O
found	O
to	O
be	O
tyrosine	O
phosphorylated	O
persistently	O
(	O
up	O
to	O
6	O
hours	O
)	O
in	O
freshly	O
isolated	O
PB	O
and	O
ST	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
.	O

STAT3	B-Protein
is	O
activated	O
by	O
a	O
variety	O
of	O
cytokines	O
,	O
notably	O
the	O
IL	O
-	O
6	O
family	O
of	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
11	I-Protein
,	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
,	O
and	O
oncostatin	B-Protein
M	I-Protein
)	O
and	O
growth	O
factors	O
,	O
in	O
addition	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
4	O
]	O
.	O

Of	O
these	O
cytokines	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
plays	O
a	O
predominant	O
role	O
in	O
eliciting	O
a	O
systemic	O
reaction	O
such	O
as	O
the	O
acute	O
phase	O
response	O
in	O
active	O
RA	O
,	O
due	O
mainly	O
to	O
its	O
abundance	O
in	O
the	O
blood	O
circulation	O
[	O
27	O
]	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
was	O
the	O
major	O
STAT3	B-Protein
-	O
activating	O
factor	O
contained	O
in	O
the	O
serum	O
of	O
active	O
RA	O
patients	O
,	O
and	O
the	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
suppressed	O
in	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
after	O
36	O
hours	O
of	O
incubation	O
with	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

These	O
results	O
suggest	O
that	O
both	O
the	O
sustained	O
STAT3	B-Protein
activation	O
and	O
the	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
found	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
may	O
be	O
induced	O
after	O
chronic	O
exposure	O
in	O
vivo	O
to	O
high	O
concentrations	O
of	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

However	O
,	O
it	O
is	O
also	O
possible	O
that	O
STAT3	B-Protein
activity	O
could	O
be	O
constitutively	O
induced	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
by	O
their	O
own	O
IL	B-Protein
-	I-Protein
10	I-Protein
secretion	O
,	O
leading	O
to	O
the	O
loss	O
of	O
sensitivity	O
to	O
exogenous	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
because	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
ST	O
are	O
capable	O
of	O
producing	O
significant	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
[	O
34	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
isolated	O
from	O
the	O
ST	O
of	O
RA	O
also	O
showed	O
a	O
defect	O
in	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
induced	O
STAT3	B-Protein
signaling	O
pathway	O
.	O

It	O
is	O
most	O
probable	O
that	O
the	O
resistance	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
can	O
be	O
even	O
augmented	O
after	O
migration	O
into	O
the	O
inflamed	O
ST	O
,	O
because	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
highly	O
concentrated	O
compared	O
with	O
the	O
blood	O
level	O
[	O
27	O
]	O
.	O

In	O
addition	O
,	O
the	O
involvement	O
of	O
other	O
essential	O
proinflammatory	O
cytokines	O
in	O
this	O
process	O
was	O
suggested	O
by	O
our	O
preliminary	O
experiments	O
demonstrating	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
inhibition	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
reduced	O
by	O
pretreatment	O
with	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
although	O
less	O
effectively	O
than	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

Furthermore	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
themselves	O
could	O
be	O
responsible	O
for	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
in	O
the	O
ST	O
,	O
because	O
T	O
-	O
cell	O
infiltrates	O
produce	O
both	O
cytokines	O
[	O
34	O
,	O
35	O
]	O
.	O

In	O
an	O
autocrine	O
fashion	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
persistently	O
stimulate	O
STAT3	B-Protein
activation	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
can	O
induce	O
SOCS1	B-Protein
protein	O
as	O
a	O
crosstalk	O
inhibitor	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
[	O
32	O
]	O
.	O

The	O
T	O
-	O
cell	O
-	O
inhibitory	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
therefore	O
be	O
modulated	O
complicatedly	O
upon	O
exposure	O
to	O
an	O
inflammatory	O
environment	O
in	O
RA	O
joints	O
,	O
where	O
many	O
cytokines	O
are	O
present	O
substantially	O
[	O
10	O
]	O
.	O

STAT3	B-Protein
activation	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
RA	O
.	O
<EOS>	B-X
STAT3	B-X
Mediates	B-X
the	B-X
Differential	B-X
Effects	B-X
of	B-X
Oncostatin	B-X
M	B-X
and	B-X
TNFα	B-X
on	B-X
RA	B-X
Synovial	B-X
Fibroblast	B-X
and	B-X
Endothelial	B-X
Cell	B-X
Function	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
a	B-X
T	B-X
helper	B-X
17	B-X
cytokine	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
many	B-X
autoimmune	B-X
diseases	B-X
,	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Although	B-X
IL-17A	B-X
has	B-X
a	B-X
well-established	B-X
role	B-X
in	B-X
murine	B-X
pulmonary	B-X
fibrosis	B-X
models	B-X
,	B-X
its	B-X
role	B-X
in	B-X
the	B-X
tissue	B-X
remodeling	B-X
and	B-X
fibrosis	B-X
occurring	B-X
in	B-X
idiopathic	B-X
pulmonary	B-X
fibrosis	B-X
(	B-X
IPF	B-X
)	B-X
and	B-X
RA-associated	B-X
interstitial	B-X
lung	B-X
disease	B-X
(	B-X
RA-ILD	B-X
)	B-X
is	B-X
not	B-X
very	B-X
well	B-X
defined	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
utilized	B-X
complimentary	B-X
studies	B-X
to	B-X
determine	B-X
responsiveness	B-X
of	B-X
human	B-X
normal	B-X
and	B-X
pathogenic	B-X
lung	B-X
fibroblasts	B-X
to	B-X
IL-17A	B-X
and	B-X
used	B-X
lung	B-X
biopsies	B-X
acquired	B-X
from	B-X
patients	B-X
with	B-X
IPF	B-X
and	B-X
RA-ILD	B-X
to	B-X
determine	B-X
IL-17A	B-X
receptor	B-X
(	B-X
IL-17RA	B-X
)	B-X
expression	B-X
.	B-X
Both	B-X
normal	B-X
and	B-X
pathogenic	B-X
IPF	B-X
lung	B-X
fibroblasts	B-X
express	B-X
functional	B-X
IL-17RA	B-X
and	B-X
respond	B-X
to	B-X
IL-17A	B-X
stimulation	B-X
with	B-X
cell	B-X
proliferation	B-X
,	B-X
generation	B-X
of	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
proteins	B-X
,	B-X
and	B-X
induction	B-X
of	B-X
myofibroblast	B-X
transdifferentiation	B-X
.	B-X
Small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
silencing	B-X
of	B-X
IL-17RA	B-X
attenuated	B-X
this	B-X
fibroblast	B-X
response	B-X
to	B-X
IL-17A	B-X
on	B-X
ECM	B-X
production	B-X
.	B-X
Lung	B-X
biopsies	B-X
of	B-X
RA-ILD	B-X
patients	B-X
demonstrate	B-X
significantly	B-X
higher	B-X
IL-17RA	B-X
expression	B-X
in	B-X
areas	B-X
of	B-X
fibroblast	B-X
accumulation	B-X
and	B-X
fibrosis	B-X
,	B-X
compared	B-X
with	B-X
either	B-X
IPF	B-X
or	B-X
normal	B-X
lung	B-X
tissue	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
a	B-X
direct	B-X
role	B-X
for	B-X
IL-17A	B-X
in	B-X
lung	B-X
fibrosis	B-X
that	B-X
may	B-X
be	B-X
particularly	B-X
relevant	B-X
in	B-X
the	B-X
context	B-X
of	B-X
RA-ILD	B-X
.	B-X

Active	O
STAT3	B-Protein
is	O
constitutively	O
expressed	O
in	O
synovial	O
fluid	O
mononuclear	O
cells	O
from	O
RA	O
patients	O
[	O
36	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
the	O
major	O
STAT3	B-Protein
-	O
activating	O
factor	O
present	O
in	O
synovial	O
fluid	O
,	O
which	O
has	O
a	O
crucial	O
role	O
in	O
the	O
activation	O
of	O
monocyte	O
functions	O
such	O
as	O
gene	O
expression	O
of	O
the	O
Fc	B-Protein
gamma	I-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
and	O
type	B-Protein
III	I-Protein
and	O
of	O
HLA	O
-	O
DR	O
[	O
31	O
]	O
.	O

More	O
recently	O
,	O
high	O
levels	O
of	O
activated	O
STAT3	B-Protein
,	O
thought	O
to	O
be	O
induced	O
mainly	O
by	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
have	O
been	O
detected	O
in	O
the	O
ST	O
,	O
and	O
STAT3	B-Protein
activation	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
synovial	O
fibroblast	O
proliferation	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
[	O
37	O
]	O
.	O

In	O
this	O
regard	O
,	O
STAT3	B-Protein
is	O
critical	O
in	O
the	O
survival	O
and	O
expansion	O
of	O
growth	O
factor	O
-	O
dependent	O
synovial	O
fibroblasts	O
[	O
38	O
]	O
.	O

Furthermore	O
,	O
the	O
significance	O
of	O
persistent	O
STAT3	B-Protein
signaling	O
in	O
Th1	O
-	O
cell	O
-	O
dominated	O
autoimmune	O
arthritis	O
has	O
been	O
suggested	O
by	O
studies	O
of	O
the	O
gp130F759	B-Protein
/	O
F759	O
mice	O
,	O
in	O
which	O
the	O
Src	O
homology	O
phosphatase	O
-	O
2	O
binding	O
site	O
of	O
gp130	B-Protein
(	O
the	O
transmembrane	B-Protein
glycoprotein	I-Protein
beta	I-Protein
subunit	I-Protein
of	I-Protein
the	I-Protein
IL	I-Protein
-	I-Protein
6	I-Protein
family	I-Protein
cytokine	I-Protein
receptor	I-Protein
)	O
,	O
tyrosine	O
759	O
,	O
was	O
mutated	O
to	O
phenylalanine	O
[	O
39	O
]	O
.	O

In	O
the	O
gp130F759	B-Protein
/	O
F759	O
mice	O
,	O
T	O
cells	O
,	O
particularly	O
the	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
subset	O
,	O
are	O
chronically	O
activated	O
and	O
resistant	O
to	O
activation	O
-	O
induced	O
cell	O
death	O
through	O
gp130	B-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
.	O

The	O
longevity	O
of	O
cytokine	O
signals	O
transduced	O
by	O
the	O
JAK	O
-	O
STAT	O
pathway	O
is	O
regulated	O
by	O
the	O
SOCS	O
family	O
proteins	O
[	O
7	O
]	O
.	O

We	O
found	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
patients	O
with	O
active	O
RA	O
expressed	O
higher	O
levels	O
of	O
SOCS1	B-Protein
,	O
but	O
lower	O
levels	O
of	O
SOCS3	B-Protein
,	O
compared	O
with	O
normal	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

SOCS1	B-Protein
prevents	O
activation	O
of	O
JAK	O
by	O
directly	O
binding	O
to	O
JAK	O
,	O
and	O
SOCS3	B-Protein
inhibits	O
the	O
action	O
of	O
JAK	O
by	O
binding	O
to	O
the	O
Src	O
homology	O
phosphatase	O
-	O
2	O
-	O
binding	O
domain	O
of	O
receptors	O
such	O
as	O
gp130	B-Protein
[	O
40	O
]	O
.	O

SOCS1	B-Protein
and	O
SOCS3	B-Protein
are	O
induced	O
by	O
various	O
cytokines	O
,	O
including	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
as	O
mediators	O
of	O
negative	O
feedback	O
and	O
crosstalk	O
inhibition	O
[	O
7	O
]	O
.	O

Recent	O
studies	O
with	O
mice	O
lacking	O
SOCS3	B-Protein
or	O
SOCS1	B-Protein
revealed	O
that	O
SOCS3	B-Protein
is	O
a	O
negative	O
regulator	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
signaling	O
but	O
not	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
signaling	O
.	O
<EOS>	B-X
Although	B-X
many	B-X
TRIMs	B-X
regulate	B-X
type	B-X
I	B-X
IFN	B-X
expression	B-X
following	B-X
cytosolic	B-X
nucleic	B-X
acid	B-X
sensing	B-X
of	B-X
viruses	B-X
,	B-X
their	B-X
contribution	B-X
to	B-X
innate	B-X
immune	B-X
signaling	B-X
and	B-X
gene	B-X
expression	B-X
during	B-X
bacterial	B-X
infection	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Many	B-X
cytokines	B-X
and	B-X
pathogenic	B-X
mediators	B-X
induce	B-X
expression	B-X
of	B-X
SOCS	B-X
,	B-X
which	B-X
act	B-X
in	B-X
a	B-X
negative	B-X
feedback	B-X
loop	B-X
to	B-X
inhibit	B-X
further	B-X
signal	B-X
transduction	B-X
.	B-X
miR-19a	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
SOCS1	B-X
expression	B-X
during	B-X
mutiple	B-X
myeloma	B-X
and	B-X
be	B-X
induced	B-X
by	B-X
the	B-X
anti-viral	B-X
cytokine	B-X
interferon-	B-X
(	B-X
IFN	B-X
)	B-X
-α	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
JAK-STAT	B-X
pathway	B-X
.	B-X
Bioinformatic	B-X
analysis	B-X
identified	B-X
highly	B-X
conserved	B-X
3'UTR	B-X
miR-19a	B-X
target	B-X
sequences	B-X
in	B-X
several	B-X
JAK-STAT	B-X
associated	B-X
genes	B-X
,	B-X
including	B-X
SOCS1	B-X
,	B-X
SOCS3	B-X
,	B-X
SOCS5	B-X
and	B-X
Cullin	B-X
(	B-X
Cul	B-X
)	B-X
5	B-X
.	B-X
Functional	B-X
studies	B-X
revealed	B-X
that	B-X
miR-19a	B-X
significantly	B-X
decreased	B-X
SOCS3	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
while	B-X
a	B-X
miR-19a	B-X
antagomir	B-X
specifically	B-X
reversed	B-X
its	B-X
inhibitory	B-X
effect	B-X
.	B-X
Furthermore	B-X
,	B-X
miR-19a-mediated	B-X
reduction	B-X
of	B-X
SOCS3	B-X
enhanced	B-X
IFN-α	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
signal	B-X
transduction	B-X
through	B-X
STAT3	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
miR-19a	B-X
may	B-X
augment	B-X
JAK-STAT	B-X
signal	B-X
transduction	B-X
via	B-X
control	B-X
of	B-X
SOCS3	B-X
expression	B-X
and	B-X
are	B-X
fundamental	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Studies	O
of	O
conditional	O
SOCS3	B-Protein
-	O
deficient	O
mice	O
have	O
shown	O
that	O
SOCS3	B-Protein
deficiency	O
,	O
but	O
not	O
SOCS1	B-Protein
deficiency	O
,	O
results	O
in	O
sustained	O
activation	O
of	O
STAT3	B-Protein
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
6	I-Protein
[	O
8	O
,	O
41	O
]	O
.	O
<EOS>	B-X
Type	B-X
1	B-X
diabetes	B-X
results	B-X
from	B-X
the	B-X
selective	B-X
destruction	B-X
of	B-X
insulin-producing	B-X
pancreatic	B-X
beta-cells	B-X
during	B-X
islet	B-X
inflammation	B-X
,	B-X
which	B-X
involves	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
free	B-X
radicals	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
define	B-X
the	B-X
role	B-X
of	B-X
SOCS3	B-X
on	B-X
beta-cell	B-X
destruction	B-X
using	B-X
beta-cell-specific	B-X
SOCS3-conditional	B-X
knockout	B-X
(	B-X
cKO	B-X
)	B-X
mice	B-X
.	B-X
The	B-X
beta-cell-specific	B-X
SOCS3-deficient	B-X
mice	B-X
were	B-X
resistant	B-X
to	B-X
the	B-X
development	B-X
of	B-X
diabetes	B-X
caused	B-X
by	B-X
streptozotocin	B-X
(	B-X
STZ	B-X
)	B-X
,	B-X
a	B-X
genotoxic	B-X
methylating	B-X
agent	B-X
,	B-X
which	B-X
has	B-X
been	B-X
used	B-X
to	B-X
trigger	B-X
beta-cell	B-X
destruction	B-X
.	B-X
The	B-X
islets	B-X
from	B-X
cKO	B-X
mice	B-X
demonstrated	B-X
hyperactivation	B-X
of	B-X
STAT3	B-X
and	B-X
higher	B-X
induction	B-X
of	B-X
Bcl-xL	B-X
than	B-X
did	B-X
islets	B-X
from	B-X
WT	B-X
mice	B-X
,	B-X
and	B-X
SOCS3-deficient	B-X
beta-cells	B-X
were	B-X
more	B-X
resistant	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
STZ	B-X
in	B-X
vitro	B-X
than	B-X
were	B-X
WT	B-X
beta-cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
enhanced	B-X
STAT3	B-X
signaling	B-X
protects	B-X
beta-cells	B-X
from	B-X
destruction	B-X
induced	B-X
by	B-X
a	B-X
genotoxic	B-X
stress	B-X
and	B-X
that	B-X
STAT3/SOCS3	B-X
can	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X

The	O
analysis	O
of	O
SOCS3	B-Protein
-	O
deficient	O
macrophages	O
has	O
indicated	O
that	O
SOCS3	B-Protein
is	O
a	O
crucial	O
inhibitor	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
induced	O
transcriptional	O
response	O
[	O
42	O
]	O
.	O

However	O
,	O
SOCS3	B-Protein
is	O
dispensable	O
for	O
both	O
the	O
negative	O
feedback	O
inhibition	O
and	O
the	O
immunoregulatory	O
action	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
macrophages	O
[	O
41	O
]	O
.	O

On	O
the	O
contrary	O
,	O
SOCS1	B-Protein
was	O
found	O
to	O
directly	O
inhibit	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
signaling	O
[	O
43	O
]	O
.	O

Increased	O
SOCS1	B-Protein
expression	O
in	O
RA	O
CD4	B-Protein
+	O
T	O
cells	O
may	O
therefore	O
be	O
associated	O
with	O
both	O
the	O
impaired	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
,	O
and	O
defective	O
SOCS3	B-Protein
expression	O
may	O
be	O
responsible	O
for	O
persistent	O
STAT3	B-Protein
activation	O
in	O
response	O
to	O
serum	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

There	O
is	O
a	O
possibility	O
that	O
SOCS1	B-Protein
induction	O
may	O
be	O
associated	O
with	O
the	O
ability	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
to	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
because	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
could	O
produce	O
high	O
levels	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
because	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
has	O
been	O
known	O
as	O
a	O
potent	O
inducer	O
of	O
SOCS1	B-Protein
[	O
32	O
]	O
.	O

It	O
is	O
of	O
interest	O
in	O
this	O
regard	O
to	O
indicate	O
that	O
polarized	O
Th1	O
and	O
Th2	O
cells	O
express	O
high	O
levels	O
of	O
SOCS1	B-Protein
and	O
SOCS3	B-Protein
mRNA	O
,	O
respectively	O
[	O
44	O
]	O
.	O

IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
activation	O
is	O
inhibited	O
by	O
SOCS3	B-Protein
induction	O
in	O
Th2	O
cells	O
,	O
whereas	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
STAT6	B-Protein
signaling	O
is	O
diminished	O
by	O
SOCS1	B-Protein
induction	O
in	O
Th1	O
cells	O
.	O

SOCS1	B-Protein
and	O
SOCS3	B-Protein
may	O
thus	O
have	O
important	O
roles	O
as	O
Th1	O
-	O
specific	O
and	O
Th2	O
-	O
specific	O
,	O
mutually	O
exclusive	O
,	O
cross	O
-	O
talk	O
repressors	O
of	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
STAT6	B-Protein
and	O
the	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
STAT4	B-Protein
signaling	O
pathways	O
,	O
respectively	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
PB	O
T	O
cells	O
from	O
patients	O
with	O
allergic	O
diseases	O
significantly	O
express	O
high	O
levels	O
of	O
SOCS3	B-Protein
transcripts	O
,	O
and	O
the	O
SOCS3	B-Protein
expression	O
correlates	O
well	O
with	O
serum	O
IgE	O
levels	O
and	O
disease	O
pathology	O
[	O
45	O
]	O
.	O

Higher	O
SOCS1	B-Protein
expression	O
with	O
lower	O
SOCS3	B-Protein
expression	O
in	O
PB	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
RA	O
patients	O
,	O
compared	O
with	O
healthy	O
controls	O
,	O
is	O
therefore	O
probably	O
consistent	O
with	O
their	O
systemic	O
bias	O
towards	O
a	O
Th1	O
phenotype	O
,	O
as	O
has	O
previously	O
been	O
demonstrated	O
[	O
46	O
-	O
49	O
]	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
from	O
active	O
RA	O
patients	O
are	O
characterized	O
by	O
their	O
resistance	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
due	O
to	O
constitutive	O
STAT3	B-Protein
phosphorylation	O
and	O
impaired	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
mediated	O
STAT3	B-Protein
activation	O
.	O

The	O
defective	O
STAT3	B-Protein
signaling	O
is	O
possibly	O
associated	O
with	O
SOCS1	B-Protein
predominance	O
over	O
SOCS3	B-Protein
.	O

These	O
abnormalities	O
in	O
active	O
RA	O
are	O
thought	O
to	O
be	O
induced	O
mainly	O
after	O
chronic	O
exposure	O
to	O
high	O
concentrations	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

The	O
limited	O
efficacy	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
treatment	O
of	O
RA	O
patients	O
[	O
50	O
]	O
may	O
be	O
explained	O
in	O
part	O
by	O
the	O
unresponsiveness	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
of	O
inflammatory	O
cells	O
,	O
including	O
T	O
cells	O
.	O

On	O
the	O
contrary	O
,	O
the	O
therapeutic	O
efficacy	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
6	I-Protein
receptor	I-Protein
antibody	O
has	O
been	O
reported	O
in	O
RA	O
patients	O
[	O
51	O
]	O
,	O
and	O
one	O
of	O
the	O
effects	O
of	O
this	O
therapy	O
may	O
be	O
to	O
normalize	O
T	O
cells	O
through	O
the	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
dependent	O
STAT3	B-Protein
activation	O
.	O

More	O
specific	O
therapy	O
targeting	O
STAT3	B-Protein
activation	O
will	O
be	O
awaited	O
;	O
for	O
example	O
,	O
the	O
induction	O
of	O
the	O
SOCS3	B-Protein
gene	O
,	O
the	O
efficacy	O
of	O
which	O
has	O
been	O
demonstrated	O
in	O
animal	O
models	O
[	O
37	O
]	O
.	O

Increased	O
interleukin	B-Protein
-	I-Protein
17	I-Protein
production	O
via	O
a	O
phosphoinositide	O
3	O
-	O
kinase	O
/	O
Akt	B-Protein
and	O
nuclear	O
factor	O
?	O
B	O
-	O
dependent	O
pathway	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O

Inflammatory	O
mediators	O
have	O
been	O
recognized	O
as	O
being	O
important	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O
<EOS>	B-X
It	B-X
is	B-X
widely	B-X
recognized	B-X
that	B-X
IMID	B-X
patients	B-X
are	B-X
at	B-X
a	B-X
higher	B-X
risk	B-X
for	B-X
developing	B-X
secondary	B-X
inflammation-related	B-X
conditions	B-X
.	B-X
This	B-X
study	B-X
used	B-X
16S	B-X
rRNA	B-X
gene	B-X
amplicon	B-X
sequencing	B-X
to	B-X
compare	B-X
the	B-X
gut	B-X
microbiota	B-X
of	B-X
patients	B-X
with	B-X
Crohn	B-X
's	B-X
disease	B-X
(	B-X
CD	B-X
;	B-X
N	B-X
=	B-X
20	B-X
)	B-X
,	B-X
ulcerative	B-X
colitis	B-X
(	B-X
UC	B-X
;	B-X
N	B-X
=	B-X
19	B-X
)	B-X
,	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
;	B-X
N	B-X
=	B-X
19	B-X
)	B-X
,	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
;	B-X
N	B-X
=	B-X
21	B-X
)	B-X
versus	B-X
healthy	B-X
controls	B-X
(	B-X
HC	B-X
;	B-X
N	B-X
=	B-X
23	B-X
)	B-X
.	B-X
Liver	B-X
disease	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
causes	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
worldwide	B-X
whose	B-X
prevalence	B-X
is	B-X
dramatically	B-X
increasing	B-X
.	B-X
In	B-X
chronic	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
psoriatic	B-X
arthritis	B-X
(	B-X
PsA	B-X
)	B-X
,	B-X
in	B-X
which	B-X
the	B-X
CVD	B-X
risk	B-X
is	B-X
high	B-X
,	B-X
hepatic	B-X
alterations	B-X
seem	B-X
to	B-X
be	B-X
more	B-X
prevalent	B-X
compared	B-X
to	B-X
the	B-X
general	B-X
population	B-X
and	B-X
other	B-X
rheumatic	B-X
disorders	B-X
.	B-X
The	B-X
pathogenic	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
this	B-X
comorbidity	B-X
are	B-X
still	B-X
unraveled	B-X
,	B-X
although	B-X
chronic	B-X
inflammation	B-X
,	B-X
autoimmunity	B-X
,	B-X
treatments	B-X
,	B-X
and	B-X
metabolic	B-X
deregulation	B-X
seem	B-X
to	B-X
have	B-X
an	B-X
important	B-X
role	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
involvement	B-X
of	B-X
liver	B-X
disease	B-X
in	B-X
the	B-X
cardiovascular	B-X
risk	B-X
associated	B-X
with	B-X
inflammatory	B-X
arthritis	B-X
,	B-X
the	B-X
pathogenic	B-X
mechanisms	B-X
,	B-X
and	B-X
the	B-X
recognized	B-X
factors	B-X
involved	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
will	B-X
examine	B-X
the	B-X
latest	B-X
controversies	B-X
that	B-X
have	B-X
been	B-X
raised	B-X
about	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
current	B-X
therapies	B-X
used	B-X
to	B-X
control	B-X
the	B-X
inflammation	B-X
in	B-X
RA	B-X
and	B-X
PsA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
damage	B-X
of	B-X
those	B-X
patients	B-X
,	B-X
such	B-X
as	B-X
methotrexate	B-X
,	B-X
leflunomide	B-X
or	B-X
biologics	B-X
.	B-X

Interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
17	I-Protein
is	O
an	O
important	O
regulator	O
of	O
immune	O
and	O
inflammatory	O
responses	O
,	O
including	O
the	O
induction	O
of	O
proinflammatory	O
cytokines	O
and	O
osteoclastic	O
bone	O
resorption	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Evidence	O
for	O
the	O
expression	O
and	O
proinflammatory	O
activity	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
been	O
demonstrated	O
in	O
RA	O
synovium	O
and	O
in	O
animal	O
models	O
of	O
RA	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Although	O
some	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
IL	B-Protein
-	I-Protein
23	I-Protein
)	O
have	O
been	O
reported	O
to	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
,	O
the	O
intracellular	O
signaling	O
pathways	O
that	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
remain	O
unknown	O
.	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
pathway	O
in	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
patients	O
with	O
RA	O
(	O
n	O
=	O
24	O
)	O
were	O
separated	O
,	O
then	O
stimulated	O
with	O
various	O
agents	O
including	O
anti	O
-	O
CD3	O
,	O
anti	O
-	O
CD28	B-Protein
,	O
phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
and	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
were	O
determined	O
by	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
<EOS>	B-X
The	B-X
study	B-X
is	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
changes	B-X
and	B-X
roles	B-X
of	B-X
T	B-X
helper	B-X
type	B-X
17/regulatory	B-X
T	B-X
cells	B-X
(	B-X
Th17/T	B-X
(	B-X
reg	B-X
)	B-X
)	B-X
in	B-X
the	B-X
immunological	B-X
pathogenesis	B-X
of	B-X
Kawasaki	B-X
disease	B-X
(	B-X
KD	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
alteration	B-X
and	B-X
significance	B-X
of	B-X
Th17	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
intravenous	B-X
immune	B-X
globulin-resistant	B-X
KD	B-X
.	B-X
Real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17A/F	B-X
,	B-X
retinoic	B-X
acid-related	B-X
orphan	B-X
receptor	B-X
(	B-X
ROR	B-X
)	B-X
-γt	B-X
and	B-X
forkhead	B-X
box	B-X
P3	B-X
(	B-X
FoxP3	B-X
)	B-X
in	B-X
CD4-positive	B-X
cells	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
Th17	B-X
cells	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
FoxP3	B-X
(	B-X
high	B-X
)	B-X
T	B-X
(	B-X
regs	B-X
)	B-X
were	B-X
analysed	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Plasma	B-X
cytokine	B-X
[	B-X
IL-17A	B-X
,	B-X
IL-6	B-X
,	B-X
IL-23	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-β	B-X
]	B-X
concentrations	B-X
were	B-X
measured	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
Th17	B-X
proportions	B-X
and	B-X
expression	B-X
levels	B-X
of	B-X
cytokines	B-X
(	B-X
IL-17	B-X
,	B-X
IL-6	B-X
and	B-X
IL-23	B-X
)	B-X
and	B-X
transcription	B-X
factors	B-X
(	B-X
IL-17A/F	B-X
,	B-X
ROR-γt	B-X
)	B-X
were	B-X
up-regulated	B-X
significantly	B-X
,	B-X
while	B-X
T	B-X
(	B-X
reg	B-X
)	B-X
proportions	B-X
and	B-X
expression	B-X
levels	B-X
of	B-X
T	B-X
(	B-X
reg	B-X
)	B-X
transcription	B-X
factor	B-X
(	B-X
FoxP3	B-X
)	B-X
were	B-X
down-regulated	B-X
significantly	B-X
in	B-X
children	B-X
with	B-X
acute	B-X
KD	B-X
(	B-X
P	B-X
<	B-X
0·01	B-X
)	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
sensitive	B-X
group	B-X
,	B-X
the	B-X
Th17	B-X
proportions	B-X
were	B-X
up-regulated	B-X
significantly	B-X
during	B-X
the	B-X
acute	B-X
phase	B-X
in	B-X
immune	B-X
globulin-resistant	B-X
KD	B-X
(	B-X
P	B-X
<	B-X
0·01	B-X
)	B-X
.	B-X
The	B-X
plasma	B-X
IL-17A	B-X
,	B-X
IL-6	B-X
and	B-X
IL-23	B-X
concentrations	B-X
in	B-X
patients	B-X
with	B-X
KD	B-X
were	B-X
significantly	B-X
higher	B-X
compared	B-X
with	B-X
the	B-X
concentrations	B-X
in	B-X
normal	B-X
controls	B-X
(	B-X
NC	B-X
)	B-X
and	B-X
infectious	B-X
disease	B-X
(	B-X
ID	B-X
)	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Th17/T	B-X
(	B-X
reg	B-X
)	B-X
cells	B-X
imbalance	B-X
exists	B-X
in	B-X
the	B-X
patients	B-X
with	B-X
KD	B-X
.	B-X
Th17/T	B-X
cells	B-X
imbalance	B-X
may	B-X
be	B-X
important	B-X
factors	B-X
causing	B-X
disturbed	B-X
immunological	B-X
function	B-X
and	B-X
resulting	B-X
in	B-X
immunoglobulin-resistant	B-X
KD	B-X
.	B-X

The	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
was	O
significantly	O
increased	O
in	O
cells	O
treated	O
with	O
anti	O
-	O
CD3	O
antibody	O
with	O
or	O
without	O
anti	O
-	O
CD28	B-Protein
and	O
PHA	B-Protein
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
<EOS>	B-X
Pathogenesis	B-X
of	B-X
chronic	B-X
graft-versus-host	B-X
disease	B-X
(	B-X
cGVHD	B-X
)	B-X
is	B-X
incompletely	B-X
defined	B-X
,	B-X
involving	B-X
donor-derived	B-X
CD4	B-X
and	B-X
CD8-positive	B-X
T	B-X
lymphocytes	B-X
as	B-X
well	B-X
as	B-X
B	B-X
cells	B-X
.	B-X
Standard	B-X
treatment	B-X
is	B-X
lacking	B-X
for	B-X
steroid-dependent/refractory	B-X
cases	B-X
;	B-X
therefore	B-X
,	B-X
the	B-X
potential	B-X
usefulness	B-X
of	B-X
tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
TKIs	B-X
)	B-X
has	B-X
been	B-X
suggested	B-X
,	B-X
based	B-X
on	B-X
their	B-X
potent	B-X
antifibrotic	B-X
effect	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
from	B-X
healthy	B-X
donors	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
increasing	B-X
concentrations	B-X
of	B-X
nilotinib	B-X
,	B-X
imatinib	B-X
,	B-X
dasatinib	B-X
,	B-X
and	B-X
ponatinib	B-X
;	B-X
in	B-X
parallel	B-X
,	B-X
44	B-X
PBMC	B-X
samples	B-X
from	B-X
15	B-X
patients	B-X
with	B-X
steroid-dependent/refractory	B-X
cGVHD	B-X
treated	B-X
with	B-X
nilotinib	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
a	B-X
phase	B-X
I/II	B-X
trial	B-X
were	B-X
analyzed	B-X
at	B-X
baseline	B-X
,	B-X
after	B-X
90	B-X
,	B-X
and	B-X
after	B-X
180	B-X
days	B-X
of	B-X
therapy	B-X
.	B-X
Flow	B-X
cytometry	B-X
was	B-X
performed	B-X
after	B-X
labeling	B-X
lymphocytes	B-X
with	B-X
a	B-X
panel	B-X
of	B-X
monoclonal	B-X
antibodies	B-X
(	B-X
CD3	B-X
,	B-X
CD4	B-X
,	B-X
CD16	B-X
,	B-X
CD56	B-X
,	B-X
CD25	B-X
,	B-X
CD19	B-X
,	B-X
CD45RA	B-X
,	B-X
FoxP3	B-X
,	B-X
CD127	B-X
,	B-X
and	B-X
7-amino	B-X
actinomycin	B-X
D	B-X
)	B-X
.	B-X
Cytokine	B-X
production	B-X
was	B-X
assessed	B-X
in	B-X
supernatants	B-X
of	B-X
purified	B-X
CD3	B-X

Among	O
tested	O
cytokines	O
and	O
chemokines	O
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
upregulated	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
or	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
did	O
not	O
.	O
<EOS>	B-X
The	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
is	B-X
the	B-X
prototype	B-X
of	B-X
the	B-X
TGF-β	B-X
family	B-X
of	B-X
growth	B-X
and	B-X
differentiation	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
encoded	B-X
by	B-X
33	B-X
genes	B-X
in	B-X
mammals	B-X
and	B-X
comprises	B-X
homo-	B-X
and	B-X
heterodimers	B-X
.	B-X
It	B-X
also	B-X
introduces	B-X
TGF-β	B-X
as	B-X
the	B-X
best-studied	B-X
factor	B-X
among	B-X
the	B-X
TGF-β	B-X
family	B-X
proteins	B-X
,	B-X
with	B-X
its	B-X
diversity	B-X
of	B-X
roles	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
immune	B-X
system	B-X
,	B-X
and	B-X
its	B-X
key	B-X
roles	B-X
in	B-X
pathology	B-X
,	B-X
for	B-X
example	B-X
,	B-X
skeletal	B-X
diseases	B-X
,	B-X
fibrosis	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
The	B-X
TGF-beta	B-X
family	B-X
of	B-X
cytokines	B-X
are	B-X
ubiquitous	B-X
,	B-X
multifunctional	B-X
and	B-X
essential	B-X
to	B-X
survival	B-X
.	B-X
They	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
growth	B-X
and	B-X
development	B-X
,	B-X
inflammation	B-X
and	B-X
repair	B-X
and	B-X
host	B-X
immunity	B-X
.	B-X
The	B-X
mammalian	B-X
TGF-beta	B-X
isoforms	B-X
(	B-X
TGF-beta	B-X
1	B-X
,	B-X
beta	B-X
2	B-X
and	B-X
beta	B-X
3	B-X
)	B-X
are	B-X
secreted	B-X
as	B-X
latent	B-X
precursors	B-X
and	B-X
have	B-X
multiple	B-X
cell	B-X
surface	B-X
receptors	B-X
of	B-X
which	B-X
at	B-X
least	B-X
two	B-X
mediate	B-X
signal	B-X
transduction	B-X
.	B-X
Autocrine	B-X
and	B-X
paracrine	B-X
effects	B-X
of	B-X
TGF-beta	B-X
's	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
extracellular	B-X
matrix	B-X
,	B-X
neighbouring	B-X
cells	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
The	B-X
vital	B-X
role	B-X
of	B-X
the	B-X
TGF-beta	B-X
family	B-X
is	B-X
illustrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
approximately	B-X
50	B-X
%	B-X
of	B-X
TGF-beta	B-X
1	B-X
gene	B-X
knockout	B-X
mice	B-X
die	B-X
in	B-X
utero	B-X
and	B-X
the	B-X
remainder	B-X
succumb	B-X
to	B-X
uncontrolled	B-X
inflammation	B-X
after	B-X
birth	B-X
.	B-X
TGF-beta	B-X
2	B-X
and	B-X
TGF-beta	B-X
3	B-X
gene	B-X
knockout	B-X
mice	B-X
are	B-X
not	B-X
yet	B-X
described	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
novel	B-X
TGF-beta-like	B-X
molecules	B-X
have	B-X
been	B-X
described	B-X
which	B-X
share	B-X
some	B-X
of	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
mammalian	B-X
TGF-beta	B-X
isoforms	B-X
.	B-X
The	B-X
role	B-X
of	B-X
TGF-beta	B-X
in	B-X
homeostatic	B-X
and	B-X
pathogenic	B-X
processes	B-X
suggests	B-X
numerous	B-X
applications	B-X
in	B-X
the	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
various	B-X
diseases	B-X
characterised	B-X
by	B-X
inflammation	B-X
and	B-X
fibrosis	B-X
.	B-X

IL	B-Protein
-	I-Protein
17	I-Protein
was	O
also	O
detected	O
in	O
the	O
PBMC	O
of	O
patients	O
with	O
osteoarthritis	O
,	O
but	O
their	O
expression	O
levels	O
were	O
much	O
lower	O
than	O
those	O
of	O
RA	O
PBMC	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Anti	O
-	O
CD3	O
antibody	O
activated	O
the	O
PI3K	O
/	O
Akt	B-Protein
pathway	O
;	O
activation	O
of	O
this	O
pathway	O
resulted	O
in	O
a	O
pronounced	O
augmentation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
DNA	O
-	O
binding	O
activity	O
.	O
<EOS>	B-X
Human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2	B-X
(	B-X
HER2	B-X
)	B-X
is	B-X
overexpressed	B-X
in	B-X
multiple	B-X
cancers	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
poor	B-X
prognosis	B-X
.	B-X
With	B-X
glucose	B-X
being	B-X
the	B-X
preferred	B-X
source	B-X
of	B-X
energy	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
targeting	B-X
glycolysis	B-X
has	B-X
become	B-X
an	B-X
attractive	B-X
therapeutic	B-X
intervention	B-X
point	B-X
for	B-X
chronic	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
(	B-X
IBD	B-X
)	B-X
.	B-X
The	B-X
switch	B-X
to	B-X
glycolysis	B-X
is	B-X
mediated	B-X
by	B-X
phosphoinositide-3-kinases	B-X
(	B-X
PI3K	B-X
)	B-X
which	B-X
relay	B-X
signals	B-X
from	B-X
surface	B-X
receptors	B-X
to	B-X
the	B-X
AKT	B-X
pathway	B-X
.	B-X
Second	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
PI3K	B-X
inhibitor	B-X
copanlisib	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
.	B-X
Ex	B-X
vivo	B-X
,	B-X
copanlisib	B-X
suppressed	B-X
the	B-X
ECAR	B-X
significantly	B-X
in	B-X
T	B-X
cells	B-X
activated	B-X
by	B-X
anti-CD3	B-X
antibodies	B-X
and	B-X
significantly	B-X
decreased	B-X
ECAR	B-X
rates	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
copanlisib	B-X
(	B-X
anti-CD3	B-X
:	B-X
58.24	B-X
±	B-X
29.06	B-X
;	B-X
copanlisib	B-X
:	B-X
43.16	B-X
±	B-X
20.23	B-X
,	B-X
p	B-X
<	B-X
.000	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
copanlisib	B-X
impaired	B-X
the	B-X
activation	B-X
of	B-X
CD4	B-X

IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
activated	O
RA	O
PBMC	O
is	O
completely	O
or	O
partly	O
blocked	O
in	O
the	O
presence	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
PI3K	O
/	O
Akt	B-Protein
inhibitor	O
wortmannin	O
and	O
LY294002	O
,	O
respectively	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

However	O
,	O
inhibition	O
of	O
activator	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O
<EOS>	B-X
Previously	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
in	B-X
papilloma-producing	B-X
308	B-X
mouse	B-X
keratinocytes	B-X
,	B-X
the	B-X
tumor	B-X
promoter	B-X
okadaic	B-X
acid	B-X
,	B-X
a	B-X
serine-threonine	B-X
phosphatase	B-X
inhibitor	B-X
,	B-X
increased	B-X
binding	B-X
of	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
to	B-X
a	B-X
consensus	B-X
12-O-tetradecanoylphorbol-13-acetate-responsive	B-X
element	B-X
(	B-X
Rosenberger	B-X
,	B-X
S.	B-X
F.	B-X
,	B-X
and	B-X
Bowden	B-X
,	B-X
G.	B-X
T.	B-X
(	B-X
1996	B-X
)	B-X
Oncogene	B-X
12	B-X
,	B-X
2301-2308	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
correlation	B-X
between	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transactivation	B-X
and	B-X
examined	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Using	B-X
a	B-X
luciferase	B-X
reporter	B-X
driven	B-X
by	B-X
region	B-X
-74	B-X
to	B-X
+63	B-X
of	B-X
the	B-X
human	B-X
collagenase	B-X
gene	B-X
,	B-X
we	B-X
demonstrated	B-X
induction	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
following	B-X
okadaic	B-X
acid	B-X
treatment	B-X
.	B-X
By	B-X
performing	B-X
in	B-X
vitro	B-X
kinase	B-X
assays	B-X
,	B-X
we	B-X
found	B-X
elevated	B-X
activities	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
1/2	B-X
,	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
,	B-X
and	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
.	B-X
The	B-X
ERK-1/2-specific	B-X
inhibitor	B-X
PD	B-X
98059	B-X
completely	B-X
abrogated	B-X
okadaic	B-X
acid-induced	B-X
AP-1	B-X
transactivation	B-X
without	B-X
altering	B-X
AP-1	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
or	B-X
complex	B-X
composition	B-X
.	B-X
Phosphorylation	B-X
analyses	B-X
indicated	B-X
that	B-X
inhibition	B-X
of	B-X
ERK-1/2	B-X
decreased	B-X
okadaic	B-X
acid-elevated	B-X
phosphorylation	B-X
of	B-X
JunD	B-X
and	B-X
FosB	B-X
.	B-X
To	B-X
further	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
JunD	B-X
and	B-X
FosB	B-X
in	B-X
okadaic	B-X
acid-induced	B-X
AP-1	B-X
transactivation	B-X
,	B-X
we	B-X
generated	B-X
fusion	B-X
proteins	B-X
of	B-X
the	B-X
DNA-binding	B-X
domain	B-X
of	B-X
the	B-X
yeast	B-X
transcription	B-X
factor	B-X
Gal4	B-X
and	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
either	B-X
JunD	B-X
or	B-X
FosB	B-X
.	B-X
Treatment	B-X
with	B-X
PD	B-X
98059	B-X
reduced	B-X
JunD/FosB-dependent	B-X
transactivation	B-X
,	B-X
suggesting	B-X
that	B-X
ERK-1/2-mediated	B-X
phosphorylation	B-X
is	B-X
a	B-X
critical	B-X
component	B-X
in	B-X
this	B-X
process	B-X
.	B-X

These	O
results	O
suggest	O
that	O
signal	O
transduction	O
pathways	O
dependent	O
on	O
PI3K	O
/	O
Akt	B-Protein
and	O
NF	O
-	O
kappaB	O
are	O
involved	O
in	O
the	O
overproduction	O
of	O
the	O
key	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
characterized	O
by	O
infiltrations	O
of	O
macrophages	O
and	O
T	O
cells	O
into	O
the	O
joint	O
,	O
and	O
synovial	O
hyperplasia	O
.	O

Proinflammatory	O
cytokines	O
released	O
from	O
these	O
cells	O
are	O
known	O
to	O
be	O
important	O
in	O
the	O
destruction	O
of	O
joints	O
in	O
RA	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Platelet	B-X
microparticles	B-X
(	B-X
pMPs	B-X
)	B-X
are	B-X
small	B-X
membrane-coated	B-X
vesicles	B-X
that	B-X
are	B-X
released	B-X
from	B-X
the	B-X
plasma	B-X
membrane	B-X
upon	B-X
platelet	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
joint	B-X
fluid	B-X
of	B-X
patients	B-X
with	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
pMP	B-X
can	B-X
interact	B-X
with	B-X
and	B-X
activate	B-X
fibroblast-like	B-X
synoviocytes	B-X
(	B-X
FLS	B-X
)	B-X
,	B-X
which	B-X
are	B-X
important	B-X
effector	B-X
cells	B-X
that	B-X
mediate	B-X
both	B-X
immune	B-X
activation	B-X
and	B-X
joint	B-X
destruction	B-X
.	B-X
The	B-X
signaling	B-X
process	B-X
by	B-X
which	B-X
engagement	B-X
of	B-X
glycoprotein	B-X
VI	B-X
(	B-X
GPVI	B-X
)	B-X
,	B-X
a	B-X
surface	B-X
glycoprotein	B-X
receptor	B-X
for	B-X
collagen	B-X
which	B-X
is	B-X
expressed	B-X
on	B-X
platelets	B-X
,	B-X
triggers	B-X
pMP	B-X
generation	B-X
is	B-X
poorly	B-X
understood	B-X
,	B-X
but	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
involve	B-X
Spleen	B-X
Tyrosine	B-X
Kinase	B-X
(	B-X
SYK	B-X
)	B-X
,	B-X
best	B-X
known	B-X
as	B-X
an	B-X
upstream	B-X
activator	B-X
of	B-X
Bruton	B-X
's	B-X
Tyrosine	B-X
Kinase	B-X
(	B-X
BTK	B-X
)	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
a	B-X
co-culture	B-X
system	B-X
consisting	B-X
of	B-X
human	B-X
primary	B-X
synovial	B-X
FLS	B-X
and	B-X
activated	B-X
human	B-X
platelets	B-X
,	B-X
convulxin	B-X
stimulation	B-X
resulted	B-X
in	B-X
elevated	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
,	B-X
IL-6	B-X
and	B-X
IL-8	B-X
,	B-X
an	B-X
effect	B-X
which	B-X
was	B-X
dose-dependently	B-X
blocked	B-X
by	B-X
RN486	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
further	B-X
support	B-X
the	B-X
potential	B-X
therapeutic	B-X
utility	B-X
of	B-X
BTK	B-X
inhibitors	B-X
in	B-X
RA	B-X
therapy	B-X
,	B-X
by	B-X
inhibiting	B-X
GPVI-mediated	B-X
platelet	B-X
activation	B-X
and	B-X
thus	B-X
subsequent	B-X
amplification	B-X
of	B-X
inflammation	B-X
driven	B-X
by	B-X
pMP-induced	B-X
FLS	B-X
cytokines	B-X
production	B-X
.	B-X

The	O
favorable	O
clinical	O
benefits	O
obtained	O
with	O
inhibitors	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	I-Protein
TNF	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
suggest	O
that	O
the	O
blockade	O
of	O
key	O
inflammatory	O
cytokines	O
has	O
been	O
the	O
important	O
issue	O
in	O
the	O
development	O
of	O
new	O
therapeutic	O
applications	O
[	O
2	O
]	O
.	O

A	O
little	O
over	O
a	O
decade	O
ago	O
,	O
the	O
primacy	O
of	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
such	O
as	O
RA	O
was	O
undisputed	O
because	O
they	O
are	O
the	O
largest	O
cell	O
population	O
infiltrating	O
the	O
synovium	O
.	O

However	O
,	O
a	O
series	O
of	O
studies	O
demonstrated	O
paucity	O
of	O
T	O
cell	O
-	O
derived	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
in	O
the	O
joints	O
of	O
RA	O
,	O
whereas	O
macrophage	O
and	O
fibroblast	O
cytokines	O
including	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
were	O
abundant	O
in	O
rheumatoid	O
synovium	O
.	O

This	O
paradox	O
has	O
questioned	O
the	O
role	O
of	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
RA	O
[	O
3	O
]	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
and	B-X
debilitating	B-X
inflammatory	B-X
autoimmune	B-X
disease	B-X
of	B-X
unknown	B-X
etiology	B-X
.	B-X
As	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
autoimmune	B-X
disorders	B-X
,	B-X
evidence	B-X
of	B-X
elevated	B-X
tryptophan	B-X
catabolism	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
RA	B-X
patients	B-X
indicative	B-X
of	B-X
activation	B-X
of	B-X
the	B-X
immunomodulatory	B-X
enzyme	B-X
IDO	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
that	B-X
IDO	B-X
plays	B-X
in	B-X
the	B-X
disease	B-X
process	B-X
is	B-X
not	B-X
well	B-X
understood	B-X
.	B-X
Recent	B-X
results	B-X
in	B-X
cancer	B-X
models	B-X
,	B-X
however	B-X
,	B-X
suggest	B-X
a	B-X
more	B-X
complex	B-X
role	B-X
for	B-X
IDO	B-X
as	B-X
an	B-X
integral	B-X
component	B-X
of	B-X
the	B-X
inflammatory	B-X
microenvironment	B-X
necessary	B-X
for	B-X
supporting	B-X
tumor	B-X
outgrowth	B-X
.	B-X
This	B-X
has	B-X
led	B-X
us	B-X
to	B-X
investigate	B-X
the	B-X
involvement	B-X
of	B-X
IDO	B-X
in	B-X
the	B-X
pathological	B-X
inflammation	B-X
associated	B-X
with	B-X
RA	B-X
.	B-X
Using	B-X
the	B-X
K/BxN	B-X
murine	B-X
RA	B-X
model	B-X
and	B-X
IDO	B-X
inhibitor	B-X
1-methyl-tryptophan	B-X
,	B-X
we	B-X
found	B-X
that	B-X
inhibiting	B-X
IDO	B-X
activity	B-X
had	B-X
the	B-X
unexpected	B-X
consequence	B-X
of	B-X
ameliorating	B-X
,	B-X
rather	B-X
than	B-X
exacerbating	B-X
arthritis	B-X
symptoms	B-X
.	B-X
This	B-X
alleviation	B-X
of	B-X
arthritis	B-X
was	B-X
not	B-X
due	B-X
to	B-X
an	B-X
altered	B-X
T	B-X
cell	B-X
response	B-X
,	B-X
but	B-X
rather	B-X
resulted	B-X
from	B-X
a	B-X
diminished	B-X
autoreactive	B-X
B	B-X
cell	B-X
response	B-X
,	B-X
thus	B-X
demonstrating	B-X
a	B-X
previously	B-X
unappreciated	B-X
role	B-X
for	B-X
IDO	B-X
in	B-X
stimulating	B-X
B	B-X
cell	B-X
responses	B-X
.	B-X
Our	B-X
findings	B-X
raise	B-X
the	B-X
question	B-X
of	B-X
how	B-X
an	B-X
immunosuppressive	B-X
enzyme	B-X
can	B-X
paradoxically	B-X
drive	B-X
autoimmunity	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
IDO	B-X
is	B-X
not	B-X
simply	B-X
immunosuppressive	B-X
,	B-X
but	B-X
rather	B-X
plays	B-X
a	B-X
more	B-X
complex	B-X
role	B-X
in	B-X
modulating	B-X
inflammatory	B-X
responses	B-X
,	B-X
in	B-X
particular	B-X
those	B-X
that	B-X
are	B-X
driven	B-X
by	B-X
autoreactive	B-X
B	B-X
cells	B-X
.	B-X

Because	O
we	O
have	O
already	O
demonstrated	O
the	O
enhanced	O
proliferation	O
of	O
antigen	O
specific	O
T	O
cells	O
,	O
especially	O
to	O
type	O
II	O
collagen	O
,	O
and	O
the	O
skewing	O
of	O
T	O
helper	O
type	O
1	O
(	O
Th1	O
)	O
cytokines	O
in	O
RA	O
[	O
4	O
]	O
,	O
the	O
role	O
of	O
T	O
cells	O
needs	O
to	O
be	O
elucidated	O
in	O
different	O
aspects	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
is	O
one	O
of	O
the	O
inflammatory	O
cytokines	O
secreted	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
which	O
can	O
induce	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
by	O
fibroblasts	O
[	O
5	O
]	O
.	O
<EOS>	B-X
IL-23/IL-23R	B-X
and	B-X
PGE	B-X
CD28	B-X
is	B-X
a	B-X
crucial	B-X
costimulatory	B-X
receptor	B-X
necessary	B-X
full	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
The	B-X
role	B-X
of	B-X
CD28	B-X
in	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
has	B-X
been	B-X
evaluated	B-X
as	B-X
the	B-X
source	B-X
of	B-X
costimulatory	B-X
signals	B-X
integrating	B-X
those	B-X
delivered	B-X
by	B-X
TCR	B-X
.	B-X
However	B-X
,	B-X
CD28	B-X
is	B-X
also	B-X
able	B-X
to	B-X
act	B-X
as	B-X
a	B-X
unique	B-X
signaling	B-X
receptor	B-X
and	B-X
to	B-X
deliver	B-X
TCR-independent	B-X
autonomous	B-X
signals	B-X
,	B-X
which	B-X
regulate	B-X
the	B-X
expression	B-X
and	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
By	B-X
comparing	B-X
the	B-X
cytokine/chemokine	B-X
profiles	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
relapsing-remitting	B-X
multiple	B-X
sclerosis	B-X
(	B-X
RRMS	B-X
)	B-X
patients	B-X
and	B-X
healthy	B-X
donors	B-X
(	B-X
HD	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD28	B-X
engagement	B-X
without	B-X
TCR	B-X
strongly	B-X
up-regulates	B-X
IL-8	B-X
and	B-X
IL-6	B-X
expression	B-X
in	B-X
RRMS	B-X
compared	B-X
to	B-X
HD	B-X
.	B-X
More	B-X
interestingly	B-X
,	B-X
in	B-X
RRMS	B-X
but	B-X
not	B-X
in	B-X
HD	B-X
,	B-X
CD28	B-X
stimulation	B-X
selectively	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
IL-17A	B-X
by	B-X
cooperating	B-X
with	B-X
IL-6-mediated	B-X
signals	B-X
.	B-X
By	B-X
using	B-X
specific	B-X
inhibitory	B-X
drugs	B-X
,	B-X
we	B-X
also	B-X
identify	B-X
the	B-X
phosphatidylinositol	B-X
3	B-X
kinase	B-X
(	B-X
PI3K	B-X
)	B-X
as	B-X
the	B-X
critical	B-X
regulator	B-X
of	B-X
CD28	B-X
proinflammatory	B-X
functions	B-X
in	B-X
MS	B-X
.	B-X

This	O
cytokine	O
is	O
of	O
interest	O
for	O
two	O
major	O
reasons	O
:	O
first	O
,	O
similarly	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
proinflammatory	O
properties	O
;	O
second	O
,	O
it	O
is	O
produced	O
by	O
T	O
cells	O
[	O
6	O
]	O
.	O

Recent	O
observations	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
17	I-Protein
can	O
also	O
activate	O
osteoclastic	O
bone	O
resorption	O
by	O
the	O
induction	O
of	O
RANKL	B-Protein
(	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
nuclear	I-Protein
factor	I-Protein
kappaB	I-Protein
[	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
]	I-Protein
ligand	I-Protein
)	O
,	O
which	O
is	O
involved	O
in	O
bony	O
erosion	O
in	O
RA	O
[	O
7	O
]	O
.	O

It	O
also	O
stimulates	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
leukemia	B-Protein
inhibitory	I-Protein
factor	I-Protein
by	O
synoviocytes	O
,	O
and	O
of	O
prostaglandin	O
E2	O
and	O
nitric	O
oxide	O
by	O
chondrocytes	O
,	O
and	O
has	O
the	O
ability	O
to	O
differentiate	O
and	O
activate	O
the	O
dendritic	O
cells	O
[	O
8	O
-	O
10	O
]	O
.	O

Levels	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
synovial	O
fluids	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
RA	O
than	O
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
and	O
it	O
was	O
produced	O
by	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
synovium	O
[	O
11	O
,	O
12	O
]	O
.	O
<EOS>	B-X
To	B-X
delineate	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
IL-17	B-X
Receptor	B-X
(	B-X
IL-17RA	B-X
)	B-X
and	B-X
characterize	B-X
the	B-X
IL-17	B-X
producing	B-X
T	B-X
cell	B-X
(	B-X
Th17	B-X
)	B-X
subpopulation	B-X
in	B-X
psoriatic	B-X
arthritis	B-X
(	B-X
PsA	B-X
)	B-X
.	B-X
Mononuclear	B-X
cells	B-X
from	B-X
blood	B-X
and	B-X
synovial	B-X
fluid	B-X
(	B-X
SF	B-X
)	B-X
were	B-X
obtained	B-X
from	B-X
PsA	B-X
(	B-X
n=20	B-X
)	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
,	B-X
n=20	B-X
)	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
,	B-X
n=20	B-X
)	B-X
patients	B-X
.	B-X
Synoviocytes	B-X
(	B-X
FLS	B-X
)	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
synovium	B-X
of	B-X
RA	B-X
(	B-X
n=5	B-X
)	B-X
,	B-X
PsA	B-X
(	B-X
n=5	B-X
)	B-X
and	B-X
OA	B-X
(	B-X
n=5	B-X
)	B-X
patients	B-X
.	B-X
IL-17RA	B-X
expression	B-X
in	B-X
FLS	B-X
was	B-X
identified	B-X
by	B-X
western	B-X
blotting	B-X
(	B-X
WB	B-X
)	B-X
and	B-X
flowcytometry	B-X
.	B-X
T	B-X
lymphocytes	B-X
derived	B-X
from	B-X
the	B-X
SF	B-X
of	B-X
these	B-X
patients	B-X
were	B-X
studied	B-X
to	B-X
identify	B-X
and	B-X
phenotype	B-X
the	B-X
Th17	B-X
cells	B-X
.	B-X
The	B-X
functional	B-X
significance	B-X
of	B-X
IL-17RA	B-X
was	B-X
determined	B-X
by	B-X
evaluating	B-X
its	B-X
regulatory	B-X
role	B-X
on	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
endopeptidase	B-X
.	B-X
IL-17RA	B-X
expression	B-X
was	B-X
found	B-X
to	B-X
be	B-X
significantly	B-X
higher	B-X
in	B-X
FLS	B-X
of	B-X
RA	B-X
(	B-X
15.7	B-X
%	B-X
±4.9	B-X
)	B-X
and	B-X
PsA	B-X
(	B-X
4.5	B-X
%	B-X
±0.9	B-X
)	B-X
in	B-X
comparison	B-X
to	B-X
OA	B-X
(	B-X
1.14	B-X
%	B-X
±0.9	B-X
)	B-X
.	B-X
Western	B-X
blot	B-X
analyses	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
intensity	B-X
(	B-X
RI	B-X
)	B-X
of	B-X
IL-17RA	B-X
protein	B-X
was	B-X
higher	B-X
in	B-X
RA	B-X
and	B-X
PsA	B-X
compared	B-X
to	B-X
OA	B-X
(	B-X
Fisher	B-X
exact	B-X
,	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
A	B-X
significant	B-X
enrichment	B-X
of	B-X
IL-17-producing	B-X
CD4+	B-X
T	B-X
cells	B-X
(	B-X
7.9	B-X
%	B-X
±2.8	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
SF	B-X
of	B-X
PsA	B-X
patients	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
OA	B-X
patients	B-X
(	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
.	B-X
Compared	B-X
to	B-X
OA-FLS	B-X
,	B-X
recombinant	B-X
IL-17	B-X
induced	B-X
higher	B-X
levels	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
MMP-3	B-X
production	B-X
in	B-X
PsA-FLS	B-X
.	B-X
Blockage	B-X
of	B-X
IL-17RA	B-X
with	B-X
an	B-X
anti-IL-17RA	B-X
antibody	B-X
inhibited	B-X
the	B-X
production	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
MMP-3	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
demonstrate	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
IL-17RA	B-X
in	B-X
PsA	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
IL-17RA	B-X
blocking	B-X
antibodies	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
be	B-X
a	B-X
therapeutic	B-X
option	B-X
for	B-X
psoriatic	B-X
arthritis	B-X
.	B-X

IL	B-Protein
-	I-Protein
15	I-Protein
,	O
secreted	O
from	O
activated	O
macrophages	O
,	O
has	O
been	O
reported	O
to	O
be	O
an	O
important	O
trigger	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
by	O
cyclosporine	O
and	O
steroid	O
sensitive	O
pathways	O
[	O
13	O
]	O
.	O

Recently	O
,	O
Happel	O
and	O
colleagues	O
also	O
showed	O
that	O
IL	B-Protein
-	I-Protein
23	I-Protein
could	O
be	O
an	O
efficient	O
trigger	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
from	O
both	O
CD4	B-Protein
+	O
and	O
CD8	B-Protein
+	O
T	O
cells	O
[	O
14	O
]	O
.	O

Although	O
the	O
contribution	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
joint	O
inflammation	O
in	O
RA	O
has	O
been	O
documented	O
in	O
earlier	O
studies	O
[	O
12	O
,	O
15	O
,	O
16	O
]	O
,	O
the	O
intracellular	O
signal	O
transduction	O
pathway	O
for	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
remains	O
uncertain	O
.	O

In	O
the	O
present	O
study	O
we	O
used	O
various	O
stimuli	O
to	O
investigate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
of	O
patients	O
with	O
RA	O
and	O
its	O
signaling	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
the	O
intracellular	O
signaling	O
pathway	O
involving	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
and	O
NF	O
-	O
kappaB	O
might	O
be	O
involved	O
in	O
the	O
overproduction	O
of	O
the	O
key	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

These	O
results	O
might	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
of	O
RA	O
and	O
future	O
directions	O
for	O
new	O
therapeutic	O
strategies	O
in	O
RA	O
.	O
<EOS>	B-X
J.	B-X
Solé-Violán	B-X
,	B-X
M.	B-X
López-Rodríguez	B-X
,	B-X
E.	B-X
Herrera-Ramos	B-X
,	B-X
J.	B-X
Ruíz-Hernández	B-X
,	B-X
L.	B-X
Borderías	B-X
,	B-X
J.	B-X
Horcajada	B-X
,	B-X
N.	B-X
González-Quevedo	B-X
,	B-X
O.	B-X
Rajas	B-X
,	B-X
M.	B-X
Briones	B-X
,	B-X
F.	B-X
Rodríguez	B-X
de	B-X
Castro	B-X
,	B-X
C.	B-X
Rodríguez	B-X
Gallego	B-X
P003	B-X
-	B-X
Brain	B-X
protective	B-X
effects	B-X
of	B-X
intravenous	B-X
immunoglobulin	B-X
through	B-X
inhibition	B-X
of	B-X
complement	B-X
activation	B-X
and	B-X
apoptosis	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
sepsis	B-X
F.	B-X
Esen	B-X
,	B-X
G.	B-X
Orhun	B-X
,	B-X
P.	B-X
Ergin	B-X
Ozcan	B-X
,	B-X
E.	B-X
Senturk	B-X
,	B-X
C.	B-X
Ugur	B-X
Yilmaz	B-X
,	B-X
N.	B-X
Orhan	B-X
,	B-X
N.	B-X
Arican	B-X
,	B-X
M.	B-X
Kaya	B-X
,	B-X
M.	B-X
Kucukerden	B-X
,	B-X
M.	B-X
Giris	B-X
,	B-X
U.	B-X
Akcan	B-X
,	B-X
S.	B-X
Bilgic	B-X
Gazioglu	B-X
,	B-X
E.	B-X
Tuzun	B-X
P004	B-X
-	B-X
Adenosine	B-X
a1	B-X
receptor	B-X
dysfunction	B-X
is	B-X
associated	B-X
with	B-X
leukopenia	B-X
:	B-X
A	B-X
possible	B-X
mechanism	B-X
for	B-X
sepsis-induced	B-X
leukopenia	B-X
R.	B-X
Riff	B-X
,	B-X
O.	B-X
Naamani	B-X
,	B-X
A.	B-X
Douvdevani	B-X
P005	B-X
-	B-X
Analysis	B-X
of	B-X
neutrophil	B-X
by	B-X
hyper	B-X
spectral	B-X
imaging	B-X
-	B-X
A	B-X
preliminary	B-X
report	B-X
R.	B-X
Takegawa	B-X
,	B-X
H.	B-X
Yoshida	B-X
,	B-X
T.	B-X
Hirose	B-X
,	B-X
N.	B-X
Yamamoto	B-X
,	B-X
H.	B-X
Hagiya	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
Y.	B-X
Akeda	B-X
,	B-X
O.	B-X
Tasaki	B-X
,	B-X
K.	B-X
Tomono	B-X
,	B-X
T.	B-X
Shimazu	B-X
P006	B-X
-	B-X
Chemiluminescent	B-X
intensity	B-X
assessed	B-X
by	B-X
eaa	B-X
predicts	B-X
the	B-X
incidence	B-X
of	B-X
postoperative	B-X
infectious	B-X
complications	B-X
following	B-X
gastrointestinal	B-X
surgery	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Kubo	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
T.	B-X
Ikeda	B-X
P007	B-X
-	B-X
Serial	B-X
change	B-X
of	B-X
c1	B-X
inhibitor	B-X
in	B-X
patients	B-X
with	B-X
sepsis	B-X
–	B-X
A	B-X
prospective	B-X
observational	B-X
study	B-X
T.	B-X
Hirose	B-X
,	B-X
H.	B-X
Ogura	B-X
,	B-X
H.	B-X
Takahashi	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
J.	B-X
Kang	B-X
,	B-X
Y.	B-X
Nakamura	B-X
,	B-X
T.	B-X
Kojima	B-X
,	B-X
T.	B-X
Shimazu	B-X
P008	B-X
-	B-X
Comparison	B-X
of	B-X
bacteremia	B-X
and	B-X
sepsis	B-X
on	B-X
sepsis	B-X
related	B-X
biomarkers	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
Y.	B-X
Izutani	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
S.	B-X
Ono	B-X
P009	B-X
-	B-X
The	B-X
changes	B-X
of	B-X
procalcitonin	B-X
levels	B-X
in	B-X
critical	B-X
patients	B-X
with	B-X
abdominal	B-X
septic	B-X
shock	B-X
during	B-X
blood	B-X
purification	B-X
T.	B-X
Taniguchi	B-X
,	B-X
M.	B-X
O	B-X
P010	B-X
-	B-X
Validation	B-X
of	B-X
a	B-X
new	B-X
sensitive	B-X
point	B-X
of	B-X
care	B-X
device	B-X
for	B-X
rapid	B-X
measurement	B-X
of	B-X
procalcitonin	B-X
C.	B-X
Dinter	B-X
,	B-X
J.	B-X
Lotz	B-X
,	B-X
B.	B-X
Eilers	B-X
,	B-X
C.	B-X
Wissmann	B-X
,	B-X
R.	B-X
Lott	B-X
P011	B-X
-	B-X
Infection	B-X
biomarkers	B-X
in	B-X
primary	B-X
care	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
tract	B-X
infections	B-X
–	B-X
Comparison	B-X
of	B-X
procalcitonin	B-X
and	B-X
C-reactive	B-X
protein	B-X
M.	B-X
M.	B-X
Meili	B-X
,	B-X
P.	B-X
S.	B-X
Schuetz	B-X
P012	B-X
-	B-X
Do	B-X
we	B-X
need	B-X
a	B-X
lower	B-X
procalcitonin	B-X
cut	B-X
off	B-X
?	B-X
A	B-X
pilot	B-X
study	B-X
M.	B-X
Popescu	B-X
,	B-X
D.	B-X
Tomescu	B-X
P022	B-X
-	B-X
Comparison	B-X
of	B-X
CD64	B-X
levels	B-X
performed	B-X
by	B-X
the	B-X
facs	B-X
and	B-X
accellix	B-X
systems	B-X
C.	B-X
L.	B-X
Sprung	B-X
,	B-X
R.	B-X
Calderon	B-X
Morales	B-X
,	B-X
G.	B-X
Munteanu	B-X
,	B-X
E.	B-X
Orenbuch-Harroch	B-X
,	B-X
P.	B-X
Levin	B-X
,	B-X
H.	B-X
Kasdan	B-X
,	B-X
A.	B-X
Reiter	B-X
,	B-X
T.	B-X
Volker	B-X
,	B-X
Y.	B-X
Himmel	B-X
,	B-X
Y.	B-X
Cohen	B-X
,	B-X
J.	B-X
Meissonnier	B-X
P023	B-X
-	B-X
Diagnosing	B-X
sepsis	B-X
in	B-X
5	B-X
minutes	B-X
:	B-X
Nanofluidic	B-X
technology	B-X
study	B-X
with	B-X
pancreatic-stone	B-X
protein	B-X
(	B-X
PSP/	B-X
reg	B-X
)	B-X
L.	B-X
Girard	B-X
,	B-X
F.	B-X
Rebeaud	B-X
P024	B-X
-	B-X
How	B-X
nanotechnology-based	B-X
approaches	B-X
could	B-X
contribute	B-X
to	B-X
sepsis	B-X
prevention	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
I.	B-X
Herrmann	B-X
P025	B-X
-	B-X
Il7r	B-X
transcriptional	B-X
expression	B-X
analysis	B-X
during	B-X
septic	B-X
shock	B-X
B.	B-X
Delwarde	B-X
,	B-X
E.	B-X
Peronnet	B-X
,	B-X
E.	B-X
Cerrato	B-X
,	B-X
F.	B-X
Venet	B-X
,	B-X
A.	B-X
Lepape	B-X
,	B-X
T.	B-X
Rimmelé	B-X
,	B-X
G.	B-X
Monneret	B-X
,	B-X
J.	B-X
Textoris	B-X
P026	B-X
-	B-X
Disbalance	B-X
of	B-X
microbial	B-X
metabolites	B-X
of	B-X
aromatic	B-X
acids	B-X
affects	B-X
the	B-X
severity	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
N.	B-X
Beloborodova	B-X
,	B-X
V.	B-X
Moroz	B-X
,	B-X
A.	B-X
Osipov	B-X
,	B-X
A.	B-X
Bedova	B-X
,	B-X
Y.	B-X
Sarshor	B-X
,	B-X
A.	B-X
Pautova	B-X
,	B-X
A.	B-X
Sergeev	B-X
,	B-X
E.	B-X
Chernevskaya	B-X
P027	B-X
-	B-X
Copeptin	B-X
predicts	B-X
10-year	B-X
all-cause	B-X
mortality	B-X
in	B-X
community	B-X
patients	B-X
J.	B-X
Odermatt	B-X
,	B-X
R.	B-X
Bolliger	B-X
,	B-X
L.	B-X
Hersberger	B-X
,	B-X
M.	B-X
Ottiger	B-X
,	B-X
M.	B-X
Christ-Crain	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P028	B-X
-	B-X
Identification	B-X
of	B-X
differential	B-X
proteomic	B-X
response	B-X
in	B-X
septic	B-X
patients	B-X
secondary	B-X
to	B-X
community	B-X
and	B-X
hospital	B-X
acquired	B-X
pneumonia	B-X
N.	B-X
K.	B-X
Sharma	B-X
,	B-X
A.	B-X
K.	B-X
Tashima	B-X
,	B-X
M.	B-X
K.	B-X
Brunialti	B-X
,	B-X
F.	B-X
R.	B-X
Machado	B-X
,	B-X
M.	B-X
Assuncao	B-X
,	B-X
O.	B-X
Rigato	B-X
,	B-X
R.	B-X
Salomao	B-X
P029	B-X
-	B-X
Monocyte	B-X
HLA-DR	B-X
expression	B-X
in	B-X
community-acquired	B-X
bacteremic	B-X
sepsis	B-X
-	B-X
dynamics	B-X
associated	B-X
to	B-X
aetiology	B-X
and	B-X
prediction	B-X
of	B-X
secondary	B-X
sepsis	B-X
S.	B-X
C.	B-X
Cajander	B-X
,	B-X
G.	B-X
Rasmussen	B-X
,	B-X
E.	B-X
Tina	B-X
,	B-X
B.	B-X
Söderquist	B-X
,	B-X
J.	B-X
Källman	B-X
,	B-X
K.	B-X
Strålin	B-X
P030	B-X
-	B-X
Soluble	B-X
B-	B-X
and	B-X
T-lymphocyte	B-X
attenuator	B-X
:	B-X
A	B-X
possible	B-X
prognostic	B-X
marker	B-X
in	B-X
sepsis	B-X
A.	B-X
L.	B-X
Lange	B-X
,	B-X
J.	B-X
S.	B-X
Sundén-Cullberg	B-X
,	B-X
A.	B-X
M.	B-X
Magnuson	B-X
,	B-X
O.	B-X
H.	B-X
Hultgren	B-X
P031	B-X
-	B-X
Fractal	B-X
dimension	B-X
:	B-X
A	B-X
new	B-X
biomarker	B-X
for	B-X
quantifying	B-X
clot	B-X
microstructure	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
G.	B-X
Davies	B-X
,	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P032	B-X
-	B-X
Comparison	B-X
between	B-X
the	B-X
new	B-X
biomarker	B-X
for	B-X
coagulation	B-X
,	B-X
clot	B-X
microstructure	B-X
(	B-X
Df	B-X
)	B-X
with	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P033	B-X
-	B-X
Changes	B-X
in	B-X
fibrinolysis	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
:	B-X
The	B-X
use	B-X
of	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
lysis	B-X
index	B-X
(	B-X
LI60	B-X
)	B-X
and	B-X
D-Dimer	B-X
concentration	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P034	B-X
-	B-X
The	B-X
intensive	B-X
care	B-X
infection	B-X
score	B-X
–	B-X
a	B-X
promising	B-X
marker	B-X
for	B-X
the	B-X
prediction	B-X
of	B-X
infection	B-X
and	B-X
its	B-X
severity	B-X
.	B-X
Obstacles	B-X
on	B-X
the	B-X
4	B-X
year	B-X
journey	B-X
and	B-X
our	B-X
strategies	B-X
to	B-X
overcome	B-X
them	B-X
–	B-X
experience	B-X
from	B-X
an	B-X
Indian	B-X
ICU	B-X
V.	B-X
Adora	B-X
,	B-X
A.	B-X
Kar	B-X
,	B-X
A.	B-X
Chakraborty	B-X
,	B-X
S.	B-X
Roy	B-X
,	B-X
A.	B-X
Bandyopadhyay	B-X
,	B-X
M.	B-X
Das	B-X
P060	B-X
-	B-X
Novel	B-X
molecular	B-X
techniques	B-X
to	B-X
identify	B-X
central	B-X
venous	B-X
catheter	B-X
(	B-X
CVC	B-X
)	B-X
associated	B-X
blood	B-X
stream	B-X
infections	B-X
(	B-X
BSIs	B-X
)	B-X
T.	B-X
Mann	B-X
Ben	B-X
Yehudah	B-X
,	B-X
G.	B-X
Ben	B-X
Yehudah	B-X
,	B-X
M.	B-X
Salim	B-X
,	B-X
N.	B-X
Kumar	B-X
,	B-X
L.	B-X
Arabi	B-X
,	B-X
T.	B-X
Burger	B-X
,	B-X
P.	B-X
Lephart	B-X
,	B-X
E.	B-X
Toth-martin	B-X
P061	B-X
-	B-X
Zero	B-X
clabsi	B-X
”	B-X
–	B-X
can	B-X
we	B-X
get	B-X
there	B-X
?	B-X
Obstacles	B-X
on	B-X
the	B-X
4	B-X
year	B-X
journey	B-X
and	B-X
our	B-X
strategies	B-X
to	B-X
overcome	B-X
them	B-X
–	B-X
experience	B-X
from	B-X
an	B-X
Indian	B-X
ICU	B-X
R.	B-X
Rao	B-X
,	B-X
A.	B-X
Kar	B-X
,	B-X
A.	B-X
Chakraborty	B-X
P062	B-X
-	B-X
Prevention	B-X
of	B-X
central	B-X
line-associated	B-X
bloodstream	B-X
infections	B-X
in	B-X
intensive	B-X
care	B-X
units	B-X
:	B-X
An	B-X
international	B-X
online	B-X
survey	B-X
C.	B-X
Valencia	B-X
,	B-X
N.	B-X
Hammami	B-X
,	B-X
S.	B-X
Blot	B-X
,	B-X
J.	B-X
L.	B-X
Vincent	B-X
,	B-X
M.	B-X
L.	B-X
Lambert	B-X
P063	B-X
-	B-X
30	B-X
days	B-X
antimicrobial	B-X
efficacy	B-X
of	B-X
non-leaching	B-X
central	B-X
venous	B-X
catheters	B-X
J.	B-X
Brunke	B-X
,	B-X
T.	B-X
Riemann	B-X
,	B-X
I.	B-X
Roschke	B-X
P064	B-X
-	B-X
Efficacy	B-X
of	B-X
noble	B-X
metal	B-X
alloy-coated	B-X
catheter	B-X
in	B-X
prevention	B-X
of	B-X
bacteriuria	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P065	B-X
-	B-X
Predicting	B-X
bacteremic	B-X
urinary	B-X
tract	B-X
infection	B-X
in	B-X
community	B-X
setting	B-X
:	B-X
A	B-X
prospective	B-X
observational	B-X
study	B-X
S.	B-X
Nimitvilai	B-X
,	B-X
K.	B-X
Jintanapramote	B-X
,	B-X
S.	B-X
Jarupongprapa	B-X
P066	B-X
-	B-X
Eight-year	B-X
analysis	B-X
of	B-X
acinetobacter	B-X
spp	B-X
.	B-X
M.	B-X
Day	B-X
,	B-X
G.	B-X
Penrice	B-X
,	B-X
K.	B-X
Roy	B-X
,	B-X
P.	B-X
Robertson	B-X
,	B-X
G.	B-X
Godbole	B-X
,	B-X
B.	B-X
Jones	B-X
,	B-X
M.	B-X
Booth	B-X
,	B-X
L.	B-X
Donaldson	B-X
P072	B-X
-	B-X
Surveillance	B-X
of	B-X
ESBL-producing	B-X
enterobacteriaceae	B-X
fecal	B-X
carriers	B-X
in	B-X
the	B-X
ICU	B-X
Y.	B-X
Kawano	B-X
,	B-X
H.	B-X
Ishikura	B-X
P073	B-X
-	B-X
Prevalence	B-X
of	B-X
ESBL	B-X
and	B-X
carbapenemase	B-X
producing	B-X
uropathogens	B-X
in	B-X
a	B-X
newly	B-X
opened	B-X
hospital	B-X
in	B-X
south	B-X
India	B-X
S.	B-X
Sreevidya	B-X
,	B-X
N.	B-X
Brahmananda	B-X
Reddy	B-X
,	B-X
P.	B-X
Muraray	B-X
Govind	B-X
,	B-X
R.	B-X
Pratheema	B-X
,	B-X
J.	B-X
Devachandran	B-X
Apollo	B-X
Speciality	B-X
Hospital	B-X
-	B-X
OMR	B-X
,	B-X
Chennai	B-X
,	B-X
India	B-X
P074	B-X
-	B-X
Prevalence	B-X
,	B-X
risk	B-X
factors	B-X
and	B-X
outcomes	B-X
of	B-X
methicillin-resistant	B-X
staphylococcus	B-X
aureus	B-X
nasal	B-X
colonization	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
M.	B-X
Almutairi	B-X
,	B-X
B.	B-X
Alhamadi	B-X
,	B-X
A.	B-X
Crizaldo	B-X
Toledo	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
B.	B-X
Al	B-X
Raiy	B-X
,	B-X
Y.	B-X
Arabi	B-X
P075	B-X
-	B-X
Multidrug-resistant	B-X
Acinetobacter	B-X
baumannii	B-X
infection	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
patients	B-X
in	B-X
a	B-X
hospital	B-X
with	B-X
building	B-X
construction	B-X
:	B-X
Is	B-X
there	B-X
an	B-X
association	B-X
?	B-X
R.	B-X
Iqbal	B-X
,	B-X
Y.	B-X
Alhamdi	B-X
,	B-X
N.	B-X
Venugopal	B-X
,	B-X
S.	B-X
Abrams	B-X
,	B-X
C.	B-X
Downey	B-X
,	B-X
C.	B-X
H.	B-X
Toh	B-X
,	B-X
I.	B-X
D.	B-X
Welters	B-X
P128	B-X
-	B-X
Validity	B-X
of	B-X
the	B-X
age-adjusted	B-X
d-dimer	B-X
cutoff	B-X
in	B-X
patients	B-X
with	B-X
COPD	B-X
B.	B-X
Bombay	B-X
,	B-X
J.	B-X
M.	B-X
Chauny	B-X
,	B-X
R.	B-X
D.	B-X
Daoust	B-X
,	B-X
J.	B-X
L.	B-X
Lessard	B-X
,	B-X
M.	B-X
M.	B-X
Marquis	B-X
,	B-X
J.	B-X
P.	B-X
Paquet	B-X
P129	B-X
-	B-X
A	B-X
scoping	B-X
review	B-X
of	B-X
strategies	B-X
for	B-X
prevention	B-X
and	B-X
management	B-X
of	B-X
bleeding	B-X
following	B-X
paediatric	B-X
cardiopulmonary	B-X
bypass	B-X
surgery	B-X
K.	B-X
Siemens	B-X
,	B-X
D.	B-X
Sangaran	B-X
,	B-X
B.	B-X
J	B-X
.	B-X
A.	B-X
Omar	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
O.	B-X
Bilala	B-X
,	B-X
A.	B-X
Kindawi	B-X
,	B-X
H.	B-X
Ewila	B-X
P138	B-X
-	B-X
Dexamethasone	B-X
administration	B-X
during	B-X
cardiopulmonary	B-X
bypass	B-X
has	B-X
no	B-X
beneficial	B-X
effects	B-X
on	B-X
elective	B-X
postoperative	B-X
cardiac	B-X
surgery	B-X
patients	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
D.	B-X
Moisidou	B-X
,	B-X
M.	B-X
Nastou	B-X
,	B-X
E.	B-X
Dalampini	B-X
,	B-X
A.	B-X
Malamas	B-X
,	B-X
E.	B-X
Vasilarou	B-X
,	B-X
G.	B-X
Drossos	B-X
P139	B-X
-	B-X
Intra-aortic	B-X
balloon	B-X
counterpulsation	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
(	B-X
IABCS	B-X
)	B-X
:	B-X
preliminary	B-X
results	B-X
G.	B-X
Ferreira	B-X
,	B-X
J.	B-X
Caldas	B-X
,	B-X
J.	B-X
Fukushima	B-X
,	B-X
E.	B-X
A.	B-X
Osawa	B-X
,	B-X
E.	B-X
Arita	B-X
,	B-X
L.	B-X
Camara	B-X
,	B-X
S.	B-X
Zeferino	B-X
,	B-X
J.	B-X
Jardim	B-X
,	B-X
F.	B-X
Gaioto	B-X
,	B-X
L.	B-X
Dallan	B-X
,	B-X
F.	B-X
B.	B-X
Jatene	B-X
,	B-X
R.	B-X
Kalil	B-X
Filho	B-X
,	B-X
.F	B-X
Galas	B-X
,	B-X
L.	B-X
A.	B-X
Hajjar	B-X
P140	B-X
-	B-X
Effects	B-X
of	B-X
low-dose	B-X
atrial	B-X
natriuretic	B-X
peptide	B-X
infusion	B-X
on	B-X
cardiac	B-X
surgery-associated	B-X
acute	B-X
kidney	B-X
injury	B-X
C.	B-X
Mitaka	B-X
,	B-X
T.	B-X
Ohnuma	B-X
,	B-X
T.	B-X
Murayama	B-X
,	B-X
F.	B-X
Kunimoto	B-X
,	B-X
M.	B-X
Nagashima	B-X
,	B-X
T.	B-X
Takei	B-X
,	B-X
M.	B-X
Tomita	B-X
P141	B-X
-	B-X
Acute	B-X
kidney	B-X
injury	B-X
influence	B-X
on	B-X
high	B-X
sensitive	B-X
troponin	B-X
measurements	B-X
after	B-X
cardiac	B-X
surgery	B-X
A.	B-X
Omar	B-X
,	B-X
K.	B-X
Mahmoud	B-X
,	B-X
S.	B-X
Hanoura	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
P.	B-X
Sivadasan	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
Y.	B-X
Shouman	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P142	B-X
-	B-X
Complex	B-X
evaluation	B-X
of	B-X
endothelial	B-X
dysfunction	B-X
markers	B-X
for	B-X
prognosis	B-X
of	B-X
outcomes	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
I.	B-X
Mandel	B-X
,	B-X
S.	B-X
Mikheev	B-X
,	B-X
I.	B-X
Suhodolo	B-X
,	B-X
V.	B-X
Kiselev	B-X
,	B-X
Y.	B-X
Svirko	B-X
,	B-X
Y.	B-X
Podoksenov	B-X
P143	B-X
-	B-X
New-onset	B-X
atrial	B-X
fibrillation	B-X
in	B-X
intensive	B-X
care	B-X
:	B-X
incidence	B-X
,	B-X
management	B-X
and	B-X
outcome	B-X
S.	B-X
A.	B-X
Jenkins	B-X
,	B-X
R.	B-X
Griffin	B-X
P144	B-X
-	B-X
One	B-X
single	B-X
spot	B-X
measurement	B-X
of	B-X
the	B-X
sublingual	B-X
microcirculation	B-X
during	B-X
acute	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
pig	B-X
model	B-X
of	B-X
shock	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
A.	B-X
Lima	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
C.	B-X
Ince	B-X
P145	B-X
-	B-X
Assessment	B-X
of	B-X
levosimendan	B-X
as	B-X
a	B-X
therapeutic	B-X
option	B-X
to	B-X
recruit	B-X
the	B-X
microcirculation	B-X
in	B-X
cardiogenic	B-X
shock	B-X
–	B-X
initial	B-X
experience	B-X
in	B-X
cardiac	B-X
ICU	B-X
A.	B-X
Taha	B-X
,	B-X
A.	B-X
Shafie	B-X
,	B-X
M.	B-X
Mostafa	B-X
,	B-X
N.	B-X
Syed	B-X
,	B-X
H.	B-X
Hon	B-X
P146	B-X
-	B-X
Terlipressin	B-X
vs.	B-X
norepinephrine	B-X
in	B-X
the	B-X
Potential	B-X
Multiorgan	B-X
Donor	B-X
(	B-X
PMD	B-X
)	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
,	B-X
G.	B-X
Castellano	B-X
P147	B-X
-	B-X
Echocardiography	B-X
in	B-X
the	B-X
potential	B-X
heart	B-X
donor	B-X
exposed	B-X
to	B-X
substitution	B-X
hormonotherapy	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
P148	B-X
-	B-X
Machine	B-X
learning	B-X
can	B-X
reduce	B-X
rate	B-X
of	B-X
monitor	B-X
alarms	B-X
M.	B-X
Hravnak	B-X
,	B-X
L.	B-X
C.	B-X
Chen	B-X
,	B-X
A.	B-X
D.	B-X
Dubrawski	B-X
,	B-X
G.	B-X
C.	B-X
Clermont	B-X
,	B-X
M.	B-X
R.	B-X
Pinsky	B-X
P149	B-X
-	B-X
Peripherally	B-X
inserted	B-X
central	B-X
catheters	B-X
placed	B-X
in	B-X
the	B-X
ICU	B-X
S.	B-X
Gonzalez	B-X
,	B-X
D.	B-X
Macias	B-X
,	B-X
J.	B-X
Acosta	B-X
,	B-X
P.	B-X
Jimenez	B-X
,	B-X
A.	B-X
Loza	B-X
,	B-X
A.	B-X
Lesmes	B-X
,	B-X
F.	B-X
Lucena	B-X
,	B-X
C.	B-X
Leon	B-X
P150	B-X
-	B-X
Recordings	B-X
of	B-X
abnormal	B-X
central	B-X
venous	B-X
pressure	B-X
waveform	B-X
morphology	B-X
during	B-X
an	B-X
episode	B-X
of	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
porcine	B-X
shock	B-X
model	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
C.	B-X
Ince	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
A.	B-X
Lima	B-X
P151	B-X
-	B-X
Ultrasound	B-X
guided	B-X
central	B-X
venous	B-X
access	B-X
technique	B-X
among	B-X
French	B-X
intensivists	B-X
M.	B-X
Bastide	B-X
,	B-X
J.	B-X
Richecoeur	B-X
,	B-X
E.	B-X
Frenoy	B-X
,	B-X
C.	B-X
Lemaire	B-X
,	B-X
B.	B-X
Sauneuf	B-X
,	B-X
F.	B-X
Tamion	B-X
,	B-X
S.	B-X
Nseir	B-X
,	B-X
D.	B-X
Du	B-X
Cheyron	B-X
,	B-X
H.	B-X
Dupont	B-X
,	B-X
J.	B-X
Maizel	B-X
P152	B-X
-	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Pv-aCO2	B-X
gap	B-X
in	B-X
patients	B-X
with	B-X
shock	B-X
M.	B-X
Shaban	B-X
,	B-X
R.	B-X
Kolko	B-X
,	B-X
N.	B-X
Salahuddin	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
AbuRageila	B-X
,	B-X
A.	B-X
AlHussain	B-X
P153	B-X
-	B-X
Comparison	B-X
of	B-X
echocardiography	B-X
and	B-X
pulmonary	B-X
artery	B-X
catheter	B-X
measurements	B-X
of	B-X
hemodynamic	B-X
parameters	B-X
in	B-X
critical	B-X
ill	B-X
patients	B-X
P.	B-X
Mercado	B-X
,	B-X
J.	B-X
Maizel	B-X
,	B-X
L.	B-X
Kontar	B-X
,	B-X
D.	B-X
Titeca	B-X
,	B-X
F.	B-X
Brazier	B-X
,	B-X
A.	B-X
Riviere	B-X
,	B-X
M.	B-X
Joris	B-X
,	B-X
T.	B-X
Soupison	B-X
,	B-X
B.	B-X
T.	B-X
E.	B-X
Doris	B-X
,	B-X
D.	B-X
Monkhouse	B-X
,	B-X
T.	B-X
Shipley	B-X
,	B-X
S.	B-X
Kardasz	B-X
,	B-X
I	B-X
Gonzalez	B-X
P185	B-X
-	B-X
High	B-X
initiation	B-X
creatinine	B-X
associated	B-X
with	B-X
lower	B-X
28-day	B-X
mortality	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
necessitating	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Stads	B-X
,	B-X
A.	B-X
J.	B-X
Groeneveld	B-X
P186	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
Karnofsky	B-X
performance	B-X
scale	B-X
on	B-X
outcomes	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
patients	B-X
receiving	B-X
renal	B-X
replacement	B-X
therapy	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
I.	B-X
Elsayed	B-X
,	B-X
N.	B-X
Ward	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
A.	B-X
Raithatha	B-X
P187	B-X
-	B-X
Severe	B-X
hypophosphatemia	B-X
during	B-X
citrate-anticoagulated	B-X
CRRT	B-X
A.	B-X
Steuber	B-X
,	B-X
C.	B-X
Pelletier	B-X
,	B-X
S.	B-X
Schroeder	B-X
,	B-X
E.	B-X
Michael	B-X
,	B-X
T.	B-X
Slowinski	B-X
,	B-X
D.	B-X
Kindgen-Milles	B-X
P188	B-X
-	B-X
Citrate	B-X
regional	B-X
anticoagulation	B-X
for	B-X
post	B-X
dilution	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Ghabina	B-X
P189	B-X
-	B-X
Citrate	B-X
18	B-X
mmol/l	B-X
improves	B-X
anticoagulation	B-X
during	B-X
RRT	B-X
with	B-X
adsorbing	B-X
filters	B-X
F.	B-X
Turani	B-X
,	B-X
A.	B-X
Belli	B-X
,	B-X
S.	B-X
Busatti	B-X
,	B-X
G.	B-X
Barettin	B-X
,	B-X
F.	B-X
Candidi	B-X
,	B-X
F.	B-X
Gargano	B-X
,	B-X
R.	B-X
Barchetta	B-X
,	B-X
M.	B-X
Falco	B-X
P190	B-X
-	B-X
Calcium	B-X
gluconate	B-X
instead	B-X
of	B-X
calcium	B-X
chloride	B-X
in	B-X
citrate-anticoagulated	B-X
CVVHD	B-X
O.	B-X
Demirkiran	B-X
,	B-X
M.	B-X
Kosuk	B-X
,	B-X
S.	B-X
Bozbay	B-X
P191	B-X
-	B-X
Enhanced	B-X
clearance	B-X
of	B-X
interleukin-6	B-X
with	B-X
continuous	B-X
veno-venous	B-X
haemodialysis	B-X
(	B-X
CVVHD	B-X
)	B-X
using	B-X
Ultraflux	B-X
EMiC2	B-X
vs.	B-X
Ultraflux	B-X
AV1000S	B-X
V.	B-X
Weber	B-X
,	B-X
J.	B-X
Hartmann	B-X
,	B-X
S.	B-X
Harm	B-X
,	B-X
I.	B-X
Linsberger	B-X
,	B-X
T.	B-X
Eichhorn	B-X
,	B-X
G.	B-X
Valicek	B-X
,	B-X
G.	B-X
Miestinger	B-X
,	B-X
C.	B-X
Hoermann	B-X
P192	B-X
-	B-X
Removal	B-X
of	B-X
bilirubin	B-X
with	B-X
a	B-X
new	B-X
adsorbent	B-X
system	B-X
:	B-X
in	B-X
vitro	B-X
kinetics	B-X
S.	B-X
Faenza	B-X
,	B-X
D.	B-X
Ricci	B-X
,	B-X
E.	B-X
Mancini	B-X
,	B-X
C.	B-X
Gemelli	B-X
,	B-X
A.	B-X
Cuoghi	B-X
,	B-X
S.	B-X
Magnani	B-X
,	B-X
M.	B-X
Atti	B-X
P193	B-X
-	B-X
Case	B-X
series	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
treated	B-X
with	B-X
a	B-X
new	B-X
extracorporeal	B-X
sorbent	B-X
T.	B-X
Laddomada	B-X
,	B-X
A.	B-X
Doronzio	B-X
,	B-X
B.	B-X
Balicco	B-X
P194	B-X
-	B-X
In	B-X
vitro	B-X
adsorption	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
inflammatory	B-X
mediators	B-X
with	B-X
CytoSorb®	B-X
hemoadsorbent	B-X
polymer	B-X
beads	B-X
M.	B-X
C.	B-X
Gruda	B-X
,	B-X
P.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
V.	B-X
P.	B-X
Dan	B-X
,	B-X
T.	B-X
Guliashvili	B-X
,	B-X
A.	B-X
Scheirer	B-X
,	B-X
T.	B-X
D.	B-X
Golobish	B-X
,	B-X
V.	B-X
J.	B-X
Capponi	B-X
,	B-X
P.	B-X
P.	B-X
Chan	B-X
P195	B-X
-	B-X
Observations	B-X
in	B-X
early	B-X
vs.	B-X
late	B-X
use	B-X
of	B-X
cytosorb	B-X
therapy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
K.	B-X
Kogelmann	B-X
,	B-X
M.	B-X
Drüner	B-X
,	B-X
D.	B-X
Jarczak	B-X
P196	B-X
-	B-X
Oxiris	B-X
membrane	B-X
decreases	B-X
endotoxin	B-X
during	B-X
rrt	B-X
in	B-X
septic	B-X
patients	B-X
with	B-X
basal	B-X
EAA	B-X
>	B-X
0,6	B-X
F.	B-X
Turani	B-X
,	B-X
A	B-X
.	B-X
A	B-X
single	B-X
center	B-X
retrospective	B-X
study	B-X
S.	B-X
Hanoura	B-X
,	B-X
A.	B-X
Omar	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
M.	B-X
Maksoud	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P216	B-X
-	B-X
Post-operative	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
major	B-X
non-cardiac	B-X
surgery	B-X
and	B-X
its	B-X
association	B-X
with	B-X
death	B-X
in	B-X
the	B-X
following	B-X
year	B-X
M.	B-X
E.	B-X
O	B-X
’	B-X
Connor	B-X
,	B-X
R.	B-X
W.	B-X
Hewson	B-X
,	B-X
C.	B-X
J.	B-X
Kirwan	B-X
,	B-X
R.	B-X
M.	B-X
Pearse	B-X
,	B-X
J.	B-X
Prowle	B-X
P217	B-X
-	B-X
Factors	B-X
affecting	B-X
acute	B-X
renal	B-X
failure	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
effect	B-X
of	B-X
these	B-X
factors	B-X
on	B-X
mortality	B-X
O.	B-X
Uzundere	B-X
,	B-X
D.	B-X
Memis	B-X
,	B-X
M.	B-X
Ýnal	B-X
,	B-X
A.	B-X
,	B-X
N.	B-X
Turan	B-X
P218	B-X
-	B-X
Results	B-X
of	B-X
the	B-X
live	B-X
kidney	B-X
transplantations	B-X
according	B-X
to	B-X
national	B-X
data	B-X
of	B-X
turkish	B-X
organ	B-X
and	B-X
tissue	B-X
information	B-X
system	B-X
M.	B-X
A.	B-X
Aydin	B-X
,	B-X
H.	B-X
Basar	B-X
,	B-X
I.	B-X
Sencan	B-X
,	B-X
A.	B-X
Kapuagasi	B-X
,	B-X
M.	B-X
Ozturk	B-X
,	B-X
Z.	B-X
Uzundurukan	B-X
,	B-X
D.	B-X
Gokmen	B-X
,	B-X
A.	B-X
Ozcan	B-X
,	B-X
C.	B-X
Kaymak	B-X
P219	B-X
-	B-X
Anaesthesia	B-X
procedure	B-X
and	B-X
intensive	B-X
therapy	B-X
in	B-X
patients	B-X
with	B-X
neck	B-X
phlegmon	B-X
V.	B-X
A.	B-X
Artemenko	B-X
,	B-X
A.	B-X
Budnyuk	B-X
P220	B-X
-	B-X
Nasal	B-X
high	B-X
flow	B-X
oygen	B-X
for	B-X
acute	B-X
respiratory	B-X
failure	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
R.	B-X
Pugh	B-X
,	B-X
S.	B-X
Bhandari	B-X
P221	B-X
-	B-X
Setting	B-X
optimal	B-X
flow	B-X
rate	B-X
during	B-X
high	B-X
flow	B-X
nasal	B-X
cannula	B-X
support	B-X
:	B-X
preliminary	B-X
results	B-X
T.	B-X
Mauri	B-X
,	B-X
C.	B-X
Turrini	B-X
,	B-X
T.	B-X
Langer	B-X
,	B-X
P.	B-X
Taccone	B-X
,	B-X
C.	B-X
A.	B-X
Volta	B-X
,	B-X
C.	B-X
Marenghi	B-X
,	B-X
L.	B-X
Gattinoni	B-X
,	B-X
A.	B-X
Pesenti	B-X
P222	B-X
-	B-X
Dose	B-X
to	B-X
dose	B-X
consistency	B-X
across	B-X
two	B-X
different	B-X
gas	B-X
flow	B-X
rates	B-X
using	B-X
cystic	B-X
fibrosis	B-X
and	B-X
normal	B-X
adult	B-X
breathing	B-X
profiles	B-X
during	B-X
nasal	B-X
high	B-X
flow	B-X
oxygen	B-X
therapy	B-X
L.	B-X
Sweeney	B-X
,	B-X
A	B-X
.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P223	B-X
-	B-X
Final	B-X
results	B-X
of	B-X
an	B-X
evaluation	B-X
of	B-X
airway	B-X
medix	B-X
closed	B-X
suction	B-X
system	B-X
compared	B-X
to	B-X
a	B-X
standard	B-X
closed	B-X
suction	B-X
system	B-X
M.	B-X
Pfeffer	B-X
,	B-X
J.	B-X
T.	B-X
Thomas	B-X
,	B-X
G.	B-X
B.	B-X
Bregman	B-X
,	B-X
G.	B-X
K.	B-X
Karp	B-X
,	B-X
E.	B-X
K.	B-X
Kishinevsky	B-X
,	B-X
D.	B-X
S.	B-X
Stavi	B-X
,	B-X
N.	B-X
A.	B-X
Adi	B-X
P224	B-X
-	B-X
Different	B-X
cuff	B-X
materials	B-X
and	B-X
different	B-X
leak	B-X
tests	B-X
-	B-X
one	B-X
size	B-X
does	B-X
not	B-X
fit	B-X
all	B-X
T.	B-X
Poropat	B-X
,	B-X
R.	B-X
Knafelj	B-X
P225	B-X
-	B-X
Observational	B-X
study	B-X
on	B-X
the	B-X
value	B-X
of	B-X
the	B-X
cuff-leak	B-X
test	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
upper	B-X
airway	B-X
obstruction	B-X
after	B-X
extubation	B-X
E.	B-X
Llopart	B-X
,	B-X
M.	B-X
Batlle	B-X
,	B-X
C.	B-X
De	B-X
Haro	B-X
,	B-X
J.	B-X
Mesquida	B-X
,	B-X
A.	B-X
Artigas	B-X
P226	B-X
-	B-X
A	B-X
device	B-X
for	B-X
emergency	B-X
transtracheal	B-X
lung	B-X
ventilation	B-X
D.	B-X
Pavlovic	B-X
,	B-X
L.	B-X
Lewerentz	B-X
,	B-X
A.	B-X
Spassov	B-X
,	B-X
R.	B-X
Schneider	B-X
P227	B-X
-	B-X
Long-term	B-X
outcome	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
patients	B-X
discharged	B-X
from	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
with	B-X
a	B-X
tracheostomy	B-X
and	B-X
with	B-X
or	B-X
without	B-X
prolonged	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
De	B-X
Smet	B-X
,	B-X
S.	B-X
De	B-X
Raedt	B-X
,	B-X
E.	B-X
Derom	B-X
,	B-X
P	B-X
Depuydt	B-X
,	B-X
S.	B-X
Oeyen	B-X
,	B-X
D.	B-X
Benoit	B-X
,	B-X
J.	B-X
Decruyenaere	B-X
P228	B-X
-	B-X
Ultrasound-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
versus	B-X
bronchoscopy-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
(	B-X
trachus	B-X
)	B-X
:	B-X
a	B-X
randomized	B-X
clinical	B-X
trial	B-X
A.	B-X
Gobatto	B-X
,	B-X
B.	B-X
Bese	B-X
,	B-X
P.	B-X
Tierno	B-X
,	B-X
L.	B-X
Melro	B-X
,	B-X
P.	B-X
Mendes	B-X
,	B-X
F.	B-X
Cadamuro	B-X
,	B-X
M.	B-X
Park	B-X
,	B-X
L.	B-X
M.	B-X
Malbouisson	B-X
P229	B-X
-	B-X
Is	B-X
it	B-X
safe	B-X
to	B-X
discharge	B-X
patients	B-X
with	B-X
tracheostomy	B-X
from	B-X
the	B-X
ICU	B-X
to	B-X
the	B-X
ward	B-X
?	B-X
B.	B-X
C.	B-X
Civanto	B-X
,	B-X
J.	B-X
L.	B-X
Lopez	B-X
,	B-X
A.	B-X
Robles	B-X
,	B-X
J.	B-X
Figueira	B-X
,	B-X
S.	B-X
Yus	B-X
,	B-X
A.	B-X
Garcia	B-X
P230	B-X
-	B-X
The	B-X
application	B-X
of	B-X
tracheostomy	B-X
in	B-X
children	B-X
in	B-X
ICU	B-X
A.	B-X
Oglinda	B-X
,	B-X
G.	B-X
Ciobanu	B-X
,	B-X
C.	B-X
Oglinda	B-X
,	B-X
L.	B-X
Schirca	B-X
,	B-X
T.	B-X
Sertinean	B-X
,	B-X
V.	B-X
Lupu	B-X
P231	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
passive	B-X
humidifiers	B-X
on	B-X
aerosol	B-X
drug	B-X
delivery	B-X
during	B-X
mechanical	B-X
ventilation	B-X
P.	B-X
Kelly	B-X
,	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P232	B-X
-	B-X
Evaluation	B-X
of	B-X
vibrating	B-X
mesh	B-X
and	B-X
jet	B-X
nebuliser	B-X
performance	B-X
at	B-X
two	B-X
different	B-X
attachment	B-X
setups	B-X
in	B-X
line	B-X
with	B-X
a	B-X
humidifier	B-X
nebuliser	B-X
system	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
M.	B-X
Wolny	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P233	B-X
-	B-X
Psv-niv	B-X
versus	B-X
cpap	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
acute	B-X
cardiogenic	B-X
pulmonary	B-X
edema	B-X
A.	B-X
Pagano	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
G.	B-X
Vison	B-X
,	B-X
L.	B-X
Saldamarco	B-X
,	B-X
T.	B-X
Russo	B-X
,	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Paladino	B-X
P234	B-X
-	B-X
Noninvasive	B-X
ventilation	B-X
in	B-X
patients	B-X
with	B-X
haematologic	B-X
malignancy	B-X
:	B-X
a	B-X
retrospective	B-X
review	B-X
C.	B-X
Bell	B-X
,	B-X
J.	B-X
Liu	B-X
,	B-X
J.	B-X
Debacker	B-X
,	B-X
C.	B-X
Lee	B-X
,	B-X
E.	B-X
Tamberg	B-X
,	B-X
V.	B-X
Campbell	B-X
,	B-X
S.	B-X
Mehta	B-X
P235	B-X
-	B-X
Use	B-X
of	B-X
non-invasive	B-X
ventilation	B-X
in	B-X
infectious	B-X
diseases	B-X
besides	B-X
classical	B-X
indications	B-X
A.	B-X
Silva-Pinto	B-X
,	B-X
A.	B-X
Sarmento	B-X
,	B-X
L.	B-X
Santos	B-X
P236	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
fragility	B-X
on	B-X
noninvasive	B-X
mechanical	B-X
ventilation	B-X
application	B-X
and	B-X
results	B-X
in	B-X
the	B-X
ICU	B-X
Ý.	B-X
Kara	B-X
,	B-X
F.	B-X
Yýldýrým	B-X
,	B-X
A.	B-X
Zerman	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
N.	B-X
Boyacý	B-X
,	B-X
B.	B-X
Basarýk	B-X
Aydogan	B-X
,	B-X
Ü.	B-X
Gaygýsýz	B-X
,	B-X
K.	B-X
Gönderen	B-X
,	B-X
G.	B-X
Arýk	B-X
,	B-X
M.	B-X
Turkoglu	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Aygencel	B-X
,	B-X
Z.	B-X
Ülger	B-X
,	B-X
G.	B-X
Gursel	B-X
P237	B-X
-	B-X
Effects	B-X
of	B-X
metabolic	B-X
alkalosis	B-X
on	B-X
noninvasive	B-X
ventilation	B-X
success	B-X
and	B-X
ICU	B-X
outcome	B-X
in	B-X
patients	B-X
with	B-X
hypercapnic	B-X
respiratory	B-X
failure	B-X
N.	B-X
Boyacý	B-X
,	B-X
Z.	B-X
Isýkdogan	B-X
,	B-X
Ö.	B-X
Özdedeoglu	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
M.	B-X
Badoglu	B-X
,	B-X
U.	B-X
Gaygýsýz	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Gursel	B-X
P238	B-X
-	B-X
Asynchrony	B-X
index	B-X
and	B-X
breathing	B-X
patterns	B-X
of	B-X
acute	B-X
exacerbation	B-X
copd	B-X
patients	B-X
assisted	B-X
with	B-X
noninvasive	B-X
pressure	B-X
support	B-X
ventilation	B-X
and	B-X
neurally	B-X
adjusted	B-X
ventilatory	B-X
assist	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
C.	B-X
Sittipunt	B-X
P239	B-X
-	B-X
High	B-X
frequency	B-X
jet	B-X
ventilation	B-X
for	B-X
severe	B-X
acute	B-X
hypoxemia	B-X
A.	B-X
Eden	B-X
,	B-X
Y.	B-X
Kokhanovsky	B-X
,	B-X
S.	B-X
Bursztein	B-X
–	B-X
De	B-X
Myttenaere	B-X
,	B-X
R.	B-X
Pizov	B-X
P240	B-X
-	B-X
HFOV	B-X
revisited	B-X
:	B-X
a	B-X
7	B-X
year	B-X
retrospective	B-X
analysis	B-X
of	B-X
patients	B-X
receiving	B-X
HFOV	B-X
who	B-X
met	B-X
oscillate	B-X
trial	B-X
entry	B-X
criteria	B-X
L.	B-X
Neilans	B-X
,	B-X
N.	B-X
MacIntyre	B-X
P241	B-X
-	B-X
Implementation	B-X
of	B-X
a	B-X
goal-directed	B-X
mechanical	B-X
ventilation	B-X
order	B-X
set	B-X
driven	B-X
by	B-X
respiratory	B-X
therapists	B-X
can	B-X
improve	B-X
compliance	B-X
with	B-X
best	B-X
practices	B-X
for	B-X
mechanical	B-X
ventilation	B-X
M.	B-X
Radosevich	B-X
,	B-X
B.	B-X
Wanta	B-X
,	B-X
V.	B-X
Weber	B-X
,	B-X
T.	B-X
Meyer	B-X
,	B-X
N.	B-X
Smischney	B-X
,	B-X
D.	B-X
Brown	B-X
,	B-X
D.	B-X
Diedrich	B-X
P242	B-X
-	B-X
A	B-X
reduction	B-X
in	B-X
tidal	B-X
volumes	B-X
for	B-X
ventilated	B-X
patients	B-X
on	B-X
ICU	B-X
calculated	B-X
from	B-X
IBW	B-X
.	B-X
can	B-X
it	B-X
minimise	B-X
mortality	B-X
in	B-X
comparison	B-X
to	B-X
traditional	B-X
strategies	B-X
?	B-X
M.	B-X
Thijssen	B-X
,	B-X
L.	B-X
Janssen	B-X
,	B-X
N.	B-X
Foudraine	B-X
P249	B-X
-	B-X
Ventilation	B-X
is	B-X
a	B-X
better	B-X
assessment	B-X
of	B-X
respiratory	B-X
status	B-X
than	B-X
EtCO2	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
P250	B-X
-	B-X
Evaluation	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
non-invasive	B-X
minute	B-X
ventilation	B-X
and	B-X
end-tidal	B-X
CO2	B-X
in	B-X
patients	B-X
undergoing	B-X
general	B-X
vs	B-X
spinal	B-X
anesthesia	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P251	B-X
-	B-X
Respiratory	B-X
volume	B-X
monitoring	B-X
provides	B-X
early	B-X
warning	B-X
of	B-X
respiratory	B-X
depression	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
reduce	B-X
false	B-X
alarms	B-X
in	B-X
non-intubated	B-X
patients	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
D.	B-X
Eversole	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P252	B-X
-	B-X
P/i	B-X
index	B-X
:	B-X
a	B-X
predictive	B-X
edi-derived	B-X
weaning	B-X
index	B-X
during	B-X
nava	B-X
S.	B-X
Muttini	B-X
,	B-X
R.	B-X
Bigi	B-X
,	B-X
G.	B-X
Villani	B-X
,	B-X
N.	B-X
Patroniti	B-X
P253	B-X
-	B-X
Adequacy	B-X
of	B-X
ventilation	B-X
in	B-X
patients	B-X
receiving	B-X
opioids	B-X
in	B-X
the	B-X
post	B-X
anesthesia	B-X
care	B-X
unit	B-X
:	B-X
minute	B-X
ventilation	B-X
versus	B-X
respiratory	B-X
rate	B-X
G.	B-X
Williams	B-X
,	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P254	B-X
-	B-X
Comparison	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constants	B-X
measured	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
(	B-X
EIT	B-X
)	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P255	B-X
-	B-X
Electrical	B-X
impedance	B-X
tomography	B-X
:	B-X
robustness	B-X
of	B-X
a	B-X
new	B-X
pixel	B-X
wise	B-X
regional	B-X
expiratory	B-X
time	B-X
constant	B-X
calculation	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P256	B-X
-	B-X
Validation	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constant	B-X
measurement	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
in	B-X
ards	B-X
and	B-X
obstructive	B-X
pulmonary	B-X
diseases	B-X
C.	B-X
K.	B-X
Karagiannidis	B-X
,	B-X
A.	B-X
W.	B-X
Waldmann	B-X
,	B-X
S.	B-X
B.	B-X
Böhm	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
W.	B-X
W.	B-X
Windisch	B-X
P257	B-X
-	B-X
Transpulmonary	B-X
pressure	B-X
in	B-X
a	B-X
model	B-X
with	B-X
elastic	B-X
recoiling	B-X
lung	B-X
and	B-X
expanding	B-X
chest	B-X
wall	B-X
P.	B-X
Persson	B-X
,	B-X
S.	B-X
Lundin	B-X
,	B-X
O.	B-X
Stenqvist	B-X
P258	B-X
-	B-X
Lactate	B-X
in	B-X
pleural	B-X
and	B-X
abdominal	B-X
effusion	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
C.	B-X
S.	B-X
Serra	B-X
,	B-X
A.	B-X
P.	B-X
Pagano	B-X
,	B-X
M.	B-X
M.	B-X
Masarone	B-X
,	B-X
L.	B-X
R.	B-X
Rinaldi	B-X
,	B-X
A	B-X
.	B-X
A.	B-X
Kellum	B-X
P266	B-X
-	B-X
Procalcitonin	B-X
as	B-X
predictor	B-X
of	B-X
primary	B-X
graft	B-X
dysfunction	B-X
and	B-X
mortality	B-X
in	B-X
post-lung	B-X
transplantation	B-X
C.	B-X
Mazo	B-X
Torre	B-X
,	B-X
J.	B-X
Riera	B-X
,	B-X
S.	B-X
Ramirez	B-X
,	B-X
B.	B-X
Borgatta	B-X
,	B-X
L.	B-X
Lagunes	B-X
,	B-X
J.	B-X
Rello	B-X
P267	B-X
-	B-X
New	B-X
molecular	B-X
biomarkers	B-X
of	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
in	B-X
abdominal	B-X
sepsis	B-X
A.	B-X
K.	B-X
Kuzovlev	B-X
,	B-X
V.	B-X
Moroz	B-X
,	B-X
A.	B-X
Goloubev	B-X
,	B-X
S.	B-X
Polovnikov	B-X
,	B-X
S.	B-X
Nenchuk	B-X
P268	B-X
-	B-X
Tight	B-X
junction	B-X
’	B-X
s	B-X
proteins	B-X
claudin	B-X
-5	B-X
and	B-X
regulation	B-X
by	B-X
tnf	B-X
in	B-X
experimental	B-X
murine	B-X
lung	B-X
injury	B-X
model	B-X
of	B-X
ali/ards	B-X
V.	B-X
Karavana	B-X
,	B-X
C.	B-X
Glynos	B-X
,	B-X
A.	B-X
Asimakos	B-X
,	B-X
K.	B-X
Pappas	B-X
,	B-X
C.	B-X
Vrettou	B-X
,	B-X
M.	B-X
Magkou	B-X
,	B-X
E.	B-X
Ischaki	B-X
,	B-X
G.	B-X
Stathopoulos	B-X
,	B-X
S.	B-X
Zakynthinos	B-X
P269	B-X
-	B-X
Cell	B-X
counts	B-X
in	B-X
endobronchial	B-X
aspirate	B-X
to	B-X
assess	B-X
airway	B-X
inflammation	B-X
in	B-X
ARDS	B-X
patients	B-X
:	B-X
a	B-X
pilot	B-X
study	B-X
S.	B-X
Spadaro	B-X
,	B-X
I.	B-X
Kozhevnikova	B-X
,	B-X
F.	B-X
Dalla	B-X
Corte	B-X
,	B-X
S.	B-X
Grasso	B-X
,	B-X
P.	B-X
Casolari	B-X
,	B-X
G.	B-X
Caramori	B-X
,	B-X
C.	B-X
Volta	B-X
P270	B-X
-	B-X
Epidemiological	B-X
and	B-X
clinical	B-X
profile	B-X
of	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
in	B-X
the	B-X
surgical	B-X
intensive	B-X
care	B-X
unit	B-X
surgical	B-X
,	B-X
hospital	B-X
JRA	B-X
,	B-X
Antananarivo	B-X
T.	B-X
Andrianjafiarinoa	B-X
,	B-X
T.	B-X
Randriamandrato	B-X
,	B-X
T.	B-X
Rajaonera	B-X
P271	B-X
-	B-X
Effect	B-X
of	B-X
high	B-X
PEEP	B-X
after	B-X
recruitment	B-X
maneuver	B-X
on	B-X
right	B-X
ventricular	B-X
function	B-X
in	B-X
ARDS	B-X
.	B-X
T.	B-X
Oshima	B-X
,	B-X
S.	B-X
Graf	B-X
,	B-X
C.	B-X
Heidegger	B-X
,	B-X
L.	B-X
Genton	B-X
,	B-X
V.	B-X
Karsegard	B-X
,	B-X
Y.	B-X
Dupertuis	B-X
,	B-X
C.	B-X
Pichard	B-X
P285	B-X
-	B-X
Revisiting	B-X
the	B-X
refeeding	B-X
syndrome	B-X
:	B-X
results	B-X
of	B-X
a	B-X
systematic	B-X
review	B-X
N.	B-X
Friedli	B-X
,	B-X
Z.	B-X
Stanga	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P286	B-X
-	B-X
Compliance	B-X
with	B-X
the	B-X
new	B-X
protocol	B-X
for	B-X
parenteral	B-X
nutrition	B-X
in	B-X
our	B-X
ICU	B-X
L.	B-X
Vandersteen	B-X
,	B-X
B.	B-X
Stessel	B-X
,	B-X
S.	B-X
Evers	B-X
,	B-X
A.	B-X
R.	B-X
Marinho	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
J.	B-X
Valente	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
C.	B-X
Magalhaes	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
A.	B-X
Marinho	B-X
P288	B-X
-	B-X
Should	B-X
we	B-X
provide	B-X
more	B-X
protein	B-X
to	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Duarte	B-X
,	B-X
S.	B-X
Castro	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P289	B-X
Protein	B-X
provision	B-X
in	B-X
an	B-X
adult	B-X
intensive	B-X
care	B-X
unit	B-X
S.	B-X
Gray	B-X
P290	B-X
-	B-X
Prevalence	B-X
and	B-X
clinical	B-X
outcomes	B-X
of	B-X
vitamin	B-X
d	B-X
deficiency	B-X
in	B-X
the	B-X
medical	B-X
critically	B-X
ill	B-X
patients	B-X
in	B-X
Songklanagarind	B-X
hospital	B-X
K.	B-X
Maipang	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
P291	B-X
-	B-X
Vitamin	B-X
d	B-X
deficiency	B-X
strongly	B-X
predicts	B-X
adverse	B-X
medical	B-X
outcome	B-X
across	B-X
different	B-X
medical	B-X
inpatient	B-X
populations	B-X
:	B-X
results	B-X
from	B-X
a	B-X
prospective	B-X
study	B-X
L.	B-X
G.	B-X
Grädel	B-X
,	B-X
P.	B-X
Schütz	B-X
P292	B-X
-	B-X
Omega-3	B-X
fatty	B-X
acids	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
P.	B-X
Langlois	B-X
,	B-X
W.	B-X
Manzanares	B-X
P293	B-X
-	B-X
Can	B-X
5-hydroxytriptophan	B-X
prevent	B-X
post-traumatic	B-X
stress	B-X
disorder	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
M.	B-X
Hoshino	B-X
,	B-X
Y.	B-X
Haraguchi	B-X
,	B-X
S.	B-X
Kajiwara	B-X
,	B-X
T.	B-X
Mitsuhashi	B-X
,	B-X
T.	B-X
Tsubata	B-X
,	B-X
M.	B-X
Aida	B-X
P299	B-X
-	B-X
A	B-X
study	B-X
of	B-X
glycemic	B-X
control	B-X
by	B-X
subcutaneous	B-X
glargine	B-X
injection	B-X
transition	B-X
from	B-X
continuous	B-X
regular	B-X
insulin	B-X
infusion	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
T.	B-X
Rattanapraphat	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
,	B-X
C.	B-X
Kongkamol	B-X
,	B-X
B.	B-X
Khwannimit	B-X
P300	B-X
-	B-X
Glycemic	B-X
control	B-X
in	B-X
Portuguese	B-X
intensive	B-X
care	B-X
unit	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
B.	B-X
Xavier	B-X
,	B-X
J.	B-X
Valente	B-X
,	B-X
C.	B-X
Magalhaes	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P301	B-X
-	B-X
Impact	B-X
of	B-X
hyperglycemia	B-X
duration	B-X
on	B-X
the	B-X
day	B-X
of	B-X
operation	B-X
on	B-X
short-term	B-X
outcome	B-X
of	B-X
cardiac	B-X
surgery	B-X
patients	B-X
D.	B-X
Moisidou	B-X
,	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
C.	B-X
Koutsogiannidis	B-X
,	B-X
M.	B-X
Moschopoulou	B-X
,	B-X
G.	B-X
Drossos	B-X
P302	B-X
-	B-X
Lactate	B-X
levels	B-X
in	B-X
diabetic	B-X
ketoacidosis	B-X
patients	B-X
at	B-X
ICU	B-X
admissions	B-X
G.	B-X
Taskin	B-X
,	B-X
M.	B-X
Çakir	B-X
,	B-X
AK	B-X
Güler	B-X
,	B-X
A.	B-X
Taskin	B-X
,	B-X
N.	B-X
Öcal	B-X
,	B-X
S.	B-X
Özer	B-X
,	B-X
L.	B-X
Yamanel	B-X
P303	B-X
-	B-X
Intensive	B-X
care	B-X
implications	B-X
of	B-X
merging	B-X
heart	B-X
attack	B-X
centre	B-X
units	B-X
in	B-X
London	B-X
J.	B-X
M.	B-X
Wong	B-X
,	B-X
C.	B-X
Fitton	B-X
,	B-X
S.	B-X
Anwar	B-X
,	B-X
S.	B-X
Stacey	B-X
P304	B-X
-	B-X
Special	B-X
characteristics	B-X
of	B-X
in-hospital	B-X
cardiac	B-X
arrests	B-X
M.	B-X
Aggou	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Lolakos	B-X
,	B-X
E.	B-X
Papapostolou	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P305	B-X
-	B-X
Clinical	B-X
evaluation	B-X
of	B-X
ICU-admitted	B-X
patients	B-X
who	B-X
were	B-X
resuscitated	B-X
in	B-X
the	B-X
general	B-X
medicine	B-X
ward	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
Y.	B-X
Izutani	B-X
P306	B-X
-	B-X
Serious	B-X
game	B-X
evaluation	B-X
of	B-X
a	B-X
one-hour	B-X
training	B-X
basic	B-X
life	B-X
support	B-X
session	B-X
for	B-X
secondary	B-X
school	B-X
students	B-X
:	B-X
new	B-X
tools	B-X
for	B-X
future	B-X
bystanders	B-X
S.	B-X
Gaudry	B-X
,	B-X
V.	B-X
Desailly	B-X
,	B-X
P.	B-X
Pasquier	B-X
,	B-X
PB	B-X
Brun	B-X
,	B-X
AT	B-X
Tesnieres	B-X
,	B-X
JD	B-X
Ricard	B-X
,	B-X
D.	B-X
Dreyfuss	B-X
,	B-X
A.	B-X
Mignon	B-X
P307	B-X
-	B-X
Public	B-X
and	B-X
clinical	B-X
staff	B-X
perceptions	B-X
and	B-X
knowledge	B-X
of	B-X
CPR	B-X
compared	B-X
to	B-X
local	B-X
and	B-X
national	B-X
data	B-X
J	B-X
.	B-X
Dean	B-X
,	B-X
A.	B-X
Stilwell	B-X
,	B-X
G.	B-X
Friedlaender	B-X
P308	B-X
Dispatcher-assisted	B-X
telephone	B-X
cardiopulmonary	B-X
resuscitation	B-X
using	B-X
a	B-X
French-language	B-X
compression-ventilation	B-X
pediatric	B-X
protocol	B-X
M.	B-X
Peters	B-X
,	B-X
S.	B-X
Stipulante	B-X
,	B-X
A.	B-X
Delfosse	B-X
,	B-X
AF	B-X
Donneau	B-X
,	B-X
A.	B-X
Ghuysen	B-X
P309	B-X
Dantrolene	B-X
versus	B-X
amiodarone	B-X
for	B-X
resuscitation	B-X
–	B-X
an	B-X
experimental	B-X
study	B-X
C.	B-X
Feldmann	B-X
,	B-X
D.	B-X
Freitag	B-X
,	B-X
W.	B-X
Dersch	B-X
,	B-X
M.	B-X
Irqsusi	B-X
,	B-X
D.	B-X
Eschbach	B-X
,	B-X
T.	B-X
Steinfeldt	B-X
,	B-X
H.	B-X
Wulf	B-X
,	B-X
T.	B-X
Wiesmann	B-X
P310	B-X
Long	B-X
term	B-X
survival	B-X
and	B-X
functional	B-X
neurological	B-X
outcome	B-X
in	B-X
comatose	B-X
survivors	B-X
undergoing	B-X
therapeutic	B-X
hypothermia	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
J.	B-X
Cholkraisuwat	B-X
P311	B-X
Impact	B-X
of	B-X
kidney	B-X
disease	B-X
on	B-X
mortality	B-X
and	B-X
neurological	B-X
outcome	B-X
in	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
prospective	B-X
observational	B-X
study	B-X
S.	B-X
Beitland	B-X
,	B-X
E.	B-X
Nakstad	B-X
,	B-X
H.	B-X
Stær-Jensen	B-X
,	B-X
T.	B-X
Drægni	B-X
,	B-X
G.	B-X
Andersen	B-X
,	B-X
D.	B-X
Jacobsen	B-X
,	B-X
C.	B-X
Brunborg	B-X
,	B-X
B.	B-X
Waldum-Grevbo	B-X
,	B-X
K.	B-X
Sunde	B-X
P312	B-X
ICU	B-X
dependency	B-X
of	B-X
patients	B-X
admitted	B-X
after	B-X
primary	B-X
percutaneous	B-X
coronary	B-X
intervention	B-X
(	B-X
PPCI	B-X
)	B-X
following	B-X
out	B-X
of	B-X
the	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
K.	B-X
Hoyland	B-X
,	B-X
D.	B-X
Pandit	B-X
P313	B-X
Prognostic	B-X
indicators	B-X
and	B-X
outcome	B-X
prediction	B-X
model	B-X
for	B-X
patients	B-X
with	B-X
return	B-X
of	B-X
spontaneous	B-X
circulation	B-X
from	B-X
cardiopulmonary	B-X
arrest	B-X
:	B-X
comprehensive	B-X
registry	B-X
of	B-X
in-hospital	B-X
intensive	B-X
care	B-X
on	B-X
OHCA	B-X
survival	B-X
(	B-X
critical	B-X
)	B-X
study	B-X
in	B-X
Osaka	B-X
,	B-X
Japan	B-X
K.	B-X
Hayakawa	B-X
P314	B-X
Cerebral	B-X
oxygen	B-X
saturation	B-X
during	B-X
resuscitation	B-X
in	B-X
a	B-X
porcine	B-X
model	B-X
of	B-X
cardiac	B-X
arrest	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Kotzampassi	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
L.	B-X
Loukipoudi	B-X
,	B-X
E.	B-X
Doumaki	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P315	B-X
Presumption	B-X
of	B-X
cardiopulmonary	B-X
resuscitation	B-X
for	B-X
sustaining	B-X
cerebral	B-X
oxidation	B-X
using	B-X
regional	B-X
cerebral	B-X
saturation	B-X
of	B-X
oxygen	B-X
:	B-X
observational	B-X
cohort	B-X
study	B-X
(	B-X
press	B-X
study	B-X
)	B-X
H.	B-X
Yasuda	B-X
P316	B-X
EEG	B-X
reactivity	B-X
in	B-X
patients	B-X
after	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
close	B-X
look	B-X
at	B-X
stimuli	B-X
MM	B-X
Admiraal	B-X
,	B-X
M.	B-X
Van	B-X
Assen	B-X
,	B-X
MJ	B-X
Van	B-X
Putten	B-X
,	B-X
M.	B-X
Tjepkema-Cloostermans	B-X
,	B-X
AF	B-X
Van	B-X
Rootselaar	B-X
,	B-X
J.	B-X
Horn	B-X
P317	B-X
Prognostic	B-X
value	B-X
of	B-X
neuron-specific	B-X
enolase	B-X
after	B-X
cardiac	B-X
arrest	B-X
F.	B-X
Ragusa	B-X
,	B-X
A.	B-X
Marudi	B-X
,	B-X
S.	B-X
Baroni	B-X
,	B-X
A.	B-X
Gaspari	B-X
,	B-X
E.	B-X
Bertellini	B-X
P318	B-X
Correlation	B-X
between	B-X
electroencephalographic	B-X
findings	B-X
and	B-X
serum	B-X
neuron	B-X
specific	B-X
enolase	B-X
with	B-X
outcome	B-X
of	B-X
post	B-X
cardiac	B-X
arrest	B-X
patients	B-X
A.	B-X
Taha	B-X
,	B-X
T.	B-X
Abdullah	B-X
,	B-X
S.	B-X
Abdel	B-X
Monem	B-X
P319	B-X
Introduction	B-X
of	B-X
a	B-X
targeted	B-X
temperature	B-X
management	B-X
strategy	B-X
following	B-X
cardiac	B-X
arrest	B-X
in	B-X
a	B-X
district	B-X
general	B-X
hospital	B-X
intensive	B-X
care	B-X
unit	B-X
.	B-X
S.	B-X
Alcorn	B-X
,	B-X
S.	B-X
McNeill	B-X
,	B-X
S.	B-X
Russell	B-X
P320	B-X
The	B-X
evolution	B-X
of	B-X
cerebral	B-X
oxygen	B-X
saturation	B-X
in	B-X
post-cardiac	B-X
arrest	B-X
patients	B-X
treated	B-X
with	B-X
therapeutic	B-X
hypothermia	B-X
W.	B-X
Eertmans	B-X
,	B-X
C.	B-X
Genbrugge	B-X
,	B-X
I.	B-X
Meex	B-X
,	B-X
J.	B-X
Dens	B-X
,	B-X
F.	B-X
Jans	B-X
,	B-X
C.	B-X
De	B-X
Deyne	B-X
P321	B-X
Prognostic	B-X
factors	B-X
and	B-X
neurological	B-X
outcomes	B-X
of	B-X
therapeutic	B-X
hypothermia	B-X
in	B-X
comatose	B-X
survivors	B-X
from	B-X
cardiac	B-X
arrest	B-X
:	B-X
8-year	B-X
single	B-X
center	B-X
experience	B-X
J.	B-X
Cholkraisuwat	B-X
,	B-X
N.	B-X
Kongpolprom	B-X
P322	B-X
Adherence	B-X
to	B-X
targeted	B-X
temperature	B-X
management	B-X
after	B-X
out	B-X
of	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
B.	B-X
Avard	B-X
,	B-X
R.	B-X
Burns	B-X
P323	B-X
Implementation	B-X
of	B-X
a	B-X
therapeutic	B-X
hypothermia	B-X
protocol	B-X
for	B-X
comatose	B-X
survivors	B-X
of	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
.	B-X
P.	B-X
Wacharasint	B-X
,	B-X
P.	B-X
Fuengfoo	B-X
,	B-X
N.	B-X
Sukcharoen	B-X
,	B-X
R.	B-X
Rangsin	B-X
P386	B-X
-	B-X
The	B-X
national	B-X
early	B-X
warning	B-X
score	B-X
(	B-X
news	B-X
)	B-X
reliably	B-X
improves	B-X
adverse	B-X
clinical	B-X
outcome	B-X
prediction	B-X
in	B-X
community-acquired	B-X
pneumonia	B-X
-	B-X
results	B-X
from	B-X
a	B-X
6	B-X
year	B-X
follow-up	B-X
D.	B-X
Sbiti-Rohr	B-X
,	B-X
P.	B-X
Schuetz	B-X
P387	B-X
-	B-X
Clinical	B-X
usefulness	B-X
of	B-X
the	B-X
charlson¡¯s	B-X
weighted	B-X
index	B-X
of	B-X
comorbidities	B-X
_as	B-X
prognostic	B-X
factor	B-X
in	B-X
patients	B-X
with	B-X
prolonged	B-X
acute	B-X
mechanical	B-X
ventilation	B-X
H.	B-X
Na	B-X
,	B-X
S.	B-X
Song	B-X
,	B-X
S.	B-X
Lee	B-X
,	B-X
E.	B-X
Jeong	B-X
,	B-X
K.	B-X
Lee	B-X
P388	B-X
-	B-X
Comparison	B-X
of	B-X
mortality	B-X
prediction	B-X
scoring	B-X
systems	B-X
in	B-X
patients	B-X
with	B-X
cirrhosis	B-X
admitted	B-X
to	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
M.	B-X
Cooper	B-X
,	B-X
K.	B-X
Milinis	B-X
,	B-X
G.	B-X
Williams	B-X
,	B-X
E.	B-X
McCarron	B-X
,	B-X
S.	B-X
Simants	B-X
,	B-X
I.	B-X
Patanwala	B-X
,	B-X
I.	B-X
D.	B-X
Welters	B-X
P389	B-X
-	B-X
Impact	B-X
of	B-X
admission	B-X
source	B-X
and	B-X
time	B-X
of	B-X
admission	B-X
on	B-X
outcome	B-X
of	B-X
pediatric	B-X
intensive	B-X
care	B-X
patients	B-X
:	B-X
retrospective	B-X
15	B-X
years	B-X
study	B-X
E.	B-X
Zoumpelouli	B-X
,	B-X
EA	B-X
Volakli	B-X
,	B-X
V.	B-X
Chrysohoidou	B-X
,	B-X
S.	B-X
Georgiou	B-X
,	B-X
K.	B-X
Charisopoulou	B-X
,	B-X
E.	B-X
Kotzapanagiotou	B-X
,	B-X
V.	B-X
Panagiotidou	B-X
,	B-X
K.	B-X
Manavidou	B-X
,	B-X
Z.	B-X
Stathi	B-X
,	B-X
M.	B-X
Sdougka	B-X
P390	B-X
-	B-X
Heart	B-X
rate	B-X
variability	B-X
and	B-X
outcomes	B-X
prediction	B-X
in	B-X
critical	B-X
illness	B-X
N.	B-X
Salahuddin	B-X
,	B-X
B.	B-X
AlGhamdi	B-X
,	B-X
Q.	B-X
Marashly	B-X
,	B-X
K.	B-X
Zaza	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
Khurshid	B-X
,	B-X
Z.	B-X
Ali	B-X
,	B-X
M.	B-X
Malgapo	B-X
,	B-X
M.	B-X
Jamil	B-X
,	B-X
A.	B-X
Shafquat	B-X
,	B-X
M.	B-X
Shoukri	B-X
,	B-X
M.	B-X
Hijazi	B-X
P391	B-X
-	B-X
The	B-X
incidence	B-X
and	B-X
outcome	B-X
of	B-X
hyperlactatemia	B-X
in	B-X
the	B-X
post	B-X
anaesthesia	B-X
care	B-X
unit	B-X
T.	B-X
Abe	B-X
,	B-X
S.	B-X
Uchino	B-X
,	B-X
M.	B-X
Takinami	B-X
P392	B-X
-	B-X
Correlation	B-X
between	B-X
arterial	B-X
blood	B-X
gas	B-X
disturbances	B-X
and	B-X
arterial	B-X
lactate	B-X
levels	B-X
during	B-X
hospitalization	B-X
and	B-X
outcome	B-X
in	B-X
critically	B-X
septic	B-X
patients	B-X
N.	B-X
R.	B-X
Rangel	B-X
Neto	B-X
,	B-X
S.	B-X
Oliveira	B-X
,	B-X
F.	B-X
Q.	B-X
Reis	B-X
,	B-X
F.	B-X
A.	B-X
Rocha	B-X
P393	B-X
-	B-X
External	B-X
validation	B-X
of	B-X
saps	B-X
3	B-X
and	B-X
mpm	B-X
iii	B-X
scores	B-X
in	B-X
48,816	B-X
patients	B-X
from	B-X
72	B-X
brazilian	B-X
icus	B-X
G.	B-X
Moralez	B-X
,	B-X
K.	B-X
Ebecken	B-X
,	B-X
L.	B-X
S.	B-X
Rabello	B-X
,	B-X
M.	B-X
F.	B-X
Lima	B-X
,	B-X
R.	B-X
Hatum	B-X
,	B-X
F.	B-X
V.	B-X
De	B-X
Marco	B-X
,	B-X
A.	B-X
Alves	B-X
,	B-X
J.	B-X
E.	B-X
Pinto	B-X
,	B-X
M.	B-X
Godoy	B-X
,	B-X
P.	B-X
E.	B-X
Brasil	B-X
,	B-X
F.	B-X
A.	B-X
Bozza	B-X
,	B-X
J.	B-X
I.	B-X
Salluh	B-X
,	B-X
M.	B-X
Soares	B-X
P394	B-X
-	B-X
The	B-X
frailty	B-X
penalty	B-X
:	B-X
pre-admission	B-X
functional	B-X
status	B-X
confounds	B-X
mortality	B-X
prediction	B-X
models	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
J.	B-X
Krinsley	B-X
,	B-X
G.	B-X
Kang	B-X
P395	B-X
-	B-X
‘	B-X
sooner	B-X
rather	B-X
than	B-X
later	B-X
”	B-X
:	B-X
how	B-X
delayed	B-X
discharge	B-X
from	B-X
critical	B-X
care	B-X
leads	B-X
to	B-X
increased	B-X
out	B-X
of	B-X
hours	B-X
discharges	B-X
and	B-X
subsequent	B-X
increase	B-X
in	B-X
in-hospital	B-X
mortality	B-X
.	B-X

Patients	O
<EOS>	B-X
``	B-X
Patients	B-X
deserve	B-X
agency	B-X
when	B-X
it	B-X
comes	B-X
to	B-X
their	B-X
body	B-X
''	B-X
:	B-X
a	B-X
patient	B-X
's	B-X
experience	B-X
with	B-X
endometriosis	B-X
.	B-X

Informed	O
consent	O
was	O
obtained	O
from	O
24	O
patients	O
(	O
5	O
men	O
and	O
19	O
women	O
)	O
with	O
RA	O
who	O
fulfilled	O
the	O
1987	O
revised	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Rheumatology	O
(	O
formerly	O
the	O
American	O
Rheumatism	O
Association	O
)	O
[	O
17	O
]	O
.	O

The	O
age	O
of	O
the	O
patients	O
with	O
RA	O
was	O
50	O
+	O
/	O
-	O
8	O
(	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
years	O
(	O
range	O
23	O
-	O
71	O
years	O
)	O
.	O

All	O
medications	O
were	O
stopped	O
48	O
hours	O
before	O
entry	O
to	O
the	O
study	O
.	O

Comparisons	O
were	O
made	O
with	O
14	O
patients	O
with	O
OA	O
(	O
3	O
men	O
and	O
11	O
women	O
)	O
and	O
with	O
14	O
healthy	O
controls	O
(	O
3	O
men	O
and	O
11	O
women	O
)	O
who	O
had	O
no	O
rheumatic	O
diseases	O
.	O
<EOS>	B-X
Changes	B-X
in	B-X
pelvic	B-X
position	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
affect	B-X
acetabular	B-X
coverage	B-X
of	B-X
the	B-X
femoral	B-X
head	B-X
in	B-X
total	B-X
hip	B-X
arthroplasty	B-X
(	B-X
THA	B-X
)	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
complications	B-X
such	B-X
as	B-X
impingement	B-X
,	B-X
dislocation	B-X
,	B-X
or	B-X
early	B-X
wear	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
following	B-X
in	B-X
patients	B-X
who	B-X
had	B-X
unilateral	B-X
hip	B-X
OA	B-X
:	B-X
1	B-X
)	B-X
dynamic	B-X
changes	B-X
;	B-X
and	B-X
2	B-X
)	B-X
variability	B-X
;	B-X
in	B-X
the	B-X
following	B-X
pelvic	B-X
position	B-X
parameters	B-X
:	B-X
A	B-X
)	B-X
tilt	B-X
;	B-X
B	B-X
)	B-X
obliquity	B-X
;	B-X
and	B-X
C	B-X
)	B-X
rotation	B-X
standing	B-X
position	B-X
to	B-X
walking	B-X
.	B-X

The	O
mean	O
ages	O
of	O
the	O
patients	O
with	O
OA	O
and	O
the	O
healthy	O
controls	O
were	O
50	O
+	O
/	O
-	O
8	O
years	O
(	O
range	O
34	O
-	O
68	O
years	O
)	O
and	O
30	O
+	O
/	O
-	O
6	O
years	O
(	O
range	O
24	O
-	O
57	O
years	O
)	O
.	O

Informed	O
consent	O
was	O
obtained	O
,	O
and	O
the	O
protocol	O
was	O
approved	O
by	O
the	O
Catholic	O
University	O
of	O
Korea	O
Human	O
Research	O
Ethics	O
Committee	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
association	B-X
between	B-X
vitamin	B-X
D	B-X
,	B-X
MetS	B-X
,	B-X
and	B-X
its	B-X
components	B-X
in	B-X
Korean	B-X
elderly	B-X
men	B-X
and	B-X
women	B-X
.	B-X
KLASS	B-X
(	B-X
the	B-X
Korean	B-X
Laparoendoscopic	B-X
Gastrointestinal	B-X
Surgery	B-X
Study	B-X
)	B-X
is	B-X
a	B-X
time-honored	B-X
study	B-X
group	B-X
that	B-X
has	B-X
established	B-X
laparoscopic	B-X
surgery	B-X
for	B-X
gastrointestinal	B-X
disease	B-X
in	B-X
Korea	B-X
and	B-X
has	B-X
performed	B-X
some	B-X
important	B-X
studies	B-X
for	B-X
the	B-X
rationale	B-X
of	B-X
laparoscopic	B-X
gastrointestinal	B-X
surgery	B-X
.	B-X
A	B-X
multi-center	B-X
RCT	B-X
(	B-X
randomized	B-X
controlled	B-X
trial	B-X
)	B-X
to	B-X
compare	B-X
the	B-X
quality	B-X
of	B-X
life	B-X
(	B-X
QOL	B-X
)	B-X
of	B-X
patients	B-X
undergoing	B-X
totally	B-X
laparoscopic	B-X
distal	B-X
gastrectomy	B-X
(	B-X
TLDG	B-X
)	B-X
and	B-X
laparoscopy-assisted	B-X
distal	B-X
gastrectomy	B-X
(	B-X
LADG	B-X
)	B-X
for	B-X
gastric	B-X
cancer	B-X
,	B-X
named	B-X
as	B-X
KLASS	B-X
07	B-X
,	B-X
has	B-X
been	B-X
currently	B-X
prepared	B-X
in	B-X
Korea	B-X
.	B-X

Reagents	O
<EOS>	B-X
Critical	B-X
reagents	B-X
:	B-X
evolution	B-X
of	B-X
WRIB	B-X
recommendations	B-X
on	B-X
critical	B-X
reagents	B-X
.	B-X
Analyte-specific	B-X
reagents	B-X
.	B-X
Increasing	B-X
robustness	B-X
,	B-X
reliability	B-X
and	B-X
storage	B-X
stability	B-X
of	B-X
critical	B-X
reagents	B-X
by	B-X
freeze-drying	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
quality	B-X
critical	B-X
reagents	B-X
for	B-X
the	B-X
entire	B-X
developmental	B-X
lifecycle	B-X
of	B-X
a	B-X
biopharmaceutical	B-X
:	B-X
a	B-X
pharmacokinetic	B-X
case	B-X
study	B-X
.	B-X

Recombinant	O
IL	B-Protein
-	I-Protein
17	I-Protein
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
MCP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
(	I-Protein
MIP	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
,	O
MIP	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
were	O
purchased	O
from	O
R	O
&	O
D	O
systems	O
(	O
Minneapolis	O
,	O
MN	O
,	O
USA	O
)	O
.	O

Recombinant	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TGF	I-Protein
)	I-Protein
-	I-Protein
beta	I-Protein
was	O
purchased	O
from	O
Peprotech	O
(	O
London	O
,	O
UK	O
)	O
.	O

Recombinant	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
were	O
purchased	O
from	O
Endogen	O
Inc	O
.	O

(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Cyclosporin	O
A	O
was	O
provided	O
by	O
Sandos	O
Ltd	O
.	O

(	O
Basel	O
,	O
Switzerland	O
)	O
.	O
<EOS>	B-X
The	B-X
reproductive	B-X
number	B-X
in	B-X
Switzerland	B-X
was	B-X
between	B-X
1.5	B-X
and	B-X
2	B-X
during	B-X
the	B-X
first	B-X
third	B-X
of	B-X
March	B-X
,	B-X
and	B-X
has	B-X
consistently	B-X
decreased	B-X
to	B-X
around	B-X
1	B-X
.	B-X
There	B-X
are	B-X
numerous	B-X
contributions	B-X
to	B-X
the	B-X
development	B-X
of	B-X
ophthalmology	B-X
from	B-X
Switzerland	B-X
,	B-X
a	B-X
country	B-X
that	B-X
holds	B-X
a	B-X
very	B-X
special	B-X
place	B-X
in	B-X
the	B-X
history	B-X
of	B-X
medicine	B-X
from	B-X
the	B-X
age	B-X
of	B-X
Paracelsus	B-X
and	B-X
Vesal	B-X
to	B-X
the	B-X
current	B-X
time	B-X
.	B-X
A	B-X
leading	B-X
role	B-X
in	B-X
this	B-X
evolution	B-X
of	B-X
modern	B-X
ophthalmology	B-X
has	B-X
been	B-X
played	B-X
by	B-X
physicians	B-X
from	B-X
Basel	B-X
,	B-X
home	B-X
of	B-X
Switzerland	B-X
's	B-X
oldest	B-X
university	B-X
.	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
various	B-X
stressful	B-X
situations	B-X
and	B-X
the	B-X
psychological	B-X
impact	B-X
of	B-X
the	B-X
first	B-X
COVID-19	B-X
pandemic	B-X
lockdown	B-X
among	B-X
youths	B-X
in	B-X
Switzerland	B-X
.	B-X
During	B-X
the	B-X
first	B-X
lockdown	B-X
in	B-X
Switzerland	B-X
,	B-X
the	B-X
most	B-X
common	B-X
sources	B-X
of	B-X
perceived	B-X
stress	B-X
were	B-X
the	B-X
disruption	B-X
of	B-X
social	B-X
life	B-X
and	B-X
important	B-X
activities	B-X
,	B-X
uncertainty	B-X
about	B-X
how	B-X
long	B-X
the	B-X
state	B-X
of	B-X
affairs	B-X
would	B-X
last	B-X
,	B-X
and	B-X
the	B-X
pandemic	B-X
itself	B-X
.	B-X
The	B-X
study	B-X
showed	B-X
considerable	B-X
stress	B-X
perceived	B-X
by	B-X
young	B-X
adults	B-X
and	B-X
symptoms	B-X
of	B-X
mental	B-X
health	B-X
problems	B-X
,	B-X
especially	B-X
among	B-X
females	B-X
,	B-X
during	B-X
the	B-X
first	B-X
COVID-19	B-X
lockdown	B-X
in	B-X
Switzerland	B-X
.	B-X

Phytohemagglutinin	B-Protein
(	O
PHA	B-Protein
)	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
rapamycin	O
,	O
dexamethasone	O
and	O
curcumin	O
were	O
all	O
obtained	O
from	O
the	O
Sigma	O
Chemical	O
Co	O
.	O

(	O
St	O
Louis	O
,	O
MA	O
,	O
USA	O
)	O
.	O
<EOS>	B-X
Behavioral	B-X
Interventions	B-X
for	B-X
Smoking	B-X
Cessation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
clinical	B-X
considerations	B-X
related	B-X
to	B-X
the	B-X
pathogenesis	B-X
,	B-X
diagnosis	B-X
,	B-X
and	B-X
management	B-X
of	B-X
idiopathic	B-X
hypersomnia	B-X
will	B-X
be	B-X
discussed	B-X
,	B-X
including	B-X
perspectives	B-X
from	B-X
the	B-X
European	B-X
Union	B-X
and	B-X
United	B-X
States	B-X
.	B-X
Strategies	B-X
to	B-X
mitigate	B-X
muscle	B-X
cramps	B-X
are	B-X
a	B-X
top	B-X
research	B-X
priority	B-X
for	B-X
patients	B-X
receiving	B-X
hemodialysis	B-X
.	B-X
Mild	B-X
cognitive	B-X
impairment	B-X
in	B-X
rapid	B-X
eye	B-X
movement	B-X
sleep	B-X
behavior	B-X
disorder	B-X
:	B-X
a	B-X
predictor	B-X
of	B-X
dementia	B-X
?	B-X

Anti	O
-	O
CD3	O
monoclonal	O
antibody	O
and	O
anti	O
-	O
CD28	B-Protein
monoclonal	O
antibody	O
were	O
obtained	O
from	O
BD	O
Biosciences	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

LY294002	O
,	O
SB203580	O
,	O
FK506	O
,	O
wortmannin	O
and	O
PD98059	O
were	O
obtained	O
from	O
Calbiochem	O
(	O
Schwalbach	O
,	O
Germany	O
)	O
.	O

Production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
by	O
T	O
cell	O
receptor	O
activation	O
,	O
cytokines	O
or	O
chemokines	O
<EOS>	B-X
The	B-X
chemokine	B-X
superfamily	B-X
consists	B-X
of	B-X
a	B-X
large	B-X
number	B-X
of	B-X
ligands	B-X
and	B-X
receptors	B-X
.	B-X
At	B-X
first	B-X
glance	B-X
,	B-X
this	B-X
family	B-X
appears	B-X
redundant	B-X
and	B-X
their	B-X
ligand-receptor	B-X
relationships	B-X
promiscuous	B-X
,	B-X
making	B-X
its	B-X
study	B-X
challenging	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
functions	B-X
of	B-X
a	B-X
subgroup	B-X
of	B-X
chemokines	B-X
(	B-X
designated	B-X
homeostatic	B-X
chemokines	B-X
)	B-X
have	B-X
played	B-X
pivotal	B-X
roles	B-X
in	B-X
advancing	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
organization	B-X
and	B-X
function	B-X
of	B-X
the	B-X
cellular	B-X
networks	B-X
that	B-X
shape	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
update	B-X
the	B-X
full	B-X
scope	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
chemokine	B-X
superfamilies	B-X
and	B-X
their	B-X
relationships	B-X
and	B-X
summarize	B-X
several	B-X
important	B-X
roles	B-X
that	B-X
homeostatic	B-X
chemokines	B-X
play	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
.	B-X

PBMC	O
were	O
prepared	O
from	O
heparinized	O
blood	O
by	O
Ficoll	O
-	O
Hypaque	O
(	O
SG1077	O
)	O
density	O
-	O
gradient	O
centrifugation	O
.	O

Cell	O
cultures	O
were	O
performed	O
as	O
described	O
previously	O
[	O
18	O
]	O
.	O
<EOS>	B-X
An	B-X
overview	B-X
of	B-X
classical	B-X
and	B-X
recent	B-X
methods	B-X
used	B-X
to	B-X
identify	B-X
specific	B-X
CSNB	B-X
genotypes	B-X
is	B-X
provided	B-X
and	B-X
a	B-X
meta-analysis	B-X
of	B-X
all	B-X
previously	B-X
published	B-X
and	B-X
novel	B-X
data	B-X
is	B-X
performed	B-X
to	B-X
determine	B-X
the	B-X
prevalence	B-X
of	B-X
disease-causing	B-X
mutations	B-X
.	B-X
Many	B-X
reproductive	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
in	B-X
equids	B-X
,	B-X
but	B-X
new	B-X
in	B-X
vitro	B-X
methods	B-X
to	B-X
study	B-X
the	B-X
endometrium	B-X
of	B-X
mares	B-X
remain	B-X
unexplored	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
there	B-X
is	B-X
a	B-X
description	B-X
of	B-X
the	B-X
normal	B-X
anatomy	B-X
and	B-X
physiology	B-X
of	B-X
the	B-X
mare	B-X
endometrium	B-X
in	B-X
vivo	B-X
,	B-X
in	B-X
vitro	B-X
endometrial	B-X
cell	B-X
culture	B-X
techniques	B-X
that	B-X
have	B-X
been	B-X
previously	B-X
described	B-X
for	B-X
the	B-X
mare	B-X
,	B-X
and	B-X
opportunities	B-X
for	B-X
future	B-X
reproductive	B-X
research	B-X
using	B-X
in	B-X
vitro	B-X
methods	B-X
.	B-X
The	B-X
isolation	B-X
of	B-X
proteins	B-X
on	B-X
nascent	B-X
DNA	B-X
(	B-X
iPOND	B-X
)	B-X
technique	B-X
developed	B-X
by	B-X
the	B-X
Cortez	B-X
laboratory	B-X
allows	B-X
a	B-X
previously	B-X
unparalleled	B-X
ability	B-X
to	B-X
examine	B-X
proteins	B-X
associated	B-X
with	B-X
replicating	B-X
and	B-X
newly	B-X
synthesized	B-X
DNA	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Both	B-X
the	B-X
original	B-X
,	B-X
formaldehyde-based	B-X
iPOND	B-X
technique	B-X
and	B-X
a	B-X
more	B-X
recent	B-X
derivative	B-X
,	B-X
accelerated	B-X
native	B-X
iPOND	B-X
(	B-X
aniPOND	B-X
)	B-X
,	B-X
have	B-X
mostly	B-X
been	B-X
performed	B-X
in	B-X
adherent	B-X
cell	B-X
lines	B-X
.	B-X

In	O
brief	O
,	O
the	O
cell	O
suspensions	O
were	O
adjusted	O
to	O
a	O
concentration	O
of	O
106	O
/	O
ml	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
,	O
100	O
mg	O
/	O
ml	O
streptomycin	O
and	O
2	O
mM	O
L	O
-	O
glutamine	O
.	O

Cell	O
suspension	O
(	O
1	O
ml	O
)	O
was	O
dispensed	O
into	O
24	O
-	O
well	O
multi	O
-	O
well	O
plates	O
(	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
,	O
and	O
incubated	O
for	O
24	O
hours	O
at	O
37degreesC	O
in	O
5	O
%	O
CO2	O
.	O

Subsequently	O
,	O
various	O
concentrations	O
of	O
cyclosporin	O
A	O
(	O
10	O
-	O
500	O
ng	O
/	O
ml	O
)	O
were	O
added	O
to	O
the	O
medium	O
and	O
cells	O
were	O
incubated	O
for	O
24	O
hours	O
.	O

To	O
each	O
well	O
was	O
added	O
FK506	O
,	O
rapamycin	O
,	O
curcumin	O
,	O
PDTC	O
,	O
LY294002	O
,	O
SB203580	O
,	O
PD98059	O
,	O
dexamethasone	O
or	O
wortmannin	O
.	O
<EOS>	B-X
Finally	B-X
,	B-X
Stattic	B-X
,	B-X
the	B-X
STAT-3	B-X
inhibitor	B-X
and	B-X
wortmannin	B-X
were	B-X
administered	B-X
in	B-X
both	B-X
EMPA	B-X
and	B-X
DAPA	B-X
groups	B-X
to	B-X
establish	B-X
causal	B-X
relationships	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
protection	B-X
.	B-X
Stattic	B-X
and	B-X
wortmannin	B-X
attenuated	B-X
the	B-X
cardioprotection	B-X
afforded	B-X
by	B-X
EMPA	B-X
and	B-X
DAPA	B-X
.	B-X
The	B-X
minimal	B-X
H2AX	B-X
phosphorylation	B-X
in	B-X
Atm-/-	B-X
fibroblasts	B-X
can	B-X
be	B-X
abolished	B-X
by	B-X
low	B-X
concentrations	B-X
of	B-X
wortmannin	B-X
suggesting	B-X
that	B-X
DNA-PK	B-X
,	B-X
rather	B-X
than	B-X
ATR	B-X
,	B-X
is	B-X
responsible	B-X
for	B-X
low	B-X
levels	B-X
of	B-X
H2AX	B-X
phosphorylation	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ATM	B-X
.	B-X
By	B-X
using	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
inhibitors	B-X
of	B-X
phosphatidylinositol	B-X
(	B-X
Pl	B-X
)	B-X
3-kinase	B-X
,	B-X
a	B-X
requirement	B-X
for	B-X
this	B-X
activity	B-X
has	B-X
been	B-X
established	B-X
in	B-X
order	B-X
for	B-X
fusion	B-X
to	B-X
proceed	B-X
efficiently	B-X
.	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
Pl	B-X
3-kinase	B-X
activity	B-X
is	B-X
required	B-X
downstream	B-X
of	B-X
rab5	B-X
activation	B-X
,	B-X
although	B-X
a	B-X
large	B-X
excess	B-X
of	B-X
activated	B-X
rab5	B-X
can	B-X
overcome	B-X
wortmannin	B-X
inhibition	B-X
.	B-X
EEA1	B-X
dissociates	B-X
from	B-X
membranes	B-X
following	B-X
wortmannin	B-X
treatment	B-X
.	B-X

After	O
incubation	O
for	O
24	O
hours	O
(	O
unless	O
otherwise	O
stated	O
)	O
,	O
cell	O
-	O
free	O
media	O
were	O
collected	O
and	O
stored	O
at	O
-	O
20degreesC	O
until	O
assayed	O
.	O

All	O
cultures	O
were	O
set	O
up	O
in	O
triplicate	O
,	O
and	O
results	O
are	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O

CD4	B-Protein
+	O
T	O
-	O
cell	O
isolation	O
by	O
MACS	O
<EOS>	B-X
Tracking	B-X
deuterium	B-X
(	B-X
(	B-X
2	B-X
)	B-X
H	B-X
)	B-X
incorporation	B-X
into	B-X
cellular	B-X
DNA	B-X
,	B-X
after	B-X
administration	B-X
of	B-X
(	B-X
2	B-X
)	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
or	B-X
(	B-X
2	B-X
)	B-X
H	B-X
(	B-X
2	B-X
)	B-X
-glucose	B-X
,	B-X
is	B-X
a	B-X
recently	B-X
developed	B-X
,	B-X
broadly	B-X
applicable	B-X
method	B-X
for	B-X
measuring	B-X
in	B-X
vivo	B-X
cell	B-X
proliferation	B-X
and	B-X
turnover	B-X
that	B-X
can	B-X
be	B-X
used	B-X
safely	B-X
in	B-X
humans	B-X
.	B-X
This	B-X
approach	B-X
has	B-X
been	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
turnover	B-X
of	B-X
T-cell	B-X
subpopulations	B-X
purified	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
HIV-1-infected	B-X
patients	B-X
using	B-X
fluorescence-activated	B-X
cell	B-X
sorting	B-X
(	B-X
FACS	B-X
)	B-X
.	B-X
A	B-X
requirement	B-X
for	B-X
widespread	B-X
adoption	B-X
of	B-X
this	B-X
approach	B-X
for	B-X
medical	B-X
decision-making	B-X
and	B-X
for	B-X
use	B-X
in	B-X
larger	B-X
clinical	B-X
trials	B-X
is	B-X
a	B-X
simple	B-X
,	B-X
reproducible	B-X
,	B-X
high-throughput	B-X
method	B-X
for	B-X
isolation	B-X
of	B-X
highly	B-X
purified	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
peripheral	B-X
blood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
a	B-X
simple	B-X
method	B-X
,	B-X
which	B-X
does	B-X
not	B-X
require	B-X
FACS	B-X
,	B-X
for	B-X
isolating	B-X
these	B-X
cells	B-X
in	B-X
sufficient	B-X
purity	B-X
and	B-X
yield	B-X
for	B-X
analysis	B-X
of	B-X
(	B-X
2	B-X
)	B-X
H	B-X
incorporation	B-X
into	B-X
DNA	B-X
.	B-X
When	B-X
blood	B-X
from	B-X
HIV-1-infected	B-X
patients	B-X
was	B-X
used	B-X
,	B-X
neither	B-X
the	B-X
depletion	B-X
of	B-X
unwanted	B-X
cell	B-X
lineages	B-X
by	B-X
erythrocyte	B-X
crosslinking	B-X
(	B-X
RosetteSep	B-X
)	B-X
nor	B-X
the	B-X
enrichment	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
by	B-X
immunomagnetic	B-X
beads	B-X
(	B-X
MACS	B-X
)	B-X
individually	B-X
resulted	B-X
in	B-X
sufficient	B-X
purity	B-X
.	B-X
The	B-X
successive	B-X
application	B-X
of	B-X
the	B-X
two	B-X
techniques	B-X
,	B-X
however	B-X
,	B-X
permitted	B-X
isolation	B-X
of	B-X
>	B-X
95	B-X
%	B-X
pure	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
adequate	B-X
yield	B-X
(	B-X
>	B-X
10	B-X
(	B-X
6	B-X
)	B-X
cells/10	B-X
ml	B-X
blood	B-X
)	B-X
from	B-X
healthy	B-X
donors	B-X
and	B-X
HIV-1-infected	B-X
patients	B-X
with	B-X
CD4	B-X
counts	B-X
between	B-X
300	B-X
and	B-X
700	B-X
cells/microl	B-X
.	B-X
Moreover	B-X
,	B-X
(	B-X
2	B-X
)	B-X
H	B-X
incorporation	B-X
into	B-X
cellular	B-X
DNA	B-X
after	B-X
administration	B-X
of	B-X
(	B-X
2	B-X
)	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
to	B-X
HIV-1-infected	B-X
patients	B-X
was	B-X
indistinguishable	B-X
between	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
isolated	B-X
by	B-X
RosetteSep/MACS	B-X
and	B-X
FACS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
FACS	B-X
and	B-X
the	B-X
new	B-X
method	B-X
isolate	B-X
a	B-X
similar	B-X
mixture	B-X
of	B-X
long-	B-X
and	B-X
short-lived	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
practice	B-X
,	B-X
the	B-X
RosetteSep/MACS	B-X
method	B-X
is	B-X
simple	B-X
,	B-X
rapid	B-X
,	B-X
robust	B-X
and	B-X
capable	B-X
of	B-X
high	B-X
throughput	B-X
.	B-X

Anti	O
-	O
CD4	B-Protein
microbeads	O
were	O
used	O
essentially	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
Miltenyi	O
)	O
[	O
19	O
]	O
.	O

PBMC	O
were	O
resuspended	O
in	O
80	O
mul	O
of	O
FBS	O
staining	O
buffer	O
.	O

Anti	O
-	O
CD4	B-Protein
microbeads	O
(	O
20	O
mul	O
)	O
were	O
added	O
and	O
incubated	O
for	O
15	O
min	O
at	O
6	O
-	O
12degreesC	O
.	O

Saturating	O
amounts	O
of	O
fluorochrome	O
-	O
conjugated	O
antibodies	O
were	O
added	O
for	O
a	O
further	O
10	O
min	O
.	O

Cells	O
were	O
diluted	O
in	O
2	O
.	O
5	O
ml	O
of	O
FBS	O
staining	O
buffer	O
,	O
pelleted	O
,	O
resuspended	O
in	O
500	O
mul	O
and	O
magnetically	O
separated	O
,	O
usually	O
on	O
an	O
AutoMACS	O
magnet	O
fitted	O
with	O
a	O
MACS	O
MS	O
column	O
.	O

Flow	O
-	O
through	O
and	O
two	O
1	O
ml	O
washes	O
were	O
collected	O
as	O
the	O
negative	O
fraction	O
.	O
<EOS>	B-X
Data	B-X
from	B-X
two	B-X
arterio-venous	B-X
(	B-X
A-V	B-X
)	B-X
difference	B-X
studies	B-X
,	B-X
that	B-X
used	B-X
a	B-X
common	B-X
set	B-X
of	B-X
multicatheterised	B-X
lactating	B-X
Holstein	B-X
cows	B-X
,	B-X
assigned	B-X
to	B-X
different	B-X
nutritional	B-X
treatments	B-X
,	B-X
were	B-X
used	B-X
to	B-X
assess	B-X
ruminal	B-X
metabolism	B-X
.	B-X
Study	B-X
1	B-X
consisted	B-X
of	B-X
three	B-X
dietary	B-X
treatments	B-X
at	B-X
calving	B-X
[	B-X
an	B-X
alfalfa-glucogenic	B-X
diet	B-X
,	B-X
a	B-X
glucogenic	B-X
diet	B-X
(	B-X
GLCG	B-X
)	B-X
,	B-X
or	B-X
a	B-X
ketogenic	B-X
diet	B-X
(	B-X
KETO	B-X
)	B-X
]	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
dietary	B-X
nutrients	B-X
and	B-X
increasing	B-X
intake	B-X
postpartum	B-X
on	B-X
RDV	B-X
metabolism	B-X
of	B-X
AA	B-X
at	B-X
-14	B-X
,	B-X
+4	B-X
,	B-X
+15	B-X
,	B-X
and	B-X
+29	B-X
days	B-X
relative	B-X
to	B-X
calving	B-X
(	B-X
DRTC	B-X
)	B-X
.	B-X
Study	B-X
2	B-X
consisted	B-X
of	B-X
two	B-X
dietary	B-X
levels	B-X
of	B-X
CP	B-X
(	B-X
17	B-X
or	B-X
13	B-X
%	B-X
)	B-X
and	B-X
three	B-X
ruminal	B-X
buffers	B-X
(	B-X
ammonia	B-X
,	B-X
butyrate	B-X
,	B-X
and	B-X
control	B-X
)	B-X
to	B-X
investigate	B-X
the	B-X
level	B-X
of	B-X
dietary	B-X
CP	B-X
and	B-X
ruminal	B-X
fermentation	B-X
products	B-X
on	B-X
RDV	B-X
metabolism	B-X
of	B-X
AA	B-X
.	B-X
Blood	B-X
was	B-X
collected	B-X
at	B-X
9	B-X
,	B-X
20	B-X
,	B-X
and	B-X
30	B-X
min	B-X
after	B-X
buffer	B-X
administration	B-X
.	B-X
Regardless	B-X
of	B-X
dietary	B-X
nutrients	B-X
or	B-X
fermentation	B-X
products	B-X
present	B-X
in	B-X
ruminal	B-X
fluid	B-X
,	B-X
net	B-X
RDV	B-X
uptake	B-X
was	B-X
positive	B-X
for	B-X
most	B-X
AA	B-X
,	B-X
excepting	B-X
Asp	B-X
,	B-X
Cys	B-X
,	B-X
Glu	B-X
,	B-X
and	B-X
Ser	B-X
,	B-X
which	B-X
were	B-X
consistently	B-X
negative	B-X
.	B-X
The	B-X
adaptive	B-X
responses	B-X
alter	B-X
the	B-X
fraction	B-X
of	B-X
absorbed	B-X
AA	B-X
utilised	B-X
for	B-X
non-productive	B-X
purposes	B-X
and	B-X
thus	B-X
the	B-X
efficiency	B-X
of	B-X
conversion	B-X
of	B-X
those	B-X
AA	B-X
to	B-X
product	B-X
.	B-X

Enriched	O
cells	O
were	O
collected	O
in	O
two	O
0	O
.	O
5	O
ml	O
aliquots	O
from	O
the	O
column	O
after	O
removal	O
from	O
the	O
magnet	O
.	O

Alternatively	O
,	O
cells	O
stained	O
with	O
anti	O
-	O
CD4	B-Protein
-	O
phycoerythrin	O
were	O
washed	O
,	O
magnetically	O
labeled	O
with	O
anti	O
-	O
phycoerythrin	O
microbeads	O
(	O
20	O
mul	O
added	O
to	O
80	O
mul	O
of	O
cell	O
suspension	O
;	O
15	O
min	O
,	O
6	O
-	O
12degreesC	O
)	O
,	O
and	O
magnetically	O
separated	O
as	O
described	O
above	O
.	O

The	O
purity	O
of	O
cells	O
was	O
assessed	O
by	O
flow	O
cytometric	O
analysis	O
of	O
stained	O
cells	O
on	O
a	O
FACS	O
Vantage	O
sorter	O
.	O

Most	O
(	O
more	O
than	O
97	O
%	O
)	O
of	O
the	O
isolated	O
cells	O
had	O
the	O
CD4	B-Protein
T	O
cell	O
marker	O
.	O
<EOS>	B-X
Gut	B-X
microbiota	B-X
and	B-X
immune	B-X
activation	B-X
were	B-X
studied	B-X
in	B-X
36	B-X
non-HIV-infected	B-X
subjects	B-X
(	B-X
healthy	B-X
controls	B-X
)	B-X
and	B-X
58	B-X
HIV-infected	B-X
individuals	B-X
,	B-X
including	B-X
28	B-X
immunological	B-X
responders	B-X
(	B-X
IR	B-X
)	B-X
and	B-X
30	B-X
immunological	B-X
non-responders	B-X
(	B-X
INR	B-X
)	B-X
(	B-X
≥500	B-X
and	B-X
<	B-X
200	B-X
CD4+	B-X
T-cell	B-X
counts/μl	B-X
after	B-X
2	B-X
years	B-X
of	B-X
HIV-1	B-X
viral	B-X
suppression	B-X
respectively	B-X
)	B-X
without	B-X
comorbidities	B-X
.	B-X
The	B-X
quantitative	B-X
identification	B-X
and	B-X
enrichment	B-X
of	B-X
viable	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
requires	B-X
reliable	B-X
surface	B-X
markers	B-X
that	B-X
are	B-X
selectively	B-X
expressed	B-X
on	B-X
Treg	B-X
.	B-X
Foxp3	B-X
is	B-X
the	B-X
accepted	B-X
marker	B-X
of	B-X
natural	B-X
Treg	B-X
,	B-X
but	B-X
it	B-X
can	B-X
not	B-X
be	B-X
used	B-X
to	B-X
isolate	B-X
cells	B-X
for	B-X
functional	B-X
studies	B-X
.	B-X
CD127	B-X
is	B-X
a	B-X
new	B-X
surface	B-X
marker	B-X
expressed	B-X
in	B-X
Treg	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
two	B-X
populations	B-X
of	B-X
Treg	B-X
,	B-X
including	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
profiles	B-X
of	B-X
the	B-X
Foxp3	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
cells	B-X
were	B-X
compared	B-X
to	B-X
evaluate	B-X
which	B-X
population	B-X
is	B-X
better	B-X
.	B-X
The	B-X
peripheral	B-X
blood	B-X
cells	B-X
were	B-X
collected	B-X
and	B-X
spleen	B-X
suspension	B-X
of	B-X
BALB/C	B-X
mice	B-X
were	B-X
prepared	B-X
,	B-X
and	B-X
using	B-X
triple	B-X
staining	B-X
CD4	B-X
,	B-X
CD25	B-X
,	B-X
CD127	B-X
and	B-X
CD4	B-X
,	B-X
CD25	B-X
,	B-X
Foxp3	B-X
.	B-X
The	B-X
profiles	B-X
of	B-X
Treg	B-X
,	B-X
including	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
were	B-X
detected	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
The	B-X
quadruple	B-X
staining	B-X
CD4	B-X
,	B-X
CD25	B-X
,	B-X
Foxp3	B-X
and	B-X
CD127	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
CD127	B-X
expression	B-X
in	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
on	B-X
T	B-X
cell	B-X
subset	B-X
the	B-X
median	B-X
expression	B-X
levels	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
were	B-X
39.02	B-X
%	B-X
,	B-X
5.35	B-X
%	B-X
in	B-X
peripheral	B-X
blood	B-X
and	B-X
23.49	B-X
%	B-X
,	B-X
3.86	B-X
%	B-X
in	B-X
spleen	B-X
.	B-X
On	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
subset	B-X
,	B-X
the	B-X
median	B-X
expression	B-X
level	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
7.13	B-X
%	B-X
,	B-X
3.97	B-X
%	B-X
in	B-X
peripheral	B-X
blood	B-X
and	B-X
12.8	B-X
%	B-X
,	B-X
8.23	B-X
%	B-X
in	B-X
spleen	B-X
.	B-X
The	B-X
ratio	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
T	B-X
cells	B-X
was	B-X
higher	B-X
than	B-X
that	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
in	B-X
both	B-X
peripheral	B-X
blood	B-X
and	B-X
spleen	B-X
cells	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
cells	B-X
highly	B-X
expressed	B-X
Foxp3	B-X
,	B-X
while	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
lowly	B-X
expressed	B-X
CD127	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
compared	B-X
with	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
populations	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
T	B-X
cells	B-X
better	B-X
fit	B-X
the	B-X
definition	B-X
of	B-X
naturally	B-X
occurring	B-X
regulatory	B-X
T	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
cells	B-X
and	B-X
spleen	B-X
of	B-X
BALB/C	B-X
mice	B-X
.	B-X
CD127	B-X
(	B-X
low/-	B-X
)	B-X
is	B-X
a	B-X
characteristic	B-X
marker	B-X
on	B-X
surface	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Treg	B-X
cells	B-X
,	B-X
and	B-X
has	B-X
been	B-X
confirmed	B-X
to	B-X
be	B-X
more	B-X
specific	B-X
marker	B-X
for	B-X
quantitatively	B-X
sorting	B-X
Treg	B-X
cells	B-X
.	B-X

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
quantify	B-X
the	B-X
PBMCs	B-X
that	B-X
secrete	B-X
four	B-X
types	B-X
of	B-X
cytokines	B-X
;	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-10	B-X
and	B-X
IL-17A	B-X
in	B-X
two	B-X
cohorts	B-X
of	B-X
active	B-X
RA	B-X
patients	B-X
(	B-X
early	B-X
RA	B-X
patients	B-X
and	B-X
established	B-X
RA	B-X
patients	B-X
)	B-X
,	B-X
compared	B-X
to	B-X
healthy	B-X
controls	B-X
(	B-X
HC	B-X
)	B-X
,	B-X
using	B-X
the	B-X
enzyme-linked	B-X
immunosorbent	B-X
spot	B-X
(	B-X
ELISPOT	B-X
)	B-X
assay	B-X
,	B-X
and	B-X
to	B-X
assess	B-X
their	B-X
association	B-X
with	B-X
measures	B-X
of	B-X
disease	B-X
activity	B-X
of	B-X
RA	B-X
.	B-X
The	B-X
cytokine	B-X
expression	B-X
was	B-X
evaluated	B-X
using	B-X
freshly	B-X
separated	B-X
PBMCs	B-X
from	B-X
whole	B-X
blood	B-X
of	B-X
RA	B-X
patients	B-X
using	B-X
the	B-X
ELISPOT	B-X
assay	B-X
.	B-X
The	B-X
number	B-X
of	B-X
PBMCs	B-X
(	B-X
counted	B-X
as	B-X
spot-forming	B-X
cells	B-X
(	B-X
SFCs	B-X
)	B-X
per	B-X
105	B-X
PBMCs	B-X
)	B-X
that	B-X
secreted	B-X
the	B-X
cytokine	B-X
of	B-X
interest	B-X
were	B-X
statistically	B-X
significantly	B-X
higher	B-X
in	B-X
early	B-X
RA	B-X
patients	B-X
,	B-X
compared	B-X
to	B-X
HC	B-X
,	B-X
for	B-X
IL-17A	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
correlation	B-X
analysis	B-X
showed	B-X
that	B-X
IL-17A	B-X
is	B-X
having	B-X
a	B-X
moderate	B-X
correlation	B-X
(	B-X
Spearman	B-X
`	B-X
s	B-X
ρ	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
with	B-X
five	B-X
clinical	B-X
measures	B-X
of	B-X
disease	B-X
activity	B-X
,	B-X
including	B-X
disease	B-X
activity	B-X
score	B-X
28	B-X
(	B-X
DAS28	B-X
)	B-X
.	B-X
According	B-X
to	B-X
the	B-X
multivariable	B-X
linear	B-X
regression	B-X
models	B-X
,	B-X
IL17A	B-X
was	B-X
a	B-X
good	B-X
predictor	B-X
of	B-X
both	B-X
the	B-X
disease	B-X
activity	B-X
score	B-X
28	B-X
(	B-X
DAS28	B-X
)	B-X
and	B-X
clinical	B-X
disease	B-X
activity	B-X
index	B-X
(	B-X
CDAI	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
IL-17A	B-X
has	B-X
potential	B-X
applicability	B-X
as	B-X
a	B-X
biomarker	B-X
of	B-X
disease	B-X
activity	B-X
of	B-X
RA	B-X
.	B-X

IL	B-Protein
-	I-Protein
17	I-Protein
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
as	O
described	O
previously	O
[	O
20	O
]	O
.	O

In	O
brief	O
,	O
a	O
96	O
-	O
well	O
plate	O
(	O
Nunc	O
)	O
was	O
coated	O
with	O
4	O
mug	O
/	O
ml	O
monoclonal	O
antibodies	O
against	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
at	O
4degreesC	O
overnight	O
.	O

After	O
blocking	O
with	O
phosphate	O
-	O
buffered	O
saline	O
/	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
(	O
22	O
-	O
25degreesC	O
)	O
,	O
test	O
samples	O
and	O
the	O
standard	O
recombinant	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
added	O
to	O
the	O
96	O
-	O
well	O
plate	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
2	O
hours	O
.	O

Plates	O
were	O
washed	O
four	O
times	O
with	O
phosphate	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
,	O
and	O
then	O
incubated	O
with	O
500	O
ng	O
/	O
ml	O
biotinylated	O
mouse	O
monoclonal	O
antibodies	O
against	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
R	O
&	O
D	O
Systems	O
)	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
,	O
streptavidin	O
-	O
alkaline	O
phosphate	O
-	O
horseradish	O
peroxidase	O
conjugate	O
(	O
Sigma	O
)	O
was	O
incubated	O
for	O
2	O
hours	O
,	O
then	O
washed	O
again	O
and	O
incubated	O
with	O
1	O
mg	O
/	O
ml	O
p	O
-	O
nitrophenyl	O
phosphate	O
(	O
Sigma	O
)	O
dissolved	O
in	O
diethanolamine	O
(	O
Sigma	O
)	O
to	O
develop	O
the	O
color	O
reaction	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
the	O
addition	O
of	O
1	O
M	O
NaOH	O
and	O
the	O
optical	O
density	O
of	O
each	O
well	O
was	O
read	O
at	O
405	O
nm	O
.	O

The	O
lower	O
limit	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
detection	O
was	O
10	O
pg	O
/	O
ml	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
cytokines	B-X
associated	B-X
with	B-X
the	B-X
progression	B-X
of	B-X
acute	B-X
hepatic	B-X
injury	B-X
(	B-X
AHI	B-X
)	B-X
,	B-X
we	B-X
comprehensively	B-X
evaluated	B-X
the	B-X
serum	B-X
levels	B-X
of	B-X
17	B-X
cytokines	B-X
.	B-X
However	B-X
,	B-X
limited	B-X
by	B-X
high	B-X
density	B-X
and	B-X
complicated	B-X
modification	B-X
procedure	B-X
,	B-X
the	B-X
traditional	B-X
nanoparticles	B-X
such	B-X
as	B-X
Au	B-X
nanoparticles	B-X
(	B-X
AuNPs	B-X
)	B-X
usually	B-X
induce	B-X
large	B-X
background	B-X
signal	B-X
and	B-X
poor	B-X
reproducibility	B-X
in	B-X
ELISA	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
functional	B-X
lightweigh	B-X
nanoparticle	B-X
polystyrene	B-X
@	B-X
polydopamine	B-X
(	B-X
PS	B-X
@	B-X
PDA	B-X
)	B-X
was	B-X
prepared	B-X
and	B-X
induced	B-X
as	B-X
the	B-X
carrier	B-X
of	B-X
detection	B-X
antibody	B-X
and	B-X
horseradish	B-X
peroxidase	B-X
(	B-X
HRP	B-X
)	B-X
to	B-X
form	B-X
PS	B-X
@	B-X
PDA	B-X
@	B-X
Ab	B-X
To	B-X
investigate	B-X
T-cell	B-X
activation	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
peripheral	B-X
T	B-X
regulatory	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
,	B-X
Th17	B-X
cells	B-X
and	B-X
the	B-X
circulating	B-X
cytokine	B-X
profile	B-X
in	B-X
systemic	B-X
sclerosis	B-X
(	B-X
SSc	B-X
)	B-X
.	B-X

Recombinant	O
human	O
IL	B-Protein
-	I-Protein
17	I-Protein
diluted	O
in	O
culture	O
medium	O
was	O
used	O
as	O
a	O
calibration	O
standard	O
,	O
ranging	O
from	O
10	O
to	O
2000	O
pg	O
/	O
ml	O
.	O

A	O
standard	O
curve	O
was	O
drawn	O
by	O
plotting	O
optical	O
density	O
against	O
the	O
log	O
of	O
the	O
concentration	O
of	O
recombinant	O
cytokines	O
,	O
and	O
used	O
for	O
determination	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
test	O
samples	O
.	O

Quantification	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
by	O
semiquantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
<EOS>	B-X
We	B-X
sought	B-X
to	B-X
characterize	B-X
this	B-X
persistent	B-X
gastritis	B-X
,	B-X
and	B-X
demonstrate	B-X
the	B-X
persistence	B-X
of	B-X
HP-specific	B-X
Th17	B-X
responses	B-X
in	B-X
individuals	B-X
previously	B-X
infected	B-X
with	B-X
HP	B-X
but	B-X
who	B-X
no	B-X
longer	B-X
had	B-X
evidence	B-X
of	B-X
ongoing	B-X
infection	B-X
.	B-X

PBMC	O
were	O
incubated	O
with	O
various	O
concentrations	O
of	O
anti	O
-	O
CD3	O
in	O
the	O
presence	O
or	O
absence	O
of	O
inhibitors	O
(	O
LY294002	O
,	O
PDTC	O
)	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
cytokines	B-X
can	B-X
induce	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
in	B-X
an	B-X
antigen-independent	B-X
manner	B-X
.	B-X
However	B-X
,	B-X
experimental	B-X
conditions	B-X
have	B-X
included	B-X
the	B-X
use	B-X
of	B-X
fetal	B-X
serum	B-X
and	B-X
nanogram	B-X
concentrations	B-X
of	B-X
added	B-X
cytokines	B-X
.	B-X
To	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
generated	B-X
by	B-X
activated	B-X
immune	B-X
cells	B-X
on	B-X
the	B-X
phenotypic	B-X
profile	B-X
of	B-X
human	B-X
memory	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
FBS-free	B-X
conditions	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL-15	B-X
and	B-X
5	B-X
%	B-X
of	B-X
hAB	B-X
serum	B-X
and	B-X
incubated	B-X
with	B-X
conditioned	B-X
medium	B-X
(	B-X
CM	B-X
)	B-X
obtained	B-X
from	B-X
PBMC	B-X
activated	B-X
through	B-X
the	B-X
TCR	B-X
using	B-X
anti-CD3/CD28/CD2	B-X
antibodies	B-X
(	B-X
TCR-CM	B-X
)	B-X
or	B-X
through	B-X
TLR4	B-X
using	B-X
bacterial	B-X
LPS	B-X
(	B-X
TLR4-CM	B-X
)	B-X
.	B-X
Cell	B-X
viability	B-X
was	B-X
maintained	B-X
by	B-X
TLR4-CM	B-X
plus	B-X
IL-15	B-X
for	B-X
8	B-X
days	B-X
but	B-X
decreased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
TCR-CM	B-X
plus	B-X
IL-15	B-X
.	B-X
In	B-X
combination	B-X
with	B-X
IL-15	B-X
,	B-X
the	B-X
TLR4-CM	B-X
,	B-X
but	B-X
not	B-X
the	B-X
TCR-CM	B-X
,	B-X
maintained	B-X
the	B-X
expression	B-X
of	B-X
CD3	B-X
and	B-X
CD4	B-X
stable	B-X
.	B-X
This	B-X
study	B-X
indicates	B-X
that	B-X
resting	B-X
memory	B-X
CD4	B-X
T	B-X
cells	B-X
are	B-X
not	B-X
activated	B-X
by	B-X
,	B-X
but	B-X
may	B-X
be	B-X
sensitive	B-X
to	B-X
soluble	B-X
factors	B-X
produced	B-X
by	B-X
antigen	B-X
or	B-X
PAMP-stimulated	B-X
cells	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
their	B-X
homeostasis	B-X
and	B-X
favor	B-X
the	B-X
CXCR4	B-X
expression	B-X
.	B-X

After	O
16	O
hours	O
of	O
incubation	O
,	O
mRNA	O
was	O
extracted	O
with	O
RNAzol	O
B	O
(	O
Biotex	O
Laboratories	O
,	O
Houston	O
,	O
TX	O
,	O
USA	O
)	O
in	O
accordance	O
with	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Reverse	O
transcription	O
of	O
2	O
mug	O
of	O
total	O
mRNA	O
was	O
performed	O
at	O
42degreesC	O
using	O
the	O
Superscript	O
(	O
TM	O
)	O
reverse	O
transcription	O
system	O
(	O
Takara	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

PCR	O
amplification	O
of	O
cDNA	O
aliquots	O
was	O
performed	O
by	O
adding	O
2	O
.	O
5	O
mM	O
dNTPs	O
,	O
2	O
.	O
5	O
U	O
of	O
Taq	B-Protein
DNA	O
polymerase	O
(	O
Takara	O
)	O
and	O
0	O
.	O
25	O
muM	O
of	O
sense	O
and	O
antisense	O
primers	O
.	O

The	O
reaction	O
was	O
performed	O
in	O
PCR	O
buffer	O
(	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
50	O
mM	O
KCl	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
3	O
)	O
in	O
a	O
total	O
volume	O
of	O
25	O
mul	O
.	O

The	O
following	O
sense	O
and	O
antisense	O
primers	O
for	O
each	O
molecules	O
were	O
used	O
:	O
IL	B-Protein
-	I-Protein
17	I-Protein
sense	O
,	O
5	O
'	O
-	O
ATG	O
ACT	O
CCT	O
GGG	O
AAG	O
ACC	O
TCA	O
TTG	O
-	O
3	O
'	O
;	O
IL	O
-	O
17	O
antisense	O
,	O
5	O
'	O
-	O
TTA	O
GGC	O
CAC	O
ATG	O
GTG	O
GAC	O
AAT	O
CGG	O
-	O
3	O
'	O
;	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
(	O
GAPDH	B-Protein
)	O
sense	O
,	O
5	O
'	O
-	O
CGA	O
TGC	O
TGG	O
GCG	O
TGA	O
GTA	O
C	O
-	O
3	O
'	O
;	O
GAPDH	B-Protein
antisense	O
,	O
5	O
'	O
-	O
CGT	O
TCA	O
GCT	O
CAG	O
GGA	O
TGA	O
CC	O
-	O
3	O
'	O
.	O

Reactions	O
were	O
processed	O
in	O
a	O
DNA	O
thermal	O
cycler	O
(	O
Perkin	O
-	O
Elmer	O
Cetus	O
,	O
Norwalk	O
,	O
CT	O
,	O
USA	O
)	O
through	O
cycles	O
for	O
30	O
s	O
of	O
denaturation	O
at	O
94degreesC	O
,	O
1	O
min	O
of	O
annealing	O
at	O
56degreesC	O
for	O
GAPDH	B-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
,	O
followed	O
by	O
1	O
min	O
of	O
elongation	O
at	O
72degreesC	O
.	O

PCR	O
rounds	O
were	O
repeated	O
for	O
25	O
cycles	O
each	O
for	O
both	O
GAPDH	B-Protein
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
;	O
this	O
was	O
determined	O
as	O
falling	O
within	O
the	O
exponential	O
phase	O
of	O
amplification	O
for	O
each	O
molecule	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
was	O
presented	O
as	O
a	O
ratio	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
PCR	O
product	O
over	O
GAPDH	B-Protein
product	O
.	O

Western	O
blot	O
analysis	O
of	O
Akt	B-Protein
,	O
phosphorylated	O
Akt	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
<EOS>	B-X
Cell	B-X
viability	B-X
was	B-X
determined	B-X
using	B-X
the	B-X
Cell	B-X
Counting	B-X
kit	B-X
8	B-X
assay	B-X
and	B-X
lactate	B-X
dehydrogenase	B-X
release	B-X
,	B-X
and	B-X
TNF‑α	B-X
release	B-X
was	B-X
analyzed	B-X
by	B-X
ELISA	B-X
analysis	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
Bax	B-X
and	B-X
Bcl‑2	B-X
,	B-X
and	B-X
the	B-X
phosphorylation	B-X
and	B-X
expression	B-X
levels	B-X
of	B-X
Axl	B-X
,	B-X
Akt	B-X
,	B-X
IκB‑α	B-X
,	B-X
p65	B-X
,	B-X
c‑Jun	B-X
N‑terminal	B-X
protein	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
,	B-X
extracellular	B-X
signal‑regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
p38	B-X
were	B-X
determined	B-X
by	B-X
western	B-X
blotting	B-X
.	B-X
Furthermore	B-X
,	B-X
immunofluorescence	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
visualize	B-X
translocation	B-X
of	B-X
NF‑κB	B-X
p65	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
Gas6	B-X
suppressed	B-X
TNF‑α	B-X
release	B-X
and	B-X
inhibited	B-X
cell	B-X
apoptosis	B-X
,	B-X
and	B-X
attenuated	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
‑κB	B-X
and	B-X
mitogen‑activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
activation	B-X
via	B-X
the	B-X
Axl/PI3K/Akt	B-X
pathway	B-X
.	B-X
Pretreatment	B-X
with	B-X
TP‑0903	B-X
and	B-X
Wortmannin	B-X
abrogated	B-X
the	B-X
effects	B-X
of	B-X
Gas6	B-X
on	B-X
phosphorylated‑IκB‑α	B-X
,	B-X
IκB‑α	B-X
,	B-X
NF‑κB	B-X
,	B-X
ERK1/2	B-X
,	B-X
JNK	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
activation	B-X
of	B-X
Axl/PI3K/Akt	B-X
signaling	B-X
by	B-X
Gas6	B-X
may	B-X
inhibit	B-X
LPS‑induced	B-X
TNF‑α	B-X
expression	B-X
and	B-X
apoptosis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
MAPK	B-X
and	B-X
NF‑κB	B-X
activation	B-X
.	B-X

PBMC	O
were	O
incubated	O
with	O
anti	O
-	O
CD3	O
(	O
10	O
mug	O
/	O
ml	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LY294002	O
(	O
20	O
muM	O
)	O
.	O
<EOS>	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
BDNF	B-X
expression	B-X
and	B-X
secretion	B-X
were	B-X
evaluated	B-X
in	B-X
hippocampal	B-X
astrocytes	B-X
incubated	B-X
with	B-X
MK-801	B-X
by	B-X
ELISA	B-X
and	B-X
qPCR	B-X
,	B-X
with	B-X
and	B-X
without	B-X
NMDA	B-X
co-incubation	B-X
or	B-X
pretreatment	B-X
of	B-X
either	B-X
the	B-X
ERK1/2	B-X
inhibitor	B-X
,	B-X
PD98059	B-X
or	B-X
the	B-X
PI3K	B-X
inhibitor	B-X
,	B-X
LY294002	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
MK-801	B-X
treatment	B-X
(	B-X
20	B-X
μM	B-X
for	B-X
5	B-X
days	B-X
)	B-X
enhances	B-X
the	B-X
proliferation	B-X
of	B-X
rat	B-X
cultured	B-X
hippocampal	B-X
astrocytes	B-X
.	B-X
Expression	B-X
of	B-X
BDNF	B-X
mRNA	B-X
was	B-X
enhanced	B-X
after	B-X
24	B-X
h	B-X
in	B-X
MK-801	B-X
,	B-X
but	B-X
returned	B-X
to	B-X
near	B-X
baseline	B-X
over	B-X
the	B-X
next	B-X
24	B-X
h	B-X
in	B-X
the	B-X
continued	B-X
presence	B-X
of	B-X
MK-801	B-X
.	B-X
Two-electrode	B-X
voltage-clamping	B-X
technique	B-X
was	B-X
used	B-X
to	B-X
record	B-X
membrane	B-X
currents	B-X
upon	B-X
exposure	B-X
to	B-X
l-glutamate	B-X
(	B-X
30	B-X
μM	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
desflurane	B-X
(	B-X
0.4	B-X
,	B-X
1.0	B-X
,	B-X
2.0	B-X
,	B-X
2.6	B-X
,	B-X
or	B-X
3.2mM	B-X
)	B-X
.	B-X
Currents	B-X
were	B-X
also	B-X
measured	B-X
in	B-X
oocytes	B-X
pre-exposed	B-X
to	B-X
a	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activator	B-X
(	B-X
50	B-X
nM	B-X
phorbol-12-myristate-13-acetate	B-X
,	B-X
PMA	B-X
)	B-X
,	B-X
PKC	B-X
inhibitors	B-X
(	B-X
1	B-X
μM	B-X
staurosporine	B-X
or	B-X
50	B-X
μM	B-X
chelerythrine	B-X
)	B-X
,	B-X
or	B-X
phosphatidylinositol-3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
inhibitors	B-X
(	B-X
5	B-X
μM	B-X
wortmannin	B-X
or	B-X
10	B-X
μM	B-X
LY294002	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
pretreatment	B-X
of	B-X
oocytes	B-X
with	B-X
two	B-X
PI3K	B-X
inhibitors	B-X
(	B-X
wortmannin	B-X
or	B-X
LY294002	B-X
)	B-X
significantly	B-X
reduced	B-X
desflurane-enhanced	B-X
EAAC1	B-X
activity	B-X
without	B-X
decreasing	B-X
basal	B-X
activity	B-X
.	B-X

After	O
incubation	O
for	O
1	O
hour	O
,	O
whole	O
cell	O
lysates	O
were	O
prepared	O
from	O
about	O
107	O
cells	O
by	O
homogenization	O
in	O
the	O
lysis	O
buffer	O
,	O
and	O
centrifuged	O
at	O
14	O
,	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O

(	O
19	O
,	O
000	O
g	O
)	O
for	O
15	O
min	O
.	O

Protein	O
concentrations	O
in	O
the	O
supernatants	O
were	O
determined	O
with	O
the	O
Bradford	O
method	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Protein	O
samples	O
were	O
separated	O
by	O
10	O
%	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
.	O

For	O
western	O
hybridization	O
,	O
membrane	O
was	O
preincubated	O
with	O
0	O
.	O
1	O
%	O
skimmed	O
milk	O
in	O
TBS	O
-	O
T	O
buffer	O
(	O
0	O
.	O
1	O
%	O
Tween	O
20	O
in	O
Tris	O
-	O
buffered	O
saline	O
)	O
at	O
room	O
temperature	O
for	O
2	O
hours	O
,	O
then	O
primary	O
antibodies	O
against	O
Akt	B-Protein
,	O
phosphorylated	O
Akt	B-Protein
and	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
(	O
Cell	O
Signaling	O
Technology	O
Inc	O
.	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
,	O
diluted	O
1	O
:	O
1000	O
in	O
5	O
%	O
BSA	O
/	O
TBS	O
-	O
T	O
,	O
were	O
added	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

After	O
washing	O
four	O
times	O
with	O
TBS	O
-	O
T	O
,	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
were	O
added	O
and	O
allowed	O
to	O
incubate	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

After	O
TBS	O
-	O
T	O
washing	O
,	O
hybridized	O
bands	O
were	O
detected	O
with	O
the	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
kit	O
and	O
Hyperfilm	O
-	O
ECL	O
reagents	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

Gel	O
mobility	O
-	O
shift	O
assay	O
of	O
NF	O
-	O
kappaB	O
binding	O
site	O
<EOS>	B-X
This	B-X
study	B-X
examined	B-X
transcription	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
AP-1	B-X
,	B-X
HIF-1	B-X
,	B-X
and	B-X
NF-kappaB	B-X
DNA-binding	B-X
in	B-X
relation	B-X
to	B-X
cyclooxygenase	B-X
(	B-X
COX	B-X
)	B-X
-2	B-X
and	B-X
VEGF	B-X
RNA	B-X
and	B-X
protein	B-X
levels	B-X
in	B-X
hypoxia-triggered	B-X
monkey	B-X
choroidal	B-X
retinal	B-X
(	B-X
RF/6A	B-X
)	B-X
endothelial	B-X
cells	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
577	B-X
bp	B-X
fragment	B-X
contains	B-X
a	B-X
non-consensus	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
-binding	B-X
site	B-X
that	B-X
is	B-X
required	B-X
for	B-X
NF-kappaB	B-X
up-regulation	B-X
in	B-X
prostate	B-X
cancer	B-X
cells	B-X
,	B-X
while	B-X
NF-kappaB	B-X
failed	B-X
to	B-X
have	B-X
the	B-X
same	B-X
effect	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
Conversely	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
stopped	B-X
p65	B-X
NF-kappaB	B-X
activation	B-X
of	B-X
the	B-X
p1356	B-X
promoter	B-X
activity	B-X
.	B-X
Gel	B-X
shift	B-X
and	B-X
mutation	B-X
analyses	B-X
determined	B-X
that	B-X
AGGTGT	B-X
(	B-X
-1254/-1249	B-X
)	B-X
is	B-X
the	B-X
core	B-X
sequence	B-X
for	B-X
NF-kappaB-binding	B-X
and	B-X
activation	B-X
.	B-X
Biologically	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
activated	B-X
endogenous	B-X
PAcP	B-X
expression	B-X
in	B-X
LNCaP	B-X
human	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
data	B-X
collectively	B-X
indicate	B-X
that	B-X
NF-kappaB	B-X
up-regulates	B-X
PAcP	B-X
promoter	B-X
activity	B-X
via	B-X
its	B-X
binding	B-X
to	B-X
the	B-X
AGGTGT	B-X
motif	B-X
,	B-X
a	B-X
novel	B-X
binding	B-X
sequence	B-X
located	B-X
inside	B-X
the	B-X
cis-active	B-X
enhancer	B-X
element	B-X
in	B-X
human	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X

Nuclear	O
proteins	O
were	O
extracted	O
from	O
about	O
5	O
x	O
106	O
PBMC	O
.	O

Oligonucleotide	O
probes	O
encompassing	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
of	O
the	O
human	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
(	O
5	O
'	O
-	O
ATG	O
ACC	O
TGG	O
AAA	O
TAC	O
CCA	O
AAA	O
TTC	O
-	O
3	O
'	O
)	O
were	O
generated	O
by	O
5	O
'	O
-	O
end	O
labeling	O
of	O
the	O
sense	O
strand	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
dATP	O
(	O
Amersham	O
Pharmacia	O
)	O
and	O
T4	O
polynucleotide	O
kinase	O
(	O
TaKaRa	O
)	O
.	O

Unincorporated	O
nucleotides	O
were	O
removed	O
by	O
NucTrap	O
probe	O
purification	O
columns	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Nuclear	O
extracts	O
(	O
2	O
mug	O
of	O
protein	O
)	O
were	O
incubated	O
with	O
radiolabeled	O
DNA	O
probes	O
(	O
10	O
ng	O
;	O
100	O
,	O
000	O
c	O
.	O
p	O
.	O
m	O
.	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
in	O
20	O
mul	O
of	O
binding	O
buffer	O
consisting	O
of	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
9	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
5	O
%	O
glycerol	O
,	O
1	O
mg	O
/	O
ml	O
BSA	O
,	O
0	O
.	O
2	O
%	O
Nonidet	O
P40	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
.	O

Samples	O
were	O
subjected	O
to	O
electrophoresis	O
on	O
nondenaturing	O
5	O
%	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5	O
x	O
Tris	O
-	O
borate	O
-	O
EDTA	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
at	O
100	O
V	O
.	O

Gels	O
were	O
dried	O
under	O
vacuum	O
and	O
exposed	O
to	O
Kodak	O
X	O
-	O
OMAT	O
film	O
at	O
-	O
70degreesC	O
with	O
intensifying	O
screens	O
.	O

Rabbit	O
polyclonal	O
antibodies	O
against	O
NF	O
-	O
kappaB	O
subunits	O
p50	B-Protein
,	O
p65	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cell	O
viability	O
(	O
Trypan	O
blue	O
dye	O
exclusion	O
assay	O
)	O
<EOS>	B-X
The	B-X
dye	B-X
exclusion	B-X
test	B-X
is	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
number	B-X
of	B-X
viable	B-X
cells	B-X
present	B-X
in	B-X
a	B-X
cell	B-X
suspension	B-X
.	B-X
It	B-X
is	B-X
based	B-X
on	B-X
the	B-X
principle	B-X
that	B-X
live	B-X
cells	B-X
possess	B-X
intact	B-X
cell	B-X
membranes	B-X
that	B-X
exclude	B-X
certain	B-X
dyes	B-X
,	B-X
such	B-X
as	B-X
trypan	B-X
blue	B-X
,	B-X
Eosin	B-X
,	B-X
or	B-X
propidium	B-X
,	B-X
whereas	B-X
dead	B-X
cells	B-X
do	B-X
not	B-X
.	B-X
In	B-X
this	B-X
test	B-X
,	B-X
a	B-X
cell	B-X
suspension	B-X
is	B-X
simply	B-X
mixed	B-X
with	B-X
dye	B-X
and	B-X
then	B-X
visually	B-X
examined	B-X
to	B-X
determine	B-X
whether	B-X
cells	B-X
take	B-X
up	B-X
or	B-X
exclude	B-X
dye	B-X
.	B-X
In	B-X
the	B-X
protocol	B-X
presented	B-X
here	B-X
,	B-X
a	B-X
viable	B-X
cell	B-X
will	B-X
have	B-X
a	B-X
clear	B-X
cytoplasm	B-X
whereas	B-X
a	B-X
nonviable	B-X
cell	B-X
will	B-X
have	B-X
a	B-X
blue	B-X
cytoplasm	B-X
.	B-X

For	O
cell	O
viability	O
assays	O
,	O
the	O
trypan	O
blue	O
dye	O
exclusion	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
potential	O
of	O
direct	O
cytotoxic	O
effect	O
of	O
inhibitors	O
on	O
cells	O
.	O

After	O
incubation	O
for	O
24	O
hours	O
,	O
the	O
cells	O
were	O
harvested	O
and	O
the	O
percentage	O
cell	O
viability	O
was	O
calculated	O
with	O
the	O
formula	O
100	O
x	O
(	O
number	O
of	O
viable	O
cells	O
/	O
number	O
of	O
both	O
viable	O
and	O
dead	O
cells	O
)	O
[	O
21	O
]	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
When	B-X
combined	B-X
with	B-X
stable	B-X
isotope-labeling-an	B-X
approach	B-X
we	B-X
refer	B-X
to	B-X
as	B-X
nanoSIP-nanoSIMS	B-X
imaging	B-X
offers	B-X
a	B-X
distinctive	B-X
means	B-X
to	B-X
quantify	B-X
net	B-X
assimilation	B-X
rates	B-X
and	B-X
stoichiometry	B-X
of	B-X
individual	B-X
cell-sized	B-X
particles	B-X
in	B-X
both	B-X
low-	B-X
and	B-X
high-complexity	B-X
environments	B-X
.	B-X
It	B-X
can	B-X
be	B-X
shown	B-X
that	B-X
these	B-X
are	B-X
special	B-X
cases	B-X
of	B-X
a	B-X
more	B-X
general	B-X
model	B-X
,	B-X
called	B-X
the	B-X
mixture	B-X
of	B-X
structural	B-X
equation	B-X
models	B-X
(	B-X
mixture	B-X
of	B-X
SEMs	B-X
)	B-X
,	B-X
which	B-X
has	B-X
been	B-X
developed	B-X
in	B-X
psychometrics	B-X
.	B-X
This	B-X
model	B-X
combines	B-X
mixture	B-X
modelling	B-X
and	B-X
SEMs	B-X
by	B-X
assuming	B-X
that	B-X
component-specific	B-X
means	B-X
and	B-X
variances	B-X
are	B-X
subject	B-X
to	B-X
a	B-X
SEM	B-X
.	B-X
The	B-X
connection	B-X
with	B-X
SEM	B-X
is	B-X
useful	B-X
for	B-X
at	B-X
least	B-X
two	B-X
reasons	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
shows	B-X
the	B-X
basic	B-X
assumptions	B-X
of	B-X
existing	B-X
methods	B-X
more	B-X
explicitly	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
helps	B-X
in	B-X
straightforward	B-X
development	B-X
of	B-X
alternative	B-X
mixture	B-X
models	B-X
for	B-X
gene	B-X
expression	B-X
data	B-X
with	B-X
alternative	B-X
mean/covariance	B-X
structures	B-X
.	B-X
Different	B-X
specifications	B-X
of	B-X
mixture	B-X
of	B-X
SEMs	B-X
for	B-X
clustering	B-X
gene	B-X
expression	B-X
data	B-X
are	B-X
illustrated	B-X
using	B-X
two	B-X
benchmark	B-X
datasets	B-X
.	B-X

Statistical	O
analysis	O
was	O
performed	O
with	O
Student	O
'	O
s	O
t	O
-	O
test	O
for	O
matched	O
pairs	O
.	O

P	O
values	O
less	O
than	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
from	O
patients	O
with	O
RA	O
,	O
patients	O
with	O
OA	O
and	O
normal	O
individuals	O

PBMC	O
were	O
separated	O
and	O
cultured	O
with	O
PHA	B-Protein
(	O
5	O
mug	O
/	O
ml	O
)	O
from	O
patients	O
with	O
RA	O
,	O
patients	O
with	O
OA	O
,	O
and	O
age	O
-	O
matched	O
normal	O
controls	O
;	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
were	O
then	O
determined	O
in	O
the	O
culture	O
supernatants	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Although	O
the	O
amounts	O
of	O
basal	O
IL	B-Protein
-	I-Protein
17	I-Protein
secretion	O
were	O
not	O
different	O
between	O
RA	O
,	O
OA	O
and	O
normal	O
controls	O
(	O
62	O
+	O
/	O
-	O
31	O
,	O
43	O
+	O
/	O
-	O
19	O
and	O
43	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
,	O
respectively	O
)	O
,	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
stimulated	O
by	O
PHA	B-Protein
was	O
significantly	O
higher	O
in	O
RA	O
PBMC	O
than	O
in	O
those	O
from	O
OA	O
and	O
controls	O
(	O
768	O
+	O
/	O
-	O
295	O
versus	O
463	O
+	O
/	O
-	O
211	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
and	O
241	O
+	O
/	O
-	O
29	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
001	O
]	O
)	O
.	O

Increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
of	O
patients	O
with	O
RA	O
by	O
anti	O
-	O
CD3	O
and	O
/	O
or	O
anti	O
-	O
CD28	B-Protein
,	O
and	O
PHA	B-Protein
<EOS>	B-X
Traditionally	B-X
,	B-X
mitogenic	B-X
lectins	B-X
such	B-X
as	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
have	B-X
been	B-X
used	B-X
for	B-X
polyclonal	B-X
T	B-X
cell	B-X
stimulation	B-X
.	B-X
A	B-X
more	B-X
physiologically	B-X
relevant	B-X
approach	B-X
uses	B-X
beads	B-X
coated	B-X
with	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
to	B-X
stimulate	B-X
T	B-X
cells	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
partially	B-X
mimics	B-X
stimulation	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
the	B-X
steps	B-X
involved	B-X
in	B-X
T	B-X
cell	B-X
stimulation	B-X
and	B-X
their	B-X
subsequent	B-X
in	B-X
vitro	B-X
expansion	B-X
using	B-X
anti-CD3/CD28	B-X
beads	B-X
.	B-X
During	B-X
antigen	B-X
recognition	B-X
,	B-X
T	B-X
lymphocytes	B-X
are	B-X
primed	B-X
by	B-X
a	B-X
physical	B-X
interaction	B-X
with	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
.	B-X
One	B-X
is	B-X
provided	B-X
by	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
/CD3	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
mayor	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
,	B-X
and	B-X
another	B-X
signal	B-X
is	B-X
mediated	B-X
by	B-X
antigen-independent	B-X
molecules	B-X
,	B-X
that	B-X
is	B-X
T	B-X
cell	B-X
membrane-bound	B-X
CD28	B-X
and	B-X
its	B-X
specific	B-X
ligand	B-X
B7-1	B-X
(	B-X
CD80	B-X
)	B-X
present	B-X
in	B-X
APC	B-X
.	B-X
Our	B-X
main	B-X
goal	B-X
was	B-X
to	B-X
determine	B-X
whether	B-X
deficiency	B-X
in	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
production	B-X
shown	B-X
by	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
lepromatous	B-X
leprosy	B-X
(	B-X
LL	B-X
)	B-X
patients	B-X
,	B-X
could	B-X
be	B-X
overcome	B-X
by	B-X
reconstituting	B-X
in	B-X
vitro	B-X
the	B-X
appropriate	B-X
signals	B-X
(	B-X
by	B-X
means	B-X
of	B-X
addition	B-X
of	B-X
anti-CD28	B-X
and	B-X
anti-CD80	B-X
monoclonal	B-X
antibodies	B-X
)	B-X
.	B-X
We	B-X
also	B-X
determined	B-X
the	B-X
stimulation	B-X
index	B-X
(	B-X
SI	B-X
)	B-X
in	B-X
the	B-X
same	B-X
PBMC	B-X
.	B-X
Our	B-X
results	B-X
demonstrated	B-X
no	B-X
significant	B-X
differences	B-X
in	B-X
CD80	B-X
expression	B-X
monocytes	B-X
and	B-X
B	B-X
lymphocytes	B-X
from	B-X
LL	B-X
patients	B-X
when	B-X
compared	B-X
with	B-X
healthy	B-X
subjects	B-X
.	B-X
Nonetheless	B-X
,	B-X
CD28	B-X
expression	B-X
significantly	B-X
decreased	B-X
in	B-X
lymphocytes	B-X
from	B-X
LL	B-X
patients	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
Regarding	B-X
IFN-gamma	B-X
levels	B-X
and	B-X
SI	B-X
,	B-X
LL-PBMC	B-X
failure	B-X
before	B-X
mitogenic	B-X
stimuli	B-X
could	B-X
be	B-X
reversed	B-X
by	B-X
further	B-X
incubation	B-X
with	B-X
anti-CD28	B-X
antibody	B-X
,	B-X
but	B-X
stimulation	B-X
by	B-X
specific	B-X
antigen	B-X
of	B-X
Mycobacterium	B-X
leprae	B-X
was	B-X
not	B-X
changed	B-X
.	B-X
Addition	B-X
of	B-X
anti-CD80	B-X
antibody	B-X
significantly	B-X
increased	B-X
IFN-gamma	B-X
levels	B-X
in	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
-stimulated	B-X
PBMC	B-X
,	B-X
although	B-X
proliferation	B-X
deficiency	B-X
persisted	B-X
.	B-X
Cells	B-X
stimulated	B-X
with	B-X
specific	B-X
antigen	B-X
did	B-X
not	B-X
modify	B-X
either	B-X
their	B-X
proliferation	B-X
or	B-X
IFN-gamma	B-X
levels	B-X
.	B-X

Because	O
IL	B-Protein
-	I-Protein
17	I-Protein
was	O
already	O
known	O
from	O
earlier	O
reports	O
to	O
be	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
different	O
concentrations	O
of	O
anti	O
-	O
CD3	O
(	O
1	O
,	O
5	O
and	O
10	O
mug	O
/	O
ml	O
)	O
as	O
a	O
T	O
cell	O
activation	O
,	O
which	O
showed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

On	O
the	O
basis	O
of	O
this	O
,	O
we	O
chose	O
10	O
mug	O
/	O
ml	O
as	O
a	O
stimulation	O
concentration	O
for	O
anti	O
-	O
CD3	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
anti	O
-	O
CD3	O
significantly	O
upregulated	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
up	O
to	O
3	O
.	O
7	O
-	O
fold	O
,	O
and	O
the	O
combination	O
of	O
anti	O
-	O
CD28	B-Protein
and	O
anti	O
-	O
CD3	O
produced	O
more	O
IL	B-Protein
-	I-Protein
17	I-Protein
(	O
approximately	O
1	O
.	O
3	O
-	O
1	O
.	O
5	O
-	O
fold	O
)	O
than	O
anti	O
-	O
CD3	O
alone	O
.	O

Furthermore	O
,	O
when	O
incubated	O
with	O
T	O
cell	O
mitogens	O
such	O
as	O
PHA	B-Protein
,	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
more	O
pronounced	O
than	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
588	O
+	O
/	O
-	O
85	O
versus	O
211	O
+	O
/	O
-	O
1	O
pg	O
/	O
ml	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
by	O
inflammatory	O
cytokines	O
and	O
chemokines	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Because	O
RA	O
PBMC	O
include	O
several	O
cell	O
types	O
in	O
addition	O
to	O
T	O
cells	O
,	O
some	O
inflammatory	O
cytokines	O
released	O
from	O
macrophages	O
and	O
other	O
lymphocytes	O
might	O
have	O
affected	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
from	O
T	O
cells	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
inflammatory	O
cytokines	O
released	O
by	O
activated	O
PBMC	O
,	O
we	O
tested	O
the	O
effects	O
of	O
several	O
cytokines	O
and	O
chemokines	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O

We	O
detected	O
an	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
level	O
after	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
15	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
whereas	O
with	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
IL	B-Protein
-	I-Protein
18	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
the	O
levels	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
were	O
unchanged	O
(	O
Fig	O
.	O
2a	O
)	O
.	O

When	O
treated	O
with	O
MCP	B-Protein
-	I-Protein
1	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
IL	B-Protein
-	I-Protein
6	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
significant	O
upregulations	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
proteins	O
were	O
observed	O
(	O
62	O
+	O
/	O
-	O
42	O
and	O
50	O
+	O
/	O
-	O
10	O
versus	O
31	O
+	O
/	O
-	O
11	O
pg	O
/	O
ml	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
none	O
was	O
observed	O
with	O
IL	B-Protein
-	I-Protein
8	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
or	O
MIP	B-Protein
-	I-Protein
1beta	I-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
(	O
Fig	O
.	O
2b	O
)	O
.	O

Inhibition	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
signal	O
transduction	O
inhibitors	O
and	O
anti	O
-	O
rheumatic	O
drugs	O
<EOS>	B-X
The	B-X
subtype	B-X
nr-axSpA	B-X
has	B-X
historically	B-X
developed	B-X
because	B-X
the	B-X
approval	B-X
of	B-X
drugs	B-X
for	B-X
AS	B-X
did	B-X
not	B-X
cover	B-X
forms	B-X
without	B-X
structural	B-X
changes	B-X
in	B-X
the	B-X
sacroiliac	B-X
joints	B-X
which	B-X
is	B-X
mandatory	B-X
in	B-X
the	B-X
1984	B-X
New	B-X
York	B-X
criteria	B-X
.	B-X
Several	B-X
biologic	B-X
disease	B-X
modifying	B-X
anti-rheumatic	B-X
drugs	B-X
(	B-X
bDMARDs	B-X
)	B-X
such	B-X
as	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
inhibitors	B-X
(	B-X
TNFi	B-X
)	B-X
and	B-X
the	B-X
interleukin-17-inhibitors	B-X
(	B-X
IL-17i	B-X
)	B-X
are	B-X
approved	B-X
mostly	B-X
for	B-X
the	B-X
whole	B-X
spectrum	B-X
of	B-X
SpA	B-X
including	B-X
axSpA	B-X
and	B-X
PsA	B-X
but	B-X
L-17i	B-X
does	B-X
not	B-X
work	B-X
in	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
.	B-X
Targeted	B-X
synthetic	B-X
(	B-X
ts	B-X
)	B-X
DMARDs	B-X
cover	B-X
mainly	B-X
the	B-X
janus	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
-inhibitors	B-X
which	B-X
have	B-X
recently	B-X
been	B-X
developed	B-X
to	B-X
inhibit	B-X
inflammation	B-X
in	B-X
several	B-X
rheumatic	B-X
and	B-X
other	B-X
immune	B-X
mediated	B-X
diseases	B-X
such	B-X
as	B-X
IBD	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
physiologic	B-X
mechanism	B-X
of	B-X
JAK-mediated	B-X
signal	B-X
transduction	B-X
has	B-X
been	B-X
recognized	B-X
as	B-X
an	B-X
important	B-X
target	B-X
because	B-X
the	B-X
inhibition	B-X
of	B-X
its	B-X
actions	B-X
was	B-X
shown	B-X
to	B-X
successfully	B-X
work	B-X
as	B-X
a	B-X
therapeutic	B-X
mechanism	B-X
.	B-X
There	B-X
are	B-X
now	B-X
4	B-X
small	B-X
molecule	B-X
JAK	B-X
inhibitors	B-X
(	B-X
JAKi	B-X
)	B-X
that	B-X
currently	B-X
play	B-X
a	B-X
role	B-X
in	B-X
rheumatology	B-X
with	B-X
variable	B-X
selectivity	B-X
for	B-X
the	B-X
four	B-X
different	B-X
JAK	B-X
isoforms	B-X
:	B-X
tofacitinib	B-X
,	B-X
baricitinib	B-X
,	B-X
upadacitinib	B-X
and	B-X
filgotinib	B-X
.	B-X

Having	O
observed	O
the	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
,	O
it	O
was	O
important	O
to	O
know	O
which	O
signal	O
transduction	O
pathways	O
were	O
involved	O
.	O

As	O
illustrated	O
in	O
Fig	O
.	O
<EOS>	B-X
The	B-X
parameters	B-X
relevant	B-X
in	B-X
considering	B-X
the	B-X
optimal	B-X
use	B-X
of	B-X
antibiotics	B-X
to	B-X
treat	B-X
infections	B-X
are	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Understanding	B-X
the	B-X
function	B-X
of	B-X
all	B-X
the	B-X
existing	B-X
glycosphingolipids	B-X
and	B-X
sphingomyelin	B-X
species	B-X
will	B-X
be	B-X
a	B-X
major	B-X
undertaking	B-X
in	B-X
the	B-X
future	B-X
since	B-X
the	B-X
tools	B-X
to	B-X
study	B-X
and	B-X
measure	B-X
these	B-X
species	B-X
are	B-X
only	B-X
beginning	B-X
to	B-X
be	B-X
developed	B-X
(	B-X
see	B-X
Fig	B-X
1	B-X
for	B-X
an	B-X
illustrated	B-X
depiction	B-X
of	B-X
the	B-X
various	B-X
sphingolipid	B-X
structures	B-X
)	B-X
.	B-X
Following	B-X
the	B-X
publication	B-X
of	B-X
the	B-X
above	B-X
article	B-X
,	B-X
an	B-X
interested	B-X
reader	B-X
drew	B-X
the	B-X
authors	B-X
'	B-X
attention	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
certain	B-X
features	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
The	B-X
most	B-X
potent	B-X
CCK	B-X
antagonist	B-X
in	B-X
each	B-X
of	B-X
the	B-X
three	B-X
classes	B-X
is	B-X
illustrated	B-X
in	B-X
Fig	B-X
.	B-X

3	O
,	O
an	O
significant	O
decrease	O
in	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
observed	O
when	O
co	O
-	O
incubated	O
with	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
PDTC	O
and	O
dexamethasone	O
in	O
comparison	O
with	O
anti	O
-	O
CD3	O
alone	O
(	O
38	O
+	O
/	O
-	O
5	O
and	O
54	O
+	O
/	O
-	O
11	O
versus	O
98	O
+	O
/	O
-	O
19	O
pg	O
/	O
ml	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

LY294002	O
and	O
wortmannin	O
,	O
as	O
an	O
inhibitor	O
of	O
PI3K	O
,	O
also	O
markedly	O
inhibited	O
the	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
(	O
98	O
+	O
/	O
-	O
19	O
versus	O
38	O
+	O
/	O
-	O
10	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
005	O
]	O
and	O
48	O
+	O
/	O
-	O
4	O
pg	O
/	O
ml	O
[	O
P	O
<	O
0	O
.	O
05	O
]	O
,	O
respectively	O
)	O
.	O

The	O
calcineurin	B-Protein
inhibitors	O
cyclosporin	O
A	O
and	O
FK506	O
also	O
downregulated	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
secretion	O
as	O
well	O
as	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
p38	O
inhibitor	O
SB203580	O
did	O
,	O
whereas	O
rapamycin	O
and	O
PD98059	O
had	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
levels	O
(	O
Fig	O
.	O
3	O
)	O
.	O

To	O
evaluate	O
the	O
possibility	O
of	O
non	O
-	O
specific	O
inhibition	O
by	O
the	O
drug	O
at	O
high	O
concentrations	O
,	O
we	O
observed	O
the	O
dose	O
response	O
of	O
PDTC	O
and	O
LY294002	O
for	O
the	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
.	O

There	O
were	O
dose	O
-	O
dependent	O
inhibitions	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
with	O
chemical	O
inhibitors	O
(	O
Fig	O
.	O
4a	O
)	O
.	O

The	O
other	O
inhibitors	O
in	O
addition	O
to	O
PDTC	O
and	O
LY294002	O
showed	O
the	O
same	O
pattern	O
of	O
inhibition	O
.	O

Cytotoxic	O
effects	O
on	O
PBMC	O
by	O
the	O
chemical	O
inhibitors	O
at	O
experimental	O
concentrations	O
were	O
not	O
observed	O
(	O
Fig	O
.	O
4b	O
)	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
expression	O
in	O
RA	O
PBMC	O
<EOS>	B-X
Interleukin-33	B-X
(	B-X
IL-33	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
cytokine	B-X
of	B-X
the	B-X
IL-1	B-X
cytokine	B-X
family	B-X
that	B-X
has	B-X
been	B-X
recently	B-X
implicated	B-X
in	B-X
several	B-X
inflammatory	B-X
and	B-X
autoimmune	B-X
diseases	B-X
and	B-X
the	B-X
association	B-X
of	B-X
IL-33	B-X
with	B-X
BD	B-X
has	B-X
remained	B-X
unknown	B-X
.	B-X
Here	B-X
we	B-X
document	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
IL-33	B-X
level	B-X
and	B-X
its	B-X
association	B-X
with	B-X
BD	B-X
.	B-X
IL-17	B-X
is	B-X
a	B-X
T	B-X
cell	B-X
cytokine	B-X
with	B-X
a	B-X
complex	B-X
and	B-X
important	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
It	B-X
has	B-X
been	B-X
detected	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
synovial	B-X
membrane	B-X
and	B-X
found	B-X
to	B-X
stimulate	B-X
the	B-X
production	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokines	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
in	B-X
vitro	B-X
.	B-X
To	B-X
date	B-X
,	B-X
there	B-X
are	B-X
few	B-X
data	B-X
available	B-X
on	B-X
the	B-X
agents	B-X
that	B-X
stimulate	B-X
IL-17	B-X
production	B-X
.	B-X
We	B-X
therefore	B-X
investigated	B-X
the	B-X
in	B-X
vitro	B-X
IL-17	B-X
response	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
mitogens	B-X
and	B-X
antigens	B-X
,	B-X
and	B-X
compared	B-X
the	B-X
IL-17	B-X
response	B-X
to	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
,	B-X
IL-4	B-X
,	B-X
IL-10	B-X
and	B-X
TNF-alpha	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
used	B-X
a	B-X
type-0	B-X
antigen	B-X
,	B-X
tetanus	B-X
toxoid	B-X
(	B-X
TT	B-X
)	B-X
,	B-X
a	B-X
type-1	B-X
antigen	B-X
,	B-X
PPD	B-X
from	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
a	B-X
potential	B-X
type-2	B-X
rye	B-X
grass	B-X
(	B-X
RG	B-X
)	B-X
antigen	B-X
(	B-X
Lol	B-X
I	B-X
)	B-X
and	B-X
an	B-X
autoantigen	B-X
SS.B	B-X
(	B-X
La	B-X
)	B-X
,	B-X
to	B-X
stimulate	B-X
PBMC	B-X
from	B-X
healthy	B-X
controls	B-X
.	B-X
Cytokine	B-X
mRNA	B-X
was	B-X
measured	B-X
using	B-X
semiquantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
cytokine	B-X
protein	B-X
measured	B-X
using	B-X
specific	B-X
ELISA	B-X
techniques	B-X
,	B-X
while	B-X
the	B-X
frequency	B-X
of	B-X
IL-17-producing	B-X
T	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
The	B-X
mitogens	B-X
concanavalin	B-X
A	B-X
,	B-X
phytohaemagglutinin	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
induced	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
IL-17	B-X
,	B-X
with	B-X
the	B-X
highest	B-X
levels	B-X
being	B-X
produced	B-X
by	B-X
anti-CD3/anti-CD28	B-X
stimulation	B-X
.	B-X
The	B-X
antigens	B-X
TT	B-X
and	B-X
PPD	B-X
significantly	B-X
increased	B-X
IL-17	B-X
mRNA	B-X
expression	B-X
over	B-X
time	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
have	B-X
such	B-X
an	B-X
effect	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
.	B-X
IL-17	B-X
protein	B-X
was	B-X
also	B-X
detectable	B-X
in	B-X
both	B-X
antigen-specific	B-X
(	B-X
TT	B-X
,	B-X
SS	B-X
.	B-X
IL-17	B-X
production	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
either	B-X
the	B-X
type-1	B-X
cytokine	B-X
IFN-gamma	B-X
or	B-X
TNF-alpha	B-X
or	B-X
the	B-X
type-2	B-X
cytokine	B-X
IL-4	B-X
or	B-X
IL-10	B-X
at	B-X
either	B-X
the	B-X
mRNA	B-X
or	B-X
protein	B-X
level	B-X
.	B-X

To	O
see	O
whether	O
enhanced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
could	O
be	O
regulated	O
at	O
a	O
transcriptional	O
level	O
,	O
semi	O
-	O
quantatitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
.	O

We	O
observed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
mRNA	O
transcripts	O
after	O
stimulation	O
with	O
anti	O
-	O
CD3	O
;	O
this	O
was	O
inhibited	O
by	O
the	O
PI3K	O
inhibitor	O
LY294002	O
and	O
by	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
PDTC	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Activation	O
of	O
PI3K	O
/	O
Akt	B-Protein
signal	O
transduction	O
pathway	O
on	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
anti	O
-	O
CD3	O
<EOS>	B-X
Herein	B-X
,	B-X
we	B-X
found	B-X
a	B-X
significant	B-X
upregulation	B-X
of	B-X
signaling	B-X
lymphocytic	B-X
activation	B-X
molecule	B-X
family	B-X
member	B-X
3	B-X
(	B-X
SLAMF3	B-X
)	B-X
expression	B-X
on	B-X
T	B-X
cells	B-X
from	B-X
T2D	B-X
patients	B-X
compared	B-X
to	B-X
those	B-X
of	B-X
healthy	B-X
controls	B-X
.	B-X
Significantly	B-X
increased	B-X
SLAMF3	B-X
expression	B-X
was	B-X
seen	B-X
in	B-X
T2D	B-X
patient	B-X
T	B-X
cells	B-X
that	B-X
produce	B-X
IFN-γ	B-X
or	B-X
IL-17	B-X
upon	B-X
short	B-X
(	B-X
4-h	B-X
)	B-X
stimulation	B-X
,	B-X
compared	B-X
to	B-X
non-cytokine-producing	B-X
T	B-X
cells	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

To	O
determine	O
downstream	O
effector	O
molecules	O
of	O
the	O
PI3K	O
pathway	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
Akt	B-Protein
by	O
western	O
blotting	O
.	O
<EOS>	B-X
PRL-3	B-X
facilitates	B-X
Hepatocellular	B-X
Carcinoma	B-X
progression	B-X
by	B-X
co-amplifying	B-X
with	B-X
and	B-X
activating	B-X
FAK	B-X
.	B-X

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

6	O
,	O
at	O
10	O
min	O
of	O
incubation	O
with	O
anti	O
-	O
CD3	O
(	O
10	O
mug	O
/	O
ml	O
)	O
or	O
LY294002	O
(	O
20	O
muM	O
)	O
,	O
no	O
difference	O
in	O
the	O
amounts	O
of	O
phosphorylated	O
Akt	B-Protein
was	O
observed	O
.	O

However	O
,	O
after	O
30	O
min	O
of	O
incubation	O
,	O
phosphorylated	O
Akt	B-Protein
increased	O
(	O
lane	O
2	O
)	O
,	O
and	O
the	O
effect	O
of	O
inhibition	O
by	O
LY294002	O
(	O
lane	O
3	O
)	O
reached	O
a	O
peak	O
at	O
60	O
min	O
,	O
lasting	O
to	O
120	O
-	O
240	O
min	O
.	O

In	O
contrast	O
,	O
non	O
-	O
phosphorylated	O
Akt	B-Protein
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
remained	O
unchanged	O
regardless	O
of	O
incubation	O
time	O
.	O

PHA	B-Protein
,	O
concanavalin	O
A	O
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
also	O
demonstrated	O
the	O
same	O
effect	O
on	O
phosphorylated	O
Akt	B-Protein
as	O
shown	O
with	O
anti	O
-	O
CD3	O
,	O
which	O
was	O
an	O
inhibition	O
by	O
wortmannin	O
and	O
PDTC	O
as	O
well	O
as	O
by	O
LY294002	O
(	O
data	O
not	O
shown	O
)	O
.	O

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
activator	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
AP	B-Protein
-	I-Protein
1	I-Protein
)	O
pathway	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
region	O
<EOS>	B-X
Matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
degrade	B-X
collagen	B-X
and	B-X
mediate	B-X
tissue	B-X
remodeling	B-X
.	B-X
The	B-X
novel	B-X
cytokine	B-X
IL-17	B-X
is	B-X
expressed	B-X
during	B-X
various	B-X
inflammatory	B-X
conditions	B-X
and	B-X
modulates	B-X
MMP	B-X
expression	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
IL-17	B-X
on	B-X
MMP-1	B-X
expression	B-X
in	B-X
primary	B-X
human	B-X
cardiac	B-X
fibroblasts	B-X
(	B-X
HCF	B-X
)	B-X
and	B-X
delineated	B-X
the	B-X
signaling	B-X
pathways	B-X
involved	B-X
.	B-X
HCF	B-X
were	B-X
treated	B-X
with	B-X
recombinant	B-X
human	B-X
IL-17	B-X
.	B-X
MMP-1	B-X
expression	B-X
was	B-X
analyzed	B-X
by	B-X
Northern	B-X
blotting	B-X
,	B-X
RT-quantitative	B-X
PCR	B-X
,	B-X
Western	B-X
blotting	B-X
,	B-X
and	B-X
ELISA	B-X
;	B-X
transcriptional	B-X
induction	B-X
and	B-X
transcription	B-X
factor	B-X
binding	B-X
by	B-X
EMSA	B-X
,	B-X
ELISA	B-X
,	B-X
and	B-X
reporter	B-X
assay	B-X
;	B-X
and	B-X
p38	B-X
MAPK	B-X
and	B-X
ERK1/2	B-X
activation	B-X
by	B-X
protein	B-X
kinase	B-X
assays	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
Signal	B-X
transduction	B-X
pathways	B-X
were	B-X
investigated	B-X
using	B-X
pharmacological	B-X
inhibitors	B-X
,	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
,	B-X
and	B-X
adenoviral	B-X
dominant-negative	B-X
expression	B-X
vectors	B-X
.	B-X
IL-17	B-X
stimulated	B-X
MMP-1	B-X
gene	B-X
transcription	B-X
,	B-X
net	B-X
mRNA	B-X
levels	B-X
,	B-X
protein	B-X
,	B-X
and	B-X
promoter-reporter	B-X
activity	B-X
in	B-X
HCF	B-X
.	B-X
This	B-X
response	B-X
was	B-X
blocked	B-X
by	B-X
IL-17	B-X
receptor-Fc	B-X
chimera	B-X
and	B-X
IL-17	B-X
receptor	B-X
antibodies	B-X
,	B-X
but	B-X
not	B-X
by	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
or	B-X
IL-1beta	B-X
antibodies	B-X
.	B-X
IL-17-stimulated	B-X
type	B-X
I	B-X
collagenase	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
MMP	B-X
inhibitor	B-X
GM-6001	B-X
and	B-X
by	B-X
siRNA-mediated	B-X
MMP-1	B-X
knockdown	B-X
.	B-X
IL-17	B-X
stimulated	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
(	B-X
c-Fos	B-X
,	B-X
c-Jun	B-X
,	B-X
and	B-X
Fra-1	B-X
)	B-X
]	B-X
,	B-X
NF-kappaB	B-X
(	B-X
p50	B-X
and	B-X
p65	B-X
)	B-X
,	B-X
and	B-X
CCAAT	B-X
enhancer-binding	B-X
protein	B-X
(	B-X
C/EBP	B-X
)	B-X
-beta	B-X
DNA	B-X
binding	B-X
and	B-X
reporter	B-X
gene	B-X
activities	B-X
,	B-X
effects	B-X
attenuated	B-X
by	B-X
antisense	B-X
oligonucleotides	B-X
,	B-X
siRNA-mediated	B-X
knockdown	B-X
,	B-X
or	B-X
expression	B-X
of	B-X
dominant-negative	B-X
signaling	B-X
proteins	B-X
.	B-X
Inhibition	B-X
of	B-X
AP-1	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
C/EBP	B-X
activation	B-X
attenuated	B-X
IL-17-stimulated	B-X
MMP-1	B-X
expression	B-X
.	B-X
IL-17	B-X
induced	B-X
p38	B-X
MAPK	B-X
and	B-X
ERK1/2	B-X
activation	B-X
,	B-X
and	B-X
inhibition	B-X
by	B-X
SB-203580	B-X
and	B-X
PD-98059	B-X
blunted	B-X
IL-17-mediated	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
MMP-1	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
IL-17	B-X
induces	B-X
MMP-1	B-X
in	B-X
human	B-X
cardiac	B-X
fibroblasts	B-X
directly	B-X
via	B-X
p38	B-X
MAPK-	B-X
and	B-X
ERK-dependent	B-X
AP-1	B-X
,	B-X
NF-kappaB	B-X
,	B-X
and	B-X
C/EBP-beta	B-X
activation	B-X
and	B-X
suggest	B-X
that	B-X
IL-17	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
myocardial	B-X
remodeling	B-X
.	B-X

To	O
investigate	O
further	O
the	O
intracellular	O
signaling	O
pathway	O
activated	O
by	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
,	O
concanavalin	O
A	O
,	O
PHA	B-Protein
and	O
IL	B-Protein
-	I-Protein
15	I-Protein
,	O
and	O
responsible	O
for	O
inducing	O
IL	B-Protein
-	I-Protein
17	I-Protein
expression	O
,	O
we	O
performed	O
an	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
(	O
EMSA	O
)	O
of	O
NF	O
-	O
kappaB	O
recognition	O
sites	O
in	O
the	O
promoters	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

7a	O
,	O
nuclear	O
extracts	O
from	O
RA	O
PBMC	O
stimulated	O
with	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
lane	O
2	O
)	O
demonstrated	O
increased	O
binding	O
of	O
NF	O
-	O
kappaB	O
to	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoters	O
in	O
comparison	O
with	O
that	O
of	O
controls	O
(	O
lane	O
1	O
)	O
.	O

A	O
supershift	O
assay	O
demonstrated	O
shifted	O
bands	O
in	O
p65	B-Protein
and	O
p50	B-Protein
(	O
lanes	O
3	O
and	O
4	O
)	O
not	O
in	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
lane	O
5	O
)	O
.	O

In	O
normal	O
PBMC	O
the	O
same	O
pattern	O
was	O
observed	O
,	O
but	O
the	O
degree	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
was	O
less	O
intense	O
than	O
that	O
in	O
RA	O
PBMC	O
(	O
Fig	O
.	O
7b	O
)	O
.	O

To	O
confirm	O
the	O
link	O
between	O
PI3K	O
activity	O
and	O
NF	O
-	O
kappaB	O
,	O
we	O
performed	O
EMSA	O
to	O
determine	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
after	O
treatment	O
with	O
both	O
LY294002	O
and	O
PDTC	O
.	O

Both	O
agents	O
block	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

Western	O
blotting	O
for	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
showed	O
inhibition	O
of	O
degradation	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
by	O
LY294002	O
and	O
PDTC	O
at	O
the	O
same	O
time	O
(	O
Fig	O
.	O
7c	O
)	O
.	O

In	O
contrast	O
,	O
the	O
AP	B-Protein
-	I-Protein
1	I-Protein
pathway	O
was	O
not	O
activated	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
data	O
not	O
shown	O
)	O
,	O
demonstrating	O
that	O
NF	O
-	O
kappaB	O
is	O
the	O
main	O
intracellular	O
signaling	O
pathway	O
in	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
by	O
activated	O
PBMC	O
from	O
patients	O
with	O
RA	O
.	O

IL	B-Protein
-	I-Protein
17	I-Protein
was	O
first	O
described	O
as	O
a	O
T	O
cell	O
product	O
with	O
proinflammatory	O
properties	O
[	O
5	O
,	O
22	O
]	O
.	O

RA	O
is	O
characterized	O
by	O
hyperplasia	O
of	O
synovial	O
lining	O
cells	O
and	O
an	O
intense	O
infiltration	O
by	O
mononuclear	O
cells	O
[	O
23	O
]	O
.	O

Proinflammatory	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
are	O
abundant	O
in	O
rheumatoid	O
synovium	O
,	O
whereas	O
the	O
T	O
cell	O
-	O
derived	O
cytokines	O
,	O
especially	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
,	O
have	O
often	O
proved	O
difficult	O
to	O
detect	O
in	O
RA	O
synovium	O
[	O
24	O
]	O
.	O

Although	O
T	O
cells	O
may	O
have	O
a	O
role	O
in	O
the	O
augmentation	O
of	O
rheumatoid	O
synovial	O
inflammation	O
,	O
the	O
lack	O
of	O
T	O
cell	O
-	O
derived	O
cytokines	O
has	O
limited	O
its	O
importance	O
.	O

In	O
this	O
respect	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
is	O
appealing	O
because	O
it	O
has	O
been	O
described	O
as	O
a	O
T	O
cell	O
-	O
derived	O
cytokine	O
with	O
proinflammatory	O
properties	O
.	O

In	O
our	O
studies	O
,	O
we	O
tried	O
to	O
evaluate	O
how	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
is	O
regulated	O
in	O
RA	O
PBMC	O
,	O
and	O
which	O
signaling	O
pathway	O
it	O
used	O
.	O

Levels	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
were	O
found	O
to	O
be	O
higher	O
in	O
RA	O
synovial	O
fluid	O
than	O
in	O
OA	O
synovial	O
fluid	O
[	O
15	O
]	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
investigate	B-X
systematically	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
Synovial	B-X
Fluid	B-X
(	B-X
SF	B-X
)	B-X
and/or	B-X
serum	B-X
markers	B-X
in	B-X
patients	B-X
with	B-X
Rheumatoid	B-X
Arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
Psoriatic	B-X
Arthritis	B-X
(	B-X
PsA	B-X
)	B-X
and	B-X
Osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
,	B-X
and	B-X
their	B-X
associations	B-X
and	B-X
correlations	B-X
with	B-X
laboratory	B-X
and	B-X
clinical	B-X
data	B-X
,	B-X
with	B-X
a	B-X
view	B-X
to	B-X
providing	B-X
insights	B-X
for	B-X
future	B-X
research	B-X
.	B-X
Hyperactive	B-X
secretion	B-X
and	B-X
pathogenic	B-X
effects	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
and	B-X
IgA	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
different	B-X
arthropathies	B-X
.	B-X
To	B-X
delineate	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
IL-17	B-X
Receptor	B-X
(	B-X
IL-17RA	B-X
)	B-X
and	B-X
characterize	B-X
the	B-X
IL-17	B-X
producing	B-X
T	B-X
cell	B-X
(	B-X
Th17	B-X
)	B-X
subpopulation	B-X
in	B-X
psoriatic	B-X
arthritis	B-X
(	B-X
PsA	B-X
)	B-X
.	B-X
Mononuclear	B-X
cells	B-X
from	B-X
blood	B-X
and	B-X
synovial	B-X
fluid	B-X
(	B-X
SF	B-X
)	B-X
were	B-X
obtained	B-X
from	B-X
PsA	B-X
(	B-X
n=20	B-X
)	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
,	B-X
n=20	B-X
)	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
,	B-X
n=20	B-X
)	B-X
patients	B-X
.	B-X
Synoviocytes	B-X
(	B-X
FLS	B-X
)	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
synovium	B-X
of	B-X
RA	B-X
(	B-X
n=5	B-X
)	B-X
,	B-X
PsA	B-X
(	B-X
n=5	B-X
)	B-X
and	B-X
OA	B-X
(	B-X
n=5	B-X
)	B-X
patients	B-X
.	B-X
IL-17RA	B-X
expression	B-X
in	B-X
FLS	B-X
was	B-X
identified	B-X
by	B-X
western	B-X
blotting	B-X
(	B-X
WB	B-X
)	B-X
and	B-X
flowcytometry	B-X
.	B-X
T	B-X
lymphocytes	B-X
derived	B-X
from	B-X
the	B-X
SF	B-X
of	B-X
these	B-X
patients	B-X
were	B-X
studied	B-X
to	B-X
identify	B-X
and	B-X
phenotype	B-X
the	B-X
Th17	B-X
cells	B-X
.	B-X
The	B-X
functional	B-X
significance	B-X
of	B-X
IL-17RA	B-X
was	B-X
determined	B-X
by	B-X
evaluating	B-X
its	B-X
regulatory	B-X
role	B-X
on	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
endopeptidase	B-X
.	B-X
IL-17RA	B-X
expression	B-X
was	B-X
found	B-X
to	B-X
be	B-X
significantly	B-X
higher	B-X
in	B-X
FLS	B-X
of	B-X
RA	B-X
(	B-X
15.7	B-X
%	B-X
±4.9	B-X
)	B-X
and	B-X
PsA	B-X
(	B-X
4.5	B-X
%	B-X
±0.9	B-X
)	B-X
in	B-X
comparison	B-X
to	B-X
OA	B-X
(	B-X
1.14	B-X
%	B-X
±0.9	B-X
)	B-X
.	B-X
Western	B-X
blot	B-X
analyses	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
intensity	B-X
(	B-X
RI	B-X
)	B-X
of	B-X
IL-17RA	B-X
protein	B-X
was	B-X
higher	B-X
in	B-X
RA	B-X
and	B-X
PsA	B-X
compared	B-X
to	B-X
OA	B-X
(	B-X
Fisher	B-X
exact	B-X
,	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
A	B-X
significant	B-X
enrichment	B-X
of	B-X
IL-17-producing	B-X
CD4+	B-X
T	B-X
cells	B-X
(	B-X
7.9	B-X
%	B-X
±2.8	B-X
)	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
SF	B-X
of	B-X
PsA	B-X
patients	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
OA	B-X
patients	B-X
(	B-X
P	B-X
<	B-X
.001	B-X
)	B-X
.	B-X
Compared	B-X
to	B-X
OA-FLS	B-X
,	B-X
recombinant	B-X
IL-17	B-X
induced	B-X
higher	B-X
levels	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
MMP-3	B-X
production	B-X
in	B-X
PsA-FLS	B-X
.	B-X
Blockage	B-X
of	B-X
IL-17RA	B-X
with	B-X
an	B-X
anti-IL-17RA	B-X
antibody	B-X
inhibited	B-X
the	B-X
production	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
and	B-X
MMP-3	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
to	B-X
demonstrate	B-X
the	B-X
functional	B-X
significance	B-X
of	B-X
IL-17RA	B-X
in	B-X
PsA	B-X
.	B-X
Results	B-X
of	B-X
this	B-X
study	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
IL-17RA	B-X
blocking	B-X
antibodies	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
be	B-X
a	B-X
therapeutic	B-X
option	B-X
for	B-X
psoriatic	B-X
arthritis	B-X
.	B-X

However	O
,	O
there	O
are	O
few	O
data	O
available	O
on	O
the	O
agents	O
that	O
stimulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
although	O
the	O
highest	O
level	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
can	O
be	O
achieved	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
stimulation	O
in	O
healthy	O
individuals	O
[	O
25	O
]	O
.	O

In	O
our	O
experiments	O
,	O
PHA	B-Protein
as	O
mitogens	O
,	O
as	O
well	O
as	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
for	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
,	O
increased	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
from	O
RA	O
PBMC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
found	O
,	O
by	O
a	O
cell	O
proliferation	O
assay	O
(	O
data	O
not	O
shown	O
)	O
,	O
that	O
this	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
might	O
be	O
due	O
to	O
increased	O
cellular	O
activity	O
rather	O
than	O
to	O
cellular	O
proliferation	O
.	O
<EOS>	B-X
Fibroblast-like	B-X
synoviocytes	B-X
(	B-X
FLSs	B-X
)	B-X
are	B-X
a	B-X
major	B-X
cell	B-X
population	B-X
of	B-X
the	B-X
pannus	B-X
that	B-X
invades	B-X
adjacent	B-X
cartilage	B-X
and	B-X
bone	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
The	B-X
study	B-X
was	B-X
undertaken	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
interleukin-17	B-X
(	B-X
IL-17	B-X
)	B-X
on	B-X
the	B-X
survival	B-X
and/or	B-X
proliferation	B-X
of	B-X
FLSs	B-X
from	B-X
RA	B-X
patients	B-X
and	B-X
to	B-X
investigate	B-X
whether	B-X
signal	B-X
tranducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
is	B-X
implicated	B-X
in	B-X
this	B-X
process	B-X
.	B-X
This	B-X
is	B-X
hypothesized	B-X
to	B-X
be	B-X
due	B-X
in	B-X
part	B-X
to	B-X
regulation	B-X
of	B-X
IL-17A	B-X
,	B-X
which	B-X
UPM	B-X
is	B-X
reported	B-X
to	B-X
promote	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
used	B-X
a	B-X
myeloid	B-X
dendritic	B-X
cell	B-X
(	B-X
DC	B-X
)	B-X
-memory	B-X
CD4	B-X

IL	B-Protein
-	I-Protein
17	I-Protein
is	O
produced	O
mainly	O
by	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
especially	O
for	O
Th1	O
/	O
Th0	O
cells	O
,	O
not	O
the	O
Th2	O
phenotype	O
[	O
26	O
]	O
.	O
<EOS>	B-X
Excessive	B-X
T	B-X
helper	B-X
type	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cell	B-X
activity	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
Behçet	B-X
's	B-X
disease	B-X
(	B-X
BD	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
association	B-X
of	B-X
Th17	B-X
cells	B-X
with	B-X
certain	B-X
autoimmune	B-X
diseases	B-X
was	B-X
reported	B-X
,	B-X
and	B-X
we	B-X
thus	B-X
investigated	B-X
circulating	B-X
Th17	B-X
cells	B-X
in	B-X
BD	B-X
.	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD45RO	B-X
(	B-X
-	B-X
)	B-X
(	B-X
naive	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
cultured	B-X
with	B-X
Th0-	B-X
,	B-X
Th1-	B-X
,	B-X
Th2-	B-X
and	B-X
Th17-related	B-X
cytokines	B-X
and	B-X
antibodies	B-X
,	B-X
and	B-X
their	B-X
mRNA	B-X
was	B-X
studied	B-X
by	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
When	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
cultured	B-X
with	B-X
Th1-	B-X
and	B-X
Th17-related	B-X
cytokines	B-X
,	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
mRNA	B-X
and	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
mRNA	B-X
were	B-X
up-regulated	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
BD	B-X
patients	B-X
.	B-X
Naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
cultured	B-X
in	B-X
a	B-X
Th17	B-X
cell-inducing	B-X
condition	B-X
expressed	B-X
IL-23	B-X
receptor	B-X
(	B-X
IL-23R	B-X
)	B-X
mRNA	B-X
excessively	B-X
.	B-X
IL-17	B-X
mRNA	B-X
expression	B-X
was	B-X
induced	B-X
only	B-X
when	B-X
naive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL-23	B-X
.	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
cultured	B-X
with	B-X
Th17	B-X
cytokines	B-X
expressed	B-X
excessive	B-X
RAR-related	B-X
orphan	B-X
receptor	B-X
C	B-X
(	B-X
RORC	B-X
)	B-X
mRNA	B-X
.	B-X
Using	B-X
intracellular	B-X
cytokine	B-X
staining	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
(	B-X
memory	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
IL-17	B-X
and	B-X
IFN-γ	B-X
simultaneously	B-X
were	B-X
increased	B-X
significantly	B-X
.	B-X
Memory	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
IFN-γ	B-X
but	B-X
not	B-X
IL-17	B-X
decreased	B-X
profoundly	B-X
in	B-X
BD	B-X
patients	B-X
.	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
IL-17	B-X
and	B-X
IFN-γ	B-X
simultaneously	B-X
were	B-X
found	B-X
in	B-X
BD	B-X
skin	B-X
lesions	B-X
.	B-X
Collectively	B-X
,	B-X
we	B-X
found	B-X
excessive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
IL-17	B-X
and	B-X
IFN-γ	B-X
(	B-X
Th1/Th17	B-X
)	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
BD	B-X
,	B-X
and	B-X
possible	B-X
involvement	B-X
of	B-X
IL-23/IL-23R	B-X
pathway	B-X
for	B-X
the	B-X
appearance	B-X
of	B-X
excessive	B-X
Th1/Th17	B-X
cells	B-X
.	B-X

However	O
,	O
it	O
can	O
also	O
be	O
produced	O
by	O
CD8	B-Protein
+	O
T	O
cells	O
via	O
an	O
IL	B-Protein
-	I-Protein
23	I-Protein
triggering	O
mechanism	O
in	O
Gram	O
-	O
negative	O
pulmonary	O
infection	O
[	O
14	O
]	O
.	O

In	O
addition	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
significantly	O
augmented	O
by	O
T	O
cells	O
recognizing	O
type	O
II	O
collagen	O
in	O
a	O
collagen	O
-	O
induced	O
arthritis	O
model	O
[	O
27	O
]	O
.	O

A	O
complex	O
interaction	O
between	O
cells	O
in	O
inflamed	O
RA	O
joints	O
might	O
produce	O
a	O
variety	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
also	O
activate	O
other	O
cells	O
in	O
the	O
joints	O
.	O

For	O
example	O
,	O
IL	B-Protein
-	I-Protein
17	I-Protein
stimulates	O
rheumatoid	O
synoviocytes	O
to	O
secrete	O
several	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
stimulated	I-Protein
gene	I-Protein
6	I-Protein
as	O
well	O
as	O
prostaglandin	O
E2	O
in	O
vitro	O
[	O
12	O
,	O
28	O
,	O
29	O
]	O
.	O

There	O
are	O
as	O
yet	O
few	O
data	O
available	O
on	O
the	O
agents	O
that	O
stimulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
although	O
some	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
IL	B-Protein
-	I-Protein
23	I-Protein
)	O
have	O
been	O
known	O
to	O
regulate	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
[	O
13	O
,	O
14	O
]	O
.	O

We	O
therefore	O
investigated	O
the	O
in	O
vitro	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
responding	O
to	O
a	O
variety	O
of	O
cytokines	O
/	O
chemokines	O
and	O
mitogens	O
as	O
well	O
as	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
ligation	O
using	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
.	O

Our	O
studies	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
as	O
well	O
as	O
TCR	O
ligation	O
significantly	O
increased	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

Adding	O
IL	B-Protein
-	I-Protein
15	I-Protein
or	O
MCP	B-Protein
-	I-Protein
1	I-Protein
to	O
TCR	O
ligation	O
augmented	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
more	O
markedly	O
.	O
<EOS>	B-X
For	B-X
four	B-X
consecutive	B-X
weeks	B-X
,	B-X
high	B-X
expression	B-X
of	B-X
CD137L	B-X
by	B-X
a	B-X
K562-derived	B-X
aAPC	B-X
cell	B-X
line	B-X
could	B-X
sustain	B-X
NK	B-X
cell	B-X
expansion	B-X
by	B-X
3	B-X
×	B-X
10	B-X
Expansion	B-X
of	B-X
Human	B-X
NK	B-X
Cells	B-X
Using	B-X
K562	B-X
Cells	B-X
Expressing	B-X
OX40	B-X
Ligand	B-X
and	B-X
Short	B-X
Exposure	B-X
to	B-X
IL-21	B-X
.	B-X
Effective	B-X
boosting	B-X
of	B-X
NK	B-X
cell	B-X
function	B-X
can	B-X
be	B-X
achieved	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-15	B-X
.	B-X
However	B-X
,	B-X
its	B-X
in	B-X
vivo	B-X
half-life	B-X
is	B-X
short	B-X
and	B-X
potent	B-X
trans-presentation	B-X
by	B-X
IL-15	B-X
receptor	B-X
α	B-X
(	B-X
IL-15Rα	B-X
)	B-X
is	B-X
absent	B-X
.	B-X
Therefore	B-X
,	B-X
ImmunityBio	B-X
developed	B-X
IL-15	B-X
superagonist	B-X
N-803	B-X
,	B-X
which	B-X
combines	B-X
IL-15	B-X
with	B-X
an	B-X
activating	B-X
mutation	B-X
,	B-X
an	B-X
IL-15Rα	B-X
sushi	B-X
domain	B-X
for	B-X
trans-presentation	B-X
,	B-X
and	B-X
IgG1-Fc	B-X
for	B-X
increased	B-X
half-life	B-X
.	B-X
N-803	B-X
increased	B-X
HPC-NK	B-X
cell	B-X
proliferation	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
γ	B-X
production	B-X
.	B-X
On	B-X
leukemia	B-X
cells	B-X
,	B-X
co-culture	B-X
with	B-X
HPC-NK	B-X
cells	B-X
and	B-X
N-803	B-X
increased	B-X
ICAM-1	B-X
expression	B-X
.	B-X
Treating	B-X
OC	B-X
spheroids	B-X
with	B-X
HPC-NK	B-X
cells	B-X
and	B-X
N-803	B-X
increased	B-X
IFNγ-induced	B-X
CXCL10	B-X
secretion	B-X
,	B-X
and	B-X
target	B-X
killing	B-X
after	B-X
prolonged	B-X
exposure	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
N-803	B-X
is	B-X
a	B-X
promising	B-X
IL-15-based	B-X
compound	B-X
that	B-X
boosts	B-X
HPC-NK	B-X
cell	B-X
expansion	B-X
and	B-X
functionality	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Adding	B-X
N-803	B-X
to	B-X
HPC-NK	B-X
cell	B-X
therapy	B-X
could	B-X
improve	B-X
cancer	B-X
immunotherapy	B-X
.	B-X

In	O
contrast	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
which	O
are	O
known	O
to	O
have	O
proinflammatory	O
properties	O
and	O
to	O
be	O
increased	O
in	O
RA	O
joints	O
,	O
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
.	O

Our	O
data	O
were	O
consistent	O
with	O
a	O
recent	O
report	O
that	O
IL	B-Protein
-	I-Protein
15	I-Protein
triggered	O
in	O
vitro	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
PBMC	O
,	O
but	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
did	O
not	O
do	O
so	O
[	O
13	O
]	O
.	O

Although	O
there	O
were	O
no	O
data	O
that	O
MCP	B-Protein
-	I-Protein
1	I-Protein
directly	O
induces	O
T	O
cell	O
activation	O
,	O
it	O
might	O
exert	O
effects	O
indirectly	O
on	O
T	O
cells	O
through	O
the	O
activation	O
of	O
monocytes	O
/	O
macrophages	O
in	O
PBMC	O
cultures	O
.	O

As	O
reported	O
for	O
normal	O
individuals	O
[	O
25	O
]	O
,	O
T	O
cell	O
activation	O
through	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
also	O
increases	O
IL	B-Protein
-	I-Protein
17	I-Protein
induction	O
in	O
RA	O
PBMC	O
.	O

Although	O
the	O
signaling	O
pathway	O
for	O
the	O
induction	O
of	O
cytokines	O
/	O
chemokines	O
by	O
IL	B-Protein
-	I-Protein
17	I-Protein
has	O
been	O
documented	O
widely	O
[	O
8	O
,	O
30	O
,	O
31	O
]	O
,	O
no	O
data	O
have	O
been	O
available	O
on	O
how	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
can	O
be	O
regulated	O
by	O
certain	O
signaling	O
pathways	O
.	O

By	O
using	O
signal	O
transduction	O
inhibitors	O
,	O
we	O
therefore	O
examined	O
which	O
signaling	O
pathway	O
was	O
mainly	O
involved	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

We	O
identified	O
that	O
anti	O
-	O
CD3	B-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
PBMC	O
was	O
significantly	O
hampered	O
by	O
the	O
PI3K	O
inhibitor	O
LY294002	O
and	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
PDTC	O
to	O
comparable	O
levels	O
of	O
basal	O
production	O
without	O
stimulation	O
.	O

We	O
also	O
found	O
that	O
anti	O
-	O
CD3	O
-	O
induced	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
was	O
downregulated	O
by	O
the	O
addition	O
of	O
SB203580	O
,	O
a	O
p38	O
MAPK	O
inhibitor	O
.	O

It	O
is	O
interesting	O
that	O
a	O
series	O
of	O
evidence	O
supports	O
crosstalk	O
between	O
NF	O
-	O
kappaB	O
and	O
p38	O
.	O

In	O
myocytes	O
,	O
IkappaB	B-Protein
kinase	I-Protein
-	I-Protein
beta	I-Protein
is	O
activated	O
by	O
p38	O
[	O
32	O
]	O
,	O
and	O
the	O
activated	O
p38	O
can	O
stimulate	O
NF	O
-	O
kappaB	O
by	O
a	O
mechanism	O
involving	O
histone	O
acetylase	O
p300	B-Protein
/	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
[	O
33	O
]	O
.	O

Our	O
results	O
revealed	O
that	O
p38	O
MAPK	O
activation	O
was	O
not	O
affected	O
by	O
LY294002	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
activity	O
was	O
decreased	O
by	O
LY294002	O
,	O
which	O
provided	O
the	O
evidence	O
for	O
a	O
p38	O
MAPK	O
pathway	O
independent	O
of	O
PI3K	O
activation	O
.	O
<EOS>	B-X
Cell	B-X
viability	B-X
,	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
level	B-X
,	B-X
apoptosis	B-X
and	B-X
the	B-X
related	B-X
signaling	B-X
pathways	B-X
were	B-X
detected	B-X
with	B-X
MTT	B-X
assay	B-X
,	B-X
Rhodamine	B-X
staining	B-X
,	B-X
DCFH-DA	B-X
staining	B-X
,	B-X
Hoechst33258	B-X
staining	B-X
and	B-X
Western	B-X
blot	B-X
methods	B-X
respectively	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
cell	B-X
viability	B-X
decreased	B-X
,	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
declined	B-X
,	B-X
ROS	B-X
was	B-X
accumulated	B-X
and	B-X
apoptotic	B-X
rate	B-X
raised	B-X
in	B-X
BEAS-2B	B-X
cells	B-X
.	B-X
Meanwhile	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
B-cell	B-X
lymphoma-2	B-X
(	B-X
Bcl-2	B-X
)	B-X
was	B-X
downregulated	B-X
,	B-X
while	B-X
the	B-X
expression	B-X
of	B-X
Bcl-2-associated	B-X
X	B-X
protein	B-X
(	B-X
Bax	B-X
)	B-X
and	B-X
the	B-X
cleaved	B-X
caspase-3	B-X
was	B-X
upregulated	B-X
,	B-X
which	B-X
indicated	B-X
mitochondria-mediated	B-X
intrinsic	B-X
apoptosis	B-X
pathway	B-X
was	B-X
activated	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
JNK	B-X
,	B-X
ERK	B-X
and	B-X
p38	B-X
was	B-X
enhanced	B-X
respectively	B-X
,	B-X
which	B-X
manifested	B-X
that	B-X
MAPK	B-X
signaling	B-X
pathways	B-X
were	B-X
activated	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
could	B-X
be	B-X
concluded	B-X
that	B-X
cadmium	B-X
could	B-X
increase	B-X
intracellular	B-X
ROS	B-X
,	B-X
result	B-X
in	B-X
cellular	B-X
oxidative	B-X
stress	B-X
,	B-X
activate	B-X
JNK	B-X
,	B-X
ERK	B-X
and	B-X
p38	B-X
MAPK	B-X
pathways	B-X
and	B-X
ultimately	B-X
lead	B-X
to	B-X
apoptosis	B-X
of	B-X
BEAS-2B	B-X
cells	B-X
by	B-X
activating	B-X
mitochondria-mediated	B-X
intrinsic	B-X
apoptosis	B-X
pathway	B-X
.	B-X
This	B-X
study	B-X
provided	B-X
useful	B-X
information	B-X
to	B-X
elucidate	B-X
the	B-X
toxicity	B-X
of	B-X
cadmium	B-X
and	B-X
revealed	B-X
the	B-X
possible	B-X
mechanism	B-X
for	B-X
the	B-X
occurrence	B-X
of	B-X
lung	B-X
disease	B-X
induced	B-X
by	B-X
cadmium	B-X
.	B-X

The	O
direct	O
relationship	O
between	O
p38	O
and	O
NF	O
-	O
kappaB	O
for	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
needs	O
to	O
be	O
studied	O
in	O
future	O
experiments	O
.	O

The	O
search	O
for	O
a	O
downstream	O
pathway	O
of	O
PI3K	O
seemed	O
to	O
have	O
a	O
maximal	O
response	O
of	O
Akt	B-Protein
activation	O
at	O
1	O
hour	O
and	O
a	O
gradual	O
loss	O
of	O
activity	O
at	O
2	O
hours	O
.	O

The	O
fact	O
that	O
Akt	B-Protein
is	O
phosphorylated	O
upon	O
anti	O
-	O
CD3	O
stimulation	O
suggests	O
the	O
possible	O
involvement	O
of	O
PI3K	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
.	O

In	O
view	O
of	O
the	O
fact	O
that	O
NF	O
-	O
kappaB	O
was	O
also	O
activated	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
,	O
IL	B-Protein
-	I-Protein
15	I-Protein
or	O
mitogens	O
in	O
our	O
experiments	O
,	O
it	O
is	O
most	O
likely	O
that	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
also	O
actively	O
involved	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
PBMC	O
.	O

In	O
contrast	O
,	O
the	O
AP	B-Protein
-	I-Protein
1	I-Protein
signal	O
transduction	O
pathway	O
,	O
another	O
important	O
signaling	O
pathway	O
for	O
cytokines	O
/	O
chemokines	O
,	O
was	O
not	O
activated	O
in	O
our	O
experiments	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
the	B-X
only	B-X
direct	B-X
property	B-X
of	B-X
lymphotactin	B-X
(	B-X
Lptn	B-X
)	B-X
,	B-X
the	B-X
unique	B-X
member	B-X
of	B-X
the	B-X
C	B-X
class	B-X
of	B-X
chemokines	B-X
,	B-X
consists	B-X
of	B-X
T-cell	B-X
chemoattraction	B-X
.	B-X
Lptn	B-X
but	B-X
not	B-X
RANTES	B-X
inhibited	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T-cell	B-X
proliferation	B-X
,	B-X
through	B-X
a	B-X
decreased	B-X
production	B-X
of	B-X
Th1	B-X
(	B-X
interleukin	B-X
[	B-X
IL	B-X
]	B-X
-2	B-X
,	B-X
interferon	B-X
[	B-X
IFN	B-X
]	B-X
-gamma	B-X
)	B-X
but	B-X
not	B-X
Th2	B-X
(	B-X
IL-4	B-X
,	B-X
IL-13	B-X
)	B-X
lymphokines	B-X
,	B-X
and	B-X
decreased	B-X
IL-2R	B-X
alpha	B-X
expression	B-X
.	B-X
Transfections	B-X
in	B-X
Jurkat	B-X
cells	B-X
showed	B-X
a	B-X
Lptn-mediated	B-X
transcriptional	B-X
down-regulation	B-X
of	B-X
gene-promoter	B-X
activities	B-X
specific	B-X
for	B-X
Th1-type	B-X
lymphokines	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
but	B-X
not	B-X
AP-1	B-X
or	B-X
NF-KB	B-X
enhancer	B-X
activities	B-X
.	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T-cell	B-X
proliferation	B-X
was	B-X
completely	B-X
restored	B-X
by	B-X
exogenous	B-X
IL-2	B-X
or	B-X
reversed	B-X
by	B-X
pertussis	B-X
toxin	B-X
,	B-X
wortmannin	B-X
,	B-X
and	B-X
genistein	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
multiple	B-X
partners	B-X
in	B-X
Lptn	B-X
signaling	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
Lptn	B-X
exerted	B-X
a	B-X
potent	B-X
costimulatory	B-X
activity	B-X
on	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T-cell	B-X
proliferation	B-X
and	B-X
IL-2	B-X
secretion	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
important	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
Lptn	B-X
in	B-X
differential	B-X
regulation	B-X
of	B-X
normal	B-X
human	B-X
T-cell	B-X
activation	B-X
and	B-X
its	B-X
possible	B-X
implication	B-X
in	B-X
immune	B-X
response	B-X
disorders	B-X
.	B-X

Although	O
PI3K	O
and	O
its	O
downstream	O
kinase	O
Akt	B-Protein
in	O
association	O
with	O
NF	O
-	O
kappaB	O
have	O
been	O
reported	O
to	O
deliver	O
activating	O
signals	O
in	O
many	O
cell	O
types	O
,	O
the	O
data	O
on	O
the	O
signal	O
inducing	O
IL	B-Protein
-	I-Protein
17	I-Protein
are	O
lacking	O
.	O

Our	O
data	O
clearly	O
demonstrated	O
that	O
PI3K	O
/	O
Akt	B-Protein
and	O
resultant	O
NF	O
-	O
kappaB	O
activation	O
could	O
be	O
an	O
important	O
arbitrator	O
of	O
the	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
,	O
on	O
the	O
basis	O
of	O
our	O
experiments	O
showing	O
simultaneous	O
blocking	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
promoter	O
by	O
PDTC	O
and	O
LY294002	O
.	O

Considering	O
its	O
proinflammatory	O
activities	O
and	O
successful	O
induction	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
17	I-Protein
for	O
ameliorating	O
arthritis	O
in	O
animal	O
models	O
[	O
2	O
,	O
6	O
,	O
34	O
-	O
36	O
]	O
,	O
understanding	O
the	O
IL	B-Protein
-	I-Protein
17	I-Protein
signaling	O
pathway	O
is	O
an	O
important	O
element	O
of	O
developing	O
new	O
targeted	O
therapies	O
in	O
RA	O
.	O

We	O
have	O
detected	O
a	O
more	O
pronounced	O
production	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
from	O
RA	O
PBMC	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
15	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
as	O
well	O
as	O
stimulation	O
by	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	B-Protein
.	O

We	O
have	O
also	O
shown	O
that	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
by	O
activated	O
T	O
cells	O
in	O
patients	O
with	O
RA	O
could	O
be	O
the	O
result	O
of	O
activation	O
via	O
the	O
PI3K	O
/	O
Akt	B-Protein
pathway	O
with	O
resultant	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Inflammatory	B-X
mediators	B-X
have	B-X
been	B-X
recognized	B-X
as	B-X
being	B-X
important	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
,	B-X
including	B-X
the	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
osteoclastic	B-X
bone	B-X
resorption	B-X
.	B-X
Evidence	B-X
for	B-X
the	B-X
expression	B-X
and	B-X
proinflammatory	B-X
activity	B-X
of	B-X
IL-17	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
RA	B-X
synovium	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
Although	B-X
some	B-X
cytokines	B-X
(	B-X
IL-15	B-X
and	B-X
IL-23	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
regulate	B-X
IL-17	B-X
production	B-X
,	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
IL-17	B-X
production	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/Akt	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IL-17	B-X
production	B-X
in	B-X
RA	B-X
.	B-X
Peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
from	B-X
patients	B-X
with	B-X
RA	B-X
(	B-X
n	B-X
=	B-X
24	B-X
)	B-X
were	B-X
separated	B-X
,	B-X
then	B-X
stimulated	B-X
with	B-X
various	B-X
agents	B-X
including	B-X
anti-CD3	B-X
,	B-X
anti-CD28	B-X
,	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
and	B-X
several	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
.	B-X
IL-17	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
sandwich	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
and	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
The	B-X
production	B-X
of	B-X
IL-17	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
anti-CD3	B-X
antibody	B-X
with	B-X
or	B-X
without	B-X
anti-CD28	B-X
and	B-X
PHA	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Among	B-X
tested	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
IL-15	B-X
,	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
and	B-X
IL-6	B-X
upregulated	B-X
IL-17	B-X
production	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
whereas	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-18	B-X
or	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
did	B-X
not	B-X
.	B-X
IL-17	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
the	B-X
PBMC	B-X
of	B-X
patients	B-X
with	B-X
osteoarthritis	B-X
,	B-X
but	B-X
their	B-X
expression	B-X
levels	B-X
were	B-X
much	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
RA	B-X
PBMC	B-X
.	B-X
Anti-CD3	B-X
antibody	B-X
activated	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
;	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
resulted	B-X
in	B-X
a	B-X
pronounced	B-X
augmentation	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
DNA-binding	B-X
activity	B-X
.	B-X
IL-17	B-X
production	B-X
by	B-X
activated	B-X
RA	B-X
PBMC	B-X
is	B-X
completely	B-X
or	B-X
partly	B-X
blocked	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
inhibitor	B-X
wortmannin	B-X
and	B-X
LY294002	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
activator	B-X
protein-1	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
did	B-X
not	B-X
affect	B-X
IL-17	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
signal	B-X
transduction	B-X
pathways	B-X
dependent	B-X
on	B-X
PI3K/Akt	B-X
and	B-X
NF-kappaB	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
overproduction	B-X
of	B-X
the	B-X
key	B-X
inflammatory	B-X
cytokine	B-X
IL-17	B-X
in	B-X
RA	B-X
.	B-X

Our	O
data	O
provide	O
insights	O
into	O
cellular	O
mechanisms	O
of	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
17	I-Protein
production	O
in	O
RA	O
,	O
and	O
highlight	O
the	O
role	O
of	O
T	O
cells	O
,	O
which	O
has	O
hitherto	O
been	O
neglected	O
in	O
RA	O
pathogenesis	O
.	O

Together	O
with	O
recent	O
data	O
on	O
the	O
successful	O
introduction	O
of	O
anti	O
-	O
IL	B-Protein
-	I-Protein
17	I-Protein
in	O
RA	O
,	O
our	O
results	O
have	O
added	O
information	O
for	O
the	O
future	O
molecular	O
targeting	O
of	O
new	O
therapeutic	O
applications	O
in	O
RA	O
.	O

Sox6	B-Protein
Directly	O
Silences	O
Epsilon	B-Protein
Globin	I-Protein
Expression	O
in	O
Definitive	O
Erythropoiesis	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Sox6	B-Protein
is	O
a	O
member	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
that	O
is	O
defined	O
by	O
the	O
conserved	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
binding	O
domain	O
,	O
first	O
described	O
in	O
the	O
testis	O
determining	O
gene	O
,	O
Sry	B-Protein
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Previous	O
studies	O
have	O
suggested	O
that	O
Sox6	B-Protein
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
,	O
cartilage	O
,	O
and	O
muscle	O
.	O

In	O
the	O
Sox6	B-Protein
-	O
deficient	O
mouse	O
,	O
p100H	O
,	O
epsilony	B-Protein
globin	I-Protein
is	O
persistently	O
expressed	O
,	O
and	O
increased	O
numbers	O
of	O
nucleated	O
red	O
cells	O
are	O
present	O
in	O
the	O
fetal	O
circulation	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Transfection	O
assays	O
in	O
GM979	O
(	O
erythroleukemic	O
)	O
cells	O
define	O
a	O
36	O
-	O
base	O
pair	O
region	O
of	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
that	O
is	O
critical	O
for	O
Sox6	B-Protein
mediated	O
repression	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
demonstrate	O
that	O
Sox6	B-Protein
acts	O
as	O
a	O
repressor	O
by	O
directly	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
.	O

The	O
normal	O
expression	O
of	O
Sox6	B-Protein
in	O
wild	O
-	O
type	O
fetal	O
liver	O
and	O
the	O
ectopic	O
expression	O
of	O
epsilony	B-Protein
in	O
p100H	O
homozygous	O
fetal	O
liver	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

The	O
present	O
study	O
shows	O
that	O
Sox6	B-Protein
is	O
required	O
for	O
silencing	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
definitive	O
erythropoiesis	O
and	O
suggests	O
a	O
role	O
for	O
Sox6	B-Protein
in	O
erythroid	O
cell	O
maturation	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Thus	O
,	O
Sox6	B-Protein
regulation	O
of	O
epsilony	B-Protein
globin	I-Protein
might	O
provide	O
a	O
novel	O
therapeutical	O
target	O
in	O
the	O
treatment	O
of	O
hemoglobinopathies	O
such	O
as	O
sickle	O
cell	O
anemia	O
and	O
thalassemia	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
Sox6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
cartilage	B-X
,	B-X
and	B-X
muscle	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

Sry	B-Protein
type	O
HMG	O
box	O
(	O
Sox6	B-Protein
)	O
is	O
a	O
member	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
characterized	O
by	O
the	O
conserved	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
domain	O
,	O
consisting	O
of	O
79	O
amino	O
acids	O
involved	O
in	O
DNA	O
recognition	O
and	O
binding	O
[	O
1	O
]	O
.	O

Sox	O
transcription	O
factors	O
bind	O
to	O
the	O
minor	O
groove	O
of	O
DNA	O
and	O
cause	O
a	O
70degrees	O
-	O
85degrees	O
bend	O
of	O
the	O
DNA	O
that	O
leads	O
to	O
local	O
conformational	O
changes	O
[	O
2	O
,	O
3	O
]	O
,	O
while	O
most	O
other	O
transcription	O
factors	O
target	O
the	O
major	O
groove	O
of	O
DNA	O
[	O
4	O
]	O
.	O

Therefore	O
,	O
Sox	O
proteins	O
may	O
perform	O
part	O
of	O
their	O
function	O
as	O
architectural	O
proteins	O
by	O
organizing	O
local	O
chromatin	O
structure	O
and	O
assembling	O
other	O
DNA	O
-	O
bound	O
transcription	O
factors	O
into	O
biologically	O
active	O
,	O
sterically	O
defined	O
multiprotein	O
complexes	O
.	O

Sox6	B-Protein
has	O
been	O
reported	O
to	O
be	O
able	O
to	O
act	O
as	O
either	O
an	O
activator	O
or	O
a	O
repressor	O
,	O
depending	O
on	O
its	O
interactors	O
and	O
its	O
target	O
promoter	O
context	O
[	O
5	O
,	O
6	O
]	O
.	O

Intriguingly	O
,	O
Sox6	B-Protein
has	O
also	O
been	O
shown	O
to	O
act	O
as	O
a	O
general	O
splicing	O
factor	O
that	O
participates	O
in	O
pre	O
-	O
mRNA	O
splicing	O
[	O
7	O
]	O
.	O

Depletion	O
of	O
Sox6	B-Protein
in	O
HeLa	O
cell	O
extracts	O
blocked	O
splicing	O
of	O
multiple	O
substrates	O
,	O
and	O
expression	O
of	O
the	O
HMG	O
domain	O
of	O
either	O
Sox6	B-Protein
,	O
Sox9	B-Protein
,	O
or	O
Sry	B-Protein
in	O
the	O
extracts	O
restored	O
splicing	O
,	O
indicating	O
functional	O
overlap	O
of	O
these	O
proteins	O
[	O
7	O
]	O
.	O

Regardless	O
of	O
how	O
Sox6	B-Protein
functions	O
in	O
regulating	O
gene	O
expression	O
,	O
previous	O
studies	O
have	O
demonstrated	O
that	O
Sox6	B-Protein
is	O
an	O
important	O
regulatory	O
molecule	O
that	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
[	O
8	O
-	O
11	O
]	O
,	O
cartilage	O
[	O
6	O
,	O
12	O
,	O
13	O
]	O
,	O
and	O
muscle	O
[	O
14	O
,	O
15	O
]	O
.	O

A	O
Sox6	B-Protein
-	O
null	O
mutant	O
mouse	O
(	O
p100H	O
)	O
has	O
previously	O
been	O
identified	O
in	O
our	O
laboratory	O
[	O
14	O
]	O
.	O

Mice	O
homozygous	O
for	O
p100H	O
show	O
delayed	O
growth	O
,	O
develop	O
myopathy	O
and	O
arterioventricular	O
heart	O
block	O
,	O
and	O
die	O
within	O
2	O
wk	O
after	O
birth	O
[	O
14	O
]	O
.	O

The	O
p100H	O
mutant	O
allele	O
is	O
associated	O
with	O
a	O
Chromosome	O
7	O
inversion	O
that	O
disrupts	O
both	O
the	O
p	B-Protein
gene	O
and	O
the	O
Sox6	B-Protein
gene	O
(	O
and	O
no	O
other	O
gene	O
within	O
50	O
,	O
000	O
nucleotides	O
of	O
the	O
chromosomal	O
breakpoints	O
)	O
[	O
14	O
]	O
.	O

Because	O
the	O
p	B-Protein
gene	O
functions	O
solely	O
in	O
pigmentation	O
[	O
16	O
]	O
,	O
the	O
Sox6	B-Protein
transcription	O
factor	O
is	O
implicated	O
in	O
all	O
other	O
phenotypes	O
.	O

Among	O
the	O
HMG	O
box	O
proteins	O
distantly	O
related	O
to	O
Sry	B-Protein
(	O
the	O
first	O
member	O
identified	O
of	O
the	O
Sox	O
transcription	O
factor	O
family	O
)	O
that	O
similarly	O
bind	O
to	O
the	O
minor	O
groove	O
and	O
bend	O
DNA	O
,	O
but	O
without	O
sequence	O
specificity	O
,	O
are	O
the	O
ubiquitously	O
expressed	O
HMG1	B-Protein
and	O
HMG2	B-Protein
proteins	O
[	O
17	O
]	O
.	O

Modulation	O
of	O
DNA	O
structure	O
by	O
these	O
and	O
other	O
HMG	O
proteins	O
can	O
mediate	O
long	O
-	O
range	O
enhancer	O
function	O
on	O
both	O
DNA	O
and	O
chromatin	O
-	O
assembled	O
genes	O
by	O
bringing	O
together	O
distant	O
regions	O
of	O
DNA	O
and	O
associated	O
factors	O
.	O

Specifically	O
,	O
HMG	O
proteins	O
have	O
been	O
shown	O
to	O
modulate	O
beta	O
-	O
globin	O
genes	O
[	O
18	O
-	O
21	O
]	O
.	O

The	O
mouse	O
beta	O
-	O
globin	O
genes	O
{	O
epsilony	B-Protein
,	O
betah1	B-Protein
,	O
beta	B-Protein
-	I-Protein
major	I-Protein
,	O
and	O
beta	B-Protein
-	I-Protein
minor	I-Protein
}	O
are	O
clustered	O
on	O
Chromosome	O
7	O
and	O
they	O
are	O
highly	O
homologous	O
to	O
their	O
human	O
counterparts	O
in	O
organizational	O
structure	O
and	O
function	O
[	O
22	O
]	O
.	O

High	O
-	O
level	O
expression	O
of	O
these	O
genes	O
requires	O
a	O
regulatory	O
element	O
,	O
the	O
locus	O
control	O
region	O
that	O
is	O
characterized	O
by	O
a	O
set	O
of	O
nuclease	O
hypersensitive	O
sites	O
spread	O
over	O
25	O
kb	O
located	O
5	O
'	O
of	O
the	O
epsilony	B-Protein
gene	O
[	O
23	O
]	O
.	O

The	O
beta	O
-	O
globin	O
genes	O
are	O
expressed	O
in	O
a	O
tissue	O
-	O
and	O
development	O
-	O
specific	O
fashion	O
.	O

In	O
mice	O
,	O
erythropoiesis	O
originates	O
in	O
the	O
embryonic	O
yolk	O
sac	O
where	O
primitive	O
erythroid	O
cells	O
express	O
epsilony	B-Protein
and	O
betah	B-Protein
-	I-Protein
1	I-Protein
globins	I-Protein
[	O
22	O
]	O
.	O

At	O
11	O
.	O
5	O
d	O
post	O
coitus	O
(	O
dpc	O
)	O
,	O
erythropoiesis	O
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
definitive	O
erythroid	O
cells	O
express	O
adult	O
beta	O
globins	O
(	O
beta	B-Protein
major	I-Protein
and	O
minor	B-Protein
)	O
[	O
22	O
]	O
.	O

The	O
epsilony	B-Protein
gene	O
is	O
silenced	O
in	O
definitive	O
erythroid	O
cells	O
.	O
<EOS>	B-X
Sox6	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Sox	B-X
transcription	B-X
factor	B-X
family	B-X
that	B-X
is	B-X
defined	B-X
by	B-X
the	B-X
conserved	B-X
high	B-X
mobility	B-X
group	B-X
(	B-X
HMG	B-X
)	B-X
DNA	B-X
binding	B-X
domain	B-X
,	B-X
first	B-X
described	B-X
in	B-X
the	B-X
testis	B-X
determining	B-X
gene	B-X
,	B-X
Sry	B-X
.	B-X
In	B-X
the	B-X
Sox6-deficient	B-X
mouse	B-X
,	B-X
p100H	B-X
,	B-X
epsilony	B-X
globin	B-X
is	B-X
persistently	B-X
expressed	B-X
,	B-X
and	B-X
increased	B-X
numbers	B-X
of	B-X
nucleated	B-X
red	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
the	B-X
fetal	B-X
circulation	B-X
.	B-X
Transfection	B-X
assays	B-X
in	B-X
GM979	B-X
(	B-X
erythroleukemic	B-X
)	B-X
cells	B-X
define	B-X
a	B-X
36-base	B-X
pair	B-X
region	B-X
of	B-X
the	B-X
epsilony	B-X
proximal	B-X
promoter	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Sox6	B-X
mediated	B-X
repression	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
acts	B-X
as	B-X
a	B-X
repressor	B-X
by	B-X
directly	B-X
binding	B-X
to	B-X
the	B-X
epsilony	B-X
promoter	B-X
.	B-X
The	B-X
normal	B-X
expression	B-X
of	B-X
Sox6	B-X
in	B-X
wild-type	B-X
fetal	B-X
liver	B-X
and	B-X
the	B-X
ectopic	B-X
expression	B-X
of	B-X
epsilony	B-X
in	B-X
p100H	B-X
homozygous	B-X
fetal	B-X
liver	B-X
demonstrate	B-X
that	B-X
Sox6	B-X
functions	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
.	B-X
The	B-X
present	B-X
study	B-X
shows	B-X
that	B-X
Sox6	B-X
is	B-X
required	B-X
for	B-X
silencing	B-X
of	B-X
epsilony	B-X
globin	B-X
in	B-X
definitive	B-X
erythropoiesis	B-X
and	B-X
suggests	B-X
a	B-X
role	B-X
for	B-X
Sox6	B-X
in	B-X
erythroid	B-X
cell	B-X
maturation	B-X
.	B-X
Thus	B-X
,	B-X
Sox6	B-X
regulation	B-X
of	B-X
epsilony	B-X
globin	B-X
might	B-X
provide	B-X
a	B-X
novel	B-X
therapeutical	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
hemoglobinopathies	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
anemia	B-X
and	B-X
thalassemia	B-X
.	B-X

The	O
mechanism	O
of	O
silencing	O
of	O
its	O
human	O
counterpart	O
,	O
epsilon	B-Protein
globin	I-Protein
,	O
has	O
been	O
studied	O
extensively	O
.	O

In	O
definitive	O
erythropoiesis	O
,	O
epsilon	B-Protein
is	O
activated	O
and	O
silenced	O
autonomously	O
[	O
24	O
,	O
25	O
]	O
,	O
although	O
in	O
primitive	O
erythropoiesis	O
epsilon	B-Protein
also	O
appears	O
to	O
be	O
regulated	O
competitively	O
[	O
26	O
]	O
.	O

The	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
to	O
adult	O
beta	B-Protein
-	I-Protein
globin	I-Protein
switch	O
is	O
controlled	O
by	O
promoter	O
competition	O
for	O
the	O
LCR	O
[	O
24	O
,	O
25	O
]	O
.	O

All	O
the	O
elements	O
responsible	O
for	O
silencing	O
the	O
epsilon	B-Protein
globin	I-Protein
gene	O
are	O
within	O
the	O
epsilon	B-Protein
gene	O
or	O
in	O
adjacent	O
sequences	O
[	O
27	O
]	O
,	O
suggesting	O
that	O
silencing	O
is	O
primarily	O
gene	O
autonomous	O
.	O
<EOS>	B-X
The	B-X
human	B-X
embryonic	B-X
globin	B-X
genes	B-X
zeta	B-X
and	B-X
epsilon	B-X
are	B-X
expressed	B-X
when	B-X
erythropoiesis	B-X
is	B-X
initiated	B-X
at	B-X
about	B-X
the	B-X
third	B-X
week	B-X
of	B-X
development	B-X
but	B-X
are	B-X
subsequently	B-X
repressed	B-X
as	B-X
expression	B-X
of	B-X
the	B-X
fetal	B-X
globins	B-X
,	B-X
alpha	B-X
and	B-X
gamma	B-X
,	B-X
begins	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
human	B-X
zeta-globin	B-X
and	B-X
epsilon-globin	B-X
genes	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
regulatory	B-X
sequences	B-X
that	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
Stable	B-X
transfection	B-X
of	B-X
the	B-X
human	B-X
erythroid	B-X
cell	B-X
line	B-X
K562	B-X
with	B-X
either	B-X
a	B-X
truncated	B-X
form	B-X
of	B-X
the	B-X
zeta-globin	B-X
gene	B-X
,	B-X
containing	B-X
112	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
of	B-X
5'-flanking	B-X
sequences	B-X
,	B-X
or	B-X
a	B-X
larger	B-X
zeta-globin	B-X
construct	B-X
,	B-X
containing	B-X
several	B-X
hundred	B-X
bp	B-X
of	B-X
5'-flanking	B-X
sequence	B-X
,	B-X
revealed	B-X
that	B-X
the	B-X
zeta-globin	B-X
gene	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
its	B-X
5'-flanking	B-X
region	B-X
.	B-X
We	B-X
have	B-X
defined	B-X
the	B-X
sequences	B-X
responsible	B-X
for	B-X
this	B-X
negative	B-X
regulation	B-X
to	B-X
a	B-X
22	B-X
bp	B-X
region	B-X
immediately	B-X
upstream	B-X
of	B-X
the	B-X
proximal	B-X
promoter	B-X
sequence	B-X
of	B-X
the	B-X
zeta-globin	B-X
gene	B-X
.	B-X
A	B-X
22	B-X
bp	B-X
oligonucleotide	B-X
including	B-X
this	B-X
negative	B-X
element	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
both	B-X
the	B-X
zeta-globin	B-X
and	B-X
HSV	B-X
TK	B-X
promoters	B-X
.	B-X
We	B-X
have	B-X
also	B-X
analyzed	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
human	B-X
epsilon-globin	B-X
gene	B-X
,	B-X
since	B-X
it	B-X
is	B-X
coordinately	B-X
expressed	B-X
with	B-X
zeta-globin	B-X
.	B-X
Gel	B-X
retardation	B-X
and	B-X
methylation	B-X
interference	B-X
assays	B-X
have	B-X
provided	B-X
evidence	B-X
of	B-X
a	B-X
factor	B-X
which	B-X
binds	B-X
specifically	B-X
to	B-X
the	B-X
epsilon-globin	B-X
silencer	B-X
.	B-X
However	B-X
,	B-X
no	B-X
obvious	B-X
sequence	B-X
homology	B-X
exists	B-X
between	B-X
the	B-X
zeta	B-X
and	B-X
epsilon	B-X
negative	B-X
elements	B-X
,	B-X
and	B-X
at	B-X
least	B-X
some	B-X
of	B-X
the	B-X
factors	B-X
that	B-X
recognize	B-X
these	B-X
elements	B-X
are	B-X
distinct	B-X
.	B-X
We	B-X
postulate	B-X
that	B-X
the	B-X
negative	B-X
transcriptional	B-X
control	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
embryonic	B-X
globin	B-X
gene	B-X
promoters	B-X
contribute	B-X
to	B-X
the	B-X
observed	B-X
reduction	B-X
in	B-X
zeta-	B-X
and	B-X
epsilon-globin	B-X
gene	B-X
expression	B-X
that	B-X
occurs	B-X
during	B-X
development	B-X
.	B-X

Using	O
promoter	O
deletion	O
analyses	O
in	O
transgenic	O
mouse	O
models	O
and	O
cell	O
transfection	O
assays	O
,	O
multiple	O
DNA	O
elements	O
important	O
to	O
the	O
silencing	O
process	O
have	O
been	O
previously	O
identified	O
in	O
both	O
the	O
proximal	O
and	O
the	O
distal	O
epsilon	B-Protein
gene	O
promoter	O
[	O
27	O
]	O
.	O

Their	O
corresponding	O
transcription	O
factors	O
,	O
such	O
as	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
YY	B-Protein
-	I-Protein
1	I-Protein
,	O
COUP	B-Protein
-	I-Protein
TF	I-Protein
,	O
and	O
DRED	B-Protein
have	O
been	O
identified	O
and	O
shown	O
to	O
directly	O
bind	O
to	O
these	O
DNA	O
elements	O
(	O
as	O
part	O
of	O
protein	O
complexes	O
)	O
to	O
regulate	O
epsilon	B-Protein
silencing	O
[	O
27	O
]	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
silencing	O
of	O
the	O
epsilon	B-Protein
gene	O
involves	O
a	O
complicated	O
network	O
of	O
multiple	O
cis	O
elements	O
and	O
transacting	O
proteins	O
.	O

In	O
addition	O
to	O
playing	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
[	O
8	O
-	O
11	O
]	O
,	O
cartilage	O
[	O
6	O
,	O
12	O
,	O
13	O
]	O
,	O
and	O
muscle	O
[	O
14	O
,	O
15	O
]	O
,	O
it	O
was	O
shown	O
that	O
Sox6	B-Protein
is	O
upregulated	O
in	O
long	O
-	O
term	O
hematopoiesis	O
stem	O
cells	O
(	O
LT	O
-	O
HSC	O
)	O
compared	O
with	O
multipotent	O
progenitors	O
of	O
adult	O
mouse	O
bone	O
marrow	O
lineage	O
[	O
28	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
that	O
Sox6	B-Protein
also	O
exerts	O
pleiotropic	O
effects	O
on	O
erythropoiesis	O
.	O

These	O
effects	O
include	O
delayed	O
maturation	O
of	O
erythrocytes	O
(	O
that	O
normally	O
enucleate	O
prior	O
to	O
entering	O
the	O
bloodstream	O
[	O
27	O
]	O
)	O
and	O
higher	O
expression	O
of	O
embryonic	O
globin	O
genes	O
.	O

The	O
most	O
extreme	O
effect	O
is	O
the	O
persistence	O
of	O
high	O
expression	O
of	O
the	O
embryonic	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

Here	O
we	O
describe	O
and	O
characterize	O
the	O
effects	O
of	O
Sox6	B-Protein
on	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

We	O
show	O
that	O
Sox6	B-Protein
binds	O
to	O
the	O
proximal	O
promoter	O
of	O
epsilony	B-Protein
globin	I-Protein
and	O
represses	O
its	O
transcription	O
.	O

In	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
Sox6	B-Protein
is	O
not	O
expressed	O
in	O
yolk	O
sac	O
blood	O
islands	O
,	O
but	O
is	O
expressed	O
in	O
fetal	O
liver	O
,	O
the	O
opposite	O
expression	O
pattern	O
of	O
epsilony	B-Protein
globin	I-Protein
.	O
<EOS>	B-X
PACAP	B-X
knockout	B-X
(	B-X
KO	B-X
)	B-X
mice	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
display	B-X
early	B-X
aging	B-X
signs	B-X
affecting	B-X
several	B-X
organs	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
articular	B-X
cartilage	B-X
of	B-X
knee	B-X
joints	B-X
in	B-X
young	B-X
and	B-X
aged	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
and	B-X
PACAP	B-X
KO	B-X
mice	B-X
.	B-X
A	B-X
significant	B-X
increase	B-X
in	B-X
the	B-X
thickness	B-X
of	B-X
articular	B-X
cartilage	B-X
was	B-X
detected	B-X
in	B-X
aged	B-X
PACAP	B-X
gene-deficient	B-X
mice	B-X
.	B-X
Amongst	B-X
PACAP	B-X
receptors	B-X
,	B-X
dominantly	B-X
PAC1	B-X
receptor	B-X
was	B-X
expressed	B-X
in	B-X
WT	B-X
knee	B-X
joints	B-X
and	B-X
a	B-X
remarkable	B-X
decrease	B-X
was	B-X
found	B-X
in	B-X
aged	B-X
PACAP	B-X
KO	B-X
mice	B-X
.	B-X
Expression	B-X
of	B-X
PKA-regulated	B-X
transcription	B-X
factors	B-X
,	B-X
Sox5	B-X
,	B-X
Sox9	B-X
and	B-X
CREB	B-X
,	B-X
decreased	B-X
both	B-X
in	B-X
young	B-X
and	B-X
aged	B-X
gene	B-X
deficient	B-X
mice	B-X
,	B-X
while	B-X
Sox6	B-X
,	B-X
collagen	B-X
type	B-X
II	B-X
and	B-X
aggrecan	B-X
expressions	B-X
were	B-X
elevated	B-X
in	B-X
young	B-X
but	B-X
were	B-X
reduced	B-X
in	B-X
aged	B-X
PACAP	B-X
KO	B-X
animals	B-X
.	B-X
Increased	B-X
expression	B-X
of	B-X
hyaluronan	B-X
(	B-X
HA	B-X
)	B-X
synthases	B-X
and	B-X
HA-binding	B-X
proteins	B-X
was	B-X
detected	B-X
parallel	B-X
with	B-X
an	B-X
elevated	B-X
presence	B-X
of	B-X
HA	B-X
in	B-X
aged	B-X
PACAP	B-X
KO	B-X
mice	B-X
.	B-X

In	O
the	O
absence	O
of	O
Sox6	B-Protein
,	O
epsilony	B-Protein
globin	I-Protein
is	O
ectopically	O
expressed	O
in	O
the	O
fetal	O
liver	O
,	O
demonstrating	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O

Persistent	O
Expression	O
of	O
the	O
Embryonic	O
Globin	B-Protein
,	O
epsilony	B-Protein
,	O
in	O
Sox6	B-Protein
-	O
Deficient	O
Mice	O

The	O
epsilony	B-Protein
globin	I-Protein
gene	O
was	O
initially	O
identified	O
as	O
an	O
upregulated	O
transcript	O
in	O
the	O
p100H	O
mouse	O
using	O
subtractive	O
hybridization	O
to	O
identify	O
Sox6	B-Protein
downstream	O
targets	O
.	O

This	O
initial	O
observation	O
was	O
confirmed	O
in	O
an	O
independent	O
knock	O
-	O
out	O
allele	O
of	O
Sox6	B-Protein
[	O
13	O
]	O
using	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
quantitate	O
the	O
expression	O
levels	O
of	O
other	O
globin	O
genes	O
in	O
p100H	O
mutant	O
and	O
WT	O
mouse	O
livers	O
at	O
two	O
developmental	O
stages	O
,	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
the	O
epsilony	B-Protein
gene	O
is	O
expressed	O
at	O
high	O
levels	O
at	O
both	O
time	O
points	O
in	O
mutant	O
mice	O
,	O
in	O
contrast	O
to	O
the	O
decline	O
in	O
expression	O
observed	O
in	O
WT	O
mice	O
.	O

No	O
difference	O
was	O
seen	O
between	O
WT	O
and	O
heterozygous	O
mice	O
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
the	O
expression	O
levels	O
of	O
the	O
other	O
two	O
embryonic	O
globin	O
genes	O
(	O
zeta	B-Protein
and	O
betah1	B-Protein
)	O
are	O
also	O
higher	O
in	O
p100H	O
homozygous	O
mice	O
,	O
compared	O
with	O
WT	O
mice	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
seen	O
for	O
epsilony	B-Protein
globin	I-Protein
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

Moreover	O
,	O
the	O
expression	O
level	O
of	O
adult	O
beta	B-Protein
globin	I-Protein
is	O
also	O
somewhat	O
higher	O
in	O
p100H	O
homozygous	O
mice	O
than	O
in	O
WT	O
mice	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

Perinatal	O
lethality	O
of	O
mutant	O
mice	O
(	O
presumably	O
from	O
the	O
heart	O
defect	O
[	O
14	O
]	O
)	O
precludes	O
us	O
from	O
evaluating	O
postnatal	O
globin	O
expression	O
.	O

The	O
graphs	O
in	O
Figure	O
1	O
illustrate	O
real	O
time	O
PCR	O
results	O
that	O
were	O
performed	O
in	O
triplicate	O
(	O
standard	O
deviation	O
of	O
the	O
data	O
is	O
shown	O
by	O
error	O
bars	O
)	O
.	O

Because	O
all	O
of	O
the	O
assays	O
were	O
performed	O
at	O
the	O
same	O
time	O
with	O
the	O
same	O
internal	O
control	O
,	O
the	O
levels	O
shown	O
are	O
relative	O
levels	O
and	O
are	O
thus	O
comparable	O
across	O
all	O
samples	O
and	O
are	O
in	O
agreement	O
with	O
previously	O
published	O
results	O
for	O
WT	O
fetal	O
mice	O
[	O
29	O
]	O
.	O

We	O
note	O
that	O
the	O
level	O
of	O
epsilony	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
homozygous	O
mutant	O
mice	O
is	O
statistically	O
equivalent	O
to	O
the	O
level	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
homozygous	O
WT	O
mice	O
.	O

Transfection	O
Studies	O
Using	O
GM979	O
Cells	O
Indicate	O
That	O
Sox6	B-Protein
Directly	O
Represses	O
the	O
epsilony	B-Protein
Gene	O
Promoter	O
at	O
the	O
Transcriptional	O
Level	O

Real	O
-	O
time	O
PCR	O
assays	O
(	O
Figure	O
1	O
)	O
measure	O
steady	O
-	O
state	O
levels	O
of	O
epsilony	B-Protein
mRNA	O
,	O
not	O
transcriptional	O
activity	O
of	O
the	O
epsilony	B-Protein
promoter	O
.	O

To	O
investigate	O
whether	O
Sox6	B-Protein
directly	O
acts	O
on	O
the	O
epsilony	B-Protein
gene	O
promoter	O
at	O
the	O
transcriptional	O
level	O
,	O
we	O
used	O
an	O
in	O
vitro	O
transient	O
transfection	O
assay	O
and	O
GM979	O
cells	O
,	O
a	O
murine	O
erythroleukemic	O
cell	O
line	O
that	O
expresses	O
both	O
epsilony	B-Protein
and	O
adult	O
beta	B-Protein
globins	I-Protein
[	O
30	O
]	O
.	O

We	O
generated	O
an	O
epsilony	B-Protein
promoter	O
reporter	O
construct	O
(	O
E	O
-	O
Luc	O
)	O
by	O
fusing	O
a	O
micro	O
-	O
LCR	O
(	O
muLCR	O
)	O
element	O
(	O
2	O
.	O
5	O
kb	O
)	O
[	O
31	O
]	O
to	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
(	O
2	O
.	O
2	O
kb	O
)	O
,	O
followed	O
by	O
the	O
luciferase	B-Protein
reporter	O
gene	O
,	O
as	O
shown	O
in	O
Figure	O
2A	O
(	O
detailed	O
in	O
Materials	O
and	O
Methods	O
)	O
.	O

Overexpression	O
of	O
Sox6	B-Protein
in	O
GM979	O
cells	O
by	O
transient	O
transfection	O
leads	O
to	O
a	O
dosage	O
-	O
dependent	O
repression	O
of	O
E	O
-	O
Luc	O
reporter	O
activity	O
(	O
Figure	O
2B	O
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
a	O
truncated	O
Sox6	B-Protein
protein	O
that	O
lacks	O
its	O
HMG	O
domain	O
[	O
32	O
]	O
(	O
similar	O
to	O
the	O
p100H	O
mouse	O
allele	O
)	O
fails	O
to	O
repress	O
E	O
-	O
Luc	O
activity	O
(	O
Figure	O
2B	O
)	O
.	O

These	O
data	O
indicate	O
that	O
Sox6	B-Protein
acts	O
to	O
repress	O
the	O
epsilony	B-Protein
promoter	O
at	O
the	O
transcriptional	O
level	O
.	O

Sox6	B-Protein
has	O
been	O
shown	O
to	O
act	O
as	O
a	O
repressor	O
and	O
to	O
interact	O
with	O
a	O
widely	O
expressed	O
co	O
-	O
repressor	O
,	O
CtBP2	B-Protein
,	O
on	O
the	O
fgf	B-Protein
-	I-Protein
3	I-Protein
promoter	O
[	O
5	O
]	O
.	O

CtBP2	B-Protein
is	O
expressed	O
in	O
GM979	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
interaction	O
with	O
CtBP2	B-Protein
is	O
required	O
for	O
Sox6	B-Protein
repression	O
of	O
the	O
epsilony	B-Protein
promoter	O
,	O
we	O
introduced	O
a	O
point	O
mutation	O
(	O
L386H	O
)	O
in	O
the	O
Sox6	B-Protein
protein	O
that	O
has	O
been	O
previously	O
reported	O
to	O
be	O
sufficient	O
to	O
abolish	O
Sox6	B-Protein
-	O
CtBP2	B-Protein
interaction	O
[	O
5	O
]	O
.	O

This	O
amino	O
acid	O
change	O
is	O
not	O
in	O
the	O
HMG	O
DNA	O
binding	O
domain	O
.	O
<EOS>	B-X
Ingesting	B-X
protein-containing	B-X
supplements	B-X
and	B-X
foods	B-X
provides	B-X
essential	B-X
amino	B-X
acids	B-X
(	B-X
EAA	B-X
)	B-X
necessary	B-X
to	B-X
increase	B-X
muscle	B-X
and	B-X
whole-body	B-X
protein	B-X
synthesis	B-X
(	B-X
WBPS	B-X
)	B-X
.	B-X
Large	B-X
variations	B-X
exist	B-X
in	B-X
the	B-X
EAA	B-X
composition	B-X
of	B-X
supplements	B-X
and	B-X
foods	B-X
,	B-X
ranging	B-X
from	B-X
free-form	B-X
amino	B-X
acids	B-X
to	B-X
whole	B-X
protein	B-X
foods	B-X
.	B-X
We	B-X
sought	B-X
to	B-X
investigate	B-X
how	B-X
changes	B-X
in	B-X
peripheral	B-X
EAA	B-X
after	B-X
ingesting	B-X
various	B-X
protein	B-X
and	B-X
free	B-X
amino	B-X
acid	B-X
formats	B-X
altered	B-X
muscle	B-X
and	B-X
whole-body	B-X
protein	B-X
synthesis	B-X
.	B-X
Bacteria	B-X
produce	B-X
diverse	B-X
d-amino	B-X
acids	B-X
,	B-X
which	B-X
are	B-X
essential	B-X
components	B-X
of	B-X
cell	B-X
wall	B-X
peptidoglycan	B-X
.	B-X
Incorporation	B-X
of	B-X
these	B-X
d-amino	B-X
acids	B-X
into	B-X
peptidoglycan	B-X
contributes	B-X
to	B-X
bacterial	B-X
adaptation	B-X
to	B-X
environmental	B-X
changes	B-X
and	B-X
threats	B-X
.	B-X
d-Amino	B-X
acids	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
bacterial	B-X
growth	B-X
,	B-X
biofilm	B-X
formation	B-X
and	B-X
dispersal	B-X
and	B-X
regulation	B-X
of	B-X
peptidoglycan	B-X
metabolism	B-X
.	B-X
The	B-X
diversity	B-X
of	B-X
d-amino	B-X
acids	B-X
in	B-X
bacteria	B-X
is	B-X
primarily	B-X
due	B-X
to	B-X
the	B-X
activities	B-X
of	B-X
amino	B-X
acid	B-X
racemases	B-X
that	B-X
catalyse	B-X
the	B-X
interconversion	B-X
of	B-X
the	B-X
d-	B-X
and	B-X
l-enantiomers	B-X
of	B-X
amino	B-X
acids	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
bacteria	B-X
possess	B-X
multiple	B-X
enzymes	B-X
with	B-X
amino	B-X
acid	B-X
racemase	B-X
activities	B-X
.	B-X
Therefore	B-X
,	B-X
elucidating	B-X
d-amino	B-X
acid	B-X
metabolism	B-X
by	B-X
these	B-X
enzymes	B-X
is	B-X
critical	B-X
to	B-X
understand	B-X
the	B-X
biological	B-X
significance	B-X
and	B-X
behaviour	B-X
of	B-X
d-amino	B-X
acids	B-X
in	B-X
bacteria	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
metabolic	B-X
pathways	B-X
of	B-X
d-amino	B-X
acids	B-X
in	B-X
six	B-X
types	B-X
of	B-X
bacteria	B-X
.	B-X

However	O
,	O
this	O
mutant	O
version	O
of	O
Sox6	B-Protein
retains	O
the	O
ability	O
to	O
repress	O
the	O
epsilony	B-Protein
promoter	O
in	O
the	O
transfection	O
assay	O
(	O
Figure	O
2B	O
)	O
,	O
indicating	O
that	O
Sox6	B-Protein
represses	O
the	O
epsilony	B-Protein
promoter	O
in	O
a	O
CtBP2	B-Protein
-	O
independent	O
manner	O
.	O

Deletion	O
analysis	O
of	O
the	O
epsilony	B-Protein
promoter	O
,	O
as	O
shown	O
in	O
Figure	O
2C	O
,	O
defined	O
a	O
region	O
(	O
-	O
63	O
to	O
-	O
37	O
)	O
within	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
that	O
is	O
critical	O
for	O
Sox6	B-Protein
repression	O
.	O

Analysis	O
of	O
this	O
short	O
region	O
reveals	O
two	O
Sox	O
/	O
Sox6	O
consensus	O
binding	O
sites	O
[	O
5	O
]	O
(	O
Figure	O
3A	O
)	O
.	O

EMSA	O
and	O
ChIP	O
Assays	O
Show	O
that	O
Sox6	B-Protein
Directly	O
Binds	O
to	O
the	O
epsilony	B-Protein
Promoter	O

Sox6	B-Protein
might	O
repress	O
the	O
epsilony	B-Protein
promoter	O
,	O
either	O
through	O
direct	O
physical	O
contact	O
with	O
the	O
promoter	O
or	O
by	O
regulating	O
intermediates	O
affecting	O
the	O
epsilony	B-Protein
promoter	O
.	O

To	O
investigate	O
whether	O
Sox6	B-Protein
is	O
directly	O
associated	O
with	O
the	O
epsilony	B-Protein
promoter	O
,	O
we	O
first	O
performed	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
using	O
a	O
c	B-Protein
-	I-Protein
Myc	I-Protein
-	O
tagged	O
Sox6	B-Protein
in	O
a	O
reticulocyte	O
lysate	O
-	O
based	O
transcription	O
/	O
translation	O
in	O
vitro	O
system	O
.	O

The	O
probes	O
used	O
are	O
listed	O
in	O
Figure	O
3A	O
.	O

The	O
36	O
-	O
base	O
pair	O
(	O
bp	O
)	O
WT	O
probe	O
corresponds	O
to	O
the	O
critical	O
region	O
of	O
the	O
epsilony	B-Protein
promoter	O
defined	O
in	O
our	O
promoter	O
deletion	O
analyses	O
.	O

This	O
probe	O
contains	O
two	O
consensus	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
.	O

Also	O
included	O
in	O
our	O
EMSA	O
are	O
three	O
mutated	O
probes	O
that	O
are	O
,	O
either	O
truncated	O
(	O
M1	O
)	O
,	O
or	O
mutated	O
(	O
M2	O
and	O
M3	O
)	O
in	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
(	O
Figure	O
3A	O
)	O
.	O

Sox6	B-Protein
is	O
able	O
to	O
physically	O
associate	O
with	O
the	O
36	O
-	O
bp	O
region	O
(	O
Figure	O
3B	O
)	O
within	O
the	O
epsilony	B-Protein
promoter	O
defined	O
by	O
the	O
deletion	O
analysis	O
experiments	O
(	O
Figure	O
2C	O
)	O
.	O

The	O
36	O
-	O
bp	O
probe	O
was	O
shifted	O
by	O
the	O
tagged	O
Sox6	B-Protein
protein	O
.	O

Moreover	O
,	O
both	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
Sox6	B-Protein
antibodies	O
supershift	O
the	O
band	O
,	O
indicating	O
that	O
the	O
binding	O
is	O
Sox6	B-Protein
-	O
specific	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
c	B-Protein
-	I-Protein
Myc	I-Protein
tag	O
itself	O
binds	O
to	O
the	O
probe	O
,	O
an	O
HA	B-Protein
-	O
tagged	O
Sox6	B-Protein
was	O
used	O
in	O
another	O
EMSA	O
that	O
confirmed	O
these	O
results	O
(	O
Figure	O
3C	O
)	O
.	O

Next	O
,	O
nuclear	O
extracts	O
from	O
MEL	O
cells	O
were	O
used	O
in	O
EMSA	O
employing	O
the	O
same	O
36	O
-	O
bp	O
probe	O
.	O

MEL	O
cells	O
,	O
a	O
murine	O
erythroleukemic	O
cell	O
line	O
,	O
express	O
adult	O
beta	B-Protein
globins	I-Protein
,	O
but	O
not	O
epsilony	B-Protein
[	O
33	O
]	O
.	O

Sox6	B-Protein
directly	O
binds	O
to	O
this	O
DNA	O
sequence	O
in	O
MEL	O
cells	O
(	O
Figure	O
3D	O
)	O
.	O

The	O
intact	O
consensus	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
of	O
the	O
DNA	O
probe	O
are	O
required	O
for	O
the	O
binding	O
,	O
as	O
shown	O
in	O
the	O
competition	O
assay	O
(	O
Figure	O
3E	O
)	O
.	O

Ablation	O
of	O
putative	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
(	O
M1	O
and	O
M3	O
)	O
abolish	O
their	O
ability	O
to	O
compete	O
in	O
EMSA	O
(	O
Figure	O
3E	O
)	O
.	O

The	O
M2	O
mutant	O
probe	O
may	O
compete	O
partially	O
with	O
WT	O
binding	O
.	O

To	O
investigate	O
the	O
functional	O
significance	O
of	O
the	O
intact	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
,	O
the	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
with	O
mutagenized	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
were	O
co	O
-	O
transfected	O
with	O
the	O
Sox6	B-Protein
overexpression	O
vector	O
into	O
GM979	O
cells	O
.	O

Consistent	O
with	O
the	O
EMSA	O
results	O
,	O
the	O
mutant	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
(	O
with	O
either	O
one	O
or	O
both	O
Sox	O
/	O
Sox6	O
binding	O
sites	O
mutagenized	O
)	O
do	O
not	O
result	O
in	O
significant	O
promoter	O
repression	O
in	O
transfection	O
studies	O
(	O
Figure	O
3F	O
)	O
.	O

Thus	O
,	O
both	O
sites	O
are	O
required	O
for	O
maximal	O
repression	O
of	O
epsilony	B-Protein
by	O
Sox6	B-Protein
,	O
but	O
not	O
to	O
the	O
same	O
degree	O
.	O

We	O
also	O
tested	O
whether	O
Sox6	B-Protein
binds	O
to	O
the	O
epsilony	B-Protein
promoter	O
in	O
vivo	O
using	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
(	O
Figure	O
4	O
)	O
.	O

The	O
Sox6	B-Protein
-	O
containing	O
complex	O
was	O
immunoprecipitated	O
from	O
MEL	O
cells	O
or	O
from	O
liver	O
cells	O
of	O
15	O
.	O
5	O
dpc	O
WT	O
mice	O
using	O
Sox6	B-Protein
antibody	O
.	O

Figure	O
4	O
shows	O
that	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
is	O
readily	O
immunoprecipitated	O
with	O
Sox6	B-Protein
antibody	O
in	O
both	O
MEL	O
cells	O
and	O
liver	O
cells	O
.	O

Normal	O
IgG	O
was	O
used	O
as	O
a	O
negative	O
control	O
(	O
Figure	O
4A	O
)	O
.	O

The	O
above	O
data	O
(	O
Figures	O
3	O
and	O
4	O
)	O
clearly	O
indicate	O
that	O
Sox6	B-Protein
acts	O
as	O
a	O
repressor	O
of	O
the	O
epsilony	B-Protein
gene	O
by	O
directly	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
,	O
probably	O
as	O
a	O
dimer	O
.	O

The	O
Persistent	O
Expression	O
of	O
epsilony	B-Protein
Globin	I-Protein
in	O
Sox6	B-Protein
-	O
Deficient	O
Mice	O
Is	O
Due	O
to	O
a	O
Defect	O
in	O
the	O
epsilony	B-Protein
-	O
Gene	O
-	O
Silencing	O
Mechanism	O
in	O
Definitive	O
Erythroid	O
Cells	O

Normally	O
,	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
is	O
exclusively	O
expressed	O
in	O
primitive	O
erythrocytes	O
and	O
silenced	O
in	O
definitive	O
erythrocytes	O
.	O

To	O
determine	O
whether	O
the	O
persistent	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
is	O
due	O
to	O
residual	O
primitive	O
erythrocytes	O
or	O
is	O
due	O
to	O
ectopic	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
definitive	O
erythrocytes	O
,	O
we	O
examined	O
the	O
spatial	O
pattern	O
of	O
epsilony	B-Protein
globin	I-Protein
transcripts	O
in	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization	O
(	O
Figure	O
5	O
)	O
.	O

As	O
expected	O
,	O
epsilony	B-Protein
globin	I-Protein
is	O
not	O
expressed	O
in	O
the	O
WT	O
14	O
.	O
5	O
-	O
dpc	O
liver	O
,	O
the	O
site	O
of	O
definitive	O
erythropoiesis	O
in	O
the	O
fetus	O
.	O

In	O
contrast	O
,	O
abundant	O
ectopic	O
epsilony	B-Protein
mRNA	O
expression	O
is	O
seen	O
in	O
the	O
liver	O
of	O
14	O
.	O
5	O
-	O
dpc	O
mutants	O
(	O
Figure	O
5	O
A	O
-	O
D	O
)	O
.	O

However	O
,	O
the	O
expression	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
globin	I-Protein
is	O
equally	O
abundant	O
in	O
both	O
WT	O
and	O
p100H	O
mutant	O
mice	O
(	O
Figure	O
5	O
E	O
and	O
F	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
persistent	O
high	O
levels	O
of	O
epsilony	B-Protein
are	O
due	O
to	O
ectopic	O
expression	O
in	O
the	O
definitive	O
erythroid	O
cells	O
that	O
mature	O
in	O
the	O
fetal	O
liver	O
,	O
suggesting	O
that	O
there	O
is	O
an	O
intrinsic	O
defect	O
of	O
the	O
epsilony	B-Protein
silencing	O
mechanism	O
in	O
Sox6	B-Protein
-	O
null	O
mice	O
.	O

The	O
Expression	O
Pattern	O
of	O
Sox6	B-Protein
Suggests	O
a	O
Role	O
in	O
Definitive	O
Erythropoiesis	O

The	O
observation	O
that	O
Sox6	B-Protein
-	O
deficient	O
mice	O
ectopically	O
express	O
epsilony	B-Protein
globin	I-Protein
in	O
liver	O
,	O
where	O
definitive	O
erythroid	O
cells	O
mature	O
,	O
suggests	O
that	O
Sox6	B-Protein
is	O
an	O
important	O
regulator	O
in	O
definitive	O
erythropoiesis	O
.	O

To	O
determine	O
the	O
temporal	O
and	O
spatial	O
expression	O
pattern	O
of	O
Sox6	B-Protein
,	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
assays	O
were	O
employed	O
.	O

As	O
shown	O
in	O
Figure	O
6A	O
,	O
Sox6	B-Protein
is	O
detectable	O
by	O
Northern	O
blot	O
beginning	O
at	O
10	O
.	O
5	O
dpc	O
,	O
coincident	O
with	O
the	O
temporal	O
onset	O
of	O
definitive	O
erythropoiesis	O
in	O
the	O
liver	O
.	O

Furthermore	O
,	O
in	O
situ	O
hybridization	O
shows	O
that	O
Sox6	B-Protein
is	O
highly	O
transcribed	O
in	O
12	O
.	O
5	O
-	O
dpc	O
liver	O
,	O
but	O
not	O
in	O
yolk	O
sac	O
blood	O
islands	O
at	O
7	O
.	O
5	O
dpc	O
(	O
Figure	O
6B	O
)	O
.	O

Therefore	O
,	O
Sox6	B-Protein
expression	O
is	O
temporally	O
and	O
spatially	O
coincident	O
with	O
definitive	O
,	O
but	O
not	O
primitive	O
,	O
erythropoiesis	O
.	O

These	O
data	O
,	O
taken	O
together	O
with	O
the	O
observation	O
that	O
epsilony	B-Protein
globin	I-Protein
is	O
highly	O
expressed	O
in	O
the	O
liver	O
cells	O
of	O
14	O
.	O
5	O
-	O
dpc	O
p100H	O
mutant	O
mice	O
(	O
Figure	O
5	O
)	O
,	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
.	O

Mutant	O
p100H	O
Mice	O
Have	O
Higher	O
Numbers	O
of	O
Nucleated	O
Red	O
Cells	O

Among	O
the	O
other	O
Sox6	B-Protein
effects	O
in	O
erythropoiesis	O
,	O
we	O
have	O
noticed	O
that	O
there	O
are	O
more	O
nucleated	O
red	O
blood	O
cells	O
circulating	O
in	O
p100H	O
mutant	O
mice	O
than	O
in	O
WT	O
mice	O
at	O
14	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
7A	O
)	O
.	O

However	O
,	O
at	O
postnatal	O
day	O
10	O
.	O
5	O
,	O
we	O
do	O
not	O
see	O
circulating	O
nucleated	O
red	O
cells	O
in	O
either	O
WT	O
or	O
mutant	O
mice	O
,	O
suggesting	O
that	O
this	O
may	O
be	O
a	O
transient	O
effect	O
.	O
<EOS>	B-X
Mechanistically	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ATF4	B-X
interacts	B-X
with	B-X
transient	B-X
receptor	B-X
potential	B-X
cation	B-X
channel	B-X
subfamily	B-X
M	B-X
member-3	B-X
(	B-X
TRPM3	B-X
)	B-X
and	B-X
mediates	B-X
the	B-X
membrane	B-X
trafficking	B-X
of	B-X
TRPM3	B-X
in	B-X
DRG	B-X
neurons	B-X
in	B-X
response	B-X
to	B-X
heat	B-X
.	B-X
Loss	B-X
of	B-X
ATF4	B-X
also	B-X
significantly	B-X
decreases	B-X
the	B-X
current	B-X
and	B-X
KIF17-mediated	B-X
trafficking	B-X
of	B-X
TRPM3	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
KIF17/ATF4/TRPM3	B-X
complex	B-X
is	B-X
required	B-X
for	B-X
the	B-X
neuronal	B-X
response	B-X
to	B-X
heat	B-X
stimuli	B-X
.	B-X
BRAF	B-X
mutations	B-X
occur	B-X
in	B-X
10-15	B-X
%	B-X
of	B-X
colorectal	B-X
cancers	B-X
(	B-X
CRCs	B-X
)	B-X
and	B-X
confer	B-X
adverse	B-X
outcome	B-X
.	B-X
While	B-X
RAF	B-X
inhibitors	B-X
such	B-X
as	B-X
vemurafenib	B-X
(	B-X
PLX4032	B-X
)	B-X
have	B-X
proven	B-X
effective	B-X
in	B-X
BRAF	B-X
mutant	B-X
melanoma	B-X
,	B-X
they	B-X
are	B-X
surprisingly	B-X
ineffective	B-X
in	B-X
BRAF	B-X
mutant	B-X
CRCs	B-X
,	B-X
and	B-X
the	B-X
reason	B-X
for	B-X
this	B-X
disparity	B-X
remains	B-X
unclear	B-X
.	B-X
Compared	B-X
to	B-X
BRAF	B-X
mutant	B-X
melanoma	B-X
cells	B-X
,	B-X
BRAF	B-X
mutant	B-X
CRC	B-X
cells	B-X
were	B-X
less	B-X
sensitive	B-X
to	B-X
vemurafenib	B-X
,	B-X
and	B-X
P-ERK	B-X
suppression	B-X
was	B-X
not	B-X
sustained	B-X
in	B-X
response	B-X
to	B-X
treatment	B-X
.	B-X
Although	B-X
transient	B-X
inhibition	B-X
of	B-X
phospho-ERK	B-X
by	B-X
vemurafenib	B-X
was	B-X
observed	B-X
in	B-X
CRC	B-X
,	B-X
rapid	B-X
ERK	B-X
re-activation	B-X
occurred	B-X
through	B-X
EGFR-mediated	B-X
activation	B-X
of	B-X
RAS	B-X
and	B-X
CRAF	B-X
.	B-X
BRAF	B-X
mutant	B-X
CRCs	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
phospho-EGFR	B-X
than	B-X
BRAF	B-X
mutant	B-X
melanomas	B-X
,	B-X
suggesting	B-X
that	B-X
CRCs	B-X
are	B-X
specifically	B-X
poised	B-X
for	B-X
EGFR-mediated	B-X
resistance	B-X
.	B-X
Combined	B-X
RAF	B-X
and	B-X
EGFR	B-X
inhibition	B-X
blocked	B-X
reactivation	B-X
of	B-X
MAPK	B-X
signaling	B-X
in	B-X
BRAF	B-X
mutant	B-X
CRC	B-X
cells	B-X
and	B-X
markedly	B-X
improved	B-X
efficacy	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
evaluation	B-X
of	B-X
combined	B-X
RAF	B-X
and	B-X
EGFR	B-X
inhibition	B-X
in	B-X
BRAF	B-X
mutant	B-X
CRC	B-X
patients	B-X
.	B-X

In	O
addition	O
,	O
the	O
mutant	O
liver	O
shows	O
a	O
significant	O
increase	O
in	O
hematopoietic	O
precursor	O
cells	O
including	O
nucleated	O
erythrocytes	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
7B	O
)	O
.	O

This	O
alteration	O
is	O
noted	O
as	O
early	O
as	O
14	O
.	O
5	O
dpc	O
.	O

These	O
observations	O
suggest	O
that	O
besides	O
silencing	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
,	O
Sox6	B-Protein
may	O
affect	O
red	O
cell	O
maturation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Sox6	B-Protein
is	O
a	O
novel	O
factor	O
in	O
the	O
complicated	O
regulation	O
mechanism	O
of	O
globin	O
genes	O
.	O

In	O
the	O
Sox6	B-Protein
null	O
mouse	O
,	O
there	O
is	O
a	O
transient	O
effect	O
on	O
the	O
embryonic	O
globin	O
genes	O
,	O
zeta	B-Protein
and	O
betaH1	B-Protein
,	O
and	O
a	O
persistent	O
upregulation	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
.	O

Sox6	B-Protein
directly	O
regulates	O
and	O
binds	O
to	O
the	O
proximal	O
promoter	O
of	O
epsilony	B-Protein
gene	I-Protein
and	O
represses	O
the	O
epsilony	B-Protein
-	I-Protein
globin	I-Protein
gene	O
in	O
definitive	O
erythropoiesis	O
.	O

Sox6	B-Protein
belongs	O
to	O
group	O
D	O
of	O
the	O
Sox	O
family	O
of	O
proteins	O
that	O
includes	O
Sox5	B-Protein
,	O
12	B-Protein
,	O
13	B-Protein
,	O
and	O
23	B-Protein
[	O
34	O
]	O
.	O

Group	O
D	O
Sox	O
proteins	O
contain	O
a	O
coiled	O
-	O
coiled	O
domain	O
that	O
mediates	O
homo	O
-	O
and	O
heterodimerization	O
[	O
6	O
,	O
35	O
]	O
.	O

Functionally	O
,	O
dimerization	O
of	O
Sox5	B-Protein
and	O
Sox6	B-Protein
has	O
been	O
shown	O
to	O
greatly	O
increase	O
the	O
binding	O
efficiency	O
of	O
the	O
two	O
Sox	O
proteins	O
to	O
DNA	O
that	O
contains	O
adjacent	O
Sox	O
sites	O
[	O
6	O
]	O
.	O
<EOS>	B-X
Transcripts	B-X
for	B-X
a	B-X
new	B-X
form	B-X
of	B-X
Sox5	B-X
,	B-X
called	B-X
L-Sox5	B-X
,	B-X
and	B-X
Sox6	B-X
are	B-X
coexpressed	B-X
with	B-X
Sox9	B-X
in	B-X
all	B-X
chondrogenic	B-X
sites	B-X
of	B-X
mouse	B-X
embryos	B-X
.	B-X
A	B-X
coiled-coil	B-X
domain	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
part	B-X
of	B-X
L-Sox5	B-X
,	B-X
and	B-X
absent	B-X
in	B-X
Sox5	B-X
,	B-X
showed	B-X
>	B-X
90	B-X
%	B-X
identity	B-X
with	B-X
a	B-X
similar	B-X
domain	B-X
in	B-X
Sox6	B-X
and	B-X
mediated	B-X
homodimerization	B-X
and	B-X
heterodimerization	B-X
with	B-X
Sox6	B-X
.	B-X
Dimerization	B-X
of	B-X
L-Sox5/Sox6	B-X
greatly	B-X
increased	B-X
efficiency	B-X
of	B-X
binding	B-X
of	B-X
the	B-X
two	B-X
Sox	B-X
proteins	B-X
to	B-X
DNA	B-X
containing	B-X
adjacent	B-X
HMG	B-X
sites	B-X
.	B-X
L-Sox5	B-X
,	B-X
Sox6	B-X
and	B-X
Sox9	B-X
cooperatively	B-X
activated	B-X
expression	B-X
of	B-X
the	B-X
chondrocyte	B-X
differentiation	B-X
marker	B-X
Col2a1	B-X
in	B-X
10T1/2	B-X
and	B-X
MC615	B-X
cells	B-X
.	B-X
A	B-X
48	B-X
bp	B-X
chondrocyte-specific	B-X
enhancer	B-X
in	B-X
this	B-X
gene	B-X
,	B-X
which	B-X
contains	B-X
several	B-X
HMG-like	B-X
sites	B-X
that	B-X
are	B-X
necessary	B-X
for	B-X
enhancer	B-X
activity	B-X
,	B-X
bound	B-X
the	B-X
three	B-X
Sox	B-X
proteins	B-X
and	B-X
was	B-X
cooperatively	B-X
activated	B-X
by	B-X
the	B-X
three	B-X
Sox	B-X
proteins	B-X
in	B-X
non-chondrogenic	B-X
cells	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
L-Sox5/Sox6	B-X
and	B-X
Sox9	B-X
,	B-X
which	B-X
belong	B-X
to	B-X
two	B-X
different	B-X
classes	B-X
of	B-X
Sox	B-X
transcription	B-X
factors	B-X
,	B-X
cooperate	B-X
with	B-X
each	B-X
other	B-X
in	B-X
expression	B-X
of	B-X
Col2a1	B-X
and	B-X
possibly	B-X
other	B-X
genes	B-X
of	B-X
the	B-X
chondrocytic	B-X
program	B-X
.	B-X

In	O
addition	O
,	O
Sox6	B-Protein
binds	O
more	O
strongly	O
to	O
an	O
HMG	O
-	O
box	O
dimer	O
motif	O
than	O
to	O
a	O
single	O
HMG	O
-	O
box	O
motif	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
target	O
genes	O
for	O
group	O
D	O
Sox	O
proteins	O
,	O
such	O
as	O
Sox6	B-Protein
,	O
probably	O
harbor	O
pairs	O
of	O
HMG	O
binding	O
sites	O
with	O
a	O
configuration	O
compatible	O
with	O
binding	O
of	O
D	O
-	O
Sox	O
protein	O
dimers	O
.	O

Indeed	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
defined	O
Sox6	B-Protein
target	O
sequence	O
of	O
the	O
epsilony	B-Protein
promoter	O
contains	O
two	O
Sox	O
/	O
Sox6	O
consensus	O
sites	O
(	O
Figure	O
3A	O
)	O
.	O

Functionally	O
,	O
both	O
sites	O
are	O
essential	O
for	O
Sox6	B-Protein
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
and	O
repression	O
of	O
its	O
activity	O
(	O
Figure	O
3E	O
and	O
3F	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
Sox6	B-Protein
binds	O
to	O
this	O
sequence	O
of	O
the	O
epsilony	B-Protein
promoter	O
either	O
as	O
a	O
homodimer	O
or	O
as	O
a	O
heterodimer	O
with	O
other	O
Sox	O
proteins	O
.	O
<EOS>	B-X
Sulfite	B-X
oxidase	B-X
(	B-X
SOX	B-X
)	B-X
is	B-X
a	B-X
homodimeric	B-X
molybdoheme	B-X
enzyme	B-X
that	B-X
oxidizes	B-X
sulfite	B-X
to	B-X
sulfate	B-X
at	B-X
the	B-X
molybdenum	B-X
center	B-X
.	B-X
Following	B-X
substrate	B-X
oxidation	B-X
,	B-X
molybdenum	B-X
is	B-X
reduced	B-X
and	B-X
subsequently	B-X
regenerated	B-X
by	B-X
two	B-X
sequential	B-X
electron	B-X
transfers	B-X
(	B-X
ETs	B-X
)	B-X
via	B-X
heme	B-X
to	B-X
cytochrome	B-X
c.	B-X
SOX	B-X
harbors	B-X
both	B-X
metals	B-X
in	B-X
spatially	B-X
separated	B-X
domains	B-X
within	B-X
each	B-X
subunit	B-X
,	B-X
suggesting	B-X
that	B-X
domain	B-X
movement	B-X
is	B-X
necessary	B-X
to	B-X
allow	B-X
intramolecular	B-X
ET	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
one	B-X
subunit	B-X
in	B-X
a	B-X
SOX	B-X
dimer	B-X
is	B-X
sufficient	B-X
for	B-X
catalysis	B-X
,	B-X
we	B-X
produced	B-X
heterodimeric	B-X
SOX	B-X
variants	B-X
with	B-X
abolished	B-X
sulfite	B-X
oxidation	B-X
by	B-X
replacing	B-X
the	B-X
molybdenum-coordinating	B-X
and	B-X
essential	B-X
cysteine	B-X
in	B-X
the	B-X
active	B-X
site	B-X
.	B-X
We	B-X
generated	B-X
three	B-X
SOX	B-X
heterodimers	B-X
:	B-X
(	B-X
i	B-X
)	B-X
SOX/Mo	B-X
with	B-X
two	B-X
active	B-X
molybdenum	B-X
centers	B-X
but	B-X
one	B-X
deleted	B-X
heme	B-X
domain	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
SOX/Mo_C264S	B-X
with	B-X
one	B-X
unmodified	B-X
and	B-X
one	B-X
inactive	B-X
subunit	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
SOX_C264S/Mo	B-X
harboring	B-X
a	B-X
functional	B-X
molybdenum	B-X
center	B-X
on	B-X
one	B-X
subunit	B-X
and	B-X
a	B-X
heme	B-X
domain	B-X
on	B-X
the	B-X
other	B-X
subunit	B-X
.	B-X
Steady-state	B-X
kinetics	B-X
showed	B-X
50	B-X
%	B-X
SOX	B-X
activity	B-X
for	B-X
the	B-X
SOX/Mo	B-X
and	B-X
SOX/Mo_C264S	B-X
heterodimers	B-X
,	B-X
whereas	B-X
SOX_C264S/Mo	B-X
activity	B-X
was	B-X
reduced	B-X
by	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
one	B-X
functional	B-X
subunit	B-X
in	B-X
SOX	B-X
is	B-X
sufficient	B-X
for	B-X
catalysis	B-X
and	B-X
that	B-X
electrons	B-X
derived	B-X
from	B-X
either	B-X
Mo	B-X

Because	O
Sox	O
proteins	O
recognize	O
a	O
short	O
6	O
-	O
bp	O
core	O
-	O
binding	O
sequence	O
that	O
allows	O
for	O
considerable	O
degeneracy	O
,	O
the	O
specificity	O
of	O
their	O
actions	O
is	O
thought	O
to	O
rely	O
upon	O
interactions	O
with	O
other	O
transcription	O
factors	O
[	O
36	O
]	O
.	O

In	O
our	O
EMSAs	O
,	O
we	O
had	O
to	O
run	O
the	O
electrophoresis	O
on	O
a	O
4	O
%	O
-	O
6	O
%	O
gel	O
for	O
at	O
least	O
4	O
-	O
8	O
h	O
to	O
detect	O
the	O
Sox6	B-Protein
-	O
associated	O
band	O
,	O
suggesting	O
that	O
Sox6	B-Protein
is	O
part	O
of	O
a	O
high	O
molecular	O
weight	O
complex	O
.	O

A	O
few	O
other	O
epsilony	B-Protein
globin	I-Protein
repressors	O
have	O
been	O
reported	O
to	O
bind	O
to	O
DNA	O
sequences	O
near	O
the	O
Sox	O
/	O
Sox6	O
consensus	O
sites	O
,	O
including	O
the	O
DRED	B-Protein
complex	O
[	O
37	O
]	O
and	O
COUP	B-Protein
-	O
TF	B-Protein
[	O
38	O
]	O
.	O

Sox6	B-Protein
might	O
interact	O
with	O
these	O
factors	O
and	O
form	O
a	O
large	O
repression	O
complex	O
.	O

Identification	O
of	O
other	O
components	O
of	O
the	O
Sox6	B-Protein
-	O
containing	O
complex	O
associated	O
with	O
the	O
epsilony	B-Protein
promoter	O
will	O
shed	O
light	O
on	O
its	O
mechanism	O
of	O
repression	O
.	O

Sox	O
proteins	O
bind	O
and	O
bend	O
linear	O
DNA	O
by	O
partial	O
intercalation	O
in	O
the	O
minor	O
groove	O
,	O
and	O
can	O
also	O
bind	O
to	O
four	O
-	O
way	O
junctions	O
[	O
2	O
-	O
4	O
]	O
.	O

Therefore	O
,	O
one	O
attractive	O
model	O
to	O
explain	O
how	O
Sox6	B-Protein
proteins	O
control	O
gene	O
expression	O
is	O
that	O
they	O
function	O
as	O
architectural	O
factors	O
bound	O
to	O
DNA	O
,	O
influencing	O
local	O
chromatin	O
structure	O
by	O
bending	O
DNA	O
and	O
by	O
assembling	O
multiprotein	O
transcriptional	O
complexes	O
.	O

By	O
changing	O
the	O
local	O
chromatin	O
structure	O
,	O
Sox6	B-Protein
could	O
either	O
interfere	O
with	O
binding	O
of	O
other	O
activators	O
to	O
the	O
promoter	O
or	O
facilitate	O
binding	O
of	O
other	O
repressors	O
.	O
<EOS>	B-X
CCCTC-binding	B-X
factor	B-X
(	B-X
CTCF	B-X
)	B-X
is	B-X
an	B-X
eleven	B-X
zinc	B-X
finger	B-X
(	B-X
ZF	B-X
)	B-X
,	B-X
multivalent	B-X
transcriptional	B-X
regulator	B-X
,	B-X
that	B-X
recognizes	B-X
numerous	B-X
motifs	B-X
thanks	B-X
to	B-X
the	B-X
deployment	B-X
of	B-X
distinct	B-X
combinations	B-X
of	B-X
its	B-X
ZFs	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
proportion	B-X
of	B-X
the	B-X
regions	B-X
bound	B-X
by	B-X
CTCF	B-X
intersect	B-X
genes	B-X
and	B-X
promoters	B-X
.	B-X
At	B-X
promoters	B-X
,	B-X
CTCF	B-X
can	B-X
directly	B-X
affect	B-X
transcription	B-X
.	B-X
At	B-X
more	B-X
distal	B-X
sites	B-X
,	B-X
CTCF	B-X
may	B-X
orchestrate	B-X
interactions	B-X
between	B-X
regulatory	B-X
elements	B-X
and	B-X
help	B-X
separate	B-X
eu-	B-X
and	B-X
heterochromatic	B-X
areas	B-X
in	B-X
the	B-X
genome	B-X
,	B-X
exerting	B-X
a	B-X
chromatin	B-X
barrier	B-X
function	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
outline	B-X
how	B-X
CTCF	B-X
contributes	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
three-dimensional	B-X
structure	B-X
of	B-X
chromatin	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
chromatin	B-X
domains	B-X
.	B-X
We	B-X
discuss	B-X
how	B-X
CTCF	B-X
binding	B-X
and	B-X
architectural	B-X
functions	B-X
are	B-X
regulated	B-X
.	B-X

Another	O
example	O
of	O
a	O
repressor	O
that	O
interferes	O
with	O
an	O
activator	O
on	O
the	O
epsilony	B-Protein
promoter	O
is	O
DRED	B-Protein
.	O

DRED	B-Protein
interferes	O
with	O
EKLF	B-Protein
,	O
an	O
activator	O
,	O
in	O
binding	O
to	O
the	O
epsilony	B-Protein
promoter	O
[	O
39	O
]	O
.	O

Two	O
HMG	O
architectural	O
proteins	O
(	O
distantly	O
related	O
to	O
the	O
Sox	O
family	O
of	O
transcription	O
factors	O
)	O
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
and	O
HMG	B-Protein
-	I-Protein
Y	I-Protein
,	O
were	O
demonstrated	O
to	O
bind	O
to	O
the	O
human	O
adult	O
beta	O
globin	O
silencers	O
(	O
silencers	B-Protein
I	I-Protein
and	O
II	B-Protein
)	O
and	O
cause	O
bending	O
of	O
the	O
DNA	O
,	O
facilitating	O
the	O
binding	O
of	O
other	O
repressors	O
[	O
40	O
]	O
.	O

Sox6	B-Protein
expression	O
is	O
temporally	O
and	O
spatially	O
coincident	O
with	O
definitive	O
(	O
but	O
not	O
primitive	O
)	O
erythropoiesis	O
(	O
Figure	O
6	O
)	O
,	O
and	O
Sox6	B-Protein
represses	O
epsilony	B-Protein
globin	I-Protein
expression	O
both	O
in	O
vivo	O
(	O
Figure	O
1	O
)	O
and	O
in	O
vitro	O
(	O
Figure	O
2	O
)	O
.	O

Moreover	O
,	O
in	O
situ	O
hybridization	O
clearly	O
shows	O
that	O
the	O
persistent	O
expression	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
p100H	O
mutant	O
mice	O
is	O
due	O
to	O
defects	O
in	O
the	O
silencing	O
mechanism	O
of	O
definitive	O
erythropoiesis	O
that	O
takes	O
place	O
in	O
the	O
liver	O
(	O
Figure	O
5	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
Sox6	B-Protein
functions	O
in	O
definitive	O
erythropoiesis	O
to	O
silence	O
epsilony	B-Protein
globin	I-Protein
expression	O
.	O

The	O
expression	O
level	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
homozygous	O
Sox6	B-Protein
null	O
mice	O
at	O
15	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
is	O
statistically	O
equivalent	O
to	O
the	O
level	O
of	O
betamaj	B-Protein
/	O
min	B-Protein
expression	O
in	O
the	O
livers	O
of	O
15	O
.	O
5	O
-	O
dpc	O
and	O
18	O
.	O
5	O
-	O
dpc	O
homozygous	O
WT	O
mice	O
(	O
Figure	O
1	O
)	O
.	O

This	O
demonstrates	O
that	O
ectopic	O
expression	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
gene	O
is	O
quite	O
robust	O
in	O
homozygous	O
mutant	O
mice	O
.	O

The	O
expression	O
levels	O
of	O
two	O
other	O
embryonic	O
globin	O
genes	O
(	O
zeta	B-Protein
and	O
betah1	B-Protein
)	O
are	O
also	O
higher	O
in	O
p100H	O
homozygotes	O
,	O
compared	O
with	O
WT	O
.	O

Like	O
epsilony	B-Protein
,	O
levels	O
of	O
zeta	B-Protein
and	O
betah1	B-Protein
are	O
dramatically	O
higher	O
in	O
mutant	O
mice	O
at	O
15	O
.	O
5	O
dpc	O
.	O

However	O
,	O
unlike	O
epsilony	B-Protein
globin	I-Protein
,	O
zeta	B-Protein
and	O
betah1	B-Protein
decline	O
in	O
expression	O
by	O
day	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
,	O
suggesting	O
that	O
epsilony	B-Protein
is	O
regulated	O
differently	O
than	O
zeta	B-Protein
and	O
betah1	B-Protein
.	O

It	O
is	O
possible	O
that	O
Sox6	B-Protein
has	O
a	O
general	O
effect	O
on	O
embryonic	O
globin	O
genes	O
(	O
and	O
erythrocyte	O
maturation	O
)	O
in	O
addition	O
to	O
a	O
specific	O
role	O
in	O
silencing	O
epsilony	B-Protein
.	O

Although	O
most	O
p100H	O
mutant	O
mice	O
die	O
just	O
after	O
being	O
born	O
,	O
a	O
rare	O
few	O
survive	O
longer	O
.	O

None	O
have	O
been	O
observed	O
to	O
live	O
longer	O
than	O
2	O
wk	O
after	O
birth	O
[	O
14	O
]	O
.	O

We	O
examined	O
a	O
single	O
archived	O
sample	O
of	O
liver	O
RNA	O
from	O
a	O
mutant	O
mouse	O
on	O
postnatal	O
day	O
13	O
.	O
5	O
for	O
globin	O
gene	O
expression	O
and	O
detected	O
high	O
levels	O
of	O
epsilony	B-Protein
globin	I-Protein
in	O
this	O
RNA	O
sample	O
,	O
compared	O
with	O
undetectable	O
epsilony	B-Protein
RNA	O
in	O
WT	O
control	O
mice	O
.	O

At	O
this	O
point	O
in	O
development	O
,	O
the	O
levels	O
of	O
zeta	B-Protein
and	O
betah1	B-Protein
RNA	O
were	O
undetectable	O
both	O
in	O
mutant	O
and	O
WT	O
;	O
however	O
,	O
adult	O
beta	B-Protein
-	I-Protein
like	I-Protein
globin	I-Protein
RNA	O
levels	O
were	O
moderately	O
elevated	O
in	O
the	O
mutant	O
RNA	O
compared	O
with	O
WT	O
(	O
unpublished	O
data	O
)	O
,	O
similar	O
to	O
what	O
we	O
observe	O
at	O
18	O
.	O
5	O
dpc	O
(	O
Figure	O
1	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
Sox6	B-Protein
continues	O
to	O
function	O
postnatally	O
to	O
silence	O
epsilony	B-Protein
globin	I-Protein
expression	O
and	O
has	O
a	O
unique	O
function	O
in	O
the	O
regulation	O
of	O
epsilony	B-Protein
-	I-Protein
globin	I-Protein
.	O

The	O
mechanism	O
by	O
which	O
Sox6	B-Protein
regulates	O
the	O
other	O
embryonic	O
globin	O
genes	O
remains	O
to	O
be	O
elucidated	O
.	O

Sox6	B-Protein
has	O
other	O
effects	O
in	O
erythropoiesis	O
,	O
including	O
a	O
delay	O
in	O
enucleation	O
/	O
maturation	O
in	O
p100H	O
mutant	O
mice	O
.	O

This	O
may	O
be	O
the	O
result	O
of	O
indirect	O
effects	O
,	O
such	O
as	O
stress	O
-	O
induced	O
proliferation	O
(	O
resulting	O
from	O
cardiac	O
defects	O
)	O
and	O
/	O
or	O
anemia	O
.	O
<EOS>	B-X
Therewith	B-X
most	B-X
anemias	B-X
in	B-X
general	B-X
practice	B-X
can	B-X
be	B-X
explained	B-X
.	B-X
The	B-X
most	B-X
important	B-X
types	B-X
of	B-X
anemia	B-X
,	B-X
e.g	B-X
.	B-X
iron	B-X
deficiency	B-X
anemia	B-X
,	B-X
are	B-X
discussed	B-X
as	B-X
well	B-X
as	B-X
aspects	B-X
of	B-X
diagnosis	B-X
and	B-X
therapy	B-X
.	B-X
Iron	B-X
deficiency	B-X
anemia	B-X
is	B-X
often	B-X
diagnosed	B-X
together	B-X
with	B-X
other	B-X
types	B-X
of	B-X
anemia	B-X
,	B-X
such	B-X
as	B-X
e.g	B-X
.	B-X
anemia	B-X
of	B-X
chronic	B-X
disease	B-X
.	B-X
Particular	B-X
aspects	B-X
of	B-X
anemia	B-X
in	B-X
the	B-X
elderly	B-X
as	B-X
well	B-X
as	B-X
renal	B-X
anemia	B-X
are	B-X
discussed	B-X
.	B-X

Severe	O
anemia	O
can	O
lead	O
to	O
rapid	O
premature	O
release	O
of	O
red	O
cells	O
,	O
prior	O
to	O
their	O
complete	O
maturation	O
.	O

However	O
,	O
the	O
hematocrit	O
of	O
18	O
.	O
5	O
-	O
dpc	O
mutant	O
mice	O
is	O
only	O
20	O
%	O
lower	O
than	O
that	O
of	O
WT	O
(	O
unpublished	O
data	O
)	O
,	O
and	O
this	O
mild	O
anemia	O
is	O
probably	O
not	O
sufficient	O
to	O
explain	O
the	O
extent	O
of	O
nucleated	O
red	O
cells	O
.	O

Alternatively	O
,	O
Sox6	B-Protein
itself	O
may	O
play	O
a	O
role	O
in	O
red	O
cell	O
terminal	O
differentiation	O
,	O
as	O
it	O
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
factor	O
in	O
cardiac	O
[	O
15	O
]	O
,	O
neuronal	O
[	O
10	O
]	O
,	O
astrocytic	O
[	O
11	O
]	O
,	O
and	O
cartilage	O
differentiation	O
programs	O
[	O
32	O
,	O
41	O
-	O
44	O
]	O
.	O

The	O
restoration	O
of	O
normal	O
enucleation	O
of	O
red	O
cells	O
in	O
Sox6	B-Protein
-	O
deficient	O
mouse	O
by	O
postnatal	O
day	O
10	O
.	O
5	O
may	O
result	O
from	O
functional	O
compensation	O
of	O
other	O
Sox	O
proteins	O
(	O
expressed	O
at	O
later	O
developmental	O
stages	O
)	O
,	O
since	O
functional	O
redundancy	O
is	O
a	O
recurring	O
theme	O
with	O
Sox	O
proteins	O
[	O
13	O
,	O
45	O
,	O
46	O
]	O
.	O

Moreover	O
,	O
erythropoiesis	O
has	O
already	O
shifted	O
from	O
fetal	O
liver	O
to	O
bone	O
marrow	O
by	O
postnatal	O
day	O
10	O
.	O
5	O
.	O

The	O
accompanying	O
change	O
in	O
the	O
microenvironment	O
of	O
red	O
cell	O
production	O
may	O
permit	O
normal	O
enucleation	O
.	O

Identification	O
of	O
Sox6	B-Protein
downstream	O
target	O
genes	O
and	O
its	O
interacting	O
proteins	O
will	O
shed	O
light	O
on	O
the	O
role	O
of	O
Sox6	B-Protein
in	O
red	O
cell	O
terminal	O
differentiation	O
and	O
the	O
enucleation	O
process	O
.	O

Recently	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
suggest	O
that	O
reactivation	O
of	O
human	O
epsilon	B-Protein
-	I-Protein
globin	I-Protein
would	O
be	O
therapeutically	O
beneficial	O
to	O
adults	O
with	O
sickle	O
cell	O
disease	O
[	O
47	O
]	O
,	O
providing	O
a	O
rationale	O
for	O
detailed	O
investigations	O
into	O
the	O
molecular	O
basis	O
of	O
epsilon	B-Protein
-	I-Protein
globin	I-Protein
gene	O
silencing	O
.	O

The	O
present	O
study	O
identifies	O
a	O
novel	O
repressor	O
,	O
Sox6	B-Protein
,	O
which	O
binds	O
to	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
,	O
potentially	O
as	O
part	O
of	O
a	O
larger	O
repression	O
complex	O
.	O

Because	O
murine	O
Sox6	B-Protein
and	O
its	O
human	O
counterpart	O
are	O
94	O
%	O
identical	O
at	O
the	O
amino	O
acid	O
level	O
[	O
48	O
]	O
,	O
it	O
is	O
possible	O
that	O
human	O
Sox6	B-Protein
may	O
also	O
be	O
important	O
in	O
human	O
epsilon	B-Protein
globin	I-Protein
silencing	O
.	O

There	O
is	O
significant	O
sequence	O
homology	O
between	O
the	O
human	O
and	O
mouse	O
epsilon	B-Protein
promoter	O
regions	O
,	O
and	O
the	O
human	O
promoter	O
contains	O
at	O
least	O
two	O
potential	O
Sox6	O
binding	O
sites	O
.	O

Indeed	O
,	O
the	O
existence	O
of	O
a	O
silencer	O
of	O
the	O
human	O
epsilon	B-Protein
globin	I-Protein
gene	O
has	O
been	O
proposed	O
[	O
49	O
,	O
50	O
]	O
.	O

Thus	O
,	O
elucidation	O
of	O
the	O
Sox6	B-Protein
repression	O
mechanism	O
and	O
identification	O
of	O
other	O
components	O
of	O
the	O
Sox6	B-Protein
-	O
containing	O
complex	O
may	O
further	O
our	O
understanding	O
of	O
epsilon	B-Protein
globin	I-Protein
regulation	O
and	O
potentially	O
reveal	O
additional	O
molecular	O
targets	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
and	O
beta	O
thalassemias	O
.	O

Plasmid	O
construction	O
.	O
<EOS>	B-X
Plasmids	B-X
occupy	B-X
a	B-X
place	B-X
of	B-X
honor	B-X
in	B-X
molecular	B-X
cloning	B-X
:	B-X
They	B-X
were	B-X
used	B-X
in	B-X
the	B-X
first	B-X
recombinant	B-X
DNA	B-X
experiments	B-X
and	B-X
,	B-X
40	B-X
or	B-X
more	B-X
years	B-X
later	B-X
,	B-X
they	B-X
remain	B-X
as	B-X
the	B-X
carriage	B-X
horses	B-X
of	B-X
molecular	B-X
cloning	B-X
.	B-X
In	B-X
vitro	B-X
recombinant	B-X
DNA	B-X
experiments	B-X
,	B-X
using	B-X
plasmid	B-X
pBR327	B-X
and	B-X
a	B-X
DNA	B-X
fragment	B-X
derived	B-X
from	B-X
plasmid	B-X
pSC101	B-X
containing	B-X
the	B-X
par	B-X
region	B-X
,	B-X
resulted	B-X
in	B-X
the	B-X
construction	B-X
of	B-X
plasmid	B-X
pBR327par	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
report	B-X
the	B-X
construction	B-X
in	B-X
vitro	B-X
of	B-X
chimerae	B-X
between	B-X
lambdoid	B-X
replacement	B-X
vectors	B-X
(	B-X
Murray	B-X
et	B-X
al.	B-X
,	B-X
1977	B-X
)	B-X
and	B-X
the	B-X
miniF	B-X
Apr	B-X
plasmid	B-X
:	B-X
pSC138	B-X
(	B-X
Timmis	B-X
et	B-X
al.	B-X
,	B-X
1975	B-X
)	B-X
.	B-X
We	B-X
have	B-X
extended	B-X
the	B-X
technique	B-X
of	B-X
PCR-directed	B-X
recombination	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
to	B-X
develop	B-X
a	B-X
simple	B-X
method	B-X
for	B-X
plasmid	B-X
or	B-X
gene	B-X
construction	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
suitable	B-X
restriction	B-X
sites	B-X
.	B-X

The	O
epsilony	B-Protein
promoter	O
deletion	O
reporter	O
plasmid	O
(	O
E	O
-	O
luc	O
)	O
was	O
generated	O
by	O
PCR	O
amplification	O
of	O
the	O
epsilony	B-Protein
proximal	O
promoter	O
.	O

A	O
2	O
.	O
2	O
-	O
kb	O
fragment	O
upstream	O
of	O
the	O
epsilony	B-Protein
globin	I-Protein
initiation	O
codon	O
(	O
ATG	O
)	O
was	O
used	O
,	O
because	O
it	O
has	O
been	O
shown	O
that	O
all	O
sequences	O
required	O
for	O
epsilon	B-Protein
gene	O
silencing	O
are	O
located	O
within	O
a	O
3	O
.	O
7	O
-	O
kb	O
EcoRI	O
fragment	O
containing	O
about	O
2	O
kb	O
of	O
sequence	O
upstream	O
of	O
the	O
epsilon	B-Protein
globin	I-Protein
gene	O
cap	O
site	O
[	O
50	O
]	O
.	O

Nucleotide	O
numbering	O
is	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

The	O
transcriptional	O
start	O
site	O
is	O
based	O
on	O
the	O
longest	O
cDNA	O
in	O
the	O
Fantom	O
(	O
Functional	O
Annotation	O
of	O
Mouse	O
)	O
database	O
.	O

The	O
PCR	O
primers	O
contained	O
XhoI	O
and	O
HindIII	O
sites	O
that	O
were	O
used	O
to	O
clone	O
the	O
epsilony	B-Protein
promoter	O
fragment	O
upstream	O
of	O
the	O
firefly	O
luciferase	B-Protein
gene	O
in	O
pGL3	O
Basic	O
(	O
Promega	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
.	O

A	O
2	O
.	O
5	O
-	O
kb	O
SstI	O
/	O
XhoI	O
fragment	O
of	O
muLCRbeta	O
9	O
.	O
3	O
(	O
micro	O
LCR	O
;	O
[	O
31	O
]	O
)	O
was	O
then	O
inserted	O
upstream	O
of	O
the	O
epsilony	B-Protein
promoter	O
in	O
the	O
above	O
pGL3	O
Basic	O
plasmid	O
,	O
resulting	O
in	O
a	O
reporter	O
construct	O
in	O
which	O
luciferase	B-Protein
expression	O
is	O
driven	O
by	O
the	O
epsilony	B-Protein
promoter	O
.	O

A	O
series	O
of	O
deletion	O
constructs	O
of	O
the	O
epsilony	B-Protein
promoter	O
were	O
generated	O
similarly	O
.	O

Forward	O
primers	O
with	O
an	O
XhoI	O
site	O
include	O
:	O
MHB1457	O
,	O
5	O
'	O
CCGCTCGAGTGCTAGGCAAACACTCA3	O
'	O
(	O
-	O
2077	O
to	O
-	O
2052	O
)	O
;	O
MHB1503	O
,	O
5	O
'	O
CCGCTCGAGTCTCTACACTGTCACTCCCTG3	O
'	O
(	O
-	O
634	O
to	O
-	O
605	O
)	O
;	O
MHB1505	O
,	O
5	O
'	O
CCGCTCGAGGGAGCCAAAAAAAGAATGC3	O
'	O
(	O
-	O
197	O
to	O
-	O
169	O
)	O
;	O
MHB1506	O
,	O
5	O
'	O
CCGCTCGAGCTGACCAATGGCTTCAAAG3	O
'	O
(	O
-	O
85	O
to	O
-	O
58	O
)	O
;	O
MHB1532	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGAACAAAGGGTCAGA3	O
'	O
(	O
-	O
63	O
to	O
-	O
34	O
)	O
;	O
and	O
MHB1507	O
,	O
5	O
'	O
CCGCTCGAGGTCTGCGAAGAATAAAAGGC	O
3	O
'	O
(	O
-	O
37	O
to	O
-	O
9	O
)	O
.	O

All	O
forward	O
primers	O
were	O
used	O
in	O
combination	O
with	O
the	O
reverse	O
primer	O
HindIII	O
site	O
:	O
MHB1477	O
,	O
5	O
'	O
CGGAAGCTTGGGAGGTTGCTGGTGA3	O
'	O
(	O
+	O
45	O
to	O
+	O
20	O
)	O
.	O

Sox6	B-Protein
-	O
pcDNA3	O
.	O
1	O
[	O
15	O
]	O
was	O
used	O
to	O
overexpress	O
Sox6	B-Protein
.	O
<EOS>	B-X
RN-c	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
miR-485-5p	B-X
mimics	B-X
,	B-X
miR-485-5p	B-X
inhibitors	B-X
,	B-X
si-SOX6	B-X
,	B-X
pCNDA3.1-SOX6	B-X
or	B-X
miR-485-5p	B-X
+	B-X
pCDNA3.1-SOX6	B-X
,	B-X
in	B-X
which	B-X
cell	B-X
viability	B-X
,	B-X
apoptosis	B-X
,	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
release	B-X
rate	B-X
were	B-X
assessed	B-X
.	B-X
Western	B-X
blot	B-X
detected	B-X
the	B-X
protein	B-X
expressions	B-X
of	B-X
apoptotic-related	B-X
proteins	B-X
(	B-X
caspase3	B-X
,	B-X
Bcl-2	B-X
,	B-X
Bax	B-X
)	B-X
and	B-X
the	B-X
phosphorylated	B-X
level	B-X
of	B-X
ERK1/2	B-X
.	B-X
Overexpression	B-X
of	B-X
miR-485-5p	B-X
or	B-X
SOX6	B-X
knockdown	B-X
rescued	B-X
cell	B-X
viability	B-X
and	B-X
Bcl-2	B-X
expression	B-X
,	B-X
while	B-X
attenuated	B-X
apoptosis	B-X
,	B-X
LDH	B-X
release	B-X
rate	B-X
,	B-X
expression	B-X
of	B-X
SOX6	B-X
and	B-X
the	B-X
phosphorylated	B-X
level	B-X
of	B-X
ERK1/2	B-X
.	B-X
Core-binding	B-X
factor	B-X
a1	B-X
,	B-X
Cbfa1	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
the	B-X
runt-domain	B-X
gene	B-X
family	B-X
,	B-X
is	B-X
an	B-X
essential	B-X
transcription	B-X
factor	B-X
for	B-X
osteoblastic	B-X
differentiation	B-X
and	B-X
osteogenesis	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
Cbfa1	B-X
exhibit	B-X
on	B-X
gene	B-X
expression	B-X
which	B-X
involving	B-X
in	B-X
the	B-X
chondrogenesis	B-X
.	B-X

A	O
truncated	O
version	O
of	O
the	O
Sox6	B-Protein
overexpression	O
construct	O
(	O
Sox6	B-Protein
-	O
deltaHMG	O
-	O
pcDNA3	O
.	O
1	O
)	O
that	O
lacks	O
the	O
HMG	O
domain	O
was	O
generated	O
,	O
as	O
described	O
by	O
others	O
[	O
32	O
]	O
.	O

Mutagenesis	O
of	O
Sox	O
/	O
Sox6	O
consensus	O
binding	O
sites	O
of	O
the	O
epsilony	B-Protein
promoter	O
were	O
done	O
by	O
PCR	O
.	O

Forward	O
primers	O
used	O
to	O
generate	O
these	O
mutagenized	O
epsilony	O
promoter	O
reporter	O
constructs	O
include	O
:	O
MHB1661	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGTGCCAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
-	O
63	O
to	O
-	O
19	O
)	O
;	O
MHB1662	O
,	O
5	O
'	O
CCGCTCGAGAATGCAGAACAAAGGGTCAGATGAGTGTCTGCGAAGAA3	O
'	O
(	O
-	O
63	O
to	O
-	O
16	O
)	O
;	O
and	O
MHB1663	O
,	O
5	O
'	O
CCGCTCGAGAATGCATGCCAAGGGTCAGATGAGTGTCTGCGAAGAA	O
3	O
'	O
(	O
-	O
63	O
to	O
-	O
18	O
)	O
.	O

Quantitation	O
of	O
globin	O
mRNA	O
.	O
<EOS>	B-X
Alpha-	B-X
and	B-X
β-thalassemias	B-X
and	B-X
abnormal	B-X
hemoglobin	B-X
(	B-X
Hb	B-X
)	B-X
are	B-X
common	B-X
in	B-X
tropical	B-X
countries	B-X
.	B-X
These	B-X
abnormal	B-X
globin	B-X
genes	B-X
in	B-X
different	B-X
combinations	B-X
lead	B-X
to	B-X
many	B-X
thalassemic	B-X
diseases	B-X
including	B-X
three	B-X
severe	B-X
thalassemia	B-X
diseases	B-X
,	B-X
i.e.	B-X
,	B-X
homozygous	B-X
β-thalassemia	B-X
,	B-X
β-thalassemia/Hb	B-X
E	B-X
,	B-X
and	B-X
Hb	B-X
Bart	B-X
's	B-X
hydrops	B-X
fetalis	B-X
.	B-X
Thalassemia	B-X
genotypes	B-X
can	B-X
be	B-X
characterized	B-X
by	B-X
the	B-X
intensities	B-X
between	B-X
alpha-/beta-globin	B-X
chains	B-X
or	B-X
alpha-/beta-mRNA	B-X
ratios	B-X
.	B-X
The	B-X
β-thalassemias	B-X
are	B-X
characterized	B-X
by	B-X
a	B-X
quantitative	B-X
deficiency	B-X
of	B-X
β-globin	B-X
chains	B-X
underlaid	B-X
by	B-X
a	B-X
striking	B-X
heterogeneity	B-X
of	B-X
molecular	B-X
defects	B-X
.	B-X

RNA	O
was	O
first	O
reverse	O
transcribed	O
to	O
cDNA	O
.	O
<EOS>	B-X
Spermatozoa	B-X
of	B-X
virtually	B-X
all	B-X
species	B-X
can	B-X
spontaneously	B-X
take	B-X
up	B-X
exogenous	B-X
DNA	B-X
or	B-X
RNA	B-X
molecules	B-X
and	B-X
internalize	B-X
them	B-X
into	B-X
nuclei	B-X
.	B-X
In	B-X
this	B-X
article	B-X
I	B-X
review	B-X
evidence	B-X
for	B-X
a	B-X
key	B-X
role	B-X
of	B-X
a	B-X
reverse	B-X
transcriptase	B-X
(	B-X
RT	B-X
)	B-X
activity	B-X
,	B-X
encoded	B-X
by	B-X
LINE-1	B-X
retrotransposons	B-X
,	B-X
in	B-X
the	B-X
fate	B-X
of	B-X
the	B-X
internalized	B-X
nucleic	B-X
acid	B-X
molecules	B-X
and	B-X
their	B-X
implication	B-X
in	B-X
transgenerational	B-X
inheritance	B-X
.	B-X
LINE-1-derived	B-X
RT	B-X
,	B-X
present	B-X
in	B-X
sperm	B-X
heads	B-X
,	B-X
can	B-X
reverse-transcribe	B-X
the	B-X
internalized	B-X
molecules	B-X
in	B-X
cDNA	B-X
copies	B-X
:	B-X
exogenous	B-X
RNA	B-X
is	B-X
reverse-transcribed	B-X
in	B-X
a	B-X
one-step	B-X
reaction	B-X
,	B-X
whereas	B-X
DNA	B-X
is	B-X
first	B-X
transcribed	B-X
into	B-X
RNA	B-X
and	B-X
subsequently	B-X
reverse-transcribed	B-X
.	B-X
Both	B-X
RNA	B-X
and	B-X
cDNA	B-X
molecules	B-X
can	B-X
be	B-X
delivered	B-X
from	B-X
sperm	B-X
cells	B-X
to	B-X
oocytes	B-X
at	B-X
fertilization	B-X
,	B-X
further	B-X
propagated	B-X
throughout	B-X
embryogenesis	B-X
and	B-X
inherited	B-X
in	B-X
a	B-X
non-Mendelian	B-X
fashion	B-X
in	B-X
tissues	B-X
of	B-X
adult	B-X
animals	B-X
.	B-X
The	B-X
reverse-transcribed	B-X
sequences	B-X
are	B-X
extrachromosomal	B-X
,	B-X
low-abundance	B-X
,	B-X
and	B-X
mosaic	B-X
distributed	B-X
in	B-X
tissues	B-X
of	B-X
adult	B-X
individuals	B-X
,	B-X
where	B-X
they	B-X
are	B-X
variably	B-X
expressed	B-X
.	B-X
Growing	B-X
evidence	B-X
indicate	B-X
that	B-X
cancer	B-X
tissues	B-X
produce	B-X
DNA-	B-X
and	B-X
RNA-containing	B-X
exosomes	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
these	B-X
exosomes	B-X
are	B-X
released	B-X
in	B-X
the	B-X
bloodstream	B-X
and	B-X
eventually	B-X
taken	B-X
up	B-X
into	B-X
epididymal	B-X
spermatozoa	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
emerging	B-X
view	B-X
that	B-X
a	B-X
transgenerational	B-X
flow	B-X
of	B-X
extrachromosomal	B-X
RNA	B-X
connects	B-X
soma	B-X
to	B-X
germline	B-X
and	B-X
,	B-X
further	B-X
,	B-X
to	B-X
next	B-X
generation	B-X
embryos	B-X
.	B-X

Primers	O
for	O
cDNA	O
PCR	O
amplification	O
of	O
globin	O
genes	O
were	O
obtained	O
from	O
Primerbank	O
[	O
51	O
]	O
.	O

All	O
primers	O
were	O
searched	O
against	O
the	O
NCBI	O
database	O
to	O
confirm	O
specificity	O
.	O
<EOS>	B-X
To	B-X
confirm	B-X
virus	B-X
infection	B-X
,	B-X
total	B-X
RNA	B-X
was	B-X
extracted	B-X
from	B-X
an	B-X
alstroemeria	B-X
leaf	B-X
using	B-X
a	B-X
Beniprep®	B-X
Super	B-X
Plant	B-X
RNA	B-X
extraction	B-X
kit	B-X
(	B-X
IVT7005	B-X
,	B-X
Invirustech	B-X
Co.	B-X
,	B-X
Korea	B-X
)	B-X
.	B-X
Nucleotide	B-X
blast	B-X
analysis	B-X
of	B-X
contigs	B-X
against	B-X
NCBI	B-X
viral	B-X
reference	B-X
database	B-X
revealed	B-X
that	B-X
24	B-X
assembled	B-X
contigs	B-X
(	B-X
>	B-X
1,000	B-X
bp	B-X
)	B-X
were	B-X
sequences	B-X
of	B-X
AlMV	B-X
.	B-X
To	B-X
confirm	B-X
AlMV	B-X
detection	B-X
,	B-X
raw	B-X
reads	B-X
were	B-X
mapped	B-X
to	B-X
known	B-X
AlMV	B-X
complete	B-X
genome	B-X
(	B-X
9,774	B-X
bp	B-X
)	B-X
using	B-X
Bowtie2	B-X
program	B-X
.	B-X
To	B-X
verify	B-X
the	B-X
presence	B-X
of	B-X
AlMV	B-X
,	B-X
RT-PCR	B-X
assay	B-X
was	B-X
conducted	B-X
with	B-X
AlMV	B-X
's	B-X
CP	B-X
gene-specific	B-X
primers	B-X
:	B-X
AlMV-F	B-X
(	B-X
5'-CACGAGGCTGTGAAACAAGC	B-X
-3	B-X
'	B-X
)	B-X
and	B-X
AlMV-R	B-X
(	B-X
5'-	B-X
CCAGGCGACACGGCTAAATA-3	B-X
'	B-X
)	B-X
.	B-X

For	O
epsilony	B-Protein
globin	I-Protein
:	O
MHB1666	O
,	O
5	O
'	O
TGGCCTGTGGAGTAAGGTCAA3	O
'	O
;	O
and	O
MHB1667	O
,	O
5	O
'	O
GAAGCAGAGGACAAGTTCCCA3	O
'	O
.	O
<EOS>	B-X
A	B-X
transient	B-X
erythromyeloid	B-X
wave	B-X
of	B-X
definitive	B-X
hematopoietic	B-X
progenitors	B-X
(	B-X
erythroid/myeloid	B-X
progenitors	B-X
[	B-X
EMPs	B-X
]	B-X
)	B-X
emerges	B-X
in	B-X
the	B-X
yolk	B-X
sac	B-X
beginning	B-X
at	B-X
embryonic	B-X
day	B-X
8.25	B-X
(	B-X
E8.25	B-X
)	B-X
and	B-X
colonizes	B-X
the	B-X
liver	B-X
by	B-X
E10.5	B-X
,	B-X
before	B-X
adult-repopulating	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
At	B-X
E11.5	B-X
,	B-X
we	B-X
observe	B-X
all	B-X
maturational	B-X
stages	B-X
of	B-X
erythroid	B-X
precursors	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
the	B-X
first	B-X
definitive	B-X
erythrocytes	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
These	B-X
early	B-X
fetal	B-X
liver	B-X
erythroblasts	B-X
express	B-X
predominantly	B-X
adult	B-X
β-globins	B-X
and	B-X
the	B-X
definitive	B-X
erythroid-specific	B-X
transcriptional	B-X
modifiers	B-X
c-myb	B-X
,	B-X
Sox6	B-X
,	B-X
and	B-X
Bcl11A	B-X
.	B-X
Surprisingly	B-X
,	B-X
they	B-X
also	B-X
express	B-X
low	B-X
levels	B-X
of	B-X
``	B-X
embryonic	B-X
''	B-X
βH1-	B-X
,	B-X
but	B-X
not	B-X
εy-	B-X
,	B-X
globin	B-X
transcripts	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
results	B-X
,	B-X
RNA	B-X
polymerase	B-X
and	B-X
highly	B-X
modified	B-X
histones	B-X
are	B-X
found	B-X
associated	B-X
with	B-X
βH1-	B-X
and	B-X
adult	B-X
globin	B-X
,	B-X
but	B-X
not	B-X
εy-globin	B-X
,	B-X
genes	B-X
.	B-X
E11.5	B-X
definitive	B-X
proerythroblasts	B-X
from	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
human	B-X
β-globin	B-X
locus	B-X
,	B-X
like	B-X
human	B-X
fetal	B-X
erythroblasts	B-X
,	B-X
express	B-X
predominately	B-X
human	B-X
γ-	B-X
,	B-X
low	B-X
β-	B-X
,	B-X
and	B-X
no	B-X
ε-globin	B-X
transcripts	B-X
.	B-X
Significantly	B-X
,	B-X
E9.5	B-X
yolk	B-X
sac-derived	B-X
EMPs	B-X
cultured	B-X
in	B-X
vitro	B-X
have	B-X
similar	B-X
murine	B-X
and	B-X
human	B-X
transgenic	B-X
globin	B-X
expression	B-X
patterns	B-X
.	B-X
Later	B-X
liver	B-X
proerythroblasts	B-X
express	B-X
low	B-X
levels	B-X
of	B-X
γ-globin	B-X
,	B-X
while	B-X
adult	B-X
marrow	B-X
proerythroblasts	B-X
express	B-X
only	B-X
β-globin	B-X
transcripts	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
yolk	B-X
sac-derived	B-X
EMPs	B-X
,	B-X
the	B-X
first	B-X
of	B-X
2	B-X
origins	B-X
of	B-X
definitive	B-X
erythropoiesis	B-X
,	B-X
express	B-X
a	B-X
unique	B-X
pattern	B-X
of	B-X
globin	B-X
genes	B-X
as	B-X
they	B-X
generate	B-X
the	B-X
first	B-X
definitive	B-X
erythrocytes	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
the	B-X
mammalian	B-X
embryo	B-X
.	B-X

For	O
zeta	B-Protein
globin	I-Protein
:	O
MHB1668	O
,	O
5	O
'	O
CTACCCCCAGACGAAGACCTA3	O
'	O
;	O
and	O
MHB1669	O
,	O
5	O
'	O
CTTAACCGCATCCCCTACGG3	O
'	O
.	O
<EOS>	B-X
The	B-X
human	B-X
ζ-globin	B-X
gene	B-X
(	B-X
HBZ	B-X
)	B-X
is	B-X
transcribed	B-X
in	B-X
primitive	B-X
erythroid	B-X
cells	B-X
only	B-X
during	B-X
the	B-X
embryonic	B-X
stages	B-X
of	B-X
development	B-X
.	B-X
Reactivation	B-X
of	B-X
this	B-X
embryonic	B-X
globin	B-X
synthesis	B-X
would	B-X
likely	B-X
alleviate	B-X
symptoms	B-X
both	B-X
in	B-X
α-thalassemia	B-X
and	B-X
sickle-cell	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
controlling	B-X
ζ-globin	B-X
expression	B-X
have	B-X
remained	B-X
largely	B-X
undefined	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
pharmacologic	B-X
agent	B-X
capable	B-X
of	B-X
inducing	B-X
ζ-globin	B-X
production	B-X
is	B-X
currently	B-X
unavailable	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
TRIAC	B-X
,	B-X
a	B-X
bioactive	B-X
thyroid	B-X
hormone	B-X
metabolite	B-X
,	B-X
significantly	B-X
induced	B-X
ζ-globin	B-X
gene	B-X
expression	B-X
during	B-X
zebrafish	B-X
embryogenesis	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
ζ-globin	B-X
expression	B-X
by	B-X
TRIAC	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
human	B-X
K562	B-X
erythroleukemia	B-X
cell	B-X
line	B-X
and	B-X
primary	B-X
erythroid	B-X
cells	B-X
.	B-X
Thyroid	B-X
hormone	B-X
receptor	B-X
α	B-X
(	B-X
THRA	B-X
)	B-X
deficiency	B-X
abolished	B-X
the	B-X
ζ-globin-inducing	B-X
effect	B-X
of	B-X
TRIAC	B-X
.	B-X
Furthermore	B-X
,	B-X
THRA	B-X
could	B-X
directly	B-X
bind	B-X
to	B-X
the	B-X
distal	B-X
enhancer	B-X
regulatory	B-X
element	B-X
to	B-X
regulate	B-X
ζ-globin	B-X
expression	B-X
.	B-X
Our	B-X
study	B-X
provides	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
TRIAC	B-X
acts	B-X
as	B-X
a	B-X
potent	B-X
inducer	B-X
of	B-X
ζ-globin	B-X
expression	B-X
,	B-X
which	B-X
might	B-X
serve	B-X
as	B-X
a	B-X
new	B-X
potential	B-X
therapeutic	B-X
option	B-X
for	B-X
patients	B-X
with	B-X
severe	B-X
α-thalassemia	B-X
or	B-X
sickle-cell	B-X
disease	B-X
.	B-X

For	O
betaH1	B-Protein
globin	I-Protein
:	O
MHB1672	O
,	O
5	O
'	O
TGGACAACCTCAAGGAGACC3	O
'	O
;	O
and	O
MHB1673	O
,	O
5	O
'	O
ACCTCTGGGGTGAATTCCTT3	O
'	O
.	O
<EOS>	B-X
Mammalian	B-X
beta-globin	B-X
loci	B-X
contain	B-X
multiple	B-X
genes	B-X
that	B-X
are	B-X
activated	B-X
at	B-X
different	B-X
developmental	B-X
stages	B-X
.	B-X
Deletion	B-X
of	B-X
Ey	B-X
did	B-X
not	B-X
affect	B-X
betah1	B-X
nor	B-X
did	B-X
deletion	B-X
of	B-X
betah1	B-X
affect	B-X
Ey	B-X
,	B-X
but	B-X
Ey	B-X
deletion	B-X
uniquely	B-X
activated	B-X
transcription	B-X
from	B-X
betah0	B-X
,	B-X
a	B-X
beta-like	B-X
globin	B-X
gene	B-X
immediately	B-X
downstream	B-X
of	B-X
Ey	B-X
.	B-X
Protein	B-X
analysis	B-X
showed	B-X
that	B-X
betah0	B-X
encodes	B-X
a	B-X
translatable	B-X
beta-like	B-X
globin	B-X
protein	B-X
that	B-X
can	B-X
pair	B-X
with	B-X
alpha	B-X
globin	B-X
.	B-X
A	B-X
transient	B-X
erythromyeloid	B-X
wave	B-X
of	B-X
definitive	B-X
hematopoietic	B-X
progenitors	B-X
(	B-X
erythroid/myeloid	B-X
progenitors	B-X
[	B-X
EMPs	B-X
]	B-X
)	B-X
emerges	B-X
in	B-X
the	B-X
yolk	B-X
sac	B-X
beginning	B-X
at	B-X
embryonic	B-X
day	B-X
8.25	B-X
(	B-X
E8.25	B-X
)	B-X
and	B-X
colonizes	B-X
the	B-X
liver	B-X
by	B-X
E10.5	B-X
,	B-X
before	B-X
adult-repopulating	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
At	B-X
E11.5	B-X
,	B-X
we	B-X
observe	B-X
all	B-X
maturational	B-X
stages	B-X
of	B-X
erythroid	B-X
precursors	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
the	B-X
first	B-X
definitive	B-X
erythrocytes	B-X
in	B-X
the	B-X
circulation	B-X
.	B-X
These	B-X
early	B-X
fetal	B-X
liver	B-X
erythroblasts	B-X
express	B-X
predominantly	B-X
adult	B-X
β-globins	B-X
and	B-X
the	B-X
definitive	B-X
erythroid-specific	B-X
transcriptional	B-X
modifiers	B-X
c-myb	B-X
,	B-X
Sox6	B-X
,	B-X
and	B-X
Bcl11A	B-X
.	B-X
Surprisingly	B-X
,	B-X
they	B-X
also	B-X
express	B-X
low	B-X
levels	B-X
of	B-X
``	B-X
embryonic	B-X
''	B-X
βH1-	B-X
,	B-X
but	B-X
not	B-X
εy-	B-X
,	B-X
globin	B-X
transcripts	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
results	B-X
,	B-X
RNA	B-X
polymerase	B-X
and	B-X
highly	B-X
modified	B-X
histones	B-X
are	B-X
found	B-X
associated	B-X
with	B-X
βH1-	B-X
and	B-X
adult	B-X
globin	B-X
,	B-X
but	B-X
not	B-X
εy-globin	B-X
,	B-X
genes	B-X
.	B-X
E11.5	B-X
definitive	B-X
proerythroblasts	B-X
from	B-X
mice	B-X
transgenic	B-X
for	B-X
the	B-X
human	B-X
β-globin	B-X
locus	B-X
,	B-X
like	B-X
human	B-X
fetal	B-X
erythroblasts	B-X
,	B-X
express	B-X
predominately	B-X
human	B-X
γ-	B-X
,	B-X
low	B-X
β-	B-X
,	B-X
and	B-X
no	B-X
ε-globin	B-X
transcripts	B-X
.	B-X
Significantly	B-X
,	B-X
E9.5	B-X
yolk	B-X
sac-derived	B-X
EMPs	B-X
cultured	B-X
in	B-X
vitro	B-X
have	B-X
similar	B-X
murine	B-X
and	B-X
human	B-X
transgenic	B-X
globin	B-X
expression	B-X
patterns	B-X
.	B-X
Later	B-X
liver	B-X
proerythroblasts	B-X
express	B-X
low	B-X
levels	B-X
of	B-X
γ-globin	B-X
,	B-X
while	B-X
adult	B-X
marrow	B-X
proerythroblasts	B-X
express	B-X
only	B-X
β-globin	B-X
transcripts	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
yolk	B-X
sac-derived	B-X
EMPs	B-X
,	B-X
the	B-X
first	B-X
of	B-X
2	B-X
origins	B-X
of	B-X
definitive	B-X
erythropoiesis	B-X
,	B-X
express	B-X
a	B-X
unique	B-X
pattern	B-X
of	B-X
globin	B-X
genes	B-X
as	B-X
they	B-X
generate	B-X
the	B-X
first	B-X
definitive	B-X
erythrocytes	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
the	B-X
mammalian	B-X
embryo	B-X
.	B-X

For	O
betamaj	B-Protein
/	O
min	B-Protein
globin	I-Protein
:	O
MHB1674	O
:	O
5	O
'	O
ATGGCCTGAATCACTTGGAC3	O
'	O
;	O
and	O
MHB1675	O
,	O
5	O
'	O
ACGATCATATTGCCCAGGAG3	O
'	O
.	O
<EOS>	B-X
Erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
or	B-X
KLF1	B-X
)	B-X
positively	B-X
regulates	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
definitive	B-X
erythroid	B-X
cells	B-X
.	B-X
KLF2-/-	B-X
mice	B-X
die	B-X
between	B-X
embryonic	B-X
day	B-X
12.5	B-X
(	B-X
E12.5	B-X
)	B-X
and	B-X
E14.5	B-X
,	B-X
because	B-X
of	B-X
severe	B-X
intraembryonic	B-X
hemorrhaging	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
beta-like	B-X
globin	B-X
genes	B-X
in	B-X
KLF2	B-X
knockout	B-X
mice	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
KLF2-/-	B-X
mice	B-X
have	B-X
a	B-X
significant	B-X
reduction	B-X
of	B-X
murine	B-X
embryonic	B-X
Ey-	B-X
and	B-X
beta	B-X
h1-globin	B-X
but	B-X
not	B-X
zeta-globin	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
E10.5	B-X
yolk	B-X
sac	B-X
,	B-X
compared	B-X
with	B-X
wild-type	B-X
mice	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
adult	B-X
beta	B-X
(	B-X
maj	B-X
)	B-X
-	B-X
and	B-X
beta	B-X
(	B-X
min	B-X
)	B-X
-globin	B-X
genes	B-X
is	B-X
unaffected	B-X
in	B-X
the	B-X
fetal	B-X
livers	B-X
of	B-X
E12.5	B-X
embryos	B-X
.	B-X
In	B-X
mice	B-X
carrying	B-X
the	B-X
entire	B-X
human	B-X
globin	B-X
locus	B-X
,	B-X
KLF2	B-X
also	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
embryonic	B-X
epsilon-globin	B-X
gene	B-X
but	B-X
not	B-X
the	B-X
adult	B-X
beta-globin	B-X
gene	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
developmental-stage-specific	B-X
role	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
.	B-X

Using	O
the	O
SYBR	O
green	O
supermix	O
kit	O
with	O
ROX	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
PCR	O
amplification	O
was	O
run	O
on	O
an	O
ABI7000	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
the	O
University	O
of	O
Arizona	O
core	O
facility	O
.	O

All	O
PCR	O
was	O
performed	O
in	O
a	O
25	O
-	O
mul	O
reaction	O
with	O
12	O
.	O
5	O
mul	O
SYBR	O
green	O
supermix	O
.	O

GAPDH	B-Protein
mRNA	O
levels	O
were	O
used	O
as	O
control	O
for	O
input	O
RNA	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
RNA	B-X
expression	B-X
using	B-X
real-time	B-X
PCR	B-X
(	B-X
qRT-PCR	B-X
)	B-X
traditionally	B-X
includes	B-X
reference	B-X
genes	B-X
(	B-X
RG	B-X
)	B-X
as	B-X
an	B-X
internal	B-X
control	B-X
.	B-X
We	B-X
used	B-X
qRT-PCR	B-X
to	B-X
measure	B-X
the	B-X
levels	B-X
of	B-X
six	B-X
RG	B-X
,	B-X
which	B-X
have	B-X
been	B-X
reported	B-X
in	B-X
the	B-X
literature	B-X
to	B-X
be	B-X
invariant	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
expression	B-X
by	B-X
qRT-PCR	B-X
of	B-X
mRNA	B-X
encoding	B-X
Beta-actin	B-X
(	B-X
ACTB	B-X
)	B-X
,	B-X
Beta-2-microglobulin	B-X
(	B-X
B2M	B-X
)	B-X
,	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
(	B-X
GAPDH	B-X
)	B-X
,	B-X
peptidylprolyl	B-X
isomerase	B-X
A	B-X
(	B-X
PPIA	B-X
)	B-X
,	B-X
TATA	B-X
box	B-X
binding	B-X
protein	B-X
(	B-X
TBP	B-X
)	B-X
and	B-X
ribosomal	B-X
protein	B-X
,	B-X
large	B-X
,	B-X
P0	B-X
(	B-X
RPLPO	B-X
)	B-X
.	B-X
The	B-X
mRNA	B-X
expression	B-X
of	B-X
the	B-X
following	B-X
genes	B-X
of	B-X
interest	B-X
(	B-X
GOI	B-X
)	B-X
were	B-X
analyzed	B-X
:	B-X
skeletal	B-X
muscle	B-X
alpha	B-X
1	B-X
actin	B-X
(	B-X
ACTA1	B-X
)	B-X
,	B-X
myogenin/myogenic	B-X
factor	B-X
4	B-X
(	B-X
MYOG	B-X
)	B-X
,	B-X
embryonic	B-X
skeletal	B-X
muscle	B-X
myosin	B-X
heavy	B-X
chain	B-X
3	B-X
(	B-X
MYH3	B-X
)	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
creatine	B-X
phosphokinase	B-X
(	B-X
CK	B-X
)	B-X
.	B-X
The	B-X
geNorm	B-X
,	B-X
NormFinder	B-X
and	B-X
BestKeeper	B-X
software	B-X
programs	B-X
were	B-X
used	B-X
to	B-X
ascertain	B-X
the	B-X
most	B-X
suitable	B-X
RG	B-X
to	B-X
normalize	B-X
the	B-X
RNA	B-X
input	B-X
.	B-X

Standard	O
curve	O
analyses	O
were	O
performed	O
to	O
test	O
the	O
efficiency	O
of	O
the	O
amplifications	O
.	O
<EOS>	B-X
Diagnostic	B-X
test	B-X
method	B-X
must	B-X
have	B-X
sufficient	B-X
level	B-X
of	B-X
accuracy	B-X
for	B-X
detecting	B-X
malaria	B-X
parasites	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
diagnostic	B-X
accuracy	B-X
of	B-X
rapid	B-X
diagnostic	B-X
tests	B-X
(	B-X
RDTs	B-X
)	B-X
,	B-X
microscopy	B-X
,	B-X
loop-mediated	B-X
isothermal	B-X
amplification	B-X
(	B-X
LAMP	B-X
)	B-X
and/or	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
for	B-X
the	B-X
malaria	B-X
diagnosis	B-X
in	B-X
Ethiopia	B-X
.	B-X
Serum	B-X
samples	B-X
(	B-X
n	B-X
=	B-X
440	B-X
)	B-X
were	B-X
tested	B-X
by	B-X
PRV	B-X
gB/gE	B-X
blocking	B-X
ELISAs	B-X
(	B-X
Pseudorabies	B-X
Virus	B-X
gB	B-X
Antibody	B-X
Test	B-X
Kit	B-X
and	B-X
Pseudorabies	B-X
Virus	B-X
gpI	B-X
Antibody	B-X
Test	B-X
Kit	B-X
,	B-X
IDEXX	B-X
Laboratories	B-X
,	B-X
Inc.	B-X
,	B-X
Westbrook	B-X
,	B-X
ME	B-X
)	B-X
to	B-X
monitor	B-X
PRV	B-X
status	B-X
over	B-X
time	B-X
.	B-X
For	B-X
quantitative	B-X
analyses	B-X
,	B-X
PRV	B-X
PCR	B-X
quantification	B-X
cycle	B-X
(	B-X
Cq	B-X
)	B-X
results	B-X
were	B-X
re-expressed	B-X
as	B-X
``	B-X
efficiency	B-X
standardized	B-X
Cqs	B-X
(	B-X
ECqs	B-X
)	B-X
''	B-X
as	B-X
a	B-X
function	B-X
of	B-X
PCR	B-X
efficiency	B-X
using	B-X
plate-specific	B-X
positive	B-X
amplification	B-X
controls	B-X
.	B-X
ROC	B-X
analyses	B-X
of	B-X
the	B-X
PRV	B-X
gB	B-X
PCR	B-X
ECqs	B-X
results	B-X
showed	B-X
a	B-X
similar	B-X
performance	B-X
of	B-X
the	B-X
PRV	B-X
gB	B-X
PCR	B-X
for	B-X
nasal	B-X
swab	B-X
and	B-X
oral	B-X
fluid	B-X
specimens	B-X
(	B-X
area	B-X
under	B-X
the	B-X
ROC	B-X
curve	B-X
=	B-X
85	B-X
%	B-X
vs	B-X
83	B-X
%	B-X
)	B-X
and	B-X
,	B-X
based	B-X
on	B-X
an	B-X
ECq	B-X
cutoff	B-X
of	B-X
0.01	B-X
a	B-X
diagnostic	B-X
specificity	B-X
of	B-X
100	B-X
%	B-X
and	B-X
diagnostic	B-X
sensitivities	B-X
for	B-X
oral	B-X
fluid	B-X
and	B-X
nasal	B-X
swab	B-X
specimens	B-X
of	B-X
53	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
43	B-X
%	B-X
,	B-X
62	B-X
%	B-X
)	B-X
and	B-X
70	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
55	B-X
%	B-X
,	B-X
83	B-X
%	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X

Triplicates	O
were	O
done	O
for	O
each	O
PCR	O
reaction	O
.	O
<EOS>	B-X
Fluorescence	B-X
microscopy	B-X
was	B-X
then	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
all	B-X
the	B-X
DNA	B-X
present	B-X
on	B-X
the	B-X
slides	B-X
was	B-X
recovered	B-X
by	B-X
the	B-X
swabbing	B-X
operations	B-X
and	B-X
then	B-X
direct	B-X
PCR	B-X
,	B-X
using	B-X
the	B-X
Identifiler™	B-X
Plus	B-X
kit	B-X
,	B-X
was	B-X
used	B-X
to	B-X
ensure	B-X
that	B-X
none	B-X
of	B-X
the	B-X
DNA	B-X
present	B-X
on	B-X
swabs	B-X
was	B-X
lost	B-X
during	B-X
DNA	B-X
profiling	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
using	B-X
a	B-X
DNA	B-X
binding	B-X
dye	B-X
and	B-X
direct	B-X
PCR	B-X
allowed	B-X
an	B-X
accurate	B-X
means	B-X
of	B-X
measuring	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
individuals	B-X
exhibit	B-X
different	B-X
extents	B-X
of	B-X
shedding	B-X
.	B-X
At	B-X
each	B-X
time	B-X
point	B-X
(	B-X
48	B-X
h	B-X
,	B-X
2	B-X
weeks	B-X
,	B-X
and	B-X
3	B-X
weeks	B-X
)	B-X
,	B-X
DNA	B-X
elution	B-X
procedures	B-X
were	B-X
performed	B-X
on	B-X
the	B-X
cards	B-X
,	B-X
and	B-X
the	B-X
eluents	B-X
were	B-X
analyzed	B-X
by	B-X
conventional	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
using	B-X
trichomonad-specific	B-X
primers	B-X
.	B-X
Three	B-X
PCR-positive	B-X
samples	B-X
were	B-X
detected	B-X
at	B-X
48	B-X
h	B-X
from	B-X
one	B-X
isolate	B-X
;	B-X
however	B-X
,	B-X
all	B-X
eluents	B-X
from	B-X
cards	B-X
held	B-X
for	B-X
2	B-X
and	B-X
3	B-X
weeks	B-X
were	B-X
PCR-negative	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
use	B-X
of	B-X
FTA	B-X
Elute	B-X
cards	B-X
for	B-X
nucleic	B-X
acid	B-X
storage	B-X
can	B-X
lead	B-X
to	B-X
low	B-X
PCR	B-X
sensitivity	B-X
of	B-X
T.	B-X
gallinae	B-X
in	B-X
low	B-X
concentrations	B-X
,	B-X
such	B-X
as	B-X
those	B-X
found	B-X
in	B-X
non-clinical	B-X
birds	B-X
;	B-X
however	B-X
,	B-X
more	B-X
research	B-X
is	B-X
needed	B-X
to	B-X
fully	B-X
evaluate	B-X
the	B-X
efficacy	B-X
of	B-X
FTA	B-X
Elute	B-X
cards	B-X
as	B-X
a	B-X
diagnostic	B-X
tool	B-X
for	B-X
T.	B-X
gallinae	B-X
.	B-X

Relative	O
quantitative	O
values	O
were	O
calculated	O
in	O
the	O
ABI	O
Prism	O
7000	O
SDS	O
Software	O
(	O
Applied	O
Biosystems	O
)	O
and	O
normalized	O
to	O
GAPDH	B-Protein
in	O
Microsoft	O
Excel	O
(	O
Redmond	O
,	O
Washington	O
,	O
United	O
States	O
)	O
.	O

In	O
situ	O
hybridization	O
.	O
<EOS>	B-X
In	B-X
situ	B-X
hybridization	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
nucleotide	B-X
sequences	B-X
in	B-X
cells	B-X
,	B-X
tissue	B-X
sections	B-X
,	B-X
and	B-X
even	B-X
whole	B-X
tissue	B-X
.	B-X
In	B-X
situ	B-X
hybridization	B-X
is	B-X
extensively	B-X
used	B-X
in	B-X
research	B-X
,	B-X
as	B-X
well	B-X
as	B-X
clinical	B-X
applications	B-X
,	B-X
especially	B-X
for	B-X
diagnostic	B-X
purposes	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
basic	B-X
technique	B-X
of	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X
The	B-X
standard	B-X
in	B-X
situ	B-X
hybridization	B-X
process	B-X
is	B-X
reviewed	B-X
,	B-X
and	B-X
different	B-X
types	B-X
of	B-X
in	B-X
situ	B-X
hybridization	B-X
,	B-X
their	B-X
applications	B-X
,	B-X
and	B-X
advantages	B-X
and	B-X
disadvantages	B-X
are	B-X
discussed	B-X
.	B-X

Antisense	O
probes	O
were	O
designed	O
to	O
murine	O
epsilony	B-Protein
globin	I-Protein
nucleotides	O
509	O
-	O
584	O
;	O
betamaj	B-Protein
globin	I-Protein
nucleotides	O
458	O
-	O
549	O
;	O
and	O
mouse	O
Sox6	B-Protein
nucleotides	O
1353	O
-	O
1927	O
.	O

Embryos	O
were	O
fixed	O
overnight	O
by	O
immersion	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
embedded	O
in	O
paraffin	O
,	O
sectioned	O
at	O
5	O
mum	O
,	O
and	O
adhered	O
to	O
charge	O
modified	O
slides	O
(	O
VWR	O
,	O
West	O
Chester	O
,	O
Pennsylvania	O
,	O
United	O
States	O
)	O
.	O

Slides	O
were	O
processed	O
for	O
in	O
situ	O
hybridization	O
as	O
described	O
[	O
52	O
]	O
using	O
in	O
vitro	O
transcribed	O
RNA	O
probes	O
labeled	O
with	O
33P	O
.	O

Darkfield	O
and	O
brightfield	O
images	O
were	O
obtained	O
with	O
a	O
Nikon	O
Optiphot	O
microscope	O
(	O
Nikon	O
,	O
Melville	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
and	O
SPOT	O
RT	O
-	O
Slider	O
digital	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Sterling	O
Heights	O
,	O
Michigan	O
,	O
United	O
States	O
)	O
.	O

Objectives	O
used	O
were	O
1x	O
(	O
NA	O
=	O
0	O
.	O
04	O
)	O
and	O
10x	O
(	O
NA	O
=	O
0	O
.	O
5	O
)	O
.	O

Images	O
were	O
processed	O
,	O
pseudocolored	O
,	O
and	O
combined	O
using	O
Photoshop	O
(	O
Adobe	O
,	O
San	O
Jose	O
,	O
California	O
,	O
United	O
States	O
)	O
software	O
with	O
Fovea	O
Pro	O
(	O
Reindeer	O
Graphics	O
,	O
Asheville	O
,	O
North	O
Carolina	O
,	O
United	O
States	O
)	O
plugins	O
.	O

Original	O
images	O
are	O
available	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
the	B-X
N3	B-X
algorithm	B-X
,	B-X
we	B-X
also	B-X
make	B-X
the	B-X
source	B-X
code	B-X
,	B-X
testing	B-X
,	B-X
and	B-X
technical	B-X
documentation	B-X
of	B-X
our	B-X
contribution	B-X
,	B-X
which	B-X
we	B-X
denote	B-X
as	B-X
``	B-X
N4ITK	B-X
,	B-X
''	B-X
available	B-X
to	B-X
the	B-X
public	B-X
through	B-X
the	B-X
Insight	B-X
Toolkit	B-X
of	B-X
the	B-X
National	B-X
Institutes	B-X
of	B-X
Health	B-X
.	B-X
Performance	B-X
assessment	B-X
is	B-X
demonstrated	B-X
using	B-X
simulated	B-X
data	B-X
from	B-X
the	B-X
publicly	B-X
available	B-X
Brainweb	B-X
database	B-X
,	B-X
hyperpolarized	B-X
(	B-X
3	B-X
)	B-X
He	B-X
lung	B-X
image	B-X
data	B-X
,	B-X
and	B-X
9.4T	B-X
postmortem	B-X
hippocampus	B-X
data	B-X
.	B-X
To	B-X
help	B-X
convert	B-X
this	B-X
data	B-X
into	B-X
useful	B-X
summary	B-X
information	B-X
we	B-X
have	B-X
developed	B-X
an	B-X
automated	B-X
processing	B-X
and	B-X
QC	B-X
(	B-X
Quality	B-X
Control	B-X
)	B-X
pipeline	B-X
that	B-X
is	B-X
available	B-X
for	B-X
use	B-X
by	B-X
other	B-X
researchers	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
we	B-X
present	B-X
normative	B-X
data	B-X
for	B-X
a	B-X
set	B-X
of	B-X
39	B-X
original	B-X
clipart-style	B-X
images	B-X
that	B-X
can	B-X
be	B-X
used	B-X
as	B-X
material	B-X
in	B-X
studies	B-X
involving	B-X
judgements	B-X
of	B-X
proportion	B-X
.	B-X
The	B-X
original	B-X
images	B-X
are	B-X
drawings	B-X
that	B-X
depict	B-X
different	B-X
day-to-day	B-X
scenarios	B-X
(	B-X
e.g.	B-X
,	B-X
lighted	B-X
windows	B-X
in	B-X
a	B-X
building	B-X
;	B-X
books	B-X
on	B-X
a	B-X
shelf	B-X
)	B-X
and	B-X
each	B-X
has	B-X
seven	B-X
variants	B-X
of	B-X
different	B-X
proportions	B-X
(	B-X
from	B-X
20	B-X
%	B-X
to	B-X
80	B-X
%	B-X
)	B-X
belonging	B-X
to	B-X
different	B-X
categories	B-X
(	B-X
discrete	B-X
vs	B-X
continuous	B-X
;	B-X
social	B-X
vs	B-X
non-social	B-X
;	B-X
natural	B-X
vs	B-X
artificial	B-X
;	B-X
stimuli	B-X
physical	B-X
dimensions	B-X
;	B-X
number	B-X
of	B-X
referents	B-X
)	B-X
.	B-X
Normative	B-X
data	B-X
for	B-X
these	B-X
images	B-X
are	B-X
presented	B-X
in	B-X
an	B-X
interactive	B-X
database	B-X
(	B-X
available	B-X
at	B-X
https	B-X
:	B-X
//judgment-images-and-norms.shinyapps.io/estimates_interactive/	B-X
)	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
means	B-X
of	B-X
proportion	B-X
estimates	B-X
(	B-X
in	B-X
percentage	B-X
form	B-X
)	B-X
,	B-X
the	B-X
perceived	B-X
ease	B-X
of	B-X
making	B-X
such	B-X
estimates	B-X
,	B-X
the	B-X
perceived	B-X
level	B-X
of	B-X
familiarity	B-X
and	B-X
liking	B-X
for	B-X
each	B-X
image	B-X
,	B-X
and	B-X
the	B-X
relationships	B-X
between	B-X
these	B-X
variables	B-X
.	B-X
The	B-X
analyses	B-X
presented	B-X
in	B-X
this	B-X
paper	B-X
aim	B-X
to	B-X
aid	B-X
readers	B-X
in	B-X
selecting	B-X
images	B-X
that	B-X
enable	B-X
them	B-X
to	B-X
better	B-X
address	B-X
specific	B-X
influences	B-X
on	B-X
proportional	B-X
estimates	B-X
or	B-X
to	B-X
control	B-X
for	B-X
those	B-X
influences	B-X
in	B-X
their	B-X
studies	B-X
.	B-X

Histology	O
.	O
<EOS>	B-X
Atlas	B-X
of	B-X
Animal	B-X
Anatomy	B-X
and	B-X
Histology	B-X
.	B-X
[	B-X
Comparative	B-X
histology	B-X
]	B-X
.	B-X
Research	B-X
in	B-X
anatomy	B-X
.	B-X
Snail	B-X
nervous	B-X
system	B-X
:	B-X
from	B-X
classical	B-X
histology	B-X
to	B-X
chemical	B-X
and	B-X
molecular	B-X
neuroanatomy	B-X
.	B-X

18	O
.	O
5	O
-	O
dpc	O
embryos	O
were	O
exsanguinated	O
and	O
peripheral	O
blood	O
smears	O
were	O
prepared	O
from	O
both	O
mutant	O
and	O
WT	O
mice	O
.	O

The	O
slides	O
were	O
Wright	O
-	O
stained	O
and	O
read	O
by	O
DAF	O
.	O

For	O
whole	O
mount	O
analysis	O
,	O
14	O
.	O
5	O
-	O
dpc	O
WT	O
and	O
mutant	O
embryos	O
,	O
and	O
postnatal	O
day	O
-	O
10	O
.	O
5	O
mice	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
,	O
paraffin	O
-	O
embedded	O
,	O
sectioned	O
at	O
5	O
mum	O
,	O
and	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O

Liver	O
samples	O
(	O
at	O
14	O
.	O
5	O
dpc	O
and	O
18	O
.	O
5	O
dpc	O
)	O
were	O
prepared	O
in	O
a	O
similar	O
manner	O
.	O

Images	O
were	O
obtained	O
with	O
Nikon	O
Labophot	O
-	O
2	O
microscope	O
.	O

Objectives	O
used	O
were	O
E	O
Plan	O
40	O
/	O
0	O
.	O
65	O
160	O
/	O
0	O
.	O
17	O
Nikon	O
(	O
40x	O
objective	O
)	O
,	O
E	O
Plan	O
100	O
/	O
1	O
.	O
25	O
oil	O
160	O
/	O
0	O
.	O
17	O
Nikon	O
(	O
100x	O
objective	O
)	O
.	O

The	O
camera	O
was	O
a	O
Nikon	O
Coolpix	O
4300	O
.	O

Original	O
images	O
are	O
available	O
.	O
<EOS>	B-X
Similar	B-X
to	B-X
the	B-X
N3	B-X
algorithm	B-X
,	B-X
we	B-X
also	B-X
make	B-X
the	B-X
source	B-X
code	B-X
,	B-X
testing	B-X
,	B-X
and	B-X
technical	B-X
documentation	B-X
of	B-X
our	B-X
contribution	B-X
,	B-X
which	B-X
we	B-X
denote	B-X
as	B-X
``	B-X
N4ITK	B-X
,	B-X
''	B-X
available	B-X
to	B-X
the	B-X
public	B-X
through	B-X
the	B-X
Insight	B-X
Toolkit	B-X
of	B-X
the	B-X
National	B-X
Institutes	B-X
of	B-X
Health	B-X
.	B-X
Performance	B-X
assessment	B-X
is	B-X
demonstrated	B-X
using	B-X
simulated	B-X
data	B-X
from	B-X
the	B-X
publicly	B-X
available	B-X
Brainweb	B-X
database	B-X
,	B-X
hyperpolarized	B-X
(	B-X
3	B-X
)	B-X
He	B-X
lung	B-X
image	B-X
data	B-X
,	B-X
and	B-X
9.4T	B-X
postmortem	B-X
hippocampus	B-X
data	B-X
.	B-X
To	B-X
help	B-X
convert	B-X
this	B-X
data	B-X
into	B-X
useful	B-X
summary	B-X
information	B-X
we	B-X
have	B-X
developed	B-X
an	B-X
automated	B-X
processing	B-X
and	B-X
QC	B-X
(	B-X
Quality	B-X
Control	B-X
)	B-X
pipeline	B-X
that	B-X
is	B-X
available	B-X
for	B-X
use	B-X
by	B-X
other	B-X
researchers	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
we	B-X
present	B-X
normative	B-X
data	B-X
for	B-X
a	B-X
set	B-X
of	B-X
39	B-X
original	B-X
clipart-style	B-X
images	B-X
that	B-X
can	B-X
be	B-X
used	B-X
as	B-X
material	B-X
in	B-X
studies	B-X
involving	B-X
judgements	B-X
of	B-X
proportion	B-X
.	B-X
The	B-X
original	B-X
images	B-X
are	B-X
drawings	B-X
that	B-X
depict	B-X
different	B-X
day-to-day	B-X
scenarios	B-X
(	B-X
e.g.	B-X
,	B-X
lighted	B-X
windows	B-X
in	B-X
a	B-X
building	B-X
;	B-X
books	B-X
on	B-X
a	B-X
shelf	B-X
)	B-X
and	B-X
each	B-X
has	B-X
seven	B-X
variants	B-X
of	B-X
different	B-X
proportions	B-X
(	B-X
from	B-X
20	B-X
%	B-X
to	B-X
80	B-X
%	B-X
)	B-X
belonging	B-X
to	B-X
different	B-X
categories	B-X
(	B-X
discrete	B-X
vs	B-X
continuous	B-X
;	B-X
social	B-X
vs	B-X
non-social	B-X
;	B-X
natural	B-X
vs	B-X
artificial	B-X
;	B-X
stimuli	B-X
physical	B-X
dimensions	B-X
;	B-X
number	B-X
of	B-X
referents	B-X
)	B-X
.	B-X
Normative	B-X
data	B-X
for	B-X
these	B-X
images	B-X
are	B-X
presented	B-X
in	B-X
an	B-X
interactive	B-X
database	B-X
(	B-X
available	B-X
at	B-X
https	B-X
:	B-X
//judgment-images-and-norms.shinyapps.io/estimates_interactive/	B-X
)	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
means	B-X
of	B-X
proportion	B-X
estimates	B-X
(	B-X
in	B-X
percentage	B-X
form	B-X
)	B-X
,	B-X
the	B-X
perceived	B-X
ease	B-X
of	B-X
making	B-X
such	B-X
estimates	B-X
,	B-X
the	B-X
perceived	B-X
level	B-X
of	B-X
familiarity	B-X
and	B-X
liking	B-X
for	B-X
each	B-X
image	B-X
,	B-X
and	B-X
the	B-X
relationships	B-X
between	B-X
these	B-X
variables	B-X
.	B-X
The	B-X
analyses	B-X
presented	B-X
in	B-X
this	B-X
paper	B-X
aim	B-X
to	B-X
aid	B-X
readers	B-X
in	B-X
selecting	B-X
images	B-X
that	B-X
enable	B-X
them	B-X
to	B-X
better	B-X
address	B-X
specific	B-X
influences	B-X
on	B-X
proportional	B-X
estimates	B-X
or	B-X
to	B-X
control	B-X
for	B-X
those	B-X
influences	B-X
in	B-X
their	B-X
studies	B-X
.	B-X

Northern	O
blot	O
.	O
<EOS>	B-X
Successful	B-X
detection	B-X
of	B-X
very	B-X
small	B-X
RNAs	B-X
(	B-X
tiny	B-X
RNAs	B-X
,	B-X
~8-15	B-X
nt	B-X
in	B-X
length	B-X
)	B-X
by	B-X
northern	B-X
blotting	B-X
depends	B-X
on	B-X
tailored	B-X
protocols	B-X
with	B-X
respect	B-X
to	B-X
transfer	B-X
and	B-X
immobilization	B-X
on	B-X
membranes	B-X
as	B-X
well	B-X
as	B-X
design	B-X
of	B-X
sensitive	B-X
detection	B-X
probes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
northern	B-X
blot	B-X
detection	B-X
of	B-X
tiny	B-X
RNAs	B-X
with	B-X
5'-digoxigenin-labeled	B-X
DNA/LNA	B-X
mixmer	B-X
probes	B-X
is	B-X
a	B-X
highly	B-X
sensitive	B-X
and	B-X
specific	B-X
method	B-X
and	B-X
,	B-X
in	B-X
our	B-X
hands	B-X
,	B-X
more	B-X
sensitive	B-X
than	B-X
using	B-X
a	B-X
corresponding	B-X
DNA/LNA	B-X
mixmer	B-X
probe	B-X
with	B-X
a	B-X
5'-	B-X
Northern	B-X
blot	B-X
analysis	B-X
of	B-X
large	B-X
mRNAs	B-X
.	B-X
Northern	B-X
blotting	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
technique	B-X
to	B-X
study	B-X
sRNAs	B-X
because	B-X
it	B-X
is	B-X
quantitative	B-X
,	B-X
relatively	B-X
inexpensive	B-X
,	B-X
and	B-X
readily	B-X
available	B-X
for	B-X
most	B-X
laboratories	B-X
.	B-X
This	B-X
chapter	B-X
describes	B-X
the	B-X
protocols	B-X
for	B-X
radioactive	B-X
and	B-X
non-radioactive	B-X
sRNA	B-X
Northern	B-X
blot	B-X
analysis	B-X
,	B-X
which	B-X
includes	B-X
RNA	B-X
extraction	B-X
,	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
,	B-X
membrane	B-X
transfer	B-X
,	B-X
hybridisation	B-X
and	B-X
detection	B-X
of	B-X
sRNA	B-X
using	B-X
oligonucleotide	B-X
probes	B-X
.	B-X

A	O
mouse	O
embryonic	O
tissue	O
Northern	O
blot	O
filter	O
(	O
Seegene	O
,	O
Rockville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
was	O
hybridized	O
with	O
a	O
Sox6	B-Protein
probe	O
generated	O
by	O
RT	O
-	O
PCR	O
(	O
nucleotides	O
1353	O
-	O
1927	O
)	O
and	O
labeled	O
with	O
[	O
alpha	O
-	O
32P	O
]	O
dCTP	O
,	O
by	O
random	O
primer	O
labeling	O
(	O
RediprimeII	O
;	O
Amersham	O
Biosciences	O
,	O
Buckinghamshire	O
,	O
England	O
,	O
United	O
Kingdom	O
)	O
.	O

The	O
hybridization	O
was	O
performed	O
in	O
phosphate	O
buffered	O
7	O
%	O
SDS	O
hybridization	O
solution	O
.	O

Blots	O
were	O
washed	O
with	O
0	O
.	O
2x	O
SSC	O
,	O
1	O
%	O
SDS	O
at	O
60	O
degreesC	O
prior	O
to	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
(	O
Kodak	O
,	O
Rochester	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
at	O
-	O
80	O
degreesC	O
for	O
6	O
d	O
.	O

Cell	O
culture	O
and	O
transfection	O
.	O
<EOS>	B-X
First	B-X
,	B-X
optimal	B-X
transfection	B-X
conditions	B-X
are	B-X
determined	B-X
on	B-X
a	B-X
small-scale	B-X
,	B-X
using	B-X
adherent	B-X
cells	B-X
.	B-X
These	B-X
conditions	B-X
are	B-X
then	B-X
translated	B-X
for	B-X
use	B-X
in	B-X
large-scale	B-X
suspension	B-X
cultures	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
transfection	B-X
reagents	B-X
and	B-X
nanoparticles	B-X
is	B-X
often	B-X
assessed	B-X
by	B-X
measuring	B-X
levels	B-X
of	B-X
expressed	B-X
reporter	B-X
protein	B-X
.	B-X
Monitoring	B-X
changes	B-X
in	B-X
live	B-X
cells	B-X
during	B-X
and	B-X
after	B-X
transfection	B-X
offer	B-X
opportunities	B-X
to	B-X
reveal	B-X
related	B-X
mechanisms	B-X
,	B-X
efficacy	B-X
,	B-X
and	B-X
bottlenecks	B-X
of	B-X
transfection.In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
experimental	B-X
setup	B-X
and	B-X
considerations	B-X
for	B-X
in	B-X
vitro	B-X
screening	B-X
of	B-X
delivery	B-X
vectors	B-X
.	B-X

GM979	O
cells	O
(	O
Coriell	O
Cell	O
Repositories	O
,	O
Camden	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
were	O
cultured	O
in	O
Ham	O
'	O
s	O
F12	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Ivitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
penicillin	O
(	O
100	O
units	O
/	O
ml	O
)	O
,	O
streptomycin	O
100	O
mug	O
/	O
ml	O
)	O
,	O
and	O
L	O
-	O
glutamine	O
(	O
2	O
mM	O
)	O
.	O

MEL	O
cells	O
were	O
cultured	O
in	O
DMEM	O
supplemented	O
as	O
above	O
(	O
without	O
heat	O
inactivating	O
the	O
serum	O
)	O
.	O

GM979	O
cells	O
(	O
4	O
x	O
105	O
)	O
in	O
log	O
phase	O
of	O
growth	O
were	O
transfected	O
with	O
plasmids	O
by	O
FuGENE6	O
(	O
Roche	O
,	O
Indianapolis	O
,	O
Indiana	O
,	O
United	O
States	O
)	O
.	O

Cells	O
were	O
transfected	O
with	O
epsilony	B-Protein
promoter	O
reporter	O
constructs	O
(	O
500	O
ng	O
)	O
along	O
with	O
either	O
empty	O
vector	O
or	O
Sox6	B-Protein
overexpression	O
vector	O
(	O
1000	O
ng	O
)	O
.	O

In	O
assays	O
of	O
dosage	O
effect	O
,	O
we	O
used	O
200	O
ng	O
,	O
500	O
ng	O
,	O
and	O
1000	O
ng	O
)	O
.	O
<EOS>	B-X
Micronutrients	B-X
Dietary	B-X
Supplementation	B-X
Advices	B-X
for	B-X
Celiac	B-X
Patients	B-X
on	B-X
Long-Term	B-X
Gluten-Free	B-X
Diet	B-X
with	B-X
Good	B-X
Compliance	B-X
:	B-X
A	B-X
Review	B-X
.	B-X
Itraconazole	B-X
(	B-X
ITCZ	B-X
)	B-X
is	B-X
used	B-X
to	B-X
treat	B-X
pulmonary	B-X
aspergillosis	B-X
,	B-X
but	B-X
findings	B-X
regarding	B-X
the	B-X
range	B-X
of	B-X
effective	B-X
plasma	B-X
concentrations	B-X
are	B-X
often	B-X
contradictory	B-X
.	B-X
This	B-X
study	B-X
attempted	B-X
to	B-X
determine	B-X
effective	B-X
plasma	B-X
concentrations	B-X
of	B-X
ITCZ	B-X
and	B-X
its	B-X
active	B-X
metabolite	B-X
hydroxyitraconazole	B-X
(	B-X
OH-ITCZ	B-X
)	B-X
by	B-X
retrospectively	B-X
analyzing	B-X
their	B-X
relationships	B-X
to	B-X
clinical	B-X
efficacy	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
prandial	B-X
status	B-X
and	B-X
caloric	B-X
and	B-X
fat	B-X
composition	B-X
of	B-X
meals	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
lurasidone	B-X
.	B-X

pRL	O
-	O
CMV	O
15ng	O
(	O
Promega	O
)	O
was	O
used	O
as	O
a	O
control	O
for	O
transfection	O
efficiency	O
.	O

Nuclear	O
protein	O
extract	O
and	O
in	O
vitro	O
translation	O
of	O
Sox6	B-Protein
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
attempted	B-X
to	B-X
identify	B-X
and	B-X
characterize	B-X
the	B-X
embryonic	B-X
promoter	B-X
of	B-X
Sox6	B-X
,	B-X
a	B-X
determinant	B-X
regulator	B-X
of	B-X
chondrogenic	B-X
differentiation	B-X
.	B-X
A	B-X
common	B-X
transcription	B-X
start	B-X
region	B-X
for	B-X
human	B-X
and	B-X
mouse	B-X
Sox6	B-X
was	B-X
initially	B-X
identified	B-X
,	B-X
which	B-X
contained	B-X
a	B-X
highly	B-X
conserved	B-X
sequence	B-X
,	B-X
A-box	B-X
.	B-X
Overexpressed	B-X
C/EBPbeta	B-X
activated	B-X
the	B-X
Sox6	B-X
promoter	B-X
,	B-X
and	B-X
mutant	B-X
4xCES6	B-X
constructs	B-X
lacking	B-X
the	B-X
C/EBP	B-X
motif	B-X
lost	B-X
their	B-X
basal	B-X
activity	B-X
.	B-X
CES6	B-X
and	B-X
nuclear	B-X
extracts	B-X
formed	B-X
a	B-X
specific	B-X
complex	B-X
,	B-X
which	B-X
was	B-X
supershifted	B-X
by	B-X
anti-C/EBPbeta	B-X
antibody	B-X
,	B-X
and	B-X
in	B-X
vitro	B-X
translated	B-X
C/EBPbeta	B-X
specifically	B-X
bound	B-X
to	B-X
CES6	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
successfully	B-X
identified	B-X
the	B-X
Sox6	B-X
promoter	B-X
and	B-X
its	B-X
core	B-X
enhancer	B-X
and	B-X
characterized	B-X
the	B-X
interactions	B-X
with	B-X
regulatory	B-X
transcription	B-X
factors	B-X
.	B-X

Nuclear	O
extracts	O
were	O
prepared	O
from	O
MEL	O
cells	O
(	O
2	O
x	O
107	O
)	O
using	O
a	O
kit	O
(	O
Active	O
Motif	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

The	O
Sox6	B-Protein
in	O
vitro	O
translation	O
expression	O
vector	O
,	O
tagged	O
with	O
c	B-Protein
-	I-Protein
Myc	I-Protein
and	O
HA	B-Protein
,	O
was	O
described	O
before	O
[	O
15	O
]	O
.	O

The	O
translation	O
was	O
performed	O
in	O
a	O
reticulocyte	O
lysate	O
based	O
in	O
vitro	O
translational	O
system	O
(	O
TNT	O
(	O
R	O
)	O
Quick	O
Coupled	O
Transcription	O
/	O
Translation	O
Systems	O
,	O
Promega	O
)	O
.	O

A	O
vector	O
without	O
the	O
Sox6	B-Protein
coding	O
sequence	O
was	O
also	O
translated	O
as	O
a	O
negative	O
control	O
.	O

Antibodies	O
.	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
Structure	B-X
of	B-X
antibodies	B-X
.	B-X
Antibodies	B-X
can	B-X
also	B-X
be	B-X
modified	B-X
to	B-X
deliver	B-X
toxic	B-X
or	B-X
modulatory	B-X
payloads	B-X
(	B-X
small	B-X
molecules	B-X
,	B-X
radionuclides	B-X
and	B-X
enzymes	B-X
)	B-X
and	B-X
engineered	B-X
to	B-X
bind	B-X
multiple	B-X
epitopes	B-X
(	B-X
bispecifics	B-X
)	B-X
or	B-X
even	B-X
to	B-X
have	B-X
novel	B-X
catalytic	B-X
activity	B-X
(	B-X
abzymes	B-X
)	B-X
.	B-X

Sox6	B-Protein
antibodies	O
used	O
in	O
this	O
study	O
were	O
either	O
kindly	O
provided	O
by	O
Dr	O
.	O
Enzo	O
Lalli	O
(	O
Universite	O
Louis	O
Pasteur	O
,	O
France	O
[	O
7	O
]	O
)	O
or	O
commercially	O
obtained	O
(	O
Catalog	O
No	O
.	O
sc	O
-	O
17332	O
X	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

All	O
Sox6	B-Protein
antibodies	O
generated	O
similar	O
results	O
.	O

c	B-Protein
-	I-Protein
Myc	I-Protein
antibody	O
was	O
purchased	O
from	O
Invitrogen	O
.	O

Normal	O
rabbit	O
IgG	O
antibody	O
was	O
obtained	O
from	O
Upstate	O
Biotechnology	O
(	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
.	O

EMSA	O
.	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
to	B-X
detect	B-X
formation	B-X
of	B-X
complexes	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
and	B-X
to	B-X
determine	B-X
,	B-X
among	B-X
other	B-X
parameters	B-X
,	B-X
equilibrium	B-X
constants	B-X
for	B-X
the	B-X
interaction	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
commonly	B-X
used	B-X
for	B-X
the	B-X
study	B-X
of	B-X
nucleic	B-X
acid-binding	B-X
proteins	B-X
.	B-X
A	B-X
major	B-X
disadvantage	B-X
of	B-X
the	B-X
EMSA	B-X
is	B-X
that	B-X
it	B-X
does	B-X
not	B-X
always	B-X
provide	B-X
an	B-X
absolute	B-X
certitude	B-X
that	B-X
the	B-X
band	B-X
shift	B-X
is	B-X
due	B-X
to	B-X
the	B-X
protein	B-X
under	B-X
scrutiny	B-X
,	B-X
as	B-X
contaminants	B-X
in	B-X
the	B-X
sample	B-X
could	B-X
also	B-X
cause	B-X
the	B-X
band	B-X
shift	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
a	B-X
variation	B-X
of	B-X
the	B-X
standard	B-X
EMSA	B-X
allowing	B-X
to	B-X
visualize	B-X
with	B-X
added	B-X
certitude	B-X
,	B-X
the	B-X
co-localized	B-X
band	B-X
shifts	B-X
of	B-X
a	B-X
GFP-tagged	B-X
protein	B-X
binding	B-X
to	B-X
its	B-X
cognate	B-X
nucleic	B-X
acid	B-X
target	B-X
sequence	B-X
stained	B-X
with	B-X
an	B-X
intercalator	B-X
,	B-X
such	B-X
as	B-X
GelRed	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
present	B-X
an	B-X
illustrative	B-X
protocol	B-X
of	B-X
this	B-X
useful	B-X
technique	B-X
called	B-X
GFP-EMSA	B-X
along	B-X
with	B-X
specific	B-X
notes	B-X
on	B-X
its	B-X
advantages	B-X
and	B-X
limitations	B-X
.	B-X

Single	O
-	O
stranded	O
complementary	O
oligonucleotides	O
were	O
annealed	O
and	O
end	O
-	O
labeled	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
with	O
T4	B-Protein
polynucleotide	I-Protein
kinase	I-Protein
.	O

EMSA	O
was	O
performed	O
with	O
5	O
mug	O
of	O
nuclear	O
proteins	O
from	O
MEL	O
cells	O
or	O
3	O
mul	O
of	O
in	O
vitro	O
-	O
translated	O
Sox6	B-Protein
along	O
with	O
the	O
reticulocyte	O
lysate	O
in	O
binding	O
buffer	O
:	O
100	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
200	O
ng	O
/	O
mul	O
BSA	B-Protein
,	O
50	O
ng	O
/	O
mul	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
or	O
poly	O
(	O
dG	O
-	O
dC	O
)	O
,	O
10	O
mM	O
HEPES	O
(	O
pH	O
7	O
)	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
25	O
mM	O
DTT	O
,	O
0	O
.	O
6	O
mM	O
MgCl2	O
.	O

For	O
competition	O
or	O
supershift	O
assays	O
,	O
the	O
indicated	O
unlabelled	O
oligonucleotide	O
competitor	O
(	O
200	O
-	O
fold	O
molar	O
excess	O
)	O
or	O
antibody	O
(	O
3	O
mul	O
)	O
was	O
added	O
30	O
min	O
to	O
60	O
min	O
prior	O
to	O
addition	O
of	O
radiolabeled	O
probe	O
.	O

Following	O
addition	O
of	O
the	O
radiolabeled	O
probe	O
,	O
the	O
samples	O
were	O
incubated	O
for	O
30	O
min	O
or	O
60	O
min	O
at	O
room	O
temperature	O
and	O
loaded	O
on	O
a	O
4	O
%	O
or	O
6	O
%	O
(	O
w	O
/	O
v	O
)	O
polyacrylamide	O
gel	O
.	O

Electrophoresis	O
was	O
performed	O
at	O
a	O
constant	O
19	O
mAmp	O
for	O
4	O
-	O
8	O
h	O
at	O
room	O
temperature	O
,	O
and	O
the	O
gels	O
were	O
dried	O
prior	O
to	O
autoradiography	O
.	O

Antibodies	O
used	O
for	O
supershift	O
analyses	O
included	O
c	B-Protein
-	I-Protein
Myc	I-Protein
,	O
HA	B-Protein
,	O
and	O
Sox6	B-Protein
antibodies	O
(	O
described	O
as	O
above	O
)	O
.	O

The	O
DNA	O
sequences	O
of	O
the	O
oligonucleotides	O
are	O
as	O
follows	O
(	O
only	O
forward	O
oligos	O
are	O
listed	O
)	O
:	O
For	O
the	O
36	O
-	O
bp	O
WT	O
probe	O
:	O
5	O
'	O
AATGCAGAACAAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1556	O
)	O
;	O
for	O
mutant	O
probe	O
1	O
(	O
M1	O
)	O
:	O
5	O
'	O
AACAAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1644	O
)	O
;	O
for	O
mutant	O
probe	O
2	O
(	O
M2	O
)	O
:	O
5	O
'	O
AATGCAGAACAAAGGGTCAGAtgagTGTCTGCGAAG3	O
'	O
(	O
MHB1648	O
)	O
;	O
for	O
mutant	O
probe	O
3	O
(	O
M3	O
)	O
:	O
5	O
'	O
AATGCAGtgccAAGGGTCAGAACATTGTCTGCGAAG3	O
'	O
(	O
MHB1650	O
)	O
.	O

ChIP	O
assay	O
.	O
<EOS>	B-X
Owing	B-X
to	B-X
its	B-X
digital	B-X
nature	B-X
,	B-X
ChIP-seq	B-X
has	B-X
become	B-X
the	B-X
standard	B-X
method	B-X
for	B-X
genome-wide	B-X
ChIP	B-X
analysis	B-X
.	B-X
The	B-X
densities	B-X
of	B-X
recovered	B-X
ChIP	B-X
sequence	B-X
reads	B-X
along	B-X
the	B-X
genome	B-X
are	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
binding	B-X
sites	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Although	B-X
a	B-X
relatively	B-X
small	B-X
amount	B-X
of	B-X
ChIP	B-X
DNA	B-X
is	B-X
required	B-X
for	B-X
ChIP-seq	B-X
,	B-X
the	B-X
current	B-X
sequencing	B-X
platforms	B-X
still	B-X
require	B-X
amplification	B-X
of	B-X
the	B-X
ChIP	B-X
DNA	B-X
by	B-X
ligation-mediated	B-X
PCR	B-X
(	B-X
LM-PCR	B-X
)	B-X
.	B-X
This	B-X
protocol	B-X
,	B-X
which	B-X
involves	B-X
linker	B-X
ligation	B-X
followed	B-X
by	B-X
size	B-X
selection	B-X
,	B-X
is	B-X
the	B-X
standard	B-X
ChIP-seq	B-X
protocol	B-X
using	B-X
an	B-X
Illumina	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
size-selected	B-X
ChIP	B-X
DNA	B-X
is	B-X
amplified	B-X
by	B-X
LM-PCR	B-X
and	B-X
size-selected	B-X
for	B-X
the	B-X
second	B-X
time	B-X
.	B-X
The	B-X
purified	B-X
ChIP	B-X
DNA	B-X
is	B-X
then	B-X
loaded	B-X
into	B-X
the	B-X
Genome	B-X
Analyzer	B-X
.	B-X
The	B-X
ChIP	B-X
DNA	B-X
can	B-X
also	B-X
be	B-X
processed	B-X
in	B-X
parallel	B-X
for	B-X
ChIP-chip	B-X
results	B-X
.	B-X

As	O
described	O
by	O
Nouzova	O
[	O
53	O
]	O
,	O
in	O
brief	O
:	O
Cells	O
from	O
MEL	O
cells	O
(	O
4	O
x	O
107	O
)	O
or	O
fetal	O
liver	O
cells	O
from	O
three	O
15	O
.	O
5	O
-	O
dpc	O
WT	O
mice	O
were	O
treated	O
with	O
1	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
37	O
degreesC	O
,	O
rinsed	O
in	O
ice	O
-	O
cold	O
1x	O
Hanks	O
'	O
balanced	O
salt	O
solution	O
with	O
0	O
.	O
1	O
%	O
EDTA	O
containing	O
protease	O
inhibitors	O
,	O
collected	O
by	O
centrifugation	O
at	O
4	O
degreesC	O
,	O
resuspended	O
in	O
a	O
SDS	O
lysis	O
buffer	O
containing	O
protease	O
inhibitors	O
,	O
and	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
.	O

DNA	O
-	O
protein	O
complexes	O
were	O
sonicated	O
to	O
200	O
and	O
600	O
bp	O
.	O

One	O
-	O
tenth	O
of	O
the	O
sample	O
was	O
set	O
aside	O
for	O
input	O
control	O
,	O
and	O
the	O
remaining	O
sample	O
was	O
precleared	O
with	O
protein	B-Protein
A	I-Protein
-	O
Sepharose	O
(	O
Amersham	O
Biosciences	O
,	O
Piscataway	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
.	O

Following	O
preclearing	O
,	O
the	O
samples	O
were	O
split	O
into	O
thirds	O
:	O
one	O
sample	O
treated	O
with	O
anti	O
-	O
Sox6	B-Protein
,	O
a	O
second	O
treated	O
with	O
normal	O
rabbit	O
IgG	O
,	O
and	O
the	O
third	O
sample	O
without	O
Ab	O
.	O

The	O
last	O
two	O
were	O
used	O
as	O
negative	O
controls	O
.	O
<EOS>	B-X
Positive	B-X
Psychology	B-X
and	B-X
Gratitude	B-X
Interventions	B-X
:	B-X
A	B-X
Randomized	B-X
Clinical	B-X
Trial	B-X
.	B-X
The	B-X
approach	B-X
assumes	B-X
that	B-X
greater	B-X
awareness	B-X
will	B-X
provide	B-X
more	B-X
veridical	B-X
perception	B-X
,	B-X
reduce	B-X
negative	B-X
affect	B-X
and	B-X
improve	B-X
vitality	B-X
and	B-X
coping	B-X
.	B-X
In	B-X
the	B-X
last	B-X
two	B-X
decades	B-X
,	B-X
a	B-X
number	B-X
of	B-X
research	B-X
reports	B-X
appeared	B-X
that	B-X
seem	B-X
to	B-X
support	B-X
many	B-X
of	B-X
these	B-X
claims	B-X
.	B-X
Infections	B-X
caused	B-X
by	B-X
multidrug-resistant	B-X
bacteria	B-X
are	B-X
associated	B-X
with	B-X
prolonged	B-X
hospital	B-X
stay	B-X
and	B-X
death	B-X
compared	B-X
with	B-X
infections	B-X
caused	B-X
by	B-X
susceptible	B-X
bacteria	B-X
.	B-X

The	O
chromatin	O
-	O
antibody	O
complexes	O
were	O
eluted	O
,	O
and	O
the	O
DNA	O
protein	O
cross	O
-	O
links	O
were	O
reversed	O
with	O
5	O
M	O
NaCl	O
at	O
65	O
degreesC	O
for	O
4	O
h	O
.	O

Input	O
DNA	O
or	O
immunoprecipitated	O
DNA	O
was	O
used	O
as	O
a	O
template	O
in	O
the	O
PCR	O
reaction	O
.	O
<EOS>	B-X
Nine	B-X
formalin-fixed	B-X
paraffin-embedded	B-X
(	B-X
FFPE	B-X
)	B-X
DNA	B-X
extraction	B-X
methods	B-X
were	B-X
evaluated	B-X
using	B-X
twelve	B-X
FFPE	B-X
samples	B-X
of	B-X
varying	B-X
tissue	B-X
types	B-X
.	B-X
Quality	B-X
assessment	B-X
included	B-X
total	B-X
yield	B-X
,	B-X
percent	B-X
dsDNA	B-X
,	B-X
fragment	B-X
analysis	B-X
and	B-X
multiplex	B-X
PCR	B-X
.	B-X
After	B-X
assessment	B-X
,	B-X
three	B-X
tissue	B-X
types	B-X
from	B-X
four	B-X
FFPE	B-X
DNA	B-X
methods	B-X
were	B-X
selected	B-X
for	B-X
NGS	B-X
downstream	B-X
evaluation	B-X
,	B-X
targeted	B-X
and	B-X
whole	B-X
exome	B-X
sequencing	B-X
.	B-X
Analysis	B-X
revealed	B-X
average	B-X
coverage	B-X
across	B-X
the	B-X
target	B-X
regions	B-X
for	B-X
WES	B-X
was	B-X
~20-30X	B-X
for	B-X
all	B-X
four	B-X
FFPE	B-X
DNA	B-X
extraction	B-X
methods	B-X
.	B-X
The	B-X
genotype	B-X
concordance	B-X
was	B-X
99	B-X
%	B-X
for	B-X
the	B-X
commonly	B-X
called	B-X
variant	B-X
positions	B-X
between	B-X
all	B-X
four	B-X
extraction	B-X
methods	B-X
with	B-X
the	B-X
targeted	B-X
PCR	B-X
NGS	B-X
panel	B-X
and	B-X
96	B-X
%	B-X
with	B-X
WES	B-X
.	B-X
Assessing	B-X
quality	B-X
of	B-X
extracted	B-X
DNA	B-X
aids	B-X
in	B-X
selecting	B-X
the	B-X
optimal	B-X
NGS	B-X
approach	B-X
,	B-X
and	B-X
the	B-X
choice	B-X
of	B-X
both	B-X
DNA	B-X
extraction	B-X
and	B-X
library	B-X
preparation	B-X
approaches	B-X
can	B-X
impact	B-X
the	B-X
performance	B-X
of	B-X
archival	B-X
tissue	B-X
in	B-X
NGS	B-X
.	B-X

PCR	O
amplification	O
of	O
the	O
epsilony	B-Protein
promoter	O
was	O
performed	O
and	O
yielded	O
a	O
172	O
-	O
bp	O
amplicon	O
,	O
corresponding	O
to	O
nucleotides	O
-	O
31	O
to	O
+	O
140	O
of	O
the	O
epsilony	B-Protein
promoter	O
(	O
primers	O
MHB1688	O
,	O
5	O
'	O
CGAAGAATAAAAGGCCACCA3	O
'	O
;	O
and	O
MHB1689	O
,	O
5	O
'	O
GCTTCACCACCAACCTCTTC3	O
'	O
)	O
.	O

PCR	O
was	O
performed	O
under	O
the	O
following	O
conditions	O
:	O
95	O
degreesC	O
for	O
15	O
min	O
followed	O
by	O
30	O
cycles	O
at	O
95	O
degreesC	O
for	O
30	O
s	O
,	O
60	O
degreesC	O
for	O
30	O
s	O
,	O
and	O
72	O
degreesC	O
for	O
45	O
s	O
,	O
ending	O
with	O
a	O
final	O
extension	O
at	O
72	O
degreesC	O
for	O
5	O
min	O
.	O

beta	O
-	O
(	O
1	O
-	O
>	O
3	O
)	O
-	O
D	O
-	O
glucan	O
modulates	O
DNA	O
binding	O
of	O
nuclear	O
factors	O
kappaB	O
,	O
AT	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
leading	O
to	O
an	O
anti	O
-	O
inflammatory	O
shift	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
ratio	O

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
represent	O
a	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
and	O
are	O
able	O
to	O
modify	O
biological	O
responses	O
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X

Employing	O
a	O
comprehensive	O
methodological	O
approach	O
,	O
the	O
aim	O
of	O
our	O
in	O
vitro	O
study	O
was	O
to	O
elucidate	O
novel	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
human	O
peripheral	O
blood	O
immune	O
cells	O
mediated	O
by	O
a	O
fungal	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
,	O
i	O
.	O
e	O
.	O
glucan	O
phosphate	O
,	O
in	O
the	O
presence	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
toxic	B-Protein
shock	I-Protein
syndrome	I-Protein
toxin	I-Protein
1	I-Protein
(	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O
<EOS>	B-X
Menstrual	B-X
toxic	B-X
shock	B-X
syndrome	B-X
(	B-X
mTSS	B-X
)	B-X
is	B-X
a	B-X
life-threatening	B-X
disease	B-X
caused	B-X
by	B-X
superantigen-producing	B-X
Staphylococcus	B-X
aureus	B-X
.	B-X
Incidence	B-X
ranges	B-X
from	B-X
0·03	B-X
to	B-X
0·50	B-X
cases	B-X
per	B-X
100	B-X
000	B-X
people	B-X
,	B-X
with	B-X
overall	B-X
mortality	B-X
around	B-X
8	B-X
%	B-X
.	B-X
In	B-X
this	B-X
Grand	B-X
Round	B-X
,	B-X
we	B-X
present	B-X
the	B-X
case	B-X
of	B-X
a	B-X
previously	B-X
healthy	B-X
23-year-old	B-X
menstruating	B-X
woman	B-X
who	B-X
was	B-X
diagnosed	B-X
with	B-X
mTSS	B-X
after	B-X
she	B-X
presented	B-X
at	B-X
our	B-X
hospital	B-X
with	B-X
a	B-X
septic	B-X
condition	B-X
for	B-X
the	B-X
second	B-X
time	B-X
.	B-X
The	B-X
diagnosis	B-X
was	B-X
confirmed	B-X
by	B-X
fulfilment	B-X
of	B-X
the	B-X
clinical	B-X
criteria	B-X
outlined	B-X
by	B-X
the	B-X
US	B-X
Centers	B-X
for	B-X
Disease	B-X
Control	B-X
and	B-X
Prevention	B-X
(	B-X
CDC	B-X
;	B-X
fever	B-X
,	B-X
rash	B-X
,	B-X
desquamation	B-X
,	B-X
hypotension	B-X
,	B-X
and	B-X
multi-system	B-X
involvement	B-X
)	B-X
as	B-X
well	B-X
as	B-X
a	B-X
nasal	B-X
swab	B-X
positive	B-X
for	B-X
the	B-X
S	B-X
aureus	B-X
strain	B-X
and	B-X
presence	B-X
of	B-X
the	B-X
gene	B-X
encoding	B-X
for	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X
In	B-X
the	B-X
early	B-X
1980s	B-X
,	B-X
when	B-X
mTSS	B-X
was	B-X
first	B-X
described	B-X
,	B-X
use	B-X
of	B-X
tampons	B-X
was	B-X
considered	B-X
the	B-X
main	B-X
risk	B-X
factor	B-X
.	B-X
Today	B-X
,	B-X
the	B-X
complex	B-X
interplay	B-X
between	B-X
pathogenic	B-X
factors	B-X
of	B-X
S	B-X
aureus	B-X
,	B-X
immunological	B-X
mechanisms	B-X
of	B-X
the	B-X
host	B-X
,	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
vaginal	B-X
ecosystem	B-X
during	B-X
menstruation	B-X
has	B-X
broadened	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
and	B-X
the	B-X
CDC	B-X
criteria	B-X
have	B-X
appreciable	B-X
limitations	B-X
in	B-X
everyday	B-X
clinical	B-X
practice	B-X
.	B-X

Results	O

Despite	O
an	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappaB	O
,	O
NFinterleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
similar	O
to	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
observed	O
no	O
significant	O
production	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
or	O
interferon	B-Protein
gamma	I-Protein
induced	O
by	O
glucan	O
phosphate	O
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X
These	B-X
studies	B-X
evaluated	B-X
the	B-X
effects	B-X
treatment	B-X
with	B-X
glucan	B-X
phosphate	B-X
,	B-X
a	B-X
soluble	B-X
polysaccharide	B-X
immunomodulator	B-X
,	B-X
on	B-X
the	B-X
inflammatory	B-X
response	B-X
induced	B-X
by	B-X
burn	B-X
injury	B-X
and	B-X
on	B-X
resistance	B-X
to	B-X
Pseudomonas	B-X
aeruginosa	B-X
burn	B-X
wound	B-X
infection	B-X
.	B-X
Mice	B-X
were	B-X
exposed	B-X
to	B-X
35	B-X
%	B-X
total	B-X
body	B-X
surface	B-X
area	B-X
burns	B-X
and	B-X
were	B-X
resuscitated	B-X
with	B-X
lactated	B-X
Ringer	B-X
's	B-X
(	B-X
LR	B-X
)	B-X
solution	B-X
alone	B-X
or	B-X
LR	B-X
supplemented	B-X
with	B-X
glucan	B-X
phosphate	B-X
(	B-X
40	B-X
mg/kg	B-X
)	B-X
.	B-X
Glucan	B-X
phosphate	B-X
treatment	B-X
attenuated	B-X
burn-induced	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
IL-10	B-X
mRNAs	B-X
in	B-X
spleen	B-X
,	B-X
lung	B-X
,	B-X
and	B-X
heart	B-X
.	B-X
Plasma	B-X
concentrations	B-X
of	B-X
IL-1beta	B-X
,	B-X
IL-6	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
(	B-X
MIP	B-X
)	B-X
-2	B-X
,	B-X
and	B-X
IL-10	B-X
were	B-X
also	B-X
decreased	B-X
in	B-X
burned	B-X
mice	B-X
treated	B-X
with	B-X
glucan	B-X
phosphate	B-X
compared	B-X
with	B-X
vehicle-treated	B-X
controls	B-X
.	B-X
Early	B-X
postburn	B-X
mortality	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
control	B-X
(	B-X
20	B-X
%	B-X
)	B-X
and	B-X
glucan	B-X
phosphate-treated	B-X
(	B-X
10	B-X
%	B-X
)	B-X
mice	B-X
,	B-X
but	B-X
there	B-X
was	B-X
a	B-X
small	B-X
improvement	B-X
in	B-X
acid-base	B-X
balance	B-X
in	B-X
the	B-X
glucan	B-X
phosphate-treated	B-X
group	B-X
.	B-X
Mice	B-X
received	B-X
a	B-X
second	B-X
injection	B-X
of	B-X
glucan	B-X
phosphate	B-X
or	B-X
LR	B-X
on	B-X
day	B-X
4	B-X
postburn	B-X
and	B-X
were	B-X
infected	B-X
by	B-X
topical	B-X
application	B-X
of	B-X
P.	B-X
aeruginosa	B-X
to	B-X
the	B-X
burn	B-X
wound	B-X
on	B-X
day	B-X
5	B-X
.	B-X
Glucan	B-X
phosphate	B-X
treatment	B-X
significantly	B-X
improved	B-X
survival	B-X
in	B-X
mice	B-X
exposed	B-X
to	B-X
P.	B-X
aeruginosa	B-X
burn	B-X
wound	B-X
infection	B-X
.	B-X
The	B-X
improved	B-X
survival	B-X
correlated	B-X
with	B-X
lower	B-X
bacterial	B-X
burden	B-X
in	B-X
the	B-X
burn	B-X
wound	B-X
,	B-X
attenuated	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
and	B-X
enhanced	B-X
production	B-X
of	B-X
Th1	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
show	B-X
that	B-X
glucan	B-X
phosphate	B-X
treatment	B-X
attenuates	B-X
burn-induced	B-X
inflammation	B-X
and	B-X
increases	B-X
resistance	B-X
to	B-X
P.	B-X
aeruginosa	B-X
burn	B-X
wound	B-X
infection	B-X
in	B-X
an	B-X
experimental	B-X
model	B-X
of	B-X
burn	B-X
injury	B-X
.	B-X

Glucan	O
phosphate	O
-	O
treated	O
leukocytes	O
induced	O
a	O
substantial	O
amount	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
(	O
peak	O
at	O
18	O
h	O
:	O
5000	O
pg	O
/	O
ml	O
)	O
,	O
likely	O
due	O
to	O
binding	O
of	O
NFkappaB	O
to	O
a	O
consensus	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
.	O

An	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1receptor	I-Protein
antagonist	I-Protein
(	O
RA	B-Protein
)	O
production	O
(	O
peak	O
at	O
24	O
h	O
:	O
12000	O
pg	O
/	O
ml	O
)	O
by	O
glucan	O
phosphate	O
-	O
treated	O
cells	O
positively	O
correlated	O
with	O
IL	B-Protein
-	I-Protein
8	I-Protein
levels	O
.	O

Glucan	O
phosphate	O
induced	O
significant	O
binding	O
to	O
a	O
known	O
NFIL	O
-	O
6	O
site	O
and	O
a	O
new	O
NFAT	O
site	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
which	O
was	O
confirmed	O
by	O
inhibition	O
experiments	O
.	O

When	O
applied	O
in	O
combination	O
with	O
either	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
at	O
the	O
same	O
time	O
points	O
,	O
we	O
detected	O
that	O
glucan	O
phosphate	O
elevated	O
the	O
LPS	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
DNA	O
binding	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
,	O
leading	O
to	O
a	O
synergistic	O
increase	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O
<EOS>	B-X
Huai	B-X
Hua	B-X
San	B-X
(	B-X
HHS	B-X
)	B-X
,	B-X
a	B-X
famous	B-X
Traditional	B-X
Chinese	B-X
Medicine	B-X
(	B-X
TCM	B-X
)	B-X
formula	B-X
,	B-X
has	B-X
been	B-X
widely	B-X
applied	B-X
in	B-X
treating	B-X
ulcerative	B-X
colitis	B-X
(	B-X
UC	B-X
)	B-X
.	B-X
Previously	B-X
we	B-X
have	B-X
published	B-X
a	B-X
protocol	B-X
for	B-X
transfection	B-X
of	B-X
THP-1	B-X
macrophages	B-X
,	B-X
which	B-X
in	B-X
brief	B-X
pre-differentiates	B-X
THP-1	B-X
monocytes	B-X
for	B-X
48h	B-X
using	B-X
100ng/ml	B-X
PMA	B-X
,	B-X
followed	B-X
by	B-X
detachment	B-X
of	B-X
the	B-X
cells	B-X
and	B-X
eletroporation	B-X
using	B-X
Lonza	B-X
nucleofector	B-X
technology	B-X
and	B-X
finally	B-X
includes	B-X
further	B-X
48h	B-X
of	B-X
differentiation	B-X
with	B-X
100ng/ml	B-X
PMA	B-X
.	B-X
When	B-X
we	B-X
applied	B-X
this	B-X
protocol	B-X
to	B-X
study	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
10	B-X
dependent	B-X
polarization	B-X
,	B-X
the	B-X
cells	B-X
were	B-X
inert	B-X
to	B-X
the	B-X
IL10	B-X
stimulus	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
a	B-X
failure	B-X
to	B-X
induce	B-X
IL10	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
SOCS3	B-X
.	B-X
Further	B-X
investigation	B-X
revealed	B-X
that	B-X
the	B-X
cells	B-X
were	B-X
classically	B-X
activated	B-X
by	B-X
the	B-X
differentiation	B-X
agent	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
as	B-X
shown	B-X
by	B-X
induction	B-X
of	B-X
chemokine	B-X
receptor	B-X
CCR7	B-X
.	B-X
Subsequent	B-X
reduction	B-X
of	B-X
PMA	B-X
concentration	B-X
during	B-X
THP-1	B-X
macrophage	B-X
differentiation	B-X
significantly	B-X
improved	B-X
their	B-X
response	B-X
to	B-X
IL10	B-X
as	B-X
SOCS3	B-X
increased	B-X
more	B-X
than	B-X
40-fold	B-X
.	B-X
This	B-X
increased	B-X
responsiveness	B-X
of	B-X
the	B-X
THP-1	B-X
macrophages	B-X
was	B-X
also	B-X
confirmed	B-X
for	B-X
polarization	B-X
with	B-X
LPS	B-X
and	B-X
IFNγ	B-X
.	B-X
Up-regulation	B-X
of	B-X
classical	B-X
activation	B-X
markers	B-X
CCL3	B-X
,	B-X
CCR7	B-X
and	B-X
TNFα	B-X
was	B-X
enhanced	B-X
from	B-X
18-	B-X
,	B-X
21-	B-X
and	B-X
70-fold	B-X
,	B-X
respectively	B-X
,	B-X
to	B-X
48-	B-X
,	B-X
222-	B-X
and	B-X
951-fold	B-X
,	B-X
respectively	B-X
.	B-X
Expression	B-X
of	B-X
macrophage	B-X
differentiation	B-X
markers	B-X
CD11b	B-X
and	B-X
CD68	B-X
as	B-X
well	B-X
as	B-X
cell	B-X
morphology	B-X
remained	B-X
unchanged	B-X
.	B-X

Further	O
,	O
glucan	O
phosphate	O
modulated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
inflammatory	O
response	O
via	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X

As	O
a	O
consequence	O
,	O
glucan	O
phosphate	O
shifted	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
towards	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X

Subsequently	O
,	O
glucan	O
phosphate	O
decreased	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

Thus	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
may	O
induce	O
beneficial	O
effects	O
in	O
the	O
presence	O
of	O
pro	O
-	O
inflammatory	O
responses	O
,	O
downstream	O
of	O
receptor	O
binding	O
and	O
signaling	O
by	O
switching	O
a	O
pro	O
-	O
to	O
an	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
-	O
mediated	O
reaction	O
.	O

Our	O
results	O
also	O
offer	O
new	O
insights	O
into	O
the	O
complex	O
regulation	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
gene	O
,	O
which	O
can	O
be	O
modulated	O
by	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
.	O
<EOS>	B-X
Beta-1	B-X
--	B-X
>	B-X
3-D-glucans	B-X
represent	B-X
a	B-X
pathogen-associated	B-X
molecular	B-X
pattern	B-X
and	B-X
are	B-X
able	B-X
to	B-X
modify	B-X
biological	B-X
responses	B-X
.	B-X
Employing	B-X
a	B-X
comprehensive	B-X
methodological	B-X
approach	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
our	B-X
in	B-X
vitro	B-X
study	B-X
was	B-X
to	B-X
elucidate	B-X
novel	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
human	B-X
peripheral	B-X
blood	B-X
immune	B-X
cells	B-X
mediated	B-X
by	B-X
a	B-X
fungal	B-X
beta-1	B-X
--	B-X
>	B-X
3-D-glucan	B-X
,	B-X
i.e	B-X
.	B-X
glucan	B-X
phosphate	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
1	B-X
(	B-X
TSST-1	B-X
)	B-X
.	B-X

beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
occur	O
as	O
a	O
principal	O
component	O
of	O
microbial	O
cell	O
walls	O
or	O
can	O
be	O
secreted	O
from	O
both	O
,	O
non	O
-	O
pathogenic	O
and	O
pathogenic	O
fungi	O
such	O
as	O
S	O
.	O
cerevisae	O
and	O
C	O
.	O
albicans	O
[	O
1	O
]	O
.	O

These	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
linked	O
glucose	O
polymers	O
are	O
characterized	O
as	O
a	O
fungal	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
(	O
PAMP	O
)	O
[	O
2	O
]	O
.	O

The	O
primary	O
cellular	O
recognition	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
is	O
mediated	O
by	O
several	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
receptors	O
on	O
phagocytes	O
[	O
3	O
,	O
4	O
]	O
and	O
other	O
cells	O
[	O
5	O
,	O
6	O
]	O
.	O

Human	O
as	O
well	O
as	O
murine	O
Dectin	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
demonstrated	O
to	O
be	O
the	O
major	O
pattern	O
recognition	O
receptor	O
(	O
PRR	O
)	O
for	O
intact	O
yeast	O
and	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
-	O
containing	O
particles	O
(	O
i	O
.	O
e	O
.	O
zymosan	O
)	O
on	O
monocytes	O
/	O
macrophages	O
as	O
well	O
as	O
neutrophils	O
and	O
on	O
primary	O
cells	O
[	O
7	O
-	O
11	O
]	O
.	O

In	O
the	O
murine	O
system	O
,	O
binding	O
of	O
zymosan	O
to	O
Dectin	B-Protein
-	I-Protein
1	I-Protein
resulted	O
in	O
production	O
of	O
TNFalpha	B-Protein
through	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
and	O
the	O
adaptor	O
protein	O
MyD88	B-Protein
[	O
12	O
]	O
.	O

Another	O
water	O
-	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
(	O
PGG	O
-	O
glucan	O
)	O
has	O
been	O
described	O
to	O
activate	O
NFkappaB	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
in	O
murine	O
cell	O
lines	O
[	O
13	O
,	O
14	O
]	O
.	O

Similarly	O
,	O
it	O
has	O
been	O
shown	O
that	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
activate	O
NFkappaB	O
in	O
a	O
human	O
monocyte	O
-	O
like	O
cell	O
line	O
[	O
15	O
]	O
and	O
in	O
human	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
,	O
in	O
the	O
latter	O
case	O
without	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNFalpha	B-Protein
)	O
[	O
16	O
]	O
.	O

One	O
study	O
proposed	O
that	O
the	O
production	O
of	O
the	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
1	I-Protein
by	O
human	O
monocytes	O
may	O
be	O
a	O
potentially	O
protective	O
mechanism	O
induced	O
by	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
17	O
]	O
.	O
<EOS>	B-X
IL-1β	B-X
is	B-X
considered	B-X
one	B-X
of	B-X
the	B-X
most	B-X
impactful	B-X
cytokines	B-X
in	B-X
OA	B-X
disease	B-X
and	B-X
therefore	B-X
,	B-X
its	B-X
blockage	B-X
offers	B-X
a	B-X
promising	B-X
approach	B-X
for	B-X
the	B-X
modulation	B-X
of	B-X
OA	B-X
.	B-X
Interleukin-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
IL-1Ra	B-X
)	B-X
is	B-X
a	B-X
naturally	B-X
occurring	B-X
anti-inflammatory	B-X
protein	B-X
belonging	B-X
to	B-X
the	B-X
IL-1	B-X
family	B-X
that	B-X
competes	B-X
with	B-X
IL-1β	B-X
for	B-X
occupancy	B-X
of	B-X
its	B-X
receptors	B-X
,	B-X
without	B-X
triggering	B-X
the	B-X
same	B-X
downstream	B-X
inflammatory	B-X
response	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
natural	B-X
anti-inflammatory	B-X
properties	B-X
,	B-X
different	B-X
methods	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
use	B-X
IL-1Ra	B-X
therapeutically	B-X
in	B-X
OA	B-X
.	B-X
These	B-X
processes	B-X
result	B-X
in	B-X
hemoderivatives	B-X
with	B-X
high	B-X
concentrations	B-X
of	B-X
IL-1Ra	B-X
and	B-X
other	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
with	B-X
potential	B-X
modulatory	B-X
effects	B-X
on	B-X
OA	B-X
progression	B-X
.	B-X
Several	B-X
studies	B-X
have	B-X
demonstrated	B-X
potential	B-X
anti-inflammatory	B-X
effect	B-X
of	B-X
these	B-X
therapies	B-X
with	B-X
promising	B-X
clinical	B-X
results	B-X
.	B-X
However	B-X
,	B-X
as	B-X
with	B-X
any	B-X
hemoderivatives	B-X
,	B-X
clinical	B-X
outcomes	B-X
may	B-X
vary	B-X
.	B-X
Additionally	B-X
,	B-X
differences	B-X
between	B-X
ACS	B-X
and	B-X
APS	B-X
treatments	B-X
may	B-X
not	B-X
be	B-X
clear	B-X
for	B-X
many	B-X
clients	B-X
and	B-X
clinicians	B-X
.	B-X

Three	O
other	O
investigations	O
have	O
reported	O
that	O
human	O
leukocytes	O
and	O
human	O
vascular	O
endothelial	O
cells	O
produce	O
IL	B-Protein
-	I-Protein
8	I-Protein
in	O
response	O
to	O
zymosan	O
[	O
18	O
]	O
or	O
a	O
water	O
-	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
6	O
,	O
19	O
]	O
.	O
<EOS>	B-X
The	B-X
laminarans	B-X
are	B-X
biologically	B-X
active	B-X
water-soluble	B-X
polysaccharide	B-X
(	B-X
1,3	B-X
;	B-X
1,6-β-D-glucans	B-X
)	B-X
of	B-X
brown	B-X
algae	B-X
.	B-X
1,3-β-D-glucanases	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
for	B-X
studying	B-X
the	B-X
structure	B-X
of	B-X
laminarans	B-X
,	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
obtain	B-X
new	B-X
biologically	B-X
active	B-X
derivatives	B-X
.	B-X
We	B-X
focused	B-X
on	B-X
information	B-X
about	B-X
sources	B-X
,	B-X
structure	B-X
and	B-X
properties	B-X
of	B-X
laminarans	B-X
and	B-X
1,3-β-D-glucanases	B-X
,	B-X
methods	B-X
of	B-X
obtaining	B-X
and	B-X
structural	B-X
elucidation	B-X
of	B-X
laminarans	B-X
,	B-X
and	B-X
biological	B-X
activity	B-X
of	B-X
laminarans	B-X
and	B-X
products	B-X
of	B-X
their	B-X
enzymatic	B-X
transformation	B-X
.	B-X
About	B-X
40	B-X
%	B-X
of	B-X
newly-discovered	B-X
entities	B-X
are	B-X
poorly	B-X
soluble	B-X
in	B-X
water	B-X
,	B-X
and	B-X
this	B-X
may	B-X
be	B-X
an	B-X
obstacle	B-X
in	B-X
the	B-X
creation	B-X
of	B-X
new	B-X
drugs	B-X
.	B-X
Cyclodextrins	B-X
are	B-X
cyclic	B-X
oligosaccharides	B-X
containing	B-X
six	B-X
or	B-X
more	B-X
D-	B-X
(	B-X
+	B-X
)	B-X
-	B-X
glucopyranose	B-X
units	B-X
linked	B-X
by	B-X
α-1,4-glycosidic	B-X
bonds	B-X
,	B-X
which	B-X
are	B-X
characterized	B-X
by	B-X
a	B-X
favourable	B-X
toxicological	B-X
profile	B-X
,	B-X
low	B-X
local	B-X
toxicity	B-X
and	B-X
low	B-X
mucous	B-X
and	B-X
eye	B-X
irritability	B-X
;	B-X
they	B-X
are	B-X
virtually	B-X
non-toxic	B-X
when	B-X
administered	B-X
orally	B-X
.	B-X

In	O
addition	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
seem	O
to	O
be	O
able	O
to	O
modify	O
the	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
or	O
even	O
sepsis	O
.	O
<EOS>	B-X
Biomarkers	B-X
can	B-X
be	B-X
useful	B-X
for	B-X
identifying	B-X
or	B-X
ruling	B-X
out	B-X
sepsis	B-X
,	B-X
identifying	B-X
patients	B-X
who	B-X
may	B-X
benefit	B-X
from	B-X
specific	B-X
therapies	B-X
or	B-X
assessing	B-X
the	B-X
response	B-X
to	B-X
therapy	B-X
.	B-X
Sepsis	B-X
is	B-X
defined	B-X
as	B-X
life-threatening	B-X
organ	B-X
dysfunction	B-X
caused	B-X
by	B-X
a	B-X
dysregulated	B-X
host	B-X
response	B-X
to	B-X
infection	B-X
.	B-X
Recently	B-X
was	B-X
been	B-X
found	B-X
that	B-X
pyroptosis	B-X
is	B-X
a	B-X
unique	B-X
form	B-X
of	B-X
proinflammatory	B-X
programmed	B-X
death	B-X
,	B-X
that	B-X
is	B-X
different	B-X
from	B-X
apoptosis	B-X
.	B-X
A	B-X
growing	B-X
number	B-X
of	B-X
studies	B-X
have	B-X
investigated	B-X
pyroptosis	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
sepsis	B-X
,	B-X
including	B-X
the	B-X
mechanisms	B-X
,	B-X
role	B-X
,	B-X
and	B-X
relevant	B-X
targets	B-X
of	B-X
pyroptosis	B-X
in	B-X
sepsis	B-X
.	B-X
While	B-X
moderate	B-X
pyroptosis	B-X
in	B-X
sepsis	B-X
can	B-X
control	B-X
pathogen	B-X
infection	B-X
,	B-X
excessive	B-X
pyroptosis	B-X
can	B-X
lead	B-X
to	B-X
a	B-X
dysregulated	B-X
host	B-X
immune	B-X
response	B-X
and	B-X
even	B-X
organ	B-X
dysfunction	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
mechanisms	B-X
and	B-X
potential	B-X
therapeutic	B-X
targets	B-X
underlying	B-X
pyroptosis	B-X
in	B-X
sepsis	B-X
identified	B-X
in	B-X
recent	B-X
decades	B-X
,	B-X
looking	B-X
forward	B-X
to	B-X
the	B-X
future	B-X
direction	B-X
of	B-X
treatment	B-X
for	B-X
sepsis	B-X
.	B-X

In	O
a	O
murine	O
polymicrobial	O
sepsis	O
model	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
[	O
20	O
]	O
treatment	O
resulted	O
in	O
decreased	O
septic	O
morbidity	O
and	O
mortality	O
mediated	O
via	O
inhibition	O
of	O
NFkappaB	O
and	O
stimulation	O
of	O
the	O
phosphoinositide	O
-	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
[	O
21	O
,	O
22	O
]	O
.	O

These	O
and	O
other	O
animal	O
studies	O
[	O
23	O
,	O
24	O
]	O
as	O
well	O
as	O
a	O
clinical	O
trial	O
[	O
25	O
]	O
support	O
a	O
protective	O
role	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
in	O
certain	O
pro	O
-	O
inflammatory	O
conditions	O
.	O

The	O
mechanisms	O
underlying	O
these	O
beneficial	O
effects	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
are	O
only	O
partially	O
resolved	O
,	O
especially	O
in	O
humans	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
molecular	O
and	O
cellular	O
mechanisms	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
on	O
human	O
leukocytes	O
in	O
pro	O
-	O
inflammatory	O
conditions	O
with	O
special	O
emphasis	O
on	O
the	O
cytokine	O
profile	O
and	O
its	O
transcriptional	O
regulation	O
.	O

For	O
this	O
purpose	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
exposed	O
to	O
a	O
well	O
-	O
defined	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
,	O
i	O
.	O
e	O
.	O
glucan	O
phosphate	O
(	O
GP	O
)	O
[	O
20	O
,	O
26	O
]	O
,	O
alone	O
or	O
simultaneously	O
with	O
LPS	O
from	O
gram	O
-	O
negative	O
bacteria	O
or	O
the	O
superantigen	O
TSST	B-Protein
-	I-Protein
1	I-Protein
from	O
gram	O
-	O
positive	O
bacteria	O
over	O
48	O
h	O
.	O
<EOS>	B-X
In	B-X
Gram-negative	B-X
bacteria	B-X
,	B-X
the	B-X
cell	B-X
envelope	B-X
largely	B-X
consists	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
class	B-X
of	B-X
heterogeneous	B-X
glycolipids	B-X
.	B-X
As	B-X
a	B-X
fundamental	B-X
component	B-X
of	B-X
the	B-X
outer	B-X
membrane	B-X
,	B-X
LPS	B-X
provides	B-X
stability	B-X
to	B-X
the	B-X
bacterial	B-X
cell	B-X
and	B-X
forms	B-X
a	B-X
protective	B-X
cover	B-X
shielding	B-X
it	B-X
from	B-X
hostile	B-X
environments	B-X
.	B-X
LPS	B-X
is	B-X
not	B-X
only	B-X
fundamental	B-X
to	B-X
bacterial	B-X
viability	B-X
,	B-X
but	B-X
also	B-X
makes	B-X
a	B-X
substantial	B-X
contribution	B-X
both	B-X
directly	B-X
and	B-X
indirectly	B-X
to	B-X
multiple	B-X
aspects	B-X
of	B-X
inter-organismic	B-X
interactions	B-X
.	B-X
During	B-X
infection	B-X
of	B-X
animal	B-X
and	B-X
plant	B-X
hosts	B-X
,	B-X
LPS	B-X
promotes	B-X
bacterial	B-X
virulence	B-X
but	B-X
simultaneously	B-X
betrays	B-X
bacteria	B-X
to	B-X
the	B-X
host	B-X
immune	B-X
system	B-X
.	B-X
Moreover	B-X
,	B-X
dynamic	B-X
remodulation	B-X
of	B-X
LPS	B-X
structures	B-X
allows	B-X
bacteria	B-X
to	B-X
fine-tune	B-X
OM	B-X
properties	B-X
and	B-X
quickly	B-X
adapt	B-X
to	B-X
diverse	B-X
and	B-X
often	B-X
hostile	B-X
environments	B-X
,	B-X
such	B-X
as	B-X
those	B-X
encountered	B-X
in	B-X
host	B-X
tissues	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
recent	B-X
insights	B-X
into	B-X
the	B-X
multiple	B-X
functions	B-X
of	B-X
LPS	B-X
in	B-X
plant-bacteria	B-X
interactions	B-X
and	B-X
discuss	B-X
what	B-X
we	B-X
can	B-X
learn	B-X
from	B-X
the	B-X
latest	B-X
advances	B-X
in	B-X
the	B-X
field	B-X
of	B-X
animal	B-X
immunity	B-X
.	B-X
We	B-X
further	B-X
pinpoint	B-X
open	B-X
questions	B-X
and	B-X
future	B-X
challenges	B-X
to	B-X
unravel	B-X
the	B-X
different	B-X
roles	B-X
of	B-X
LPS	B-X
in	B-X
the	B-X
dynamic	B-X
interplay	B-X
between	B-X
bacteria	B-X
and	B-X
plant	B-X
hosts	B-X
at	B-X
the	B-X
mechanistic	B-X
level	B-X
.	B-X

Because	O
of	O
the	O
potential	O
effect	O
of	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
on	O
cytokine	O
production	O
[	O
12	O
,	O
16	O
-	O
19	O
]	O
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
were	O
measured	O
as	O
well	O
as	O
IFNgamma	B-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
TGFbeta1	B-Protein
.	O

Correspondingly	O
,	O
four	O
NFkappaB	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
(	O
kappa	O
consensus	O
,	O
kappa1	O
,	O
kappa2	O
,	O
kappa3	O
)	O
[	O
27	O
]	O
,	O
a	O
kappa	O
consensus	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
[	O
28	O
]	O
,	O
an	O
NFAT	O
site	O
from	O
the	O
IFNgamma	B-Protein
promoter	O
(	O
ATP2	O
)	O
[	O
29	O
]	O
and	O
a	O
consensus	O
NFIL	O
-	O
6	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
[	O
13	O
]	O
were	O
examined	O
.	O

Because	O
of	O
the	O
anti	O
-	O
inflammatory	O
role	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
we	O
focused	O
on	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

An	O
inhibitory	O
element	O
and	O
three	O
positive	O
-	O
acting	O
LPS	O
-	O
response	O
elements	O
(	O
LRE	O
-	O
1	O
,	O
LRE	O
-	O
2	O
and	O
LRE	O
-	O
3	O
)	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
including	O
NFkappaB	O
,	O
PU	O
.	O
1	O
and	O
NFIL	O
-	O
6	O
sites	O
,	O
have	O
been	O
characterized	O
previously	O
[	O
30	O
-	O
33	O
]	O
.	O

Using	O
computational	O
analysis	O
for	O
homology	O
search	O
[	O
34	O
]	O
,	O
we	O
looked	O
for	O
new	O
binding	O
motifs	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
activities	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
from	O
human	O
PBMC	O
to	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNgamma	B-Protein
promoters	O
following	O
an	O
in	O
vitro	O
stimulation	O
(	O
1	O
h	O
)	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein

GP	O
induced	O
band	O
shifts	O
,	O
indicating	O
binding	O
of	O
NFkappaB	O
as	O
well	O
as	O
of	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
to	O
the	O
corresponding	O
DNA	O
oligonucleotides	O
(	O
kappa	O
consensus	O
,	O
kappa1	O
,	O
kappa2	O
,	O
kappa3	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
;	O
kappa	O
consensus	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
;	O
NFIL	O
-	O
6consensus	O
from	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
;	O
Table	O
1	O
;	O
Fig	O
.	O
1A	O
)	O
.	O

The	O
extent	O
of	O
the	O
band	O
shifts	O
induced	O
by	O
GP	O
was	O
not	O
statistically	O
different	O
when	O
compared	O
to	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Fig	O
.	O
1B	O
)	O
.	O
<EOS>	B-X
Its	B-X
pathogenicity	B-X
leads	B-X
to	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
including	B-X
tumors	B-X
that	B-X
result	B-X
from	B-X
EBV	B-X
's	B-X
ability	B-X
to	B-X
readily	B-X
transform	B-X
B-lymphocytes	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
epithelial	B-X
cells	B-X
.	B-X
EBV	B-X
utilizes	B-X
CD21/CR2	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
B	B-X
cells	B-X
to	B-X
initiate	B-X
the	B-X
infection	B-X
process	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
while	B-X
both	B-X
purified	B-X
recombinant	B-X
gp350	B-X
(	B-X
rgp350	B-X
)	B-X
and	B-X
EBV	B-X
upregulate	B-X
IL-6	B-X
mRNA	B-X
synthesis	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
EBV-induced	B-X
IL-6	B-X
gene	B-X
activation	B-X
occurs	B-X
for	B-X
a	B-X
significantly	B-X
longer	B-X
period	B-X
of	B-X
time	B-X
(	B-X
i.e	B-X
.	B-X
12	B-X
hours	B-X
for	B-X
EBV	B-X
as	B-X
compared	B-X
to	B-X
6	B-X
hours	B-X
for	B-X
rgp350	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
half-life	B-X
of	B-X
EBV-induced	B-X
IL-6	B-X
mRNA	B-X
was	B-X
also	B-X
significantly	B-X
longer	B-X
(	B-X
10	B-X
hours	B-X
)	B-X
than	B-X
that	B-X
of	B-X
mRNA	B-X
induced	B-X
by	B-X
rgp350	B-X
(	B-X
about	B-X
6	B-X
hours	B-X
)	B-X
.	B-X
Both	B-X
EBV	B-X
and	B-X
gp350	B-X
enhance	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
NF-kappaB	B-X
transcription	B-X
factor	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
band-shift	B-X
and	B-X
augment	B-X
NF-kappaB-mediated	B-X
activation	B-X
of	B-X
a	B-X
CAT	B-X
reporter	B-X
plasmid	B-X
.	B-X

A	O
supershift	O
,	O
conducted	O
for	O
an	O
NFkappaB	O
consensus	O
site	O
from	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
,	O
demonstrated	O
a	O
GP	O
-	O
induced	O
predominant	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
to	O
a	O
lesser	O
degree	O
of	O
p50	B-Protein
(	O
Fig	O
.	O
1A	O
)	O
.	O

Accordingly	O
,	O
an	O
immunoblot	O
of	O
nuclear	O
extracts	O
from	O
GP	O
-	O
treated	O
PBMC	O
showed	O
a	O
strong	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
a	O
weaker	O
reaction	O
of	O
p50	B-Protein
,	O
whereas	O
p52	B-Protein
was	O
negative	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Simultaneous	O
co	O
-	O
treatment	O
of	O
PBMC	O
with	O
GP	O
did	O
not	O
change	O
the	O
LPS	O
-	O
induced	O
NFkappaB	O
binding	O
to	O
oligos	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
significantly	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
but	O
substantially	O
decreased	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
NFkappaB	O
binding	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
(	O
100	O
mug	O
)	O
and	O
thus	O
differed	O
completely	O
from	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
n	O
=	O
4	O
;	O
p	O
<	O
0	O
.	O
05	O
vs	O
.	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
and	O
p	O
=	O
0	O
.	O
07	O
vs	O
.	O
TSST	B-Protein
-	I-Protein
1	I-Protein
;	O
Fig	O
.	O
1B	O
)	O
.	O
<EOS>	B-X
T-cell	B-X
immunoglobulin	B-X
domain	B-X
and	B-X
mucin	B-X
domain	B-X
4	B-X
(	B-X
TIM-4	B-X
)	B-X
is	B-X
a	B-X
transmembrane	B-X
protein	B-X
that	B-X
promotes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cells	B-X
.	B-X
Most	B-X
transmembrane	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
N-glycosylation	B-X
in	B-X
cancer	B-X
cell	B-X
metastasis	B-X
has	B-X
been	B-X
well	B-X
appreciated	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
TIM-4	B-X
is	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
role	B-X
of	B-X
TIM-4	B-X
N-glycosylation	B-X
in	B-X
NSCLC	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
TIM-4	B-X
was	B-X
extensively	B-X
N-glycosylated	B-X
at	B-X
Asn291	B-X
.	B-X
After	B-X
the	B-X
removal	B-X
of	B-X
N-glycosylation	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
TIM-4	B-X
protein	B-X
was	B-X
decreased	B-X
and	B-X
TIM-4	B-X
was	B-X
more	B-X
susceptible	B-X
to	B-X
degradation	B-X
by	B-X
ER-localized	B-X
ubiquitin	B-X
ligase-mediated	B-X
ERAD	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
TIM-4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
was	B-X
decreased	B-X
,	B-X
which	B-X
suppressed	B-X
TIM-4-mediated	B-X
metastasis	B-X
in	B-X
NSCLC	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
the	B-X
present	B-X
study	B-X
identifies	B-X
TIM-4	B-X
N-glycosylation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
NSCLS	B-X
migration	B-X
,	B-X
which	B-X
would	B-X
provide	B-X
a	B-X
valuable	B-X
biomarker	B-X
for	B-X
developing	B-X
drugs	B-X
targeting	B-X
N-glycosylation	B-X
at	B-X
Asn291	B-X
on	B-X
TIM-4	B-X
.	B-X

GP	O
was	O
also	O
able	O
to	O
induce	O
band	O
shifts	O
indicative	O
of	O
binding	O
of	O
particular	O
variants	O
of	O
NFAT	B-Protein
to	O
an	O
oligo	O
from	O
the	O
IFNgamma	B-Protein
promoter	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

An	O
immunoblot	O
for	O
two	O
NFAT	B-Protein
subunits	O
demonstrated	O
a	O
GP	O
-	O
induced	O
binding	O
of	O
NFATc2	B-Protein
and	O
to	O
a	O
lesser	O
degree	O
of	O
NFATc1	B-Protein
(	O
Fig	O
.	O
2	O
)	O
.	O

Cytokine	O
profile	O
of	O
human	O
PBMC	O
following	O
a	O
48	O
h	O
in	O
vitro	O
stimulation	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein

Because	O
of	O
the	O
GP	O
-	O
induced	O
band	O
shifts	O
to	O
seven	O
sites	O
from	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNgamma	B-Protein
promoters	O
,	O
it	O
could	O
be	O
assumed	O
that	O
GP	O
treatment	O
of	O
human	O
PBMC	O
would	O
lead	O
to	O
production	O
of	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IFNgamma	B-Protein
and	O
other	O
pro	O
-	O
inflammatory	O
mediators	O
.	O

Previous	O
studies	O
reported	O
that	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
induced	O
only	O
a	O
limited	O
cytokine	O
secretion	O
of	O
human	O
blood	O
cells	O
[	O
15	O
-	O
18	O
]	O
.	O

Corroborating	O
and	O
extending	O
these	O
singular	O
findings	O
in	O
terms	O
of	O
examining	O
pro	O
-	O
(	O
eight	O
)	O
as	O
well	O
as	O
anti	O
-	O
(	O
three	O
)	O
inflammatory	O
cytokines	O
over	O
time	O
(	O
48	O
h	O
)	O
and	O
six	O
additional	O
transcription	O
factor	O
binding	O
sites	O
,	O
our	O
comprehensive	O
analysis	O
revealed	O
the	O
following	O
cytokine	O
profile	O
of	O
human	O
leukocytes	O
in	O
response	O
to	O
a	O
highly	O
purified	O
water	O
soluble	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
and	O
in	O
comparison	O
to	O
two	O
pro	O
-	O
inflammatory	O
mediators	O
(	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
:	O

(	O
i	O
)	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
IL-1β	B-X
release	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
elusive	B-X
.	B-X
Here	B-X
we	B-X
summarise	B-X
these	B-X
observations	B-X
and	B-X
propose	B-X
that	B-X
secretion	B-X
of	B-X
IL-1β	B-X
occurs	B-X
on	B-X
a	B-X
continuum	B-X
,	B-X
dependent	B-X
upon	B-X
stimulus	B-X
strength	B-X
and	B-X
the	B-X
extracellular	B-X
IL-1β	B-X
requirement	B-X
.	B-X
Once	B-X
activated	B-X
,	B-X
it	B-X
orchestrates	B-X
the	B-X
inflammatory	B-X
response	B-X
by	B-X
secreting	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
interleukin-1	B-X
(	B-X
IL-1	B-X
)	B-X
-type	B-X
cytokines	B-X
,	B-X
in	B-X
particular	B-X
IL-1beta	B-X
.	B-X
IL-1	B-X
mediates	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
vast	B-X
array	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
secondary	B-X
inflammation	B-X
.	B-X
IL-1-responsive	B-X
genes	B-X
coordinate	B-X
all	B-X
aspects	B-X
of	B-X
local	B-X
inflammation	B-X
and	B-X
also	B-X
attract	B-X
and	B-X
activate	B-X
cells	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
at	B-X
sites	B-X
of	B-X
infection	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
essential	B-X
components	B-X
of	B-X
the	B-X
NALP3-inflammasome	B-X
that	B-X
control	B-X
processing	B-X
and	B-X
release	B-X
of	B-X
IL-1beta	B-X
.	B-X

There	O
was	O
no	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
detectable	O
following	O
PBMC	O
treatment	O
with	O
1	O
nor	O
100	O
mug	O
GP	O
.	O

An	O
insignificant	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
for	O
GP	O
+	O
LPS	O
was	O
observed	O
in	O
comparison	O
with	O
LPS	O
.	O

For	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
found	O
a	O
significant	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
from	O
18	O
h	O
-	O
24	O
h	O
,	O
for	O
the	O
latter	O
by	O
about	O
40	O
%	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
n	O
=	O
6	O
;	O
both	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
<EOS>	B-X
Formamidinatoantimony	B-X
(	B-X
I/III	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
successfully	B-X
synthesized	B-X
as	B-X
monomers	B-X
or	B-X
dimers	B-X
in	B-X
the	B-X
solid	B-X
state	B-X
featuring	B-X
a	B-X
variety	B-X
of	B-X
coordination	B-X
geometries	B-X
and	B-X
have	B-X
also	B-X
been	B-X
comprehensively	B-X
characterized	B-X
.	B-X
The	B-X
antimony	B-X
(	B-X
I	B-X
)	B-X
formamidinate	B-X
complex	B-X
bis	B-X
[	B-X
μ-N	B-X
,	B-X
N'-bis	B-X
(	B-X
2,6-diisopropylphenyl	B-X
)	B-X
formamidinato	B-X
]	B-X
diantimony	B-X
(	B-X
I	B-X
)	B-X
(	B-X
2	B-X
Sb-Sb	B-X
)	B-X
tetrahydrofuran	B-X
heptasolvate	B-X
,	B-X
[	B-X
Sb	B-X
Superatoms	B-X
have	B-X
exciting	B-X
properties	B-X
,	B-X
including	B-X
diverse	B-X
functionalization	B-X
,	B-X
redox	B-X
activity	B-X
,	B-X
and	B-X
magnetic	B-X
ordering	B-X
,	B-X
so	B-X
the	B-X
resulting	B-X
cluster-assembled	B-X
solids	B-X
hold	B-X
the	B-X
promise	B-X
of	B-X
high	B-X
tunability	B-X
,	B-X
atomic	B-X
precision	B-X
,	B-X
and	B-X
robust	B-X
architectures	B-X
.	B-X
By	B-X
utilizing	B-X
adamantane-like	B-X
clusters	B-X
as	B-X
building	B-X
blocks	B-X
,	B-X
a	B-X
new	B-X
class	B-X
of	B-X
superatoms	B-X
N	B-X

On	O
the	O
whole	O
,	O
GP	O
mediated	O
a	O
reduction	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
amount	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
by	O
about	O
50	O
%	O
(	O
Fig	O
.	O
3A	O
)	O
.	O

(	O
ii	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
10-week-old	B-X
male	B-X
C57BL/6	B-X
mice	B-X
were	B-X
randomly	B-X
subjected	B-X
to	B-X
infusion	B-X
of	B-X
angiotensin	B-X
(	B-X
Ang	B-X
)	B-X
II	B-X
(	B-X
1.5	B-X
mg/kg/d	B-X
)	B-X
or	B-X
saline	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Notably	B-X
,	B-X
elabela	B-X
strikingly	B-X
alleviated	B-X
Ang	B-X
II-induced	B-X
upregulation	B-X
of	B-X
iron	B-X
levels	B-X
and	B-X
lipid	B-X
peroxidation	B-X
in	B-X
hypertensive	B-X
mice	B-X
by	B-X
suppressing	B-X
cardiac	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
/STAT3	B-X
signaling	B-X
and	B-X
activating	B-X
the	B-X
xCT/glutathione	B-X
peroxidase	B-X
(	B-X
GPX4	B-X
)	B-X
signaling	B-X
.	B-X
In	B-X
cultured	B-X
CMVECs	B-X
,	B-X
exposure	B-X
to	B-X
Ang	B-X
II	B-X
resulted	B-X
in	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
elabela	B-X
levels	B-X
and	B-X
obvious	B-X
increases	B-X
in	B-X
cellular	B-X
ferroptosis	B-X
,	B-X
proliferation	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
superoxide	B-X
production	B-X
,	B-X
which	B-X
were	B-X
rescued	B-X
by	B-X
elabela	B-X
or	B-X
ferrostatin-1	B-X
while	B-X
were	B-X
blocked	B-X
by	B-X
co-treatment	B-X
with	B-X
rhIL-6	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
elabela	B-X
antagonizes	B-X
Ang	B-X
II-mediated	B-X
promotion	B-X
of	B-X
CMVECs	B-X
ferroptosis	B-X
,	B-X
adverse	B-X
myocardial	B-X
remodeling	B-X
,	B-X
fibrosis	B-X
and	B-X
heart	B-X
dysfunction	B-X
through	B-X
modulating	B-X
the	B-X
IL-6/STAT3/GPX4	B-X
signaling	B-X
pathway	B-X
.	B-X

GP	O
induced	O
only	O
a	O
small	O
amount	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
there	O
was	O
no	O
significant	O
alteration	O
of	O
the	O
LPS	O
-	O
induced	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
by	O
GP	O
.	O

On	O
the	O
contrary	O
,	O
we	O
observed	O
a	O
decreased	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
for	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
especially	O
at	O
24	O
h	O
by	O
about	O
40	O
%	O
(	O
n	O
=	O
5	O
;	O
both	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

(	O
iii	O
)	O
IL	B-Protein
-	I-Protein
8	I-Protein
<EOS>	B-X
Inflammation	B-X
contributes	B-X
to	B-X
tumor	B-X
progression	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
excessive	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
in	B-X
situ	B-X
binding	B-X
assay	B-X
we	B-X
demonstrated	B-X
the	B-X
presence	B-X
of	B-X
binding	B-X
sites	B-X
for	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
and	B-X
RANTES	B-X
,	B-X
but	B-X
not	B-X
monocyte	B-X
inflammatory	B-X
protein-1	B-X
alpha	B-X
on	B-X
the	B-X
endothelium	B-X
of	B-X
postcapillary	B-X
venules	B-X
and	B-X
small	B-X
veins	B-X
in	B-X
human	B-X
skin	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
venules	B-X
and	B-X
veins	B-X
in	B-X
various	B-X
anatomical	B-X
locations	B-X
showed	B-X
dramatically	B-X
differing	B-X
IL-8	B-X
binding	B-X
patterns	B-X
.	B-X
The	B-X
subcellular	B-X
distribution	B-X
of	B-X
IL-8	B-X
in	B-X
the	B-X
venular	B-X
endothelial	B-X
cells	B-X
following	B-X
its	B-X
in	B-X
vivo	B-X
and	B-X
ex	B-X
vivo	B-X
injections	B-X
was	B-X
studied	B-X
by	B-X
use	B-X
of	B-X
electron	B-X
microscopy	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
IL-8	B-X
was	B-X
internalized	B-X
by	B-X
the	B-X
endothelial	B-X
cells	B-X
,	B-X
transported	B-X
transcellularly	B-X
via	B-X
plasmalemmal	B-X
vesicles	B-X
,	B-X
and	B-X
released	B-X
onto	B-X
the	B-X
luminal	B-X
surface	B-X
where	B-X
it	B-X
appeared	B-X
located	B-X
preferentially	B-X
on	B-X
tips	B-X
of	B-X
membrane	B-X
protrusions	B-X
.	B-X
We	B-X
were	B-X
unable	B-X
to	B-X
study	B-X
the	B-X
endothelial	B-X
IL-8	B-X
binding	B-X
or	B-X
transport	B-X
in	B-X
vitro	B-X
because	B-X
all	B-X
the	B-X
in	B-X
vitro	B-X
propagated	B-X
endothelial	B-X
cell	B-X
lines	B-X
and	B-X
primary	B-X
endothelial	B-X
cells	B-X
tested	B-X
lacked	B-X
IL-8	B-X
binding	B-X
sites	B-X
.	B-X
This	B-X
includes	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
,	B-X
which	B-X
also	B-X
did	B-X
not	B-X
bind	B-X
IL-8	B-X
in	B-X
situ	B-X
.	B-X
However	B-X
,	B-X
HUVECs	B-X
provided	B-X
a	B-X
satisfactory	B-X
in	B-X
vitro	B-X
system	B-X
to	B-X
study	B-X
the	B-X
secretion	B-X
of	B-X
IL-8	B-X
by	B-X
the	B-X
endothelial	B-X
cells	B-X
.	B-X

We	O
found	O
that	O
GP	O
induced	O
a	O
substantial	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
,	O
in	O
comparison	O
with	O
medium	O
control	O
,	O
especially	O
at	O
24	O
h	O
(	O
n	O
=	O
13	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
combination	O
of	O
GP	O
and	O
LPS	O
resulted	O
in	O
a	O
non	O
-	O
significant	O
increase	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
when	O
compared	O
to	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O

There	O
was	O
no	O
significant	O
alteration	O
in	O
IL	B-Protein
-	I-Protein
8	I-Protein
production	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
surveys	B-X
big	B-X
data	B-X
with	B-X
highlighting	B-X
the	B-X
big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
.	B-X
Big	B-X
data	B-X
characteristics	B-X
:	B-X
value	B-X
,	B-X
volume	B-X
,	B-X
velocity	B-X
,	B-X
variety	B-X
,	B-X
veracity	B-X
and	B-X
variability	B-X
are	B-X
described	B-X
.	B-X
Big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
covers	B-X
integration	B-X
and	B-X
analysis	B-X
of	B-X
large	B-X
amount	B-X
of	B-X
complex	B-X
heterogeneous	B-X
data	B-X
such	B-X
as	B-X
various	B-X
-	B-X
omics	B-X
data	B-X
(	B-X
genomics	B-X
,	B-X
epigenomics	B-X
,	B-X
transcriptomics	B-X
,	B-X
proteomics	B-X
,	B-X
metabolomics	B-X
,	B-X
interactomics	B-X
,	B-X
pharmacogenomics	B-X
,	B-X
diseasomics	B-X
)	B-X
,	B-X
biomedical	B-X
data	B-X
and	B-X
electronic	B-X
health	B-X
records	B-X
data	B-X
.	B-X
We	B-X
underline	B-X
the	B-X
challenging	B-X
issues	B-X
about	B-X
big	B-X
data	B-X
privacy	B-X
and	B-X
security	B-X
.	B-X
Regarding	B-X
big	B-X
data	B-X
characteristics	B-X
,	B-X
some	B-X
directions	B-X
of	B-X
using	B-X
suitable	B-X
and	B-X
promising	B-X
open-source	B-X
distributed	B-X
data	B-X
processing	B-X
software	B-X
platform	B-X
are	B-X
given	B-X
.	B-X

(	O
iv	O
)	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
<EOS>	B-X
Cytokine	B-X
storm	B-X
refers	B-X
to	B-X
a	B-X
set	B-X
of	B-X
clinical	B-X
conditions	B-X
caused	B-X
by	B-X
excessive	B-X
immune	B-X
reactions	B-X
and	B-X
has	B-X
been	B-X
recognized	B-X
as	B-X
a	B-X
leading	B-X
cause	B-X
of	B-X
severe	B-X
COVID-19	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
impaired	B-X
response	B-X
of	B-X
type-1	B-X
IFNs	B-X
in	B-X
early	B-X
stage	B-X
of	B-X
COVID-19	B-X
infection	B-X
played	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
cytokine	B-X
storm	B-X
,	B-X
and	B-X
various	B-X
cytokines	B-X
such	B-X
as	B-X
IL-6	B-X
and	B-X
IL-1	B-X
were	B-X
involved	B-X
in	B-X
severe	B-X
COVID-19	B-X
.	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
therapy	B-X
is	B-X
dose	B-X
limited	B-X
by	B-X
a	B-X
severe	B-X
vascular	B-X
leak	B-X
with	B-X
resulting	B-X
systemic	B-X
and	B-X
pulmonary	B-X
toxicity	B-X
.	B-X
Although	B-X
recognized	B-X
as	B-X
a	B-X
mediator	B-X
of	B-X
septic	B-X
shock	B-X
and	B-X
vascular	B-X
leak	B-X
,	B-X
the	B-X
relative	B-X
role	B-X
of	B-X
IL-1	B-X
in	B-X
IL-2	B-X
toxicity	B-X
is	B-X
unclear	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
effect	B-X
of	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
IL-1ra	B-X
)	B-X
on	B-X
IL-2	B-X
lethality	B-X
,	B-X
pulmonary	B-X
vascular	B-X
leak	B-X
,	B-X
and	B-X
treatment	B-X
of	B-X
pulmonary	B-X
metastases	B-X
in	B-X
a	B-X
murine	B-X
model	B-X
.	B-X
In	B-X
vivo	B-X
induction	B-X
of	B-X
mRNA	B-X
for	B-X
IL-1	B-X
alpha	B-X
was	B-X
evaluated	B-X
in	B-X
liver	B-X
by	B-X
Northern	B-X
blots	B-X
after	B-X
0	B-X
,	B-X
5	B-X
,	B-X
8	B-X
,	B-X
and	B-X
11	B-X
doses	B-X
of	B-X
IL-2	B-X
in	B-X
C3H/HEN	B-X
mice	B-X
.	B-X
The	B-X
expression	B-X
index	B-X
for	B-X
the	B-X
IL-1	B-X
alpha	B-X
gene	B-X
increased	B-X
from	B-X
0.16	B-X
to	B-X
0.74	B-X
after	B-X
5	B-X
doses	B-X
of	B-X
IL-2	B-X
,	B-X
and	B-X
further	B-X
increased	B-X
to	B-X
1.04	B-X
after	B-X
11	B-X
doses	B-X
of	B-X
IL-2	B-X
.	B-X
C3H/HEN	B-X
mice	B-X
(	B-X
n	B-X
=	B-X
56	B-X
)	B-X
were	B-X
randomized	B-X
to	B-X
receive	B-X
phosphate-buffered	B-X
saline	B-X
(	B-X
PBS	B-X
)	B-X
,	B-X
IL-1ra	B-X
high	B-X
dose	B-X
(	B-X
HD	B-X
)	B-X
,	B-X
or	B-X
IL-1ra	B-X
low	B-X
dose	B-X
(	B-X
LD	B-X
)	B-X
by	B-X
continuous	B-X
subcutaneous	B-X
infusion	B-X
via	B-X
Alzet	B-X
mini-pumps	B-X
.	B-X
The	B-X
biologic	B-X
effectiveness	B-X
of	B-X
the	B-X
dose	B-X
and	B-X
administration	B-X
of	B-X
IL-1ra	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
ability	B-X
to	B-X
block	B-X
IL-1-induced	B-X
IL-6	B-X
production	B-X
in	B-X
vivo	B-X
.	B-X
Mean	B-X
serum	B-X
IL-6	B-X
levels	B-X
3	B-X
hr	B-X
after	B-X
intraperitoneal	B-X
IL-1	B-X
alpha	B-X
(	B-X
10	B-X
micrograms/kg	B-X
)	B-X
were	B-X
:	B-X
PBS	B-X
,	B-X
3730	B-X
+/-	B-X
526	B-X
(	B-X
mean	B-X
+/-	B-X
SEM	B-X
pg/ml	B-X
)	B-X
;	B-X
IL-1ra	B-X
(	B-X
LD	B-X
)	B-X
,	B-X
1156	B-X
+/-	B-X
398	B-X
;	B-X
and	B-X
IL-1ra	B-X
(	B-X
HD	B-X
)	B-X
,	B-X
594	B-X
+/-	B-X
30	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
,	B-X
IL-1ra	B-X
HD	B-X
or	B-X
LD	B-X
vs	B-X
PBS	B-X
)	B-X
.	B-X
Pulmonary	B-X
vascular	B-X
leak	B-X
was	B-X
measured	B-X
by	B-X
iv	B-X
I125	B-X
albumin	B-X
after	B-X
8	B-X
doses	B-X
of	B-X
IL-2	B-X
(	B-X
100,000	B-X
U	B-X
ip	B-X
q	B-X
8	B-X
hr	B-X
)	B-X
.	B-X

Besides	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
was	O
the	O
only	O
mediator	O
which	O
was	O
produced	O
in	O
significant	O
quantities	O
following	O
GP	O
treatment	O
,	O
especially	O
at	O
24	O
h	O
(	O
n	O
=	O
14	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

When	O
compared	O
to	O
LPS	O
stimulation	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
GP	O
+	O
LPS	O
did	O
not	O
alter	O
the	O
kinetic	O
course	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
.	O
<EOS>	B-X
Production	B-X
of	B-X
interleukin	B-X
1	B-X
beta	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
,	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
,	B-X
interferon	B-X
gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
and	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
after	B-X
stimulation	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
was	B-X
studied	B-X
in	B-X
1/10	B-X
diluted	B-X
whole	B-X
blood	B-X
(	B-X
WB	B-X
)	B-X
culture	B-X
and	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cell	B-X
(	B-X
PBMC	B-X
)	B-X
culture	B-X
.	B-X
Cytokines	B-X
IL-1	B-X
beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
are	B-X
preferentially	B-X
stimulated	B-X
by	B-X
LPS	B-X
whereas	B-X
IL-2	B-X
,	B-X
IFN-gamma	B-X
and	B-X
GM-CSF	B-X
are	B-X
stimulated	B-X
by	B-X
PHA	B-X
.	B-X
Combination	B-X
of	B-X
5	B-X
micrograms/ml	B-X
PHA	B-X
and	B-X
25	B-X
micrograms/ml	B-X
LPS	B-X
gave	B-X
the	B-X
most	B-X
reliable	B-X
production	B-X
of	B-X
the	B-X
six	B-X
cytokines	B-X
studied	B-X
.	B-X
IL-1	B-X
beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
represent	B-X
a	B-X
homogeneous	B-X
group	B-X
of	B-X
early-produced	B-X
cytokines	B-X
positively	B-X
correlated	B-X
among	B-X
themselves	B-X
and	B-X
with	B-X
the	B-X
number	B-X
of	B-X
monocytes	B-X
in	B-X
the	B-X
culture	B-X
(	B-X
LeuM3	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
IL-1	B-X
beta	B-X
was	B-X
negatively	B-X
correlated	B-X
with	B-X
the	B-X
number	B-X
of	B-X
T8	B-X
lymphocytes	B-X
.	B-X
IL-2	B-X
,	B-X
IFN-gamma	B-X
and	B-X
GM-CSF	B-X
represent	B-X
a	B-X
group	B-X
of	B-X
late-produced	B-X
cytokines	B-X
.	B-X
Kinetics	B-X
and	B-X
production	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
GM-CSF	B-X
are	B-X
similar	B-X
in	B-X
WB	B-X
and	B-X
PBMC	B-X
cultures	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
production	B-X
levels	B-X
of	B-X
TNF-alpha	B-X
and	B-X
IFN-gamma	B-X
are	B-X
higher	B-X
in	B-X
WB	B-X
than	B-X
in	B-X
PBMC	B-X
whereas	B-X
production	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
IL-2	B-X
are	B-X
lower	B-X
in	B-X
WB	B-X
than	B-X
in	B-X
PBMC	B-X
.	B-X
Individual	B-X
variation	B-X
in	B-X
responses	B-X
to	B-X
PHA	B-X
+	B-X
LPS	B-X
was	B-X
always	B-X
higher	B-X
in	B-X
PBMC	B-X
cultures	B-X
than	B-X
in	B-X
WB	B-X
cultures	B-X
.	B-X
The	B-X
capacity	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
number	B-X
of	B-X
mononuclear	B-X
cells	B-X
is	B-X
higher	B-X
in	B-X
WB	B-X
,	B-X
or	B-X
in	B-X
PBMC	B-X
having	B-X
the	B-X
same	B-X
mononuclear	B-X
cell	B-X
concentration	B-X
as	B-X
WB	B-X
,	B-X
than	B-X
in	B-X
conventional	B-X
cultures	B-X
of	B-X
concentrated	B-X
PBMC	B-X
(	B-X
10	B-X
(	B-X
6	B-X
)	B-X
/ml	B-X
)	B-X
.	B-X
Because	B-X
it	B-X
mimics	B-X
the	B-X
natural	B-X
environment	B-X
,	B-X
diluted	B-X
WB	B-X
culture	B-X
may	B-X
be	B-X
the	B-X
most	B-X
appropriate	B-X
milieu	B-X
in	B-X
which	B-X
to	B-X
study	B-X
cytokine	B-X
production	B-X
in	B-X
vitro	B-X
.	B-X

However	O
,	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
found	O
a	O
synergistic	O
increase	O
in	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
from	O
18	O
h	O
to	O
48	O
h	O
,	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
for	O
instance	O
at	O
24	O
h	O
:	O
n	O
=	O
6	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
or	O
to	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
from	O
18	O
h	O
to	O
36	O
h	O
)	O
.	O
<EOS>	B-X
Phenylethanethiol	B-X
protected	B-X
nanomolecules	B-X
such	B-X
as	B-X
Au	B-X
A	B-X
novel	B-X
copper-based	B-X
catalyst	B-X
supported	B-X
by	B-X
a	B-X
long-chain	B-X
hydrocarbon	B-X
stearic	B-X
acid	B-X
(	B-X
Cu	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
H	B-X
In	B-X
the	B-X
title	B-X
triangulo-triruthenium	B-X
compound	B-X
,	B-X
[	B-X
Ru	B-X
(	B-X
3	B-X
)	B-X
(	B-X
C	B-X
(	B-X
25	B-X
)	B-X
H	B-X
(	B-X
22	B-X
)	B-X
As	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
36	B-X
)	B-X
H	B-X
(	B-X
27	B-X
)	B-X
As	B-X
)	B-X
(	B-X
CO	B-X
)	B-X
(	B-X
9	B-X
)	B-X
]	B-X
,	B-X
the	B-X
bis-	B-X
(	B-X
diphenyl-arsan-yl	B-X
)	B-X
methane	B-X
ligand	B-X
bridges	B-X
an	B-X
Ru-Ru	B-X
bond	B-X
and	B-X
the	B-X
monodentate	B-X
arsine	B-X
ligand	B-X
bonds	B-X
to	B-X
the	B-X
third	B-X
Ru	B-X
atom	B-X
.	B-X
Both	B-X
arsine	B-X
ligands	B-X
are	B-X
equatorial	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
Ru	B-X
(	B-X
3	B-X
)	B-X
triangle	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
each	B-X
Ru	B-X
atom	B-X
carries	B-X
one	B-X
equatorial	B-X
and	B-X
two	B-X
axial	B-X
terminal	B-X
carbonyl	B-X
ligands	B-X
.	B-X
The	B-X
phenyl	B-X
rings	B-X
of	B-X
biphenyl	B-X
are	B-X
twisted	B-X
from	B-X
each	B-X
other	B-X
by	B-X
dihedral	B-X
angles	B-X
of	B-X
50.5	B-X
(	B-X
2	B-X
)	B-X
,	B-X
44.5	B-X
(	B-X
2	B-X
)	B-X
and	B-X
27.8	B-X
(	B-X
2	B-X
)	B-X
°	B-X
.	B-X
The	B-X
arsine-substituted	B-X
phenyl	B-X
rings	B-X
make	B-X
dihedral	B-X
angles	B-X
of	B-X
61.56	B-X
(	B-X
18	B-X
)	B-X
,	B-X
89.36	B-X
(	B-X
18	B-X
)	B-X
and	B-X
83.27	B-X
(	B-X
18	B-X
)	B-X
°	B-X
with	B-X
each	B-X
other	B-X
.	B-X
The	B-X
dihedral	B-X
angles	B-X
between	B-X
the	B-X
two	B-X
benzene	B-X
rings	B-X
are	B-X
87.5	B-X
(	B-X
2	B-X
)	B-X
and	B-X
81.95	B-X
(	B-X
19	B-X
)	B-X
°	B-X
for	B-X
the	B-X
two	B-X
diphenyl-arsanyl	B-X
groups	B-X
.	B-X
In	B-X
the	B-X
crystal	B-X
,	B-X
mol-ecules	B-X
are	B-X
linked	B-X
into	B-X
dimers	B-X
by	B-X
inter-molecular	B-X
C-H⋯O	B-X
hydrogen	B-X
bonds	B-X
.	B-X
Weak	B-X
inter-molecular	B-X
C-H⋯π	B-X
and	B-X
π-π	B-X
[	B-X
centroid-centroid	B-X
distance	B-X
=	B-X
3.601	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
inter-actions	B-X
stabilize	B-X
the	B-X
crystal	B-X
structure	B-X
.	B-X

Over	O
the	O
time	O
course	O
of	O
48	O
h	O
,	O
GP	O
elevated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
amount	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
approximately	O
200	O
%	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Positive	O
correlation	O
between	O
GP	O
-	O
induced	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
productions	O
.	O

Following	O
stimulation	O
with	O
GP	O
(	O
24	O
h	O
)	O
,	O
we	O
observed	O
a	O
positive	O
correlation	O
between	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O

Moreover	O
,	O
we	O
found	O
this	O
correlation	O
to	O
be	O
dose	O
-	O
dependent	O
,	O
since	O
100	O
mug	O
of	O
GP	O
induced	O
larger	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
1	O
mug	O
GP	O
(	O
n	O
=	O
5	O
,	O
p	O
<	O
=	O
0	O
.	O
002	O
,	O
r	O
=	O
0	O
.	O
9	O
and	O
0	O
.	O
98	O
,	O
respectively	O
)	O
.	O

(	O
v	O
)	O
TNFalpha	B-Protein
<EOS>	B-X
Seronegative	B-X
spondyloarthritis	B-X
is	B-X
a	B-X
progressive	B-X
inflammatory	B-X
disease	B-X
with	B-X
a	B-X
wide	B-X
and	B-X
varied	B-X
range	B-X
of	B-X
symptoms	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
provide	B-X
basic	B-X
information	B-X
on	B-X
therapeutic	B-X
options	B-X
for	B-X
exercise	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
ankylosing	B-X
spondylitis	B-X
.	B-X
Therapeutic	B-X
exercise	B-X
is	B-X
the	B-X
most	B-X
important	B-X
non-pharmacological	B-X
intervention	B-X
in	B-X
patients	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
positive	B-X
metabolic	B-X
effects	B-X
,	B-X
exercise	B-X
also	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
improving	B-X
spinal	B-X
mobility	B-X
and	B-X
muscle	B-X
strength	B-X
.	B-X
Exercise	B-X
improves	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
physical	B-X
condition	B-X
,	B-X
and	B-X
symptoms	B-X
associated	B-X
with	B-X
ankylosing	B-X
spondylitis	B-X
.	B-X

With	O
respect	O
to	O
TNFalpha	B-Protein
production	O
,	O
100	O
mug	O
of	O
GP	O
yielded	O
minor	O
,	O
statistically	O
not	O
distinguishable	O
amounts	O
,	O
when	O
compared	O
to	O
medium	O
control	O
.	O

GP	O
+	O
LPS	O
did	O
not	O
change	O
the	O
TNFalpha	B-Protein
production	O
when	O
compared	O
to	O
LPS	O
supplementation	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
<EOS>	B-X
Transient	B-X
receptor	B-X
potential	B-X
(	B-X
TRP	B-X
)	B-X
channels	B-X
are	B-X
one	B-X
primary	B-X
type	B-X
of	B-X
calcium	B-X
(	B-X
Ca	B-X
Autotaxin	B-X
(	B-X
ATX	B-X
,	B-X
ENPP2	B-X
)	B-X
is	B-X
a	B-X
secreted	B-X
glycoprotein	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
extracellular	B-X
production	B-X
of	B-X
lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
which	B-X
exerts	B-X
multiple	B-X
effects	B-X
in	B-X
almost	B-X
all	B-X
cell	B-X
types	B-X
through	B-X
its	B-X
at	B-X
least	B-X
six	B-X
G-protein-coupled	B-X
LPA	B-X
receptors	B-X
(	B-X
LPARs	B-X
)	B-X
.	B-X
Mice	B-X
with	B-X
50	B-X
%	B-X
reduced	B-X
serum	B-X
ATX	B-X
levels	B-X
showed	B-X
improved	B-X
survival	B-X
upon	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
compared	B-X
to	B-X
their	B-X
littermate	B-X
controls	B-X
.	B-X
Similarly	B-X
,	B-X
mice	B-X
bearing	B-X
the	B-X
inducible	B-X
inactivation	B-X
of	B-X
ATX	B-X
and	B-X
presenting	B-X
with	B-X
>	B-X
70	B-X
%	B-X
decreased	B-X
ATX	B-X
levels	B-X
were	B-X
even	B-X
more	B-X
protected	B-X
against	B-X
LPS-induced	B-X
endotoxemia	B-X
;	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
effects	B-X
were	B-X
observed	B-X
upon	B-X
the	B-X
chronic	B-X
and	B-X
systemic	B-X
transgenic	B-X
overexpression	B-X
of	B-X
ATX	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
a	B-X
role	B-X
for	B-X
ATX	B-X
in	B-X
LPS-induced	B-X
sepsis	B-X
and	B-X
suggest	B-X
possible	B-X
therapeutic	B-X
benefits	B-X
of	B-X
pharmacologically	B-X
targeting	B-X
ATX	B-X
in	B-X
severe	B-X
,	B-X
systemic	B-X
inflammatory	B-X
disorders	B-X
.	B-X

When	O
combined	O
with	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
GP	O
seemed	O
to	O
exert	O
a	O
synergistic	O
effect	O
on	O
TNFalpha	B-Protein
secretion	O
after	O
36	O
h	O
(	O
n	O
=	O
3	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
overall	O
an	O
enhancement	O
of	O
only	O
10	O
%	O
was	O
observed	O
(	O
p	O
>	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O
<EOS>	B-X
Atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
a	B-X
condition	B-X
affecting	B-X
30	B-X
million	B-X
persons	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X
AD	B-X
patients	B-X
are	B-X
heavily	B-X
infected	B-X
with	B-X
Staphylococcus	B-X
aureus	B-X
on	B-X
the	B-X
skin	B-X
.	B-X
A	B-X
particularly	B-X
severe	B-X
form	B-X
of	B-X
AD	B-X
is	B-X
eczema	B-X
herpeticum	B-X
(	B-X
ADEH	B-X
)	B-X
,	B-X
where	B-X
the	B-X
patients	B-X
'	B-X
AD	B-X
is	B-X
complicated	B-X
by	B-X
S.	B-X
aureus	B-X
and	B-X
herpes	B-X
simplex	B-X
virus	B-X
(	B-X
HSV	B-X
)	B-X
infection	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
S.	B-X
aureus	B-X
strains	B-X
from	B-X
15	B-X
ADEH	B-X
patients	B-X
,	B-X
provided	B-X
blinded	B-X
,	B-X
and	B-X
showed	B-X
a	B-X
high	B-X
association	B-X
of	B-X
ADEH	B-X
with	B-X
strains	B-X
that	B-X
produce	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin-1	B-X
(	B-X
TSST-1	B-X
;	B-X
73	B-X
%	B-X
)	B-X
compared	B-X
to	B-X
10	B-X
%	B-X
production	B-X
by	B-X
typical	B-X
AD	B-X
isolates	B-X
from	B-X
patients	B-X
without	B-X
EH	B-X
and	B-X
those	B-X
from	B-X
another	B-X
unrelated	B-X
condition	B-X
,	B-X
cystic	B-X
fibrosis	B-X
.	B-X
The	B-X
ADEH	B-X
isolates	B-X
produced	B-X
the	B-X
superantigens	B-X
associated	B-X
with	B-X
TSS	B-X
(	B-X
TSST-1	B-X
and	B-X
staphylococcal	B-X
enterotoxins	B-X
A	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
)	B-X
.	B-X
This	B-X
association	B-X
may	B-X
in	B-X
part	B-X
explain	B-X
the	B-X
potential	B-X
severity	B-X
of	B-X
ADEH	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
TSST-1	B-X
and	B-X
HSV-1	B-X
on	B-X
human	B-X
epithelial	B-X
cells	B-X
and	B-X
keratinocytes	B-X
.	B-X
TSST-1	B-X
used	B-X
CD40	B-X
as	B-X
its	B-X
receptor	B-X
on	B-X
epithelial	B-X
cells	B-X
,	B-X
and	B-X
HSV-1	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
interacted	B-X
with	B-X
CD40	B-X
.	B-X
The	B-X
consequence	B-X
of	B-X
these	B-X
interactions	B-X
was	B-X
chemokine	B-X
production	B-X
,	B-X
which	B-X
is	B-X
capable	B-X
of	B-X
causing	B-X
harmful	B-X
inflammation	B-X
,	B-X
with	B-X
epidermal/keratinocyte	B-X
barrier	B-X
disruption	B-X
.	B-X
Human	B-X
epithelial	B-X
cells	B-X
treated	B-X
first	B-X
with	B-X
TSST-1	B-X
and	B-X
then	B-X
HSV-1	B-X
resulted	B-X
in	B-X
enhanced	B-X
chemokine	B-X
production	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
TSST-1	B-X
modestly	B-X
increased	B-X
HSV-1	B-X
replication	B-X
but	B-X
did	B-X
not	B-X
increase	B-X
viral	B-X
plaque	B-X
size	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
ADEH	B-X
is	B-X
associated	B-X
with	B-X
production	B-X
of	B-X
the	B-X
major	B-X
TSS-associated	B-X
superantigens	B-X
,	B-X
together	B-X
with	B-X
HSV	B-X
reactivation	B-X
.	B-X
The	B-X
superantigens	B-X
plus	B-X
HSV	B-X
may	B-X
damage	B-X
the	B-X
skin	B-X
barrier	B-X
by	B-X
causing	B-X
harmful	B-X
inflammation	B-X
,	B-X
thereby	B-X
leading	B-X
to	B-X
increased	B-X
symptoms	B-X
.	B-X

(	O
vi	O
)	O
IFNgamma	B-Protein
<EOS>	B-X
Interferon	B-X
(	B-X
IFN	B-X
)	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
substance	B-X
'interfering	B-X
'	B-X
with	B-X
viral	B-X
replication	B-X
in	B-X
vitro	B-X
.	B-X
In	B-X
the	B-X
mouse	B-X
model	B-X
of	B-X
experimental	B-X
infections	B-X
in	B-X
vivo	B-X
,	B-X
IFN-alpha/beta	B-X
are	B-X
essential	B-X
for	B-X
immunity	B-X
to	B-X
most	B-X
viruses	B-X
tested	B-X
,	B-X
whereas	B-X
IFN-gamma	B-X
is	B-X
important	B-X
for	B-X
immunity	B-X
to	B-X
a	B-X
smaller	B-X
number	B-X
of	B-X
viruses	B-X
,	B-X
together	B-X
with	B-X
bacteria	B-X
,	B-X
fungi	B-X
,	B-X
and	B-X
parasites	B-X
,	B-X
consistent	B-X
with	B-X
IFN-gamma	B-X
acting	B-X
as	B-X
the	B-X
'macrophage	B-X
activating	B-X
factor	B-X
.	B-X
'	B-X
Disorders	B-X
of	B-X
IFN-gamma	B-X
production	B-X
,	B-X
caused	B-X
by	B-X
IL12B	B-X
,	B-X
IL12RB1	B-X
,	B-X
and	B-X
specific	B-X
NEMO	B-X
mutations	B-X
,	B-X
or	B-X
of	B-X
IFN-gamma	B-X
responses	B-X
,	B-X
caused	B-X
by	B-X
IFNGR1	B-X
,	B-X
IFNGR2	B-X
,	B-X
and	B-X
dominant	B-X
STAT1	B-X
mutations	B-X
,	B-X
confer	B-X
predisposition	B-X
to	B-X
mycobacterial	B-X
disease	B-X
in	B-X
patients	B-X
resistant	B-X
to	B-X
most	B-X
viruses	B-X
.	B-X
Consistently	B-X
,	B-X
patients	B-X
with	B-X
impaired	B-X
responses	B-X
to	B-X
IFN-alpha/beta	B-X
,	B-X
IFN-gamma	B-X
,	B-X
and	B-X
presumably	B-X
IFN-lambda	B-X
(	B-X
carrying	B-X
recessive	B-X
mutations	B-X
in	B-X
STAT1	B-X
)	B-X
,	B-X
or	B-X
with	B-X
impaired	B-X
responses	B-X
to	B-X
IFN-alpha/beta	B-X
and	B-X
impaired	B-X
IFN-gamma	B-X
production	B-X
(	B-X
carrying	B-X
mutations	B-X
in	B-X
TYK2	B-X
)	B-X
,	B-X
or	B-X
with	B-X
impaired	B-X
production	B-X
of	B-X
IFN-alpha/beta	B-X
,	B-X
IFN-gamma	B-X
,	B-X
and	B-X
IFN-lambda	B-X
(	B-X
carrying	B-X
specific	B-X
mutations	B-X
in	B-X
NEMO	B-X
)	B-X
,	B-X
are	B-X
vulnerable	B-X
to	B-X
mycobacterial	B-X
and	B-X
viral	B-X
infections	B-X
,	B-X
including	B-X
HSE	B-X
.	B-X
IFN-gamma	B-X
is	B-X
essential	B-X
for	B-X
anti-mycobacterial	B-X
immunity	B-X
,	B-X
whereas	B-X
IFN-alpha/beta	B-X
and	B-X
IFN-lambda	B-X
are	B-X
essential	B-X
for	B-X
anti-viral	B-X
immunity	B-X
.	B-X
Future	B-X
studies	B-X
in	B-X
humans	B-X
aim	B-X
to	B-X
define	B-X
the	B-X
specific	B-X
roles	B-X
of	B-X
IFN-alpha/beta	B-X
and	B-X
IFN-lambda	B-X
types	B-X
and	B-X
individual	B-X
molecules	B-X
in	B-X
host	B-X
defense	B-X
in	B-X
natura	B-X
.	B-X

No	O
IFNgamma	B-Protein
production	O
was	O
detectable	O
following	O
treatment	O
of	O
PBMC	O
with	O
100	O
mug	O
GP	O
.	O

There	O
was	O
a	O
minor	O
increase	O
in	O
IFNgamma	B-Protein
production	O
following	O
GP	O
+	O
LPS	O
at	O
36	O
h	O
,	O
when	O
compared	O
to	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
and	O
a	O
slight	O
down	O
-	O
regulation	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
at	O
24	O
h	O
and	O
36	O
h	O
,	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
surveys	B-X
big	B-X
data	B-X
with	B-X
highlighting	B-X
the	B-X
big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
.	B-X
Big	B-X
data	B-X
characteristics	B-X
:	B-X
value	B-X
,	B-X
volume	B-X
,	B-X
velocity	B-X
,	B-X
variety	B-X
,	B-X
veracity	B-X
and	B-X
variability	B-X
are	B-X
described	B-X
.	B-X
Big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
covers	B-X
integration	B-X
and	B-X
analysis	B-X
of	B-X
large	B-X
amount	B-X
of	B-X
complex	B-X
heterogeneous	B-X
data	B-X
such	B-X
as	B-X
various	B-X
-	B-X
omics	B-X
data	B-X
(	B-X
genomics	B-X
,	B-X
epigenomics	B-X
,	B-X
transcriptomics	B-X
,	B-X
proteomics	B-X
,	B-X
metabolomics	B-X
,	B-X
interactomics	B-X
,	B-X
pharmacogenomics	B-X
,	B-X
diseasomics	B-X
)	B-X
,	B-X
biomedical	B-X
data	B-X
and	B-X
electronic	B-X
health	B-X
records	B-X
data	B-X
.	B-X
We	B-X
underline	B-X
the	B-X
challenging	B-X
issues	B-X
about	B-X
big	B-X
data	B-X
privacy	B-X
and	B-X
security	B-X
.	B-X
Regarding	B-X
big	B-X
data	B-X
characteristics	B-X
,	B-X
some	B-X
directions	B-X
of	B-X
using	B-X
suitable	B-X
and	B-X
promising	B-X
open-source	B-X
distributed	B-X
data	B-X
processing	B-X
software	B-X
platform	B-X
are	B-X
given	B-X
.	B-X

(	O
vii	O
)	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
TGFbeta1	B-Protein

The	O
production	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
TGFbeta	B-Protein
1	I-Protein
was	O
not	O
induced	O
by	O
GP	O
.	O
<EOS>	B-X
Volunteers	B-X
were	B-X
orally	B-X
administered	B-X
invasive	B-X
,	B-X
non-Shiga	B-X
toxin-producing	B-X
Shigella	B-X
dysenteriae	B-X
1	B-X
to	B-X
establish	B-X
a	B-X
challenge	B-X
model	B-X
to	B-X
assess	B-X
vaccine	B-X
efficacy	B-X
.	B-X
In	B-X
stepwise	B-X
fashion	B-X
,	B-X
four	B-X
separate	B-X
groups	B-X
were	B-X
given	B-X
3	B-X
x	B-X
10	B-X
(	B-X
2	B-X
)	B-X
,	B-X
7	B-X
x	B-X
10	B-X
(	B-X
3	B-X
)	B-X
,	B-X
5	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
,	B-X
or	B-X
7	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
CFU	B-X
.	B-X
Using	B-X
PBMC	B-X
,	B-X
proliferative	B-X
responses	B-X
and	B-X
cytokine	B-X
production	B-X
were	B-X
measured	B-X
to	B-X
S.	B-X
dysenteriae	B-X
whole-cell	B-X
preparations	B-X
and	B-X
to	B-X
purified	B-X
recombinant	B-X
invasion	B-X
plasmid	B-X
Ags	B-X
(	B-X
Ipa	B-X
)	B-X
C	B-X
and	B-X
IpaD	B-X
.	B-X
Preinoculation	B-X
PBMC	B-X
produced	B-X
considerable	B-X
quantities	B-X
of	B-X
IL-10	B-X
and	B-X
IFN-gamma	B-X
,	B-X
probably	B-X
secreted	B-X
by	B-X
monocytes	B-X
and	B-X
NK	B-X
cells	B-X
,	B-X
respectively	B-X
,	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
.	B-X
Following	B-X
inoculation	B-X
,	B-X
PBMC	B-X
from	B-X
95	B-X
and	B-X
87	B-X
%	B-X
of	B-X
volunteers	B-X
exhibited	B-X
an	B-X
increased	B-X
production	B-X
of	B-X
IFN-gamma	B-X
and	B-X
IL-10	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
response	B-X
to	B-X
Shigella	B-X
Ags	B-X
.	B-X
No	B-X
IL-4	B-X
or	B-X
IL-5	B-X
responses	B-X
were	B-X
detected	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
humans	B-X
,	B-X
type	B-X
1	B-X
responses	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
mucosal	B-X
and	B-X
systemic	B-X
immunity	B-X
to	B-X
S.	B-X
dysentariae	B-X
1	B-X
.	B-X

There	O
were	O
also	O
no	O
significant	O
differences	O
between	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
LPS	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
over	O
48	O
h	O
(	O
data	O
not	O
shown	O
)	O
.	O

Role	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
binding	O
in	O
LPS	O
-	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
,	O
GP	O
-	O
,	O
GP	O
+	O
LPS	O
-	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
expression	O
by	O
human	O
PBMC	O

Because	O
GP	O
induced	O
band	O
shifts	O
to	O
NFkappaB	O
,	O
NFIL	O
-	O
6	O
and	O
NFAT	O
sites	O
,	O
but	O
no	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
or	O
IFNgamma	B-Protein
,	O
we	O
hypothesized	O
that	O
the	O
activated	O
transcription	O
factors	O
might	O
bind	O
to	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

We	O
investigated	O
previoulsy	O
described	O
and	O
newly	O
discovered	O
transcription	O
factor	O
binding	O
sites	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
Table	O
1	O
)	O
using	O
the	O
program	O
OMIGA	O
(	O
v	O
.	O
1	O
.	O
1	O
.	O
3	O
,	O
Oxford	O
Molecular	O
,	O
Oxford	O
,	O
UK	O
)	O
.	O

The	O
LPS	O
responsive	O
kappaB	O
consensus	O
site	O
of	O
LRE	O
-	O
1	O
(	O
between	O
-	O
84	O
and	O
-	O
93	O
)	O
[	O
30	O
]	O
displayed	O
band	O
shifts	O
,	O
but	O
no	O
significant	O
alterations	O
of	O
its	O
binding	O
activity	O
,	O
irrespective	O
of	O
the	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
new	O
kappaB3	O
site	O
(	O
-	O
100	O
and	O
-	O
130	O
)	O
within	O
the	O
LRE	O
-	O
1	O
[	O
30	O
]	O
showed	O
increased	O
binding	O
induced	O
by	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
30	O
%	O
vs	O
.	O
control	O
)	O
,	O
but	O
GP	O
co	O
-	O
treatment	O
up	O
-	O
regulated	O
the	O
LPS	O
(	O
+	O
65	O
%	O
vs	O
.	O
control	O
)	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
+	O
110	O
%	O
vs	O
.	O
control	O
)	O
-	O
induced	O
binding	O
in	O
a	O
superadditive	O
synergistic	O
fashion	O
,	O
when	O
compared	O
to	O
medium	O
control	O
as	O
well	O
as	O
to	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
or	O
the	O
theoretical	O
values	O
of	O
GP	O
/	O
LPS	O
calc	O
.	O
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
<EOS>	B-X
The	B-X
treatment	B-X
of	B-X
frostbite	B-X
.	B-X
The	B-X
liver	B-X
and	B-X
jaundice	B-X
.	B-X
Bullous	B-X
emphysema	B-X
.	B-X
EMPHYSEMATOUS	B-X
bullae	B-X
.	B-X

(	O
all	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
4	O
)	O
.	O

Binding	O
to	O
a	O
new	O
kappaB	O
consensus	O
site	O
(	O
between	O
-	O
266	O
and	O
-	O
280	O
)	O
was	O
significantly	O
elevated	O
for	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
p	O
<	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
LPS	O
-	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
GP	O
+	O
LPS	O
-	O
induced	O
binding	O
to	O
the	O
new	O
kappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
was	O
down	O
-	O
regulated	O
by	O
about	O
20	O
-	O
35	O
%	O
in	O
comparison	O
with	O
medium	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
NFIL	O
-	O
6	O
site	O
(	O
-	O
147	O
and	O
-	O
170	O
)	O
close	O
to	O
LRE	O
-	O
2	O
[	O
31	O
,	O
32	O
]	O
showed	O
an	O
up	O
-	O
regulation	O
of	O
binding	O
for	O
all	O
compounds	O
and	O
combinations	O
vs	O
.	O
medium	O
control	O
,	O
ranging	O
from	O
25	O
-	O
110	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Further	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
induced	O
an	O
increased	O
binding	O
to	O
the	O
NFIL	O
-	O
6	O
site	O
in	O
comparison	O
with	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
1	O
.	O
3fold	O
)	O
or	O
GP	O
(	O
1	O
.	O
6fold	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
Lisinopril	B-X
is	B-X
an	B-X
antihypertensive	B-X
drug	B-X
with	B-X
poor	B-X
intestinal	B-X
permeability	B-X
.	B-X
Enhancement	B-X
of	B-X
intestinal	B-X
absorption	B-X
depends	B-X
on	B-X
a	B-X
clear	B-X
understanding	B-X
of	B-X
the	B-X
permeation	B-X
pathways	B-X
and	B-X
absorption	B-X
mechanisms	B-X
.	B-X
Unfortunately	B-X
,	B-X
these	B-X
are	B-X
not	B-X
fully	B-X
elucidated	B-X
for	B-X
lisinopril	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
aim	B-X
was	B-X
to	B-X
determine	B-X
lisinopril	B-X
permeation	B-X
pathways	B-X
and	B-X
obstacles	B-X
limiting	B-X
membrane	B-X
transport	B-X
with	B-X
subsequent	B-X
nomination	B-X
of	B-X
appropriate	B-X
permeation	B-X
enhancers	B-X
.	B-X
This	B-X
employed	B-X
an	B-X
in	B-X
situ	B-X
rabbit	B-X
intestinal	B-X
perfusion	B-X
technique	B-X
,	B-X
which	B-X
revealed	B-X
site-dependent	B-X
absorptive	B-X
clearance	B-X
(	B-X
PeA/L	B-X
)	B-X
from	B-X
a	B-X
lisinopril	B-X
simple	B-X
solution	B-X
(	B-X
5	B-X
μg/ml	B-X
)	B-X
,	B-X
with	B-X
paracellular	B-X
absorption	B-X
playing	B-X
a	B-X
role	B-X
.	B-X
Regional	B-X
drug	B-X
permeability	B-X
ranked	B-X
as	B-X
colon	B-X
>	B-X
duodenum	B-X
>	B-X
jejunum	B-X
>	B-X
ileum	B-X
opposing	B-X
intestinal	B-X
expression	B-X
rank	B-X
of	B-X
P-glycoprotein	B-X
(	B-X
P-gp	B-X
)	B-X
efflux	B-X
transporters	B-X
.	B-X
Duodenal	B-X
and	B-X
jejunal	B-X
perfusion	B-X
of	B-X
a	B-X
higher	B-X
lisinopril	B-X
concentration	B-X
(	B-X
50	B-X
μg/ml	B-X
)	B-X
reflected	B-X
saturable	B-X
absorption	B-X
,	B-X
suggesting	B-X
carrier-mediated	B-X
transport	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
piperine	B-X
and	B-X
verapamil	B-X
as	B-X
P-gp	B-X
inhibitors	B-X
on	B-X
intestinal	B-X
absorption	B-X
of	B-X
lisinopril	B-X
was	B-X
investigated	B-X
.	B-X
Coperfusion	B-X
with	B-X
either	B-X
piperine	B-X
or	B-X
verapamil	B-X
significantly	B-X
enhanced	B-X
lisinopril	B-X
absorption	B-X
,	B-X
with	B-X
enhancement	B-X
being	B-X
dominant	B-X
in	B-X
the	B-X
ileum	B-X
segment	B-X
.	B-X
This	B-X
supported	B-X
the	B-X
contribution	B-X
of	B-X
P-gp	B-X
transporters	B-X
to	B-X
poor	B-X
lisinopril	B-X
permeability	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
coperfusion	B-X
of	B-X
lisinopril	B-X
with	B-X
zinc	B-X
acetate	B-X
dihydrate	B-X
significantly	B-X
multiplied	B-X
lisinopril	B-X
PeA/L	B-X
by	B-X
2.3-	B-X
and	B-X
6.6-fold	B-X
in	B-X
duodenum	B-X
and	B-X
ileum	B-X
segments	B-X
,	B-X
respectively	B-X
,	B-X
through	B-X
magnifying	B-X
intestinal	B-X
water	B-X
flux	B-X
.	B-X
The	B-X
study	B-X
explored	B-X
the	B-X
barriers	B-X
limiting	B-X
lisinopril	B-X
intestinal	B-X
absorption	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
study	B-X
exposed	B-X
clinically	B-X
relevant	B-X
lisinopril	B-X
interactions	B-X
with	B-X
common	B-X
coadministered	B-X
cargos	B-X
that	B-X
should	B-X
be	B-X
considered	B-X
for	B-X
an	B-X
appropriate	B-X
lisinopril	B-X
regimen	B-X
.	B-X

A	O
new	O
binding	O
site	O
for	O
NFATP2	O
/	O
3	O
was	O
found	O
more	O
distal	O
of	O
the	O
transcription	O
start	O
site	O
,	O
between	O
-	O
471	O
and	O
-	O
490	O
,	O
displaying	O
again	O
a	O
substantial	O
increase	O
of	O
binding	O
for	O
all	O
compounds	O
and	O
combinations	O
,	O
when	O
compared	O
to	O
medium	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
binding	O
to	O
the	O
NFATP2	O
/	O
3	O
site	O
following	O
both	O
,	O
GP	O
+	O
LPS	O
(	O
1	O
.	O
4fold	O
of	O
GP	O
)	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
1	O
.	O
5fold	O
of	O
GP	O
,	O
1	O
.	O
25fold	O
of	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
was	O
elevated	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
5	O
)	O
,	O
but	O
only	O
in	O
an	O
additive	O
synergistic	O
manner	O
,	O
i	O
.	O
e	O
.	O
the	O
experimental	O
results	O
were	O
not	O
different	O
from	O
the	O
theoretical	O
values	O
(	O
calc	O
.	O
)	O
.	O

GP	O
modulated	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
towards	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O

In	O
a	O
simplified	O
approach	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
might	O
represent	O
two	O
sides	O
of	O
a	O
coin	O
,	O
i	O
.	O
e	O
.	O
pro	O
-	O
or	O
anti	O
-	O
inflammatory	O
action	O
.	O
<EOS>	B-X
Non-steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
(	B-X
NSAIDs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
often	B-X
chemically	B-X
unrelated	B-X
compounds	B-X
with	B-X
some	B-X
common	B-X
therapeutic	B-X
actions	B-X
and	B-X
side	B-X
effects	B-X
.	B-X
They	B-X
have	B-X
potent	B-X
anti-inflammatory	B-X
,	B-X
analgesic	B-X
and	B-X
antipyretic	B-X
activity	B-X
,	B-X
and	B-X
are	B-X
among	B-X
the	B-X
most	B-X
widely	B-X
used	B-X
drugs	B-X
worldwide	B-X
.	B-X
It	B-X
is	B-X
generally	B-X
thought	B-X
that	B-X
one	B-X
of	B-X
their	B-X
main	B-X
mechanisms	B-X
of	B-X
action	B-X
is	B-X
the	B-X
inhibition	B-X
of	B-X
cyclo-oxygenase	B-X
(	B-X
COX	B-X
)	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
biosynthesing	B-X
the	B-X
prostaglandins	B-X
and	B-X
thromboxane	B-X
.	B-X
NSAIDs	B-X
are	B-X
also	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
adverse	B-X
gastrointestinal	B-X
,	B-X
renal	B-X
and	B-X
cardiovascular	B-X
effects	B-X
.	B-X
This	B-X
review	B-X
describes	B-X
the	B-X
clinical	B-X
pharmacology	B-X
of	B-X
NSAIDs	B-X
,	B-X
their	B-X
classification	B-X
,	B-X
molecular	B-X
mechanisms	B-X
of	B-X
action	B-X
and	B-X
adverse	B-X
effects	B-X
,	B-X
including	B-X
their	B-X
possible	B-X
contribution	B-X
to	B-X
neuro-inflammation	B-X
and	B-X
carcinogenesis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
some	B-X
recent	B-X
developments	B-X
aimed	B-X
at	B-X
designing	B-X
effective	B-X
anti-inflammatory	B-X
agents	B-X
with	B-X
improved	B-X
safety	B-X
and	B-X
tolerability	B-X
profiles	B-X
.	B-X

Therefore	O
,	O
we	O
applied	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
as	O
an	O
indicator	O
of	O
the	O
degree	O
of	O
inflammation	O
.	O

Both	O
,	O
LPS	O
and	O
GP	O
+	O
LPS	O
treatments	O
resulted	O
in	O
generating	O
more	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
than	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
at	O
early	O
time	O
points	O
,	O
i	O
.	O
e	O
.	O
up	O
to	O
24	O
h	O
.	O

Comparing	O
LPS	O
vs	O
.	O
GP	O
+	O
LPS	O
,	O
we	O
did	O
not	O
find	O
substantial	O
alterations	O
over	O
a	O
time	O
course	O
of	O
48	O
h	O
in	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
,	O
only	O
a	O
-	O
non	O
-	O
significant	O
-	O
2	O
.	O
5fold	O
higher	O
ratio	O
at	O
6	O
h	O
.	O
<EOS>	B-X
Ghrelin	B-X
is	B-X
a	B-X
hormone	B-X
mainly	B-X
produced	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
gastric	B-X
mucosa	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
possess	B-X
anti-inflammatory	B-X
and	B-X
immunomodulatory	B-X
properties	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
ghrelin	B-X
levels	B-X
during	B-X
sepsis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
an	B-X
experimental	B-X
sepsis	B-X
model	B-X
.	B-X
Alveolar	B-X
macrophages	B-X
are	B-X
the	B-X
front-line	B-X
defense	B-X
against	B-X
environmental	B-X
pathogens	B-X
.	B-X
However	B-X
,	B-X
to	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
differences	B-X
in	B-X
function	B-X
and	B-X
phenotypic	B-X
expression	B-X
levels	B-X
of	B-X
macrophages	B-X
between	B-X
neonatal	B-X
and	B-X
adult	B-X
lungs	B-X
have	B-X
not	B-X
previously	B-X
been	B-X
determined	B-X
.	B-X
The	B-X
present	B-X
study	B-X
investigated	B-X
lung	B-X
tissues	B-X
and	B-X
analyzed	B-X
blood	B-X
samples	B-X
to	B-X
find	B-X
cell	B-X
markers	B-X
of	B-X
M1	B-X
and	B-X
M2	B-X
macrophages	B-X
in	B-X
neonatal	B-X
and	B-X
adult	B-X
rats	B-X
.	B-X
Pulmonary	B-X
sepsis	B-X
was	B-X
induced	B-X
by	B-X
intrapleural	B-X
instillation	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
;	B-X
20	B-X
mg/kg	B-X
)	B-X
and	B-X
survival	B-X
time	B-X
after	B-X
administration	B-X
of	B-X
LPS	B-X
was	B-X
measured	B-X
.	B-X
In	B-X
certain	B-X
neonates	B-X
,	B-X
a	B-X
selective	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
inhibitor	B-X
,	B-X
1400w	B-X
,	B-X
was	B-X
administered	B-X
prior	B-X
to	B-X
induction	B-X
of	B-X
pulmonary	B-X
sepsis	B-X
.	B-X
Compared	B-X
with	B-X
adults	B-X
,	B-X
fetal	B-X
and	B-X
neonatal	B-X
lung	B-X
tissues	B-X
had	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
iNOS	B-X
and	B-X
CD86	B-X
(	B-X
M1	B-X
markers	B-X
)	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
CD206	B-X
and	B-X
arginase-1	B-X
(	B-X
M2	B-X
markers	B-X
)	B-X
were	B-X
lower	B-X
in	B-X
the	B-X
neonatal	B-X
lung	B-X
.	B-X
The	B-X
circulating	B-X
cells	B-X
that	B-X
co-expressed	B-X
CD68	B-X
(	B-X
monocytes	B-X
and	B-X
macrophages	B-X
)	B-X
and	B-X
CD86	B-X
in	B-X
the	B-X
blood	B-X
were	B-X
also	B-X
significantly	B-X
higher	B-X
in	B-X
neonates	B-X
than	B-X
in	B-X
adults	B-X
(	B-X
25.9±6.6	B-X
vs.	B-X
11.6±2.2	B-X
%	B-X
;	B-X
P=0.007	B-X
.	B-X
At	B-X
basal	B-X
unstimulated	B-X
conditions	B-X
,	B-X
lung	B-X
tissue	B-X
concentrations	B-X
of	B-X
nitrite	B-X
and	B-X
nitrate	B-X
(	B-X
NOx	B-X
)	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
the	B-X
neonates	B-X
than	B-X
in	B-X
adults	B-X
(	B-X
112.1±55.9	B-X
vs.	B-X
340.9±124.9	B-X
µM/g	B-X
;	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
However	B-X
,	B-X
NOx	B-X
was	B-X
increased	B-X
following	B-X
administration	B-X
of	B-X
LPS	B-X
.	B-X
Administration	B-X
of	B-X
1400w	B-X
suppressed	B-X
lung	B-X
tissue	B-X
levels	B-X
of	B-X
NOx	B-X
and	B-X
improved	B-X
the	B-X
survival	B-X
time	B-X
in	B-X
neonatal	B-X
rats	B-X
treated	B-X
with	B-X
LPS	B-X
.	B-X
The	B-X
present	B-X
study	B-X
demonstrated	B-X
that	B-X
M1	B-X
is	B-X
the	B-X
primary	B-X
macrophage	B-X
phenotype	B-X
in	B-X
the	B-X
neonatal	B-X
lung	B-X
and	B-X
that	B-X
higher	B-X
iNOS	B-X
expression	B-X
levels	B-X
do	B-X
not	B-X
have	B-X
a	B-X
protective	B-X
effect	B-X
against	B-X
pulmonary	B-X
endotoxins	B-X
in	B-X
neonates	B-X
.	B-X
Overproduction	B-X
of	B-X
NO	B-X
by	B-X
iNOS	B-X
in	B-X
neonatal	B-X
alveolar	B-X
macrophages	B-X
may	B-X
result	B-X
in	B-X
detrimental	B-X
effects	B-X
during	B-X
pulmonary	B-X
inflammation	B-X
.	B-X

With	O
respect	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
the	O
theoretical	O
value	O
of	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
conducted	B-X
whole-genome	B-X
sequencing	B-X
on	B-X
565	B-X
MRSA	B-X
isolates	B-X
from	B-X
7	B-X
provinces	B-X
and	B-X
municipalities	B-X
of	B-X
China	B-X
between	B-X
2014	B-X
and	B-X
2020	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
methicillin	B-X
and	B-X
vancomycin	B-X
resistant	B-X
strains	B-X
of	B-X
S.	B-X
aureus	B-X
(	B-X
MRSA	B-X
and	B-X
VRSA	B-X
,	B-X
respectively	B-X
)	B-X
isolated	B-X
globally	B-X
represent	B-X
daunting	B-X
medical	B-X
challenges	B-X
for	B-X
the	B-X
21	B-X
(	B-X
st	B-X
)	B-X
Century	B-X
.	B-X
One	B-X
family	B-X
of	B-X
protein	B-X
toxins	B-X
is	B-X
the	B-X
staphylococcal	B-X
enterotoxins	B-X
(	B-X
SEs	B-X
)	B-X
and	B-X
related	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin-1	B-X
(	B-X
TSST-1	B-X
)	B-X
that	B-X
act	B-X
as	B-X
superantigens	B-X
.	B-X
In	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
models	B-X
are	B-X
available	B-X
for	B-X
studying	B-X
the	B-X
SEs	B-X
and	B-X
TSST-1	B-X
,	B-X
thus	B-X
providing	B-X
important	B-X
tools	B-X
for	B-X
understanding	B-X
modes	B-X
of	B-X
action	B-X
and	B-X
subsequently	B-X
countering	B-X
these	B-X
toxins	B-X
via	B-X
experimental	B-X
vaccines	B-X
or	B-X
therapeutics	B-X
.	B-X
There	B-X
will	B-X
be	B-X
a	B-X
particular	B-X
focus	B-X
upon	B-X
the	B-X
biological	B-X
and	B-X
biochemical	B-X
properties	B-X
of	B-X
,	B-X
plus	B-X
current	B-X
neutralization	B-X
strategies	B-X
targeting	B-X
,	B-X
staphylcoccocal	B-X
superantigens	B-X
like	B-X
the	B-X
SEs	B-X
and	B-X
TSST-1	B-X
.	B-X

vs	O
.	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
observed	O
a	O
pronounced	O
anti	O
-	O
inflammatory	O
action	O
of	O
GP	O
,	O
as	O
demonstrated	O
by	O
an	O
about	O
10	O
-	O
100	O
fold	O
reduced	O
ratio	O
at	O
18	O
h	O
and	O
24	O
h	O
of	O
incubation	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
n	O
=	O
3	O
;	O
both	O
p	O
<	O
0	O
.	O
05	O
;	O
Fig	O
.	O
6	O
)	O
.	O

A	O
biological	O
relevance	O
of	O
this	O
result	O
was	O
suggested	O
by	O
a	O
decrease	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
dependent	O
release	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
from	O
murine	O
EL	O
-	O
4	O
cells	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

(	O
data	O
not	O
shown	O
in	O
detail	O
,	O
n	O
=	O
4	O
;	O
p	O
<	O
0	O
.	O
07	O
)	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
surveys	B-X
big	B-X
data	B-X
with	B-X
highlighting	B-X
the	B-X
big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
.	B-X
Big	B-X
data	B-X
characteristics	B-X
:	B-X
value	B-X
,	B-X
volume	B-X
,	B-X
velocity	B-X
,	B-X
variety	B-X
,	B-X
veracity	B-X
and	B-X
variability	B-X
are	B-X
described	B-X
.	B-X
Big	B-X
data	B-X
analytics	B-X
in	B-X
medicine	B-X
and	B-X
healthcare	B-X
covers	B-X
integration	B-X
and	B-X
analysis	B-X
of	B-X
large	B-X
amount	B-X
of	B-X
complex	B-X
heterogeneous	B-X
data	B-X
such	B-X
as	B-X
various	B-X
-	B-X
omics	B-X
data	B-X
(	B-X
genomics	B-X
,	B-X
epigenomics	B-X
,	B-X
transcriptomics	B-X
,	B-X
proteomics	B-X
,	B-X
metabolomics	B-X
,	B-X
interactomics	B-X
,	B-X
pharmacogenomics	B-X
,	B-X
diseasomics	B-X
)	B-X
,	B-X
biomedical	B-X
data	B-X
and	B-X
electronic	B-X
health	B-X
records	B-X
data	B-X
.	B-X
We	B-X
underline	B-X
the	B-X
challenging	B-X
issues	B-X
about	B-X
big	B-X
data	B-X
privacy	B-X
and	B-X
security	B-X
.	B-X
Regarding	B-X
big	B-X
data	B-X
characteristics	B-X
,	B-X
some	B-X
directions	B-X
of	B-X
using	B-X
suitable	B-X
and	B-X
promising	B-X
open-source	B-X
distributed	B-X
data	B-X
processing	B-X
software	B-X
platform	B-X
are	B-X
given	B-X
.	B-X

Inhibition	O
of	O
transcription	O
factors	O
led	O
to	O
reduced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
levels	O

Pharmacological	O
inhibitors	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
transcription	O
factor	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
are	O
relevant	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
GP	O
.	O

As	O
expected	O
,	O
an	O
inhibition	O
of	O
NFkappaB	O
via	O
CAPE	O
[	O
35	O
]	O
and	O
CyA	O
,	O
NFAT	B-Protein
via	O
CyA	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
via	O
CHX	O
[	O
36	O
]	O
could	O
not	O
be	O
overruled	O
by	O
GP	O
,	O
leading	O
to	O
a	O
down	O
-	O
regulated	O
binding	O
activity	O
of	O
the	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
sites	O
,	O
and	O
a	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
levels	O
(	O
Fig	O
.	O
7	O
)	O
.	O

The	O
extent	O
of	O
reduction	O
in	O
NFATP2	O
/	O
3	O
binding	O
is	O
exemplarily	O
shown	O
in	O
an	O
autoradiogram	O
(	O
Fig	O
.	O
7A	O
,	O
left	O
side	O
)	O
and	O
graphically	O
summarized	O
(	O
n	O
=	O
4	O
,	O
Fig	O
.	O
7A	O
,	O
right	O
side	O
)	O
.	O

The	O
results	O
for	O
the	O
NFkappaB	O
and	O
NFIL	O
-	O
6	O
binding	O
sites	O
were	O
similar	O
(	O
data	O
not	O
shown	O
)	O
.	O

Because	O
the	O
highest	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
amount	O
was	O
found	O
at	O
24	O
h	O
,	O
mRNA	O
was	O
examined	O
following	O
1	O
h	O
inhibition	O
and	O
18	O
h	O
of	O
GP	O
.	O

A	O
representative	O
gel	O
demonstrating	O
a	O
decrease	O
in	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
after	O
inhibition	O
with	O
CAPE	O
,	O
CyA	O
and	O
CHX	O
is	O
displayed	O
in	O
Fig	O
.	O

7B	O
(	O
n	O
=	O
4	O
)	O
.	O
<EOS>	B-X
β-naphthylamine	B-X
(	B-X
BNA	B-X
)	B-X
is	B-X
an	B-X
important	B-X
aromatic	B-X
amine	B-X
carcinogen	B-X
.	B-X
Current	B-X
exposures	B-X
derive	B-X
primarily	B-X
from	B-X
cigarette	B-X
smoking	B-X
including	B-X
e-cigarettes	B-X
.	B-X
Occupational	B-X
and	B-X
environmental	B-X
exposure	B-X
to	B-X
BNA	B-X
is	B-X
associated	B-X
with	B-X
urinary	B-X
bladder	B-X
cancer	B-X
which	B-X
is	B-X
the	B-X
fourth	B-X
most	B-X
frequent	B-X
cancer	B-X
in	B-X
the	B-X
United	B-X
States	B-X
.	B-X
N-acetyltransferase	B-X
2	B-X
(	B-X
NAT2	B-X
)	B-X
is	B-X
an	B-X
important	B-X
metabolizing	B-X
enzyme	B-X
for	B-X
aromatic	B-X
amines	B-X
.	B-X
Previous	B-X
studies	B-X
investigated	B-X
mutagenicity	B-X
and	B-X
genotoxicity	B-X
of	B-X
BNA	B-X
in	B-X
bacteria	B-X
and	B-X
in	B-X
rabbit	B-X
or	B-X
rat	B-X
hepatocytes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
human	B-X
NAT2	B-X
genetic	B-X
polymorphism	B-X
on	B-X
N-acetylation	B-X
and	B-X
genotoxicity	B-X
induced	B-X
by	B-X
BNA	B-X
still	B-X
need	B-X
to	B-X
be	B-X
clarified	B-X
.	B-X
We	B-X
used	B-X
nucleotide	B-X
excision	B-X
repair-deficient	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
that	B-X
were	B-X
stably	B-X
transfected	B-X
with	B-X
human	B-X
CYP1A2	B-X
and	B-X
NAT2	B-X
alleles	B-X
:	B-X
NAT2	B-X
*	B-X
4	B-X
(	B-X
reference	B-X
allele	B-X
)	B-X
,	B-X
NAT2	B-X
*	B-X
5B	B-X
(	B-X
variant	B-X
slow	B-X
acetylator	B-X
allele	B-X
common	B-X
in	B-X
Europe	B-X
)	B-X
or	B-X
NAT2	B-X
*	B-X
7B	B-X
(	B-X
variant	B-X
slow	B-X
acetylator	B-X
allele	B-X
common	B-X
in	B-X
Asia	B-X
)	B-X
.	B-X
BNA	B-X
N-acetylation	B-X
was	B-X
measured	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
situ	B-X
via	B-X
high-performance	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
.	B-X
Hypoxanthine	B-X
phosphoribosyl	B-X
transferase	B-X
(	B-X
HPRT	B-X
)	B-X
mutations	B-X
,	B-X
double-strand	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
were	B-X
measured	B-X
as	B-X
indices	B-X
of	B-X
toxicity	B-X
.	B-X
NAT2	B-X
*	B-X
4	B-X
cells	B-X
showed	B-X
significantly	B-X
higher	B-X
BNA	B-X
N-acetylation	B-X
rates	B-X
followed	B-X
by	B-X
NAT2	B-X
*	B-X
7B	B-X
and	B-X
NAT2	B-X
*	B-X
5B	B-X
.	B-X
BNA	B-X
caused	B-X
concentration-dependent	B-X
increases	B-X
in	B-X
DNA	B-X
damage	B-X
and	B-X
ROS	B-X
levels	B-X
.	B-X
NAT2	B-X
*	B-X
7B	B-X
showed	B-X
significantly	B-X
higher	B-X
levels	B-X
of	B-X
HPRT	B-X
mutants	B-X
,	B-X
DNA	B-X
damage	B-X
and	B-X
ROS	B-X
than	B-X
NAT2	B-X
*	B-X
5B	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
respectively	B-X
)	B-X
although	B-X
both	B-X
are	B-X
slow	B-X
alleles	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
BNA	B-X
N-acetylation	B-X
and	B-X
toxicity	B-X
are	B-X
modified	B-X
by	B-X
NAT2	B-X
polymorphism	B-X
.	B-X
Furthermore	B-X
,	B-X
they	B-X
confirm	B-X
heterogeneity	B-X
among	B-X
slow	B-X
acetylator	B-X
alleles	B-X
for	B-X
BNA	B-X
metabolism	B-X
and	B-X
toxicity	B-X
supporting	B-X
differential	B-X
risk	B-X
for	B-X
individuals	B-X
carrying	B-X
NAT2	B-X
*	B-X
7B	B-X
allele	B-X
.	B-X

In	O
addition	O
,	O
corresponding	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
levels	O
after	O
24	O
h	O
of	O
GP	O
are	O
shown	O
in	O
Fig	O
.	O

7C	O
(	O
n	O
=	O
3	O
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
title	B-X
compound	B-X
,	B-X
[	B-X
Co	B-X
(	B-X
C	B-X
(	B-X
7	B-X
)	B-X
H	B-X
(	B-X
2	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
7	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
10	B-X
)	B-X
H	B-X
(	B-X
8	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
2	B-X
)	B-X
]	B-X
,	B-X
the	B-X
Co	B-X
(	B-X
II	B-X
)	B-X
atom	B-X
is	B-X
coordinated	B-X
by	B-X
four	B-X
N	B-X
atoms	B-X
from	B-X
two	B-X
2,2'-bipyridine	B-X
ligands	B-X
and	B-X
two	B-X
O	B-X
atoms	B-X
from	B-X
a	B-X
3,5-dinitro-2-oxidobenzoate	B-X
ligand	B-X
,	B-X
displaying	B-X
a	B-X
distorted	B-X
octa-hedral	B-X
coordination	B-X
geometry	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
involves	B-X
C-H⋯O	B-X
hydrogen	B-X
bonds	B-X
between	B-X
the	B-X
2,2'-bipyridine	B-X
ligands	B-X
and	B-X
the	B-X
carboxyl-ate	B-X
and	B-X
NO	B-X
(	B-X
2	B-X
)	B-X
groups	B-X
of	B-X
the	B-X
3,5-dinitro-2-oxidobenzoate	B-X
ligand	B-X
.	B-X
Epidemiological	B-X
,	B-X
Clinical	B-X
,	B-X
and	B-X
Laboratory	B-X
Features	B-X
of	B-X
Children	B-X
With	B-X
COVID-19	B-X
in	B-X
Turkey	B-X
.	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
C	B-X

Altogether	O
,	O
NFkappaB	O
inhibition	O
by	O
CAPE	O
was	O
more	O
pronounced	O
at	O
the	O
binding	O
activity	O
and	O
the	O
transcription	O
,	O
whereas	O
CyA	O
and	O
CHX	O
mainly	O
led	O
to	O
a	O
decreased	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
release	O
.	O

Animal	O
models	O
of	O
sepsis	O
and	O
myocardial	O
injury	O
suggest	O
that	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
like	O
GP	O
mediates	O
its	O
protective	O
mechanisms	O
,	O
in	O
part	O
,	O
via	O
a	O
rapid	O
shift	O
from	O
NFkappaB	O
-	O
to	O
PI3K	O
-	O
signaling	O
[	O
22	O
,	O
37	O
]	O
.	O

Our	O
study	O
provides	O
novel	O
evidence	O
that	O
downstream	O
of	O
recognition	O
and	O
signaling	O
pro	O
-	O
inflammatory	O
transcription	O
factor	O
binding	O
and	O
cytokine	O
expression	O
of	O
human	O
leukocytes	O
is	O
switched	O
to	O
an	O
anti	O
-	O
inflammatory	O
phenotype	O
by	O
GP	O
.	O

We	O
confirmed	O
and	O
extended	O
previous	O
results	O
[	O
13	O
-	O
16	O
]	O
indicating	O
that	O
,	O
in	O
the	O
absence	O
of	O
other	O
stimuli	O
,	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
induced	O
binding	O
of	O
NFkappaB	O
-	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
-	O
and	O
NFAT	B-Protein
-	O
mers	O
to	O
cytokine	O
promoters	O
.	O

Because	O
of	O
the	O
multiple	O
band	O
shifts	O
observed	O
for	O
NFAT	B-Protein
binding	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
one	O
could	O
speculate	O
that	O
there	O
is	O
activation	O
of	O
several	O
different	O
NFAT	B-Protein
isoforms	O
,	O
probably	O
derived	O
from	O
alternative	O
splicing	O
[	O
38	O
]	O
.	O

Interestingly	O
,	O
the	O
GP	O
-	O
induced	O
transcription	O
factor	O
binding	O
transformed	O
only	O
into	O
a	O
very	O
limited	O
cytokine	O
response	O
,	O
namely	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
(	O
Fig	O
.	O
3B	O
)	O
.	O

Hence	O
,	O
our	O
data	O
are	O
in	O
aggreement	O
with	O
the	O
few	O
reports	O
describing	O
a	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
[	O
6	O
,	O
16	O
,	O
19	O
]	O
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
our	O
EMSA	O
/	O
supershift	O
and	O
immunoblotting	O
results	O
demonstrated	O
a	O
GP	O
-	O
mediated	O
predominant	O
binding	O
of	O
NFkappaB	O
p65	B-Protein
and	O
to	O
a	O
lesser	O
extent	O
of	O
p50	B-Protein
to	O
a	O
kappaB	O
consensus	O
site	O
of	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoter	O
(	O
Figs	O
.	O
1A	O
,	O
2	O
)	O
.	O

Results	O
by	O
Schulte	O
and	O
colleagues	O
[	O
28	O
]	O
pointed	O
to	O
an	O
induction	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
depending	O
on	O
activation	O
via	O
an	O
NFkappaB	O
p65	B-Protein
/	O
65	B-Protein
homodimer	O
,	O
rather	O
than	O
via	O
p65	B-Protein
/	O
50	B-Protein
heterodimers	O
,	O
which	O
might	O
be	O
the	O
case	O
for	O
the	O
GP	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
.	O

A	O
GP	O
-	O
mediated	O
IL	B-Protein
-	I-Protein
8	I-Protein
transcription	O
based	O
upon	O
a	O
cooperation	O
between	O
transactivated	O
NFkappaB	O
p65	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
[	O
13	O
,	O
39	O
]	O
or	O
NFATc2	B-Protein
dimer	O
binding	O
to	O
the	O
IL	B-Protein
-	I-Protein
8kappaB	I-Protein
site	O
[	O
38	O
]	O
seems	O
also	O
possible	O
.	O

The	O
IL	B-Protein
-	I-Protein
8kappaB	I-Protein
consensus	O
site	O
exhibits	O
a	O
preferentially	O
p65	B-Protein
binding	O
half	O
site	O
and	O
thus	O
differs	O
from	O
the	O
kappaB	O
half	O
site	O
described	O
for	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
[	O
27	O
,	O
40	O
]	O
,	O
supporting	O
the	O
idea	O
of	O
regulating	O
NFkappaB	O
binding	O
through	O
combinatorial	O
associations	O
of	O
the	O
subunits	O
and	O
the	O
specific	O
sequence	O
of	O
the	O
decameric	O
kappaB	O
motif	O
[	O
41	O
,	O
42	O
]	O
.	O

Unlike	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
we	O
found	O
that	O
GP	O
did	O
not	O
induce	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
but	O
it	O
strongly	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
,	O
suggesting	O
an	O
immediate	O
anti	O
-	O
inflammatory	O
potential	O
of	O
GP	O
.	O
<EOS>	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLR	B-X
)	B-X
mediate	B-X
infection-induced	B-X
inflammation	B-X
and	B-X
sterile	B-X
inflammation	B-X
by	B-X
endogenous	B-X
molecules	B-X
.	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
saturated	B-X
fatty	B-X
acids	B-X
(	B-X
SFA	B-X
)	B-X
act	B-X
as	B-X
non-microbial	B-X
TLR4	B-X
agonists	B-X
,	B-X
and	B-X
trigger	B-X
its	B-X
inflammatory	B-X
response	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
present	B-X
review	B-X
provides	B-X
a	B-X
new	B-X
perspective	B-X
on	B-X
the	B-X
potential	B-X
mechanism	B-X
by	B-X
which	B-X
SFAs	B-X
could	B-X
modulate	B-X
TLR4-induced	B-X
inflammatory	B-X
responses	B-X
:	B-X
(	B-X
1	B-X
)	B-X
SFAs	B-X
can	B-X
be	B-X
recognized	B-X
by	B-X
CD14-TLR4-MD2	B-X
complex	B-X
and	B-X
trigger	B-X
inflammatory	B-X
pathways	B-X
,	B-X
similar	B-X
to	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
(	B-X
2	B-X
)	B-X
SFAs	B-X
lead	B-X
to	B-X
modification	B-X
of	B-X
gut	B-X
microbiota	B-X
with	B-X
an	B-X
overproduction	B-X
of	B-X
LPS	B-X
after	B-X
a	B-X
high-fat	B-X
intake	B-X
,	B-X
enhancing	B-X
this	B-X
natural	B-X
TLR4	B-X
ligand	B-X
.	B-X
(	B-X
3	B-X
)	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
metabolic	B-X
endotoxemia	B-X
leads	B-X
to	B-X
an	B-X
oxidative	B-X
stress	B-X
thereby	B-X
producing	B-X
atherogenic	B-X
lipids	B-X
-	B-X
oxLDL	B-X
and	B-X
oxidized	B-X
phospholipids	B-X
-	B-X
which	B-X
trigger	B-X
CD36-TLR4-TLR6	B-X
inflammatory	B-X
response	B-X
.	B-X
The	B-X
mmLDL	B-X
,	B-X
unlike	B-X
oxLDL	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
CD14-TLR4-MD2	B-X
inflammatory	B-X
pathway	B-X
.	B-X
Those	B-X
molecules	B-X
can	B-X
induce	B-X
TLR4	B-X
inflammatory	B-X
response	B-X
by	B-X
MyD88-dependent	B-X
and/or	B-X
MyD88-independent	B-X
pathways	B-X
that	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
proinflammatory	B-X
transcript	B-X
factors	B-X
such	B-X
as	B-X
factor	B-X
nuclear	B-X
kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
inflammatory	B-X
mediators	B-X
(	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
or	B-X
costimulatory	B-X
molecules	B-X
)	B-X
implicated	B-X
in	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
many	B-X
chronic	B-X
diseases	B-X
.	B-X

Analysing	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
[	O
34	O
]	O
,	O
we	O
discovered	O
four	O
new	O
binding	O
sites	O
(	O
Fig	O
.	O
8	O
)	O
:	O
an	O
NFkappaB3	O
site	O
(	O
between	O
-	O
100	O
and	O
-	O
130	O
)	O
,	O
an	O
NFkappaB	O
consensus	O
site	O
(	O
-	O
266	O
and	O
-	O
280	O
)	O
,	O
another	O
NFkappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
and	O
a	O
more	O
distal	O
NFATP2	O
/	O
3	O
site	O
(	O
-	O
471	O
and	O
-	O
490	O
)	O
.	O

Our	O
data	O
indicated	O
that	O
GP	O
leads	O
to	O
production	O
of	O
IL	O
-	O
1RA	O
primarily	O
via	O
induction	O
of	O
NFATP2	B-Protein
/	O
3	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
DNA	O
binding	O
,	O
which	O
might	O
be	O
due	O
to	O
differences	O
in	O
the	O
binding	O
motif	O
or	O
the	O
composition	O
of	O
the	O
activated	O
transcription	O
factors	O
(	O
NFAT	B-Protein
)	O
between	O
the	O
IFNgamma	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

The	O
differential	O
decrease	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
binding	O
to	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
as	O
well	O
as	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
and	O
protein	O
induced	O
by	O
selective	O
inhibitors	O
prior	O
to	O
GP	O
treatment	O
might	O
suggest	O
that	O
these	O
steps	O
are	O
linked	O
to	O
each	O
other	O
and	O
necessary	O
for	O
induction	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
(	O
Fig	O
.	O
7	O
)	O
.	O

Regarding	O
cellular	O
sources	O
,	O
both	O
,	O
monocytes	O
as	O
well	O
as	O
neutrophils	O
have	O
been	O
reported	O
to	O
produce	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
[	O
32	O
]	O
.	O

Flow	O
cytometric	O
experiments	O
seemed	O
to	O
confirm	O
that	O
monocytes	O
and	O
neutrophils	O
were	O
able	O
to	O
produce	O
IL	B-Protein
-	I-Protein
8	I-Protein
just	O
as	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
in	O
response	O
to	O
GP	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
GP	O
-	O
induced	O
cytokine	O
profile	O
was	O
substantially	O
more	O
restricted	O
than	O
that	O
of	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
is	O
likely	O
due	O
to	O
differences	O
in	O
recognition	O
and	O
signaling	O
between	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
.	O

Recognition	O
of	O
LPS	O
is	O
mainly	O
mediated	O
through	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
and	O
subsequent	O
signaling	O
via	O
the	O
NFkappaB	O
pathway	O
,	O
leading	O
to	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
like	O
TNFalpha	B-Protein
[	O
43	O
]	O
.	O

A	O
bacterial	O
superantigen	O
like	O
TSST	B-Protein
-	I-Protein
1	I-Protein
acts	O
through	O
binding	O
to	O
MHC	O
-	O
II	O
molecules	O
and	O
subsequently	O
the	O
T	O
cell	O
receptor	O
,	O
leading	O
to	O
release	O
of	O
mainly	O
IFNgamma	B-Protein
and	O
TNFalpha	B-Protein
,	O
the	O
latter	O
via	O
both	O
,	O
PI3K	O
and	O
p38	B-Protein
mitogen	I-Protein
-	I-Protein
activated	I-Protein
kinase	I-Protein
signaling	O
[	O
44	O
,	O
45	O
]	O
.	O

Altogether	O
,	O
the	O
induction	O
of	O
the	O
neutrophil	O
-	O
attracting	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
the	O
anti	O
-	O
inflammatory	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
fungal	O
carbohydrates	O
(	O
GP	O
)	O
may	O
well	O
fit	O
to	O
a	O
benign	O
PAMP	O
response	O
,	O
mounting	O
defensive	O
mechanisms	O
against	O
a	O
possible	O
microbial	O
attack	O
.	O

Potentially	O
even	O
more	O
relevant	O
than	O
the	O
specific	O
cytokine	O
panel	O
induced	O
by	O
GP	O
,	O
we	O
found	O
that	O
,	O
in	O
the	O
presence	O
of	O
other	O
stimuli	O
(	O
LPS	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
GP	O
ameliorated	O
their	O
pro	O
-	O
inflammatory	O
immune	O
reactions	O
,	O
similar	O
to	O
the	O
effects	O
in	O
murine	O
models	O
of	O
sepsis	O
and	O
inflammation	O
[	O
21	O
-	O
24	O
]	O
.	O

Mainly	O
,	O
GP	O
altered	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
from	O
a	O
pro	O
-	O
to	O
an	O
anti	O
-	O
inflammatory	O
profile	O
via	O
down	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
at	O
the	O
same	O
time	O
there	O
was	O
a	O
synergistic	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
.	O

In	O
part	O
,	O
this	O
change	O
may	O
be	O
caused	O
by	O
GP	O
-	O
mediated	O
modulations	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
induced	O
binding	O
of	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
and	O
NFAT	B-Protein
to	O
known	O
and	O
up	O
to	O
now	O
unknown	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
instead	O
of	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
or	O
IFNgamma	B-Protein
promoter	O
.	O
<EOS>	B-X
The	B-X
PD-L1	B-X
overexpression	B-X
is	B-X
an	B-X
important	B-X
event	B-X
of	B-X
immune	B-X
escape	B-X
and	B-X
metastasis	B-X
in	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
,	B-X
but	B-X
the	B-X
molecular	B-X
mechanism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Interferon	B-X
gamma	B-X
(	B-X
IFNγ	B-X
)	B-X
represents	B-X
a	B-X
major	B-X
driving	B-X
force	B-X
behind	B-X
PD-L1	B-X
expression	B-X
in	B-X
tumor	B-X
microenvironment	B-X
,	B-X
and	B-X
histone	B-X
deacetylase	B-X
2	B-X
(	B-X
HDAC2	B-X
)	B-X
is	B-X
required	B-X
for	B-X
IFN	B-X
signaling	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
HDAC2	B-X
on	B-X
the	B-X
IFNγ-induced	B-X
PD-L1	B-X
expression	B-X
in	B-X
TNBC	B-X
cells	B-X
.	B-X
We	B-X
found	B-X
the	B-X
HDAC2	B-X
and	B-X
PD-L1	B-X
expression	B-X
in	B-X
TNBC	B-X
was	B-X
significantly	B-X
higher	B-X
than	B-X
that	B-X
in	B-X
non-TNBC	B-X
,	B-X
and	B-X
HDAC2	B-X
was	B-X
positively	B-X
correlated	B-X
with	B-X
PD-L1	B-X
expression	B-X
.	B-X
HDAC2	B-X
promoted	B-X
PD-L1	B-X
induction	B-X
by	B-X
upregulating	B-X
the	B-X
phosphorylation	B-X
of	B-X
JAK1	B-X
,	B-X
JAK2	B-X
,	B-X
and	B-X
STAT1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
translocation	B-X
of	B-X
STAT1	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
recruitment	B-X
of	B-X
STAT1	B-X
to	B-X
the	B-X
PD-L1	B-X
promoter	B-X
.	B-X
Meanwhile	B-X
,	B-X
HDAC2	B-X
was	B-X
recruited	B-X
to	B-X
the	B-X
PD-L1	B-X
promoter	B-X
by	B-X
STAT1	B-X
,	B-X
and	B-X
HDAC2	B-X
knockout	B-X
compromised	B-X
IFNγ-induced	B-X
upregulation	B-X
of	B-X
H3K27	B-X
,	B-X
H3K9	B-X
acetylation	B-X
,	B-X
and	B-X
the	B-X
BRD4	B-X
recruitment	B-X
in	B-X
PD-L1	B-X
promoter	B-X
.	B-X
Furthermore	B-X
,	B-X
HDAC2	B-X
knockout	B-X
reduced	B-X
IFNγ-induced	B-X
PD-L1	B-X
expression	B-X
,	B-X
lymphocyte	B-X
infiltration	B-X
,	B-X
and	B-X
retarded	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
in	B-X
the	B-X
breast	B-X
cancer	B-X
mouse	B-X
models	B-X
.	B-X
This	B-X
study	B-X
may	B-X
provide	B-X
evidence	B-X
that	B-X
HDAC2	B-X
promotes	B-X
IFNγ-induced	B-X
PD-L1	B-X
expression	B-X
,	B-X
suggesting	B-X
a	B-X
way	B-X
for	B-X
enhanced	B-X
antitumor	B-X
immunity	B-X
when	B-X
targeting	B-X
the	B-X
HDAC2	B-X
in	B-X
TNBC	B-X
.	B-X

Accordingly	O
,	O
we	O
found	O
that	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
of	O
NFkappaB	O
to	O
sites	O
from	O
the	O
TNFalpha	B-Protein
promoter	O
negatively	O
correlated	O
with	O
the	O
GP	O
-	O
mediated	O
enhancement	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
(	O
r	O
=	O
-	O
0	O
.	O
88	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

Of	O
the	O
four	O
examined	O
NFkappaB	O
sites	O
from	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
mostly	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
and	O
LPS	O
-	O
induced	O
binding	O
to	O
the	O
NFkappaB3	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
the	O
new	O
NFkappaB	O
consensus	O
site	O
seemed	O
to	O
be	O
increased	O
by	O
GP	O
.	O

So	O
,	O
while	O
we	O
observed	O
a	O
GP	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
the	O
LPS	O
-	O
and	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
NFkappaB	O
binding	O
to	O
sites	O
of	O
the	O
TNFalpha	B-Protein
promoter	O
,	O
there	O
was	O
an	O
up	O
-	O
regulation	O
to	O
NFkappaB3	O
and	O
NFkappaB	O
consensus	O
sites	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

These	O
seemingly	O
contradictory	O
data	O
could	O
be	O
explained	O
by	O
differences	O
in	O
either	O
NFkappaB	O
subunits	O
or	O
conserved	O
nucleotides	O
(	O
#	O
1	O
,	O
2	O
,	O
3	O
,	O
10	O
)	O
within	O
the	O
decameric	O
NFkappaB	O
binding	O
motif	O
between	O
the	O
TNFalpha	B-Protein
and	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
for	O
NFkappaB3	O
the	O
IL	O
-	O
1RA	O
motif	O
contains	O
a	O
T	O
on	O
position	O
10	O
instead	O
of	O
the	O
conserved	O
C	O
in	O
the	O
TNFalpha	O
motif	O
,	O
see	O
Table	O
1	O
)	O
,	O
probably	O
leading	O
to	O
differences	O
in	O
binding	O
[	O
41	O
,	O
42	O
]	O
.	O

Despite	O
the	O
location	O
of	O
the	O
new	O
NFkappaB	O
consensus	O
site	O
(	O
-	O
266	O
and	O
-	O
280	O
)	O
in	O
the	O
inhibitory	O
element	O
(	O
-	O
250	O
and	O
-	O
294	O
)	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
[	O
30	O
]	O
,	O
we	O
observed	O
no	O
inhibition	O
.	O

On	O
the	O
other	O
side	O
,	O
we	O
found	O
an	O
inhibitory	O
NFkappaB2	O
/	O
3	O
site	O
(	O
-	O
288	O
and	O
-	O
302	O
)	O
towards	O
the	O
end	O
of	O
the	O
inhibitory	O
element	O
,	O
demonstrating	O
down	O
-	O
regulations	O
of	O
the	O
LPS	O
-	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
,	O
which	O
could	O
not	O
be	O
altered	O
by	O
GP	O
.	O

In	O
our	O
opinion	O
,	O
this	O
site	O
may	O
therefore	O
represent	O
at	O
least	O
a	O
part	O
of	O
the	O
previoulsy	O
described	O
inhibitory	O
element	O
[	O
30	O
]	O
.	O

The	O
GP	O
-	O
modulated	O
increase	O
in	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
the	O
new	O
NFkappaB3	O
and	O
NFkappaB	O
consensus	O
site	O
,	O
the	O
NFIL	O
-	O
6	O
site	O
[	O
32	O
]	O
as	O
well	O
as	O
to	O
the	O
novel	O
NFATP2	O
/	O
3	O
site	O
may	O
explain	O
the	O
synergistic	O
up	O
-	O
regulation	O
of	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
.	O

We	O
think	O
that	O
this	O
GP	O
-	O
modulated	O
activation	O
of	O
transcription	O
was	O
reflected	O
by	O
the	O
decrease	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Fig	O
.	O
6	O
)	O
.	O

In	O
this	O
context	O
,	O
it	O
has	O
been	O
postulated	O
that	O
in	O
vitro	O
a	O
100fold	O
excess	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
over	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
might	O
control	O
the	O
biological	O
effects	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
[	O
46	O
,	O
47	O
]	O
.	O

Since	O
,	O
in	O
fact	O
,	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
is	O
partially	O
less	O
than	O
0	O
.	O
01	O
,	O
it	O
is	O
not	O
unreasonable	O
to	O
assume	O
that	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
bioactivity	O
is	O
inactivated	O
in	O
our	O
system	O
.	O

Indeed	O
,	O
GP	O
reduced	O
the	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
of	O
murine	O
EL	O
-	O
4	O
cells	O
(	O
data	O
not	O
shown	O
in	O
detail	O
)	O
.	O

The	O
weaker	O
modulating	O
effects	O
of	O
GP	O
on	O
the	O
LPS	O
-	O
induced	O
immune	O
response	O
observed	O
in	O
this	O
study	O
,	O
may	O
be	O
attributed	O
to	O
delicately	O
balanced	O
differences	O
in	O
signaling	O
pathways	O
between	O
LPS	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
[	O
43	O
-	O
45	O
]	O
.	O

TSST	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
shown	O
to	O
use	O
the	O
PI3K	O
pathway	O
for	O
signaling	O
[	O
44	O
]	O
and	O
this	O
effect	O
may	O
be	O
sustained	O
by	O
GP	O
treatment	O
[	O
22	O
,	O
37	O
]	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
in	O
septic	O
/	O
LPS	O
-	O
adapted	O
leukocytes	O
the	O
PI3K	O
pathway	O
selectively	O
controls	O
sIL	B-Protein
-	I-Protein
1RA	I-Protein
but	O
not	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
[	O
48	O
]	O
.	O

Signaling	O
via	O
PI3K	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
activation	O
of	O
NFAT	B-Protein
in	O
T	O
cells	O
[	O
49	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
can	O
also	O
take	O
place	O
via	O
PI3K	O
[	O
50	O
]	O
,	O
which	O
may	O
offer	O
an	O
explanation	O
for	O
a	O
difference	O
in	O
signaling	O
between	O
GP	O
(	O
PI3K	O
)	O
and	O
LPS	O
(	O
mitogen	O
-	O
activated	O
kinase	O
signaling	O
)	O
.	O

This	O
idea	O
may	O
be	O
supported	O
by	O
another	O
study	O
showing	O
that	O
despite	O
the	O
use	O
of	O
similar	O
PRR	O
,	O
LPS	O
and	O
peptidoglycan	O
activated	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
gene	O
through	O
different	O
mechanisms	O
/	O
DNA	O
-	O
binding	O
proteins	O
and	O
acted	O
synergistically	O
in	O
combination	O
,	O
suggestive	O
of	O
signals	O
which	O
are	O
not	O
equivalent	O
in	O
all	O
parts	O
[	O
51	O
]	O
.	O

In	O
summary	O
,	O
our	O
data	O
demonstrated	O
that	O
in	O
vitro	O
glucan	O
phosphate	O
induced	O
a	O
transcription	O
factor	O
binding	O
and	O
a	O
subsequent	O
cytokine	O
profile	O
different	O
from	O
LPS	O
and	O
also	O
from	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
,	O
moreover	O
,	O
switched	O
a	O
pro	O
-	O
inflammatory	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
response	O
to	O
an	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
-	O
mediated	O
anti	O
-	O
inflammatory	O
reaction	O
.	O

Our	O
results	O
also	O
generated	O
new	O
insights	O
into	O
a	O
very	O
complex	O
interplay	O
of	O
transcription	O
factor	O
binding	O
to	O
various	O
known	O
and	O
newly	O
identified	O
sites	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
(	O
Fig	O
.	O
8	O
)	O
,	O
which	O
can	O
be	O
regulated	O
differentially	O
by	O
a	O
fungal	O
carbohydrate	O
.	O

Together	O
with	O
the	O
in	O
vivo	O
studies	O
[	O
22	O
,	O
37	O
]	O
,	O
our	O
findings	O
might	O
support	O
the	O
concept	O
of	O
protective	O
effects	O
mediated	O
by	O
glucan	O
phosphate	O
in	O
pro	O
-	O
inflammatory	O
conditions	O
,	O
especially	O
with	O
a	O
dysregulated	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
[	O
52	O
,	O
53	O
]	O
.	O

Materials	O
<EOS>	B-X
Materials	B-X
used	B-X
without	B-X
adequate	B-X
knowledge	B-X
of	B-X
their	B-X
characteristics	B-X
can	B-X
impair	B-X
a	B-X
successful	B-X
outcome	B-X
.	B-X

Water	O
soluble	O
phosphorylated	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucan	O
(	O
GP	O
)	O
was	O
prepared	O
as	O
done	O
before	O
[	O
20	O
]	O
.	O
<EOS>	B-X
To	B-X
obtain	B-X
a	B-X
water-soluble	B-X
β-D-glucan	B-X
derivative	B-X
cleanly	B-X
and	B-X
conveniently	B-X
,	B-X
a	B-X
highly	B-X
efficient	B-X
mechanochemical	B-X
method	B-X
,	B-X
planetary	B-X
ball	B-X
milling	B-X
,	B-X
was	B-X
used	B-X
to	B-X
phosphorylate	B-X
β-D-glucan	B-X
isolated	B-X
from	B-X
yeast	B-X
Saccharomyces	B-X
cerevisiae	B-X
in	B-X
solid	B-X
state	B-X
.	B-X
Soluble	B-X
β-D-glucan	B-X
phosphate	B-X
(	B-X
GP	B-X
)	B-X
with	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
substitution	B-X
(	B-X
0.77-2.09	B-X
)	B-X
and	B-X
an	B-X
apparent	B-X
PEAK	B-X
molecular	B-X
weight	B-X
of	B-X
6.6-10.0	B-X
kDa	B-X
was	B-X
produced	B-X
when	B-X
β-D-glucan	B-X
was	B-X
co-milled	B-X
with	B-X
sodium	B-X
hexametaphosphate	B-X
at	B-X
139.5-186.0	B-X
rad/s	B-X
for	B-X
12-20	B-X
min	B-X
.	B-X
The	B-X
energy	B-X
transferred	B-X
was	B-X
3.03-11.98	B-X
KJ/g	B-X
.	B-X
The	B-X
phosphorylation	B-X
of	B-X
GPs	B-X
was	B-X
demonstrated	B-X
by	B-X
Fourier	B-X
transform	B-X
infrared	B-X
spectroscopy	B-X
and	B-X
13C	B-X
and	B-X
31P	B-X
Nuclear	B-X
magnetic	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Three	B-X
GP	B-X
products	B-X
with	B-X
different	B-X
degree	B-X
of	B-X
substitution	B-X
(	B-X
DS	B-X
)	B-X
and	B-X
degree	B-X
of	B-X
polymerisation	B-X
(	B-X
DP	B-X
)	B-X
were	B-X
able	B-X
to	B-X
upregulate	B-X
the	B-X
functional	B-X
events	B-X
mediated	B-X
by	B-X
activated	B-X
murine	B-X
macrophage	B-X
RAW264.7	B-X
cells	B-X
,	B-X
among	B-X
which	B-X
GP-2	B-X
with	B-X
a	B-X
DS	B-X
of	B-X
1.24	B-X
and	B-X
DP	B-X
of	B-X
30.5	B-X
exerted	B-X
the	B-X
highest	B-X
immunostimulating	B-X
activity	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
mechanochemical	B-X
processing	B-X
is	B-X
an	B-X
efficient	B-X
method	B-X
for	B-X
preparing	B-X
water-soluble	B-X
and	B-X
biologically	B-X
active	B-X
GP	B-X
with	B-X
high	B-X
DS	B-X
.	B-X

The	O
physicochemical	O
characteristics	O
of	O
GP	O
were	O
determined	O
as	O
reported	O
previously	O
[	O
20	O
,	O
26	O
]	O
.	O
<EOS>	B-X
The	B-X
datasets	B-X
collected	B-X
herein	B-X
report	B-X
physicochemical	B-X
parameters	B-X
of	B-X
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
VV-hemorphin-5	B-X
(	B-X
Val-Val-Tyr-Pro-Trp-Thr-Gln	B-X
)	B-X
and	B-X
analogues	B-X
,	B-X
modified	B-X
at	B-X
position	B-X
1	B-X
and	B-X
7	B-X
by	B-X
the	B-X
natural	B-X
amino	B-X
acid	B-X
isoleucine	B-X
or	B-X
the	B-X
non-proteinogenic	B-X
2-aminoisobutyric	B-X
,	B-X
2,3-diaminopropanoic	B-X
or	B-X
2,4-diaminobutanoic	B-X
amino	B-X
acids	B-X
.	B-X
These	B-X
peptides	B-X
have	B-X
been	B-X
previously	B-X
screened	B-X
for	B-X
nociceptive	B-X
activity	B-X
and	B-X
were	B-X
chosen	B-X
accordingly	B-X
.	B-X
Lipid	B-X
packing	B-X
is	B-X
accessible	B-X
from	B-X
Laurdan	B-X
intensity	B-X
profiles	B-X
and	B-X
generalized	B-X
polarization	B-X
datasets	B-X
reported	B-X
herein	B-X
.	B-X

GP	O
was	O
dissolved	O
in	O
aqueous	O
media	O
,	O
filter	O
-	O
sterilized	O
(	O
0	O
.	O
2	O
mum	O
)	O
and	O
screened	O
for	O
endotoxin	O
contamination	O
with	O
the	O
Endospecy	O
assay	O
(	O
Seigakaku	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
which	O
is	O
specific	O
for	O
endotoxin	O
but	O
does	O
not	O
respond	O
to	O
beta	O
-	O
1	O
to	O
3	O
-	O
D	O
-	O
glucans	O
.	O

Isolation	O
of	O
human	O
PBMC	O
<EOS>	B-X
The	B-X
monocyte-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
moDCs	B-X
)	B-X
are	B-X
a	B-X
subset	B-X
of	B-X
dendritic	B-X
cells	B-X
widely	B-X
used	B-X
in	B-X
immunological	B-X
studies	B-X
as	B-X
a	B-X
convenient	B-X
and	B-X
easy	B-X
approach	B-X
after	B-X
isolation	B-X
of	B-X
mononuclear	B-X
cells	B-X
directly	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
compare	B-X
three	B-X
different	B-X
protocols	B-X
for	B-X
monocyte	B-X
isolation	B-X
from	B-X
PBMC	B-X
:	B-X
1	B-X
)	B-X
Cold-aggregation	B-X
;	B-X
2	B-X
)	B-X
Percoll	B-X
gradient	B-X
;	B-X
and	B-X
3	B-X
)	B-X
Magnetic	B-X
beads	B-X
cell-enrichment	B-X
.	B-X
Purified	B-X
PBMC	B-X
followed	B-X
by	B-X
two	B-X
steps	B-X
of	B-X
cold	B-X
aggregation	B-X
,	B-X
yielded	B-X
cell	B-X
viability	B-X
around	B-X
95	B-X
%	B-X
with	B-X
poor	B-X
monocyte	B-X
enrichment	B-X
(	B-X
monocytes	B-X
increase	B-X
vs.	B-X
lymphocytes	B-X
reduction	B-X
was	B-X
not	B-X
statistically	B-X
significant	B-X
,	B-X
p	B-X
>	B-X
0.05	B-X
)	B-X
.	B-X
Conversely	B-X
,	B-X
monocyte	B-X
isolation	B-X
from	B-X
PBMC	B-X
with	B-X
discontinuous	B-X
Percoll	B-X
gradient	B-X
generated	B-X
around	B-X
50	B-X
%	B-X
cell	B-X
viability	B-X
.	B-X

Buffy	O
coats	O
were	O
obtained	O
from	O
healthy	O
blood	O
donors	O
in	O
compliance	O
with	O
the	O
Helsinki	O
declaration	O
and	O
with	O
the	O
approval	O
of	O
the	O
ethics	O
committee	O
of	O
the	O
University	O
of	O
Luebeck	O
.	O

The	O
buffy	O
coats	O
were	O
separated	O
over	O
a	O
Ficoll	O
-	O
Hypaque	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
gradient	O
[	O
54	O
,	O
55	O
]	O
.	O

Following	O
isolation	O
,	O
PBMC	O
were	O
cultured	O
at	O
a	O
final	O
concentration	O
of	O
3	O
x	O
106	O
cells	O
/	O
ml	O
(	O
for	O
ELISA	O
measurements	O
)	O
or	O
5	O
x	O
106	O
/	O
ml	O
(	O
for	O
gel	O
shifts	O
)	O
or	O
1	O
x	O
106	O
cells	O
/	O
ml	O
(	O
for	O
flow	O
cytometry	O
)	O
in	O
RPMI	O
1640	O
medium	O
(	O
BioWhittaker	O
,	O
Heidelberg	O
,	O
Germany	O
,	O
LPS	O
-	O
free	O
)	O
,	O
containing	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
(	O
FCS	O
,	O
low	O
-	O
LPS	O
,	O
Invitrogen	O
,	O
Karlsruhe	O
,	O
Germany	O
)	O
,	O
1	O
%	O
penicillin	O
(	O
10000	O
U	O
/	O
ml	O
)	O
,	O
1	O
%	O
streptomycin	O
(	O
10000	O
mug	O
/	O
ml	O
)	O
,	O
and	O
1	O
%	O
200	O
mM	O
L	O
-	O
glutamine	O
(	O
BioWhittaker	O
)	O
.	O

Stimulation	O
conditions	O
<EOS>	B-X
In	B-X
appropriate	B-X
conditions	B-X
of	B-X
use	B-X
,	B-X
they	B-X
are	B-X
now	B-X
used	B-X
for	B-X
body	B-X
rejuvenation	B-X
in	B-X
clinical	B-X
practice	B-X
.	B-X
Transcranial	B-X
Current	B-X
Stimulations	B-X
(	B-X
tCSs	B-X
)	B-X
are	B-X
non-invasive	B-X
brain	B-X
stimulation	B-X
techniques	B-X
which	B-X
modulate	B-X
cortical	B-X
excitability	B-X
and	B-X
spontaneous	B-X
brain	B-X
activity	B-X
by	B-X
the	B-X
application	B-X
of	B-X
weak	B-X
electric	B-X
currents	B-X
through	B-X
the	B-X
scalp	B-X
,	B-X
in	B-X
a	B-X
safe	B-X
,	B-X
economic	B-X
,	B-X
and	B-X
well-tolerated	B-X
manner	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
critically	B-X
review	B-X
works	B-X
that	B-X
,	B-X
by	B-X
means	B-X
of	B-X
stimulating	B-X
sleep/vigilance	B-X
patterns	B-X
,	B-X
in	B-X
the	B-X
sense	B-X
of	B-X
enhancing	B-X
or	B-X
disrupting	B-X
them	B-X
,	B-X
intended	B-X
to	B-X
ameliorate	B-X
several	B-X
clinical	B-X
conditions	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
potential	B-X
application	B-X
in	B-X
clinical	B-X
settings	B-X
of	B-X
this	B-X
neuromodulatory	B-X
technique	B-X
as	B-X
a	B-X
therapeutic	B-X
tool	B-X
for	B-X
pathological	B-X
conditions	B-X
characterized	B-X
by	B-X
alterations	B-X
in	B-X
sleep	B-X
and	B-X
arousal	B-X
domains	B-X
and	B-X
for	B-X
sleep	B-X
disorders	B-X
per	B-X
se	B-X
.	B-X

For	O
induction	O
of	O
transcription	O
factors	O
and	O
cytokines	O
,	O
PBMC	O
were	O
cultured	O
in	O
a	O
volume	O
of	O
4	O
ml	O
in	O
sterile	O
pyrogen	O
-	O
free	O
6	O
-	O
well	O
culture	O
plates	O
(	O
Falcon	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Cultures	O
were	O
stimulated	O
for	O
1	O
h	O
(	O
EMSA	O
)	O
or	O
from	O
0	O
h	O
to	O
48	O
h	O
(	O
ELISA	O
)	O
with	O
1	O
or	O
100	O
mug	O
per	O
106	O
cells	O
of	O
GP	O
,	O
with	O
250	O
ng	O
/	O
106	O
cells	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
Toxin	O
Technologies	O
,	O
Sarasota	O
,	O
FL	O
,	O
USA	O
)	O
or	O
with	O
250	O
ng	O
/	O
106	O
cells	O
wild	O
-	O
type	O
LPS	O
from	O
Escherichia	O
coli	O
serotype	O
0111	O
:	O
B4	O
(	O
Sigma	O
,	O
Munich	O
,	O
Germany	O
)	O
.	O

In	O
costimulatory	O
experiments	O
,	O
PBMC	O
were	O
supplemented	O
simultaneously	O
with	O
a	O
combination	O
of	O
GP	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
with	O
a	O
combination	O
of	O
GP	O
and	O
LPS	O
.	O
<EOS>	B-X
Neutrophil	B-X
infiltration	B-X
and	B-X
activation	B-X
in	B-X
the	B-X
lung	B-X
are	B-X
important	B-X
pathophysiological	B-X
features	B-X
in	B-X
COPD	B-X
,	B-X
severe	B-X
asthma	B-X
and	B-X
bronchiectasis	B-X
mostly	B-X
mediated	B-X
by	B-X
CXCL8	B-X
and	B-X
CXCL1	B-X
via	B-X
CXCR1	B-X
and	B-X
CXCR2	B-X
.	B-X
No	B-X
thorough	B-X
study	B-X
to	B-X
date	B-X
has	B-X
been	B-X
performed	B-X
to	B-X
compare	B-X
the	B-X
anti-inflammatory	B-X
effect	B-X
profile	B-X
of	B-X
dual	B-X
CXCR1/2	B-X
vs.	B-X
selective	B-X
CXCR2	B-X
antagonists	B-X
in	B-X
relevant	B-X
human	B-X
neutrophil	B-X
assays	B-X
and	B-X
pulmonary	B-X
inflammation	B-X
models	B-X
.	B-X
Dual	B-X
CXCR1/2	B-X
(	B-X
SCH527123	B-X
,	B-X
diaminocyclobutandione-1	B-X
)	B-X
and	B-X
selective	B-X
CXCR2	B-X
(	B-X
SB265610	B-X
,	B-X
thiopyrimidine-1	B-X
)	B-X
antagonist	B-X
activity	B-X
and	B-X
receptor	B-X
residence	B-X
time	B-X
were	B-X
determined	B-X
by	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
GTPγS	B-X
binding	B-X
in	B-X
human	B-X
(	B-X
h	B-X
)	B-X
-	B-X
and	B-X
guinea	B-X
pig	B-X
(	B-X
gp	B-X
)	B-X
-CXCR1	B-X
and	B-X
CXCR2	B-X
overexpressing	B-X
membranes	B-X
.	B-X
h-neutrophil	B-X
chemotaxis	B-X
,	B-X
degranulation	B-X
and	B-X
ROS	B-X
production	B-X
were	B-X
established	B-X
using	B-X
CXCL8	B-X
or	B-X
CXCL1	B-X
to	B-X
evaluate	B-X
dual	B-X
CXCR1/2-	B-X
or	B-X
selective	B-X
CXCR2-dependent	B-X
activities	B-X
.	B-X
LPS-induced	B-X
lung	B-X
inflammation	B-X
in	B-X
gp	B-X
was	B-X
selected	B-X
to	B-X
assess	B-X
in	B-X
vivo	B-X
potency	B-X
.	B-X
Dual	B-X
CXCR1/2	B-X
antagonists	B-X
blocked	B-X
both	B-X
CXCL8	B-X
and	B-X
CXCL1-induced	B-X
h-neutrophil	B-X
functions	B-X
and	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
GTPγS	B-X
binding	B-X
.	B-X
Upon	B-X
LPS	B-X
challenge	B-X
in	B-X
gp	B-X
,	B-X
administration	B-X
of	B-X
SCH527123	B-X
inhibited	B-X
the	B-X
increase	B-X
of	B-X
neutrophils	B-X
in	B-X
BALF	B-X
,	B-X
modestly	B-X
reduced	B-X
blood	B-X
neutrophils	B-X
and	B-X
induced	B-X
minor	B-X
neutrophil	B-X
accumulation	B-X
in	B-X
bone	B-X
marrow	B-X
.	B-X
Differentiation	B-X
of	B-X
CXCR1/2	B-X
vs.	B-X
CXCR2	B-X
antagonists	B-X
could	B-X
not	B-X
be	B-X
extended	B-X
to	B-X
in	B-X
vivo	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
CXCR1	B-X
receptor	B-X
homology	B-X
between	B-X
h	B-X
and	B-X
gp	B-X
.	B-X
Dual	B-X
CXCR1/2	B-X
therapy	B-X
may	B-X
represent	B-X
a	B-X
promising	B-X
anti-inflammatory	B-X
treatment	B-X
for	B-X
respiratory	B-X
diseases	B-X
reducing	B-X
more	B-X
effectively	B-X
neutrophil	B-X
migration	B-X
and	B-X
activation	B-X
in	B-X
the	B-X
lung	B-X
than	B-X
a	B-X
CXCR2	B-X
selective	B-X
treatment	B-X
.	B-X
However	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
confirmation	B-X
of	B-X
this	B-X
claim	B-X
is	B-X
still	B-X
missing	B-X
due	B-X
to	B-X
species	B-X
differences	B-X
in	B-X
CXCR1	B-X
.	B-X

Oligonucleotides	O
(	O
Oligos	O
)	O
and	O
5	O
'	O
-	O
32	O
-	O
P	O
-	O
Labeling	O
<EOS>	B-X
A	B-X
method	B-X
for	B-X
solid-phase	B-X
synthesis	B-X
of	B-X
stereodefined	B-X
PS-oligos	B-X
via	B-X
an	B-X
oxathiaphospholane	B-X
approach	B-X
using	B-X
pure	B-X
P-diastereomers	B-X
of	B-X
nucleoside	B-X
oxathiaphospholane	B-X
monomers	B-X
is	B-X
described	B-X
.	B-X
The	B-X
oxathiaphospholane	B-X
monomers	B-X
are	B-X
synthesized	B-X
by	B-X
phosphitylation	B-X
of	B-X
5'-O-DMTr-N-protected	B-X
deoxyribonucleosides	B-X
with	B-X
2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane	B-X
followed	B-X
by	B-X
sulfurization	B-X
.	B-X
Starting	B-X
from	B-X
an	B-X
18O-labeled	B-X
mercaptoalcohol	B-X
,	B-X
the	B-X
corresponding	B-X
18O-labeled	B-X
phosphitylating	B-X
reagent	B-X
and	B-X
nucleoside	B-X
monomers	B-X
can	B-X
be	B-X
obtained	B-X
and	B-X
used	B-X
for	B-X
synthesis	B-X
of	B-X
labeled	B-X
stereodefined	B-X
PS-oligos	B-X
,	B-X
which	B-X
are	B-X
useful	B-X
for	B-X
studying	B-X
mechanisms	B-X
of	B-X
enzymatic	B-X
reactions	B-X
.	B-X
Details	B-X
are	B-X
provided	B-X
for	B-X
chromatographic	B-X
separation	B-X
of	B-X
the	B-X
5'-O-DMTr-N-protected-deoxyribonucleoside-3'-O-	B-X
(	B-X
2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane	B-X
)	B-X
s	B-X
into	B-X
their	B-X
P-diastereomers	B-X
,	B-X
and	B-X
for	B-X
manual	B-X
solid-phase	B-X
synthesis	B-X
of	B-X
PS-oligos	B-X
.	B-X
Oxidation	B-X
of	B-X
5'-O-DMTr-N-protected-deoxyribonucleoside-3'-O-	B-X
(	B-X
2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane	B-X
)	B-X
s	B-X
with	B-X
selenium	B-X
dioxide	B-X
yields	B-X
their	B-X
2-oxo-analogs	B-X
,	B-X
which	B-X
are	B-X
suitable	B-X
either	B-X
for	B-X
elongation	B-X
of	B-X
stereodefined	B-X
PS-oligos	B-X
with	B-X
segments	B-X
consisting	B-X
of	B-X
unmodified	B-X
nucleotide	B-X
units	B-X
possessing	B-X
phosphate	B-X
internucleotide	B-X
linkages	B-X
,	B-X
or	B-X
for	B-X
generating	B-X
isotopomeric	B-X
18O-labeled	B-X
PO-oligos	B-X
of	B-X
predetermined	B-X
P-chirality	B-X
.	B-X

The	O
complementary	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
oligonucleotides	O
(	O
oligos	O
)	O
from	O
the	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IFNgamma	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoters	O
were	O
synthesised	O
from	O
single	O
stranded	O
(	O
ss	O
)	O
oligos	O
(	O
illustrated	O
in	O
Table	O
1	O
)	O
,	O
(	O
TIB	O
Molbiol	O
,	O
Berlin	O
,	O
Germany	O
)	O
and	O
32P	O
-	O
labeled	O
with	O
5	O
'	O
gamma	O
-	O
P	O
-	O
ATP	O
(	O
3	O
,	O
000	O
Ci	O
/	O
mmol	O
,	O
Amersham	O
,	O
Braunschweig	O
,	O
Germany	O
)	O
using	O
the	O
Ready	O
-	O
To	O
-	O
Go	O
-	O
Polynucleotide	O
-	O
Kinase	O
Kit	O
(	O
PNK	O
Kit	O
,	O
Pharmacia	O
LKB	O
,	O
Freiburg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

To	O
test	O
the	O
binding	O
specificity	O
of	O
the	O
oligos	O
,	O
mutated	O
oligos	O
were	O
used	O
as	O
an	O
additional	O
control	O
.	O

Mutations	O
in	O
the	O
P2	O
site	O
of	O
the	O
IFNgamma	B-Protein
promoter	O
[	O
29	O
]	O
and	O
in	O
the	O
kappa	O
consensus	O
sequence	O
of	O
the	O
TNFalpha	B-Protein
promoter	O
[	O
55	O
]	O
have	O
been	O
reported	O
to	O
interfere	O
with	O
sequences	O
,	O
which	O
seem	O
to	O
be	O
crucial	O
for	O
the	O
binding	O
of	O
NFAT	B-Protein
and	O
NFkappaB	O
proteins	O
,	O
respectively	O
.	O

Afterwards	O
,	O
the	O
ds	O
oligos	O
were	O
purified	O
via	O
gel	O
filtration	O
using	O
Probe	O
Quant	O
G	O
-	O
50	O
Micro	O
Columns	O
(	O
Pharmacia	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Preparation	O
of	O
nuclear	O
extracts	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
preparation	B-X
of	B-X
nuclear	B-X
extracts	B-X
and	B-X
the	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
STAT	B-X
species	B-X
.	B-X
We	B-X
use	B-X
the	B-X
method	B-X
for	B-X
the	B-X
investigation	B-X
of	B-X
STAT1	B-X
and	B-X
STAT3	B-X
homo-	B-X
and	B-X
heterodimers	B-X
and	B-X
show	B-X
how	B-X
the	B-X
preparation	B-X
of	B-X
the	B-X
extracts	B-X
can	B-X
influence	B-X
the	B-X
distribution	B-X
of	B-X
the	B-X
STAT	B-X
species	B-X
observed	B-X
in	B-X
the	B-X
EMSA	B-X
.	B-X
An	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
sensitive	B-X
technique	B-X
for	B-X
detecting	B-X
protein-DNA	B-X
and	B-X
protein-protein	B-X
interactions	B-X
in	B-X
which	B-X
complexes	B-X
are	B-X
separated	B-X
by	B-X
native	B-X
(	B-X
non-denaturing	B-X
)	B-X
gel	B-X
electrophoresis	B-X
.	B-X
EMSAs	B-X
can	B-X
provide	B-X
evidence	B-X
for	B-X
specific	B-X
binding	B-X
between	B-X
components	B-X
prepared	B-X
from	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
sources	B-X
,	B-X
including	B-X
not	B-X
only	B-X
highly	B-X
purified	B-X
proteins	B-X
but	B-X
also	B-X
components	B-X
of	B-X
crude	B-X
cellular	B-X
extracts	B-X
.	B-X
EMSA	B-X
experiments	B-X
were	B-X
critical	B-X
in	B-X
identifying	B-X
the	B-X
minimal	B-X
protein	B-X
requirements	B-X
for	B-X
assembly	B-X
of	B-X
transcriptionally	B-X
active	B-X
nuclear	B-X
Notch	B-X
complexes	B-X
as	B-X
well	B-X
as	B-X
the	B-X
DNA	B-X
sequence	B-X
specificity	B-X
of	B-X
Notch	B-X
transcription	B-X
complexes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
radioactive	B-X
EMSA	B-X
protocol	B-X
for	B-X
detection	B-X
of	B-X
Notch	B-X
transcription	B-X
complexes	B-X
.	B-X

Nuclear	O
extracts	O
of	O
purified	O
PBMCs	O
were	O
prepared	O
according	O
to	O
a	O
technique	O
described	O
by	O
Trede	O
et	O
al	O
.	O

[	O
27	O
]	O
and	O
modified	O
for	O
our	O
experimental	O
setup	O
[	O
56	O
]	O
.	O
<EOS>	B-X
For	B-X
each	B-X
study	B-X
,	B-X
the	B-X
model	B-X
has	B-X
to	B-X
be	B-X
modified	B-X
according	B-X
to	B-X
the	B-X
specific	B-X
investigative	B-X
aim	B-X
.	B-X
This	B-X
study	B-X
presents	B-X
the	B-X
experimental	B-X
results	B-X
of	B-X
oxygen	B-X
absorption	B-X
tests	B-X
for	B-X
conventional	B-X
and	B-X
modified	B-X
cylindrical	B-X
hydrodynamic	B-X
flow	B-X
regulators	B-X
(	B-X
patent	B-X
pending	B-X
)	B-X
.	B-X
These	B-X
devices	B-X
were	B-X
tested	B-X
in	B-X
a	B-X
closed-circuit	B-X
experimental	B-X
setup	B-X
at	B-X
the	B-X
semi-commercial	B-X
scale	B-X
.	B-X
The	B-X
modified	B-X
discharge	B-X
mode	B-X
with	B-X
two	B-X
active	B-X
outlets	B-X
allowed	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
aeration	B-X
efficiency	B-X
of	B-X
up	B-X
to	B-X
15	B-X
%	B-X
compared	B-X
to	B-X
conventional	B-X
designs	B-X
.	B-X

The	O
intensity	O
of	O
shifted	O
bands	O
was	O
normalized	O
to	O
bands	O
of	O
unstimulated	O
controls	O
.	O

Competition	O
experiments	O
with	O
labeled	O
and	O
unlabeled	O
mutated	O
oligos	O
of	O
the	O
cytokine	O
promoter	O
binding	O
sites	O
(	O
see	O
above	O
)	O
were	O
carried	O
out	O
in	O
order	O
to	O
prevent	O
non	O
-	O
specific	O
binding	O
to	O
nuclear	O
proteins	O
.	O

For	O
such	O
experiments	O
,	O
an	O
excess	O
(	O
5	O
-	O
50x	O
)	O
of	O
unlabeled	O
oligos	O
was	O
added	O
to	O
the	O
nuclear	O
extracts	O
.	O

For	O
specificity	O
of	O
binding	O
,	O
supershift	O
assays	O
for	O
NFkappaB	O
with	O
a	O
combined	O
p65	B-Protein
/	O
50	B-Protein
antibody	O
were	O
performed	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
exclude	O
non	O
-	O
specific	O
reactions	O
,	O
a	O
30	O
-	O
fold	O
molar	O
excess	O
of	O
Oct	B-Protein
-	I-Protein
1	I-Protein
DNA	O
(	O
unrelated	O
DNA	O
,	O
Table	O
1	O
)	O
was	O
used	O
,	O
which	O
did	O
not	O
compete	O
with	O
specific	O
binding	O
.	O

Immuno	O
(	O
Dot	O
)	O
blot	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
an	B-X
immuno-dot	B-X
blot	B-X
assay	B-X
for	B-X
the	B-X
inhibition	B-X
profiling	B-X
of	B-X
HKs	B-X
using	B-X
the	B-X
anti-N3-phosphohistidine	B-X
antibody	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
workflow	B-X
of	B-X
immuno	B-X
magnetic	B-X
isolation	B-X
and	B-X
analysis	B-X
of	B-X
exosomes	B-X
by	B-X
flow	B-X
cytometry	B-X
,	B-X
Western	B-X
immunoblotting	B-X
,	B-X
and	B-X
electron	B-X
microscopy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
several	B-X
protocols	B-X
for	B-X
monitoring	B-X
autophagy-mediated	B-X
degradation	B-X
of	B-X
p62	B-X
using	B-X
Western	B-X
blots	B-X
,	B-X
pulse-chase	B-X
measurement	B-X
of	B-X
p62	B-X
half-life	B-X
,	B-X
immunofluorescence	B-X
and	B-X
immuno-electron	B-X
microscopy	B-X
,	B-X
as	B-X
well	B-X
as	B-X
live	B-X
cell	B-X
imaging	B-X
with	B-X
a	B-X
pH-sensitive	B-X
mCherry-GFP	B-X
double	B-X
tag	B-X
.	B-X
We	B-X
developed	B-X
a	B-X
serological	B-X
test	B-X
implementing	B-X
flow-through	B-X
dot-blot	B-X
assay	B-X
(	B-X
FT-DBA	B-X
)	B-X
for	B-X
SARS-CoV-2	B-X
specific	B-X
IgG	B-X
detection	B-X
,	B-X
which	B-X
provides	B-X
enhanced	B-X
sensitivity	B-X
and	B-X
specificity	B-X
while	B-X
being	B-X
quick	B-X
to	B-X
perform	B-X
and	B-X
easy	B-X
to	B-X
use	B-X
.	B-X

To	O
determine	O
whether	O
the	O
DNA	O
binding	O
proteins	O
were	O
related	O
to	O
NFkappaB	O
and	O
NFAT	B-Protein
,	O
dot	O
blots	O
using	O
a	O
SRC96D	O
SNS	O
minifold	O
I	O
dot	O
blotter	O
(	O
Schleicher	O
&	O
Schull	O
,	O
Dassel	O
,	O
Germany	O
)	O
were	O
performed	O
with	O
the	O
following	O
positive	O
controls	O
and	O
antibodies	O
(	O
all	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
:	O
positive	O
controls	O
(	O
10	O
ng	O
/	O
dot	O
)	O
:	O
NFkappaB	O
p52	B-Protein
(	O
80	O
kD	O
)	O
sc	O
-	O
4095WB	O
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
61	O
kD	O
)	O
sc	O
-	O
4030WB	O
;	O
Jurkat	O
nuclear	O
extract	O
,	O
PMA	O
-	O
stimulated	O
;	O
primary	O
antibodies	O
(	O
1	O
mug	O
/	O
dot	O
)	O
:	O
anti	O
-	O
NFkappaB	O
p50	B-Protein
(	O
NLS	O
)	O
sc	O
-	O
114	O
,	O
anti	O
-	O
NFkappaB	O
p65	B-Protein
(	O
A	O
)	O
sc	O
-	O
109	O
,	O
anti	O
-	O
NFkappaB	O
p52	B-Protein
(	O
447	O
)	O
sc	O
-	O
848	O
,	O
a	O
rabbit	O
polyclonal	O
IgG1	O
antiserum	O
,	O
anti	O
-	O
c	B-Protein
-	I-Protein
rel	I-Protein
(	O
N466	O
)	O
sc	O
-	O
272	O
,	O
anti	O
-	O
NFATc2	B-Protein
(	O
M	O
-	O
20	O
)	O
sc	O
-	O
1151	O
,	O
anti	O
-	O
NFATc1	B-Protein
(	O
K	O
-	O
18	O
)	O
sc	O
-	O
1149	O
,	O
two	O
goat	O
polyclonal	O
IgG1	O
antisera	O
;	O
secondary	O
antibodies	O
(	O
0	O
.	O
8	O
mug	O
/	O
dot	O
)	O
:	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
AP	O
-	O
conjugate	O
sc	O
-	O
2007	O
,	O
and	O
donkey	O
anti	O
-	O
goat	O
IgG	O
AP	O
-	O
conjugate	O
sc	O
-	O
2022	O
.	O

The	O
nuclear	O
proteins	O
were	O
blotted	O
onto	O
a	O
nitrocellulose	O
membrane	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

After	O
blocking	O
with	O
PBS	O
/	O
3	O
%	O
BSA	O
(	O
Fluka	O
,	O
Deisenhofen	O
,	O
Germany	O
)	O
,	O
the	O
blot	O
was	O
incubated	O
overnight	O
with	O
the	O
primary	O
antibodies	O
diluted	O
1	O
:	O
2000	O
in	O
PBS	O
/	O
1	O
%	O
BSA	O
,	O
washed	O
again	O
and	O
incubated	O
with	O
the	O
alkaline	O
phosphatase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
1	O
:	O
500	O
in	O
PBS	O
/	O
1	O
%	O
BSA	O
)	O
.	O

The	O
blot	O
was	O
developed	O
using	O
the	O
Vectastain	O
(	O
R	O
)	O
staining	O
kit	O
(	O
Vector	O
Laboratories	O
Inc	O
.	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cytokine	O
measurements	O
<EOS>	B-X
It	B-X
is	B-X
the	B-X
purpose	B-X
of	B-X
this	B-X
report	B-X
to	B-X
outline	B-X
the	B-X
potential	B-X
problems	B-X
with	B-X
cytokine	B-X
assays	B-X
and	B-X
the	B-X
criteria	B-X
that	B-X
should	B-X
be	B-X
applied	B-X
before	B-X
making	B-X
measurements	B-X
in	B-X
biological	B-X
fluids	B-X
.	B-X
Cytokines	B-X
are	B-X
known	B-X
to	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
pathologic	B-X
conditions	B-X
spanning	B-X
all	B-X
organ	B-X
systems	B-X
in	B-X
every	B-X
species	B-X
studied	B-X
.	B-X
Previous	B-X
studies	B-X
that	B-X
reported	B-X
measurements	B-X
of	B-X
cytokine	B-X
concentrations	B-X
from	B-X
serum	B-X
or	B-X
plasma	B-X
in	B-X
dogs	B-X
with	B-X
infectious	B-X
,	B-X
autoimmune	B-X
,	B-X
metabolic	B-X
,	B-X
endocrine	B-X
,	B-X
and	B-X
neoplastic	B-X
diseases	B-X
yield	B-X
an	B-X
appreciation	B-X
for	B-X
the	B-X
complexity	B-X
of	B-X
cytokine	B-X
control	B-X
and	B-X
potential	B-X
applications	B-X
for	B-X
cytokine	B-X
measurements	B-X
in	B-X
the	B-X
diagnosis	B-X
,	B-X
prognosis	B-X
,	B-X
and	B-X
therapy	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
disease	B-X
conditions	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
molecular	B-X
accumulation	B-X
within	B-X
the	B-X
droplets	B-X
is	B-X
modeled	B-X
and	B-X
it	B-X
is	B-X
found	B-X
that	B-X
physical	B-X
confinement	B-X
is	B-X
crucial	B-X
for	B-X
measurements	B-X
of	B-X
protein	B-X
secretions	B-X
.	B-X
These	B-X
first	B-X
measurements	B-X
of	B-X
secretions	B-X
from	B-X
individual	B-X
spheroids	B-X
provide	B-X
several	B-X
new	B-X
biological	B-X
and	B-X
technological	B-X
insights	B-X
.	B-X

Supernatants	O
of	O
cell	O
cultures	O
were	O
harvested	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
18	O
,	O
24	O
,	O
30	O
,	O
36	O
and	O
48	O
hours	O
after	O
stimulation	O
and	O
stored	O
at	O
-	O
80	O
degreesC	O
until	O
used	O
and	O
thawed	O
only	O
once	O
.	O

IFNgamma	B-Protein
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
determined	O
using	O
an	O
ELISA	O
from	O
Bender	O
Systems	O
(	O
Vienna	O
,	O
Austria	O
)	O
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
by	O
an	O
ELISA	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Wiesbaden	O
-	O
Nordenstadt	O
,	O
Germany	O
)	O
,	O
and	O
TGFbeta	B-Protein
1	I-Protein
using	O
an	O
ELISA	O
as	O
previously	O
described	O
[	O
57	O
]	O
.	O

Quantification	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
as	O
an	O
indicator	O
for	O
the	O
bioactivity	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
was	O
done	O
as	O
previously	O
described	O
[	O
46	O
]	O
.	O

Samples	O
were	O
diluted	O
in	O
the	O
same	O
buffer	O
as	O
that	O
used	O
for	O
the	O
standards	O
.	O
<EOS>	B-X
The	B-X
hybrid	B-X
channel	B-X
enables	B-X
sample	B-X
uniform	B-X
mixing	B-X
and	B-X
quantitative	B-X
dilution	B-X
with	B-X
buffer	B-X
solution	B-X
by	B-X
inducing	B-X
the	B-X
``	B-X
horseshoe	B-X
vortex	B-X
''	B-X
phenomenon	B-X
.	B-X
The	B-X
objectives	B-X
were	B-X
to	B-X
optimize	B-X
an	B-X
isotope-dilution	B-X
method	B-X
to	B-X
increase	B-X
the	B-X
precision	B-X
and	B-X
accuracy	B-X
of	B-X
the	B-X
analysis	B-X
of	B-X
the	B-X
PFCs	B-X
and	B-X
to	B-X
eliminate	B-X
the	B-X
need	B-X
for	B-X
matrix-matched	B-X
standards	B-X
.	B-X
A	B-X
250	B-X
mL	B-X
sample	B-X
of	B-X
environmental	B-X
or	B-X
drinking	B-X
water	B-X
was	B-X
buffered	B-X
to	B-X
a	B-X
pH	B-X
of	B-X
4	B-X
,	B-X
spiked	B-X
with	B-X
labeled	B-X
surrogate	B-X
standards	B-X
,	B-X
extracted	B-X
through	B-X
solid	B-X
phase	B-X
extraction	B-X
cartridges	B-X
,	B-X
and	B-X
eluted	B-X
with	B-X
ammonium	B-X
hydroxide	B-X
in	B-X
methyl	B-X
tert-butyl	B-X
ether	B-X
:	B-X
methanol	B-X
solution	B-X
.	B-X
Various	B-X
surface	B-X
water	B-X
and	B-X
drinking	B-X
water	B-X
samples	B-X
were	B-X
used	B-X
during	B-X
method	B-X
development	B-X
to	B-X
optimize	B-X
this	B-X
method	B-X
.	B-X
The	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
samples	B-X
from	B-X
the	B-X
Mississippi	B-X
River	B-X
at	B-X
New	B-X
Orleans	B-X
and	B-X
drinking	B-X
water	B-X
samples	B-X
from	B-X
a	B-X
private	B-X
residence	B-X
in	B-X
that	B-X
same	B-X
city	B-X
.	B-X
The	B-X
method	B-X
was	B-X
also	B-X
used	B-X
to	B-X
determine	B-X
PFC	B-X
contamination	B-X
in	B-X
well	B-X
water	B-X
samples	B-X
from	B-X
a	B-X
fire	B-X
training	B-X
area	B-X
where	B-X
perfluorinated	B-X
foams	B-X
were	B-X
used	B-X
in	B-X
training	B-X
to	B-X
extinguish	B-X
fires	B-X
.	B-X

All	O
cytokines	O
were	O
quantified	O
using	O
an	O
ELISA	O
plate	O
reader	O
(	O
Anthos	O
Labotec	O
,	O
Salzburg	O
,	O
Austria	O
or	O
Microplate	O
Reader	O
,	O
BioRad	O
)	O
.	O

Cytokine	O
amounts	O
were	O
all	O
within	O
the	O
range	O
of	O
the	O
standard	O
curve	O
.	O
<EOS>	B-X
Absorbance	B-X
readings	B-X
were	B-X
taken	B-X
and	B-X
results	B-X
for	B-X
test	B-X
samples	B-X
were	B-X
extrapolated	B-X
from	B-X
standard	B-X
rIFN-gamma	B-X
inhibition	B-X
curves	B-X
constructed	B-X
as	B-X
logit-log	B-X
plots	B-X
.	B-X
Optimum	B-X
sensitivity	B-X
was	B-X
achieved	B-X
with	B-X
the	B-X
antibodies	B-X
of	B-X
higher	B-X
affinity	B-X
,	B-X
20G7	B-X
and	B-X
H-22	B-X
,	B-X
which	B-X
gave	B-X
reliable	B-X
quantification	B-X
of	B-X
IFN-gamma	B-X
over	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
concentrations	B-X
from	B-X
0.4	B-X
ng/ml	B-X
(	B-X
3.4	B-X
IU/ml	B-X
)	B-X
,	B-X
or	B-X
less	B-X
,	B-X
to	B-X
250	B-X
ng/ml	B-X
approximately	B-X
2000	B-X
IU/ml	B-X
)	B-X
.	B-X
It	B-X
also	B-X
uses	B-X
relatively	B-X
small	B-X
volumes	B-X
of	B-X
test	B-X
samples	B-X
(	B-X
50	B-X
microliters/well	B-X
)	B-X
which	B-X
is	B-X
particularly	B-X
advantageous	B-X
where	B-X
limited	B-X
amounts	B-X
of	B-X
cell	B-X
culture	B-X
supernatant	B-X
are	B-X
available	B-X
for	B-X
cytokine	B-X
assays	B-X
.	B-X
The	B-X
developed	B-X
method	B-X
demonstrated	B-X
an	B-X
accuracy	B-X
of	B-X
100.28	B-X
%	B-X
;	B-X
the	B-X
relative	B-X
standard	B-X
deviations	B-X
for	B-X
method	B-X
precision	B-X
,	B-X
repeatability	B-X
and	B-X
inter-day	B-X
precision	B-X
tests	B-X
were	B-X
found	B-X
to	B-X
be	B-X
0.57	B-X
%	B-X
,	B-X
1.54	B-X
%	B-X
and	B-X
1.83	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Linearity	B-X
of	B-X
the	B-X
method	B-X
was	B-X
assessed	B-X
in	B-X
the	B-X
range	B-X
of	B-X
concentrations	B-X
from	B-X
0.05	B-X
mg/mL	B-X
to	B-X
0.5	B-X
mg/mL	B-X
,	B-X
the	B-X
curve	B-X
obtained	B-X
had	B-X
a	B-X
determination	B-X
coefficient	B-X
(	B-X
r	B-X
(	B-X
2	B-X
)	B-X
)	B-X
of	B-X
0.9989	B-X
.	B-X

Only	O
stimulation	O
of	O
PBMC	O
observed	O
in	O
donors	O
showing	O
no	O
spontaneous	O
cytokine	O
release	O
was	O
included	O
in	O
the	O
statistics	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
<EOS>	B-X
Gene-specific	B-X
transcription	B-X
factors	B-X
are	B-X
DNA	B-X
binding	B-X
proteins	B-X
that	B-X
function	B-X
at	B-X
the	B-X
center	B-X
of	B-X
the	B-X
transcriptional	B-X
machinery	B-X
to	B-X
mediate	B-X
the	B-X
cellular	B-X
phenotype	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X
Owing	B-X
to	B-X
the	B-X
lack	B-X
of	B-X
enzymatic	B-X
activities	B-X
of	B-X
these	B-X
intracellular	B-X
proteins	B-X
,	B-X
manipulating	B-X
the	B-X
activity	B-X
of	B-X
transcription	B-X
factors	B-X
by	B-X
small	B-X
organic	B-X
molecules	B-X
is	B-X
widely	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
difficult	B-X
task	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
I	B-X
will	B-X
discuss	B-X
general	B-X
approaches	B-X
designed	B-X
to	B-X
inhibit	B-X
a	B-X
subset	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
referred	B-X
to	B-X
as	B-X
dimeric	B-X
transcription	B-X
factors	B-X
,	B-X
by	B-X
cell-permeable	B-X
small	B-X
organic	B-X
molecules	B-X
that	B-X
inhibit	B-X
protein-protein	B-X
interactions	B-X
or	B-X
protein-DNA	B-X
interactions	B-X
.	B-X
These	B-X
dimeric	B-X
transcription	B-X
factors	B-X
include	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-1	B-X
,	B-X
c-Myc	B-X
,	B-X
and	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
3	B-X
.	B-X
The	B-X
data	B-X
presented	B-X
here	B-X
indicate	B-X
that	B-X
dimeric	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
potently	B-X
and	B-X
selectively	B-X
inhibited	B-X
by	B-X
drug-like	B-X
small	B-X
molecules	B-X
.	B-X

To	O
inhibit	O
translocation	O
and	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
,	O
PBMC	O
were	O
incubated	O
for	O
1	O
h	O
with	O
each	O
of	O
the	O
following	O
substances	O
(	O
concentrations	O
were	O
based	O
upon	O
50	O
%	O
inhibition	O
)	O
:	O
50	O
mug	O
/	O
ml	O
of	O
CAPE	O
(	O
caffeic	O
-	O
3	O
,	O
4	O
-	O
dihydroxycinnamic	O
-	O
acid	O
-	O
phenyl	O
-	O
ester	O
)	O
,	O
(	O
Biomol	O
,	O
Hamburg	O
,	O
Germany	O
)	O
;	O
400	O
ng	O
/	O
ml	O
cyclosporin	O
A	O
(	O
Calbiochem	O
-	O
Merck	O
Biosciences	O
,	O
Bad	O
Soden	O
,	O
Germany	O
)	O
;	O
10	O
mug	O
/	O
ml	O
cycloheximide	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
prior	O
to	O
incubation	O
with	O
GP	O
.	O

Band	O
shifts	O
were	O
determined	O
after	O
1	O
h	O
incubation	O
with	O
GP	O
as	O
described	O
before	O
,	O
including	O
mutated	O
oligos	O
for	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
(	O
TTA	O
CAA	O
CAG	O
TGG	O
ATT	O
GCG	O
ACA	O
CTT	O
AGT	O
GGG	O
)	O
and	O
NFATP2	B-Protein
/	O
3	B-Protein
(	O
GGC	O
GCA	O
GAA	O
AAG	O
GTA	O
AAA	O
TAT	O
TTA	O
CTA	O
TCT	O
)	O
binding	O
sites	O
within	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

PBMC	O
RNA	O
was	O
isolated	O
with	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Germany	O
)	O
and	O
messenger	O
RNA	O
was	O
transcribed	O
into	O
cDNA	O
with	O
Reactin	O
Ready	O
First	O
Strand	O
kit	O
(	O
Biomol	O
)	O
and	O
analysed	O
for	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
and	O
GAPDH	B-Protein
transcripts	O
by	O
PCR	O
with	O
a	O
HotStart	O
"	O
sweet	O
"	O
PCR	O
mastermix	O
(	O
Biomol	O
)	O
(	O
95degreesC	O
,	O
30	O
sec	O
,	O
55degreesC	O
,	O
30	O
sec	O
,	O
72degreesC	O
,	O
30	O
sec	O
,	O
25	O
cycles	O
for	O
IL	O
-	O
1RA	O
and	O
94degreesC	O
for	O
30	O
sec	O
,	O
50degreesC	O
for	O
30	O
sec	O
and	O
72degreesC	O
for	O
45	O
sec	O
,	O
25	O
cycles	O
for	O
GAPDH	O
)	O
following	O
18	O
h	O
incubation	O
with	O
GP	O
.	O

IL	B-Protein
-	I-Protein
1RA	I-Protein
protein	O
was	O
measured	O
in	O
the	O
supernatant	O
by	O
ELISA	O
after	O
24	O
h	O
incubation	O
with	O
GP	O
.	O

Statistical	O
analysis	O

The	O
Kolmogorow	O
-	O
Smirnov	O
test	O
was	O
used	O
to	O
evaluate	O
,	O
whether	O
cytokine	O
amounts	O
and	O
binding	O
activities	O
to	O
transcription	O
factors	O
were	O
normally	O
distributed	O
.	O

Correlation	O
coefficients	O
and	O
corresponding	O
significances	O
were	O
analyzed	O
by	O
the	O
Pearson	O
test	O
(	O
normal	O
distribution	O
)	O
or	O
the	O
Spearman	O
test	O
(	O
non	O
-	O
normal	O
distribution	O
)	O
.	O
<EOS>	B-X
To	B-X
survey	B-X
the	B-X
use	B-X
of	B-X
Pearson	B-X
's	B-X
correlation	B-X
coefficient	B-X
(	B-X
r	B-X
)	B-X
and	B-X
related	B-X
statistical	B-X
methods	B-X
in	B-X
the	B-X
ophthalmic	B-X
literature	B-X
,	B-X
to	B-X
consider	B-X
the	B-X
limitations	B-X
of	B-X
r	B-X
,	B-X
and	B-X
to	B-X
suggest	B-X
suitable	B-X
alternative	B-X
methods	B-X
of	B-X
analysis	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
underlying	B-X
population	B-X
distribution	B-X
(	B-X
normal	B-X
,	B-X
non-normal	B-X
)	B-X
and	B-X
OLs	B-X
on	B-X
the	B-X
magnitude	B-X
of	B-X
Pearson	B-X
,	B-X
Spearman	B-X
and	B-X
Pearson	B-X
Winzorized	B-X
correlation	B-X
coefficients	B-X
through	B-X
Monte	B-X
Carlo	B-X
simulation	B-X
.	B-X
Each	B-X
,	B-X
underlying	B-X
population	B-X
correlations	B-X
of	B-X
0.12	B-X
,	B-X
0.20	B-X
,	B-X
0.31	B-X
and	B-X
0.50	B-X
under	B-X
conditions	B-X
of	B-X
bivariate	B-X
Normality	B-X
,	B-X
bivariate	B-X
Normality	B-X
with	B-X
Outliers	B-X
(	B-X
discordant	B-X
,	B-X
contaminants	B-X
)	B-X
and	B-X
Non-normal	B-X
with	B-X
different	B-X
values	B-X
of	B-X
skewness	B-X
and	B-X
kurtosis	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
outliers	B-X
have	B-X
a	B-X
greater	B-X
effect	B-X
compared	B-X
to	B-X
the	B-X
data	B-X
distributions	B-X
;	B-X
specifically	B-X
,	B-X
a	B-X
substantial	B-X
effect	B-X
occurs	B-X
in	B-X
Pearson	B-X
and	B-X
a	B-X
smaller	B-X
one	B-X
in	B-X
Spearman	B-X
and	B-X
Pearson	B-X
Winzorized	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
outliers	B-X
are	B-X
shown	B-X
to	B-X
have	B-X
an	B-X
impact	B-X
on	B-X
the	B-X
assessment	B-X
of	B-X
bivariate	B-X
normality	B-X
using	B-X
Mardia	B-X
's	B-X
test	B-X
and	B-X
problems	B-X
with	B-X
decisions	B-X
based	B-X
on	B-X
skewness	B-X
and	B-X
kurtosis	B-X
for	B-X
univariate	B-X
normality	B-X
.	B-X

To	O
compare	O
experimental	O
data	O
to	O
a	O
theoretical	O
value	O
(	O
for	O
example	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
vs	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
)	O
we	O
calculated	O
the	O
sum	O
of	O
the	O
individual	O
effects	O
and	O
added	O
these	O
values	O
into	O
Fig	O
.	O

1B	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
.	O
<EOS>	B-X
deviation	B-X
=	B-X
0.003	B-X
Å	B-X
)	B-X
,	B-X
and	B-X
the	B-X
benzene	B-X
ring	B-X
is	B-X
twisted	B-X
slightly	B-X
[	B-X
by	B-X
5.65	B-X
(	B-X
6	B-X
)	B-X
°	B-X
]	B-X
relative	B-X
to	B-X
this	B-X
moiety	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
columns	B-X
,	B-X
there	B-X
are	B-X
the	B-X
two	B-X
types	B-X
of	B-X
π-π	B-X
stacking	B-X
inter-actions	B-X
,	B-X
namely	B-X
,	B-X
(	B-X
i	B-X
)	B-X
between	B-X
two	B-X
imidazo	B-X
[	B-X
2,1-b	B-X
]	B-X
thia-zole	B-X
fragments	B-X
[	B-X
inter-planar	B-X
distance	B-X
=	B-X
3.351	B-X
(	B-X
2	B-X
)	B-X
Å	B-X
]	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
between	B-X
an	B-X
imidazo	B-X
[	B-X
2,1-b	B-X
]	B-X
thia-zole	B-X
fragment	B-X
and	B-X
the	B-X
phenyl	B-X
ring	B-X
[	B-X
inter-planar	B-X
distance	B-X
=	B-X
3.410	B-X
(	B-X
5	B-X
)	B-X
Å	B-X
]	B-X
.	B-X
Three	B-X
title	B-X
compounds	B-X
,	B-X
namely	B-X
,	B-X
2-	B-X
(	B-X
4-chloro-benz-yl	B-X
)	B-X
-5-	B-X
[	B-X
(	B-X
1	B-X
In	B-X
the	B-X
title	B-X
mol-ecule	B-X
,	B-X
C16H15BrN2S2	B-X
,	B-X
the	B-X
central	B-X
imidazo	B-X
[	B-X
2,1-b	B-X
]	B-X
thia-zole	B-X
fragment	B-X
is	B-X
almost	B-X
planar	B-X
(	B-X
r.m.s	B-X
.	B-X
deviation	B-X
=	B-X
0.012	B-X
Å	B-X
)	B-X
,	B-X
and	B-X
the	B-X
fused	B-X
5,6,7,8-tetra-hydro-benzene	B-X
ring	B-X
adopts	B-X
an	B-X
unsymmetrical	B-X
half-chair	B-X
conformation	B-X
.	B-X
The	B-X
dihedral	B-X
angle	B-X
between	B-X
the	B-X
imidazo	B-X
[	B-X
2,1-b	B-X
]	B-X
thia-zole	B-X
and	B-X
benzene	B-X
planes	B-X
is	B-X
18.25	B-X
(	B-X
4	B-X
)	B-X
°	B-X
.	B-X
In	B-X
the	B-X
crystal	B-X
,	B-X
mol-ecules	B-X
form	B-X
infinite	B-X
chains	B-X
along	B-X
[	B-X
100	B-X
]	B-X
via	B-X
secondary	B-X
Br⋯N	B-X
inter-actions	B-X
[	B-X
3.1861	B-X
(	B-X
16	B-X
)	B-X
Å	B-X
]	B-X
.	B-X

Significances	O
of	O
differences	O
between	O
experimental	O
data	O
(	O
for	O
example	O
GP	O
vs	O
LPS	O
)	O
as	O
well	O
as	O
between	O
experimental	O
data	O
and	O
theoretical	O
values	O
(	O
for	O
example	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
vs	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
)	O
were	O
analysed	O
using	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
normal	O
distribution	O
)	O
or	O
the	O
Wilcoxon	O
Signed	O
-	O
Rank	O
test	O
(	O
non	O
-	O
normal	O
distribution	O
)	O
,	O
(	O
SPSS	O
for	O
Windows	O
;	O
SPSS	O
Science	O
Software	O
,	O
Erkrath	O
,	O
Germany	O
)	O
.	O

A	O
,	O
GP	O
led	O
to	O
DNA	O
binding	O
of	O
NFAT	B-Protein
,	O
NFkappaB	O
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
.	O

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
or	O
GP	O
(	O
1	O
and	O
100	O
mug	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O
<EOS>	B-X
Human	B-X
cathelicidin	B-X
refers	B-X
to	B-X
the	B-X
cationic	B-X
antimicrobial	B-X
peptide	B-X
hCAP18/LL-37	B-X
.	B-X
LL-37	B-X
is	B-X
formed	B-X
by	B-X
cleavage	B-X
of	B-X
the	B-X
propeptide	B-X
hCAP18	B-X
coded	B-X
by	B-X
the	B-X
CAMP	B-X
gene	B-X
.	B-X
The	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D	B-X
(	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
)	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
CAMP	B-X
gene	B-X
expression	B-X
through	B-X
promoter	B-X
activation	B-X
.	B-X
We	B-X
previously	B-X
failed	B-X
to	B-X
demonstrate	B-X
in	B-X
a	B-X
clinical	B-X
trial	B-X
that	B-X
supplementation	B-X
of	B-X
25-hydroxyvitamin	B-X
D	B-X
(	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
)	B-X
improves	B-X
LL-37	B-X
serum	B-X
levels	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
impact	B-X
of	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
supplementation	B-X
on	B-X
intracellular	B-X
expression	B-X
of	B-X
CAMP	B-X
and	B-X
secretion	B-X
of	B-X
LL-37	B-X
in	B-X
an	B-X
ex	B-X
vivo	B-X
model	B-X
using	B-X
the	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
.	B-X
PBMC	B-X
collected	B-X
from	B-X
healthy	B-X
donors	B-X
and	B-X
incubated	B-X
with	B-X
different	B-X
concentrations	B-X
of	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
(	B-X
0	B-X
ng/ml	B-X
:	B-X
control	B-X
(	B-X
D0	B-X
)	B-X
;	B-X
25	B-X
ng/ml	B-X
:	B-X
deficient	B-X
(	B-X
D25	B-X
)	B-X
;	B-X
75	B-X
ng/ml	B-X
:	B-X
physiological	B-X
(	B-X
D75	B-X
)	B-X
;	B-X
125	B-X
ng/ml	B-X
:	B-X
supraphysiological	B-X
(	B-X
D125	B-X
)	B-X
)	B-X
were	B-X
stimulated	B-X
or	B-X
not	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
,	B-X
100	B-X
ng/ml	B-X
)	B-X
or	B-X
synthetic	B-X
double-stranded	B-X
RNA	B-X
Poly	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
(	B-X
PIC	B-X
,	B-X
10	B-X
µg/ml	B-X
)	B-X
.	B-X
The	B-X
intracellular	B-X
expressions	B-X
of	B-X
the	B-X
CAMP	B-X
gene	B-X
and	B-X
the	B-X
hCAP18	B-X
peptide	B-X
were	B-X
measured	B-X
respectively	B-X
after	B-X
24-h	B-X
and	B-X
48-h	B-X
incubation	B-X
periods	B-X
.	B-X
The	B-X
concentration	B-X
of	B-X
LL-37	B-X
was	B-X
determined	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
after	B-X
48-h	B-X
incubation	B-X
.	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
significantly	B-X
induced	B-X
CAMP	B-X
gene	B-X
expression	B-X
at	B-X
24	B-X
h	B-X
with	B-X
a	B-X
maximum	B-X
effect	B-X
at	B-X
a	B-X
dose	B-X
of	B-X
D125	B-X
in	B-X
either	B-X
unstimulated	B-X
(	B-X
tenfold	B-X
expression	B-X
)	B-X
or	B-X
stimulated	B-X
(	B-X
LPS	B-X
:	B-X
100-fold	B-X
expression	B-X
;	B-X
PIC	B-X
:	B-X
15-fold	B-X
expression	B-X
)	B-X
conditions	B-X
.	B-X
Intracellular	B-X
hCAP18	B-X
peptide	B-X
was	B-X
overexpressed	B-X
at	B-X
48	B-X
h	B-X
under	B-X
unstimulated	B-X
(	B-X
1.5-fold	B-X
,	B-X
D125	B-X
)	B-X
and	B-X
stimulated	B-X
conditions	B-X
,	B-X
LPS	B-X
(	B-X
twofold	B-X
,	B-X
D125	B-X
)	B-X
and	B-X
PIC	B-X
(	B-X
2.5-fold	B-X
,	B-X
D125	B-X
)	B-X
.	B-X
The	B-X
secretion	B-X
of	B-X
LL-37	B-X
in	B-X
the	B-X
culture	B-X
medium	B-X
was	B-X
significantly	B-X
induced	B-X
by	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
only	B-X
in	B-X
both	B-X
stimulated	B-X
(	B-X
LPS	B-X
and	B-X
PIC	B-X
)	B-X
conditions	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
incubation	B-X
increases	B-X
intracellular	B-X
expression	B-X
of	B-X
CAMP	B-X
and	B-X
hCAP18	B-X
,	B-X
but	B-X
extracellular	B-X
secretion	B-X
of	B-X
LL-37	B-X
antimicrobial	B-X
peptide	B-X
is	B-X
increased	B-X
by	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D	B-X
only	B-X
when	B-X
PBMC	B-X
from	B-X
healthy	B-X
donors	B-X
were	B-X
stimulated	B-X
with	B-X
bacterial	B-X
or	B-X
viral	B-X
immune	B-X
mimetic	B-X
.	B-X

Nuclear	O
extracts	O
were	O
incubated	O
with	O
a	O
32P	O
-	O
labeled	O
NFAT	B-Protein
,	O
NFkappaB	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
or	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
IFNgamma	B-Protein
,	O
TNFalpha	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
gene	O
promoters	O
(	O
Table	O
1	O
)	O
.	O

Arrows	O
with	O
the	O
black	O
head	O
indicate	O
migrational	O
location	O
of	O
the	O
NFAT	B-Protein
-	O
DNA	O
,	O
NFkappaB	O
-	O
DNA	O
,	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
-	O
DNA	O
or	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
-	O
DNA	O
complex	O
compared	O
to	O
free	O
probe	O
(	O
no	O
shift	O
)	O
.	O

Arrow	O
with	O
the	O
open	O
head	O
indicates	O
a	O
supershift	O
of	O
NFkappaB	O
-	O
IL	B-Protein
-	I-Protein
8	I-Protein
-	O
DNA	O
-	O
anti	O
-	O
p65	B-Protein
and	O
-	O
p50	B-Protein
,	O
respectively	O
.	O

An	O
autoradiogram	O
from	O
a	O
representative	O
experiment	O
is	O
shown	O
(	O
n	O
=	O
7	O
)	O
.	O
<EOS>	B-X
Follow-up	B-X
of	B-X
β-amyloid	B-X
(	B-X
Aβ	B-X
)	B-X
deposition	B-X
in	B-X
transgenic	B-X
mouse	B-X
models	B-X
of	B-X
Alzheimer	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
would	B-X
be	B-X
a	B-X
valuable	B-X
translational	B-X
tool	B-X
in	B-X
the	B-X
preclinical	B-X
evaluation	B-X
of	B-X
potential	B-X
antiamyloid	B-X
therapies	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
clinically	B-X
used	B-X
PET	B-X
tracer	B-X
(	B-X
11	B-X
)	B-X
C-Pittsburgh	B-X
compound	B-X
B	B-X
(	B-X
(	B-X
11	B-X
)	B-X
C-PIB	B-X
)	B-X
to	B-X
detect	B-X
changes	B-X
over	B-X
time	B-X
in	B-X
Aβ	B-X
deposition	B-X
in	B-X
the	B-X
brains	B-X
of	B-X
living	B-X
mice	B-X
representing	B-X
the	B-X
APP23	B-X
,	B-X
Tg2576	B-X
,	B-X
and	B-X
APP	B-X
(	B-X
swe	B-X
)	B-X
-PS1	B-X
(	B-X
dE9	B-X
)	B-X
transgenic	B-X
mouse	B-X
models	B-X
of	B-X
AD	B-X
.	B-X

B	O
,	O
Decreased	O
DNA	O
binding	O
of	O
NFkappaB	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
/	O
GP	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
associations	B-X
between	B-X
PTPN22	B-X
gene	B-X
polymorphisms	B-X
and	B-X
CU	B-X
characteristics	B-X
,	B-X
including	B-X
serum	B-X
specific	B-X
IgE	B-X
antibodies	B-X
response	B-X
to	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin-1	B-X
(	B-X
TSST-1	B-X
)	B-X
and	B-X
staphylococcal	B-X
enterotoxin	B-X
A	B-X
(	B-X
SEA	B-X
)	B-X
.	B-X
Serum	B-X
specific	B-X
IgE	B-X
to	B-X
TSST-1	B-X
and	B-X
SEA	B-X
were	B-X
measured	B-X
by	B-X
ImmunoCAP®	B-X
.	B-X
Five	B-X
PTPN22	B-X
single	B-X
nucleotide	B-X
polymorphisms	B-X
,	B-X
-1123G	B-X
>	B-X
C	B-X
,	B-X
1858C	B-X
>	B-X
T	B-X
,	B-X
13145A	B-X
>	B-X
G	B-X
,	B-X
14943C	B-X
>	B-X
T	B-X
,	B-X
and	B-X
20628A	B-X
>	B-X
G	B-X
,	B-X
were	B-X
genotyped	B-X
.	B-X
CU	B-X
patients	B-X
carrying	B-X
the	B-X
GG	B-X
genotype	B-X
at	B-X
20628A	B-X
>	B-X
G	B-X
(	B-X
P=0.035	B-X
)	B-X
or	B-X
haplotype	B-X
3	B-X
[	B-X
GGG	B-X
]	B-X
(	B-X
P=0.047	B-X
)	B-X
had	B-X
a	B-X
significantly	B-X
higher	B-X
prevalence	B-X
of	B-X
serum	B-X
specific	B-X
IgE	B-X
to	B-X
TSST-1	B-X
compared	B-X
to	B-X
non-carriers	B-X
.	B-X
Similarly	B-X
,	B-X
CT/TT	B-X
genotype	B-X
at	B-X
14943C	B-X
>	B-X
T	B-X
had	B-X
a	B-X
significantly	B-X
higher	B-X
prevalence	B-X
of	B-X
serum	B-X
specific	B-X
IgE	B-X
to	B-X
SEA	B-X
(	B-X
P=0.045	B-X
)	B-X
.	B-X
The	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
PTPN22	B-X
gene	B-X
polymorphisms	B-X
at	B-X
20628A	B-X
>	B-X
G	B-X
and	B-X
14943C	B-X
>	B-X
T	B-X
may	B-X
enhance	B-X
serum	B-X
specific	B-X
IgE	B-X
responses	B-X
to	B-X
TSST-1	B-X
and	B-X
SEA	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
CU	B-X
pathogenesis	B-X
.	B-X

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
(	O
100	O
mug	O
)	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
+	O
LPS	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O

An	O
autoradiogram	O
from	O
a	O
representative	O
experiment	O
is	O
shown	O
.	O
<EOS>	B-X
Throughout	B-X
the	B-X
experiment	B-X
lasting	B-X
5	B-X
weeks	B-X
labelled	B-X
cells	B-X
entered	B-X
zone-3	B-X
and	B-X
advanced	B-X
toward	B-X
the	B-X
terminal	B-X
hepatic	B-X
vein	B-X
.	B-X
During	B-X
the	B-X
experiment	B-X
acinus	B-X
size	B-X
did	B-X
not	B-X
change	B-X
appreciably	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
the	B-X
liver	B-X
is	B-X
essentially	B-X
a	B-X
slowly	B-X
renewing	B-X
cell	B-X
population	B-X
.	B-X
Verification	B-X
of	B-X
biological	B-X
activity	B-X
of	B-X
the	B-X
125I-GRFa	B-X
was	B-X
confirmed	B-X
prior	B-X
to	B-X
the	B-X
cross-linking	B-X
experiments	B-X
using	B-X
the	B-X
reverse	B-X
hemolytic	B-X
plaque	B-X
assay	B-X
.	B-X
Four	B-X
bands	B-X
of	B-X
72	B-X
,	B-X
50	B-X
,	B-X
30	B-X
,	B-X
and	B-X
26	B-X
kDa	B-X
were	B-X
detected	B-X
in	B-X
autoradiograms	B-X
from	B-X
cells	B-X
exposed	B-X
to	B-X
the	B-X
labeled	B-X
analog	B-X
for	B-X
20	B-X
min	B-X
(	B-X
22	B-X
degrees	B-X
C	B-X
)	B-X
followed	B-X
by	B-X
exposure	B-X
to	B-X
DSS	B-X
for	B-X
2	B-X
min	B-X
.	B-X
We	B-X
have	B-X
further	B-X
demonstrated	B-X
that	B-X
the	B-X
higher	B-X
concentrations	B-X
of	B-X
DSS	B-X
used	B-X
previously	B-X
(	B-X
5	B-X
mM	B-X
)	B-X
result	B-X
in	B-X
diffuse	B-X
autoradiograms	B-X
with	B-X
multiple	B-X
bands	B-X
,	B-X
suggesting	B-X
that	B-X
caution	B-X
should	B-X
be	B-X
exercised	B-X
when	B-X
interpreting	B-X
cross-linking	B-X
data	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X

Schematic	O
representation	O
of	O
NFkappaB	O
-	O
DNA	O
binding	O
activity	O
following	O
GP	O
(	O
1	O
and	O
100	O
mug	O
)	O
or	O
TSST	B-Protein
-	I-Protein
1	I-Protein
treatment	O
(	O
250	O
ng	O
)	O
as	O
well	O
as	O
simultaneous	O
administration	O
of	O
both	O
compounds	O
and	O
the	O
theoretical	O
value	O
(	O
GP	O
/	O
TSST	O
-	O
1	O
calc	O
.	O
)	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
and	O
significances	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
are	O
shown	O
with	O
respect	O
to	O
medium	O
control	O
(	O
n	O
=	O
4	O
)	O
.	O

NFkappaB	O
p65	B-Protein
/	O
p50	B-Protein
and	O
NFATc2	B-Protein
/	O
c1	B-Protein
were	O
involved	O
in	O
GP	O
-	O
induced	O
DNA	O
binding	O
.	O

In	O
order	O
to	O
determine	O
whether	O
the	O
DNA	O
binding	O
proteins	O
activated	O
by	O
GP	O
were	O
related	O
to	O
NFkappaB	O
and	O
NFAT	B-Protein
,	O
an	O
immuno	O
(	O
dot	O
)	O
blot	O
was	O
performed	O
.	O

A	O
representative	O
dot	O
blot	O
showing	O
staining	O
of	O
negative	O
and	O
positive	O
controls	O
(	O
recombinant	O
proteins	O
NFkappaB	O
p52	B-Protein
,	O
c	B-Protein
-	I-Protein
rel	I-Protein
;	O
nuclear	O
extracts	O
of	O
PMA	O
-	O
treated	O
Jurkat	O
cells	O
positive	O
for	O
NFkappaB	O
p50	B-Protein
,	O
p65	B-Protein
and	O
for	O
NFATc1	B-Protein
,	O
c2	B-Protein
)	O
in	O
the	O
upper	O
panel	O
and	O
staining	O
of	O
nuclear	O
extracts	O
of	O
GP	O
-	O
treated	O
PBMC	O
(	O
positive	O
for	O
NFkappaB	O
p65	B-Protein
,	O
p50	B-Protein
and	O
NFAT	B-Protein
c2	I-Protein
,	O
c1	B-Protein
)	O
in	O
the	O
lower	O
panel	O
is	O
shown	O
(	O
n	O
=	O
3	O
)	O
.	O

A	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
was	O
down	O
-	O
regulated	O
(	O
12	O
h	O
-	O
24	O
h	O
)	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
(	O
pg	O
/	O
ml	O
)	O
by	O
human	O
PBMC	O
incubated	O
with	O
medium	O
control	O
,	O
100	O
mug	O
GP	O
,	O
250	O
ng	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
250	O
ng	O
LPS	O
and	O
GP	O
+	O
LPS	O
.	O

At	O
18	O
h	O
and	O
24	O
h	O
there	O
was	O
a	O
marked	O
reduction	O
in	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
production	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Graphs	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
also	O
shown	O
.	O

IL	B-Protein
-	I-Protein
1beta	I-Protein
levels	O
in	O
the	O
supernatnant	O
were	O
obtained	O
by	O
Elisa	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

B	O
,	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
was	O
exaggerated	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
12	O
h	O
-	O
48	O
h	O
)	O
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
(	O
pg	O
/	O
ml	O
)	O
by	O
human	O
PBMC	O
incubated	O
with	O
medium	O
control	O
,	O
100	O
mug	O
GP	O
,	O
250	O
ng	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
250	O
ng	O
LPS	O
and	O
GP	O
+	O
LPS	O
.	O

Between	O
18	O
h	O
and	O
48	O
h	O
a	O
simultaneous	O
treatment	O
of	O
PBMC	O
with	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
led	O
to	O
a	O
synergistic	O
effect	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
production	O
when	O
compared	O
to	O
an	O
addition	O
of	O
the	O
single	O
values	O
for	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Graphs	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
included	O
.	O

IL	B-Protein
-	I-Protein
1RA	I-Protein
levels	O
in	O
the	O
supernatnant	O
were	O
obtained	O
by	O
Elisa	O
and	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

GP	O
modulated	O
LPS	O
-	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
binding	O
to	O
a	O
new	O
NFkappaB3	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
was	O
enhanced	O
for	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
when	O
compared	O
to	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
,	O
respectively	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
6	O
)	O
.	O

DNA	O
binding	O
was	O
assessed	O
by	O
EMSA	O
(	O
see	O
methods	O
)	O
.	O

GP	O
modulated	O
TSST	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
DNA	O
binding	O
to	O
a	O
new	O
NFATP2	O
/	O
3	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Binding	O
was	O
up	O
-	O
regulated	O
for	O
GP	O
+	O
LPS	O
and	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
when	O
compared	O
to	O
GP	O
and	O
,	O
in	O
the	O
latter	O
case	O
,	O
to	O
both	O
GP	O
and	O
TSST	B-Protein
-	I-Protein
1	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Human	O
PBMC	O
were	O
incubated	O
with	O
medium	O
control	O
,	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
and	O
GP	O
+	O
LPS	O
for	O
1	O
h	O
at	O
37degreesC	O
.	O

Schematic	O
representation	O
of	O
the	O
elevated	O
NFAT	B-Protein
-	O
DNA	O
binding	O
activity	O
to	O
the	O
site	O
in	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Bars	O
depicting	O
the	O
theoretical	O
values	O
for	O
GP	O
/	O
LPS	O
calc	O
.	O
and	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
are	O
added	O
.	O

Medium	O
control	O
levels	O
were	O
set	O
equal	O
to	O
1	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
6	O
)	O
.	O

An	O
autoradiogram	O
of	O
a	O
representative	O
experiment	O
is	O
shown	O
in	O
the	O
lower	O
panel	O
(	O
lane	O
1	O
:	O
water	O
;	O
lane	O
2	O
:	O
medium	O
control	O
;	O
lane	O
3	O
:	O
GP	O
;	O
lane	O
4	O
:	O
LPS	O
;	O
lane	O
5	O
:	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
lane	O
6	O
:	O
GP	O
+	O
LPS	O
;	O
lane	O
7	O
:	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
)	O
.	O

Decreased	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
when	O
compared	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
.	O

Time	O
course	O
(	O
48	O
h	O
)	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
following	O
incubation	O
of	O
human	O
PBMC	O
with	O
LPS	O
,	O
TSST	B-Protein
-	I-Protein
1	I-Protein
,	O
GP	O
+	O
LPS	O
,	O
GP	O
/	O
LPS	O
calc	O
.	O
,	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O

LPS	O
and	O
GP	O
+	O
LPS	O
treatments	O
resulted	O
in	O
generating	O
more	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
than	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
up	O
to	O
24	O
h	O
.	O

When	O
comparing	O
LPS	O
or	O
GP	O
/	O
LPS	O
calc	O
.	O
<EOS>	B-X
Down-regulation	B-X
of	B-X
Xist	B-X
and	B-X
Mir-7a-5p	B-X
improves	B-X
LPS-induced	B-X
myocardial	B-X
injury	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
review	B-X
the	B-X
available	B-X
data	B-X
on	B-X
LPs	B-X
while	B-X
advocating	B-X
for	B-X
the	B-X
need	B-X
for	B-X
a	B-X
randomized	B-X
controlled	B-X
trial	B-X
comparing	B-X
LPs	B-X
to	B-X
TV-PPMs	B-X
.	B-X
Bacterial	B-X
lipopolysaccharides	B-X
(	B-X
LPS	B-X
)	B-X
are	B-X
the	B-X
major	B-X
outer	B-X
surface	B-X
membrane	B-X
components	B-X
present	B-X
in	B-X
almost	B-X
all	B-X
Gram-negative	B-X
bacteria	B-X
and	B-X
act	B-X
as	B-X
extremely	B-X
strong	B-X
stimulators	B-X
of	B-X
innate	B-X
or	B-X
natural	B-X
immunity	B-X
in	B-X
diverse	B-X
eukaryotic	B-X
species	B-X
ranging	B-X
from	B-X
insects	B-X
to	B-X
humans	B-X
.	B-X
LPS	B-X
consist	B-X
of	B-X
a	B-X
poly-	B-X
or	B-X
oligosaccharide	B-X
region	B-X
that	B-X
is	B-X
anchored	B-X
in	B-X
the	B-X
outer	B-X
bacterial	B-X
membrane	B-X
by	B-X
a	B-X
specific	B-X
carbohydrate	B-X
lipid	B-X
moiety	B-X
termed	B-X
lipid	B-X
A	B-X
.	B-X
The	B-X
lipid	B-X
A	B-X
component	B-X
is	B-X
the	B-X
primary	B-X
immunostimulatory	B-X
centre	B-X
of	B-X
LPS	B-X
.	B-X
With	B-X
respect	B-X
to	B-X
immunoactivation	B-X
in	B-X
mammalian	B-X
systems	B-X
,	B-X
the	B-X
classical	B-X
group	B-X
of	B-X
strongly	B-X
agonistic	B-X
(	B-X
highly	B-X
endotoxic	B-X
)	B-X
forms	B-X
of	B-X
LPS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
comprised	B-X
of	B-X
a	B-X
rather	B-X
similar	B-X
set	B-X
of	B-X
lipid	B-X
A	B-X
types	B-X
.	B-X
Some	B-X
members	B-X
of	B-X
the	B-X
latter	B-X
more	B-X
heterogeneous	B-X
group	B-X
are	B-X
capable	B-X
of	B-X
antagonizing	B-X
the	B-X
effects	B-X
of	B-X
strongly	B-X
stimulatory	B-X
LPS/lipid	B-X
A	B-X
forms	B-X
.	B-X
Agonistic	B-X
forms	B-X
of	B-X
LPS	B-X
or	B-X
lipid	B-X
A	B-X
trigger	B-X
numerous	B-X
physiological	B-X
immunostimulatory	B-X
effects	B-X
in	B-X
mammalian	B-X
organisms	B-X
,	B-X
but	B-X
--	B-X
in	B-X
higher	B-X
doses	B-X
--	B-X
can	B-X
also	B-X
lead	B-X
to	B-X
pathological	B-X
reactions	B-X
such	B-X
as	B-X
the	B-X
induction	B-X
of	B-X
septic	B-X
shock	B-X
.	B-X
Cells	B-X
of	B-X
the	B-X
myeloid	B-X
lineage	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
cellular	B-X
sensors	B-X
for	B-X
LPS	B-X
in	B-X
the	B-X
mammalian	B-X
immune	B-X
system	B-X
.	B-X
During	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
enormous	B-X
progress	B-X
has	B-X
been	B-X
obtained	B-X
in	B-X
the	B-X
elucidation	B-X
of	B-X
the	B-X
central	B-X
LPS/lipid	B-X
A	B-X
recognition	B-X
and	B-X
signaling	B-X
system	B-X
in	B-X
mammalian	B-X
phagocytes	B-X
.	B-X
According	B-X
to	B-X
the	B-X
current	B-X
model	B-X
,	B-X
the	B-X
specific	B-X
cellular	B-X
recognition	B-X
of	B-X
agonistic	B-X
LPS/lipid	B-X
A	B-X
is	B-X
initialized	B-X
by	B-X
the	B-X
combined	B-X
extracellular	B-X
actions	B-X
of	B-X
LPS	B-X
binding	B-X
protein	B-X
(	B-X
LBP	B-X
)	B-X
,	B-X
the	B-X
membrane-bound	B-X
or	B-X
soluble	B-X
forms	B-X
of	B-X
CD14	B-X
and	B-X
the	B-X
newly	B-X
identified	B-X
Toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
*	B-X
MD-2	B-X
complex	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
rapid	B-X
activation	B-X
of	B-X
an	B-X
intracellular	B-X
signaling	B-X
network	B-X
that	B-X
is	B-X
highly	B-X
homologous	B-X
to	B-X
the	B-X
signaling	B-X
systems	B-X
of	B-X
IL-1	B-X
and	B-X
IL-18	B-X
.	B-X
The	B-X
elucidation	B-X
of	B-X
structure-activity	B-X
correlations	B-X
in	B-X
LPS	B-X
and	B-X
lipid	B-X
A	B-X
has	B-X
not	B-X
only	B-X
contributed	B-X
to	B-X
a	B-X
molecular	B-X
understanding	B-X
of	B-X
both	B-X
immunostimulatory	B-X
and	B-X
toxic	B-X
septic	B-X
processes	B-X
,	B-X
but	B-X
has	B-X
also	B-X
re-animated	B-X
the	B-X
development	B-X
of	B-X
new	B-X
pharmacological	B-X
and	B-X
immunostimulatory	B-X
strategies	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
therapy	B-X
of	B-X
infectious	B-X
and	B-X
malignant	B-X
diseases	B-X
.	B-X

vs	O
GP	O
+	O
LPS	O
we	O
did	O
not	O
find	O
significant	O
alterations	O
in	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
/	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
ratio	O
over	O
48	O
h	O
.	O
<EOS>	B-X
Ventricular	B-X
tachycardia	B-X
(	B-X
VT	B-X
)	B-X
substrate-based	B-X
ablation	B-X
has	B-X
become	B-X
the	B-X
gold	B-X
standard	B-X
treatment	B-X
for	B-X
patients	B-X
with	B-X
structural	B-X
heart	B-X
disease-related	B-X
VT.	B-X
VT	B-X
is	B-X
linked	B-X
to	B-X
re-entry	B-X
in	B-X
relation	B-X
to	B-X
myocardial	B-X
scarring	B-X
,	B-X
with	B-X
areas	B-X
of	B-X
conduction	B-X
block	B-X
(	B-X
core	B-X
scar	B-X
)	B-X
and	B-X
of	B-X
slow	B-X
conduction	B-X
(	B-X
border	B-X
zone	B-X
)	B-X
.	B-X
Slow	B-X
conduction	B-X
areas	B-X
can	B-X
be	B-X
detected	B-X
in	B-X
sinus	B-X
rhythm	B-X
as	B-X
late	B-X
potentials	B-X
(	B-X
LPs	B-X
)	B-X
.	B-X
LP	B-X
abolition	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
best	B-X
end	B-X
point	B-X
to	B-X
avoid	B-X
long-term	B-X
recurrences	B-X
.	B-X
Our	B-X
study	B-X
aimed	B-X
to	B-X
analyze	B-X
the	B-X
challenges	B-X
of	B-X
LP	B-X
abolition	B-X
and	B-X
the	B-X
predictors	B-X
of	B-X
failure	B-X
.	B-X
We	B-X
analyzed	B-X
169	B-X
consecutive	B-X
patients	B-X
with	B-X
structural	B-X
heart	B-X
disease	B-X
(	B-X
61	B-X
%	B-X
ischemic	B-X
cardiomyopathy	B-X
,	B-X
left	B-X
ventricular	B-X
ejection	B-X
fraction	B-X
:	B-X
37	B-X
±	B-X
13	B-X
%	B-X
)	B-X
who	B-X
underwent	B-X
VT	B-X
ablation	B-X
between	B-X
2013	B-X
and	B-X
2018	B-X
.	B-X
Electroanatomical	B-X
mapping	B-X
with	B-X
the	B-X
identification	B-X
of	B-X
LPs	B-X
was	B-X
performed	B-X
in	B-X
all	B-X
patients	B-X
.	B-X
Noninducibility	B-X
was	B-X
achieved	B-X
in	B-X
71	B-X
%	B-X
(	B-X
119	B-X
)	B-X
,	B-X
and	B-X
complete	B-X
LP	B-X
abolition	B-X
was	B-X
achieved	B-X
in	B-X
61	B-X
%	B-X
(	B-X
103	B-X
)	B-X
of	B-X
patients	B-X
.	B-X
Incomplete	B-X
LP	B-X
abolition	B-X
was	B-X
a	B-X
powerful	B-X
predictor	B-X
of	B-X
VT	B-X
recurrence	B-X
(	B-X
67	B-X
%	B-X
vs	B-X
33	B-X
%	B-X
,	B-X
hazard	B-X
ratio	B-X
3.19	B-X
[	B-X
2.1	B-X
to	B-X
4.7	B-X
]	B-X
;	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Lack	B-X
of	B-X
use	B-X
of	B-X
a	B-X
high-density	B-X
mapping	B-X
catheter	B-X
(	B-X
odds	B-X
ratio	B-X
6.2	B-X
,	B-X
1.2	B-X
to	B-X
38.1	B-X
;	B-X
p	B-X
=	B-X
0.028	B-X
)	B-X
,	B-X
the	B-X
septal	B-X
substrate	B-X
(	B-X
odds	B-X
ratio	B-X
9.34	B-X
,	B-X
2.27	B-X
to	B-X
38.4	B-X
;	B-X
p	B-X
=	B-X
0.002	B-X
)	B-X
,	B-X
and	B-X
larger	B-X
left	B-X
ventricular	B-X
mass	B-X
(	B-X
190	B-X
±	B-X
58	B-X
g	B-X
vs	B-X
156	B-X
±	B-X
46	B-X
g	B-X
,	B-X
p	B-X
=	B-X
0.002	B-X
)	B-X
were	B-X
predictors	B-X
of	B-X
incomplete	B-X
LP	B-X
abolition	B-X
.	B-X
The	B-X
main	B-X
reasons	B-X
that	B-X
contributed	B-X
to	B-X
unsuccessful	B-X
LP	B-X
abolition	B-X
were	B-X
anatomic	B-X
obstacles	B-X
(	B-X
such	B-X
as	B-X
the	B-X
conduction	B-X
system	B-X
)	B-X
and	B-X
large	B-X
extension	B-X
of	B-X
the	B-X
LP	B-X
area	B-X
.	B-X
Lack	B-X
of	B-X
use	B-X
of	B-X
a	B-X
high-density	B-X
mapping	B-X
catheter	B-X
,	B-X
the	B-X
septal	B-X
substrate	B-X
,	B-X
and	B-X
larger	B-X
left	B-X
ventricular	B-X
mass	B-X
are	B-X
related	B-X
to	B-X
incomplete	B-X
LP	B-X
abolition	B-X
.	B-X

With	O
respect	O
to	O
TSST	B-Protein
-	I-Protein
1	I-Protein
or	O
GP	O
/	O
TSST	B-Protein
-	I-Protein
1	I-Protein
calc	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
conducted	B-X
whole-genome	B-X
sequencing	B-X
on	B-X
565	B-X
MRSA	B-X
isolates	B-X
from	B-X
7	B-X
provinces	B-X
and	B-X
municipalities	B-X
of	B-X
China	B-X
between	B-X
2014	B-X
and	B-X
2020	B-X
.	B-X
The	B-X
prevalence	B-X
of	B-X
enterotoxins	B-X
and	B-X
toxic	B-X
shock	B-X
syndrome	B-X
toxin	B-X
(	B-X
TSST-1	B-X
)	B-X
production	B-X
in	B-X
strains	B-X
isolated	B-X
from	B-X
patients	B-X
with	B-X
Staphylococcus	B-X
aureus	B-X
septicaemia	B-X
,	B-X
and	B-X
the	B-X
serum	B-X
antibody	B-X
response	B-X
in	B-X
relation	B-X
to	B-X
toxin	B-X
production	B-X
in	B-X
vitro	B-X
of	B-X
each	B-X
isolate	B-X
,	B-X
were	B-X
investigated	B-X
.	B-X
Among	B-X
63	B-X
strains	B-X
of	B-X
S.	B-X
aureus	B-X
isolated	B-X
from	B-X
the	B-X
blood	B-X
of	B-X
patients	B-X
with	B-X
septicaemia	B-X
,	B-X
51	B-X
from	B-X
patients	B-X
with	B-X
superficial	B-X
wounds	B-X
and	B-X
49	B-X
from	B-X
nasal	B-X
carriers	B-X
,	B-X
50-60	B-X
%	B-X
produced	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
enterotoxins	B-X
A-D	B-X
or	B-X
TSST-1	B-X
.	B-X
The	B-X
most	B-X
frequent	B-X
toxins	B-X
produced	B-X
were	B-X
enterotoxins	B-X
A	B-X
and	B-X
C	B-X
and	B-X
TSST-1	B-X
.	B-X
Among	B-X
the	B-X
63	B-X
patients	B-X
with	B-X
staphylococcal	B-X
septicaemia	B-X
,	B-X
51	B-X
(	B-X
81	B-X
%	B-X
)	B-X
had	B-X
a	B-X
significant	B-X
rise	B-X
or	B-X
a	B-X
high	B-X
antibody	B-X
titre	B-X
,	B-X
or	B-X
both	B-X
,	B-X
to	B-X
at	B-X
least	B-X
one	B-X
of	B-X
the	B-X
toxins	B-X
.	B-X
A	B-X
positive	B-X
serological	B-X
response	B-X
to	B-X
toxin	B-X
A	B-X
was	B-X
found	B-X
in	B-X
78	B-X
%	B-X
,	B-X
to	B-X
enterotoxin	B-X
B	B-X
in	B-X
83	B-X
%	B-X
,	B-X
to	B-X
enterotoxin	B-X
C	B-X
in	B-X
80	B-X
%	B-X
,	B-X
to	B-X
enterotoxin	B-X
D	B-X
in	B-X
86	B-X
%	B-X
and	B-X
to	B-X
TSST-1	B-X
in	B-X
92	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
from	B-X
whom	B-X
the	B-X
isolated	B-X
strain	B-X
produced	B-X
the	B-X
respective	B-X
toxin	B-X
.	B-X
Antibodies	B-X
against	B-X
enterotoxins	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
and	B-X
D	B-X
and	B-X
TSST-1	B-X
were	B-X
also	B-X
seen	B-X
in	B-X
35	B-X
%	B-X
,	B-X
16	B-X
%	B-X
,	B-X
32	B-X
%	B-X
,	B-X
59	B-X
%	B-X
and	B-X
10	B-X
%	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
patients	B-X
infected	B-X
by	B-X
strains	B-X
that	B-X
did	B-X
not	B-X
produce	B-X
the	B-X
specific	B-X
toxin	B-X
.	B-X
No	B-X
differences	B-X
with	B-X
regard	B-X
to	B-X
enterotoxin	B-X
or	B-X
TSST-1	B-X
production	B-X
or	B-X
antibody	B-X
response	B-X
were	B-X
noted	B-X
between	B-X
patients	B-X
with	B-X
complicated	B-X
versus	B-X
uncomplicated	B-X
septicaemia	B-X
.	B-X

vs	O
GP	O
+	O
TSST	B-Protein
-	I-Protein
1	I-Protein
we	O
observed	O
a	O
pronounced	O
anti	O
-	O
inflammatory	O
action	O
of	O
GP	O
,	O
as	O
demonstrated	O
by	O
an	O
about	O
10	O
-	O
100	O
fold	O
reduced	O
ratio	O
at	O
18	O
h	O
and	O
24	O
h	O
,	O
i	O
.	O
e	O
.	O
a	O
higher	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
than	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

Inhibition	O
of	O
GP	O
-	O
induced	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
DNA	O
binding	O
to	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

A	O
,	O
A	O
representative	O
autoradiogram	O
(	O
lane	O
1	O
:	O
control	O
,	O
lane	O
2	O
:	O
GP	O
,	O
lane	O
3	O
:	O
GP	O
+	O
unlabeled	O
mutated	O
NFATP2	O
/	O
3	O
oligo	O
,	O
lane	O
4	O
:	O
GP	O
+	O
CAPE	O
,	O
lane	O
5	O
:	O
GP	O
+	O
CyA	O
,	O
lane	O
6	O
:	O
GP	O
+	O
CHX	O
,	O
lane	O
7	O
:	O
GP	O
+	O
unlabeled	O
NFATP2	O
/	O
3	O
oligo	O
,	O
lane	O
8	O
:	O
water	O
)	O
as	O
well	O
as	O
a	O
graphical	O
summary	O
for	O
the	O
NFATP2	O
/	O
3	O
site	O
,	O
depicting	O
a	O
decrease	O
in	O
binding	O
following	O
inhibition	O
when	O
compared	O
to	O
GP	O
is	O
displayed	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
4	O
)	O
.	O

B	O
,	O
Inhibition	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
resulted	O
in	O
decreased	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
mRNA	O
following	O
CHX	O
,	O
CAPE	O
or	O
CyA	O
compared	O
to	O
GP	O
.	O
<EOS>	B-X
Effects	B-X
of	B-X
concentration	B-X
of	B-X
Polyoxyethylene	B-X
(	B-X
40	B-X
)	B-X
stearate	B-X
,	B-X
Na	B-X
(	B-X
+	B-X
)	B-X
and	B-X
P-gp	B-X
inhibitor	B-X
on	B-X
cyclosporin	B-X
A	B-X
(	B-X
CyA-SD	B-X
)	B-X
absorption	B-X
were	B-X
investigated	B-X
by	B-X
in	B-X
situ	B-X
circulation	B-X
method	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
absorption	B-X
of	B-X
CyA	B-X
increased	B-X
linearly	B-X
with	B-X
its	B-X
concentration	B-X
,	B-X
indicating	B-X
a	B-X
passive	B-X
diffusion	B-X
process	B-X
was	B-X
dominated	B-X
.	B-X
CyA	B-X
absorption	B-X
decreased	B-X
with	B-X
the	B-X
carrier	B-X
concentration	B-X
.	B-X
The	B-X
P-gp	B-X
inhibitor	B-X
enhanced	B-X
the	B-X
CyA	B-X
absorption	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
The	B-X
passive	B-X
diffusion	B-X
process	B-X
during	B-X
the	B-X
intestinal	B-X
absorption	B-X
indicated	B-X
that	B-X
the	B-X
solubility	B-X
enhancement	B-X
of	B-X
CyA	B-X
is	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
for	B-X
the	B-X
absorption	B-X
of	B-X
this	B-X
water	B-X
insoluble	B-X
drug	B-X
.	B-X

GAPDH	B-Protein
is	O
used	O
as	O
housekeeping	O
control	O
(	O
representative	O
gel	O
,	O
n	O
=	O
4	O
)	O
.	O

C	O
,	O
Inhibition	O
of	O
NFkappaB	O
,	O
NFAT	B-Protein
and	O
NFIL	B-Protein
-	I-Protein
6	I-Protein
significantly	O
reduced	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
by	O
human	O
PBMC	O
following	O
treatment	O
with	O
CHX	O
,	O
CAPE	O
or	O
CyA	O
when	O
compared	O
to	O
GP	O
(	O
*	O
=	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Data	O
are	O
shown	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
)	O
.	O

Sense	O
strand	O
of	O
oligonucleotides	O
used	O
in	O
EMSAs	O
.	O

Cartoon	O
of	O
the	O
sense	O
strand	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RA	I-Protein
promoter	O
.	O

Relative	O
locations	O
of	O
previously	O
(	O
LRE	O
-	O
1	O
)	O
[	O
30	O
-	O
33	O
]	O
and	O
newly	O
described	O
(	O
boxed	O
)	O
,	O
positively	O
(	O
black	O
)	O
and	O
negatively	O
(	O
gray	O
)	O
regulatory	O
transcription	O
factor	O
binding	O
sites	O
are	O
depicted	O
.	O

Activation	O
of	O
TLR4	B-Protein
-	O
Mediated	O
NFkappaB	O
Signaling	O
in	O
Hemorrhagic	O
Brain	O
in	O
Rats	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

Inflammation	O
and	O
immunity	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
Intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
.	O
<EOS>	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
is	B-X
a	B-X
devastating	B-X
disease	B-X
with	B-X
high	B-X
rates	B-X
of	B-X
mortality	B-X
and	B-X
morbidity	B-X
.	B-X
Galactose	B-X
lectin-9	B-X
(	B-X
Gal-9	B-X
)	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
β-galactoside-binding	B-X
lectins	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
immune	B-X
tolerance	B-X
and	B-X
inflammation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
function	B-X
of	B-X
Gal-9	B-X
in	B-X
ICH	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
studied	B-X
in	B-X
details	B-X
.	B-X
Several	B-X
experiments	B-X
were	B-X
carried	B-X
out	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
Gal-9	B-X
in	B-X
the	B-X
late	B-X
period	B-X
of	B-X
ICH	B-X
.	B-X
Primarily	B-X
,	B-X
ICH	B-X
models	B-X
were	B-X
established	B-X
in	B-X
male	B-X
adult	B-X
Sprague	B-X
Dawley	B-X
(	B-X
SD	B-X
)	B-X
rats	B-X
.	B-X
Next	B-X
,	B-X
the	B-X
relative	B-X
protein	B-X
levels	B-X
of	B-X
Gal-9	B-X
at	B-X
different	B-X
time	B-X
points	B-X
after	B-X
ICH	B-X
were	B-X
examined	B-X
and	B-X
the	B-X
result	B-X
showed	B-X
that	B-X
the	B-X
level	B-X
of	B-X
Gal-9	B-X
increased	B-X
and	B-X
peaked	B-X
at	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
.	B-X
Through	B-X
co-immunoprecipitation	B-X
(	B-X
CO-IP	B-X
)	B-X
analysis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
Gal-9	B-X
combines	B-X
with	B-X
Toll-like	B-X
receptor-4	B-X
(	B-X
TLR-4	B-X
)	B-X
during	B-X
the	B-X
period	B-X
of	B-X
the	B-X
recovery	B-X
after	B-X
ICH	B-X
.	B-X
Additionally	B-X
,	B-X
several	B-X
behavioral	B-X
experiments	B-X
also	B-X
demonstrated	B-X
that	B-X
when	B-X
the	B-X
level	B-X
of	B-X
Gal-9	B-X
increased	B-X
,	B-X
the	B-X
motor	B-X
,	B-X
sensory	B-X
,	B-X
learning	B-X
,	B-X
and	B-X
memory	B-X
abilities	B-X
of	B-X
the	B-X
rats	B-X
recovered	B-X
better	B-X
compared	B-X
to	B-X
the	B-X
ICH	B-X
group	B-X
.	B-X
In	B-X
short	B-X
,	B-X
this	B-X
study	B-X
illustrated	B-X
that	B-X
Gal-9	B-X
takes	B-X
a	B-X
crucial	B-X
role	B-X
after	B-X
ICH	B-X
.	B-X
Enhancing	B-X
Gal-9	B-X
could	B-X
alleviate	B-X
brain	B-X
injury	B-X
and	B-X
promote	B-X
the	B-X
recovery	B-X
of	B-X
ICH-induced	B-X
injury	B-X
,	B-X
so	B-X
that	B-X
Gal-9	B-X
may	B-X
exploit	B-X
a	B-X
new	B-X
pathway	B-X
for	B-X
clinical	B-X
treatment	B-X
of	B-X
ICH	B-X
.	B-X

Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
-	O
(	O
TLR4	B-Protein
-	O
)	O
mediated	O
nuclear	O
factor	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
signaling	O
plays	O
critical	O
roles	O
in	O
the	O
activation	O
and	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
injured	O
brain	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

However	O
,	O
the	O
involvement	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
remains	O
unknown	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

The	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
temporal	O
profile	O
of	O
the	O
expression	O
of	O
TLR4	B-Protein
and	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
brain	O
tissues	O
of	O
Wistar	O
rats	O
after	O
ICH	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

TLR4	B-Protein
mRNA	O
and	O
protein	O
,	O
the	O
phosphorylation	O
of	O
inhibitors	B-Protein
of	I-Protein
kappa	I-Protein
B	I-Protein
(	O
p	O
-	O
IkappaBalpha	B-Protein
)	O
,	O
and	O
the	O
activity	O
of	O
NFkappaB	O
were	O
examined	O
in	O
hemorrhagic	O
cerebral	O
tissue	O
by	O
Rt	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
immunohistochemistry	O
staining	O
,	O
and	O
EMSA	O
.	O

Compared	O
with	O
saline	O
control	O
,	O
the	O
TLR4	B-Protein
mRNA	O
and	O
protein	O
significantly	O
increased	O
starting	O
at	O
6	O
hours	O
after	O
ICH	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
but	O
still	O
maintained	O
at	O
a	O
higher	O
level	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
level	O
of	O
p	O
-	O
IkappaBalpha	B-Protein
and	O
the	O
activity	O
of	O
NFkappaB	O
also	O
increased	O
in	O
the	O
brain	O
after	O
ICH	O
compared	O
with	O
saline	O
control	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

The	O
present	O
study	O
firstly	O
suggests	O
that	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
participates	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
,	O
which	O
may	O
become	O
a	O
therapeutic	O
target	O
for	O
ICH	O
-	O
induced	O
brain	O
damage	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

Intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
represents	O
10	O
%	O
-	O
15	O
%	O
of	O
all	O
strokes	O
and	O
occurs	O
with	O
increasing	O
frequency	O
as	O
a	O
complication	O
of	O
the	O
thrombolytic	O
treatment	O
of	O
ischemic	O
stroke	O
,	O
which	O
is	O
associated	O
with	O
high	O
mortality	O
and	O
severe	O
disability	O
in	O
survivors	O
[	O
1	O
,	O
2	O
]	O
.	O

Local	O
brain	O
tissue	O
deformation	O
induces	O
primary	O
brain	O
damage	O
after	O
ICH	O
;	O
more	O
importantly	O
,	O
the	O
excitotoxicity	O
and	O
inflammatory	O
responses	O
in	O
the	O
brain	O
tissue	O
induced	O
by	O
ICH	O
result	O
in	O
further	O
brain	O
damage	O
following	O
ICH	O
[	O
3	O
]	O
.	O

Both	O
innate	O
and	O
adaptive	O
immunological	O
/	O
inflammatory	O
mechanisms	O
have	O
been	O
clearly	O
shown	O
to	O
participate	O
in	O
the	O
progression	O
of	O
brain	O
injury	O
after	O
ischemic	O
stroke	O
.	O

Nevertheless	O
,	O
how	O
the	O
inflammatory	O
responses	O
in	O
ICH	O
are	O
triggered	O
and	O
regulated	O
remains	O
to	O
be	O
elucidated	O
.	O

TLRs	O
are	O
a	O
family	O
of	O
transmembrane	O
proteins	O
and	O
act	O
as	O
signal	O
transduction	O
molecules	O
[	O
4	O
]	O
.	O

Activation	O
of	O
TLRs	O
recruits	O
downstream	O
signaling	O
proteins	O
and	O
results	O
in	O
transcription	O
of	O
genes	O
encoding	O
inflammation	O
-	O
associated	O
molecules	O
and	O
cytokines	O
[	O
5	O
,	O
6	O
]	O
.	O

For	O
example	O
,	O
combined	O
with	O
specific	O
ligand	O
,	O
the	O
activation	O
of	O
TLR4	B-Protein
induces	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
IkappaB	O
)	O
and	O
dissociates	O
IkappaB	O
from	O
NF	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
.	O

Then	O
,	O
NFkappaB	O
trans	O
-	O
locates	O
into	O
the	O
nucleus	O
and	O
activates	O
and	O
regulates	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
inflammatory	O
responses	O
[	O
5	O
,	O
6	O
]	O
.	O

TLRs	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
immunological	O
/	O
inflammatory	O
responses	O
and	O
are	O
implicated	O
in	O
several	O
CNS	O
diseases	O
,	O
such	O
as	O
infectious	O
disease	O
,	O
autoimmune	O
disease	O
,	O
and	O
ischemic	O
brain	O
injury	O
[	O
7	O
,	O
8	O
]	O
.	O

Accumulating	O
evidences	O
demonstrate	O
that	O
TLR4	B-Protein
,	O
the	O
first	O
mammalian	O
TLR	O
recognized	O
,	O
contributes	O
to	O
the	O
neuronal	O
death	O
,	O
blood	O
brain	O
barrier	O
damage	O
,	O
brain	O
edema	O
,	O
and	O
inflammatory	O
responses	O
in	O
the	O
brain	O
injury	O
induced	O
by	O
ischemia	O
[	O
8	O
,	O
9	O
]	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
TLR4	B-Protein
in	O
the	O
brain	O
after	O
ICH	O
.	O
<EOS>	B-X
In	B-X
the	B-X
hours	B-X
to	B-X
days	B-X
after	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
,	B-X
there	B-X
is	B-X
an	B-X
inflammatory	B-X
response	B-X
within	B-X
the	B-X
brain	B-X
characterized	B-X
by	B-X
the	B-X
infiltration	B-X
of	B-X
peripheral	B-X
neutrophils	B-X
and	B-X
macrophages	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
brain-resident	B-X
microglia	B-X
and	B-X
astrocytes	B-X
.	B-X
Despite	B-X
the	B-X
strong	B-X
correlation	B-X
of	B-X
aging	B-X
and	B-X
ICH	B-X
incidence	B-X
,	B-X
and	B-X
increasing	B-X
information	B-X
about	B-X
cellular	B-X
responses	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
temporal-	B-X
and	B-X
age-related	B-X
molecular	B-X
responses	B-X
of	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
monitored	B-X
a	B-X
panel	B-X
of	B-X
27	B-X
genes	B-X
at	B-X
6	B-X
h	B-X
and	B-X
1	B-X
,	B-X
3	B-X
,	B-X
and	B-X
7	B-X
days	B-X
after	B-X
ICH	B-X
was	B-X
induced	B-X
by	B-X
injecting	B-X
collagenase	B-X
into	B-X
the	B-X
striatum	B-X
of	B-X
young	B-X
adult	B-X
and	B-X
aged	B-X
rats	B-X
.	B-X
Several	B-X
molecules	B-X
(	B-X
CR3	B-X
,	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
IL-1β	B-X
,	B-X
TNFα	B-X
,	B-X
iNOS	B-X
,	B-X
IL-6	B-X
)	B-X
were	B-X
selected	B-X
to	B-X
reflect	B-X
the	B-X
classical	B-X
activation	B-X
of	B-X
innate	B-X
immune	B-X
cells	B-X
(	B-X
macrophages	B-X
,	B-X
microglia	B-X
)	B-X
and	B-X
the	B-X
potential	B-X
to	B-X
exacerbate	B-X
inflammation	B-X
and	B-X
damage	B-X
brain	B-X
cells	B-X
.	B-X
Importantly	B-X
,	B-X
within	B-X
this	B-X
complex	B-X
response	B-X
to	B-X
experimental	B-X
ICH	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
pro-inflammatory	B-X
,	B-X
potentially	B-X
harmful	B-X
mediators	B-X
often	B-X
coincided	B-X
with	B-X
resolving	B-X
and	B-X
beneficial	B-X
molecules	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
detected	O
the	O
transcription	O
of	O
TLR4	B-Protein
gene	O
and	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
in	O
the	O
rat	O
brains	O
subjected	O
to	O
experimental	O
ICH	O
.	O

Our	O
data	O
firstly	O
provided	O
the	O
knowledge	O
about	O
the	O
distribution	O
of	O
TLR4	B-Protein
and	O
the	O
temporal	O
profile	O
of	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
in	O
rat	O
brain	O
tissue	O
after	O
ICH	O
.	O

2	O
.	O
1	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Animals	O
<EOS>	B-X
Lifting	B-X
the	B-X
veil	B-X
on	B-X
the	B-X
oldest-known	B-X
animals	B-X
.	B-X
EXPERIMENTS	B-X
on	B-X
animals	B-X
.	B-X
Veterinary	B-X
Medical	B-X
Ethics	B-X
.	B-X
News	B-X
&	B-X
Views	B-X
.	B-X

Ninety	O
Wister	O
rats	O
(	O
male	O
,	O
body	O
weight	O
:	O
250	O
g	O
to	O
300	O
g	O
)	O
were	O
provided	O
by	O
Experimental	O
Animal	O
Center	O
,	O
China	O
Medical	O
University	O
.	O

The	O
rats	O
were	O
assigned	O
randomly	O
to	O
three	O
groups	O
:	O
normal	O
group	O
(	O
N	O
,	O
n	O
=	O
10	O
,	O
without	O
any	O
treatment	O
)	O
,	O
normal	O
saline	O
control	O
(	O
S	O
,	O
n	O
=	O
40	O
,	O
intra	O
-	O
cerebral	O
injection	O
of	O
normal	O
saline	O
as	O
control	O
)	O
and	O
intra	O
-	O
cerebral	O
hemorrhage	O
group	O
(	O
ICH	O
,	O
n	O
=	O
40	O
)	O
.	O

The	O
experimental	O
protocol	O
used	O
for	O
animals	O
was	O
approved	O
by	O
the	O
Animal	O
Care	O
and	O
Use	O
Committee	O
,	O
China	O
Medical	O
University	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
progression	B-X
of	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
ALX	B-X
on	B-X
the	B-X
maturation	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
and	B-X
the	B-X
responses	B-X
of	B-X
effector	B-X
and	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
.	B-X
Protective	B-X
Effects	B-X
of	B-X
Trimetazidine	B-X
in	B-X
Retarding	B-X
Selenite-Induced	B-X
Lens	B-X
Opacification	B-X
.	B-X
This	B-X
study	B-X
is	B-X
to	B-X
explore	B-X
the	B-X
effect	B-X
of	B-X
ventricular	B-X
preexcitation	B-X
on	B-X
the	B-X
QRS	B-X
initial	B-X
,	B-X
maximal	B-X
and	B-X
terminal	B-X
vector	B-X
in	B-X
an	B-X
experimental	B-X
rabbit	B-X
with	B-X
preexcitation	B-X
syndrome	B-X
induced	B-X
by	B-X
programmed	B-X
electrical	B-X
stimulation	B-X
.	B-X
Caspase-11	B-X
,	B-X
a	B-X
cytosolic	B-X
receptor	B-X
of	B-X
bacterial	B-X
endotoxin	B-X
(	B-X
lipopolysaccharide	B-X
:	B-X
LPS	B-X
)	B-X
,	B-X
mediates	B-X
immune	B-X
responses	B-X
and	B-X
lethality	B-X
in	B-X
endotoxemia	B-X
and	B-X
experimental	B-X
sepsis	B-X
.	B-X

The	O
rats	O
were	O
subjected	O
to	O
intra	O
-	O
cerebral	O
injection	O
of	O
normal	O
saline	O
or	O
autologous	O
whole	O
blood	O
and	O
were	O
sacrificed	O
on	O
6	O
hours	O
,	O
1	O
day	O
,	O
3	O
days	O
and	O
7	O
days	O
after	O
the	O
injection	O
,	O
respectively	O
.	O
<EOS>	B-X
R	B-X
(	B-X
+	B-X
)	B-X
HA-966	B-X
,	B-X
a	B-X
weak	B-X
partial	B-X
agonist	B-X
at	B-X
the	B-X
glycine/NMDA	B-X
receptor	B-X
complex	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
have	B-X
anxiolytic-like	B-X
actions	B-X
on	B-X
restraint	B-X
stress-induced	B-X
mesoprefrontal	B-X
dopamine	B-X
metabolism	B-X
.	B-X
When	B-X
blood	B-X
flow	B-X
to	B-X
a	B-X
brain	B-X
region	B-X
that	B-X
has	B-X
undergone	B-X
an	B-X
ischemic	B-X
attack	B-X
is	B-X
reestablished	B-X
,	B-X
additional	B-X
injury	B-X
is	B-X
to	B-X
be	B-X
expected	B-X
from	B-X
the	B-X
reperfusion	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
intra-arterial	B-X
injection	B-X
of	B-X
nimodipine	B-X
at	B-X
reperfusion	B-X
on	B-X
infarct	B-X
volume	B-X
in	B-X
rats	B-X
subjected	B-X
to	B-X
partially	B-X
reversible	B-X
focal	B-X
neocortical	B-X
ischemia	B-X
.	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
two	B-X
types	B-X
of	B-X
rewards	B-X
,	B-X
pain	B-X
relief	B-X
by	B-X
intrathecal	B-X
injection	B-X
of	B-X
pregabalin	B-X
(	B-X
100μg	B-X
in	B-X
10μL	B-X
phosphate	B-X
buffered	B-X
saline	B-X
)	B-X
and	B-X
30	B-X
%	B-X
sucrose	B-X
solution	B-X
intake	B-X
,	B-X
on	B-X
intra-NAc	B-X
DA	B-X
release	B-X
in	B-X
rats	B-X
subjected	B-X
to	B-X
spinal	B-X
nerve	B-X
ligation	B-X
(	B-X
SNL	B-X
)	B-X
.	B-X
Specifically	B-X
,	B-X
the	B-X
effects	B-X
were	B-X
investigated	B-X
during	B-X
the	B-X
early	B-X
(	B-X
17-20days	B-X
after	B-X
ligation	B-X
)	B-X
and	B-X
late	B-X
(	B-X
31-34days	B-X
after	B-X
ligation	B-X
)	B-X
phases	B-X
of	B-X
neuropathic	B-X
pain	B-X
.	B-X
Pain	B-X
relief	B-X
increased	B-X
the	B-X
intra-NAc	B-X
DA	B-X
levels	B-X
in	B-X
the	B-X
SNL	B-X
rats	B-X
during	B-X
the	B-X
early	B-X
but	B-X
not	B-X
late	B-X
phase	B-X
of	B-X
neuropathic	B-X
pain	B-X
.	B-X
Intake	B-X
of	B-X
the	B-X
sucrose	B-X
solution	B-X
increased	B-X
the	B-X
intra-NAc	B-X
DA	B-X
levels	B-X
both	B-X
in	B-X
the	B-X
SNL	B-X
and	B-X
sham	B-X
animals	B-X
during	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
neuropathic	B-X
pain	B-X
,	B-X
while	B-X
it	B-X
induced	B-X
DA	B-X
release	B-X
in	B-X
the	B-X
sham	B-X
but	B-X
not	B-X
SNL	B-X
animals	B-X
during	B-X
the	B-X
late	B-X
phase	B-X
.	B-X

Five	O
rats	O
in	O
each	O
group	O
at	O
each	O
time	O
point	O
were	O
sacrificed	O
by	O
transcardially	O
perfusion	O
of	O
normal	O
saline	O
followed	O
by	O
4	O
%	O
buffered	O
Para	O
formaldehyde	O
(	O
pH	O
=	O
7	O
.	O
4	O
)	O
.	O

The	O
brains	O
were	O
removed	O
,	O
postfixed	O
,	O
embedded	O
in	O
paraffin	O
,	O
and	O
cut	O
into	O
sections	O
(	O
7	O
mum	O
)	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

Five	O
rats	O
in	O
each	O
group	O
at	O
each	O
time	O
point	O
were	O
sacrificed	O
by	O
over	O
dose	O
injection	O
of	O
Ketamine	O
.	O

The	O
brains	O
were	O
removed	O
and	O
stored	O
at	O
minus	O
80degreesC	O
for	O
RT	O
-	O
PCR	O
and	O
Western	O
Blots	O
.	O

2	O
.	O
2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X

Induction	O
of	O
Intracerebral	O
Hemorrhage	O
<EOS>	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
induces	B-X
potently	B-X
oxidative	B-X
stress	B-X
responses	B-X
and	B-X
inflammatory	B-X
processes	B-X
.	B-X
Glymphatic	B-X
Drainage	B-X
Blocking	B-X
Aggravates	B-X
Brain	B-X
Edema	B-X
,	B-X
Neuroinflammation	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
is	B-X
a	B-X
type	B-X
of	B-X
stroke	B-X
that	B-X
results	B-X
in	B-X
significant	B-X
mortality	B-X
and	B-X
morbidity	B-X
.	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
is	B-X
the	B-X
most	B-X
devastating	B-X
type	B-X
of	B-X
stroke	B-X
.	B-X

Since	O
most	O
intracerebral	O
hemorrhages	O
occur	O
in	O
the	O
basal	O
ganglia	O
clinically	O
,	O
in	O
the	O
present	O
study	O
,	O
rat	O
model	O
of	O
ICH	O
was	O
induced	O
in	O
left	O
basal	O
ganglia	O
.	O

Rats	O
were	O
anesthetized	O
with	O
intra	O
-	O
peritoneal	O
sodium	O
pentobarbital	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

The	O
body	O
(	O
rectal	O
)	O
temperature	O
was	O
maintained	O
at	O
37degreesC	O
during	O
the	O
surgery	O
using	O
a	O
feedback	O
-	O
controlled	O
heating	O
system	O
.	O

The	O
rats	O
were	O
positioned	O
in	O
a	O
stereotactic	O
frame	O
,	O
and	O
the	O
scalp	O
was	O
incised	O
along	O
the	O
midline	O
.	O

Using	O
a	O
sterile	O
technique	O
,	O
a	O
1	O
mm	O
burr	O
hole	O
was	O
opened	O
in	O
the	O
skull	O
on	O
the	O
left	O
coronal	O
suture	O
3	O
mm	O
lateral	O
to	O
the	O
midline	O
.	O

A	O
blunt	O
26	O
-	O
gauge	O
needle	O
was	O
inserted	O
into	O
the	O
left	O
basal	O
ganglia	O
under	O
stereotactic	O
guidance	O
(	O
coordinates	O
:	O
0	O
.	O
2	O
mm	O
anterior	O
,	O
6	O
.	O
0	O
mm	O
ventral	O
,	O
and	O
3	O
.	O
0	O
mm	O
lateral	O
to	O
the	O
midline	O
)	O
.	O

Then	O
,	O
a	O
75	O
muL	O
of	O
autologous	O
whole	O
blood	O
was	O
infused	O
at	O
a	O
rate	O
of	O
20	O
muL	O
/	O
min	O
with	O
the	O
use	O
of	O
a	O
microinfusion	O
pump	O
.	O

After	O
the	O
completion	O
of	O
the	O
infusion	O
,	O
the	O
needle	O
was	O
withdrawn	O
quickly	O
,	O
cyanoacrylate	O
glue	O
was	O
placed	O
around	O
the	O
burr	O
hole	O
,	O
and	O
the	O
skin	O
incision	O
was	O
closed	O
with	O
sutures	O
.	O

For	O
the	O
normal	O
saline	O
control	O
rats	O
,	O
only	O
75	O
muL	O
normal	O
saline	O
was	O
injected	O
.	O

2	O
.	O
3	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Detection	O
of	O
TLR4	B-Protein
mRNA	O
by	O
the	O
Method	O
of	O
RT	O
-	O
PCR	O
<EOS>	B-X
Even	B-X
though	B-X
SYBR	B-X
Green	B-X
based	B-X
real	B-X
time	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
method	B-X
to	B-X
study	B-X
cytokine	B-X
transcription	B-X
in	B-X
ruminants	B-X
,	B-X
a	B-X
lack	B-X
of	B-X
standardization	B-X
impairs	B-X
its	B-X
implementation	B-X
in	B-X
the	B-X
study	B-X
of	B-X
different	B-X
ruminant	B-X
diseases	B-X
.	B-X
In	B-X
order	B-X
to	B-X
obtain	B-X
reliable	B-X
qPCR	B-X
results	B-X
,	B-X
several	B-X
variables	B-X
need	B-X
to	B-X
be	B-X
considered	B-X
:	B-X
choice	B-X
of	B-X
reference	B-X
genes	B-X
for	B-X
optimal	B-X
normalization	B-X
,	B-X
variation	B-X
of	B-X
annealing	B-X
temperature	B-X
among	B-X
primer	B-X
sets	B-X
,	B-X
and	B-X
assay	B-X
specificity	B-X
and	B-X
sensitivity	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
developed	B-X
and	B-X
validated	B-X
a	B-X
panel	B-X
of	B-X
immune	B-X
markers	B-X
in	B-X
bovine	B-X
and	B-X
ovine	B-X
samples	B-X
using	B-X
SYBR	B-X
Green	B-X
based	B-X
qPCR	B-X
in	B-X
a	B-X
cost-effective	B-X
way	B-X
with	B-X
multiple	B-X
primer	B-X
sets	B-X
optimised	B-X
to	B-X
amplify	B-X
at	B-X
a	B-X
common	B-X
thermal	B-X
cycling	B-X
temperature	B-X
.	B-X
Relative	B-X
quantification	B-X
studies	B-X
were	B-X
performed	B-X
on	B-X
ovine	B-X
and	B-X
bovine	B-X
mRNA	B-X
obtained	B-X
from	B-X
sheep	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
stimulated	B-X
with	B-X
three	B-X
different	B-X
treatments	B-X
(	B-X
PMA/Ionomycin	B-X
,	B-X
Concanavalin	B-X
A	B-X
(	B-X
Con	B-X
A	B-X
)	B-X
and	B-X
pokeweed	B-X
mitogen	B-X
(	B-X
PWM	B-X
)	B-X
)	B-X
.	B-X
Altogether	B-X
,	B-X
we	B-X
validated	B-X
the	B-X
efficiency	B-X
and	B-X
usability	B-X
of	B-X
an	B-X
extended	B-X
real-time	B-X
PCR	B-X
panel	B-X
that	B-X
gives	B-X
the	B-X
possibility	B-X
to	B-X
rapidly	B-X
measure	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
ovine	B-X
and	B-X
bovine	B-X
immune	B-X
markers	B-X
by	B-X
using	B-X
a	B-X
single	B-X
set	B-X
of	B-X
reagents	B-X
and	B-X
protocol	B-X
thus	B-X
representing	B-X
a	B-X
valid	B-X
and	B-X
cost-effective	B-X
tool	B-X
for	B-X
research	B-X
purposes	B-X
.	B-X

Briefly	O
,	O
total	O
RNA	O
samples	O
were	O
isolated	O
from	O
peri	O
-	O
hemorrhage	O
regions	O
in	O
left	O
basal	O
ganglia	O
using	O
Simply	O
P	O
Total	O
RNA	O
isolation	O
Kit	O
(	O
BioFlux	O
,	O
HZ	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
quantity	O
of	O
total	O
RNA	O
was	O
determined	O
on	O
a	O
Nanodrop	O
(	O
ND	O
-	O
1000	O
Spectrophotometer	O
)	O
by	O
measuring	O
optical	O
density	O
at	O
A260	O
and	O
A280	O
nm	O
wavelength	O
.	O

Then	O
,	O
the	O
concentrations	O
of	O
mRNA	O
were	O
adjusted	O
to	O
1	O
.	O
0	O
g	O
/	O
mL	O
.	O

RNA	O
was	O
reverse	O
-	O
transcribed	O
into	O
cDNA	O
in	O
20	O
muL	O
reaction	O
system	O
using	O
Superscript	O
First	O
-	O
Strand	O
Synthesis	O
Kit	O
for	O
RT	O
-	O
PCR	O
(	O
promega	O
Inc	O
)	O
under	O
conditions	O
described	O
by	O
the	O
supplier	O
.	O

One	O
microliter	O
of	O
cDNA	O
was	O
used	O
to	O
amplify	O
the	O
TLR4	B-Protein
gene	O
fragment	O
with	O
1x	O
PCR	O
buffer	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
200	O
muM	O
of	O
each	O
dNTP	O
,	O
200	O
muM	O
of	O
primers	O
,	O
and	O
2u	O
Taq	B-Protein
DNA	I-Protein
polymerase	I-Protein
.	O

The	B-Protein
house	I-Protein
keep	I-Protein
gene	I-Protein
(	O
beta	B-Protein
-	I-Protein
actin	I-Protein
)	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O
<EOS>	B-X
It	B-X
is	B-X
assumed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
housekeeping	B-X
genes	B-X
is	B-X
constant	B-X
regardless	B-X
of	B-X
experimental	B-X
conditions	B-X
.	B-X
In	B-X
toxicology	B-X
,	B-X
this	B-X
assumption	B-X
has	B-X
indeed	B-X
become	B-X
a	B-X
misconception	B-X
of	B-X
reasonable	B-X
concern	B-X
,	B-X
as	B-X
these	B-X
so-called	B-X
housekeeping	B-X
genes	B-X
vary	B-X
considerably	B-X
across	B-X
different	B-X
experimental	B-X
conditions	B-X
and	B-X
thereby	B-X
lead	B-X
to	B-X
an	B-X
erroneous	B-X
interpretation	B-X
of	B-X
the	B-X
expression	B-X
profile	B-X
of	B-X
a	B-X
target	B-X
gene	B-X
.	B-X
Given	B-X
that	B-X
the	B-X
choice	B-X
of	B-X
reference	B-X
gene	B-X
will	B-X
ultimately	B-X
influence	B-X
statistical	B-X
interpretation	B-X
of	B-X
toxicological	B-X
data	B-X
,	B-X
it	B-X
is	B-X
essential	B-X
to	B-X
validate	B-X
potential	B-X
reference	B-X
genes	B-X
prior	B-X
to	B-X
their	B-X
use	B-X
,	B-X
to	B-X
establish	B-X
their	B-X
suitability	B-X
for	B-X
a	B-X
specific	B-X
experimental	B-X
purpose	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
quantitatively	B-X
evaluate	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
housekeeping	B-X
genes	B-X
in	B-X
toxicology	B-X
research	B-X
for	B-X
their	B-X
suitability	B-X
as	B-X
reference	B-X
endpoints	B-X
,	B-X
and	B-X
thus	B-X
provide	B-X
toxicology	B-X
researchers	B-X
who	B-X
have	B-X
little	B-X
experience	B-X
in	B-X
molecular	B-X
biology	B-X
but	B-X
find	B-X
themselves	B-X
interested	B-X
or	B-X
involved	B-X
with	B-X
gene	B-X
expression	B-X
analysis	B-X
with	B-X
a	B-X
summary	B-X
of	B-X
information	B-X
necessary	B-X
for	B-X
re-evaluating	B-X
their	B-X
procedures	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
beta-actin	B-X
,	B-X
beta-tubulin	B-X
,	B-X
18S	B-X
ribosomal	B-X
RNA	B-X
(	B-X
18S	B-X
rRNA	B-X
)	B-X
,	B-X
and	B-X
elongation	B-X
factor-lalpha	B-X
(	B-X
EF-lalpha	B-X
)	B-X
,	B-X
representing	B-X
commonly	B-X
used	B-X
housekeeping	B-X
genes	B-X
in	B-X
toxicology	B-X
,	B-X
was	B-X
modulated	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
random	B-X
exposure	B-X
condition	B-X
and	B-X
time	B-X
,	B-X
in	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
test	B-X
systems	B-X
of	B-X
Atlantic	B-X
salmon	B-X
(	B-X
Salmo	B-X
salar	B-X
)	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
data	B-X
presented	B-X
herein	B-X
and	B-X
several	B-X
other	B-X
reports	B-X
by	B-X
other	B-X
researchers	B-X
,	B-X
there	B-X
are	B-X
very	B-X
few	B-X
biological	B-X
justifications	B-X
to	B-X
refer	B-X
to	B-X
anything	B-X
as	B-X
a	B-X
housekeeping	B-X
gene	B-X
in	B-X
real-time	B-X
PCR	B-X
assays	B-X
for	B-X
toxicological	B-X
research	B-X
.	B-X
However	B-X
,	B-X
given	B-X
the	B-X
absolute	B-X
need	B-X
for	B-X
normalization	B-X
genes	B-X
to	B-X
correct	B-X
for	B-X
sample-to-sample	B-X
variations	B-X
,	B-X
the	B-X
choice	B-X
of	B-X
internal	B-X
control	B-X
gene	B-X
should	B-X
be	B-X
determined	B-X
empirically	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
individual	B-X
exposure	B-X
condition	B-X
and	B-X
by	B-X
the	B-X
individual	B-X
researcher	B-X
.	B-X

The	O
PCR	O
primer	O
sequences	O
were	O
designed	O
according	O
to	O
the	O
TLR4	B-Protein
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
gene	O
sequences	O
reported	O
in	O
GenBank	O
.	O

TLR4	B-Protein
(	O
145	O
bp	O
)	O
:	O
forward	O
:	O
5	O
'	O
-	O
AGCTTTGGTCAGTTGGCTCT	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
CAGGATGACACCATTGAAGC	O
-	O
3	O
'	O
;	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
701	O
bp	O
)	O
:	O
forward	O
:	O
5	O
'	O
-	O
GCCAACCGTGAAAAAGATG	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGATAGAGCCACCAAT	O
-	O
3	O
'	O
.	O

Reaction	O
cycles	O
were	O
performed	O
at	O
the	O
following	O
condition	O
:	O
94degreesC	O
2	O
min	O
,	O
94degreesC	O
40	O
s	O
,	O
55degreesC	O
40	O
s	O
,	O
and	O
72degreesC	O
60	O
s	O
.	O

The	O
reaction	O
was	O
stopped	O
after	O
31	O
cycles	O
.	O
<EOS>	B-X
Because	B-X
zearalenone	B-X
(	B-X
ZEA	B-X
)	B-X
causes	B-X
harmful	B-X
influence	B-X
to	B-X
animals	B-X
and	B-X
widely	B-X
exists	B-X
in	B-X
the	B-X
world	B-X
,	B-X
the	B-X
researches	B-X
on	B-X
ZEA	B-X
have	B-X
never	B-X
stopped	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
after	B-X
ZEA	B-X
treatment	B-X
,	B-X
ESCs	B-X
appeared	B-X
numerous	B-X
adverse	B-X
reactions	B-X
,	B-X
and	B-X
the	B-X
phenomena	B-X
of	B-X
cell	B-X
viability	B-X
decrease	B-X
,	B-X
DNA	B-X
replication	B-X
block	B-X
and	B-X
apoptosis	B-X
were	B-X
detected	B-X
by	B-X
flow	B-X
cytometry	B-X
,	B-X
Annexin	B-X
V-FITC/PI	B-X
double-staining	B-X
method	B-X
,	B-X
TUNEL	B-X
assay	B-X
,	B-X
and	B-X
so	B-X
on	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
results	B-X
suggested	B-X
that	B-X
ZEA	B-X
could	B-X
cause	B-X
a	B-X
series	B-X
of	B-X
reactions	B-X
by	B-X
cytotoxicity	B-X
to	B-X
mouse	B-X
ESCs	B-X
,	B-X
meanwhile	B-X
there	B-X
must	B-X
be	B-X
some	B-X
substances	B-X
and	B-X
mechanisms	B-X
protect	B-X
cells	B-X
against	B-X
cytotoxicity	B-X
damage	B-X
.	B-X
The	B-X
isomerization	B-X
of	B-X
glucose	B-X
into	B-X
fructose	B-X
is	B-X
a	B-X
large-scale	B-X
reaction	B-X
for	B-X
the	B-X
production	B-X
of	B-X
high-fructose	B-X
corn	B-X
syrup	B-X
(	B-X
HFCS	B-X
;	B-X
reaction	B-X
performed	B-X
by	B-X
enzyme	B-X
catalysts	B-X
)	B-X
and	B-X
recently	B-X
is	B-X
being	B-X
considered	B-X
as	B-X
an	B-X
intermediate	B-X
step	B-X
in	B-X
the	B-X
possible	B-X
route	B-X
of	B-X
biomass	B-X
to	B-X
fuels	B-X
and	B-X
chemicals	B-X
.	B-X
Specifically	B-X
,	B-X
a	B-X
10	B-X
%	B-X
(	B-X
wt/wt	B-X
)	B-X
glucose	B-X
solution	B-X
containing	B-X
a	B-X
catalytic	B-X
amount	B-X
of	B-X
Sn-Beta	B-X
(	B-X
150	B-X
Sn	B-X
:	B-X
glucose	B-X
molar	B-X
ratio	B-X
)	B-X
gives	B-X
product	B-X
yields	B-X
of	B-X
approximately	B-X
46	B-X
%	B-X
(	B-X
wt/wt	B-X
)	B-X
glucose	B-X
,	B-X
31	B-X
%	B-X
(	B-X
wt/wt	B-X
)	B-X
fructose	B-X
,	B-X
and	B-X
9	B-X
%	B-X
(	B-X
wt/wt	B-X
)	B-X
mannose	B-X
after	B-X
30	B-X
min	B-X
and	B-X
12	B-X
min	B-X
of	B-X
reaction	B-X
at	B-X
383	B-X
K	B-X
and	B-X
413	B-X
K	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
properties	B-X
of	B-X
the	B-X
large-pore	B-X
zeolite	B-X
greatly	B-X
influence	B-X
the	B-X
reaction	B-X
behavior	B-X
because	B-X
the	B-X
reaction	B-X
does	B-X
not	B-X
proceed	B-X
with	B-X
a	B-X
medium-pore	B-X
zeolite	B-X
,	B-X
and	B-X
the	B-X
isomerization	B-X
activity	B-X
is	B-X
considerably	B-X
lower	B-X
when	B-X
the	B-X
metal	B-X
centers	B-X
are	B-X
incorporated	B-X
in	B-X
ordered	B-X
mesoporous	B-X
silica	B-X
(	B-X
MCM-41	B-X
)	B-X
.	B-X
The	B-X
Sn-Beta	B-X
catalyst	B-X
can	B-X
be	B-X
used	B-X
for	B-X
multiple	B-X
cycles	B-X
,	B-X
and	B-X
the	B-X
reaction	B-X
stops	B-X
when	B-X
the	B-X
solid	B-X
is	B-X
removed	B-X
,	B-X
clearly	B-X
indicating	B-X
that	B-X
the	B-X
catalysis	B-X
is	B-X
occurring	B-X
heterogeneously	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
the	B-X
Sn-Beta	B-X
catalyst	B-X
is	B-X
able	B-X
to	B-X
perform	B-X
the	B-X
isomerization	B-X
reaction	B-X
in	B-X
highly	B-X
acidic	B-X
,	B-X
aqueous	B-X
environments	B-X
with	B-X
equivalent	B-X
activity	B-X
and	B-X
product	B-X
distribution	B-X
as	B-X
in	B-X
media	B-X
without	B-X
added	B-X
acid	B-X
.	B-X
This	B-X
enables	B-X
Sn-Beta	B-X
to	B-X
couple	B-X
isomerizations	B-X
with	B-X
other	B-X
acid-catalyzed	B-X
reactions	B-X
,	B-X
including	B-X
hydrolysis/isomerization	B-X
or	B-X
isomerization/dehydration	B-X
reaction	B-X
sequences	B-X
[	B-X
starch	B-X
to	B-X
fructose	B-X
and	B-X
glucose	B-X
to	B-X
5-hydroxymethylfurfural	B-X
(	B-X
HMF	B-X
)	B-X
demonstrated	B-X
here	B-X
]	B-X
.	B-X

PCR	O
products	O
were	O
electrophoresed	O
through	O
agarose	O
gel	O
.	O
<EOS>	B-X
Agarose	B-X
gel	B-X
electrophoresis	B-X
is	B-X
a	B-X
relatively	B-X
easy	B-X
to	B-X
use	B-X
method	B-X
,	B-X
commonly	B-X
applied	B-X
to	B-X
evaluate	B-X
PCR	B-X
reaction	B-X
success	B-X
.	B-X
To	B-X
more	B-X
closely	B-X
examine	B-X
the	B-X
suitability	B-X
of	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
to	B-X
assess	B-X
PCR	B-X
product	B-X
yield	B-X
,	B-X
we	B-X
quantified	B-X
the	B-X
brightness	B-X
of	B-X
bands	B-X
on	B-X
a	B-X
gel	B-X
and	B-X
compared	B-X
these	B-X
data	B-X
with	B-X
the	B-X
results	B-X
from	B-X
spectrophotometry	B-X
,	B-X
fluorometry	B-X
and	B-X
qPCR	B-X
.	B-X
Evaluation	B-X
of	B-X
the	B-X
results	B-X
suggests	B-X
that	B-X
assessment	B-X
of	B-X
the	B-X
relative	B-X
quantity	B-X
of	B-X
amplicons	B-X
by	B-X
band	B-X
brightness	B-X
is	B-X
precise	B-X
enough	B-X
even	B-X
for	B-X
post-PCR	B-X
analysis	B-X
steps	B-X
requiring	B-X
PCR	B-X
product	B-X
concentrations	B-X
within	B-X
a	B-X
certain	B-X
range	B-X
to	B-X
function	B-X
properly	B-X
.	B-X
This	B-X
method	B-X
involves	B-X
the	B-X
extraction	B-X
of	B-X
DNA	B-X
from	B-X
animal	B-X
tissue	B-X
samples	B-X
and	B-X
subsequent	B-X
amplification	B-X
of	B-X
genomic	B-X
regions	B-X
of	B-X
interest	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
The	B-X
amplified	B-X
products	B-X
are	B-X
analyzed	B-X
by	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
based	B-X
on	B-X
their	B-X
size	B-X
.	B-X

Image	O
Acquisition	O
and	O
Analysis	O
software	O
were	O
used	O
to	O
determine	O
band	O
densities	O
.	O
<EOS>	B-X
The	B-X
BIAS	B-X
(	B-X
Biological	B-X
Image	B-X
Analysis	B-X
System	B-X
)	B-X
was	B-X
developed	B-X
to	B-X
:	B-X
(	B-X
i	B-X
)	B-X
permit	B-X
accurate	B-X
entry	B-X
and	B-X
image	B-X
processing	B-X
of	B-X
biological	B-X
data	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
minimize	B-X
the	B-X
need	B-X
for	B-X
specialized	B-X
hardware	B-X
;	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
aid	B-X
in	B-X
the	B-X
human	B-X
genome	B-X
mapping	B-X
and	B-X
other	B-X
projects	B-X
.	B-X

The	O
abundance	O
of	O
TLR4	B-Protein
mRNA	O
was	O
expressed	O
as	O
the	O
ratio	O
of	O
TLR4	B-Protein
mRNA	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
mRNA	O
.	O

2	O
.	O
4	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Immunohistochemistry	O
(	O
IHC	O
)	O
<EOS>	B-X
Immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
that	B-X
exploits	B-X
the	B-X
specific	B-X
binding	B-X
between	B-X
an	B-X
antibody	B-X
and	B-X
antigen	B-X
to	B-X
detect	B-X
and	B-X
localize	B-X
specific	B-X
antigens	B-X
in	B-X
cells	B-X
and	B-X
tissue	B-X
,	B-X
most	B-X
commonly	B-X
detected	B-X
and	B-X
examined	B-X
with	B-X
the	B-X
light	B-X
microscope	B-X
.	B-X
A	B-X
standard	B-X
tool	B-X
in	B-X
many	B-X
fields	B-X
in	B-X
the	B-X
research	B-X
setting	B-X
,	B-X
IHC	B-X
has	B-X
become	B-X
an	B-X
essential	B-X
ancillary	B-X
technique	B-X
in	B-X
clinical	B-X
diagnostics	B-X
in	B-X
anatomic	B-X
pathology	B-X
(	B-X
Lin	B-X
F	B-X
,	B-X
Chen	B-X
Z.	B-X
Arch	B-X
Pathol	B-X
Lab	B-X
Med	B-X
138:1564-1577	B-X
,	B-X
2014	B-X
)	B-X
with	B-X
the	B-X
advent	B-X
of	B-X
antigen	B-X
retrieval	B-X
methods	B-X
allowing	B-X
it	B-X
to	B-X
be	B-X
performed	B-X
conveniently	B-X
on	B-X
formalin	B-X
fixed	B-X
paraffin	B-X
embedded	B-X
(	B-X
FFPE	B-X
)	B-X
tissue	B-X
(	B-X
Taylor	B-X
CR	B-X
,	B-X
Shi	B-X
S-R	B-X
,	B-X
Barr	B-X
NJ	B-X
.	B-X
IHC	B-X
is	B-X
frequently	B-X
utilized	B-X
to	B-X
assist	B-X
in	B-X
the	B-X
classification	B-X
of	B-X
neoplasms	B-X
,	B-X
determination	B-X
of	B-X
a	B-X
metastatic	B-X
tumor	B-X
's	B-X
site	B-X
of	B-X
origin	B-X
and	B-X
detection	B-X
of	B-X
tiny	B-X
foci	B-X
of	B-X
tumor	B-X
cells	B-X
inconspicuous	B-X
on	B-X
routine	B-X
hematoxylin	B-X
and	B-X
eosin	B-X
(	B-X
H	B-X
&	B-X
E	B-X
)	B-X
staining	B-X
.	B-X
Conventional	B-X
immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
is	B-X
a	B-X
widely	B-X
used	B-X
diagnostic	B-X
technique	B-X
in	B-X
tissue	B-X
pathology	B-X
.	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
mIHC/IF	B-X
provides	B-X
high-throughput	B-X
multiplex	B-X
staining	B-X
and	B-X
standardized	B-X
quantitative	B-X
analysis	B-X
for	B-X
highly	B-X
reproducible	B-X
,	B-X
efficient	B-X
and	B-X
cost-effective	B-X
tissue	B-X
studies	B-X
.	B-X

The	O
IHC	O
staining	O
for	O
TLR4	B-Protein
was	O
performed	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

The	O
primary	O
antibody	O
employed	O
was	O
rabbit	O
anti	O
-	O
TLR4	O
(	O
WuHan	O
,	O
BA1717	O
)	O
.	O

The	O
biotinylated	O
secondary	O
antibody	O
and	O
antibody	O
-	O
biotin	O
-	O
avidin	B-Protein
-	O
peroxidase	O
complexes	O
(	O
ABC	O
reagent	O
,	O
SC	O
-	O
2018	O
)	O
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O

(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Slides	O
processed	O
without	O
primary	O
antibodies	O
served	O
as	O
negative	O
controls	O
.	O
<EOS>	B-X
Nonradiolabeled	B-X
CC49	B-X
IgG	B-X
(	B-X
0.5	B-X
micrograms/ml	B-X
)	B-X
was	B-X
used	B-X
as	B-X
the	B-X
specific	B-X
antigen	B-X
binding	B-X
primary	B-X
antibody	B-X
in	B-X
the	B-X
immunostaining	B-X
procedures	B-X
.	B-X
Nonradiolabeled	B-X
MOPC-21	B-X
IgG	B-X
(	B-X
0.5	B-X
micrograms/ml	B-X
)	B-X
served	B-X
as	B-X
the	B-X
negative	B-X
control	B-X
.	B-X
Immunohistochemically	B-X
stained	B-X
tissue	B-X
sections	B-X
were	B-X
coated	B-X
with	B-X
photographic	B-X
emulsion	B-X
and	B-X
processed	B-X
for	B-X
autoradiographic	B-X
localization	B-X
of	B-X
125I-CC49	B-X
or	B-X
125I-MOPC-21	B-X
.	B-X
After	B-X
an	B-X
optimal	B-X
exposure	B-X
time	B-X
of	B-X
6	B-X
days	B-X
,	B-X
slides	B-X
were	B-X
processed	B-X
and	B-X
examined	B-X
under	B-X
a	B-X
light	B-X
microscope	B-X
.	B-X

2	O
.	O
5	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

Western	O
Blots	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
techniques	B-X
in	B-X
molecular	B-X
biology	B-X
and	B-X
proteomics	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
laboratory	B-X
techniques	B-X
for	B-X
identifying	B-X
proteins	B-X
and	B-X
semi-quantifying	B-X
protein	B-X
amounts	B-X
;	B-X
however	B-X
,	B-X
several	B-X
recent	B-X
findings	B-X
suggest	B-X
that	B-X
western	B-X
blots	B-X
may	B-X
not	B-X
be	B-X
as	B-X
reliable	B-X
as	B-X
previously	B-X
assumed	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
Western	B-X
blots	B-X
are	B-X
continuously	B-X
applied	B-X
and	B-X
developed	B-X
by	B-X
the	B-X
protein	B-X
community	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

Cellular	O
proteins	O
were	O
prepared	O
from	O
ICH	O
cerebral	O
hemispheres	O
,	O
electrophoresed	O
with	O
SDS	O
-	O
polyacrylamide	O
gel	O
and	O
transferred	O
onto	O
Hybond	O
ECL	O
membranes	O
(	O
Amersham	O
Pharmacia	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

The	O
ECL	O
membranes	O
were	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
(	O
WuHan	O
,	O
BA1717	O
)	O
followed	O
by	O
incubation	O
with	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Golden	O
Bridge	O
,	O
PV	O
-	O
6001	O
)	O
.	O

The	O
signals	O
were	O
detected	O
with	O
the	O
ECL	O
system	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

The	O
same	O
membranes	O
were	O
probed	O
with	O
anti	O
-	O
GAPDH	B-Protein
(	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
,	O
Biodesign	O
,	O
Saco	O
,	O
Maine	O
)	O
after	O
being	O
washed	O
with	O
stripping	O
buffer	O
.	O

The	O
signals	O
were	O
quantified	O
by	O
scanning	O
densitometry	O
and	O
computer	O
-	O
assisted	O
image	O
analysis	O
.	O

2	O
.	O
6	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
to	B-X
detect	B-X
formation	B-X
of	B-X
complexes	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
and	B-X
to	B-X
determine	B-X
,	B-X
among	B-X
other	B-X
parameters	B-X
,	B-X
equilibrium	B-X
constants	B-X
for	B-X
the	B-X
interaction	B-X
.	B-X
Interactions	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
are	B-X
frequently	B-X
analyzed	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
.	B-X
The	B-X
current	B-X
study	B-X
utilizes	B-X
recent	B-X
advances	B-X
in	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
technology	B-X
to	B-X
develop	B-X
a	B-X
new	B-X
EMSA	B-X
protocol	B-X
that	B-X
is	B-X
simpler	B-X
and	B-X
faster	B-X
than	B-X
traditional	B-X
polyacrylamide	B-X
methods	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
EMSAs	B-X
performed	B-X
using	B-X
agarose	B-X
gels	B-X
can	B-X
be	B-X
run	B-X
at	B-X
high	B-X
voltages	B-X
(	B-X
≥20	B-X
V/cm	B-X
)	B-X
with	B-X
0.5	B-X
×	B-X
TB	B-X
(	B-X
Tris-borate	B-X
)	B-X
buffer	B-X
,	B-X
allowing	B-X
for	B-X
short	B-X
run	B-X
times	B-X
while	B-X
simultaneously	B-X
yielding	B-X
high	B-X
band	B-X
resolution	B-X
.	B-X

Nuclear	O
proteins	O
were	O
isolated	O
from	O
brain	O
tissue	O
.	O
<EOS>	B-X
The	B-X
brain	B-X
consists	B-X
of	B-X
diverse	B-X
cell	B-X
types	B-X
including	B-X
neurons	B-X
,	B-X
astrocytes	B-X
,	B-X
oligodendrocytes	B-X
,	B-X
and	B-X
microglia	B-X
.	B-X
The	B-X
isolation	B-X
of	B-X
nuclei	B-X
from	B-X
these	B-X
distinct	B-X
cell	B-X
populations	B-X
provides	B-X
an	B-X
opportunity	B-X
to	B-X
identify	B-X
cell-type-specific	B-X
nuclear	B-X
proteins	B-X
,	B-X
histone	B-X
modifications	B-X
,	B-X
and	B-X
regulation	B-X
networks	B-X
that	B-X
are	B-X
altered	B-X
with	B-X
normal	B-X
brain	B-X
aging	B-X
or	B-X
neurodegenerative	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
method	B-X
by	B-X
which	B-X
intact	B-X
neuronal	B-X
and	B-X
non-neuronal	B-X
nuclei	B-X
were	B-X
purified	B-X
from	B-X
human	B-X
post-mortem	B-X
brain	B-X
employing	B-X
a	B-X
modification	B-X
of	B-X
fluorescence	B-X
activated	B-X
cell	B-X
sorting	B-X
(	B-X
FACS	B-X
)	B-X
termed	B-X
fluorescence	B-X
activated	B-X
nuclei	B-X
sorting	B-X
(	B-X
FANS	B-X
)	B-X
.	B-X
Utilizing	B-X
mass	B-X
spectrometry	B-X
(	B-X
MS	B-X
)	B-X
based	B-X
label-free	B-X
quantitative	B-X
proteomics	B-X
,	B-X
we	B-X
identified	B-X
1755	B-X
proteins	B-X
from	B-X
sorted	B-X
NeuN-positive	B-X
and	B-X
negative	B-X
nuclear	B-X
extracts	B-X
.	B-X
Approximately	B-X
20	B-X
%	B-X
of	B-X
these	B-X
proteins	B-X
were	B-X
significantly	B-X
enriched	B-X
or	B-X
depleted	B-X
in	B-X
neuronal	B-X
versus	B-X
non-neuronal	B-X
populations	B-X
.	B-X
These	B-X
comparative	B-X
proteomic	B-X
data	B-X
sets	B-X
also	B-X
reveal	B-X
a	B-X
number	B-X
of	B-X
transcription	B-X
and	B-X
splicing	B-X
factors	B-X
that	B-X
are	B-X
selectively	B-X
enriched	B-X
in	B-X
a	B-X
cell-type-specific	B-X
manner	B-X
in	B-X
human	B-X
brain	B-X
.	B-X

Briefly	O
,	O
after	O
removal	O
of	O
supernatant	O
(	O
cytoplasmic	O
extract	O
)	O
,	O
the	O
pellets	O
were	O
resuspended	O
in	O
nuclear	O
extraction	O
reagent	O
.	O

The	O
tubes	O
containing	O
pellets	O
were	O
put	O
on	O
vortex	O
for	O
15	O
seconds	O
every	O
10	O
minutes	O
,	O
for	O
a	O
total	O
of	O
40	O
minutes	O
.	O

The	O
tubes	O
were	O
centrifuged	O
at	O
maximum	O
speed	O
(	O
~	O
16	O
,	O
000	O
x	O
g	O
)	O
in	O
a	O
micro	O
centrifuge	O
for	O
10	O
minutes	O
.	O

The	O
supernatants	O
(	O
nuclear	O
extract	O
)	O
were	O
transferred	O
to	O
a	O
clean	O
prechilled	O
tube	O
and	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

EMSA	O
was	O
performed	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O
<EOS>	B-X
A	B-X
chemically	B-X
modified	B-X
RNA	B-X
aptamer	B-X
(	B-X
F3B	B-X
)	B-X
,	B-X
fully	B-X
resistant	B-X
to	B-X
nucleases	B-X
was	B-X
previously	B-X
described	B-X
.	B-X
Quantitative	B-X
biodistribution	B-X
studies	B-X
were	B-X
performed	B-X
at	B-X
30	B-X
min	B-X
,	B-X
1h	B-X
and	B-X
2	B-X
h	B-X
post	B-X
injection	B-X
of	B-X
99mTc-MAG-aptamer	B-X
and	B-X
111In-DOTA-F3B	B-X
.	B-X
Such	B-X
difference	B-X
in	B-X
tumor	B-X
accumulation	B-X
has	B-X
been	B-X
confirmed	B-X
by	B-X
ex	B-X
vivo	B-X
scintigraphic	B-X
images	B-X
performed	B-X
at	B-X
1h	B-X
post	B-X
injection	B-X
and	B-X
by	B-X
autoradiography	B-X
,	B-X
which	B-X
revealed	B-X
the	B-X
overexpression	B-X
of	B-X
hMMP-9	B-X
in	B-X
sections	B-X
of	B-X
human	B-X
melanomas	B-X
.	B-X
Methyltransferase	B-X
RlmCD	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
introduction	B-X
of	B-X
C5	B-X
methylation	B-X
at	B-X
both	B-X
U747	B-X
and	B-X
U1939	B-X
of	B-X
the	B-X
23S	B-X
ribosomal	B-X
RNA	B-X
in	B-X
Streptococcus	B-X
pneumoniae	B-X
.	B-X
An	B-X
in-vitro	B-X
methyltransferase	B-X
assay	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
were	B-X
performed	B-X
to	B-X
validate	B-X
these	B-X
findings	B-X
.	B-X

NFkappaB	O
binding	O
activity	O
was	O
examined	O
in	O
a	O
15	O
muL	O
binding	O
reaction	O
mixture	O
containing	O
15	O
mug	O
of	O
nuclear	O
proteins	O
and	O
35	O
fmol	O
[	O
gamma	O
-	O
32P	O
]	O
labeled	O
double	O
-	O
stranded	O
NFkappaB	O
consensus	O
oligonucleotide	O
.	O

A	O
super	O
shift	O
assay	O
using	O
antibodies	O
to	O
P65	B-Protein
and	O
P50	B-Protein
was	O
performed	O
to	O
confirm	O
NFkappaB	O
binding	O
specificity	O
as	O
previously	O
described	O
.	O

2	O
.	O
7	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X

Statistical	O
Analysis	O

All	O
data	O
were	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
The	B-X
Medline	B-X
,	B-X
CINAHL	B-X
,	B-X
and	B-X
Central	B-X
databases	B-X
were	B-X
searched	B-X
for	B-X
relevant	B-X
studies	B-X
up	B-X
to	B-X
July	B-X
2020	B-X
.	B-X
Absolute	B-X
reliability	B-X
was	B-X
determined	B-X
by	B-X
test-retest	B-X
studies	B-X
presenting	B-X
standard	B-X
error	B-X
of	B-X
measurement	B-X
(	B-X
SEM	B-X
%	B-X
)	B-X
and/or	B-X
minimal	B-X
detectable	B-X
change	B-X
(	B-X
MDC	B-X
%	B-X
)	B-X
expressed	B-X
as	B-X
percentage	B-X
of	B-X
the	B-X
mean	B-X
.	B-X
In	B-X
most	B-X
clinical	B-X
and	B-X
experimental	B-X
studies	B-X
,	B-X
the	B-X
standard	B-X
deviation	B-X
(	B-X
SD	B-X
)	B-X
and	B-X
the	B-X
estimated	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
(	B-X
SEM	B-X
)	B-X
are	B-X
used	B-X
to	B-X
present	B-X
the	B-X
characteristics	B-X
of	B-X
sample	B-X
data	B-X
and	B-X
to	B-X
explain	B-X
statistical	B-X
analysis	B-X
results	B-X
.	B-X
However	B-X
,	B-X
some	B-X
authors	B-X
occasionally	B-X
muddle	B-X
the	B-X
distinctive	B-X
usage	B-X
between	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
in	B-X
medical	B-X
literature	B-X
.	B-X
Because	B-X
the	B-X
process	B-X
of	B-X
calculating	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
includes	B-X
different	B-X
statistical	B-X
inferences	B-X
,	B-X
each	B-X
of	B-X
them	B-X
has	B-X
its	B-X
own	B-X
meaning	B-X
.	B-X
SD	B-X
is	B-X
the	B-X
dispersion	B-X
of	B-X
data	B-X
in	B-X
a	B-X
normal	B-X
distribution	B-X
.	B-X
In	B-X
other	B-X
words	B-X
,	B-X
SD	B-X
indicates	B-X
how	B-X
accurately	B-X
the	B-X
mean	B-X
represents	B-X
sample	B-X
data	B-X
.	B-X
However	B-X
the	B-X
meaning	B-X
of	B-X
SEM	B-X
includes	B-X
statistical	B-X
inference	B-X
based	B-X
on	B-X
the	B-X
sampling	B-X
distribution	B-X
.	B-X
SEM	B-X
is	B-X
the	B-X
SD	B-X
of	B-X
the	B-X
theoretical	B-X
distribution	B-X
of	B-X
the	B-X
sample	B-X
means	B-X
(	B-X
the	B-X
sampling	B-X
distribution	B-X
)	B-X
.	B-X
While	B-X
either	B-X
SD	B-X
or	B-X
SEM	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
describe	B-X
data	B-X
and	B-X
statistical	B-X
results	B-X
,	B-X
one	B-X
should	B-X
be	B-X
aware	B-X
of	B-X
reasonable	B-X
methods	B-X
with	B-X
which	B-X
to	B-X
use	B-X
SD	B-X
and	B-X
SEM	B-X
.	B-X
We	B-X
aim	B-X
to	B-X
elucidate	B-X
the	B-X
distinctions	B-X
between	B-X
SD	B-X
and	B-X
SEM	B-X
and	B-X
to	B-X
provide	B-X
proper	B-X
usage	B-X
guidelines	B-X
for	B-X
both	B-X
,	B-X
which	B-X
summarize	B-X
data	B-X
and	B-X
describe	B-X
statistical	B-X
results	B-X
.	B-X

The	O
measurements	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
or	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O
<EOS>	B-X
The	B-X
implant	B-X
stability	B-X
quotient	B-X
(	B-X
ISQ	B-X
)	B-X
was	B-X
assessed	B-X
immediately	B-X
after	B-X
the	B-X
IT	B-X
,	B-X
and	B-X
was	B-X
measured	B-X
weekly	B-X
via	B-X
resonance	B-X
frequency	B-X
analysis	B-X
during	B-X
3	B-X
months	B-X
.	B-X
The	B-X
data	B-X
were	B-X
analyzed	B-X
by	B-X
a	B-X
one-way	B-X
ANOVA	B-X
,	B-X
the	B-X
Bonferroni	B-X
test	B-X
,	B-X
paired	B-X
t	B-X
tests	B-X
and	B-X
Pearson	B-X
's	B-X
correlation	B-X
coefficient	B-X
.	B-X
Chronic	B-X
ankle	B-X
instability	B-X
(	B-X
CAI	B-X
)	B-X
occurs	B-X
in	B-X
some	B-X
people	B-X
after	B-X
a	B-X
lateral	B-X
ankle	B-X
sprain	B-X
and	B-X
often	B-X
results	B-X
in	B-X
residual	B-X
feelings	B-X
of	B-X
instability	B-X
and	B-X
episodes	B-X
of	B-X
the	B-X
ankle	B-X
's	B-X
giving	B-X
way	B-X
.	B-X
Compared	B-X
with	B-X
healthy	B-X
people	B-X
,	B-X
patients	B-X
with	B-X
CAI	B-X
demonstrated	B-X
poor	B-X
postural	B-X
control	B-X
and	B-X
used	B-X
a	B-X
more	B-X
anteriorly	B-X
and	B-X
laterally	B-X
positioned	B-X
center	B-X
of	B-X
pressure	B-X
(	B-X
COP	B-X
)	B-X
during	B-X
a	B-X
single-limb	B-X
static-balance	B-X
task	B-X
on	B-X
a	B-X
force	B-X
plate	B-X
.	B-X

The	O
P	O
<	O
.	O
05	O
level	O
of	O
probability	O
was	O
used	O
as	O
the	O
criteria	O
of	O
significance	O
.	O

3	O
.	O
1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

TLR4	B-Protein
mRNA	O
Increased	O
in	O
Brain	O
Tissue	O
after	O
ICH	O
<EOS>	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

TLR4	B-Protein
mRNA	O
levels	O
were	O
detected	O
by	O
Rt	O
-	O
PCR	O
.	O

The	O
low	O
level	O
of	O
TLR4	B-Protein
mRNA	O
was	O
observed	O
in	O
normal	O
rat	O
brain	O
tissue	O
.	O

In	O
the	O
saline	O
control	O
group	O
,	O
the	O
TLR4	B-Protein
mRNA	O
slightly	O
increased	O
,	O
but	O
was	O
not	O
significantly	O
different	O
from	O
normal	O
group	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
visfatin	B-X
on	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-induced	B-X
acute	B-X
lung	B-X
injury	B-X
(	B-X
ALI	B-X
)	B-X
,	B-X
thirty	B-X
Kunming	B-X
mice	B-X
were	B-X
divided	B-X
into	B-X
Saline	B-X
,	B-X
LPS	B-X
,	B-X
and	B-X
LPS	B-X
+	B-X
visfatin	B-X
groups	B-X
.	B-X
Compared	B-X
with	B-X
the	B-X
Saline	B-X
group	B-X
,	B-X
neutrophil	B-X
percentage	B-X
,	B-X
peripheral	B-X
blood	B-X
neutrophil	B-X
count	B-X
,	B-X
and	B-X
the	B-X
ratio	B-X
of	B-X
lymphocyte	B-X
count	B-X
(	B-X
NLR	B-X
)	B-X
were	B-X
upregulated	B-X
in	B-X
LPS	B-X
group	B-X
.	B-X
Moreover	B-X
,	B-X
Masson	B-X
staining	B-X
showed	B-X
alterations	B-X
in	B-X
lung	B-X
tissue	B-X
structure	B-X
;	B-X
the	B-X
mRNA	B-X
level	B-X
of	B-X
different	B-X
cytokines	B-X
(	B-X
IL-6	B-X
,	B-X
IL-1β	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-10	B-X
,	B-X
TLR4	B-X
,	B-X
IFN-γ	B-X
)	B-X
was	B-X
upregulated	B-X
;	B-X
and	B-X
the	B-X
protein	B-X
expression	B-X
of	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
,	B-X
myeloperoxidase	B-X
(	B-X
MPO	B-X
)	B-X
,	B-X
and	B-X
transforming	B-X
growth	B-X
factor-β1	B-X
(	B-X
TGF-β	B-X
)	B-X
was	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
different	B-X
in	B-X
LPS	B-X
group	B-X
.	B-X
Compared	B-X
with	B-X
LPS	B-X
group	B-X
,	B-X
neutrophil	B-X
percentage	B-X
significantly	B-X
decreased	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
,	B-X
the	B-X
numbers	B-X
of	B-X
lymphocytes	B-X
significantly	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
increased	B-X
,	B-X
NLR	B-X
decreased	B-X
,	B-X
Masson	B-X
staining	B-X
of	B-X
the	B-X
lung	B-X
was	B-X
extremely	B-X
different	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
lung	B-X
was	B-X
slightly	B-X
damaged	B-X
,	B-X
and	B-X
the	B-X
myeloperoxidase	B-X
values	B-X
of	B-X
lung	B-X
showed	B-X
no	B-X
differences	B-X
in	B-X
LPS	B-X
+	B-X
visfatin	B-X
.	B-X

However	O
,	O
the	O
TLR4	B-Protein
mRNA	O
after	O
ICH	O
significantly	O
increased	O
starting	O
from	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
but	O
still	O
maintained	O
a	O
higher	O
level	O
compared	O
with	O
saline	O
control	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
1	O
)	O
.	O

3	O
.	O
2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Expression	O
of	O
TLR4	B-Protein
Protein	O
Increased	O
in	O
Brain	O
Tissue	O
after	O
ICH	O
<EOS>	B-X
Inflammation	B-X
and	B-X
apoptosis	B-X
caused	B-X
by	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
are	B-X
two	B-X
important	B-X
factors	B-X
that	B-X
affect	B-X
patient	B-X
prognosis	B-X
and	B-X
survival	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
triggers	B-X
activation	B-X
of	B-X
the	B-X
inflammatory	B-X
pathway	B-X
,	B-X
causing	B-X
synthesis	B-X
and	B-X
release	B-X
of	B-X
inflammatory	B-X
factors	B-X
.	B-X
However	B-X
,	B-X
no	B-X
studies	B-X
have	B-X
reported	B-X
the	B-X
role	B-X
of	B-X
TLR4	B-X
in	B-X
inflammation	B-X
and	B-X
apoptosis	B-X
.	B-X
Inflammation	B-X
and	B-X
immunity	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
Intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4-	B-X
(	B-X
TLR4-	B-X
)	B-X
mediated	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NFkappaB	B-X
)	B-X
signaling	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
in	B-X
injured	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
remains	B-X
unknown	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
temporal	B-X
profile	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
TLR4	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
in	B-X
brain	B-X
tissues	B-X
of	B-X
Wistar	B-X
rats	B-X
after	B-X
ICH	B-X
.	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
inhibitors	B-X
of	B-X
kappa	B-X
B	B-X
(	B-X
p-IkappaBalpha	B-X
)	B-X
,	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
were	B-X
examined	B-X
in	B-X
hemorrhagic	B-X
cerebral	B-X
tissue	B-X
by	B-X
Rt-PCR	B-X
,	B-X
Western	B-X
blots	B-X
,	B-X
immunohistochemistry	B-X
staining	B-X
,	B-X
and	B-X
EMSA	B-X
.	B-X
Compared	B-X
with	B-X
saline	B-X
control	B-X
,	B-X
the	B-X
TLR4	B-X
mRNA	B-X
and	B-X
protein	B-X
significantly	B-X
increased	B-X
starting	B-X
at	B-X
6	B-X
hours	B-X
after	B-X
ICH	B-X
,	B-X
peaked	B-X
on	B-X
the	B-X
3rd	B-X
day	B-X
after	B-X
ICH	B-X
,	B-X
and	B-X
then	B-X
decreased	B-X
but	B-X
still	B-X
maintained	B-X
at	B-X
a	B-X
higher	B-X
level	B-X
on	B-X
the	B-X
7th	B-X
day	B-X
after	B-X
ICH	B-X
(	B-X
P	B-X
<	B-X
.05	B-X
)	B-X
.	B-X
The	B-X
level	B-X
of	B-X
p-IkappaBalpha	B-X
and	B-X
the	B-X
activity	B-X
of	B-X
NFkappaB	B-X
also	B-X
increased	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
ICH	B-X
compared	B-X
with	B-X
saline	B-X
control	B-X
.	B-X
The	B-X
present	B-X
study	B-X
firstly	B-X
suggests	B-X
that	B-X
TLR4-mediated	B-X
NFkappaB	B-X
signaling	B-X
participates	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
ICH	B-X
,	B-X
which	B-X
may	B-X
become	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
ICH-induced	B-X
brain	B-X
damage	B-X
.	B-X

To	O
investigate	O
the	O
increased	O
TLR4	B-Protein
at	O
the	O
protein	O
level	O
,	O
the	O
expression	O
of	O
TLR4	B-Protein
protein	O
was	O
measured	O
in	O
brain	O
tissue	O
by	O
the	O
method	O
of	O
Western	O
Blots	O
using	O
specific	O
antibodies	O
for	O
TLR4	B-Protein
.	O

Our	O
results	O
showed	O
that	O
a	O
low	O
level	O
of	O
TLR4	B-Protein
protein	O
was	O
detectable	O
in	O
the	O
saline	O
control	O
group	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
nalmefene	B-X
hydrochloride	B-X
on	B-X
TLR4	B-X
signaling	B-X
pathway	B-X
in	B-X
rats	B-X
with	B-X
lung	B-X
ischemia-reperfusion	B-X
injury	B-X
.	B-X
To	B-X
discuss	B-X
the	B-X
effects	B-X
of	B-X
dragon	B-X
's	B-X
blood	B-X
extract	B-X
,	B-X
a	B-X
Chinese	B-X
herb	B-X
,	B-X
on	B-X
periodontal	B-X
tissue	B-X
repair	B-X
and	B-X
toll	B-X
like	B-X
receptor	B-X
4/nuclear	B-X
transcription	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
TLR4/NF-κB	B-X
)	B-X
in	B-X
gingivitis	B-X
rats	B-X
.	B-X
To	B-X
be	B-X
specific	B-X
,	B-X
female	B-X
KM	B-X
mice	B-X
were	B-X
randomized	B-X
into	B-X
control	B-X
group	B-X
(	B-X
i.g.	B-X
,	B-X
normal	B-X
saline	B-X
)	B-X
,	B-X
model	B-X
group	B-X
,	B-X
fluco-nazole	B-X
group	B-X
(	B-X
i.g.	B-X
,	B-X
20	B-X
mg·kg~	B-X
(	B-X
-1	B-X
)	B-X
)	B-X
,	B-X
and	B-X
low-dose	B-X
,	B-X
medium-dose	B-X
,	B-X
and	B-X
high-dose	B-X
BAEB	B-X
groups	B-X
(	B-X
i.g.	B-X
,	B-X
20	B-X
,	B-X
40	B-X
,	B-X
and	B-X
80	B-X
mg·kg~	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
VVC	B-X
was	B-X
induced	B-X
in	B-X
mice	B-X
except	B-X
the	B-X
control	B-X
group	B-X
.	B-X
The	B-X
protein	B-X
expression	B-X
of	B-X
NLRP3	B-X
,	B-X
ASC	B-X
,	B-X
caspase-1	B-X
,	B-X
Dectin-1	B-X
,	B-X
Syk	B-X
,	B-X
MyD88	B-X
,	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
in	B-X
vaginal	B-X
tissues	B-X
was	B-X
detected	B-X
by	B-X
Western	B-X
blot	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
and	B-X
distribution	B-X
of	B-X
NLRP3	B-X
,	B-X
Dectin-1	B-X
,	B-X
Syk	B-X
,	B-X
MyD88	B-X
,	B-X
TLR2	B-X
,	B-X
and	B-X
TLR4	B-X
in	B-X
vaginal	B-X
tissues	B-X
were	B-X
determined	B-X
with	B-X
the	B-X
immunohistochemical	B-X
method	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
BAEB	B-X
can	B-X
improve	B-X
the	B-X
general	B-X
conditions	B-X
of	B-X
VVC	B-X
mice	B-X
,	B-X
reduce	B-X
the	B-X
fungal	B-X
load	B-X
and	B-X
C.	B-X
albicans	B-X
hyphae	B-X
in	B-X
vaginal	B-X
secretion	B-X
,	B-X
decrease	B-X
ROS	B-X
content	B-X
in	B-X
vaginal	B-X
tissues	B-X
and	B-X
content	B-X
of	B-X
cytokines	B-X
in	B-X
vaginal	B-X
lavage	B-X
fluid	B-X
,	B-X
and	B-X
down-regulate	B-X
the	B-X
expression	B-X
of	B-X
NLRP3	B-X
,	B-X
ASC	B-X
,	B-X
caspase-1	B-X
,	B-X
Dectin-1	B-X
,	B-X
Syk	B-X
,	B-X
MyD88	B-X
,	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
and	B-X
NF-κB	B-X
in	B-X
vaginal	B-X
tissues	B-X
.	B-X
The	B-X
above	B-X
results	B-X
indicate	B-X
that	B-X
BAEB	B-X
exerts	B-X
therapeutic	B-X
effect	B-X
on	B-X
VVC	B-X
mice	B-X
by	B-X
down-regulating	B-X
the	B-X
key	B-X
proteins	B-X
in	B-X
the	B-X
TLRs/MyD88	B-X
and	B-X
Dectin-1/Syk	B-X
signal	B-X
pathways	B-X
and	B-X
NLRP3	B-X
inflammasome	B-X
.	B-X

The	O
expression	O
of	O
TLR4	B-Protein
significantly	O
increased	O
starting	O
from	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
the	O
3rd	O
day	O
after	O
ICH	O
,	O
and	O
then	O
decreased	O
but	O
still	O
maintained	O
at	O
a	O
high	O
level	O
on	O
the	O
7th	O
day	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
2	O
)	O
.	O

This	O
observation	O
of	O
TLR4	B-Protein
protein	O
was	O
consistent	O
with	O
the	O
temporal	O
profile	O
of	O
the	O
TLR4	B-Protein
mRNA	O
after	O
ICH	O
.	O

3	O
.	O
3	O
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Distribution	O
of	O
TLR4	B-Protein
in	O
Brain	O
Subjected	O
to	O
ICH	O

To	O
explore	O
the	O
distribution	O
of	O
TLR4	B-Protein
protein	O
,	O
the	O
TLR4	B-Protein
was	O
detected	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Results	O
showed	O
that	O
TLR4	B-Protein
immunoreactivity	O
was	O
not	O
detectable	O
in	O
brain	O
tissue	O
from	O
normal	O
and	O
sham	O
control	O
.	O
<EOS>	B-X
Shuangxinfang	B-X
Prevents	B-X
S100A9-Induced	B-X
Macrophage/Microglial	B-X
Inflammation	B-X
to	B-X
Improve	B-X
Cardiac	B-X
Function	B-X
and	B-X
Depression-Like	B-X
Behavior	B-X
in	B-X
Rats	B-X
After	B-X
Acute	B-X
Myocardial	B-X
Infarction	B-X
.	B-X
The	B-X
Wolffian	B-X
duct	B-X
(	B-X
WD	B-X
)	B-X
is	B-X
an	B-X
embryonic	B-X
tissue	B-X
that	B-X
undergoes	B-X
androgen-induced	B-X
morphological	B-X
changes	B-X
to	B-X
become	B-X
the	B-X
epididymis	B-X
.	B-X
Toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
-	B-X
and	B-X
nuclear	B-X
factor	B-X
kB	B-X
(	B-X
NFKB	B-X
)	B-X
-induced	B-X
effectors	B-X
are	B-X
expressed	B-X
in	B-X
the	B-X
adult	B-X
epididymis	B-X
and	B-X
represent	B-X
important	B-X
players	B-X
in	B-X
epididymal	B-X
innate	B-X
immune	B-X
responses	B-X
.	B-X
TLR4/NFKB	B-X
signaling	B-X
pathway	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
and	B-X
plays	B-X
a	B-X
critical	B-X
morphogenetic	B-X
role	B-X
in	B-X
several	B-X
species	B-X
;	B-X
however	B-X
,	B-X
its	B-X
function	B-X
during	B-X
WD	B-X
morphogenesis	B-X
is	B-X
unknown	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
TLR4/NFKB	B-X
pathway	B-X
plays	B-X
a	B-X
role	B-X
during	B-X
WD	B-X
development	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
TLR4	B-X
expression	B-X
and	B-X
regulation	B-X
of	B-X
TLR4-target	B-X
genes	B-X
during	B-X
rat	B-X
WD	B-X
morphogenesis	B-X
between	B-X
embryonic	B-X
days	B-X
(	B-X
e	B-X
)	B-X
17.5-20.5	B-X
.	B-X
The	B-X
functionality	B-X
of	B-X
TLR4/NFKB	B-X
signaling	B-X
was	B-X
examined	B-X
using	B-X
WD	B-X
organotypic	B-X
cultures	B-X
treated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
from	B-X
E.	B-X
coli	B-X
(	B-X
TLR4	B-X
agonist	B-X
)	B-X
and	B-X
PDTC	B-X
(	B-X
NFKB	B-X
inhibitor	B-X
)	B-X
.	B-X
TLR4	B-X
was	B-X
detected	B-X
at	B-X
mRNA	B-X
level	B-X
in	B-X
e17.5	B-X
(	B-X
uncoiled	B-X
duct	B-X
)	B-X
and	B-X
e20.5	B-X
(	B-X
coiled	B-X
duct	B-X
)	B-X
WDs	B-X
,	B-X
and	B-X
spatio-temporal	B-X
changes	B-X
in	B-X
TLR4	B-X
immunoreactivity	B-X
were	B-X
observed	B-X
between	B-X
these	B-X
two	B-X
time	B-X
points	B-X
.	B-X
Expression	B-X
level	B-X
analysis	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
TLR4-regulated	B-X
genes	B-X
showed	B-X
that	B-X
TLR4/NFKB	B-X
pathway	B-X
was	B-X
activated	B-X
after	B-X
exposure	B-X
of	B-X
cultured	B-X
WD	B-X
to	B-X
LPS	B-X
(	B-X
4	B-X
h	B-X
)	B-X
,	B-X
an	B-X
event	B-X
that	B-X
was	B-X
abrogated	B-X
by	B-X
PDTC	B-X
.	B-X
Our	B-X
results	B-X
unveil	B-X
the	B-X
epididymal	B-X
morphogenesis	B-X
as	B-X
an	B-X
event	B-X
equipped	B-X
with	B-X
TLR4/NFKB	B-X
signaling	B-X
components	B-X
that	B-X
may	B-X
serve	B-X
developmental	B-X
functions	B-X
,	B-X
and	B-X
eventually	B-X
transition	B-X
to	B-X
host	B-X
defense	B-X
function	B-X
when	B-X
the	B-X
fetus	B-X
is	B-X
exposed	B-X
to	B-X
an	B-X
infectious	B-X
or	B-X
noninfectious	B-X
threat	B-X
.	B-X

However	O
,	O
immunoreactivity	O
for	O
TLR4	B-Protein
was	O
consistently	O
demonstrated	O
in	O
peri	O
-	O
hemorrhage	O
areas	O
,	O
the	O
hippocampus	O
,	O
cortex	O
,	O
thalamic	O
nuclei	O
,	O
and	O
some	O
white	O
matter	O
tracts	O
(	O
Figure	O
3	O
)	O
.	O

3	O
.	O
4	O
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Activation	O
of	O
TLR4	B-Protein
-	O
Mediated	O
NF	O
-	O
Kappa	O
-	O
B	O
Signaling	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
regulatory	B-X
mechanism	B-X
of	B-X
the	B-X
gut	B-X
flora	B-X
in	B-X
the	B-X
host	B-X
defense	B-X
against	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-induced	B-X
ALI	B-X
through	B-X
the	B-X
TLR4/NF-kB	B-X
pathway	B-X
by	B-X
constructing	B-X
a	B-X
gut	B-X
microflora	B-X
dysbiosis-model	B-X
with	B-X
antibiotic	B-X
administration	B-X
and	B-X
reconstruction	B-X
of	B-X
the	B-X
intestinal	B-X
microecology	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
TLR4	B-X
,	B-X
NF-kB	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
oxidative	B-X
stress	B-X
and	B-X
the	B-X
lung	B-X
wet/dry	B-X
(	B-X
W/D	B-X
)	B-X
ratio	B-X
were	B-X
evaluated	B-X
to	B-X
assess	B-X
lung	B-X
damage	B-X
.	B-X
Accordingly	B-X
,	B-X
gut	B-X
microbiota	B-X
imbalance	B-X
may	B-X
regulate	B-X
the	B-X
TLR4/NF-kB	B-X
signaling	B-X
pathway	B-X
in	B-X
the	B-X
lung	B-X
immune	B-X
system	B-X
,	B-X
activating	B-X
oxidative	B-X
stress	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
mediating	B-X
lung	B-X
injury	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
gut	B-X
barrier	B-X
.	B-X
However	B-X
,	B-X
fecal	B-X
microbiota	B-X
transplantation	B-X
(	B-X
FMT	B-X
)	B-X
impairs	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
TLR4/NF-kB	B-X
signaling	B-X
pathway	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
decreases	B-X
oxidative	B-X
stress	B-X
in	B-X
animals	B-X
with	B-X
ALI	B-X
by	B-X
restoring	B-X
the	B-X
gut	B-X
microecology	B-X
.	B-X
CONCLUSIONS	B-X
:	B-X
Our	B-X
results	B-X
indicated	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
gut	B-X
flora	B-X
in	B-X
regulating	B-X
immunity	B-X
of	B-X
LPS-induced	B-X
ALI	B-X
by	B-X
modulating	B-X
the	B-X
TLR4/NF-kB	B-X
signaling	B-X
pathway	B-X
which	B-X
may	B-X
induce	B-X
inflammation	B-X
and	B-X
oxidative	B-X
stress	B-X
.	B-X

Activation	O
of	O
TLR4	B-Protein
induces	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
IkappaB	O
)	O
,	O
which	O
dissociates	O
IkappaB	O
with	O
NF	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
.	O

Then	O
,	O
NFkappaB	O
translocates	O
into	O
the	O
nucleus	O
and	O
activates	O
and	O
regulates	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
inflammatory	O
responses	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
unilateral	B-X
ureteric	B-X
obstruction	B-X
model	B-X
in	B-X
proximal	B-X
tubule-specific	B-X
autophagy-deficient	B-X
mice	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
ablation	B-X
of	B-X
epithelial	B-X
ATG5	B-X
genes	B-X
markedly	B-X
impaired	B-X
autophagy	B-X
,	B-X
resulting	B-X
in	B-X
enhanced	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
activation	B-X
,	B-X
macrophage	B-X
and	B-X
lymphocyte	B-X
infiltration	B-X
,	B-X
and	B-X
proinflammatory	B-X
cytokines	B-X
production	B-X
in	B-X
obstructed	B-X
kidneys	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
wild-type	B-X
mice	B-X
.	B-X
Overexpressed	B-X
ATG5	B-X
,	B-X
but	B-X
not	B-X
the	B-X
autophagy-incompetent	B-X
ATG5	B-X
mutant	B-X
K130R	B-X
in	B-X
HK-2	B-X
cells	B-X
,	B-X
rendered	B-X
resistant	B-X
to	B-X
Ang	B-X
II-induced	B-X
inflammatory	B-X
response	B-X
.	B-X
Immunofluorescence	B-X
assay	B-X
indicated	B-X
that	B-X
ATG5	B-X
and	B-X
p65	B-X
colocalized	B-X
in	B-X
the	B-X
nucleus	B-X
and	B-X
cytoplasm	B-X
,	B-X
and	B-X
their	B-X
interaction	B-X
was	B-X
verified	B-X
in	B-X
immunoprecipitation	B-X
assay	B-X
from	B-X
HEK-293T	B-X
cell	B-X
extracts	B-X
.	B-X
Genetic	B-X
downregulation	B-X
of	B-X
endogenous	B-X
ATG5	B-X
increased	B-X
Ang	B-X
II-induced	B-X
phosphorylation	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
p65	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
whereas	B-X
the	B-X
overexpressed	B-X
ATG5	B-X
,	B-X
rather	B-X
than	B-X
ATG5	B-X
mutant	B-X
K130R	B-X
,	B-X
hampered	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
suggest	B-X
an	B-X
autophagy-dependent	B-X
anti-inflammatory	B-X
effect	B-X
of	B-X
ATG5	B-X
.	B-X

To	O
detectd	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
,	O
the	O
phosphorylation	O
of	O
inhibitor	O
of	O
kappa	O
-	O
B	O
(	O
p	O
-	O
IkappaB	O
)	O
and	O
activity	O
of	O
NFkappaB	O
were	O
measured	O
by	O
methods	O
of	O
Western	O
Blots	O
and	O
EMSA	O
.	O

Results	O
showed	O
that	O
the	O
p	O
-	O
IkappaB	O
increased	O
at	O
6	O
hours	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
peaked	O
on	O
3	O
days	O
after	O
ICH	O
,	O
and	O
maintained	O
a	O
high	O
level	O
on	O
7	O
days	O
after	O
ICH	O
(	O
P	O
<	O
.	O
05	O
,	O
Figure	O
5	O
)	O
.	O

As	O
expected	O
,	O
the	O
activity	O
of	O
NFkappaB	O
was	O
also	O
increased	O
in	O
the	O
same	O
manner	O
as	O
that	O
of	O
the	O
p	O
-	O
IkappaB	O
(	O
Figure	O
4	O
)	O
.	O

Intra	O
-	O
cerebral	O
hemorrhage	O
(	O
ICH	O
)	O
represents	O
10	O
-	O
15	O
%	O
of	O
all	O
strokes	O
,	O
and	O
occurs	O
with	O
increasing	O
frequency	O
as	O
a	O
complication	O
of	O
the	O
thrombolytic	O
treatment	O
of	O
ischemic	O
stroke	O
[	O
1	O
]	O
.	O

The	O
mortality	O
of	O
ICH	O
is	O
higher	O
than	O
that	O
of	O
ischemic	O
stroke	O
.	O
<EOS>	B-X
Alteplase	B-X
is	B-X
an	B-X
approved	B-X
treatment	B-X
for	B-X
acute	B-X
ischemic	B-X
stroke	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
both	B-X
drugs	B-X
in	B-X
adult	B-X
patients	B-X
with	B-X
acute	B-X
ischemic	B-X
stroke	B-X
undergoing	B-X
thrombolysis	B-X
.	B-X
Spontaneous	B-X
non-traumatic	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
has	B-X
a	B-X
worse	B-X
prognosis	B-X
than	B-X
ischemic	B-X
stroke	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
was	B-X
to	B-X
update	B-X
the	B-X
reader	B-X
on	B-X
epidemiology	B-X
,	B-X
prognosis	B-X
and	B-X
secondary	B-X
prevention	B-X
strategies	B-X
of	B-X
ICH	B-X
.	B-X

Only	O
31	O
%	O
are	O
functionally	O
independent	O
at	O
3	O
months	O
.	O
<EOS>	B-X
Subjects	B-X
in	B-X
DIET	B-X
and	B-X
RT+DIET	B-X
were	B-X
provided	B-X
with	B-X
daily	B-X
macronutrient	B-X
and	B-X
calorie	B-X
goals	B-X
based	B-X
on	B-X
DXA	B-X
and	B-X
RMR	B-X
tests	B-X
,	B-X
with	B-X
protein	B-X
maintained	B-X
at	B-X
3.1	B-X
g/kg/day	B-X
.	B-X
Only	B-X
31	B-X
%	B-X
are	B-X
functionally	B-X
independent	B-X
at	B-X
3	B-X
months	B-X
.	B-X
Only	B-X
38	B-X
%	B-X
of	B-X
the	B-X
patients	B-X
survive	B-X
the	B-X
1	B-X
(	B-X
st	B-X
)	B-X
year	B-X
.	B-X
ICH	B-X
has	B-X
3	B-X
main	B-X
pathophysiological	B-X
phases	B-X
:	B-X
arterial	B-X
rupture	B-X
and	B-X
haematoma	B-X
formation	B-X
,	B-X
haematoma	B-X
enlargement	B-X
and	B-X
peri-haematoma	B-X
oedema	B-X
.	B-X

Only	O
38	O
%	O
of	O
the	O
patients	O
survive	O
the	O
1st	O
year	O
[	O
10	O
]	O
.	O

Unfortunately	O
,	O
the	O
method	O
for	O
treatment	O
of	O
this	O
disease	O
and	O
protection	O
of	O
the	O
brain	O
tissue	O
after	O
ICH	O
are	O
not	O
effective	O
.	O

Mass	O
effect	O
,	O
ischemia	O
,	O
and	O
toxicity	O
of	O
blood	O
components	O
after	O
ICH	O
induce	O
brain	O
tissue	O
damage	O
.	O

In	O
addition	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
inflammatory	O
processes	O
are	O
involved	O
in	O
cerebrovascular	O
events	O
.	O
<EOS>	B-X
The	B-X
global	B-X
burden	B-X
of	B-X
cerebrovascular	B-X
disease	B-X
,	B-X
especially	B-X
cerebral	B-X
infarction	B-X
has	B-X
been	B-X
increasing	B-X
at	B-X
an	B-X
alarming	B-X
rate	B-X
with	B-X
the	B-X
atherosclerosis	B-X
in	B-X
carotid	B-X
arteries	B-X
as	B-X
the	B-X
primary	B-X
risk	B-X
factor	B-X
.	B-X
Despite	B-X
the	B-X
active	B-X
involvement	B-X
of	B-X
minimally	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
in	B-X
atherosclerosis	B-X
,	B-X
limited	B-X
information	B-X
is	B-X
available	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
oxLDL	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
cerebrovascular	B-X
diseases	B-X
.	B-X
The	B-X
present	B-X
study	B-X
utilized	B-X
the	B-X
carotid	B-X
bifurcation	B-X
tissues	B-X
and	B-X
isolated	B-X
carotid	B-X
SMCs	B-X
challenged	B-X
with	B-X
oxLDL	B-X
from	B-X
clinically	B-X
relevant	B-X
minimally	B-X
invasive	B-X
minimally-oxLDL-induced	B-X
carotid	B-X
atheroma	B-X
microswine	B-X
model	B-X
to	B-X
examine	B-X
the	B-X
levels	B-X
of	B-X
pro-atherogenic	B-X
and	B-X
pro-inflammatory	B-X
mediators	B-X
and	B-X
cellular	B-X
processes	B-X
following	B-X
immunostaining	B-X
approaches	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
SMCs	B-X
treated	B-X
with	B-X
oxLDL	B-X
were	B-X
resistant	B-X
to	B-X
the	B-X
peroxidation	B-X
of	B-X
lipids	B-X
as	B-X
evident	B-X
from	B-X
lipid	B-X
peroxidation	B-X
staining	B-X
.	B-X
Overall	B-X
,	B-X
oxLDL	B-X
alters	B-X
the	B-X
expression	B-X
status	B-X
of	B-X
pathological	B-X
mediators	B-X
and	B-X
multiple	B-X
biological	B-X
processes	B-X
in	B-X
carotid	B-X
SMCs	B-X
aggravating	B-X
carotid	B-X
atherosclerosis	B-X
.	B-X
The	B-X
understanding	B-X
regarding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
oxLDL-driven	B-X
pathological	B-X
events	B-X
would	B-X
open	B-X
novel	B-X
translational	B-X
avenues	B-X
in	B-X
the	B-X
management	B-X
of	B-X
carotid	B-X
atherosclerosis	B-X
.	B-X

After	O
ICH	O
,	O
inflammatory	O
mediators	O
from	O
the	O
blood	O
might	O
enter	O
to	O
the	O
brain	O
and	O
induce	O
an	O
inflammatory	O
reaction	O
and	O
the	O
brain	O
cells	O
itself	O
are	O
also	O
capable	O
of	O
producing	O
many	O
of	O
these	O
agents	O
[	O
11	O
]	O
.	O

The	O
inflammatory	O
responses	O
are	O
responsible	O
for	O
the	O
ICH	O
induced	O
brain	O
injury	O
,	O
which	O
could	O
provide	O
new	O
therapeutic	O
targets	O
for	O
ICH	O
.	O

Various	O
constituents	O
of	O
the	O
inflammatory	O
response	O
,	O
including	O
adhesion	O
molecules	O
,	O
cytokines	O
,	O
leukocytes	O
,	O
immunoglobulins	O
,	O
and	O
complement	O
,	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
.	O

However	O
,	O
how	O
the	O
inflammatory	O
responses	O
is	O
activated	O
and	O
regulated	O
in	O
the	O
brain	O
tissue	O
after	O
ICH	O
is	O
unclear	O
.	O
<EOS>	B-X
Interleukin-18	B-X
(	B-X
IL-18	B-X
)	B-X
,	B-X
a	B-X
pro-inflammatory	B-X
cytokine	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
inflammation	B-X
in	B-X
many	B-X
neurological	B-X
diseases	B-X
such	B-X
as	B-X
ischemic	B-X
stroke	B-X
and	B-X
poststroke	B-X
depression	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
IL-18	B-X
in	B-X
inflammatory	B-X
injury	B-X
after	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
remains	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
established	B-X
the	B-X
ICH	B-X
model	B-X
in	B-X
male	B-X
mice	B-X
and	B-X
found	B-X
that	B-X
IL-18	B-X
expression	B-X
including	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
brain	B-X
tissues	B-X
after	B-X
ICH	B-X
.	B-X
Meanwhile	B-X
,	B-X
exogenous	B-X
IL-18	B-X
exacerbated	B-X
cerebral	B-X
hematoma	B-X
and	B-X
neurological	B-X
deficits	B-X
following	B-X
ICH	B-X
.	B-X
In	B-X
the	B-X
IL-18	B-X
knockout	B-X
group	B-X
,	B-X
the	B-X
size	B-X
of	B-X
hematoma	B-X
and	B-X
neurological	B-X
functions	B-X
after	B-X
ICH	B-X
was	B-X
decreased	B-X
compared	B-X
with	B-X
the	B-X
wild-type	B-X
group	B-X
,	B-X
suggesting	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
IL-18	B-X
on	B-X
the	B-X
modulation	B-X
of	B-X
brain	B-X
injury	B-X
after	B-X
ICH	B-X
.	B-X
Importantly	B-X
,	B-X
exogenous	B-X
IL-18	B-X
increased	B-X
microglial	B-X
activation	B-X
in	B-X
brain	B-X
tissues	B-X
after	B-X
ICH	B-X
.	B-X
Furthermore	B-X
,	B-X
IL-18	B-X
knockout	B-X
resulted	B-X
in	B-X
the	B-X
reduction	B-X
of	B-X
activated	B-X
microglia	B-X
after	B-X
ICH	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
IL-18	B-X
may	B-X
regulate	B-X
the	B-X
inflammatory	B-X
response	B-X
after	B-X
ICH	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
microglia	B-X
.	B-X
Thus	B-X
,	B-X
IL-18	B-X
is	B-X
expected	B-X
to	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
target	B-X
for	B-X
secondary	B-X
brain	B-X
injury	B-X
after	B-X
ICH	B-X
.	B-X

Transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
-	O
B	O
(	O
NFkappaB	O
)	O
is	O
an	O
important	O
nuclear	O
transcription	O
factor	O
,	O
which	O
initiates	O
transcription	O
of	O
genes	O
associated	O
with	O
immune	O
responses	O
and	O
inflammation	O
[	O
12	O
,	O
13	O
]	O
and	O
also	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
inflammation	O
in	O
brain	O
pathologies	O
.	O

It	O
has	O
been	O
reported	O
that	O
NFkappaB	O
increased	O
in	O
the	O
region	O
of	O
perihematoma	O
after	O
ICH	O
[	O
14	O
]	O
.	O

NFkappaB	O
activation	O
occurs	O
within	O
minutes	O
and	O
persists	O
for	O
at	O
least	O
a	O
week	O
in	O
response	O
to	O
ICH	O
,	O
which	O
is	O
associated	O
with	O
the	O
expression	O
of	O
selected	O
target	O
genes	O
[	O
15	O
]	O
.	O
<EOS>	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
temporal	B-X
changes	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
NF-kappaB	B-X
subunit	B-X
expression	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
selected	B-X
NF-kappaB-regulated	B-X
gene	B-X
products	B-X
[	B-X
inducible	B-X
form	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
and	B-X
cyclooxygenase-2	B-X
]	B-X
,	B-X
at	B-X
the	B-X
transcriptional	B-X
and	B-X
translational	B-X
level	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
.	B-X
Employing	B-X
the	B-X
intrastriatal	B-X
injection	B-X
of	B-X
autologous	B-X
blood	B-X
in	B-X
rats	B-X
to	B-X
model	B-X
ICH	B-X
,	B-X
we	B-X
demonstrated	B-X
,	B-X
using	B-X
NF-kappaB-DNA	B-X
binding	B-X
assay	B-X
,	B-X
a	B-X
robust	B-X
and	B-X
prolonged	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
starting	B-X
as	B-X
early	B-X
as	B-X
15	B-X
min	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
ICH	B-X
.	B-X
Consequently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
for	B-X
p50	B-X
,	B-X
p52	B-X
,	B-X
p65	B-X
,	B-X
c-Rel	B-X
,	B-X
and	B-X
RelB	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
as	B-X
well	B-X
as	B-X
IkappaBalpha	B-X
were	B-X
all	B-X
up-regulated	B-X
,	B-X
with	B-X
a	B-X
time	B-X
course	B-X
ranging	B-X
from	B-X
minutes	B-X
to	B-X
days	B-X
following	B-X
ICH	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
subunit	B-X
.	B-X
Using	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
to	B-X
analyze	B-X
mRNA	B-X
and	B-X
immunoblotting	B-X
to	B-X
analyze	B-X
protein	B-X
in	B-X
ICH-affected	B-X
tissue	B-X
,	B-X
we	B-X
found	B-X
robust	B-X
induction	B-X
of	B-X
iNOS	B-X
at	B-X
both	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
that	B-X
followed	B-X
a	B-X
time-course	B-X
similar	B-X
to	B-X
changes	B-X
in	B-X
p65	B-X
,	B-X
p52	B-X
,	B-X
and	B-X
RelB	B-X
mRNA	B-X
.	B-X
Oddly	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
iNOS	B-X
,	B-X
cyclooxygenase-2	B-X
mRNA	B-X
and	B-X
protein	B-X
following	B-X
an	B-X
early	B-X
transient	B-X
increase	B-X
demonstrated	B-X
significant	B-X
reduction	B-X
in	B-X
response	B-X
to	B-X
ICH	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
NF-kappaB	B-X
activation	B-X
occurs	B-X
within	B-X
minutes	B-X
and	B-X
persists	B-X
for	B-X
at	B-X
least	B-X
a	B-X
week	B-X
in	B-X
response	B-X
to	B-X
ICH	B-X
.	B-X
This	B-X
reaction	B-X
utilizes	B-X
different	B-X
NF-kappaB	B-X
regulatory	B-X
subunits	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
selected	B-X
target	B-X
genes	B-X
.	B-X

Activation	O
of	O
NFkappaB	O
initiates	O
inflammatory	O
responses	O
and	O
contributes	O
to	O
the	O
pathobiology	O
of	O
perilesional	O
cell	O
death	O
after	O
ICH	O
[	O
16	O
]	O
.	O

Inhibition	O
of	O
NFkappaB	O
activity	O
has	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
on	O
experimental	O
ICH	O
,	O
such	O
as	O
reduce	O
inflammation	O
,	O
behavioral	O
dysfunction	O
,	O
and	O
neuronal	O
damage	O
produced	O
by	O
ICH	O
[	O
17	O
]	O
.	O

The	O
knowledge	O
about	O
how	O
NFkappaB	O
is	O
activated	O
in	O
the	O
brain	O
subjected	O
to	O
ICH	O
is	O
critical	O
for	O
seeking	O
a	O
new	O
neuroprotective	O
method	O
for	O
ICH	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
are	O
a	O
family	O
of	O
signal	O
transduction	O
molecules	O
and	O
play	O
a	O
critical	O
role	O
in	O
the	O
induction	O
of	O
innate	O
and	O
adaptive	O
immunity	O
[	O
4	O
]	O
.	O

TLR	O
-	O
mediated	O
signaling	O
pathways	O
mainly	O
stimulate	O
the	O
activation	O
of	O
NFkappaB	O
[	O
12	O
,	O
13	O
]	O
.	O
<EOS>	B-X
It	B-X
is	B-X
well	B-X
known	B-X
that	B-X
localized	B-X
acupuncture-mediated	B-X
anti-inflammatory	B-X
effects	B-X
involve	B-X
the	B-X
regulation	B-X
of	B-X
multiple	B-X
populations	B-X
and	B-X
functions	B-X
of	B-X
immune	B-X
cells	B-X
,	B-X
including	B-X
macrophages	B-X
,	B-X
granulocytes	B-X
,	B-X
mast	B-X
cells	B-X
,	B-X
and	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
acupuncture	B-X
stimulation	B-X
,	B-X
macrophages	B-X
transform	B-X
from	B-X
the	B-X
M1	B-X
to	B-X
the	B-X
M2	B-X
phenotype	B-X
and	B-X
the	B-X
negative	B-X
TLR4	B-X
regulator	B-X
PPARγ	B-X
is	B-X
activated	B-X
to	B-X
inhibit	B-X
the	B-X
intracellular	B-X
TLR/MyD88	B-X
and	B-X
NOD	B-X
signaling	B-X
pathways	B-X
.	B-X
The	B-X
downstream	B-X
IκBα/NF-κB	B-X
and	B-X
P38	B-X
MAPK	B-X
pathways	B-X
are	B-X
subsequently	B-X
inhibited	B-X
by	B-X
acupuncture	B-X
,	B-X
followed	B-X
by	B-X
suppressed	B-X
production	B-X
of	B-X
inflammasome	B-X
and	B-X
proinflammatory	B-X
mediators	B-X
.	B-X
As	B-X
part	B-X
of	B-X
its	B-X
anti-inflammatory	B-X
action	B-X
,	B-X
acupuncture	B-X
deforms	B-X
connective	B-X
tissue	B-X
and	B-X
upregulates	B-X
the	B-X
secretion	B-X
of	B-X
various	B-X
molecules	B-X
in	B-X
acupoints	B-X
,	B-X
further	B-X
activating	B-X
the	B-X
NF-κB	B-X
,	B-X
MAPK	B-X
,	B-X
and	B-X
ERK	B-X
pathways	B-X
in	B-X
mast	B-X
cells	B-X
,	B-X
fibroblasts	B-X
,	B-X
keratinocytes	B-X
,	B-X
and	B-X
monocytes/macrophages	B-X
.	B-X
Upon	B-X
information	B-X
integration	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
acupuncture	B-X
further	B-X
stimulates	B-X
multiple	B-X
neuro-immune	B-X
pathways	B-X
,	B-X
including	B-X
the	B-X
cholinergic	B-X
anti-inflammatory	B-X
,	B-X
vagus-adrenal	B-X
medulla-dopamine	B-X
,	B-X
and	B-X
sympathetic	B-X
pathways	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hypothalamus-pituitary-adrenal	B-X
axis	B-X
,	B-X
ultimately	B-X
acting	B-X
immune	B-X
cells	B-X
via	B-X
the	B-X
release	B-X
of	B-X
crucial	B-X
neurotransmitters	B-X
and	B-X
hormones	B-X
.	B-X

TLR4	B-Protein
,	O
the	O
first	O
mammalian	O
TLR	O
recognized	O
,	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
several	O
central	O
nervous	O
(	O
CNS	O
)	O
system	O
diseases	O
,	O
such	O
as	O
inflammatory	O
or	O
autoimmune	O
CNS	O
diseases	O
and	O
cerebral	O
ischemic	O
injury	O
[	O
7	O
,	O
8	O
]	O
.	O
<EOS>	B-X
Ischemic	B-X
stroke	B-X
,	B-X
which	B-X
accounts	B-X
for	B-X
75-80	B-X
%	B-X
of	B-X
all	B-X
strokes	B-X
,	B-X
is	B-X
the	B-X
predominant	B-X
cause	B-X
of	B-X
morbidity	B-X
and	B-X
mortality	B-X
worldwide	B-X
.	B-X
The	B-X
post-stroke	B-X
immune	B-X
response	B-X
has	B-X
recently	B-X
emerged	B-X
as	B-X
a	B-X
new	B-X
breakthrough	B-X
target	B-X
in	B-X
the	B-X
treatment	B-X
strategy	B-X
for	B-X
ischemic	B-X
stroke	B-X
.	B-X
Glial	B-X
cells	B-X
,	B-X
including	B-X
microglia	B-X
,	B-X
astrocytes	B-X
,	B-X
and	B-X
oligodendrocytes	B-X
,	B-X
are	B-X
the	B-X
primary	B-X
components	B-X
of	B-X
the	B-X
peri-infarct	B-X
environment	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
and	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
post-stroke	B-X
immune	B-X
regulation	B-X
.	B-X
However	B-X
,	B-X
increasing	B-X
evidence	B-X
suggests	B-X
that	B-X
glial	B-X
cells	B-X
exert	B-X
beneficial	B-X
and	B-X
detrimental	B-X
effects	B-X
during	B-X
ischemic	B-X
stroke	B-X
.	B-X
Microglia	B-X
,	B-X
which	B-X
survey	B-X
CNS	B-X
homeostasis	B-X
and	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
,	B-X
are	B-X
rapidly	B-X
activated	B-X
after	B-X
ischemic	B-X
stroke	B-X
.	B-X
Activated	B-X
microglia	B-X
release	B-X
inflammatory	B-X
cytokines	B-X
that	B-X
induce	B-X
neuronal	B-X
tissue	B-X
injury	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
and	B-X
neurotrophic	B-X
factors	B-X
secreted	B-X
by	B-X
alternatively	B-X
activated	B-X
microglia	B-X
are	B-X
beneficial	B-X
for	B-X
recovery	B-X
after	B-X
ischemic	B-X
stroke	B-X
.	B-X
Astrocyte	B-X
activation	B-X
and	B-X
reactive	B-X
gliosis	B-X
in	B-X
ischemic	B-X
stroke	B-X
contribute	B-X
to	B-X
limiting	B-X
brain	B-X
injury	B-X
and	B-X
re-establishing	B-X
CNS	B-X
homeostasis	B-X
.	B-X
Myelin-associated	B-X
antigens	B-X
released	B-X
from	B-X
oligodendrocytes	B-X
activate	B-X
peripheral	B-X
T	B-X
cells	B-X
,	B-X
thereby	B-X
resulting	B-X
in	B-X
the	B-X
autoimmune	B-X
response	B-X
.	B-X
Oligodendrocyte	B-X
precursor	B-X
cells	B-X
,	B-X
which	B-X
can	B-X
differentiate	B-X
into	B-X
oligodendrocytes	B-X
,	B-X
follow	B-X
an	B-X
ischemic	B-X
stroke	B-X
and	B-X
may	B-X
result	B-X
in	B-X
functional	B-X
recovery	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
potential	B-X
roles	B-X
of	B-X
various	B-X
glial	B-X
cells	B-X
at	B-X
different	B-X
stages	B-X
of	B-X
ischemic	B-X
stroke	B-X
and	B-X
discuss	B-X
future	B-X
intervention	B-X
targets	B-X
.	B-X

Although	O
previous	O
reports	O
indicated	O
that	O
the	O
activation	O
of	O
NFkappaB	O
was	O
attributed	O
to	O
the	O
oxidative	O
stress	O
or	O
glutamate	O
receptor	O
activation	O
induced	O
by	O
red	O
blood	O
cells	O
and	O
/	O
or	O
plasma	O
constituents	O
[	O
17	O
]	O
,	O
very	O
few	O
studies	O
have	O
been	O
directed	O
to	O
investigate	O
the	O
role	O
and	O
the	O
relationship	O
between	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
and	O
ICH	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
high	B-X
metabolic	B-X
demands	B-X
of	B-X
brain	B-X
cells	B-X
require	B-X
iron	B-X
as	B-X
a	B-X
redox-active	B-X
metal	B-X
for	B-X
ATP-producing	B-X
enzymes	B-X
,	B-X
the	B-X
brain	B-X
is	B-X
highly	B-X
vulnerable	B-X
to	B-X
the	B-X
devastating	B-X
consequences	B-X
of	B-X
excessive	B-X
iron-induced	B-X
oxidative	B-X
stress	B-X
and	B-X
,	B-X
as	B-X
recently	B-X
found	B-X
,	B-X
to	B-X
ferroptosis	B-X
as	B-X
well	B-X
.	B-X
The	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
protects	B-X
the	B-X
brain	B-X
from	B-X
fluctuations	B-X
in	B-X
systemic	B-X
iron	B-X
.	B-X
Under	B-X
pathological	B-X
conditions	B-X
,	B-X
especially	B-X
in	B-X
acute	B-X
brain	B-X
pathologies	B-X
such	B-X
as	B-X
stroke	B-X
,	B-X
the	B-X
BBB	B-X
is	B-X
disrupted	B-X
,	B-X
and	B-X
iron	B-X
pools	B-X
from	B-X
the	B-X
blood	B-X
gain	B-X
sudden	B-X
access	B-X
to	B-X
the	B-X
brain	B-X
parenchyma	B-X
,	B-X
which	B-X
is	B-X
crucial	B-X
in	B-X
mediating	B-X
stroke-induced	B-X
neurodegeneration	B-X
.	B-X
However	B-X
,	B-X
during	B-X
ischemia	B-X
,	B-X
neurons	B-X
are	B-X
challenged	B-X
with	B-X
excess	B-X
extracellular	B-X
glutamate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
high	B-X
levels	B-X
of	B-X
extracellular	B-X
iron	B-X
;	B-X
this	B-X
causes	B-X
glutamate	B-X
receptor	B-X
overactivation	B-X
that	B-X
boosts	B-X
neuronal	B-X
iron	B-X
uptake	B-X
and	B-X
a	B-X
subsequent	B-X
overproduction	B-X
of	B-X
membrane	B-X
peroxides	B-X
.	B-X
This	B-X
glutamate-driven	B-X
neuronal	B-X
death	B-X
can	B-X
be	B-X
attenuated	B-X
by	B-X
iron-chelating	B-X
compounds	B-X
or	B-X
free	B-X
radical	B-X
scavenger	B-X
molecules	B-X
.	B-X
Moreover	B-X
,	B-X
vascular	B-X
wall	B-X
rupture	B-X
in	B-X
hemorrhagic	B-X
stroke	B-X
results	B-X
in	B-X
the	B-X
accumulation	B-X
and	B-X
lysis	B-X
of	B-X
iron-rich	B-X
red	B-X
blood	B-X
cells	B-X
at	B-X
the	B-X
brain	B-X
parenchyma	B-X
and	B-X
the	B-X
subsequent	B-X
presence	B-X
of	B-X
hemoglobin	B-X
and	B-X
heme	B-X
iron	B-X
at	B-X
the	B-X
extracellular	B-X
milieu	B-X
,	B-X
thereby	B-X
contributing	B-X
to	B-X
iron-induced	B-X
lipid	B-X
peroxidation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
established	O
the	O
rat	O
model	O
of	O
experimental	O
ICH	O
and	O
detected	O
the	O
TLR4	B-Protein
mRNA	O
and	O
protein	O
.	O

Our	O
data	O
showed	O
that	O
transcription	O
of	O
TLR4	B-Protein
as	O
well	O
as	O
the	O
expression	O
of	O
TLR4	B-Protein
protein	O
after	O
ICH	O
significantly	O
elevated	O
in	O
brain	O
tissue	O
.	O

These	O
changes	O
started	O
as	O
early	O
as	O
6	O
hours	O
after	O
the	O
ICH	O
insult	O
and	O
maintained	O
at	O
a	O
high	O
level	O
for	O
7	O
days	O
afterward	O
.	O

The	O
TLR4	B-Protein
protein	O
,	O
detected	O
by	O
immunohistochemistry	O
,	O
was	O
consistently	O
distributed	O
in	O
peri	O
-	O
hemorrhage	O
areas	O
,	O
the	O
hippocampus	O
,	O
cortex	O
,	O
thalamic	O
nuclei	O
,	O
and	O
some	O
white	O
matter	O
tracts	O
.	O

These	O
data	O
indicated	O
that	O
increased	O
expression	O
of	O
TLR4	B-Protein
may	O
be	O
related	O
to	O
the	O
triggering	O
of	O
the	O
inflammatory	O
responses	O
in	O
the	O
brain	O
tissue	O
after	O
ICH	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
ICH	O
initiates	O
inflammatory	O
responses	O
,	O
which	O
are	O
associated	O
with	O
secondary	O
growth	O
of	O
hemorrhage	O
and	O
cell	O
death	O
[	O
18	O
]	O
.	O

It	O
is	O
now	O
believed	O
that	O
TLR4	B-Protein
-	O
mediated	O
-	O
NFkappaB	O
pathway	O
activates	O
and	O
regulates	O
immunological	O
and	O
inflammatory	O
responses	O
.	O

To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
increased	O
inflammatory	O
responses	O
in	O
the	O
brain	O
after	O
ICH	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
by	O
detecting	O
the	O
p	O
-	O
IkappaB	O
and	O
the	O
activity	O
of	O
NFkappaB	O
in	O
hemorrhagic	O
brains	O
.	O

NFkappaB	O
is	O
an	O
important	O
transcription	O
factor	O
downstream	O
in	O
the	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
pathway	O
.	O
<EOS>	B-X
With	B-X
the	B-X
development	B-X
of	B-X
high-throughput	B-X
screening	B-X
and	B-X
bioinformatics	B-X
technology	B-X
,	B-X
natural	B-X
products	B-X
with	B-X
a	B-X
range	B-X
of	B-X
pharmacological	B-X
targets	B-X
in	B-X
multiple	B-X
diseases	B-X
have	B-X
become	B-X
important	B-X
sources	B-X
of	B-X
new	B-X
drug	B-X
discovery	B-X
.	B-X
Baicalin	B-X
plays	B-X
a	B-X
therapeutic	B-X
role	B-X
mainly	B-X
by	B-X
mediating	B-X
downstream	B-X
apoptosis	B-X
and	B-X
immune	B-X
response	B-X
pathways	B-X
induced	B-X
by	B-X
upstream	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammation	B-X
.	B-X
During	B-X
oxidative	B-X
stress	B-X
regulation	B-X
,	B-X
PI3K/Akt/NRF2	B-X
,	B-X
Keap-1	B-X
,	B-X
NF-κB	B-X
and	B-X
HO-1	B-X
are	B-X
key	B-X
factors	B-X
associated	B-X
with	B-X
the	B-X
healing	B-X
effects	B-X
of	B-X
baicalin	B-X
on	B-X
NAFLD/NASH	B-X
,	B-X
ulcerative	B-X
colitis	B-X
and	B-X
cholestasis	B-X
.	B-X
Regarding	B-X
the	B-X
apoptosis	B-X
pathway	B-X
,	B-X
Bax	B-X
,	B-X
Bcl-2	B-X
,	B-X
Caspase-3	B-X
and	B-X
Caspase-9	B-X
are	B-X
key	B-X
factors	B-X
related	B-X
to	B-X
the	B-X
suppression	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
and	B-X
attenuation	B-X
of	B-X
liver	B-X
injury	B-X
and	B-X
colorectal	B-X
cancer	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
immune	B-X
regulation	B-X
,	B-X
PD-1/PDL-1	B-X
and	B-X
TLR4-NF-κB	B-X
are	B-X
correlated	B-X
with	B-X
the	B-X
alleviation	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
,	B-X
ulcerative	B-X
colitis	B-X
and	B-X
colorectal	B-X
cancer	B-X
by	B-X
baicalin	B-X
.	B-X
In	B-X
general	B-X
,	B-X
a	B-X
comprehensive	B-X
analysis	B-X
of	B-X
this	B-X
natural	B-X
compound	B-X
was	B-X
conducted	B-X
to	B-X
determine	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
it	B-X
regulates	B-X
bile	B-X
acid	B-X
metabolism	B-X
,	B-X
the	B-X
intestinal	B-X
flora	B-X
and	B-X
related	B-X
signaling	B-X
pathways	B-X
,	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
pharmacological	B-X
effects	B-X
of	B-X
baicalin	B-X
.	B-X

Activation	O
of	O
TLR4	B-Protein
stimulates	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
degradation	O
,	O
resulting	O
in	O
nuclear	O
translocation	O
of	O
NFkappaB	O
,	O
which	O
initiates	O
transcription	O
of	O
genes	O
associated	O
with	O
innate	O
immune	O
responses	O
and	O
inflammation	O
[	O
5	O
,	O
6	O
]	O
.	O

We	O
observed	O
that	O
the	O
levels	O
of	O
phosphorylation	O
of	O
IkappaB	O
and	O
the	O
activity	O
of	O
NFkappaB	O
were	O
significantly	O
increased	O
in	O
brain	O
tissue	O
after	O
ICH	O
.	O

The	O
temporal	O
profile	O
of	O
the	O
expression	O
of	O
p	O
-	O
IkappaB	O
and	O
the	O
activation	O
of	O
NFkappaB	O
was	O
similar	O
to	O
that	O
of	O
the	O
expression	O
of	O
TLR4	B-Protein
.	O

Our	O
data	O
suggest	O
that	O
ICH	O
stimulates	O
activation	O
of	O
the	O
TLR4	B-Protein
/	O
NFkappaB	O
signaling	O
pathway	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
that	O
activation	O
of	O
NFkappaB	O
is	O
regulated	O
through	O
the	O
TLR4	B-Protein
-	O
mediated	O
signaling	O
pathway	O
.	O

TLR4	B-Protein
plays	O
an	O
important	O
role	O
in	O
the	O
recognition	O
of	O
microbial	O
components	O
[	O
19	O
,	O
20	O
]	O
and	O
can	O
also	O
recognize	O
endogenous	O
molecules	O
such	O
as	O
the	O
degradation	O
products	O
of	O
macromolecules	O
,	O
products	O
of	O
proteolytic	O
cascades	O
,	O
intracellular	O
components	O
of	O
ruptured	O
cells	O
,	O
and	O
products	O
of	O
genes	O
that	O
are	O
activated	O
by	O
inflammation	O
.	O

For	O
instance	O
,	O
HSP70	B-Protein
,	O
HSP32	B-Protein
,	O
HSP27	B-Protein
,	O
and	O
enzymes	O
involved	O
in	O
oxidative	O
stress	O
are	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
brain	O
after	O
ICH	O
,	O
which	O
may	O
be	O
produced	O
by	O
injured	O
neuronal	O
cells	O
or	O
blood	O
cells	O
[	O
21	O
]	O
.	O
<EOS>	B-X
Current	B-X
evidence	B-X
suggests	B-X
that	B-X
ferroptosis	B-X
can	B-X
obviously	B-X
affect	B-X
the	B-X
function	B-X
of	B-X
blood	B-X
cells	B-X
.	B-X
This	B-X
paper	B-X
aims	B-X
to	B-X
elaborate	B-X
the	B-X
role	B-X
of	B-X
ferroptosis	B-X
in	B-X
blood	B-X
cells	B-X
and	B-X
related	B-X
diseases	B-X
.	B-X
First	B-X
,	B-X
abnormal	B-X
ferroptosis	B-X
damages	B-X
the	B-X
developing	B-X
red	B-X
blood	B-X
cells	B-X
by	B-X
breaking	B-X
systemic	B-X
iron	B-X
homeostasis	B-X
,	B-X
leading	B-X
to	B-X
erythropoiesis	B-X
suppression	B-X
and	B-X
anaemia	B-X
.	B-X
In	B-X
T-cells	B-X
,	B-X
ferroptosis	B-X
induces	B-X
a	B-X
novel	B-X
point	B-X
of	B-X
synergy	B-X
between	B-X
immunotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X
Additionally	B-X
,	B-X
ferroptosis	B-X
may	B-X
mediate	B-X
B	B-X
cells	B-X
differentiation	B-X
,	B-X
antibody	B-X
responses	B-X
and	B-X
lymphoma	B-X
.	B-X
Nevertheless	B-X
,	B-X
increased	B-X
ferroptosis	B-X
can	B-X
ameliorate	B-X
acute	B-X
myeloid	B-X
leukaemia	B-X
and	B-X
T-cell	B-X
leukaemia/lymphoma	B-X
by	B-X
inducing	B-X
iron-dependent	B-X
cancer	B-X
cells	B-X
death	B-X
.	B-X
Interestingly	B-X
,	B-X
ferroptosis	B-X
is	B-X
also	B-X
considered	B-X
as	B-X
a	B-X
critical	B-X
player	B-X
in	B-X
COVID-19	B-X
infections	B-X
,	B-X
while	B-X
targetting	B-X
ferroptosis	B-X
may	B-X
also	B-X
improve	B-X
thromboembolism	B-X
and	B-X
prognosis	B-X
in	B-X
patients	B-X
with	B-X
COVID-19	B-X
infection	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
crucial	B-X
role	B-X
of	B-X
ferroptosis	B-X
in	B-X
blood	B-X
cells	B-X
will	B-X
show	B-X
a	B-X
new	B-X
therapeutic	B-X
potential	B-X
in	B-X
blood	B-X
cell-related	B-X
diseases.HighlightsFerroptosis	B-X
shows	B-X
a	B-X
new	B-X
therapeutic	B-X
potential	B-X
for	B-X
blood	B-X
cell-related	B-X
diseases.Ferroptosis	B-X
damages	B-X
erythropoiesis	B-X
and	B-X
thus	B-X
induces	B-X
anaemia.Ferroptosis	B-X
induces	B-X
platelet	B-X
activation	B-X
and	B-X
leads	B-X
to	B-X
thromboembolism.Ferroptosis	B-X
regulates	B-X
T-cell	B-X
and	B-X
B-cell	B-X
immunity	B-X
,	B-X
which	B-X
participant	B-X
in	B-X
infectious	B-X
diseases.Inversely	B-X
,	B-X
ferroptosis	B-X
ameliorates	B-X
acute	B-X
myeloid	B-X
leukaemia	B-X
and	B-X
T-cell	B-X
leukaemia	B-X
.	B-X

It	O
may	O
be	O
speculated	O
that	O
these	O
molecules	O
produced	O
in	O
damaged	O
brain	O
or	O
came	O
from	O
blood	O
cells	O
and	O
constituents	O
of	O
plasma	O
server	O
as	O
endogenous	O
TLR4	B-Protein
ligands	O
,	O
activate	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
,	O
and	O
initiate	O
the	O
inflammatory	O
responses	O
in	O
IHC	O
brain	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
article	B-X
is	B-X
to	B-X
amalgamate	B-X
previous	B-X
results	B-X
into	B-X
a	B-X
speculative	B-X
synthesis	B-X
that	B-X
sheds	B-X
light	B-X
on	B-X
the	B-X
causes	B-X
of	B-X
secondary	B-X
brain	B-X
damage	B-X
following	B-X
either	B-X
global/forebrain	B-X
or	B-X
focal	B-X
ischemia	B-X
.	B-X
The	B-X
hypothesis	B-X
is	B-X
based	B-X
on	B-X
the	B-X
well-founded	B-X
assumption	B-X
that	B-X
the	B-X
pathophysiology	B-X
of	B-X
the	B-X
brain	B-X
damage	B-X
incurred	B-X
by	B-X
global	B-X
or	B-X
forebrain	B-X
ischemia	B-X
is	B-X
different	B-X
from	B-X
that	B-X
of	B-X
focal	B-X
ischemia	B-X
.	B-X
In	B-X
global	B-X
or	B-X
forebrain	B-X
ischemia	B-X
,	B-X
calcium	B-X
influx	B-X
through	B-X
channels	B-X
gated	B-X
by	B-X
voltage	B-X
or	B-X
glutamate	B-X
receptors	B-X
is	B-X
envisaged	B-X
to	B-X
trigger	B-X
reactions	B-X
that	B-X
limit	B-X
the	B-X
survival	B-X
of	B-X
neurons	B-X
during	B-X
reperfusion	B-X
,	B-X
leading	B-X
to	B-X
secondary	B-X
neuronal	B-X
death	B-X
after	B-X
hours	B-X
or	B-X
days	B-X
of	B-X
survival	B-X
.	B-X
Alternatively	B-X
,	B-X
a	B-X
sustained	B-X
perturbation	B-X
of	B-X
the	B-X
intracellular	B-X
signal	B-X
transduction	B-X
pathway	B-X
leads	B-X
to	B-X
changes	B-X
in	B-X
transcription	B-X
or	B-X
translation	B-X
,	B-X
bereaving	B-X
the	B-X
cells	B-X
of	B-X
heat	B-X
shock	B-X
and	B-X
stress	B-X
proteins	B-X
,	B-X
of	B-X
trophic	B-X
factors	B-X
,	B-X
or	B-X
of	B-X
enzymes	B-X
required	B-X
for	B-X
survival	B-X
.	B-X
During	B-X
continuous	B-X
ischemia	B-X
,	B-X
or	B-X
during	B-X
recirculation	B-X
following	B-X
1-3	B-X
h	B-X
of	B-X
ischemia	B-X
,	B-X
these	B-X
mediators	B-X
activate	B-X
adhesion	B-X
molecules	B-X
in	B-X
endothelial	B-X
cells	B-X
or	B-X
polymorphonuclear	B-X
leucocytes	B-X
,	B-X
or	B-X
oxidize	B-X
key	B-X
proteins	B-X
.	B-X
This	B-X
may	B-X
be	B-X
because	B-X
expression	B-X
of	B-X
mRNAs	B-X
for	B-X
adhesion	B-X
molecules	B-X
and	B-X
their	B-X
synthesis	B-X
are	B-X
relatively	B-X
slow	B-X
processes	B-X
,	B-X
and	B-X
because	B-X
the	B-X
nitrones	B-X
act	B-X
on	B-X
events	B-X
that	B-X
involve	B-X
adhesion	B-X
of	B-X
leukocytes	B-X
to	B-X
the	B-X
endothelial	B-X
cells	B-X
,	B-X
with	B-X
plugging	B-X
of	B-X
capillaries	B-X
and	B-X
postcapillary	B-X
venules	B-X
,	B-X
and	B-X
on	B-X
the	B-X
ensuing	B-X
inflammatory	B-X
response	B-X
.	B-X

However	O
,	O
the	O
specific	O
endogenous	O
ligands	O
for	O
TLR4	B-Protein
in	O
hemorrhagic	O
brain	O
have	O
not	O
been	O
determined	O
and	O
need	O
to	O
be	O
identified	O
through	O
further	O
research	O
.	O
<EOS>	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
are	B-X
pattern	B-X
recognition	B-X
receptors	B-X
which	B-X
mediate	B-X
an	B-X
inflammatory	B-X
response	B-X
upon	B-X
the	B-X
detection	B-X
of	B-X
specific	B-X
molecular	B-X
patterns	B-X
found	B-X
on	B-X
foreign	B-X
organisms	B-X
and	B-X
on	B-X
endogenous	B-X
damage-related	B-X
molecules	B-X
.	B-X
It	B-X
is	B-X
well	B-X
established	B-X
that	B-X
immune	B-X
activation	B-X
,	B-X
in	B-X
both	B-X
the	B-X
brain	B-X
and	B-X
periphery	B-X
,	B-X
is	B-X
a	B-X
feature	B-X
of	B-X
Parkinson	B-X
's	B-X
disease	B-X
as	B-X
well	B-X
as	B-X
other	B-X
α-synucleinopathies	B-X
.	B-X
Aggregated	B-X
forms	B-X
of	B-X
α-synuclein	B-X
can	B-X
act	B-X
as	B-X
ligands	B-X
for	B-X
TLRs	B-X
(	B-X
particularly	B-X
TLR2	B-X
and	B-X
TLR4	B-X
)	B-X
,	B-X
and	B-X
hence	B-X
these	B-X
receptors	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
mediating	B-X
a	B-X
detrimental	B-X
immune	B-X
response	B-X
to	B-X
this	B-X
protein	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
inflammatory	B-X
signals	B-X
in	B-X
Parkinson	B-X
's	B-X
and	B-X
related	B-X
α-synucleinopathies	B-X
.	B-X
Existing	B-X
evidence	B-X
comes	B-X
predominantly	B-X
from	B-X
studies	B-X
in	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
models	B-X
,	B-X
as	B-X
well	B-X
as	B-X
analyses	B-X
of	B-X
postmortem	B-X
human	B-X
brain	B-X
tissue	B-X
and	B-X
pre-clinical	B-X
studies	B-X
of	B-X
TLR	B-X
inhibitors	B-X
.	B-X

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
the	O
temporal	O
profile	O
of	O
the	O
activation	O
of	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
in	O
brain	O
tissue	O
in	O
a	O
rat	O
model	O
of	O
experimental	O
ICH	O
,	O
which	O
suggests	O
that	O
TLR4	B-Protein
-	O
mediated	O
NFkappaB	O
signaling	O
participates	O
in	O
the	O
pathogenesis	O
of	O
ICH	O
,	O
which	O
may	O
be	O
a	O
therapeutic	O
target	O
for	O
the	O
prevention	O
of	O
ICH	O
-	O
induced	O
brain	O
damage	O
.	O

Negative	O
regulation	O
of	O
NF	O
-	O
kappaB	O
and	O
its	O
involvement	O
in	O
rheumatoid	O
arthritis	O
<EOS>	B-X
Increased	B-X
osteoclast	B-X
(	B-X
OC	B-X
)	B-X
differentiation	B-X
and	B-X
activity	B-X
is	B-X
the	B-X
critical	B-X
event	B-X
that	B-X
results	B-X
in	B-X
bone	B-X
loss	B-X
and	B-X
joint	B-X
destruction	B-X
in	B-X
common	B-X
pathological	B-X
bone	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
osteoporosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
TNFα	B-X
can	B-X
induce	B-X
OC	B-X
differentiation	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
RANKL/RANK	B-X
system	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
factors	B-X
that	B-X
negatively	B-X
and	B-X
positively	B-X
regulate	B-X
TNFα	B-X
induction	B-X
of	B-X
OC	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
mechanisms	B-X
involved	B-X
to	B-X
inform	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anti-resorptive	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
bone	B-X
conditions	B-X
with	B-X
enhanced	B-X
OC	B-X
formation	B-X
.	B-X
Similar	B-X
to	B-X
,	B-X
and	B-X
being	B-X
independent	B-X
of	B-X
,	B-X
RANKL	B-X
,	B-X
TNFα	B-X
recruits	B-X
TNF	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
to	B-X
sequentially	B-X
activate	B-X
transcriptional	B-X
factors	B-X
NF-κB	B-X
p50	B-X
and	B-X
p52	B-X
,	B-X
followed	B-X
by	B-X
c-Fos	B-X
,	B-X
and	B-X
then	B-X
NFATc1	B-X
to	B-X
induce	B-X
OC	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
induction	B-X
of	B-X
OC	B-X
formation	B-X
by	B-X
TNFα	B-X
alone	B-X
is	B-X
very	B-X
limited	B-X
,	B-X
since	B-X
it	B-X
also	B-X
induces	B-X
many	B-X
inhibitory	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
TRAF3	B-X
,	B-X
p100	B-X
,	B-X
IRF8	B-X
,	B-X
and	B-X
RBP-j	B-X
.	B-X
TNFα	B-X
induction	B-X
of	B-X
OC	B-X
differentiation	B-X
is	B-X
,	B-X
however	B-X
,	B-X
versatile	B-X
,	B-X
and	B-X
Interleukin-1	B-X
or	B-X
TGFβ1	B-X
can	B-X
enhance	B-X
TNFα-induced	B-X
OC	B-X
formation	B-X
through	B-X
a	B-X
mechanism	B-X
which	B-X
is	B-X
independent	B-X
of	B-X
RANKL	B-X
,	B-X
TRAF6	B-X
,	B-X
and/or	B-X
NF-κB	B-X
.	B-X
However	B-X
,	B-X
TNFα	B-X
polarized	B-X
macrophages	B-X
also	B-X
produce	B-X
anabolic	B-X
factors	B-X
,	B-X
including	B-X
insulin	B-X
such	B-X
as	B-X
6	B-X
peptide	B-X
and	B-X
Jagged1	B-X
,	B-X
to	B-X
slow	B-X
down	B-X
bone	B-X
loss	B-X
in	B-X
the	B-X
pathological	B-X
conditions	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
approaches	B-X
targeting	B-X
TNFα	B-X
signaling	B-X
should	B-X
focus	B-X
on	B-X
its	B-X
downstream	B-X
molecules	B-X
that	B-X
do	B-X
not	B-X
affect	B-X
its	B-X
anabolic	B-X
effect	B-X
.	B-X

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
plays	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
inflammation	O
and	O
mmune	O
responses	O
,	O
and	O
inappropriate	O
NF	O
-	O
kappaB	O
activity	O
has	O
been	O
linked	O
with	O
many	O
autoimmune	O
and	O
inflammatory	O
diseases	O
,	O
including	O
rheumatoid	O
arthritis	O
.	O

Cells	O
employ	O
a	O
multilayered	O
control	O
system	O
to	O
keep	O
NF	O
-	O
kappaB	O
signalling	O
in	O
check	O
,	O
including	O
a	O
repertoire	O
of	O
negative	O
feedback	O
regulators	O
ensuring	O
termination	O
of	O
NF	O
-	O
kappaB	O
responses	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
inflammation	B-X
and	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
inappropriate	B-X
NF-κB	B-X
activity	B-X
has	B-X
been	B-X
linked	B-X
with	B-X
many	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
,	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Cells	B-X
employ	B-X
a	B-X
multilayered	B-X
control	B-X
system	B-X
to	B-X
keep	B-X
NF-κB	B-X
signalling	B-X
in	B-X
check	B-X
,	B-X
including	B-X
a	B-X
repertoire	B-X
of	B-X
negative	B-X
feedback	B-X
regulators	B-X
ensuring	B-X
termination	B-X
of	B-X
NF-κB	B-X
responses	B-X
.	B-X
Here	B-X
we	B-X
will	B-X
review	B-X
various	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
that	B-X
have	B-X
evolved	B-X
to	B-X
control	B-X
NF-κB	B-X
signalling	B-X
and	B-X
which	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Here	O
we	O
will	O
review	O
various	O
negative	O
regulatory	O
mechanisms	O
that	O
have	O
evolved	O
to	O
control	O
NF	O
-	O
kappaB	O
signalling	O
and	O
which	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
plays	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
inflammation	B-X
and	B-X
immune	B-X
responses	B-X
,	B-X
and	B-X
inappropriate	B-X
NF-κB	B-X
activity	B-X
has	B-X
been	B-X
linked	B-X
with	B-X
many	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
diseases	B-X
,	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X
Cells	B-X
employ	B-X
a	B-X
multilayered	B-X
control	B-X
system	B-X
to	B-X
keep	B-X
NF-κB	B-X
signalling	B-X
in	B-X
check	B-X
,	B-X
including	B-X
a	B-X
repertoire	B-X
of	B-X
negative	B-X
feedback	B-X
regulators	B-X
ensuring	B-X
termination	B-X
of	B-X
NF-κB	B-X
responses	B-X
.	B-X
Here	B-X
we	B-X
will	B-X
review	B-X
various	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
that	B-X
have	B-X
evolved	B-X
to	B-X
control	B-X
NF-κB	B-X
signalling	B-X
and	B-X
which	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
the	O
most	O
common	O
inflammatory	O
arthritis	O
,	O
affecting	O
up	O
to	O
1	O
%	O
of	O
the	O
adult	O
population	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
systemic	B-X
inflammatory	B-X
disorder	B-X
that	B-X
affects	B-X
approximately	B-X
1	B-X
%	B-X
of	B-X
the	B-X
population	B-X
,	B-X
in	B-X
a	B-X
female	B-X
to	B-X
male	B-X
ratio	B-X
of	B-X
3:1	B-X
.	B-X
The	B-X
disease	B-X
can	B-X
occur	B-X
at	B-X
any	B-X
age	B-X
,	B-X
but	B-X
it	B-X
is	B-X
most	B-X
common	B-X
among	B-X
those	B-X
aged	B-X
40-70	B-X
years	B-X
.	B-X
Despite	B-X
many	B-X
years	B-X
of	B-X
study	B-X
,	B-X
the	B-X
etiology	B-X
of	B-X
RA	B-X
is	B-X
still	B-X
undefined	B-X
.	B-X
However	B-X
,	B-X
with	B-X
increased	B-X
understanding	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
the	B-X
pathogenesis	B-X
of	B-X
RA	B-X
has	B-X
become	B-X
clearer	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
cytokine	B-X
profile	B-X
of	B-X
T	B-X
helper	B-X
cells	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
the	B-X
disease	B-X
,	B-X
the	B-X
cytokine	B-X
repertoire	B-X
of	B-X
inflamed	B-X
synovia	B-X
is	B-X
categorized	B-X
as	B-X
that	B-X
of	B-X
T	B-X
helper	B-X
1	B-X
response	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
RA	B-X
elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
or	B-X
inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
Tumor	B-X
Necrosis	B-X
Factor	B-X
-	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
Interleukin	B-X
-1	B-X
beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
have	B-X
been	B-X
detected	B-X
.	B-X
Hypoxia	B-X
up-regulates	B-X
TNF-alpha	B-X
and	B-X
IL-1beta	B-X
;	B-X
therefore	B-X
,	B-X
considerable	B-X
research	B-X
interest	B-X
has	B-X
been	B-X
focused	B-X
on	B-X
the	B-X
biological	B-X
consequences	B-X
of	B-X
the	B-X
hypoxic	B-X
nature	B-X
of	B-X
the	B-X
rheumatoid	B-X
synovium	B-X
.	B-X
In	B-X
this	B-X
short	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
our	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
link	B-X
between	B-X
cytokines	B-X
and	B-X
RA	B-X
and	B-X
the	B-X
role	B-X
of	B-X
hypoxia	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
the	B-X
disease	B-X
.	B-X

RA	O
is	O
characterised	O
by	O
a	O
symmetrical	O
polyarthritis	O
in	O
which	O
chronic	O
inflammation	O
of	O
joints	O
is	O
associated	O
with	O
a	O
progressive	O
destruction	O
of	O
cartilage	O
and	O
bone	O
,	O
leading	O
to	O
functional	O
decline	O
and	O
disability	O
.	O

Infiltration	O
of	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
into	O
the	O
joint	O
space	O
drives	O
the	O
local	O
production	O
of	O
proinflammatory	O
T	O
-	O
helper	O
type	O
1	O
and	O
T	O
-	O
helper	O
type	O
17	O
cytokines	O
,	O
chemokines	O
,	O
and	O
matrix	O
metalloproteinases	O
by	O
infiltrating	O
monocytes	O
and	O
synovial	O
cells	O
.	O

Proliferation	O
of	O
synovial	O
fibroblasts	O
leads	O
to	O
the	O
formation	O
of	O
pannus	O
tissue	O
,	O
which	O
invades	O
and	O
degrades	O
articular	O
cartilage	O
and	O
subchondral	O
bone	O
.	O

The	O
aetiology	O
of	O
RA	O
is	O
still	O
not	O
understood	O
,	O
but	O
it	O
is	O
well	O
accepted	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
RA	O
and	O
many	O
other	O
autoimmune	O
diseases	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
inflammatory	B-X
autoimmune	B-X
disease	B-X
influenced	B-X
by	B-X
both	B-X
genetic	B-X
and	B-X
environmental	B-X
factors	B-X
.	B-X
Over	B-X
the	B-X
last	B-X
few	B-X
years	B-X
,	B-X
particular	B-X
attention	B-X
has	B-X
been	B-X
given	B-X
to	B-X
novel	B-X
genes	B-X
and	B-X
to	B-X
the	B-X
close	B-X
interaction	B-X
between	B-X
genetic	B-X
factors	B-X
and	B-X
epigenetic	B-X
mechanisms	B-X
.	B-X
Research	B-X
has	B-X
also	B-X
focused	B-X
on	B-X
the	B-X
influence	B-X
of	B-X
environmental	B-X
factors	B-X
on	B-X
disease	B-X
development	B-X
,	B-X
and	B-X
on	B-X
new	B-X
mechanisms	B-X
of	B-X
the	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
system	B-X
that	B-X
can	B-X
influence	B-X
the	B-X
different	B-X
stages	B-X
of	B-X
RA	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
still	B-X
several	B-X
aspects	B-X
of	B-X
the	B-X
disease	B-X
that	B-X
need	B-X
further	B-X
investigation	B-X
.	B-X
Shedding	B-X
some	B-X
light	B-X
on	B-X
the	B-X
different	B-X
aspects	B-X
of	B-X
RA	B-X
pathogenesis	B-X
will	B-X
help	B-X
to	B-X
improve	B-X
the	B-X
current	B-X
diagnostic	B-X
tools	B-X
and	B-X
to	B-X
identify	B-X
new	B-X
targets	B-X
for	B-X
the	B-X
development	B-X
of	B-X
disease-modifying	B-X
therapies	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
this	B-X
review	B-X
we	B-X
summarise	B-X
the	B-X
new	B-X
insights	B-X
in	B-X
RA	B-X
pathogenesis	B-X
,	B-X
resulting	B-X
from	B-X
literature	B-X
research	B-X
data	B-X
published	B-X
in	B-X
the	B-X
last	B-X
year	B-X
.	B-X

NF	O
-	O
kappaB	O
represents	O
a	O
family	O
of	O
structurally	O
related	O
and	O
evolutionarily	O
conserved	O
proteins	O
(	O
p100	B-Protein
or	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
,	O
p105	B-Protein
or	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
,	O
p65	B-Protein
or	O
RelA	B-Protein
,	O
RelB	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
)	O
that	O
function	O
as	O
homodimers	O
or	O
heterodimers	O
[	O
1	O
]	O
,	O
and	O
that	O
regulate	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
-	O
such	O
as	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
cyclo	B-Protein
-	I-Protein
oxygenase	I-Protein
-	I-Protein
2	I-Protein
,	O
chemokines	O
,	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
,	O
and	O
matrix	O
metalloproteinases	O
-	O
that	O
are	O
involved	O
in	O
RA	O
.	O

In	O
addition	O
,	O
TNF	B-Protein
and	O
IL	O
-	O
1	O
are	O
themselves	O
very	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
(	O
reviewed	O
in	O
[	O
2	O
,	O
3	O
]	O
)	O
.	O

NF	O
-	O
kappaB	O
activation	O
can	O
be	O
detected	O
in	O
cultured	O
synovial	O
fibroblasts	O
and	O
synovial	O
tissue	O
from	O
RA	O
patients	O
,	O
and	O
animal	O
models	O
of	O
inflammatory	O
arthritis	O
also	O
demonstrate	O
the	O
active	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
development	O
and	O
progression	O
of	O
RA	O
(	O
reviewed	O
in	O
[	O
4	O
]	O
)	O
.	O

The	O
time	O
course	O
of	O
NF	O
-	O
kappaB	O
activation	O
appears	O
to	O
precede	O
the	O
onset	O
of	O
disease	O
,	O
and	O
blockade	O
of	O
NF	O
-	O
kappaB	O
by	O
different	O
means	O
decreases	O
disease	O
severity	O
[	O
5	O
,	O
6	O
]	O
.	O

Next	O
to	O
its	O
role	O
in	O
proinflammatory	O
gene	O
expression	O
,	O
NF	O
-	O
kappaB	O
is	O
also	O
essential	O
for	O
osteoclastogenesis	O
,	O
mainly	O
by	O
mediating	O
the	O
effects	O
of	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
ligand	I-Protein
(	O
RANKL	B-Protein
)	O
.	O

Defects	O
in	O
the	O
regulation	O
of	O
osteoclastogenesis	O
are	O
the	O
major	O
cause	O
of	O
bone	O
erosion	O
in	O
osteolytic	O
diseases	O
such	O
as	O
RA	O
[	O
7	O
]	O
.	O

Finally	O
,	O
recent	O
discoveries	O
revealing	O
a	O
genetic	O
association	O
with	O
several	O
genes	O
relevant	O
to	O
NF	O
-	O
kappaB	O
signalling	O
,	O
including	O
CD40	B-Protein
,	O
TRAF1	B-Protein
,	O
TNFAIP3	B-Protein
,	O
and	O
c	B-Protein
-	I-Protein
REL	I-Protein
,	O
further	O
highlight	O
the	O
importance	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
RA	O
pathogenesis	O
[	O
8	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
is	O
central	O
to	O
the	O
process	O
of	O
inflammation	O
in	O
RA	O
,	O
much	O
research	O
deals	O
with	O
the	O
identification	O
of	O
the	O
molecular	O
triggers	O
that	O
activate	O
NF	O
-	O
kappaB	O
in	O
RA	O
.	O

It	O
is	O
well	O
accepted	O
that	O
proinflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
and	O
IL	O
-	O
1	O
play	O
an	O
important	O
role	O
,	O
and	O
administration	O
of	O
TNF	B-Protein
antagonists	O
is	O
an	O
effective	O
treatment	O
for	O
severe	O
RA	O
(	O
reviewed	O
in	O
[	O
9	O
]	O
)	O
.	O

TNF	B-Protein
and	O
IL	O
-	O
1	O
are	O
both	O
very	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
and	O
it	O
can	O
be	O
expected	O
that	O
NF	O
-	O
kappaB	O
activation	O
by	O
these	O
cytokines	O
mediates	O
most	O
of	O
their	O
pro	O
-	O
inflammatory	O
activities	O
in	O
RA	O
(	O
reviewed	O
in	O
[	O
3	O
]	O
)	O
.	O

NF	O
-	O
kappaB	O
activation	O
by	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
(	O
RANK	B-Protein
)	O
,	O
a	O
TNF	O
receptor	O
family	O
member	O
,	O
is	O
important	O
for	O
osteoclastogenesis	O
,	O
and	O
defects	O
in	O
proper	O
RANK	B-Protein
-	O
NF	O
-	O
kappaB	O
signalling	O
are	O
likely	O
to	O
be	O
involved	O
in	O
RA	O
pathology	O
and	O
other	O
diseases	O
associated	O
with	O
bone	O
loss	O
[	O
7	O
]	O
.	O

CD40	B-Protein
is	O
another	O
TNF	B-Protein
receptor	I-Protein
family	I-Protein
member	I-Protein
that	O
is	O
functionally	O
expressed	O
on	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
smooth	O
muscle	O
fibroblasts	O
from	O
normal	O
and	O
RA	O
patients	O
and	O
RA	O
synovial	O
cells	O
,	O
B	O
cells	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
and	O
can	O
be	O
upregulated	O
by	O
proinflammatory	O
cytokines	O
including	O
TNF	B-Protein
[	O
10	O
]	O
.	O

Binding	O
of	O
the	O
CD40	B-Protein
ligand	I-Protein
(	O
CD154	B-Protein
)	O
,	O
which	O
is	O
transiently	O
expressed	O
on	O
the	O
surface	O
of	O
activated	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
triggers	O
NF	O
-	O
kappaB	O
activation	O
resulting	O
in	O
fibroblast	O
proliferation	O
and	O
secretion	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
contributes	O
to	O
joint	O
destruction	O
.	O

However	O
,	O
studies	O
with	O
antagonistic	O
anti	O
-	O
CD40	O
or	O
anti	O
-	O
CD154	O
antibodies	O
led	O
to	O
the	O
conclusion	O
that	O
CD40	B-Protein
signals	O
may	O
be	O
important	O
at	O
the	O
initial	O
stages	O
of	O
arthritis	O
induction	O
,	O
but	O
are	O
not	O
required	O
once	O
disease	O
is	O
established	O
and	O
pathogenic	O
antibodies	O
are	O
already	O
present	O
[	O
11	O
,	O
12	O
]	O
.	O
<EOS>	B-X
Recent	B-X
success	B-X
in	B-X
cancer	B-X
immunotherapy	B-X
(	B-X
anti-CTLA-4	B-X
,	B-X
anti-PD1/PD-L1	B-X
)	B-X
has	B-X
confirmed	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
immune	B-X
system	B-X
can	B-X
control	B-X
many	B-X
cancers	B-X
across	B-X
various	B-X
histologies	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
producing	B-X
durable	B-X
responses	B-X
in	B-X
a	B-X
way	B-X
not	B-X
seen	B-X
with	B-X
many	B-X
small-molecule	B-X
drugs	B-X
.	B-X
However	B-X
,	B-X
only	B-X
less	B-X
than	B-X
25	B-X
%	B-X
of	B-X
all	B-X
patients	B-X
do	B-X
respond	B-X
to	B-X
immuno-oncology	B-X
drugs	B-X
and	B-X
several	B-X
resistance	B-X
mechanisms	B-X
have	B-X
been	B-X
identified	B-X
(	B-X
e.g	B-X
.	B-X
TIM-3	B-X
,	B-X
VISTA	B-X
,	B-X
LAG-3	B-X
,	B-X
IDO	B-X
,	B-X
KIR	B-X
)	B-X
and	B-X
newly	B-X
developed	B-X
co-stimulatory	B-X
antibodies	B-X
(	B-X
e.g	B-X
.	B-X
CD40	B-X
,	B-X
GITR	B-X
,	B-X
OX40	B-X
,	B-X
CD137	B-X
,	B-X
ICOS	B-X
)	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
note	B-X
that	B-X
co-stimulatory	B-X
agents	B-X
strikingly	B-X
differ	B-X
in	B-X
their	B-X
proposed	B-X
mechanism	B-X
of	B-X
action	B-X
compared	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
accomplish	B-X
immune	B-X
activation	B-X
by	B-X
blocking	B-X
negative	B-X
checkpoint	B-X
molecules	B-X
such	B-X
as	B-X
CTLA-4	B-X
or	B-X
PD-1/PD-1	B-X
or	B-X
others	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
prospect	B-X
of	B-X
combining	B-X
agonistic	B-X
with	B-X
antagonistic	B-X
agents	B-X
is	B-X
enticing	B-X
and	B-X
represents	B-X
a	B-X
real	B-X
immunologic	B-X
opportunity	B-X
to	B-X
'step	B-X
on	B-X
the	B-X
gas	B-X
'	B-X
while	B-X
'cutting	B-X
the	B-X
brakes	B-X
'	B-X
,	B-X
although	B-X
this	B-X
strategy	B-X
as	B-X
a	B-X
novel	B-X
cancer	B-X
therapy	B-X
has	B-X
not	B-X
been	B-X
universally	B-X
endorsed	B-X
so	B-X
far	B-X
.	B-X
Although	B-X
initial	B-X
phase	B-X
I/II	B-X
clinical	B-X
trials	B-X
of	B-X
agonistic	B-X
and	B-X
novel	B-X
antagonistic	B-X
drugs	B-X
have	B-X
shown	B-X
highly	B-X
promising	B-X
results	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
disabling	B-X
toxicity	B-X
,	B-X
both	B-X
in	B-X
single-agent	B-X
studies	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
chemotherapy	B-X
or	B-X
other	B-X
immune	B-X
system	B-X
targeting	B-X
drugs	B-X
;	B-X
however	B-X
,	B-X
numerous	B-X
questions	B-X
remain	B-X
about	B-X
dose	B-X
,	B-X
schedule	B-X
,	B-X
route	B-X
of	B-X
administration	B-X
and	B-X
formulation	B-X
as	B-X
well	B-X
as	B-X
identifying	B-X
the	B-X
appropriate	B-X
patient	B-X
populations	B-X
.	B-X
In	B-X
our	B-X
view	B-X
,	B-X
with	B-X
such	B-X
a	B-X
wealth	B-X
of	B-X
potential	B-X
mechanisms	B-X
of	B-X
action	B-X
and	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
fine-tune	B-X
monoclonal	B-X
antibody	B-X
structure	B-X
and	B-X
function	B-X
to	B-X
suit	B-X
particular	B-X
requirements	B-X
,	B-X
the	B-X
second	B-X
and	B-X
third	B-X
wave	B-X
of	B-X
immuno-oncology	B-X
drugs	B-X
are	B-X
likely	B-X
to	B-X
provide	B-X
rapid	B-X
advances	B-X
with	B-X
new	B-X
combinations	B-X
of	B-X
novel	B-X
immunotherapy	B-X
(	B-X
especially	B-X
co-stimulatory	B-X
antibodies	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
will	B-X
review	B-X
the	B-X
mechanisms	B-X
of	B-X
action	B-X
and	B-X
the	B-X
clinical	B-X
data	B-X
of	B-X
these	B-X
new	B-X
antibodies	B-X
and	B-X
discuss	B-X
the	B-X
major	B-X
issues	B-X
facing	B-X
this	B-X
rapidly	B-X
evolving	B-X
field	B-X
.	B-X

Enhanced	O
expression	O
of	O
the	O
TNF	O
receptor	O
family	O
member	O
B	B-Protein
-	I-Protein
cell	I-Protein
activating	I-Protein
factor	I-Protein
(	O
BAFF	B-Protein
)	O
,	O
allowing	O
the	O
survival	O
of	O
autoantibody	O
-	O
producing	O
B	O
lymphocytes	O
,	O
is	O
also	O
characteristic	O
for	O
RA	O
,	O
and	O
antagonists	O
of	O
BAFF	B-Protein
have	O
been	O
developed	O
to	O
counter	O
RA	O
[	O
13	O
]	O
.	O

Finally	O
,	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
signalling	O
has	O
been	O
implicated	O
in	O
tertiary	O
lymphoid	O
organ	O
formation	O
at	O
sites	O
of	O
chronic	O
inflammation	O
including	O
RA	O
[	O
13	O
]	O
.	O

Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
have	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
autoimmune	O
diseases	O
and	O
are	O
potential	O
candidates	O
for	O
inducing	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammation	O
in	O
RA	O
.	O

In	O
addition	O
to	O
microbial	O
ligands	O
,	O
an	O
increasing	O
number	O
of	O
endogenous	O
ligands	O
-	O
a	O
group	O
of	O
proteins	O
derived	O
from	O
host	O
tissues	O
and	O
cells	O
-	O
have	O
been	O
reported	O
as	O
candidate	O
activators	O
of	O
TLRs	O
inducing	O
so	O
-	O
called	O
sterile	O
inflammation	O
(	O
reviewed	O
in	O
[	O
14	O
,	O
15	O
]	O
)	O
.	O

TLRs	O
are	O
expressed	O
in	O
RA	O
synovial	O
tissues	O
and	O
various	O
endogenous	O
ligands	O
are	O
present	O
within	O
the	O
inflamed	O
joints	O
of	O
RA	O
patients	O
.	O

Moreover	O
,	O
animal	O
models	O
using	O
TLR	O
knockout	O
mice	O
or	O
strategies	O
to	O
block	O
TLR	O
signalling	O
clearly	O
identify	O
TLR	O
-	O
dependent	O
inflammation	O
as	O
being	O
important	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
5	B-X
deficiency	B-X
diminishes	B-X
doxorubicin-induced	B-X
acute	B-X
cardiotoxicity	B-X
in	B-X
mice	B-X
.	B-X
Endogenous	B-X
nucleic	B-X
acids	B-X
and	B-X
their	B-X
receptors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
systemic	B-X
autoimmune	B-X
diseases	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
As	B-X
the	B-X
role	B-X
of	B-X
the	B-X
DNA	B-X
sensing	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
9	B-X
in	B-X
RA	B-X
is	B-X
unclear	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
its	B-X
involvement	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
autoimmune	B-X
arthritis	B-X
using	B-X
three	B-X
different	B-X
experimental	B-X
models	B-X
of	B-X
RA	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
revealed	B-X
involvement	B-X
of	B-X
TLR9	B-X
in	B-X
the	B-X
T	B-X
cell-dependent	B-X
phase	B-X
of	B-X
inflammatory	B-X
arthritis	B-X
.	B-X
In	B-X
rats	B-X
with	B-X
pristane-induced	B-X
arthritis	B-X
(	B-X
PIA	B-X
)	B-X
,	B-X
TLR9	B-X
inhibition	B-X
before	B-X
disease	B-X
onset	B-X
reduced	B-X
arthritis	B-X
significantly	B-X
and	B-X
almost	B-X
completely	B-X
abolished	B-X
bone	B-X
erosion	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
TLR9	B-X

High	B-Protein
mobility	I-Protein
group	I-Protein
box	I-Protein
chromosomal	I-Protein
protein	I-Protein
1	I-Protein
(	O
HMGB1	B-Protein
)	O
,	O
a	O
highly	O
conserved	O
chromatin	B-Protein
component	I-Protein
that	O
can	O
be	O
actively	O
secreted	O
by	O
macrophages	O
or	O
passively	O
released	O
by	O
necrotic	O
cells	O
,	O
is	O
one	O
of	O
the	O
most	O
putative	O
endogenous	O
TLR4	B-Protein
ligands	I-Protein
involved	O
in	O
RA	O
pathology	O
.	O

HMGB1	B-Protein
is	O
increased	O
in	O
RA	O
synovial	O
tissue	O
and	O
HMGB1	B-Protein
neutralising	O
antibodies	O
or	O
the	O
antagonistic	O
BoxA	O
domain	O
of	O
HMGB1	B-Protein
protect	O
against	O
collagen	O
-	O
induced	O
arthritis	O
in	O
mice	O
[	O
16	O
]	O
.	O
<EOS>	B-X
High-mobility	B-X
group	B-X
box	B-X
protein	B-X
1	B-X
(	B-X
HMGB1	B-X
)	B-X
,	B-X
a	B-X
nonhistone	B-X
nuclear	B-X
protein	B-X
and	B-X
a	B-X
cytokine	B-X
mediator	B-X
,	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Extracellular	B-X
HMGB1	B-X
binds	B-X
to	B-X
its	B-X
receptors	B-X
and	B-X
triggers	B-X
downstream	B-X
signal	B-X
cascade	B-X
leading	B-X
to	B-X
the	B-X
perpetuation	B-X
of	B-X
synovitis	B-X
and	B-X
local	B-X
tissue	B-X
invasion	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
HMGB1	B-X
in	B-X
regulating	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-1α	B-X
to	B-X
mediate	B-X
angiogenesis	B-X
in	B-X
RA	B-X
synovium	B-X
.	B-X
HIF-1α	B-X
mRNA	B-X
levels	B-X
and	B-X
activities	B-X
in	B-X
synovial	B-X
fibroblasts	B-X
from	B-X
RA	B-X
patients	B-X
were	B-X
enhanced	B-X
by	B-X
HMGB1	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
TLR4	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
blocked	B-X
the	B-X
HMGB1-dependent	B-X
upregulation	B-X
of	B-X
HIF-1α	B-X
mRNA	B-X
expression	B-X
and	B-X
its	B-X
activity	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
transcriptional	B-X
regulation	B-X
.	B-X
HMGB1	B-X
stimulated	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
HIF-1α	B-X
attenuated	B-X
HMGB1-induced	B-X
VEGF	B-X
.	B-X
Conditioned	B-X
media	B-X
derived	B-X
from	B-X
HMGB1-stimulated	B-X
synovial	B-X
fibroblasts	B-X
enhanced	B-X
tube	B-X
formation	B-X
in	B-X
human	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
by	B-X
upregulating	B-X
HIF-1α	B-X
.	B-X
In	B-X
the	B-X
joint	B-X
tissues	B-X
of	B-X
mice	B-X
with	B-X
collagen-induced	B-X
arthritis	B-X
,	B-X
treatment	B-X
with	B-X
anti-HMGB1	B-X
neutralizing	B-X
antibody	B-X
prevented	B-X
blood	B-X
vessel	B-X
formation	B-X
in	B-X
association	B-X
with	B-X
decreased	B-X
expression	B-X
of	B-X
HIF-1α	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
increased	B-X
HMGB1	B-X
induces	B-X
an	B-X
extension	B-X
of	B-X
inflamed	B-X
synovium	B-X
by	B-X
accelerating	B-X
angiogenesis	B-X
in	B-X
RA	B-X
through	B-X
enhancement	B-X
of	B-X
HIF-1α	B-X
activation	B-X
.	B-X
Therefore	B-X
,	B-X
inhibition	B-X
of	B-X
HMGB1	B-X
could	B-X
prove	B-X
beneficial	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
angiogenesis	B-X
in	B-X
RA	B-X
.	B-X

Myeloid	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
8	I-Protein
and	O
myeloid	B-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
14	I-Protein
,	O
damage	O
-	O
associated	O
molecular	O
pattern	O
molecules	O
belonging	O
to	O
the	O
S100	O
family	O
of	O
calcium	O
-	O
binding	O
proteins	O
,	O
are	O
also	O
abundantly	O
present	O
in	O
RA	O
synovial	O
fluid	O
,	O
and	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
TLR4	B-Protein
-	O
induced	O
chronic	O
inflammation	O
in	O
RA	O
[	O
17	O
,	O
18	O
]	O
.	O

Other	O
endogenous	O
TLR	O
ligands	O
that	O
may	O
be	O
involved	O
in	O
RA	O
pathology	O
are	O
extracellular	O
matrix	O
components	O
such	O
as	O
fibrinogen	O
,	O
fibronectin	B-Protein
,	O
biglycan	B-Protein
,	O
tenascin	B-Protein
C	I-Protein
,	O
and	O
hyal	O
-	O
uronic	O
acid	O
fragments	O
(	O
reviewed	O
in	O
[	O
14	O
,	O
15	O
]	O
)	O
.	O

Together	O
,	O
these	O
studies	O
suggest	O
that	O
several	O
TLR	O
ligands	O
in	O
the	O
inflamed	O
joint	O
tissue	O
may	O
contribute	O
to	O
NF	O
-	O
kappaB	O
activation	O
and	O
inflammatory	O
gene	O
expression	O
in	O
RA	O
.	O

NF	O
-	O
kappaB	O
proteins	O
are	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
latent	O
complexes	O
by	O
inhibitory	O
proteins	O
referred	O
to	O
as	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
)	O
proteins	O
,	O
which	O
prevent	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
[	O
19	O
]	O
.	O

Whereas	O
the	O
majority	O
of	O
IkappaBs	O
(	O
IkappaBalpha	B-Protein
,	O
IkappaBbeta	B-Protein
,	O
IkappaBepsilon	B-Protein
,	O
p105	B-Protein
(	O
also	O
known	O
as	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
)	O
,	O
p100	B-Protein
(	O
also	O
known	O
as	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
)	O
)	O
serve	O
as	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
,	O
IkappaBxi	B-Protein
and	O
Bcl	B-Protein
-	I-Protein
3	I-Protein
instead	O
potentiate	O
NF	O
-	O
kappaB	O
transactivation	O
in	O
the	O
nucleus	O
.	O

p100	B-Protein
and	O
p105	B-Protein
are	O
precursors	O
of	O
the	O
p52	B-Protein
and	O
p50	B-Protein
NF	O
-	O
kappaB	O
subunits	O
,	O
respectively	O
.	O
<EOS>	B-X
Two	B-X
members	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
)	B-X
/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
,	B-X
NF-kappaB1	B-X
and	B-X
NF-kappaB2	B-X
,	B-X
are	B-X
produced	B-X
as	B-X
precursor	B-X
proteins	B-X
,	B-X
NF-kappaB1	B-X
p105	B-X
and	B-X
NF-kappaB2	B-X
p100	B-X
respectively	B-X
.	B-X
These	B-X
are	B-X
proteolytically	B-X
processed	B-X
by	B-X
the	B-X
proteasome	B-X
to	B-X
produce	B-X
the	B-X
mature	B-X
transcription	B-X
factors	B-X
NF-kappaB1	B-X
p50	B-X
and	B-X
NF-kappaB2	B-X
p52	B-X
.	B-X
p105	B-X
and	B-X
p100	B-X
are	B-X
known	B-X
to	B-X
function	B-X
additionally	B-X
as	B-X
IkappaBs	B-X
(	B-X
inhibitors	B-X
of	B-X
NF-kappaB	B-X
)	B-X
,	B-X
which	B-X
retain	B-X
associated	B-X
NF-kappaB	B-X
subunits	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
unstimulated	B-X
cells	B-X
.	B-X
The	B-X
present	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
latest	B-X
advances	B-X
in	B-X
research	B-X
on	B-X
the	B-X
function	B-X
of	B-X
NF-kappaB1	B-X
and	B-X
NF-kappaB2	B-X
in	B-X
immune	B-X
cells	B-X
.	B-X
NF-kappaB2	B-X
p100	B-X
processing	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
stimulated	B-X
by	B-X
a	B-X
subset	B-X
of	B-X
NF-kappaB	B-X
inducers	B-X
,	B-X
including	B-X
lymphotoxin-beta	B-X
,	B-X
B-cell	B-X
activating	B-X
factor	B-X
and	B-X
CD40	B-X
ligand	B-X
,	B-X
via	B-X
a	B-X
novel	B-X
signalling	B-X
pathway	B-X
.	B-X
This	B-X
promotes	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
p52-containing	B-X
NF-kappaB	B-X
dimers	B-X
,	B-X
which	B-X
regulate	B-X
peripheral	B-X
lymphoid	B-X
organogenesis	B-X
and	B-X
B-lymphocyte	B-X
differentiation	B-X
.	B-X
Increased	B-X
p100	B-X
processing	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
malignant	B-X
phenotype	B-X
of	B-X
certain	B-X
T-	B-X
and	B-X
B-cell	B-X
lymphomas	B-X
.	B-X
NF-kappaB1	B-X
has	B-X
a	B-X
distinct	B-X
function	B-X
from	B-X
NF-kappaB2	B-X
,	B-X
and	B-X
is	B-X
important	B-X
in	B-X
controlling	B-X
lymphocyte	B-X
and	B-X
macrophage	B-X
function	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
In	B-X
contrast	B-X
with	B-X
p100	B-X
,	B-X
p105	B-X
is	B-X
constitutively	B-X
processed	B-X
to	B-X
p50	B-X
.	B-X
However	B-X
,	B-X
after	B-X
stimulation	B-X
with	B-X
agonists	B-X
,	B-X
such	B-X
as	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
lipopolysaccharide	B-X
,	B-X
p105	B-X
is	B-X
completely	B-X
degraded	B-X
by	B-X
the	B-X
proteasome	B-X
.	B-X
This	B-X
releases	B-X
associated	B-X
p50	B-X
,	B-X
which	B-X
translocates	B-X
into	B-X
the	B-X
nucleus	B-X
to	B-X
modulate	B-X
target	B-X
gene	B-X
expression	B-X
.	B-X
p105	B-X
degradation	B-X
also	B-X
liberates	B-X
the	B-X
p105-associated	B-X
MAP	B-X
kinase	B-X
(	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
)	B-X
kinase	B-X
kinase	B-X
TPL-2	B-X
(	B-X
tumour	B-X
progression	B-X
locus-2	B-X
)	B-X
,	B-X
which	B-X
can	B-X
then	B-X
activate	B-X
the	B-X
ERK	B-X
(	B-X
extracellular-signal-regulated	B-X
kinase	B-X
)	B-X
/MAP	B-X
kinase	B-X
cascade	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
its	B-X
role	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
p105	B-X
functions	B-X
as	B-X
a	B-X
regulator	B-X
of	B-X
MAP	B-X
kinase	B-X
signalling	B-X
.	B-X

There	O
are	O
two	O
unique	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
,	O
termed	O
canonical	O
(	O
or	O
classical	O
)	O
and	O
noncanonical	O
(	O
or	O
alternative	O
)	O
NF	O
-	O
kappaB	O
pathways	O
.	O

The	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
plays	O
a	O
major	O
role	O
in	O
innate	O
and	O
adaptive	O
immunity	O
,	O
and	O
is	O
triggered	O
by	O
many	O
stimuli	O
including	O
proinflammatory	O
cytokines	O
(	O
for	O
example	O
,	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
)	O
,	O
antigens	O
,	O
RANKL	B-Protein
,	O
and	O
TLR	O
ligands	O
.	O

NF	O
-	O
kappaB	O
signalling	O
initiated	O
by	O
different	O
receptors	O
requires	O
the	O
formation	O
of	O
proximal	O
protein	O
-	O
protein	O
interactions	O
that	O
are	O
often	O
receptor	O
specific	O
,	O
but	O
ultimately	O
converge	O
in	O
the	O
activation	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
,	O
which	O
mediates	O
phosphorylation	O
of	O
the	O
inhibitory	O
IkappaB	O
protein	O
leading	O
to	O
its	O
K48	O
-	O
polyubiquitination	O
and	O
degradation	O
by	O
the	O
proteasome	O
[	O
20	O
]	O
.	O

The	O
IKK	O
complex	O
is	O
comprised	O
of	O
the	O
two	O
catalytic	O
subunits	O
IKK1	B-Protein
and	O
IKK2	B-Protein
(	O
also	O
known	O
as	O
IKKalpha	B-Protein
and	O
IKKbeta	B-Protein
)	O
and	O
the	O
regulatory	O
subunit	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
essential	I-Protein
modulator	I-Protein
(	O
NEMO	B-Protein
-	O
also	O
known	O
as	O
IKKgamma	B-Protein
)	O
(	O
Figure	O
1	O
)	O
.	O

Gene	O
targeting	O
experiments	O
showed	O
that	O
IKK2	B-Protein
and	O
NEMO	B-Protein
,	O
but	O
not	O
IKK1	B-Protein
,	O
are	O
required	O
for	O
canonical	O
NF	O
-	O
kappaB	O
activation	O
[	O
21	O
]	O
.	O

One	O
of	O
the	O
best	O
studied	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
is	O
the	O
TNF	B-Protein
pathway	O
.	O
<EOS>	B-X
TNF	B-X
is	B-X
a	B-X
multifunctional	B-X
cytokine	B-X
that	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
by	B-X
inducing	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
an	B-X
inflammatory	B-X
response	B-X
.	B-X
TNF-induced	B-X
NF-κB	B-X
activation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
best	B-X
studied	B-X
signaling	B-X
pathways	B-X
in	B-X
mammalian	B-X
cells	B-X
and	B-X
has	B-X
recently	B-X
led	B-X
to	B-X
a	B-X
revival	B-X
of	B-X
research	B-X
in	B-X
the	B-X
biology	B-X
of	B-X
ubiquitin	B-X
.	B-X
Many	B-X
NF-κB	B-X
signaling	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
specific	B-X
ubiquitin	B-X
ligases	B-X
with	B-X
different	B-X
types	B-X
of	B-X
ubiquitin	B-X
chains	B-X
that	B-X
are	B-X
recognized	B-X
by	B-X
other	B-X
proteins	B-X
and	B-X
which	B-X
determine	B-X
the	B-X
outcome	B-X
of	B-X
ubiquitination	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
recent	B-X
findings	B-X
that	B-X
have	B-X
shaped	B-X
our	B-X
current	B-X
understanding	B-X
on	B-X
the	B-X
role	B-X
of	B-X
cytoplasmic	B-X
ubiquitination	B-X
events	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
TNF-induced	B-X
NF-κB	B-X
signaling	B-X
.	B-X

TNF	B-Protein
stimulation	O
results	O
in	O
the	O
recruitment	O
of	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
1	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
(	O
TRADD	B-Protein
)	O
protein	O
and	O
of	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
(	O
RIP1	B-Protein
)	O
,	O
which	O
function	O
as	O
adaptor	O
proteins	O
for	O
the	O
E3	O
ubiquitin	O
ligases	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
(	I-Protein
TRAF	I-Protein
)	I-Protein
2	I-Protein
and	O
TRAF5	B-Protein
,	O
which	O
in	O
turn	O
bind	O
the	O
E3	O
ubiquitin	O
ligases	O
cellular	B-Protein
inhibitor	I-Protein
of	I-Protein
apoptosis	I-Protein
(	I-Protein
cIAP	I-Protein
)	I-Protein
1	I-Protein
and	O
cIAP2	B-Protein
(	O
Figure	O
1	O
)	O
.	O

On	O
TNF	B-Protein
stimulation	O
,	O
TNF	O
-	O
receptor	O
bound	O
RIP1	B-Protein
is	O
rapidly	O
modified	O
by	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

TRAF2	B-Protein
/	O
5	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
are	O
good	O
candidates	O
for	O
RIP1	B-Protein
ubiquitination	O
,	O
but	O
the	O
specific	O
role	O
of	O
each	O
is	O
still	O
unclear	O
.	O

The	O
polyubiquitin	O
chains	O
on	O
RIP1	B-Protein
are	O
believed	O
to	O
create	O
a	O
scaffold	O
to	O
recruit	O
the	O
IKK	O
and	O
TAK1	B-Protein
complex	O
via	O
the	O
ubiquitin	O
-	O
binding	O
proteins	O
NEMO	B-Protein
and	O
TAB1	B-Protein
/	O
2	B-Protein
,	O
respectively	O
.	O

The	O
recent	O
identification	O
of	O
a	O
distinct	O
E2	O
/	O
E3	O
enzyme	O
complex	O
that	O
modifies	O
NEMO	B-Protein
with	O
linear	O
polyubiquitin	O
chains	O
and	O
is	O
essential	O
for	O
TNF	B-Protein
-	O
activated	O
NF	O
-	O
kappaB	O
signalling	O
adds	O
further	O
complexity	O
[	O
22	O
]	O
.	O

The	O
exact	O
role	O
of	O
protein	O
-	O
anchored	O
polyubiquitin	O
chains	O
remains	O
unclear	O
,	O
as	O
it	O
was	O
recently	O
suggested	O
that	O
unanchored	O
polyubiquitin	O
chains	O
can	O
directly	O
activate	O
the	O
TAK1	B-Protein
complex	O
[	O
23	O
]	O
.	O

Similar	O
signalling	O
principles	O
apply	O
to	O
other	O
receptors	O
.	O
<EOS>	B-X
The	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
(	B-X
BMP	B-X
)	B-X
signaling	B-X
pathway	B-X
comprises	B-X
multiple	B-X
ligands	B-X
and	B-X
receptors	B-X
that	B-X
interact	B-X
promiscuously	B-X
with	B-X
one	B-X
another	B-X
and	B-X
typically	B-X
appear	B-X
in	B-X
combinations	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
a	B-X
direct	B-X
signal-processing	B-X
role	B-X
for	B-X
promiscuous	B-X
receptor-ligand	B-X
interactions	B-X
and	B-X
establish	B-X
operational	B-X
principles	B-X
for	B-X
quantitatively	B-X
controlling	B-X
cells	B-X
with	B-X
BMP	B-X
ligands	B-X
.	B-X
Similar	B-X
principles	B-X
could	B-X
apply	B-X
to	B-X
other	B-X
promiscuous	B-X
signaling	B-X
pathways	B-X
.	B-X

For	O
example	O
,	O
TLR4	B-Protein
stimulation	O
by	O
lipopolysaccharide	O
induces	O
the	O
recruitment	O
of	O
Toll	B-Protein
/	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
adaptor	I-Protein
protein	I-Protein
(	O
also	O
referred	O
to	O
as	O
Mal	B-Protein
)	O
and	O
TRIF	B-Protein
-	I-Protein
related	I-Protein
adaptor	I-Protein
molecule	I-Protein
(	O
TRAM	B-Protein
)	O
,	O
which	O
most	O
probably	O
serve	O
as	O
bridging	O
factors	O
to	O
recruit	O
myeloid	B-Protein
differentiation	I-Protein
primary	I-Protein
response	I-Protein
gene	I-Protein
88	I-Protein
(	O
MyD88	B-Protein
)	O
and	O
TIR	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
adaptor	I-Protein
-	I-Protein
inducing	I-Protein
IFNbeta	I-Protein
(	O
TRIF	B-Protein
)	O
,	O
respectively	O
.	O

MyD88	B-Protein
in	O
turn	O
recruits	O
members	O
of	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
family	O
and	O
TRAF6	B-Protein
,	O
leading	O
to	O
oligomerisation	O
and	O
selfubiquitination	O
of	O
TRAF6	B-Protein
[	O
24	O
]	O
.	O

TRIF	B-Protein
also	O
recruits	O
TRAF6	B-Protein
[	O
25	O
]	O
and	O
RIP1	B-Protein
[	O
26	O
]	O
via	O
a	O
direct	O
interaction	O
.	O

Both	O
pathways	O
then	O
activate	O
TAK1	B-Protein
and	O
IKK	O
in	O
a	O
ubiquitination	O
-	O
dependent	O
manner	O
similar	O
to	O
the	O
TNF	B-Protein
pathway	O
(	O
Figure	O
1	O
)	O
.	O

The	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
can	O
be	O
activated	O
by	O
the	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
,	O
BAFF	B-Protein
receptor	I-Protein
,	O
CD40	B-Protein
,	O
and	O
RANK	B-Protein
(	O
Figure	O
2	O
)	O
.	O

In	O
this	O
pathway	O
,	O
p100	B-Protein
is	O
processed	O
by	O
the	O
proteasome	O
to	O
p52	B-Protein
,	O
which	O
together	O
with	O
the	O
RelB	B-Protein
NF	O
-	O
kappaB	O
subunit	O
regulates	O
a	O
distinct	O
set	O
of	O
target	O
genes	O
that	O
control	O
B	O
-	O
cell	O
development	O
,	O
secondary	O
lymphoid	O
organ	O
development	O
,	O
and	O
osteoclastogenesis	O
[	O
27	O
]	O
The	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
is	O
strictly	O
dependent	O
on	O
IKK1	B-Protein
,	O
which	O
is	O
activated	O
upon	O
phosphorylation	O
by	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
.	O

NIK	B-Protein
is	O
predominantly	O
regulated	O
at	O
the	O
post	O
-	O
translational	O
level	O
and	O
is	O
present	O
at	O
extremely	O
low	O
levels	O
in	O
most	O
cell	O
types	O
.	O

In	O
unstimulated	O
cells	O
,	O
NIK	B-Protein
occurs	O
in	O
a	O
cytoplasmic	O
complex	O
with	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
K48	O
-	O
polyubiquitinates	O
NIK	B-Protein
,	O
leading	O
to	O
its	O
continuous	O
degradation	O
by	O
the	O
proteasome	O
.	O

Receptor	O
ligation	O
has	O
been	O
shown	O
not	O
only	O
to	O
remove	O
TRAF3	B-Protein
from	O
this	O
complex	O
by	O
recruiting	O
it	O
to	O
the	O
receptor	O
,	O
but	O
also	O
to	O
attract	O
TRAF2	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
are	O
essential	O
for	O
subsequent	O
TRAF3	B-Protein
degradation	O
.	O
<EOS>	B-X
Though	B-X
plumbagin	B-X
's	B-X
hepatoprotective	B-X
potential	B-X
attracts	B-X
attention	B-X
,	B-X
currently	B-X
no	B-X
experimental	B-X
evidence	B-X
exists	B-X
on	B-X
its	B-X
effectiveness	B-X
against	B-X
cholestatic	B-X
liver	B-X
injury	B-X
.	B-X
Hepatoprotective	B-X
actions	B-X
of	B-X
plumbagin	B-X
were	B-X
accompanied	B-X
by	B-X
reduction	B-X
of	B-X
Transforming	B-X
Growth	B-X
Factor	B-X
β1	B-X
(	B-X
TGF-β1	B-X
)	B-X
/Smad	B-X
,	B-X
High	B-X
Mobility	B-X
Group	B-X
Box-1	B-X
(	B-X
HMGB1	B-X
)	B-X
/Toll-Like	B-X
Receptor-4	B-X
(	B-X
TLR4	B-X
)	B-X
,	B-X
Hypoxia-Inducible	B-X
Factor-1α	B-X
(	B-X
HIF-1α	B-X
)	B-X
,	B-X
Aryl	B-X
Hydrocarbon	B-X
Receptor	B-X
(	B-X
AhR	B-X
)	B-X
,	B-X
Heat	B-X
Shock	B-X
Protein	B-X
90	B-X
(	B-X
HSP90	B-X
)	B-X
,	B-X
caveolin-1	B-X
,	B-X
NF-κB/AP-1	B-X
,	B-X
Dynamin	B-X
Related	B-X
Protein-1	B-X
(	B-X
Drp1	B-X
)	B-X
,	B-X
malondialdehyde	B-X
level	B-X
,	B-X
Interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
,	B-X
p62/SQSTM1	B-X
,	B-X
and	B-X
caspase	B-X
3	B-X
as	B-X
well	B-X
as	B-X
increase	B-X
of	B-X
Farnesoid	B-X
X	B-X
Receptor	B-X
(	B-X
FXR	B-X
)	B-X
,	B-X
bile	B-X
acid	B-X
efflux	B-X
transporters	B-X
,	B-X
glutathione	B-X
,	B-X
LC3-II	B-X
,	B-X
Beclin1	B-X
,	B-X
and	B-X
nuclear	B-X
NF-E2-Related	B-X
Factor-2	B-X
(	B-X
Nrf2	B-X
)	B-X
and	B-X
Transcription	B-X
Factor	B-X
EB	B-X
(	B-X
TFEB	B-X
)	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
nuclear	B-X
Nrf2	B-X
caused	B-X
by	B-X
plumbagin	B-X
correlated	B-X
well	B-X
with	B-X
the	B-X
improvement	B-X
in	B-X
bile	B-X
acid	B-X
retention	B-X
,	B-X
liver	B-X
histology	B-X
,	B-X
serum	B-X
biochemical	B-X
,	B-X
ductular	B-X
reaction	B-X
,	B-X
mitochondrial	B-X
dysfunction	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
inflammation	B-X
,	B-X
apoptosis	B-X
,	B-X
impaired	B-X
autophagy	B-X
,	B-X
and	B-X
fibrosis	B-X
,	B-X
involving	B-X
interplay	B-X
of	B-X
multiple	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X
Despite	B-X
the	B-X
lack	B-X
of	B-X
sufficient	B-X
randomized	B-X
prospective	B-X
studies	B-X
,	B-X
ACE	B-X
inhibitors	B-X
are	B-X
first	B-X
line	B-X
and	B-X
ß-receptor	B-X
antagonists	B-X
are	B-X
second-line	B-X
strategies	B-X
in	B-X
children	B-X
.	B-X
Following	B-X
the	B-X
adult	B-X
guidelines	B-X
,	B-X
without	B-X
having	B-X
data	B-X
concerning	B-X
the	B-X
pediatric	B-X
population	B-X
,	B-X
mineral	B-X
corticoids	B-X
are	B-X
also	B-X
accepted	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
pediatric	B-X
heart	B-X
failure	B-X
,	B-X
while	B-X
diuretics	B-X
should	B-X
only	B-X
be	B-X
used	B-X
to	B-X
achieve	B-X
a	B-X
euvolemic	B-X
status	B-X
.	B-X

All	O
this	O
contributes	O
to	O
releasing	O
NIK	B-Protein
from	O
its	O
constitutive	O
degradation	O
,	O
resulting	O
in	O
NIK	B-Protein
accumulation	O
and	O
IKK1	B-Protein
phosphorylation	O
[	O
28	O
,	O
29	O
]	O
(	O
Figure	O
2	O
)	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
CD40	B-Protein
,	O
lymphotoxin	B-Protein
beta	I-Protein
receptor	I-Protein
and	O
RANK	B-Protein
mediate	O
the	O
activation	O
of	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
signalling	O
pathways	O
.	O

Upon	O
binding	O
of	O
their	O
ligand	O
,	O
CD40	B-Protein
and	O
RANK	B-Protein
interact	O
with	O
several	O
TRAF	O
members	O
,	O
including	O
TRAF1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
TRAF5	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
and	O
this	O
leads	O
to	O
the	O
proteolysis	O
of	O
both	O
TRAF2	B-Protein
and	O
TRAF3	B-Protein
,	O
which	O
represents	O
an	O
important	O
step	O
in	O
the	O
activation	O
of	O
the	O
noncanonical	O
pathway	O
as	O
described	O
above	O
.	O

Specific	O
TRAF	O
molecules	O
are	O
associated	O
with	O
overlapping	O
and	O
distinct	O
CD40	B-Protein
-	O
mediated	O
functions	O
.	O
<EOS>	B-X
TNF-receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
are	B-X
intracellular	B-X
proteins	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
cytoplasmic	B-X
portion	B-X
of	B-X
TNF	B-X
receptors	B-X
and	B-X
mediate	B-X
downstream	B-X
signaling	B-X
.	B-X
The	B-X
six	B-X
known	B-X
TRAF	B-X
proteins	B-X
play	B-X
overlapping	B-X
yet	B-X
distinct	B-X
roles	B-X
in	B-X
controlling	B-X
immune	B-X
responses	B-X
as	B-X
well	B-X
as	B-X
cellular	B-X
processes	B-X
such	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
JNK	B-X
signaling	B-X
pathways	B-X
.	B-X
For	B-X
example	B-X
,	B-X
CD40	B-X
binds	B-X
to	B-X
TRAF2	B-X
,	B-X
TRAF3	B-X
and	B-X
TRAF6	B-X
to	B-X
control	B-X
B	B-X
cell	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
growth	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
binding	B-X
of	B-X
lymphotoxin-beta	B-X
receptor	B-X
(	B-X
LTbetaR	B-X
)	B-X
to	B-X
TRAF2	B-X
and	B-X
TRAF5	B-X
propagates	B-X
signals	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
while	B-X
binding	B-X
to	B-X
TRAF3	B-X
induces	B-X
negative	B-X
regulation	B-X
of	B-X
this	B-X
pathway	B-X
and	B-X
leads	B-X
to	B-X
apoptosis	B-X
in	B-X
tumor	B-X
cells	B-X
.	B-X
Binding	B-X
recognition	B-X
is	B-X
mediated	B-X
by	B-X
specific	B-X
contacts	B-X
of	B-X
a	B-X
consensus	B-X
recognition	B-X
sequence	B-X
in	B-X
the	B-X
partner	B-X
with	B-X
residues	B-X
in	B-X
a	B-X
hydrophobic	B-X
crevice	B-X
on	B-X
the	B-X
TRAF	B-X
molecule	B-X
.	B-X
Since	B-X
each	B-X
of	B-X
these	B-X
protein-protein	B-X
interactions	B-X
occurs	B-X
within	B-X
this	B-X
same	B-X
binding	B-X
crevice	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
TRAF-mediated	B-X
cellular	B-X
mechanisms	B-X
may	B-X
be	B-X
regulated	B-X
,	B-X
in	B-X
part	B-X
,	B-X
by	B-X
the	B-X
level	B-X
of	B-X
expression	B-X
or	B-X
recruitment	B-X
of	B-X
the	B-X
adaptor	B-X
proteins	B-X
or	B-X
receptors	B-X
that	B-X
are	B-X
competing	B-X
for	B-X
the	B-X
crevice	B-X
.	B-X
The	B-X
specific	B-X
contacts	B-X
of	B-X
CD40	B-X
,	B-X
LTbetaR	B-X
and	B-X
BAFF-R	B-X
have	B-X
been	B-X
defined	B-X
in	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
complex	B-X
with	B-X
TRAF3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
downstream	B-X
regulator	B-X
TANK	B-X
and	B-X
the	B-X
viral	B-X
oncogenic	B-X
protein	B-X
LMP1	B-X
from	B-X
the	B-X
Epstein	B-X
Barr	B-X
virus	B-X
also	B-X
bind	B-X
to	B-X
the	B-X
same	B-X
TRAF	B-X
crevice	B-X
and	B-X
these	B-X
contacts	B-X
have	B-X
also	B-X
been	B-X
described	B-X
crystallographically	B-X
.	B-X
Comparison	B-X
of	B-X
these	B-X
five	B-X
crystal	B-X
structures	B-X
has	B-X
revealed	B-X
that	B-X
the	B-X
recognition	B-X
motifs	B-X
in	B-X
each	B-X
of	B-X
these	B-X
proteins	B-X
are	B-X
accommodated	B-X
in	B-X
one	B-X
TRAF3	B-X
binding	B-X
crevice	B-X
and	B-X
that	B-X
the	B-X
binding	B-X
interface	B-X
is	B-X
structurally	B-X
and	B-X
functionally	B-X
adaptive	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
the	B-X
molecular	B-X
details	B-X
of	B-X
the	B-X
interactions	B-X
will	B-X
be	B-X
described	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
functional	B-X
implications	B-X
for	B-X
multiple	B-X
TRAF3	B-X
roles	B-X
in	B-X
cellular	B-X
regulation	B-X
.	B-X

For	O
example	O
,	O
in	O
B	O
cells	O
TRAF6	B-Protein
is	O
required	O
for	O
CD40	B-Protein
-	O
mediated	O
JNK	O
activation	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
,	O
while	O
TRAF2	B-Protein
is	O
required	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
TRAF3	B-Protein
serves	O
as	O
a	O
negative	O
regulator	O
of	O
CD40	B-Protein
signalling	O
[	O
30	O
,	O
31	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
activation	O
is	O
so	O
crucial	O
to	O
many	O
cellular	O
processes	O
,	O
a	O
tight	O
regulation	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
and	O
the	O
genes	O
it	O
induces	O
is	O
an	O
absolute	O
requirement	O
to	O
fine	O
-	O
tune	O
the	O
inflammatory	O
response	O
.	O

Moreover	O
,	O
terminating	O
an	O
NF	O
-	O
kappaB	O
response	O
is	O
essential	O
to	O
prevent	O
persistent	O
NF	O
-	O
kappaB	O
activation	O
that	O
may	O
lead	O
to	O
chronic	O
inflammation	O
and	O
/	O
or	O
tumorigenesis	O
.	O
<EOS>	B-X
Being	B-X
the	B-X
second	B-X
leading	B-X
cause	B-X
of	B-X
death	B-X
globally	B-X
,	B-X
cancer	B-X
has	B-X
been	B-X
a	B-X
long-standing	B-X
and	B-X
rapidly	B-X
evolving	B-X
focus	B-X
of	B-X
biomedical	B-X
research	B-X
and	B-X
practice	B-X
in	B-X
the	B-X
world	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
made	B-X
an	B-X
attempt	B-X
to	B-X
scrutinize	B-X
evidences	B-X
that	B-X
indicate	B-X
the	B-X
role	B-X
of	B-X
stem	B-X
cells	B-X
in	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
,	B-X
and	B-X
cancer	B-X
relapse	B-X
.	B-X
Cells	B-X
use	B-X
mitophagy	B-X
to	B-X
remove	B-X
dysfunctional	B-X
or	B-X
excess	B-X
mitochondria	B-X
,	B-X
frequently	B-X
in	B-X
response	B-X
to	B-X
imposed	B-X
stresses	B-X
,	B-X
such	B-X
as	B-X
hypoxia	B-X
and	B-X
nutrient	B-X
deprivation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
upstream	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
mitophagy	B-X
,	B-X
including	B-X
components	B-X
of	B-X
the	B-X
mitochondrial	B-X
fission	B-X
machinery	B-X
,	B-X
AMPK	B-X
,	B-X
ATF4	B-X
,	B-X
FoxOs	B-X
,	B-X
Sirtuins	B-X
,	B-X
and	B-X
mtDNA	B-X
release	B-X
,	B-X
and	B-X
address	B-X
the	B-X
significance	B-X
of	B-X
these	B-X
pathways	B-X
for	B-X
stress	B-X
responses	B-X
in	B-X
tumorigenesis	B-X
and	B-X
metastasis	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
interrogate	B-X
how	B-X
mitophagy	B-X
affects	B-X
tissue	B-X
atrophy	B-X
during	B-X
cancer	B-X
cachexia	B-X
and	B-X
therapy	B-X
responses	B-X
in	B-X
the	B-X
clinic	B-X
.	B-X

To	O
achieve	O
this	O
,	O
cells	O
employ	O
different	O
mechanisms	O
,	O
including	O
the	O
expression	O
of	O
inhibitory	O
proteins	O
that	O
downregulate	O
NF	O
-	O
kappaB	O
signalling	O
[	O
32	O
]	O
.	O

Below	O
we	O
give	O
an	O
overview	O
of	O
a	O
number	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
dampening	O
or	O
termination	O
of	O
the	O
NF	O
-	O
kappaB	O
response	O
,	O
some	O
of	O
them	O
under	O
the	O
control	O
of	O
NF	O
-	O
kappaB	O
itself	O
and	O
thus	O
acting	O
in	O
a	O
negative	O
feedback	O
loop	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
potential	O
role	O
of	O
these	O
NF	O
-	O
kappaB	O
inhibitory	O
factors	O
in	O
the	O
immunopathology	O
of	O
RA	O
.	O

Several	O
other	O
proteins	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammatory	O
responses	O
,	O
such	O
as	O
MyD88s	B-Protein
,	O
IRAK	B-Protein
-	I-Protein
M	I-Protein
,	O
and	O
TOLLIP	B-Protein
,	O
have	O
been	O
described	O
(	O
reviewed	O
in	O
[	O
33	O
]	O
)	O
.	O

These	O
proteins	O
are	O
not	O
discussed	O
here	O
,	O
since	O
a	O
link	O
with	O
RA	O
pathology	O
has	O
not	O
yet	O
been	O
reported	O
.	O
Although	O
IKK1	B-Protein
is	O
a	O
critical	O
component	O
of	O
the	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
,	O
it	O
should	O
be	O
mentioned	O
that	O
this	O
kinase	O
also	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
pathways	O
.	O
<EOS>	B-X
The	B-X
intracellular	B-X
sorting	B-X
of	B-X
newly	B-X
synthesized	B-X
precursor	B-X
proteins	B-X
(	B-X
preproteins	B-X
)	B-X
to	B-X
mitochondria	B-X
depends	B-X
on	B-X
the	B-X
``	B-X
mitochondria-targeting	B-X
sequence	B-X
''	B-X
(	B-X
MTS	B-X
)	B-X
,	B-X
which	B-X
is	B-X
located	B-X
at	B-X
the	B-X
amino	B-X
termini	B-X
of	B-X
the	B-X
preproteins	B-X
.	B-X
MTS	B-X
is	B-X
required	B-X
,	B-X
however	B-X
,	B-X
not	B-X
only	B-X
for	B-X
targeting	B-X
newly	B-X
synthesized	B-X
preproteins	B-X
to	B-X
mitochondria	B-X
,	B-X
but	B-X
also	B-X
for	B-X
all	B-X
the	B-X
following	B-X
steps	B-X
along	B-X
the	B-X
mitochondrial	B-X
protein	B-X
import	B-X
pathway	B-X
.	B-X
MTS	B-X
of	B-X
nascent	B-X
preproteins	B-X
is	B-X
first	B-X
recognized	B-X
by	B-X
a	B-X
cytoplasmic	B-X
molecular	B-X
chaperone	B-X
,	B-X
MSF	B-X
,	B-X
and	B-X
then	B-X
by	B-X
Tom70	B-X
and	B-X
Tom20	B-X
of	B-X
the	B-X
mitochondrial	B-X
outer	B-X
membrane	B-X
receptor	B-X
complex	B-X
,	B-X
Tom5	B-X
and	B-X
Tom40	B-X
of	B-X
the	B-X
outer	B-X
membrane	B-X
protein	B-X
translocation	B-X
machinery	B-X
,	B-X
Tim23	B-X
of	B-X
the	B-X
inner	B-X
membrane	B-X
protein	B-X
translocation	B-X
machinery	B-X
,	B-X
and	B-X
finally	B-X
the	B-X
processing	B-X
peptidase	B-X
,	B-X
MPP	B-X
,	B-X
in	B-X
the	B-X
matrix	B-X
.	B-X
MTS	B-X
is	B-X
a	B-X
multi-role	B-X
sorting	B-X
sequence	B-X
which	B-X
specifically	B-X
interacts	B-X
with	B-X
various	B-X
components	B-X
along	B-X
the	B-X
mitochondrial	B-X
protein	B-X
import	B-X
pathway	B-X
.	B-X
Recognition	B-X
of	B-X
MTS	B-X
at	B-X
multiple	B-X
steps	B-X
during	B-X
the	B-X
import	B-X
of	B-X
preproteins	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
strict	B-X
sorting	B-X
of	B-X
proteins	B-X
destined	B-X
for	B-X
mitochondria	B-X
.	B-X

Macrophages	O
from	O
IKK1	B-Protein
-	O
deficient	O
mice	O
or	O
knockin	O
mice	O
expressing	O
inactive	O
IKK1	B-Protein
show	O
increased	O
production	O
of	O
proinflammatory	O
cytokines	O
as	O
a	O
result	O
of	O
enhanced	O
IKK2	B-Protein
activation	O
and	O
IkappaBalpha	B-Protein
degradation	O
[	O
34	O
]	O
.	O
<EOS>	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
plays	B-X
a	B-X
key	B-X
regulatory	B-X
role	B-X
in	B-X
macrophages	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
during	B-X
both	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
Because	B-X
IKK1-/-	B-X
mice	B-X
died	B-X
at	B-X
birth	B-X
,	B-X
we	B-X
differentiated	B-X
functional	B-X
macrophages	B-X
from	B-X
embryonic	B-X
day	B-X
15.5	B-X
IKK1	B-X
mutant	B-X
embryonic	B-X
liver	B-X
.	B-X
The	B-X
embryonic	B-X
liver-derived	B-X
macrophage	B-X
(	B-X
ELDM	B-X
)	B-X
showed	B-X
enhanced	B-X
phagocytotic	B-X
clearance	B-X
of	B-X
bacteria	B-X
,	B-X
more	B-X
efficient	B-X
antigen-presenting	B-X
capacity	B-X
,	B-X
elevated	B-X
secretion	B-X
of	B-X
several	B-X
key	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
,	B-X
and	B-X
known	B-X
NFkappaB	B-X
target	B-X
genes	B-X
.	B-X
Increased	B-X
NFkappaB	B-X
activity	B-X
in	B-X
IKK1	B-X
mutant	B-X
ELDM	B-X
was	B-X
the	B-X
result	B-X
of	B-X
prolonged	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
in	B-X
response	B-X
to	B-X
infectious	B-X
pathogens	B-X
.	B-X
The	B-X
delayed	B-X
restoration	B-X
of	B-X
IkappaBalpha	B-X
in	B-X
pathogen-activated	B-X
IKK1-/-	B-X
ELDM	B-X
was	B-X
a	B-X
direct	B-X
consequence	B-X
of	B-X
uncontrolled	B-X
IKK2	B-X
kinase	B-X
activity	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
IKK1	B-X
plays	B-X
a	B-X
checkpoint	B-X
role	B-X
in	B-X
the	B-X
proper	B-X
control	B-X
of	B-X
IkappaBalpha	B-X
kinase	B-X
activity	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X

IKK1	B-Protein
has	O
also	O
been	O
shown	O
to	O
inhibit	O
nuclear	O
NF	O
-	O
kappaB	O
and	O
to	O
downregulate	O
proinflammatory	O
signalling	O
by	O
phosphorylating	O
STAT1	B-Protein
[	O
35	O
]	O
.	O

Interestingly	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
that	O
IKK1	B-Protein
phosphorylates	O
NIK	B-Protein
in	O
negative	O
feedback	O
regulation	O
of	O
the	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
[	O
36	O
]	O
,	O
supporting	O
the	O
idea	O
that	O
IKK1	B-Protein
plays	O
important	O
roles	O
in	O
terminating	O
both	O
canonical	O
and	O
noncanonical	O
NF	O
-	O
kappaB	O
pathways	O
with	O
possible	O
implications	O
for	O
chronic	O
inflammatory	O
diseases	O
like	O
RA	O
.	O

A20	B-Protein
protein	O
<EOS>	B-X
Ubiquitination	B-X
,	B-X
a	B-X
covalent	B-X
posttranslational	B-X
modification	B-X
of	B-X
target	B-X
proteins	B-X
with	B-X
ubiquitin	B-X
,	B-X
has	B-X
a	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
stability	B-X
and	B-X
activity	B-X
of	B-X
its	B-X
substrates	B-X
,	B-X
thereby	B-X
regulating	B-X
the	B-X
immune	B-X
system	B-X
at	B-X
molecular	B-X
and	B-X
cellular	B-X
levels	B-X
.	B-X
Through	B-X
the	B-X
cooperative	B-X
actions	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
and	B-X
deubiquitinases	B-X
,	B-X
ubiquitin	B-X
modifications	B-X
are	B-X
implicated	B-X
in	B-X
several	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
proteasomal	B-X
degradation	B-X
,	B-X
transcriptional	B-X
regulation	B-X
,	B-X
regulation	B-X
of	B-X
protein-protein	B-X
interactions	B-X
,	B-X
endocytosis	B-X
,	B-X
autophagy	B-X
,	B-X
DNA	B-X
repair	B-X
,	B-X
and	B-X
cell	B-X
cycle	B-X
regulation	B-X
.	B-X
A20	B-X
(	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α-induced	B-X
protein	B-X
3	B-X
or	B-X
TNFAIP3	B-X
)	B-X
is	B-X
a	B-X
ubiquitin-editing	B-X
enzyme	B-X
that	B-X
mainly	B-X
functions	B-X
as	B-X
an	B-X
endogenous	B-X
regulator	B-X
of	B-X
inflammation	B-X
through	B-X
termination	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
activation	B-X
as	B-X
part	B-X
of	B-X
a	B-X
negative	B-X
feedback	B-X
loop	B-X
.	B-X
A20	B-X
interacts	B-X
with	B-X
substrates	B-X
that	B-X
reside	B-X
downstream	B-X
of	B-X
immune	B-X
sensors	B-X
,	B-X
including	B-X
Toll-like	B-X
receptors	B-X
,	B-X
nucleotide-binding	B-X
oligomerization	B-X
domain-containing	B-X
receptors	B-X
,	B-X
lymphocyte	B-X
receptors	B-X
,	B-X
and	B-X
cytokine	B-X
receptors	B-X
.	B-X
Due	B-X
to	B-X
its	B-X
pleiotropic	B-X
functions	B-X
as	B-X
a	B-X
ubiquitin	B-X
binding	B-X
protein	B-X
,	B-X
deubiquitinase	B-X
and	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
and	B-X
its	B-X
versatile	B-X
role	B-X
in	B-X
various	B-X
signaling	B-X
pathways	B-X
,	B-X
aberrant	B-X
A20	B-X
levels	B-X
are	B-X
associated	B-X
with	B-X
numerous	B-X
conditions	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
diabetes	B-X
,	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
,	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
psoriasis	B-X
,	B-X
Sjögren	B-X
syndrome	B-X
,	B-X
coronary	B-X
artery	B-X
disease	B-X
,	B-X
multiple	B-X
sclerosis	B-X
,	B-X
cystic	B-X
fibrosis	B-X
,	B-X
asthma	B-X
,	B-X
cancer	B-X
,	B-X
neurological	B-X
disorders	B-X
,	B-X
and	B-X
aging-related	B-X
sequelae	B-X
.	B-X
Similarly	B-X
,	B-X
A20	B-X
has	B-X
recently	B-X
been	B-X
implicated	B-X
as	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
inflammation	B-X
in	B-X
the	B-X
oral	B-X
cavity	B-X
.	B-X
This	B-X
review	B-X
presents	B-X
information	B-X
on	B-X
the	B-X
ubiquitin	B-X
system	B-X
and	B-X
regulation	B-X
of	B-X
NF-κB	B-X
by	B-X
ubiquitination	B-X
using	B-X
A20	B-X
as	B-X
a	B-X
representative	B-X
molecule	B-X
and	B-X
highlights	B-X
how	B-X
the	B-X
dysregulation	B-X
of	B-X
this	B-X
system	B-X
can	B-X
lead	B-X
to	B-X
several	B-X
immune	B-X
pathologies	B-X
,	B-X
including	B-X
oral	B-X
cavity-related	B-X
disorders	B-X
mainly	B-X
focusing	B-X
on	B-X
periodontitis	B-X
.	B-X

A20	B-Protein
(	O
also	O
known	O
as	O
TNFAIP3	B-Protein
)	O
is	O
a	O
ubiquitin	B-Protein
-	I-Protein
editing	I-Protein
protein	I-Protein
that	O
negatively	O
regulates	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	O
dependent	O
gene	O
expression	O
in	O
response	O
to	O
different	O
immune	O
-	O
activating	O
stimuli	O
,	O
including	O
TNF	B-Protein
,	O
IL	O
-	O
1	O
and	O
antigens	O
,	O
and	O
the	O
triggering	O
of	O
TLRs	O
and	O
the	O
nucleotide	O
-	O
binding	O
oligomerisation	O
domain	O
-	O
containing	O
2	O
receptor	O
(	O
reviewed	O
in	O
[	O
37	O
]	O
)	O
.	O

A20	B-Protein
is	O
believed	O
to	O
inhibit	O
NF	O
-	O
kappaB	O
function	O
by	O
deubiquitinating	O
specific	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
,	O
such	O
as	O
RIP1	B-Protein
,	O
RIP2	B-Protein
,	O
TRAF6	B-Protein
and	O
MALT1	B-Protein
,	O
which	O
disrupts	O
specific	O
protein	O
-	O
protein	O
interactions	O
[	O
38	O
-	O
41	O
]	O
(	O
Figure	O
1	O
)	O
.	O

Recently	O
,	O
the	O
disruption	O
of	O
interactions	O
between	O
E2	O
ubiquitin	O
conjugating	O
enzymes	O
(	O
Ubc13	B-Protein
and	O
Ubc5hc	B-Protein
)	O
and	O
E3	O
ubiquitin	O
ligases	O
(	O
TRAF6	B-Protein
,	O
TRAF2	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
)	O
were	O
described	O
as	O
another	O
important	O
mechanism	O
used	O
by	O
A20	B-Protein
to	O
downregulate	O
NF	O
-	O
kappaB	O
signalling	O
[	O
42	O
]	O
.	O

The	O
association	O
of	O
A20	B-Protein
with	O
its	O
targets	O
requires	O
specific	O
ubiquitin	O
-	O
binding	O
adaptor	O
proteins	O
,	O
including	O
A20	B-Protein
-	I-Protein
binding	I-Protein
inhibitor	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
(	I-Protein
ABIN	I-Protein
)	I-Protein
1	I-Protein
and	O
Tax1	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
[	O
43	O
-	O
46	O
]	O
.	O

Next	O
to	O
its	O
role	O
in	O
suppressing	O
NF	O
-	O
kappaB	O
activation	O
,	O
A20	B-Protein
is	O
also	O
a	O
strong	O
inhibitor	O
of	O
apoptosis	O
,	O
at	O
least	O
in	O
some	O
cell	O
types	O
.	O

The	O
mechanisms	O
by	O
which	O
A20	B-Protein
regulates	O
apoptotic	O
signalling	O
,	O
however	O
,	O
are	O
still	O
elusive	O
.	O

A20	B-Protein
-	O
deficient	O
mice	O
spontaneously	O
develop	O
multiorgan	O
inflammation	O
and	O
cachexia	O
and	O
die	O
within	O
2	O
weeks	O
of	O
birth	O
,	O
illustrating	O
the	O
potent	O
anti	O
-	O
inflammatory	O
function	O
of	O
this	O
molecule	O
[	O
46	O
]	O
.	O

A20	B-Protein
-	O
deficient	O
cells	O
are	O
also	O
more	O
susceptible	O
to	O
TNF	B-Protein
-	O
mediated	O
apoptosis	O
,	O
confirming	O
its	O
role	O
as	O
an	O
antiapoptotic	O
protein	O
.	O

We	O
recently	O
showed	O
that	O
mice	O
specifically	O
lacking	O
A20	B-Protein
in	O
intestinal	O
epithelial	O
cells	O
exhibit	O
increased	O
susceptibility	O
to	O
experimental	O
colitis	O
due	O
to	O
the	O
hypersensitivity	O
of	O
their	O
intestinal	O
epithelial	O
cells	O
to	O
TNF	B-Protein
-	O
induced	O
apoptosis	O
,	O
confirming	O
A20	B-Protein
as	O
a	O
major	O
antiapoptotic	O
protein	O
in	O
the	O
intestinal	O
epithelium	O
[	O
47	O
]	O
.	O

Two	O
independent	O
studies	O
showed	O
that	O
mice	O
lacking	O
A20	B-Protein
in	O
B	O
cells	O
develop	O
autoimmunity	O
due	O
to	O
hyperactive	O
NF	O
-	O
kappaB	O
responses	O
in	O
B	O
cells	O
leading	O
to	O
unrestricted	O
B	O
-	O
cell	O
survival	O
[	O
48	O
,	O
49	O
]	O
.	O

A20	B-Protein
expression	O
has	O
been	O
observed	O
in	O
several	O
cell	O
types	O
that	O
play	O
important	O
roles	O
in	O
the	O
pathophysiology	O
of	O
RA	O
,	O
such	O
as	O
fibroblasts	O
,	O
synoviocytes	O
and	O
lymphocytes	O
.	O

Interestingly	O
,	O
A20	B-Protein
expression	O
is	O
itself	O
regulated	O
by	O
NF	O
-	O
kappaB	O
[	O
50	O
]	O
,	O
implicating	O
A20	B-Protein
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
signalling	O
.	O

Recently	O
,	O
intra	O
-	O
articular	O
injection	O
of	O
an	O
A20	B-Protein
-	O
expressing	O
adenovirus	O
was	O
shown	O
to	O
reduce	O
the	O
severity	O
of	O
synovial	O
inflammation	O
and	O
joint	O
destruction	O
in	O
a	O
mouse	O
model	O
of	O
collagen	O
-	O
induced	O
arthritis	O
,	O
even	O
in	O
untreated	O
joints	O
,	O
in	O
both	O
a	O
prophylactic	O
and	O
therapeutic	O
setting	O
.	O

A20	B-Protein
expression	O
in	O
synovial	O
tissue	O
was	O
associated	O
with	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
decreased	O
levels	O
of	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
soluble	O
RANKL	B-Protein
,	O
monocyte	B-Protein
chemo	I-Protein
-	I-Protein
attractant	I-Protein
protein	I-Protein
1	I-Protein
,	O
and	O
IL	O
-	O
17	O
,	O
suggesting	O
that	O
A20	B-Protein
induces	O
a	O
protective	O
effect	O
in	O
collagen	O
-	O
induced	O
arthritis	O
mice	O
through	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
[	O
51	O
]	O
.	O

Because	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
known	O
to	O
mediate	O
synovitis	O
,	O
pannus	O
formation	O
,	O
and	O
erosion	O
of	O
cartilage	O
and	O
bone	O
in	O
RA	O
,	O
the	O
decreased	O
serum	O
levels	O
of	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
A20	B-Protein
-	O
transduced	O
mice	O
might	O
explain	O
the	O
beneficial	O
effects	O
in	O
the	O
clinical	O
,	O
pathological	O
,	O
and	O
radiological	O
findings	O
.	O

This	O
study	O
also	O
demonstrated	O
that	O
A20	B-Protein
overexpression	O
leads	O
to	O
a	O
decrease	O
in	O
the	O
number	O
of	O
activated	O
osteoclasts	O
in	O
joint	O
tissue	O
.	O

A20	B-Protein
might	O
therefore	O
minimise	O
joint	O
destruction	O
through	O
decreasing	O
the	O
osteoclast	O
number	O
and	O
activity	O
.	O

It	O
will	O
be	O
interesting	O
to	O
analyse	O
in	O
future	O
the	O
susceptibility	O
of	O
conditional	O
knockout	O
mice	O
that	O
lack	O
A20	B-Protein
in	O
specific	O
cell	O
types	O
such	O
as	O
synovial	O
fibroblasts	O
,	O
macrophages	O
,	O
dendritic	O
cells	O
,	O
B	O
cells	O
or	O
T	O
cells	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
key	B-X
mediators	B-X
of	B-X
tumor	B-X
destruction	B-X
and	B-X
their	B-X
specificity	B-X
for	B-X
tumor-expressed	B-X
antigens	B-X
is	B-X
of	B-X
paramount	B-X
importance	B-X
,	B-X
but	B-X
other	B-X
T	B-X
cell-intrinsic	B-X
qualities	B-X
,	B-X
such	B-X
as	B-X
durability	B-X
,	B-X
longevity	B-X
,	B-X
and	B-X
functionality	B-X
also	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
determining	B-X
the	B-X
efficacy	B-X
of	B-X
immunotherapy	B-X
.	B-X
The	B-X
cellular	B-X
energetic	B-X
pathways	B-X
that	B-X
are	B-X
utilized	B-X
by	B-X
T	B-X
cells	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
regulating	B-X
each	B-X
of	B-X
these	B-X
qualities	B-X
.	B-X
Metabolic	B-X
activity	B-X
,	B-X
which	B-X
both	B-X
regulates	B-X
and	B-X
is	B-X
regulated	B-X
by	B-X
cellular	B-X
signaling	B-X
pathways	B-X
and	B-X
epigenetics	B-X
,	B-X
also	B-X
profoundly	B-X
influences	B-X
the	B-X
trajectories	B-X
of	B-X
T	B-X
cell	B-X
differentiation	B-X
and	B-X
fate	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
discuss	B-X
how	B-X
cell	B-X
metabolism	B-X
influences	B-X
T	B-X
cell	B-X
anti-tumor	B-X
activity	B-X
,	B-X
the	B-X
metabolic	B-X
qualities	B-X
of	B-X
highly-functional	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
strategies	B-X
to	B-X
modulate	B-X
metabolism	B-X
for	B-X
improving	B-X
the	B-X
immune	B-X
response	B-X
to	B-X
tumors	B-X
.	B-X

Importantly	O
,	O
several	O
SNPs	O
in	O
the	O
human	O
A20	B-Protein
locus	O
have	O
been	O
associated	O
with	O
increased	O
susceptibility	O
to	O
development	O
of	O
autoimmune	O
pathologies	O
(	O
reviewed	O
in	O
[	O
52	O
]	O
)	O
.	O

Several	O
genome	O
-	O
wide	O
association	O
studies	O
also	O
revealed	O
a	O
clear	O
association	O
between	O
mutations	O
in	O
the	O
A20	B-Protein
locus	O
in	O
the	O
6q23	O
chromosome	O
and	O
susceptibility	O
to	O
RA	O
[	O
52	O
]	O
.	O

Although	O
the	O
identified	O
variants	O
are	O
not	O
located	O
in	O
a	O
gene	O
,	O
they	O
are	O
thought	O
to	O
influence	O
A20	B-Protein
as	O
its	O
nearest	O
gene	O
(	O
~	O
150	O
kb	O
downstream	O
of	O
A20	B-Protein
)	O
,	O
probably	O
by	O
the	O
presence	O
of	O
potential	O
regulatory	O
DNA	O
elements	O
in	O
this	O
region	O
.	O
<EOS>	B-X
Due	B-X
to	B-X
the	B-X
complex	B-X
pathophysiology	B-X
involving	B-X
multiple	B-X
pathways	B-X
and	B-X
proteins	B-X
,	B-X
single	B-X
genetic	B-X
diagnostic	B-X
tests	B-X
can	B-X
not	B-X
be	B-X
determined	B-X
.	B-X
Many	B-X
genes	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
PCOS	B-X
,	B-X
which	B-X
affect	B-X
fertility	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
review	B-X
the	B-X
current	B-X
genetic	B-X
understanding	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
have	B-X
discussed	B-X
the	B-X
clinical	B-X
spectrum	B-X
,	B-X
the	B-X
genetics	B-X
,	B-X
and	B-X
the	B-X
variants	B-X
identified	B-X
as	B-X
being	B-X
associated	B-X
with	B-X
PCOS	B-X
.	B-X
The	B-X
mechanisms	B-X
by	B-X
which	B-X
variants	B-X
in	B-X
the	B-X
genes	B-X
confer	B-X
risk	B-X
to	B-X
PCOS	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
physical	B-X
and	B-X
genetic	B-X
interaction	B-X
between	B-X
the	B-X
genetic	B-X
elements	B-X
underlying	B-X
PCOS	B-X
remain	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Elucidation	B-X
of	B-X
genetic	B-X
players	B-X
and	B-X
cellular	B-X
pathways	B-X
underlying	B-X
PCOS	B-X
will	B-X
certainly	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
this	B-X
syndrome	B-X
.	B-X

As	O
A20	B-Protein
is	O
required	O
for	O
termination	O
of	O
TNF	B-Protein
-	O
induced	O
signals	O
,	O
and	O
TNF	B-Protein
is	O
the	O
primary	O
inflammatory	O
cytokine	B-Protein
in	O
RA	O
,	O
these	O
findings	O
reveal	O
A20	B-Protein
as	O
a	O
candidate	O
susceptibility	O
locus	O
for	O
RA	O
.	O

How	O
these	O
variants	O
affect	O
normal	O
A20	B-Protein
activity	O
and	O
how	O
they	O
cause	O
RA	O
,	O
however	O
,	O
remain	O
unclear	O
.	O

Recently	O
,	O
Elsby	O
and	O
colleagues	O
functionally	O
evaluated	O
in	O
vitro	O
the	O
regulatory	O
ability	O
of	O
RA	O
-	O
associated	O
SNP	O
variants	O
on	O
A20	B-Protein
promoter	O
activity	O
,	O
and	O
could	O
show	O
repressed	O
A20	B-Protein
transcription	O
for	O
some	O
of	O
the	O
SNPs	O
investigated	O
[	O
53	O
]	O
.	O

It	O
will	O
be	O
of	O
interest	O
to	O
identify	O
the	O
actual	O
causal	O
variants	O
and	O
to	O
elucidate	O
the	O
functional	O
consequences	O
of	O
these	O
variants	O
.	O

In	O
this	O
context	O
,	O
knockin	O
mice	O
for	O
the	O
corresponding	O
A20	B-Protein
SNPs	O
,	O
combined	O
with	O
mouse	O
models	O
for	O
RA	O
,	O
will	O
be	O
very	O
valuable	O
tools	O
.	O

A20	B-Protein
-	O
binding	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
<EOS>	B-X
The	B-X
family	B-X
of	B-X
A20-Binding	B-X
Inhibitors	B-X
of	B-X
NF-kappaB	B-X
(	B-X
ABINs	B-X
)	B-X
consists	B-X
of	B-X
three	B-X
proteins	B-X
,	B-X
ABIN-1	B-X
,	B-X
ABIN-2	B-X
and	B-X
ABIN-3	B-X
,	B-X
which	B-X
were	B-X
originally	B-X
identified	B-X
as	B-X
A20-binding	B-X
proteins	B-X
and	B-X
inhibitors	B-X
of	B-X
cytokines	B-X
and	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
ABIN	B-X
family	B-X
members	B-X
have	B-X
limited	B-X
sequence	B-X
homology	B-X
in	B-X
a	B-X
number	B-X
of	B-X
short	B-X
regions	B-X
that	B-X
mediate	B-X
A20-binding	B-X
,	B-X
ubiquitin-binding	B-X
,	B-X
and	B-X
NF-kappaB	B-X
inhibition	B-X
.	B-X
The	B-X
functional	B-X
role	B-X
of	B-X
A20	B-X
binding	B-X
to	B-X
ABINs	B-X
remains	B-X
unclear	B-X
,	B-X
although	B-X
an	B-X
adaptor	B-X
function	B-X
has	B-X
been	B-X
suggested	B-X
.	B-X
ABIN-1	B-X
and	B-X
ABIN-3	B-X
expression	B-X
is	B-X
upregulated	B-X
when	B-X
cells	B-X
are	B-X
triggered	B-X
by	B-X
NF-kappaB-activating	B-X
stimuli	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
for	B-X
these	B-X
ABINs	B-X
in	B-X
a	B-X
negative	B-X
feedback	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X
Additional	B-X
ABIN	B-X
functions	B-X
have	B-X
been	B-X
reported	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
TNF-induced	B-X
hepatocyte	B-X
apoptosis	B-X
,	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
for	B-X
ABIN-1	B-X
,	B-X
and	B-X
Tumor	B-X
Progression	B-X
Locus	B-X
2	B-X
(	B-X
TPL-2	B-X
)	B-X
-mediated	B-X
Extracellular	B-X
signal-Regulated	B-X
Kinase	B-X
(	B-X
ERK	B-X
)	B-X
activation	B-X
for	B-X
ABIN-2	B-X
.	B-X
In	B-X
mice	B-X
,	B-X
ABIN-1	B-X
overexpression	B-X
reduces	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
TNF-mediated	B-X
liver	B-X
injury	B-X
,	B-X
ABIN-2	B-X
overexpression	B-X
delays	B-X
liver	B-X
regeneration	B-X
,	B-X
and	B-X
ABIN-3	B-X
overexpression	B-X
partially	B-X
protects	B-X
against	B-X
LPS-induced	B-X
acute	B-X
liver	B-X
failure	B-X
.	B-X
Future	B-X
studies	B-X
should	B-X
clarify	B-X
the	B-X
functional	B-X
implication	B-X
of	B-X
the	B-X
A20-ABIN	B-X
interaction	B-X
in	B-X
supporting	B-X
ABINs	B-X
'	B-X
mechanisms	B-X
of	B-X
action	B-X
.	B-X

ABIN	B-Protein
-	I-Protein
1	I-Protein
,	O
ABIN	B-Protein
-	I-Protein
2	I-Protein
and	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
(	O
also	O
known	O
as	O
TNIP	B-Protein
-	I-Protein
1	I-Protein
,	O
TNIP	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
TNIP	B-Protein
-	I-Protein
3	I-Protein
)	O
were	O
identified	O
as	O
ubiquitously	O
expressed	O
A20	B-Protein
interacting	O
proteins	O
and	O
were	O
shown	O
to	O
inhibit	O
NF	O
-	O
kappaB	O
activation	O
by	O
TNF	B-Protein
and	O
several	O
other	O
inflammatory	O
stimuli	O
upon	O
overexpression	O
.	O

Because	O
ABINs	O
contain	O
a	O
specific	O
ubiquitin	O
-	O
binding	O
motif	O
,	O
they	O
have	O
been	O
proposed	O
to	O
target	O
A20	B-Protein
to	O
polyubiquitinated	O
substrates	O
[	O
43	O
,	O
44	O
]	O
.	O

Similar	O
to	O
A20	B-Protein
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
and	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
expression	O
is	O
NF	O
-	O
kappaB	O
dependent	O
,	O
implicating	O
a	O
potential	O
role	O
for	O
the	O
A20	B-Protein
/	O
ABIN	O
complex	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
reviewed	O
in	O
[	O
54	O
]	O
)	O
.	O
<EOS>	B-X
ABINs	B-X
have	B-X
been	B-X
described	B-X
as	B-X
three	B-X
different	B-X
proteins	B-X
(	B-X
ABIN-1	B-X
,	B-X
ABIN-2	B-X
,	B-X
ABIN-3	B-X
)	B-X
that	B-X
bind	B-X
the	B-X
ubiquitin-editing	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
inhibitor	B-X
protein	B-X
A20	B-X
and	B-X
which	B-X
show	B-X
limited	B-X
sequence	B-X
homology	B-X
.	B-X
Overexpression	B-X
of	B-X
ABINs	B-X
inhibits	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
and	B-X
several	B-X
other	B-X
stimuli	B-X
.	B-X
Similar	B-X
to	B-X
A20	B-X
,	B-X
ABIN-1	B-X
and	B-X
ABIN-3	B-X
expression	B-X
is	B-X
NF-kappaB	B-X
dependent	B-X
,	B-X
implicating	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
the	B-X
A20/ABIN	B-X
complex	B-X
in	B-X
the	B-X
negative	B-X
feedback	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Adenoviral	B-X
gene	B-X
transfer	B-X
of	B-X
ABIN-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
reduce	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
mouse	B-X
liver	B-X
and	B-X
lungs	B-X
.	B-X
However	B-X
,	B-X
ABIN-1	B-X
as	B-X
well	B-X
as	B-X
ABIN-2	B-X
deficient	B-X
mice	B-X
exhibit	B-X
only	B-X
slightly	B-X
increased	B-X
or	B-X
normal	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
respectively	B-X
,	B-X
possibly	B-X
reflecting	B-X
redundant	B-X
NF-kappaB	B-X
inhibitory	B-X
activities	B-X
of	B-X
multiple	B-X
ABINs	B-X
.	B-X
Other	B-X
functions	B-X
of	B-X
ABINs	B-X
might	B-X
be	B-X
non-redundant	B-X
.	B-X
For	B-X
example	B-X
,	B-X
ABIN-1	B-X
shares	B-X
with	B-X
A20	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
TNF-induced	B-X
apoptosis	B-X
and	B-X
as	B-X
a	B-X
result	B-X
ABIN-1	B-X
deficient	B-X
mice	B-X
die	B-X
during	B-X
embryogenesis	B-X
due	B-X
to	B-X
TNF-dependent	B-X
fetal	B-X
liver	B-X
apoptosis	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
ABIN-2	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
TPL-2	B-X
dependent	B-X
extracellularly	B-X
regulated	B-X
kinase	B-X
activation	B-X
in	B-X
macrophages	B-X
treated	B-X
with	B-X
TNF	B-X
or	B-X
Toll-like	B-X
receptor	B-X
ligands	B-X
.	B-X
ABINs	B-X
have	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
contain	B-X
an	B-X
ubiquitin-binding	B-X
domain	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
their	B-X
NF-kappaB	B-X
inhibitory	B-X
and	B-X
anti-apoptotic	B-X
activities	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
ABINs	B-X
were	B-X
proposed	B-X
to	B-X
function	B-X
as	B-X
adaptors	B-X
between	B-X
ubiquitinated	B-X
proteins	B-X
and	B-X
other	B-X
regulatory	B-X
proteins	B-X
.	B-X
Alternatively	B-X
,	B-X
ABINs	B-X
might	B-X
disrupt	B-X
signaling	B-X
complexes	B-X
by	B-X
competing	B-X
with	B-X
other	B-X
ubiquitin-binding	B-X
proteins	B-X
for	B-X
the	B-X
binding	B-X
to	B-X
specific	B-X
ubiquitinated	B-X
targets	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
findings	B-X
implicate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
ABINs	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
immunity	B-X
and	B-X
tissue	B-X
homeostasis	B-X
.	B-X

Unexpectedly	O
,	O
both	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
and	O
ABIN	B-Protein
-	I-Protein
2	I-Protein
-	O
deficient	O
mice	O
exhibit	O
only	O
slightly	O
increased	O
or	O
normal	O
NF	O
-	O
kappaB	O
responses	O
,	O
respectively	O
,	O
possibly	O
reflecting	O
redundant	O
NF	O
-	O
kappaB	O
inhibitory	O
activities	O
of	O
multiple	O
ABINs	O
[	O
55	O
,	O
56	O
]	O
.	O

Functional	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
is	O
expressed	O
in	O
humans	O
,	O
but	O
mice	O
only	O
express	O
a	O
truncated	B-Protein
and	I-Protein
inactive	I-Protein
form	I-Protein
lacking	O
the	O
crucial	O
ubiquitin	O
-	O
binding	O
domain	O
[	O
57	O
]	O
.	O

As	O
for	O
A20	B-Protein
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
also	O
strongly	O
inhibits	O
TNF	B-Protein
-	O
induced	O
apoptosis	O
[	O
58	O
]	O
,	O
and	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
deficient	O
mice	O
die	O
embryonically	O
due	O
to	O
TNF	B-Protein
-	O
dependent	O
foetal	O
liver	O
apoptosis	O
[	O
56	O
]	O
.	O

Using	O
oligonucleotide	O
microarray	O
analysis	O
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
was	O
identified	O
among	O
TNF	B-Protein
-	O
induced	O
genes	O
in	O
human	O
synoviocytes	O
,	O
and	O
high	O
levels	O
of	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
were	O
detected	O
in	O
RA	O
tissue	O
biopsies	O
,	O
indicating	O
a	O
potential	O
role	O
for	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
,	O
together	O
with	O
A20	B-Protein
,	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
signalling	O
and	O
the	O
pathogenesis	O
of	O
RA	O
[	O
59	O
]	O
.	O

In	O
a	O
recent	O
study	O
,	O
inhibition	O
of	O
TLR	O
responses	O
by	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
-	O
coupled	O
receptors	O
was	O
shown	O
to	O
depend	O
on	O
the	O
expression	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
proteins	O
ABIN	B-Protein
-	I-Protein
3	I-Protein
and	O
A20	B-Protein
.	O

Moreover	O
,	O
this	O
protective	O
effect	O
of	O
the	O
ITAM	O
was	O
strongly	O
suppressed	O
in	O
inflammatory	O
arthritis	O
synovial	O
macrophages	O
[	O
60	O
]	O
.	O

Interestingly	O
,	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
polymorphisms	O
have	O
been	O
associated	O
with	O
psoriasis	O
and	O
systemic	O
lupus	O
erythematosus	O
in	O
humans	O
[	O
61	O
,	O
62	O
]	O
.	O

A	O
high	O
degree	O
of	O
overlap	O
between	O
systemic	O
lupus	O
erythematosus	O
and	O
RA	O
susceptibility	O
loci	O
might	O
be	O
expected	O
as	O
the	O
two	O
diseases	O
show	O
some	O
clinical	O
overlap	O
in	O
joint	O
involvement	O
,	O
autoantibody	O
production	O
,	O
systemic	O
features	O
and	O
response	O
to	O
treatments	O
such	O
as	O
B	O
-	O
cell	O
depletion	O
(	O
rituximab	O
)	O
.	O

It	O
will	O
therefore	O
be	O
interesting	O
to	O
investigate	O
whether	O
SNPs	O
that	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
systemic	O
lupus	O
erythematosus	O
are	O
also	O
associated	O
with	O
RA	O
.	O

Cylindromatosis	B-Protein
protein	O
<EOS>	B-X
We	B-X
identify	B-X
the	B-X
tripartite	B-X
motif-containing	B-X
protein	B-X
TRIM15	B-X
as	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
and	B-X
the	B-X
tumour	B-X
suppressor	B-X
CYLD	B-X
as	B-X
a	B-X
deubiquitinase	B-X
of	B-X
ERK1/2	B-X
.	B-X
Since	B-X
its	B-X
discovery	B-X
forty	B-X
years	B-X
ago	B-X
,	B-X
protein	B-X
ubiquitination	B-X
has	B-X
been	B-X
an	B-X
ever-expanding	B-X
field	B-X
.	B-X
Virtually	B-X
all	B-X
biological	B-X
processes	B-X
are	B-X
controlled	B-X
by	B-X
the	B-X
post-translational	B-X
conjugation	B-X
of	B-X
ubiquitin	B-X
onto	B-X
target	B-X
proteins	B-X
.	B-X
Due	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
remodel	B-X
the	B-X
proteome	B-X
by	B-X
altering	B-X
protein	B-X
degradation	B-X
dynamics	B-X
,	B-X
DUBs	B-X
play	B-X
an	B-X
important	B-X
and	B-X
underappreciated	B-X
role	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
proliferation	B-X
of	B-X
both	B-X
normal	B-X
and	B-X
cancer	B-X
cells	B-X
.	B-X

Cylindromatosis	B-Protein
(	O
CYLD	B-Protein
)	O
protein	O
was	O
originally	O
identified	O
as	O
a	O
tumour	O
suppressor	O
involved	O
in	O
familial	O
cylindromatosis	O
[	O
63	O
]	O
.	O

CYLD	B-Protein
is	O
also	O
involved	O
,	O
however	O
,	O
in	O
diverse	O
physiological	O
processes	O
ranging	O
from	O
immunity	O
and	O
inflammation	O
to	O
cell	O
cycle	O
progression	O
,	O
spermatogenesis	O
,	O
and	O
osteoclastogenesis	O
(	O
reviewed	O
in	O
[	O
64	O
]	O
)	O
.	O
<EOS>	B-X
Indeed	B-X
,	B-X
recent	B-X
studies	B-X
show	B-X
that	B-X
a	B-X
tumor	B-X
suppressor	B-X
DUB	B-X
,	B-X
cylindromatosis	B-X
(	B-X
CYLD	B-X
)	B-X
,	B-X
has	B-X
a	B-X
predominant	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
promotes	B-X
cell	B-X
survival	B-X
and	B-X
oncogenesis	B-X
.	B-X
By	B-X
deconjugating	B-X
these	B-X
K63-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulates	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
which	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumor	B-X
suppressor	B-X
function	B-X
.	B-X
CYLD	B-X
also	B-X
regulates	B-X
diverse	B-X
physiological	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
immune	B-X
response	B-X
and	B-X
inflammation	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
spermatogenesis	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
.	B-X
Interestingly	B-X
,	B-X
CYLD	B-X
itself	B-X
is	B-X
subject	B-X
to	B-X
different	B-X
mechanisms	B-X
of	B-X
regulation	B-X
.	B-X

CYLD	B-Protein
is	O
a	O
deubiquitinating	B-Protein
enzyme	I-Protein
that	O
negatively	O
regulates	O
NF	O
-	O
kappaB	O
signalling	O
initiated	O
by	O
TNFR	O
,	O
RANK	B-Protein
and	O
T	O
-	O
cell	O
receptor	O
stimulation	O
(	O
reviewed	O
in	O
[	O
64	O
]	O
)	O
(	O
Figure	O
1	O
)	O
,	O
by	O
deubiquitina	O
-	O
ting	O
several	O
NF	O
-	O
kappaB	O
signalling	O
proteins	O
including	O
NEMO	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF6	B-Protein
,	O
TRAF7	B-Protein
,	O
RIP1	B-Protein
and	O
TAK1	B-Protein
.	O

Many	O
of	O
these	O
are	O
also	O
targeted	O
by	O
A20	B-Protein
and	O
it	O
is	O
still	O
not	O
clear	O
why	O
the	O
cell	O
needs	O
A20	B-Protein
as	O
well	O
as	O
CYLD	B-Protein
to	O
control	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Persistent	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
central	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
many	B-X
inflammatory	B-X
disorders	B-X
,	B-X
including	B-X
those	B-X
of	B-X
the	B-X
lung	B-X
such	B-X
as	B-X
cystic	B-X
fibrosis	B-X
(	B-X
CF	B-X
)	B-X
,	B-X
asthma	B-X
,	B-X
and	B-X
chronic	B-X
obstructive	B-X
pulmonary	B-X
disease	B-X
(	B-X
COPD	B-X
)	B-X
.	B-X
Despite	B-X
recent	B-X
advances	B-X
in	B-X
treatment	B-X
,	B-X
management	B-X
of	B-X
the	B-X
inflammatory	B-X
component	B-X
of	B-X
these	B-X
diseases	B-X
still	B-X
remains	B-X
suboptimal	B-X
.	B-X
A20	B-X
is	B-X
an	B-X
endogenous	B-X
negative	B-X
regulator	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
which	B-X
has	B-X
been	B-X
widely	B-X
described	B-X
in	B-X
several	B-X
autoimmune	B-X
and	B-X
inflammatory	B-X
disorders	B-X
and	B-X
more	B-X
recently	B-X
in	B-X
terms	B-X
of	B-X
chronic	B-X
lung	B-X
disorders	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
for	B-X
the	B-X
apparent	B-X
lack	B-X
of	B-X
A20	B-X
in	B-X
CF	B-X
,	B-X
COPD	B-X
,	B-X
and	B-X
asthma	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Transcriptional	B-X
regulation	B-X
of	B-X
A20	B-X
is	B-X
complex	B-X
and	B-X
requires	B-X
coordination	B-X
of	B-X
different	B-X
transcription	B-X
factors	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
examine	B-X
the	B-X
existing	B-X
body	B-X
of	B-X
research	B-X
evidence	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
A20	B-X
,	B-X
concentrating	B-X
on	B-X
pulmonary	B-X
inflammation	B-X
.	B-X
Special	B-X
focus	B-X
is	B-X
given	B-X
to	B-X
the	B-X
repressor	B-X
downstream	B-X
regulatory	B-X
element	B-X
antagonist	B-X
modulator	B-X
(	B-X
DREAM	B-X
)	B-X
and	B-X
its	B-X
nuclear	B-X
and	B-X
cytosolic	B-X
action	B-X
to	B-X
regulate	B-X
inflammation	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
that	B-X
would	B-X
suggest	B-X
the	B-X
A20-DREAM	B-X
axis	B-X
to	B-X
be	B-X
an	B-X
important	B-X
player	B-X
in	B-X
(	B-X
airway	B-X
)	B-X
inflammatory	B-X
responses	B-X
and	B-X
point	B-X
to	B-X
DREAM	B-X
as	B-X
a	B-X
potential	B-X
future	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
modification	B-X
of	B-X
phenotypic	B-X
changes	B-X
in	B-X
airway	B-X
inflammatory	B-X
disorders	B-X
.	B-X
A	B-X
schematic	B-X
summary	B-X
describing	B-X
the	B-X
role	B-X
of	B-X
DREAM	B-X
in	B-X
inflammation	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
chronic	B-X
lung	B-X
diseases	B-X
as	B-X
well	B-X
as	B-X
the	B-X
possible	B-X
consequences	B-X
of	B-X
altered	B-X
DREAM	B-X
expression	B-X
on	B-X
immune	B-X
responses	B-X
is	B-X
provided	B-X
.	B-X

As	O
A20	B-Protein
is	O
only	O
expressed	O
in	O
many	O
cell	O
types	O
upon	O
stimulation	O
,	O
it	O
has	O
been	O
suggested	O
that	O
this	O
protein	O
mainly	O
regulates	O
later	O
phases	O
of	O
NF	O
-	O
kappaB	O
signalling	O
,	O
whereas	O
CYLD	B-Protein
would	O
regulate	O
constitutive	O
and	O
early	O
signalling	O
.	O

In	O
addition	O
,	O
their	O
relative	O
activity	O
might	O
also	O
be	O
cell	O
-	O
type	O
dependent	O
[	O
64	O
]	O
.	O
<EOS>	B-X
Hormones	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
integrated	B-X
communication	B-X
of	B-X
several	B-X
physiological	B-X
systems	B-X
responsible	B-X
for	B-X
modulating	B-X
cellular	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Although	B-X
the	B-X
specific	B-X
hormonal	B-X
influence	B-X
must	B-X
be	B-X
considered	B-X
within	B-X
the	B-X
context	B-X
of	B-X
the	B-X
entire	B-X
endocrine	B-X
system	B-X
and	B-X
its	B-X
relationship	B-X
with	B-X
other	B-X
physiological	B-X
systems	B-X
,	B-X
three	B-X
key	B-X
hormones	B-X
are	B-X
considered	B-X
the	B-X
``	B-X
anabolic	B-X
giants	B-X
''	B-X
in	B-X
cellular	B-X
growth	B-X
and	B-X
repair	B-X
:	B-X
testosterone	B-X
,	B-X
the	B-X
growth	B-X
hormone	B-X
superfamily	B-X
,	B-X
and	B-X
the	B-X
insulin-like	B-X
growth	B-X
factor	B-X
(	B-X
IGF	B-X
)	B-X
superfamily	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
anabolic	B-X
hormones	B-X
,	B-X
glucocorticoids	B-X
,	B-X
mainly	B-X
cortisol	B-X
must	B-X
also	B-X
be	B-X
considered	B-X
because	B-X
of	B-X
their	B-X
profound	B-X
opposing	B-X
influence	B-X
on	B-X
human	B-X
skeletal	B-X
muscle	B-X
anabolism	B-X
in	B-X
many	B-X
instances	B-X
.	B-X
Specifically	B-X
,	B-X
the	B-X
review	B-X
describes	B-X
(	B-X
1	B-X
)	B-X
Testosterone	B-X
as	B-X
the	B-X
primary	B-X
anabolic	B-X
hormone	B-X
,	B-X
with	B-X
an	B-X
anabolic	B-X
influence	B-X
largely	B-X
dictated	B-X
primarily	B-X
by	B-X
genomic	B-X
and	B-X
possible	B-X
non-genomic	B-X
signaling	B-X
,	B-X
satellite	B-X
cell	B-X
activation	B-X
,	B-X
interaction	B-X
with	B-X
other	B-X
anabolic	B-X
signaling	B-X
pathways	B-X
,	B-X
upregulation	B-X
or	B-X
downregulation	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
,	B-X
and	B-X
potential	B-X
roles	B-X
in	B-X
co-activators	B-X
and	B-X
transcriptional	B-X
activity	B-X
;	B-X
(	B-X
2	B-X
)	B-X
Differential	B-X
influences	B-X
of	B-X
growth	B-X
hormones	B-X
depending	B-X
on	B-X
the	B-X
``	B-X
type	B-X
''	B-X
of	B-X
the	B-X
hormone	B-X
being	B-X
assayed	B-X
and	B-X
the	B-X
magnitude	B-X
of	B-X
the	B-X
physiological	B-X
stress	B-X
;	B-X
(	B-X
3	B-X
)	B-X
The	B-X
exquisite	B-X
regulation	B-X
of	B-X
IGF-1	B-X
by	B-X
a	B-X
family	B-X
of	B-X
binding	B-X
proteins	B-X
(	B-X
IGFBPs	B-X
1-6	B-X
)	B-X
,	B-X
which	B-X
can	B-X
either	B-X
stimulate	B-X
or	B-X
inhibit	B-X
biological	B-X
action	B-X
depending	B-X
on	B-X
binding	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
Circadian	B-X
patterning	B-X
and	B-X
newly	B-X
discovered	B-X
variants	B-X
of	B-X
glucocorticoid	B-X
isoforms	B-X
largely	B-X
dictating	B-X
glucocorticoid	B-X
sensitivity	B-X
and	B-X
catabolic	B-X
,	B-X
muscle	B-X
sparing	B-X
,	B-X
or	B-X
pathological	B-X
influence	B-X
.	B-X
The	B-X
downstream	B-X
integrated	B-X
anabolic	B-X
and	B-X
catabolic	B-X
mechanisms	B-X
of	B-X
these	B-X
hormones	B-X
not	B-X
only	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
skeletal	B-X
muscle	B-X
to	B-X
generate	B-X
force	B-X
;	B-X
they	B-X
also	B-X
have	B-X
implications	B-X
for	B-X
pharmaceutical	B-X
treatments	B-X
,	B-X
aging	B-X
,	B-X
and	B-X
prevalent	B-X
chronic	B-X
conditions	B-X
such	B-X
as	B-X
metabolic	B-X
syndrome	B-X
,	B-X
insulin	B-X
resistance	B-X
,	B-X
and	B-X
hypertension	B-X
.	B-X

Interestingly	O
,	O
CYLD	B-Protein
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
RANK	B-Protein
signalling	O
and	O
osteoclastogenesis	O
in	O
mice	O
[	O
65	O
]	O
.	O
<EOS>	B-X
Osteoclastogenesis	B-X
is	B-X
a	B-X
tightly	B-X
regulated	B-X
biological	B-X
process	B-X
,	B-X
and	B-X
deregulation	B-X
can	B-X
lead	B-X
to	B-X
severe	B-X
bone	B-X
disorders	B-X
such	B-X
as	B-X
osteoporosis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
osteoclastic	B-X
signaling	B-X
is	B-X
incompletely	B-X
understood	B-X
,	B-X
but	B-X
ubiquitination	B-X
of	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
(	B-X
TRAF6	B-X
)	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
important	B-X
in	B-X
mediating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
therefore	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
recently	B-X
identified	B-X
deubiquitinating	B-X
enzyme	B-X
CYLD	B-X
in	B-X
osteoclastogenesis	B-X
and	B-X
found	B-X
that	B-X
mice	B-X
with	B-X
a	B-X
genetic	B-X
deficiency	B-X
of	B-X
CYLD	B-X
had	B-X
aberrant	B-X
osteoclast	B-X
differentiation	B-X
and	B-X
developed	B-X
severe	B-X
osteoporosis	B-X
.	B-X
Cultured	B-X
osteoclast	B-X
precursors	B-X
derived	B-X
from	B-X
CYLD-deficient	B-X
mice	B-X
were	B-X
hyperresponsive	B-X
to	B-X
RANKL-induced	B-X
differentiation	B-X
and	B-X
produced	B-X
more	B-X
and	B-X
larger	B-X
osteoclasts	B-X
than	B-X
did	B-X
controls	B-X
upon	B-X
stimulation	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CYLD	B-X
and	B-X
found	B-X
that	B-X
it	B-X
was	B-X
drastically	B-X
upregulated	B-X
during	B-X
RANKL-induced	B-X
differentiation	B-X
of	B-X
preosteoclasts	B-X
.	B-X
Furthermore	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulated	B-X
RANK	B-X
signaling	B-X
by	B-X
inhibiting	B-X
TRAF6	B-X
ubiquitination	B-X
and	B-X
activation	B-X
of	B-X
downstream	B-X
signaling	B-X
events	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CYLD	B-X
interacted	B-X
physically	B-X
with	B-X
the	B-X
signaling	B-X
adaptor	B-X
p62	B-X
and	B-X
thereby	B-X
was	B-X
recruited	B-X
to	B-X
TRAF6	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
CYLD	B-X
as	B-X
a	B-X
crucial	B-X
negative	B-X
regulator	B-X
of	B-X
osteoclastogenesis	B-X
and	B-X
suggest	B-X
its	B-X
involvement	B-X
in	B-X
the	B-X
p62/TRAF6	B-X
signaling	B-X
axis	B-X
.	B-X

Mice	O
with	O
a	O
genetic	O
deficiency	O
of	O
CYLD	B-Protein
have	O
aberrant	O
osteoclast	O
differentiation	O
and	O
develop	O
severe	O
osteoporosis	O
.	O
<EOS>	B-X
Osteoclastogenesis	B-X
is	B-X
a	B-X
tightly	B-X
regulated	B-X
biological	B-X
process	B-X
,	B-X
and	B-X
deregulation	B-X
can	B-X
lead	B-X
to	B-X
severe	B-X
bone	B-X
disorders	B-X
such	B-X
as	B-X
osteoporosis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
osteoclastic	B-X
signaling	B-X
is	B-X
incompletely	B-X
understood	B-X
,	B-X
but	B-X
ubiquitination	B-X
of	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
(	B-X
TRAF6	B-X
)	B-X
has	B-X
recently	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
important	B-X
in	B-X
mediating	B-X
this	B-X
process	B-X
.	B-X
We	B-X
therefore	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
recently	B-X
identified	B-X
deubiquitinating	B-X
enzyme	B-X
CYLD	B-X
in	B-X
osteoclastogenesis	B-X
and	B-X
found	B-X
that	B-X
mice	B-X
with	B-X
a	B-X
genetic	B-X
deficiency	B-X
of	B-X
CYLD	B-X
had	B-X
aberrant	B-X
osteoclast	B-X
differentiation	B-X
and	B-X
developed	B-X
severe	B-X
osteoporosis	B-X
.	B-X
Cultured	B-X
osteoclast	B-X
precursors	B-X
derived	B-X
from	B-X
CYLD-deficient	B-X
mice	B-X
were	B-X
hyperresponsive	B-X
to	B-X
RANKL-induced	B-X
differentiation	B-X
and	B-X
produced	B-X
more	B-X
and	B-X
larger	B-X
osteoclasts	B-X
than	B-X
did	B-X
controls	B-X
upon	B-X
stimulation	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
expression	B-X
pattern	B-X
of	B-X
CYLD	B-X
and	B-X
found	B-X
that	B-X
it	B-X
was	B-X
drastically	B-X
upregulated	B-X
during	B-X
RANKL-induced	B-X
differentiation	B-X
of	B-X
preosteoclasts	B-X
.	B-X
Furthermore	B-X
,	B-X
CYLD	B-X
negatively	B-X
regulated	B-X
RANK	B-X
signaling	B-X
by	B-X
inhibiting	B-X
TRAF6	B-X
ubiquitination	B-X
and	B-X
activation	B-X
of	B-X
downstream	B-X
signaling	B-X
events	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CYLD	B-X
interacted	B-X
physically	B-X
with	B-X
the	B-X
signaling	B-X
adaptor	B-X
p62	B-X
and	B-X
thereby	B-X
was	B-X
recruited	B-X
to	B-X
TRAF6	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
CYLD	B-X
as	B-X
a	B-X
crucial	B-X
negative	B-X
regulator	B-X
of	B-X
osteoclastogenesis	B-X
and	B-X
suggest	B-X
its	B-X
involvement	B-X
in	B-X
the	B-X
p62/TRAF6	B-X
signaling	B-X
axis	B-X
.	B-X

Osteoclast	O
precursors	O
of	O
these	O
mice	O
are	O
hyper	O
-	O
responsive	O
to	O
RANKL	B-Protein
-	O
induced	O
differentiation	O
and	O
produce	O
more	O
and	O
larger	O
osteoclasts	O
.	O

CYLD	B-Protein
expression	O
is	O
markedly	O
upregulated	O
under	O
conditions	O
of	O
RANKL	B-Protein
-	O
induced	O
osteoclastogenesis	O
and	O
is	O
recruited	O
to	O
ubiquitinated	O
TRAF6	B-Protein
via	O
the	O
ubiquitin	B-Protein
-	O
binding	O
adaptor	O
protein	O
p62	B-Protein
(	O
also	O
known	O
as	O
sequestosome	B-Protein
1	I-Protein
)	O
[	O
65	O
]	O
,	O
followed	O
by	O
the	O
CYLD	B-Protein
-	O
mediated	O
deubiquitination	O
of	O
TRAF6	B-Protein
.	O

In	O
this	O
context	O
,	O
it	O
is	O
worth	O
mentioning	O
that	O
transgenic	O
mice	O
expressing	O
a	O
mutated	O
form	O
of	O
p62	B-Protein
also	O
display	O
abnormal	O
osteoclastogenesis	O
and	O
develop	O
progressive	O
bone	O
loss	O
[	O
66	O
]	O
.	O

These	O
findings	O
suggest	O
that	O
CYLD	B-Protein
-	O
mediated	O
inhibi	O
-	O
tion	O
of	O
RANK	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
signalling	O
plays	O
a	O
key	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
osteoclastogenesis	O
and	O
indicate	O
CYLD	B-Protein
as	O
a	O
potential	O
genetic	O
factor	O
involved	O
in	O
the	O
pathology	O
of	O
bone	O
disorders	O
such	O
as	O
RA	O
.	O

Single	B-Protein
-	I-Protein
immunoglobulin	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
protein	O
<EOS>	B-X
The	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-Toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
signaling	B-X
pathway	B-X
in	B-X
alveolar	B-X
epithelial	B-X
cells	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
many	B-X
pathologic	B-X
processes	B-X
such	B-X
as	B-X
acute	B-X
lung	B-X
injury	B-X
(	B-X
ALI	B-X
)	B-X
.	B-X
The	B-X
single	B-X
immunoglobulin	B-X
IL-1	B-X
receptor-related	B-X
protein	B-X
(	B-X
SIGIRR	B-X
)	B-X
is	B-X
an	B-X
inhibitor	B-X
of	B-X
LPS-TLR4	B-X
signaling	B-X
,	B-X
but	B-X
its	B-X
expression	B-X
and	B-X
function	B-X
in	B-X
alveolar	B-X
epithelial	B-X
cells	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
Following	B-X
LPS	B-X
exposure	B-X
,	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
was	B-X
measured	B-X
using	B-X
a	B-X
dual-luciferase	B-X
reporter	B-X
assay	B-X
system	B-X
,	B-X
and	B-X
the	B-X
concentration	B-X
of	B-X
IL-1beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
was	B-X
determined	B-X
by	B-X
ELISA	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
was	B-X
measured	B-X
by	B-X
MTT	B-X
.	B-X
In	B-X
A549	B-X
cells	B-X
that	B-X
over-expressed	B-X
SIGIRR	B-X
,	B-X
LPS	B-X
treatment	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
and	B-X
cell	B-X
growth	B-X
inhibition	B-X
ratio	B-X
,	B-X
as	B-X
well	B-X
as	B-X
lower	B-X
levels	B-X
of	B-X
secreted	B-X
IL-1beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
.	B-X

Single	B-Protein
-	I-Protein
immunoglobulin	I-Protein
IL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
(	O
SIGIRR	B-Protein
)	O
protein	O
,	O
also	O
known	O
as	O
TIR	B-Protein
-	I-Protein
8	I-Protein
,	O
is	O
a	O
member	O
of	O
the	O
TLR	O
/	O
IL	O
-	O
1R	O
family	O
that	O
has	O
been	O
extensively	O
characterised	O
as	O
an	O
inhibitor	O
of	O
IL	B-Protein
-	I-Protein
1R	I-Protein
and	O
TLR	O
signalling	O
,	O
probably	O
through	O
direct	O
interaction	O
with	O
these	O
receptors	O
,	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
or	O
TRAF6	B-Protein
[	O
67	O
]	O
(	O
Figure	O
1	O
)	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
evaluate	B-X
the	B-X
effects	B-X
of	B-X
Saccharomyces	B-X
boulardii	B-X
(	B-X
Sb	B-X
)	B-X
and	B-X
Bacillus	B-X
subtilis	B-X
B10	B-X
(	B-X
Bs	B-X
)	B-X
on	B-X
intestinal	B-X
epithelial	B-X
Toll	B-X
like	B-X
receptors	B-X
(	B-X
TLR	B-X
)	B-X
,	B-X
and	B-X
Cytokine	B-X
expression	B-X
response	B-X
to	B-X
understand	B-X
the	B-X
intestinal	B-X
epithelial	B-X
innate	B-X
immune	B-X
mechanism	B-X
in	B-X
broilers	B-X
.	B-X
A	B-X
total	B-X
of	B-X
300	B-X
birds	B-X
(	B-X
Sanhuang	B-X
broilers	B-X
)	B-X
were	B-X
allotted	B-X
into	B-X
three	B-X
groups	B-X
(	B-X
n	B-X
=	B-X
100	B-X
)	B-X
and	B-X
each	B-X
divided	B-X
into	B-X
five	B-X
replications	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
.	B-X
Control	B-X
group	B-X
(	B-X
Ctr	B-X
)	B-X
birds	B-X
were	B-X
fed	B-X
basal	B-X
diet	B-X
,	B-X
broilers	B-X
in	B-X
experimental	B-X
groups	B-X
received	B-X
(	B-X
1×108cfu/kg	B-X
feed	B-X
)	B-X
Sb	B-X
and	B-X
Bs	B-X
respectively	B-X
in	B-X
addition	B-X
to	B-X
basal	B-X
diet	B-X
for	B-X
72	B-X
days	B-X
.	B-X
The	B-X
result	B-X
showed	B-X
significant	B-X
increase	B-X
in	B-X
mRNA	B-X
expression	B-X
level	B-X
of	B-X
TLR2	B-X
,	B-X
TLR4	B-X
and	B-X
TLR15	B-X
.	B-X
Down	B-X
streaming	B-X
MyD88	B-X
,	B-X
TRAF6	B-X
,	B-X
TAB2	B-X
and	B-X
NF-κB	B-X
mRNA	B-X
level	B-X
noted	B-X
higher	B-X
,	B-X
in	B-X
the	B-X
jejunum	B-X
and	B-X
ileum	B-X
as	B-X
compared	B-X
to	B-X
control	B-X
group	B-X
.	B-X
Meanwhile	B-X
,	B-X
IL-6	B-X
,	B-X
TNFα	B-X
,	B-X
IL-10	B-X
,	B-X
TGF-β	B-X
expression	B-X
levels	B-X
showed	B-X
high	B-X
expression	B-X
in	B-X
the	B-X
jejunum	B-X
of	B-X
Sb	B-X
and	B-X
Bs	B-X
groups	B-X
.	B-X
IL-10	B-X
expression	B-X
level	B-X
increased	B-X
in	B-X
the	B-X
ileum	B-X
and	B-X
IL-6	B-X
,	B-X
TNFα	B-X
,	B-X
IL-10	B-X
and	B-X
TGF-β	B-X
expression	B-X
levels	B-X
increased	B-X
in	B-X
the	B-X
jejunum	B-X
of	B-X
Sb	B-X
group	B-X
.	B-X
Levels	B-X
of	B-X
IL-1	B-X
β	B-X
,	B-X
IL-17	B-X
,	B-X
and	B-X
IL-4	B-X
,	B-X
increased	B-X
merely	B-X
in	B-X
Sb	B-X
group	B-X
.	B-X
Ileal	B-X
cytokines	B-X
IL-1β	B-X
,	B-X
IL-17	B-X
and	B-X
IL-4concentration	B-X
were	B-X
noted	B-X
higher	B-X
in	B-X
Sb	B-X
group	B-X
,	B-X
and	B-X
IL-1β	B-X
,	B-X
and	B-X
IL-4	B-X
levels	B-X
were	B-X
up-regulated	B-X
in	B-X
Bs	B-X
group	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
INF-γ	B-X
and	B-X
IL-8	B-X
level	B-X
decreased	B-X
in	B-X
Sb	B-X
and	B-X
BS	B-X
groups	B-X
.	B-X
Our	B-X
findings	B-X
illustrated	B-X
that	B-X
S.	B-X
boulardii	B-X
and	B-X
B.	B-X
subtilis	B-X
B10	B-X
may	B-X
have	B-X
a	B-X
role	B-X
to	B-X
induce	B-X
mucosal	B-X
immunity	B-X
by	B-X
activating	B-X
the	B-X
TLRs	B-X
and	B-X
cytokines	B-X
expressions	B-X
in	B-X
broilers	B-X
.	B-X

Given	O
the	O
important	O
role	O
of	O
IL	B-Protein
-	I-Protein
1R	I-Protein
and	O
TLR	O
signalling	O
in	O
the	O
chronic	O
inflammation	O
observed	O
in	O
RA	O
[	O
68	O
]	O
,	O
a	O
regulatory	O
role	O
for	O
SIGIRR	B-Protein
in	O
RA	O
is	O
not	O
unlikely	O
.	O

SIGIRR	B-Protein
has	O
a	O
very	O
restricted	O
expression	O
pattern	O
,	O
being	O
expressed	O
in	O
epithelial	O
cells	O
,	O
monocytes	O
and	O
immature	O
dendritic	O
cells	O
,	O
but	O
not	O
in	O
mature	O
macro	O
-	O
phages	O
[	O
69	O
,	O
70	O
]	O
.	O

Recently	O
,	O
SIGIRR	B-Protein
overexpression	O
was	O
shown	O
to	O
inhibit	O
the	O
spontaneous	O
release	O
of	O
inflammatory	O
cytokines	O
by	O
human	O
RA	O
synovial	O
cells	O
.	O

This	O
inhibitory	O
function	O
of	O
SIGIRR	B-Protein
was	O
further	O
confirmed	O
in	O
vivo	O
,	O
since	O
SIGIRR	B-Protein
-	O
deficient	O
mice	O
developed	O
a	O
more	O
severe	O
disease	O
in	O
zymosan	O
-	O
induced	O
arthritis	O
,	O
as	O
well	O
as	O
collagen	O
-	O
induced	O
arthritis	O
mouse	O
models	O
[	O
70	O
]	O
.	O

It	O
will	O
be	O
interesting	O
to	O
compare	O
the	O
expression	O
of	O
SIGIRR	B-Protein
in	O
RA	O
patients	O
with	O
its	O
expression	O
in	O
control	O
patients	O
,	O
or	O
to	O
investigate	O
whether	O
the	O
function	O
of	O
SIGIRR	B-Protein
is	O
compromised	O
in	O
RA	O
patients	O
.	O

Because	O
of	O
its	O
restricted	O
expression	O
pattern	O
,	O
SIGIRR	B-Protein
may	O
also	O
be	O
an	O
interesting	O
therapeutic	O
target	O
in	O
RA	O
.	O

TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
1	I-Protein
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
is	B-X
the	B-X
prototypic	B-X
member	B-X
of	B-X
the	B-X
TNF	B-X
ligand	B-X
family	B-X
and	B-X
has	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
inflammatory	B-X
processes	B-X
.	B-X
TNF	B-X
exerts	B-X
its	B-X
functions	B-X
by	B-X
interaction	B-X
with	B-X
the	B-X
death	B-X
domain-containing	B-X
TNF-receptor	B-X
1	B-X
(	B-X
TNF-R1	B-X
)	B-X
and	B-X
the	B-X
non-death	B-X
domain-containing	B-X
TNF-receptor	B-X
2	B-X
(	B-X
TNF-R2	B-X
)	B-X
,	B-X
both	B-X
members	B-X
of	B-X
a	B-X
receptor	B-X
family	B-X
complementary	B-X
to	B-X
the	B-X
TNF	B-X
ligand	B-X
family	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
prototypic	B-X
features	B-X
of	B-X
the	B-X
TNF	B-X
receptors	B-X
and	B-X
their	B-X
importance	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
inflammation	B-X
,	B-X
the	B-X
signal	B-X
transduction	B-X
mechanisms	B-X
utilized	B-X
by	B-X
these	B-X
receptors	B-X
have	B-X
been	B-X
extensively	B-X
studied	B-X
.	B-X
Several	B-X
proteins	B-X
that	B-X
interact	B-X
directly	B-X
or	B-X
indirectly	B-X
with	B-X
the	B-X
cytoplasmic	B-X
domains	B-X
of	B-X
TNF-R1	B-X
and	B-X
TNF-R2	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
recent	B-X
years	B-X
giving	B-X
ideas	B-X
how	B-X
these	B-X
receptors	B-X
are	B-X
connected	B-X
to	B-X
the	B-X
apoptotic	B-X
pathway	B-X
and	B-X
the	B-X
signaling	B-X
cascades	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
JNK	B-X
.	B-X
Of	B-X
special	B-X
interest	B-X
are	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
and	B-X
2	B-X
,	B-X
which	B-X
defines	B-X
a	B-X
novel	B-X
group	B-X
of	B-X
adaptor	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
by	B-X
most	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor	B-X
family	B-X
,	B-X
of	B-X
IL-1	B-X
receptor	B-X
and	B-X
IL-17	B-X
receptor	B-X
as	B-X
well	B-X
as	B-X
some	B-X
members	B-X
of	B-X
the	B-X
TOLL-like	B-X
receptor	B-X
family	B-X
.	B-X
TRAF	B-X
2	B-X
is	B-X
currently	B-X
the	B-X
best-characterized	B-X
TRAF	B-X
family	B-X
member	B-X
,	B-X
having	B-X
a	B-X
key	B-X
role	B-X
in	B-X
mediating	B-X
TNF-R1-induced	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
JNK	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
underlay	B-X
signal	B-X
initiation	B-X
by	B-X
TNF-R1	B-X
and	B-X
TNF-R2	B-X
,	B-X
with	B-X
particular	B-X
consideration	B-X
of	B-X
the	B-X
role	B-X
of	B-X
TRAF	B-X
2	B-X
,	B-X
and	B-X
highlights	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
molecule	B-X
for	B-X
the	B-X
integration	B-X
of	B-X
such	B-X
antagonizing	B-X
pathways	B-X
as	B-X
death	B-X
induction	B-X
and	B-X
NF-kappaB-mediated	B-X
surviving	B-X
signals	B-X
.	B-X

TRAF1	B-Protein
is	O
a	O
unique	O
member	O
of	O
the	O
TRAF	O
protein	O
family	O
because	O
it	O
lacks	O
a	O
RING	O
finger	O
domain	O
and	O
therefore	O
lacks	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O
<EOS>	B-X
TNF-receptor	B-X
associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
proteins	B-X
are	B-X
key	B-X
adaptor	B-X
molecules	B-X
containing	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
that	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
immune	B-X
cell	B-X
signaling	B-X
.	B-X
TRAF1	B-X
is	B-X
a	B-X
unique	B-X
family	B-X
of	B-X
TRAF	B-X
lacking	B-X
the	B-X
N-terminal	B-X
RING	B-X
finger	B-X
domain	B-X
.	B-X
TRAF1	B-X
is	B-X
an	B-X
important	B-X
scaffold	B-X
protein	B-X
that	B-X
participates	B-X
in	B-X
TNFR2	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
as	B-X
a	B-X
negative	B-X
or	B-X
positive	B-X
regulator	B-X
via	B-X
direct	B-X
interaction	B-X
with	B-X
TRAF2	B-X
,	B-X
which	B-X
has	B-X
recently	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
pro-apoptotic	B-X
regulator	B-X
in	B-X
neuronal	B-X
cell	B-X
death	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
first	B-X
crystal	B-X
structure	B-X
of	B-X
the	B-X
TRAF1	B-X
TRAF	B-X
domain	B-X
containing	B-X
both	B-X
the	B-X
TRAF-N	B-X
coiled-coil	B-X
domain	B-X
and	B-X
the	B-X
TRAF-C	B-X
domain	B-X
.	B-X
Our	B-X
structure	B-X
reveals	B-X
both	B-X
similarities	B-X
and	B-X
differences	B-X
with	B-X
other	B-X
TRAF	B-X
family	B-X
members	B-X
,	B-X
which	B-X
may	B-X
be	B-X
functionally	B-X
relevant	B-X
to	B-X
TRAFs	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
TRAF-N	B-X
coiled-coil	B-X
domain	B-X
of	B-X
TRAF1	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
trimer	B-X
formation	B-X
and	B-X
stability	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
conserved	B-X
surface	B-X
residues	B-X
on	B-X
the	B-X
TRAF1	B-X
TRAF	B-X
domain	B-X
that	B-X
might	B-X
be	B-X
binding	B-X
hot	B-X
spots	B-X
that	B-X
are	B-X
critical	B-X
for	B-X
interaction	B-X
with	B-X
signaling	B-X
molecules	B-X
.	B-X

Accumulating	O
data	O
support	O
a	O
role	O
for	O
TRAF1	B-Protein
as	O
both	O
a	O
negative	O
and	O
a	O
positive	O
modulator	O
of	O
NF	O
-	O
kappaB	O
signalling	O
by	O
certain	O
TNF	O
family	O
receptors	O
,	O
possibly	O
in	O
a	O
cell	O
-	O
type	O
-	O
dependent	O
manner	O
[	O
71	O
,	O
72	O
]	O
.	O

Expression	O
of	O
TRAF1	B-Protein
is	O
inducible	O
by	O
TNF	B-Protein
and	O
overexpression	O
of	O
TRAF1	B-Protein
inhibits	O
TNF	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
EBV-associated	B-X
gastric	B-X
carcinoma	B-X
(	B-X
EBVaGC	B-X
)	B-X
is	B-X
a	B-X
specific	B-X
subgroup	B-X
of	B-X
gastric	B-X
carcinoma	B-X
,	B-X
and	B-X
the	B-X
multifunctional	B-X
transcriptional	B-X
factor	B-X
NF-κB	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
tumorigenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
comprehensively	B-X
characterized	B-X
NF-κB	B-X
signaling	B-X
in	B-X
EBVaGC	B-X
using	B-X
qRT-PCR	B-X
,	B-X
western	B-X
blot	B-X
,	B-X
immunofluorescence	B-X
assays	B-X
,	B-X
ELISA	B-X
,	B-X
and	B-X
immunohistochemistry	B-X
staining	B-X
.	B-X
NF-κB-signaling	B-X
inhibitors	B-X
may	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
EBVaGC	B-X
cells	B-X
and	B-X
induce	B-X
significant	B-X
apoptosis	B-X
.	B-X
IκBα	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
molecule	B-X
,	B-X
and	B-X
repression	B-X
of	B-X
IκBα	B-X
can	B-X
contribute	B-X
to	B-X
aberrant	B-X
NF-κB	B-X
activation	B-X
.	B-X
Overexpression	B-X
of	B-X
LMP1	B-X
and	B-X
LMP2A	B-X
in	B-X
the	B-X
EBV-negative	B-X
GC	B-X
cell	B-X
line	B-X
SGC7901	B-X
could	B-X
inhibit	B-X
the	B-X
expression	B-X
of	B-X
IκBα	B-X
and	B-X
induce	B-X
NF-κB	B-X
activation	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
canonical	B-X
NF-κB	B-X
signal	B-X
is	B-X
constitutively	B-X
activated	B-X
and	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
EBVaGC	B-X
tumorigenesis	B-X
.	B-X

TRAF1	B-Protein
-	O
deficient	O
T	O
cells	O
are	O
hyper	O
-	O
responsive	O
to	O
TNF	B-Protein
,	O
with	O
enhanced	O
proliferation	O
and	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
signalling	O
pathway	O
.	O

TRAF1	B-Protein
also	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
CD40	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
-dependent	B-X
gene	B-X
expression	B-X
and	B-X
apoptosis	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
numerous	B-X
cellular	B-X
processes	B-X
,	B-X
and	B-X
defects	B-X
in	B-X
their	B-X
regulation	B-X
may	B-X
contribute	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
including	B-X
inflammation	B-X
and	B-X
cancer	B-X
.	B-X
Although	B-X
there	B-X
has	B-X
recently	B-X
been	B-X
tremendous	B-X
progress	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
signaling	B-X
pathways	B-X
that	B-X
lead	B-X
to	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
apoptosis	B-X
,	B-X
signaling	B-X
mechanisms	B-X
that	B-X
negatively	B-X
regulate	B-X
these	B-X
processes	B-X
are	B-X
only	B-X
partially	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
deals	B-X
with	B-X
the	B-X
zinc	B-X
finger	B-X
protein	B-X
A20	B-X
,	B-X
which	B-X
has	B-X
been	B-X
characterized	B-X
as	B-X
a	B-X
dual	B-X
inhibitor	B-X
of	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
apoptosis	B-X
.	B-X
Its	B-X
inducible	B-X
expression	B-X
by	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
stimuli	B-X
,	B-X
including	B-X
cytokines	B-X
such	B-X
as	B-X
tumor	B-X
necrosis	B-X
factor	B-X
,	B-X
interleukin-1	B-X
,	B-X
and	B-X
CD40	B-X
,	B-X
as	B-X
well	B-X
as	B-X
bacterial	B-X
and	B-X
viral	B-X
products	B-X
such	B-X
as	B-X
lipopolysaccharide	B-X
,	B-X
Epstein-Barr	B-X
virus	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
,	B-X
and	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
Tax	B-X
,	B-X
suggests	B-X
that	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
negative	B-X
feedback	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X

TRAF1	B-Protein
-	O
deficient	O
dendritic	O
cells	O
,	O
however	O
,	O
show	O
attenuated	O
responses	O
to	O
secondary	O
stimulation	O
by	O
TRAF2	B-Protein
-	O
dependent	O
factors	O
,	O
suggesting	O
a	O
positive	O
regulatory	O
role	O
in	O
these	O
cells	O
.	O

The	O
mechanism	O
by	O
which	O
TRAF1	B-Protein
modulates	O
NF	O
-	O
kappaB	O
activation	O
is	O
still	O
unclear	O
.	O

Most	O
probably	O
,	O
TRAF1	B-Protein
competes	O
with	O
TRAF	O
family	O
members	O
for	O
binding	O
to	O
the	O
receptor	O
or	O
other	O
signalling	O
proteins	O
.	O
<EOS>	B-X
The	B-X
Hippo	B-X
signalling	B-X
pathway	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
major	B-X
player	B-X
in	B-X
many	B-X
aspects	B-X
of	B-X
liver	B-X
biology	B-X
,	B-X
such	B-X
as	B-X
development	B-X
,	B-X
cell	B-X
fate	B-X
determination	B-X
,	B-X
homeostatic	B-X
function	B-X
and	B-X
regeneration	B-X
from	B-X
injury	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
Hippo	B-X
signalling	B-X
is	B-X
complex	B-X
,	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
pathway	B-X
by	B-X
diverse	B-X
upstream	B-X
inputs	B-X
including	B-X
signals	B-X
from	B-X
cellular	B-X
adhesion	B-X
,	B-X
mechanotransduction	B-X
and	B-X
crosstalk	B-X
with	B-X
other	B-X
signalling	B-X
pathways	B-X
.	B-X
Pathological	B-X
activation	B-X
of	B-X
the	B-X
downstream	B-X
transcriptional	B-X
co-activators	B-X
yes-associated	B-X
protein	B-X
1	B-X
(	B-X
YAP	B-X
)	B-X
and	B-X
transcriptional	B-X
co-activator	B-X
with	B-X
PDZ-binding	B-X
motif	B-X
(	B-X
TAZ	B-X
,	B-X
encoded	B-X
by	B-X
WWTR1	B-X
)	B-X
,	B-X
which	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
Hippo	B-X
signalling	B-X
,	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
multiple	B-X
aspects	B-X
of	B-X
chronic	B-X
liver	B-X
disease	B-X
,	B-X
such	B-X
as	B-X
the	B-X
development	B-X
of	B-X
liver	B-X
fibrosis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
Thus	B-X
,	B-X
development	B-X
of	B-X
pharmacological	B-X
inhibitors	B-X
of	B-X
YAP-TAZ	B-X
signalling	B-X
has	B-X
been	B-X
an	B-X
area	B-X
of	B-X
great	B-X
interest	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
diverse	B-X
roles	B-X
of	B-X
Hippo	B-X
signalling	B-X
in	B-X
liver	B-X
biology	B-X
and	B-X
highlight	B-X
areas	B-X
where	B-X
outstanding	B-X
questions	B-X
remain	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
Greater	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
of	B-X
Hippo	B-X
signalling	B-X
in	B-X
liver	B-X
function	B-X
should	B-X
help	B-X
facilitate	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapies	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
liver	B-X
disease	B-X
.	B-X

Alternatively	O
,	O
TRAF1	B-Protein
might	O
recruit	O
A20	B-Protein
with	O
which	O
it	O
can	O
physically	O
interact	O
[	O
73	O
]	O
.	O

A	O
genome	O
-	O
wide	O
association	O
study	O
examining	O
more	O
than	O
300	O
,	O
000	O
SNPs	O
among	O
approximately	O
1	O
,	O
500	O
autoantibody	O
-	O
positive	O
RA	O
cases	O
and	O
1	O
,	O
800	O
controls	O
identified	O
a	O
genetic	O
variation	O
at	O
the	O
TRAF1	B-Protein
-	O
complement	O
component	O
5	O
locus	O
as	O
an	O
important	O
RA	O
risk	O
locus	O
[	O
74	O
]	O
.	O

Subsequent	O
work	O
indicates	O
that	O
TRAF1	B-Protein
is	O
more	O
likely	O
to	O
be	O
the	O
causative	O
locus	O
[	O
75	O
]	O
.	O

Recent	O
work	O
in	O
a	O
Korean	O
population	O
also	O
demonstrates	O
genetic	O
association	O
of	O
the	O
TRAF1	B-Protein
region	O
with	O
RA	O
[	O
76	O
]	O
.	O

microRNAs	O
<EOS>	B-X
Circulating	B-X
microRNAs	B-X
(	B-X
c-microRNAs	B-X
,	B-X
c-miRNAs	B-X
)	B-X
,	B-X
which	B-X
are	B-X
present	B-X
in	B-X
almost	B-X
all	B-X
biological	B-X
fluids	B-X
,	B-X
are	B-X
promising	B-X
sensitive	B-X
biomarkers	B-X
for	B-X
various	B-X
diseases	B-X
(	B-X
oncological	B-X
and	B-X
cardiovascular	B-X
diseases	B-X
,	B-X
neurodegenerative	B-X
pathologies	B-X
,	B-X
etc	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
exogenous	B-X
microRNAs	B-X
can	B-X
be	B-X
used	B-X
as	B-X
high-precision	B-X
therapeutic	B-X
agents	B-X
for	B-X
these	B-X
purposes	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
in	B-X
1993	B-X
followed	B-X
by	B-X
developments	B-X
and	B-X
discoveries	B-X
in	B-X
small	B-X
RNA	B-X
biology	B-X
have	B-X
redefined	B-X
the	B-X
biological	B-X
landscape	B-X
by	B-X
significantly	B-X
altering	B-X
the	B-X
longstanding	B-X
dogmas	B-X
that	B-X
defined	B-X
gene	B-X
regulation	B-X
.	B-X
Endogenous	B-X
RNA	B-X
silencing	B-X
molecules	B-X
,	B-X
microRNAs	B-X
,	B-X
are	B-X
regulators	B-X
of	B-X
these	B-X
metabolic/phenotypic	B-X
shifts	B-X
in	B-X
skeletal	B-X
muscles	B-X
.	B-X
Therefore	B-X
,	B-X
microRNAs	B-X
emerge	B-X
as	B-X
key	B-X
regulators	B-X
of	B-X
metabolic	B-X
health/capacity	B-X
and	B-X
hormetic	B-X
adaptability	B-X
.	B-X
In	B-X
this	B-X
narrative	B-X
review	B-X
,	B-X
we	B-X
summarise	B-X
the	B-X
literature	B-X
exploring	B-X
the	B-X
links	B-X
between	B-X
microRNAs	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
as	B-X
well	B-X
as	B-X
systemic	B-X
adaptation	B-X
to	B-X
exercise	B-X
.	B-X

miRNAs	O
are	O
recently	O
discovered	O
regulators	O
of	O
gene	O
expression	O
and	O
represent	O
a	O
class	O
of	O
noncoding	O
RNA	O
molecules	O
essential	O
in	O
many	O
cellular	O
and	O
developmental	O
processes	O
,	O
including	O
immune	O
responses	O
and	O
inflammation	O
.	O

They	O
bind	O
the	O
3	O
'	O
-	O
UTR	O
of	O
target	O
mRNAs	O
leading	O
to	O
the	O
repression	O
of	O
protein	O
expression	O
and	O
the	O
promotion	O
of	O
target	O
mRNA	O
degradation	O
[	O
77	O
]	O
.	O

miR	B-Protein
-	I-Protein
146a	I-Protein
/	O
b	B-Protein
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
are	O
of	O
particular	O
interest	O
for	O
inflammatory	O
signalling	O
to	O
NF	O
-	O
kappaB	O
,	O
since	O
these	O
miRNAs	O
can	O
be	O
induced	O
by	O
inflammatory	O
stimuli	O
such	O
as	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
TNF	B-Protein
and	O
TLRs	O
[	O
78	O
,	O
79	O
]	O
.	O

In	O
addition	O
,	O
miR	B-Protein
-	I-Protein
146a	I-Protein
is	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
,	O
and	O
the	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
were	O
identified	O
as	O
target	O
genes	O
of	O
miR	B-Protein
-	I-Protein
146a	I-Protein
[	O
78	O
]	O
(	O
Figure	O
1	O
)	O
.	O

Similarly	O
,	O
miR	B-Protein
-	I-Protein
155	I-Protein
was	O
shown	O
to	O
target	O
transcripts	O
for	O
the	O
NF	O
-	O
kappaB	O
signalling	O
molecules	O
IKKepsilon	B-Protein
and	O
RIP1	B-Protein
[	O
79	O
,	O
80	O
]	O
.	O

Notably	O
,	O
both	O
miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
are	O
expressed	O
at	O
higher	O
levels	O
in	O
RA	O
synovial	O
fibroblasts	O
and	O
synovial	O
tissue	O
[	O
81	O
,	O
82	O
]	O
,	O
as	O
well	O
as	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
RA	O
patients	O
[	O
83	O
]	O
.	O

miR	B-Protein
-	I-Protein
146a	I-Protein
is	O
also	O
overexpressed	O
in	O
CD4	B-Protein
+	O
and	O
IL	B-Protein
-	I-Protein
17	I-Protein
-	O
producing	O
T	O
cells	O
from	O
RA	O
patients	O
[	O
84	O
,	O
85	O
]	O
.	O

Interestingly	O
,	O
a	O
polymorphism	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
the	O
miR	B-Protein
-	I-Protein
146a	I-Protein
target	O
gene	O
was	O
recently	O
shown	O
to	O
be	O
associated	O
with	O
RA	O
susceptibility	O
[	O
86	O
]	O
.	O

miR	B-Protein
-	I-Protein
155	I-Protein
overexpression	O
in	O
synovial	O
fibroblasts	O
was	O
able	O
to	O
prevent	O
the	O
TLR	O
and	O
cytokine	O
-	O
inducible	O
expression	O
of	O
specific	O
matrix	O
metalloproteinases	O
that	O
mediate	O
tissue	O
destruction	O
in	O
RA	O
[	O
81	O
]	O
.	O

Moreover	O
,	O
miR	B-Protein
-	I-Protein
155	I-Protein
was	O
shown	O
to	O
promote	O
TNF	B-Protein
production	O
,	O
a	O
key	O
process	O
in	O
the	O
pathogenesis	O
of	O
RA	O
[	O
87	O
]	O
.	O

miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
may	O
therefore	O
be	O
important	O
negative	O
regulators	O
of	O
inflammation	O
in	O
RA	O
and	O
their	O
potential	O
for	O
the	O
development	O
of	O
new	O
treatments	O
is	O
substantial	O
.	O

In	O
addition	O
,	O
their	O
increased	O
expression	O
in	O
RA	O
patients	O
is	O
potentially	O
useful	O
as	O
a	O
marker	O
for	O
disease	O
diagnosis	O
,	O
progression	O
,	O
or	O
treatment	O
efficacy	O
[	O
88	O
]	O
,	O
but	O
this	O
will	O
require	O
confirmation	O
using	O
a	O
large	O
and	O
well	O
-	O
defined	O
cohort	O
.	O
<EOS>	B-X
Emerging	B-X
antimicrobial	B-X
resistance	B-X
is	B-X
a	B-X
global	B-X
health	B-X
concern	B-X
,	B-X
prompting	B-X
research	B-X
interest	B-X
in	B-X
non-antibiotic	B-X
agents	B-X
such	B-X
as	B-X
methenamine	B-X
hippurate	B-X
,	B-X
but	B-X
comparative	B-X
data	B-X
on	B-X
their	B-X
efficacy	B-X
and	B-X
safety	B-X
are	B-X
lacking	B-X
.	B-X
MicroRNAs	B-X
are	B-X
small	B-X
noncoding	B-X
RNA	B-X
molecules	B-X
that	B-X
negatively	B-X
regulate	B-X
gene	B-X
expression	B-X
via	B-X
degradation	B-X
or	B-X
translational	B-X
repression	B-X
of	B-X
their	B-X
targeted	B-X
mRNAs	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
aberrant	B-X
microRNA	B-X
expression	B-X
can	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
cancer	B-X
,	B-X
but	B-X
the	B-X
role	B-X
of	B-X
microRNAs	B-X
in	B-X
autoimmune	B-X
diseases	B-X
is	B-X
only	B-X
beginning	B-X
to	B-X
emerge	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
selected	B-X
microRNAs	B-X
is	B-X
examined	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
.	B-X

Besides	O
miR	O
-	O
146	O
and	O
miR	B-Protein
-	I-Protein
155	I-Protein
,	O
a	O
number	O
of	O
other	O
miRNAs	O
with	O
a	O
potential	O
role	O
in	O
the	O
control	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
inflammatory	O
responses	O
in	O
RA	O
pathology	O
were	O
recently	O
identified	O
.	O

In	O
this	O
context	O
,	O
miR	B-Protein
-	I-Protein
124a	I-Protein
-	O
a	O
key	O
regulator	O
of	O
the	O
chemokine	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
1	I-Protein
-	O
was	O
shown	O
to	O
be	O
decreased	O
in	O
synoviocytes	O
from	O
RA	O
patients	O
[	O
89	O
]	O
.	O

Similarly	O
,	O
elevated	O
levels	O
of	O
miR	B-Protein
-	I-Protein
203	I-Protein
-	O
leading	O
to	O
increased	O
secretion	O
of	O
matrix	B-Protein
metalloproteinase	I-Protein
-	I-Protein
1	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
-	O
were	O
detected	O
in	O
RA	O
synovial	O
fibroblasts	O
[	O
90	O
]	O
.	O

Finally	O
,	O
miR	B-Protein
-	I-Protein
16	I-Protein
,	O
miR	B-Protein
-	I-Protein
132	I-Protein
,	O
and	O
miR	B-Protein
-	I-Protein
223	I-Protein
were	O
also	O
shown	O
to	O
have	O
an	O
altered	O
expression	O
in	O
RA	O
patients	O
,	O
indicating	O
their	O
potential	O
as	O
diagnostic	O
biomarkers	O
for	O
pathogenesis	O
[	O
83	O
,	O
88	O
,	O
91	O
]	O
.	O

The	O
NF	O
-	O
kappaB	O
family	O
of	O
transcription	O
factors	O
plays	O
crucial	O
roles	O
in	O
the	O
inflammatory	O
processes	O
in	O
RA	O
leading	O
to	O
cartilage	O
and	O
bone	O
destruction	O
.	O

Keeping	O
NF	O
-	O
kappaB	O
activation	O
under	O
control	O
can	O
thus	O
be	O
very	O
important	O
for	O
the	O
design	O
of	O
specific	O
therapeutics	O
.	O

The	O
existence	O
of	O
multiple	O
negative	O
regulators	O
ensuring	O
a	O
tight	O
regulation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
however	O
,	O
raises	O
the	O
question	O
of	O
the	O
specific	O
role	O
of	O
each	O
of	O
these	O
regulators	O
and	O
the	O
relationship	O
between	O
them	O
.	O

In	O
addition	O
,	O
given	O
the	O
number	O
of	O
miRNAs	O
in	O
humans	O
and	O
the	O
multiple	O
mRNAs	O
they	O
target	O
,	O
intense	O
complexity	O
can	O
be	O
expected	O
.	O

How	O
all	O
these	O
regulatory	O
signals	O
are	O
themselves	O
regulated	O
will	O
be	O
an	O
important	O
question	O
in	O
order	O
to	O
clarify	O
how	O
NF	O
-	O
kappaB	O
signalling	O
is	O
organised	O
,	O
and	O
,	O
more	O
importantly	O
,	O
how	O
this	O
knowledge	O
may	O
lead	O
to	O
new	O
treatments	O
for	O
inflammatory	O
diseases	O
such	O
as	O
RA	O
.	O

Canonical	O
NF	O
-	O
kappaB	O
signalling	O
and	O
negative	O
regulators	O
.	O
<EOS>	B-X
The	B-X
non-canonical	B-X
NF-κB	B-X
signalling	B-X
cascade	B-X
is	B-X
essential	B-X
for	B-X
lymphoid	B-X
organogenesis	B-X
,	B-X
B	B-X
cell	B-X
maturation	B-X
,	B-X
osteoclast	B-X
differentiation	B-X
,	B-X
and	B-X
inflammation	B-X
in	B-X
mammals	B-X
Conversely	B-X
,	B-X
during	B-X
infection	B-X
with	B-X
Salmonella	B-X
enterica	B-X
serovar	B-X
Typhimurium	B-X
,	B-X
vesicular	B-X
stomatitis	B-X
virus	B-X
,	B-X
Klebsiella	B-X
pneumoniae	B-X
,	B-X
or	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
and	B-X
in	B-X
colonic	B-X
tumorigenesis	B-X
,	B-X
NLRP12	B-X
acts	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
NFκB	B-X
and	B-X
MAPK	B-X
signaling	B-X
pathways	B-X
.	B-X
NLRP12	B-X
also	B-X
negatively	B-X
regulates	B-X
canonical	B-X
and	B-X
non-canonical	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
causes	B-X
exacerbated	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
NLRP12	B-X
to	B-X
function	B-X
as	B-X
an	B-X
inflammasome	B-X
or	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
is	B-X
context-dependent	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
NLR	B-X
family	B-X
members	B-X
and	B-X
summarize	B-X
recent	B-X
insights	B-X
into	B-X
the	B-X
roles	B-X
of	B-X
NLRP12	B-X
as	B-X
an	B-X
inflammasome	B-X
and	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
.	B-X

Ligand	O
engagement	O
of	O
specific	O
membrane	O
receptors	O
such	O
as	O
TNFR1	B-Protein
,	O
CD40	B-Protein
,	O
RANK	B-Protein
,	O
and	O
TLR4	B-Protein
trigger	O
the	O
recruitment	O
of	O
specific	O
adaptor	O
proteins	O
(	O
TNF	B-Protein
receptor	I-Protein
1	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	I-Protein
(	O
TRADD	B-Protein
)	O
,	O
MyD88	B-Protein
,	O
MAL	B-Protein
,	O
TIR	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
adaptor	I-Protein
-	I-Protein
inducing	I-Protein
IFNbeta	I-Protein
(	O
TRIF	B-Protein
)	O
)	O
,	O
kinases	O
(	O
RIP1	B-Protein
,	O
IRAK1	B-Protein
,	O
IRAK4	B-Protein
)	O
,	O
and	O
ubiquitin	O
ligases	O
(	O
TRAF2	B-Protein
,	O
TRAF6	B-Protein
,	O
cIAP1	B-Protein
,	O
cIAP2	B-Protein
)	O
to	O
the	O
receptor	O
.	O

K63	O
-	O
linked	O
polyubiquitination	O
of	O
TRAFs	O
,	O
RIP1	B-Protein
and	O
IRAK1	B-Protein
,	O
is	O
recognised	O
by	O
NEMO	B-Protein
and	O
TAB	O
proteins	O
,	O
resulting	O
in	O
the	O
recruitment	O
and	O
activation	O
of	O
respectively	O
IKK2	B-Protein
and	O
TAK1	B-Protein
.	O

TAK1	B-Protein
then	O
phosphorylates	O
and	O
activates	O
IKK2	B-Protein
,	O
which	O
in	O
turn	O
phosphorylates	O
IkappaBalpha	B-Protein
,	O
triggering	O
its	O
K48	O
-	O
linked	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

This	O
allows	O
NF	O
-	O
kappaB	O
(	O
here	O
shown	O
as	O
a	O
heterodimer	O
of	O
p65	B-Protein
and	O
p50	B-Protein
)	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
promote	O
target	O
gene	O
expression	O
.	O

TRAF1	B-Protein
,	O
which	O
has	O
no	O
ubiquitin	O
ligase	O
activity	O
,	O
can	O
negatively	O
regulate	O
NF	O
-	O
kappaB	O
activation	O
,	O
most	O
probably	O
by	O
competing	O
with	O
other	O
TRAFs	O
.	O

A20	B-Protein
and	O
CYLD	B-Protein
are	O
deubiquitinating	O
enzymes	O
that	O
control	O
NF	O
-	O
kappaB	O
activation	O
by	O
targeting	O
specific	O
signalling	O
proteins	O
including	O
RIP1	B-Protein
and	O
TRAF6	B-Protein
,	O
to	O
which	O
they	O
are	O
recruited	O
using	O
specific	O
ubiquitin	O
-	O
binding	O
adaptor	O
proteins	O
such	O
as	O
ABIN	B-Protein
-	I-Protein
1	I-Protein
and	O
p62	B-Protein
.	O

miR	O
-	O
146	O
is	O
thought	O
to	O
negatively	O
regulate	O
TLR	O
signalling	O
by	O
inhibiting	O
expression	O
of	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

Finally	O
,	O
TLR	O
signalling	O
can	O
also	O
be	O
inhibited	O
by	O
the	O
transmembrane	O
protein	O
SIGIRR	B-Protein
,	O
which	O
has	O
been	O
proposed	O
to	O
compete	O
with	O
TLR4	B-Protein
for	O
binding	O
to	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

The	O
expression	O
of	O
many	O
of	O
these	O
negative	O
regulatory	O
molecules	O
is	O
NF	O
-	O
kappaB	O
dependent	O
,	O
implicating	O
them	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

ABIN	B-Protein
,	O
A20	B-Protein
-	I-Protein
binding	I-Protein
inhibitor	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
cIAP	O
,	O
cellular	O
inhibitor	O
of	O
apoptosis	O
;	O
CYLD	B-Protein
,	O
cylindromatosis	B-Protein
;	O
IKK	O
,	O
IkappaB	O
kinase	O
;	O
IkappaB	O
,	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
;	O
IRAK	O
,	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
;	O
MyD88	B-Protein
,	O
myeloid	B-Protein
differentiation	I-Protein
primary	I-Protein
response	I-Protein
gene	I-Protein
88	I-Protein
;	O
NEMO	B-Protein
,	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
essential	I-Protein
modulator	I-Protein
;	O
NF	O
,	O
nuclear	O
factor	O
;	O
RANK	B-Protein
,	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
RIP1	B-Protein
,	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
1	I-Protein
;	O
SIGIRR	B-Protein
,	O
single	B-Protein
-	I-Protein
immunoglobulinIL	I-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
;	O
TIR	O
,	O
Toll	O
-	O
like	O
receptor	O
/	O
IL	O
-	O
1R	O
;	O
TRAF	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
;	O
TLR	O
,	O
Toll	O
-	O
like	O
receptor	O
;	O
TNF	B-Protein
,	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
.	O
<EOS>	B-X
The	B-X
family	B-X
of	B-X
A20-Binding	B-X
Inhibitors	B-X
of	B-X
NF-kappaB	B-X
(	B-X
ABINs	B-X
)	B-X
consists	B-X
of	B-X
three	B-X
proteins	B-X
,	B-X
ABIN-1	B-X
,	B-X
ABIN-2	B-X
and	B-X
ABIN-3	B-X
,	B-X
which	B-X
were	B-X
originally	B-X
identified	B-X
as	B-X
A20-binding	B-X
proteins	B-X
and	B-X
inhibitors	B-X
of	B-X
cytokines	B-X
and	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
ABIN	B-X
family	B-X
members	B-X
have	B-X
limited	B-X
sequence	B-X
homology	B-X
in	B-X
a	B-X
number	B-X
of	B-X
short	B-X
regions	B-X
that	B-X
mediate	B-X
A20-binding	B-X
,	B-X
ubiquitin-binding	B-X
,	B-X
and	B-X
NF-kappaB	B-X
inhibition	B-X
.	B-X
The	B-X
functional	B-X
role	B-X
of	B-X
A20	B-X
binding	B-X
to	B-X
ABINs	B-X
remains	B-X
unclear	B-X
,	B-X
although	B-X
an	B-X
adaptor	B-X
function	B-X
has	B-X
been	B-X
suggested	B-X
.	B-X
ABIN-1	B-X
and	B-X
ABIN-3	B-X
expression	B-X
is	B-X
upregulated	B-X
when	B-X
cells	B-X
are	B-X
triggered	B-X
by	B-X
NF-kappaB-activating	B-X
stimuli	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
for	B-X
these	B-X
ABINs	B-X
in	B-X
a	B-X
negative	B-X
feedback	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X
Additional	B-X
ABIN	B-X
functions	B-X
have	B-X
been	B-X
reported	B-X
such	B-X
as	B-X
inhibition	B-X
of	B-X
TNF-induced	B-X
hepatocyte	B-X
apoptosis	B-X
,	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
for	B-X
ABIN-1	B-X
,	B-X
and	B-X
Tumor	B-X
Progression	B-X
Locus	B-X
2	B-X
(	B-X
TPL-2	B-X
)	B-X
-mediated	B-X
Extracellular	B-X
signal-Regulated	B-X
Kinase	B-X
(	B-X
ERK	B-X
)	B-X
activation	B-X
for	B-X
ABIN-2	B-X
.	B-X
In	B-X
mice	B-X
,	B-X
ABIN-1	B-X
overexpression	B-X
reduces	B-X
allergic	B-X
airway	B-X
inflammation	B-X
and	B-X
TNF-mediated	B-X
liver	B-X
injury	B-X
,	B-X
ABIN-2	B-X
overexpression	B-X
delays	B-X
liver	B-X
regeneration	B-X
,	B-X
and	B-X
ABIN-3	B-X
overexpression	B-X
partially	B-X
protects	B-X
against	B-X
LPS-induced	B-X
acute	B-X
liver	B-X
failure	B-X
.	B-X
Analysis	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
ABIN-1	B-X
or	B-X
ABIN-2	B-X
demonstrates	B-X
the	B-X
important	B-X
immune	B-X
regulatory	B-X
function	B-X
of	B-X
ABINs	B-X
.	B-X
Future	B-X
studies	B-X
should	B-X
clarify	B-X
the	B-X
functional	B-X
implication	B-X
of	B-X
the	B-X
A20-ABIN	B-X
interaction	B-X
in	B-X
supporting	B-X
ABINs	B-X
'	B-X
mechanisms	B-X
of	B-X
action	B-X
.	B-X

Noncanonical	O
NF	O
-	O
kappaB	O
signalling	O
.	O
<EOS>	B-X
NF-κB	B-X
pathway	B-X
consists	B-X
of	B-X
canonical	B-X
and	B-X
non-canonical	B-X
pathways	B-X
.	B-X
The	B-X
canonical	B-X
NF-κB	B-X
is	B-X
activated	B-X
by	B-X
various	B-X
stimuli	B-X
,	B-X
transducing	B-X
a	B-X
quick	B-X
but	B-X
transient	B-X
transcriptional	B-X
activity	B-X
,	B-X
to	B-X
regulate	B-X
the	B-X
expression	B-X
of	B-X
various	B-X
proinflammatory	B-X
genes	B-X
and	B-X
also	B-X
serve	B-X
as	B-X
the	B-X
critical	B-X
mediator	B-X
for	B-X
inflammatory	B-X
response	B-X
.	B-X
Meanwhile	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
non-canonical	B-X
NF-κB	B-X
pathway	B-X
occurs	B-X
through	B-X
a	B-X
handful	B-X
of	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
members	B-X
.	B-X
Since	B-X
the	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
involves	B-X
protein	B-X
synthesis	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
non-canonical	B-X
NF-κB	B-X
activation	B-X
is	B-X
slow	B-X
but	B-X
persistent	B-X
,	B-X
in	B-X
concordance	B-X
with	B-X
its	B-X
biological	B-X
functions	B-X
in	B-X
the	B-X
development	B-X
of	B-X
immune	B-X
cell	B-X
and	B-X
lymphoid	B-X
organ	B-X
,	B-X
immune	B-X
homeostasis	B-X
and	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
the	B-X
canonical	B-X
and	B-X
non-canonical	B-X
NF-κB	B-X
pathway	B-X
is	B-X
tightly	B-X
controlled	B-X
,	B-X
highlighting	B-X
the	B-X
vital	B-X
roles	B-X
of	B-X
ubiquitination	B-X
in	B-X
these	B-X
pathways	B-X
.	B-X
Emerging	B-X
studies	B-X
indicate	B-X
that	B-X
dysregulated	B-X
NF-κB	B-X
activity	B-X
causes	B-X
inflammation-related	B-X
diseases	B-X
as	B-X
well	B-X
as	B-X
cancers	B-X
,	B-X
and	B-X
NF-κB	B-X
has	B-X
been	B-X
long	B-X
proposed	B-X
as	B-X
the	B-X
potential	B-X
target	B-X
for	B-X
therapy	B-X
of	B-X
diseases	B-X
.	B-X
This	B-X
review	B-X
attempts	B-X
to	B-X
summarize	B-X
our	B-X
current	B-X
knowledge	B-X
and	B-X
updates	B-X
on	B-X
the	B-X
mechanisms	B-X
of	B-X
NF-κB	B-X
pathway	B-X
regulation	B-X
and	B-X
the	B-X
potential	B-X
therapeutic	B-X
application	B-X
of	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
signaling	B-X
in	B-X
cancer	B-X
and	B-X
inflammatory	B-X
diseases	B-X
.	B-X

CD40	B-Protein
and	O
RANK	B-Protein
can	O
activate	O
the	O
noncanonical	O
NF	O
-	O
kappaB	O
pathway	O
that	O
is	O
dependent	O
on	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
expression	O
levels	O
.	O

In	O
unstimulated	O
cells	O
NIK	B-Protein
forms	O
a	O
cytosolic	O
complex	O
with	O
the	O
ubiquitin	O
ligases	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
and	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
which	O
facilitates	O
the	O
K48	O
-	O
linked	O
polyubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
NIK	B-Protein
,	O
keeping	O
NIK	B-Protein
levels	O
low	O
.	O

Upon	O
ligand	O
binding	O
,	O
TRAF3	B-Protein
is	O
recruited	O
to	O
the	O
receptor	O
,	O
where	O
TRAF2	B-Protein
directs	O
nondegradative	O
K63	O
-	O
linked	O
polyubiquitination	O
of	O
cIAP1	B-Protein
/	O
2	B-Protein
,	O
resulting	O
in	O
their	O
activation	O
.	O

Subsequently	O
cIAP1	B-Protein
/	O
2	B-Protein
directs	O
its	O
K48	O
-	O
linked	O
polyubiquitination	O
to	O
TRAF3	B-Protein
,	O
rather	O
than	O
NIK	B-Protein
.	O

As	O
a	O
result	O
,	O
TRAF3	B-Protein
is	O
degraded	O
and	O
NIK	B-Protein
is	O
stabilised	O
,	O
resulting	O
in	O
increased	O
NIK	B-Protein
levels	O
in	O
the	O
cell	O
.	O
<EOS>	B-X
Ser/Thr	B-X
kinase	B-X
NIK	B-X
(	B-X
NF-κB-inducing	B-X
kinase	B-X
)	B-X
mediates	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
noncanonical	B-X
NF-κB2	B-X
pathway	B-X
,	B-X
and	B-X
it	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
immune	B-X
cell	B-X
development	B-X
and	B-X
liver	B-X
homeostasis	B-X
.	B-X
NIK	B-X
levels	B-X
are	B-X
extremely	B-X
low	B-X
in	B-X
quiescent	B-X
cells	B-X
due	B-X
to	B-X
ubiquitin/proteasome-mediated	B-X
degradation	B-X
,	B-X
and	B-X
cytokines	B-X
stimulate	B-X
NIK	B-X
activation	B-X
through	B-X
increasing	B-X
NIK	B-X
stability	B-X
;	B-X
however	B-X
,	B-X
regulation	B-X
of	B-X
NIK	B-X
stability	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
CHIP	B-X
(	B-X
carboxyl	B-X
terminus	B-X
of	B-X
HSC70-interacting	B-X
protein	B-X
)	B-X
as	B-X
a	B-X
new	B-X
negative	B-X
regulator	B-X
of	B-X
NIK	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
CHIP	B-X
bound	B-X
to	B-X
NIK	B-X
via	B-X
its	B-X
TPR	B-X
domain	B-X
.	B-X
In	B-X
both	B-X
HEK293	B-X
and	B-X
primary	B-X
hepatocytes	B-X
,	B-X
overexpression	B-X
of	B-X
CHIP	B-X
markedly	B-X
decreased	B-X
NIK	B-X
levels	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
increasing	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
NIK	B-X
.	B-X
Accordingly	B-X
,	B-X
CHIP	B-X
suppressed	B-X
NIK-induced	B-X
activation	B-X
of	B-X
the	B-X
noncanonical	B-X
NF-κB2	B-X
pathway	B-X
.	B-X
CHIP	B-X
also	B-X
bound	B-X
to	B-X
TRAF3	B-X
,	B-X
and	B-X
CHIP	B-X
and	B-X
TRAF3	B-X
acted	B-X
coordinately	B-X
to	B-X
efficiently	B-X
promote	B-X
NIK	B-X
degradation	B-X
.	B-X
The	B-X
TPR	B-X
but	B-X
not	B-X
the	B-X
U-box	B-X
domain	B-X
was	B-X
required	B-X
for	B-X
CHIP	B-X
to	B-X
promote	B-X
NIK	B-X
degradation	B-X
.	B-X
In	B-X
mice	B-X
,	B-X
hepatocyte-specific	B-X
overexpression	B-X
of	B-X
NIK	B-X
resulted	B-X
in	B-X
liver	B-X
inflammation	B-X
and	B-X
injury	B-X
,	B-X
leading	B-X
to	B-X
death	B-X
,	B-X
and	B-X
liver-specific	B-X
expression	B-X
of	B-X
CHIP	B-X
reversed	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
hepatic	B-X
NIK	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CHIP/TRAF3/NIK	B-X
interactions	B-X
recruit	B-X
NIK	B-X
to	B-X
E3	B-X
ligase	B-X
complexes	B-X
for	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
,	B-X
thus	B-X
maintaining	B-X
NIK	B-X
at	B-X
low	B-X
levels	B-X
.	B-X
Defects	B-X
in	B-X
CHIP	B-X
regulation	B-X
of	B-X
NIK	B-X
may	B-X
result	B-X
in	B-X
aberrant	B-X
NIK	B-X
activation	B-X
in	B-X
the	B-X
liver	B-X
,	B-X
contributing	B-X
to	B-X
live	B-X
injury	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
disease	B-X
.	B-X

NIK	B-Protein
then	O
phosphorylates	O
and	O
activates	O
IKK1	B-Protein
,	O
which	O
mediates	O
NF	O
-	O
kappaB	O
p100	B-Protein
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
heterodimer	B-X
formed	B-X
by	B-X
the	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
subunits	B-X
p52	B-X
and	B-X
RelB	B-X
is	B-X
the	B-X
product	B-X
of	B-X
noncanonical	B-X
signaling	B-X
in	B-X
which	B-X
the	B-X
key	B-X
event	B-X
is	B-X
the	B-X
proteolytic	B-X
processing	B-X
of	B-X
p100	B-X
to	B-X
generate	B-X
p52	B-X
.	B-X
The	B-X
kinases	B-X
NF-κB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
and	B-X
inhibitor	B-X
of	B-X
κB	B-X
kinase	B-X
1	B-X
(	B-X
IKK1	B-X
;	B-X
also	B-X
known	B-X
as	B-X
IKKα	B-X
)	B-X
are	B-X
activated	B-X
during	B-X
noncanonical	B-X
signaling	B-X
and	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
p100	B-X
processing	B-X
.	B-X
In	B-X
resting	B-X
cells	B-X
,	B-X
RelB	B-X
remains	B-X
associated	B-X
with	B-X
unprocessed	B-X
p100	B-X
as	B-X
a	B-X
transcriptionally	B-X
inert	B-X
p100	B-X
:	B-X
RelB	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
a	B-X
larger	B-X
assembly	B-X
with	B-X
other	B-X
NF-κB	B-X
factors	B-X
known	B-X
as	B-X
the	B-X
``	B-X
kappaBsome	B-X
.	B-X
''	B-X
We	B-X
found	B-X
that	B-X
RelB	B-X
controls	B-X
the	B-X
extent	B-X
of	B-X
both	B-X
p100	B-X
processing	B-X
and	B-X
kappaBsome	B-X
formation	B-X
during	B-X
noncanonical	B-X
signaling	B-X
.	B-X
Within	B-X
an	B-X
apparently	B-X
``	B-X
transitional	B-X
''	B-X
complex	B-X
that	B-X
contains	B-X
RelB	B-X
,	B-X
NIK	B-X
,	B-X
IKK1	B-X
,	B-X
and	B-X
p100	B-X
,	B-X
RelB	B-X
and	B-X
the	B-X
NIK	B-X
:	B-X
IKK1	B-X
complex	B-X
competed	B-X
with	B-X
each	B-X
other	B-X
for	B-X
binding	B-X
to	B-X
a	B-X
region	B-X
of	B-X
p100	B-X
.	B-X
A	B-X
fraction	B-X
of	B-X
p100	B-X
in	B-X
the	B-X
transitional	B-X
complex	B-X
was	B-X
refractory	B-X
to	B-X
processing	B-X
,	B-X
which	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
kappaBsome	B-X
.	B-X
However	B-X
,	B-X
another	B-X
fraction	B-X
of	B-X
p100	B-X
protein	B-X
underwent	B-X
NIK	B-X
:	B-X
IKK1-mediated	B-X
phosphorylation	B-X
and	B-X
processing	B-X
while	B-X
remaining	B-X
bound	B-X
to	B-X
RelB	B-X
,	B-X
thus	B-X
forming	B-X
the	B-X
p52	B-X
:	B-X
RelB	B-X
heterodimer	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
changes	B-X
in	B-X
the	B-X
relative	B-X
concentrations	B-X
of	B-X
RelB	B-X
,	B-X
NIK	B-X
:	B-X
IKK1	B-X
,	B-X
and	B-X
p100	B-X
during	B-X
noncanonical	B-X
signaling	B-X
modulate	B-X
this	B-X
transitional	B-X
complex	B-X
and	B-X
are	B-X
critical	B-X
for	B-X
maintaining	B-X
the	B-X
fine	B-X
balance	B-X
between	B-X
the	B-X
processing	B-X
and	B-X
protection	B-X
of	B-X
p100	B-X
.	B-X

This	O
is	O
followed	O
by	O
K48	O
-	O
linked	O
polyubiquitination	O
and	O
partial	O
proteasomal	O
degradation	O
of	O
p100	B-Protein
to	O
p52	B-Protein
,	O
which	O
forms	O
a	O
heterodimer	O
with	O
RelB	B-Protein
to	O
activate	O
transcription	O
.	O

Next	O
to	O
TRAF3	B-Protein
,	O
TRAF1	B-Protein
has	O
also	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
this	O
pathway	O
,	O
most	O
probably	O
by	O
competing	O
with	O
other	O
TNF	O
receptor	O
-	O
associated	O
factors	O
.	O

cIAP	O
,	O
cellular	O
inhibitor	O
of	O
apoptosis	O
;	O
IKK	O
,	O
IkappaB	O
kinase	O
;	O
NF	O
,	O
nuclear	O
factor	O
;	O
RANK	B-Protein
,	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
;	O
TRAF	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
;	O
TNF	B-Protein
,	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
.	O
<EOS>	B-X
Neutrophils	B-X
express	B-X
a	B-X
large	B-X
number	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
for	B-X
the	B-X
recognition	B-X
of	B-X
pathogen	B-X
invasion	B-X
and	B-X
the	B-X
inflammatory	B-X
environment	B-X
.	B-X
Those	B-X
include	B-X
G-protein-coupled	B-X
chemokine	B-X
and	B-X
chemoattractant	B-X
receptors	B-X
,	B-X
Fc-receptors	B-X
,	B-X
adhesion	B-X
receptors	B-X
such	B-X
as	B-X
selectins/selectin	B-X
ligands	B-X
and	B-X
integrins	B-X
,	B-X
various	B-X
cytokine	B-X
receptors	B-X
,	B-X
as	B-X
well	B-X
as	B-X
innate	B-X
immune	B-X
receptors	B-X
such	B-X
as	B-X
Toll-like	B-X
receptors	B-X
and	B-X
C-type	B-X
lectins	B-X
.	B-X
The	B-X
various	B-X
cell	B-X
surface	B-X
receptors	B-X
trigger	B-X
very	B-X
diverse	B-X
signal	B-X
transduction	B-X
pathways	B-X
including	B-X
activation	B-X
of	B-X
heterotrimeric	B-X
and	B-X
monomeric	B-X
G-proteins	B-X
,	B-X
receptor-induced	B-X
and	B-X
store-operated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
signals	B-X
,	B-X
protein	B-X
and	B-X
lipid	B-X
kinases	B-X
,	B-X
adapter	B-X
proteins	B-X
and	B-X
cytoskeletal	B-X
rearrangement	B-X
.	B-X
Here	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
receptors	B-X
involved	B-X
in	B-X
neutrophil	B-X
activation	B-X
and	B-X
the	B-X
intracellular	B-X
signal	B-X
transduction	B-X
processes	B-X
they	B-X
trigger	B-X
.	B-X

A20	O
(	O
Tnfaip3	B-Protein
)	O
Deficiency	O
in	O
Myeloid	O
Cells	O
Protects	O
against	O
Influenza	O
A	O
Virus	O
Infection	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

The	O
innate	O
immune	O
response	O
provides	O
the	O
first	O
line	O
of	O
defense	O
against	O
viruses	O
and	O
other	O
pathogens	O
by	O
responding	O
to	O
specific	O
microbial	O
molecules	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Conversely	B-X
,	B-X
silencing	B-X
A20	B-X
expression	B-X
markedly	B-X
enhanced	B-X
IRF3-mediated	B-X
innate	B-X
antiviral	B-X
responses	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
findings	B-X
described	B-X
in	B-X
this	B-X
study	B-X
support	B-X
and	B-X
extend	B-X
previous	B-X
results	B-X
on	B-X
interferon-antagonistic	B-X
strategies	B-X
of	B-X
IAV	B-X
NS1	B-X
by	B-X
showing	B-X
an	B-X
induced	B-X
host	B-X
target	B-X
A20	B-X
,	B-X
which	B-X
restricts	B-X
IAV-induced	B-X
host	B-X
innate	B-X
immune	B-X
antiviral	B-X
responses	B-X
and	B-X
thereby	B-X
facilitates	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

Influenza	O
A	O
virus	O
(	O
IAV	O
)	O
produces	O
double	O
-	O
stranded	O
RNA	O
as	O
an	O
intermediate	O
during	O
the	O
replication	O
life	O
cycle	O
,	O
which	O
activates	O
the	O
intracellular	O
pathogen	B-Protein
recognition	I-Protein
receptor	I-Protein
RIG	B-Protein
-	I-Protein
I	I-Protein
and	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
and	O
antiviral	O
interferon	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

Understanding	O
the	O
mechanisms	O
that	O
regulate	O
innate	O
immune	O
responses	O
to	O
IAV	O
and	O
other	O
viruses	O
is	O
of	O
key	O
importance	O
to	O
develop	O
novel	O
therapeutic	O
strategies	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

Here	O
we	O
used	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
to	O
examine	O
the	O
role	O
of	O
the	O
ubiquitin	O
-	O
editing	O
protein	O
A20	O
in	O
the	O
response	O
of	O
myeloid	O
cells	O
to	O
IAV	O
infection	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

A20	O
deficient	O
macrophages	O
were	O
hyperresponsive	O
to	O
double	O
stranded	O
RNA	O
and	O
IAV	O
infection	O
,	O
as	O
illustrated	O
by	O
enhanced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
concomitant	O
with	O
increased	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
chemokines	O
and	O
type	O
I	O
interferon	O
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

In	O
vivo	O
this	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
alveolar	O
macrophages	O
and	O
neutrophils	O
in	O
the	O
lungs	O
of	O
IAV	O
infected	O
mice	O
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

Surprisingly	O
,	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
are	O
protected	O
against	O
lethal	O
IAV	O
infection	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

These	O
results	O
challenge	O
the	O
general	O
belief	O
that	O
an	O
excessive	O
host	O
proinflammatory	O
response	O
is	O
associated	O
with	O
IAV	O
-	O
induced	O
lethality	O
,	O
and	O
suggest	O
that	O
under	O
certain	O
conditions	O
inhibition	O
of	O
A20	O
might	O
be	O
of	O
interest	O
in	O
the	O
management	O
of	O
IAV	O
infections	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
viruses	B-X
and	B-X
other	B-X
pathogens	B-X
by	B-X
responding	B-X
to	B-X
specific	B-X
microbial	B-X
molecules	B-X
.	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

Viruses	O
are	O
a	O
class	O
of	O
highly	O
diverse	O
pathogens	O
which	O
depend	O
on	O
the	O
host	O
cell	O
for	O
their	O
replication	O
.	O

The	O
initiation	O
of	O
a	O
protective	O
innate	O
antiviral	O
immune	O
response	O
involves	O
the	O
action	O
of	O
specialized	O
pattern	O
recognition	O
receptors	O
(	O
PRR	O
)	O
,	O
which	O
detect	O
conserved	O
molecular	O
structures	O
of	O
the	O
invading	O
pathogen	O
.	O

Triggering	O
of	O
PRRs	O
induces	O
the	O
production	O
of	O
host	O
proinflammatory	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
type	O
I	O
interferons	O
(	O
interferon	B-Protein
-	I-Protein
alpha	I-Protein
(	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
)	O
through	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
that	O
control	O
various	O
transcription	O
factors	O
such	O
as	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
,	O
IRF3	B-Protein
and	O
IRF7	B-Protein
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

The	O
presence	O
of	O
viral	O
nucleic	O
acids	O
,	O
such	O
as	O
viral	O
RNA	O
and	O
DNA	O
,	O
viral	O
replication	O
intermediates	O
and	O
viral	O
transcription	O
products	O
,	O
can	O
be	O
sensed	O
by	O
specific	O
intracellular	O
PRRs	O
[	O
3	O
]	O
.	O

Endosomal	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
and	O
cytoplasmic	O
RNA	O
helicase	O
RIG	O
-	O
I	O
-	O
like	O
receptors	O
(	O
RLRs	O
)	O
or	O
Nod	O
-	O
like	O
receptors	O
(	O
NLRs	O
)	O
detect	O
the	O
presence	O
of	O
viral	O
single	O
stranded	O
(	O
TLR7	B-Protein
,	O
TLR8	B-Protein
,	O
Nod2	B-Protein
)	O
or	O
double	O
stranded	O
RNA	O
(	O
TLR3	B-Protein
,	O
RIG	B-Protein
-	I-Protein
I	I-Protein
,	O
MDA5	B-Protein
)	O
.	O
<EOS>	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
and	B-X
RIG-I-like	B-X
receptors	B-X
(	B-X
RLRs	B-X
)	B-X
constitute	B-X
distinct	B-X
families	B-X
of	B-X
pattern-recognition	B-X
receptors	B-X
that	B-X
sense	B-X
nucleic	B-X
acids	B-X
derived	B-X
from	B-X
viruses	B-X
and	B-X
trigger	B-X
antiviral	B-X
innate	B-X
immune	B-X
responses	B-X
.	B-X
TLR3	B-X
,	B-X
TLR7	B-X
,	B-X
and	B-X
TLR9	B-X
are	B-X
membrane	B-X
proteins	B-X
localized	B-X
to	B-X
the	B-X
endosome	B-X
that	B-X
recognize	B-X
viral	B-X
double-stranded	B-X
RNA	B-X
,	B-X
single-stranded	B-X
RNA	B-X
,	B-X
and	B-X
DNA	B-X
,	B-X
respectively	B-X
,	B-X
while	B-X
RLRs	B-X
,	B-X
including	B-X
RIG-I	B-X
,	B-X
Mda5	B-X
,	B-X
and	B-X
LGP2	B-X
,	B-X
are	B-X
cytoplasmic	B-X
proteins	B-X
that	B-X
recognize	B-X
viral	B-X
RNA	B-X
.	B-X
Upon	B-X
recognition	B-X
of	B-X
these	B-X
nucleic	B-X
acid	B-X
species	B-X
,	B-X
TLRs	B-X
and	B-X
RLRs	B-X
recruit	B-X
specific	B-X
intracellular	B-X
adaptor	B-X
proteins	B-X
to	B-X
initiate	B-X
signaling	B-X
pathways	B-X
culminating	B-X
in	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
MAP	B-X
kinases	B-X
,	B-X
and	B-X
IRFs	B-X
that	B-X
control	B-X
the	B-X
transcription	B-X
of	B-X
genes	B-X
encoding	B-X
type	B-X
I	B-X
interferon	B-X
and	B-X
other	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
eliminating	B-X
viruses	B-X
.	B-X
Current	B-X
research	B-X
and	B-X
development	B-X
of	B-X
antigens	B-X
for	B-X
vaccination	B-X
often	B-X
center	B-X
on	B-X
purified	B-X
recombinant	B-X
proteins	B-X
,	B-X
viral	B-X
subunits	B-X
,	B-X
synthetic	B-X
oligopeptides	B-X
or	B-X
oligosaccharides	B-X
,	B-X
most	B-X
of	B-X
them	B-X
suffering	B-X
from	B-X
being	B-X
poorly	B-X
immunogenic	B-X
and	B-X
subject	B-X
to	B-X
degradation	B-X
.	B-X
Particulate	B-X
delivery	B-X
systems	B-X
like	B-X
emulsions	B-X
,	B-X
liposomes	B-X
,	B-X
nanoparticles	B-X
and	B-X
microspheres	B-X
may	B-X
provide	B-X
protection	B-X
from	B-X
degradation	B-X
and	B-X
facilitate	B-X
the	B-X
co-formulation	B-X
of	B-X
both	B-X
the	B-X
antigen	B-X
and	B-X
the	B-X
immunostimulant	B-X
.	B-X
Synthetic	B-X
double-stranded	B-X
(	B-X
ds	B-X
)	B-X
RNA	B-X
,	B-X
such	B-X
as	B-X
polyriboinosinic	B-X
acid-polyribocytidylic	B-X
acid	B-X
,	B-X
poly	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
,	B-X
is	B-X
a	B-X
mimic	B-X
of	B-X
viral	B-X
dsRNA	B-X
and	B-X
,	B-X
as	B-X
such	B-X
,	B-X
a	B-X
promising	B-X
immunostimulant	B-X
candidate	B-X
for	B-X
vaccines	B-X
directed	B-X
against	B-X
intracellular	B-X
pathogens	B-X
.	B-X
Poly	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
signaling	B-X
is	B-X
primarily	B-X
dependent	B-X
on	B-X
Toll-like	B-X
receptor	B-X
3	B-X
(	B-X
TLR3	B-X
)	B-X
,	B-X
and	B-X
on	B-X
melanoma	B-X
differentiation-associated	B-X
gene-5	B-X
(	B-X
MDA-5	B-X
)	B-X
,	B-X
and	B-X
strongly	B-X
drives	B-X
cell-mediated	B-X
immunity	B-X
and	B-X
a	B-X
potent	B-X
type	B-X
I	B-X
interferon	B-X
response	B-X
.	B-X
However	B-X
,	B-X
stability	B-X
and	B-X
toxicity	B-X
issues	B-X
so	B-X
far	B-X
prevented	B-X
the	B-X
clinical	B-X
application	B-X
of	B-X
dsRNAs	B-X
as	B-X
they	B-X
undergo	B-X
rapid	B-X
enzymatic	B-X
degradation	B-X
and	B-X
bear	B-X
the	B-X
potential	B-X
to	B-X
trigger	B-X
undue	B-X
immune	B-X
stimulation	B-X
as	B-X
well	B-X
as	B-X
autoimmune	B-X
disorders	B-X
.	B-X
This	B-X
review	B-X
addresses	B-X
these	B-X
concerns	B-X
and	B-X
suggests	B-X
strategies	B-X
to	B-X
improve	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
immunostimulatory	B-X
dsRNA	B-X
formulations	B-X
.	B-X

Intracellular	O
DNA	O
sensors	O
that	O
mediate	O
antiviral	O
immune	O
responses	O
to	O
DNA	O
viruses	O
include	O
TLR9	B-Protein
,	O
DAI	B-Protein
[	O
4	O
]	O
and	O
the	O
PYHIN	O
domain	O
containing	O
proteins	O
AIM2	B-Protein
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
and	O
IFI16	B-Protein
[	O
8	O
]	O
.	O

TLR	O
mediated	O
antiviral	O
responses	O
are	O
restricted	O
to	O
specialized	O
type	O
I	O
IFN	O
producing	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
)	O
,	O
while	O
most	O
other	O
cell	O
types	O
,	O
including	O
conventional	O
DC	O
(	O
cDC	O
)	O
,	O
macrophages	O
and	O
fibroblasts	O
,	O
depend	O
on	O
the	O
cytosolic	O
RNA	O
and	O
DNA	O
sensors	O
for	O
the	O
production	O
of	O
antiviral	O
proteins	O
[	O
9	O
]	O
.	O

Influenza	O
A	O
virus	O
(	O
IAV	O
)	O
is	O
the	O
etiological	O
agent	O
of	O
a	O
contagious	O
acute	O
respiratory	O
disease	O
that	O
causes	O
considerable	O
mortality	O
,	O
which	O
is	O
generally	O
believed	O
to	O
be	O
due	O
to	O
an	O
excessive	O
host	O
inflammatory	O
response	O
.	O

Emergence	O
of	O
drug	O
-	O
resistant	O
strains	O
of	O
influenza	O
viruses	O
with	O
pandemic	O
potential	O
underscores	O
the	O
importance	O
of	O
developing	O
novel	O
antiviral	O
strategies	O
.	O
<EOS>	B-X
Avian	B-X
influenza	B-X
H5N1	B-X
viruses	B-X
that	B-X
have	B-X
spread	B-X
to	B-X
a	B-X
number	B-X
of	B-X
countries	B-X
in	B-X
Asia	B-X
,	B-X
the	B-X
Middle	B-X
East	B-X
,	B-X
and	B-X
Africa	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
cause	B-X
a	B-X
pandemic	B-X
.	B-X
The	B-X
most	B-X
effective	B-X
public	B-X
health	B-X
intervention	B-X
strategy	B-X
is	B-X
to	B-X
combine	B-X
preventive	B-X
vaccination	B-X
with	B-X
nonpharmaceutical	B-X
intervention	B-X
strategies	B-X
and	B-X
enhanced	B-X
surveillance	B-X
activities	B-X
.	B-X
Hence	B-X
,	B-X
developing	B-X
novel	B-X
adjuvants	B-X
is	B-X
crucial	B-X
for	B-X
pandemic	B-X
influenza	B-X
vaccine	B-X
development	B-X
.	B-X
Although	B-X
the	B-X
use	B-X
of	B-X
antiviral	B-X
drugs	B-X
is	B-X
also	B-X
an	B-X
important	B-X
public	B-X
health	B-X
countermeasure	B-X
for	B-X
preventing	B-X
and	B-X
treating	B-X
influenza	B-X
,	B-X
the	B-X
emergence	B-X
of	B-X
drug-resistant	B-X
strains	B-X
of	B-X
avian	B-X
H5N1	B-X
viruses	B-X
underscores	B-X
the	B-X
need	B-X
to	B-X
develop	B-X
not	B-X
only	B-X
new	B-X
drugs	B-X
but	B-X
other	B-X
novel	B-X
preventive	B-X
and	B-X
therapeutic	B-X
strategies	B-X
such	B-X
as	B-X
vaccines	B-X
.	B-X

In	O
this	O
context	O
,	O
understanding	O
of	O
the	O
mechanisms	O
that	O
regulate	O
IAV	O
-	O
induced	O
immune	O
responses	O
is	O
critical	O
.	O

IAV	O
infection	O
leads	O
to	O
the	O
exposure	O
in	O
the	O
host	O
cell	O
of	O
single	O
-	O
stranded	O
genomic	O
RNA	O
and	O
double	O
stranded	O
RNA	O
,	O
the	O
latter	O
being	O
an	O
intermediate	O
of	O
viral	O
replication	O
.	O

TLR3	B-Protein
and	O
RIG	B-Protein
-	I-Protein
I	I-Protein
have	O
been	O
implicated	O
as	O
sensors	O
of	O
IAV	O
infection	O
[	O
10	O
]	O
-	O
[	O
12	O
]	O
.	O

Both	O
receptors	O
contribute	O
to	O
the	O
proinflammatory	O
response	O
to	O
IAV	O
,	O
but	O
the	O
initiation	O
of	O
the	O
innate	O
antiviral	O
immune	O
response	O
largely	O
depends	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
mediated	O
signaling	O
[	O
13	O
]	O
.	O

Interestingly	O
,	O
RIG	B-Protein
-	I-Protein
I	I-Protein
deficient	O
mice	O
are	O
highly	O
susceptible	O
to	O
IAV	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
whereas	O
TLR3	B-Protein
deficient	O
mice	O
have	O
a	O
survival	O
advantage	O
to	O
acute	O
infection	O
[	O
16	O
]	O
.	O

These	O
results	O
indicate	O
that	O
an	O
imbalance	O
between	O
the	O
beneficial	O
and	O
harmful	O
effects	O
of	O
mediators	O
released	O
by	O
immune	O
cells	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
influenza	O
.	O

RIG	B-Protein
-	I-Protein
I	I-Protein
contains	O
a	O
C	O
-	O
terminal	O
DExD	O
/	O
H	O
box	O
helicase	O
domain	O
,	O
which	O
is	O
required	O
for	O
ligand	O
recognition	O
,	O
and	O
two	O
N	O
-	O
terminal	O
CARD	O
domains	O
.	O

Upon	O
ligand	O
binding	O
,	O
the	O
CARD	O
domains	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
associate	O
with	O
the	O
CARD	O
domain	O
of	O
the	O
MAVS	B-Protein
(	O
also	O
termed	O
IPS	B-Protein
-	I-Protein
1	I-Protein
,	O
VISA	B-Protein
,	O
Cardif	B-Protein
)	O
adaptor	O
protein	O
,	O
which	O
subsequently	O
translocates	O
to	O
and	O
inserts	O
in	O
the	O
outer	O
mitochondrial	O
membrane	O
via	O
its	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
[	O
17	O
]	O
-	O
[	O
20	O
]	O
.	O

Signaling	O
downstream	O
of	O
MAVS	B-Protein
requires	O
the	O
action	O
of	O
various	O
ubiquitin	O
modifying	O
enzymes	O
,	O
which	O
both	O
positively	O
and	O
negatively	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
mediated	O
signal	O
transduction	O
[	O
21	O
]	O
.	O

K63	O
-	O
specific	O
ubiquitin	O
ligases	O
(	O
E3s	O
)	O
,	O
such	O
as	O
TRIM25	B-Protein
[	O
22	O
]	O
and	O
Riplet	B-Protein
[	O
23	O
]	O
,	O
[	O
24	O
]	O
,	O
have	O
been	O
shown	O
to	O
directly	O
promote	O
RIG	B-Protein
-	I-Protein
I	I-Protein
activation	O
.	O

In	O
addition	O
,	O
well	O
characterized	O
ubiquitin	O
ligases	O
such	O
as	O
TRAF6	B-Protein
[	O
25	O
]	O
,	O
[	O
26	O
]	O
and	O
TRAF3	B-Protein
[	O
27	O
]	O
mediate	O
respectively	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
upon	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
.	O

On	O
the	O
other	O
hand	O
,	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
,	O
such	O
as	O
DUBA	B-Protein
[	O
28	O
]	O
,	O
CYLD	B-Protein
[	O
29	O
]	O
,	O
[	O
30	O
]	O
and	O
OTUB1	O
/	O
2	O
[	O
31	O
]	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
RLR	B-Protein
signaling	O
by	O
specifically	O
removing	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
from	O
several	O
signaling	O
molecules	O
.	O

Furthermore	O
,	O
various	O
K48	O
-	O
specific	O
ubiquitin	O
ligases	O
,	O
such	O
as	O
AIP4	B-Protein
[	O
32	O
]	O
and	O
TRIAD3A	B-Protein
[	O
33	O
]	O
mark	O
respectively	O
MAVS	B-Protein
and	O
TRAF3	B-Protein
for	O
proteasome	O
mediated	O
degradation	O
,	O
thus	O
inhibiting	O
further	O
downstream	O
signaling	O
.	O

Additionally	O
,	O
the	O
attachment	O
of	O
K48	O
-	O
specific	O
polyubiquitin	O
chains	O
to	O
the	O
IRF3	B-Protein
and	O
IRF7	B-Protein
transcription	O
factors	O
by	O
E3s	O
such	O
as	O
RAUL	B-Protein
[	O
34	O
]	O
,	O
TRIM21	B-Protein
[	O
35	O
]	O
and	O
RBCK1	B-Protein
[	O
36	O
]	O
further	O
dampens	O
antiviral	O
signal	O
transduction	O
.	O

A20	O
is	O
an	O
ubiquitin	O
-	O
editing	O
enzyme	O
belonging	O
to	O
the	O
OTU	O
-	O
domain	O
family	O
of	O
DUBs	O
.	O

Interestingly	O
,	O
A20	O
also	O
harbors	O
atypical	O
zinc	O
finger	O
dependent	O
K48	O
-	O
specific	O
E3	O
ubiquitin	O
ligase	O
activity	O
.	O

Both	O
catalytic	O
and	O
noncatalytic	O
mechanisms	O
were	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
proinflammatory	O
signaling	O
by	O
A20	O
in	O
response	O
to	O
multiple	O
receptors	O
such	O
as	O
TNF	B-Protein
receptor	I-Protein
I	I-Protein
[	O
37	O
]	O
-	O
[	O
39	O
]	O
,	O
TLR4	B-Protein
[	O
40	O
]	O
,	O
and	O
IL	B-Protein
-	I-Protein
1R	I-Protein
[	O
41	O
]	O
.	O

The	O
anti	O
-	O
inflammatory	O
role	O
of	O
A20	O
is	O
clearly	O
demonstrated	O
by	O
the	O
fact	O
that	O
A20	O
deficient	O
mice	O
die	O
early	O
after	O
birth	O
due	O
to	O
severe	O
multi	O
-	O
organ	O
inflammation	O
and	O
cachexia	O
[	O
37	O
]	O
.	O

More	O
recently	O
,	O
gene	O
targeting	O
of	O
A20	O
in	O
specific	O
cell	O
types	O
was	O
shown	O
to	O
be	O
associated	O
with	O
autoimmunity	O
and	O
chronic	O
inflammation	O
[	O
42	O
]	O
-	O
[	O
48	O
]	O
,	O
further	O
illustrating	O
that	O
A20	O
is	O
an	O
important	O
brake	O
on	O
the	O
inflammatory	O
response	O
.	O

The	O
relevance	O
of	O
these	O
findings	O
for	O
human	O
disease	O
has	O
recently	O
been	O
illustrated	O
through	O
the	O
identification	O
of	O
polymorphisms	O
in	O
the	O
A20	O
locus	O
that	O
are	O
associated	O
with	O
several	O
autoimmune	O
diseases	O
and	O
chronic	O
inflammation	O
[	O
45	O
]	O
.	O

In	O
contrast	O
to	O
its	O
well	O
established	O
function	O
in	O
the	O
regulation	O
of	O
proinflammatory	O
responses	O
,	O
the	O
role	O
of	O
A20	O
in	O
the	O
regulation	O
of	O
antiviral	O
immune	O
responses	O
is	O
less	O
well	O
described	O
and	O
limited	O
to	O
a	O
number	O
of	O
in	O
vitro	O
studies	O
using	O
overexpression	O
or	O
silencing	O
in	O
specific	O
cell	O
lines	O
,	O
indicating	O
that	O
A20	O
may	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
and	O
TLR3	B-Protein
-	O
induced	O
signaling	O
to	O
NF	O
-	O
kappaB	O
and	O
IRF	B-Protein
-	I-Protein
3	I-Protein
[	O
49	O
]	O
-	O
[	O
52	O
]	O
.	O

However	O
,	O
the	O
precise	O
in	O
vivo	O
role	O
of	O
A20	O
in	O
the	O
response	O
to	O
viral	O
infection	O
remains	O
to	O
be	O
clarified	O
.	O

Using	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
(	O
A20myel	O
-	O
KO	O
)	O
that	O
were	O
recently	O
generated	O
in	O
our	O
lab	O
and	O
primary	O
cells	O
derived	O
of	O
these	O
mice	O
,	O
we	O
here	O
provide	O
evidence	O
that	O
A20	O
is	O
a	O
crucial	O
negative	O
regulator	O
of	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
signaling	O
in	O
macrophages	O
.	O

Interestingly	O
,	O
A20myel	O
-	O
KO	O
mice	O
show	O
enhanced	O
survival	O
and	O
reduced	O
morbidity	O
in	O
response	O
to	O
IAV	O
lung	O
infection	O
compared	O
to	O
wild	O
type	O
mice	O
.	O

Protection	O
against	O
IAV	O
in	O
A20myel	O
-	O
KO	O
mice	O
is	O
associated	O
with	O
increased	O
cytokine	O
and	O
chemokine	O
production	O
,	O
augmented	O
recruitment	O
of	O
innate	O
immune	O
cells	O
such	O
as	O
neutophils	O
and	O
alveolar	O
macrophages	O
,	O
and	O
enhanced	O
viral	O
clearance	O
.	O

These	O
results	O
suggest	O
that	O
boosting	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
by	O
targeting	O
A20	O
activity	O
in	O
myeloid	O
cells	O
might	O
have	O
therapeutic	O
potential	O
.	O

A20	O
inhibits	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
induces	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
IRF3	B-Protein
and	O
IRF7	B-Protein
transcription	O
factors	O
,	O
which	O
promote	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
and	O
type	O
I	O
IFNs	O
that	O
restrict	O
further	O
viral	O
propagation	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
ectopically	O
expressed	O
A20	O
negatively	O
regulates	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
upon	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
[	O
50	O
]	O
-	O
[	O
52	O
]	O
.	O

Similarly	O
,	O
we	O
show	O
that	O
A20	O
overexpression	O
in	O
HEK293T	O
cells	O
prevents	O
NF	O
-	O
kappaB	O
-	O
and	O
IRF3	B-Protein
-	O
dependent	O
luciferase	B-Protein
reporter	O
gene	O
activation	O
induced	O
by	O
transfection	O
of	O
a	O
truncated	B-Protein
constitutive	I-Protein
active	I-Protein
form	I-Protein
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
[	O
53	O
]	O
,	O
corresponding	O
to	O
only	O
the	O
two	O
N	O
-	O
terminal	O
CARD	O
domains	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
[	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
]	O
(	O
figure	O
1A	O
,	O
left	O
and	O
middle	O
graph	O
)	O
.	O

We	O
next	O
investigated	O
whether	O
A20	O
also	O
inhibits	O
IRF7	B-Protein
activation	O
.	O

Unlike	O
IRF3	B-Protein
,	O
IRF7	B-Protein
is	O
not	O
or	O
weakly	O
expressed	O
under	O
naive	O
conditions	O
and	O
IRF7	B-Protein
protein	O
levels	O
are	O
rapidly	O
upregulated	O
upon	O
virus	O
-	O
induced	O
IRF3	B-Protein
activation	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
.	O
<EOS>	B-X
The	B-X
filoviruses	B-X
,	B-X
Ebola	B-X
virus	B-X
(	B-X
EBOV	B-X
)	B-X
and	B-X
Marburg	B-X
virus	B-X
(	B-X
MARV	B-X
)	B-X
,	B-X
cause	B-X
frequently	B-X
lethal	B-X
viral	B-X
hemorrhagic	B-X
fever	B-X
.	B-X
These	B-X
infections	B-X
induce	B-X
potent	B-X
cytokine	B-X
production	B-X
,	B-X
yet	B-X
these	B-X
host	B-X
responses	B-X
fail	B-X
to	B-X
prevent	B-X
systemic	B-X
virus	B-X
replication	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
filoviruses	B-X
have	B-X
been	B-X
found	B-X
to	B-X
encode	B-X
proteins	B-X
VP35	B-X
and	B-X
VP24	B-X
that	B-X
block	B-X
host	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-alpha/beta	B-X
production	B-X
and	B-X
inhibit	B-X
signaling	B-X
downstream	B-X
of	B-X
the	B-X
IFN-alpha/beta	B-X
and	B-X
the	B-X
IFN-gamma	B-X
receptors	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
VP35	B-X
is	B-X
a	B-X
dsRNA-binding	B-X
protein	B-X
,	B-X
and	B-X
mutations	B-X
that	B-X
disrupt	B-X
dsRNA	B-X
binding	B-X
impair	B-X
VP35	B-X
IFN-antagonist	B-X
activity	B-X
while	B-X
leaving	B-X
its	B-X
RNA	B-X
replication	B-X
functions	B-X
intact	B-X
.	B-X
The	B-X
EBOV	B-X
VP24	B-X
protein	B-X
inhibits	B-X
IFN	B-X
signaling	B-X
through	B-X
an	B-X
interaction	B-X
with	B-X
select	B-X
host	B-X
cell	B-X
karyopherin-alpha	B-X
proteins	B-X
,	B-X
preventing	B-X
the	B-X
nuclear	B-X
import	B-X
of	B-X
otherwise	B-X
activated	B-X
STAT1	B-X
.	B-X
Notably	B-X
,	B-X
the	B-X
Marburg	B-X
virus	B-X
VP24	B-X
protein	B-X
does	B-X
not	B-X
detectably	B-X
block	B-X
STAT1	B-X
nuclear	B-X
import	B-X
,	B-X
and	B-X
,	B-X
unlike	B-X
EBOV	B-X
,	B-X
MARV	B-X
infection	B-X
inhibits	B-X
STAT1	B-X
and	B-X
STAT2	B-X
phosphorylation	B-X
.	B-X
Thus	B-X
,	B-X
despite	B-X
their	B-X
similarities	B-X
,	B-X
there	B-X
are	B-X
fundamental	B-X
differences	B-X
by	B-X
which	B-X
these	B-X
deadly	B-X
viruses	B-X
counteract	B-X
the	B-X
IFN	B-X
system	B-X
.	B-X

To	O
determine	O
the	O
effect	O
of	O
A20	O
on	O
IRF7	B-Protein
activation	O
,	O
we	O
therefore	O
transfected	O
minor	O
amounts	O
of	O
an	O
IRF7	B-Protein
expression	O
plasmid	O
together	O
with	O
plasmids	O
encoding	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
,	O
A20	O
and	O
an	O
IRF7	B-Protein
-	O
specific	O
IFNalpha4	O
luciferase	B-Protein
reporter	O
construct	O
.	O

RIG	O
-	O
I	O
(	O
2CARD	O
)	O
expression	O
in	O
the	O
absence	O
of	O
IRF7	B-Protein
co	O
-	O
expression	O
showed	O
negligible	O
IFNalpha4	O
promoter	O
activation	O
(	O
grey	O
bar	O
,	O
figure	O
1A	O
,	O
right	O
graph	O
)	O
,	O
whereas	O
significant	O
reporter	O
gene	O
expression	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IRF7	B-Protein
.	O

Similar	O
to	O
its	O
inhibitory	O
effect	O
on	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
A20	O
also	O
prevented	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
IRF7	B-Protein
activation	O
(	O
figure	O
1A	O
,	O
right	O
graph	O
)	O
.	O

These	O
results	O
demonstrate	O
the	O
potential	O
of	O
A20	O
to	O
inhibit	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
/	O
7	B-Protein
activation	O
.	O

To	O
study	O
the	O
effect	O
of	O
endogenously	O
expressed	O
A20	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
signaling	O
in	O
a	O
more	O
immunological	O
relevant	O
context	O
,	O
we	O
performed	O
further	O
experiments	O
in	O
A20	O
deficient	O
primary	O
macrophages	O
.	O

Since	O
A20	O
full	O
knockout	O
mice	O
die	O
prematurely	O
as	O
a	O
result	O
of	O
severe	O
multi	O
-	O
organ	O
inflammation	O
[	O
37	O
]	O
,	O
we	O
generated	O
mice	O
carrying	O
a	O
conditional	O
A20	O
allele	O
in	O
which	O
exon	O
IV	O
and	O
exon	O
V	O
were	O
flanked	O
by	O
two	O
loxP	O
sites	O
[	O
56	O
]	O
.	O

Crossing	O
these	O
mice	O
with	O
transgenic	O
mice	O
expressing	O
Cre	O
recombinase	O
under	O
control	O
of	O
the	O
lysozyme	O
M	O
promoter	O
leads	O
to	O
specific	O
deletion	O
in	O
myeloid	O
cells	O
and	O
allowed	O
us	O
to	O
generate	O
myeloid	O
cell	O
specific	O
A20	O
knockout	O
mice	O
[	O
48	O
]	O
.	O

To	O
stimulate	O
the	O
RIG	B-Protein
-	I-Protein
I	I-Protein
receptor	O
,	O
we	O
transfected	O
A20myel	O
-	O
KO	O
BMDM	O
and	O
wild	O
type	O
control	O
cells	O
with	O
minimal	O
amounts	O
of	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
poly	O
(	O
I	O
:	O
C	O
)	O
,	O
which	O
is	O
known	O
to	O
preferentially	O
bind	O
and	O
activate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
rather	O
than	O
MDA5	B-Protein
[	O
57	O
]	O
.	O

Of	O
note	O
,	O
this	O
concentration	O
of	O
poly	O
(	O
I	O
:	O
C	O
)	O
was	O
unable	O
to	O
induce	O
significant	O
TLR3	B-Protein
dependent	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
or	O
cytokine	O
production	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
Cytokines	B-X
appear	B-X
to	B-X
be	B-X
major	B-X
regulators	B-X
of	B-X
adipose	B-X
tissue	B-X
metabolism	B-X
.	B-X
Therapeutic	B-X
modulation	B-X
of	B-X
cytokine	B-X
systems	B-X
offers	B-X
the	B-X
possibility	B-X
of	B-X
major	B-X
changes	B-X
in	B-X
adipose	B-X
tissue	B-X
behaviour	B-X
.	B-X
Cytokines	B-X
within	B-X
adipose	B-X
tissue	B-X
originate	B-X
from	B-X
adipocyte	B-X
,	B-X
preadipocyte	B-X
and	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
mRNA	B-X
expression	B-X
studies	B-X
show	B-X
that	B-X
adipocytes	B-X
can	B-X
synthesise	B-X
both	B-X
tumour	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
several	B-X
interleukins	B-X
(	B-X
IL	B-X
)	B-X
,	B-X
notably	B-X
IL-1beta	B-X
and	B-X
IL-6	B-X
.	B-X
Cytokine	B-X
secretion	B-X
within	B-X
adipocytes	B-X
appears	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
other	B-X
cells	B-X
.	B-X
There	B-X
is	B-X
general	B-X
agreement	B-X
that	B-X
circulating	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
concentrations	B-X
are	B-X
mildly	B-X
elevated	B-X
in	B-X
obesity	B-X
.	B-X
Most	B-X
studies	B-X
suggest	B-X
increased	B-X
TNF-alpha	B-X
mRNA	B-X
expression	B-X
or	B-X
secretion	B-X
in	B-X
vitro	B-X
in	B-X
adipose	B-X
tissue	B-X
from	B-X
obese	B-X
subjects	B-X
.	B-X
The	B-X
factors	B-X
regulating	B-X
cytokine	B-X
release	B-X
within	B-X
adipose	B-X
tissue	B-X
appear	B-X
to	B-X
include	B-X
usual	B-X
'inflammatory	B-X
'	B-X
stimuli	B-X
such	B-X
as	B-X
lipopolysaccaride	B-X
,	B-X
but	B-X
also	B-X
the	B-X
size	B-X
of	B-X
the	B-X
fat	B-X
cells	B-X
per	B-X
se	B-X
and	B-X
catecholamines	B-X
.	B-X
There	B-X
is	B-X
conflicting	B-X
data	B-X
about	B-X
whether	B-X
insulin	B-X
and	B-X
cortisol	B-X
regulate	B-X
TNF-alpha	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
cytokines	B-X
within	B-X
adipose	B-X
tissue	B-X
include	B-X
some	B-X
actions	B-X
that	B-X
might	B-X
be	B-X
characterised	B-X
as	B-X
metabolic	B-X
.	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
inhibit	B-X
lipoprotein	B-X
lipase	B-X
,	B-X
and	B-X
TNF-alpha	B-X
additionally	B-X
stimulates	B-X
hormone-sensitive	B-X
lipase	B-X
and	B-X
induces	B-X
uncoupling	B-X
protein	B-X
expression	B-X
.	B-X
TNF-alpha	B-X
also	B-X
down	B-X
regulates	B-X
insulin-stimulated	B-X
glucose	B-X
uptake	B-X
via	B-X
effects	B-X
on	B-X
glucose	B-X
transporter	B-X
4	B-X
,	B-X
insulin	B-X
receptor	B-X
autophosphorylation	B-X
and	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
.	B-X
Cytokines	B-X
are	B-X
important	B-X
stimulators	B-X
and	B-X
repressors	B-X
of	B-X
other	B-X
cytokines	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
cytokines	B-X
appear	B-X
to	B-X
modulate	B-X
other	B-X
regulatory	B-X
systems	B-X
.	B-X
There	B-X
seems	B-X
to	B-X
be	B-X
no	B-X
clear	B-X
agreement	B-X
as	B-X
to	B-X
which	B-X
cytokines	B-X
derived	B-X
from	B-X
adipose	B-X
tissue	B-X
act	B-X
as	B-X
remote	B-X
regulators	B-X
,	B-X
i.e	B-X
.	B-X
Leptin	B-X
,	B-X
which	B-X
is	B-X
structurally	B-X
a	B-X
cytokine	B-X
,	B-X
is	B-X
also	B-X
a	B-X
hormone	B-X
.	B-X
IL-6	B-X
appears	B-X
to	B-X
be	B-X
released	B-X
systemically	B-X
by	B-X
adipose	B-X
tissue	B-X
,	B-X
but	B-X
TNF-alpha	B-X
is	B-X
probably	B-X
not	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
in	B-X
whole-body	B-X
energy	B-X
balance	B-X
provides	B-X
a	B-X
rationale	B-X
for	B-X
the	B-X
links	B-X
between	B-X
cytokines	B-X
and	B-X
adipose	B-X
tissue	B-X
.	B-X
It	B-X
seems	B-X
clear	B-X
that	B-X
TNF-alpha	B-X
is	B-X
a	B-X
powerful	B-X
autocrine	B-X
and	B-X
paracrine	B-X
regulator	B-X
of	B-X
adipose	B-X
tissue	B-X
.	B-X
Other	B-X
cytokines	B-X
,	B-X
notably	B-X
leptin	B-X
,	B-X
and	B-X
possibly	B-X
IL-6	B-X
,	B-X
have	B-X
lesser	B-X
actions	B-X
on	B-X
adipose	B-X
tissue	B-X
.	B-X
These	B-X
cytokines	B-X
act	B-X
as	B-X
hormones	B-X
,	B-X
reporting	B-X
the	B-X
state	B-X
of	B-X
adipose	B-X
tissue	B-X
stores	B-X
throughout	B-X
the	B-X
body	B-X
.	B-X

As	O
expected	O
,	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfection	O
induced	O
the	O
rapid	O
expression	O
of	O
A20	O
in	O
wild	O
type	O
,	O
but	O
not	O
in	O
A20myel	O
-	O
KO	O
BMDM	O
(	O
figure	O
1B	O
,	O
upper	O
panel	O
)	O
.	O

At	O
early	O
time	O
points	O
,	O
slightly	O
slower	O
migrating	O
forms	O
of	O
A20	O
were	O
observed	O
,	O
indicating	O
that	O
A20	O
undergoes	O
a	O
yet	O
unknown	O
modification	O
upon	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfection	O
.	O

Compared	O
to	O
wild	O
type	O
BMBM	O
,	O
A20	O
deficient	O
cells	O
showed	O
enhanced	O
NF	O
-	O
kappaB	O
activation	O
as	O
indicated	O
by	O
increased	O
phosphorylation	O
and	O
sustained	O
degradation	O
of	O
IkappaBalpha	B-Protein
(	O
figure	O
1B	O
)	O
.	O

Furthermore	O
,	O
nuclear	O
translocation	O
of	O
the	O
p65	B-Protein
NF	O
-	O
kappaB	O
subunit	O
was	O
enhanced	O
in	O
poly	O
(	O
I	O
:	O
C	O
)	O
transfected	O
A20myel	O
-	O
KO	O
BMDM	O
,	O
reaching	O
a	O
maximum	O
at	O
earlier	O
time	O
points	O
compared	O
to	O
wild	O
type	O
cells	O
(	O
figure	O
1C	O
)	O
.	O

IRF3	B-Protein
is	O
known	O
to	O
be	O
activated	O
upon	O
phosphorylation	O
of	O
a	O
series	O
of	O
carboxyl	O
terminal	O
serine	O
residues	O
by	O
the	O
IKK	O
-	O
like	O
kinases	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
[	O
58	O
]	O
,	O
leading	O
to	O
its	O
dimerization	O
and	O
subsequent	O
translocation	O
to	O
the	O
nucleus	O
[	O
59	O
]	O
.	O

Using	O
immunoblotting	O
with	O
an	O
antibody	O
directed	O
against	O
phosphorylated	O
Ser396	O
,	O
maximum	O
IRF3	B-Protein
phosphorylation	O
was	O
detected	O
at	O
earlier	O
time	O
points	O
in	O
A20myel	O
-	O
KO	O
BMDM	O
compared	O
to	O
wild	O
type	O
BMDM	O
(	O
figure	O
1B	O
)	O
.	O

Similar	O
to	O
p65	B-Protein
,	O
IRF3	B-Protein
nuclear	O
translocation	O
reached	O
its	O
maximum	O
at	O
an	O
earlier	O
time	O
point	O
in	O
A20	O
deficient	O
BMDM	O
compared	O
to	O
wild	O
type	O
cells	O
(	O
figure	O
1C	O
)	O
.	O

NF	O
-	O
kappaB	O
controls	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	B-Protein
,	O
and	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
control	O
the	O
expression	O
of	O
IFNbeta	B-Protein
.	O
<EOS>	B-X
At	B-X
the	B-X
molecular	B-X
level	B-X
,	B-X
the	B-X
hallmark	B-X
of	B-X
sepsis	B-X
is	B-X
the	B-X
elevated	B-X
expression	B-X
of	B-X
a	B-X
multitude	B-X
of	B-X
potent	B-X
cytokines	B-X
,	B-X
i.e	B-X
.	B-X
IL-6	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
CXCL10	B-X
,	B-X
and	B-X
IFN-β	B-X
)	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
could	B-X
be	B-X
due	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
to	B-X
COB-187	B-X
reducing	B-X
NF-κB	B-X
(	B-X
p65/p50	B-X
)	B-X
DNA	B-X
binding	B-X
activity	B-X
as	B-X
well	B-X
as	B-X
reducing	B-X
IRF-3	B-X
phosphorylation	B-X
at	B-X
Serine	B-X
396	B-X
.	B-X
Structural	B-X
maintenance	B-X
of	B-X
chromosome	B-X
(	B-X
Smc	B-X
)	B-X
protein	B-X
complex	B-X
(	B-X
condensin	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
organizing	B-X
and	B-X
compacting	B-X
chromosomes	B-X
,	B-X
which	B-X
determines	B-X
DNA-binding	B-X
activity	B-X
and	B-X
gene	B-X
expression	B-X
;	B-X
however	B-X
,	B-X
the	B-X
role	B-X
of	B-X
condensin	B-X
Smc	B-X
in	B-X
innate	B-X
immunity	B-X
and	B-X
inflammation	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Knockdown	B-X
or	B-X
deficiency	B-X
of	B-X
Smc4	B-X
inhibited	B-X
TLR-	B-X
or	B-X
virus-triggered	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
IL-6	B-X
,	B-X
TNF-α	B-X
and	B-X
IFN-β	B-X
in	B-X
macrophages	B-X
.	B-X
Mechanistically	B-X
,	B-X
Smc4	B-X
enhanced	B-X
NEMO	B-X
transcription	B-X
by	B-X
recruiting	B-X
H4K5ac	B-X
to	B-X
and	B-X
increasing	B-X
H4K5	B-X
acetylation	B-X
of	B-X
nemo	B-X
promoter	B-X
,	B-X
leading	B-X
to	B-X
innate	B-X
signals-triggered	B-X
more	B-X
potent	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
pathways	B-X
.	B-X
Therefore	B-X
,	B-X
Smc4	B-X
promotes	B-X
inflammatory	B-X
innate	B-X
immune	B-X
responses	B-X
by	B-X
enhancing	B-X
NEMO	B-X
transcription	B-X
,	B-X
and	B-X
our	B-X
data	B-X
add	B-X
insight	B-X
to	B-X
epigenetic	B-X
regulation	B-X
of	B-X
innate	B-X
immunity	B-X
and	B-X
inflammation	B-X
,	B-X
and	B-X
outline	B-X
potential	B-X
target	B-X
for	B-X
controlling	B-X
inflammatory	B-X
diseases	B-X
.	B-X

In	O
line	O
with	O
the	O
enhanced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
as	O
described	O
above	O
,	O
A20myel	O
-	O
KO	O
BMDM	O
secreted	O
increased	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
(	O
figure	O
1D	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
peritoneal	O
macrophages	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
A	B-X
hallmark	B-X
of	B-X
chronic	B-X
inflammatory	B-X
disorders	B-X
is	B-X
persistence	B-X
of	B-X
proinflammatory	B-X
macrophages	B-X
in	B-X
diseased	B-X
tissues	B-X
.	B-X
In	B-X
obesity	B-X
,	B-X
proinflammatory	B-X
macrophages	B-X
accumulate	B-X
in	B-X
adipose	B-X
tissue	B-X
and	B-X
trigger	B-X
chronic	B-X
low-grade	B-X
inflammation	B-X
,	B-X
that	B-X
promotes	B-X
the	B-X
development	B-X
of	B-X
systemic	B-X
insulin	B-X
resistance	B-X
,	B-X
yet	B-X
changes	B-X
in	B-X
their	B-X
intracellular	B-X
energy	B-X
metabolism	B-X
are	B-X
currently	B-X
unknown	B-X
.	B-X
We	B-X
therefore	B-X
set	B-X
out	B-X
to	B-X
study	B-X
metabolic	B-X
signatures	B-X
of	B-X
adipose	B-X
tissue	B-X
macrophages	B-X
(	B-X
ATMs	B-X
)	B-X
in	B-X
lean	B-X
and	B-X
obese	B-X
conditions	B-X
.	B-X
We	B-X
collected	B-X
peritoneal	B-X
fluid	B-X
samples	B-X
and	B-X
clinical	B-X
data	B-X
from	B-X
a	B-X
cohort	B-X
of	B-X
women	B-X
receiving	B-X
diagnostic	B-X
laparoscopy	B-X
for	B-X
suspected	B-X
endometriosis	B-X
(	B-X

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
A20	O
plays	O
an	O
important	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
primary	O
macrophages	O
.	O

A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
BMDM	O

To	O
investigate	O
the	O
role	O
of	O
A20	O
in	O
the	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
innate	O
immune	O
responses	O
,	O
we	O
infected	O
A20	O
deficient	O
and	O
control	O
BMDM	O
with	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
)	O
.	O

A20	O
mRNA	O
levels	O
were	O
rapidly	O
induced	O
in	O
wild	O
type	O
BMDM	O
,	O
but	O
not	O
in	O
A20	O
deficient	O
BMDM	O
,	O
upon	O
viral	O
infection	O
(	O
figure	O
2A	O
)	O
.	O

Furthermore	O
,	O
A20myel	O
-	O
KO	O
BMDM	O
show	O
enhanced	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
mRNA	O
after	O
IAV	O
infection	O
compared	O
to	O
control	O
cells	O
(	O
figure	O
2A	O
)	O
.	O

In	O
accordance	O
with	O
these	O
data	O
,	O
cell	O
culture	O
supernatant	O
collected	O
from	O
these	O
cells	O
contained	O
higher	O
levels	O
of	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
(	O
figure	O
2B	O
)	O
.	O

Upon	O
host	O
infection	O
with	O
IAV	O
,	O
alveolar	O
macrophages	O
are	O
an	O
important	O
source	O
of	O
cytokines	O
and	O
chemokines	O
,	O
attracting	O
innate	O
immune	O
cells	O
to	O
the	O
lung	O
during	O
the	O
primary	O
phase	O
of	O
infection	O
.	O

To	O
test	O
whether	O
A20	O
directly	O
controls	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
alveolar	O
macrophages	O
,	O
we	O
isolated	O
these	O
cells	O
from	O
lungs	O
of	O
A20myel	O
-	O
KO	O
and	O
control	O
littermates	O
and	O
infected	O
them	O
in	O
vitro	O
with	O
IAV	O
X	O
-	O
47	O
.	O

Expression	O
and	O
secretion	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	B-Protein
,	O
the	O
type	O
-	O
I	O
IFN	O
IFNbeta	B-Protein
and	O
IFNalpha4	B-Protein
and	O
the	O
chemokines	O
MCP	B-Protein
-	I-Protein
1	I-Protein
(	O
ccl2	B-Protein
)	O
and	O
KC	B-Protein
(	O
cxcl1	B-Protein
)	O
was	O
significantly	O
higher	O
in	O
IAV	O
infected	O
cells	O
lacking	O
A20	O
compared	O
to	O
infected	O
wild	O
type	O
cells	O
(	O
figure	O
2C	O
and	O
figure	O
S1	O
)	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
proinflammatory	O
and	O
antiviral	O
gene	O
expression	O
in	O
alveolar	O
macrophages	O
,	O
consistent	O
with	O
the	O
inhibitory	O
effect	O
of	O
A20	O
seen	O
on	O
RIG	B-Protein
-	I-Protein
I	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
.	O

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
IAV	O
lung	O
infection	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

To	O
determine	O
the	O
role	O
of	O
A20	O
expression	O
in	O
myeloid	O
cells	O
during	O
an	O
IAV	O
infection	O
in	O
vivo	O
,	O
we	O
intranasally	O
inoculated	O
both	O
A20myel	O
-	O
KO	O
mice	O
and	O
control	O
littermates	O
with	O
a	O
sublethal	O
dose	O
of	O
the	O
mouse	O
adapted	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
)	O
strain	O
and	O
monitored	O
morbidity	O
in	O
terms	O
of	O
weight	O
loss	O
.	O

A20myel	O
-	O
KO	O
mice	O
showed	O
reduced	O
weight	O
loss	O
compared	O
to	O
wild	O
type	O
control	O
littermates	O
and	O
recovered	O
faster	O
from	O
the	O
viral	O
challenge	O
(	O
figure	O
3A	O
)	O
.	O

Also	O
,	O
total	O
protein	O
concentration	O
in	O
BAL	O
fluid	O
,	O
which	O
reflects	O
lung	O
damage	O
and	O
vascular	O
leakage	O
,	O
was	O
increased	O
significantly	O
at	O
7	O
and	O
10	O
days	O
post	O
infection	O
in	O
both	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
mice	O
,	O
and	O
was	O
slightly	O
lower	O
in	O
A20myel	O
-	O
KO	O
mice	O
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
measured	O
pulmonary	O
viral	O
titers	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
post	O
infection	O
.	O

No	O
differences	O
in	O
viral	O
titers	O
were	O
observed	O
in	O
A20myel	O
-	O
KO	O
mice	O
versus	O
wild	O
type	O
mice	O
at	O
day	O
4	O
and	O
7	O
post	O
infection	O
.	O

However	O
,	O
after	O
10	O
days	O
,	O
almost	O
no	O
virus	O
could	O
be	O
detected	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
while	O
abundant	O
infectious	O
viral	O
particles	O
could	O
still	O
be	O
isolated	O
from	O
lungs	O
of	O
all	O
wild	O
type	O
mice	O
(	O
figure	O
3B	O
)	O
.	O

This	O
indicates	O
that	O
loss	O
of	O
A20	O
in	O
myeloid	O
cells	O
does	O
not	O
affect	O
early	O
viral	O
replication	O
but	O
contributes	O
to	O
viral	O
clearance	O
at	O
later	O
stages	O
during	O
infection	O
.	O
<EOS>	B-X
Inflammation	B-X
and	B-X
inflammatory	B-X
cytokines	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
exert	B-X
both	B-X
positive	B-X
and	B-X
negative	B-X
effects	B-X
on	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
(	B-X
HSCs	B-X
)	B-X
and	B-X
hematopoiesis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
identified	B-X
A20	B-X
as	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
inflammation	B-X
controlled	B-X
hematopoietic	B-X
cell	B-X
fate	B-X
decisions	B-X
of	B-X
HSCs	B-X
.	B-X
A20	B-X
deficiency	B-X
in	B-X
HSCs	B-X
leads	B-X
to	B-X
increased	B-X
differentiation	B-X
of	B-X
myeloid	B-X
cells	B-X
and	B-X
myeloproliferation	B-X
.	B-X
Analysis	B-X
of	B-X
erythroid	B-X
lineage	B-X
cells	B-X
of	B-X
A20	B-X
deficient	B-X
mice	B-X
indicated	B-X
a	B-X
striking	B-X
reduction	B-X
of	B-X
erythrocytes	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
,	B-X
but	B-X
elevated	B-X
numbers	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
Loss	B-X
of	B-X
A20	B-X
in	B-X
HSCs	B-X
causes	B-X
a	B-X
severe	B-X
blockade	B-X
of	B-X
B	B-X
cell	B-X
differentiation	B-X
in	B-X
the	B-X
BM	B-X
and	B-X
absence	B-X
of	B-X
peripheral	B-X
B	B-X
cells	B-X
in	B-X
the	B-X
spleen	B-X
,	B-X
liver	B-X
and	B-X
blood	B-X
.	B-X
T	B-X
cell	B-X
differentiation	B-X
studies	B-X
revealed	B-X
a	B-X
reduction	B-X
of	B-X
both	B-X
T	B-X
cell	B-X
progenitors	B-X
and	B-X
differentiated	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
thymus	B-X
and	B-X
altered	B-X
T	B-X
cell	B-X
numbers	B-X
in	B-X
the	B-X
spleens	B-X
of	B-X
A20	B-X
mutant	B-X
mice	B-X
.	B-X
Analysis	B-X
of	B-X
lineage	B-X
committed	B-X
progenitors	B-X
of	B-X
the	B-X
myeloid	B-X
,	B-X
erythroid	B-X
and	B-X
lymphoid	B-X
lineages	B-X
specified	B-X
an	B-X
altered	B-X
composition	B-X
in	B-X
the	B-X
A20	B-X
deficient	B-X
BM	B-X
.	B-X
Genetic	B-X
studies	B-X
identified	B-X
that	B-X
specific	B-X
loss	B-X
of	B-X
A20	B-X
in	B-X
the	B-X
myeloid	B-X
lineage	B-X
cells	B-X
results	B-X
in	B-X
myeloproliferation	B-X
.	B-X
Bone	B-X
marrow	B-X
transplantation	B-X
studies	B-X
and	B-X
mixed	B-X
bone	B-X
marrow	B-X
chimera	B-X
studies	B-X
suggested	B-X
an	B-X
involvement	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
particularly	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-	B-X
γ	B-X
,	B-X
in	B-X
the	B-X
onset	B-X
of	B-X
myeloproliferation	B-X
and	B-X
lymphopenia	B-X
of	B-X
A20	B-X
deficient	B-X
mice	B-X
.	B-X
Finally	B-X
,	B-X
ablation	B-X
of	B-X
IFNγ	B-X
signals	B-X
in	B-X
A20	B-X
deficient	B-X
mice	B-X
rescued	B-X
the	B-X
hematopoietic	B-X
defects	B-X
.	B-X
In	B-X
essence	B-X
,	B-X
these	B-X
studies	B-X
highlight	B-X
a	B-X
previously	B-X
unknown	B-X
role	B-X
for	B-X
A20	B-X
in	B-X
the	B-X
restriction	B-X
of	B-X
inflammation	B-X
driven	B-X
pathologic	B-X
hematopoiesis	B-X
.	B-X
We	B-X
believe	B-X
that	B-X
our	B-X
studies	B-X
based	B-X
on	B-X
A20	B-X
mutant	B-X
mice	B-X
will	B-X
be	B-X
helpful	B-X
in	B-X
understanding	B-X
the	B-X
pathophysiology	B-X
and	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
A20	B-X
(	B-X
TNFAIP3	B-X
)	B-X
mutations	B-X
.	B-X

To	O
verify	O
if	O
A20	O
deficiency	O
in	O
myeloid	O
cells	O
affects	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
the	O
lung	O
,	O
we	O
analyzed	O
the	O
levels	O
of	O
several	O
chemokines	O
and	O
cytokines	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
at	O
day	O
4	O
,	O
7	O
and	O
day	O
10	O
following	O
infection	O
.	O

Levels	O
of	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
chemokines	O
,	O
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
significantly	O
higher	O
at	O
day	O
7	O
p	O
.	O
i	O
.	O
in	O
BAL	O
from	O
IAV	O
infected	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
IAV	O
infected	O
wild	O
type	O
mice	O
(	O
figure	O
3C	O
)	O
.	O

Unlike	O
our	O
observations	O
with	O
in	O
vitro	O
stimulated	O
primary	O
macrophages	O
we	O
could	O
not	O
detect	O
a	O
significant	O
increase	O
in	O
MCP	B-Protein
-	I-Protein
1	I-Protein
or	O
IFNalpha	O
production	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
animals	O
(	O
figure	O
3C	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
several	B-X
clinically-significant	B-X
microorganisms	B-X
do	B-X
not	B-X
cause	B-X
the	B-X
same	B-X
pathology	B-X
in	B-X
mice	B-X
,	B-X
or	B-X
mice	B-X
may	B-X
not	B-X
be	B-X
susceptible	B-X
to	B-X
these	B-X
infections	B-X
.	B-X
These	B-X
demonstrate	B-X
the	B-X
utility	B-X
of	B-X
other	B-X
animal	B-X
models	B-X
-	B-X
either	B-X
as	B-X
the	B-X
primary	B-X
method	B-X
to	B-X
study	B-X
a	B-X
particular	B-X
infection	B-X
,	B-X
or	B-X
to	B-X
confirm	B-X
or	B-X
refute	B-X
findings	B-X
in	B-X
the	B-X
mouse	B-X
before	B-X
translating	B-X
basic	B-X
science	B-X
into	B-X
clinical	B-X
practice	B-X
.	B-X
Because	B-X
of	B-X
variable	B-X
yield	B-X
and	B-X
difficult	B-X
extraction	B-X
from	B-X
tissue	B-X
,	B-X
the	B-X
preferred	B-X
method	B-X
of	B-X
producing	B-X
Mφ	B-X
for	B-X
in	B-X
vitro	B-X
studies	B-X
is	B-X
to	B-X
expand	B-X
murine	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
precursors	B-X
with	B-X
mouse	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
.	B-X
This	B-X
method	B-X
may	B-X
prove	B-X
useful	B-X
for	B-X
in	B-X
vitro	B-X
studies	B-X
of	B-X
Mφ	B-X
in	B-X
the	B-X
guinea	B-X
pig	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
translation	B-X
of	B-X
results	B-X
found	B-X
using	B-X
mouse	B-X
BM-derived	B-X
Mφ	B-X
towards	B-X
studies	B-X
in	B-X
human	B-X
immunology	B-X
and	B-X
infectious	B-X
disease	B-X
.	B-X

KC	B-Protein
is	O
the	O
murine	O
orthologue	O
of	O
IL	B-Protein
-	I-Protein
8	I-Protein
and	O
serves	O
together	O
with	O
MIP	B-Protein
-	I-Protein
2	I-Protein
as	O
a	O
chemoattractant	O
for	O
neutrophils	O
,	O
while	O
MCP	B-Protein
-	I-Protein
1	I-Protein
is	O
mainly	O
known	O
as	O
a	O
chemoattractant	O
for	O
monocytes	O
,	O
which	O
eventually	O
develop	O
into	O
macrophages	O
upon	O
entering	O
the	O
alveolar	O
lumen	O
[	O
60	O
]	O
.	O

Consistent	O
with	O
the	O
higher	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
levels	O
in	O
A20myel	O
-	O
KO	O
mice	O
,	O
the	O
number	O
of	O
neutrophils	O
(	O
CD11b	O
+	O
Ly6C	O
+	O
Ly6G	O
+	O
F4	B-Protein
/	I-Protein
80	I-Protein
-	O
)	O
that	O
were	O
recruited	O
in	O
the	O
bronchoalveolar	O
spaces	O
upon	O
IAV	O
infection	O
was	O
clearly	O
higher	O
throughout	O
infection	O
in	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
control	O
animals	O
(	O
figure	O
3D	O
)	O
.	O

Although	O
we	O
could	O
detect	O
a	O
significant	O
increase	O
in	O
monocyte	O
(	O
CD11b	O
+	O
Ly6C	O
+	O
)	O
recruitment	O
at	O
day	O
4	O
post	O
infection	O
,	O
this	O
was	O
not	O
evident	O
at	O
later	O
time	O
points	O
after	O
infection	O
(	O
figure	O
3D	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
equal	O
expression	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
in	O
both	O
groups	O
of	O
mice	O
.	O

The	O
number	O
of	O
resident	O
alveolar	O
macrophages	O
(	O
autofluorescent	O
+	O
CD11c	O
+	O
F4	B-Protein
/	I-Protein
80	I-Protein
+	O
CD11b	O
-	O
)	O
was	O
also	O
elevated	O
in	O
A20myel	O
-	O
KO	O
mice	O
but	O
did	O
not	O
differ	O
significantly	O
between	O
IAV	O
infected	O
or	O
mock	O
infected	O
mice	O
(	O
figure	O
3D	O
)	O
.	O

Elimination	O
of	O
IAV	O
infected	O
cells	O
depends	O
on	O
the	O
clonal	O
expansion	O
of	O
virus	O
specific	O
cytotoxic	O
CD8	O
+	O
T	O
cells	O
(	O
CTL	O
)	O
[	O
61	O
]	O
,	O
[	O
62	O
]	O
,	O
[	O
63	O
]	O
.	O

To	O
test	O
whether	O
A20	O
expression	O
in	O
myeloid	O
cells	O
regulates	O
the	O
antiviral	O
CTL	O
response	O
,	O
total	O
CD8	O
+	O
T	O
cells	O
and	O
virus	O
specific	O
Granzyme	B-Protein
B	I-Protein
(	O
GrB	B-Protein
)	O
and	O
IFNgamma	O
expressing	O
CD8	O
+	O
T	O
cells	O
were	O
measured	O
in	O
BAL	O
and	O
lung	O
parenchyma	O
of	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
mice	O
.	O

A	O
clear	O
increase	O
in	O
CD8	O
+	O
T	O
cells	O
could	O
be	O
detected	O
at	O
day	O
7	O
and	O
10	O
post	O
infection	O
,	O
but	O
no	O
differences	O
were	O
observed	O
between	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
mice	O
(	O
figure	O
S2A	O
and	O
figure	O
S2C	O
)	O
.	O

Also	O
,	O
the	O
number	O
of	O
GrB	B-Protein
and	O
IFNgamma	O
CD8	O
+	O
T	O
cells	O
as	O
well	O
as	O
IFNgamma	O
expression	O
levels	O
in	O
the	O
lungs	O
were	O
not	O
altered	O
by	O
the	O
absence	O
of	O
A20	O
in	O
myeloid	O
cells	O
(	O
figure	O
S2A	O
-	O
C	O
)	O
.	O

Protection	O
against	O
IAV	O
infection	O
is	O
also	O
provided	O
by	O
the	O
humoral	O
immune	O
response	O
.	O
<EOS>	B-X
Despite	B-X
efforts	B-X
made	B-X
to	B-X
develop	B-X
efficient	B-X
preventive	B-X
strategies	B-X
,	B-X
infections	B-X
with	B-X
influenza	B-X
A	B-X
viruses	B-X
(	B-X
IAV	B-X
)	B-X
continue	B-X
to	B-X
cause	B-X
serious	B-X
clinical	B-X
and	B-X
economic	B-X
problems	B-X
.	B-X
These	B-X
vaccines	B-X
provide	B-X
incomplete	B-X
protection	B-X
against	B-X
IAV	B-X
in	B-X
high-risk	B-X
groups	B-X
and	B-X
are	B-X
poorly/not	B-X
effective	B-X
against	B-X
the	B-X
constant	B-X
antigenic	B-X
drift/shift	B-X
occurring	B-X
in	B-X
circulating	B-X
strains	B-X
.	B-X
Advances	B-X
in	B-X
mucosal	B-X
vaccinology	B-X
and	B-X
in	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
protective	B-X
anti-influenza	B-X
immune	B-X
mechanisms	B-X
suggest	B-X
that	B-X
intranasal	B-X
immunization	B-X
is	B-X
a	B-X
promising	B-X
strategy	B-X
to	B-X
fight	B-X
against	B-X
IAV	B-X
.	B-X
To	B-X
date	B-X
,	B-X
human	B-X
mucosal	B-X
anti-influenza	B-X
vaccines	B-X
consist	B-X
of	B-X
live	B-X
attenuated	B-X
strains	B-X
administered	B-X
intranasally	B-X
,	B-X
which	B-X
elicit	B-X
higher	B-X
local	B-X
humoral	B-X
and	B-X
cellular	B-X
immune	B-X
responses	B-X
than	B-X
conventional	B-X
parenteral	B-X
vaccines	B-X
.	B-X
To	B-X
prime	B-X
and	B-X
induce	B-X
potent	B-X
and	B-X
long-lived	B-X
protective	B-X
immune	B-X
responses	B-X
,	B-X
mucosal	B-X
vaccine	B-X
formulations	B-X
need	B-X
to	B-X
ensure	B-X
the	B-X
immunoavailability	B-X
and	B-X
the	B-X
immunostimulating	B-X
capacity	B-X
of	B-X
the	B-X
vaccine	B-X
antigen	B-X
(	B-X
s	B-X
)	B-X
at	B-X
the	B-X
mucosal	B-X
surfaces	B-X
,	B-X
while	B-X
being	B-X
minimally	B-X
reactogenic/toxic	B-X
.	B-X
The	B-X
capacity	B-X
of	B-X
these	B-X
vaccines	B-X
to	B-X
trigger	B-X
specific	B-X
mucosal	B-X
and	B-X
systemic	B-X
humoral	B-X
and	B-X
cellular	B-X
responses	B-X
against	B-X
IAV	B-X
and	B-X
their	B-X
(	B-X
cross	B-X
)	B-X
-protective	B-X
potential	B-X
are	B-X
considered	B-X
.	B-X

To	O
test	O
whether	O
loss	O
of	O
A20	O
in	O
myeloid	O
cells	O
affects	O
B	O
cell	O
mediated	O
immunity	O
,	O
we	O
determined	O
hemagglutinin	O
(	O
HA	O
)	O
antibody	O
titers	O
in	O
the	O
serum	O
of	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
littermates	O
.	O

However	O
,	O
no	O
differences	O
could	O
be	O
detected	O
between	O
wild	O
type	O
and	O
A20myel	O
-	O
KO	O
animals	O
(	O
figure	O
S2D	O
)	O
,	O
indicating	O
that	O
humoral	O
immunity	O
is	O
not	O
affected	O
by	O
A20	O
expression	O
in	O
myeloid	O
cells	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
mechanisms	O
other	O
than	O
adaptive	O
immunity	O
,	O
such	O
as	O
an	O
increased	O
innate	O
immune	O
response	O
,	O
characterized	O
by	O
an	O
increased	O
influx	O
of	O
neutrophils	O
and	O
increased	O
numbers	O
of	O
alveolar	O
macrophages	O
,	O
contribute	O
to	O
the	O
better	O
viral	O
clearance	O
in	O
A20myel	O
-	O
KO	O
mice	O
.	O

It	O
is	O
generally	O
believed	O
that	O
IAV	O
-	O
induced	O
mortality	O
is	O
due	O
to	O
an	O
excessive	O
proinflammatory	O
response	O
in	O
the	O
lung	O
.	O

We	O
therefore	O
analyzed	O
whether	O
the	O
increased	O
proinflammatory	O
cytokine	O
production	O
and	O
infiltration	O
of	O
proinflammatory	O
cells	O
in	O
A20myel	O
-	O
KO	O
mice	O
affects	O
mortality	O
induced	O
by	O
intranasal	O
infection	O
with	O
a	O
lethal	O
dose	O
of	O
IAV	O
X	O
-	O
47	O
.	O

Surprisingly	O
,	O
almost	O
all	O
A20myel	O
-	O
KO	O
mice	O
survived	O
(	O
10	O
/	O
11	O
)	O
,	O
while	O
all	O
control	O
mice	O
succumbed	O
(	O
0	O
/	O
11	O
)	O
within	O
16	O
days	O
after	O
infection	O
(	O
figure	O
4A	O
)	O
.	O

A20myel	O
-	O
KO	O
mice	O
still	O
showed	O
significant	O
weight	O
loss	O
and	O
lung	O
damage	O
(	O
as	O
reflected	O
by	O
increased	O
total	O
protein	O
concentration	O
in	O
the	O
BAL	O
;	O
data	O
not	O
shown	O
)	O
during	O
the	O
course	O
of	O
infection	O
but	O
were	O
able	O
to	O
recover	O
,	O
in	O
contrast	O
to	O
wild	O
type	O
mice	O
that	O
succumbed	O
(	O
figure	O
4B	O
)	O
.	O

Similar	O
to	O
our	O
observations	O
with	O
sublethal	O
IAV	O
infection	O
,	O
pulmonary	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
production	O
was	O
stronger	O
in	O
A20myel	O
-	O
KO	O
animals	O
compared	O
to	O
wild	O
type	O
mice	O
following	O
lethal	O
IAV	O
infection	O
(	O
figure	O
4C	O
)	O
,	O
which	O
correlates	O
with	O
the	O
increased	O
numbers	O
of	O
neutrophils	O
in	O
the	O
lungs	O
of	O
these	O
mice	O
(	O
figure	O
4C	O
)	O
.	O

Also	O
levels	O
of	O
the	O
proinflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
which	O
are	O
often	O
associated	O
with	O
immunopathogenesis	O
in	O
humans	O
[	O
64	O
]	O
,	O
were	O
increased	O
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
control	O
animals	O
(	O
figure	O
4C	O
and	O
figure	O
S3A	O
)	O
.	O

Again	O
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
production	O
was	O
not	O
increased	O
and	O
even	O
lower	O
in	O
A20myel	O
-	O
KO	O
mice	O
(	O
figure	O
4C	O
)	O
,	O
and	O
also	O
monocyte	O
recruitment	O
was	O
not	O
different	O
between	O
both	O
groups	O
of	O
mice	O
.	O
<EOS>	B-X
In	B-X
1989	B-X
,	B-X
we	B-X
reported	B-X
the	B-X
purification	B-X
of	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
from	B-X
culture	B-X
supernatants	B-X
of	B-X
mitogen-activated	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
tumor	B-X
cells	B-X
.	B-X
MCP-1	B-X
is	B-X
a	B-X
potent	B-X
monocyte-attracting	B-X
chemokine	B-X
,	B-X
identical	B-X
to	B-X
the	B-X
previously	B-X
described	B-X
lymphocyte-derived	B-X
chemotactic	B-X
factor	B-X
or	B-X
tumor-derived	B-X
chemotactic	B-X
factor	B-X
,	B-X
and	B-X
greatly	B-X
contributes	B-X
to	B-X
the	B-X
recruitment	B-X
of	B-X
blood	B-X
monocytes	B-X
into	B-X
sites	B-X
of	B-X
inflammatory	B-X
responses	B-X
and	B-X
tumors	B-X
.	B-X
Because	B-X
in	B-X
vitro-cultured	B-X
tumor	B-X
cells	B-X
often	B-X
produce	B-X
significant	B-X
amounts	B-X
of	B-X
MCP-1	B-X
,	B-X
tumor	B-X
cells	B-X
are	B-X
considered	B-X
to	B-X
be	B-X
the	B-X
main	B-X
source	B-X
of	B-X
MCP-1	B-X
.	B-X
However	B-X
,	B-X
various	B-X
non-tumor	B-X
cells	B-X
in	B-X
the	B-X
tumor	B-X
stroma	B-X
also	B-X
produce	B-X
MCP-1	B-X
in	B-X
response	B-X
to	B-X
stimuli	B-X
.	B-X
Studies	B-X
performed	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
have	B-X
provided	B-X
evidence	B-X
that	B-X
MCP-1	B-X
production	B-X
in	B-X
tumors	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
complex	B-X
interactions	B-X
between	B-X
tumor	B-X
cells	B-X
and	B-X
non-tumor	B-X
cells	B-X
and	B-X
that	B-X
both	B-X
tumor	B-X
cells	B-X
and	B-X
non-tumor	B-X
cells	B-X
contribute	B-X
to	B-X
the	B-X
production	B-X
of	B-X
MCP-1	B-X
.	B-X
Although	B-X
MCP-1	B-X
production	B-X
was	B-X
once	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
part	B-X
of	B-X
host	B-X
defense	B-X
against	B-X
tumors	B-X
,	B-X
it	B-X
is	B-X
now	B-X
believed	B-X
to	B-X
regulate	B-X
the	B-X
vicious	B-X
cycle	B-X
between	B-X
tumor	B-X
cells	B-X
and	B-X
macrophages	B-X
that	B-X
promotes	B-X
the	B-X
progression	B-X
of	B-X
tumors	B-X
.	B-X

We	O
could	O
also	O
not	O
detect	O
any	O
differences	O
in	O
viral	O
clearance	O
or	O
antiviral	O
adaptive	O
immunity	O
at	O
6	O
h	O
post	O
infection	O
(	O
figure	O
S3B	O
-	O
F	O
)	O
.	O

Collectively	O
these	O
data	O
indicate	O
that	O
A20	O
deficiency	O
in	O
myeloid	O
cells	O
is	O
associated	O
with	O
an	O
increased	O
innate	O
immune	O
response	O
and	O
protection	O
against	O
a	O
lethal	O
IAV	O
infection	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
investigated	O
the	O
contribution	O
of	O
A20	O
expression	O
in	O
myeloid	O
cells	O
in	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
lung	O
infection	O
.	O

In	O
the	O
pulmonary	O
environment	O
,	O
macrophages	O
populate	O
both	O
lung	O
parenchyma	O
and	O
the	O
alveolar	O
lumen	O
where	O
they	O
are	O
referred	O
to	O
as	O
alveolar	O
macrophages	O
.	O

Under	O
naive	O
conditions	O
,	O
alveolar	O
macrophages	O
exert	O
important	O
immunomodulatory	O
functions	O
[	O
65	O
]	O
,	O
[	O
66	O
]	O
.	O

However	O
,	O
alveolar	O
macrophages	O
are	O
also	O
crucial	O
in	O
the	O
innate	O
immune	O
response	O
against	O
IAV	O
as	O
they	O
are	O
one	O
of	O
the	O
first	O
cells	O
that	O
encounter	O
infectious	O
IAV	O
particles	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
.	O

They	O
are	O
an	O
important	O
source	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
that	O
attract	O
innate	O
immune	O
cells	O
to	O
the	O
lung	O
during	O
the	O
primary	O
phase	O
of	O
infection	O
[	O
69	O
]	O
,	O
and	O
they	O
are	O
the	O
primary	O
producers	O
of	O
type	O
I	O
IFNs	O
[	O
70	O
]	O
.	O

Alveolar	O
macrophages	O
are	O
also	O
known	O
to	O
phagocytose	O
virus	O
infected	O
apoptotic	O
cells	O
and	O
antibody	O
coated	O
viral	O
particles	O
,	O
further	O
contributing	O
to	O
viral	O
clearance	O
.	O

We	O
could	O
show	O
that	O
BMDM	O
or	O
alveolar	O
macrophages	O
derived	O
from	O
A20myel	O
-	O
KO	O
mice	O
express	O
higher	O
amounts	O
of	O
chemokines	O
,	O
cytokines	O
and	O
type	O
I	O
IFNs	O
compared	O
to	O
wild	O
type	O
mice	O
in	O
response	O
to	O
in	O
vitro	O
infection	O
.	O
<EOS>	B-X
Insulin	B-X
resistance	B-X
is	B-X
a	B-X
major	B-X
pathophysiologic	B-X
defect	B-X
in	B-X
type	B-X
2	B-X
diabetes	B-X
and	B-X
obesity	B-X
,	B-X
while	B-X
anti-inflammatory	B-X
M2-like	B-X
macrophages	B-X
are	B-X
important	B-X
in	B-X
maintaining	B-X
normal	B-X
metabolic	B-X
homeostasis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
M2	B-X
polarized	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
(	B-X
BMDMs	B-X
)	B-X
secrete	B-X
miRNA-containing	B-X
exosomes	B-X
(	B-X
Exos	B-X
)	B-X
,	B-X
which	B-X
improve	B-X
glucose	B-X
tolerance	B-X
and	B-X
insulin	B-X
sensitivity	B-X
when	B-X
given	B-X
to	B-X
obese	B-X
mice	B-X
.	B-X
Depletion	B-X
of	B-X
their	B-X
miRNA	B-X
cargo	B-X
blocks	B-X
the	B-X
ability	B-X
of	B-X
M2	B-X
BMDM	B-X
Exos	B-X
to	B-X
enhance	B-X
insulin	B-X
sensitivity	B-X
.	B-X
We	B-X
found	B-X
that	B-X
miR-690	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
M2	B-X
BMDM	B-X
Exos	B-X
and	B-X
functions	B-X
as	B-X
an	B-X
insulin	B-X
sensitizer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
Expressing	B-X
an	B-X
miR-690	B-X
mimic	B-X
in	B-X
miRNA-depleted	B-X
BMDMs	B-X
generates	B-X
Exos	B-X
that	B-X
recapitulate	B-X
the	B-X
effects	B-X
of	B-X
M2	B-X
BMDM	B-X
Exos	B-X
on	B-X
metabolic	B-X
phenotypes	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
miR-690	B-X
could	B-X
be	B-X
a	B-X
new	B-X
therapeutic	B-X
insulin-sensitizing	B-X
agent	B-X
for	B-X
metabolic	B-X
disease	B-X
.	B-X

Similarly	O
,	O
in	O
vivo	O
infection	O
with	O
IAV	O
resulted	O
in	O
higher	O
levels	O
of	O
primarily	O
neutrophil	O
attracting	O
chemokines	O
such	O
as	O
KC	B-Protein
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
and	O
several	O
proinflammatory	O
cytokines	O
such	O
as	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
in	O
the	O
lungs	O
of	O
A20myel	O
-	O
KO	O
mice	O
compared	O
to	O
wild	O
type	O
mice	O
.	O

This	O
was	O
associated	O
with	O
a	O
selective	O
enhancement	O
of	O
neutrophil	O
recruitment	O
to	O
the	O
bronchoalveolar	O
compartment	O
,	O
and	O
resulted	O
in	O
improved	O
viral	O
clearance	O
later	O
on	O
during	O
infection	O
.	O

Although	O
the	O
role	O
of	O
neutrophils	O
during	O
viral	O
infection	O
is	O
still	O
under	O
debate	O
,	O
recent	O
evidence	O
supports	O
a	O
protective	O
function	O
of	O
these	O
cells	O
during	O
IAV	O
infection	O
[	O
71	O
]	O
,	O
[	O
72	O
]	O
.	O

MCP	B-Protein
-	I-Protein
1	I-Protein
levels	O
were	O
not	O
affected	O
by	O
the	O
absence	O
of	O
A20	O
in	O
myeloid	O
cells	O
,	O
which	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
airway	O
epithelial	O
cells	O
are	O
the	O
primary	O
source	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
production	O
during	O
IAV	O
infection	O
[	O
73	O
]	O
.	O
<EOS>	B-X
MCP-1	B-X
(	B-X
Monocyte	B-X
chemoattractant	B-X
protein-1	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
Chemokine	B-X
(	B-X
CC-motif	B-X
)	B-X
ligand	B-X
2	B-X
(	B-X
CCL2	B-X
)	B-X
,	B-X
is	B-X
from	B-X
family	B-X
of	B-X
CC	B-X
chemokines	B-X
.	B-X
It	B-X
has	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
the	B-X
process	B-X
of	B-X
inflammation	B-X
,	B-X
where	B-X
it	B-X
attracts	B-X
or	B-X
enhances	B-X
the	B-X
expression	B-X
of	B-X
other	B-X
inflammatory	B-X
factors/cells	B-X
.	B-X
It	B-X
leads	B-X
to	B-X
the	B-X
advancement	B-X
of	B-X
many	B-X
disorders	B-X
by	B-X
this	B-X
main	B-X
mechanism	B-X
of	B-X
migration	B-X
and	B-X
infiltration	B-X
of	B-X
inflammatory	B-X
cells	B-X
like	B-X
monocytes/macrophages	B-X
and	B-X
other	B-X
cytokines	B-X
at	B-X
the	B-X
site	B-X
of	B-X
inflammation	B-X
.	B-X
MCP-1	B-X
has	B-X
been	B-X
inculpated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
numerous	B-X
disease	B-X
conditions	B-X
either	B-X
directly	B-X
or	B-X
indirectly	B-X
like	B-X
novel	B-X
corona	B-X
virus	B-X
,	B-X
cancers	B-X
,	B-X
neuroinflammatory	B-X
diseases	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
cardiovascular	B-X
diseases	B-X
.	B-X
The	B-X
elevated	B-X
MCP-1	B-X
level	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
COVID-19	B-X
patients	B-X
and	B-X
proven	B-X
to	B-X
be	B-X
a	B-X
biomarker	B-X
associated	B-X
with	B-X
the	B-X
extremity	B-X
of	B-X
disease	B-X
along	B-X
with	B-X
IP-10	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
involvement	B-X
and	B-X
role	B-X
of	B-X
MCP-1	B-X
in	B-X
various	B-X
pathological	B-X
conditions	B-X
.	B-X

Mice	O
deficient	O
for	O
the	O
MCP	O
-	O
1	O
receptor	O
CCR2	O
,	O
which	O
is	O
expressed	O
on	O
a	O
subset	O
of	O
circulating	O
monocytes	O
,	O
are	O
protected	O
against	O
IAV	O
infection	O
and	O
display	O
reduced	O
signs	O
of	O
immunopathology	O
[	O
74	O
]	O
-	O
[	O
76	O
]	O
.	O

During	O
IAV	O
infection	O
these	O
monocytes	O
develop	O
into	O
inflammatory	O
dendritic	O
cells	O
or	O
proinflammatory	O
macrophages	O
[	O
77	O
]	O
and	O
are	O
considered	O
major	O
contributors	O
to	O
IAV	O
-	O
induced	O
immunopathology	O
[	O
78	O
]	O
.	O

A20myel	O
-	O
KO	O
mice	O
were	O
protected	O
against	O
a	O
lethal	O
IAV	O
infection	O
,	O
which	O
is	O
rather	O
surprising	O
since	O
an	O
excessive	O
proinflammatory	O
cytokine	O
response	O
and	O
an	O
excessive	O
influx	O
of	O
inflammatory	O
cells	O
is	O
generally	O
believed	O
to	O
be	O
associated	O
with	O
increased	O
lethality	O
[	O
64	O
]	O
,	O
[	O
79	O
]	O
.	O

However	O
,	O
the	O
selective	O
effect	O
of	O
A20	O
deficiency	O
on	O
neutrophil	O
recruitment	O
,	O
without	O
altering	O
inflammatory	O
monocyte	O
(	O
Ly6C	O
+	O
CD11b	O
+	O
)	O
recruitment	O
,	O
further	O
support	O
the	O
idea	O
that	O
monocytes	O
and	O
not	O
neutrophils	O
are	O
major	O
contributors	O
to	O
IAV	O
-	O
associated	O
immunopathology	O
and	O
lethality	O
[	O
78	O
]	O
.	O

We	O
show	O
that	O
A20	O
deficient	O
BMDM	O
display	O
enhanced	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
response	O
to	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
by	O
synthetic	O
LMW	O
double	O
stranded	O
RNA	O
.	O

RIG	B-Protein
-	I-Protein
I	I-Protein
has	O
previously	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
innate	O
immune	O
response	O
to	O
IAV	O
[	O
13	O
]	O
,	O
suggesting	O
that	O
the	O
increased	O
immune	O
response	O
of	O
A20myel	O
-	O
KO	O
mice	O
to	O
IAV	O
lung	O
infection	O
reflects	O
enhanced	O
RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
.	O

We	O
propose	O
that	O
A20	O
inhibits	O
IAV	O
-	O
induced	O
proinflammatory	O
gene	O
expression	O
(	O
as	O
shown	O
in	O
our	O
manuscript	O
for	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
IFNbeta	B-Protein
)	O
by	O
negatively	O
regulating	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
,	O
which	O
are	O
the	O
major	O
pathways	O
controlling	O
these	O
genes	O
.	O

However	O
,	O
this	O
does	O
not	O
exclude	O
an	O
additional	O
effect	O
of	O
A20	O
on	O
other	O
signaling	O
pathways	O
that	O
may	O
contribute	O
to	O
proinflammatory	O
gene	O
expression	O
.	O

A20	O
is	O
believed	O
to	O
exert	O
its	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
inhibitory	O
functions	O
by	O
modulating	O
the	O
ubiquitination	O
status	O
of	O
different	O
signaling	O
proteins	O
[	O
80	O
]	O
.	O

In	O
this	O
context	O
,	O
it	O
was	O
recently	O
shown	O
that	O
A20	O
cooperates	O
with	O
the	O
ubiquitin	O
-	O
binding	O
proteins	O
TAX1BP1	O
and	O
ABIN1	B-Protein
to	O
to	O
disrupt	O
the	O
TRAF3	O
-	O
TBK1	O
-	O
IKKepsilon	O
complex	O
,	O
thereby	O
negatively	O
affecting	O
K63	O
-	O
polyubiquitination	O
of	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
,	O
and	O
their	O
ability	O
to	O
activity	O
IRF3	B-Protein
[	O
81	O
]	O
,	O
[	O
82	O
]	O
.	O

Whether	O
similar	O
mechanisms	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
induced	O
NF	O
-	O
kappaB	O
activation	O
is	O
still	O
unclear	O
.	O

So	O
far	O
we	O
were	O
unable	O
to	O
clearly	O
detect	O
ubiquitination	O
of	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
in	O
primary	O
macrophages	O
,	O
preventing	O
us	O
from	O
studying	O
the	O
effect	O
of	O
A20	O
deficiency	O
on	O
their	O
ubiquitination	O
status	O
.	O

It	O
cannot	O
be	O
excluded	O
however	O
that	O
A20	O
also	O
targets	O
other	O
substrates	O
that	O
mediate	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
myeloid	O
cells	O
.	O

The	O
identification	O
of	O
these	O
substrates	O
will	O
be	O
the	O
topic	O
of	O
future	O
investigations	O
in	O
our	O
laboratory	O
.	O

Multiple	O
other	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
,	O
such	O
as	O
DUBA	O
[	O
28	O
]	O
,	O
CYLD	B-Protein
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
OTUB1	O
/	O
2	O
[	O
31	O
]	O
,	O
and	O
A20	O
[	O
49	O
]	O
-	O
[	O
52	O
]	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
RIG	B-Protein
-	I-Protein
I	I-Protein
signaling	O
to	O
NF	O
-	O
kappaB	O
and	O
IRF	B-Protein
-	I-Protein
3	I-Protein
,	O
implicating	O
possible	O
redundancy	O
.	O

However	O
,	O
evidence	O
so	O
far	O
was	O
limited	O
to	O
in	O
vitro	O
data	O
and	O
was	O
obtained	O
under	O
non	O
-	O
physiological	O
conditions	O
.	O

The	O
clear	O
protective	O
phenotype	O
of	O
A20myel	O
-	O
KO	O
mice	O
that	O
we	O
here	O
describe	O
indicates	O
that	O
A20	O
expression	O
in	O
myeloid	O
cells	O
is	O
a	O
central	O
gatekeeper	O
of	O
RIG	B-Protein
-	I-Protein
I	I-Protein
induced	O
signaling	O
in	O
response	O
to	O
IAV	O
infection	O
and	O
that	O
other	O
DUBs	O
cannot	O
substitute	O
for	O
A20	O
deficiency	O
under	O
physiological	O
conditions	O
.	O

If	O
A20	O
has	O
a	O
similar	O
non	O
-	O
redundant	O
role	O
in	O
other	O
cell	O
types	O
that	O
are	O
implicated	O
in	O
the	O
response	O
to	O
IAV	O
,	O
such	O
as	O
lung	O
epithelial	O
cells	O
,	O
remains	O
to	O
be	O
investigated	O
.	O

Understanding	O
and	O
controlling	O
the	O
activation	O
of	O
innate	O
antiviral	O
immune	O
responses	O
is	O
an	O
important	O
step	O
toward	O
novel	O
therapies	O
.	O

About	O
a	O
fifth	O
of	O
world	O
'	O
s	O
population	O
is	O
infected	O
by	O
IAV	O
annually	O
,	O
leading	O
to	O
high	O
morbidity	O
and	O
mortality	O
,	O
particularly	O
in	O
infants	O
,	O
the	O
elderly	O
and	O
the	O
immunocompromised	O
.	O

The	O
high	O
mutation	O
rate	O
of	O
IAV	O
turns	O
all	O
attempts	O
of	O
vaccine	O
and	O
antiviral	O
design	O
into	O
a	O
never	O
ending	O
battle	O
.	O

In	O
recent	O
years	O
,	O
RNA	O
interference	O
,	O
triggered	O
by	O
synthetic	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
has	O
rapidly	O
evolved	O
as	O
a	O
potent	O
antiviral	O
regimen	O
.	O
<EOS>	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
RNA	B-X
interference	B-X
,	B-X
triggered	B-X
by	B-X
synthetic	B-X
short	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
,	B-X
has	B-X
rapidly	B-X
evolved	B-X
as	B-X
a	B-X
potent	B-X
antiviral	B-X
regimen	B-X
.	B-X
Properly	B-X
designed	B-X
siRNAs	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
function	B-X
as	B-X
potent	B-X
inhibitors	B-X
of	B-X
influenza	B-X
virus	B-X
replication	B-X
.	B-X
The	B-X
siRNAs	B-X
outperform	B-X
traditional	B-X
small	B-X
molecule	B-X
antivirals	B-X
in	B-X
a	B-X
number	B-X
of	B-X
areas	B-X
,	B-X
such	B-X
as	B-X
ease	B-X
of	B-X
design	B-X
,	B-X
modest	B-X
cost	B-X
,	B-X
and	B-X
fast	B-X
turnaround	B-X
.	B-X
Although	B-X
specificity	B-X
and	B-X
tissue	B-X
delivery	B-X
remain	B-X
major	B-X
bottlenecks	B-X
in	B-X
the	B-X
clinical	B-X
applications	B-X
of	B-X
RNAi	B-X
in	B-X
general	B-X
,	B-X
intranasal	B-X
application	B-X
of	B-X
siRNA	B-X
against	B-X
respiratory	B-X
viruses	B-X
including	B-X
,	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
influenza	B-X
virus	B-X
,	B-X
has	B-X
experienced	B-X
significant	B-X
success	B-X
and	B-X
optimism	B-X
,	B-X
which	B-X
is	B-X
reviewed	B-X
here	B-X
.	B-X

Properly	O
designed	O
siRNAs	O
have	O
been	O
shown	O
to	O
function	O
as	O
potent	O
inhibitors	O
of	O
influenza	O
virus	O
replication	O
.	O
<EOS>	B-X
Influenza	B-X
virus	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
prevalent	B-X
and	B-X
ancient	B-X
infections	B-X
in	B-X
humans	B-X
.	B-X
About	B-X
a	B-X
fifth	B-X
of	B-X
world	B-X
's	B-X
population	B-X
is	B-X
infected	B-X
by	B-X
influenza	B-X
virus	B-X
annually	B-X
,	B-X
leading	B-X
to	B-X
high	B-X
morbidity	B-X
and	B-X
mortality	B-X
,	B-X
particularly	B-X
in	B-X
infants	B-X
,	B-X
the	B-X
elderly	B-X
and	B-X
the	B-X
immunocompromised	B-X
.	B-X
In	B-X
the	B-X
US	B-X
alone	B-X
,	B-X
influenza	B-X
outbreaks	B-X
lead	B-X
to	B-X
roughly	B-X
30,000	B-X
deaths	B-X
each	B-X
year	B-X
.	B-X
Current	B-X
vaccines	B-X
and	B-X
anti-influenza	B-X
drugs	B-X
are	B-X
of	B-X
limited	B-X
use	B-X
due	B-X
to	B-X
high	B-X
mutation	B-X
rate	B-X
of	B-X
the	B-X
virus	B-X
and	B-X
side	B-X
effects	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
RNA	B-X
interference	B-X
,	B-X
triggered	B-X
by	B-X
synthetic	B-X
short	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
,	B-X
has	B-X
rapidly	B-X
evolved	B-X
as	B-X
a	B-X
potent	B-X
antiviral	B-X
regimen	B-X
.	B-X
Properly	B-X
designed	B-X
siRNAs	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
function	B-X
as	B-X
potent	B-X
inhibitors	B-X
of	B-X
influenza	B-X
virus	B-X
replication	B-X
.	B-X
The	B-X
siRNAs	B-X
outperform	B-X
traditional	B-X
small	B-X
molecule	B-X
antivirals	B-X
in	B-X
a	B-X
number	B-X
of	B-X
areas	B-X
,	B-X
such	B-X
as	B-X
ease	B-X
of	B-X
design	B-X
,	B-X
modest	B-X
cost	B-X
,	B-X
and	B-X
fast	B-X
turnaround	B-X
.	B-X
Although	B-X
specificity	B-X
and	B-X
tissue	B-X
delivery	B-X
remain	B-X
major	B-X
bottlenecks	B-X
in	B-X
the	B-X
clinical	B-X
applications	B-X
of	B-X
RNAi	B-X
in	B-X
general	B-X
,	B-X
intranasal	B-X
application	B-X
of	B-X
siRNA	B-X
against	B-X
respiratory	B-X
viruses	B-X
including	B-X
,	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
influenza	B-X
virus	B-X
,	B-X
has	B-X
experienced	B-X
significant	B-X
success	B-X
and	B-X
optimism	B-X
,	B-X
which	B-X
is	B-X
reviewed	B-X
here	B-X
.	B-X

Although	O
specificity	O
and	O
tissue	O
delivery	O
remain	O
major	O
bottlenecks	O
in	O
the	O
clinical	O
applications	O
of	O
RNAi	O
in	O
general	O
,	O
intranasal	O
application	O
of	O
siRNA	O
against	O
respiratory	O
viruses	O
including	O
,	O
but	O
not	O
limited	O
to	O
influenza	O
virus	O
,	O
has	O
experienced	O
significant	O
success	O
and	O
optimism	O
[	O
83	O
]	O
.	O

Our	O
results	O
suggest	O
that	O
not	O
only	O
siRNA	O
targeting	O
IAV	O
components	O
,	O
but	O
boosting	O
the	O
antiviral	O
immune	O
response	O
by	O
intranasal	O
administration	O
of	O
siRNA	O
against	O
A20	O
might	O
be	O
a	O
valid	O
therapeutic	O
approach	O
.	O
<EOS>	B-X
The	B-X
most	B-X
well-established	B-X
finding	B-X
gleaned	B-X
from	B-X
decades	B-X
of	B-X
experimental	B-X
hypnosis	B-X
research	B-X
is	B-X
that	B-X
individuals	B-X
display	B-X
marked	B-X
variability	B-X
in	B-X
responsiveness	B-X
to	B-X
hypnotic	B-X
suggestions	B-X
.	B-X
Insofar	B-X
as	B-X
this	B-X
variability	B-X
impacts	B-X
both	B-X
treatment	B-X
outcome	B-X
in	B-X
therapeutic	B-X
applications	B-X
of	B-X
hypnosis	B-X
as	B-X
well	B-X
as	B-X
responsiveness	B-X
to	B-X
suggestions	B-X
in	B-X
experimental	B-X
contexts	B-X
,	B-X
it	B-X
is	B-X
imperative	B-X
that	B-X
clinicians	B-X
and	B-X
researchers	B-X
use	B-X
robust	B-X
measures	B-X
of	B-X
hypnotic	B-X
suggestibility	B-X
.	B-X
The	B-X
current	B-X
paper	B-X
critically	B-X
evaluates	B-X
contemporary	B-X
measures	B-X
of	B-X
hypnotic	B-X
suggestibility	B-X
.	B-X
After	B-X
reviewing	B-X
the	B-X
most	B-X
widely	B-X
used	B-X
measures	B-X
,	B-X
we	B-X
identify	B-X
multiple	B-X
properties	B-X
of	B-X
these	B-X
instruments	B-X
that	B-X
result	B-X
in	B-X
the	B-X
loss	B-X
of	B-X
valuable	B-X
information	B-X
,	B-X
including	B-X
binary	B-X
scoring	B-X
and	B-X
single-trial	B-X
sampling	B-X
,	B-X
and	B-X
hinder	B-X
their	B-X
utility	B-X
,	B-X
such	B-X
as	B-X
the	B-X
inclusion	B-X
of	B-X
suboptimal	B-X
suggestion	B-X
content	B-X
.	B-X
We	B-X
conclude	B-X
by	B-X
outlining	B-X
ways	B-X
in	B-X
which	B-X
the	B-X
measurement	B-X
of	B-X
hypnotic	B-X
suggestibility	B-X
can	B-X
be	B-X
advanced	B-X
.	B-X

Also	O
small	O
compound	O
inhibitors	O
of	O
A20	O
might	O
be	O
an	O
interesting	O
alternative	O
.	O

Finally	O
,	O
similar	O
targeting	O
of	O
A20	O
might	O
be	O
of	O
interest	O
in	O
the	O
battle	O
against	O
other	O
viral	O
infections	O
including	O
RSV	O
and	O
SARS	O
coronavirus	O
.	O

Ethics	O
statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
This	B-X
is	B-X
a	B-X
condensed	B-X
summary	B-X
of	B-X
an	B-X
international	B-X
multisociety	B-X
statement	B-X
on	B-X
ethics	B-X
of	B-X
artificial	B-X
intelligence	B-X
(	B-X
AI	B-X
)	B-X
in	B-X
radiology	B-X
produced	B-X
by	B-X
the	B-X
ACR	B-X
,	B-X
European	B-X
Society	B-X
of	B-X
Radiology	B-X
,	B-X
RSNA	B-X
,	B-X
Society	B-X
for	B-X
Imaging	B-X
Informatics	B-X
in	B-X
Medicine	B-X
,	B-X
European	B-X
Society	B-X
of	B-X
Medical	B-X
Imaging	B-X
Informatics	B-X
,	B-X
Canadian	B-X
Association	B-X
of	B-X
Radiologists	B-X
,	B-X
and	B-X
American	B-X
Association	B-X
of	B-X
Physicists	B-X
in	B-X
Medicine	B-X
.	B-X
This	B-X
statement	B-X
highlights	B-X
our	B-X
consensus	B-X
that	B-X
ethical	B-X
use	B-X
of	B-X
AI	B-X
in	B-X
radiology	B-X
should	B-X
promote	B-X
well-being	B-X
,	B-X
minimize	B-X
harm	B-X
,	B-X
and	B-X
ensure	B-X
that	B-X
the	B-X
benefits	B-X
and	B-X
harms	B-X
are	B-X
distributed	B-X
among	B-X
stakeholders	B-X
in	B-X
a	B-X
just	B-X
manner	B-X
.	B-X

All	O
experiments	O
on	O
mice	O
were	O
conducted	O
according	O
to	O
the	O
national	O
(	O
Belgian	O
Law	O
14	O
/	O
08	O
/	O
1986	O
and	O
22	O
/	O
12	O
/	O
2003	O
,	O
Belgian	O
Royal	O
Decree	O
06	O
/	O
04	O
/	O
2010	O
)	O
and	O
European	O
(	O
EU	O
Directives	O
2010	O
/	O
63	O
/	O
EU	O
,	O
86	O
/	O
609	O
/	O
EEG	O
)	O
animal	O
regulations	O
.	O

Animal	O
protocols	O
were	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
Ghent	O
University	O
(	O
permit	O
number	O
LA1400091	O
,	O
approval	O
ID	O
2010	O
/	O
001	O
)	O
.	O

All	O
efforts	O
were	O
made	O
to	O
ameliorate	O
suffering	O
of	O
animals	O
.	O
<EOS>	B-X
There	B-X
are	B-X
more	B-X
than	B-X
one	B-X
million	B-X
patients	B-X
worldwide	B-X
suffering	B-X
paralysis	B-X
caused	B-X
by	B-X
spinal	B-X
cord	B-X
injury	B-X
(	B-X
SCI	B-X
)	B-X
.	B-X
Stem	B-X
cell	B-X
transplantation	B-X
therapy	B-X
,	B-X
which	B-X
can	B-X
ameliorate	B-X
damage	B-X
or	B-X
regenerate	B-X
neurological	B-X
networks	B-X
,	B-X
has	B-X
been	B-X
proposed	B-X
as	B-X
a	B-X
promising	B-X
candidate	B-X
for	B-X
SCI	B-X
treatment	B-X
,	B-X
and	B-X
many	B-X
basic	B-X
and	B-X
clinical	B-X
experiments	B-X
using	B-X
stem	B-X
cells	B-X
for	B-X
SCI	B-X
treatment	B-X
have	B-X
been	B-X
launched	B-X
,	B-X
with	B-X
promising	B-X
results	B-X
.	B-X
Bacteria	B-X
can	B-X
be	B-X
used	B-X
as	B-X
anticancer	B-X
agents	B-X
,	B-X
but	B-X
efforts	B-X
to	B-X
utilize	B-X
attenuated	B-X
pathogenic	B-X
bacteria	B-X
suffer	B-X
from	B-X
the	B-X
risk	B-X
of	B-X
toxicity	B-X
or	B-X
infection	B-X
.	B-X
In	B-X
recent	B-X
times	B-X
,	B-X
capsaicinoids	B-X
especially	B-X
capsaicin	B-X
can	B-X
ameliorate	B-X
important	B-X
viral	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
SARS-CoV-2	B-X
.	B-X
In	B-X
this	B-X
artifact	B-X
,	B-X
an	B-X
effort	B-X
has	B-X
been	B-X
made	B-X
to	B-X
address	B-X
in	B-X
an	B-X
accessible	B-X
format	B-X
the	B-X
nutritional	B-X
and	B-X
biomedical	B-X
perspectives	B-X
of	B-X
chilli	B-X
pepper	B-X
,	B-X
which	B-X
could	B-X
precisely	B-X
upgrade	B-X
and	B-X
enrich	B-X
our	B-X
pharmaceutical	B-X
industries	B-X
towards	B-X
human	B-X
well-being	B-X
.	B-X

Mice	O
were	O
anesthetized	O
by	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injection	O
of	O
a	O
mixture	O
of	O
ketamine	O
(	O
12	O
mg	O
/	O
kg	O
)	O
and	O
xylazine	O
(	O
60	O
mg	O
/	O
kg	O
)	O
.	O

Mice	O
<EOS>	B-X
The	B-X
problem	B-X
of	B-X
passenger	B-X
genes	B-X
in	B-X
transgenic	B-X
mice	B-X
.	B-X
Studies	B-X
on	B-X
cryopreservation	B-X
of	B-X
embryos	B-X
and	B-X
gametes	B-X
in	B-X
mice	B-X
.	B-X
Mice	B-X
may	B-X
become	B-X
caught	B-X
in	B-X
nesting	B-X
material	B-X
.	B-X
Mice	B-X
cloned	B-X
from	B-X
cultured	B-X
stem	B-X
cells	B-X
.	B-X

A20fl	O
/	O
fl	O
mice	O
were	O
generated	O
as	O
previously	O
described	O
[	O
56	O
]	O
.	O

A20fl	O
/	O
fl	O
mice	O
were	O
crossed	O
with	O
LysM	O
-	O
Cre	O
mice	O
[	O
84	O
]	O
(	O
provided	O
by	O
I	O
.	O
Forster	O
,	O
Institute	O
of	O
Genetics	O
,	O
University	O
of	O
Cologne	O
,	O
Germany	O
)	O
to	O
generate	O
A20fl	O
/	O
fl	O
LysMCre	O
transgenes	O
and	O
are	O
described	O
in	O
detail	O
elsewhere	O
[	O
48	O
]	O
.	O

Mice	O
were	O
housed	O
in	O
individually	O
ventilated	O
cages	O
at	O
the	O
VIB	O
Department	O
of	O
Molecular	O
Biomedical	O
Research	O
in	O
specific	O
pathogen	O
-	O
free	O
animal	O
facilities	O
.	O

Influenza	O
infections	O
were	O
performed	O
on	O
age	O
-	O
(	O
between	O
7	O
and	O
9	O
weeks	O
old	O
)	O
and	O
sex	O
-	O
matched	O
littermates	O
.	O

A20fl	O
/	O
fl	O
LysM	O
-	O
Cre	O
animals	O
were	O
backcrossed	O
three	O
times	O
to	O
the	O
C57Bl	O
/	O
6	O
background	O
.	O

A20fl	O
/	O
fl	O
mice	O
expressing	O
or	O
lacking	O
the	O
LysM	O
-	O
Cre	O
transgene	O
were	O
termed	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
respectively	O
.	O
<EOS>	B-X
Microbial	B-X
dysbiosis	B-X
commonly	B-X
occurs	B-X
in	B-X
patients	B-X
with	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
(	B-X
IBD	B-X
)	B-X
.	B-X
A20	B-X
is	B-X
a	B-X
potent	B-X
regulator	B-X
of	B-X
signals	B-X
triggered	B-X
by	B-X
microbial	B-X
pattern	B-X
molecules	B-X
,	B-X
and	B-X
A20	B-X
regulates	B-X
susceptibility	B-X
to	B-X
intestinal	B-X
inflammation	B-X
in	B-X
mice	B-X
and	B-X
in	B-X
humans	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
mice	B-X
lacking	B-X
A20	B-X
expression	B-X
in	B-X
dendritic	B-X
cells	B-X
,	B-X
A20FL/FL	B-X
CD11c-Cre	B-X
mice	B-X
(	B-X
or	B-X
A20dDC	B-X
mice	B-X
)	B-X
,	B-X
spontaneously	B-X
develop	B-X
colitogenic	B-X
intestinal	B-X
dysbiosis	B-X
that	B-X
is	B-X
evident	B-X
upon	B-X
weaning	B-X
and	B-X
precedes	B-X
the	B-X
onset	B-X
of	B-X
colitis	B-X
.	B-X
Intestines	B-X
from	B-X
A20dDC	B-X
mice	B-X
express	B-X
increased	B-X
amounts	B-X
of	B-X
Reg3β	B-X
and	B-X
Reg3γ	B-X
,	B-X
but	B-X
not	B-X
Ang4	B-X
.	B-X
Moreover	B-X
,	B-X
A20	B-X
deficient	B-X
DCs	B-X
directly	B-X
induce	B-X
expression	B-X
of	B-X
Reg3β	B-X
and	B-X
Reg3γ	B-X
but	B-X
not	B-X
Ang	B-X
4	B-X
in	B-X
normal	B-X
intestinal	B-X
epithelial	B-X
cell	B-X
enteroid	B-X
cultures	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
These	B-X
findings	B-X
reveal	B-X
a	B-X
pathophysiological	B-X
pathway	B-X
in	B-X
which	B-X
defective	B-X
expression	B-X
of	B-X
an	B-X
IBD	B-X
susceptibility	B-X
gene	B-X
in	B-X
DCs	B-X
drives	B-X
aberrant	B-X
expression	B-X
of	B-X
anti-bacterial	B-X
peptides	B-X
and	B-X
luminal	B-X
dysbiosis	B-X
that	B-X
in	B-X
turn	B-X
confers	B-X
host	B-X
susceptibility	B-X
to	B-X
intestinal	B-X
inflammation	B-X
.	B-X

Viral	O
infection	O
and	O
determination	O
of	O
viral	O
titers	O
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
United	B-X
States	B-X
blood	B-X
supply	B-X
offers	B-X
a	B-X
relatively	B-X
low	B-X
risk	B-X
of	B-X
viral	B-X
infection	B-X
.	B-X
Consequently	B-X
,	B-X
there	B-X
is	B-X
continuing	B-X
interest	B-X
in	B-X
the	B-X
development	B-X
of	B-X
safe	B-X
and	B-X
effective	B-X
procedures	B-X
for	B-X
viral	B-X
inactivation	B-X
of	B-X
single	B-X
donor	B-X
blood	B-X
components	B-X
.	B-X
In	B-X
order	B-X
to	B-X
establish	B-X
appropriate	B-X
expectations	B-X
for	B-X
such	B-X
inactivation	B-X
procedures	B-X
,	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
understand	B-X
the	B-X
titers	B-X
and	B-X
distributions	B-X
of	B-X
viral	B-X
contaminants	B-X
in	B-X
blood	B-X
components	B-X
.	B-X
Viruses	B-X
may	B-X
variously	B-X
occur	B-X
free	B-X
in	B-X
the	B-X
plasma	B-X
,	B-X
as	B-X
replicative	B-X
forms	B-X
in	B-X
actively	B-X
infected	B-X
leukocytes	B-X
,	B-X
as	B-X
integrated	B-X
proviral	B-X
DNA	B-X
and	B-X
perhaps	B-X
,	B-X
nonspecifically	B-X
associated	B-X
with	B-X
cellular	B-X
surfaces	B-X
.	B-X

Mouse	O
adapted	O
IAV	O
X	O
-	O
47	O
(	O
H3N2	O
;	O
PR8xA	O
/	O
Victoria	O
/	O
3	O
/	O
75	O
)	O
was	O
propagated	O
in	O
MDCK	O
cells	O
.	O

For	O
viral	O
inoculation	O
,	O
mice	O
were	O
anesthetized	O
by	O
i	O
.	O
p	O
.	O
injection	O
with	O
ketamine	O
(	O
12	O
mg	O
/	O
kg	O
)	O
and	O
xylazine	O
(	O
60	O
mg	O
/	O
kg	O
)	O
and	O
50	O
microl	O
X	O
-	O
47	O
diluted	O
in	O
PBS	O
was	O
administered	O
intranasally	O
.	O

For	O
lethal	O
and	O
sublethal	O
infection	O
,	O
mice	O
received	O
respectively	O
2	O
-	O
LD50	O
or	O
0	O
.	O
05	O
-	O
LD50	O
X	O
-	O
47	O
.	O

To	O
determine	O
pulmonary	O
viral	O
titers	O
,	O
median	O
tissue	O
culture	O
infectious	O
dose	O
(	O
TCID50	O
)	O
was	O
measured	O
as	O
follows	O
:	O
lungs	O
were	O
homogenized	O
with	O
a	O
Polytron	O
homogenizer	O
(	O
Kinematica	O
)	O
in	O
PBS	O
.	O

Eight	O
-	O
fold	O
serial	O
dilutions	O
of	O
lung	O
homogenates	O
were	O
incubated	O
on	O
MDCK	O
cells	O
for	O
5	O
days	O
in	O
DMEM	O
supplemented	O
with	O
trypsin	O
(	O
1	O
microg	O
/	O
ml	O
)	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

For	O
read	O
-	O
out	O
,	O
0	O
.	O
5	O
%	O
chicken	O
red	O
blood	O
cells	O
(	O
RBC	O
)	O
were	O
added	O
and	O
end	O
-	O
point	O
dilution	O
of	O
hemagglutination	O
was	O
monitored	O
.	O

TCID50	O
titers	O
were	O
then	O
calculated	O
according	O
to	O
the	O
method	O
of	O
Reed	O
and	O
Muench	O
[	O
85	O
]	O
.	O

Determination	O
of	O
HAI	O
(	O
hemagglutination	O
inhibition	O
)	O
titers	O
<EOS>	B-X
The	B-X
hemagglutination	B-X
inhibition	B-X
(	B-X
HI	B-X
)	B-X
assay	B-X
is	B-X
a	B-X
prominent	B-X
and	B-X
commonly	B-X
accepted	B-X
method	B-X
used	B-X
to	B-X
determine	B-X
quantitative	B-X
antibody	B-X
titers	B-X
for	B-X
influenza	B-X
virus	B-X
.	B-X
The	B-X
panel	B-X
of	B-X
human	B-X
sera	B-X
comprised	B-X
samples	B-X
with	B-X
expected	B-X
low	B-X
,	B-X
medium	B-X
,	B-X
and	B-X
high	B-X
HI	B-X
titers	B-X
against	B-X
two	B-X
influenza	B-X
viruses	B-X
:	B-X
A/H1N1/California/07/2009	B-X
and	B-X
B/Victoria/Brisbane/60/2008	B-X
.	B-X
The	B-X
hemagglutination	B-X
inhibition	B-X
assay	B-X
(	B-X
HAI	B-X
)	B-X
is	B-X
widely	B-X
used	B-X
to	B-X
evaluate	B-X
vaccine-induced	B-X
antibody	B-X
responses	B-X
as	B-X
well	B-X
as	B-X
to	B-X
antigenically	B-X
characterize	B-X
influenza	B-X
viruses	B-X
.	B-X
The	B-X
results	B-X
of	B-X
an	B-X
HAI	B-X
assay	B-X
are	B-X
based	B-X
on	B-X
an	B-X
endpoint	B-X
titration	B-X
where	B-X
the	B-X
titers	B-X
are	B-X
generally	B-X
manually	B-X
interpreted	B-X
and	B-X
recorded	B-X
by	B-X
a	B-X
well-trained	B-X
expert	B-X
.	B-X
For	B-X
example	B-X
,	B-X
tilting	B-X
HAI	B-X
plates	B-X
at	B-X
45-60	B-X
degrees	B-X
to	B-X
look	B-X
for	B-X
a	B-X
``	B-X
tear	B-X
drop	B-X
pattern	B-X
''	B-X
with	B-X
avian	B-X
red	B-X
blood	B-X
cells	B-X
is	B-X
a	B-X
common	B-X
practice	B-X
by	B-X
many	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
research	B-X
laboratories	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
an	B-X
automated	B-X
image	B-X
analysis	B-X
algorithm	B-X
can	B-X
be	B-X
used	B-X
to	B-X
achieve	B-X
an	B-X
accurate	B-X
and	B-X
non-subjective	B-X
interpretation	B-X
of	B-X
HAI	B-X
assays-specifically	B-X
without	B-X
the	B-X
need	B-X
to	B-X
tilt	B-X
plates	B-X
.	B-X
In	B-X
a	B-X
side-by-side	B-X
comparison	B-X
study	B-X
performed	B-X
during	B-X
FDA	B-X
's	B-X
biannual	B-X
serological	B-X
screening	B-X
process	B-X
for	B-X
influenza	B-X
viruses	B-X
,	B-X
titer	B-X
calls	B-X
for	B-X
more	B-X
than	B-X
2200	B-X
serum	B-X
samples	B-X
were	B-X
made	B-X
by	B-X
the	B-X
Cypher	B-X
One	B-X
automated	B-X
hemagglutination	B-X
analyzer	B-X
without	B-X
tilting	B-X
and	B-X
by	B-X
an	B-X
expert	B-X
human	B-X
with	B-X
tilting	B-X
.	B-X
Overall	B-X
these	B-X
results	B-X
support	B-X
the	B-X
postulate	B-X
that	B-X
algorithm-based	B-X
interpretation	B-X
of	B-X
a	B-X
digital	B-X
record	B-X
with	B-X
no	B-X
plate	B-X
tilting	B-X
could	B-X
replace	B-X
manual	B-X
reading	B-X
for	B-X
greater	B-X
consistency	B-X
in	B-X
HAI	B-X
assays	B-X
.	B-X

To	O
determine	O
the	O
HAI	O
titers	O
in	O
infected	O
mice	O
,	O
sera	O
of	O
these	O
were	O
treated	O
with	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
/	O
Cholera	O
filtrate	O
;	O
Sigma	O
)	O
to	O
remove	O
sialic	O
acids	O
from	O
serum	O
proteins	O
capable	O
of	O
aspecific	O
inhibition	O
of	O
agglutination	O
.	O

After	O
incubation	O
overnight	O
at	O
37degreesC	O
,	O
the	O
RDE	O
was	O
inactivated	O
by	O
addition	O
of	O
0	O
.	O
75	O
%	O
sodium	O
citrate	O
in	O
PBS	O
and	O
heating	O
to	O
56degreesC	O
for	O
30	O
min	O
.	O

To	O
remove	O
sialic	O
acid	O
binding	O
proteins	O
,	O
sera	O
were	O
cleared	O
with	O
1	O
/	O
10	O
volume	O
50	O
%	O
chicken	O
RBC	O
.	O

Titration	O
was	O
done	O
by	O
incubating	O
a	O
two	O
-	O
fold	O
dilution	O
series	O
of	O
sera	O
with	O
4	O
HA	O
units	O
of	O
X	O
-	O
47	O
virus	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
in	O
96	O
-	O
well	O
U	O
-	O
bottom	O
plates	O
.	O

Finally	O
,	O
an	O
equal	O
volume	O
of	O
0	O
.	O
5	O
%	O
chicken	O
RBC	O
was	O
added	O
and	O
titers	O
were	O
read	O
30	O
min	O
later	O
.	O

Negative	O
controls	O
included	O
PBS	O
instead	O
of	O
immune	O
serum	O
(	O
agglutination	O
control	O
)	O
or	O
PR8	O
instead	O
of	O
X	O
-	O
47	O
virus	O
(	O
control	O
for	O
agglutination	O
effect	O
of	O
sera	O
)	O
;	O
as	O
positive	O
control	O
,	O
serum	O
from	O
a	O
mouse	O
infected	O
twice	O
with	O
a	O
sublethal	O
dose	O
of	O
X	O
-	O
47	O
was	O
used	O
.	O

In	O
vivo	O
intracellular	O
GrB	B-Protein
and	O
IFNgamma	O
staining	O
of	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O

Granzyme	B-Protein
B	I-Protein
(	O
GrB	B-Protein
)	O
and	O
IFNgamma	O
expressing	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
determined	O
by	O
treating	O
the	O
mice	O
intranasally	O
with	O
50	O
microg	O
Brefeldin	O
A	O
(	O
Sigma	O
)	O
as	O
previously	O
described	O
[	O
86	O
]	O
.	O

6	O
h	O
later	O
,	O
BAL	O
and	O
lungs	O
were	O
isolated	O
and	O
single	O
cell	O
suspensions	O
were	O
prepared	O
from	O
the	O
lung	O
in	O
the	O
presence	O
of	O
3	O
microg	O
/	O
ml	O
Brefeldin	O
A	O
.	O
Cells	O
were	O
stained	O
,	O
fixed	O
and	O
permeabilized	O
(	O
Cytofix	O
/	O
Cytoperm	O
,	O
BD	O
Biosciences	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Activated	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
based	O
on	O
CD62lo	O
CD3	B-Protein
+	O
and	O
CD8	B-Protein
+	O
expression	O
.	O

Live	O
/	O
Dead	O
fixable	O
aqua	O
dead	O
cell	O
stain	O
kit	O
(	O
Molecular	O
Probes	O
)	O
was	O
used	O
to	O
discriminate	O
live	O
from	O
dead	O
cells	O
.	O

Cells	O
and	O
transfection	O
<EOS>	B-X
Transient	B-X
transfection	B-X
of	B-X
mammalian	B-X
cells	B-X
is	B-X
used	B-X
in	B-X
the	B-X
biotechnology	B-X
industry	B-X
to	B-X
quickly	B-X
supply	B-X
recombinant	B-X
protein	B-X
for	B-X
research	B-X
and	B-X
large	B-X
molecule	B-X
drug	B-X
development	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
method	B-X
for	B-X
high	B-X
throughput	B-X
transient	B-X
transfection	B-X
of	B-X
Human	B-X
Embryonic	B-X
Kidney	B-X
293	B-X
(	B-X
HEK293	B-X
)	B-X
cells	B-X
in	B-X
30	B-X
mL	B-X
tubespins	B-X
using	B-X
polyethylenimine	B-X
(	B-X
PEI	B-X
)	B-X
as	B-X
a	B-X
transfection	B-X
reagent	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
valproic	B-X
acid	B-X
(	B-X
VPA	B-X
)	B-X
to	B-X
transfection	B-X
cultures	B-X
enhances	B-X
recombinant	B-X
protein	B-X
production	B-X
.	B-X
The	B-X
thawing	B-X
and	B-X
passaging	B-X
operations	B-X
for	B-X
HEK293	B-X
cultures	B-X
to	B-X
source	B-X
the	B-X
transient	B-X
transfections	B-X
are	B-X
also	B-X
described	B-X
.	B-X

HEK293T	O
and	O
MDCK	O
cells	O
were	O
grown	O
in	O
DMEM	O
(	O
Gibco	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

HEK293T	O
cells	O
were	O
transfected	O
using	O
the	O
calcium	O
phosphate	O
precipitate	O
transfection	O
method	O
with	O
specific	O
expression	O
vectors	O
(	O
pCAGGS	O
-	O
E	O
-	O
hA20	O
(	O
LMBP	O
3778	O
)	O
,	O
pCAGGS	O
-	O
E	O
-	O
RIG	O
-	O
I	O
-	O
CARD	O
(	O
LMBP	O
6517	O
)	O
,	O
pEF	O
-	O
HA	O
-	O
IRF	O
-	O
7	O
(	O
kindly	O
provided	O
by	O
T	O
.	O
Taniguchi	O
,	O
Graduate	O
School	O
of	O
Medicine	O
and	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
)	O
)	O
,	O
NF	O
-	O
kappaB	O
,	O
IRF3	B-Protein
,	O
IRF7	B-Protein
reporter	O
plasmids	O
(	O
respectively	O
pConLuc	O
(	O
LMBP3248	O
)	O
,	O
pISRE	O
-	O
luc	O
(	O
LMBP4011	O
)	O
,	O
pGL3	O
-	O
IFNalpha4	O
-	O
luc	O
(	O
kindly	O
provided	O
by	O
J	O
.	O
Hiscott	O
,	O
McGill	O
University	O
,	O
Montreal	O
,	O
Quebec	O
,	O
Canada	O
)	O
,	O
and	O
pACTbetagal	O
(	O
LMBP4341	O
)	O
for	O
transfection	O
efficiency	O
normalization	O
.	O

Details	O
of	O
plasmids	O
are	O
presented	O
along	O
with	O
detailed	O
sequence	O
maps	O
at	O
the	O
BCCM	O
-	O
LMBP	O
plasmid	O
databank	O
http	O
:	O
/	O
/	O
bccm	O
.	O
belspo	O
.	O
be	O
/	O
index	O
.	O
php	O
.	O

For	O
the	O
generation	O
of	O
BMDM	O
,	O
bone	O
marrow	O
cells	O
were	O
cultured	O
7	O
days	O
in	O
RPMI	O
1640	O
(	O
Gibco	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
,	O
antibiotics	O
and	O
40	O
ng	O
/	O
ml	O
recombinant	O
M	O
-	O
CSF	O
.	O

BMDM	O
were	O
of	O
>	O
=	O
95	O
%	O
purity	O
as	O
measured	O
by	O
flow	O
cytometry	O
using	O
F4	O
/	O
80	O
and	O
CD11b	O
specific	O
antibodies	O
.	O

For	O
the	O
isolation	O
of	O
alveolar	O
macrophages	O
,	O
the	O
trachea	O
was	O
canulated	O
and	O
the	O
lung	O
was	O
flushed	O
4	O
times	O
with	O
HBSS	O
containing	O
1	O
mM	O
EDTA	O
.	O

Alveolar	O
macrophages	O
were	O
cultured	O
in	O
RPMI	O
1640	O
(	O
Gibco	O
)	O
supplemented	O
with	O
1	O
%	O
FCS	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
4	O
mM	O
sodium	O
pyruvate	O
and	O
antibiotics	O
.	O

Western	O
blotting	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
techniques	B-X
in	B-X
molecular	B-X
biology	B-X
and	B-X
proteomics	B-X
.	B-X
Since	B-X
western	B-X
blotting	B-X
is	B-X
a	B-X
multistep	B-X
protocol	B-X
,	B-X
variations	B-X
and	B-X
errors	B-X
can	B-X
occur	B-X
at	B-X
any	B-X
step	B-X
reducing	B-X
the	B-X
reliability	B-X
and	B-X
reproducibility	B-X
of	B-X
this	B-X
technique	B-X
.	B-X
Areas	B-X
covered	B-X
:	B-X
In	B-X
this	B-X
review	B-X
,	B-X
improvements	B-X
in	B-X
different	B-X
areas	B-X
of	B-X
western	B-X
blotting	B-X
,	B-X
including	B-X
protein	B-X
transfer	B-X
and	B-X
antibody	B-X
validation	B-X
,	B-X
are	B-X
summarized	B-X
.	B-X
The	B-X
review	B-X
discusses	B-X
the	B-X
most	B-X
advanced	B-X
western	B-X
blotting	B-X
techniques	B-X
available	B-X
and	B-X
highlights	B-X
the	B-X
relationship	B-X
between	B-X
next	B-X
generation	B-X
western	B-X
blotting	B-X
techniques	B-X
and	B-X
its	B-X
clinical	B-X
relevance	B-X
.	B-X
New	B-X
methods	B-X
such	B-X
as	B-X
single	B-X
cell-resolution	B-X
western	B-X
blot	B-X
,	B-X
capillary	B-X
electrophoresis	B-X
,	B-X
DigiWest	B-X
,	B-X
automated	B-X
microfluid	B-X
western	B-X
blotting	B-X
and	B-X
microchip	B-X
electrophoresis	B-X
have	B-X
all	B-X
been	B-X
developed	B-X
to	B-X
reduce	B-X
potential	B-X
problems	B-X
associated	B-X
with	B-X
the	B-X
western	B-X
blotting	B-X
technique	B-X
.	B-X

For	O
total	O
lysates	O
,	O
cells	O
were	O
lysed	O
at	O
4degreesC	O
for	O
15	O
min	O
in	O
lysis	O
buffer	O
(	O
200	O
mM	O
NaCl	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
5	O
mM	O
EDTA	O
,	O
2	O
mM	O
DTT	O
)	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
.	O

Nuclear	O
and	O
cytoplasmic	O
lysates	O
were	O
prepared	O
by	O
resuspending	O
cells	O
in	O
B1	O
(	O
10	O
mM	O
Hepes	O
pH	O
7	O
.	O
5	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
5	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
and	O
0	O
.	O
1	O
mM	O
EGTA	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Next	O
,	O
NP	O
-	O
40	O
detergent	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0	O
.	O
65	O
%	O
and	O
cells	O
were	O
centrifuged	O
at	O
500	O
g	O
for	O
5	O
min	O
.	O

The	O
nuclear	O
fraction	O
containing	O
pellet	O
was	O
lyzed	O
in	O
B2	O
(	O
20	O
mM	O
Hepes	O
pH	O
7	O
.	O
5	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
400	O
mM	O
NaCl	O
,	O
10	O
mM	O
KCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
20	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
and	O
0	O
.	O
1	O
mM	O
EGTA	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

The	O
lysates	O
were	O
subsequently	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
analyzed	O
by	O
western	O
blotting	O
and	O
ECL	O
detection	O
(	O
Perkin	O
Elmer	O
Life	O
Sciences	O
)	O
.	O

Immunoblots	O
were	O
revealed	O
with	O
anti	O
-	O
A20	O
,	O
anti	O
-	O
IkappaBalpha	O
,	O
anti	O
-	O
p65	O
,	O
and	O
anti	O
-	O
histon	O
H1	O
(	O
Santa	O
Cruz	O
)	O
,	O
anti	O
-	O
IRF3	O
(	O
Invitrogen	O
)	O
,	O
anti	O
-	O
phospho	O
-	O
IRF3	O
and	O
anti	O
-	O
phospho	O
-	O
IkappaBalpha	O
(	O
Cell	O
Signaling	O
)	O
and	O
anti	O
-	O
actin	O
(	O
MP	O
Biomedicals	O
)	O
.	O

The	O
density	O
of	O
the	O
bands	O
was	O
quantified	O
(	O
fold	O
induction	O
)	O
with	O
the	O
ImageJ	O
(	O
http	O
:	O
/	O
/	O
rsbweb	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
)	O
Gel	O
analyzer	O
tool	O
.	O

All	O
intensities	O
were	O
calculated	O
relative	O
to	O
the	O
first	O
lane	O
(	O
=	O
time	O
0	O
)	O
.	O

Flow	O
cytometry	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
technology	B-X
that	B-X
provides	B-X
rapid	B-X
multi-parametric	B-X
analysis	B-X
of	B-X
single	B-X
cells	B-X
in	B-X
solution	B-X
.	B-X
Flow	B-X
cytometers	B-X
utilize	B-X
lasers	B-X
as	B-X
light	B-X
sources	B-X
to	B-X
produce	B-X
both	B-X
scattered	B-X
and	B-X
fluorescent	B-X
light	B-X
signals	B-X
that	B-X
are	B-X
read	B-X
by	B-X
detectors	B-X
such	B-X
as	B-X
photodiodes	B-X
or	B-X
photomultiplier	B-X
tubes	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
fluorescent	B-X
reagents	B-X
are	B-X
utilized	B-X
in	B-X
flow	B-X
cytometry	B-X
.	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
that	B-X
has	B-X
applications	B-X
in	B-X
immunology	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
bacteriology	B-X
,	B-X
virology	B-X
,	B-X
cancer	B-X
biology	B-X
,	B-X
and	B-X
infectious	B-X
disease	B-X
monitoring	B-X
.	B-X

Lungs	O
were	O
dissected	O
and	O
incubated	O
with	O
collagenase	B-Protein
type	I-Protein
IV	I-Protein
(	O
1	O
mg	O
/	O
ml	O
;	O
Sigma	O
)	O
and	O
DNAse	O
(	O
100	O
U	O
/	O
ml	O
;	O
Roche	O
)	O
at	O
37degreesC	O
for	O
30	O
min	O
.	O

Subsequently	O
,	O
samples	O
were	O
filtered	O
through	O
a	O
70	O
microm	O
and	O
40	O
microm	O
nylon	O
mesh	O
.	O

For	O
the	O
preparation	O
of	O
BAL	O
,	O
trachea	O
were	O
canulated	O
and	O
airway	O
lumen	O
was	O
flushed	O
4	O
times	O
with	O
HBSS	O
with	O
1	O
mM	O
EDTA	O
.	O

Cells	O
were	O
stained	O
with	O
monoclonal	O
antibodies	O
directed	O
against	O
MHC	O
-	O
II	O
(	O
I	O
-	O
A	O
/	O
I	O
-	O
E	O
)	O
FITC	O
(	O
M5	O
/	O
114	O
.	O
15	O
.	O
2	O
)	O
,	O
CD11c	O
PerCP	O
-	O
Cy5	O
.	O
5	O
(	O
N418	O
)	O
,	O
F4	O
/	O
80	O
APC	O
(	O
BM8	O
)	O
,	O
CD62L	B-Protein
PE	O
(	O
MEL	O
-	O
14	O
)	O
,	O
Granzyme	B-Protein
B	I-Protein
FITC	O
(	O
NGZB	O
)	O
from	O
eBiosciences	O
and	O
CD3	B-Protein
Molecular	O
Complex	O
Horizon	O
v450	O
(	O
17A2	O
)	O
,	O
Ly6C	O
Horizon	O
v450	O
(	O
AL	O
-	O
21	O
)	O
,	O
Ly6G	B-Protein
PE	O
(	O
1A8	O
)	O
,	O
CD11b	O
APC	O
-	O
Cy7	O
(	O
M1	O
/	O
70	O
)	O
,	O
CD8alpha	B-Protein
PerCP	O
(	O
53	O
-	O
6	O
.	O
7	O
)	O
,	O
IFNgamma	B-Protein
Alexa	O
647	O
(	O
XMG1	O
.	O
2	O
)	O
and	O
CD16	B-Protein
/	O
32	O
(	O
2	O
.	O
4G2	O
)	O
from	O
BD	O
Pharmingen	O
.	O

Samples	O
were	O
acquired	O
on	O
a	O
LSRII	O
Cytometer	O
and	O
analyzed	O
using	O
FACSDiva	O
software	O
(	O
BD	O
Biosciences	O
)	O
.	O

Propidium	O
iodide	O
was	O
used	O
to	O
discriminate	O
between	O
live	O
and	O
dead	O
cells	O
.	O
<EOS>	B-X
Propidium	B-X
iodide	B-X
(	B-X
PI	B-X
)	B-X
is	B-X
a	B-X
small	B-X
fluorescent	B-X
molecule	B-X
that	B-X
binds	B-X
to	B-X
DNA	B-X
but	B-X
can	B-X
not	B-X
passively	B-X
traverse	B-X
into	B-X
cells	B-X
that	B-X
possess	B-X
an	B-X
intact	B-X
plasma	B-X
membrane	B-X
.	B-X
PI	B-X
uptake	B-X
versus	B-X
exclusion	B-X
can	B-X
be	B-X
used	B-X
to	B-X
discriminate	B-X
dead	B-X
cells	B-X
,	B-X
in	B-X
which	B-X
plasma	B-X
membranes	B-X
become	B-X
permeable	B-X
regardless	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
death	B-X
,	B-X
from	B-X
live	B-X
cells	B-X
with	B-X
intact	B-X
membranes	B-X
.	B-X
This	B-X
protocol	B-X
for	B-X
PI	B-X
staining	B-X
can	B-X
be	B-X
used	B-X
to	B-X
quantitate	B-X
cell	B-X
death	B-X
in	B-X
most	B-X
modern	B-X
research	B-X
facilities	B-X
and	B-X
universities	B-X
.	B-X
The	B-X
discrimination	B-X
between	B-X
dead	B-X
and	B-X
live	B-X
cells	B-X
is	B-X
crucial	B-X
for	B-X
cell	B-X
viability	B-X
evaluation	B-X
.	B-X
Carbon	B-X
dots	B-X
(	B-X
CDs	B-X
)	B-X
,	B-X
with	B-X
advantages	B-X
like	B-X
simple	B-X
and	B-X
cost-effective	B-X
synthesis	B-X
,	B-X
excellent	B-X
biocompatibility	B-X
,	B-X
and	B-X
high	B-X
photostability	B-X
,	B-X
have	B-X
shown	B-X
potential	B-X
for	B-X
realizing	B-X
selective	B-X
live/dead	B-X
cell	B-X
staining	B-X
.	B-X
However	B-X
,	B-X
most	B-X
of	B-X
the	B-X
developed	B-X
CDs	B-X
with	B-X
the	B-X
live/dead	B-X
cell	B-X
discrimination	B-X
capacity	B-X
usually	B-X
have	B-X
low	B-X
photoluminescence	B-X
quantum	B-X
yields	B-X
(	B-X
PLQYs	B-X
)	B-X
and	B-X
excitation	B-X
wavelength-dependent	B-X
fluorescence	B-X
emission	B-X
(	B-X
which	B-X
can	B-X
cause	B-X
fluorescence	B-X
overlap	B-X
with	B-X
other	B-X
fluorescent	B-X
probes	B-X
and	B-X
make	B-X
dual-color	B-X
live/dead	B-X
staining	B-X
impossible	B-X
)	B-X
,	B-X
and	B-X
hence	B-X
,	B-X
developing	B-X
ultrabright	B-X
CDs	B-X
with	B-X
excitation	B-X
wavelength-independent	B-X
fluorescence	B-X
emission	B-X
property	B-X
for	B-X
live/dead	B-X
cell	B-X
discrimination	B-X
becomes	B-X
an	B-X
important	B-X
task	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
a	B-X
one-pot	B-X
hydrothermal	B-X
method	B-X
,	B-X
we	B-X
prepared	B-X
ultrasmall	B-X
(	B-X
∼1.6	B-X
nm	B-X
)	B-X
,	B-X
ultrabright	B-X
(	B-X
PLQY	B-X
:	B-X
∼78	B-X
%	B-X
)	B-X
,	B-X
and	B-X
excitation	B-X
wavelength-independent	B-X
sulfur-doped	B-X
carbon	B-X
dots	B-X
(	B-X
termed	B-X
S-CDs	B-X
)	B-X
using	B-X
rose	B-X
bengal	B-X
and	B-X
1,4-dimercaptobenzene	B-X
as	B-X
raw	B-X
materials	B-X
and	B-X
demonstrated	B-X
that	B-X
the	B-X
S-CDs	B-X
could	B-X
rapidly	B-X
(	B-X
∼5	B-X
min	B-X
)	B-X
and	B-X
accurately	B-X
distinguish	B-X
dead	B-X
cells	B-X
from	B-X
live	B-X
ones	B-X
for	B-X
almost	B-X
all	B-X
the	B-X
cell	B-X
types	B-X
including	B-X
bacterial	B-X
,	B-X
fungal	B-X
,	B-X
and	B-X
animal	B-X
cells	B-X
in	B-X
a	B-X
wash-free	B-X
manner	B-X
.	B-X
We	B-X
confirmed	B-X
that	B-X
the	B-X
S-CDs	B-X
could	B-X
rapidly	B-X
pass	B-X
through	B-X
the	B-X
dead	B-X
cell	B-X
surfaces	B-X
to	B-X
enter	B-X
the	B-X
interior	B-X
of	B-X
the	B-X
dead	B-X
cells	B-X
,	B-X
thus	B-X
visualizing	B-X
these	B-X
dead	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
S-CDs	B-X
could	B-X
not	B-X
enter	B-X
the	B-X
interior	B-X
of	B-X
live	B-X
cells	B-X
and	B-X
thus	B-X
could	B-X
not	B-X
stain	B-X
these	B-X
live	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
verified	B-X
that	B-X
the	B-X
S-CDs	B-X
presented	B-X
better	B-X
biocompatibility	B-X
and	B-X
higher	B-X
photostability	B-X
than	B-X
the	B-X
commercial	B-X
live/dead	B-X
staining	B-X
dye	B-X
propidium	B-X
iodide	B-X
,	B-X
ensuring	B-X
its	B-X
bright	B-X
application	B-X
prospect	B-X
in	B-X
cell	B-X
imaging	B-X
and	B-X
cell	B-X
viability	B-X
assessment	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
work	B-X
develops	B-X
a	B-X
type	B-X
of	B-X
CDs	B-X
capable	B-X
of	B-X
realizing	B-X
the	B-X
live/dead	B-X
cell	B-X
discrimination	B-X
of	B-X
almost	B-X
all	B-X
the	B-X
cell	B-X
types	B-X
(	B-X
bacterial	B-X
,	B-X
fungal	B-X
,	B-X
and	B-X
animal	B-X
cells	B-X
)	B-X
,	B-X
which	B-X
has	B-X
seldom	B-X
been	B-X
achieved	B-X
by	B-X
other	B-X
fluorescent	B-X
nanoprobes	B-X
.	B-X

Cytokine	O
quantification	O
<EOS>	B-X
Cytokines	B-X
are	B-X
critical	B-X
mediators	B-X
that	B-X
oversee	B-X
and	B-X
regulate	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
via	B-X
complex	B-X
networks	B-X
and	B-X
serve	B-X
as	B-X
biomarkers	B-X
for	B-X
many	B-X
diseases	B-X
.	B-X
Cytokines	B-X
and	B-X
their	B-X
clinical	B-X
significance	B-X
are	B-X
introduced	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
their	B-X
pro-	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
.	B-X
Factors	B-X
affecting	B-X
cytokines	B-X
quantification	B-X
in	B-X
biological	B-X
fluids	B-X
,	B-X
native	B-X
levels	B-X
in	B-X
different	B-X
body	B-X
fluids	B-X
,	B-X
sample	B-X
processing	B-X
and	B-X
storage	B-X
conditions	B-X
,	B-X
sensitivity	B-X
to	B-X
freeze-thaw	B-X
,	B-X
and	B-X
soluble	B-X
cytokine	B-X
receptors	B-X
are	B-X
discussed	B-X
.	B-X
Various	B-X
quantification	B-X
platforms	B-X
for	B-X
high-sensitivity	B-X
and	B-X
reliable	B-X
measurement	B-X
of	B-X
cytokines	B-X
in	B-X
different	B-X
scenarios	B-X
are	B-X
discussed	B-X
,	B-X
and	B-X
commercially	B-X
available	B-X
cytokine	B-X
assays	B-X
are	B-X
compared	B-X
.	B-X
A	B-X
discussion	B-X
of	B-X
challenges	B-X
in	B-X
the	B-X
development	B-X
and	B-X
advancement	B-X
of	B-X
technologies	B-X
for	B-X
cytokine	B-X
quantification	B-X
that	B-X
aim	B-X
to	B-X
achieve	B-X
real-time	B-X
multiplex	B-X
cytokine	B-X
analysis	B-X
for	B-X
point-of-care	B-X
situations	B-X
applicable	B-X
for	B-X
both	B-X
biomedical	B-X
research	B-X
and	B-X
clinical	B-X
practice	B-X
are	B-X
discussed	B-X
.	B-X

For	O
TNF	B-Protein
ELISA	O
,	O
96	O
-	O
well	O
plates	O
were	O
coated	O
with	O
TNF	B-Protein
coating	O
(	O
TN3	O
-	O
19	O
,	O
eBioscience	O
)	O
and	O
detection	O
(	O
R4	O
-	O
6A2	O
,	O
eBioscience	O
)	O
antibodies	O
.	O

IFNalpha	O
and	O
IFNbeta	B-Protein
protein	O
levels	O
were	O
determined	O
with	O
an	O
ELISA	O
kit	O
(	O
PBL	O
Biomedical	O
Laboratories	O
)	O
.	O

For	O
IFNgamma	O
ELISA	O
,	O
96	O
-	O
well	O
plates	O
were	O
coated	O
with	O
IFNgamma	O
coating	O
(	O
XMG1	O
.	O
2	O
)	O
and	O
detection	O
(	O
R4	O
-	O
6A2	O
)	O
antibodies	O
(	O
eBiosciences	O
)	O
.	O

Detection	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
KC	B-Protein
,	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
BAL	O
fluid	O
was	O
performed	O
using	O
Bioplex	O
(	O
BioRad	O
)	O
technology	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Milliplex	O
technology	O
(	O
Millipore	O
)	O
was	O
used	O
for	O
the	O
detection	O
of	O
MIP	O
-	O
2	O
in	O
BAL	O
fluid	O
.	O

RNA	O
isolation	O
,	O
cDNA	O
synthesis	O
and	O
qPCR	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
scalable	B-X
method	B-X
for	B-X
measuring	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
following	B-X
RNAi	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
outlines	B-X
methods	B-X
to	B-X
transfect	B-X
cells	B-X
,	B-X
isolate	B-X
total	B-X
RNA	B-X
,	B-X
perform	B-X
cDNA	B-X
synthesis	B-X
,	B-X
run	B-X
qPCR	B-X
reactions	B-X
with	B-X
multiplexed	B-X
TaqMan	B-X
dual	B-X
hydrolysis	B-X
probes	B-X
,	B-X
and	B-X
analyze	B-X
the	B-X
results	B-X
from	B-X
qPCR	B-X
using	B-X
relative	B-X
quantification	B-X
(	B-X
Fleige	B-X
et	B-X
al.	B-X
,	B-X
2006	B-X
)	B-X
.	B-X
These	B-X
methods	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
relative	B-X
knockdown	B-X
of	B-X
a	B-X
set	B-X
of	B-X
siRNAs	B-X
against	B-X
a	B-X
target	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
the	B-X
most	B-X
effective	B-X
molecule	B-X
and	B-X
they	B-X
can	B-X
be	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
potency	B-X
of	B-X
a	B-X
siRNA	B-X
or	B-X
group	B-X
of	B-X
siRNAs	B-X
when	B-X
performed	B-X
over	B-X
a	B-X
range	B-X
of	B-X
doses	B-X
.	B-X
When	B-X
screening	B-X
panels	B-X
of	B-X
siRNAs	B-X
targeting	B-X
a	B-X
given	B-X
gene	B-X
,	B-X
knockdown	B-X
can	B-X
be	B-X
assessed	B-X
in	B-X
two	B-X
phases	B-X
.	B-X

Total	O
RNA	O
was	O
extracted	O
using	O
Aurum	O
Total	O
RNA	O
mini	O
kit	O
(	O
BioRad	O
)	O
and	O
reverse	O
transcribed	O
into	O
cDNA	O
with	O
iScript	O
cDNA	O
synthesis	O
kit	O
(	O
BioRad	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

qPCR	O
was	O
performed	O
by	O
using	O
SYBR	O
Green	O
I	O
master	O
mix	O
I	O
(	O
Roche	O
)	O
in	O
the	O
Lightcycler	O
480	O
detection	O
system	O
(	O
Roche	O
)	O
with	O
the	O
following	O
primers	O
:	O
HPRT	O
:	O
5	O
'	O
-	O
AGTGTTGGATACAGGCCAGAC	O
-	O
3	O
'	O
and	O
5	O
'	O
CGTGATTCAAATCCCTGAAGT	O
-	O
3	O
'	O
;	O
IL	B-Protein
-	I-Protein
6	I-Protein
:	O
5	O
'	O
-	O
GAGGATACCACTCCCAACAGACC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
AAGTGCATCATCGTTGTTCATACA	O
-	O
3	O
'	O
;	O
IFNbeta	B-Protein
:	O
5	O
'	O
-	O
TCAGAATGAGTGGTGGTTGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GACCTTTCAAATGCAGTAGATTCA	O
-	O
3	O
'	O
;	O
A20	B-Protein
:	O
5	O
'	O
-	O
AAACCAATGGTGATGGAAACTG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GTTGTCCCATTCGTCATTCC	O
-	O
3	O
'	O
;	O
CCL2	B-Protein
:	O
5	O
'	O
-	O
TTAAAAACCTGGATCGGAACCAA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GCATTAGCTTCAGATTTACGGGT	O
-	O
3	O
'	O
;	O
CXCL1	B-Protein
:	O
5	O
'	O
-	O
GAGCCTCTAACCAGTTCCAG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TGAGTGTGGCTATGACTTCG	O
-	O
3	O
'	O
and	O
IFNalpha4	B-Protein
:	O
5	O
'	O
-	O
TGATGAGCTACTACTGGTCAGC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GATCTCTTAGCACAAGGATGGC	O
-	O
3	O
'	O
.	O

Primers	O
were	O
designed	O
with	O
PerlPrimer	O
(	O
http	O
:	O
/	O
/	O
perlprimer	O
.	O
sourceforge	O
.	O
net	O
)	O
.	O
<EOS>	B-X
PerlPrimer	B-X
is	B-X
a	B-X
cross-platform	B-X
graphical	B-X
user	B-X
interface	B-X
application	B-X
for	B-X
the	B-X
design	B-X
of	B-X
primers	B-X
for	B-X
standard	B-X
,	B-X
bisulphite	B-X
and	B-X
real-time	B-X
PCR	B-X
,	B-X
and	B-X
sequencing	B-X
.	B-X

Quantification	O
was	O
performed	O
using	O
the	O
comparative	O
CT	O
method	O
(	O
deltadeltaCT	O
)	O
.	O
<EOS>	B-X
A	B-X
highly	B-X
sensitive	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
method	B-X
for	B-X
BCL2L12	B-X
mRNA	B-X
quantification	B-X
was	B-X
developed	B-X
using	B-X
SYBR	B-X
Green	B-X
chemistry	B-X
.	B-X
Relative	B-X
quantification	B-X
analysis	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
comparative	B-X
C	B-X
(	B-X
T	B-X
)	B-X
(	B-X
2	B-X
(	B-X
-ΔΔCT	B-X
)	B-X
)	B-X
method	B-X
.	B-X
A	B-X
highly	B-X
sensitive	B-X
and	B-X
specific	B-X
reverse	B-X
transcription	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
was	B-X
developed	B-X
for	B-X
quantification	B-X
of	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
BAX	B-X
and	B-X
BCL2	B-X
,	B-X
using	B-X
beta‑2	B-X
microglobulin	B-X
as	B-X
an	B-X
endogenous	B-X
control	B-X
for	B-X
normalization	B-X
purposes	B-X
.	B-X
Gene	B-X
expression	B-X
analysis	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
comparative	B-X
Ct	B-X
(	B-X
2	B-X
(	B-X
‑ΔΔCt	B-X
)	B-X
)	B-X
method	B-X
.	B-X

Results	O
are	O
expressed	O
relative	O
to	O
HPRT	O
values	O
.	O
<EOS>	B-X
Real-time	B-X
quantitative	B-X
PCR	B-X
(	B-X
RT-qPCR	B-X
)	B-X
is	B-X
a	B-X
widely	B-X
applied	B-X
technique	B-X
for	B-X
relative	B-X
quantification	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
expression	B-X
pattern	B-X
of	B-X
eight	B-X
RGs	B-X
(	B-X
ACTB	B-X
,	B-X
GAPDH	B-X
,	B-X
HPRT	B-X
,	B-X
YWHAZ	B-X
,	B-X
B2M	B-X
,	B-X
PPIA	B-X
,	B-X
TUBA	B-X
and	B-X
18S	B-X
)	B-X
were	B-X
evaluated	B-X
by	B-X
RT-qPCR	B-X
in	B-X
different	B-X
sample	B-X
groups	B-X
classified	B-X
based	B-X
on	B-X
genetic	B-X
background	B-X
,	B-X
muscle	B-X
tissue	B-X
type	B-X
,	B-X
and	B-X
growth	B-X
stage	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
a	B-X
C2C12	B-X
myoblast	B-X
cell	B-X
line	B-X
model	B-X
.	B-X
Collectively	B-X
,	B-X
ACTB	B-X
,	B-X
HPRT	B-X
and	B-X
YWHAZ	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
most	B-X
stable	B-X
RGs	B-X
,	B-X
while	B-X
GADPH	B-X
and	B-X
18S	B-X
were	B-X
the	B-X
least	B-X
stable	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
combined	B-X
use	B-X
of	B-X
ACTB	B-X
,	B-X
HPRT	B-X
and	B-X
YWHAZ	B-X
is	B-X
recommended	B-X
for	B-X
the	B-X
normalization	B-X
of	B-X
gene	B-X
expression	B-X
results	B-X
in	B-X
experiments	B-X
with	B-X
murine	B-X
skeletal	B-X
muscle	B-X
.	B-X

Statistics	O
<EOS>	B-X
Statistics	B-X
is	B-X
the	B-X
science	B-X
of	B-X
data	B-X
.	B-X
Appropriate	B-X
Statistics	B-X
for	B-X
Determining	B-X
Chance-Removed	B-X
Interpractitioner	B-X
Agreement	B-X
.	B-X
Statistics	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
diagonally	B-X
weighted	B-X
least	B-X
squares	B-X
(	B-X
cat-DWLS	B-X
)	B-X
estimator	B-X
and	B-X
with	B-X
the	B-X
unweighted	B-X
least	B-X
squares	B-X
(	B-X
cat-ULS	B-X
)	B-X
estimator	B-X
were	B-X
studied	B-X
.	B-X
This	B-X
fourth	B-X
installment	B-X
of	B-X
Explorations	B-X
in	B-X
Statistics	B-X
explores	B-X
the	B-X
bootstrap	B-X
.	B-X

Results	O
are	O
expressed	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
PEDOT/Cs/Gel	B-X
scaffolds	B-X
were	B-X
characterized	B-X
by	B-X
scanning	B-X
electron	B-X
microscopy	B-X
(	B-X
SEM	B-X
)	B-X
,	B-X
Fourier	B-X
transform	B-X
infrared	B-X
spectroscopy	B-X
(	B-X
FTIR	B-X
)	B-X
,	B-X
and	B-X
Raman	B-X
spectroscopy	B-X
.	B-X
The	B-X
results	B-X
confirmed	B-X
the	B-X
deposition	B-X
of	B-X
PEDOT	B-X
nanoparticles	B-X
with	B-X
the	B-X
mean	B-X
diameter	B-X
of	B-X
50	B-X
nm	B-X
on	B-X
the	B-X
Cs/Gel	B-X
scaffold	B-X
channel	B-X
surface	B-X
.	B-X
The	B-X
accurate	B-X
normalization	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
in	B-X
lung	B-X
cancer	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
novel	B-X
therapeutic	B-X
targets	B-X
and	B-X
biomarkers	B-X
by	B-X
real	B-X
time	B-X
RT-PCR	B-X
and	B-X
microarrays	B-X
.	B-X
The	B-X
role	B-X
of	B-X
ELAM-1	B-X
gene	B-X
in	B-X
mediating	B-X
the	B-X
adhesion	B-X
of	B-X
tumor	B-X
cells	B-X
to	B-X
endothelial	B-X
cells	B-X
by	B-X
binding	B-X
to	B-X
ELAM-1	B-X
ligands	B-X
expressed	B-X
by	B-X
eosinophils	B-X
,	B-X
neutrophils	B-X
,	B-X
monocytes	B-X
,	B-X
natural	B-X
killer	B-X
cell	B-X
effectors	B-X
,	B-X
T	B-X
lymphocyte	B-X
cells	B-X
,	B-X
and	B-X
cancer	B-X
(	B-X
progenitor/stem	B-X
)	B-X
cells	B-X
is	B-X
well	B-X
studied	B-X
.	B-X

Statistical	O
significance	O
between	O
groups	O
was	O
assessed	O
using	O
two	O
-	O
way	O
ANOVA	O
.	O
<EOS>	B-X
If	B-X
the	B-X
distribution	B-X
is	B-X
uncertain	B-X
,	B-X
the	B-X
data	B-X
can	B-X
be	B-X
plotted	B-X
as	B-X
a	B-X
normal	B-X
probability	B-X
plot	B-X
and	B-X
visually	B-X
inspected	B-X
,	B-X
or	B-X
tested	B-X
for	B-X
normality	B-X
using	B-X
one	B-X
of	B-X
a	B-X
number	B-X
of	B-X
goodness	B-X
of	B-X
fit	B-X
tests	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Kolmogorov-Smirnov	B-X
test	B-X
.	B-X
The	B-X
means	B-X
of	B-X
two	B-X
independent	B-X
samples	B-X
may	B-X
be	B-X
compared	B-X
for	B-X
a	B-X
statistically	B-X
significant	B-X
difference	B-X
by	B-X
the	B-X
unpaired	B-X
or	B-X
independent	B-X
samples	B-X
t-test	B-X
.	B-X
If	B-X
the	B-X
data	B-X
sets	B-X
are	B-X
related	B-X
in	B-X
some	B-X
way	B-X
,	B-X
their	B-X
means	B-X
may	B-X
be	B-X
compared	B-X
by	B-X
the	B-X
paired	B-X
or	B-X
dependent	B-X
samples	B-X
t-test	B-X
.	B-X
The	B-X
t-test	B-X
should	B-X
not	B-X
be	B-X
used	B-X
to	B-X
compare	B-X
the	B-X
means	B-X
of	B-X
more	B-X
than	B-X
two	B-X
groups	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
compare	B-X
groups	B-X
in	B-X
pairs	B-X
,	B-X
when	B-X
there	B-X
are	B-X
more	B-X
than	B-X
two	B-X
groups	B-X
,	B-X
this	B-X
will	B-X
increase	B-X
the	B-X
probability	B-X
of	B-X
a	B-X
Type	B-X
I	B-X
error	B-X
.	B-X
The	B-X
one-way	B-X
analysis	B-X
of	B-X
variance	B-X
(	B-X
ANOVA	B-X
)	B-X
is	B-X
employed	B-X
to	B-X
compare	B-X
the	B-X
means	B-X
of	B-X
three	B-X
or	B-X
more	B-X
independent	B-X
data	B-X
sets	B-X
that	B-X
are	B-X
normally	B-X
distributed	B-X
.	B-X
Comparison	B-X
of	B-X
means	B-X
in	B-X
such	B-X
a	B-X
situation	B-X
requires	B-X
repeated	B-X
measures	B-X
ANOVA	B-X
.	B-X
It	B-X
is	B-X
to	B-X
be	B-X
noted	B-X
that	B-X
while	B-X
a	B-X
multiple	B-X
group	B-X
comparison	B-X
test	B-X
such	B-X
as	B-X
ANOVA	B-X
can	B-X
point	B-X
to	B-X
a	B-X
significant	B-X
difference	B-X
,	B-X
it	B-X
does	B-X
not	B-X
identify	B-X
exactly	B-X
between	B-X
which	B-X
two	B-X
groups	B-X
the	B-X
difference	B-X
lies	B-X
.	B-X
An	B-X
example	B-X
is	B-X
the	B-X
Tukey	B-X
's	B-X
honestly	B-X
significant	B-X
difference	B-X
test	B-X
following	B-X
ANOVA	B-X
.	B-X
These	B-X
include	B-X
Mann-Whitney	B-X
U-test	B-X
as	B-X
the	B-X
nonparametric	B-X
counterpart	B-X
of	B-X
the	B-X
unpaired	B-X
Student	B-X
's	B-X
t-test	B-X
,	B-X
Wilcoxon	B-X
signed-rank	B-X
test	B-X
as	B-X
the	B-X
counterpart	B-X
of	B-X
the	B-X
paired	B-X
Student	B-X
's	B-X
t-test	B-X
,	B-X
Kruskal-Wallis	B-X
test	B-X
as	B-X
the	B-X
nonparametric	B-X
equivalent	B-X
of	B-X
ANOVA	B-X
and	B-X
the	B-X
Friedman	B-X
's	B-X
test	B-X
as	B-X
the	B-X
counterpart	B-X
of	B-X
repeated	B-X
measures	B-X
ANOVA	B-X
.	B-X

The	O
differences	O
for	O
in	O
vivo	O
experiments	O
(	O
at	O
least	O
5	O
mice	O
per	O
group	O
)	O
were	O
calculated	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
for	O
unpaired	O
data	O
.	O

Statistical	O
significance	O
of	O
differences	O
between	O
survival	O
rates	O
was	O
analyzed	O
by	O
comparing	O
Kaplan	O
-	O
Meier	O
curves	O
using	O
the	O
log	O
-	O
rank	O
test	O
(	O
GraphPad	O
Prism	O
version	O
5	O
,	O
GraphPad	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

A20	O
inhibits	O
NF	O
-	O
kappaB	O
and	O
IRF3	B-Protein
activation	O
in	O
response	O
to	O
RIG	B-Protein
-	I-Protein
I	I-Protein
stimulation	O
.	O

(	O
A	O
)	O
HEK293T	O
cells	O
were	O
transfected	O
with	O
NF	O
-	O
kappaB	O
(	O
left	O
)	O
,	O
IRF3	B-Protein
(	O
middle	O
)	O
or	O
IRF7	B-Protein
dependent	O
luciferase	B-Protein
reporter	O
(	O
right	O
)	O
plasmids	O
,	O
together	O
with	O
plasmids	O
expressing	O
RIG	O
-	O
I	O
(	O
2CARD	O
)	O
,	O
IRF7	B-Protein
(	O
right	O
)	O
and	O
increasing	O
amounts	O
of	O
A20	O
.	O

Luciferase	O
activity	O
in	O
cell	O
extracts	O
was	O
analyzed	O
in	O
a	O
luminometer	O
.	O

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SD	O
of	O
3	O
samples	O
per	O
set	O
-	O
up	O
.	O
<EOS>	B-X
Data	B-X
have	B-X
been	B-X
collected	B-X
from	B-X
the	B-X
Tuscany	B-X
regional	B-X
hospital	B-X
discharge	B-X
register	B-X
,	B-X
extracting	B-X
the	B-X
relative	B-X
Hospital	B-X
Discharge	B-X
Forms	B-X
(	B-X
SDO	B-X
)	B-X
.	B-X
During	B-X
the	B-X
period	B-X
of	B-X
the	B-X
study	B-X
,	B-X
1537	B-X
patients	B-X
underwent	B-X
uncemented	B-X
total	B-X
hip	B-X
arthroplasty	B-X
for	B-X
osteoarthritis	B-X
or	B-X
avascular	B-X
necrosis	B-X
.	B-X
The	B-X
sample	B-X
was	B-X
divided	B-X
in	B-X
two	B-X
subgroups	B-X
:	B-X
1142	B-X
patients	B-X
(	B-X
74.3	B-X
%	B-X
)	B-X
operated	B-X
on	B-X
with	B-X
standard	B-X
manual	B-X
technique	B-X
and	B-X
395	B-X
patients	B-X
(	B-X
25.7	B-X
%	B-X
)	B-X
operated	B-X
on	B-X
with	B-X
Mako-	B-X
Stryker	B-X
Robotic	B-X
System	B-X
.	B-X
The	B-X
significance	B-X
threshold	B-X
was	B-X
set	B-X
up	B-X
at	B-X
p	B-X
<	B-X
0.05	B-X
.	B-X
During	B-X
the	B-X
period	B-X
of	B-X
the	B-X
study	B-X
we	B-X
observed	B-X
a	B-X
decrease	B-X
in	B-X
standard	B-X
surgery	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
robotic	B-X
surgery	B-X
;	B-X
an	B-X
increasing	B-X
number	B-X
of	B-X
women	B-X
per	B-X
year	B-X
underwent	B-X
total	B-X
uncemented	B-X
total	B-X
hip	B-X
arthroplasty	B-X
.	B-X
We	B-X
found	B-X
a	B-X
statistical	B-X
significance	B-X
in	B-X
favor	B-X
of	B-X
robotic	B-X
procedures	B-X
in	B-X
terms	B-X
of	B-X
transfusion	B-X
percentage	B-X
(	B-X
OR	B-X
6.10	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
2.96-12.59	B-X
,	B-X
p	B-X
<	B-X
0,001	B-X
)	B-X
,	B-X
highlighting	B-X
the	B-X
greatest	B-X
risk	B-X
in	B-X
women	B-X
(	B-X
OR	B-X
1.90	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
1.30-2.78	B-X
,	B-X
p=0.001	B-X
)	B-X
,	B-X
length	B-X
of	B-X
hospital	B-X
stay	B-X
(	B-X
Mr=4.24	B-X
,	B-X
SD=2.04	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
4.04-4.44	B-X
)	B-X
(	B-X
Ms=8.04	B-X
,	B-X
SD=2.84	B-X
,	B-X
95	B-X
%	B-X
CI	B-X
7.88-8.21	B-X
)	B-X
,	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
Operative	B-X
time	B-X
in	B-X
the	B-X
robotic	B-X
sample	B-X
decreased	B-X
substantially	B-X
with	B-X
the	B-X
rise	B-X
of	B-X
surgical	B-X
experience	B-X
(	B-X
106.75±13.4	B-X
mins	B-X
in	B-X
2014	B-X
;	B-X
82.79±15.95	B-X
mins	B-X
in	B-X
2018	B-X
)	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
Our	B-X
paper	B-X
,	B-X
comparing	B-X
conventional	B-X
vs	B-X
robotic	B-X
assisted	B-X
THA	B-X
,	B-X
showed	B-X
in	B-X
favor	B-X
of	B-X
the	B-X
robotic	B-X
one	B-X
,	B-X
a	B-X
statistically	B-X
significant	B-X
reduction	B-X
of	B-X
number	B-X
of	B-X
transfusions	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
length	B-X
of	B-X
hospital	B-X
stay	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X

(	O
B	O
-	O
D	O
)	O
A20myel	O
-	O
KO	O
and	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
BMDM	O
were	O
transfected	O
with	O
LMW	O
poly	O
(	O
I	O
:	O
C	O
)	O
and	O
analyzed	O
at	O
different	O
time	O
points	O
(	O
minutes	O
)	O
after	O
the	O
start	O
of	O
transfection	O
for	O
IkappaBalpha	B-Protein
phosphorylation	O
and	O
degradation	O
,	O
and	O
IRF3	B-Protein
phosphorylation	O
by	O
immunoblotting	O
of	O
total	O
cell	O
extracts	O
(	O
B	O
)	O
.	O

The	O
band	O
that	O
is	O
non	O
-	O
specifically	O
recognized	O
by	O
the	O
anti	O
-	O
IkappaBalpha	O
antibody	O
(	O
indicated	O
by	O
an	O
asterisk	O
)	O
can	O
be	O
used	O
as	O
a	O
loading	O
control	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p65	B-Protein
)	O
and	O
IRF3	B-Protein
was	O
analyzed	O
by	O
immunoblotting	O
of	O
cytoplasmic	O
or	O
nuclear	O
fractions	O
(	O
C	O
)	O
.	O
<EOS>	B-X
By	B-X
surveying	B-X
the	B-X
subcellular	B-X
localizations	B-X
of	B-X
human	B-X
deubiquitylases	B-X
,	B-X
USP42	B-X
was	B-X
identified	B-X
to	B-X
form	B-X
nuclear	B-X
punctate	B-X
structures	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
phase	B-X
separation	B-X
properties	B-X
.	B-X
Bioinformatic	B-X
analysis	B-X
demonstrated	B-X
that	B-X
the	B-X
USP42	B-X
C-terminal	B-X
sequence	B-X
was	B-X
intrinsically	B-X
disordered	B-X
,	B-X
which	B-X
was	B-X
further	B-X
experimentally	B-X
confirmed	B-X
to	B-X
confer	B-X
phase	B-X
separation	B-X
features	B-X
.	B-X
USP42	B-X
is	B-X
distributed	B-X
to	B-X
SC35-positive	B-X
nuclear	B-X
speckles	B-X
in	B-X
a	B-X
positively	B-X
charged	B-X
C-terminal	B-X
residue-	B-X
and	B-X
enzymatic	B-X
activity-dependent	B-X
manner	B-X
.	B-X
Notably	B-X
,	B-X
USP42	B-X
directs	B-X
the	B-X
integration	B-X
of	B-X
the	B-X
spliceosome	B-X
component	B-X
PLRG1	B-X
into	B-X
nuclear	B-X
speckles	B-X
,	B-X
and	B-X
its	B-X
depletion	B-X
interferes	B-X
with	B-X
the	B-X
conformation	B-X
of	B-X
SC35	B-X
foci	B-X
.	B-X
As	B-X
a	B-X
deubiquitylase	B-X
capable	B-X
of	B-X
dynamically	B-X
guiding	B-X
nuclear	B-X
speckle	B-X
phase	B-X
separation	B-X
and	B-X
mRNA	B-X
splicing	B-X
,	B-X
USP42	B-X
inhibition	B-X
presents	B-X
a	B-X
novel	B-X
anticancer	B-X
strategy	B-X
by	B-X
targeting	B-X
phase	B-X
separation	B-X
.	B-X

Quantification	O
of	O
band	O
density	O
for	O
nuclear	O
p65	B-Protein
and	O
IRF3	B-Protein
is	O
shown	O
in	O
bar	O
graphs	O
(	O
expressed	O
as	O
relative	O
density	O
compared	O
to	O
the	O
first	O
lane	O
;	O
=	O
time	O
0	O
)	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
levels	O
in	O
the	O
supernatant	O
of	O
cells	O
used	O
in	O
(	O
B	O
)	O
were	O
determined	O
by	O
bioassay	O
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
and	O
ELISA	O
(	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
)	O
as	O
described	O
in	O
the	O
'	O
materials	O
and	O
methods	O
'	O
section	O
(	O
D	O
)	O
.	O

Data	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O
<EOS>	B-X
No	B-X
independent	B-X
cross-validation	B-X
of	B-X
success	B-X
rate	B-X
for	B-X
studies	B-X
utilizing	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
for	B-X
gene	B-X
silencing	B-X
has	B-X
been	B-X
completed	B-X
before	B-X
.	B-X
We	B-X
utilized	B-X
gene	B-X
chip	B-X
data	B-X
published	B-X
for	B-X
siRNA	B-X
experiments	B-X
to	B-X
assess	B-X
success	B-X
rate	B-X
and	B-X
to	B-X
compare	B-X
methods	B-X
used	B-X
in	B-X
these	B-X
experiments	B-X
.	B-X
All	B-X
together	B-X
1,643	B-X
samples	B-X
representing	B-X
429	B-X
experiments	B-X
published	B-X
in	B-X
207	B-X
studies	B-X
were	B-X
evaluated	B-X
.	B-X
The	B-X
fold	B-X
change	B-X
(	B-X
FC	B-X
)	B-X
of	B-X
down-regulation	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
was	B-X
above	B-X
0.7	B-X
in	B-X
18.5	B-X
%	B-X
and	B-X
was	B-X
above	B-X
0.5	B-X
in	B-X
38.7	B-X
%	B-X
of	B-X
experiments	B-X
.	B-X
Studies	B-X
utilizing	B-X
Western	B-X
blot	B-X
for	B-X
validation	B-X
performed	B-X
better	B-X
than	B-X
those	B-X
with	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
or	B-X
microarray	B-X
(	B-X
FC	B-X
=	B-X
0.43	B-X
,	B-X
FC	B-X
=	B-X
0.47	B-X
,	B-X
and	B-X
FC	B-X
=	B-X
0.55	B-X
,	B-X
respectively	B-X
,	B-X
P	B-X
=	B-X
2.8E-04	B-X
)	B-X
.	B-X
Although	B-X
gene	B-X
silencing	B-X
is	B-X
a	B-X
robust	B-X
feature	B-X
successfully	B-X
cross-validated	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
experiments	B-X
,	B-X
efficiency	B-X
remained	B-X
insufficient	B-X
in	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
studies	B-X
.	B-X

A20	O
negatively	O
regulates	O
IAV	O
-	O
induced	O
gene	O
expression	O
in	O
BMDM	O
and	O
alveolar	O
macrophages	O
.	O

(	O
A	O
-	O
B	O
)	O
BMDM	O
isolated	O
from	O
A20myel	O
-	O
WT	O
and	O
A20myel	O
-	O
KO	O
animals	O
were	O
infected	O
with	O
IAV	O
(	O
moi	O
1	O
)	O
.	O

At	O
different	O
hours	O
post	O
infection	O
(	O
hours	O
p	O
.	O
i	O
.	O
)	O
cells	O
were	O
lysed	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IFNbeta	B-Protein
and	O
A20	O
mRNA	O
expression	O
was	O
analyzed	O
by	O
qPCR	O
(	O
A	O
)	O
.	O

18	O
hours	O
post	O
infection	O
cell	O
culture	O
supernatant	O
was	O
analyzed	O
for	O
TNF	B-Protein
and	O
IFNbeta	B-Protein
protein	O
levels	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
B	O
)	O
.	O

(	O
C	O
-	O
D	O
)	O
Alveolar	O
macrophages	O
were	O
mock	O
treated	O
or	O
infected	O
with	O
IAV	O
(	O
moi	O
1	O
)	O
for	O
18	O
hours	O
.	O
<EOS>	B-X
The	B-X
influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
2009	B-X
H1N1	B-X
pandemic	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
maternal	B-X
mortality	B-X
,	B-X
preterm	B-X
birth	B-X
,	B-X
and	B-X
stillbirth	B-X
.	B-X
The	B-X
underlying	B-X
mechanism	B-X
for	B-X
severe	B-X
maternal	B-X
lung	B-X
disease	B-X
and	B-X
stillbirth	B-X
is	B-X
incompletely	B-X
understood	B-X
,	B-X
but	B-X
IAV	B-X
infection	B-X
is	B-X
known	B-X
to	B-X
activate	B-X
innate	B-X
immunity	B-X
triggering	B-X
the	B-X
release	B-X
of	B-X
cytokines	B-X
.	B-X
Elucidating	B-X
the	B-X
impact	B-X
of	B-X
progesterone	B-X
(	B-X
P4	B-X
)	B-X
,	B-X
a	B-X
key	B-X
hormone	B-X
elevated	B-X
in	B-X
pregnancy	B-X
,	B-X
on	B-X
the	B-X
innate	B-X
immune	B-X
and	B-X
inflammatory	B-X
response	B-X
to	B-X
IAV	B-X
infection	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
understanding	B-X
the	B-X
pathogenesis	B-X
of	B-X
adverse	B-X
maternal-fetal	B-X
outcomes	B-X
.	B-X
IAV	B-X
H1N1	B-X
pdm/09	B-X
was	B-X
used	B-X
to	B-X
infect	B-X
cell	B-X
lines	B-X
Calu-3	B-X
(	B-X
lung	B-X
adenoma	B-X
)	B-X
and	B-X
ACH-3P	B-X
(	B-X
extravillous	B-X
trophoblast	B-X
)	B-X
with	B-X
or	B-X
without	B-X
P4	B-X
(	B-X
100	B-X
nM	B-X
)	B-X
at	B-X
multiplicity	B-X
of	B-X
infections	B-X
(	B-X
MOI	B-X
)	B-X
0	B-X
,	B-X
0.5	B-X
,	B-X
and	B-X
3	B-X
.	B-X
Cells	B-X
were	B-X
harvested	B-X
at	B-X
24	B-X
and	B-X
48	B-X
hours	B-X
post	B-X
infection	B-X
(	B-X
hpi	B-X
)	B-X
and	B-X
analyzed	B-X
for	B-X
cytopathic	B-X
effects	B-X
(	B-X
CPE	B-X
)	B-X
,	B-X
replicating	B-X
virus	B-X
(	B-X
TCID50	B-X
)	B-X
,	B-X
cytotoxicity	B-X
(	B-X
Lactate	B-X
Dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
assay	B-X
)	B-X
,	B-X
and	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
(	B-X
caspase-1	B-X
activity	B-X
,	B-X
fluorometric	B-X
assay	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
antiviral	B-X
innate	B-X
immunity	B-X
was	B-X
quantified	B-X
(	B-X
RT-qPCR	B-X
,	B-X
Luminex	B-X
)	B-X
by	B-X
measuring	B-X
biomarker	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
innate	B-X
immune	B-X
activation	B-X
(	B-X

IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
mRNA	O
expression	O
was	O
determined	O
by	O
qPCR	O
(	O
C	O
)	O
.	O
<EOS>	B-X
Theiler	B-X
's	B-X
murine	B-X
encephalomyelitis	B-X
virus	B-X
(	B-X
TMEV	B-X
)	B-X
is	B-X
a	B-X
single-stranded	B-X
RNA	B-X
virus	B-X
that	B-X
causes	B-X
encephalitis	B-X
followed	B-X
by	B-X
chronic	B-X
demyelination	B-X
in	B-X
SJL	B-X
mice	B-X
and	B-X
spontaneous	B-X
seizures	B-X
in	B-X
C57BL/6	B-X
mice	B-X
.	B-X
Since	B-X
earlier	B-X
studies	B-X
indicated	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
type	B-X
I	B-X
interferon	B-X
(	B-X
IFN-I	B-X
)	B-X
signaling	B-X
in	B-X
the	B-X
control	B-X
of	B-X
viral	B-X
replication	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
,	B-X
mouse	B-X
strain-specific	B-X
differences	B-X
in	B-X
pathways	B-X
induced	B-X
by	B-X
the	B-X
IFN-I	B-X
receptor	B-X
(	B-X
IFNAR	B-X
)	B-X
might	B-X
determine	B-X
the	B-X
outcome	B-X
of	B-X
TMEV	B-X
infection	B-X
.	B-X

Cell	O
culture	O
supernatant	O
was	O
analyzed	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNbeta	B-Protein
protein	O
levels	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
D	O
)	O
.	O

Error	O
bars	O
represent	O
mean	O
values	O
(	O
+	O
/	O
-	O
SEM	O
)	O
of	O
2	O
-	O
3	O
samples	O
.	O

Results	O
are	O
representative	O
for	O
2	O
independent	O
experiments	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
single-cell	B-X
RNA	B-X
sequencing	B-X
was	B-X
performed	B-X
on	B-X
macular	B-X
and	B-X
peripheral	B-X
regions	B-X
of	B-X
RPE-choroid	B-X
from	B-X
7	B-X
human	B-X
donor	B-X
eyes	B-X
in	B-X
2	B-X
independent	B-X
experiments	B-X
.	B-X
We	B-X
report	B-X
five	B-X
experiments	B-X
that	B-X
investigate	B-X
how	B-X
the	B-X
different	B-X
perspectives	B-X
adopted	B-X
while	B-X
experiencing	B-X
entities	B-X
are	B-X
reflected	B-X
in	B-X
conceptualizations	B-X
(	B-X
towards	B-X
vs.	B-X
away	B-X
,	B-X
near	B-X
vs.	B-X
far	B-X
,	B-X
beside	B-X
vs.	B-X
above	B-X
,	B-X
inside	B-X
vs.	B-X
outside	B-X
and	B-X
vision	B-X
vs.	B-X
audition	B-X
vs.	B-X
touch	B-X
)	B-X
.	B-X
If	B-X
conceptualizations	B-X
have	B-X
perspectives	B-X
,	B-X
then	B-X
participants	B-X
should	B-X
produce	B-X
features	B-X
from	B-X
a	B-X
perspective	B-X
entrenched	B-X
in	B-X
memory	B-X
that	B-X
reflects	B-X
typical	B-X
interactions	B-X
with	B-X
objects	B-X
,	B-X
independently	B-X
of	B-X
their	B-X
assigned	B-X
perspective	B-X
(	B-X
entrenched	B-X
perspective	B-X
)	B-X
.	B-X
Results	B-X
across	B-X
the	B-X
experiments	B-X
indicate	B-X
that	B-X
conceptualizations	B-X
contain	B-X
both	B-X
entrenched	B-X
and	B-X
situational	B-X
perspectives	B-X
.	B-X

*	O
*	O
*	O
p	O
<	O
0	O
,	O
001	O
.	O
<EOS>	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Vaccine	B-X
effectiveness	B-X
against	B-X
COVID-19	B-X
beyond	B-X
6	B-X
months	B-X
remains	B-X
incompletely	B-X
understood	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effectiveness	B-X
of	B-X
COVID-19	B-X
vaccination	B-X
against	B-X
the	B-X
risk	B-X
of	B-X
infection	B-X
,	B-X
hospitalisation	B-X
,	B-X
and	B-X
death	B-X
during	B-X
the	B-X
first	B-X
9	B-X
months	B-X
after	B-X
vaccination	B-X
for	B-X
the	B-X
total	B-X
population	B-X
of	B-X
Sweden	B-X
.	B-X

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
IAV	O
lung	O
infection	O
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

A20myel	O
-	O
WT	O
and	O
A20myel	O
-	O
KO	O
mice	O
were	O
infected	O
intranasally	O
with	O
a	O
sublethal	O
dose	O
of	O
IAV	O
and	O
weight	O
loss	O
was	O
monitored	O
(	O
A	O
)	O
.	O

At	O
day	O
4	O
,	O
7	O
and	O
10	O
post	O
infection	O
(	O
p	O
.	O
i	O
.	O
)	O
viral	O
titers	O
in	O
the	O
lung	O
were	O
measured	O
and	O
expressed	O
as	O
mean	O
TCID50	O
(	O
B	O
)	O
.	O

The	O
dashed	O
line	O
represents	O
the	O
detection	O
limit	O
.	O

ND	O
,	O
not	O
detectable	O
.	O

BAL	O
was	O
isolated	O
from	O
IAV	O
infected	O
mice	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
p	O
.	O
i	O
.	O
and	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNalpha	O
protein	O
levels	O
were	O
analyzed	O
by	O
ELISA	O
and	O
multiplexing	O
technologies	O
(	O
C	O
)	O
.	O

Absolute	O
numbers	O
of	O
resident	O
alveolar	O
macrophages	O
,	O
neutrophils	O
and	O
monocytes	O
in	O
BAL	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
4	O
,	O
7	O
and	O
10	O
days	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
.	O
<EOS>	B-X
Understanding	B-X
vitamin	B-X
D	B-X
deficiency	B-X
.	B-X

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
5	O
mice	O
per	O
group	O
and	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

A20	O
deficiency	O
in	O
myeloid	O
cells	O
protects	O
against	O
lethal	O
IAV	O
infection	O
.	O
<EOS>	B-X
Influenza	B-X
A	B-X
virus	B-X
(	B-X
IAV	B-X
)	B-X
produces	B-X
double-stranded	B-X
RNA	B-X
as	B-X
an	B-X
intermediate	B-X
during	B-X
the	B-X
replication	B-X
life	B-X
cycle	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
intracellular	B-X
pathogen	B-X
recognition	B-X
receptor	B-X
RIG-I	B-X
and	B-X
induces	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
antiviral	B-X
interferon	B-X
.	B-X
Understanding	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
innate	B-X
immune	B-X
responses	B-X
to	B-X
IAV	B-X
and	B-X
other	B-X
viruses	B-X
is	B-X
of	B-X
key	B-X
importance	B-X
to	B-X
develop	B-X
novel	B-X
therapeutic	B-X
strategies	B-X
.	B-X
Here	B-X
we	B-X
used	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
to	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
the	B-X
ubiquitin-editing	B-X
protein	B-X
A20	B-X
in	B-X
the	B-X
response	B-X
of	B-X
myeloid	B-X
cells	B-X
to	B-X
IAV	B-X
infection	B-X
.	B-X
A20	B-X
deficient	B-X
macrophages	B-X
were	B-X
hyperresponsive	B-X
to	B-X
double	B-X
stranded	B-X
RNA	B-X
and	B-X
IAV	B-X
infection	B-X
,	B-X
as	B-X
illustrated	B-X
by	B-X
enhanced	B-X
NF-κB	B-X
and	B-X
IRF3	B-X
activation	B-X
,	B-X
concomitant	B-X
with	B-X
increased	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
chemokines	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
.	B-X
In	B-X
vivo	B-X
this	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
number	B-X
of	B-X
alveolar	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
IAV	B-X
infected	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
myeloid	B-X
cell	B-X
specific	B-X
A20	B-X
knockout	B-X
mice	B-X
are	B-X
protected	B-X
against	B-X
lethal	B-X
IAV	B-X
infection	B-X
.	B-X
These	B-X
results	B-X
challenge	B-X
the	B-X
general	B-X
belief	B-X
that	B-X
an	B-X
excessive	B-X
host	B-X
proinflammatory	B-X
response	B-X
is	B-X
associated	B-X
with	B-X
IAV-induced	B-X
lethality	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
under	B-X
certain	B-X
conditions	B-X
inhibition	B-X
of	B-X
A20	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
management	B-X
of	B-X
IAV	B-X
infections	B-X
.	B-X

A20myel	O
-	O
WT	O
(	O
n	O
=	O
11	O
)	O
and	O
A20myel	O
-	O
KO	O
(	O
n	O
=	O
11	O
)	O
mice	O
were	O
intranasally	O
infected	O
with	O
a	O
lethal	O
dose	O
of	O
IAV	O
and	O
survival	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
A	O
)	O
and	O
weight	O
loss	O
+	O
/	O
-	O
SEM	O
(	O
B	O
)	O
was	O
monitored	O
for	O
respectively	O
21	O
and	O
15	O
days	O
p	O
.	O
i	O
.	O

BAL	O
fluid	O
was	O
collected	O
from	O
wild	O
type	O
(	O
A20myel	O
-	O
WT	O
)	O
and	O
A20myel	O
-	O
KO	O
mice	O
6	O
days	O
following	O
infection	O
with	O
a	O
lethal	O
dose	O
IAV	O
and	O
KC	B-Protein
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
,	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IFNalpha	B-Protein
protein	O
levels	O
were	O
determined	O
(	O
C	O
)	O
.	O

Absolute	O
numbers	O
of	O
alveolar	O
macrophages	O
,	O
neutrophils	O
and	O
monocytes	O
in	O
BAL	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
6	O
days	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
.	O
<EOS>	B-X
Understanding	B-X
vitamin	B-X
D	B-X
deficiency	B-X
.	B-X

Numbers	O
are	O
averages	O
+	O
/	O
-	O
SEM	O
of	O
at	O
least	O
5	O
mice	O
per	O
group	O
.	O

Data	O
are	O
representative	O
of	O
2	O
independent	O
experiments	O
.	O
<EOS>	B-X
No	B-X
independent	B-X
cross-validation	B-X
of	B-X
success	B-X
rate	B-X
for	B-X
studies	B-X
utilizing	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
for	B-X
gene	B-X
silencing	B-X
has	B-X
been	B-X
completed	B-X
before	B-X
.	B-X
We	B-X
utilized	B-X
gene	B-X
chip	B-X
data	B-X
published	B-X
for	B-X
siRNA	B-X
experiments	B-X
to	B-X
assess	B-X
success	B-X
rate	B-X
and	B-X
to	B-X
compare	B-X
methods	B-X
used	B-X
in	B-X
these	B-X
experiments	B-X
.	B-X
All	B-X
together	B-X
1,643	B-X
samples	B-X
representing	B-X
429	B-X
experiments	B-X
published	B-X
in	B-X
207	B-X
studies	B-X
were	B-X
evaluated	B-X
.	B-X
The	B-X
fold	B-X
change	B-X
(	B-X
FC	B-X
)	B-X
of	B-X
down-regulation	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
was	B-X
above	B-X
0.7	B-X
in	B-X
18.5	B-X
%	B-X
and	B-X
was	B-X
above	B-X
0.5	B-X
in	B-X
38.7	B-X
%	B-X
of	B-X
experiments	B-X
.	B-X
Studies	B-X
utilizing	B-X
Western	B-X
blot	B-X
for	B-X
validation	B-X
performed	B-X
better	B-X
than	B-X
those	B-X
with	B-X
quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
or	B-X
microarray	B-X
(	B-X
FC	B-X
=	B-X
0.43	B-X
,	B-X
FC	B-X
=	B-X
0.47	B-X
,	B-X
and	B-X
FC	B-X
=	B-X
0.55	B-X
,	B-X
respectively	B-X
,	B-X
P	B-X
=	B-X
2.8E-04	B-X
)	B-X
.	B-X
Although	B-X
gene	B-X
silencing	B-X
is	B-X
a	B-X
robust	B-X
feature	B-X
successfully	B-X
cross-validated	B-X
in	B-X
the	B-X
majority	B-X
of	B-X
experiments	B-X
,	B-X
efficiency	B-X
remained	B-X
insufficient	B-X
in	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
studies	B-X
.	B-X

*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

Tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
threonine	O
435	O
phosphorylation	O
of	O
p65	B-Protein
nuclear	O
factor	O
-	O
kappaB	O
subunit	O
in	O
endothelial	O
cells	O
induces	O
vasogenic	O
edema	O
and	O
neutrophil	O
infiltration	O
in	O
the	O
rat	O
piriform	O
cortex	O
following	O
status	O
epilepticus	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Status	O
epilepticus	O
(	O
SE	O
)	O
induces	O
severe	O
vasogenic	O
edema	O
in	O
the	O
piriform	O
cortex	O
(	O
PC	O
)	O
accompanied	O
by	O
neuronal	O
and	O
astroglial	O
damages	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
the	B-X
up-regulation	B-X
of	B-X
laminin	B-X
expression	B-X
represents	B-X
the	B-X
astroglio-vascular	B-X
responses	B-X
to	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
to	B-X
better	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
vasogenic	B-X
edema	B-X
in	B-X
epileptogenic	B-X
insult	B-X
.	B-X
In	B-X
the	B-X
hippocampus	B-X
,	B-X
vasogenic	B-X
edema	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
hippocampus	B-X
12h	B-X
after	B-X
SE	B-X
when	B-X
astroglial	B-X
degeneration	B-X
was	B-X
undetected	B-X
.	B-X
Vasogenic	B-X
edema	B-X
in	B-X
the	B-X
hippocampus	B-X
was	B-X
more	B-X
severe	B-X
in	B-X
the	B-X
CA1	B-X
region	B-X
where	B-X
astroglial	B-X
loss	B-X
was	B-X
absent	B-X
than	B-X
in	B-X
the	B-X
dentate	B-X
gyrus	B-X
showing	B-X
astroglial	B-X
degeneration	B-X
.	B-X
In	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
,	B-X
vasogenic	B-X
edema	B-X
was	B-X
accompanied	B-X
by	B-X
appearance	B-X
of	B-X
astroglial	B-X
degeneration	B-X
12h	B-X
after	B-X
SE	B-X
.	B-X
Laminin	B-X
expression	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
was	B-X
increased	B-X
3	B-X
days	B-X
and	B-X
4	B-X
days	B-X
after	B-X
SE	B-X
,	B-X
respectively	B-X
.	B-X
Laminin	B-X
expression	B-X
was	B-X
up-regulated	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
with	B-X
concomitant	B-X
reduction	B-X
of	B-X
SMI-71	B-X
(	B-X
the	B-X
endothelial	B-X
barrier	B-X
antigen	B-X
)	B-X
expression	B-X
.	B-X
Four	B-X
weeks	B-X
after	B-X
SE	B-X
,	B-X
laminin	B-X
expression	B-X
was	B-X
reduced	B-X
in	B-X
vessels	B-X
showing	B-X
strong	B-X
SMI-71	B-X
expression	B-X
within	B-X
vasogenic	B-X
edema	B-X
lesion	B-X
.	B-X
Inhibition	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
formation	B-X
by	B-X
BQ788	B-X
effectively	B-X
prevented	B-X
laminin	B-X
over-expression	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
be	B-X
one	B-X
of	B-X
consequences	B-X
from	B-X
vasogenic	B-X
edema	B-X
rather	B-X
than	B-X
astroglial	B-X
loss	B-X
,	B-X
and	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
promote	B-X
migration	B-X
of	B-X
astrocytes	B-X
to	B-X
damaged	B-X
or	B-X
newly	B-X
generated	B-X
vessels	B-X
to	B-X
repair	B-X
brain-blood	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
accompanied	B-X
by	B-X
the	B-X
reconstruction	B-X
of	B-X
endothelial	B-X
barrier	B-X
.	B-X

To	O
elucidate	O
the	O
mechanism	O
of	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	I-Protein
TNF	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
in	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
disruption	O
during	O
vasogenic	O
edema	O
and	O
its	O
related	O
events	O
in	O
rat	O
epilepsy	O
models	O
provoked	O
by	O
pilocarpine	O
-	O
induced	O
SE	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Methods	O
<EOS>	B-X
Methods	B-X
to	B-X
calculate	B-X
the	B-X
sample	B-X
size	B-X
are	B-X
explained	B-X
in	B-X
statistical	B-X
textbooks	B-X
,	B-X
but	B-X
because	B-X
there	B-X
are	B-X
many	B-X
different	B-X
formulas	B-X
available	B-X
,	B-X
it	B-X
can	B-X
be	B-X
difficult	B-X
for	B-X
investigators	B-X
to	B-X
decide	B-X
which	B-X
method	B-X
to	B-X
use	B-X
.	B-X

SE	O
was	O
induced	O
by	O
pilocarpine	O
in	O
rats	O
that	O
were	O
intracerebroventricularly	O
infused	O
with	O
saline	O
-	O
,	O
and	O
soluble	O
TNF	B-Protein
p55	I-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
)	O
prior	O
to	O
SE	O
induction	O
.	O

Thereafter	O
,	O
we	O
performed	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
and	O
immunohistochemical	O
studies	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
NF	O
-	O
kappaB	O
subunits	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X
The	B-X
release	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
appears	B-X
depend	B-X
on	B-X
the	B-X
P2X7	B-X
receptor	B-X
,	B-X
a	B-X
purinergic	B-X
receptor	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
P2X7	B-X
receptor-mediated	B-X
TNF-α	B-X
regulation	B-X
is	B-X
involved	B-X
in	B-X
pathogenesis	B-X
and	B-X
outcome	B-X
of	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
.	B-X

Results	O

Following	O
SE	O
,	O
most	O
activated	O
microglia	O
showed	O
strong	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

In	O
addition	O
,	O
TNF	B-Protein
p75	I-Protein
receptor	I-Protein
expression	O
was	O
detected	O
in	O
endothelial	O
cells	O
as	O
well	O
as	O
astrocytes	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

In	O
addition	O
,	O
only	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
was	O
increased	O
in	O
endothelial	O
cells	O
accompanied	O
by	O
SMI	O
-	O
71	O
expression	O
(	O
an	O
endothelial	O
barrier	O
antigen	O
)	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Neutralization	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
by	O
soluble	O
TNF	B-Protein
p55	I-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
)	O
infusion	O
attenuated	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damages	O
via	O
inhibition	O
of	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
reduced	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
impairments	O
of	O
endothelial	O
cell	O
functions	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Thr	O
485	O
NF	O
-	O
kappaB	O
phosphorylation	O
may	O
be	O
involved	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
.	O

Subsequently	O
,	O
vasogenic	O
edema	O
results	O
in	O
extensive	O
neutrophil	O
infiltration	O
and	O
neuronal	O
-	O
astroglial	O
loss	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

Status	O
epilepticus	O
(	O
SE	O
)	O
is	O
a	O
medical	O
emergency	O
with	O
significant	O
mortality	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Super-refractory	B-X
status	B-X
epilepticus	B-X
(	B-X
SRSE	B-X
)	B-X
is	B-X
a	B-X
life-threatening	B-X
neurological	B-X
emergency	B-X
with	B-X
high	B-X
morbidity	B-X
and	B-X
mortality	B-X
.	B-X
It	B-X
is	B-X
defined	B-X
as	B-X
``	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
that	B-X
continues	B-X
or	B-X
recurs	B-X
24	B-X
hours	B-X
or	B-X
more	B-X
after	B-X
the	B-X
onset	B-X
of	B-X
anesthesia	B-X
,	B-X
including	B-X
those	B-X
cases	B-X
in	B-X
which	B-X
SE	B-X
recurs	B-X
on	B-X
the	B-X
reduction	B-X
or	B-X
withdrawal	B-X
of	B-X
anesthesia	B-X
.	B-X
''	B-X
This	B-X
condition	B-X
is	B-X
resistant	B-X
to	B-X
normal	B-X
protocols	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
status	B-X
epilepticus	B-X
and	B-X
exposes	B-X
patients	B-X
to	B-X
increased	B-X
risks	B-X
of	B-X
neuronal	B-X
death	B-X
,	B-X
neuronal	B-X
injury	B-X
,	B-X
and	B-X
disruption	B-X
of	B-X
neuronal	B-X
networks	B-X
if	B-X
not	B-X
treated	B-X
in	B-X
a	B-X
timely	B-X
manner	B-X
.	B-X
It	B-X
is	B-X
mainly	B-X
seen	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
acute	B-X
onset	B-X
brain	B-X
injury	B-X
or	B-X
presentation	B-X
of	B-X
new-onset	B-X
refractory	B-X
status	B-X
epilepticus	B-X
(	B-X
NORSE	B-X
)	B-X
.	B-X
The	B-X
mortality	B-X
,	B-X
neurological	B-X
deficits	B-X
,	B-X
and	B-X
functional	B-X
impairments	B-X
are	B-X
significant	B-X
depending	B-X
on	B-X
the	B-X
duration	B-X
of	B-X
status	B-X
epilepticus	B-X
and	B-X
the	B-X
resultant	B-X
brain	B-X
damage	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
wide	B-X
range	B-X
of	B-X
therapies	B-X
used	B-X
in	B-X
the	B-X
management	B-X
of	B-X
SRSE	B-X
,	B-X
provide	B-X
suggestions	B-X
regarding	B-X
its	B-X
treatment	B-X
,	B-X
and	B-X
comment	B-X
on	B-X
future	B-X
directions	B-X
.	B-X

SE	O
has	O
been	O
defined	O
as	O
continuous	O
seizure	O
activity	O
,	O
which	O
causes	O
neuronal	O
cell	O
death	O
,	O
epileptogenesis	O
and	O
learning	O
impairment	O
[	O
2	O
,	O
3	O
]	O
.	O

Some	O
brain	O
regions	O
vulnerable	O
to	O
SE	O
play	O
a	O
role	O
in	O
the	O
generation	O
and	O
propagation	O
of	O
paroxysmal	O
activity	O
in	O
experimental	O
epilepsy	O
models	O
.	O

The	O
piriform	O
cortex	O
(	O
PC	O
)	O
is	O
one	O
of	O
the	O
most	O
susceptible	O
brain	O
regions	O
to	O
seizure	O
-	O
induced	O
damage	O
in	O
the	O
kainate	O
,	O
pilocarpine	O
and	O
other	O
models	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
[	O
4	O
-	O
6	O
]	O
.	O

Pilocarpine	O
,	O
a	O
cholinergic	O
agonist	O
,	O
induces	O
SE	O
in	O
rodents	O
.	O

This	O
pilocarpine	O
-	O
induced	O
SE	O
,	O
similar	O
to	O
human	O
TLE	O
,	O
shows	O
massive	O
neuronal	O
loss	O
in	O
the	O
hippocampus	O
followed	O
by	O
glial	O
proliferation	O
.	O

This	O
neuronal	O
damage	O
in	O
the	O
pilocarpine	O
model	O
is	O
not	O
restricted	O
to	O
the	O
hippocampus	O
,	O
but	O
often	O
extends	O
to	O
extrahippocampal	O
limbic	O
structures	O
.	O
<EOS>	B-X
Understanding	B-X
the	B-X
pathophysiogenesis	B-X
of	B-X
temporal	B-X
lobe	B-X
epilepsy	B-X
(	B-X
TLE	B-X
)	B-X
largely	B-X
rests	B-X
on	B-X
the	B-X
use	B-X
of	B-X
models	B-X
of	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
,	B-X
as	B-X
in	B-X
the	B-X
case	B-X
of	B-X
the	B-X
pilocarpine	B-X
model	B-X
.	B-X
The	B-X
main	B-X
features	B-X
of	B-X
TLE	B-X
are	B-X
:	B-X
(	B-X
i	B-X
)	B-X
epileptic	B-X
foci	B-X
in	B-X
the	B-X
limbic	B-X
system	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
an	B-X
``	B-X
initial	B-X
precipitating	B-X
injury	B-X
''	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
the	B-X
so-called	B-X
``	B-X
latent	B-X
period	B-X
''	B-X
;	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
presence	B-X
of	B-X
hippocampal	B-X
sclerosis	B-X
leading	B-X
to	B-X
reorganization	B-X
of	B-X
neuronal	B-X
networks	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
characteristics	B-X
can	B-X
be	B-X
reproduced	B-X
in	B-X
rodents	B-X
by	B-X
systemic	B-X
injection	B-X
of	B-X
pilocarpine	B-X
;	B-X
in	B-X
this	B-X
animal	B-X
model	B-X
,	B-X
SE	B-X
is	B-X
followed	B-X
by	B-X
a	B-X
latent	B-X
period	B-X
and	B-X
later	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
spontaneous	B-X
recurrent	B-X
seizures	B-X
(	B-X
SRSs	B-X
)	B-X
.	B-X
These	B-X
processes	B-X
are	B-X
,	B-X
however	B-X
,	B-X
influenced	B-X
by	B-X
experimental	B-X
conditions	B-X
such	B-X
as	B-X
rodent	B-X
species	B-X
,	B-X
strain	B-X
,	B-X
gender	B-X
,	B-X
age	B-X
,	B-X
doses	B-X
and	B-X
routes	B-X
of	B-X
pilocarpine	B-X
administration	B-X
,	B-X
as	B-X
well	B-X
as	B-X
combinations	B-X
with	B-X
other	B-X
drugs	B-X
administered	B-X
before	B-X
and/or	B-X
after	B-X
SE	B-X
.	B-X
In	B-X
the	B-X
attempt	B-X
to	B-X
limit	B-X
these	B-X
sources	B-X
of	B-X
variability	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
methodological	B-X
procedures	B-X
used	B-X
by	B-X
several	B-X
investigators	B-X
in	B-X
the	B-X
pilocarpine	B-X
model	B-X
;	B-X
in	B-X
particular	B-X
,	B-X
we	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
behavioural	B-X
,	B-X
electrophysiological	B-X
and	B-X
histopathological	B-X
findings	B-X
obtained	B-X
with	B-X
different	B-X
protocols	B-X
.	B-X
We	B-X
addressed	B-X
the	B-X
various	B-X
experimental	B-X
approaches	B-X
published	B-X
to	B-X
date	B-X
,	B-X
by	B-X
comparing	B-X
mortality	B-X
rates	B-X
,	B-X
onset	B-X
of	B-X
SRSs	B-X
,	B-X
neuronal	B-X
damage	B-X
,	B-X
and	B-X
network	B-X
reorganization	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
evidence	B-X
reviewed	B-X
here	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
pilocarpine	B-X
model	B-X
can	B-X
be	B-X
a	B-X
valuable	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
TLE	B-X
,	B-X
and	B-X
even	B-X
more	B-X
so	B-X
when	B-X
standardized	B-X
to	B-X
reduce	B-X
mortality	B-X
at	B-X
the	B-X
time	B-X
of	B-X
pilocarpine	B-X
injection	B-X
,	B-X
differences	B-X
in	B-X
latent	B-X
period	B-X
duration	B-X
,	B-X
variability	B-X
in	B-X
the	B-X
lesion	B-X
extent	B-X
,	B-X
and	B-X
SRS	B-X
frequency	B-X
.	B-X

Indeed	O
,	O
pilocarpine	O
-	O
induced	O
SE	O
results	O
in	O
acute	O
neuronal	O
damages	O
within	O
layers	O
II	O
and	O
III	O
of	O
the	O
PC	O
[	O
5	O
,	O
6	O
]	O
.	O

SE	O
also	O
induces	O
severe	O
vasogenic	O
edema	O
in	O
the	O
PC	O
accompanied	O
by	O
neuronal	O
and	O
astroglial	O
damages	O
[	O
5	O
-	O
8	O
]	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
the	B-X
up-regulation	B-X
of	B-X
laminin	B-X
expression	B-X
represents	B-X
the	B-X
astroglio-vascular	B-X
responses	B-X
to	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
to	B-X
better	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
vasogenic	B-X
edema	B-X
in	B-X
epileptogenic	B-X
insult	B-X
.	B-X
In	B-X
the	B-X
hippocampus	B-X
,	B-X
vasogenic	B-X
edema	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
hippocampus	B-X
12h	B-X
after	B-X
SE	B-X
when	B-X
astroglial	B-X
degeneration	B-X
was	B-X
undetected	B-X
.	B-X
Vasogenic	B-X
edema	B-X
in	B-X
the	B-X
hippocampus	B-X
was	B-X
more	B-X
severe	B-X
in	B-X
the	B-X
CA1	B-X
region	B-X
where	B-X
astroglial	B-X
loss	B-X
was	B-X
absent	B-X
than	B-X
in	B-X
the	B-X
dentate	B-X
gyrus	B-X
showing	B-X
astroglial	B-X
degeneration	B-X
.	B-X
In	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
,	B-X
vasogenic	B-X
edema	B-X
was	B-X
accompanied	B-X
by	B-X
appearance	B-X
of	B-X
astroglial	B-X
degeneration	B-X
12h	B-X
after	B-X
SE	B-X
.	B-X
Laminin	B-X
expression	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
was	B-X
increased	B-X
3	B-X
days	B-X
and	B-X
4	B-X
days	B-X
after	B-X
SE	B-X
,	B-X
respectively	B-X
.	B-X
Laminin	B-X
expression	B-X
was	B-X
up-regulated	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
with	B-X
concomitant	B-X
reduction	B-X
of	B-X
SMI-71	B-X
(	B-X
the	B-X
endothelial	B-X
barrier	B-X
antigen	B-X
)	B-X
expression	B-X
.	B-X
Four	B-X
weeks	B-X
after	B-X
SE	B-X
,	B-X
laminin	B-X
expression	B-X
was	B-X
reduced	B-X
in	B-X
vessels	B-X
showing	B-X
strong	B-X
SMI-71	B-X
expression	B-X
within	B-X
vasogenic	B-X
edema	B-X
lesion	B-X
.	B-X
Inhibition	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
formation	B-X
by	B-X
BQ788	B-X
effectively	B-X
prevented	B-X
laminin	B-X
over-expression	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
be	B-X
one	B-X
of	B-X
consequences	B-X
from	B-X
vasogenic	B-X
edema	B-X
rather	B-X
than	B-X
astroglial	B-X
loss	B-X
,	B-X
and	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
promote	B-X
migration	B-X
of	B-X
astrocytes	B-X
to	B-X
damaged	B-X
or	B-X
newly	B-X
generated	B-X
vessels	B-X
to	B-X
repair	B-X
brain-blood	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
accompanied	B-X
by	B-X
the	B-X
reconstruction	B-X
of	B-X
endothelial	B-X
barrier	B-X
.	B-X

Brain	O
edema	O
proceeds	O
in	O
two	O
phases	O
,	O
early	O
cytotoxic	O
edema	O
phase	O
and	O
late	O
vasogenic	O
edema	O
phase	O
.	O

Early	O
cytotoxic	O
osmotic	O
edema	O
is	O
due	O
to	O
excess	O
stimulation	O
of	O
glutamatergic	O
pathways	O
during	O
SE	O
,	O
which	O
increases	O
intracellular	O
Na	O
+	O
and	O
Ca2	O
+	O
concentrations	O
.	O

The	O
vasogenic	O
edema	O
results	O
from	O
dysfunction	O
of	O
endothelial	O
cells	O
and	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O
<EOS>	B-X
As	B-X
part	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
,	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
is	B-X
a	B-X
unique	B-X
,	B-X
dynamic	B-X
regulatory	B-X
boundary	B-X
that	B-X
limits	B-X
and	B-X
regulates	B-X
the	B-X
exchange	B-X
of	B-X
molecules	B-X
,	B-X
ions	B-X
,	B-X
and	B-X
cells	B-X
between	B-X
the	B-X
blood	B-X
and	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
BBB	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
neurological	B-X
dysfunction	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X
Blood-borne	B-X
substances	B-X
and	B-X
cells	B-X
have	B-X
restricted	B-X
access	B-X
to	B-X
the	B-X
brain	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
tight	B-X
junctions	B-X
between	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
the	B-X
BBB	B-X
.	B-X
Following	B-X
stroke	B-X
,	B-X
there	B-X
is	B-X
loss	B-X
of	B-X
BBB	B-X
tight	B-X
junction	B-X
integrity	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
paracellular	B-X
permeability	B-X
,	B-X
which	B-X
results	B-X
in	B-X
vasogenic	B-X
edema	B-X
,	B-X
hemorrhagic	B-X
transformation	B-X
,	B-X
and	B-X
increased	B-X
mortality	B-X
.	B-X
Thus	B-X
,	B-X
understanding	B-X
principal	B-X
mediators	B-X
and	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
BBB	B-X
disruption	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapeutics	B-X
to	B-X
treat	B-X
ischemic	B-X
stroke	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
how	B-X
neuroinflammation	B-X
contributes	B-X
to	B-X
BBB	B-X
damage	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X
Specifically	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
updated	B-X
overview	B-X
of	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
oxidative	B-X
and	B-X
nitrosative	B-X
stress	B-X
,	B-X
adhesion	B-X
molecules	B-X
,	B-X
matrix	B-X
metalloproteinases	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
as	B-X
well	B-X
as	B-X
the	B-X
role	B-X
of	B-X
different	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
BBB	B-X
permeability	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X

Many	O
studies	O
have	O
reported	O
increased	O
permeability	O
of	O
the	O
BBB	O
during	O
epileptic	O
activity	O
[	O
9	O
-	O
13	O
]	O
.	O

A	O
fast	O
and	O
significant	O
increase	O
in	O
systemic	O
blood	O
pressure	O
,	O
particularly	O
shown	O
during	O
tonic	O
epileptic	O
seizures	O
,	O
induces	O
a	O
marked	O
vasodilation	O
of	O
the	O
large	O
cerebral	O
arteries	O
and	O
an	O
increase	O
in	O
blood	O
pressure	O
in	O
capillaries	O
,	O
small	O
arteries	O
,	O
and	O
veins	O
leading	O
to	O
leakage	O
of	O
the	O
BBB	O
[	O
9	O
]	O
.	O

Loss	O
of	O
BBB	O
integrity	O
is	O
not	O
only	O
due	O
to	O
an	O
abrupt	O
increase	O
in	O
the	O
intraluminal	O
pressure	O
but	O
also	O
influenced	O
by	O
the	O
properties	O
of	O
cerebral	O
tissue	O
.	O
<EOS>	B-X
As	B-X
part	B-X
of	B-X
the	B-X
neurovascular	B-X
unit	B-X
,	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
is	B-X
a	B-X
unique	B-X
,	B-X
dynamic	B-X
regulatory	B-X
boundary	B-X
that	B-X
limits	B-X
and	B-X
regulates	B-X
the	B-X
exchange	B-X
of	B-X
molecules	B-X
,	B-X
ions	B-X
,	B-X
and	B-X
cells	B-X
between	B-X
the	B-X
blood	B-X
and	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
BBB	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
neurological	B-X
dysfunction	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X
Blood-borne	B-X
substances	B-X
and	B-X
cells	B-X
have	B-X
restricted	B-X
access	B-X
to	B-X
the	B-X
brain	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
tight	B-X
junctions	B-X
between	B-X
the	B-X
endothelial	B-X
cells	B-X
of	B-X
the	B-X
BBB	B-X
.	B-X
Following	B-X
stroke	B-X
,	B-X
there	B-X
is	B-X
loss	B-X
of	B-X
BBB	B-X
tight	B-X
junction	B-X
integrity	B-X
,	B-X
leading	B-X
to	B-X
increased	B-X
paracellular	B-X
permeability	B-X
,	B-X
which	B-X
results	B-X
in	B-X
vasogenic	B-X
edema	B-X
,	B-X
hemorrhagic	B-X
transformation	B-X
,	B-X
and	B-X
increased	B-X
mortality	B-X
.	B-X
Thus	B-X
,	B-X
understanding	B-X
principal	B-X
mediators	B-X
and	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
BBB	B-X
disruption	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapeutics	B-X
to	B-X
treat	B-X
ischemic	B-X
stroke	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
how	B-X
neuroinflammation	B-X
contributes	B-X
to	B-X
BBB	B-X
damage	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X
Specifically	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
updated	B-X
overview	B-X
of	B-X
the	B-X
role	B-X
of	B-X
cytokines	B-X
,	B-X
chemokines	B-X
,	B-X
oxidative	B-X
and	B-X
nitrosative	B-X
stress	B-X
,	B-X
adhesion	B-X
molecules	B-X
,	B-X
matrix	B-X
metalloproteinases	B-X
,	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
as	B-X
well	B-X
as	B-X
the	B-X
role	B-X
of	B-X
different	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
BBB	B-X
permeability	B-X
in	B-X
ischemic	B-X
stroke	B-X
.	B-X

Indeed	O
,	O
an	O
acute	O
increase	O
in	O
blood	O
pressure	O
or	O
epileptic	O
activity	O
causes	O
an	O
increase	O
in	O
pinocytosis	O
at	O
the	O
level	O
of	O
the	O
cerebral	O
endothelium	O
[	O
11	O
-	O
13	O
]	O
.	O
<EOS>	B-X
Coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
outbreak	B-X
,	B-X
caused	B-X
by	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
represents	B-X
a	B-X
real	B-X
challenge	B-X
for	B-X
health-care	B-X
systems	B-X
worldwide	B-X
.	B-X
Early	B-X
reports	B-X
suggested	B-X
that	B-X
hypertension	B-X
might	B-X
represent	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
susceptibility	B-X
to	B-X
SARS-CoV-2	B-X
infection	B-X
,	B-X
a	B-X
more	B-X
severe	B-X
course	B-X
of	B-X
COVID-19	B-X
and	B-X
increased	B-X
COVID-19-related	B-X
deaths	B-X
.	B-X
Indeed	B-X
,	B-X
preclinical	B-X
studies	B-X
using	B-X
these	B-X
classes	B-X
of	B-X
drugs	B-X
have	B-X
suggested	B-X
a	B-X
potential	B-X
upregulation	B-X
of	B-X
angiotensin-converting-enzyme	B-X
2	B-X
(	B-X
ACE2	B-X
)	B-X
which	B-X
is	B-X
the	B-X
key	B-X
binding	B-X
receptor	B-X
promoting	B-X
cell	B-X
entry	B-X
of	B-X
SARS-CoV-2	B-X
in	B-X
the	B-X
organism	B-X
.	B-X
The	B-X
acute	B-X
respiratory	B-X
distress	B-X
(	B-X
ARDS	B-X
)	B-X
lung	B-X
is	B-X
usually	B-X
characterized	B-X
by	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
inhomogeneity	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
same	B-X
lung	B-X
may	B-X
show	B-X
a	B-X
wide	B-X
spectrum	B-X
of	B-X
aeration	B-X
alterations	B-X
,	B-X
ranging	B-X
from	B-X
completely	B-X
gasless	B-X
regions	B-X
,	B-X
up	B-X
to	B-X
hyperinflated	B-X
areas	B-X
.	B-X
This	B-X
inhomogeneity	B-X
is	B-X
normally	B-X
caused	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
lung	B-X
edema	B-X
and/or	B-X
anatomical	B-X
variations	B-X
,	B-X
and	B-X
is	B-X
deeply	B-X
influenced	B-X
by	B-X
the	B-X
gravitational	B-X
forces.For	B-X
any	B-X
given	B-X
airway	B-X
pressure	B-X
generated	B-X
by	B-X
the	B-X
ventilator	B-X
,	B-X
the	B-X
pressure	B-X
acting	B-X
directly	B-X
on	B-X
the	B-X
lung	B-X
(	B-X
i.e.	B-X
,	B-X
the	B-X
transpulmonary	B-X
pressure	B-X
or	B-X
lung	B-X
stress	B-X
)	B-X
is	B-X
determined	B-X
by	B-X
two	B-X
main	B-X
factors	B-X
:	B-X
1	B-X
)	B-X
the	B-X
ratio	B-X
between	B-X
lung	B-X
elastance	B-X
and	B-X
the	B-X
total	B-X
elastance	B-X
of	B-X
the	B-X
respiratory	B-X
system	B-X
(	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
vary	B-X
widely	B-X
in	B-X
ARDS	B-X
patients	B-X
,	B-X
between	B-X
0.2	B-X
and	B-X
0.8	B-X
)	B-X
;	B-X
and	B-X
2	B-X
)	B-X
the	B-X
lung	B-X
size	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
the	B-X
ARDS	B-X
lung	B-X
contains	B-X
areas	B-X
acting	B-X
as	B-X
local	B-X
stress	B-X
multipliers	B-X
and	B-X
they	B-X
could	B-X
multiply	B-X
the	B-X
stress	B-X
by	B-X
a	B-X
factor	B-X
~	B-X
2	B-X
,	B-X
meaning	B-X
that	B-X
in	B-X
those	B-X
regions	B-X
the	B-X
transpulmonary	B-X
pressure	B-X
could	B-X
be	B-X
double	B-X
that	B-X
present	B-X
in	B-X
other	B-X
parts	B-X
of	B-X
the	B-X
same	B-X
lung	B-X
.	B-X
The	B-X
determinants	B-X
of	B-X
mechanical	B-X
power	B-X
are	B-X
not	B-X
only	B-X
the	B-X
tidal	B-X
volume	B-X
,	B-X
but	B-X
also	B-X
respiratory	B-X
rate	B-X
,	B-X
inspiratory	B-X
flow	B-X
,	B-X
and	B-X
positive	B-X
end-expiratory	B-X
pressure	B-X
(	B-X
PEEP	B-X
)	B-X
.	B-X

Recently	O
,	O
reports	O
have	O
also	O
emphasized	O
that	O
seizure	O
or	O
epilepsy	O
is	O
a	O
prolonged	O
inflammatory	O
condition	O
,	O
and	O
that	O
seizure	O
activity	O
rapidly	O
increases	O
the	O
synthesis	O
and	O
release	O
of	O
various	O
interleukins	O
in	O
rodent	O
brain	O
areas	O
involved	O
in	O
seizure	O
onset	O
and	O
their	O
generalization	O
.	O
<EOS>	B-X
Several	B-X
clinical	B-X
trials	B-X
emphasized	B-X
that	B-X
montelukast	B-X
can	B-X
be	B-X
considered	B-X
a	B-X
safe	B-X
drug	B-X
.	B-X
Despite	B-X
the	B-X
availability	B-X
of	B-X
over	B-X
30	B-X
antiseizure	B-X
medications	B-X
(	B-X
ASMs	B-X
)	B-X
,	B-X
there	B-X
is	B-X
no	B-X
``	B-X
one	B-X
size	B-X
fits	B-X
it	B-X
all	B-X
,	B-X
''	B-X
so	B-X
there	B-X
is	B-X
a	B-X
continuing	B-X
search	B-X
for	B-X
novel	B-X
ASMs	B-X
.	B-X
There	B-X
are	B-X
divergent	B-X
data	B-X
demonstrating	B-X
that	B-X
modulation	B-X
of	B-X
distinct	B-X
serotonin	B-X
(	B-X
5-hydroxytryptamine	B-X
,	B-X
5-HT	B-X
)	B-X
receptors	B-X
subtypes	B-X
could	B-X
be	B-X
beneficial	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
epilepsy	B-X
and	B-X
its	B-X
comorbidities	B-X
,	B-X
whereas	B-X
only	B-X
a	B-X
few	B-X
ASM	B-X
,	B-X
such	B-X
as	B-X
fenfluramine	B-X
(	B-X
FA	B-X
)	B-X
,	B-X
act	B-X
via	B-X
5-HT	B-X
.	B-X
There	B-X
are	B-X
14	B-X
different	B-X
5-HT	B-X
receptor	B-X
subtypes	B-X
,	B-X
and	B-X
most	B-X
epilepsy	B-X
studies	B-X
focus	B-X
on	B-X
one	B-X
or	B-X
a	B-X
few	B-X
of	B-X
these	B-X
subtypes	B-X
,	B-X
using	B-X
different	B-X
animal	B-X
models	B-X
and	B-X
different	B-X
ligands	B-X
.	B-X
Our	B-X
search	B-X
included	B-X
medical	B-X
subject	B-X
heading	B-X
(	B-X
MeSH	B-X
)	B-X
and	B-X
free	B-X
terms	B-X
of	B-X
each	B-X
``	B-X
5-HT	B-X
subtype	B-X
''	B-X
separately	B-X
and	B-X
its	B-X
relation	B-X
to	B-X
``	B-X
epilepsy	B-X
or	B-X
seizures	B-X
.	B-X
''	B-X
Most	B-X
research	B-X
underlines	B-X
the	B-X
antiseizure	B-X
activity	B-X
of	B-X
5-HT	B-X

Cytokines	O
act	O
on	O
endothelial	O
cells	O
and	O
change	O
the	O
permeability	O
of	O
the	O
BBB	O
,	O
which	O
exerts	O
significant	O
effects	O
on	O
neuronal	O
viability	O
and	O
excitability	O
[	O
14	O
,	O
15	O
]	O
.	O

Indeed	O
,	O
Sztriha	O
[	O
16	O
]	O
reported	O
that	O
dexamethasone	O
pretreatment	O
reduces	O
vasogenic	O
edema	O
in	O
thalamus	O
following	O
kainic	O
acid	O
-	O
induced	O
seizure	O
.	O

Among	O
cytokines	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
is	O
a	O
17	O
kDa	O
protein	O
that	O
is	O
produced	O
mainly	O
by	O
activated	O
macrophages	O
and	O
T	O
cells	O
in	O
the	O
immune	O
system	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
expressed	O
at	O
low	O
levels	O
in	O
normal	O
brain	O
and	O
is	O
rapidly	O
upregulated	O
in	O
glia	O
,	O
neurons	O
and	O
endothelial	O
cells	O
in	O
various	O
pathophysiological	O
conditions	O
,	O
including	O
SE	O
[	O
17	O
,	O
18	O
]	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
shows	O
various	O
effects	O
on	O
brain	O
function	O
depending	O
on	O
its	O
local	O
tissue	O
concentration	O
,	O
the	O
type	O
of	O
target	O
cells	O
,	O
and	O
especially	O
the	O
specific	O
receptor	O
subtype	O
:	O
TNF	B-Protein
receptor	I-Protein
I	I-Protein
,	O
or	O
p55	B-Protein
receptor	I-Protein
(	O
TNFp55R	B-Protein
)	O
;	O
and	O
TNF	B-Protein
receptor	I-Protein
II	I-Protein
,	O
or	O
p75	B-Protein
receptor	I-Protein
(	O
TNFp75R	B-Protein
)	O
[	O
19	O
]	O
.	O
<EOS>	B-X
Localized	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNFalpha	B-X
)	B-X
elevation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
brain	B-X
injury	B-X
often	B-X
attributed	B-X
to	B-X
signaling	B-X
via	B-X
TNFp55	B-X
or	B-X
TNFp75	B-X
receptors	B-X
.	B-X
Both	B-X
dentate	B-X
granule	B-X
cells	B-X
and	B-X
CA	B-X
pyramidal	B-X
cells	B-X
express	B-X
TNF	B-X
receptors	B-X
(	B-X
TNFR	B-X
)	B-X
at	B-X
low	B-X
levels	B-X
in	B-X
a	B-X
punctate	B-X
pattern	B-X
.	B-X
Using	B-X
a	B-X
model	B-X
to	B-X
induce	B-X
selective	B-X
death	B-X
of	B-X
dentate	B-X
granule	B-X
cells	B-X
(	B-X
trimethyltin	B-X
;	B-X
2	B-X
mg/kg	B-X
,	B-X
i.p	B-X
.	B-X
)	B-X
,	B-X
neuronal	B-X
apoptosis	B-X
[	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase-mediated	B-X
dUTP-biotin	B-X
in	B-X
situ	B-X
end	B-X
labeling	B-X
,	B-X
active	B-X
caspase	B-X
3	B-X
(	B-X
AC3	B-X
)	B-X
]	B-X
was	B-X
accompanied	B-X
by	B-X
amoeboid	B-X
microglia	B-X
and	B-X
elevated	B-X
TNFalpha	B-X
mRNA	B-X
levels	B-X
.	B-X
TNFp55R	B-X
(	B-X
55	B-X
kDa	B-X
type-1	B-X
TNFR	B-X
)	B-X
and	B-X
TNFp75R	B-X
(	B-X
75	B-X
kDa	B-X
type-2	B-X
TNFR	B-X
)	B-X
immunoreactivity	B-X
in	B-X
AC3	B-X
(	B-X
+	B-X
)	B-X
neurons	B-X
displayed	B-X
a	B-X
pattern	B-X
suggestive	B-X
of	B-X
receptor	B-X
internalization	B-X
and	B-X
a	B-X
temporal	B-X
sequence	B-X
of	B-X
expression	B-X
of	B-X
TNFp55R	B-X
followed	B-X
by	B-X
TNFp75R	B-X
associated	B-X
with	B-X
the	B-X
progression	B-X
of	B-X
apoptosis	B-X
.	B-X
A	B-X
distinct	B-X
ramified	B-X
microglia	B-X
response	B-X
occurred	B-X
around	B-X
CA1	B-X
neurons	B-X
and	B-X
healthy	B-X
dentate	B-X
neurons	B-X
that	B-X
displayed	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
normal	B-X
punctate	B-X
pattern	B-X
of	B-X
TNFRs	B-X
.	B-X
injection	B-X
of	B-X
TNFalpha	B-X
antibody	B-X
and	B-X
in	B-X
TNFp55R-/-p75R-/-	B-X
mice	B-X
that	B-X
showed	B-X
higher	B-X
constitutive	B-X
mRNA	B-X
levels	B-X
for	B-X
interleukin	B-X
(	B-X
IL-1alpha	B-X
)	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1-alpha	B-X
(	B-X
MIP-1alpha	B-X
)	B-X
,	B-X
TNFalpha	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
beta1	B-X
,	B-X
Fas	B-X
,	B-X
and	B-X
TNFRSF6-assoicated	B-X
via	B-X
death	B-X
domain	B-X
(	B-X
FADD	B-X
)	B-X
.	B-X
TNFp75R-/-	B-X
mice	B-X
showed	B-X
exacerbated	B-X
injury	B-X
and	B-X
elevated	B-X
mRNA	B-X
levels	B-X
for	B-X
IL-1alpha	B-X
,	B-X
MIP-1alpha	B-X
,	B-X
and	B-X
TNFalpha	B-X
.	B-X
In	B-X
TNFp55R-/-	B-X
mice	B-X
,	B-X
constitutive	B-X
mRNA	B-X
levels	B-X
for	B-X
TNFalpha	B-X
,	B-X
IL-6	B-X
,	B-X
caspase	B-X
8	B-X
,	B-X
FADD	B-X
,	B-X
and	B-X
Fas-associated	B-X
phosphatase	B-X
were	B-X
higher	B-X
;	B-X
IL-1alpha	B-X
,	B-X
MIP-1alpha	B-X
,	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
beta1	B-X
lower	B-X
.	B-X
The	B-X
mice	B-X
displayed	B-X
exacerbated	B-X
neuronal	B-X
death	B-X
,	B-X
delayed	B-X
microglia	B-X
response	B-X
,	B-X
increased	B-X
FADD	B-X
and	B-X
TNFp75R	B-X
mRNA	B-X
levels	B-X
,	B-X
and	B-X
co-expression	B-X
of	B-X
TNFp75R	B-X
in	B-X
AC3	B-X
(	B-X
+	B-X
)	B-X
neurons	B-X
.	B-X
The	B-X
data	B-X
demonstrate	B-X
TNFR-mediated	B-X
apoptotic	B-X
death	B-X
of	B-X
dentate	B-X
granule	B-X
neurons	B-X
utilizing	B-X
both	B-X
TNFRs	B-X
and	B-X
suggest	B-X
a	B-X
TNFp75R-mediated	B-X
apoptosis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
normal	B-X
TNFp55R	B-X
activity	B-X
.	B-X

Furthermore	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
induces	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
(	O
MIP	B-Protein
-	I-Protein
2	I-Protein
)	O
that	O
recruits	O
neutrophils	O
under	O
pathological	O
conditions	O
,	O
including	O
SE	O
[	O
14	O
,	O
20	O
]	O
.	O

Neurons	O
,	O
microglia	O
,	O
and	O
astrocytes	O
produce	O
MIP	B-Protein
-	I-Protein
2	I-Protein
when	O
incubated	O
with	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
/	O
or	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
or	O
after	O
injury	O
[	O
21	O
-	O
23	O
]	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
Essential	B-X
for	B-X
the	B-X
host-response	B-X
and	B-X
resistance	B-X
to	B-X
pathogens	B-X
,	B-X
it	B-X
also	B-X
exacerbates	B-X
damage	B-X
during	B-X
chronic	B-X
disease	B-X
and	B-X
acute	B-X
tissue	B-X
injury	B-X
.	B-X
It	B-X
is	B-X
not	B-X
surprising	B-X
therefore	B-X
that	B-X
there	B-X
is	B-X
a	B-X
huge	B-X
level	B-X
of	B-X
interest	B-X
in	B-X
how	B-X
this	B-X
protein	B-X
is	B-X
produced	B-X
and	B-X
exported	B-X
from	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
IL-1β	B-X
release	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
elusive	B-X
.	B-X
A	B-X
literature	B-X
full	B-X
of	B-X
disparate	B-X
observations	B-X
arising	B-X
from	B-X
numerous	B-X
experimental	B-X
systems	B-X
,	B-X
has	B-X
contributed	B-X
to	B-X
a	B-X
complicated	B-X
mix	B-X
of	B-X
diverse	B-X
proposals	B-X
.	B-X
Here	B-X
we	B-X
summarise	B-X
these	B-X
observations	B-X
and	B-X
propose	B-X
that	B-X
secretion	B-X
of	B-X
IL-1β	B-X
occurs	B-X
on	B-X
a	B-X
continuum	B-X
,	B-X
dependent	B-X
upon	B-X
stimulus	B-X
strength	B-X
and	B-X
the	B-X
extracellular	B-X
IL-1β	B-X
requirement	B-X
.	B-X

Indeed	O
,	O
we	O
have	O
recently	O
reported	O
that	O
SE	O
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
is	O
relevant	O
to	O
leukocyte	O
infiltrations	O
following	O
SE	O
in	O
an	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
independent	O
manner	O
[	O
20	O
]	O
.	O

However	O
,	O
the	O
relationship	O
between	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
system	O
and	O
BBB	O
disruption	O
/	O
neutrophil	O
infiltration	O
during	O
vasogenic	O
edema	O
formation	O
induced	O
by	O
epileptogenic	O
insults	O
has	O
not	O
been	O
fully	O
clarified	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
vasogenic	O
edema	O
and	O
its	O
related	O
events	O
in	O
rat	O
epilepsy	O
models	O
provoked	O
by	O
pilocarpine	O
-	O
induced	O
SE	O
.	O

Experimental	O
animals	O
<EOS>	B-X
Immunogenetics	B-X
and	B-X
experimental	B-X
animals	B-X
.	B-X
[	B-X
Experimental	B-X
animals	B-X
in	B-X
the	B-X
era	B-X
of	B-X
genomics	B-X
]	B-X
.	B-X
Studies	B-X
on	B-X
coprophagy	B-X
in	B-X
experimental	B-X
animals	B-X
.	B-X
Studies	B-X
on	B-X
bone	B-X
marrow	B-X
cells	B-X
in	B-X
experimental	B-X
animals	B-X
:	B-X
bone	B-X
marrow	B-X
testing	B-X
in	B-X
the	B-X
safety	B-X
study	B-X
.	B-X

This	O
study	O
utilized	O
progeny	O
of	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
(	O
male	O
,	O
9	O
-	O
11	O
weeks	O
old	O
)	O
obtained	O
from	O
Experimental	O
Animal	O
Center	O
,	O
Hallym	O
University	O
,	O
Chunchon	O
,	O
South	O
Korea	O
.	O

The	O
animals	O
were	O
provided	O
with	O
a	O
commercial	O
diet	O
and	O
water	O
ad	O
libitum	O
under	O
controlled	O
temperature	O
,	O
humidity	O
and	O
lighting	O
conditions	O
(	O
22	O
+	O
/	O
-	O
2degreesC	O
,	O
55	O
+	O
/	O
-	O
5	O
%	O
and	O
a	O
12	O
:	O
12	O
light	O
/	O
dark	O
cycle	O
with	O
lights	O
)	O
.	O

Animal	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Hallym	O
University	O
.	O
<EOS>	B-X
Animals	B-X
subjected	B-X
to	B-X
20-minute	B-X
BCCAO	B-X
died	B-X
in	B-X
at	B-X
least	B-X
2	B-X
days	B-X
.	B-X
The	B-X
experimental	B-X
protocol	B-X
was	B-X
approved	B-X
by	B-X
Institutional	B-X
Animal	B-X
Care	B-X
and	B-X
Use	B-X
Committee	B-X
(	B-X
AICUC	B-X
)	B-X
of	B-X
Kangwon	B-X
National	B-X
University	B-X
(	B-X
approval	B-X
No	B-X
.	B-X

Procedures	O
involving	O
animals	O
and	O
their	O
care	O
were	O
conducted	O
in	O
accord	O
with	O
our	O
institutional	O
guidelines	O
that	O
comply	O
with	O
NIH	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
(	O
NIH	O
Publications	O
No	O
.	O
80	O
-	O
23	O
,	O
1996	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
made	O
all	O
efforts	O
to	O
minimize	O
the	O
number	O
of	O
animals	O
used	O
and	O
their	O
suffering	O
.	O
<EOS>	B-X
Leptospirosis	B-X
is	B-X
a	B-X
zoonotic	B-X
disease	B-X
caused	B-X
by	B-X
a	B-X
diverse	B-X
pathogenic	B-X
leptospira	B-X
species	B-X
and	B-X
serovars	B-X
.	B-X
Mepiquat	B-X
chloride	B-X
(	B-X
MC	B-X
)	B-X
is	B-X
a	B-X
plant	B-X
growth	B-X
regulator	B-X
widely	B-X
used	B-X
in	B-X
cotton	B-X
(	B-X
Gossypium	B-X
hirsutum	B-X
L.	B-X
)	B-X
production	B-X
to	B-X
suppress	B-X
excessive	B-X
vegetative	B-X
growth	B-X
,	B-X
increase	B-X
root	B-X
growth	B-X
and	B-X
avoid	B-X
yield	B-X
losses	B-X
.	B-X
To	B-X
increase	B-X
root	B-X
growth	B-X
,	B-X
cotton	B-X
seeds	B-X
were	B-X
treated	B-X
with	B-X
MC	B-X
to	B-X
increase	B-X
the	B-X
number	B-X
of	B-X
lateral	B-X
root	B-X
(	B-X
LRs	B-X
)	B-X
and	B-X
improve	B-X
drought	B-X
resistance	B-X
.	B-X
Despite	B-X
this	B-X
high	B-X
prevalence	B-X
,	B-X
30	B-X
%	B-X
of	B-X
patients	B-X
suffering	B-X
from	B-X
epilepsy	B-X
are	B-X
not	B-X
successfully	B-X
managed	B-X
by	B-X
current	B-X
medication	B-X
suggesting	B-X
a	B-X
critical	B-X
need	B-X
for	B-X
new	B-X
anti-epileptic	B-X
drugs	B-X
(	B-X
AEDs	B-X
)	B-X
.	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
discover	B-X
new	B-X
therapeutics	B-X
for	B-X
the	B-X
management	B-X
of	B-X
epilepsy	B-X
,	B-X
we	B-X
began	B-X
our	B-X
study	B-X
by	B-X
screening	B-X
drugs	B-X
that	B-X
,	B-X
like	B-X
some	B-X
currently	B-X
used	B-X
AEDs	B-X
,	B-X
inhibit	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
using	B-X
a	B-X
well-established	B-X
larval	B-X
zebrafish	B-X
model	B-X
.	B-X
In	B-X
this	B-X
model	B-X
,	B-X
7-day	B-X
post	B-X
fertilization	B-X
(	B-X
dpf	B-X
)	B-X
larvae	B-X
are	B-X
treated	B-X
with	B-X
the	B-X
widely	B-X
used	B-X
seizure-inducing	B-X
compound	B-X
pentylenetetrazol	B-X
(	B-X
PTZ	B-X
)	B-X
which	B-X
stimulates	B-X
a	B-X
rapid	B-X
increase	B-X
in	B-X
swimming	B-X
behavior	B-X
previously	B-X
determined	B-X
to	B-X
be	B-X
a	B-X
measurable	B-X
manifestation	B-X
of	B-X
seizures	B-X
.	B-X
In	B-X
our	B-X
first	B-X
screen	B-X
,	B-X
we	B-X
tested	B-X
a	B-X
number	B-X
of	B-X
different	B-X
HDAC	B-X
inhibitors	B-X
and	B-X
found	B-X
that	B-X
one	B-X
,	B-X
2-benzamido-1	B-X
4-naphthoquinone	B-X
(	B-X
NQN1	B-X
)	B-X
,	B-X
significantly	B-X
decreased	B-X
swim	B-X
activity	B-X
to	B-X
levels	B-X
equal	B-X
to	B-X
that	B-X
of	B-X
valproic	B-X
acid	B-X
,	B-X
2-n-propylpentanoic	B-X
acid	B-X
(	B-X
VPA	B-X
)	B-X
.	B-X
We	B-X
continued	B-X
to	B-X
screen	B-X
structurally	B-X
related	B-X
compounds	B-X
including	B-X
Vitamin	B-X
K3	B-X
(	B-X
VK3	B-X
)	B-X
and	B-X
a	B-X
number	B-X
of	B-X
novel	B-X
Vitamin	B-X
K	B-X
(	B-X
VK	B-X
)	B-X
analogs	B-X
.	B-X

Intracerebroventricular	O
drug	O
infusion	O
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
intracerebroventricular	B-X
infusion	B-X
of	B-X
dopamine	B-X
and	B-X
dopamine	B-X
agonists	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
dopamine	B-X
deficiency	B-X
as	B-X
an	B-X
experimental	B-X
approach	B-X
to	B-X
the	B-X
treatment	B-X
of	B-X
levodopa	B-X
induced	B-X
fluctuations	B-X
in	B-X
Parkinson	B-X
's	B-X
disease	B-X
.	B-X
The	B-X
animals	B-X
were	B-X
treated	B-X
with	B-X
intracerebral	B-X
infusions	B-X
of	B-X
dopamine	B-X
(	B-X
with	B-X
or	B-X
without	B-X
associated	B-X
intraperitoneal	B-X
administration	B-X
or	B-X
intracerebroventricular	B-X
infusion	B-X
of	B-X
pargyline	B-X
)	B-X
,	B-X
lisuride	B-X
and	B-X
pergolide	B-X
.	B-X
The	B-X
intracerebroventricular	B-X
infusion	B-X
of	B-X
these	B-X
drugs	B-X
was	B-X
performed	B-X
with	B-X
osmotic	B-X
minipumps	B-X
in	B-X
rats	B-X
and	B-X
with	B-X
infusaid	B-X
pumps	B-X
in	B-X
the	B-X
monkeys	B-X
.	B-X
The	B-X
infusion	B-X
of	B-X
dopamine	B-X
or	B-X
dopamine	B-X
agonists	B-X
in	B-X
rats	B-X
with	B-X
unilateral	B-X
lesions	B-X
by	B-X
6-OH-dopamine	B-X
produced	B-X
a	B-X
persistent	B-X
rotation	B-X
contralateral	B-X
to	B-X
the	B-X
lesioned	B-X
and	B-X
implanted	B-X
side	B-X
.	B-X
The	B-X
infusion	B-X
of	B-X
dopamine	B-X
reversed	B-X
reserpine-induced	B-X
akinesia	B-X
only	B-X
when	B-X
pargyline	B-X
was	B-X
associated	B-X
.	B-X
Intracerebral	B-X
infusion	B-X
of	B-X
dopamine	B-X
agonists	B-X
may	B-X
be	B-X
a	B-X
possible	B-X
experimental	B-X
alternative	B-X
to	B-X
the	B-X
treatment	B-X
of	B-X
levodopa	B-X
induced	B-X
fluctuations	B-X
in	B-X
Parkinson	B-X
's	B-X
disease	B-X
but	B-X
stable	B-X
and	B-X
soluble	B-X
dopamine	B-X
agonists	B-X
and	B-X
suitable	B-X
delivery	B-X
systems	B-X
are	B-X
needed	B-X
.	B-X

Rats	O
were	O
divided	O
into	O
two	O
groups	O
:	O
vehicle	O
(	O
saline	O
)	O
-	O
treated	O
and	O
soluble	O
TNFp55	B-Protein
receptor	I-Protein
(	O
sTNFp55R	B-Protein
,	O
50	O
mug	O
/	O
ml	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
-	O
treated	O
groups	O
.	O

The	O
dosage	O
of	O
sTNFp55R	B-Protein
was	O
determined	O
as	O
the	O
highest	O
dose	O
that	O
induced	O
SE	O
of	O
comparable	O
severity	O
in	O
100	O
%	O
of	O
animals	O
with	O
5	O
%	O
mortality	O
in	O
the	O
preliminary	O
study	O
.	O

Animals	O
were	O
anesthetized	O
(	O
Zolretil	O
,	O
50	O
mg	O
/	O
kg	O
,	O
i	O
.	O
m	O
.	O
;	O
Virbac	O
Laboratories	O
,	O
France	O
)	O
and	O
placed	O
in	O
a	O
stereotaxic	O
frames	O
.	O

For	O
the	O
osmotic	O
pump	O
implantation	O
,	O
holes	O
were	O
drilled	O
through	O
the	O
skull	O
to	O
introduce	O
a	O
brain	O
infusion	O
kit	O
1	O
(	O
Alzet	O
,	O
Cupertino	O
,	O
CA	O
)	O
into	O
the	O
right	O
lateral	O
ventricle	O
(	O
1	O
mm	O
posterior	O
;	O
1	O
.	O
5	O
mm	O
lateral	O
;	O
-	O
3	O
.	O
5	O
mm	O
depth	O
;	O
flat	O
skull	O
position	O
with	O
bregma	O
as	O
reference	O
)	O
,	O
according	O
to	O
the	O
atlas	O
of	O
Paxinos	O
and	O
Watson	O
[	O
24	O
]	O
.	O

The	O
infusion	O
kit	O
was	O
sealed	O
with	O
dental	O
cement	O
and	O
connected	O
to	O
an	O
osmotic	O
pump	O
(	O
1007D	O
,	O
Alzet	O
,	O
Cupertino	O
,	O
CA	O
)	O
.	O

The	O
pump	O
was	O
placed	O
in	O
a	O
subcutaneous	O
pocket	O
in	O
the	O
dorsal	O
region	O
.	O

Animals	O
received	O
0	O
.	O
5	O
mul	O
/	O
hr	O
of	O
vehicle	O
or	O
compound	O
for	O
1	O
week	O
.	O
<EOS>	B-X
Discovered	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
ago	B-X
,	B-X
vigabatrin	B-X
is	B-X
approved	B-X
in	B-X
more	B-X
than	B-X
50	B-X
countries	B-X
as	B-X
adjunctive	B-X
therapy	B-X
for	B-X
adult	B-X
patients	B-X
with	B-X
refractory	B-X
complex	B-X
partial	B-X
seizures	B-X
who	B-X
have	B-X
responded	B-X
inadequately	B-X
to	B-X
several	B-X
alternative	B-X
treatments	B-X
and	B-X
as	B-X
monotherapy	B-X
for	B-X
pediatric	B-X
patients	B-X
aged	B-X
1	B-X
month	B-X
to	B-X
2	B-X
years	B-X
with	B-X
infantile	B-X
spasms	B-X
.	B-X
Contrary	B-X
to	B-X
a	B-X
fairly	B-X
common	B-X
misperception	B-X
,	B-X
the	B-X
compound	B-X
's	B-X
mechanism	B-X
of	B-X
action	B-X
is	B-X
very	B-X
well-characterized	B-X
in	B-X
animal	B-X
models	B-X
and	B-X
cell	B-X
cultures	B-X
.	B-X
γ-Aminobutyric	B-X
acid	B-X
(	B-X
GABA	B-X
)	B-X
-ergic	B-X
synapses	B-X
comprise	B-X
approximately	B-X
30	B-X
%	B-X
of	B-X
all	B-X
synapses	B-X
within	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
,	B-X
and	B-X
therein	B-X
underlies	B-X
the	B-X
primary	B-X
mode	B-X
of	B-X
synaptic	B-X
inhibition	B-X
.	B-X
Despite	B-X
the	B-X
short	B-X
half-life	B-X
of	B-X
vigabatrin	B-X
in	B-X
the	B-X
body	B-X
(	B-X
5-7	B-X
h	B-X
)	B-X
and	B-X
its	B-X
relatively	B-X
low	B-X
concentration	B-X
in	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
10	B-X
%	B-X
of	B-X
the	B-X
concentration	B-X
observed	B-X
in	B-X
plasma	B-X
)	B-X
,	B-X
it	B-X
has	B-X
the	B-X
profound	B-X
effect	B-X
of	B-X
increasing	B-X
GABA	B-X
concentration	B-X
in	B-X
the	B-X
brain	B-X
for	B-X
more	B-X
than	B-X
a	B-X
week	B-X
after	B-X
a	B-X
single	B-X
dose	B-X
in	B-X
humans	B-X
.	B-X

Therefore	O
,	O
the	O
dose	O
of	O
sTNFp55R	B-Protein
was	O
0	O
.	O
6	O
mug	O
/	O
day	O
per	O
each	O
animal	O
.	O

The	O
compounds	O
began	O
to	O
be	O
immediately	O
infused	O
after	O
surgery	O
.	O

Since	O
the	O
volume	O
of	O
vasogenic	O
edema	O
peaked	O
at	O
2	O
-	O
3	O
days	O
after	O
SE	O
in	O
our	O
previous	O
studies	O
[	O
5	O
-	O
8	O
,	O
20	O
]	O
,	O
we	O
chose	O
this	O
time	O
point	O
.	O

Thus	O
,	O
our	O
experimental	O
schedules	O
at	O
least	O
inhibit	O
the	O
function	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
from	O
3	O
days	O
prior	O
to	O
SE	O
to	O
4	O
days	O
after	O
SE	O
when	O
the	O
volume	O
of	O
vasogenic	O
edema	O
peaked	O
.	O

Seizure	O
induction	O
<EOS>	B-X
A	B-X
model	B-X
of	B-X
ECT	B-X
seizure	B-X
induction	B-X
by	B-X
rapid	B-X
kindling	B-X
is	B-X
described	B-X
.	B-X
Electroconvulsive	B-X
therapy	B-X
(	B-X
ECT	B-X
)	B-X
is	B-X
indicated	B-X
for	B-X
various	B-X
psychiatric	B-X
situations	B-X
that	B-X
are	B-X
difficult	B-X
to	B-X
manage	B-X
otherwise	B-X
and	B-X
may	B-X
be	B-X
regarded	B-X
as	B-X
a	B-X
last	B-X
resort	B-X
but	B-X
seizure	B-X
induction	B-X
is	B-X
sometimes	B-X
difficult	B-X
,	B-X
resulting	B-X
in	B-X
inadequate	B-X
trials	B-X
and	B-X
futile	B-X
outcomes	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
utility	B-X
of	B-X
suggestive	B-X
seizure	B-X
induction	B-X
for	B-X
inpatient	B-X
work-up	B-X
of	B-X
suspected	B-X
psychogenic	B-X
nonepileptic	B-X
seizures	B-X
(	B-X
PNES	B-X
)	B-X
.	B-X
Seizure	B-X
induction	B-X
was	B-X
considered	B-X
ethical	B-X
,	B-X
preferring	B-X
the	B-X
least	B-X
invasive	B-X
techniques	B-X
.	B-X

Three	O
days	O
after	O
surgery	O
,	O
rats	O
were	O
treated	O
with	O
pilocarpine	O
(	O
380	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
at	O
20	O
min	O
after	O
methylscopolamine	O
(	O
5	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

Using	O
this	O
treatment	O
paradigm	O
,	O
behavioral	O
seizures	O
typically	O
began	O
within	O
20	O
-	O
40	O
min	O
.	O

Approximately	O
80	O
%	O
of	O
pilocarpine	O
treated	O
rats	O
showed	O
acute	O
behavioral	O
features	O
of	O
SE	O
(	O
including	O
akinesia	O
,	O
facial	O
automatisms	O
,	O
limbic	O
seizures	O
consisting	O
of	O
forelimb	O
clonus	O
with	O
rearing	O
,	O
salivation	O
,	O
masticatory	O
jaw	O
movements	O
,	O
and	O
falling	O
)	O
.	O

We	O
applied	O
the	O
2	O
hr	O
-	O
SE	O
rat	O
model	O
,	O
because	O
>	O
90	O
%	O
of	O
the	O
rats	O
that	O
we	O
monitored	O
in	O
our	O
previous	O
studies	O
[	O
25	O
]	O
displayed	O
spontaneous	O
,	O
recurrent	O
seizures	O
within	O
1	O
-	O
3	O
months	O
after	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
.	O

Diazepam	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Hoffman	O
Ia	O
Roche	O
,	O
Neuilly	O
sur	O
-	O
Seine	O
)	O
was	O
administered	O
2	O
hours	O
after	O
onset	O
of	O
SE	O
and	O
repeated	O
,	O
as	O
needed	O
.	O

The	O
rats	O
were	O
then	O
observed	O
3	O
-	O
4	O
hours	O
a	O
day	O
in	O
the	O
vivarium	O
for	O
general	O
behavior	O
and	O
occurrence	O
of	O
spontaneous	O
seizures	O
.	O

Non	O
-	O
experienced	O
SE	O
(	O
non	O
-	O
SE	O
)	O
rats	O
(	O
showing	O
only	O
acute	O
seizure	O
behaviors	O
during	O
10	O
-	O
30	O
min	O
,	O
n	O
=	O
8	O
)	O
and	O
age	O
-	O
matched	O
normal	O
rats	O
were	O
used	O
as	O
controls	O
(	O
n	O
=	O
7	O
)	O
.	O

Tissue	O
processing	O
<EOS>	B-X
Tissue	B-X
engineering	B-X
technology	B-X
provides	B-X
a	B-X
revolutionary	B-X
strategy	B-X
to	B-X
completely	B-X
restore	B-X
the	B-X
structure	B-X
and	B-X
function	B-X
of	B-X
damaged	B-X
tissues	B-X
or	B-X
organs	B-X
.	B-X
Digital	B-X
light	B-X
processing	B-X
(	B-X
DLP	B-X
)	B-X
,	B-X
as	B-X
a	B-X
kind	B-X
of	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
printing	B-X
technology	B-X
,	B-X
has	B-X
great	B-X
advantages	B-X
in	B-X
printing	B-X
resolution	B-X
and	B-X
efficiency	B-X
,	B-X
with	B-X
low	B-X
requirements	B-X
for	B-X
bioinks	B-X
.	B-X
Tissue	B-X
engineering	B-X
has	B-X
already	B-X
proven	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
regenerating	B-X
bone	B-X
tissue	B-X
,	B-X
but	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
able	B-X
to	B-X
become	B-X
an	B-X
economically	B-X
viable	B-X
solution	B-X
due	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
tissue	B-X
,	B-X
which	B-X
is	B-X
very	B-X
difficult	B-X
to	B-X
be	B-X
replicated	B-X
,	B-X
eventually	B-X
requiring	B-X
the	B-X
utilization	B-X
of	B-X
highly	B-X
labor-intensive	B-X
processes	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
present	B-X
issues	B-X
surrounding	B-X
the	B-X
allograft	B-X
industry	B-X
,	B-X
including	B-X
regulation	B-X
of	B-X
tissues	B-X
and	B-X
tissue	B-X
banks	B-X
and	B-X
procurement	B-X
,	B-X
processing	B-X
,	B-X
sterilization	B-X
,	B-X
and	B-X
storage	B-X
of	B-X
allograft	B-X
tissue	B-X
.	B-X
Tissue	B-X
bank	B-X
regulation	B-X
is	B-X
ultimately	B-X
under	B-X
the	B-X
jurisdiction	B-X
and	B-X
authority	B-X
of	B-X
the	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
;	B-X
some	B-X
individual	B-X
states	B-X
regulate	B-X
tissue	B-X
banks	B-X
.	B-X
The	B-X
American	B-X
Association	B-X
of	B-X
Tissue	B-X
Banks	B-X
is	B-X
a	B-X
scientific	B-X
organization	B-X
that	B-X
encourages	B-X
education	B-X
,	B-X
research	B-X
,	B-X
and	B-X
voluntary	B-X
accreditation	B-X
of	B-X
tissue	B-X
banks	B-X
.	B-X
It	B-X
promotes	B-X
safety	B-X
and	B-X
standards	B-X
for	B-X
retrieval	B-X
,	B-X
processing	B-X
,	B-X
storage	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
transplantable	B-X
human	B-X
tissue	B-X
.	B-X
Tissue	B-X
sterilization	B-X
is	B-X
difficult	B-X
and	B-X
controversial	B-X
.	B-X
Tissue	B-X
banks	B-X
historically	B-X
have	B-X
used	B-X
one	B-X
of	B-X
two	B-X
methods	B-X
of	B-X
sterilization	B-X
,	B-X
ethylene	B-X
oxide	B-X
or	B-X
gamma	B-X
radiation	B-X
.	B-X

At	O
designated	O
time	O
points	O
(	O
non	O
-	O
SE	O
:	O
12	O
hr	O
,	O
1	O
day	O
,	O
2	O
days	O
,	O
3	O
days	O
,	O
4	O
days	O
and	O
1	O
week	O
after	O
SE	O
;	O
n	O
=	O
5	O
,	O
for	O
each	O
time	O
point	O
)	O
,	O
animals	O
were	O
perfused	O
transcardially	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
in	O
0	O
.	O
1	O
M	O
phosphate	O
buffer	O
(	O
PB	O
,	O
pH	O
7	O
.	O
4	O
)	O
under	O
urethane	O
anesthesia	O
(	O
1	O
.	O
5	O
g	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
;	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

The	O
brains	O
were	O
removed	O
,	O
and	O
postfixed	O
in	O
the	O
same	O
fixative	O
for	O
4	O
hr	O
.	O

The	O
brain	O
tissues	O
were	O
cryoprotected	O
by	O
infiltration	O
with	O
30	O
%	O
sucrose	O
overnight	O
.	O

Thereafter	O
,	O
the	O
entire	O
hippocampus	O
was	O
frozen	O
and	O
sectioned	O
with	O
a	O
cryostat	O
at	O
30	O
mum	O
and	O
consecutive	O
sections	O
were	O
contained	O
in	O
six	O
-	O
well	O
plates	O
containing	O
PBS	O
.	O

For	O
stereological	O
study	O
,	O
every	O
sixth	O
section	O
in	O
the	O
series	O
throughout	O
the	O
entire	O
hippocampus	O
was	O
used	O
in	O
some	O
animals	O
.	O

Immunohistochemistry	O
<EOS>	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
for	B-X
tissue-based	B-X
diagnostics	B-X
and	B-X
biomarker	B-X
detection	B-X
with	B-X
broad	B-X
worldwide	B-X
adoption	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
in	B-X
many	B-X
veterinary	B-X
laboratories	B-X
for	B-X
diagnostic	B-X
and	B-X
research	B-X
purposes	B-X
.	B-X
Next-Generation	B-X
Pathology	B-X
by	B-X
Multiplexed	B-X
Immunohistochemistry	B-X
.	B-X

Free	O
-	O
floating	O
sections	O
were	O
first	O
incubated	O
with	O
10	O
%	O
normal	O
goat	O
serum	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

They	O
were	O
then	O
incubated	O
in	O
rabbit	O
anti	O
-	O
MPO	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Thermo	O
fisher	O
scientific	O
)	O
or	O
rabbit	O
anti	O
-	O
MIP	O
-	O
2	O
IgG	O
(	O
1	O
:	O
200	O
,	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
in	O
PBS	O
containing	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
and	O
2	O
%	O
normal	O
goat	O
serum	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
three	O
times	O
for	O
10	O
min	O
with	O
PBS	O
,	O
the	O
sections	O
were	O
incubated	O
sequentially	O
,	O
in	O
goat	O
anti	O
-	O
rabbit	O
or	O
horse	O
anti	O
-	O
mouse	O
IgG	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
and	O
ABC	O
complex	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
,	O
diluted	O
1	O
:	O
200	O
in	O
the	O
same	O
solution	O
as	O
the	O
primary	O
antiserum	O
.	O

Between	O
the	O
incubations	O
,	O
the	O
tissues	O
were	O
washed	O
with	O
PBS	O
three	O
times	O
for	O
10	O
min	O
each	O
.	O
<EOS>	B-X
Osteosarcoma	B-X
MG-63	B-X
and	B-X
colon	B-X
cancer	B-X
DLD1	B-X
cells	B-X
were	B-X
seeded	B-X
at	B-X
1	B-X
×	B-X
10	B-X
For	B-X
TPIA	B-X
,	B-X
nitrocellulose	B-X
membrane	B-X
was	B-X
used	B-X
to	B-X
imprint	B-X
fresh	B-X
sections	B-X
of	B-X
healthy	B-X
and	B-X
infected	B-X
plant	B-X
materials	B-X
,	B-X
and	B-X
for	B-X
DIBA	B-X
10	B-X
microl	B-X
of	B-X
extracts	B-X
was	B-X
doted	B-X
onto	B-X
nitrocellulose	B-X
membranes	B-X
.	B-X
Both	B-X
membranes	B-X
were	B-X
incubated	B-X
1	B-X
hour	B-X
in	B-X
blocking	B-X
buffer	B-X
,	B-X
and	B-X
then	B-X
incubated	B-X
2	B-X
h	B-X
in	B-X
1:1000	B-X
dilution	B-X
of	B-X
IgG-conjugate	B-X
.	B-X
After	B-X
incubation	B-X
the	B-X
membranes	B-X
were	B-X
washed	B-X
three	B-X
times	B-X
with	B-X
PBS-T	B-X
buffer	B-X
for	B-X
15	B-X
min	B-X
.	B-X
After	B-X
some	B-X
minutes	B-X
prints	B-X
or	B-X
blots	B-X
of	B-X
infected	B-X
tissues	B-X
turned	B-X
dark	B-X
violet	B-X
,	B-X
whereas	B-X
prints	B-X
or	B-X
blots	B-X
of	B-X
healthy	B-X
ones	B-X
did	B-X
not	B-X
show	B-X
any	B-X
color	B-X
changes	B-X
.	B-X

To	O
confirm	O
vasogenic	O
edema	O
,	O
some	O
tissue	O
sections	O
were	O
reacted	O
for	O
serum	O
-	O
proteins	O
using	O
horse	O
anti	O
-	O
rat	O
IgG	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
as	O
a	O
primary	O
antibody	O
.	O

The	O
sections	O
were	O
visualized	O
with	O
3	O
,	O
3	O
'	O
-	O
diaminobenzidine	O
(	O
DAB	O
,	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
in	O
0	O
.	O
1	O
M	O
Tris	O
buffer	O
and	O
mounted	O
on	O
the	O
gelatin	O
-	O
coated	O
slides	O
.	O

The	O
immunoreactions	O
were	O
observed	O
under	O
the	O
Axioscope	O
microscope	O
(	O
Carl	O
Zeiss	O
,	O
Munchen	O
-	O
Hallbergmoos	O
)	O
.	O

For	O
negative	O
controls	O
,	O
rat	O
hippocampal	O
tissues	O
were	O
incubated	O
with	O
1	O
mug	O
of	O
the	O
antibody	O
that	O
was	O
preincubated	O
with	O
1	O
mug	O
of	O
purified	O
peptide	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
or	O
incubated	O
with	O
pre	O
-	O
immune	O
serum	O
instead	O
of	O
the	O
primary	O
antibody	O
.	O

For	O
negative	O
controls	O
,	O
tissues	O
were	O
incubated	O
with	O
pre	O
-	O
immune	O
serum	O
instead	O
of	O
primary	O
antibody	O
.	O

Double	O
immunofluorescence	O
study	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
we	B-X
investigated	B-X
and	B-X
compared	B-X
the	B-X
expression	B-X
of	B-X
two	B-X
endothelial	B-X
cell	B-X
markers	B-X
:	B-X
platelet	B-X
endothelial	B-X
cell	B-X
adhesion	B-X
molecule	B-X
(	B-X
PECAM-1	B-X
)	B-X
(	B-X
CD31	B-X
)	B-X
and	B-X
endoglin	B-X
(	B-X
CD105	B-X
)	B-X
using	B-X
immunohistochemistry	B-X
(	B-X
IHC	B-X
)	B-X
and	B-X
immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
to	B-X
identify	B-X
and	B-X
quantify	B-X
newly	B-X
formed	B-X
blood	B-X
vessels	B-X
in	B-X
subcutaneous	B-X
implants	B-X
of	B-X
polyether-polyurethane	B-X
sponge	B-X
of	B-X
formalin-fixed	B-X
paraffin-embedded	B-X
tissue	B-X
.	B-X
Nowadays	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
find	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
molecular	B-X
tools	B-X
available	B-X
to	B-X
study	B-X
parasite-host	B-X
cell	B-X
interactions	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
protocol	B-X
demonstrates	B-X
how	B-X
to	B-X
use	B-X
polyclonal	B-X
and	B-X
monoclonal	B-X
antibodies	B-X
raised	B-X
in	B-X
the	B-X
same	B-X
species	B-X
to	B-X
perform	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
to	B-X
study	B-X
host	B-X
cell	B-X
and	B-X
pathogen	B-X
interactions	B-X
.	B-X
To	B-X
achieve	B-X
the	B-X
double	B-X
labeling	B-X
immunofluorescence	B-X
,	B-X
it	B-X
is	B-X
crucial	B-X
to	B-X
incubate	B-X
first	B-X
the	B-X
mouse	B-X
polyclonal	B-X
antibody	B-X
and	B-X
then	B-X
follow	B-X
the	B-X
incubation	B-X
with	B-X
the	B-X
secondary	B-X
mouse	B-X
IgG	B-X
antibody	B-X
conjugated	B-X
to	B-X
any	B-X
fluorochrome	B-X
.	B-X
Additionally	B-X
,	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
perform	B-X
triple	B-X
labeling	B-X
immunofluorescence	B-X
using	B-X
a	B-X
third	B-X
antibody	B-X
raised	B-X
in	B-X
a	B-X
different	B-X
species	B-X
.	B-X

Sections	O
were	O
incubated	O
with	O
3	O
%	O
bovine	O
serum	B-Protein
albumin	I-Protein
in	O
PBS	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Sections	O
were	O
then	O
incubated	O
in	O
a	O
mixture	O
of	O
goat	O
anti	O
-	O
TNF	O
-	O
alpha	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
R	O
&	O
D	O
systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
/	O
mouse	O
anti	O
-	O
OX	O
-	O
42	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Serotec	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
an	O
astroglial	O
marker	O
,	O
Millipore	O
Corporation	O
,	O
Billerica	O
,	O
MA	O
)	O
/	O
rabbit	O
anti	O
-	O
TNFp55R	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
TNFp75R	O
IgG	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
(	O
1	O
:	O
1000	O
,	O
Covance	O
,	O
Berkeley	O
,	O
CA	O
)	O
/	O
rabbit	O
anti	O
-	O
TNFp75R	O
IgG	O
,	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
NF	O
-	O
kappaB	O
(	O
p65	O
-	O
Ser276	O
,	O
p65	O
-	O
Ser311	O
,	O
p65	O
-	O
Ser529	O
,	O
and	O
p65	O
-	O
Thr435	O
)	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
/	O
rabbit	O
anti	O
-	O
p65	O
-	O
Thr435	O
NF	O
-	O
kappaB	O
IgG	O
,	O
mouse	O
anti	O
-	O
SMI	O
-	O
71	O
IgM	O
/	O
rabbit	O
anti	O
-	O
GLUT	O
-	O
1	O
IgG	O
(	O
1	O
:	O
100	O
,	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
or	O
mouse	O
anti	O
-	O
GFAP	O
IgG	O
/	O
rabbit	O
anti	O
-	O
MIP	O
-	O
2	O
IgG	O
(	O
1	O
:	O
100	O
)	O
in	O
PBS	O
containing	O
0	O
.	O
3	O
%	O
triton	O
X	O
-	O
100	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
three	O
times	O
for	O
10	O
minutes	O
with	O
PBS	O
,	O
sections	O
were	O
also	O
incubated	O
in	O
a	O
mixture	O
of	O
FITC	O
-	O
and	O
Cy3	O
-	O
conjugated	O
secondary	O
antisera	O
(	O
Amersham	O
,	O
San	O
Francisco	O
,	O
CA	O
)	O
,	O
diluted	O
1	O
:	O
200	O
,	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
.	O

The	O
sections	O
were	O
washed	O
three	O
times	O
for	O
10	O
min	O
with	O
PBS	O
,	O
and	O
mounted	O
on	O
gelatin	O
-	O
coated	O
slides	O
.	O

For	O
nuclei	O
counterstaining	O
,	O
we	O
used	O
Vectashield	O
mounting	O
medium	O
with	O
DAPI	O
(	O
Vector	O
,	O
Burlingame	O
,	O
CA	O
)	O
.	O

All	O
images	O
were	O
captured	O
using	O
an	O
AxioImage	O
M2	O
microscope	O
and	O
AxioVision	O
Rel	O
.	O

4	O
.	O
8	O
software	O
.	O
<EOS>	B-X
This	B-X
is	B-X
in	B-X
addition	B-X
to	B-X
other	B-X
eHealth	B-X
applications	B-X
available	B-X
on	B-X
other	B-X
platforms	B-X
such	B-X
as	B-X
PC	B-X
software	B-X
,	B-X
web	B-X
sites	B-X
and	B-X
even	B-X
gaming	B-X
consoles	B-X
.	B-X
AKL-T01	B-X
is	B-X
an	B-X
investigational	B-X
digital	B-X
therapeutic	B-X
designed	B-X
to	B-X
target	B-X
attention	B-X
and	B-X
cognitive	B-X
control	B-X
delivered	B-X
through	B-X
a	B-X
video	B-X
game-like	B-X
interface	B-X
via	B-X
at-home	B-X
play	B-X
for	B-X
25	B-X
min	B-X
per	B-X
day	B-X
,	B-X
5	B-X
days	B-X
per	B-X
week	B-X
for	B-X
4	B-X
weeks	B-X
.	B-X
The	B-X
current	B-X
version	B-X
of	B-X
MetaboAnalyst	B-X
(	B-X
4.0	B-X
)	B-X
features	B-X
a	B-X
complete	B-X
overhaul	B-X
of	B-X
the	B-X
user	B-X
interface	B-X
and	B-X
significantly	B-X
expanded	B-X
underlying	B-X
knowledge	B-X
bases	B-X
(	B-X
compound	B-X
database	B-X
,	B-X
pathway	B-X
libraries	B-X
,	B-X
and	B-X
metabolite	B-X
sets	B-X
)	B-X
.	B-X
This	B-X
article	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
main	B-X
functional	B-X
modules	B-X
and	B-X
the	B-X
general	B-X
workflow	B-X
of	B-X
MetaboAnalyst	B-X
4.0	B-X
,	B-X
followed	B-X
by	B-X
12	B-X
detailed	B-X
protocols	B-X
:	B-X
©	B-X
2019	B-X
by	B-X
John	B-X
Wiley	B-X
&	B-X
Sons	B-X
,	B-X
Inc	B-X
.	B-X
Basic	B-X
Protocol	B-X
1	B-X
:	B-X
Data	B-X
uploading	B-X
,	B-X
processing	B-X
,	B-X
and	B-X
normalization	B-X
Basic	B-X
Protocol	B-X
2	B-X
:	B-X
Identification	B-X
of	B-X
significant	B-X
variables	B-X
Basic	B-X
Protocol	B-X
3	B-X
:	B-X
Multivariate	B-X
exploratory	B-X
data	B-X
analysis	B-X
Basic	B-X
Protocol	B-X
4	B-X
:	B-X
Functional	B-X
interpretation	B-X
of	B-X
metabolomic	B-X
data	B-X
Basic	B-X
Protocol	B-X
5	B-X
:	B-X
Biomarker	B-X
analysis	B-X
based	B-X
on	B-X
receiver	B-X
operating	B-X
characteristic	B-X
(	B-X
ROC	B-X
)	B-X
curves	B-X
Basic	B-X
Protocol	B-X
6	B-X
:	B-X
Time-series	B-X
and	B-X
two-factor	B-X
data	B-X
analysis	B-X
Basic	B-X
Protocol	B-X
7	B-X
:	B-X
Sample	B-X
size	B-X
estimation	B-X
and	B-X
power	B-X
analysis	B-X
Basic	B-X
Protocol	B-X
8	B-X
:	B-X
Joint	B-X
pathway	B-X
analysis	B-X
Basic	B-X
Protocol	B-X
9	B-X
:	B-X
MS	B-X
peaks	B-X
to	B-X
pathway	B-X
activities	B-X
Basic	B-X
Protocol	B-X
10	B-X
:	B-X
Biomarker	B-X
meta-analysis	B-X
Basic	B-X
Protocol	B-X
11	B-X
:	B-X
Knowledge-based	B-X
network	B-X
exploration	B-X
of	B-X
multi-omics	B-X
data	B-X
Basic	B-X
Protocol	B-X
12	B-X
:	B-X
MetaboAnalystR	B-X
introduction	B-X
.	B-X

Fluoro	O
-	O
Jade	O
B	O
staining	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
damage/death	B-X
of	B-X
granule	B-X
cells	B-X
in	B-X
the	B-X
gerbil	B-X
DG	B-X
at	B-X
5	B-X
days	B-X
after	B-X
various	B-X
durations	B-X
(	B-X
5	B-X
,	B-X
10	B-X
,	B-X
and	B-X
15	B-X
min	B-X
)	B-X
of	B-X
single	B-X
tGCI	B-X
and	B-X
repeated	B-X
tGCI	B-X
(	B-X
two	B-X
5-min	B-X
tGCI	B-X
with	B-X
1-h	B-X
interval	B-X
)	B-X
using	B-X
cresyl	B-X
violet	B-X
staining	B-X
,	B-X
NeuN	B-X
immunohistochemistry	B-X
and	B-X
Fluoro-Jade	B-X
B	B-X
(	B-X
F-J	B-X
B	B-X
)	B-X
histofluorescence	B-X
staining	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
repeated	B-X
tGCI-operated	B-X
group	B-X
,	B-X
massive	B-X
neuronal	B-X
death	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
granule	B-X
cell	B-X
layer	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
polymorphic	B-X
layer	B-X
by	B-X
using	B-X
F-J	B-X
B	B-X
histofluorescence	B-X
staining	B-X
.	B-X
Fluoro-Jade	B-X
B	B-X
is	B-X
known	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
fluorescent	B-X
marker	B-X
for	B-X
the	B-X
localization	B-X
of	B-X
neuronal	B-X
degeneration	B-X
during	B-X
acute	B-X
neuronal	B-X
distress	B-X
.	B-X
However	B-X
,	B-X
one	B-X
study	B-X
suggested	B-X
that	B-X
fluoro-Jade	B-X
B	B-X
stains	B-X
reactive	B-X
astroglia	B-X
in	B-X
the	B-X
primate	B-X
cerebral	B-X
cortex	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
staining	B-X
of	B-X
fluoro-Jade	B-X
B	B-X
alone	B-X
or	B-X
combined	B-X
with	B-X
specific	B-X
markers	B-X
for	B-X
detection	B-X
of	B-X
glial	B-X
fibrillary	B-X
acidic	B-X
protein	B-X
(	B-X
GFAP	B-X
)	B-X
or	B-X
activated	B-X
CD68	B-X
microglia	B-X
in	B-X
the	B-X
double	B-X
APP	B-X
(	B-X
SL	B-X
)	B-X
/PS1	B-X
KI	B-X
transgenic	B-X
mice	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
,	B-X
which	B-X
display	B-X
a	B-X
massive	B-X
neuronal	B-X
loss	B-X
in	B-X
the	B-X
CA1	B-X
region	B-X
of	B-X
the	B-X
hippocampus	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
fluoro-Jade	B-X
B	B-X
did	B-X
not	B-X
stain	B-X
normal	B-X
and	B-X
degenerating	B-X
neurons	B-X
in	B-X
this	B-X
double	B-X
mouse	B-X
transgenic	B-X
model	B-X
.	B-X
Fluoro-Jade	B-X
B	B-X
was	B-X
co-localized	B-X
with	B-X
Abeta	B-X
in	B-X
the	B-X
core	B-X
of	B-X
amyloid	B-X
deposits	B-X
and	B-X
in	B-X
glia-like	B-X
cells	B-X
expressing	B-X
Abeta	B-X
.	B-X
Furthermore	B-X
,	B-X
fluoro-Jade	B-X
B	B-X
was	B-X
co-localized	B-X
with	B-X
CD68/macrosialin	B-X
,	B-X
a	B-X
specific	B-X
marker	B-X
of	B-X
activated	B-X
microglia	B-X
,	B-X
and	B-X
with	B-X
GFAP	B-X
for	B-X
astrocytes	B-X
in	B-X
APP	B-X
(	B-X
SL	B-X
)	B-X
/PS1	B-X
KI	B-X
transgenic	B-X
mice	B-X
of	B-X
AD	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
showed	B-X
that	B-X
fluoro-Jade	B-X
B	B-X
can	B-X
be	B-X
used	B-X
to	B-X
label	B-X
activated	B-X
microglia	B-X
and	B-X
astrocytes	B-X
which	B-X
are	B-X
abundant	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
these	B-X
AD	B-X
transgenic	B-X
mice	B-X
.	B-X

Fluoro	O
-	O
Jade	O
B	O
(	O
FJB	O
)	O
staining	O
was	O
used	O
to	O
identify	O
degenerating	O
neurons	O
in	O
tissues	O
obtained	O
from	O
non	O
-	O
SE	O
and	O
3	O
days	O
post	O
-	O
SE	O
animals	O
in	O
every	O
group	O
.	O

In	O
our	O
previous	O
[	O
18	O
,	O
25	O
]	O
and	O
preliminary	O
data	O
,	O
neuronal	O
damage	O
was	O
first	O
detectable	O
at	O
3	O
days	O
after	O
SE	O
.	O
<EOS>	B-X
J.	B-X
Solé-Violán	B-X
,	B-X
M.	B-X
López-Rodríguez	B-X
,	B-X
E.	B-X
Herrera-Ramos	B-X
,	B-X
J.	B-X
Ruíz-Hernández	B-X
,	B-X
L.	B-X
Borderías	B-X
,	B-X
J.	B-X
Horcajada	B-X
,	B-X
N.	B-X
González-Quevedo	B-X
,	B-X
O.	B-X
Rajas	B-X
,	B-X
M.	B-X
Briones	B-X
,	B-X
F.	B-X
Rodríguez	B-X
de	B-X
Castro	B-X
,	B-X
C.	B-X
Rodríguez	B-X
Gallego	B-X
P003	B-X
-	B-X
Brain	B-X
protective	B-X
effects	B-X
of	B-X
intravenous	B-X
immunoglobulin	B-X
through	B-X
inhibition	B-X
of	B-X
complement	B-X
activation	B-X
and	B-X
apoptosis	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
sepsis	B-X
F.	B-X
Esen	B-X
,	B-X
G.	B-X
Orhun	B-X
,	B-X
P.	B-X
Ergin	B-X
Ozcan	B-X
,	B-X
E.	B-X
Senturk	B-X
,	B-X
C.	B-X
Ugur	B-X
Yilmaz	B-X
,	B-X
N.	B-X
Orhan	B-X
,	B-X
N.	B-X
Arican	B-X
,	B-X
M.	B-X
Kaya	B-X
,	B-X
M.	B-X
Kucukerden	B-X
,	B-X
M.	B-X
Giris	B-X
,	B-X
U.	B-X
Akcan	B-X
,	B-X
S.	B-X
Bilgic	B-X
Gazioglu	B-X
,	B-X
E.	B-X
Tuzun	B-X
P004	B-X
-	B-X
Adenosine	B-X
a1	B-X
receptor	B-X
dysfunction	B-X
is	B-X
associated	B-X
with	B-X
leukopenia	B-X
:	B-X
A	B-X
possible	B-X
mechanism	B-X
for	B-X
sepsis-induced	B-X
leukopenia	B-X
R.	B-X
Riff	B-X
,	B-X
O.	B-X
Naamani	B-X
,	B-X
A.	B-X
Douvdevani	B-X
P005	B-X
-	B-X
Analysis	B-X
of	B-X
neutrophil	B-X
by	B-X
hyper	B-X
spectral	B-X
imaging	B-X
-	B-X
A	B-X
preliminary	B-X
report	B-X
R.	B-X
Takegawa	B-X
,	B-X
H.	B-X
Yoshida	B-X
,	B-X
T.	B-X
Hirose	B-X
,	B-X
N.	B-X
Yamamoto	B-X
,	B-X
H.	B-X
Hagiya	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
Y.	B-X
Akeda	B-X
,	B-X
O.	B-X
Tasaki	B-X
,	B-X
K.	B-X
Tomono	B-X
,	B-X
T.	B-X
Shimazu	B-X
P006	B-X
-	B-X
Chemiluminescent	B-X
intensity	B-X
assessed	B-X
by	B-X
eaa	B-X
predicts	B-X
the	B-X
incidence	B-X
of	B-X
postoperative	B-X
infectious	B-X
complications	B-X
following	B-X
gastrointestinal	B-X
surgery	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Kubo	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
T.	B-X
Ikeda	B-X
P007	B-X
-	B-X
Serial	B-X
change	B-X
of	B-X
c1	B-X
inhibitor	B-X
in	B-X
patients	B-X
with	B-X
sepsis	B-X
–	B-X
A	B-X
prospective	B-X
observational	B-X
study	B-X
T.	B-X
Hirose	B-X
,	B-X
H.	B-X
Ogura	B-X
,	B-X
H.	B-X
Takahashi	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
J.	B-X
Kang	B-X
,	B-X
Y.	B-X
Nakamura	B-X
,	B-X
T.	B-X
Kojima	B-X
,	B-X
T.	B-X
Shimazu	B-X
P008	B-X
-	B-X
Comparison	B-X
of	B-X
bacteremia	B-X
and	B-X
sepsis	B-X
on	B-X
sepsis	B-X
related	B-X
biomarkers	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
Y.	B-X
Izutani	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
S.	B-X
Ono	B-X
P009	B-X
-	B-X
The	B-X
changes	B-X
of	B-X
procalcitonin	B-X
levels	B-X
in	B-X
critical	B-X
patients	B-X
with	B-X
abdominal	B-X
septic	B-X
shock	B-X
during	B-X
blood	B-X
purification	B-X
T.	B-X
Taniguchi	B-X
,	B-X
M.	B-X
O	B-X
P010	B-X
-	B-X
Validation	B-X
of	B-X
a	B-X
new	B-X
sensitive	B-X
point	B-X
of	B-X
care	B-X
device	B-X
for	B-X
rapid	B-X
measurement	B-X
of	B-X
procalcitonin	B-X
C.	B-X
Dinter	B-X
,	B-X
J.	B-X
Lotz	B-X
,	B-X
B.	B-X
Eilers	B-X
,	B-X
C.	B-X
Wissmann	B-X
,	B-X
R.	B-X
Lott	B-X
P011	B-X
-	B-X
Infection	B-X
biomarkers	B-X
in	B-X
primary	B-X
care	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
tract	B-X
infections	B-X
–	B-X
Comparison	B-X
of	B-X
procalcitonin	B-X
and	B-X
C-reactive	B-X
protein	B-X
M.	B-X
M.	B-X
Meili	B-X
,	B-X
P.	B-X
S.	B-X
Schuetz	B-X
P012	B-X
-	B-X
Do	B-X
we	B-X
need	B-X
a	B-X
lower	B-X
procalcitonin	B-X
cut	B-X
off	B-X
?	B-X
H.	B-X
Hawa	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
Aburageila	B-X
,	B-X
N.	B-X
Salahuddin	B-X
P013	B-X
-	B-X
The	B-X
predictive	B-X
role	B-X
of	B-X
C-reactive	B-X
protein	B-X
and	B-X
procalcitonin	B-X
biomarkers	B-X
in	B-X
central	B-X
nervous	B-X
system	B-X
infections	B-X
with	B-X
extensively	B-X
drug	B-X
resistant	B-X
bacteria	B-X
V.	B-X
Chantziara	B-X
,	B-X
S.	B-X
Georgiou	B-X
,	B-X
A.	B-X
Tsimogianni	B-X
,	B-X
P.	B-X
Alexandropoulos	B-X
,	B-X
A.	B-X
Vassi	B-X
,	B-X
F.	B-X
Lagiou	B-X
,	B-X
M.	B-X
Valta	B-X
,	B-X
G.	B-X
Micha	B-X
,	B-X
E.	B-X
Chinou	B-X
,	B-X
G.	B-X
Michaloudis	B-X
P014	B-X
-	B-X
Changes	B-X
in	B-X
endotoxin	B-X
activity	B-X
assay	B-X
and	B-X
procalcitonin	B-X
levels	B-X
after	B-X
direct	B-X
hemoperfusion	B-X
with	B-X
polymyxin-b	B-X
immobilized	B-X
fiber	B-X
A.	B-X
Kodaira	B-X
,	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
Y.	B-X
Izutani	B-X
,	B-X
H.	B-X
Imaizumi	B-X
P015	B-X
-	B-X
Diagnostic	B-X
usefullness	B-X
of	B-X
combination	B-X
biomarkers	B-X
on	B-X
ICU	B-X
admission	B-X
M.	B-X
V.	B-X
De	B-X
la	B-X
Torre-Prados	B-X
,	B-X
A.	B-X
Garcia-De	B-X
la	B-X
Torre	B-X
,	B-X
A.	B-X
Enguix-Armada	B-X
,	B-X
A.	B-X
Puerto-Morlan	B-X
,	B-X
V.	B-X
Perez-Valero	B-X
,	B-X
A.	B-X
Garcia-Alcantara	B-X
P016	B-X
-	B-X
Platelet	B-X
function	B-X
analysis	B-X
utilising	B-X
the	B-X
PFA-100	B-X
does	B-X
not	B-X
predict	B-X
infection	B-X
,	B-X
bacteraemia	B-X
,	B-X
sepsis	B-X
or	B-X
outcome	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
N.	B-X
Bolton	B-X
,	B-X
J.	B-X
Dudziak	B-X
,	B-X
S.	B-X
Bonney	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
P.	B-X
Nee	B-X
P017	B-X
-	B-X
Extracellular	B-X
histone	B-X
H3	B-X
levels	B-X
are	B-X
inversely	B-X
correlated	B-X
with	B-X
antithrombin	B-X
levels	B-X
and	B-X
platelet	B-X
counts	B-X
and	B-X
are	B-X
associated	B-X
with	B-X
mortality	B-X
in	B-X
sepsis	B-X
patients	B-X
G.	B-X
Nicolaes	B-X
,	B-X
M.	B-X
Wiewel	B-X
,	B-X
M.	B-X
Schultz	B-X
,	B-X
K.	B-X
Wildhagen	B-X
,	B-X
J.	B-X
Horn	B-X
,	B-X
R.	B-X
Schrijver	B-X
,	B-X
T.	B-X
Van	B-X
der	B-X
Poll	B-X
,	B-X
C.	B-X
Reutelingsperger	B-X
P018	B-X
-	B-X
Il-8	B-X
:	B-X
is	B-X
this	B-X
a	B-X
more	B-X
reliable	B-X
biomarker	B-X
for	B-X
sepsis	B-X
severity	B-X
than	B-X
CRP	B-X
,	B-X
Procalcitonin	B-X
,	B-X
E-selectin	B-X
,	B-X
IL-6	B-X
and	B-X
TNF-	B-X
[	B-X
alpha	B-X
]	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P019	B-X
-	B-X
Relation	B-X
between	B-X
adrenomedullin	B-X
and	B-X
short-term	B-X
outcome	B-X
in	B-X
ICU	B-X
patients	B-X
:	B-X
Results	B-X
from	B-X
the	B-X
frog	B-X
ICU	B-X
study	B-X
E.	B-X
G.	B-X
Gayat	B-X
,	B-X
J	B-X
.	B-X
A	B-X
pilot	B-X
study	B-X
M.	B-X
Popescu	B-X
,	B-X
D.	B-X
Tomescu	B-X
P022	B-X
-	B-X
Comparison	B-X
of	B-X
CD64	B-X
levels	B-X
performed	B-X
by	B-X
the	B-X
facs	B-X
and	B-X
accellix	B-X
systems	B-X
C.	B-X
L.	B-X
Sprung	B-X
,	B-X
R.	B-X
Calderon	B-X
Morales	B-X
,	B-X
G.	B-X
Munteanu	B-X
,	B-X
E.	B-X
Orenbuch-Harroch	B-X
,	B-X
P.	B-X
Levin	B-X
,	B-X
H.	B-X
Kasdan	B-X
,	B-X
A.	B-X
Reiter	B-X
,	B-X
T.	B-X
Volker	B-X
,	B-X
Y.	B-X
Himmel	B-X
,	B-X
Y.	B-X
Cohen	B-X
,	B-X
J.	B-X
Meissonnier	B-X
P023	B-X
-	B-X
Diagnosing	B-X
sepsis	B-X
in	B-X
5	B-X
minutes	B-X
:	B-X
Nanofluidic	B-X
technology	B-X
study	B-X
with	B-X
pancreatic-stone	B-X
protein	B-X
(	B-X
PSP/	B-X
reg	B-X
)	B-X
L.	B-X
Girard	B-X
,	B-X
F.	B-X
Rebeaud	B-X
P024	B-X
-	B-X
How	B-X
nanotechnology-based	B-X
approaches	B-X
could	B-X
contribute	B-X
to	B-X
sepsis	B-X
prevention	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
I.	B-X
Herrmann	B-X
P025	B-X
-	B-X
Il7r	B-X
transcriptional	B-X
expression	B-X
analysis	B-X
during	B-X
septic	B-X
shock	B-X
B.	B-X
Delwarde	B-X
,	B-X
E.	B-X
Peronnet	B-X
,	B-X
E.	B-X
Cerrato	B-X
,	B-X
F.	B-X
Venet	B-X
,	B-X
A.	B-X
Lepape	B-X
,	B-X
T.	B-X
Rimmelé	B-X
,	B-X
G.	B-X
Monneret	B-X
,	B-X
J.	B-X
Textoris	B-X
P026	B-X
-	B-X
Disbalance	B-X
of	B-X
microbial	B-X
metabolites	B-X
of	B-X
aromatic	B-X
acids	B-X
affects	B-X
the	B-X
severity	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
N.	B-X
Beloborodova	B-X
,	B-X
V.	B-X
Moroz	B-X
,	B-X
A.	B-X
Osipov	B-X
,	B-X
A.	B-X
Bedova	B-X
,	B-X
Y.	B-X
Sarshor	B-X
,	B-X
A.	B-X
Pautova	B-X
,	B-X
A.	B-X
Sergeev	B-X
,	B-X
E.	B-X
Chernevskaya	B-X
P027	B-X
-	B-X
Copeptin	B-X
predicts	B-X
10-year	B-X
all-cause	B-X
mortality	B-X
in	B-X
community	B-X
patients	B-X
J.	B-X
Odermatt	B-X
,	B-X
R.	B-X
Bolliger	B-X
,	B-X
L.	B-X
Hersberger	B-X
,	B-X
M.	B-X
Ottiger	B-X
,	B-X
M.	B-X
Christ-Crain	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P028	B-X
-	B-X
Identification	B-X
of	B-X
differential	B-X
proteomic	B-X
response	B-X
in	B-X
septic	B-X
patients	B-X
secondary	B-X
to	B-X
community	B-X
and	B-X
hospital	B-X
acquired	B-X
pneumonia	B-X
N.	B-X
K.	B-X
Sharma	B-X
,	B-X
A.	B-X
K.	B-X
Tashima	B-X
,	B-X
M.	B-X
K.	B-X
Brunialti	B-X
,	B-X
F.	B-X
R.	B-X
Machado	B-X
,	B-X
M.	B-X
Assuncao	B-X
,	B-X
O.	B-X
Rigato	B-X
,	B-X
R.	B-X
Salomao	B-X
P029	B-X
-	B-X
Monocyte	B-X
HLA-DR	B-X
expression	B-X
in	B-X
community-acquired	B-X
bacteremic	B-X
sepsis	B-X
-	B-X
dynamics	B-X
associated	B-X
to	B-X
aetiology	B-X
and	B-X
prediction	B-X
of	B-X
secondary	B-X
sepsis	B-X
S.	B-X
C.	B-X
Cajander	B-X
,	B-X
G.	B-X
Rasmussen	B-X
,	B-X
E.	B-X
Tina	B-X
,	B-X
B.	B-X
Söderquist	B-X
,	B-X
J.	B-X
Källman	B-X
,	B-X
K.	B-X
Strålin	B-X
P030	B-X
-	B-X
Soluble	B-X
B-	B-X
and	B-X
T-lymphocyte	B-X
attenuator	B-X
:	B-X
A	B-X
possible	B-X
prognostic	B-X
marker	B-X
in	B-X
sepsis	B-X
A.	B-X
L.	B-X
Lange	B-X
,	B-X
J.	B-X
S.	B-X
Sundén-Cullberg	B-X
,	B-X
A.	B-X
M.	B-X
Magnuson	B-X
,	B-X
O.	B-X
H.	B-X
Hultgren	B-X
P031	B-X
-	B-X
Fractal	B-X
dimension	B-X
:	B-X
A	B-X
new	B-X
biomarker	B-X
for	B-X
quantifying	B-X
clot	B-X
microstructure	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
G.	B-X
Davies	B-X
,	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P032	B-X
-	B-X
Comparison	B-X
between	B-X
the	B-X
new	B-X
biomarker	B-X
for	B-X
coagulation	B-X
,	B-X
clot	B-X
microstructure	B-X
(	B-X
Df	B-X
)	B-X
with	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P033	B-X
-	B-X
Changes	B-X
in	B-X
fibrinolysis	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
:	B-X
The	B-X
use	B-X
of	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
lysis	B-X
index	B-X
(	B-X
LI60	B-X
)	B-X
and	B-X
D-Dimer	B-X
concentration	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P034	B-X
-	B-X
The	B-X
intensive	B-X
care	B-X
infection	B-X
score	B-X
–	B-X
a	B-X
promising	B-X
marker	B-X
for	B-X
the	B-X
prediction	B-X
of	B-X
infection	B-X
and	B-X
its	B-X
severity	B-X
.	B-X
P.	B-X
Van	B-X
der	B-X
Geest	B-X
,	B-X
M.	B-X
Mohseni	B-X
,	B-X
J.	B-X
Linssen	B-X
,	B-X
R.	B-X
De	B-X
Jonge	B-X
,	B-X
S.	B-X
Duran	B-X
,	B-X
J.	B-X
Groeneveld	B-X
P035	B-X
-	B-X
Challenges	B-X
in	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
sepsis	B-X
R.	B-X
Miller	B-X
III	B-X
,	B-X
B.	B-X
K.	B-X
Lopansri	B-X
,	B-X
L.	B-X
C.	B-X
McHugh	B-X
,	B-X
A.	B-X
Seldon	B-X
,	B-X
J.	B-X
P.	B-X
Burke	B-X
P036	B-X
-	B-X
Does	B-X
zero	B-X
heat	B-X
flux	B-X
thermometry	B-X
more	B-X
accurately	B-X
identify	B-X
sepsis	B-X
on	B-X
intensive	B-X
care	B-X
?	B-X
Bond	B-X
,	B-X
A.	B-X
Molokhia	B-X
P037	B-X
-	B-X
Advancing	B-X
quality	B-X
(	B-X
AQ	B-X
)	B-X
sepsis	B-X
programme	B-X
:	B-X
Improving	B-X
early	B-X
identification	B-X
&	B-X
treatment	B-X
of	B-X
sepsis	B-X
in	B-X
North	B-X
West	B-X
England	B-X
.	B-X
C.	B-X
Mcgrath	B-X
,	B-X
E.	B-X
Nsutebu	B-X
P038	B-X
-	B-X
Prehospital	B-X
transport	B-X
of	B-X
acute	B-X
septic	B-X
patients	B-X
P.	B-X
Bank	B-X
Pedersen	B-X
,	B-X
D.	B-X
Pilsgaard	B-X
Henriksen	B-X
,	B-X
S.	B-X
Mikkelsen	B-X
,	B-X
A.	B-X
Touborg	B-X
Lassen	B-X
P039	B-X
-	B-X
Vasodilatory	B-X
plant	B-X
extracts	B-X
gel	B-X
as	B-X
an	B-X
alternative	B-X
treatment	B-X
for	B-X
fever	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P040	B-X
-	B-X
Host	B-X
response	B-X
and	B-X
outcome	B-X
of	B-X
hypothermic	B-X
sepsis	B-X
M.	B-X
A.	B-X
Wiewel	B-X
,	B-X
M.	B-X
B.	B-X
Harmon	B-X
,	B-X
L.	B-X
A	B-X
.	B-X
Van	B-X
Vught	B-X
,	B-X
B.	B-X
P.	B-X
Scicluna	B-X
,	B-X
A.	B-X
J.	B-X
Hoogendijk	B-X
,	B-X
J.	B-X
Horn	B-X
,	B-X
A.	B-X
H.	B-X
Zwinderman	B-X
,	B-X
O.	B-X
L.	B-X
Cremer	B-X
,	B-X
M.	B-X
J.	B-X
Bonten	B-X
,	B-X
M.	B-X
J.	B-X
Schultz	B-X
,	B-X
T.	B-X
Van	B-X
der	B-X
Poll	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
,	B-X
W.	B-X
J.	B-X
Wiersinga	B-X
P041	B-X
-	B-X
Septic	B-X
shock	B-X
alert	B-X
over	B-X
SIRS	B-X
criteria	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
outcome	B-X
but	B-X
needs	B-X
to	B-X
be	B-X
revised	B-X
G.	B-X
Eren	B-X
,	B-X
Y	B-X
Tekdos	B-X
,	B-X
M.	B-X
Dogan	B-X
,	B-X
O.	B-X
Acicbe	B-X
,	B-X
E.	B-X
Kaya	B-X
,	B-X
O.	B-X
Hergunsel	B-X
P042	B-X
-	B-X
Association	B-X
between	B-X
previous	B-X
prescription	B-X
of	B-X
βblockers	B-X
and	B-X
mortality	B-X
rate	B-X
among	B-X
septic	B-X
patients	B-X
:	B-X
A	B-X
retrospective	B-X
observational	B-X
study	B-X
S.	B-X
Alsolamy	B-X
,	B-X
G.	B-X
Ghamdi	B-X
,	B-X
L.	B-X
Alswaidan	B-X
,	B-X
S.	B-X
Alharbi	B-X
,	B-X
F.	B-X
Alenezi	B-X
,	B-X
Y.	B-X
Arabi	B-X
P043	B-X
-	B-X
Recognition	B-X
and	B-X
treatment	B-X
of	B-X
sepsis	B-X
on	B-X
labour	B-X
ward–	B-X
teaching	B-X
&	B-X
information	B-X
resources	B-X
can	B-X
improve	B-X
knowledge	B-X
J.	B-X
Heaton	B-X
,	B-X
A.	B-X
Boyce	B-X
,	B-X
L.	B-X
Nolan	B-X
,	B-X
J.	B-X
Johnston	B-X
,	B-X
A.	B-X
Dukoff-Gordon	B-X
,	B-X
A.	B-X
T.	B-X
Mann	B-X
Ben	B-X
Yehudah	B-X
P045	B-X
-	B-X
Organ	B-X
dysfunction	B-X
in	B-X
severe	B-X
sepsis	B-X
patients	B-X
identified	B-X
in	B-X
administrative	B-X
data	B-X
in	B-X
Germany	B-X
,	B-X
2007-2013	B-X
C.	B-X
Fleischmann	B-X
,	B-X
D.	B-X
Thomas-Rueddel	B-X
,	B-X
C.	B-X
Haas	B-X
,	B-X
U.	B-X
Dennler	B-X
,	B-X
K.	B-X
Reinhart	B-X
P046	B-X
-	B-X
A	B-X
comparison	B-X
of	B-X
residents	B-X
’	B-X
knowledge	B-X
regarding	B-X
;	B-X
the	B-X
Surviving	B-X
Sepsis	B-X
Campaign	B-X
2012	B-X
guideline	B-X
O.	B-X
Suntornlohanakul	B-X
,	B-X
B.	B-X
Khwannimit	B-X
P047	B-X
-	B-X
Effectiveness	B-X
of	B-X
a	B-X
septic	B-X
shock	B-X
bundle	B-X
to	B-X
improve	B-X
outcomes	B-X
in	B-X
the	B-X
ICU	B-X
F.	B-X
Breckenridge	B-X
,	B-X
A.	B-X
Puxty	B-X
P048	B-X
-	B-X
Dose	B-X
of	B-X
norepinephrine	B-X
in	B-X
the	B-X
first	B-X
24	B-X
hours	B-X
as	B-X
a	B-X
parameter	B-X
evaluating	B-X
the	B-X
effectiveness	B-X
of	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
P.	B-X
Szturz	B-X
,	B-X
P.	B-X
Folwarzcny	B-X
,	B-X
J.	B-X
Svancara	B-X
,	B-X
R.	B-X
Kula	B-X
,	B-X
P.	B-X
Sevcik	B-X
P049	B-X
-	B-X
Norepinephrine	B-X
or	B-X
vasopressin	B-X
+	B-X
norepinephrine	B-X
in	B-X
septic	B-X
shock	B-X
.	B-X
A	B-X
retrospective	B-X
series	B-X
of	B-X
39	B-X
patients	B-X
L.	B-X
Caneva	B-X
,	B-X
A.	B-X
Casazza	B-X
,	B-X
E.	B-X
Bellazzi	B-X
,	B-X
S.	B-X
Marra	B-X
,	B-X
L.	B-X
Pagani	B-X
,	B-X
M.	B-X
Vetere	B-X
,	B-X
R.	B-X
Vanzino	B-X
,	B-X
D.	B-X
Ciprandi	B-X
,	B-X
R.	B-X
Preda	B-X
,	B-X
R.	B-X
Boschi	B-X
,	B-X
L.	B-X
Carnevale	B-X
P050	B-X
-	B-X
Methylene	B-X
blue	B-X
effectiveness	B-X
as	B-X
contributory	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
V.	B-X
Lopez	B-X
,	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
A.	B-X
Escalante	B-X
,	B-X
J.	B-X
Gongora	B-X
,	B-X
M.	B-X
Cetina	B-X
P051	B-X
-	B-X
Coagulation	B-X
disorders	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
DIC	B-X
evaluated	B-X
with	B-X
thromboelastometry	B-X
.	B-X
Singer	B-X
,	B-X
J.	B-X
Boyd	B-X
,	B-X
D.	B-X
Fineberg	B-X
,	B-X
M.	B-X
Williams	B-X
,	B-X
J.	B-X
Russell	B-X
P053	B-X
-	B-X
Assessment	B-X
of	B-X
coagulopathy	B-X
in	B-X
cancer	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
or	B-X
septic	B-X
shock	B-X
.	B-X
A	B-X
case-control	B-X
pilot	B-X
study	B-X
E.	B-X
Scarlatescu	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
G.	B-X
Droc	B-X
,	B-X
S.	B-X
Arama	B-X
P054	B-X
-	B-X
Thromboelastometry	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
M.	B-X
Müller	B-X
,	B-X
M.	B-X
Straat	B-X
,	B-X
S.	B-X
S.	B-X
Zeerleder	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
P055	B-X
-	B-X
Cessation	B-X
of	B-X
a	B-X
preexisting	B-X
chronic	B-X
antiplatelet	B-X
therapy	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
mortality	B-X
rates	B-X
in	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
C.	B-X
F.	B-X
Fuchs	B-X
,	B-X
C.	B-X
S.	B-X
Scheer	B-X
,	B-X
S.	B-X
W.	B-X
Wauschkuhn	B-X
,	B-X
M.	B-X
V.	B-X
Vollmer	B-X
,	B-X
K.	B-X
M.	B-X
Meissner	B-X
,	B-X
S.	B-X
K.	B-X
Kuhn	B-X
,	B-X
K.	B-X
H.	B-X
Hahnenkamp	B-X
,	B-X
S.	B-X
R.	B-X
Rehberg	B-X
,	B-X
M.	B-X
G.	B-X
Gründling	B-X
P056	B-X
-	B-X
Neutrophil	B-X
Extracellular	B-X
Traps	B-X
(	B-X
NETs	B-X
)	B-X
production	B-X
under	B-X
hypoxic	B-X
condition	B-X
N.	B-X
Yamamoto	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
S.	B-X
Hamaguchi	B-X
,	B-X
T.	B-X
Hirose	B-X
,	B-X
Y.	B-X
Akeda	B-X
,	B-X
R.	B-X
Takegawa	B-X
,	B-X
O.	B-X
Tasaki	B-X
,	B-X
T.	B-X
Shimazu	B-X
,	B-X
K.	B-X
Tomono	B-X
P057	B-X
-	B-X
Impact	B-X
of	B-X
ultraviolet	B-X
air	B-X
sterilizer	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
room	B-X
,	B-X
and	B-X
clinical	B-X
outcomes	B-X
of	B-X
patients	B-X
E.	B-X
Gómez-Sánchez	B-X
,	B-X
M.	B-X
Heredia-Rodríguez	B-X
,	B-X
E.	B-X
Álvarez-Fuente	B-X
,	B-X
M.	B-X
Lorenzo-López	B-X
,	B-X
E.	B-X
Gómez-Pesquera	B-X
,	B-X
M.	B-X
Aragón-Camino	B-X
,	B-X
P.	B-X
Liu-Zhu	B-X
,	B-X
A.	B-X
Sánchez-López	B-X
,	B-X
A.	B-X
Hernández-Lozano	B-X
,	B-X
M.	B-X
T.	B-X
Peláez-Jareño	B-X
,	B-X
E.	B-X
Tamayo	B-X
P058	B-X
-	B-X
Focus	B-X
of	B-X
infection	B-X
in	B-X
severe	B-X
sepsis	B-X
-	B-X
comparison	B-X
of	B-X
administrative	B-X
data	B-X
and	B-X
prospective	B-X
cohorts	B-X
from	B-X
Germany	B-X
D.	B-X
O.	B-X
Thomas-Rüddel	B-X
,	B-X
C.	B-X
Fleischmann	B-X
,	B-X
C.	B-X
Haas	B-X
,	B-X
U.	B-X
Dennler	B-X
,	B-X
K.	B-X
Reinhart	B-X
P059	B-X
-	B-X
“	B-X
Zero	B-X
CLABSI	B-X
”	B-X
–	B-X
can	B-X
we	B-X
get	B-X
there	B-X
?	B-X
Obstacles	B-X
on	B-X
the	B-X
4	B-X
year	B-X
journey	B-X
and	B-X
our	B-X
strategies	B-X
to	B-X
overcome	B-X
them	B-X
–	B-X
experience	B-X
from	B-X
an	B-X
Indian	B-X
ICU	B-X
R.	B-X
Rao	B-X
,	B-X
A.	B-X
Kar	B-X
,	B-X
A.	B-X
Chakraborty	B-X
P062	B-X
-	B-X
Prevention	B-X
of	B-X
central	B-X
line-associated	B-X
bloodstream	B-X
infections	B-X
in	B-X
intensive	B-X
care	B-X
units	B-X
:	B-X
An	B-X
international	B-X
online	B-X
survey	B-X
C.	B-X
Valencia	B-X
,	B-X
N.	B-X
Hammami	B-X
,	B-X
S.	B-X
Blot	B-X
,	B-X
J.	B-X
L.	B-X
Vincent	B-X
,	B-X
M.	B-X
L.	B-X
Lambert	B-X
P063	B-X
-	B-X
30	B-X
days	B-X
antimicrobial	B-X
efficacy	B-X
of	B-X
non-leaching	B-X
central	B-X
venous	B-X
catheters	B-X
J.	B-X
Brunke	B-X
,	B-X
T.	B-X
Riemann	B-X
,	B-X
I.	B-X
Roschke	B-X
P064	B-X
-	B-X
Efficacy	B-X
of	B-X
noble	B-X
metal	B-X
alloy-coated	B-X
catheter	B-X
in	B-X
prevention	B-X
of	B-X
bacteriuria	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P065	B-X
-	B-X
Predicting	B-X
bacteremic	B-X
urinary	B-X
tract	B-X
infection	B-X
in	B-X
community	B-X
setting	B-X
:	B-X
A	B-X
prospective	B-X
observational	B-X
study	B-X
S.	B-X
Nimitvilai	B-X
,	B-X
K.	B-X
Jintanapramote	B-X
,	B-X
S.	B-X
Jarupongprapa	B-X
P066	B-X
-	B-X
Eight-year	B-X
analysis	B-X
of	B-X
acinetobacter	B-X
spp	B-X
.	B-X
M.	B-X
Day	B-X
,	B-X
G.	B-X
Penrice	B-X
,	B-X
K.	B-X
Roy	B-X
,	B-X
P.	B-X
Robertson	B-X
,	B-X
G.	B-X
Godbole	B-X
,	B-X
B.	B-X
Jones	B-X
,	B-X
M.	B-X
Booth	B-X
,	B-X
L.	B-X
Donaldson	B-X
P072	B-X
-	B-X
Surveillance	B-X
of	B-X
ESBL-producing	B-X
enterobacteriaceae	B-X
fecal	B-X
carriers	B-X
in	B-X
the	B-X
ICU	B-X
Y.	B-X
Kawano	B-X
,	B-X
H.	B-X
Ishikura	B-X
P073	B-X
-	B-X
Prevalence	B-X
of	B-X
ESBL	B-X
and	B-X
carbapenemase	B-X
producing	B-X
uropathogens	B-X
in	B-X
a	B-X
newly	B-X
opened	B-X
hospital	B-X
in	B-X
south	B-X
India	B-X
S.	B-X
Sreevidya	B-X
,	B-X
N.	B-X
Brahmananda	B-X
Reddy	B-X
,	B-X
P.	B-X
Muraray	B-X
Govind	B-X
,	B-X
R.	B-X
Pratheema	B-X
,	B-X
J.	B-X
Devachandran	B-X
Apollo	B-X
Speciality	B-X
Hospital	B-X
-	B-X
OMR	B-X
,	B-X
Chennai	B-X
,	B-X
India	B-X
P074	B-X
-	B-X
Prevalence	B-X
,	B-X
risk	B-X
factors	B-X
and	B-X
outcomes	B-X
of	B-X
methicillin-resistant	B-X
staphylococcus	B-X
aureus	B-X
nasal	B-X
colonization	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
M.	B-X
Almutairi	B-X
,	B-X
B.	B-X
Alhamadi	B-X
,	B-X
A.	B-X
Crizaldo	B-X
Toledo	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
B.	B-X
Al	B-X
Raiy	B-X
,	B-X
Y.	B-X
Arabi	B-X
P075	B-X
-	B-X
Multidrug-resistant	B-X
Acinetobacter	B-X
baumannii	B-X
infection	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
patients	B-X
in	B-X
a	B-X
hospital	B-X
with	B-X
building	B-X
construction	B-X
:	B-X
Is	B-X
there	B-X
an	B-X
association	B-X
?	B-X
A.	B-X
R.	B-X
Robles	B-X
Caballero	B-X
,	B-X
B.	B-X
Civantos	B-X
,	B-X
J.	B-X
C.	B-X
Figueira	B-X
,	B-X
J.	B-X
López	B-X
P080	B-X
-	B-X
Mediterranean	B-X
spotted	B-X
fever	B-X
in	B-X
an	B-X
infectious	B-X
diseases	B-X
intensive	B-X
care	B-X
unit	B-X
A.	B-X
Silva-Pinto	B-X
,	B-X
F.	B-X
Ceia	B-X
,	B-X
A.	B-X
Sarmento	B-X
,	B-X
L.	B-X
Santos	B-X
P081	B-X
-	B-X
Clinical	B-X
features	B-X
and	B-X
outcomes	B-X
of	B-X
patients	B-X
with	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
requiring	B-X
admission	B-X
to	B-X
a	B-X
saudi	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
A	B-X
retrospective	B-X
analysis	B-X
of	B-X
31	B-X
cases	B-X
G.	B-X
Almekhlafi	B-X
,	B-X
Y.	B-X
Sakr	B-X
P082	B-X
-	B-X
The	B-X
ICU	B-X
response	B-X
to	B-X
a	B-X
hospital	B-X
outbreak	B-X
of	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
infection	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
S.	B-X
Baharoon	B-X
,	B-X
A.	B-X
Aldawood	B-X
,	B-X
A.	B-X
Matroud	B-X
,	B-X
J.	B-X
Alchin	B-X
,	B-X
S.	B-X
Al	B-X
Johani	B-X
,	B-X
H.	B-X
Balkhy	B-X
,	B-X
Y.	B-X
Arabi	B-X
P083	B-X
-	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
:	B-X
Surveillance	B-X
data	B-X
analysis	B-X
S.	B-X
Alsolamy	B-X
,	B-X
S.	B-X
Y.	B-X
Yousif	B-X
,	B-X
B.	B-X
O.	B-X
Alotabi	B-X
,	B-X
A.	B-X
S.	B-X
Alsaawi	B-X
P085	B-X
-	B-X
Use	B-X
of	B-X
Taqman	B-X
array	B-X
card	B-X
molecular	B-X
diagnostics	B-X
in	B-X
severe	B-X
pneumonia	B-X
:	B-X
A	B-X
case	B-X
series	B-X
J.	B-X
Ang	B-X
,	B-X
MD	B-X
Curran	B-X
,	B-X
D.	B-X
Enoch	B-X
,	B-X
V.	B-X
Navapurkar	B-X
,	B-X
A.	B-X
Conway	B-X
Morris	B-X
P086	B-X
-	B-X
‘	B-X
BUNS	B-X
’	B-X
:	B-X
An	B-X
investigation	B-X
protocol	B-X
improves	B-X
the	B-X
ICU	B-X
management	B-X
of	B-X
pneumonia	B-X
R.	B-X
Sharvill	B-X
,	B-X
J.	B-X
Astin	B-X
P087	B-X
-	B-X
Pneumonia	B-X
in	B-X
patients	B-X
following	B-X
secondary	B-X
peritonitis	B-X
:	B-X
epidemiological	B-X
features	B-X
and	B-X
impact	B-X
on	B-X
mortality	B-X
M.	B-X
Heredia-Rodríguez	B-X
,	B-X
E.	B-X
Gómez-Sánchez	B-X
,	B-X
M.	B-X
T.	B-X
Peláez-Jareño	B-X
,	B-X
E.	B-X
Gómez-Pesquera	B-X
,	B-X
M.	B-X
Lorenzo-López	B-X
,	B-X
P.	B-X
Liu-Zhu	B-X
,	B-X
M.	B-X
Aragón-Camino	B-X
,	B-X
A.	B-X
Hernández-Lozano	B-X
,	B-X
A.	B-X
Sánchez-López	B-X
,	B-X
E.	B-X
Álvarez-Fuente	B-X
,	B-X
E.	B-X
Tamayo	B-X
P088	B-X
-	B-X
The	B-X
use	B-X
of	B-X
the	B-X
“	B-X
CURB-65	B-X
score	B-X
”	B-X
by	B-X
emergency	B-X
room	B-X
clinicians	B-X
in	B-X
a	B-X
large	B-X
teaching	B-X
hospital	B-X
J.	B-X
Patel	B-X
,	B-X
C.	B-X
Kruger	B-X
P089	B-X
-	B-X
Incidence	B-X
of	B-X
community	B-X
acquired	B-X
pneumonia	B-X
with	B-X
viral	B-X
infection	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
in	B-X
the	B-X
medical	B-X
intensive	B-X
care	B-X
unit	B-X
J.	B-X
O	B-X
’	B-X
Neal	B-X
,	B-X
H.	B-X
Rhodes	B-X
,	B-X
J.	B-X
Jancik	B-X
P090	B-X
-	B-X
The	B-X
SAATELLITE	B-X
Study	B-X
:	B-X
Prevention	B-X
of	B-X
S	B-X
aureus	B-X
Nosocomial	B-X
Pneumonia	B-X
(	B-X
NP	B-X
)	B-X
with	B-X
MEDI4893	B-X
,	B-X
a	B-X
Human	B-X
Monoclonal	B-X
Antibody	B-X
(	B-X
mAb	B-X
)	B-X
Against	B-X
S	B-X
aureus	B-X
B.	B-X
François	B-X
,	B-X
P.	B-X
F.	B-X
Laterre	B-X
,	B-X
P.	B-X
Eggimann	B-X
,	B-X
A.	B-X
Torres	B-X
,	B-X
M.	B-X
Sánchez	B-X
,	B-X
P.	B-X
F.	B-X
Dequin	B-X
,	B-X
G.	B-X
L.	B-X
Bassi	B-X
,	B-X
J.	B-X
Chastre	B-X
,	B-X
H.	B-X
S.	B-X
Jafri	B-X
P091	B-X
-	B-X
Risk	B-X
factors	B-X
and	B-X
microbiological	B-X
profile	B-X
for	B-X
nosocomial	B-X
infections	B-X
in	B-X
trauma	B-X
patients	B-X
M.	B-X
Ben	B-X
Romdhane	B-X
,	B-X
Z.	B-X
Douira	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
M.	B-X
Bousselmi	B-X
,	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
Y.	B-X
Boussarsar	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.S	B-X
.	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P093	B-X
-	B-X
A	B-X
comparison	B-X
of	B-X
two	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
surveillance	B-X
techniques	B-X
T.	B-X
H.	B-X
Craven	B-X
,	B-X
G.	B-X
Wojcik	B-X
,	B-X
K.	B-X
Kefala	B-X
,	B-X
J.	B-X
McCoubrey	B-X
,	B-X
J.	B-X
Reilly	B-X
,	B-X
R.	B-X
Paterson	B-X
,	B-X
D.	B-X
Inverarity	B-X
,	B-X
I.	B-X
Laurenson	B-X
,	B-X
T.	B-X
S.	B-X
Walsh	B-X
P094	B-X
-	B-X
Lung	B-X
ultrasound	B-X
before	B-X
and	B-X
after	B-X
fiberbronchoscopy	B-X
-	B-X
modifications	B-X
may	B-X
improve	B-X
ventilator-associated	B-X
pneumonia	B-X
diagnosis	B-X
S.	B-X
Mongodi	B-X
,	B-X
B.	B-X
Bouhemad	B-X
,	B-X
A.	B-X
Orlando	B-X
,	B-X
A.	B-X
Stella	B-X
,	B-X
G.	B-X
Via	B-X
,	B-X
G.	B-X
Iotti	B-X
,	B-X
A.	B-X
Braschi	B-X
,	B-X
F.	B-X
Mojoli	B-X
P095	B-X
-	B-X
Comparing	B-X
the	B-X
accuracy	B-X
of	B-X
predictors	B-X
of	B-X
mortality	B-X
in	B-X
ventilator-associated	B-X
pneumonia	B-X
M.	B-X
Haliloglu	B-X
,	B-X
B.	B-X
Bilgili	B-X
,	B-X
U.	B-X
Kasapoglu	B-X
,	B-X
I.	B-X
Sayan	B-X
,	B-X
M.	B-X
Süzer	B-X
Aslan	B-X
,	B-X
A.	B-X
Yalcın	B-X
,	B-X
I.	B-X
Cinel	B-X
P096	B-X
-	B-X
Impact	B-X
of	B-X
pRBCs	B-X
transfusion	B-X
on	B-X
percentage	B-X
of	B-X
ventilated	B-X
patients	B-X
developed	B-X
VAP	B-X
in	B-X
ICU	B-X
patients	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P097	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
a	B-X
series	B-X
of	B-X
interventions	B-X
on	B-X
the	B-X
rate	B-X
of	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
in	B-X
a	B-X
large	B-X
teaching	B-X
hospital	B-X
H.	B-X
E.	B-X
Ellis	B-X
,	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
D.	B-X
Miller	B-X
,	B-X
A	B-X
Temple	B-X
P098	B-X
-	B-X
The	B-X
EVADE	B-X
study	B-X
:	B-X
Prevention	B-X
of	B-X
Nosocomial	B-X
Pneumonia	B-X
(	B-X
NP	B-X
)	B-X
caused	B-X
by	B-X
P	B-X
aeruginosa	B-X
with	B-X
MEDI3902	B-X
,	B-X
a	B-X
Novel	B-X
Bispecific	B-X
Monoclonal	B-X
Antibody	B-X
,	B-X
against	B-X
P	B-X
aeruginosa	B-X
virulence	B-X
factors	B-X
J.	B-X
Chastre	B-X
,	B-X
B.	B-X
François	B-X
,	B-X
A.	B-X
Torres	B-X
,	B-X
C.	B-X
E.	B-X
Luyt	B-X
,	B-X
M.	B-X
Sánchez	B-X
,	B-X
M.	B-X
Singer	B-X
,	B-X
H.	B-X
S.	B-X
Jafri	B-X
P099	B-X
-	B-X
Short-term	B-X
inhaled	B-X
colistin	B-X
adjunctive	B-X
therapy	B-X
for	B-X
ventilator-associated	B-X
pneumonia	B-X
Y.	B-X
Nassar	B-X
,	B-X
M.	B-X
S.	B-X
Ayad	B-X
P100	B-X
-	B-X
Effect	B-X
of	B-X
aerosolised	B-X
colistin	B-X
on	B-X
weaning	B-X
from	B-X
mechanical	B-X
ventilation	B-X
A.	B-X
Trifi	B-X
,	B-X
S.	B-X
Abdellatif	B-X
,	B-X
F.	B-X
Daly	B-X
,	B-X
R.	B-X
Nasri	B-X
,	B-X
S.	B-X
Ben	B-X
Lakhal	B-X
P101	B-X
-	B-X
Septic	B-X
shock	B-X
is	B-X
an	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
colistin-induced	B-X
severe	B-X
acute	B-X
kidney	B-X
injury	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
study	B-X
B.	B-X
Bilgili	B-X
,	B-X
M.	B-X
Haliloglu	B-X
,	B-X
F.	B-X
Gul	B-X
,	B-X
I.	B-X
Cinel	B-X
P102	B-X
-	B-X
Nosocomial	B-X
pneumonia	B-X
-	B-X
emphasis	B-X
on	B-X
inhaled	B-X
tobramycin	B-X
A.	B-X
Kuzovlev	B-X
,	B-X
A.	B-X
Shabanov	B-X
,	B-X
S.	B-X
Polovnikov	B-X
,	B-X
V.	B-X
Moroz	B-X
P103	B-X
-	B-X
In	B-X
vitro	B-X
evaluation	B-X
of	B-X
amikacin	B-X
inhale	B-X
and	B-X
commercial	B-X
nebulizers	B-X
in	B-X
a	B-X
mechanical	B-X
ventilator	B-X
N.	B-X
Kadrichu	B-X
,	B-X
T.	B-X
Dang	B-X
,	B-X
K.	B-X
Corkery	B-X
,	B-X
P.	B-X
Challoner	B-X
P104	B-X
-	B-X
The	B-X
effects	B-X
of	B-X
nebulized	B-X
amikacin/fosfomycin	B-X
and	B-X
systemic	B-X
meropenem	B-X
on	B-X
severe	B-X
amikacin-resistant	B-X
meropenem-susceptible	B-X
P.aeruginosa	B-X
pneumonia	B-X
G.	B-X
Li	B-X
Bassi	B-X
,	B-X
E.	B-X
Aguilera	B-X
,	B-X
C.	B-X
Chiurazzi	B-X
,	B-X
C.	B-X
Travierso	B-X
,	B-X
A.	B-X
Motos	B-X
,	B-X
L.	B-X
Fernandez	B-X
,	B-X
R.	B-X
Amaro	B-X
,	B-X
T.	B-X
Senussi	B-X
,	B-X
F.	B-X
Idone	B-X
,	B-X
J.	B-X
Bobi	B-X
,	B-X
M.	B-X
Rigol	B-X
,	B-X
A.	B-X
Torres	B-X
P105	B-X
-	B-X
Optimization	B-X
of	B-X
gentamicin	B-X
peak	B-X
concentrations	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
C.	B-X
J.	B-X
Hodiamont	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
,	B-X
J.	B-X
M.	B-X
Janssen	B-X
,	B-X
C.	B-X
S.	B-X
Bouman	B-X
,	B-X
R.	B-X
A.	B-X
Mathôt	B-X
,	B-X
M.	B-X
D.	B-X
De	B-X
Jong	B-X
,	B-X
R.	B-X
M.	B-X
Van	B-X
Hest	B-X
P106	B-X
-	B-X
Systematic	B-X
review	B-X
of	B-X
cefepime	B-X
induced	B-X
neurotoxicity	B-X
L.	B-X
Payne	B-X
,	B-X
G.	B-X
L.	B-X
Fraser	B-X
P107	B-X
-	B-X
Unasyn®	B-X
causes	B-X
QT	B-X
prolongation	B-X
during	B-X
treatment	B-X
of	B-X
intensive	B-X
care	B-X
patients	B-X
B.	B-X
Tudor	B-X
,	B-X
M.	B-X
Lahner	B-X
,	B-X
G.	B-X
Roth	B-X
,	B-X
C.	B-X
Krenn	B-X
P108	B-X
-	B-X
Comparative	B-X
study	B-X
between	B-X
teicoplanin	B-X
and	B-X
vancomycin	B-X
in	B-X
methicillin-resistant	B-X
staphylococcus	B-X
aureus	B-X
(	B-X
mrsa	B-X
)	B-X
infectious	B-X
of	B-X
toxicological	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ticu	B-X
)	B-X
patients	B-X
–	B-X
Tehran	B-X
,	B-X
Iran	B-X
H.	B-X
Talaie	B-X
P109	B-X
-	B-X
Phage	B-X
therapy	B-X
against	B-X
antimicrobial	B-X
resistance	B-X
,	B-X
design	B-X
of	B-X
the	B-X
first	B-X
clinical	B-X
study	B-X
phagoburn	B-X
P.	B-X
Jault	B-X
,	B-X
J.	B-X
Gabard	B-X
,	B-X
T.	B-X
Leclerc	B-X
,	B-X
S.	B-X
Jennes	B-X
,	B-X
Y.	B-X
Que	B-X
,	B-X
A.	B-X
Rousseau	B-X
,	B-X
F.	B-X
Ravat	B-X
P110	B-X
-	B-X
Antibiotic	B-X
dosing	B-X
errors	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
or	B-X
septic	B-X
shock	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
A.	B-X
Eissa	B-X
,	B-X
S.	B-X
Al-Harbi	B-X
,	B-X
T.	B-X
Aldabbagh	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
Y.	B-X
Arabi	B-X
P111	B-X
-	B-X
Does	B-X
empiric	B-X
antifungal	B-X
therapy	B-X
improve	B-X
survival	B-X
in	B-X
septic	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
(	B-X
immunocompromised	B-X
excluded	B-X
)	B-X
A.	B-X
Trifi	B-X
,	B-X
S.	B-X
Abdellatif	B-X
,	B-X
F.	B-X
Daly	B-X
,	B-X
R.	B-X
Nasri	B-X
,	B-X
S.	B-X
Ben	B-X
Lakhal	B-X
P112	B-X
-	B-X
Neurocysticercosis-Qatar	B-X
experience	B-X
F.	B-X
Paramba	B-X
,	B-X
N.	B-X
Purayil	B-X
,	B-X
V.	B-X
Naushad	B-X
,	B-X
O.	B-X
Mohammad	B-X
,	B-X
V.	B-X
Negi	B-X
,	B-X
P.	B-X
Chandra	B-X
P113	B-X
-	B-X
Early	B-X
indicators	B-X
in	B-X
acute	B-X
haemorrhagic	B-X
shock	B-X
A.	B-X
Kleinsasser	B-X
P114	B-X
-	B-X
Filtering	B-X
of	B-X
red	B-X
blood	B-X
cells	B-X
reduces	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
pulmonary	B-X
cells	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
model	B-X
of	B-X
mechanical	B-X
ventilation	B-X
M.	B-X
R.	B-X
Witrz	B-X
,	B-X
J.	B-X
F.	B-X
Buchner-Doeven	B-X
,	B-X
A.	B-X
M.	B-X
Tuip-de	B-X
Boer	B-X
,	B-X
J.	B-X
C.	B-X
Goslings	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
P115	B-X
-	B-X
Microparticles	B-X
from	B-X
red	B-X
blood	B-X
cell	B-X
transfusion	B-X
induce	B-X
a	B-X
pro-coagulant	B-X
and	B-X
pro-inflammatory	B-X
endothelial	B-X
cell	B-X
response	B-X
M.	B-X
Van	B-X
Hezel	B-X
,	B-X
M.	B-X
Straat	B-X
,	B-X
A	B-X
Boing	B-X
,	B-X
R	B-X
Van	B-X
Bruggen	B-X
,	B-X
N	B-X
Juffermans	B-X
P116	B-X
-	B-X
The	B-X
contribution	B-X
of	B-X
cytokines	B-X
on	B-X
thrombosis	B-X
development	B-X
during	B-X
hospitalization	B-X
in	B-X
ICU	B-X
D.	B-X
Markopoulou	B-X
,	B-X
K.	B-X
Venetsanou	B-X
,	B-X
V.	B-X
Kaldis	B-X
,	B-X
D.	B-X
Koutete	B-X
,	B-X
D.	B-X
Chroni	B-X
,	B-X
I.	B-X
Alamanos	B-X
P117	B-X
-	B-X
Prophylactic	B-X
enoxaparin	B-X
dosing	B-X
and	B-X
adjustment	B-X
through	B-X
anti-xa	B-X
monitoring	B-X
in	B-X
an	B-X
inpatient	B-X
burn	B-X
unit	B-X
L.	B-X
Koch	B-X
,	B-X
J.	B-X
Jancik	B-X
,	B-X
H.	B-X
Rhodes	B-X
,	B-X
E.	B-X
Walter	B-X
P118	B-X
-	B-X
Determination	B-X
of	B-X
optimal	B-X
cut-off	B-X
values	B-X
of	B-X
haemoglobin	B-X
,	B-X
platelet	B-X
count	B-X
and	B-X
fibrinogen	B-X
at	B-X
24	B-X
hours	B-X
after	B-X
injury	B-X
associated	B-X
with	B-X
mortality	B-X
in	B-X
trauma	B-X
patients	B-X
K.	B-X
Maekawa	B-X
,	B-X
M.	B-X
Hayakawa	B-X
,	B-X
S.	B-X
Kushimoto	B-X
,	B-X
A.	B-X
Shiraishi	B-X
,	B-X
H.	B-X
Kato	B-X
,	B-X
J.	B-X
Sasaki	B-X
,	B-X
H.	B-X
Ogura	B-X
,	B-X
T.	B-X
Matauoka	B-X
,	B-X
T.	B-X
Uejima	B-X
,	B-X
N.	B-X
Morimura	B-X
,	B-X
H.	B-X
Ishikura	B-X
,	B-X
A.	B-X
Hagiwara	B-X
,	B-X
M.	B-X
Takeda	B-X
P119	B-X
-	B-X
Trauma-induced	B-X
coagulopathy	B-X
-	B-X
prothrombin	B-X
complex	B-X
concentrate	B-X
vs	B-X
fresh	B-X
frozen	B-X
plasma	B-X
O.	B-X
Tarabrin	B-X
,	B-X
S.	B-X
Shcherbakow	B-X
,	B-X
D.	B-X
Gavrychenko	B-X
,	B-X
G.	B-X
Mazurenko	B-X
,	B-X
V.	B-X
Ivanova	B-X
,	B-X
O.	B-X
Chystikov	B-X
P120	B-X
-	B-X
First	B-X
study	B-X
to	B-X
prove	B-X
the	B-X
superiority	B-X
of	B-X
prothrombin	B-X
complex	B-X
concentrates	B-X
on	B-X
mortality	B-X
rate	B-X
over	B-X
fresh	B-X
frozen	B-X
plasma	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
bleeding	B-X
C.	B-X
Plourde	B-X
,	B-X
J.	B-X
Lessard	B-X
,	B-X
J.	B-X
Chauny	B-X
,	B-X
R.	B-X
Daoust	B-X
P121	B-X
-	B-X
Prothrombin	B-X
complex	B-X
concentrate	B-X
vs	B-X
fresh	B-X
frozen	B-X
plasma	B-X
in	B-X
obstetric	B-X
massive	B-X
bleeding	B-X
S.	B-X
Shcherbakow	B-X
,	B-X
O.	B-X
Tarabrin	B-X
,	B-X
D.	B-X
Gavrychenko	B-X
,	B-X
G.	B-X
Mazurenko	B-X
,	B-X
O.	B-X
Chystikov	B-X
P122	B-X
-	B-X
Impact	B-X
of	B-X
FFP	B-X
transfusion	B-X
on	B-X
VAP	B-X
in	B-X
ICU	B-X
patients	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P123	B-X
-	B-X
Preoperative	B-X
platelet	B-X
function	B-X
test	B-X
and	B-X
the	B-X
thrombin	B-X
generation	B-X
assay	B-X
are	B-X
predictive	B-X
for	B-X
blood	B-X
loss	B-X
after	B-X
cardiac	B-X
surgery	B-X
L.	B-X
Kropman	B-X
,	B-X
L.	B-X
In	B-X
het	B-X
Panhuis	B-X
,	B-X
J.	B-X
Konings	B-X
,	B-X
D.	B-X
Huskens	B-X
,	B-X
E.	B-X
Schurgers	B-X
,	B-X
M.	B-X
Roest	B-X
,	B-X
B	B-X
.	B-X
De	B-X
Laat	B-X
,	B-X
M.	B-X
Lance	B-X
P124	B-X
-	B-X
Rotational	B-X
thromboelastometry	B-X
versus	B-X
standard	B-X
coagulation	B-X
tests	B-X
before	B-X
surgical	B-X
interventions	B-X
M.	B-X
Durila	B-X
,	B-X
P.	B-X
Lukas	B-X
,	B-X
M.	B-X
Astraverkhava	B-X
,	B-X
J.	B-X
Jonas	B-X
P125	B-X
-	B-X
Correction	B-X
of	B-X
impaired	B-X
clot	B-X
quality	B-X
and	B-X
stability	B-X
by	B-X
fibrinogen	B-X
and	B-X
activated	B-X
prothrombin	B-X
complex	B-X
concentrate	B-X
in	B-X
a	B-X
model	B-X
of	B-X
severe	B-X
thrombocytopenia	B-X
I.	B-X
Budnik	B-X
,	B-X
B.	B-X
Shenkman	B-X
P126	B-X
-	B-X
Assessment	B-X
of	B-X
point-of-care	B-X
prothrombin	B-X
time	B-X
analyzer	B-X
as	B-X
a	B-X
monitor	B-X
after	B-X
cardiopulmonary	B-X
bypass	B-X
H.	B-X
Hayami	B-X
,	B-X
Y.	B-X
Koide	B-X
,	B-X
T.	B-X
Goto	B-X
P127	B-X
-	B-X
Disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
dic	B-X
)	B-X
is	B-X
underdiagnosed	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
do	B-X
we	B-X
need	B-X
d-dimer	B-X
measurements	B-X
?	B-X
A.	B-X
Murdoch	B-X
,	B-X
S.	B-X
M.	B-X
Tibby	B-X
P130	B-X
-	B-X
Nadir	B-X
hemoglobulin	B-X
during	B-X
cardiopulmonary	B-X
bypass	B-X
:	B-X
impact	B-X
on	B-X
postoperative	B-X
morbidity	B-X
and	B-X
mortality	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
D.	B-X
Moisidou	B-X
,	B-X
E.	B-X
Dalampini	B-X
,	B-X
M.	B-X
Nastou	B-X
,	B-X
E.	B-X
Vasilarou	B-X
,	B-X
V.	B-X
Kalaizi	B-X
,	B-X
H.	B-X
Chatzikostenoglou	B-X
,	B-X
G.	B-X
Drossos	B-X
P131	B-X
-	B-X
Red	B-X
blood	B-X
cell	B-X
transfusion	B-X
do	B-X
not	B-X
influence	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
RDW	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
S.	B-X
Spadaro	B-X
,	B-X
A.	B-X
Fogagnolo	B-X
,	B-X
T.	B-X
Fiore	B-X
,	B-X
A.	B-X
Schiavi	B-X
,	B-X
V.	B-X
Fontana	B-X
,	B-X
F.	B-X
Taccone	B-X
,	B-X
C.	B-X
Volta	B-X
P132	B-X
-	B-X
Reasons	B-X
for	B-X
admission	B-X
in	B-X
the	B-X
paediatric	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
the	B-X
need	B-X
for	B-X
blood	B-X
and	B-X
blood	B-X
products	B-X
transfusions	B-X
E.	B-X
Chochliourou	B-X
,	B-X
E.	B-X
Volakli	B-X
,	B-X
A.	B-X
Violaki	B-X
,	B-X
E.	B-X
Samkinidou	B-X
,	B-X
G.	B-X
Evlavis	B-X
,	B-X
V.	B-X
Panagiotidou	B-X
,	B-X
M.	B-X
Sdougka	B-X
P133	B-X
-	B-X
The	B-X
implementation	B-X
of	B-X
a	B-X
massive	B-X
haemorrhage	B-X
protocol	B-X
(	B-X
mhp	B-X
)	B-X
for	B-X
the	B-X
management	B-X
of	B-X
major	B-X
trauma	B-X
:	B-X
a	B-X
ten	B-X
year	B-X
,	B-X
single-centre	B-X
study	B-X
R.	B-X
Mothukuri	B-X
,	B-X
C.	B-X
Battle	B-X
,	B-X
K.	B-X
Guy	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
P.	B-X
Evans	B-X
P134	B-X
-	B-X
An	B-X
integrated	B-X
major	B-X
haemorrhage	B-X
protocol	B-X
for	B-X
pre-hospital	B-X
and	B-X
retrieval	B-X
medical	B-X
teams	B-X
J.	B-X
Wijesuriya	B-X
,	B-X
S.	B-X
Keogh	B-X
P135	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
transfusion	B-X
thresholds	B-X
on	B-X
mortality	B-X
and	B-X
cardiovascular	B-X
events	B-X
in	B-X
patients	B-X
with	B-X
cardiovascular	B-X
disease	B-X
(	B-X
non-cardiac	B-X
surgery	B-X
)	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
A.	B-X
Docherty	B-X
,	B-X
R.	B-X
O	B-X
’	B-X
Donnell	B-X
,	B-X
S.	B-X
Brunskill	B-X
,	B-X
M.	B-X
Trivella	B-X
,	B-X
C.	B-X
Doree	B-X
,	B-X
L.	B-X
Holst	B-X
,	B-X
M.	B-X
Parker	B-X
,	B-X
M.	B-X
Gregersen	B-X
,	B-X
J.	B-X
Almeida	B-X
,	B-X
T.	B-X
Walsh	B-X
,	B-X
S.	B-X
Stanworth	B-X
P136	B-X
-	B-X
The	B-X
relationship	B-X
between	B-X
poor	B-X
pre-operative	B-X
immune	B-X
status	B-X
and	B-X
outcome	B-X
from	B-X
cardiac	B-X
surgery	B-X
is	B-X
specific	B-X
to	B-X
the	B-X
peri-operative	B-X
antigenic	B-X
threat	B-X
S.	B-X
Moravcova	B-X
,	B-X
J.	B-X
Mansell	B-X
,	B-X
A.	B-X
Rogers	B-X
,	B-X
R.	B-X
A.	B-X
Smith	B-X
,	B-X
C.	B-X
Hamilton-Davies	B-X
P137	B-X
-	B-X
Impact	B-X
of	B-X
simple	B-X
clinical	B-X
practice	B-X
guidelines	B-X
for	B-X
reducing	B-X
post-operative	B-X
atrial	B-X
fibrillation	B-X
after	B-X
cardiac	B-X
surgery	B-X
.	B-X
A.	B-X
Omar	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
O.	B-X
Bilala	B-X
,	B-X
A.	B-X
Kindawi	B-X
,	B-X
H.	B-X
Ewila	B-X
P138	B-X
-	B-X
Dexamethasone	B-X
administration	B-X
during	B-X
cardiopulmonary	B-X
bypass	B-X
has	B-X
no	B-X
beneficial	B-X
effects	B-X
on	B-X
elective	B-X
postoperative	B-X
cardiac	B-X
surgery	B-X
patients	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
D.	B-X
Moisidou	B-X
,	B-X
M.	B-X
Nastou	B-X
,	B-X
E.	B-X
Dalampini	B-X
,	B-X
A.	B-X
Malamas	B-X
,	B-X
E.	B-X
Vasilarou	B-X
,	B-X
G.	B-X
Drossos	B-X
P139	B-X
-	B-X
Intra-aortic	B-X
balloon	B-X
counterpulsation	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
(	B-X
IABCS	B-X
)	B-X
:	B-X
preliminary	B-X
results	B-X
G.	B-X
Ferreira	B-X
,	B-X
J.	B-X
Caldas	B-X
,	B-X
J.	B-X
Fukushima	B-X
,	B-X
E.	B-X
A.	B-X
Osawa	B-X
,	B-X
E.	B-X
Arita	B-X
,	B-X
L.	B-X
Camara	B-X
,	B-X
S.	B-X
Zeferino	B-X
,	B-X
J.	B-X
Jardim	B-X
,	B-X
F.	B-X
Gaioto	B-X
,	B-X
L.	B-X
Dallan	B-X
,	B-X
F.	B-X
B.	B-X
Jatene	B-X
,	B-X
R.	B-X
Kalil	B-X
Filho	B-X
,	B-X
.F	B-X
Galas	B-X
,	B-X
L.	B-X
A.	B-X
Hajjar	B-X
P140	B-X
-	B-X
Effects	B-X
of	B-X
low-dose	B-X
atrial	B-X
natriuretic	B-X
peptide	B-X
infusion	B-X
on	B-X
cardiac	B-X
surgery-associated	B-X
acute	B-X
kidney	B-X
injury	B-X
C.	B-X
Mitaka	B-X
,	B-X
T.	B-X
Ohnuma	B-X
,	B-X
T.	B-X
Murayama	B-X
,	B-X
F.	B-X
Kunimoto	B-X
,	B-X
M.	B-X
Nagashima	B-X
,	B-X
T.	B-X
Takei	B-X
,	B-X
M.	B-X
Tomita	B-X
P141	B-X
-	B-X
Acute	B-X
kidney	B-X
injury	B-X
influence	B-X
on	B-X
high	B-X
sensitive	B-X
troponin	B-X
measurements	B-X
after	B-X
cardiac	B-X
surgery	B-X
A.	B-X
Omar	B-X
,	B-X
K.	B-X
Mahmoud	B-X
,	B-X
S.	B-X
Hanoura	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
P.	B-X
Sivadasan	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
Y.	B-X
Shouman	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P142	B-X
-	B-X
Complex	B-X
evaluation	B-X
of	B-X
endothelial	B-X
dysfunction	B-X
markers	B-X
for	B-X
prognosis	B-X
of	B-X
outcomes	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
I.	B-X
Mandel	B-X
,	B-X
S.	B-X
Mikheev	B-X
,	B-X
I.	B-X
Suhodolo	B-X
,	B-X
V.	B-X
Kiselev	B-X
,	B-X
Y.	B-X
Svirko	B-X
,	B-X
Y.	B-X
Podoksenov	B-X
P143	B-X
-	B-X
New-onset	B-X
atrial	B-X
fibrillation	B-X
in	B-X
intensive	B-X
care	B-X
:	B-X
incidence	B-X
,	B-X
management	B-X
and	B-X
outcome	B-X
S.	B-X
A.	B-X
Jenkins	B-X
,	B-X
R.	B-X
Griffin	B-X
P144	B-X
-	B-X
One	B-X
single	B-X
spot	B-X
measurement	B-X
of	B-X
the	B-X
sublingual	B-X
microcirculation	B-X
during	B-X
acute	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
pig	B-X
model	B-X
of	B-X
shock	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
A.	B-X
Lima	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
C.	B-X
Ince	B-X
P145	B-X
-	B-X
Assessment	B-X
of	B-X
levosimendan	B-X
as	B-X
a	B-X
therapeutic	B-X
option	B-X
to	B-X
recruit	B-X
the	B-X
microcirculation	B-X
in	B-X
cardiogenic	B-X
shock	B-X
–	B-X
initial	B-X
experience	B-X
in	B-X
cardiac	B-X
ICU	B-X
A.	B-X
Taha	B-X
,	B-X
A.	B-X
Shafie	B-X
,	B-X
M.	B-X
Mostafa	B-X
,	B-X
N.	B-X
Syed	B-X
,	B-X
H.	B-X
Hon	B-X
P146	B-X
-	B-X
Terlipressin	B-X
vs.	B-X
norepinephrine	B-X
in	B-X
the	B-X
Potential	B-X
Multiorgan	B-X
Donor	B-X
(	B-X
PMD	B-X
)	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
,	B-X
G.	B-X
Castellano	B-X
P147	B-X
-	B-X
Echocardiography	B-X
in	B-X
the	B-X
potential	B-X
heart	B-X
donor	B-X
exposed	B-X
to	B-X
substitution	B-X
hormonotherapy	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
P148	B-X
-	B-X
Machine	B-X
learning	B-X
can	B-X
reduce	B-X
rate	B-X
of	B-X
monitor	B-X
alarms	B-X
M.	B-X
Hravnak	B-X
,	B-X
L.	B-X
C.	B-X
Chen	B-X
,	B-X
A.	B-X
D.	B-X
Dubrawski	B-X
,	B-X
G.	B-X
C.	B-X
Clermont	B-X
,	B-X
M.	B-X
R.	B-X
Pinsky	B-X
P149	B-X
-	B-X
Peripherally	B-X
inserted	B-X
central	B-X
catheters	B-X
placed	B-X
in	B-X
the	B-X
ICU	B-X
S.	B-X
Gonzalez	B-X
,	B-X
D.	B-X
Macias	B-X
,	B-X
J.	B-X
Acosta	B-X
,	B-X
P.	B-X
Jimenez	B-X
,	B-X
A.	B-X
Loza	B-X
,	B-X
A.	B-X
Lesmes	B-X
,	B-X
F.	B-X
Lucena	B-X
,	B-X
C.	B-X
Leon	B-X
P150	B-X
-	B-X
Recordings	B-X
of	B-X
abnormal	B-X
central	B-X
venous	B-X
pressure	B-X
waveform	B-X
morphology	B-X
during	B-X
an	B-X
episode	B-X
of	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
porcine	B-X
shock	B-X
model	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
C.	B-X
Ince	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
A.	B-X
Lima	B-X
P151	B-X
-	B-X
Ultrasound	B-X
guided	B-X
central	B-X
venous	B-X
access	B-X
technique	B-X
among	B-X
French	B-X
intensivists	B-X
M.	B-X
Bastide	B-X
,	B-X
J.	B-X
Richecoeur	B-X
,	B-X
E.	B-X
Frenoy	B-X
,	B-X
C.	B-X
Lemaire	B-X
,	B-X
B.	B-X
Sauneuf	B-X
,	B-X
F.	B-X
Tamion	B-X
,	B-X
S.	B-X
Nseir	B-X
,	B-X
D.	B-X
Du	B-X
Cheyron	B-X
,	B-X
H.	B-X
Dupont	B-X
,	B-X
J.	B-X
Maizel	B-X
P152	B-X
-	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Pv-aCO2	B-X
gap	B-X
in	B-X
patients	B-X
with	B-X
shock	B-X
M.	B-X
Shaban	B-X
,	B-X
R.	B-X
Kolko	B-X
,	B-X
N.	B-X
Salahuddin	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
AbuRageila	B-X
,	B-X
A.	B-X
AlHussain	B-X
P153	B-X
-	B-X
Comparison	B-X
of	B-X
echocardiography	B-X
and	B-X
pulmonary	B-X
artery	B-X
catheter	B-X
measurements	B-X
of	B-X
hemodynamic	B-X
parameters	B-X
in	B-X
critical	B-X
ill	B-X
patients	B-X
P.	B-X
Mercado	B-X
,	B-X
J.	B-X
Maizel	B-X
,	B-X
L.	B-X
Kontar	B-X
,	B-X
D.	B-X
Titeca	B-X
,	B-X
F.	B-X
Brazier	B-X
,	B-X
A.	B-X
Riviere	B-X
,	B-X
M.	B-X
Joris	B-X
,	B-X
T.	B-X
Soupison	B-X
,	B-X
B	B-X
.	B-X
De	B-X
Cagny	B-X
,	B-X
M.	B-X
Slama	B-X
P154	B-X
-	B-X
The	B-X
volume	B-X
clamp	B-X
method	B-X
for	B-X
noninvasive	B-X
cardiac	B-X
output	B-X
measurement	B-X
in	B-X
postoperative	B-X
cardiothoracic	B-X
surgery	B-X
patients	B-X
:	B-X
a	B-X
comparison	B-X
with	B-X
intermittent	B-X
pulmonary	B-X
artery	B-X
thermodilution	B-X
J.	B-X
Wagner	B-X
,	B-X
A.	B-X
Körner	B-X
,	B-X
M.	B-X
Kubik	B-X
,	B-X
S.	B-X
Kluge	B-X
,	B-X
D.	B-X
Reuter	B-X
,	B-X
B.	B-X
Saugel	B-X
P155	B-X
-	B-X
Hemodynamic	B-X
monitoring	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
(	B-X
SS	B-X
)	B-X
–	B-X
CPCCO	B-X
(	B-X
continuous	B-X
pulse	B-X
contour	B-X
cardiac	B-X
output	B-X
)	B-X
vs.	B-X
TEE	B-X
(	B-X
transesophageal	B-X
echocardiography	B-X
)	B-X
E.	B-X
Colombaroli	B-X
,	B-X
F.	B-X
Righetti	B-X
,	B-X
G.	B-X
Castellano	B-X
P156	B-X
-	B-X
Cardiac	B-X
output	B-X
measurement	B-X
with	B-X
transthoracic	B-X
echocardiography	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
a	B-X
pragmatic	B-X
clinical	B-X
study	B-X
T.	B-X
Tran	B-X
,	B-X
D.	B-X
De	B-X
Bels	B-X
,	B-X
A.	B-X
Cudia	B-X
,	B-X
M.	B-X
Strachinaru	B-X
,	B-X
P.	B-X
Ghottignies	B-X
,	B-X
J.	B-X
Devriendt	B-X
,	B-X
C.	B-X
Pierrakos	B-X
P157	B-X
-	B-X
Left	B-X
ventricular	B-X
outflow	B-X
tract	B-X
velocity	B-X
time	B-X
integral	B-X
correlates	B-X
with	B-X
stroke	B-X
volume	B-X
index	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
Ó.	B-X
Martínez	B-X
González	B-X
,	B-X
R.	B-X
Blancas	B-X
,	B-X
J.	B-X
Luján	B-X
,	B-X
D.	B-X
Ballesteros	B-X
,	B-X
C.	B-X
Martínez	B-X
Díaz	B-X
,	B-X
A.	B-X
Núñez	B-X
,	B-X
C.	B-X
Martín	B-X
Parra	B-X
,	B-X
B.	B-X
López	B-X
Matamala	B-X
,	B-X
M.	B-X
Alonso	B-X
Fernández	B-X
,	B-X
M.	B-X
Chana	B-X
P158	B-X
-	B-X
Transpulmonary	B-X
thermodilution	B-X
(	B-X
TPTD	B-X
)	B-X
derived	B-X
from	B-X
femoral	B-X
vs.	B-X
jugular	B-X
central	B-X
venous	B-X
catheter	B-X
:	B-X
validation	B-X
of	B-X
a	B-X
previously	B-X
published	B-X
correction	B-X
formula	B-X
and	B-X
a	B-X
proprietary	B-X
correction	B-X
formula	B-X
for	B-X
global	B-X
end-diastolic	B-X
volume	B-X
index	B-X
(	B-X
GEDVI	B-X
)	B-X
W.	B-X
Huber	B-X
,	B-X
M.	B-X
Eckmann	B-X
,	B-X
F.	B-X
Elkmann	B-X
,	B-X
A.	B-X
Gruber	B-X
,	B-X
I.	B-X
Klein	B-X
,	B-X
R.	B-X
M.	B-X
Schmid	B-X
,	B-X
T.	B-X
Lahmer	B-X
P160	B-X
-	B-X
Dynamic	B-X
arterial	B-X
elastance	B-X
calculated	B-X
with	B-X
lidcoplus	B-X
monitor	B-X
does	B-X
not	B-X
predict	B-X
changes	B-X
in	B-X
arterial	B-X
pressure	B-X
after	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
postsurgical	B-X
patients	B-X
D.	B-X
Bastoni	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
L.	B-X
Toscani	B-X
,	B-X
L.	B-X
Pigozzi	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P159	B-X
-	B-X
Venous	B-X
return	B-X
driving	B-X
pressure	B-X
and	B-X
resistance	B-X
in	B-X
acute	B-X
blood	B-X
volume	B-X
changes	B-X
P.	B-X
W.	B-X
Moller	B-X
,	B-X
S.	B-X
Sondergaard	B-X
,	B-X
S.	B-X
M.	B-X
Jakob	B-X
,	B-X
J.	B-X
Takala	B-X
,	B-X
D.	B-X
Berger	B-X
P160	B-X
-	B-X
Dynamic	B-X
arterial	B-X
elastance	B-X
calculated	B-X
with	B-X
lidcoplus	B-X
monitor	B-X
does	B-X
not	B-X
predict	B-X
changes	B-X
in	B-X
arterial	B-X
pressure	B-X
after	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
postsurgical	B-X
patients	B-X
D.	B-X
Bastoni	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
L.	B-X
Toscani	B-X
,	B-X
L.	B-X
Pigozzi	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P161	B-X
-	B-X
Analysis	B-X
of	B-X
duration	B-X
of	B-X
post-operative	B-X
goal-directed	B-X
therapy	B-X
protocol	B-X
C.	B-X
Ostrowska	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
A.	B-X
Abbas	B-X
,	B-X
J.	B-X
Mellinghoff	B-X
,	B-X
C.	B-X
Ryan	B-X
,	B-X
D.	B-X
Dawson	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P162	B-X
-	B-X
Hemodynamic	B-X
optimization	B-X
–	B-X
back	B-X
to	B-X
square	B-X
one	B-X
?	B-X
Wall	B-X
,	B-X
E.	B-X
Nyberg	B-X
,	B-X
R.	B-X
Zeng	B-X
,	B-X
C.	B-X
Svensen	B-X
,	B-X
J.	B-X
Mårtensson	B-X
,	B-X
E.	B-X
Joelsson-Alm	B-X
P163	B-X
-	B-X
Effectiveness	B-X
of	B-X
fluid	B-X
thoracic	B-X
content	B-X
measurement	B-X
by	B-X
bioimpedance	B-X
guiding	B-X
intravascular	B-X
volume	B-X
optimization	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
V.	B-X
Lopez	B-X
,	B-X
M.	B-X
Cetina	B-X
P164	B-X
-	B-X
A	B-X
systematic	B-X
review	B-X
on	B-X
the	B-X
role	B-X
of	B-X
internal	B-X
jugular	B-X
vein	B-X
ultrasound	B-X
measurements	B-X
in	B-X
assessment	B-X
of	B-X
volume	B-X
status	B-X
in	B-X
critical	B-X
shock	B-X
patients	B-X
N.	B-X
Parenti	B-X
,	B-X
C.	B-X
Palazzi	B-X
,	B-X
L.	B-X
A.	B-X
Amidei	B-X
,	B-X
F.	B-X
B.	B-X
Borrelli	B-X
,	B-X
S.	B-X
C.	B-X
Campanale	B-X
,	B-X
F.	B-X
T.	B-X
Tagliazucchi	B-X
,	B-X
G.	B-X
S.	B-X
Sedoni	B-X
,	B-X
D.	B-X
L.	B-X
Lucchesi	B-X
,	B-X
E.	B-X
C.	B-X
Carella	B-X
,	B-X
A.	B-X
L	B-X
Luciani	B-X
P165	B-X
-	B-X
Importance	B-X
of	B-X
recognizing	B-X
dehydration	B-X
in	B-X
medical	B-X
Intensive	B-X
Care	B-X
Unit	B-X
M.	B-X
Mackovic	B-X
,	B-X
N.	B-X
Maric	B-X
,	B-X
M.	B-X
Bakula	B-X
P166	B-X
-	B-X
Effect	B-X
of	B-X
volume	B-X
for	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
septic	B-X
patients	B-X
H.	B-X
Aya	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
R.	B-X
M.	B-X
Grounds	B-X
,	B-X
N.	B-X
Fletcher	B-X
,	B-X
M.	B-X
Cecconi	B-X
P167	B-X
-	B-X
Fluid	B-X
bolus	B-X
practices	B-X
in	B-X
a	B-X
large	B-X
Australian	B-X
intensive	B-X
care	B-X
unit	B-X
B.	B-X
Avard	B-X
,	B-X
P.	B-X
Zhang	B-X
P168	B-X
-	B-X
Liberal	B-X
late	B-X
fluid	B-X
management	B-X
is	B-X
associated	B-X
with	B-X
longer	B-X
ventilation	B-X
duration	B-X
and	B-X
worst	B-X
outcome	B-X
in	B-X
severe	B-X
trauma	B-X
patients	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
of	B-X
294	B-X
patients	B-X
M.	B-X
Mezidi	B-X
,	B-X
J.	B-X
Charbit	B-X
,	B-X
M.	B-X
Ould-Chikh	B-X
,	B-X
P.	B-X
Deras	B-X
,	B-X
C.	B-X
Maury	B-X
,	B-X
O.	B-X
Martinez	B-X
,	B-X
X.	B-X
Capdevila	B-X
P169	B-X
-	B-X
Association	B-X
of	B-X
fluids	B-X
and	B-X
outcomes	B-X
in	B-X
emergency	B-X
department	B-X
patients	B-X
hospitalized	B-X
with	B-X
community-acquired	B-X
pneumonia	B-X
P.	B-X
Hou	B-X
,	B-X
W.	B-X
Z.	B-X
Linde-Zwirble	B-X
,	B-X
I.	B-X
D.	B-X
Douglas	B-X
,	B-X
N.	B-X
S.	B-X
Shapiro	B-X
P170	B-X
-	B-X
Association	B-X
of	B-X
positive	B-X
fluid	B-X
balance	B-X
with	B-X
poor	B-X
outcome	B-X
in	B-X
medicosurgical	B-X
ICU	B-X
patients	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
I.	B-X
Mezghani	B-X
,	B-X
Y.	B-X
Ben	B-X
Aicha	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
B.	B-X
Laribi	B-X
,	B-X
B.	B-X
Jeribi	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.	B-X
S.	B-X
Mebazaa	B-X
P171	B-X
-	B-X
Impact	B-X
of	B-X
fluid	B-X
balance	B-X
to	B-X
organ	B-X
dysfunction	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
C.	B-X
Pereira	B-X
,	B-X
R.	B-X
Marinho	B-X
,	B-X
R.	B-X
Antunes	B-X
,	B-X
A.	B-X
Marinho	B-X
P172	B-X
-	B-X
Volume	B-X
bolus	B-X
in	B-X
ICU	B-X
patients	B-X
:	B-X
do	B-X
we	B-X
need	B-X
to	B-X
balance	B-X
our	B-X
crystalloids	B-X
?	B-X
M.	B-X
Crivits	B-X
,	B-X
M.	B-X
Raes	B-X
,	B-X
J.	B-X
Decruyenaere	B-X
,	B-X
E.	B-X
Hoste	B-X
P173	B-X
-	B-X
The	B-X
use	B-X
of	B-X
6	B-X
%	B-X
HES	B-X
solution	B-X
do	B-X
not	B-X
reduce	B-X
total	B-X
fluid	B-X
requirement	B-X
in	B-X
the	B-X
therapy	B-X
of	B-X
patients	B-X
with	B-X
burn	B-X
shock	B-X
V.	B-X
Bagin	B-X
,	B-X
V.	B-X
Rudnov	B-X
,	B-X
A.	B-X
Savitsky	B-X
,	B-X
M.	B-X
Astafyeva	B-X
,	B-X
I.	B-X
Korobko	B-X
,	B-X
V.	B-X
Vein	B-X
P174	B-X
-	B-X
Electron	B-X
microscopic	B-X
assessment	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
septic	B-X
sheep	B-X
resuscitated	B-X
with	B-X
crystalloids	B-X
or	B-X
different	B-X
colloids	B-X
T.	B-X
Kampmeier	B-X
,	B-X
P.	B-X
Arnemann	B-X
,	B-X
M.	B-X
Hessler	B-X
,	B-X
A.	B-X
Wald	B-X
,	B-X
K.	B-X
Bockbreder	B-X
,	B-X
A.	B-X
Morelli	B-X
,	B-X
H.	B-X
Van	B-X
Aken	B-X
,	B-X
S.	B-X
Rehberg	B-X
,	B-X
C.	B-X
Ertmer	B-X
P175	B-X
-	B-X
Alterations	B-X
of	B-X
conjunctival	B-X
microcirculation	B-X
in	B-X
a	B-X
sheep	B-X
model	B-X
of	B-X
haemorrhagic	B-X
shock	B-X
and	B-X
resuscitation	B-X
with	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
balanced	B-X
tetrastarch	B-X
P.	B-X
Arnemann	B-X
,	B-X
M.	B-X
Hessler	B-X
,	B-X
T.	B-X
Kampmeier	B-X
,	B-X
S.	B-X
Rehberg	B-X
,	B-X
H.	B-X
Van	B-X
Aken	B-X
,	B-X
C.	B-X
Ince	B-X
,	B-X
C.	B-X
Ertmer	B-X
P176	B-X
-	B-X
A	B-X
single	B-X
centre	B-X
nested	B-X
pilot	B-X
study	B-X
investigating	B-X
the	B-X
effect	B-X
of	B-X
using	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
Plasma-Lyte	B-X
148	B-X
®	B-X
as	B-X
crystalloid	B-X
fluid	B-X
therapy	B-X
on	B-X
gastrointestinal	B-X
feeding	B-X
intolerance	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
receiving	B-X
nasogastric	B-X
enteral	B-X
nutrition	B-X
S.	B-X
Reddy	B-X
,	B-X
M.	B-X
Bailey	B-X
,	B-X
R.	B-X
Beasley	B-X
,	B-X
R.	B-X
Bellomo	B-X
,	B-X
D.	B-X
Mackle	B-X
,	B-X
A.	B-X
Psirides	B-X
,	B-X
P.	B-X
Young	B-X
P177	B-X
-	B-X
A	B-X
single	B-X
centre	B-X
nested	B-X
pilot	B-X
study	B-X
investigating	B-X
the	B-X
effect	B-X
on	B-X
post-operative	B-X
bleeding	B-X
of	B-X
using	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
Plasma-Lyte®	B-X
148	B-X
as	B-X
crystalloid	B-X
fluid	B-X
therapy	B-X
in	B-X
adults	B-X
in	B-X
ICU	B-X
after	B-X
heart	B-X
surgery	B-X
S.	B-X
Reddy	B-X
,	B-X
M.	B-X
Bailey	B-X
,	B-X
R.	B-X
Beasley	B-X
,	B-X
R.	B-X
Bellomo	B-X
,	B-X
D.	B-X
Mackle	B-X
,	B-X
P.	B-X
Young	B-X
P178	B-X
-	B-X
Extreme	B-X
hypernatremia	B-X
and	B-X
sepsis	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
Huntington	B-X
’	B-X
s	B-X
dementia	B-X
:	B-X
a	B-X
conundrum	B-X
in	B-X
fluid	B-X
management	B-X
H.	B-X
Venkatesh	B-X
,	B-X
S.	B-X
Ramachandran	B-X
,	B-X
A.	B-X
Basu	B-X
,	B-X
H.	B-X
Nair	B-X
P179	B-X
-	B-X
Diagnosis	B-X
and	B-X
management	B-X
of	B-X
severe	B-X
hypernatraemia	B-X
in	B-X
the	B-X
critical	B-X
care	B-X
setting	B-X
S.	B-X
Egan	B-X
,	B-X
J.	B-X
Bates	B-X
P180	B-X
-	B-X
Correlation	B-X
between	B-X
arterial	B-X
blood	B-X
gas	B-X
and	B-X
electrolyte	B-X
disturbances	B-X
during	B-X
hospitalization	B-X
and	B-X
outcome	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
S.	B-X
Oliveira	B-X
,	B-X
N.	B-X
R.	B-X
Rangel	B-X
Neto	B-X
,	B-X
F.	B-X
Q.	B-X
Reis	B-X
P181	B-X
-	B-X
Missing	B-X
the	B-X
“	B-X
I	B-X
”	B-X
in	B-X
MUDPILES	B-X
–	B-X
a	B-X
rare	B-X
cause	B-X
of	B-X
high	B-X
anion	B-X
gap	B-X
metabolic	B-X
acidosis	B-X
(	B-X
HAGMA	B-X
)	B-X
C.	B-X
P.	B-X
Lee	B-X
,	B-X
X.	B-X
L.	B-X
Lin	B-X
,	B-X
C.	B-X
Choong	B-X
,	B-X
K.	B-X
M.	B-X
Eu	B-X
,	B-X
W.	B-X
Y.	B-X
Sim	B-X
,	B-X
K.	B-X
S.	B-X
Tee	B-X
,	B-X
J.	B-X
Pau	B-X
,	B-X
J.	B-X
Abisheganaden	B-X
P182	B-X
-	B-X
Plasma	B-X
NGAL	B-X
and	B-X
urinary	B-X
output	B-X
:	B-X
potential	B-X
parameters	B-X
for	B-X
early	B-X
initiation	B-X
of	B-X
renal	B-X
replacement	B-X
therapy	B-X
K.	B-X
Maas	B-X
,	B-X
H.	B-X
De	B-X
Geus	B-X
P183	B-X
-	B-X
Renal	B-X
replacement	B-X
therapy	B-X
for	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
an	B-X
intermittent	B-X
continuity	B-X
E.	B-X
Lafuente	B-X
,	B-X
R.	B-X
Marinho	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
R.	B-X
Antunes	B-X
,	B-X
A.	B-X
Marinho	B-X
P184	B-X
-	B-X
A	B-X
survey	B-X
of	B-X
practices	B-X
related	B-X
to	B-X
renal	B-X
replacement	B-X
therapy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
in	B-X
the	B-X
north	B-X
of	B-X
England	B-X
.	B-X
T.	B-X
E.	B-X
Doris	B-X
,	B-X
D.	B-X
Monkhouse	B-X
,	B-X
T.	B-X
Shipley	B-X
,	B-X
S.	B-X
Kardasz	B-X
,	B-X
I	B-X
Gonzalez	B-X
P185	B-X
-	B-X
High	B-X
initiation	B-X
creatinine	B-X
associated	B-X
with	B-X
lower	B-X
28-day	B-X
mortality	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
necessitating	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Stads	B-X
,	B-X
A.	B-X
J.	B-X
Groeneveld	B-X
P186	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
Karnofsky	B-X
performance	B-X
scale	B-X
on	B-X
outcomes	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
patients	B-X
receiving	B-X
renal	B-X
replacement	B-X
therapy	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
I.	B-X
Elsayed	B-X
,	B-X
N.	B-X
Ward	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
A.	B-X
Raithatha	B-X
P187	B-X
-	B-X
Severe	B-X
hypophosphatemia	B-X
during	B-X
citrate-anticoagulated	B-X
CRRT	B-X
A.	B-X
Steuber	B-X
,	B-X
C.	B-X
Pelletier	B-X
,	B-X
S.	B-X
Schroeder	B-X
,	B-X
E.	B-X
Michael	B-X
,	B-X
T.	B-X
Slowinski	B-X
,	B-X
D.	B-X
Kindgen-Milles	B-X
P188	B-X
-	B-X
Citrate	B-X
regional	B-X
anticoagulation	B-X
for	B-X
post	B-X
dilution	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Ghabina	B-X
P189	B-X
-	B-X
Citrate	B-X
18	B-X
mmol/l	B-X
improves	B-X
anticoagulation	B-X
during	B-X
RRT	B-X
with	B-X
adsorbing	B-X
filters	B-X
F.	B-X
Turani	B-X
,	B-X
A.	B-X
Belli	B-X
,	B-X
S.	B-X
Busatti	B-X
,	B-X
G.	B-X
Barettin	B-X
,	B-X
F.	B-X
Candidi	B-X
,	B-X
F.	B-X
Gargano	B-X
,	B-X
R.	B-X
Barchetta	B-X
,	B-X
M.	B-X
Falco	B-X
P190	B-X
-	B-X
Calcium	B-X
gluconate	B-X
instead	B-X
of	B-X
calcium	B-X
chloride	B-X
in	B-X
citrate-anticoagulated	B-X
CVVHD	B-X
O.	B-X
Demirkiran	B-X
,	B-X
M.	B-X
Kosuk	B-X
,	B-X
S.	B-X
Bozbay	B-X
P191	B-X
-	B-X
Enhanced	B-X
clearance	B-X
of	B-X
interleukin-6	B-X
with	B-X
continuous	B-X
veno-venous	B-X
haemodialysis	B-X
(	B-X
CVVHD	B-X
)	B-X
using	B-X
Ultraflux	B-X
EMiC2	B-X
vs.	B-X
Ultraflux	B-X
AV1000S	B-X
V.	B-X
Weber	B-X
,	B-X
J.	B-X
Hartmann	B-X
,	B-X
S.	B-X
Harm	B-X
,	B-X
I.	B-X
Linsberger	B-X
,	B-X
T.	B-X
Eichhorn	B-X
,	B-X
G.	B-X
Valicek	B-X
,	B-X
G.	B-X
Miestinger	B-X
,	B-X
C.	B-X
Hoermann	B-X
P192	B-X
-	B-X
Removal	B-X
of	B-X
bilirubin	B-X
with	B-X
a	B-X
new	B-X
adsorbent	B-X
system	B-X
:	B-X
in	B-X
vitro	B-X
kinetics	B-X
S.	B-X
Faenza	B-X
,	B-X
D.	B-X
Ricci	B-X
,	B-X
E.	B-X
Mancini	B-X
,	B-X
C.	B-X
Gemelli	B-X
,	B-X
A.	B-X
Cuoghi	B-X
,	B-X
S.	B-X
Magnani	B-X
,	B-X
M.	B-X
Atti	B-X
P193	B-X
-	B-X
Case	B-X
series	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
treated	B-X
with	B-X
a	B-X
new	B-X
extracorporeal	B-X
sorbent	B-X
T.	B-X
Laddomada	B-X
,	B-X
A.	B-X
Doronzio	B-X
,	B-X
B.	B-X
Balicco	B-X
P194	B-X
-	B-X
In	B-X
vitro	B-X
adsorption	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
inflammatory	B-X
mediators	B-X
with	B-X
CytoSorb®	B-X
hemoadsorbent	B-X
polymer	B-X
beads	B-X
M.	B-X
C.	B-X
Gruda	B-X
,	B-X
P.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
V.	B-X
P.	B-X
Dan	B-X
,	B-X
T.	B-X
Guliashvili	B-X
,	B-X
A.	B-X
Scheirer	B-X
,	B-X
T.	B-X
D.	B-X
Golobish	B-X
,	B-X
V.	B-X
J.	B-X
Capponi	B-X
,	B-X
P.	B-X
P.	B-X
Chan	B-X
P195	B-X
-	B-X
Observations	B-X
in	B-X
early	B-X
vs.	B-X
late	B-X
use	B-X
of	B-X
cytosorb	B-X
therapy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
K.	B-X
Kogelmann	B-X
,	B-X
M.	B-X
Drüner	B-X
,	B-X
D.	B-X
Jarczak	B-X
P196	B-X
-	B-X
Oxiris	B-X
membrane	B-X
decreases	B-X
endotoxin	B-X
during	B-X
rrt	B-X
in	B-X
septic	B-X
patients	B-X
with	B-X
basal	B-X
EAA	B-X
>	B-X
0,6	B-X
F.	B-X
Turani	B-X
,	B-X
A	B-X
.	B-X
B.	B-X
Belli	B-X
,	B-X
S.	B-X
M.	B-X
Martni	B-X
,	B-X
V.	B-X
C.	B-X
Cotticelli	B-X
,	B-X
F.	B-X
Mounajergi	B-X
,	B-X
R.	B-X
Barchetta	B-X
P197	B-X
-	B-X
An	B-X
observational	B-X
prospective	B-X
study	B-X
on	B-X
the	B-X
onset	B-X
of	B-X
augmented	B-X
renal	B-X
clearance	B-X
:	B-X
the	B-X
first	B-X
report	B-X
S.	B-X
Morimoto	B-X
,	B-X
H.	B-X
Ishikura	B-X
P198	B-X
-	B-X
An	B-X
ultrasound-	B-X
guided	B-X
algorithm	B-X
for	B-X
the	B-X
management	B-X
of	B-X
oliguria	B-X
in	B-X
severe	B-X
sepsis	B-X
I.	B-X
Hussain	B-X
,	B-X
N.	B-X
Salahuddin	B-X
,	B-X
A.	B-X
Nadeem	B-X
,	B-X
K.	B-X
Ghorab	B-X
,	B-X
K.	B-X
Maghrabi	B-X
P199	B-X
-	B-X
Ultrasound	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
aki	B-X
)	B-X
.	B-X
First	B-X
findings	B-X
of	B-X
farius	B-X
,	B-X
an	B-X
education-programme	B-X
in	B-X
structural	B-X
ultrasonography	B-X
S.	B-X
K.	B-X
Kloesel	B-X
,	B-X
C.	B-X
Goldfuss	B-X
,	B-X
A.	B-X
Stieglitz	B-X
,	B-X
A.	B-X
S.	B-X
Stieglitz	B-X
,	B-X
L.	B-X
Krstevska	B-X
,	B-X
G.	B-X
Albuszies	B-X
P200	B-X
-	B-X
Effectiveness	B-X
of	B-X
renal	B-X
angina	B-X
index	B-X
score	B-X
predicting	B-X
acute	B-X
kidney	B-X
injury	B-X
on	B-X
critically	B-X
ill	B-X
patients	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
V.	B-X
Lopez	B-X
,	B-X
A.	B-X
Escalante	B-X
,	B-X
G.	B-X
Jimmy	B-X
,	B-X
M.	B-X
Cetina	B-X
P201	B-X
-	B-X
Time	B-X
length	B-X
below	B-X
blood	B-X
pressure	B-X
thresholds	B-X
and	B-X
progression	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
sepsis	B-X
:	B-X
a	B-X
retrospective	B-X
,	B-X
exploratory	B-X
cohort	B-X
study	B-X
J.	B-X
Izawa	B-X
,	B-X
T.	B-X
Iwami	B-X
,	B-X
S.	B-X
Uchino	B-X
,	B-X
M.	B-X
Takinami	B-X
,	B-X
T.	B-X
Kitamura	B-X
,	B-X
T.	B-X
Kawamura	B-X
P202	B-X
-	B-X
Anaemia	B-X
does	B-X
not	B-X
affect	B-X
renal	B-X
recovery	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
J.	B-X
G.	B-X
Powell-Tuck	B-X
,	B-X
S.	B-X
Crichton	B-X
,	B-X
M.	B-X
Raimundo	B-X
,	B-X
L.	B-X
Camporota	B-X
,	B-X
D.	B-X
Wyncoll	B-X
,	B-X
M.	B-X
Ostermann	B-X
P203	B-X
-	B-X
Estimated	B-X
glomerular	B-X
filtration	B-X
rate	B-X
based	B-X
on	B-X
serum	B-X
creatinine	B-X
:	B-X
actual	B-X
practice	B-X
in	B-X
Dutch	B-X
ICU	B-X
’	B-X
s	B-X
A.	B-X
Hana	B-X
,	B-X
H.	B-X
R.	B-X
De	B-X
Geus	B-X
P204	B-X
-	B-X
Comparison	B-X
of	B-X
estimated	B-X
glomerular	B-X
filtration	B-X
rate	B-X
calculated	B-X
by	B-X
mdrd	B-X
,	B-X
ckd-epi-serum-creatinine	B-X
and	B-X
ckd-epi-cystatin-c	B-X
in	B-X
adult	B-X
critically	B-X
ill	B-X
patients	B-X
H.	B-X
R.	B-X
De	B-X
Geus	B-X
,	B-X
A.	B-X
Hana	B-X
P205	B-X
-	B-X
Early	B-X
diagnosis	B-X
of	B-X
septic	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
medical	B-X
critical	B-X
care	B-X
patients	B-X
with	B-X
a	B-X
urine	B-X
cell	B-X
cycle	B-X
arrest	B-X
marker	B-X
:	B-X
insulin	B-X
like	B-X
growth	B-X
factor	B-X
binding	B-X
protein-7	B-X
(	B-X
IGFBP-7	B-X
)	B-X
M.	B-X
Aydogdu	B-X
,	B-X
N.	B-X
Boyaci	B-X
,	B-X
S.	B-X
Yuksel	B-X
,	B-X
G.	B-X
Gursel	B-X
,	B-X
A	B-X
.	B-X
B.	B-X
Cayci	B-X
Sivri	B-X
P206	B-X
-	B-X
Urinary	B-X
neutrophil	B-X
gelatinase-associated	B-X
lipocalin	B-X
as	B-X
early	B-X
biomarker	B-X
of	B-X
severe	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
intensive	B-X
care	B-X
J.	B-X
Meza-Márquez	B-X
,	B-X
J.	B-X
Nava-López	B-X
,	B-X
R.	B-X
Carrillo-Esper	B-X
P207	B-X
-	B-X
Shrunken	B-X
pore	B-X
syndrome	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
sharp	B-X
rise	B-X
in	B-X
mortality	B-X
in	B-X
patients	B-X
undergoing	B-X
elective	B-X
coronary	B-X
artery	B-X
bypass	B-X
grafting	B-X
A.	B-X
Dardashti	B-X
,	B-X
A.	B-X
Grubb	B-X
P208	B-X
-	B-X
The	B-X
biomarker	B-X
nephrocheck™	B-X
can	B-X
discriminate	B-X
the	B-X
septic	B-X
shock	B-X
patients	B-X
with	B-X
an	B-X
akin	B-X
1	B-X
or	B-X
2	B-X
acute	B-X
renal	B-X
failure	B-X
who	B-X
will	B-X
not	B-X
progress	B-X
toward	B-X
the	B-X
akin	B-X
3	B-X
level	B-X
J.	B-X
Maizel	B-X
,	B-X
M.	B-X
Wetzstein	B-X
,	B-X
D.	B-X
Titeca	B-X
,	B-X
L.	B-X
Kontar	B-X
,	B-X
F.	B-X
Brazier	B-X
,	B-X
B	B-X
.	B-X
Sell	B-X
P212	B-X
-	B-X
Incidences	B-X
and	B-X
associations	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
major	B-X
trauma	B-X
S.	B-X
Lin	B-X
,	B-X
H.	B-X
Torrence	B-X
,	B-X
M.	B-X
O	B-X
’	B-X
Dwyer	B-X
,	B-X
C.	B-X
Kirwan	B-X
,	B-X
J.	B-X
Prowle	B-X
P213	B-X
-	B-X
Acute	B-X
kidney	B-X
injury	B-X
of	B-X
major	B-X
trauma	B-X
patients	B-X
T	B-X
Kim	B-X
P214	B-X
-	B-X
Trajectory	B-X
of	B-X
serum	B-X
creatinine	B-X
after	B-X
major	B-X
surgery	B-X
and	B-X
the	B-X
diagnosis	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
M.	B-X
E.	B-X
O	B-X
’	B-X
Connor	B-X
,	B-X
R.	B-X
W.	B-X
Hewson	B-X
,	B-X
C.	B-X
J.	B-X
Kirwan	B-X
,	B-X
R.	B-X
M.	B-X
Pearse	B-X
,	B-X
J.	B-X
Prowle	B-X
P215	B-X
-	B-X
Epidemiology	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
cardiac	B-X
surgery	B-X
.	B-X
A	B-X
single	B-X
center	B-X
retrospective	B-X
study	B-X
S.	B-X
Hanoura	B-X
,	B-X
A.	B-X
Omar	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
M.	B-X
Maksoud	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P216	B-X
-	B-X
Post-operative	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
major	B-X
non-cardiac	B-X
surgery	B-X
and	B-X
its	B-X
association	B-X
with	B-X
death	B-X
in	B-X
the	B-X
following	B-X
year	B-X
M.	B-X
E.	B-X
O	B-X
’	B-X
Connor	B-X
,	B-X
R.	B-X
W.	B-X
Hewson	B-X
,	B-X
C.	B-X
J.	B-X
Kirwan	B-X
,	B-X
R.	B-X
M.	B-X
Pearse	B-X
,	B-X
J.	B-X
Prowle	B-X
P217	B-X
-	B-X
Factors	B-X
affecting	B-X
acute	B-X
renal	B-X
failure	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
effect	B-X
of	B-X
these	B-X
factors	B-X
on	B-X
mortality	B-X
O.	B-X
Uzundere	B-X
,	B-X
D.	B-X
Memis	B-X
,	B-X
M.	B-X
Ýnal	B-X
,	B-X
A.	B-X
,	B-X
N.	B-X
Turan	B-X
P218	B-X
-	B-X
Results	B-X
of	B-X
the	B-X
live	B-X
kidney	B-X
transplantations	B-X
according	B-X
to	B-X
national	B-X
data	B-X
of	B-X
turkish	B-X
organ	B-X
and	B-X
tissue	B-X
information	B-X
system	B-X
M.	B-X
A.	B-X
Aydin	B-X
,	B-X
H.	B-X
Basar	B-X
,	B-X
I.	B-X
Sencan	B-X
,	B-X
A.	B-X
Kapuagasi	B-X
,	B-X
M.	B-X
Ozturk	B-X
,	B-X
Z.	B-X
Uzundurukan	B-X
,	B-X
D.	B-X
Gokmen	B-X
,	B-X
A.	B-X
Ozcan	B-X
,	B-X
C.	B-X
Kaymak	B-X
P219	B-X
-	B-X
Anaesthesia	B-X
procedure	B-X
and	B-X
intensive	B-X
therapy	B-X
in	B-X
patients	B-X
with	B-X
neck	B-X
phlegmon	B-X
V.	B-X
A.	B-X
Artemenko	B-X
,	B-X
A.	B-X
Budnyuk	B-X
P220	B-X
-	B-X
Nasal	B-X
high	B-X
flow	B-X
oygen	B-X
for	B-X
acute	B-X
respiratory	B-X
failure	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
R.	B-X
Pugh	B-X
,	B-X
S.	B-X
Bhandari	B-X
P221	B-X
-	B-X
Setting	B-X
optimal	B-X
flow	B-X
rate	B-X
during	B-X
high	B-X
flow	B-X
nasal	B-X
cannula	B-X
support	B-X
:	B-X
preliminary	B-X
results	B-X
T.	B-X
Mauri	B-X
,	B-X
C.	B-X
Turrini	B-X
,	B-X
T.	B-X
Langer	B-X
,	B-X
P.	B-X
Taccone	B-X
,	B-X
C.	B-X
A.	B-X
Volta	B-X
,	B-X
C.	B-X
Marenghi	B-X
,	B-X
L.	B-X
Gattinoni	B-X
,	B-X
A.	B-X
Pesenti	B-X
P222	B-X
-	B-X
Dose	B-X
to	B-X
dose	B-X
consistency	B-X
across	B-X
two	B-X
different	B-X
gas	B-X
flow	B-X
rates	B-X
using	B-X
cystic	B-X
fibrosis	B-X
and	B-X
normal	B-X
adult	B-X
breathing	B-X
profiles	B-X
during	B-X
nasal	B-X
high	B-X
flow	B-X
oxygen	B-X
therapy	B-X
L.	B-X
Sweeney	B-X
,	B-X
A	B-X
.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P223	B-X
-	B-X
Final	B-X
results	B-X
of	B-X
an	B-X
evaluation	B-X
of	B-X
airway	B-X
medix	B-X
closed	B-X
suction	B-X
system	B-X
compared	B-X
to	B-X
a	B-X
standard	B-X
closed	B-X
suction	B-X
system	B-X
M.	B-X
Pfeffer	B-X
,	B-X
J.	B-X
T.	B-X
Thomas	B-X
,	B-X
G.	B-X
B.	B-X
Bregman	B-X
,	B-X
G.	B-X
K.	B-X
Karp	B-X
,	B-X
E.	B-X
K.	B-X
Kishinevsky	B-X
,	B-X
D.	B-X
S.	B-X
Stavi	B-X
,	B-X
N.	B-X
A.	B-X
Adi	B-X
P224	B-X
-	B-X
Different	B-X
cuff	B-X
materials	B-X
and	B-X
different	B-X
leak	B-X
tests	B-X
-	B-X
one	B-X
size	B-X
does	B-X
not	B-X
fit	B-X
all	B-X
T.	B-X
Poropat	B-X
,	B-X
R.	B-X
Knafelj	B-X
P225	B-X
-	B-X
Observational	B-X
study	B-X
on	B-X
the	B-X
value	B-X
of	B-X
the	B-X
cuff-leak	B-X
test	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
upper	B-X
airway	B-X
obstruction	B-X
after	B-X
extubation	B-X
E.	B-X
Llopart	B-X
,	B-X
M.	B-X
Batlle	B-X
,	B-X
C.	B-X
De	B-X
Haro	B-X
,	B-X
J.	B-X
Mesquida	B-X
,	B-X
A.	B-X
Artigas	B-X
P226	B-X
-	B-X
A	B-X
device	B-X
for	B-X
emergency	B-X
transtracheal	B-X
lung	B-X
ventilation	B-X
D.	B-X
Pavlovic	B-X
,	B-X
L.	B-X
Lewerentz	B-X
,	B-X
A.	B-X
Spassov	B-X
,	B-X
R.	B-X
Schneider	B-X
P227	B-X
-	B-X
Long-term	B-X
outcome	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
patients	B-X
discharged	B-X
from	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
with	B-X
a	B-X
tracheostomy	B-X
and	B-X
with	B-X
or	B-X
without	B-X
prolonged	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
De	B-X
Smet	B-X
,	B-X
S.	B-X
De	B-X
Raedt	B-X
,	B-X
E.	B-X
Derom	B-X
,	B-X
P	B-X
Depuydt	B-X
,	B-X
S.	B-X
Oeyen	B-X
,	B-X
D.	B-X
Benoit	B-X
,	B-X
J.	B-X
Decruyenaere	B-X
P228	B-X
-	B-X
Ultrasound-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
versus	B-X
bronchoscopy-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
(	B-X
trachus	B-X
)	B-X
:	B-X
a	B-X
randomized	B-X
clinical	B-X
trial	B-X
A.	B-X
Gobatto	B-X
,	B-X
B.	B-X
Bese	B-X
,	B-X
P.	B-X
Tierno	B-X
,	B-X
L.	B-X
Melro	B-X
,	B-X
P.	B-X
Mendes	B-X
,	B-X
F.	B-X
Cadamuro	B-X
,	B-X
M.	B-X
Park	B-X
,	B-X
L.	B-X
M.	B-X
Malbouisson	B-X
P229	B-X
-	B-X
Is	B-X
it	B-X
safe	B-X
to	B-X
discharge	B-X
patients	B-X
with	B-X
tracheostomy	B-X
from	B-X
the	B-X
ICU	B-X
to	B-X
the	B-X
ward	B-X
?	B-X
B.	B-X
C.	B-X
Civanto	B-X
,	B-X
J.	B-X
L.	B-X
Lopez	B-X
,	B-X
A.	B-X
Robles	B-X
,	B-X
J.	B-X
Figueira	B-X
,	B-X
S.	B-X
Yus	B-X
,	B-X
A.	B-X
Garcia	B-X
P230	B-X
-	B-X
The	B-X
application	B-X
of	B-X
tracheostomy	B-X
in	B-X
children	B-X
in	B-X
ICU	B-X
A.	B-X
Oglinda	B-X
,	B-X
G.	B-X
Ciobanu	B-X
,	B-X
C.	B-X
Oglinda	B-X
,	B-X
L.	B-X
Schirca	B-X
,	B-X
T.	B-X
Sertinean	B-X
,	B-X
V.	B-X
Lupu	B-X
P231	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
passive	B-X
humidifiers	B-X
on	B-X
aerosol	B-X
drug	B-X
delivery	B-X
during	B-X
mechanical	B-X
ventilation	B-X
P.	B-X
Kelly	B-X
,	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P232	B-X
-	B-X
Evaluation	B-X
of	B-X
vibrating	B-X
mesh	B-X
and	B-X
jet	B-X
nebuliser	B-X
performance	B-X
at	B-X
two	B-X
different	B-X
attachment	B-X
setups	B-X
in	B-X
line	B-X
with	B-X
a	B-X
humidifier	B-X
nebuliser	B-X
system	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
M.	B-X
Wolny	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P233	B-X
-	B-X
Psv-niv	B-X
versus	B-X
cpap	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
acute	B-X
cardiogenic	B-X
pulmonary	B-X
edema	B-X
A.	B-X
Pagano	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
G.	B-X
Vison	B-X
,	B-X
L.	B-X
Saldamarco	B-X
,	B-X
T.	B-X
Russo	B-X
,	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Paladino	B-X
P234	B-X
-	B-X
Noninvasive	B-X
ventilation	B-X
in	B-X
patients	B-X
with	B-X
haematologic	B-X
malignancy	B-X
:	B-X
a	B-X
retrospective	B-X
review	B-X
C.	B-X
Bell	B-X
,	B-X
J.	B-X
Liu	B-X
,	B-X
J.	B-X
Debacker	B-X
,	B-X
C.	B-X
Lee	B-X
,	B-X
E.	B-X
Tamberg	B-X
,	B-X
V.	B-X
Campbell	B-X
,	B-X
S.	B-X
Mehta	B-X
P235	B-X
-	B-X
Use	B-X
of	B-X
non-invasive	B-X
ventilation	B-X
in	B-X
infectious	B-X
diseases	B-X
besides	B-X
classical	B-X
indications	B-X
A.	B-X
Silva-Pinto	B-X
,	B-X
A.	B-X
Sarmento	B-X
,	B-X
L.	B-X
Santos	B-X
P236	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
fragility	B-X
on	B-X
noninvasive	B-X
mechanical	B-X
ventilation	B-X
application	B-X
and	B-X
results	B-X
in	B-X
the	B-X
ICU	B-X
Ý.	B-X
Kara	B-X
,	B-X
F.	B-X
Yýldýrým	B-X
,	B-X
A.	B-X
Zerman	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
N.	B-X
Boyacý	B-X
,	B-X
B.	B-X
Basarýk	B-X
Aydogan	B-X
,	B-X
Ü.	B-X
Gaygýsýz	B-X
,	B-X
K.	B-X
Gönderen	B-X
,	B-X
G.	B-X
Arýk	B-X
,	B-X
M.	B-X
Turkoglu	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Aygencel	B-X
,	B-X
Z.	B-X
Ülger	B-X
,	B-X
G.	B-X
Gursel	B-X
P237	B-X
-	B-X
Effects	B-X
of	B-X
metabolic	B-X
alkalosis	B-X
on	B-X
noninvasive	B-X
ventilation	B-X
success	B-X
and	B-X
ICU	B-X
outcome	B-X
in	B-X
patients	B-X
with	B-X
hypercapnic	B-X
respiratory	B-X
failure	B-X
N.	B-X
Boyacý	B-X
,	B-X
Z.	B-X
Isýkdogan	B-X
,	B-X
Ö.	B-X
Özdedeoglu	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
M.	B-X
Badoglu	B-X
,	B-X
U.	B-X
Gaygýsýz	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Gursel	B-X
P238	B-X
-	B-X
Asynchrony	B-X
index	B-X
and	B-X
breathing	B-X
patterns	B-X
of	B-X
acute	B-X
exacerbation	B-X
copd	B-X
patients	B-X
assisted	B-X
with	B-X
noninvasive	B-X
pressure	B-X
support	B-X
ventilation	B-X
and	B-X
neurally	B-X
adjusted	B-X
ventilatory	B-X
assist	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
C.	B-X
Sittipunt	B-X
P239	B-X
-	B-X
High	B-X
frequency	B-X
jet	B-X
ventilation	B-X
for	B-X
severe	B-X
acute	B-X
hypoxemia	B-X
A.	B-X
Eden	B-X
,	B-X
Y.	B-X
Kokhanovsky	B-X
,	B-X
S.	B-X
Bursztein	B-X
–	B-X
De	B-X
Myttenaere	B-X
,	B-X
R.	B-X
Pizov	B-X
P240	B-X
-	B-X
HFOV	B-X
revisited	B-X
:	B-X
a	B-X
7	B-X
year	B-X
retrospective	B-X
analysis	B-X
of	B-X
patients	B-X
receiving	B-X
HFOV	B-X
who	B-X
met	B-X
oscillate	B-X
trial	B-X
entry	B-X
criteria	B-X
L.	B-X
Neilans	B-X
,	B-X
N.	B-X
MacIntyre	B-X
P241	B-X
-	B-X
Implementation	B-X
of	B-X
a	B-X
goal-directed	B-X
mechanical	B-X
ventilation	B-X
order	B-X
set	B-X
driven	B-X
by	B-X
respiratory	B-X
therapists	B-X
can	B-X
improve	B-X
compliance	B-X
with	B-X
best	B-X
practices	B-X
for	B-X
mechanical	B-X
ventilation	B-X
M.	B-X
Radosevich	B-X
,	B-X
B.	B-X
Wanta	B-X
,	B-X
V.	B-X
Weber	B-X
,	B-X
T.	B-X
Meyer	B-X
,	B-X
N.	B-X
Smischney	B-X
,	B-X
D.	B-X
Brown	B-X
,	B-X
D.	B-X
Diedrich	B-X
P242	B-X
-	B-X
A	B-X
reduction	B-X
in	B-X
tidal	B-X
volumes	B-X
for	B-X
ventilated	B-X
patients	B-X
on	B-X
ICU	B-X
calculated	B-X
from	B-X
IBW	B-X
.	B-X
Fuller	B-X
,	B-X
P.	B-X
McLindon	B-X
,	B-X
K.	B-X
Sim	B-X
P243	B-X
-	B-X
Predictive	B-X
value	B-X
of	B-X
lung	B-X
aeration	B-X
scoring	B-X
using	B-X
lung	B-X
ultrasound	B-X
in	B-X
weaning	B-X
failure	B-X
M.	B-X
Shoaeir	B-X
,	B-X
K.	B-X
Noeam	B-X
,	B-X
A.	B-X
Mahrous	B-X
,	B-X
R.	B-X
Matsa	B-X
,	B-X
A.	B-X
Ali	B-X
P244	B-X
-	B-X
Conventional	B-X
versus	B-X
automated	B-X
weaning	B-X
from	B-X
mechanical	B-X
ventilation	B-X
using	B-X
SmartCare™	B-X
C.	B-X
Dridi	B-X
,	B-X
S.	B-X
Koubaji	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
F.	B-X
Haddad	B-X
,	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
B.	B-X
Laribi	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.	B-X
S.	B-X
Mebazaa	B-X
P245	B-X
-	B-X
Ultrasonographic	B-X
evaluation	B-X
protocol	B-X
for	B-X
weaning	B-X
from	B-X
mechanichal	B-X
ventilation	B-X
A.	B-X
Pérez-Calatayud	B-X
,	B-X
R.	B-X
Carrillo-Esper	B-X
,	B-X
A.	B-X
Zepeda-Mendoza	B-X
,	B-X
M.	B-X
Diaz-Carrillo	B-X
,	B-X
E.	B-X
Arch-Tirado	B-X
P246	B-X
-	B-X
Diaphragm	B-X
ultrasonography	B-X
:	B-X
a	B-X
method	B-X
for	B-X
weaning	B-X
patients	B-X
from	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
Carbognin	B-X
,	B-X
L.	B-X
Pelacani	B-X
,	B-X
F.	B-X
Zannoni	B-X
,	B-X
A.	B-X
Agnoli	B-X
,	B-X
G.	B-X
Gagliardi	B-X
P247	B-X
-	B-X
Dorsal	B-X
diaphragmatic	B-X
excursion	B-X
tracks	B-X
transpulmonary	B-X
pressure	B-X
in	B-X
ventilated	B-X
ARDS	B-X
patients	B-X
:	B-X
a	B-X
potential	B-X
non-invasive	B-X
indicator	B-X
of	B-X
lung	B-X
recruitment	B-X
?	B-X
M.	B-X
Thijssen	B-X
,	B-X
L.	B-X
Janssen	B-X
,	B-X
N.	B-X
Foudraine	B-X
P249	B-X
-	B-X
Ventilation	B-X
is	B-X
a	B-X
better	B-X
assessment	B-X
of	B-X
respiratory	B-X
status	B-X
than	B-X
EtCO2	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
P250	B-X
-	B-X
Evaluation	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
non-invasive	B-X
minute	B-X
ventilation	B-X
and	B-X
end-tidal	B-X
CO2	B-X
in	B-X
patients	B-X
undergoing	B-X
general	B-X
vs	B-X
spinal	B-X
anesthesia	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P251	B-X
-	B-X
Respiratory	B-X
volume	B-X
monitoring	B-X
provides	B-X
early	B-X
warning	B-X
of	B-X
respiratory	B-X
depression	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
reduce	B-X
false	B-X
alarms	B-X
in	B-X
non-intubated	B-X
patients	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
D.	B-X
Eversole	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P252	B-X
-	B-X
P/i	B-X
index	B-X
:	B-X
a	B-X
predictive	B-X
edi-derived	B-X
weaning	B-X
index	B-X
during	B-X
nava	B-X
S.	B-X
Muttini	B-X
,	B-X
R.	B-X
Bigi	B-X
,	B-X
G.	B-X
Villani	B-X
,	B-X
N.	B-X
Patroniti	B-X
P253	B-X
-	B-X
Adequacy	B-X
of	B-X
ventilation	B-X
in	B-X
patients	B-X
receiving	B-X
opioids	B-X
in	B-X
the	B-X
post	B-X
anesthesia	B-X
care	B-X
unit	B-X
:	B-X
minute	B-X
ventilation	B-X
versus	B-X
respiratory	B-X
rate	B-X
G.	B-X
Williams	B-X
,	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P254	B-X
-	B-X
Comparison	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constants	B-X
measured	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
(	B-X
EIT	B-X
)	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P255	B-X
-	B-X
Electrical	B-X
impedance	B-X
tomography	B-X
:	B-X
robustness	B-X
of	B-X
a	B-X
new	B-X
pixel	B-X
wise	B-X
regional	B-X
expiratory	B-X
time	B-X
constant	B-X
calculation	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P256	B-X
-	B-X
Validation	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constant	B-X
measurement	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
in	B-X
ards	B-X
and	B-X
obstructive	B-X
pulmonary	B-X
diseases	B-X
C.	B-X
K.	B-X
Karagiannidis	B-X
,	B-X
A.	B-X
W.	B-X
Waldmann	B-X
,	B-X
S.	B-X
B.	B-X
Böhm	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
W.	B-X
W.	B-X
Windisch	B-X
P257	B-X
-	B-X
Transpulmonary	B-X
pressure	B-X
in	B-X
a	B-X
model	B-X
with	B-X
elastic	B-X
recoiling	B-X
lung	B-X
and	B-X
expanding	B-X
chest	B-X
wall	B-X
P.	B-X
Persson	B-X
,	B-X
S.	B-X
Lundin	B-X
,	B-X
O.	B-X
Stenqvist	B-X
P258	B-X
-	B-X
Lactate	B-X
in	B-X
pleural	B-X
and	B-X
abdominal	B-X
effusion	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
C.	B-X
S.	B-X
Serra	B-X
,	B-X
A.	B-X
P.	B-X
Pagano	B-X
,	B-X
M.	B-X
M.	B-X
Masarone	B-X
,	B-X
L.	B-X
R.	B-X
Rinaldi	B-X
,	B-X
A	B-X
.	B-X
A.	B-X
Amelia	B-X
,	B-X
M.	B-X
F.	B-X
Fascione	B-X
,	B-X
L.	B-X
A.	B-X
Adinolfi	B-X
,	B-X
E.	B-X
R.	B-X
Ruggiero	B-X
P259	B-X
-	B-X
Outcome	B-X
of	B-X
patients	B-X
admitted	B-X
to	B-X
the	B-X
intensive	B-X
care	B-X
with	B-X
pulmonary	B-X
fibrosis	B-X
F.	B-X
Asota	B-X
,	B-X
K.	B-X
O	B-X
’	B-X
Rourke	B-X
,	B-X
S.	B-X
Ranjan	B-X
,	B-X
P.	B-X
Morgan	B-X
P260	B-X
-	B-X
Sedation	B-X
and	B-X
analgesia	B-X
practice	B-X
in	B-X
extra-corporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
ECMO	B-X
)	B-X
-treated	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
(	B-X
ARDS	B-X
)	B-X
:	B-X
a	B-X
retrospective	B-X
study	B-X
J.	B-X
W.	B-X
DeBacker	B-X
,	B-X
E.	B-X
Tamberg	B-X
,	B-X
L.	B-X
O	B-X
’	B-X
Neill	B-X
,	B-X
L.	B-X
Munshi	B-X
,	B-X
L.	B-X
Burry	B-X
,	B-X
E.	B-X
Fan	B-X
,	B-X
S.	B-X
Mehta	B-X
P261	B-X
-	B-X
Characteristics	B-X
and	B-X
outcomes	B-X
of	B-X
patients	B-X
deemed	B-X
not	B-X
eligible	B-X
when	B-X
referred	B-X
for	B-X
veno-venous	B-X
extracorporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
vv-ECMO	B-X
)	B-X
S.	B-X
Poo	B-X
,	B-X
K.	B-X
Mahendran	B-X
,	B-X
J.	B-X
Fowles	B-X
,	B-X
C.	B-X
Gerrard	B-X
,	B-X
A.	B-X
Vuylsteke	B-X
P262	B-X
-	B-X
The	B-X
SAVE	B-X
SMR	B-X
for	B-X
veno-arterial	B-X
ECMO	B-X
R.	B-X
Loveridge	B-X
,	B-X
C.	B-X
Chaddock	B-X
,	B-X
S.	B-X
Patel	B-X
,	B-X
V.	B-X
Kakar	B-X
,	B-X
C.	B-X
Willars	B-X
,	B-X
T.	B-X
Hurst	B-X
,	B-X
C.	B-X
Park	B-X
,	B-X
T.	B-X
Best	B-X
,	B-X
A.	B-X
Vercueil	B-X
,	B-X
G.	B-X
Auzinger	B-X
P263	B-X
-	B-X
A	B-X
simplified	B-X
score	B-X
to	B-X
predict	B-X
early	B-X
(	B-X
48	B-X
h	B-X
)	B-X
mortality	B-X
in	B-X
patients	B-X
being	B-X
considered	B-X
for	B-X
VA-ECMO	B-X
A.	B-X
Borgman	B-X
,	B-X
A.	B-X
G.	B-X
Proudfoot	B-X
,	B-X
E.	B-X
Grins	B-X
,	B-X
K.	B-X
E.	B-X
Emiley	B-X
,	B-X
J.	B-X
Schuitema	B-X
,	B-X
S.	B-X
J.	B-X
Fitch	B-X
,	B-X
G.	B-X
Marco	B-X
,	B-X
J.	B-X
Sturgill	B-X
,	B-X
M.	B-X
G.	B-X
Dickinson	B-X
,	B-X
M.	B-X
Strueber	B-X
,	B-X
A.	B-X
Khaghani	B-X
,	B-X
P.	B-X
Wilton	B-X
,	B-X
S.	B-X
M.	B-X
Jovinge	B-X
P264	B-X
-	B-X
Lung	B-X
function	B-X
six	B-X
months	B-X
post	B-X
extra	B-X
corporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
ECMO	B-X
)	B-X
for	B-X
severe	B-X
acute	B-X
respiratory	B-X
failure	B-X
in	B-X
adult	B-X
survivors	B-X
C.	B-X
Sampson	B-X
,	B-X
S.	B-X
Harris-Fox	B-X
P265	B-X
-	B-X
Bicarbonate	B-X
dialysis	B-X
removes	B-X
carbon	B-X
dioxide	B-X
in	B-X
hypoventilated	B-X
rodents	B-X
.	B-X
De	B-X
Cagny	B-X
,	B-X
S.	B-X
El	B-X
Dash	B-X
,	B-X
M.	B-X
Slama	B-X
P273	B-X
-	B-X
Inhaled	B-X
nitric	B-X
oxide	B-X
–	B-X
is	B-X
switching	B-X
supplier	B-X
cost	B-X
effective	B-X
?	B-X
Experience	B-X
review	B-X
J.	B-X
Fernández	B-X
Villanueva	B-X
,	B-X
R.	B-X
Fernández	B-X
Garda	B-X
,	B-X
A.	B-X
López	B-X
Lago	B-X
,	B-X
E.	B-X
Rodríguez	B-X
Ruíz	B-X
,	B-X
R.	B-X
Hernández	B-X
Vaquero	B-X
,	B-X
S.	B-X
Tomé	B-X
Martínez	B-X
de	B-X
Rituerto	B-X
,	B-X
E.	B-X
Varo	B-X
Pérez	B-X
P279	B-X
-	B-X
Diarrhea	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
liver	B-X
injury	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
intestinal	B-X
failure	B-X
associated	B-X
liver	B-X
disease	B-X
in	B-X
critical	B-X
illness	B-X
N.	B-X
Lefel	B-X
,	B-X
F.	B-X
Schaap	B-X
,	B-X
D.	B-X
Bergmans	B-X
,	B-X
S.	B-X
Olde	B-X
Damink	B-X
,	B-X
M.	B-X
Van	B-X
de	B-X
Poll	B-X
P280	B-X
-	B-X
Bowel	B-X
care	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
constipation	B-X
guideline	B-X
compliance	B-X
and	B-X
complications	B-X
K.	B-X
Tizard	B-X
,	B-X
C.	B-X
Lister	B-X
,	B-X
L.	B-X
Poole	B-X
P281	B-X
-	B-X
Malnutrition	B-X
assessed	B-X
by	B-X
phase	B-X
angle	B-X
determines	B-X
outcomes	B-X
in	B-X
low	B-X
risk	B-X
cardiac	B-X
surgery	B-X
patients	B-X
D.	B-X
Ringaitiene	B-X
,	B-X
D.	B-X
Gineityte	B-X
,	B-X
V.	B-X
Vicka	B-X
,	B-X
I.	B-X
Norkiene	B-X
,	B-X
J.	B-X
Sipylaite	B-X
P282	B-X
-	B-X
Preoperative	B-X
fasting	B-X
times	B-X
in	B-X
an	B-X
irish	B-X
hospital	B-X
A.	B-X
O	B-X
’	B-X
Loughlin	B-X
,	B-X
V.	B-X
Maraj	B-X
,	B-X
J.	B-X
Dowling	B-X
P283	B-X
-	B-X
Costs	B-X
and	B-X
final	B-X
outcome	B-X
of	B-X
early	B-X
x	B-X
delayed	B-X
feeding	B-X
in	B-X
a	B-X
private	B-X
Brazil	B-X
ICU	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
,	B-X
E.	B-X
B.	B-X
Dias	B-X
,	B-X
S.	B-X
L.	B-X
Fernandes	B-X
P284	B-X
-	B-X
Can	B-X
ventilator	B-X
derived	B-X
energy	B-X
expenditure	B-X
measurements	B-X
replace	B-X
indirect	B-X
calorimetry	B-X
?	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Duarte	B-X
,	B-X
S.	B-X
Castro	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P289	B-X
Protein	B-X
provision	B-X
in	B-X
an	B-X
adult	B-X
intensive	B-X
care	B-X
unit	B-X
S.	B-X
Gray	B-X
P290	B-X
-	B-X
Prevalence	B-X
and	B-X
clinical	B-X
outcomes	B-X
of	B-X
vitamin	B-X
d	B-X
deficiency	B-X
in	B-X
the	B-X
medical	B-X
critically	B-X
ill	B-X
patients	B-X
in	B-X
Songklanagarind	B-X
hospital	B-X
K.	B-X
Maipang	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
P291	B-X
-	B-X
Vitamin	B-X
d	B-X
deficiency	B-X
strongly	B-X
predicts	B-X
adverse	B-X
medical	B-X
outcome	B-X
across	B-X
different	B-X
medical	B-X
inpatient	B-X
populations	B-X
:	B-X
results	B-X
from	B-X
a	B-X
prospective	B-X
study	B-X
L.	B-X
G.	B-X
Grädel	B-X
,	B-X
P.	B-X
Schütz	B-X
P292	B-X
-	B-X
Omega-3	B-X
fatty	B-X
acids	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
P.	B-X
Langlois	B-X
,	B-X
W.	B-X
Manzanares	B-X
P293	B-X
-	B-X
Can	B-X
5-hydroxytriptophan	B-X
prevent	B-X
post-traumatic	B-X
stress	B-X
disorder	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
M.	B-X
Hoshino	B-X
,	B-X
Y.	B-X
Haraguchi	B-X
,	B-X
S.	B-X
Kajiwara	B-X
,	B-X
T.	B-X
Mitsuhashi	B-X
,	B-X
T.	B-X
Tsubata	B-X
,	B-X
M.	B-X
Aida	B-X
P299	B-X
-	B-X
A	B-X
study	B-X
of	B-X
glycemic	B-X
control	B-X
by	B-X
subcutaneous	B-X
glargine	B-X
injection	B-X
transition	B-X
from	B-X
continuous	B-X
regular	B-X
insulin	B-X
infusion	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
T.	B-X
Rattanapraphat	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
,	B-X
C.	B-X
Kongkamol	B-X
,	B-X
B.	B-X
Khwannimit	B-X
P300	B-X
-	B-X
Glycemic	B-X
control	B-X
in	B-X
Portuguese	B-X
intensive	B-X
care	B-X
unit	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
B.	B-X
Xavier	B-X
,	B-X
J.	B-X
Valente	B-X
,	B-X
C.	B-X
Magalhaes	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P301	B-X
-	B-X
Impact	B-X
of	B-X
hyperglycemia	B-X
duration	B-X
on	B-X
the	B-X
day	B-X
of	B-X
operation	B-X
on	B-X
short-term	B-X
outcome	B-X
of	B-X
cardiac	B-X
surgery	B-X
patients	B-X
D.	B-X
Moisidou	B-X
,	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
C.	B-X
Koutsogiannidis	B-X
,	B-X
M.	B-X
Moschopoulou	B-X
,	B-X
G.	B-X
Drossos	B-X
P302	B-X
-	B-X
Lactate	B-X
levels	B-X
in	B-X
diabetic	B-X
ketoacidosis	B-X
patients	B-X
at	B-X
ICU	B-X
admissions	B-X
G.	B-X
Taskin	B-X
,	B-X
M.	B-X
Çakir	B-X
,	B-X
AK	B-X
Güler	B-X
,	B-X
A.	B-X
Taskin	B-X
,	B-X
N.	B-X
Öcal	B-X
,	B-X
S.	B-X
Özer	B-X
,	B-X
L.	B-X
Yamanel	B-X
P303	B-X
-	B-X
Intensive	B-X
care	B-X
implications	B-X
of	B-X
merging	B-X
heart	B-X
attack	B-X
centre	B-X
units	B-X
in	B-X
London	B-X
J.	B-X
M.	B-X
Wong	B-X
,	B-X
C.	B-X
Fitton	B-X
,	B-X
S.	B-X
Anwar	B-X
,	B-X
S.	B-X
Stacey	B-X
P304	B-X
-	B-X
Special	B-X
characteristics	B-X
of	B-X
in-hospital	B-X
cardiac	B-X
arrests	B-X
M.	B-X
Aggou	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Lolakos	B-X
,	B-X
E.	B-X
Papapostolou	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P305	B-X
-	B-X
Clinical	B-X
evaluation	B-X
of	B-X
ICU-admitted	B-X
patients	B-X
who	B-X
were	B-X
resuscitated	B-X
in	B-X
the	B-X
general	B-X
medicine	B-X
ward	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
Y.	B-X
Izutani	B-X
P306	B-X
-	B-X
Serious	B-X
game	B-X
evaluation	B-X
of	B-X
a	B-X
one-hour	B-X
training	B-X
basic	B-X
life	B-X
support	B-X
session	B-X
for	B-X
secondary	B-X
school	B-X
students	B-X
:	B-X
new	B-X
tools	B-X
for	B-X
future	B-X
bystanders	B-X
S.	B-X
Gaudry	B-X
,	B-X
V.	B-X
Desailly	B-X
,	B-X
P.	B-X
Pasquier	B-X
,	B-X
PB	B-X
Brun	B-X
,	B-X
AT	B-X
Tesnieres	B-X
,	B-X
JD	B-X
Ricard	B-X
,	B-X
D.	B-X
Dreyfuss	B-X
,	B-X
A.	B-X
Mignon	B-X
P307	B-X
-	B-X
Public	B-X
and	B-X
clinical	B-X
staff	B-X
perceptions	B-X
and	B-X
knowledge	B-X
of	B-X
CPR	B-X
compared	B-X
to	B-X
local	B-X
and	B-X
national	B-X
data	B-X
J	B-X
.	B-X
Dean	B-X
,	B-X
A.	B-X
Stilwell	B-X
,	B-X
G.	B-X
Friedlaender	B-X
P308	B-X
Dispatcher-assisted	B-X
telephone	B-X
cardiopulmonary	B-X
resuscitation	B-X
using	B-X
a	B-X
French-language	B-X
compression-ventilation	B-X
pediatric	B-X
protocol	B-X
M.	B-X
Peters	B-X
,	B-X
S.	B-X
Stipulante	B-X
,	B-X
A.	B-X
Delfosse	B-X
,	B-X
AF	B-X
Donneau	B-X
,	B-X
A.	B-X
Ghuysen	B-X
P309	B-X
Dantrolene	B-X
versus	B-X
amiodarone	B-X
for	B-X
resuscitation	B-X
–	B-X
an	B-X
experimental	B-X
study	B-X
C.	B-X
Feldmann	B-X
,	B-X
D.	B-X
Freitag	B-X
,	B-X
W.	B-X
Dersch	B-X
,	B-X
M.	B-X
Irqsusi	B-X
,	B-X
D.	B-X
Eschbach	B-X
,	B-X
T.	B-X
Steinfeldt	B-X
,	B-X
H.	B-X
Wulf	B-X
,	B-X
T.	B-X
Wiesmann	B-X
P310	B-X
Long	B-X
term	B-X
survival	B-X
and	B-X
functional	B-X
neurological	B-X
outcome	B-X
in	B-X
comatose	B-X
survivors	B-X
undergoing	B-X
therapeutic	B-X
hypothermia	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
J.	B-X
Cholkraisuwat	B-X
P311	B-X
Impact	B-X
of	B-X
kidney	B-X
disease	B-X
on	B-X
mortality	B-X
and	B-X
neurological	B-X
outcome	B-X
in	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
prospective	B-X
observational	B-X
study	B-X
S.	B-X
Beitland	B-X
,	B-X
E.	B-X
Nakstad	B-X
,	B-X
H.	B-X
Stær-Jensen	B-X
,	B-X
T.	B-X
Drægni	B-X
,	B-X
G.	B-X
Andersen	B-X
,	B-X
D.	B-X
Jacobsen	B-X
,	B-X
C.	B-X
Brunborg	B-X
,	B-X
B.	B-X
Waldum-Grevbo	B-X
,	B-X
K.	B-X
Sunde	B-X
P312	B-X
ICU	B-X
dependency	B-X
of	B-X
patients	B-X
admitted	B-X
after	B-X
primary	B-X
percutaneous	B-X
coronary	B-X
intervention	B-X
(	B-X
PPCI	B-X
)	B-X
following	B-X
out	B-X
of	B-X
the	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
K.	B-X
Hoyland	B-X
,	B-X
D.	B-X
Pandit	B-X
P313	B-X
Prognostic	B-X
indicators	B-X
and	B-X
outcome	B-X
prediction	B-X
model	B-X
for	B-X
patients	B-X
with	B-X
return	B-X
of	B-X
spontaneous	B-X
circulation	B-X
from	B-X
cardiopulmonary	B-X
arrest	B-X
:	B-X
comprehensive	B-X
registry	B-X
of	B-X
in-hospital	B-X
intensive	B-X
care	B-X
on	B-X
OHCA	B-X
survival	B-X
(	B-X
critical	B-X
)	B-X
study	B-X
in	B-X
Osaka	B-X
,	B-X
Japan	B-X
K.	B-X
Hayakawa	B-X
P314	B-X
Cerebral	B-X
oxygen	B-X
saturation	B-X
during	B-X
resuscitation	B-X
in	B-X
a	B-X
porcine	B-X
model	B-X
of	B-X
cardiac	B-X
arrest	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Kotzampassi	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
L.	B-X
Loukipoudi	B-X
,	B-X
E.	B-X
Doumaki	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P315	B-X
Presumption	B-X
of	B-X
cardiopulmonary	B-X
resuscitation	B-X
for	B-X
sustaining	B-X
cerebral	B-X
oxidation	B-X
using	B-X
regional	B-X
cerebral	B-X
saturation	B-X
of	B-X
oxygen	B-X
:	B-X
observational	B-X
cohort	B-X
study	B-X
(	B-X
press	B-X
study	B-X
)	B-X
H.	B-X
Yasuda	B-X
P316	B-X
EEG	B-X
reactivity	B-X
in	B-X
patients	B-X
after	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
close	B-X
look	B-X
at	B-X
stimuli	B-X
MM	B-X
Admiraal	B-X
,	B-X
M.	B-X
Van	B-X
Assen	B-X
,	B-X
MJ	B-X
Van	B-X
Putten	B-X
,	B-X
M.	B-X
Tjepkema-Cloostermans	B-X
,	B-X
AF	B-X
Van	B-X
Rootselaar	B-X
,	B-X
J.	B-X
Horn	B-X
P317	B-X
Prognostic	B-X
value	B-X
of	B-X
neuron-specific	B-X
enolase	B-X
after	B-X
cardiac	B-X
arrest	B-X
F.	B-X
Ragusa	B-X
,	B-X
A.	B-X
Marudi	B-X
,	B-X
S.	B-X
Baroni	B-X
,	B-X
A.	B-X
Gaspari	B-X
,	B-X
E.	B-X
Bertellini	B-X
P318	B-X
Correlation	B-X
between	B-X
electroencephalographic	B-X
findings	B-X
and	B-X
serum	B-X
neuron	B-X
specific	B-X
enolase	B-X
with	B-X
outcome	B-X
of	B-X
post	B-X
cardiac	B-X
arrest	B-X
patients	B-X
A.	B-X
Taha	B-X
,	B-X
T.	B-X
Abdullah	B-X
,	B-X
S.	B-X
Abdel	B-X
Monem	B-X
P319	B-X
Introduction	B-X
of	B-X
a	B-X
targeted	B-X
temperature	B-X
management	B-X
strategy	B-X
following	B-X
cardiac	B-X
arrest	B-X
in	B-X
a	B-X
district	B-X
general	B-X
hospital	B-X
intensive	B-X
care	B-X
unit	B-X
.	B-X
S.	B-X
Alcorn	B-X
,	B-X
S.	B-X
McNeill	B-X
,	B-X
S.	B-X
Russell	B-X
P320	B-X
The	B-X
evolution	B-X
of	B-X
cerebral	B-X
oxygen	B-X
saturation	B-X
in	B-X
post-cardiac	B-X
arrest	B-X
patients	B-X
treated	B-X
with	B-X
therapeutic	B-X
hypothermia	B-X
W.	B-X
Eertmans	B-X
,	B-X
C.	B-X
Genbrugge	B-X
,	B-X
I.	B-X
Meex	B-X
,	B-X
J.	B-X
Dens	B-X
,	B-X
F.	B-X
Jans	B-X
,	B-X
C.	B-X
De	B-X
Deyne	B-X
P321	B-X
Prognostic	B-X
factors	B-X
and	B-X
neurological	B-X
outcomes	B-X
of	B-X
therapeutic	B-X
hypothermia	B-X
in	B-X
comatose	B-X
survivors	B-X
from	B-X
cardiac	B-X
arrest	B-X
:	B-X
8-year	B-X
single	B-X
center	B-X
experience	B-X
J.	B-X
Cholkraisuwat	B-X
,	B-X
N.	B-X
Kongpolprom	B-X
P322	B-X
Adherence	B-X
to	B-X
targeted	B-X
temperature	B-X
management	B-X
after	B-X
out	B-X
of	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
B.	B-X
Avard	B-X
,	B-X
R.	B-X
Burns	B-X
P323	B-X
Implementation	B-X
of	B-X
a	B-X
therapeutic	B-X
hypothermia	B-X
protocol	B-X
for	B-X
comatose	B-X
survivors	B-X
of	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
.	B-X
A.	B-X
Patarchi	B-X
,	B-X
T.	B-X
Spina	B-X
P324	B-X
Factors	B-X
associated	B-X
with	B-X
ventilator	B-X
weaning	B-X
after	B-X
targeted	B-X
temperature	B-X
management	B-X
for	B-X
cardiac	B-X
arrest	B-X
patients	B-X
in	B-X
japan	B-X
H.	B-X
Tanaka	B-X
,	B-X
N.	B-X
Otani	B-X
,	B-X
S.	B-X
Ode	B-X
,	B-X
S.	B-X
Ishimatsu	B-X
P325	B-X
Differential	B-X
activation	B-X
of	B-X
c-fos	B-X
in	B-X
paraventricular	B-X
nuclei	B-X
of	B-X
the	B-X
hypothalamus	B-X
and	B-X
thalamus	B-X
of	B-X
the	B-X
rat	B-X
following	B-X
myocardial	B-X
infarction	B-X
J.	B-X
Cho	B-X
,	B-X
J	B-X
.	B-X
Moon	B-X
,	B-X
C.	B-X
W.	B-X
Park	B-X
,	B-X
T.	B-X
G.	B-X
Ohk	B-X
,	B-X
M.	B-X
C.	B-X
Shin	B-X
,	B-X
M.	B-X
H.	B-X
Won	B-X
P326	B-X
Monitoring	B-X
of	B-X
cTroponin	B-X
I	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
ischemic	B-X
stroke	B-X
-	B-X
predictor	B-X
of	B-X
inhospital	B-X
mortality	B-X
S.	B-X
Dakova	B-X
,	B-X
Z.	B-X
Ramsheva	B-X
,	B-X
K.	B-X
Ramshev	B-X
P327	B-X
Hyperthermic	B-X
preconditioning	B-X
severely	B-X
accelerates	B-X
neuronal	B-X
damage	B-X
in	B-X
the	B-X
gerbil	B-X
ischemic	B-X
hippocampal	B-X
dentate	B-X
gyrus	B-X
via	B-X
decreasing	B-X
sods	B-X
expressions	B-X
J.	B-X
Cho	B-X
,	B-X
J	B-X
.	B-X
Moon	B-X
,	B-X
C.	B-X
W.	B-X
Park	B-X
,	B-X
T.	B-X
G.	B-X
Ohk	B-X
,	B-X
M.	B-X
C.	B-X
Shin	B-X
P328	B-X
Failure	B-X
in	B-X
neuroprotection	B-X
of	B-X
remote	B-X
limb	B-X
ischemic	B-X
post	B-X
conditioning	B-X
in	B-X
the	B-X
hippocampus	B-X
of	B-X
a	B-X
gerbil	B-X
model	B-X
of	B-X
transient	B-X
cerebral	B-X
ischemia	B-X
J.	B-X
Cho	B-X
,	B-X
J	B-X
.	B-X
Moon	B-X
,	B-X
C.	B-X
W.	B-X
Park	B-X
,	B-X
T.	B-X
G.	B-X
Ohk	B-X
,	B-X
M.	B-X
C.	B-X
Shin	B-X
P329	B-X
Brain	B-X
death	B-X
and	B-X
admission	B-X
diagnosis	B-X
in	B-X
neurologic	B-X
intensive	B-X
care	B-X
unit	B-X
,	B-X
a	B-X
correlation	B-X
?	B-X
A	B-X
Marudi	B-X
,	B-X
S	B-X
Baroni	B-X
,	B-X
A	B-X
Gaspari	B-X
,	B-X
E	B-X
Bertellini	B-X
P330	B-X
Brain	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
findings	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
G.	B-X
Orhun	B-X
,	B-X
E.	B-X
Senturk	B-X
,	B-X
P.	B-X
E.	B-X
Ozcan	B-X
,	B-X
S.	B-X
Sencer	B-X
,	B-X
C.	B-X
Ulusoy	B-X
,	B-X
E.	B-X
Tuzun	B-X
,	B-X
F	B-X
.	B-X
Esen	B-X
P331	B-X
Benefits	B-X
of	B-X
L-carnitine	B-X
in	B-X
valproic	B-X
acid	B-X
induced	B-X
encephalopathy	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P332Automatic	B-X
analysis	B-X
of	B-X
EEG	B-X
reactivity	B-X
in	B-X
comatose	B-X
patients	B-X
M.	B-X
Van	B-X
Assen	B-X
,	B-X
M.	B-X
M.	B-X
Admiraal	B-X
,	B-X
M.	B-X
J	B-X
.	B-X
Van	B-X
Putten	B-X
,	B-X
M.	B-X
Tjepkema-Cloostermans	B-X
,	B-X
A.	B-X
F.	B-X
Van	B-X
Rootselaar	B-X
,	B-X
J.	B-X
Horn	B-X
P333	B-X
Usefulness	B-X
of	B-X
common	B-X
ICU	B-X
severity	B-X
scoring	B-X
systems	B-X
in	B-X
predicting	B-X
outcome	B-X
after	B-X
spontaneous	B-X
intracerebral	B-X
hemorrhage	B-X
M.	B-X
Fallenius	B-X
,	B-X
M.	B-X
B.	B-X
Skrifvars	B-X
,	B-X
M.	B-X
Reinikainen	B-X
,	B-X
S.	B-X
Bendel	B-X
,	B-X
R.	B-X
Raj	B-X
P334	B-X
Evalution	B-X
of	B-X
patients	B-X
with	B-X
suspected	B-X
subarachnoid	B-X
haemorrhage	B-X
and	B-X
negative	B-X
ct	B-X
imaging	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
C.	B-X
Hymers	B-X
,	B-X
A.	B-X
Borowska	B-X
,	B-X
H.	B-X
Sivadhas	B-X
,	B-X
S.	B-X
Sahiba	B-X
,	B-X
S.	B-X
Perkins	B-X
P335	B-X
Timing	B-X
of	B-X
endovascular	B-X
and	B-X
surgical	B-X
treatment	B-X
for	B-X
aneurysmal	B-X
subarachnoid	B-X
haemorrhage	B-X
:	B-X
early	B-X
but	B-X
not	B-X
so	B-X
fast	B-X
.	B-X
A.	B-X
Rubio	B-X
,	B-X
R.	B-X
Sierra	B-X
P336	B-X
Red	B-X
blood	B-X
cell	B-X
transfusion	B-X
in	B-X
aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
–	B-X
the	B-X
Sahara	B-X
cohort	B-X
study	B-X
S.	B-X
English	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
A.	B-X
Turgeon	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
A.	B-X
Garland	B-X
,	B-X
D.	B-X
Fergusson	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
A.	B-X
Tinmouth	B-X
,	B-X
C.	B-X
Van	B-X
Walraven	B-X
,	B-X
K.	B-X
Montroy	B-X
,	B-X
J.	B-X
Ziegler	B-X
,	B-X
R.	B-X
Dupont	B-X
Chouinard	B-X
,	B-X
R.	B-X
Carignan	B-X
,	B-X
A.	B-X
Dhaliwal	B-X
,	B-X
C.	B-X
Lum	B-X
,	B-X
J.	B-X
Sinclair	B-X
,	B-X
G.	B-X
Pagliarello	B-X
,	B-X
L.	B-X
McIntyre	B-X
P337	B-X
-	B-X
Aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
and	B-X
anemia	B-X
:	B-X
a	B-X
canadian	B-X
multi-centre	B-X
retrospective	B-X
cohort	B-X
study	B-X
S.	B-X
English	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
A.	B-X
Turgeon	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
A.	B-X
Garland	B-X
,	B-X
D.	B-X
Fergusson	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
A.	B-X
Tinmouth	B-X
,	B-X
C.	B-X
Van	B-X
Walraven	B-X
,	B-X
K.	B-X
Montroy	B-X
,	B-X
J.	B-X
Ziegler	B-X
,	B-X
R.	B-X
Dupont	B-X
Chouinard	B-X
,	B-X
R.	B-X
Carignan	B-X
,	B-X
A.	B-X
Dhaliwal	B-X
,	B-X
C.	B-X
Lum	B-X
,	B-X
J.	B-X
Sinclair	B-X
,	B-X
G.	B-X
Pagliarello	B-X
,	B-X
L.	B-X
McIntyre	B-X
P338	B-X
-	B-X
Does	B-X
the	B-X
neutrophil-to-lymphocyte	B-X
(	B-X
NLR	B-X
)	B-X
ratio	B-X
predict	B-X
symptomatic	B-X
vasospasm	B-X
or	B-X
delayed	B-X
cerebral	B-X
ischemia	B-X
(	B-X
DCI	B-X
)	B-X
after	B-X
aneurysmal	B-X
subarachnoid	B-X
haemorrhage	B-X
(	B-X
SAH	B-X
)	B-X
?	B-X
T.	B-X
Groza	B-X
,	B-X
N.	B-X
Moreau	B-X
,	B-X
D.	B-X
Castanares-Zapatero	B-X
,	B-X
P.	B-X
Hantson	B-X
P339	B-X
-	B-X
ICU-acquired	B-X
infections	B-X
in	B-X
aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
patients	B-X
:	B-X
impact	B-X
on	B-X
ICU	B-X
and	B-X
hospital	B-X
length	B-X
of	B-X
stay	B-X
M.	B-X
Carbonara	B-X
,	B-X
F.	B-X
Ortolano	B-X
,	B-X
T.	B-X
Zoerle	B-X
,	B-X
S.	B-X
Magnoni	B-X
,	B-X
S.	B-X
Pifferi	B-X
,	B-X
V.	B-X
Conte	B-X
,	B-X
N.	B-X
Stocchetti	B-X
P340	B-X
-	B-X
Cerebral	B-X
metabolic	B-X
effects	B-X
of	B-X
normobaric	B-X
hyperoxia	B-X
during	B-X
the	B-X
acute	B-X
phase	B-X
of	B-X
aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
L.	B-X
Carteron	B-X
,	B-X
T.	B-X
Suys	B-X
,	B-X
C.	B-X
Patet	B-X
,	B-X
H.	B-X
Quintard	B-X
,	B-X
M.	B-X
Oddo	B-X
P341	B-X
-	B-X
Postoperative	B-X
care	B-X
for	B-X
elective	B-X
craniotomy	B-X
:	B-X
where	B-X
is	B-X
best	B-X
done	B-X
?	B-X
A.	B-X
Rubio	B-X
,	B-X
J.	B-X
Rubio	B-X
,	B-X
R.	B-X
Sierra	B-X
P342	B-X
-	B-X
5-year	B-X
follow-up	B-X
of	B-X
patients	B-X
after	B-X
transplantation	B-X
of	B-X
organs	B-X
from	B-X
donors	B-X
from	B-X
neurocritical	B-X
care	B-X
V.	B-X
Spatenkova	B-X
,	B-X
E.	B-X
Pokorna	B-X
,	B-X
P.	B-X
Suchomel	B-X
P343	B-X
-	B-X
Evaluation	B-X
of	B-X
levetiracetam	B-X
pharmacokinetics	B-X
after	B-X
severe	B-X
traumatic	B-X
brain	B-X
injury	B-X
in	B-X
neurocritical	B-X
care	B-X
patients	B-X
at	B-X
a	B-X
level	B-X
one	B-X
trauma	B-X
center	B-X
N.	B-X
Ebert	B-X
,	B-X
J.	B-X
Jancik	B-X
,	B-X
H.	B-X
Rhodes	B-X
P344	B-X
-	B-X
Model	B-X
based	B-X
time	B-X
series	B-X
cluster	B-X
analysis	B-X
to	B-X
determine	B-X
unique	B-X
patient	B-X
states	B-X
in	B-X
traumatic	B-X
brain	B-X
injury	B-X
T.	B-X
Bylinski	B-X
,	B-X
C.	B-X
Hawthorne	B-X
,	B-X
M.	B-X
Shaw	B-X
,	B-X
I.	B-X
Piper	B-X
,	B-X
J.	B-X
Kinsella	B-X
P345	B-X
-	B-X
Brain	B-X
compartment	B-X
monitoring	B-X
capabilities	B-X
from	B-X
ICP	B-X
to	B-X
BI	B-X
(	B-X
bioimpedance	B-X
)	B-X
during	B-X
HS	B-X
(	B-X
hypertonic	B-X
saline	B-X
)	B-X
administration	B-X
.	B-X
State	B-X
of	B-X
art	B-X
simulation	B-X
outcome	B-X
depending	B-X
on	B-X
brain	B-X
swelling	B-X
type	B-X
A.	B-X
K.	B-X
Kink	B-X
,	B-X
I.	B-X
R.	B-X
Rätsep	B-X
P346	B-X
-	B-X
Transfusion	B-X
of	B-X
red	B-X
blood	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
traumatic	B-X
brain	B-X
injury	B-X
admitted	B-X
to	B-X
Canadian	B-X
trauma	B-X
health	B-X
centers	B-X
:	B-X
a	B-X
multicenter	B-X
cohort	B-X
study	B-X
A.	B-X
Boutin	B-X
,	B-X
L.	B-X
Moore	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
S.	B-X
English	B-X
,	B-X
L.	B-X
McIntyre	B-X
,	B-X
J.	B-X
Lacroix	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
P.	B-X
Lessard-Bonaventure	B-X
,	B-X
A.	B-X
F.	B-X
Turgeon	B-X
P347	B-X
-	B-X
Hemoglobin	B-X
thresholds	B-X
and	B-X
red	B-X
blood	B-X
cell	B-X
transfusions	B-X
in	B-X
adult	B-X
patients	B-X
with	B-X
moderate	B-X
or	B-X
severe	B-X
traumatic	B-X
brain	B-X
injury	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
study	B-X
A.	B-X
Boutin	B-X
,	B-X
L.	B-X
Moore	B-X
,	B-X
R.	B-X
Green	B-X
,	B-X
P.	B-X
Lessard-Bonaventure	B-X
,	B-X
M.	B-X
Erdogan	B-X
,	B-X
M.	B-X
Butler	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
S.	B-X
English	B-X
,	B-X
L.	B-X
McIntyre	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
J.	B-X
Lacroix	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
P.	B-X
Desjardins	B-X
,	B-X
D.	B-X
A.	B-X
Fergusson	B-X
,	B-X
A.	B-X
F.	B-X
Turgeon	B-X
P348	B-X
-	B-X
Characteristics	B-X
of	B-X
patients	B-X
with	B-X
gunshot	B-X
wounds	B-X
to	B-X
the	B-X
head	B-X
-	B-X
an	B-X
observational	B-X
Brazilian	B-X
study	B-X
B.	B-X
Goncalves	B-X
,	B-X
B.	B-X
Vidal	B-X
,	B-X
C.	B-X
Valdez	B-X
,	B-X
A.	B-X
C.	B-X
Rodrigues	B-X
,	B-X
L.	B-X
Miguez	B-X
,	B-X
G.	B-X
Moralez	B-X
P349	B-X
-	B-X
Base	B-X
excess	B-X
as	B-X
predictor	B-X
for	B-X
ICU	B-X
admission	B-X
and	B-X
the	B-X
injury	B-X
severity	B-X
in	B-X
blunt	B-X
trauma	B-X
patients	B-X
T.	B-X
Hong	B-X
P350	B-X
-	B-X
Enhancement	B-X
of	B-X
usual	B-X
emergency	B-X
department	B-X
care	B-X
with	B-X
proadrenomedullin	B-X
to	B-X
improve	B-X
outcome	B-X
prediction	B-X
-	B-X
Results	B-X
from	B-X
the	B-X
multi-national	B-X
,	B-X
prospective	B-X
,	B-X
observational	B-X
TRIAGE	B-X
study	B-X
A.	B-X
Kutz	B-X
,	B-X
P.	B-X
Hausfater	B-X
,	B-X
D.	B-X
Amin	B-X
,	B-X
T.	B-X
Struja	B-X
,	B-X
S.	B-X
Haubitz	B-X
,	B-X
A.	B-X
Huber	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P351	B-X
-	B-X
Developing	B-X
an	B-X
innovative	B-X
emergency	B-X
medicine	B-X
point-of-care	B-X
simulation	B-X
programme	B-X
T.	B-X
Brown	B-X
,	B-X
J.	B-X
Collinson	B-X
,	B-X
C.	B-X
Pritchett	B-X
,	B-X
T.	B-X
Slade	B-X
P352	B-X
-	B-X
The	B-X
InSim	B-X
program	B-X
:	B-X
an	B-X
in	B-X
situ	B-X
simulation	B-X
program	B-X
for	B-X
junior	B-X
trainees	B-X
in	B-X
intensive	B-X
care	B-X
M.	B-X
Le	B-X
Guen	B-X
,	B-X
S.	B-X
Hellings	B-X
,	B-X
R.	B-X
Ramsaran	B-X
P353	B-X
-	B-X
Impact	B-X
of	B-X
excessive	B-X
and	B-X
inappropriate	B-X
troponin	B-X
testing	B-X
in	B-X
the	B-X
emergency	B-X
setting	B-X
how	B-X
good	B-X
are	B-X
we	B-X
A.	B-X
Alsheikhly	B-X
P354	B-X
-	B-X
The	B-X
development	B-X
of	B-X
time	B-X
tracking	B-X
monitor	B-X
at	B-X
emergency	B-X
department	B-X
T.	B-X
Abe	B-X
P355	B-X
-	B-X
Role	B-X
of	B-X
focussed	B-X
echocardiography	B-X
in	B-X
emergency	B-X
assessment	B-X
of	B-X
syncope	B-X
L.	B-X
Kanapeckaite	B-X
,	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
R.	B-X
Bahl	B-X
P356	B-X
-	B-X
Insertion	B-X
of	B-X
an	B-X
open-ended	B-X
14-gauge	B-X
catheter	B-X
through	B-X
the	B-X
chest	B-X
wall	B-X
causes	B-X
a	B-X
significant	B-X
pneumothorax	B-X
in	B-X
a	B-X
self-ventilating	B-X
swine	B-X
model	B-X
M.	B-X
Q	B-X
Russell	B-X
,	B-X
K.	B-X
J	B-X
.	B-X
Real	B-X
,	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
R.	B-X
M.	B-X
Lyon	B-X
,	B-X
N.	B-X
P.	B-X
Oveland	B-X
P357	B-X
-	B-X
Ez-io®	B-X
intraosseous	B-X
access	B-X
teaching	B-X
in	B-X
the	B-X
workplace	B-X
using	B-X
a	B-X
mobile	B-X
‘	B-X
tea	B-X
trolley	B-X
’	B-X
training	B-X
method	B-X
J.	B-X
Penketh	B-X
,	B-X
M.	B-X
Mcdonald	B-X
,	B-X
F.	B-X
Kelly	B-X
P358	B-X
-	B-X
Black	B-X
widow	B-X
envenomation	B-X
in	B-X
Saudi	B-X
Arabia	B-X
:	B-X
a	B-X
prospective	B-X
observational	B-X
case	B-X
series	B-X
M.	B-X
Alfafi	B-X
,	B-X
S.	B-X
Alsolamy	B-X
,	B-X
W.	B-X
Almutairi	B-X
,	B-X
B.	B-X
Alotaibi	B-X
P359	B-X
-	B-X
Mechanical	B-X
ventilation	B-X
in	B-X
patients	B-X
with	B-X
overdose	B-X
not	B-X
yet	B-X
intubated	B-X
on	B-X
icu	B-X
admission	B-X
A.	B-X
E.	B-X
Van	B-X
den	B-X
Berg	B-X
,	B-X
Y.	B-X
Schriel	B-X
,	B-X
L.	B-X
Dawson	B-X
,	B-X
I	B-X
.	B-X
A.	B-X
Meynaar	B-X
P360	B-X
-	B-X
Central	B-X
nervous	B-X
system	B-X
depressants	B-X
poisoning	B-X
and	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
:	B-X
an	B-X
underrated	B-X
risk	B-X
factor	B-X
in	B-X
toxicological	B-X
intensive	B-X
care	B-X
unit	B-X
H.	B-X
Talaie	B-X
P361	B-X
-	B-X
Acute	B-X
barium	B-X
intoxication	B-X
treated	B-X
with	B-X
hemodiafiltration	B-X
D.	B-X
Silva	B-X
,	B-X
S.	B-X
Fernandes	B-X
,	B-X
J.	B-X
Gouveia	B-X
,	B-X
J.	B-X
Santos	B-X
Silva	B-X
P362	B-X
-	B-X
Major	B-X
trauma	B-X
presenting	B-X
to	B-X
the	B-X
emergency	B-X
department	B-X
.	B-X
the	B-X
spectrum	B-X
of	B-X
cycling	B-X
injuries	B-X
in	B-X
Ireland	B-X
J.	B-X
Foley	B-X
,	B-X
A.	B-X
Kaskovagheorgescu	B-X
,	B-X
D.	B-X
Evoy	B-X
,	B-X
J.	B-X
Cronin	B-X
,	B-X
J.	B-X
Ryan	B-X
P363	B-X
-	B-X
Burns	B-X
from	B-X
French	B-X
military	B-X
operations	B-X
:	B-X
a	B-X
14-year	B-X
retrospective	B-X
observational	B-X
analysis	B-X
.	B-X
M.	B-X
Huck	B-X
,	B-X
C.	B-X
Hoffmann	B-X
,	B-X
J.	B-X
Renner	B-X
,	B-X
P.	B-X
Laitselart	B-X
,	B-X
N.	B-X
Donat	B-X
,	B-X
A.	B-X
Cirodde	B-X
,	B-X
J.	B-X
V.	B-X
Schaal	B-X
,	B-X
Y.	B-X
Masson	B-X
,	B-X
A.	B-X
Nau	B-X
,	B-X
T.	B-X
Leclerc	B-X
P364	B-X
-	B-X
A	B-X
comparison	B-X
of	B-X
mortality	B-X
scores	B-X
in	B-X
burns	B-X
patients	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
.	B-X
O.	B-X
Howarth	B-X
,	B-X
K.	B-X
Davenport	B-X
,	B-X
P.	B-X
Jeanrenaud	B-X
,	B-X
S.	B-X
Raftery	B-X
P365	B-X
-	B-X
Clasification	B-X
of	B-X
pain	B-X
and	B-X
its	B-X
treatment	B-X
and	B-X
an	B-X
intensive	B-X
care	B-X
rehabiliation	B-X
clinic	B-X
P.	B-X
MacTavish	B-X
,	B-X
H.	B-X
Devine	B-X
,	B-X
J.	B-X
McPeake	B-X
,	B-X
M.	B-X
Daniel	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
T.	B-X
Quasim	B-X
P366	B-X
-	B-X
Pain	B-X
management	B-X
adequacy	B-X
in	B-X
critical	B-X
care	B-X
areas	B-X
,	B-X
the	B-X
process	B-X
and	B-X
the	B-X
barriers	B-X
perceived	B-X
by	B-X
critical	B-X
care	B-X
nurses	B-X
S.	B-X
Alrabiee	B-X
,	B-X
A.	B-X
Alrashid	B-X
,	B-X
S.	B-X
Alsolamy	B-X
P367	B-X
-	B-X
Pain	B-X
assessment	B-X
in	B-X
critically	B-X
ill	B-X
adult	B-X
patients	B-X
:	B-X
validation	B-X
of	B-X
the	B-X
Turkish	B-X
version	B-X
of	B-X
the	B-X
critical-care	B-X
pain	B-X
observation	B-X
tool	B-X
O.	B-X
Gundogan	B-X
,	B-X
C.	B-X
Bor	B-X
,	B-X
E.	B-X
Akýn	B-X
Korhan	B-X
,	B-X
K.	B-X
Demirag	B-X
,	B-X
M.	B-X
Uyar	B-X
P368	B-X
-	B-X
An	B-X
audit	B-X
of	B-X
pain	B-X
and	B-X
sedation	B-X
assessments	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
recommendations	B-X
for	B-X
clinical	B-X
practice	B-X
F.	B-X
Frame	B-X
,	B-X
C.	B-X
Ashton	B-X
,	B-X
L.	B-X
Bergstrom	B-X
Niska	B-X
P369	B-X
-	B-X
Impact	B-X
of	B-X
pharmaceutical	B-X
care	B-X
on	B-X
treatment	B-X
of	B-X
pain	B-X
and	B-X
agitation	B-X
in	B-X
medical	B-X
intensive	B-X
care	B-X
unit	B-X
P.	B-X
Dilokpattanamongkol	B-X
,	B-X
T.	B-X
Suansanae	B-X
,	B-X
C.	B-X
Suthisisang	B-X
,	B-X
S.	B-X
Morakul	B-X
,	B-X
C.	B-X
Karnjanarachata	B-X
,	B-X
V.	B-X
Tangsujaritvijit	B-X
P370	B-X
-	B-X
Agitation	B-X
in	B-X
trauma	B-X
ICU	B-X
,	B-X
prevention	B-X
and	B-X
outcome	B-X
S.	B-X
Mahmood	B-X
,	B-X
H.	B-X
Al	B-X
Thani	B-X
,	B-X
A.	B-X
Almenyar	B-X
P371	B-X
Correlation	B-X
between	B-X
percentages	B-X
of	B-X
ventilated	B-X
patients	B-X
developed	B-X
vap	B-X
and	B-X
use	B-X
of	B-X
sedative	B-X
agents	B-X
in	B-X
icu	B-X
patients	B-X
.	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P372	B-X
-	B-X
Improving	B-X
recording	B-X
of	B-X
sedation	B-X
events	B-X
in	B-X
the	B-X
Emergency	B-X
Department	B-X
:	B-X
The	B-X
implementation	B-X
of	B-X
the	B-X
SIVA	B-X
International	B-X
Taskforce	B-X
adverse	B-X
event	B-X
reporting	B-X
tool	B-X
for	B-X
procedural	B-X
sedation	B-X
R.	B-X
Sharvill	B-X
,	B-X
J.	B-X
Penketh	B-X
P373	B-X
-	B-X
Impact	B-X
of	B-X
sedative	B-X
drug	B-X
use	B-X
on	B-X
the	B-X
length	B-X
of	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
E.	B-X
Morton	B-X
,	B-X
Y.	B-X
S.	B-X
Chiew	B-X
,	B-X
C.	B-X
Pretty	B-X
,	B-X
J.	B-X
G.	B-X
Chase	B-X
,	B-X
G.	B-X
M.	B-X
Shaw	B-X
P374	B-X
-	B-X
Co-administration	B-X
of	B-X
nitric	B-X
oxide	B-X
and	B-X
sevoflurane	B-X
using	B-X
anaconda	B-X
R.	B-X
Knafelj	B-X
,	B-X
P.	B-X
Kordis	B-X
P375	B-X
-	B-X
A	B-X
retrospective	B-X
study	B-X
of	B-X
the	B-X
use	B-X
of	B-X
Dexmedetomidine	B-X
in	B-X
an	B-X
oncological	B-X
critical	B-X
care	B-X
setting	B-X
S.	B-X
Patel	B-X
,	B-X
V.	B-X
Grover	B-X
P376	B-X
-	B-X
Dexmedetomidine	B-X
and	B-X
posttraumatic	B-X
stress	B-X
disorder	B-X
incidence	B-X
in	B-X
alcohol	B-X
withdrawal	B-X
icu	B-X
patients	B-X
I.	B-X
Kuchyn	B-X
,	B-X
K.	B-X
Bielka	B-X
P377	B-X
-	B-X
Hemodynamic	B-X
effects	B-X
of	B-X
dexmedetomidine	B-X
in	B-X
a	B-X
porcine	B-X
model	B-X
of	B-X
septic	B-X
shock	B-X
Z.	B-X
Aidoni	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
,	B-X
K.	B-X
Kotzampassi	B-X
,	B-X
G.	B-X
Stavrou	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
C.	B-X
Skourtis	B-X
P378	B-X
-	B-X
Ketamine	B-X
for	B-X
analgosedation	B-X
in	B-X
severe	B-X
hypoxic	B-X
respiratory	B-X
failure	B-X
S.	B-X
D.	B-X
Lee	B-X
,	B-X
K.	B-X
Williams	B-X
,	B-X
I.	B-X
D.	B-X
Weltes	B-X
P379	B-X
-	B-X
Madness	B-X
from	B-X
the	B-X
moon	B-X
?	B-X
lunar	B-X
cycle	B-X
and	B-X
the	B-X
incidence	B-X
of	B-X
delirium	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
S.	B-X
Berhane	B-X
,	B-X
C.	B-X
Arrowsmith	B-X
,	B-X
C.	B-X
Peters	B-X
,	B-X
S.	B-X
Robert	B-X
P380	B-X
-	B-X
Impaired	B-X
dynamic	B-X
cerebral	B-X
autoregulation	B-X
after	B-X
coronary	B-X
artery	B-X
bypass	B-X
grafting	B-X
and	B-X
association	B-X
with	B-X
postoperative	B-X
delirium	B-X
J.	B-X
Caldas	B-X
,	B-X
R.	B-X
B.	B-X
Panerai	B-X
,	B-X
T.	B-X
G.	B-X
Robinson	B-X
,	B-X
L.	B-X
Camara	B-X
,	B-X
G.	B-X
Ferreira	B-X
,	B-X
E.	B-X
Borg-Seng-Shu	B-X
,	B-X
M.	B-X
De	B-X
Lima	B-X
Oliveira	B-X
,	B-X
N.	B-X
C.	B-X
Mian	B-X
,	B-X
L.	B-X
Santos	B-X
,	B-X
R.	B-X
Nogueira	B-X
,	B-X
S.	B-X
P.	B-X
Zeferino	B-X
,	B-X
M.	B-X
Jacobsen	B-X
Teixeira	B-X
,	B-X
F.	B-X
Galas	B-X
,	B-X
L.	B-X
A.	B-X
Hajjar	B-X
P381	B-X
-	B-X
Risk	B-X
factors	B-X
predicting	B-X
prolonged	B-X
intensive	B-X
care	B-X
unit	B-X
length	B-X
of	B-X
stay	B-X
after	B-X
major	B-X
elective	B-X
surgery	B-X
.	B-X
P.	B-X
Killeen	B-X
,	B-X
M.	B-X
McPhail	B-X
,	B-X
W.	B-X
Bernal	B-X
,	B-X
J.	B-X
Maggs	B-X
,	B-X
J.	B-X
Wendon	B-X
,	B-X
T.	B-X
Hughes	B-X
P382	B-X
-	B-X
Systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
criteria	B-X
and	B-X
hospital	B-X
mortality	B-X
prediction	B-X
in	B-X
a	B-X
brazilian	B-X
cohort	B-X
of	B-X
critically	B-X
ill	B-X
patients	B-X
L.	B-X
U.	B-X
Taniguchi	B-X
,	B-X
E.	B-X
M.	B-X
Siqueira	B-X
,	B-X
J.	B-X
M.	B-X
Vieira	B-X
Jr	B-X
,	B-X
L.	B-X
C.	B-X
Azevedo	B-X
P383	B-X
-	B-X
Evaluating	B-X
the	B-X
efficacy	B-X
of	B-X
a	B-X
risk	B-X
predictor	B-X
panel	B-X
in	B-X
identifying	B-X
patients	B-X
at	B-X
elevated	B-X
risk	B-X
of	B-X
morbidity	B-X
following	B-X
emergency	B-X
admission	B-X
A.	B-X
N.	B-X
Ahmad	B-X
,	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
R.	B-X
Bahl	B-X
,	B-X
E.	B-X
Helme	B-X
,	B-X
S.	B-X
Hadfield	B-X
,	B-X
R.	B-X
Loveridge	B-X
P384	B-X
-	B-X
A	B-X
retrospective	B-X
comparison	B-X
of	B-X
outcomes	B-X
for	B-X
elective	B-X
surgical	B-X
patients	B-X
admitted	B-X
post-operatively	B-X
to	B-X
the	B-X
critical	B-X
care	B-X
unit	B-X
or	B-X
general	B-X
ward	B-X
J.	B-X
Shak	B-X
,	B-X
C.	B-X
Senver	B-X
,	B-X
R.	B-X
Howard-Griffin	B-X
P385	B-X
-	B-X
Effect	B-X
of	B-X
obesity	B-X
on	B-X
mortality	B-X
in	B-X
surgical	B-X
critically	B-X
ill	B-X
patients	B-X
.	B-X
P.	B-X
Wacharasint	B-X
,	B-X
P.	B-X
Fuengfoo	B-X
,	B-X
N.	B-X
Sukcharoen	B-X
,	B-X
R.	B-X
Rangsin	B-X
P386	B-X
-	B-X
The	B-X
national	B-X
early	B-X
warning	B-X
score	B-X
(	B-X
news	B-X
)	B-X
reliably	B-X
improves	B-X
adverse	B-X
clinical	B-X
outcome	B-X
prediction	B-X
in	B-X
community-acquired	B-X
pneumonia	B-X
-	B-X
results	B-X
from	B-X
a	B-X
6	B-X
year	B-X
follow-up	B-X
D.	B-X
Sbiti-Rohr	B-X
,	B-X
P.	B-X
Schuetz	B-X
P387	B-X
-	B-X
Clinical	B-X
usefulness	B-X
of	B-X
the	B-X
charlson¡¯s	B-X
weighted	B-X
index	B-X
of	B-X
comorbidities	B-X
_as	B-X
prognostic	B-X
factor	B-X
in	B-X
patients	B-X
with	B-X
prolonged	B-X
acute	B-X
mechanical	B-X
ventilation	B-X
H.	B-X
Na	B-X
,	B-X
S.	B-X
Song	B-X
,	B-X
S.	B-X
Lee	B-X
,	B-X
E.	B-X
Jeong	B-X
,	B-X
K.	B-X
Lee	B-X
P388	B-X
-	B-X
Comparison	B-X
of	B-X
mortality	B-X
prediction	B-X
scoring	B-X
systems	B-X
in	B-X
patients	B-X
with	B-X
cirrhosis	B-X
admitted	B-X
to	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
M.	B-X
Cooper	B-X
,	B-X
K.	B-X
Milinis	B-X
,	B-X
G.	B-X
Williams	B-X
,	B-X
E.	B-X
McCarron	B-X
,	B-X
S.	B-X
Simants	B-X
,	B-X
I.	B-X
Patanwala	B-X
,	B-X
I.	B-X
D.	B-X
Welters	B-X
P389	B-X
-	B-X
Impact	B-X
of	B-X
admission	B-X
source	B-X
and	B-X
time	B-X
of	B-X
admission	B-X
on	B-X
outcome	B-X
of	B-X
pediatric	B-X
intensive	B-X
care	B-X
patients	B-X
:	B-X
retrospective	B-X
15	B-X
years	B-X
study	B-X
E.	B-X
Zoumpelouli	B-X
,	B-X
EA	B-X
Volakli	B-X
,	B-X
V.	B-X
Chrysohoidou	B-X
,	B-X
S.	B-X
Georgiou	B-X
,	B-X
K.	B-X
Charisopoulou	B-X
,	B-X
E.	B-X
Kotzapanagiotou	B-X
,	B-X
V.	B-X
Panagiotidou	B-X
,	B-X
K.	B-X
Manavidou	B-X
,	B-X
Z.	B-X
Stathi	B-X
,	B-X
M.	B-X
Sdougka	B-X
P390	B-X
-	B-X
Heart	B-X
rate	B-X
variability	B-X
and	B-X
outcomes	B-X
prediction	B-X
in	B-X
critical	B-X
illness	B-X
N.	B-X
Salahuddin	B-X
,	B-X
B.	B-X
AlGhamdi	B-X
,	B-X
Q.	B-X
Marashly	B-X
,	B-X
K.	B-X
Zaza	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
Khurshid	B-X
,	B-X
Z.	B-X
Ali	B-X
,	B-X
M.	B-X
Malgapo	B-X
,	B-X
M.	B-X
Jamil	B-X
,	B-X
A.	B-X
Shafquat	B-X
,	B-X
M.	B-X
Shoukri	B-X
,	B-X
M.	B-X
Hijazi	B-X
P391	B-X
-	B-X
The	B-X
incidence	B-X
and	B-X
outcome	B-X
of	B-X
hyperlactatemia	B-X
in	B-X
the	B-X
post	B-X
anaesthesia	B-X
care	B-X
unit	B-X
T.	B-X
Abe	B-X
,	B-X
S.	B-X
Uchino	B-X
,	B-X
M.	B-X
Takinami	B-X
P392	B-X
-	B-X
Correlation	B-X
between	B-X
arterial	B-X
blood	B-X
gas	B-X
disturbances	B-X
and	B-X
arterial	B-X
lactate	B-X
levels	B-X
during	B-X
hospitalization	B-X
and	B-X
outcome	B-X
in	B-X
critically	B-X
septic	B-X
patients	B-X
N.	B-X
R.	B-X
Rangel	B-X
Neto	B-X
,	B-X
S.	B-X
Oliveira	B-X
,	B-X
F.	B-X
Q.	B-X
Reis	B-X
,	B-X
F.	B-X
A.	B-X
Rocha	B-X
P393	B-X
-	B-X
External	B-X
validation	B-X
of	B-X
saps	B-X
3	B-X
and	B-X
mpm	B-X
iii	B-X
scores	B-X
in	B-X
48,816	B-X
patients	B-X
from	B-X
72	B-X
brazilian	B-X
icus	B-X
G.	B-X
Moralez	B-X
,	B-X
K.	B-X
Ebecken	B-X
,	B-X
L.	B-X
S.	B-X
Rabello	B-X
,	B-X
M.	B-X
F.	B-X
Lima	B-X
,	B-X
R.	B-X
Hatum	B-X
,	B-X
F.	B-X
V.	B-X
De	B-X
Marco	B-X
,	B-X
A.	B-X
Alves	B-X
,	B-X
J.	B-X
E.	B-X
Pinto	B-X
,	B-X
M.	B-X
Godoy	B-X
,	B-X
P.	B-X
E.	B-X
Brasil	B-X
,	B-X
F.	B-X
A.	B-X
Bozza	B-X
,	B-X
J.	B-X
I.	B-X
Salluh	B-X
,	B-X
M.	B-X
Soares	B-X
P394	B-X
-	B-X
The	B-X
frailty	B-X
penalty	B-X
:	B-X
pre-admission	B-X
functional	B-X
status	B-X
confounds	B-X
mortality	B-X
prediction	B-X
models	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
J.	B-X
Krinsley	B-X
,	B-X
G.	B-X
Kang	B-X
P395	B-X
-	B-X
‘	B-X
sooner	B-X
rather	B-X
than	B-X
later	B-X
”	B-X
:	B-X
how	B-X
delayed	B-X
discharge	B-X
from	B-X
critical	B-X
care	B-X
leads	B-X
to	B-X
increased	B-X
out	B-X
of	B-X
hours	B-X
discharges	B-X
and	B-X
subsequent	B-X
increase	B-X
in	B-X
in-hospital	B-X
mortality	B-X
.	B-X
J.	B-X
Perry	B-X
,	B-X
H.	B-X
Hines	B-X
P396	B-X
-	B-X
Identifying	B-X
poor	B-X
outcome	B-X
patient	B-X
groups	B-X
in	B-X
a	B-X
resource-constrained	B-X
critical	B-X
care	B-X
unit	B-X
K.	B-X
M.	B-X
Wilkinson	B-X
,	B-X
C.	B-X
Tordoff	B-X
,	B-X
B.	B-X
Sloan	B-X
,	B-X
M.	B-X
C.	B-X
Bellamy	B-X
P397	B-X
-	B-X
Effects	B-X
of	B-X
icu	B-X
weekend	B-X
admission	B-X
and	B-X
discharge	B-X
on	B-X
mortality	B-X
.	B-X
E.	B-X
Moreira	B-X
,	B-X
F.	B-X
Verga	B-X
,	B-X
M.	B-X
Barbato	B-X
,	B-X
G.	B-X
Burghi	B-X
P398	B-X
-	B-X
Organizational	B-X
factors	B-X
,	B-X
outcomes	B-X
and	B-X
resource	B-X
use	B-X
in	B-X
9,946	B-X
cancer	B-X
patients	B-X
admitted	B-X
to	B-X
70	B-X
ICUs	B-X
M	B-X
Soares	B-X
,	B-X
U.	B-X
V.	B-X
Silva	B-X
,	B-X
L.	B-X
C.	B-X
Azevedo	B-X
,	B-X
A.	B-X
P.	B-X
Torelly	B-X
,	B-X
J.	B-X
M.	B-X
Kahn	B-X
,	B-X
D.	B-X
C.	B-X
Angus	B-X
,	B-X
M.	B-X
F.	B-X
Knibel	B-X
,	B-X
P.	B-X
E.	B-X
Brasil	B-X
,	B-X
F.	B-X
A.	B-X
Bozza	B-X
,	B-X
J.	B-X
I.	B-X
Salluh	B-X
P399	B-X
-	B-X
Evaluation	B-X
of	B-X
oncological	B-X
critically	B-X
ill	B-X
patients	B-X
,	B-X
severity	B-X
score	B-X
and	B-X
outcome	B-X
compared	B-X
to	B-X
not	B-X
oncological	B-X
in	B-X
a	B-X
particular	B-X
hospital	B-X
cti	B-X
.	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
P400	B-X
-	B-X
Outcomes	B-X
of	B-X
patients	B-X
admitted	B-X
to	B-X
a	B-X
large	B-X
uk	B-X
critical	B-X
care	B-X
department	B-X
with	B-X
palliative	B-X
oncological	B-X
diagnoses	B-X
R.	B-X
Marshall	B-X
,	B-X
T.	B-X
Gilpin	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
A.	B-X
Raithatha	B-X
P401	B-X
-	B-X
Predictors	B-X
of	B-X
mortality	B-X
in	B-X
febrile	B-X
neutropenic	B-X
patients	B-X
with	B-X
haematological	B-X
malignancies	B-X
admitted	B-X
to	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
of	B-X
a	B-X
cancer	B-X
center	B-X
D.	B-X
Mota	B-X
,	B-X
B.	B-X
Loureiro	B-X
,	B-X
J.	B-X
Dias	B-X
,	B-X
O.	B-X
Afonso	B-X
,	B-X
F.	B-X
Coelho	B-X
,	B-X
A.	B-X
Martins	B-X
,	B-X
F.	B-X
Faria	B-X
P402	B-X
-	B-X
Patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
requiring	B-X
invasive	B-X
mechanical	B-X
ventilation	B-X
:	B-X
characteristics	B-X
and	B-X
predictors	B-X
of	B-X
mortality	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
H.	B-X
Al	B-X
Orainni	B-X
,	B-X
F.	B-X
AlEid	B-X
,	B-X
H.	B-X
Tlaygeh	B-X
,	B-X
A.	B-X
Itani	B-X
,	B-X
A.	B-X
Hejazi	B-X
,	B-X
Y.	B-X
Arabi	B-X
P403	B-X
-	B-X
Patient-important	B-X
outcomes	B-X
in	B-X
randomized	B-X
controlled	B-X
trials	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
S.	B-X
Gaudry	B-X
,	B-X
J.	B-X
Messika	B-X
,	B-X
J.	B-X
D.	B-X
Ricard	B-X
,	B-X
S.	B-X
Guillo	B-X
,	B-X
B.	B-X
Pasquet	B-X
,	B-X
E.	B-X
Dubief	B-X
,	B-X
D.	B-X
Dreyfuss	B-X
,	B-X
F.	B-X
Tubach	B-X
P404	B-X
-	B-X
Alopecia	B-X
in	B-X
survivors	B-X
of	B-X
critical	B-X
illness	B-X
:	B-X
a	B-X
qualitative	B-X
study	B-X
C	B-X
.	B-X
Battle	B-X
,	B-X
K.	B-X
James	B-X
,	B-X
P.	B-X
Temblett	B-X
P405	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
mental	B-X
health	B-X
on	B-X
icu	B-X
admission	B-X
L.	B-X
Davies	B-X
,	B-X
C.	B-X
Battle	B-X
,	B-X
C.	B-X
Lynch	B-X
P406	B-X
-	B-X
Cognitive	B-X
impairment	B-X
5	B-X
years	B-X
after	B-X
ICU	B-X
discharge	B-X
S.	B-X
Pereira	B-X
,	B-X
S.	B-X
Cavaco	B-X
,	B-X
J.	B-X
Fernandes	B-X
,	B-X
I.	B-X
Moreira	B-X
,	B-X
E.	B-X
Almeida	B-X
,	B-X
F.	B-X
Seabra	B-X
Pereira	B-X
,	B-X
M.	B-X
Malheiro	B-X
,	B-X
F.	B-X
Cardoso	B-X
,	B-X
I.	B-X
Aragão	B-X
,	B-X
T.	B-X
Cardoso	B-X
P407	B-X
-	B-X
Apache	B-X
ii	B-X
versus	B-X
apache	B-X
iv	B-X
for	B-X
octagenerians	B-X
in	B-X
medical	B-X
icu	B-X
M.	B-X
Fister	B-X
,	B-X
R.	B-X
Knafelj	B-X
P408	B-X
-	B-X
Outcomes	B-X
of	B-X
octagenarians	B-X
in	B-X
an	B-X
indian	B-X
icu	B-X
P.	B-X
Muraray	B-X
Govind	B-X
,	B-X
N.	B-X
Brahmananda	B-X
Reddy	B-X
,	B-X
R.	B-X
Pratheema	B-X
,	B-X
E.	B-X
D.	B-X
Arul	B-X
,	B-X
J.	B-X
Devachandran	B-X
P409	B-X
-	B-X
Mortality	B-X
and	B-X
outcomes	B-X
in	B-X
elderly	B-X
patients	B-X
80	B-X
years	B-X
of	B-X
age	B-X
or	B-X
older	B-X
admitted	B-X
to	B-X
the	B-X
icu	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
P410	B-X
-	B-X
Octagenerians	B-X
in	B-X
medical	B-X
icu	B-X
-	B-X
adding	B-X
days	B-X
to	B-X
life	B-X
or	B-X
life	B-X
to	B-X
days	B-X
?	B-X
R.	B-X
Knafelj	B-X
,	B-X
M.	B-X
Fister	B-X
P411	B-X
-	B-X
The	B-X
very	B-X
elderly	B-X
admitted	B-X
to	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
outcomes	B-X
and	B-X
economic	B-X
evaluation	B-X
N.	B-X
Chin-Yee	B-X
,	B-X
G.	B-X
D	B-X
’	B-X
Egidio	B-X
,	B-X
K.	B-X
Thavorn	B-X
,	B-X
D.	B-X
Heyland	B-X
,	B-X
K.	B-X
Kyeremanteng	B-X
P412	B-X
-	B-X
The	B-X
very	B-X
elderly	B-X
in	B-X
intensive	B-X
care	B-X
:	B-X
relationship	B-X
between	B-X
acuity	B-X
of	B-X
illness	B-X
and	B-X
long-term	B-X
mortality	B-X
A.	B-X
G.	B-X
Murchison	B-X
,	B-X
K.	B-X
Swalwell	B-X
,	B-X
J.	B-X
Mandeville	B-X
,	B-X
D.	B-X
Stott	B-X
P413	B-X
-	B-X
Acquired	B-X
weakness	B-X
in	B-X
an	B-X
oncological	B-X
intensive	B-X
care	B-X
unit	B-X
I.	B-X
Guerreiro	B-X
P414	B-X
-	B-X
Musculoskeletal	B-X
problems	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ICU	B-X
)	B-X
patients	B-X
post-discharge	B-X
H.	B-X
Devine	B-X
,	B-X
P.	B-X
MacTavish	B-X
,	B-X
J.	B-X
McPeake	B-X
,	B-X
T.	B-X
Quasim	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
M.	B-X
Daniel	B-X
P415	B-X
-	B-X
Premorbid	B-X
obesity	B-X
,	B-X
but	B-X
not	B-X
nutrition	B-X
,	B-X
prevents	B-X
critical	B-X
illness-induced	B-X
muscle	B-X
wasting	B-X
and	B-X
weakness	B-X
C.	B-X
Goossens	B-X
M.	B-X
B.	B-X
Marques	B-X
,	B-X
S.	B-X
Derde	B-X
,	B-X
S.	B-X
Vander	B-X
Perre	B-X
,	B-X
T.	B-X
Dufour	B-X
,	B-X
S.	B-X
E.	B-X
Thiessen	B-X
,	B-X
F.	B-X
Güiza	B-X
,	B-X
T.	B-X
Janssens	B-X
,	B-X
G.	B-X
Hermans	B-X
,	B-X
I.	B-X
Vanhorebeek	B-X
,	B-X
K.	B-X
De	B-X
Bock	B-X
,	B-X
G.	B-X
Van	B-X
den	B-X
Berghe	B-X
,	B-X
L.	B-X
Langouche	B-X
P416	B-X
-	B-X
Physical	B-X
outcome	B-X
measures	B-X
for	B-X
critical	B-X
care	B-X
patients	B-X
following	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
icu	B-X
)	B-X
discharge	B-X
H.	B-X
Devine	B-X
,	B-X
P.	B-X
MacTavish	B-X
,	B-X
T.	B-X
Quasim	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
M.	B-X
Daniel	B-X
,	B-X
J.	B-X
McPeake	B-X
P417	B-X
-	B-X
Improving	B-X
active	B-X
mobilisation	B-X
in	B-X
a	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
B	B-X
.	B-X
Miles	B-X
,	B-X
S.	B-X
Madden	B-X
,	B-X
H.	B-X
Devine	B-X
P418	B-X
-	B-X
Mobilization	B-X
in	B-X
patients	B-X
on	B-X
vasoactive	B-X
drugs	B-X
use	B-X
–	B-X
a	B-X
pilot	B-X
study	B-X
.	B-X
T.	B-X
Hall	B-X
,	B-X
W.	B-X
C.	B-X
Ngu	B-X
,	B-X
J.	B-X
M.	B-X
Jack	B-X
,	B-X
P.	B-X
Morgan	B-X
P423	B-X
-	B-X
Measuring	B-X
urine	B-X
output	B-X
in	B-X
ward	B-X
patients	B-X
:	B-X
is	B-X
it	B-X
helpful	B-X
?	B-X
Bor	B-X
,	B-X
E.	B-X
Akin	B-X
Korhan	B-X
,	B-X
K.	B-X
Demirag	B-X
,	B-X
M.	B-X
Uyar	B-X
P425	B-X
-	B-X
Intensivist/patient	B-X
ratios	B-X
in	B-X
closed	B-X
ICUs	B-X
in	B-X
Alexandria	B-X
,	B-X
Egypt	B-X
;	B-X
an	B-X
overview	B-X
M.	B-X
Shirazy	B-X
,	B-X
A.	B-X
Fayed	B-X
P426	B-X
-	B-X
Eicu	B-X
(	B-X
electronic	B-X
intensive	B-X
care	B-X
unit	B-X
)	B-X
:	B-X
impact	B-X
on	B-X
ALOS	B-X
(	B-X
average	B-X
length	B-X
of	B-X
stay	B-X
)	B-X
in	B-X
a	B-X
developing	B-X
country	B-X
like	B-X
India	B-X
S.	B-X
Gupta	B-X
,	B-X
A.	B-X
Kaushal	B-X
,	B-X
S.	B-X
Dewan	B-X
,	B-X
A.	B-X
Varma	B-X
P427	B-X
-	B-X
Predicting	B-X
deterioration	B-X
in	B-X
general	B-X
ward	B-X
using	B-X
early	B-X
deterioration	B-X
indicator	B-X
E.	B-X
Ghosh	B-X
,	B-X
L.	B-X
Yang	B-X
,	B-X
L.	B-X
Eshelman	B-X
,	B-X
B.	B-X
Lord	B-X
,	B-X
E.	B-X
Carlson	B-X
P428	B-X
-	B-X
High	B-X
impact	B-X
enhanced	B-X
critical	B-X
care	B-X
outreach	B-X
-	B-X
the	B-X
imobile	B-X
service	B-X
:	B-X
making	B-X
a	B-X
difference	B-X
E.	B-X
Helme	B-X
,	B-X
R.	B-X
Broderick	B-X
,	B-X
S.	B-X
Hadfield	B-X
,	B-X
R.	B-X
Loveridge	B-X
P429	B-X
-	B-X
Impact	B-X
of	B-X
bed	B-X
availability	B-X
and	B-X
cognitive	B-X
load	B-X
on	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ICU	B-X
)	B-X
bed	B-X
allocation	B-X
:	B-X
a	B-X
vignette-based	B-X
trial	B-X
J.	B-X
Ramos	B-X
,	B-X
D.	B-X
Forte	B-X
P430	B-X
-	B-X
Characteristics	B-X
of	B-X
critically	B-X
ill	B-X
patients	B-X
admitted	B-X
through	B-X
the	B-X
emergency	B-X
department	B-X
F.	B-X
Yang	B-X
,	B-X
P.	B-X
Hou	B-X
P431	B-X
-	B-X
Admission	B-X
to	B-X
critical	B-X
care	B-X
:	B-X
the	B-X
quantification	B-X
of	B-X
functional	B-X
reserve	B-X
J.	B-X
Dudziak	B-X
,	B-X
J.	B-X
Feeney	B-X
,	B-X
K.	B-X
Wilkinson	B-X
,	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
K.	B-X
Shuker	B-X
,	B-X
M.	B-X
Faulds	B-X
,	B-X
A.	B-X
Raithatha	B-X
,	B-X
D.	B-X
Bryden	B-X
,	B-X
L.	B-X
England	B-X
,	B-X
N.	B-X
Bolton	B-X
,	B-X
A.	B-X
Tridente	B-X
P432	B-X
-	B-X
Admission	B-X
to	B-X
critical	B-X
care	B-X
:	B-X
the	B-X
importance	B-X
of	B-X
frailty	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
K	B-X
Shuker	B-X
,	B-X
A	B-X
Tridente	B-X
,	B-X
M	B-X
Faulds	B-X
,	B-X
A	B-X
Matheson	B-X
,	B-X
J.	B-X
Gaynor	B-X
,	B-X
D	B-X
Bryden	B-X
,	B-X
S	B-X
South	B-X
Yorkshire	B-X
Hospitals	B-X
Research	B-X
Collaboration	B-X
P433	B-X
-	B-X
Development	B-X
of	B-X
an	B-X
instrument	B-X
to	B-X
aid	B-X
triage	B-X
decisions	B-X
for	B-X
intensive	B-X
care	B-X
unit	B-X
admission	B-X
J.	B-X
Ramos	B-X
,	B-X
B.	B-X
Peroni	B-X
,	B-X
R.	B-X
Daglius-Dias	B-X
,	B-X
L.	B-X
Miranda	B-X
,	B-X
C.	B-X
Cohen	B-X
,	B-X
C.	B-X
Carvalho	B-X
,	B-X
I	B-X
.	B-X
Velasco	B-X
,	B-X
D.	B-X
Forte	B-X
P434	B-X
-	B-X
Using	B-X
selective	B-X
serotonin	B-X
re-uptake	B-X
inhibitors	B-X
and	B-X
serotonin-norepinephrine	B-X
re-uptake	B-X
inhibitors	B-X
in	B-X
critical	B-X
care	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
evidence	B-X
for	B-X
benefit	B-X
or	B-X
harm	B-X
J.	B-X
M.	B-X
Kelly	B-X
,	B-X
A.	B-X
Neill	B-X
,	B-X
G.	B-X
Rubenfeld	B-X
,	B-X
N.	B-X
Masson	B-X
,	B-X
A.	B-X
Min	B-X
P435	B-X
-	B-X
Measuring	B-X
adaptive	B-X
coping	B-X
of	B-X
hospitalized	B-X
patients	B-X
with	B-X
a	B-X
severe	B-X
medical	B-X
condition	B-X
:	B-X
the	B-X
sickness	B-X
insight	B-X
in	B-X
coping	B-X
questionnaire	B-X
(	B-X
sicq	B-X
)	B-X
E.	B-X
Boezeman	B-X
,	B-X
J.	B-X
Hofhuis	B-X
,	B-X
A.	B-X
Hovingh	B-X
,	B-X
R.	B-X
De	B-X
Vries	B-X
,	B-X
P.	B-X
Spronk	B-X
P436	B-X
-	B-X
Results	B-X
of	B-X
a	B-X
national	B-X
survey	B-X
regarding	B-X
intensive	B-X
care	B-X
medicine	B-X
training	B-X
G.	B-X
Cabral-Campello	B-X
,	B-X
I.	B-X
Aragão	B-X
,	B-X
T.	B-X
Cardoso	B-X
P437	B-X
-	B-X
Work	B-X
engagement	B-X
among	B-X
healthcare	B-X
professionals	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
M.	B-X
Van	B-X
Mol	B-X
,	B-X
M.	B-X
Nijkamp	B-X
,	B-X
E	B-X
.	B-X
Kompanje	B-X
P438	B-X
-	B-X
Empowering	B-X
the	B-X
intensive	B-X
care	B-X
practitioners	B-X
.	B-X
P.	B-X
Ostrowski	B-X
,	B-X
A.	B-X
Omar	B-X
P439	B-X
-	B-X
Icu	B-X
patients	B-X
suffer	B-X
from	B-X
circadian	B-X
rhythm	B-X
desynchronisation	B-X
K.	B-X
Kiss	B-X
,	B-X
B.	B-X
Köves	B-X
,	B-X
V.	B-X
Csernus	B-X
,	B-X
Z.	B-X
Molnár	B-X
P440	B-X
-	B-X
Noise	B-X
reduction	B-X
in	B-X
the	B-X
ICU	B-X
:	B-X
feasible	B-X
?	B-X
C.	B-X
Stone	B-X
,	B-X
T.	B-X
Wigmore	B-X
P443	B-X
-	B-X
Use	B-X
of	B-X
a	B-X
modified	B-X
cristal	B-X
score	B-X
to	B-X
predict	B-X
futility	B-X
of	B-X
critical	B-X
care	B-X
in	B-X
the	B-X
elderly	B-X
Y.	B-X
Arunan	B-X
,	B-X
A.	B-X
Wheeler	B-X
,	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
D.	B-X
Bryden	B-X
P444	B-X
-	B-X
Improvement	B-X
of	B-X
Referral	B-X
Rate	B-X
to	B-X
Palliative	B-X
Care	B-X
for	B-X
Patients	B-X
with	B-X
Poor	B-X
Prognosis	B-X
in	B-X
Neurosurgical	B-X
Intensive	B-X
Care	B-X
Unit	B-X
Y.	B-X
Wong	B-X
,	B-X
C.	B-X
Poi	B-X
,	B-X
C.	B-X
Gu	B-X
P445	B-X
-	B-X
Factors	B-X
associated	B-X
with	B-X
limitation	B-X
of	B-X
life	B-X
supporting	B-X
care	B-X
(	B-X
lsc	B-X
)	B-X
in	B-X
a	B-X
medico-surgical	B-X
intermediate	B-X
care	B-X
unit	B-X
,	B-X
and	B-X
outcome	B-X
of	B-X
patients	B-X
with	B-X
lsc	B-X
limitation	B-X
:	B-X
a	B-X
monocentric	B-X
,	B-X
six-month	B-X
study	B-X
.	B-X
A.	B-X
Marudi	B-X
,	B-X
S.	B-X
Baroni	B-X
,	B-X
F.	B-X
Ragusa	B-X
,	B-X
E.	B-X
Bertellini	B-X
P451	B-X
-	B-X
Death	B-X
analysis	B-X
in	B-X
pediatric	B-X
intensive	B-X
care	B-X
patients	B-X
E.	B-X
A.	B-X
Volakli	B-X
,	B-X
E.	B-X
Chochliourou	B-X
,	B-X
M.	B-X
Dimitriadou	B-X
,	B-X
A.	B-X
Violaki	B-X
,	B-X
P.	B-X
Mantzafleri	B-X
,	B-X
E.	B-X
Samkinidou	B-X
,	B-X
O.	B-X
Vrani	B-X
,	B-X
A.	B-X
Arbouti	B-X
,	B-X
T.	B-X
Varsami	B-X
,	B-X
M.	B-X
Sdougka	B-X
P452	B-X
-	B-X
The	B-X
potential	B-X
impact	B-X
of	B-X
euthanasia	B-X
on	B-X
organ	B-X
donation	B-X
:	B-X
analysis	B-X
of	B-X
data	B-X
from	B-X
belgium	B-X
J	B-X
.	B-X
A.	B-X
Bollen	B-X
,	B-X
T.	B-X
C.	B-X
Van	B-X
Smaalen	B-X
,	B-X
W.	B-X
C.	B-X
De	B-X
Jongh	B-X
,	B-X
M.	B-X
M.	B-X
Ten	B-X
Hoopen	B-X
,	B-X
D.	B-X
Ysebaert	B-X
,	B-X
L.	B-X
W.	B-X
Van	B-X
Heurn	B-X
,	B-X
W.	B-X
N.	B-X
Van	B-X
Mook	B-X
P453	B-X
-	B-X
Communication	B-X
within	B-X
an	B-X
intensive	B-X
care	B-X
setting	B-X
K.	B-X
Sim	B-X
,	B-X
A.	B-X
Fuller	B-X
P454	B-X
-	B-X
Development	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
longitudinal	B-X
communication	B-X
curriculum	B-X
for	B-X
critical	B-X
care	B-X
medicine	B-X
fellows	B-X
A.	B-X
Roze	B-X
des	B-X
Ordons	B-X
,	B-X
P.	B-X
Couillard	B-X
,	B-X
C.	B-X
Doig	B-X
P455	B-X
-	B-X
Staff-family	B-X
conflict	B-X
in	B-X
a	B-X
multi-ethnic	B-X
intensive	B-X
care	B-X
unit	B-X
R.	B-X
V.	B-X
Van	B-X
Keer	B-X
,	B-X
R.	B-X
D.	B-X
Deschepper	B-X
,	B-X
A.	B-X
F.	B-X
Francke	B-X
,	B-X
L.	B-X
H.	B-X
Huyghens	B-X
,	B-X
J	B-X
.	B-X

Therefore	O
,	O
we	O
determined	O
3	O
days	O
after	O
SE	O
as	O
the	O
best	O
time	O
point	O
to	O
look	O
FJB	O
.	O

Briefly	O
,	O
sections	O
were	O
rinsed	O
in	O
distilled	O
water	O
,	O
and	O
mounted	O
onto	O
gelatin	O
-	O
coated	O
slides	O
and	O
then	O
dried	O
on	O
a	O
slide	O
warmer	O
.	O

The	O
slides	O
were	O
immersed	O
in	O
100	O
%	O
ethanol	O
for	O
3	O
min	O
,	O
followed	O
by	O
70	O
%	O
ethanol	O
for	O
2	O
min	O
and	O
distilled	O
water	O
for	O
2	O
min	O
.	O

The	O
slides	O
were	O
then	O
transferred	O
to	O
0	O
.	O
06	O
%	O
potassium	O
permanganate	O
for	O
15	O
min	O
and	O
gently	O
agitated	O
.	O

After	O
rinsing	O
in	O
distilled	O
water	O
for	O
2	O
min	O
,	O
the	O
slides	O
were	O
incubated	O
for	O
30	O
min	O
in	O
0	O
.	O
001	O
%	O
FJB	O
(	O
Histo	O
-	O
Chem	O
Inc	O
.	O
,	O
Jefferson	O
,	O
AR	O
)	O
,	O
freshly	O
prepared	O
by	O
adding	O
20	O
ml	O
of	O
a	O
0	O
.	O
01	O
%	O
stock	O
FJB	O
solution	O
to	O
180	O
ml	O
of	O
0	O
.	O
1	O
%	O
acetic	O
acid	O
,	O
with	O
gentle	O
shaking	O
in	O
the	O
dark	O
.	O

After	O
rinsing	O
for	O
1	O
min	O
in	O
each	O
of	O
three	O
changes	O
of	O
distilled	O
water	O
,	O
the	O
slides	O
were	O
dried	O
,	O
dehydrated	O
in	O
xylene	O
and	O
coverslipped	O
with	O
DPX	O
(	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

For	O
stereological	O
study	O
,	O
every	O
sixth	O
section	O
in	O
the	O
series	O
throughout	O
the	O
entire	O
PC	O
was	O
used	O
(	O
see	O
below	O
)	O
.	O

Volumetric	O
analysis	O
and	O
cell	O
counts	O
<EOS>	B-X
Vero	B-X
cells	B-X
are	B-X
considered	B-X
as	B-X
the	B-X
most	B-X
widely	B-X
accepted	B-X
continuous	B-X
cell	B-X
line	B-X
by	B-X
the	B-X
regulatory	B-X
authorities	B-X
(	B-X
such	B-X
as	B-X
WHO	B-X
)	B-X
for	B-X
the	B-X
manufacture	B-X
of	B-X
viral	B-X
vaccines	B-X
for	B-X
human	B-X
use	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
Vero	B-X
cells	B-X
is	B-X
anchorage-dependent	B-X
.	B-X
Adaptation	B-X
of	B-X
Vero	B-X
cells	B-X
to	B-X
grow	B-X
in	B-X
suspension	B-X
will	B-X
simplify	B-X
subcultivation	B-X
and	B-X
process	B-X
scale-up	B-X
significantly	B-X
,	B-X
and	B-X
therefore	B-X
reduce	B-X
the	B-X
production	B-X
cost	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
on	B-X
a	B-X
successful	B-X
adaptation	B-X
of	B-X
adherent	B-X
Vero	B-X
cells	B-X
to	B-X
grow	B-X
in	B-X
suspension	B-X
in	B-X
a	B-X
serum-free	B-X
and	B-X
animal	B-X
component-free	B-X
medium	B-X
(	B-X
IHM03	B-X
)	B-X
developed	B-X
in-house	B-X
.	B-X
The	B-X
suspension	B-X
adapted	B-X
Vero	B-X
cell	B-X
cultures	B-X
in	B-X
IHM03	B-X
grew	B-X
to	B-X
similar	B-X
or	B-X
better	B-X
maximum	B-X
cell	B-X
density	B-X
as	B-X
what	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
adherent	B-X
Vero	B-X
cells	B-X
grown	B-X
in	B-X
commercial	B-X
serum-free	B-X
media	B-X
and	B-X
with	B-X
a	B-X
cell	B-X
doubling	B-X
time	B-X
of	B-X
40-44	B-X
h.	B-X
Much	B-X
higher	B-X
cell	B-X
density	B-X
(	B-X
8	B-X
×	B-X
10	B-X

To	O
measure	O
vasogenic	O
edema	O
,	O
the	O
volume	O
of	O
anti	O
-	O
rat	O
IgG	O
positive	O
region	O
in	O
PC	O
was	O
estimated	O
according	O
to	O
the	O
formula	O
based	O
on	O
the	O
modified	O
Cavalieri	O
method	O
:	O
V	O
=	O
sigmaa	O
x	O
tnom	O
x	O
1	O
/	O
ssf	O
,	O
where	O
a	O
is	O
area	O
of	O
the	O
region	O
of	O
the	O
delineated	O
subfield	O
measured	O
by	O
AxioVision	O
Rel	O
.	O

4	O
.	O
8	O
software	O
,	O
tnom	O
is	O
the	O
nominal	O
section	O
thickness	O
(	O
of	O
30	O
mum	O
in	O
this	O
study	O
)	O
,	O
and	O
ssf	O
is	O
the	O
fraction	O
of	O
the	O
sections	O
sampled	O
or	O
section	O
sampling	O
fraction	O
(	O
of	O
1	O
/	O
6	O
in	O
this	O
study	O
)	O
.	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
Echinacoside	B-X
for	B-X
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B-X
(	B-X
MPTP	B-X
)	B-X
induced	B-X
dopaminergic	B-X
(	B-X
DA	B-X
)	B-X
neurons	B-X
injury	B-X
in	B-X
the	B-X
subacute	B-X
mouse	B-X
model	B-X
of	B-X
Parkinson	B-X
's	B-X
disease	B-X
(	B-X
PD	B-X
)	B-X
and	B-X
to	B-X
explore	B-X
its	B-X
mechanism	B-X
of	B-X
action	B-X
.	B-X
We	B-X
systematically	B-X
reviewed	B-X
the	B-X
European	B-X
real-world	B-X
evidence	B-X
(	B-X
RWE	B-X
)	B-X
about	B-X
sacubitril-valsartan	B-X
for	B-X
heart	B-X
failure	B-X
with	B-X
reduced	B-X
ejection	B-X
fraction	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
temporal	B-X
trends	B-X
in	B-X
the	B-X
incidence	B-X
of	B-X
and	B-X
mortality	B-X
associated	B-X
with	B-X
heart	B-X
failure	B-X
(	B-X
HF	B-X
)	B-X
and	B-X
its	B-X
subtypes	B-X
(	B-X
heart	B-X
failure	B-X
with	B-X
reduced	B-X
ejection	B-X
fraction	B-X
[	B-X
HFrEF	B-X
]	B-X
and	B-X
heart	B-X
rate	B-X
with	B-X
preserved	B-X
ejection	B-X
fraction	B-X
[	B-X
HFpEF	B-X
]	B-X
)	B-X
in	B-X
the	B-X
community	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
oncology-related	B-X
immunotherapy	B-X
,	B-X
specifically	B-X
in	B-X
targeting	B-X
of	B-X
programmed	B-X
cell	B-X
death-1	B-X
(	B-X
PD-1	B-X
)	B-X
/programmed	B-X
death-ligand	B-X
1	B-X
(	B-X
PD-L1	B-X
)	B-X
pathways	B-X
,	B-X
have	B-X
identified	B-X
a	B-X
new	B-X
treatment	B-X
potential	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
tumors	B-X
,	B-X
including	B-X
advanced	B-X
and	B-X
rare	B-X
tumors	B-X
.	B-X
Only	B-X
a	B-X
fraction	B-X
of	B-X
patients	B-X
being	B-X
treated	B-X
by	B-X
immune	B-X
checkpoint	B-X
inhibitors	B-X
have	B-X
shown	B-X
to	B-X
benefit	B-X
from	B-X
it	B-X
,	B-X
displaying	B-X
a	B-X
need	B-X
for	B-X
strategies	B-X
which	B-X
identify	B-X
patients	B-X
who	B-X
may	B-X
most	B-X
likely	B-X
show	B-X
a	B-X
favorable	B-X
response	B-X
.	B-X
Building	B-X
on	B-X
recent	B-X
,	B-X
promising	B-X
outcomes	B-X
in	B-X
a	B-X
clinical	B-X
study	B-X
of	B-X
metastatic	B-X
PPGL	B-X
using	B-X
pembrolizumab	B-X
,	B-X
a	B-X
humanized	B-X
IgG4κ	B-X
monoclonal	B-X
antibody	B-X
targeting	B-X
the	B-X
PD-1/PD-L1	B-X
pathway	B-X
,	B-X
we	B-X
examined	B-X
PD-L1	B-X
and	B-X
PD-L2	B-X
expression	B-X
in	B-X
relation	B-X
to	B-X
oncogenic	B-X
drivers	B-X
in	B-X
our	B-X
PPGL	B-X
patient	B-X
cohort	B-X
to	B-X
explore	B-X
whether	B-X
expression	B-X
can	B-X
predict	B-X
metastatic	B-X
potential	B-X
and/or	B-X
be	B-X
considered	B-X
a	B-X
predictive	B-X
marker	B-X
for	B-X
targeted	B-X
therapy	B-X
.	B-X
We	B-X
evaluated	B-X
RNA	B-X
expression	B-X
in	B-X
the	B-X
NIH	B-X
cohort	B-X
of	B-X
48	B-X
patients	B-X
with	B-X
known	B-X
genetic	B-X
predisposition	B-X
(	B-X
sporadic	B-X
;	B-X
pseudohypoxia	B-X
:	B-X

The	O
subfield	O
areas	O
were	O
delineated	O
with	O
a	O
2	O
.	O
5	O
x	O
objective	O
lens	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
18	O
,	O
25	O
]	O
.	O

The	O
volumes	O
are	O
reported	O
as	O
mm3	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
the	B-X
absolute	B-X
volume	B-X
of	B-X
the	B-X
human	B-X
spinal	B-X
cord	B-X
has	B-X
rarely	B-X
been	B-X
reported	B-X
,	B-X
if	B-X
ever	B-X
.	B-X
However	B-X
,	B-X
inconsistent	B-X
results	B-X
have	B-X
been	B-X
reported	B-X
with	B-X
respect	B-X
to	B-X
which	B-X
subfield	B-X
volumes	B-X
are	B-X
most	B-X
related	B-X
to	B-X
age	B-X
.	B-X
The	B-X
use	B-X
of	B-X
2	B-X
malignancy	B-X
prediction	B-X
calculators	B-X
to	B-X
better	B-X
characterize	B-X
the	B-X
risk	B-X
of	B-X
malignancy	B-X
was	B-X
firmly	B-X
supported	B-X
by	B-X
evidence	B-X
,	B-X
as	B-X
were	B-X
the	B-X
recommendations	B-X
for	B-X
a	B-X
higher	B-X
nodule	B-X
size	B-X
threshold	B-X
for	B-X
follow‑up	B-X
(	B-X
≥5	B-X
mm	B-X
or	B-X
≥80	B-X
mm3	B-X
)	B-X
and	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
follow‑up	B-X
period	B-X
to	B-X
1	B-X
year	B-X
for	B-X
solid	B-X
pulmonary	B-X
nodules	B-X
.	B-X
We	B-X
carried	B-X
out	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
published	B-X
literature	B-X
reporting	B-X
left	B-X
and	B-X
right	B-X
amygdala	B-X
volumes	B-X
from	B-X
MRI	B-X
in	B-X
non-clinical	B-X
subjects	B-X
.	B-X
The	B-X
overall	B-X
range	B-X
of	B-X
reported	B-X
volumes	B-X
was	B-X
1050	B-X
mm	B-X
(	B-X
3	B-X
)	B-X
to	B-X
3880	B-X
mm	B-X
(	B-X
3	B-X
)	B-X
.	B-X
Studies	B-X
using	B-X
'Watson	B-X
's	B-X
criteria	B-X
'	B-X
(	B-X
Neurology	B-X
42	B-X
(	B-X
1992	B-X
)	B-X
1743	B-X
)	B-X
produced	B-X
significantly	B-X
larger	B-X
volumes	B-X
than	B-X
the	B-X
remainder	B-X
.	B-X

An	O
optical	O
fractionator	O
was	O
used	O
to	O
estimate	O
cell	O
numbers	O
.	O
<EOS>	B-X
Although	B-X
histogenesis	B-X
is	B-X
well-documented	B-X
,	B-X
only	B-X
a	B-X
few	B-X
studies	B-X
have	B-X
quantified	B-X
cell	B-X
numbers	B-X
across	B-X
normal	B-X
human	B-X
fetal	B-X
brain	B-X
growth	B-X
.	B-X
Furthermore	B-X
,	B-X
many	B-X
studies	B-X
of	B-X
brain	B-X
cell	B-X
numbers	B-X
have	B-X
employed	B-X
biased	B-X
counting	B-X
methods	B-X
,	B-X
whereas	B-X
innovations	B-X
in	B-X
stereology	B-X
during	B-X
the	B-X
past	B-X
20-30	B-X
years	B-X
enable	B-X
reliable	B-X
and	B-X
efficient	B-X
estimates	B-X
of	B-X
cell	B-X
numbers	B-X
.	B-X
However	B-X
,	B-X
estimates	B-X
of	B-X
cell	B-X
volumes	B-X
and	B-X
densities	B-X
in	B-X
fetal	B-X
brain	B-X
samples	B-X
are	B-X
unreliable	B-X
due	B-X
to	B-X
unpredictable	B-X
shrinking	B-X
artifacts	B-X
,	B-X
and	B-X
the	B-X
fragility	B-X
of	B-X
the	B-X
fetal	B-X
brain	B-X
requires	B-X
particular	B-X
care	B-X
in	B-X
handling	B-X
and	B-X
processing	B-X
.	B-X
The	B-X
optical	B-X
fractionator	B-X
design	B-X
offers	B-X
a	B-X
direct	B-X
and	B-X
robust	B-X
estimate	B-X
of	B-X
total	B-X
cell	B-X
numbers	B-X
in	B-X
the	B-X
fetal	B-X
brain	B-X
with	B-X
a	B-X
minimum	B-X
of	B-X
handling	B-X
of	B-X
the	B-X
tissue	B-X
.	B-X
Bearing	B-X
this	B-X
in	B-X
mind	B-X
,	B-X
we	B-X
have	B-X
used	B-X
the	B-X
optical	B-X
fractionator	B-X
to	B-X
quantify	B-X
the	B-X
growth	B-X
of	B-X
total	B-X
cell	B-X
numbers	B-X
as	B-X
a	B-X
function	B-X
of	B-X
fetal	B-X
age	B-X
.	B-X
We	B-X
discovered	B-X
a	B-X
two-phased	B-X
development	B-X
in	B-X
total	B-X
cell	B-X
numbers	B-X
in	B-X
the	B-X
human	B-X
fetal	B-X
forebrain	B-X
consisting	B-X
of	B-X
an	B-X
initial	B-X
steep	B-X
rise	B-X
in	B-X
total	B-X
cell	B-X
numbers	B-X
between	B-X
13	B-X
and	B-X
20	B-X
weeks	B-X
of	B-X
gestation	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
slower	B-X
linear	B-X
phase	B-X
extending	B-X
from	B-X
mid-gestation	B-X
to	B-X
40	B-X
weeks	B-X
of	B-X
gestation	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
have	B-X
demonstrated	B-X
a	B-X
reduced	B-X
total	B-X
cell	B-X
number	B-X
in	B-X
the	B-X
forebrain	B-X
in	B-X
fetuses	B-X
with	B-X
Down	B-X
syndome	B-X
at	B-X
midgestation	B-X
and	B-X
in	B-X
intrauterine	B-X
growth-restricted	B-X
fetuses	B-X
during	B-X
the	B-X
third	B-X
trimester	B-X
.	B-X

The	O
optical	O
fractionator	O
(	O
a	O
combination	O
of	O
performing	O
counting	O
with	O
the	O
optical	O
dissector	O
,	O
with	O
fractionator	O
sampling	O
)	O
is	O
a	O
stereological	O
method	O
based	O
on	O
a	O
properly	O
designed	O
systematic	O
random	O
sampling	O
method	O
that	O
by	O
definition	O
yields	O
unbiased	O
estimates	O
of	O
population	O
number	O
.	O

The	O
sampling	O
procedure	O
is	O
accomplished	O
by	O
focusing	O
through	O
the	O
depth	O
of	O
the	O
tissue	O
(	O
the	O
optical	O
dissector	O
height	O
,	O
h	O
;	O
15	O
mum	O
in	O
all	O
cases	O
for	O
this	O
study	O
)	O
.	O

The	O
number	O
of	O
each	O
cell	O
type	O
(	O
C	O
)	O
in	O
each	O
of	O
the	O
subregions	O
is	O
estimated	O
as	O
:	O
C	O
=	O
sigmaQ	O
-	O
x	O
t	O
/	O
h	O
x	O
1	O
/	O
asf	O
x	O
1	O
/	O
ssf	O
,	O
where	O
Q	O
-	O
is	O
the	O
number	O
of	O
cells	O
actually	O
counted	O
in	O
the	O
dissectors	O
that	O
fell	O
within	O
the	O
sectional	O
profiles	O
of	O
the	O
subregion	O
seen	O
on	O
the	O
sampled	O
sections	O
,	O
and	O
Asf	O
is	O
the	O
areal	O
sampling	O
fraction	O
calculated	O
by	O
the	O
area	O
of	O
the	O
counting	O
frame	O
of	O
the	O
dissector	O
,	O
a	O
(	O
frame	O
)	O
(	O
of	O
50	O
x	O
50	O
mum2	O
in	O
this	O
study	O
)	O
and	O
the	O
area	O
associated	O
with	O
each	O
x	O
,	O
y	O
movement	O
,	O
grid	O
(	O
x	O
,	O
y	O
step	O
)	O
(	O
of	O
250	O
x	O
250	O
mum2	O
in	O
this	O
study	O
)	O
{	O
asf	O
=	O
(	O
a	O
(	O
frame	O
)	O
/	O
a	O
(	O
x	O
,	O
y	O
step	O
)	O
)	O
}	O
.	O

The	O
immunoreactive	O
cells	O
were	O
counted	O
with	O
a	O
40x	O
objective	O
lens	O
.	O

The	O
immunoreactive	O
cells	O
were	O
counted	O
with	O
a	O
40x	O
objective	O
lens	O
.	O

All	O
immunoreactive	O
cells	O
were	O
counted	O
regardless	O
the	O
intensity	O
of	O
labeling	O
.	O
<EOS>	B-X
Positively	B-X
labeled	B-X
neurons	B-X
were	B-X
counted	B-X
in	B-X
six	B-X
caudal-rostral	B-X
sections	B-X
containing	B-X
CVLM	B-X
.	B-X
Hypoxia	B-X
progressively	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
Fos-immunoreactive	B-X
CVLM	B-X
cells	B-X
(	B-X
21	B-X
%	B-X
,	B-X
19	B-X
±	B-X
6	B-X
;	B-X
12	B-X
%	B-X
,	B-X
49	B-X
±	B-X
2	B-X
;	B-X
10	B-X
%	B-X
,	B-X
117	B-X
±	B-X
8	B-X
;	B-X
8	B-X
%	B-X
,	B-X
179	B-X
±	B-X
7	B-X
;	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
Catecholaminergic	B-X
cells	B-X
colabeled	B-X
with	B-X
Fos	B-X
immunoreactivity	B-X
in	B-X
the	B-X
CVLM	B-X
were	B-X
observed	B-X
following	B-X
12	B-X
%	B-X
O2	B-X
,	B-X
and	B-X
further	B-X
increases	B-X
in	B-X
hypoxia	B-X
severity	B-X
caused	B-X
markedly	B-X
more	B-X
activation	B-X
.	B-X
PVN-projecting	B-X
CVLM	B-X
cells	B-X
were	B-X
activated	B-X
following	B-X
more	B-X
severe	B-X
hypoxia	B-X
(	B-X
10	B-X
%	B-X
and	B-X
8	B-X
%	B-X
O2	B-X
)	B-X
.	B-X
A	B-X
large	B-X
proportion	B-X
(	B-X
89	B-X
±	B-X
3	B-X
%	B-X
)	B-X
of	B-X
all	B-X
activated	B-X
PVN-projecting	B-X
CVLM	B-X
neurons	B-X
were	B-X
catecholaminergic	B-X
,	B-X
regardless	B-X
of	B-X
hypoxia	B-X
intensity	B-X
.	B-X

Cell	O
counts	O
were	O
performed	O
by	O
two	O
different	O
investigators	O
who	O
were	O
blind	O
to	O
the	O
classification	O
of	O
tissues	O
.	O

SE	O
-	O
induced	O
PC	O
atrophy	O
is	O
evident	O
[	O
8	O
]	O
,	O
so	O
changes	O
in	O
cell	O
number	O
may	O
be	O
caused	O
by	O
an	O
alterations	O
in	O
the	O
volume	O
of	O
the	O
PC	O
.	O

Therefore	O
,	O
the	O
total	O
number	O
of	O
cells	O
was	O
corrected	O
by	O
multiplying	O
with	O
appropriate	O
correction	O
factors	O
(	O
CF	O
)	O
representing	O
the	O
degree	O
of	O
shrinkage	O
(	O
or	O
swelling	O
)	O
compared	O
with	O
the	O
Non	O
-	O
SE	O
.	O

Quantification	O
of	O
data	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
performed	B-X
meta-analysis	B-X
using	B-X
public	B-X
RNA-seq	B-X
data	B-X
from	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
and	B-X
show	B-X
that	B-X
IR	B-X
can	B-X
impact	B-X
TEs	B-X
quantification	B-X
using	B-X
established	B-X
tools	B-X
with	B-X
default	B-X
parameters	B-X
.	B-X
We	B-X
confirmed	B-X
these	B-X
results	B-X
using	B-X
additional	B-X
independent	B-X
datasets	B-X
,	B-X
demonstrating	B-X
that	B-X
this	B-X
bias	B-X
does	B-X
not	B-X
appear	B-X
in	B-X
samples	B-X
where	B-X
IR	B-X
is	B-X
not	B-X
present	B-X
and	B-X
that	B-X
differential	B-X
TEs	B-X
expression	B-X
does	B-X
not	B-X
impact	B-X
on	B-X
IR	B-X
quantification	B-X
.	B-X
Our	B-X
results	B-X
should	B-X
be	B-X
taken	B-X
into	B-X
account	B-X
for	B-X
a	B-X
correct	B-X
quantification	B-X
of	B-X
TEs	B-X
expression	B-X
from	B-X
RNA-seq	B-X
data	B-X
,	B-X
especially	B-X
in	B-X
samples	B-X
in	B-X
which	B-X
IR	B-X
is	B-X
abundant	B-X
.	B-X
This	B-X
paper	B-X
presents	B-X
data	B-X
on	B-X
the	B-X
optimization	B-X
and	B-X
validation	B-X
of	B-X
an	B-X
RP-HPLC-PDA	B-X
method	B-X
for	B-X
quantification	B-X
of	B-X
30	B-X
phenolic	B-X
constituents	B-X
of	B-X
the	B-X
blackthorn	B-X
(	B-X

The	O
fluorescence	O
intensities	O
of	O
SMI	O
-	O
71	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
or	O
GFPA	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
were	O
measured	O
using	O
a	O
computer	O
-	O
assisted	O
image	O
analysis	O
program	O
(	O
The	O
University	O
of	O
Texas	O
ImageTool	O
program	O
V	O
.	O
3	O
.	O
0	O
and	O
AxioVision	O
Rel	O
.	O
4	O
.	O
8	O
software	O
)	O
.	O

After	O
regions	O
were	O
outlined	O
,	O
30	O
areas	O
/	O
rat	O
(	O
300	O
mum2	O
/	O
area	O
)	O
were	O
randomly	O
selected	O
within	O
the	O
PC	O
,	O
and	O
double	O
immunofluorescent	O
merge	O
images	O
were	O
captured	O
from	O
the	O
PC	O
(	O
15	O
sections	O
from	O
each	O
animal	O
)	O
.	O

Merge	O
images	O
were	O
digitally	O
separated	O
to	O
red	O
or	O
green	O
image	O
,	O
and	O
converted	O
to	O
grayscale	O
images	O
,	O
respectively	O
(	O
n	O
=	O
36	O
per	O
region	O
examined	O
,	O
in	O
non	O
-	O
SE	O
,	O
12	O
hr	O
post	O
-	O
SE	O
and	O
1	O
day	O
post	O
-	O
SE	O
)	O
.	O
<EOS>	B-X
Digital	B-X
images	B-X
used	B-X
in	B-X
the	B-X
field	B-X
of	B-X
ophthalmology	B-X
are	B-X
among	B-X
the	B-X
most	B-X
important	B-X
methods	B-X
for	B-X
automatic	B-X
detection	B-X
of	B-X
certain	B-X
eye	B-X
diseases	B-X
.	B-X
These	B-X
processes	B-X
include	B-X
image	B-X
enhancement	B-X
as	B-X
a	B-X
primary	B-X
step	B-X
to	B-X
assist	B-X
optometrists	B-X
in	B-X
identifying	B-X
diseases	B-X
.	B-X
Therefore	B-X
,	B-X
many	B-X
algorithms	B-X
and	B-X
methods	B-X
have	B-X
been	B-X
developed	B-X
for	B-X
the	B-X
enhancement	B-X
of	B-X
retinal	B-X
fundus	B-X
images	B-X
,	B-X
which	B-X
may	B-X
experience	B-X
challenges	B-X
that	B-X
typically	B-X
accompany	B-X
enhancement	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
artificial	B-X
borders	B-X
and	B-X
dim	B-X
lighting	B-X
that	B-X
mask	B-X
image	B-X
details	B-X
.	B-X
To	B-X
eliminate	B-X
these	B-X
problems	B-X
,	B-X
a	B-X
new	B-X
algorithm	B-X
is	B-X
proposed	B-X
in	B-X
this	B-X
paper	B-X
based	B-X
on	B-X
separating	B-X
colour	B-X
images	B-X
into	B-X
three	B-X
channels	B-X
(	B-X
red	B-X
,	B-X
green	B-X
,	B-X
and	B-X
blue	B-X
)	B-X
.	B-X
The	B-X
green	B-X
channel	B-X
is	B-X
passed	B-X
through	B-X
a	B-X
Wiener	B-X
filter	B-X
and	B-X
reinforced	B-X
using	B-X
the	B-X
CLAHE	B-X
technique	B-X
before	B-X
merging	B-X
with	B-X
the	B-X
original	B-X
red	B-X
and	B-X
blue	B-X
channels	B-X
.	B-X
Reducing	B-X
the	B-X
green	B-X
channel	B-X
noise	B-X
with	B-X
this	B-X
approach	B-X
is	B-X
proven	B-X
effective	B-X
over	B-X
the	B-X
other	B-X
colour	B-X
channels	B-X
.	B-X
Results	B-X
from	B-X
the	B-X
Contrast	B-X
Improvement	B-X
Index	B-X
(	B-X
CII	B-X
)	B-X
and	B-X
linear	B-X
index	B-X
of	B-X
fuzziness	B-X
(	B-X
r	B-X
)	B-X
test	B-X
indicate	B-X
the	B-X
success	B-X
of	B-X
the	B-X
proposed	B-X
algorithm	B-X
compared	B-X
with	B-X
alternate	B-X
algorithms	B-X
in	B-X
the	B-X
application	B-X
of	B-X
improving	B-X
blood	B-X
vessel	B-X
imagery	B-X
and	B-X
other	B-X
details	B-X
within	B-X
ten	B-X
test	B-X
fundus	B-X
images	B-X
selected	B-X
from	B-X
the	B-X
DRIVER	B-X
database	B-X
.	B-X

The	O
range	O
of	O
intensity	O
values	O
was	O
obtained	O
from	O
the	O
selected	O
images	O
.	O
<EOS>	B-X
Multidimensional	B-X
MRI	B-X
is	B-X
an	B-X
emerging	B-X
approach	B-X
that	B-X
combines	B-X
T1	B-X
,	B-X
T2	B-X
,	B-X
and	B-X
diffusion	B-X
,	B-X
and	B-X
replaces	B-X
voxel-averaged	B-X
values	B-X
with	B-X
distributions	B-X
,	B-X
which	B-X
allows	B-X
selective	B-X
isolation	B-X
of	B-X
specific	B-X
potential	B-X
abnormal	B-X
components	B-X
.	B-X
A	B-X
robust	B-X
image	B-X
co-registration	B-X
method	B-X
was	B-X
applied	B-X
to	B-X
accurately	B-X
match	B-X
MRI-derived	B-X
parameters	B-X
and	B-X
histopathology	B-X
,	B-X
after	B-X
which	B-X
12	B-X
regions	B-X
of	B-X
interest	B-X
per	B-X
tissue	B-X
block	B-X
were	B-X
selected	B-X
based	B-X
on	B-X
APP	B-X
density	B-X
,	B-X
but	B-X
blind	B-X
to	B-X
MRI	B-X
.	B-X
We	B-X
identified	B-X
abnormal	B-X
multidimensional	B-X
T1-T2	B-X
,	B-X
diffusion-T2	B-X
,	B-X
and	B-X
diffusion-T1	B-X
components	B-X
that	B-X
are	B-X
strongly	B-X
associated	B-X
with	B-X
DAI	B-X
and	B-X
used	B-X
them	B-X
to	B-X
generate	B-X
axonal	B-X
injury	B-X
images	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
abnormal	B-X
T1-T2	B-X
,	B-X
diffusion-T1	B-X
,	B-X
and	B-X
diffusion-T2	B-X
components	B-X
and	B-X
their	B-X
axonal	B-X
damage	B-X
images	B-X
were	B-X
strongly	B-X
correlated	B-X
with	B-X
quantitative	B-X
APP	B-X
staining	B-X
(	B-X
r	B-X
=	B-X
0.876	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
;	B-X
r	B-X
=	B-X
0.727	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
;	B-X
and	B-X
r	B-X
=	B-X
0.743	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
while	B-X
producing	B-X
negligible	B-X
intensities	B-X
in	B-X
grey	B-X
matter	B-X
and	B-X
in	B-X
normal-appearing	B-X
white	B-X
matter	B-X
.	B-X

Based	O
on	O
the	O
mean	O
range	O
of	O
intensity	O
values	O
,	O
each	O
image	O
was	O
normalized	O
by	O
adjusting	O
the	O
black	O
and	O
white	O
range	O
of	O
the	O
image	O
.	O

Manipulation	O
of	O
the	O
images	O
was	O
restricted	O
to	O
threshold	O
and	O
brightness	O
adjustments	O
to	O
the	O
whole	O
image	O
.	O

Intensity	O
measurements	O
are	O
represented	O
as	O
the	O
mean	O
number	O
of	O
a	O
256	O
gray	O
scale	O
(	O
NIH	O
Image	O
1	O
.	O
59	O
software	O
and	O
AxioVision	O
Rel	O
.	O
4	O
.	O
8	O
software	O
)	O
.	O

Values	O
for	O
background	O
staining	O
were	O
obtained	O
from	O
the	O
corpus	O
callosum	O
.	O
<EOS>	B-X
The	B-X
corpus	B-X
callosum	B-X
is	B-X
a	B-X
heterogeneous	B-X
white-matter	B-X
tract	B-X
that	B-X
connects	B-X
the	B-X
cerebral	B-X
hemispheres	B-X
.	B-X

Optical	O
density	O
values	O
were	O
then	O
corrected	O
by	O
subtracting	O
the	O
average	O
values	O
of	O
background	O
noise	O
obtained	O
from	O
15	O
image	O
inputs	O
.	O

Data	O
analysis	O
<EOS>	B-X
Downstream	B-X
analysis	B-X
tools	B-X
formulate	B-X
spatial	B-X
organization	B-X
and	B-X
cell-cell	B-X
communications	B-X
as	B-X
quantifiable	B-X
properties	B-X
,	B-X
and	B-X
provide	B-X
algorithms	B-X
to	B-X
derive	B-X
such	B-X
properties	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
state	B-X
of	B-X
the	B-X
art	B-X
of	B-X
spatial	B-X
transcriptomic	B-X
data	B-X
analysis	B-X
methods	B-X
and	B-X
pipelines	B-X
,	B-X
and	B-X
discuss	B-X
how	B-X
they	B-X
operate	B-X
on	B-X
different	B-X
technological	B-X
platforms	B-X
.	B-X
To	B-X
better	B-X
deal	B-X
with	B-X
microarray	B-X
datasets	B-X
,	B-X
the	B-X
development	B-X
of	B-X
microarray	B-X
data	B-X
analysis	B-X
protocols	B-X
simple	B-X
to	B-X
use	B-X
as	B-X
well	B-X
as	B-X
able	B-X
to	B-X
produce	B-X
accurate	B-X
reports	B-X
,	B-X
and	B-X
comprehensible	B-X
results	B-X
arise	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
protocol	B-X
to	B-X
construct	B-X
an	B-X
RNA-Seq	B-X
library	B-X
for	B-X
sequencing	B-X
on	B-X
Illumina	B-X
NGS	B-X
platforms	B-X
and	B-X
a	B-X
computational	B-X
pipeline	B-X
to	B-X
perform	B-X
RNA-Seq	B-X
data	B-X
analysis	B-X
.	B-X
The	B-X
protocols	B-X
described	B-X
in	B-X
this	B-X
chapter	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
the	B-X
analysis	B-X
of	B-X
differential	B-X
gene	B-X
expression	B-X
in	B-X
control	B-X
versus	B-X
17β-estradiol	B-X
treatment	B-X
of	B-X
in	B-X
vivo	B-X
or	B-X
in	B-X
vitro	B-X
systems	B-X
.	B-X

Data	O
obtained	O
from	O
volumetric	O
analysis	O
,	O
cell	O
counts	O
,	O
and	O
quantitative	O
measurements	O
were	O
analyzed	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
to	O
determine	O
statistical	O
significance	O
.	O

Linear	O
regression	O
analysis	O
was	O
also	O
performed	O
to	O
determine	O
correlations	O
with	O
SMI	O
-	O
71	O
/	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
,	O
and	O
the	O
number	O
of	O
MPO	O
cells	O
/	O
vasogenic	O
edema	O
areas	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
TNF	O
receptor	O
expression	O
<EOS>	B-X
Tumor	B-X
Necrosis	B-X
Factor	B-X
(	B-X
TNF	B-X
)	B-X
is	B-X
a	B-X
potent	B-X
inflammatory	B-X
cytokine	B-X
that	B-X
exerts	B-X
its	B-X
functions	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
two	B-X
distinct	B-X
receptors	B-X
,	B-X
TNFR1	B-X
and	B-X
TNFR2	B-X
.	B-X
Both	B-X
receptors	B-X
can	B-X
activate	B-X
canonical	B-X
NF-κB	B-X
and	B-X
JNK	B-X
MAP	B-X
kinase	B-X
signaling	B-X
,	B-X
while	B-X
TNFR2	B-X
can	B-X
also	B-X
activate	B-X
non-canonical	B-X
NF-κB	B-X
signaling	B-X
,	B-X
leading	B-X
to	B-X
numerous	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
that	B-X
drive	B-X
inflammation	B-X
,	B-X
cell	B-X
proliferation	B-X
and	B-X
cell	B-X
survival	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
TNFR1	B-X
also	B-X
activates	B-X
signaling	B-X
pathways	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
by	B-X
either	B-X
apoptosis	B-X
or	B-X
necroptosis	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
cellular	B-X
context	B-X
.	B-X
A	B-X
key	B-X
player	B-X
in	B-X
TNFR1-	B-X
and	B-X
TNFR2-induced	B-X
signaling	B-X
is	B-X
the	B-X
RING	B-X
finger	B-X
protein	B-X
TRAF2	B-X
,	B-X
which	B-X
is	B-X
recruited	B-X
to	B-X
both	B-X
receptors	B-X
upon	B-X
their	B-X
stimulation	B-X
.	B-X
TRAF2	B-X
exerts	B-X
multiple	B-X
receptor-specific	B-X
functions	B-X
but	B-X
also	B-X
mediates	B-X
cross-talk	B-X
between	B-X
TNFR1	B-X
and	B-X
TNFR2	B-X
,	B-X
dictating	B-X
the	B-X
outcome	B-X
of	B-X
TNF	B-X
stimulation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
role	B-X
of	B-X
TRAF2	B-X
in	B-X
different	B-X
TNFR1	B-X
and	B-X
TNFR2	B-X
signaling	B-X
pathways	B-X
.	B-X

In	O
non	O
-	O
SE	O
induced	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
groups	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
was	O
weakly	O
detected	O
in	O
PC	O
neurons	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
most	O
of	O
the	O
activated	O
microglia	O
showed	O
strong	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
(	O
Figure	O
1A	O
)	O
.	O

This	O
expression	O
pattern	O
was	O
maintained	O
up	O
to	O
1	O
week	O
after	O
SE	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
16-week	B-X
progressive	B-X
high-intensity	B-X
strength	B-X
training	B-X
(	B-X
HIST	B-X
)	B-X
program	B-X
on	B-X
peripheral	B-X
markers	B-X
of	B-X
bone	B-X
turnover	B-X
(	B-X
bone	B-X
Gla	B-X
protein	B-X
,	B-X
BGP	B-X
;	B-X
bone	B-X
alkaline	B-X
phosphatase	B-X
,	B-X
B-AP	B-X
;	B-X
N-terminal	B-X
propeptide	B-X
of	B-X
type	B-X
I	B-X
procollagen	B-X
,	B-X
PINP	B-X
;	B-X
C-terminal	B-X
cross-linked	B-X
telopeptide	B-X
of	B-X
type	B-X
I	B-X
collagen	B-X
,	B-X
ICTP	B-X
)	B-X
in	B-X
healthy	B-X
,	B-X
elderly	B-X
men	B-X
over	B-X
65	B-X
yr	B-X
of	B-X
age	B-X
.	B-X
Thirty	B-X
healthy	B-X
men	B-X
(	B-X
aged	B-X
65-81	B-X
yr	B-X
)	B-X
,	B-X
performing	B-X
light	B-X
to	B-X
moderate	B-X
daily	B-X
physical	B-X
activity	B-X
,	B-X
were	B-X
randomly	B-X
divided	B-X
into	B-X
two	B-X
groups	B-X
.	B-X
Group	B-X
1	B-X
(	B-X
no.=16	B-X
)	B-X
followed	B-X
a	B-X
supervised	B-X
16-week	B-X
progressive	B-X
HIST	B-X
program	B-X
,	B-X
while	B-X
subjects	B-X
of	B-X
group	B-X
2	B-X
(	B-X
no.=14	B-X
)	B-X
,	B-X
used	B-X
as	B-X
controls	B-X
,	B-X
were	B-X
requested	B-X
to	B-X
maintain	B-X
their	B-X
habitual	B-X
level	B-X
of	B-X
physical	B-X
activity	B-X
for	B-X
16	B-X
weeks	B-X
.	B-X
Three	B-X
sessions/	B-X
week	B-X
,	B-X
during	B-X
which	B-X
10	B-X
repetitions	B-X
of	B-X
each	B-X
exercise	B-X
set	B-X
were	B-X
completed	B-X
,	B-X
were	B-X
performed	B-X
.	B-X
Lower	B-X
limb	B-X
exercises	B-X
shifted	B-X
from	B-X
50	B-X
to	B-X
80	B-X
%	B-X
of	B-X
the	B-X
one	B-X
maximal	B-X
repetition	B-X
(	B-X
1	B-X
MR	B-X
)	B-X
during	B-X
the	B-X
first	B-X
month	B-X
of	B-X
the	B-X
protocol	B-X
and	B-X
were	B-X
thereafter	B-X
maintained	B-X
at	B-X
an	B-X
intensity	B-X
of	B-X
80	B-X
%	B-X
1	B-X
MR	B-X
throughout	B-X
the	B-X
training	B-X
.	B-X
Upper	B-X
limb	B-X
exercises	B-X
shifted	B-X
from	B-X
40	B-X
to	B-X
65	B-X
%	B-X
of	B-X
1	B-X
MR	B-X
with	B-X
a	B-X
similar	B-X
pattern	B-X
.	B-X
All	B-X
sessions	B-X
were	B-X
preceded	B-X
by	B-X
15	B-X
min	B-X
of	B-X
cycloergometer	B-X
exercise	B-X
at	B-X
50	B-X
%	B-X
of	B-X
maximal	B-X
oxygen	B-X
uptake	B-X
and	B-X
by	B-X
a	B-X
warm-up	B-X
of	B-X
15	B-X
repetitions	B-X
at	B-X
20	B-X
%	B-X
of	B-X
1	B-X
MR	B-X
of	B-X
each	B-X
exercise	B-X
set	B-X
.	B-X
The	B-X
HIST	B-X
program	B-X
did	B-X
not	B-X
significantly	B-X
change	B-X
BGP	B-X
(	B-X
mean	B-X
SE	B-X
,	B-X
before	B-X
:	B-X
15.6	B-X
+/-	B-X
1.2	B-X
microg/l	B-X
vs	B-X
after	B-X
:	B-X
16.0	B-X
+/-	B-X
1.2	B-X
microg/l	B-X
,	B-X
NS	B-X
)	B-X
and	B-X
PINP	B-X
levels	B-X
(	B-X
before	B-X
:	B-X
44.6	B-X
+/-	B-X
6.7	B-X
microg/l	B-X
vs	B-X
after	B-X
:	B-X
43.1	B-X
+/-	B-X
6.0	B-X
microg/l	B-X
,	B-X
NS	B-X
)	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
serum	B-X
B-AP	B-X
significantly	B-X
increased	B-X
(	B-X
before	B-X
:	B-X
50.2	B-X
+/-	B-X
6.1	B-X
IU/l	B-X
vs	B-X
after	B-X
:	B-X
62.3	B-X
+/-	B-X
7.0	B-X
lU/l	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
and	B-X
serum	B-X
ICTP	B-X
slightly	B-X
reduced	B-X
(	B-X
before	B-X
:	B-X
4.0	B-X
+/-	B-X
0.3	B-X
microg/l	B-X
vs	B-X
after	B-X
:	B-X
3.8	B-X
+/-	B-X
0.3	B-X
microg/l	B-X
,	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
When	B-X
bone	B-X
turnover	B-X
was	B-X
expressed	B-X
as	B-X
the	B-X
ratio	B-X
between	B-X
bone	B-X
formation	B-X
to	B-X
bone	B-X
resorption	B-X
(	B-X
B-AP/ICTP	B-X
ratio	B-X
)	B-X
,	B-X
a	B-X
significant	B-X
improvement	B-X
in	B-X
this	B-X
ratio	B-X
was	B-X
found	B-X
in	B-X
all	B-X
subjects	B-X
of	B-X
group	B-X
1	B-X
(	B-X
before	B-X
:	B-X
12.9	B-X
+/-	B-X
1.3	B-X
lU/microg	B-X
vs	B-X
after	B-X
:	B-X
17.3	B-X
+/-	B-X
1.5	B-X
IU/microg	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
while	B-X
no	B-X
significant	B-X
changes	B-X
were	B-X
observed	B-X
in	B-X
Group	B-X
2	B-X
.	B-X
No	B-X
significant	B-X
changes	B-X
of	B-X
BGP	B-X
,	B-X
PINP	B-X
,	B-X
B-AP	B-X
,	B-X
ICTP	B-X
,	B-X
B-AP-ICTP	B-X
ratio	B-X
and	B-X
IGF-I	B-X
levels	B-X
were	B-X
observed	B-X
in	B-X
controls	B-X
(	B-X
group	B-X
2	B-X
)	B-X
during	B-X
the	B-X
16	B-X
weeks	B-X
of	B-X
observation	B-X
.	B-X

In	O
non	O
-	O
SE	O
-	O
induced	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
groups	O
,	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
immunoreactivities	O
were	O
also	O
weakly	O
observed	O
in	O
astrocytes	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
TNFp55R	B-Protein
immunoreactivity	O
was	O
observed	O
in	O
astrocytes	O
(	O
Figure	O
1B	O
)	O
.	O

Unlike	O
TNFp55R	B-Protein
,	O
TNFp75R	B-Protein
immunoreactivity	O
was	O
detected	O
in	O
endothelial	O
cells	O
as	O
well	O
as	O
astrocytes	O
(	O
Figures	O
1C	O
-	O
E	O
)	O
.	O

One	O
day	O
to	O
1	O
week	O
after	O
SE	O
,	O
both	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
immunoreactivities	O
were	O
significantly	O
reduced	O
in	O
astrocytes	O
,	O
not	O
in	O
endothelial	O
cells	O
,	O
due	O
to	O
massive	O
astroglial	O
loss	O
(	O
data	O
not	O
shown	O
)	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
20	O
]	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
SE	O
-	O
induced	O
serum	O
-	O
protein	O
extravasation	O
and	O
neuronal	O
damage	O

In	O
our	O
previous	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
20	O
]	O
and	O
preliminary	O
data	O
,	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
were	O
noticeable	O
at	O
1	O
day	O
and	O
3	O
days	O
after	O
SE	O
,	O
respectively	O
.	O

Therefore	O
,	O
we	O
determined	O
that	O
3	O
days	O
after	O
SE	O
was	O
the	O
best	O
time	O
point	O
to	O
evaluate	O
the	O
effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
both	O
vasogenic	O
edema	O
and	O
neuronal	O
damages	O
induced	O
by	O
SE	O
.	O

In	O
saline	O
-	O
treated	O
animals	O
,	O
the	O
PC	O
was	O
stained	O
diffusely	O
with	O
anti	O
-	O
rat	O
IgG	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
volume	O
of	O
vasogenic	O
edema	O
was	O
17	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
mm3	O
(	O
Figure	O
2E	O
)	O
.	O

The	O
number	O
of	O
FJB	O
-	O
positive	O
neurons	O
in	O
the	O
PC	O
was	O
236	O
,	O
145	O
+	O
/	O
-	O
49	O
,	O
469	O
(	O
Figure	O
2B	O
)	O
.	O

In	O
sTNFp55R	B-Protein
-	O
treated	O
animals	O
,	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
was	O
attenuated	O
to	O
9	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
7	O
mm3	O
(	O
Figures	O
2C	O
and	O
2E	O
)	O
.	O

In	O
addition	O
,	O
the	O
number	O
of	O
FJB	O
-	O
positive	O
neurons	O
in	O
the	O
PC	O
was	O
89	O
,	O
138	O
+	O
/	O
-	O
5	O
,	O
698	O
(	O
Figures	O
2D	O
-	O
E	O
)	O
.	O

Thus	O
,	O
sTNFp55R	B-Protein
infusion	O
attenuated	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
compared	O
to	O
saline	O
-	O
infused	O
animals	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

NF	O
-	O
kappaB	O
phosphorylation	O
<EOS>	B-X
Nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
crucial	B-X
roles	B-X
in	B-X
inflammation	B-X
,	B-X
immunity	B-X
,	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
.	B-X
Activation	B-X
of	B-X
NF-kappaB	B-X
mainly	B-X
occurs	B-X
via	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
-mediated	B-X
phosphorylation	B-X
of	B-X
inhibitory	B-X
molecules	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
.	B-X
Optimal	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
target	B-X
genes	B-X
also	B-X
requires	B-X
phosphorylation	B-X
of	B-X
NF-kappaB	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
p65	B-X
,	B-X
within	B-X
their	B-X
transactivation	B-X
domain	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
kinases	B-X
in	B-X
response	B-X
to	B-X
distinct	B-X
stimuli	B-X
.	B-X
Whether	B-X
,	B-X
and	B-X
how	B-X
,	B-X
phosphorylation	B-X
modulates	B-X
the	B-X
function	B-X
of	B-X
other	B-X
NF-kappaB	B-X
and	B-X
IkappaB	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
B-cell	B-X
lymphoma	B-X
3	B-X
,	B-X
remains	B-X
unclear	B-X
.	B-X
The	B-X
identification	B-X
and	B-X
characterization	B-X
of	B-X
all	B-X
the	B-X
kinases	B-X
known	B-X
to	B-X
phosphorylate	B-X
NF-kappaB	B-X
and	B-X
IkappaB	B-X
proteins	B-X
are	B-X
described	B-X
here	B-X
.	B-X
Because	B-X
deregulation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
IkappaB	B-X
phosphorylations	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
chronic	B-X
inflammatory	B-X
diseases	B-X
and	B-X
cancer	B-X
,	B-X
newly	B-X
designed	B-X
drugs	B-X
targeting	B-X
these	B-X
constitutively	B-X
activated	B-X
signalling	B-X
pathways	B-X
represent	B-X
promising	B-X
therapeutic	B-X
tools	B-X
.	B-X

It	O
is	O
well	O
established	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
one	O
of	O
the	O
major	O
stimuli	O
toward	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
.	O

To	O
confirm	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
signaling	O
following	O
SE	O
,	O
we	O
performed	O
an	O
immunohistochemical	O
study	O
using	O
five	O
phospho	O
-	O
NF	O
-	O
kappaB	O
antibodies	O
.	O

Compared	O
to	O
non	O
-	O
SE	O
animals	O
(	O
data	O
not	O
shown	O
)	O
,	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
showed	O
p65	B-Protein
-	O
Ser276	O
,	O
p65	B-Protein
-	O
Ser311	O
,	O
p65	B-Protein
-	O
Ser529	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
in	O
astrocytes	O
(	O
not	O
endothelial	O
cells	O
)	O
.	O

sTNFp55R	B-Protein
infusion	O
effectively	O
reduced	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311	O
phosphorylation	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
,	O
while	O
it	O
could	O
not	O
affect	O
p65	B-Protein
-	O
Ser529	O
or	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
(	O
Figures	O
3	O
and	O
4A	O
)	O
.	O

In	O
contrast	O
,	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
was	O
increased	O
in	O
endothelial	O
cells	O
(	O
not	O
astrocytes	O
)	O
within	O
the	O
PC	O
of	O
saline	O
-	O
infused	O
animals	O
12	O
hr	O
after	O
SE	O
(	O
Figure	O
5A	O
)	O
.	O

In	O
addition	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
alleviated	O
SE	O
-	O
induced	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
,	O
compared	O
to	O
saline	O
infusion	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
5B	O
)	O
.	O

SMI	O
-	O
71	O
expression	O
<EOS>	B-X
Cardiovascular	B-X
risk	B-X
(	B-X
CVR	B-X
)	B-X
has	B-X
been	B-X
observed	B-X
to	B-X
be	B-X
higher	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
mental	B-X
illness	B-X
(	B-X
SMI	B-X
)	B-X
than	B-X
in	B-X
the	B-X
general	B-X
population	B-X
.	B-X
However	B-X
,	B-X
some	B-X
studies	B-X
suggest	B-X
that	B-X
CVR	B-X
is	B-X
not	B-X
equally	B-X
increased	B-X
in	B-X
different	B-X
subgroups	B-X
of	B-X
SMI	B-X
.	B-X
The	B-X
purposes	B-X
of	B-X
this	B-X
review	B-X
are	B-X
to	B-X
summarise	B-X
CVR	B-X
scores	B-X
of	B-X
SMI	B-X
patients	B-X
and	B-X
to	B-X
determine	B-X
the	B-X
differences	B-X
in	B-X
CVR	B-X
between	B-X
patients	B-X
with	B-X
different	B-X
SMIs	B-X
and	B-X
between	B-X
SMI	B-X
patients	B-X
and	B-X
the	B-X
control-population	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
the	B-X
up-regulation	B-X
of	B-X
laminin	B-X
expression	B-X
represents	B-X
the	B-X
astroglio-vascular	B-X
responses	B-X
to	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
in	B-X
the	B-X
rat	B-X
brain	B-X
to	B-X
better	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
vasogenic	B-X
edema	B-X
in	B-X
epileptogenic	B-X
insult	B-X
.	B-X
Laminin	B-X
expression	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
was	B-X
increased	B-X
3	B-X
days	B-X
and	B-X
4	B-X
days	B-X
after	B-X
SE	B-X
,	B-X
respectively	B-X
.	B-X
Laminin	B-X
expression	B-X
was	B-X
up-regulated	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
the	B-X
PC	B-X
with	B-X
concomitant	B-X
reduction	B-X
of	B-X
SMI-71	B-X
(	B-X
the	B-X
endothelial	B-X
barrier	B-X
antigen	B-X
)	B-X
expression	B-X
.	B-X
Four	B-X
weeks	B-X
after	B-X
SE	B-X
,	B-X
laminin	B-X
expression	B-X
was	B-X
reduced	B-X
in	B-X
vessels	B-X
showing	B-X
strong	B-X
SMI-71	B-X
expression	B-X
within	B-X
vasogenic	B-X
edema	B-X
lesion	B-X
.	B-X
Inhibition	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
formation	B-X
by	B-X
BQ788	B-X
effectively	B-X
prevented	B-X
laminin	B-X
over-expression	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
be	B-X
one	B-X
of	B-X
consequences	B-X
from	B-X
vasogenic	B-X
edema	B-X
rather	B-X
than	B-X
astroglial	B-X
loss	B-X
,	B-X
and	B-X
that	B-X
laminin	B-X
over-expression	B-X
may	B-X
promote	B-X
migration	B-X
of	B-X
astrocytes	B-X
to	B-X
damaged	B-X
or	B-X
newly	B-X
generated	B-X
vessels	B-X
to	B-X
repair	B-X
brain-blood	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
accompanied	B-X
by	B-X
the	B-X
reconstruction	B-X
of	B-X
endothelial	B-X
barrier	B-X
.	B-X

Previously	O
,	O
we	O
reported	O
that	O
SMI	O
-	O
71	O
(	O
an	O
endothelial	O
barrier	O
antigen	O
)	O
immunoreactivity	O
decreased	O
in	O
the	O
PC	O
1	O
day	O
after	O
SE	O
[	O
5	O
]	O
.	O

Similarly	O
,	O
in	O
1	O
day	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
,	O
loss	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
detected	O
in	O
layer	O
III	O
/	O
IV	O
of	O
the	O
PC	O
as	O
compared	O
to	O
non	O
-	O
SE	O
animals	O
(	O
Figures	O
4B	O
and	O
5C	O
-	O
E	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Thus	O
,	O
loss	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
correlated	O
with	O
volume	O
of	O
vasogenic	O
edema	O
following	O
SE	O
.	O

This	O
reduction	O
in	O
SMI	O
-	O
71	O
was	O
accompanied	O
by	O
increased	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
(	O
Figures	O
5C	O
-	O
D	O
)	O
.	O

Therefore	O
,	O
the	O
degree	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
inversely	O
correlated	O
to	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
-	O
0	O
.	O
6324	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
4C	O
)	O
.	O

In	O
addition	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
alleviated	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
and	O
preserved	O
SMI	O
-	O
71	O
immunoreactivity	O
in	O
endothelial	O
cells	O
following	O
SE	O
,	O
as	O
compared	O
to	O
saline	O
infusion	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figures	O
4A	O
-	O
B	O
,	O
5D	O
and	O
5F	O
)	O
.	O

Neutrophil	O
infiltration	O
<EOS>	B-X
Neutrophils	B-X
have	B-X
traditionally	B-X
been	B-X
thought	B-X
of	B-X
as	B-X
simple	B-X
foot	B-X
soldiers	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
with	B-X
a	B-X
restricted	B-X
set	B-X
of	B-X
pro-inflammatory	B-X
functions	B-X
.	B-X
Neutrophils	B-X
have	B-X
not	B-X
consistently	B-X
been	B-X
detected	B-X
in	B-X
exercise-injured	B-X
skeletal	B-X
muscle	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
neutrophil	B-X
infiltration	B-X
in	B-X
this	B-X
muscle	B-X
has	B-X
become	B-X
a	B-X
controversial	B-X
issue	B-X
.	B-X
level	B-X
,	B-X
uphill	B-X
or	B-X
downhill	B-X
running	B-X
,	B-X
eccentric	B-X
contractions	B-X
,	B-X
or	B-X
swimming	B-X
)	B-X
were	B-X
analysed	B-X
to	B-X
help	B-X
clarify	B-X
the	B-X
relationship	B-X
between	B-X
neutrophil	B-X
infiltration	B-X
and	B-X
exercise-induced	B-X
muscle	B-X
injury	B-X
.	B-X
Intramuscular	B-X
neutrophil	B-X
infiltration	B-X
was	B-X
present	B-X
in	B-X
85	B-X
%	B-X
and	B-X
55	B-X
%	B-X
of	B-X
the	B-X
animal	B-X
and	B-X
human	B-X
studies	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
no	B-X
consistent	B-X
relationship	B-X
between	B-X
the	B-X
potential	B-X
damaging	B-X
effect	B-X
of	B-X
the	B-X
exercise	B-X
type	B-X
and	B-X
neutrophil	B-X
infiltration	B-X
can	B-X
be	B-X
conclusively	B-X
established	B-X
from	B-X
these	B-X
studies	B-X
.	B-X
General	B-X
categories	B-X
of	B-X
methods	B-X
that	B-X
have	B-X
been	B-X
used	B-X
to	B-X
detect	B-X
neutrophil	B-X
infiltration	B-X
are	B-X
microscopy	B-X
,	B-X
myeloperoxidase	B-X
(	B-X
MPO	B-X
)	B-X
biochemical	B-X
assay	B-X
,	B-X
antibody	B-X
staining	B-X
and	B-X
white	B-X
blood	B-X
cell	B-X
radionuclide	B-X
imaging	B-X
.	B-X
Only	B-X
studies	B-X
employing	B-X
white	B-X
blood	B-X
cell	B-X
radionuclide	B-X
imaging	B-X
have	B-X
consistently	B-X
detected	B-X
neutrophil	B-X
infiltration	B-X
.	B-X
Research	B-X
recommendations	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
warranted	B-X
to	B-X
resolve	B-X
the	B-X
neutrophil	B-X
infiltration	B-X
controversy	B-X
.	B-X
The	B-X
first	B-X
approach	B-X
encompasses	B-X
(	B-X
i	B-X
)	B-X
studying	B-X
or	B-X
measuring	B-X
factors	B-X
that	B-X
could	B-X
influence	B-X
neutrophil	B-X
infiltration	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
using	B-X
quantitative	B-X
antibody	B-X
staining	B-X
analysis	B-X
(	B-X
in	B-X
all	B-X
studies	B-X
and	B-X
employing	B-X
a	B-X
panel	B-X
of	B-X
anti-neutrophil	B-X
antibodies	B-X
)	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
examining	B-X
the	B-X
relationship	B-X
between	B-X
fibre	B-X
morphological	B-X
changes	B-X
and	B-X
neutrophil	B-X
antigen	B-X
expression	B-X
;	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
developing	B-X
a	B-X
neutrophil	B-X
antibody-radionuclide	B-X
imaging	B-X
technique	B-X
.	B-X

Recent	O
studies	O
have	O
reported	O
that	O
neutrophils	O
infiltrate	O
the	O
brain	O
under	O
certain	O
pathological	O
conditions	O
[	O
26	O
]	O
.	O

Indeed	O
,	O
we	O
have	O
reported	O
massive	O
neutrophil	O
infiltration	O
in	O
layer	O
III	O
/	O
IV	O
of	O
the	O
PC	O
1	O
day	O
after	O
SE	O
[	O
20	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
1	O
day	O
-	O
post	O
-	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
showed	O
infiltration	O
of	O
MPO	O
-	O
positive	O
neutrophils	O
into	O
the	O
PC	O
.	O

Similarly	O
,	O
1	O
day	O
-	O
post	O
-	O
SE	O
animals	O
of	O
the	O
sTNFp55R	B-Protein
-	O
infused	O
group	O
showed	O
neutrophil	O
infiltration	O
into	O
the	O
PC	O
1	O
day	O
after	O
SE	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
number	O
of	O
neutrophils	O
/	O
area	O
in	O
the	O
PC	O
region	O
(	O
including	O
the	O
vasogenic	O
edema	O
region	O
and	O
the	O
non	O
-	O
vasogenic	O
edema	O
region	O
)	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
saline	O
-	O
infused	O
group	O
(	O
Figure	O
6D	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
neutrophil	O
infiltration	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
the	O
saline	O
-	O
and	O
sTNFp55R	B-Protein
-	O
infused	O
groups	O
(	O
Figure	O
6D	O
)	O
.	O

Furthermore	O
,	O
neutrophil	O
infiltration	O
showed	O
a	O
direct	O
proportion	O
to	O
the	O
area	O
of	O
vasogenic	O
edema	O
,	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
0	O
.	O
8631	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
6E	O
)	O
.	O

Therefore	O
,	O
our	O
findings	O
indicate	O
that	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
into	O
the	O
PC	O
may	O
be	O
correlated	O
to	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
vasogenic	O
edema	O
formation	O
.	O

MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
<EOS>	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
investigate	B-X
the	B-X
expressions	B-X
of	B-X
IL-6	B-X
,	B-X
MIP-2	B-X
,	B-X
and	B-X
MCP-5	B-X
,	B-X
as	B-X
biomarkers	B-X
in	B-X
relation	B-X
with	B-X
MeHg-induced	B-X
CNS	B-X
impairment	B-X
and	B-X
N-acetyl-L-cysteine	B-X
(	B-X
NAC	B-X
)	B-X
treatment	B-X
in	B-X
mice	B-X
,	B-X
as	B-X
well	B-X
as	B-X
histopathological	B-X
changes	B-X
of	B-X
brain	B-X
tissue	B-X
and	B-X
clinical	B-X
symptom	B-X
such	B-X
as	B-X
ataxia	B-X
.	B-X
MeHg	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
IL-6	B-X
,	B-X
MIP-2	B-X
,	B-X
and	B-X
MCP-5	B-X
in	B-X
the	B-X
serum	B-X
,	B-X
with	B-X
median	B-X
values	B-X
(	B-X
those	B-X
in	B-X
controls	B-X
)	B-X
of	B-X
55.06	B-X
(	B-X
9.44	B-X
)	B-X
,	B-X
15.94	B-X
(	B-X
9.30	B-X
)	B-X
,	B-X
and	B-X
458.91	B-X
(	B-X
239.91	B-X
)	B-X
mg/dl	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
a	B-X
statistical	B-X
significance	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
IL-6	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
MIP-2	B-X
and	B-X
MCP-5	B-X
expressions	B-X
tended	B-X
to	B-X
increase	B-X
in	B-X
the	B-X
cerebrum	B-X
of	B-X
MeHg-treated	B-X
group	B-X
compared	B-X
with	B-X
controls	B-X
;	B-X
however	B-X
,	B-X
the	B-X
difference	B-X
was	B-X
not	B-X
statistically	B-X
significant	B-X
.	B-X
MeHg	B-X
treatment	B-X
also	B-X
increased	B-X
IL-6	B-X
expression	B-X
in	B-X
the	B-X
cerebellum	B-X
(	B-X
7.73	B-X
and	B-X
4.81	B-X
mg/dl	B-X
in	B-X
MeHg-treated	B-X
group	B-X
and	B-X
controls	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
with	B-X
a	B-X
marginal	B-X
significance	B-X
.	B-X
NAC	B-X
significantly	B-X
suppressed	B-X
MeHg-induced	B-X
IL-6	B-X
and	B-X
MIP-2	B-X
expressions	B-X
in	B-X
the	B-X
serum	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
for	B-X
both	B-X
)	B-X
,	B-X
and	B-X
slightly	B-X
reduced	B-X
MCP-5	B-X
expression	B-X
in	B-X
the	B-X
cerebrum	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
MeHg	B-X
induced	B-X
neurotoxicity	B-X
by	B-X
elevating	B-X
the	B-X
expression	B-X
of	B-X
IL-6	B-X
,	B-X
MIP-2	B-X
,	B-X
and	B-X
MCP-5	B-X
and	B-X
causing	B-X
ataxia	B-X
symptoms	B-X
,	B-X
and	B-X
NAC	B-X
reduced	B-X
MeHg-mediated	B-X
effects	B-X
on	B-X
the	B-X
CNS	B-X
.	B-X

MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
a	O
powerful	O
chemokine	B-Protein
that	O
contributes	O
to	O
recruitment	O
of	O
neutrophils	O
[	O
27	O
]	O
.	O

MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
undetectable	O
or	O
present	O
at	O
low	O
levels	O
under	O
physiological	O
conditions	O
,	O
and	O
shows	O
transient	O
increases	O
under	O
pathological	O
conditions	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
/	O
or	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
-	O
dependent	O
mechanisms	O
[	O
14	O
]	O
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
IL-1β	B-X
release	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
elusive	B-X
.	B-X
It	B-X
does	B-X
not	B-X
follow	B-X
the	B-X
conventional	B-X
ER-Golgi	B-X
route	B-X
of	B-X
secretion	B-X
.	B-X
Here	B-X
we	B-X
summarise	B-X
these	B-X
observations	B-X
and	B-X
propose	B-X
that	B-X
secretion	B-X
of	B-X
IL-1β	B-X
occurs	B-X
on	B-X
a	B-X
continuum	B-X
,	B-X
dependent	B-X
upon	B-X
stimulus	B-X
strength	B-X
and	B-X
the	B-X
extracellular	B-X
IL-1β	B-X
requirement	B-X
.	B-X

Thus	O
,	O
it	O
would	O
be	O
plausible	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
may	O
provoke	O
SE	O
-	O
induced	O
neutrophil	O
infiltrations	O
.	O

To	O
confirm	O
this	O
hypothesis	O
,	O
we	O
investigated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
the	O
PC	O
.	O

Consistent	O
with	O
our	O
previous	O
study	O
[	O
20	O
]	O
,	O
some	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
astrocytes	O
were	O
observed	O
in	O
the	O
core	O
and	O
periphery	O
of	O
the	O
vasogenic	O
edema	O
lesions	O
,	O
but	O
not	O
in	O
the	O
non	O
-	O
vasogenic	O
edema	O
region	O
(	O
Figure	O
6B	O
and	O
6C	O
)	O
.	O

Although	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
in	O
the	O
PC	O
region	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
saline	O
-	O
infused	O
group	O
due	O
to	O
reduction	O
of	O
the	O
area	O
of	O
vasogenic	O
edema	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
and	O
saline	O
-	O
infused	O
animals	O
(	O
Figure	O
6F	O
)	O
.	O

Furthermore	O
,	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
cells	O
showed	O
a	O
direct	O
proportion	O
to	O
the	O
unit	O
area	O
of	O
vasogenic	O
edema	O
with	O
a	O
linear	O
coefficient	O
of	O
correlation	O
of	O
0	O
.	O
682	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figure	O
6G	O
)	O
.	O

Therefore	O
,	O
together	O
with	O
reduction	O
in	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
region	O
of	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
,	O
our	O
findings	O
provide	O
evidence	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
may	O
regulate	O
SE	O
-	O
induced	O
neutrophil	O
infiltration	O
at	O
least	O
in	O
the	O
PC	O
via	O
vasogenic	O
edema	O
formation	O
and	O
not	O
via	O
direct	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
astrocytes	O
.	O

The	O
major	O
findings	O
in	O
the	O
present	O
study	O
are	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
showed	O
cellular	O
specific	O
responses	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
in	O
the	O
PC	O
following	O
SE	O
,	O
which	O
may	O
be	O
related	O
to	O
vasogenic	O
edema	O
formation	O
followed	O
by	O
neutrophil	O
infiltration	O
.	O

BBB	O
disruption	O
has	O
been	O
reported	O
in	O
experimental	O
and	O
human	O
epilepsy	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O
<EOS>	B-X
Blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
dysfunction	B-X
is	B-X
associated	B-X
with	B-X
worse	B-X
epilepsy	B-X
outcomes	B-X
however	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
of	B-X
BBB	B-X
dysfunction	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
Tight	B-X
junction	B-X
proteins	B-X
are	B-X
important	B-X
regulators	B-X
of	B-X
BBB	B-X
integrity	B-X
and	B-X
in	B-X
particular	B-X
,	B-X
the	B-X
tight	B-X
junction	B-X
protein	B-X
claudin-5	B-X
is	B-X
the	B-X
most	B-X
enriched	B-X
in	B-X
brain	B-X
endothelial	B-X
cells	B-X
and	B-X
regulates	B-X
size-selectivity	B-X
at	B-X
the	B-X
BBB	B-X
.	B-X
Additionally	B-X
,	B-X
disruption	B-X
of	B-X
claudin-5	B-X
expression	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
numerous	B-X
disorders	B-X
including	B-X
schizophrenia	B-X
,	B-X
depression	B-X
and	B-X
traumatic	B-X
brain	B-X
injury	B-X
,	B-X
yet	B-X
its	B-X
role	B-X
in	B-X
epilepsy	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
deciphered	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
claudin-5	B-X
protein	B-X
levels	B-X
are	B-X
significantly	B-X
diminished	B-X
in	B-X
surgically	B-X
resected	B-X
brain	B-X
tissue	B-X
from	B-X
patients	B-X
with	B-X
treatment-resistant	B-X
epilepsy	B-X
.	B-X
Concomitantly	B-X
,	B-X
dynamic	B-X
contrast-enhanced	B-X
MRI	B-X
in	B-X
these	B-X
patients	B-X
showed	B-X
widespread	B-X
BBB	B-X
disruption	B-X
.	B-X
We	B-X
show	B-X
that	B-X
targeted	B-X
disruption	B-X
of	B-X
claudin-5	B-X
in	B-X
the	B-X
hippocampus	B-X
or	B-X
genetic	B-X
heterozygosity	B-X
of	B-X
claudin-5	B-X
in	B-X
mice	B-X
exacerbates	B-X
kainic	B-X
acid-induced	B-X
seizures	B-X
and	B-X
BBB	B-X
disruption	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
identify	B-X
that	B-X
RepSox	B-X
,	B-X
a	B-X
regulator	B-X
of	B-X
claudin-5	B-X
expression	B-X
,	B-X
can	B-X
prevent	B-X
seizure	B-X
activity	B-X
in	B-X
experimental	B-X
epilepsy	B-X
.	B-X
Altogether	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
BBB	B-X
stabilizing	B-X
drugs	B-X
could	B-X
represent	B-X
a	B-X
new	B-X
generation	B-X
of	B-X
agents	B-X
to	B-X
prevent	B-X
seizure	B-X
activity	B-X
in	B-X
epilepsy	B-X
patients	B-X
.	B-X

Leakage	O
of	O
serum	O
-	O
derived	O
components	O
into	O
the	O
extracellular	O
space	O
is	O
associated	O
with	O
hyperexcitability	O
and	O
seizure	O
onset	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O

Furthermore	O
,	O
dysfunction	O
of	O
the	O
BBB	O
leads	O
to	O
epileptogenesis	O
and	O
contributes	O
to	O
progression	O
of	O
epilepsy	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
16	O
,	O
28	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
was	O
obviously	O
observed	O
in	O
microglia	O
in	O
the	O
PC	O
following	O
SE	O
.	O

TNF	O
receptor	O
expressions	O
were	O
also	O
up	O
-	O
regulated	O
in	O
astrocytes	O
(	O
TNFp55R	B-Protein
and	O
TNFp75R	B-Protein
)	O
and	O
endothelial	O
cells	O
(	O
TNFp75R	B-Protein
)	O
.	O

Furthermore	O
,	O
blockade	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
by	O
sTNFp55	B-Protein
infusion	O
effectively	O
(	O
but	O
not	O
completely	O
)	O
reduced	O
volumes	O
of	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
in	O
the	O
PC	O
.	O

These	O
findings	O
indicate	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
may	O
participate	O
in	O
astroglial	O
and	O
endothelial	O
responses	O
to	O
SE	O
,	O
which	O
are	O
relevant	O
to	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
formation	O
[	O
5	O
-	O
8	O
]	O
.	O

Indeed	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
increases	O
BBB	O
permeability	O
in	O
various	O
experimental	O
disease	O
models	O
[	O
29	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
sTNFp55	B-Protein
infusion	O
could	O
not	O
completely	O
prevent	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
in	O
the	O
PC	O
.	O

Therefore	O
,	O
our	O
findings	O
suggest	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
signaling	O
may	O
not	O
be	O
a	O
unique	O
upstream	O
event	O
in	O
vasogenic	O
edema	O
development	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
a	B-X
greater	B-X
understanding	B-X
of	B-X
TME	B-X
networks	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
cancer	B-X
therapies	B-X
.	B-X
Furthermore	B-X
,	B-X
tumor-infiltrating	B-X
inflammatory	B-X
cells	B-X
secrete	B-X
various	B-X
cytokines	B-X
,	B-X
including	B-X
TNF-α	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
TNF-α	B-X
in	B-X
TGF-β-induced	B-X
EndMT	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
TNF-α	B-X
on	B-X
TGF-β-induced	B-X
EndMT	B-X
in	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
ECs	B-X
)	B-X
.	B-X
Various	B-X
types	B-X
of	B-X
human	B-X
ECs	B-X
underwent	B-X
EndMT	B-X
in	B-X
response	B-X
to	B-X
TGF-β	B-X
and	B-X
TNF-α	B-X
,	B-X
which	B-X
was	B-X
accompanied	B-X
by	B-X
increased	B-X
and	B-X
decreased	B-X
expression	B-X
of	B-X
mesenchymal	B-X
cell	B-X
and	B-X
EC	B-X
markers	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
treatment	B-X
of	B-X
ECs	B-X
with	B-X
TGF-β	B-X
and	B-X
TNF-α	B-X
exhibited	B-X
sustained	B-X
activation	B-X
of	B-X
Smad2/3	B-X
signals	B-X
,	B-X
which	B-X
was	B-X
presumably	B-X
induced	B-X
by	B-X
elevated	B-X
expression	B-X
of	B-X
TGF-β	B-X
type	B-X
I	B-X
receptor	B-X
,	B-X
TGF-β2	B-X
,	B-X
activin	B-X
A	B-X
,	B-X
and	B-X
integrin	B-X
αv	B-X
,	B-X
suggesting	B-X
that	B-X
TNF-α	B-X
enhanced	B-X
TGF-β-induced	B-X
EndMT	B-X
by	B-X
augmenting	B-X
TGF-β	B-X
family	B-X
signals	B-X
.	B-X
Furthermore	B-X
,	B-X
oral	B-X
squamous	B-X
cell	B-X
carcinoma-derived	B-X
cells	B-X
underwent	B-X
epithelial-to-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
in	B-X
response	B-X
to	B-X
humoral	B-X
factors	B-X
produced	B-X
by	B-X
TGF-β	B-X
and	B-X
TNF-α-cultured	B-X
ECs	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
TNF-α	B-X
enhances	B-X
TGF-β-dependent	B-X
EndMT	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
tumor	B-X
progression	B-X
.	B-X

p65	B-Protein
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
enhances	O
its	O
transactivation	O
potential	O
,	O
and	O
p65	B-Protein
phosphorylation	O
occurs	O
in	O
either	O
the	O
cytoplasm	O
or	O
the	O
nucleus	O
[	O
30	O
]	O
.	O
<EOS>	B-X
The	B-X
nucleus	B-X
is	B-X
the	B-X
largest	B-X
and	B-X
stiffest	B-X
cellular	B-X
organelle	B-X
and	B-X
a	B-X
mechanical	B-X
obstacle	B-X
for	B-X
migration	B-X
through	B-X
constrictions	B-X
.	B-X
However	B-X
,	B-X
the	B-X
nucleus	B-X
is	B-X
also	B-X
essential	B-X
for	B-X
3D	B-X
cell	B-X
migration	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
nucleus	B-X
in	B-X
leukocyte	B-X
migration	B-X
,	B-X
focusing	B-X
on	B-X
how	B-X
cells	B-X
deform	B-X
their	B-X
nuclei	B-X
to	B-X
aid	B-X
cell	B-X
motility	B-X
and	B-X
the	B-X
contributions	B-X
of	B-X
the	B-X
nucleus	B-X
to	B-X
cell	B-X
migration	B-X
.	B-X
We	B-X
then	B-X
summarize	B-X
the	B-X
functions	B-X
of	B-X
nesprins	B-X
and	B-X
SUN	B-X
proteins	B-X
in	B-X
leukocytes	B-X
and	B-X
discuss	B-X
how	B-X
forces	B-X
are	B-X
exerted	B-X
on	B-X
the	B-X
nucleus	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
mechanical	B-X
roles	B-X
of	B-X
the	B-X
nucleus	B-X
in	B-X
cell	B-X
migration	B-X
,	B-X
including	B-X
its	B-X
roles	B-X
in	B-X
regulating	B-X
the	B-X
direction	B-X
of	B-X
migration	B-X
and	B-X
path	B-X
selection	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
p65	B-Protein
-	O
Thr435	O
immunoreactivity	O
was	O
detected	O
in	O
endothelial	O
cells	O
,	O
and	O
its	O
immunoreactivity	O
showed	O
an	O
inverse	O
correlation	O
to	O
the	O
degree	O
of	O
SMI	O
-	O
71	O
expression	O
.	O

SMI	O
-	O
71	O
,	O
an	O
endothelial	O
barrier	O
antigen	O
,	O
is	O
a	O
protein	O
expressed	O
by	O
endothelial	O
cells	O
of	O
rat	O
BBB	O
[	O
31	O
]	O
.	O

Under	O
pathological	O
conditions	O
,	O
SMI	O
-	O
71	O
expression	O
is	O
lost	O
in	O
endothelial	O
cells	O
[	O
5	O
,	O
7	O
,	O
8	O
,	O
30	O
,	O
32	O
]	O
.	O

Acute	O
phases	O
of	O
the	O
above	O
pathological	O
conditions	O
are	O
accompanied	O
by	O
opening	O
of	O
the	O
BBB	O
and	O
development	O
of	O
vasogenic	O
edema	O
[	O
33	O
]	O
.	O

Indeed	O
,	O
neutralization	O
of	O
SMI	O
-	O
71	O
in	O
vivo	O
leads	O
to	O
widening	O
of	O
intercellular	O
junctions	O
between	O
endothelial	O
cells	O
and	O
swelling	O
of	O
perivascular	O
astrocytic	O
processes	O
[	O
34	O
]	O
,	O
although	O
SMI	O
-	O
71	O
is	O
not	O
localized	O
at	O
endothelial	O
cell	O
junctions	O
[	O
35	O
-	O
38	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
SMI	O
-	O
71	O
immunoreactivity	O
was	O
significantly	O
reduced	O
in	O
blood	O
vessels	O
1	O
day	O
after	O
SE	O
when	O
vasogenic	O
edema	O
and	O
neuronal	O
damage	O
were	O
observed	O
.	O
<EOS>	B-X
Endothelin-1	B-X
(	B-X
ET-1	B-X
)	B-X
is	B-X
one	B-X
of	B-X
potential	B-X
factors	B-X
to	B-X
induce	B-X
vasogenic	B-X
edema	B-X
formation	B-X
,	B-X
since	B-X
exogenous	B-X
ET-1	B-X
treatment	B-X
decreases	B-X
aquaporin	B-X
4	B-X
(	B-X
AQP4	B-X
)	B-X
expression	B-X
and	B-X
increases	B-X
chemokines	B-X
induction	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
role	B-X
of	B-X
endogenous	B-X
ET-1	B-X
in	B-X
vasogenic	B-X
edema	B-X
formation	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
correlation	B-X
between	B-X
endogenous	B-X
ET-1	B-X
expression	B-X
and	B-X
vasogenic	B-X
edema	B-X
formation	B-X
in	B-X
the	B-X
pirifom	B-X
cortex	B-X
following	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
SMI-71	B-X
(	B-X
a	B-X
brain-blood	B-X
barrier	B-X
marker	B-X
)	B-X
immunoreactivity	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
blood	B-X
vessels	B-X
at	B-X
1	B-X
day	B-X
after	B-X
SE	B-X
when	B-X
vasogenic	B-X
edema	B-X
and	B-X
neuronal	B-X
damage	B-X
were	B-X
observed	B-X
.	B-X
ET-1	B-X
expression	B-X
was	B-X
up-regulated	B-X
in	B-X
endothelial	B-X
cells	B-X
prior	B-X
to	B-X
reduction	B-X
in	B-X
SMI-71	B-X
immunoreactivity	B-X
.	B-X
Furthermore	B-X
,	B-X
ET-1	B-X
expressing	B-X
endothelial	B-X
cells	B-X
showed	B-X
the	B-X
absence	B-X
of	B-X
SMI-71	B-X
immunoreactivity	B-X
.	B-X
Increase	B-X
in	B-X
ET-1	B-X
expression	B-X
was	B-X
followed	B-X
by	B-X
reduced	B-X
AQP4	B-X
immunoreactivity	B-X
prior	B-X
to	B-X
vasogenic	B-X
edema	B-X
formation	B-X
.	B-X
Only	B-X
a	B-X
few	B-X
microglia	B-X
showed	B-X
monocyte	B-X
chemotactic	B-X
protein-1	B-X
(	B-X
a	B-X
chemokine	B-X
induced	B-X
by	B-X
ET-1	B-X
)	B-X
outside	B-X
vasogenic	B-X
edema	B-X
lesion	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
suggest	B-X
that	B-X
endothelial	B-X
ET-1	B-X
expression	B-X
may	B-X
contribute	B-X
to	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
formation	B-X
via	B-X
brain-blood	B-X
barrier	B-X
disruption	B-X
at	B-X
AQP4/MCP-1	B-X
independent	B-X
manners	B-X
.	B-X

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
prevented	O
SE	O
-	O
induced	O
SMI	O
-	O
71	O
down	O
-	O
regulation	O
.	O

With	O
respect	O
to	O
the	O
phosphorylation	O
of	O
p65	B-Protein
-	O
Thr435	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
[	O
39	O
]	O
,	O
our	O
findings	O
indicate	O
that	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
vasogenic	O
edema	O
induction	O
via	O
SMI	O
-	O
71	O
degradation	O
or	O
its	O
posttranslational	O
dysfunction	O
influencing	O
BBB	O
permeability	O
.	O

In	O
our	O
previous	O
studies	O
[	O
5	O
,	O
8	O
]	O
,	O
dystrophin	B-Protein
(	O
an	O
actin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
[	O
40	O
]	O
)	O
immunoreactivity	O
was	O
detected	O
in	O
blood	O
vessels	O
and	O
in	O
astrocytic	O
perivascular	O
end	O
-	O
feet	O
,	O
and	O
was	O
down	O
-	O
regulated	O
12	O
hrs	O
after	O
SE	O
prior	O
to	O
the	O
appearance	O
of	O
vasogenic	O
edema	O
and	O
down	O
-	O
regulation	O
of	O
SMI	O
-	O
71	O
immunoreactivity	O
.	O

With	O
respect	O
to	O
this	O
previous	O
report	O
,	O
changes	O
in	O
SMI	O
immunoreactivity	O
would	O
be	O
causes	O
/	O
results	O
of	O
interaction	O
between	O
endothelial	O
cells	O
and	O
perivascular	O
astrocytes	O
.	O

In	O
the	O
present	O
study	O
,	O
p65	B-Protein
-	O
Ser276	O
,	O
p65	B-Protein
-	O
Ser311	O
,	O
p65	B-Protein
-	O
Ser529	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylation	O
was	O
observed	O
in	O
astrocytes	O
following	O
SE	O
.	O

Furthermore	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
inhibited	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311phosphorylation	O
in	O
astrocytes	O
following	O
SE	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
enhanced	O
p65	B-Protein
-	O
Ser276	O
and	O
p65	B-Protein
-	O
Ser311	O
phosphorylation	O
may	O
be	O
involved	O
in	O
TNF	B-Protein
-	O
alpha	O
-	O
mediated	O
BBB	O
disruption	O
.	O

However	O
,	O
sTNFp55R	B-Protein
infusion	O
could	O
not	O
prevent	O
p65	B-Protein
-	O
Ser529	O
and	O
p65	B-Protein
-	O
Ser536	O
phosphorylations	O
from	O
SE	O
insults	O
.	O
<EOS>	B-X
Clasmatodendritic	B-X
astrocytes	B-X
also	B-X
showed	B-X
p65/RelA-Ser529	B-X
phosphorylation	B-X
in	B-X
the	B-X
nuclei	B-X
.	B-X
The	B-X
neutralization	B-X
of	B-X
TNF-α	B-X
by	B-X
sTNFp55R	B-X
infusion	B-X
reduced	B-X
clasmatodendritic	B-X
astrocytes	B-X
with	B-X
nuclear	B-X
p65/RelA-Ser529	B-X
phosphorylation	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
clasmatodendrosis	B-X
may	B-X
be	B-X
autophagic	B-X
astroglial	B-X
death	B-X
in	B-X
response	B-X
to	B-X
epileptic	B-X
seizures	B-X
through	B-X
TNF-α-mediated	B-X
p65/RelA-Ser529	B-X
phosphorylation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
addressed	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
P2X7	B-X
receptor-mediated	B-X
TNF-α	B-X
regulation	B-X
is	B-X
involved	B-X
in	B-X
pathogenesis	B-X
and	B-X
outcome	B-X
of	B-X
status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
.	B-X

Since	O
p65	B-Protein
-	O
Ser529	O
and	O
p65	B-Protein
-	O
Ser536	O
are	O
phosphorylated	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
[	O
41	O
]	O
,	O
it	O
is	O
likely	O
that	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
mediated	O
p65	B-Protein
-	O
Ser529	O
/	O
Ser536	O
phosphorylation	O
may	O
also	O
play	O
a	O
role	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
.	O

Therefore	O
,	O
our	O
findings	O
indicate	O
that	O
both	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
may	O
be	O
synergists	O
to	O
play	O
either	O
a	O
direct	O
(	O
by	O
endothelial	O
cells	O
)	O
or	O
indirect	O
(	O
by	O
astrocytes	O
)	O
role	O
in	O
the	O
maintenance	O
of	O
BBB	O
permeability	O
.	O
<EOS>	B-X
Pial	B-X
microvessels	B-X
have	B-X
commonly	B-X
been	B-X
used	B-X
as	B-X
model	B-X
systems	B-X
for	B-X
studying	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
properties	B-X
instead	B-X
of	B-X
cerebral	B-X
cortical	B-X
microvessels	B-X
.	B-X
Measurements	B-X
of	B-X
electrical	B-X
resistance	B-X
across	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
their	B-X
barrier	B-X
properties	B-X
have	B-X
been	B-X
made	B-X
exclusively	B-X
from	B-X
pial	B-X
microvessels	B-X
in	B-X
in	B-X
vivo	B-X
BBB	B-X
studies	B-X
.	B-X
Similarly	B-X
the	B-X
observed	B-X
responses	B-X
of	B-X
microvessels	B-X
to	B-X
the	B-X
application	B-X
of	B-X
pharmacological	B-X
agents	B-X
have	B-X
commonly	B-X
been	B-X
made	B-X
on	B-X
pial	B-X
microvessels	B-X
as	B-X
representative	B-X
of	B-X
BBB	B-X
vasculature	B-X
.	B-X
In	B-X
this	B-X
review	B-X
the	B-X
properties	B-X
of	B-X
pial	B-X
and	B-X
cerebral	B-X
microvessels	B-X
are	B-X
compared	B-X
to	B-X
determine	B-X
whether	B-X
the	B-X
use	B-X
of	B-X
the	B-X
pial	B-X
microvessel	B-X
as	B-X
a	B-X
model	B-X
for	B-X
BBB	B-X
studies	B-X
is	B-X
valid	B-X
.	B-X
Similarities	B-X
are	B-X
described	B-X
in	B-X
their	B-X
ultrastructural	B-X
features	B-X
,	B-X
permeability	B-X
to	B-X
electron	B-X
dense	B-X
tracers	B-X
and	B-X
molecular	B-X
characteristics	B-X
.	B-X
Measurements	B-X
of	B-X
electrical	B-X
resistance	B-X
from	B-X
pial	B-X
microvessels	B-X
are	B-X
compared	B-X
with	B-X
measurements	B-X
from	B-X
cerebral	B-X
EC	B-X
monolayers	B-X
in	B-X
tissue	B-X
culture	B-X
and	B-X
indirect	B-X
determinations	B-X
for	B-X
cerebral	B-X
microvessels	B-X
in	B-X
situ	B-X
.	B-X
The	B-X
distribution	B-X
of	B-X
the	B-X
endothelial	B-X
barrier	B-X
antigen	B-X
(	B-X
EBA	B-X
)	B-X
is	B-X
uniform	B-X
between	B-X
EC	B-X
of	B-X
cerebral	B-X
microvessels	B-X
.	B-X
The	B-X
role	B-X
of	B-X
astrocytes	B-X
in	B-X
the	B-X
induction	B-X
and	B-X
maintenance	B-X
of	B-X
the	B-X
BBB	B-X
characteristics	B-X
is	B-X
briefly	B-X
reviewed	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
caution	B-X
is	B-X
urged	B-X
in	B-X
employing	B-X
pial	B-X
microvessels	B-X
in	B-X
BBB	B-X
studies	B-X
and	B-X
the	B-X
need	B-X
for	B-X
more	B-X
information	B-X
on	B-X
possible	B-X
pial	B-X
microvessel	B-X
heterogeneity	B-X
is	B-X
stressed	B-X
.	B-X

Neutrophil	O
infiltration	O
into	O
brain	O
parenchyma	O
is	O
transiently	O
observed	O
during	O
the	O
acute	O
phase	O
of	O
SE	O
(	O
4	O
-	O
36	O
hr	O
after	O
SE	O
)	O
and	O
disappears	O
thereafter	O
[	O
20	O
]	O
.	O

SE	O
rapidly	O
increases	O
synthesis	O
and	O
release	O
of	O
chemokines	O
in	O
various	O
areas	O
of	O
the	O
rodent	O
brain	O
[	O
42	O
]	O
.	O

Among	O
them	O
,	O
MIP	B-Protein
-	I-Protein
2	I-Protein
is	O
required	O
for	O
efficient	O
neutrophil	O
or	O
lymphocyte	O
recruitment	O
to	O
brain	O
parenchyma	O
[	O
43	O
]	O
.	O
<EOS>	B-X
Preclinical	B-X
and	B-X
clinical	B-X
research	B-X
has	B-X
demonstrated	B-X
that	B-X
inflammation	B-X
is	B-X
a	B-X
critical	B-X
factor	B-X
regulating	B-X
intracerebral	B-X
hemorrhage	B-X
(	B-X
ICH	B-X
)	B-X
-induced	B-X
brain	B-X
injury	B-X
.	B-X
Growing	B-X
evidence	B-X
suggests	B-X
that	B-X
myeloid	B-X
cells	B-X
and	B-X
lymphocytes	B-X
have	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
pathophysiological	B-X
processes	B-X
associated	B-X
with	B-X
ICH	B-X
,	B-X
such	B-X
as	B-X
inflammation	B-X
,	B-X
immune	B-X
responses	B-X
,	B-X
perihematomal	B-X
edema	B-X
formation	B-X
,	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
integrity	B-X
,	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
infiltrated	B-X
into	B-X
the	B-X
brain	B-X
parenchyma	B-X
after	B-X
ICH	B-X
.	B-X
Infiltrating	B-X
NK	B-X
cells	B-X
may	B-X
mediate	B-X
brain	B-X
injury	B-X
through	B-X
degranulation	B-X
and	B-X
recruitment	B-X
of	B-X
other	B-X
cells	B-X
.	B-X

In	O
our	O
previous	O
study	O
[	O
20	O
]	O
,	O
neutrophil	O
infiltration	O
in	O
the	O
frontoparietal	O
cortex	O
was	O
regulated	O
by	O
P2X7	B-Protein
receptor	I-Protein
-	O
mediated	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
.	O

In	O
the	O
PC	O
,	O
however	O
,	O
neither	O
a	O
P2X7	O
receptor	O
agonist	O
/	O
antagonist	O
nor	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
(	O
an	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
antagonist	I-Protein
)	O
infusion	O
could	O
not	O
affect	O
leukocyte	O
infiltration	O
.	O

In	O
the	O
present	O
study	O
,	O
sTNFp55R	B-Protein
infusion	O
effectively	O
inhibited	O
neutrophil	O
infiltration	O
in	O
the	O
PC	O
by	O
reducing	O
vasogenic	O
edema	O
formation	O
in	O
a	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
manner	O
.	O

With	O
respect	O
to	O
the	O
present	O
and	O
our	O
previous	O
reports	O
,	O
it	O
is	O
therefore	O
likely	O
that	O
vasogenic	O
edema	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
can	O
induce	O
neutrophil	O
infiltration	O
and	O
press	O
injury	O
to	O
evoke	O
neuronal	O
-	O
astroglial	O
loss	O
in	O
the	O
PC	O
,	O
unlike	O
other	O
brain	O
regions	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
reveal	O
that	O
impairments	O
of	O
endothelial	O
cell	O
function	O
via	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
mediated	O
p65	B-Protein
-	O
Thr	O
435	O
NF	O
-	O
kappaB	O
phosphorylation	O
may	O
be	O
involved	O
in	O
SE	O
-	O
induced	O
vasogenic	O
edema	O
,	O
which	O
is	O
relevant	O
to	O
neutrophil	O
infiltration	O
and	O
neuronal	O
-	O
astroglial	O
loss	O
.	O

Expression	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
TNF	O
receptor	O
in	O
the	O
PC	O
12	O
hr	O
-	O
post	O
SE	O
.	O

(	O
A	O
)	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
immunoreactivity	O
in	O
Ox	O
-	O
42	O
-	O
positive	O
microglia	O
(	O
arrows	O
)	O
.	O

(	O
B	O
)	O
TNFp55R	B-Protein
expression	O
in	O
astrocytes	O
(	O
arrows	O
)	O
.	O

(	O
C	O
-	O
D	O
)	O
TNFp75R	B-Protein
expression	O
in	O
astrocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

Bar	O
=	O
25	O
(	O
A	O
-	O
D	O
)	O
mum	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
SE	O
-	O
induced	O
serum	O
-	O
protein	O
extravasation	O
and	O
neuronal	O
damage	O
.	O

(	O
A	O
-	O
D	O
)	O
Serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damages	O
in	O
the	O
PC	O
3	O
days	O
after	O
SE	O
.	O

Compared	O
to	O
saline	O
-	O
infused	O
animals	O
,	O
serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damage	O
is	O
markedly	O
ameliorated	O
in	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
.	O

Bars	O
=	O
400	O
(	O
A	O
and	O
C	O
)	O
and	O
50	O
(	O
B	O
and	O
D	O
)	O
mum	O
.	O

(	O
E	O
)	O
Quantitative	O
analyses	O
of	O
serum	O
-	O
protein	O
extravasation	O
and	O
FJB	O
-	O
positive	O
neuronal	O
damage	O
in	O
the	O
PC	O
3	O
days	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
treated	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
in	O
astrocytes	O
12	O
hr	O
after	O
SE	O
.	O

In	O
12	O
hr	O
-	O
post	O
SE	O
animals	O
of	O
the	O
saline	O
-	O
infused	O
group	O
(	O
A	O
,	O
C	O
,	O
E	O
and	O
G	O
)	O
,	O
astrocytes	O
show	O
p65	B-Protein
-	O
Ser276	O
(	O
A	O
)	O
,	O
p65	B-Protein
-	O
Ser311	O
(	O
C	O
)	O
,	O
p65	B-Protein
-	O
Ser529	O
(	O
E	O
)	O
,	O
and	O
p65	B-Protein
-	O
Ser536	O
(	O
G	O
)	O
phosphorylation	O
(	O
arrows	O
)	O
.	O

sTNFp55R	B-Protein
infusion	O
(	O
B	O
,	O
D	O
,	O
F	O
and	O
H	O
)	O
effectively	O
reduces	O
p65	B-Protein
-	O
Ser276	O
(	O
B	O
)	O
and	O
p65	B-Protein
-	O
Ser311	O
(	O
D	O
)	O
phosphorylation	O
,	O
while	O
it	O
does	O
not	O
affect	O
p65	B-Protein
-	O
Ser529	O
(	O
F	O
)	O
and	O
p65	B-Protein
-	O
Ser536	O
(	O
H	O
)	O
phosphorylation	O
(	O
arrows	O
)	O
.	O

Bar	O
=	O
12	O
.	O
5	O
mum	O
.	O
<EOS>	B-X
We	B-X
used	B-X
BV2	B-X
cells	B-X
,	B-X
primary	B-X
microglia	B-X
,	B-X
Nrf2-KO	B-X
C57BL/6J	B-X
mice	B-X
,	B-X
and	B-X
autopsied	B-X
brain	B-X
tissues	B-X
of	B-X
METH-abusing	B-X
,	B-X
HIV	B-X
infection	B-X
,	B-X
and	B-X
METH-abusing	B-X
individuals	B-X
comorbid	B-X
with	B-X
HIV	B-X
to	B-X
explore	B-X
the	B-X
regulatory	B-X
role	B-X
of	B-X
Nrf2/NQO1/HO-1	B-X
signal	B-X
pathway	B-X
on	B-X
microglia	B-X
autophagy	B-X
.	B-X
METH	B-X
and	B-X
HIV-1Tat	B-X
protein	B-X
combination	B-X
significantly	B-X
increase	B-X
the	B-X
autophagy-related	B-X
proteins	B-X
(	B-X
LC3-II	B-X
,	B-X
Beclin-1	B-X
,	B-X
ATG5	B-X
,	B-X
and	B-X
ATG7	B-X
)	B-X
expression	B-X
in	B-X
microglia	B-X
and	B-X
striatum	B-X
of	B-X
C57BL/6J	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
MDPT-Zn	B-X
(	B-X
II	B-X
)	B-X
complex	B-X
was	B-X
50-fold	B-X
more	B-X
stable	B-X
than	B-X
the	B-X
MDP-Zn	B-X
(	B-X
II	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
MDPT	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
Cu	B-X
(	B-X
I	B-X
)	B-X
-catalyzed	B-X
Fenton	B-X
reaction	B-X
(	B-X
IC50	B-X
26	B-X
μM	B-X
)	B-X
2.5	B-X
times	B-X
more	B-X
potently	B-X
than	B-X
a	B-X
Fe	B-X
(	B-X
II	B-X
)	B-X
-catalyzed	B-X
Fenton	B-X
reaction	B-X
,	B-X
and	B-X
2.5	B-X
times	B-X
more	B-X
potently	B-X
than	B-X
EDTA	B-X
(	B-X
IC50	B-X
64	B-X
μM	B-X
)	B-X
in	B-X
the	B-X
Cu	B-X
(	B-X
I	B-X
)	B-X
/H2O2	B-X
system	B-X
,	B-X
as	B-X
monitored	B-X
by	B-X
electron	B-X
spin	B-X
resonance	B-X
(	B-X
ESR	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
MDPT	B-X
was	B-X
found	B-X
to	B-X
be	B-X
relatively	B-X
stable	B-X
in	B-X
both	B-X
acidic	B-X
(	B-X
pD	B-X
1.9	B-X
,	B-X
t	B-X
(	B-X
½	B-X
)	B-X
=	B-X
71.5	B-X
h	B-X
)	B-X
and	B-X
basic	B-X
media	B-X
(	B-X
pD	B-X
12.4	B-X
,	B-X
t	B-X
(	B-X
½	B-X
)	B-X
=	B-X
81	B-X
h	B-X
)	B-X
as	B-X
monitored	B-X
by	B-X
(	B-X
31	B-X
)	B-X
P/	B-X
(	B-X
1	B-X
)	B-X
H	B-X
NMR	B-X
.	B-X

Quantitative	O
analyses	O
of	O
the	O
effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
and	O
SMI	O
-	O
71	O
expression	O
.	O

(	O
A	O
)	O
Quantitative	O
analysis	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
12	O
hr	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
B	O
)	O
Quantitative	O
analysis	O
of	O
SMI	O
-	O
71	O
expression	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
C	O
)	O
Linear	O
regression	O
analysis	O
between	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
and	O
SMI	O
-	O
71	O
in	O
the	O
PC	O
following	O
SE	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
endothelial	O
cells	O
following	O
SE	O
.	O
<EOS>	B-X
Status	B-X
epilepticus	B-X
(	B-X
SE	B-X
)	B-X
induces	B-X
severe	B-X
vasogenic	B-X
edema	B-X
in	B-X
the	B-X
piriform	B-X
cortex	B-X
(	B-X
PC	B-X
)	B-X
accompanied	B-X
by	B-X
neuronal	B-X
and	B-X
astroglial	B-X
damages	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanism	B-X
of	B-X
SE-induced	B-X
vasogenic	B-X
edema	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
disruption	B-X
during	B-X
vasogenic	B-X
edema	B-X
and	B-X
its	B-X
related	B-X
events	B-X
in	B-X
rat	B-X
epilepsy	B-X
models	B-X
provoked	B-X
by	B-X
pilocarpine-induced	B-X
SE	B-X
.	B-X

(	O
A	O
-	O
B	O
)	O
Inhibition	O
of	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
by	O
sTNFp55R	B-Protein
infusion	O
12	O
hr	O
after	O
SE	O
.	O

p65	B-Protein
-	O
Thr435	O
phosphorylation	O
is	O
rarely	O
observed	O
in	O
astrocytes	O
(	O
arrows	O
)	O
.	O

(	O
C	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
non	O
-	O
SE	O
animals	O
.	O

(	O
D	O
-	O
E	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
saline	O
-	O
infused	O
animals	O
1	O
day	O
after	O
SE	O
.	O

p65	B-Protein
-	O
Thr435	O
phosphorylation	O
is	O
enhanced	O
,	O
while	O
SMI	O
-	O
71	O
expression	O
is	O
reduced	O
in	O
GLUT	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

(	O
F	O
-	O
G	O
)	O
Endothelial	O
p65	B-Protein
-	O
Thr435	O
phosphorylation	O
in	O
sTNFp55R	B-Protein
-	O
infused	O
animal	O
1	O
day	O
after	O
SE	O
.	O

sTNFp55R	B-Protein
infusion	O
effectively	O
reduces	O
p65	B-Protein
-	O
Thr435	O
and	O
preserves	O
SMI	O
-	O
71	O
expression	O
in	O
GLUT	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
endothelial	O
cells	O
(	O
arrows	O
)	O
.	O

Bars	O
=	O
12	O
.	O
5	O
(	O
A	O
-	O
D	O
)	O
and	O
25	O
(	O
E	O
-	O
G	O
)	O
mum	O
.	O

Effect	O
of	O
sTNFp55R	B-Protein
infusion	O
on	O
neutrophil	O
infiltration	O
and	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
following	O
SE	O
.	O

(	O
A	O
)	O
Neutrophil	O
infiltration	O
in	O
vasogenic	O
edema	O
lesion	O
1	O
day	O
after	O
SE	O
.	O

(	O
B	O
)	O
MIP	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
the	O
PC	O
1	O
day	O
after	O
SE	O
.	O

(	O
C	O
)	O
Astroglial	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
(	O
arrows	O
)	O
.	O

Bars	O
=	O
12	O
.	O
5	O
(	O
A	O
and	O
C	O
)	O
and	O
150	O
(	O
B	O
)	O
mum	O
.	O

(	O
D	O
)	O
Quantitative	O
analysis	O
of	O
neutrophil	O
infiltration	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

Significant	O
differences	O
from	O
saline	O
-	O
infused	O
animals	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
E	O
)	O
Linear	O
regression	O
analysis	O
between	O
the	O
number	O
of	O
infiltrated	O
neutrophils	O
/	O
area	O
in	O
the	O
vasogenic	O
edema	O
region	O
and	O
the	O
area	O
of	O
vasogenic	O
edema	O
in	O
the	O
PC	O
.	O

(	O
F	O
)	O
Quantitative	O
analysis	O
of	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
the	O
unit	O
area	O
of	O
vasogenic	O
edema	O
1	O
day	O
after	O
SE	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
)	O
.	O

There	O
is	O
no	O
difference	O
in	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
-	O
positive	O
cells	O
per	O
unit	O
area	O
of	O
vasogenic	O
edema	O
between	O
sTNFp55R	B-Protein
-	O
infused	O
animals	O
and	O
saline	O
-	O
infused	O
animals	O
.	O

(	O
G	O
)	O
Linear	O
regression	O
analysis	O
between	O
the	O
number	O
of	O
MIP	B-Protein
-	I-Protein
2	I-Protein
positive	O
cells	O
per	O
unit	O
area	O
in	O
vasogenic	O
edema	O
region	O
and	O
the	O
area	O
of	O
vasogenic	O
edema	O
in	O
the	O
PC	O
.	O

The	O
Absence	O
of	O
Nrf2	O
Enhances	O
NF	O
-	O
kappaB	O
-	O
Dependent	O
Inflammation	O
following	O
Scratch	O
Injury	O
in	O
Mouse	O
Primary	O
Cultured	O
Astrocytes	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

It	O
has	O
been	O
proved	O
that	O
Nrf2	O
depletion	O
enhances	O
inflammatory	O
process	O
through	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
brain	O
after	O
TBI	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
Nrf2	O
and	O
NF	O
-	O
kappaB	O
in	O
astrocytes	O
after	O
TBI	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Hence	O
,	O
we	O
used	O
primary	O
cultured	O
astrocytes	O
from	O
either	O
Nrf2	O
wildtype	O
or	O
knockout	O
mice	O
to	O
study	O
the	O
influence	O
of	O
Nrf2	O
on	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
a	O
model	O
of	O
TBI	O
in	O
vitro	O
.	O
<EOS>	B-X
Hence	B-X
,	B-X
clarifying	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
GSH	B-X
deficiency	B-X
may	B-X
help	B-X
deepen	B-X
our	B-X
knowledge	B-X
of	B-X
PD	B-X
pathogenesis	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
the	B-X
astrocytic	B-X
dopamine	B-X
D2	B-X
receptor	B-X
(	B-X
DRD2	B-X
)	B-X
regulates	B-X
GSH	B-X
synthesis	B-X
via	B-X
PKM2-mediated	B-X
Nrf2	B-X
transactivation	B-X
.	B-X
Further	B-X
experiments	B-X
show	B-X
that	B-X
pyridoxine	B-X
supplementation	B-X
increases	B-X
the	B-X
resistance	B-X
of	B-X
nigral	B-X
dopaminergic	B-X
neurons	B-X
to	B-X
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B-X
(	B-X
MPTP	B-X
)	B-X
-induced	B-X
neurotoxicity	B-X
in	B-X
wild-type	B-X
mice	B-X
as	B-X
well	B-X
as	B-X
in	B-X
astrocytic	B-X
Drd2	B-X
conditional	B-X
knockout	B-X
mice	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
MMP9	B-X
were	B-X
also	B-X
elevated	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Primary	O
cultured	O
astrocytes	O
were	O
scratched	O
to	O
mimic	O
the	O
traumatic	O
injury	O
in	O
vitro	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Then	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
evaluated	O
by	O
EMSA	O
.	O
<EOS>	B-X
Nuclear	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
has	B-X
diverse	B-X
pathophysiological	B-X
functions	B-X
,	B-X
and	B-X
NF-κB	B-X
inhibitors	B-X
are	B-X
considered	B-X
to	B-X
be	B-X
candidates	B-X
for	B-X
multiple	B-X
therapeutic	B-X
applications	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
a	B-X
novel	B-X
triazine-based	B-X
NF-κB	B-X
inhibitor	B-X
,	B-X
2-anilino-4,6-dichloro-1,3,5-triazine	B-X
(	B-X
NI241	B-X
)	B-X
,	B-X
that	B-X
directly	B-X
inhibits	B-X
DNA	B-X
binding	B-X
of	B-X
NF-κB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
synthesis	B-X
of	B-X
a	B-X
series	B-X
of	B-X
triazine	B-X
derivatives	B-X
and	B-X
evaluation	B-X
of	B-X
their	B-X
structure-activity	B-X
relationships	B-X
for	B-X
NF-κB	B-X
inhibition	B-X
.	B-X
We	B-X
found	B-X
that	B-X
2-amino-4,6-dichloro-1,3,5-triazine	B-X
substructure	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
inhibitory	B-X
activity	B-X
of	B-X
the	B-X
lead	B-X
compound	B-X
NI241	B-X
,	B-X
and	B-X
modification	B-X
of	B-X
NI241	B-X
by	B-X
introduction	B-X
of	B-X
an	B-X
m-methoxy	B-X
substituent	B-X
on	B-X
the	B-X
phenyl	B-X
ring	B-X
afforded	B-X
the	B-X
more	B-X
potent	B-X
derivative	B-X
28	B-X
.	B-X
The	B-X
structure-activity	B-X
relationships	B-X
identified	B-X
in	B-X
this	B-X
study	B-X
suggested	B-X
a	B-X
possible	B-X
mechanism	B-X
of	B-X
irreversible	B-X
NF-κB	B-X
inhibition	B-X
by	B-X
NI241	B-X
,	B-X
and	B-X
should	B-X
be	B-X
helpful	B-X
in	B-X
the	B-X
design	B-X
of	B-X
other	B-X
NF-κB	B-X
inhibitors	B-X
.	B-X

The	O
mRNA	O
and	O
protein	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
were	O
also	O
evaluated	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
DIM	B-X
on	B-X
Matrix	B-X
metalloproteinases	B-X
(	B-X
MMPs	B-X
)	B-X
and	B-X
some	B-X
inflammatory	B-X
factors	B-X
mRNA	B-X
and	B-X
key	B-X
molecules	B-X
such	B-X
as	B-X
some	B-X
inflammatory	B-X
factors	B-X
and	B-X
those	B-X
involved	B-X
in	B-X
aberrantly-activated	B-X
signaling	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
tumor	B-X
necrosis	B-X
factor	B-X
α	B-X
(	B-X
TNF-α	B-X
)	B-X
,	B-X
a	B-X
typical	B-X
characteristic	B-X
mediator	B-X
in	B-X
RA-FLS	B-X
,	B-X
were	B-X
quantitatively	B-X
measured	B-X
by	B-X
real-time	B-X
PCR	B-X
and	B-X
western	B-X
blotting	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
DIM	B-X
on	B-X
adjuvant	B-X
induced	B-X
arthritis	B-X
(	B-X
AIA	B-X
)	B-X
models	B-X
was	B-X
evaluated	B-X
with	B-X
C57BL/6	B-X
mice	B-X
Previous	B-X
investigations	B-X
have	B-X
revealed	B-X
that	B-X
50	B-X
%	B-X
ethanolic	B-X
extract	B-X
of	B-X
G.	B-X
Wilfordii	B-X
has	B-X
anti-inflammatory	B-X
and	B-X
anti-proliferation	B-X
activities	B-X
on	B-X
TNF-α	B-X
induced	B-X
murine	B-X
fibrosarcoma	B-X
L929	B-X
cells	B-X
.	B-X
Corilagin	B-X
(	B-X
COR	B-X
)	B-X
is	B-X
a	B-X
main	B-X
compound	B-X
in	B-X
G.	B-X
Wilfordii	B-X
with	B-X
the	B-X
content	B-X
up	B-X
to	B-X
1.69	B-X
mg/g	B-X
.	B-X

Gelatin	O
zymography	O
was	O
performed	O
to	O
detect	O
the	O
activity	O
of	O
MMP9	B-Protein
.	O
<EOS>	B-X
Hematoxylin	B-X
and	B-X
eosin	B-X
and	B-X
elastin	B-X
van	B-X
Gieson	B-X
staining	B-X
were	B-X
performed	B-X
to	B-X
observe	B-X
morphology	B-X
,	B-X
integrity	B-X
of	B-X
the	B-X
elastin	B-X
layers	B-X
and	B-X
elastin	B-X
degradation	B-X
.	B-X
CD68	B-X
expression	B-X
was	B-X
detected	B-X
by	B-X
immunohistochemical	B-X
staining	B-X
.	B-X
Reverse	B-X
transcription‑quantitative	B-X
PCR	B-X
and	B-X
western	B-X
blotting	B-X
were	B-X
used	B-X
for	B-X
detection	B-X
of	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
The	B-X
gelatinolytic	B-X
activities	B-X
of	B-X
MMP‑2	B-X
and	B-X
MMP‑9	B-X
were	B-X
quantified	B-X
via	B-X
gelatin	B-X
zymography	B-X
analysis	B-X
.	B-X
These	B-X
results	B-X
showed	B-X
that	B-X
ADAM10	B-X
inhibited	B-X
HMGB1/RAGE/NF‑κB	B-X
signaling	B-X
and	B-X
MMP	B-X
activity	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
pancreatic	B-X
elastase‑induced	B-X
AAA	B-X
,	B-X
which	B-X
provide	B-X
insight	B-X
into	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
AAA	B-X
and	B-X
suggested	B-X
that	B-X
ADAM10	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
AAA	B-X
.	B-X

The	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
expression	O
of	O
proinflammatory	O
cytokines	O
mentioned	O
above	O
were	O
upregulated	O
at	O
24	O
h	O
after	O
scratch	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
Gelatin	B-X
zymography	B-X
was	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
activity	B-X
of	B-X
MMP9	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
MMP9	B-X
were	B-X
also	B-X
elevated	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

The	O
expression	O
and	O
activity	O
of	O
MMP9	B-Protein
were	O
also	O
elevated	O
.	O
<EOS>	B-X
Although	B-X
it	B-X
is	B-X
widely	B-X
accepted	B-X
that	B-X
sialic	B-X
acid	B-X
is	B-X
an	B-X
essential	B-X
substrate	B-X
for	B-X
brain	B-X
development	B-X
via	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
nerve	B-X
transfers	B-X
,	B-X
structure	B-X
of	B-X
glycosides	B-X
,	B-X
and	B-X
synaptogenesis	B-X
phenomena	B-X
,	B-X
there	B-X
are	B-X
some	B-X
reports	B-X
on	B-X
the	B-X
elevated	B-X
levels	B-X
of	B-X
sialic	B-X
acid	B-X
and	B-X
prevalence	B-X
of	B-X
neurodegeneration	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
analyze	B-X
the	B-X
possible	B-X
effect	B-X
of	B-X
the	B-X
sialic	B-X
acid	B-X
solution	B-X
exposure	B-X
in	B-X
the	B-X
human	B-X
C118	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
was	B-X
derived	B-X
from	B-X
a	B-X
human	B-X
brain	B-X
astrocytoma	B-X
(	B-X
glial	B-X
cells	B-X
)	B-X
,	B-X
on	B-X
the	B-X
expression	B-X
patterns	B-X
of	B-X
miR-218	B-X
,	B-X
NF-kB	B-X
,	B-X
MMP-9	B-X
,	B-X
and	B-X
TIMP-1	B-X
.	B-X
MMP9	B-X
is	B-X
a	B-X
matricellular	B-X
protein	B-X
associated	B-X
with	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
remodelling	B-X
,	B-X
that	B-X
promotes	B-X
tumour	B-X
progression	B-X
,	B-X
and	B-X
modulates	B-X
the	B-X
activity	B-X
of	B-X
cell	B-X
adhesion	B-X
molecules	B-X
and	B-X
cytokines	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
assess	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
MMP9	B-X
and	B-X
its	B-X
association	B-X
with	B-X
cytoskeletal	B-X
modulators	B-X
in	B-X
early-stage	B-X
invasive	B-X
breast	B-X
cancer	B-X
(	B-X
BC	B-X
)	B-X
.	B-X

And	O
such	O
tendency	O
was	O
much	O
more	O
prominent	O
in	O
Nrf2	O
KO	O
astrocytes	O
than	O
that	O
in	O
WT	O
astrocytes	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
absence	O
of	O
Nrf2	O
may	O
induce	O
more	O
aggressive	O
inflammation	O
through	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
downstream	O
proinflammatory	O
cytokines	O
in	O
astrocytes	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Brain	O
damage	O
following	O
traumatic	O
injury	O
is	O
a	O
result	O
of	O
direct	O
(	O
primary	O
injury	O
)	O
and	O
indirect	O
(	O
secondary	O
or	O
delayed	O
injury	O
)	O
mechanisms	O
.	O
<EOS>	B-X
Traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
refers	B-X
to	B-X
any	B-X
insult	B-X
to	B-X
the	B-X
brain	B-X
resulting	B-X
in	B-X
primary	B-X
(	B-X
direct	B-X
)	B-X
and	B-X
secondary	B-X
(	B-X
indirect	B-X
)	B-X
damage	B-X
to	B-X
the	B-X
brain	B-X
parenchyma	B-X
.	B-X
Secondary	B-X
damage	B-X
is	B-X
often	B-X
linked	B-X
to	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
occur	B-X
post	B-X
TBI	B-X
and	B-X
result	B-X
in	B-X
excitotoxicity	B-X
,	B-X
neuroinflammation	B-X
and	B-X
cytokine	B-X
damage	B-X
,	B-X
oxidative	B-X
damage	B-X
,	B-X
and	B-X
eventual	B-X
cell	B-X
death	B-X
as	B-X
prominent	B-X
mechanisms	B-X
of	B-X
cell	B-X
damage	B-X
.	B-X
We	B-X
present	B-X
a	B-X
review	B-X
highlighting	B-X
the	B-X
relation	B-X
of	B-X
each	B-X
of	B-X
these	B-X
mechanisms	B-X
with	B-X
TBI	B-X
,	B-X
their	B-X
mode	B-X
of	B-X
damaging	B-X
brain	B-X
tissue	B-X
,	B-X
and	B-X
therapeutic	B-X
correlation	B-X
.	B-X
We	B-X
also	B-X
mention	B-X
the	B-X
long-term	B-X
sequelae	B-X
and	B-X
their	B-X
pathophysiology	B-X
in	B-X
relation	B-X
to	B-X
TBI	B-X
focusing	B-X
on	B-X
Parkinson	B-X
disease	B-X
,	B-X
Alzheimer	B-X
disease	B-X
,	B-X
epilepsy	B-X
,	B-X
and	B-X
chronic	B-X
traumatic	B-X
encephalopathy	B-X
.	B-X
Understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
is	B-X
important	B-X
in	B-X
order	B-X
to	B-X
realize	B-X
the	B-X
secondary	B-X
and	B-X
long-term	B-X
sequelae	B-X
that	B-X
follow	B-X
primary	B-X
TBI	B-X
and	B-X
to	B-X
devise	B-X
targeted	B-X
therapy	B-X
for	B-X
quick	B-X
recovery	B-X
accordingly	B-X
.	B-X

The	O
secondary	O
injury	O
mechanism	O
involves	O
the	O
initiation	O
of	O
an	O
acute	O
inflammatory	O
response	O
,	O
including	O
breakdown	O
of	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
brain	O
edema	O
,	O
infiltration	O
of	O
peripheral	O
blood	O
cells	O
,	O
and	O
activation	O
of	O
resident	O
immunocompetent	O
cells	O
,	O
as	O
well	O
as	O
the	O
release	O
of	O
numerous	O
immune	O
mediators	O
such	O
as	O
interleukins	O
and	O
chemotactic	O
factors	O
[	O
1	O
]	O
.	O
<EOS>	B-X
TBI	B-X
(	B-X
traumatic	B-X
brain	B-X
injury	B-X
)	B-X
is	B-X
a	B-X
major	B-X
cause	B-X
of	B-X
death	B-X
among	B-X
youth	B-X
in	B-X
industrialized	B-X
societies	B-X
.	B-X
Brain	B-X
damage	B-X
following	B-X
traumatic	B-X
injury	B-X
is	B-X
a	B-X
result	B-X
of	B-X
direct	B-X
and	B-X
indirect	B-X
mechanisms	B-X
;	B-X
indirect	B-X
or	B-X
secondary	B-X
injury	B-X
involves	B-X
the	B-X
initiation	B-X
of	B-X
an	B-X
acute	B-X
inflammatory	B-X
response	B-X
,	B-X
including	B-X
the	B-X
breakdown	B-X
of	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
,	B-X
brain	B-X
edema	B-X
,	B-X
infiltration	B-X
of	B-X
peripheral	B-X
blood	B-X
cells	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
resident	B-X
immunocompetent	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
numerous	B-X
immune	B-X
mediators	B-X
such	B-X
as	B-X
interleukins	B-X
and	B-X
chemotactic	B-X
factors	B-X
.	B-X
TBI	B-X
typically	B-X
disturbs	B-X
brain	B-X
functions	B-X
such	B-X
as	B-X
executive	B-X
actions	B-X
,	B-X
cognitive	B-X
grade	B-X
,	B-X
attention	B-X
,	B-X
memory	B-X
data	B-X
processing	B-X
,	B-X
and	B-X
language	B-X
abilities	B-X
.	B-X
For	B-X
many	B-X
years	B-X
,	B-X
the	B-X
first	B-X
approach	B-X
to	B-X
manage	B-X
TBI	B-X
has	B-X
been	B-X
treatment	B-X
of	B-X
the	B-X
injured	B-X
tissue	B-X
with	B-X
interventions	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
complex	B-X
secondary-injury	B-X
cascade	B-X
.	B-X
Several	B-X
studies	B-X
in	B-X
the	B-X
literature	B-X
have	B-X
stressed	B-X
the	B-X
importance	B-X
of	B-X
more	B-X
closely	B-X
examining	B-X
injuries	B-X
,	B-X
including	B-X
endothelial	B-X
,	B-X
microglia	B-X
,	B-X
astroglia	B-X
,	B-X
oligodendroglia	B-X
,	B-X
and	B-X
precursor	B-X
cells	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
is	B-X
to	B-X
review	B-X
TBI	B-X
pathophysiology	B-X
and	B-X
existing	B-X
and	B-X
potential	B-X
new	B-X
therapeutic	B-X
strategies	B-X
in	B-X
the	B-X
management	B-X
of	B-X
inflammatory	B-X
events	B-X
and	B-X
behavioral	B-X
deficits	B-X
associated	B-X
with	B-X
TBI	B-X
.	B-X

And	O
the	O
subsequent	O
inflammation	O
leads	O
to	O
secondary	O
damage	O
not	O
only	O
in	O
brain	O
but	O
also	O
in	O
other	O
organs	O
[	O
2	O
-	O
4	O
]	O
.	O
<EOS>	B-X
Stimulator	B-X
of	B-X
interferon	B-X
genes	B-X
(	B-X
STING	B-X
)	B-X
contributes	B-X
to	B-X
immune	B-X
responses	B-X
against	B-X
tumors	B-X
and	B-X
may	B-X
control	B-X
viral	B-X
infection	B-X
including	B-X
SARS-CoV-2	B-X
infection	B-X
.	B-X
However	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
STING	B-X
pathway	B-X
by	B-X
airway	B-X
silica	B-X
or	B-X
smoke	B-X
exposure	B-X
leads	B-X
to	B-X
cell	B-X
death	B-X
,	B-X
self-dsDNA	B-X
release	B-X
,	B-X
and	B-X
STING/type	B-X
I	B-X
IFN	B-X
dependent	B-X
acute	B-X
lung	B-X
inflammation/ARDS	B-X
.	B-X
A	B-X
low	B-X
dose	B-X
of	B-X
diABZI	B-X
(	B-X
1	B-X
µg	B-X
by	B-X
endotracheal	B-X
route	B-X
for	B-X
3	B-X
consecutive	B-X
days	B-X
)	B-X
triggered	B-X
an	B-X
acute	B-X
neutrophilic	B-X
inflammation	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
respiratory	B-X
barrier	B-X
,	B-X
DNA	B-X
release	B-X
with	B-X
NET	B-X
formation	B-X
,	B-X
PANoptosis	B-X
cell	B-X
death	B-X
,	B-X
and	B-X
inflammatory	B-X
cytokines	B-X
with	B-X
type	B-X
I	B-X
IFN	B-X
dependent	B-X
acute	B-X
lung	B-X
inflammation	B-X
.	B-X
Downstream	B-X
upregulation	B-X
of	B-X
DNA	B-X
sensors	B-X
including	B-X
cGAS	B-X
,	B-X
DDX41	B-X
,	B-X
IFI204	B-X
,	B-X
as	B-X
well	B-X
as	B-X
NLRP3	B-X
and	B-X
AIM2	B-X
inflammasomes	B-X
,	B-X
suggested	B-X
a	B-X
secondary	B-X
inflammatory	B-X
response	B-X
to	B-X
dsDNA	B-X
as	B-X
a	B-X
danger	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
airway	B-X
targeting	B-X
by	B-X
STING	B-X
activator	B-X
as	B-X
a	B-X
therapeutic	B-X
strategy	B-X
for	B-X
infection	B-X
may	B-X
enhance	B-X
lung	B-X
inflammation	B-X
with	B-X
severe	B-X
ARDS	B-X
.	B-X
STING	B-X
agonist	B-X
diABZI	B-X
induces	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
and	B-X
PANoptosis	B-X
A	B-X
,	B-X
Airway	B-X
STING	B-X
priming	B-X
induce	B-X
a	B-X
neutrophilic	B-X
lung	B-X
inflammation	B-X
with	B-X
epithelial	B-X
barrier	B-X
damage	B-X
,	B-X
double-stranded	B-X
DNA	B-X
release	B-X
in	B-X
the	B-X
bronchoalvelolar	B-X
space	B-X
,	B-X
cell	B-X
death	B-X
,	B-X
NETosis	B-X
and	B-X
type	B-X
I	B-X
interferon	B-X
release	B-X
.	B-X
STING	B-X
activation	B-X
also	B-X
leads	B-X
to	B-X
NF-kB	B-X
activation	B-X
and	B-X
the	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
TNFα	B-X
and	B-X
IL-6	B-X
.	B-X
2	B-X
.	B-X
This	B-X
can	B-X
also	B-X
leads	B-X
to	B-X
Caspase-3	B-X
cleavage	B-X
and	B-X
apoptosis	B-X
induction	B-X
.	B-X
4	B-X
.	B-X
Self-dsDNA	B-X
or	B-X
mtDNA	B-X
sensing	B-X
by	B-X
NLRP3	B-X
or	B-X
AIM2	B-X
induces	B-X
inflammsome	B-X
formation	B-X
leading	B-X
to	B-X
Gasdermin	B-X
D	B-X
cleavage	B-X
enabling	B-X
Gasdermin	B-X
D	B-X
pore	B-X
formation	B-X
and	B-X
the	B-X
release	B-X
mature	B-X
IL-1β	B-X
and	B-X
pyroptosis	B-X
.	B-X
A	B-X
second	B-X
signal	B-X
of	B-X
STING	B-X
activation	B-X
with	B-X
diABZI	B-X
induces	B-X
cell	B-X
death	B-X
and	B-X
the	B-X
release	B-X
of	B-X
self-DNA	B-X
which	B-X
is	B-X
sensed	B-X
by	B-X
cGAS	B-X
and	B-X
form	B-X
2	B-X
'	B-X
3'-cGAMP	B-X
leading	B-X
to	B-X
STING	B-X
hyper	B-X
activation	B-X
,	B-X
the	B-X
amplification	B-X
of	B-X
TBK1/IRF3	B-X
and	B-X
NF-kB	B-X
pathway	B-X
and	B-X
the	B-X
subsequent	B-X
production	B-X
of	B-X
IFN-I	B-X
and	B-X
inflammatory	B-X
TNFα	B-X
and	B-X
IL-6	B-X
.	B-X
This	B-X
also	B-X
leads	B-X
to	B-X
IFI204	B-X
and	B-X
DDX41	B-X
upregulation	B-X
thus	B-X
,	B-X
amplifying	B-X
the	B-X
inflammatory	B-X
loop	B-X
.	B-X

Nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor2	O
(	O
Nrf2	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
regulates	O
many	O
kinds	O
of	O
antioxidant	O
genes	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
Nrf2	O
regulates	O
the	O
inflammation	O
in	O
the	O
brain	O
after	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
.	O
<EOS>	B-X
Microglial	B-X
activation	B-X
and	B-X
the	B-X
inflammatory	B-X
response	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
secondary	B-X
damage	B-X
after	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
ARE	B-X
is	B-X
known	B-X
to	B-X
associate	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
NF-E2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDACs	B-X
)	B-X
.	B-X
This	B-X
pathway	B-X
,	B-X
known	B-X
as	B-X
the	B-X
Nrf2/ARE	B-X
pathway	B-X
,	B-X
is	B-X
a	B-X
critical	B-X
antioxidative	B-X
factor	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
balance	B-X
of	B-X
oxygen	B-X
free	B-X
radicals	B-X
and	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
and	B-X
is	B-X
also	B-X
related	B-X
to	B-X
autophagic	B-X
activities	B-X
.	B-X
Although	B-X
valproic	B-X
acid	B-X
(	B-X
VPA	B-X
)	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
HDACs	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
whether	B-X
VPA	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
microglia-mediated	B-X
neuroinflammatory	B-X
response	B-X
after	B-X
TBI	B-X
via	B-X
regulating	B-X
oxidative	B-X
stress	B-X
and	B-X
autophagy	B-X
induced	B-X
by	B-X
the	B-X
Nrf2/ARE	B-X
signaling	B-X
pathway	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
microglial	B-X
activation	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
autophagy	B-X
,	B-X
and	B-X
the	B-X
Nrf2/ARE	B-X
signaling	B-X
pathway	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
secondary	B-X
injury	B-X
following	B-X
TBI	B-X
.	B-X
Treatment	B-X
with	B-X
VPA	B-X
alleviated	B-X
TBI-induced	B-X
secondary	B-X
brain	B-X
injury	B-X
,	B-X
including	B-X
neurological	B-X
deficits	B-X
,	B-X
cerebral	B-X
edema	B-X
,	B-X
and	B-X
neuronal	B-X
apoptosis	B-X
.	B-X
Moreover	B-X
,	B-X
VPA	B-X
treatment	B-X
upregulated	B-X
the	B-X
occurrence	B-X
of	B-X
autophagy	B-X
and	B-X
Nrf2/ARE	B-X
pathway	B-X
activity	B-X
after	B-X
TBI	B-X
,	B-X
and	B-X
there	B-X
was	B-X
an	B-X
increase	B-X
in	B-X
H3	B-X
,	B-X
H4	B-X
histone	B-X
acetylation	B-X
levels	B-X
,	B-X
accompanied	B-X
by	B-X
decreased	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
HDAC3	B-X
promoter	B-X
in	B-X
cortical	B-X
lesions	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
VPA-mediated	B-X
up-regulation	B-X
of	B-X
autophagy	B-X
and	B-X
antioxidative	B-X
responses	B-X
are	B-X
likely	B-X
due	B-X
to	B-X
increased	B-X
activation	B-X
of	B-X
Nrf2/ARE	B-X
pathway	B-X
,	B-X
through	B-X
direct	B-X
inhibition	B-X
of	B-X
HDAC3	B-X
.	B-X
This	B-X
inhibition	B-X
further	B-X
reduces	B-X
TBI-induced	B-X
microglial	B-X
activation	B-X
and	B-X
the	B-X
subsequent	B-X
inflammatory	B-X
response	B-X
,	B-X
ultimately	B-X
leading	B-X
to	B-X
neuroprotection	B-X
.	B-X

It	O
was	O
also	O
showed	O
that	O
TBI	O
could	O
induce	O
more	O
aggravated	O
damage	O
in	O
Nrf2	O
knockout	O
mice	O
than	O
in	O
wildtype	O
mice	O
[	O
5	O
]	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neuroprotection	B-X
and	B-X
recover	B-X
.	B-X
Our	B-X
studies	B-X
have	B-X
showed	B-X
that	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress-induced	B-X
apoptosis	B-X
aggravates	B-X
secondary	B-X
damage	B-X
following	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
Whether	B-X
Nrf2	B-X
involved	B-X
in	B-X
ER	B-X
stress	B-X
and	B-X
ER	B-X
stress-mediated	B-X
apoptosis	B-X
is	B-X
not	B-X
clearly	B-X
investigated	B-X
.	B-X
This	B-X
present	B-X
study	B-X
explored	B-X
the	B-X
effect	B-X
of	B-X
Nrf2	B-X
knockout	B-X
on	B-X
ER	B-X
stress	B-X
and	B-X
ER	B-X
stress-induced	B-X
apoptosis	B-X
in	B-X
TBI	B-X
mice	B-X
.	B-X
A	B-X
lateral	B-X
fluid	B-X
percussion	B-X
injury	B-X
(	B-X
FPI	B-X
)	B-X
model	B-X
of	B-X
TBI	B-X
was	B-X
built	B-X
based	B-X
on	B-X
Nrf2	B-X
knockout	B-X
(	B-X
Nrf2	B-X

On	O
the	O
contrary	O
,	O
such	O
inflammation	O
can	O
be	O
extenuated	O
through	O
elevating	O
the	O
level	O
of	O
Nrf2	O
by	O
its	O
inducers	O
,	O
such	O
as	O
sulforaphane	O
(	O
SFN	O
)	O
[	O
6	O
]	O
.	O

It	O
is	O
well	O
documented	O
that	O
astrocytes	O
play	O
a	O
critical	O
role	O
in	O
maintaining	O
normal	O
brain	O
physiology	O
and	O
responding	O
to	O
injury	O
or	O
disease	O
.	O
<EOS>	B-X
Organoids	B-X
derived	B-X
from	B-X
adult	B-X
stem	B-X
cells	B-X
exploit	B-X
the	B-X
tissue	B-X
regeneration	B-X
process	B-X
that	B-X
is	B-X
driven	B-X
by	B-X
these	B-X
cells	B-X
,	B-X
and	B-X
they	B-X
can	B-X
be	B-X
established	B-X
directly	B-X
from	B-X
the	B-X
healthy	B-X
or	B-X
diseased	B-X
epithelium	B-X
of	B-X
many	B-X
organs	B-X
.	B-X
Applications	B-X
in	B-X
experimental	B-X
biology	B-X
involve	B-X
the	B-X
modeling	B-X
of	B-X
tissue	B-X
physiology	B-X
and	B-X
disease	B-X
,	B-X
including	B-X
malignant	B-X
,	B-X
hereditary	B-X
,	B-X
and	B-X
infectious	B-X
diseases	B-X
.	B-X
According	B-X
to	B-X
the	B-X
disease	B-X
module	B-X
hypothesis	B-X
,	B-X
the	B-X
cellular	B-X
components	B-X
associated	B-X
with	B-X
a	B-X
disease	B-X
segregate	B-X
in	B-X
the	B-X
same	B-X
neighborhood	B-X
of	B-X
the	B-X
human	B-X
interactome	B-X
,	B-X
the	B-X
map	B-X
of	B-X
biologically	B-X
relevant	B-X
molecular	B-X
interactions	B-X
.	B-X
Yet	B-X
,	B-X
given	B-X
the	B-X
incompleteness	B-X
of	B-X
the	B-X
interactome	B-X
and	B-X
the	B-X
limited	B-X
knowledge	B-X
of	B-X
disease-associated	B-X
genes	B-X
,	B-X
it	B-X
is	B-X
not	B-X
obvious	B-X
if	B-X
the	B-X
available	B-X
data	B-X
have	B-X
sufficient	B-X
coverage	B-X
to	B-X
map	B-X
out	B-X
modules	B-X
associated	B-X
with	B-X
each	B-X
disease	B-X
.	B-X
Here	B-X
we	B-X
derive	B-X
mathematical	B-X
conditions	B-X
for	B-X
the	B-X
identifiability	B-X
of	B-X
disease	B-X
modules	B-X
and	B-X
show	B-X
that	B-X
the	B-X
network-based	B-X
location	B-X
of	B-X
each	B-X
disease	B-X
module	B-X
determines	B-X
its	B-X
pathobiological	B-X
relationship	B-X
to	B-X
other	B-X
diseases	B-X
.	B-X
For	B-X
example	B-X
,	B-X
diseases	B-X
with	B-X
overlapping	B-X
network	B-X
modules	B-X
show	B-X
significant	B-X
coexpression	B-X
patterns	B-X
,	B-X
symptom	B-X
similarity	B-X
,	B-X
and	B-X
comorbidity	B-X
,	B-X
whereas	B-X
diseases	B-X
residing	B-X
in	B-X
separated	B-X
network	B-X
neighborhoods	B-X
are	B-X
phenotypically	B-X
distinct	B-X
.	B-X
These	B-X
tools	B-X
represent	B-X
an	B-X
interactome-based	B-X
platform	B-X
to	B-X
predict	B-X
molecular	B-X
commonalities	B-X
between	B-X
phenotypically	B-X
related	B-X
diseases	B-X
,	B-X
even	B-X
if	B-X
they	B-X
do	B-X
not	B-X
share	B-X
primary	B-X
disease	B-X
genes	B-X
.	B-X

In	O
fact	O
,	O
all	O
the	O
aforementioned	O
studies	O
are	O
performed	O
in	O
vivo	O
.	O
<EOS>	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
acidic	B-X
fibroblast	B-X
growth	B-X
factor	B-X
(	B-X
aFGF	B-X
)	B-X
has	B-X
been	B-X
a	B-X
long-standing	B-X
potent	B-X
mitogen	B-X
for	B-X
cells	B-X
from	B-X
various	B-X
origins	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
are	B-X
the	B-X
first	B-X
to	B-X
develop	B-X
a	B-X
multimodal	B-X
treatment	B-X
combining	B-X
the	B-X
aforementioned	B-X
physicochemical	B-X
and	B-X
pharmacological	B-X
treatments	B-X
and	B-X
investigated	B-X
their	B-X
individual	B-X
and	B-X
combined	B-X
effects	B-X
on	B-X
wound	B-X
healing	B-X
,	B-X
angiogenesis	B-X
,	B-X
neurogenesis	B-X
,	B-X
and	B-X
osteogenesis	B-X
.	B-X
This	B-X
work	B-X
was	B-X
performed	B-X
at	B-X
the	B-X
tissue	B-X
,	B-X
cellular	B-X
,	B-X
protein	B-X
,	B-X
and	B-X
gene	B-X
levels	B-X
,	B-X
using	B-X
histochemical	B-X
staining	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
ELISA	B-X
,	B-X
and	B-X
PCR	B-X
,	B-X
respectively	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
type	B-X
of	B-X
target	B-X
tissue	B-X
,	B-X
various	B-X
combinations	B-X
of	B-X
aforementioned	B-X
methods	B-X
were	B-X
used	B-X
.	B-X
The	B-X
former	B-X
was	B-X
manifested	B-X
by	B-X
increased	B-X
murine	B-X
fibroblast	B-X
proliferation	B-X
and	B-X
reduced	B-X
cutaneous	B-X
tissue	B-X
inflammation	B-X
,	B-X
whereas	B-X
the	B-X
latter	B-X
by	B-X
upregulated	B-X
proangiogenic	B-X
markers	B-X
in	B-X
vivo	B-X
,	B-X
for	B-X
example	B-X
,	B-X
CD31	B-X
,	B-X
VEGF	B-X
,	B-X
and	B-X
TGF-β	B-X
,	B-X
and	B-X
downregulated	B-X
antiangiogenic	B-X
proteins	B-X
in	B-X
vitro	B-X
,	B-X
for	B-X
example	B-X
,	B-X
angiostatin	B-X
and	B-X
angiopoietin-2	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
aFGF	B-X
outperformed	B-X
CAP	B-X
during	B-X
neurogenesis	B-X
,	B-X
which	B-X
was	B-X
evidenced	B-X
by	B-X
superior	B-X
neurite	B-X
outgrowth	B-X
,	B-X
while	B-X
CAP	B-X
exceeded	B-X
aFGF	B-X
in	B-X
osteogenesis	B-X
which	B-X
was	B-X
demonstrated	B-X
by	B-X
more	B-X
substantial	B-X
bone	B-X
nodule	B-X
formation	B-X
.	B-X
These	B-X
novel	B-X
findings	B-X
not	B-X
only	B-X
support	B-X
the	B-X
fact	B-X
that	B-X
CAP	B-X
and	B-X
aFGF	B-X
are	B-X
both	B-X
multipotent	B-X
agents	B-X
during	B-X
tissue	B-X
regeneration	B-X
,	B-X
but	B-X
also	B-X
highlight	B-X
the	B-X
potential	B-X
of	B-X
our	B-X
multimodal	B-X
treatment	B-X
combining	B-X
the	B-X
individual	B-X
advantages	B-X
of	B-X
CAP	B-X
and	B-X
aFGF	B-X
.	B-X

Little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
Nrf2	O
and	O
inflammation	O
in	O
astrocytes	O
after	O
TBI	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Therefore	O
,	O
here	O
we	O
analysed	O
the	O
influence	O
of	O
Nrf2	O
on	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
primary	O
cultured	O
astrocytes	O
from	O
transgenic	O
mice	O
after	O
scratch	O
injury	O
.	O

2	O
.	O
1	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X

Primary	O
Culture	O
and	O
Identification	O
of	O
Mouse	O
Astrocytes	O
<EOS>	B-X
Astrocytes	B-X
and	B-X
neurons	B-X
display	B-X
a	B-X
patchy	B-X
pattern	B-X
of	B-X
immunostaining	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
channels	B-X
sort	B-X
themselves	B-X
in	B-X
clusters	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Mouse	B-X
enhancer	B-X
RNA	B-X
is	B-X
shown	B-X
to	B-X
be	B-X
at	B-X
highest	B-X
levels	B-X
in	B-X
collagen-rich	B-X
tissues	B-X
,	B-X
especially	B-X
tendon	B-X
.	B-X
Astrocytes	B-X
are	B-X
important	B-X
regulators	B-X
of	B-X
normal	B-X
brain	B-X
function	B-X
in	B-X
mammals	B-X
,	B-X
including	B-X
roles	B-X
in	B-X
synaptic	B-X
signaling	B-X
,	B-X
synapse	B-X
formation	B-X
,	B-X
and	B-X
neuronal	B-X
health	B-X
and	B-X
survival	B-X
.	B-X

Nrf2	O
knockout	O
ICR	O
mice	O
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Thomas	O
W	O
.	O
Kensler	O
(	O
Johns	O
Hopkins	O
University	O
,	O
Baltimore	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Primary	O
astrocytes	O
were	O
obtained	O
from	O
postnatal	O
2	O
-	O
day	O
-	O
old	O
Nrf2	O
wide	O
type	O
(	O
WT	O
)	O
and	O
knockout	O
(	O
KO	O
)	O
mice	O
(	O
6	O
mice	O
for	O
each	O
genotype	O
)	O
.	O

Following	O
decapitation	O
,	O
the	O
cortices	O
were	O
dissected	O
out	O
,	O
and	O
the	O
meninges	O
and	O
associated	O
blood	O
vessels	O
were	O
removed	O
.	O

The	O
tissue	O
was	O
roughly	O
chopped	O
with	O
a	O
scalpel	O
blade	O
,	O
incubated	O
in	O
0	O
.	O
5	O
%	O
trypsin	O
for	O
10	O
minutes	O
at	O
37degreesC	O
,	O
and	O
agitated	O
every	O
few	O
minutes	O
.	O

After	O
digestion	O
,	O
the	O
tissue	O
was	O
rinsed	O
twice	O
in	O
DMEM	O
with	O
10	O
%	O
FBS	O
,	O
followed	O
by	O
a	O
mechanical	O
dissociation	O
in	O
DMEM	O
with	O
20	O
%	O
FBS	O
and	O
5	O
units	O
/	O
mL	O
penicillin	O
,	O
5	O
mug	O
/	O
mL	O
streptomycin	O
(	O
complete	O
culture	O
medium	O
)	O
.	O

After	O
incubation	O
for	O
1	O
h	O
,	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
flask	O
or	O
dish	O
(	O
Costar	O
,	O
USA	O
)	O
for	O
depleting	O
the	O
residual	O
epithelial	O
cells	O
.	O

Then	O
the	O
cells	O
were	O
cultivated	O
at	O
37degreesC	O
with	O
5	O
%	O
CO2	O
.	O
<EOS>	B-X
Cell	B-X
proliferation	B-X
rate	B-X
and	B-X
3H-thymidine	B-X
labeling	B-X
index	B-X
of	B-X
``	B-X
young	B-X
''	B-X
(	B-X
i.	B-X
e.	B-X
harvested	B-X
in	B-X
3	B-X
days	B-X
after	B-X
subcultivation	B-X
)	B-X
cultured	B-X
Chinese	B-X
hamster	B-X
cells	B-X
(	B-X
B11	B-X
dii-FAF28	B-X
line	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
growth	B-X
medium	B-X
conditioned	B-X
by	B-X
the	B-X
same	B-X
cells	B-X
for	B-X
various	B-X
periods	B-X
of	B-X
time	B-X
during	B-X
their	B-X
growth	B-X
and	B-X
subsequent	B-X
``	B-X
stationary	B-X
phase	B-X
aging	B-X
''	B-X
(	B-X
medium	B-X
of	B-X
different	B-X
``	B-X
age	B-X
''	B-X
)	B-X
.	B-X
The	B-X
``	B-X
young	B-X
''	B-X
cells	B-X
were	B-X
seeded	B-X
in	B-X
Carrel	B-X
's	B-X
flasks	B-X
(	B-X
4500	B-X
cells/cm2	B-X
)	B-X
with	B-X
fresh	B-X
growth	B-X
medium	B-X
and	B-X
placed	B-X
at	B-X
37	B-X
degreesC	B-X
.	B-X
The	B-X
cells	B-X
from	B-X
all	B-X
3	B-X
flasks	B-X
were	B-X
collected	B-X
by	B-X
trypsin	B-X
treatment	B-X
and	B-X
counted	B-X
with	B-X
hemocytometer	B-X
.	B-X
Then	B-X
,	B-X
the	B-X
``	B-X
young	B-X
''	B-X
cells	B-X
in	B-X
fresh	B-X
medium	B-X
were	B-X
seeded	B-X
into	B-X
tissue	B-X
culture	B-X
plates	B-X
with	B-X
cover	B-X
slips	B-X
placed	B-X
into	B-X
wells	B-X
of	B-X
the	B-X
plates	B-X
(	B-X
26,600	B-X
cells/cm2	B-X
)	B-X
and	B-X
grown	B-X
at	B-X
37degreesC	B-X
,	B-X
5	B-X
%	B-X
CO2	B-X
for	B-X
2	B-X
h.	B-X
At	B-X
this	B-X
point	B-X
,	B-X
the	B-X
medium	B-X
was	B-X
replaced	B-X
with	B-X
media	B-X
of	B-X
different	B-X
``	B-X
age	B-X
''	B-X
.	B-X
On	B-X
the	B-X
next	B-X
day	B-X
(	B-X
i.	B-X
e.	B-X
in	B-X
2	B-X
days	B-X
after	B-X
seeding	B-X
)	B-X
3H-thymidine	B-X
was	B-X
added	B-X
to	B-X
every	B-X
well	B-X
to	B-X
final	B-X
concentration	B-X
1.85	B-X
x	B-X
10	B-X
(	B-X
4	B-X
)	B-X
Bq/ml	B-X
.	B-X
Autoradiography	B-X
was	B-X
performed	B-X
in	B-X
standard	B-X
manner	B-X
by	B-X
photoemulsion	B-X
exposing	B-X
for	B-X
5	B-X
days	B-X
and	B-X
subsequent	B-X
developing	B-X
in	B-X
amidol	B-X
developer	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
obtained	B-X
results	B-X
,	B-X
two	B-X
basic	B-X
parameters	B-X
were	B-X
evaluated	B-X
for	B-X
every	B-X
``	B-X
age	B-X
''	B-X
medium	B-X
:	B-X
1	B-X
)	B-X
cell	B-X
proliferation	B-X
activity	B-X
index	B-X
calculated	B-X
as	B-X
log2	B-X
(	B-X
N3/N1	B-X
)	B-X
,	B-X
where	B-X
N1	B-X
-	B-X
cell	B-X
density	B-X
on	B-X
the	B-X
first	B-X
day	B-X
after	B-X
seeding	B-X
,	B-X
and	B-X
N3	B-X
-	B-X
the	B-X
same	B-X
parameter	B-X
on	B-X
the	B-X
third	B-X
day	B-X
after	B-X
seeding	B-X
;	B-X
2	B-X
)	B-X
cell	B-X
labeling	B-X
index	B-X
calculated	B-X
as	B-X
percentage	B-X
of	B-X
cells	B-X
with	B-X
nuclei	B-X
labeled	B-X
by	B-X
3H-thymidine	B-X
during	B-X
incubation	B-X
from	B-X
2nd	B-X
to	B-X
3rd	B-X
day	B-X
of	B-X
cultivation	B-X
.	B-X
These	B-X
two	B-X
indexes	B-X
for	B-X
cell	B-X
growth	B-X
in	B-X
different	B-X
``	B-X
age	B-X
''	B-X
media	B-X
appeared	B-X
to	B-X
be	B-X
highly	B-X
correlating	B-X
(	B-X
R	B-X
=	B-X
0.85	B-X
)	B-X
.	B-X
Besides	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
the	B-X
observed	B-X
``	B-X
age-related	B-X
''	B-X
diminishing	B-X
of	B-X
ability	B-X
of	B-X
the	B-X
growth	B-X
media	B-X
of	B-X
different	B-X
``	B-X
age	B-X
''	B-X
to	B-X
stimulate	B-X
proliferation	B-X
of	B-X
``	B-X
young	B-X
''	B-X
cells	B-X
can	B-X
not	B-X
completely	B-X
explain	B-X
the	B-X
``	B-X
stationary	B-X
phase	B-X
aging	B-X
''	B-X
phenomenon	B-X
(	B-X
in	B-X
particular	B-X
,	B-X
even	B-X
for	B-X
the	B-X
``	B-X
oldest	B-X
''	B-X
medium	B-X
cell	B-X
labeling	B-X
index	B-X
was	B-X
65	B-X
%	B-X
)	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
phenomenon	B-X
is	B-X
based	B-X
on	B-X
exactly	B-X
intrinsic	B-X
changes	B-X
of	B-X
cells	B-X
,	B-X
most	B-X
likely	B-X
on	B-X
molecular	B-X
level	B-X
,	B-X
though	B-X
environmental	B-X
effects	B-X
can	B-X
not	B-X
be	B-X
entirely	B-X
excluded	B-X
.	B-X

And	O
the	O
complete	O
culture	O
medium	O
was	O
half	O
-	O
changed	O
twice	O
a	O
week	O
.	O

Astrocytes	O
expanded	O
for	O
about	O
7	O
days	O
to	O
reach	O
confluence	O
.	O

Then	O
the	O
flasks	O
or	O
dishes	O
were	O
shaken	O
at	O
150	O
rpm	O
for	O
4	O
h	O
to	O
deplete	O
the	O
microglia	O
and	O
less	O
adherent	O
cells	O
from	O
the	O
cultures	O
.	O
<EOS>	B-X
The	B-X
Solubility	B-X
of	B-X
Halothane	B-X
in	B-X
Blood	B-X
and	B-X
Tissue	B-X
Homogenates	B-X
.	B-X
By	B-X
Larson	B-X
CP	B-X
,	B-X
Eger	B-X
EI	B-X
,	B-X
Severinghaus	B-X
JW	B-X
.	B-X
Anesthesiology	B-X
1962	B-X
;	B-X
23:349-55	B-X
.	B-X
Measured	B-X
samples	B-X
of	B-X
human	B-X
and	B-X
bovine	B-X
blood	B-X
,	B-X
human	B-X
hemoglobin	B-X
,	B-X
and	B-X
tissue	B-X
homogenates	B-X
from	B-X
human	B-X
fat	B-X
and	B-X
both	B-X
human	B-X
and	B-X
bovine	B-X
liver	B-X
,	B-X
kidney	B-X
,	B-X
muscle	B-X
,	B-X
whole	B-X
brain	B-X
,	B-X
and	B-X
separated	B-X
gray	B-X
and	B-X
white	B-X
cortex	B-X
were	B-X
added	B-X
to	B-X
stoppered	B-X
2,000-ml	B-X
Erlenmeyer	B-X
flasks	B-X
.	B-X
To	B-X
each	B-X
flask	B-X
,	B-X
0.1	B-X
ml	B-X
of	B-X
liquid	B-X
halothane	B-X
was	B-X
added	B-X
under	B-X
negative	B-X
pressure	B-X
using	B-X
a	B-X
calibrated	B-X
micropipette	B-X
.	B-X
After	B-X
the	B-X
flask	B-X
was	B-X
agitated	B-X
for	B-X
2	B-X
to	B-X
4	B-X
h	B-X
to	B-X
achieve	B-X
equilibrium	B-X
between	B-X
the	B-X
gas	B-X
and	B-X
blood	B-X
or	B-X
tissue	B-X
contents	B-X
,	B-X
a	B-X
calibrated	B-X
infrared	B-X
halothane	B-X
analyzer	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
the	B-X
concentration	B-X
of	B-X
halothane	B-X
vapor	B-X
.	B-X
Calculated	B-X
partition	B-X
coefficients	B-X
ranged	B-X
from	B-X
0.7	B-X
for	B-X
water	B-X
to	B-X
2.3	B-X
for	B-X
blood	B-X
and	B-X
from	B-X
3.5	B-X
for	B-X
human	B-X
or	B-X
bovine	B-X
kidney	B-X
to	B-X
6	B-X
for	B-X
human	B-X
whole	B-X
brain	B-X
or	B-X
liver	B-X
and	B-X
8	B-X
for	B-X
human	B-X
muscle	B-X
.	B-X
Human	B-X
peritoneal	B-X
fat	B-X
had	B-X
a	B-X
value	B-X
of	B-X
138	B-X
.	B-X
The	B-X
human	B-X
blood-gas	B-X
partition	B-X
coefficient	B-X
of	B-X
2.3	B-X
as	B-X
determined	B-X
by	B-X
this	B-X
equilibration	B-X
method	B-X
was	B-X
well	B-X
below	B-X
the	B-X
previously	B-X
published	B-X
value	B-X
of	B-X
3.6	B-X
.	B-X

After	O
shaking	O
,	O
the	O
resulting	O
cultures	O
were	O
mainly	O
astrocytes	O
,	O
which	O
were	O
determined	O
by	O
immunoreactivity	O
for	O
GFAP	O
(	O
sc	O
-	O
166481	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Cells	O
passaged	O
for	O
2	O
-	O
3	O
generations	O
were	O
used	O
in	O
the	O
following	O
studies	O
.	O
<EOS>	B-X
In	B-X
a	B-X
recent	B-X
study	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
human	B-X
fibroblasts	B-X
can	B-X
be	B-X
reprogrammed	B-X
into	B-X
induced	B-X
trophoblast	B-X
stem	B-X
(	B-X
iTS	B-X
)	B-X
cells	B-X
by	B-X
transcription	B-X
factor-mediated	B-X
nuclear	B-X
reprogramming	B-X
using	B-X
the	B-X
Yamanaka	B-X
factors	B-X
OCT4	B-X
,	B-X
KLF4	B-X
,	B-X
SOX2	B-X
and	B-X
c-MYC	B-X
(	B-X
OKSM	B-X
)	B-X
and	B-X
a	B-X
selection	B-X
of	B-X
TS	B-X
cell	B-X
culture	B-X
conditions	B-X
.	B-X
The	B-X
protocol	B-X
consists	B-X
of	B-X
four	B-X
main	B-X
sections	B-X
:	B-X
(	B-X
1	B-X
)	B-X
recovery	B-X
of	B-X
cryopreserved	B-X
human	B-X
dermal	B-X
fibroblasts	B-X
,	B-X
(	B-X
2	B-X
)	B-X
somatic	B-X
cell	B-X
reprogramming	B-X
,	B-X
(	B-X
3	B-X
)	B-X
passaging	B-X
of	B-X
reprogramming	B-X
intermediates	B-X
and	B-X
(	B-X
4	B-X
)	B-X
derivation	B-X
of	B-X
iTS	B-X
cell	B-X
cultures	B-X
followed	B-X
by	B-X
routine	B-X
maintenance	B-X
of	B-X
iTS	B-X
cells	B-X
.	B-X
These	B-X
iTS	B-X
cell	B-X
lines	B-X
can	B-X
be	B-X
established	B-X
in	B-X
2-3	B-X
weeks	B-X
and	B-X
cultured	B-X
long	B-X
term	B-X
over	B-X
50	B-X
passages	B-X
.	B-X
Historical	B-X
cottontail	B-X
rabbit	B-X
papillomavirus	B-X
studies	B-X
raised	B-X
early	B-X
indications	B-X
of	B-X
a	B-X
mammalian	B-X
DNA	B-X
oncogenic	B-X
virus	B-X
.	B-X
8	B-X
early	B-X
(	B-X
E1-E8	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
and	B-X
2	B-X
late	B-X
(	B-X
L1	B-X
,	B-X
L2	B-X
)	B-X
ORFs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
all	B-X
papillomaviruses	B-X
.	B-X
Three	B-X
possible	B-X
courses	B-X
of	B-X
events	B-X
can	B-X
follow	B-X
papillomaviruses	B-X
entry	B-X
into	B-X
cells	B-X
:	B-X
(	B-X
1	B-X
)	B-X
viral	B-X
DNA	B-X
are	B-X
maintained	B-X
as	B-X
intranuclear	B-X
,	B-X
extrachromosomal	B-X
,	B-X
circular	B-X
DNA	B-X
episomes	B-X
,	B-X
which	B-X
replicates	B-X
synchronously	B-X
with	B-X
the	B-X
host	B-X
cell	B-X
,	B-X
establishing	B-X
a	B-X
latent	B-X
infection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
conversion	B-X
from	B-X
latent	B-X
into	B-X
productive	B-X
infection	B-X
with	B-X
assembly	B-X
of	B-X
complete	B-X
infective	B-X
virions	B-X
;	B-X
(	B-X
3	B-X
)	B-X
integration	B-X
of	B-X
viral	B-X
DNA	B-X
into	B-X
host	B-X
cellular	B-X
genome	B-X
,	B-X
a	B-X
phenomenon	B-X
seen	B-X
in	B-X
HPV	B-X
infections	B-X
associated	B-X
with	B-X
malignant	B-X
transformation	B-X
.	B-X
Various	B-X
skin	B-X
warts	B-X
are	B-X
well	B-X
known	B-X
to	B-X
be	B-X
HPV-associated	B-X
(	B-X
HPVs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
7	B-X
and	B-X
10	B-X
)	B-X
.	B-X
Besides	B-X
HPVs	B-X
3	B-X
and	B-X
10	B-X
,	B-X
HPVs	B-X
5	B-X
,	B-X
8	B-X
,	B-X
17	B-X
and	B-X
20	B-X
have	B-X
been	B-X
recovered	B-X
from	B-X
Epidermodysplasia	B-X
verruciformis	B-X
lesions	B-X
.	B-X
HPVs	B-X
described	B-X
in	B-X
uterine	B-X
cervical	B-X
lesions	B-X
are	B-X
generally	B-X
categorized	B-X
into	B-X
those	B-X
associated	B-X
with	B-X
high	B-X
(	B-X
16	B-X
,	B-X
18	B-X
)	B-X
,	B-X
intermediate	B-X
(	B-X
31	B-X
,	B-X
33	B-X
,	B-X
35	B-X
,	B-X
39	B-X
,	B-X
45	B-X
,	B-X
51	B-X
,	B-X
52	B-X
,	B-X
56	B-X
,	B-X
58	B-X
,	B-X
59	B-X
,	B-X
68	B-X
)	B-X
and	B-X
low	B-X
(	B-X
6	B-X
,	B-X
11	B-X
,	B-X
26	B-X
,	B-X
40	B-X
,	B-X
42	B-X
,	B-X
43	B-X
,	B-X
44	B-X
,	B-X
53	B-X
,	B-X
54	B-X
,	B-X
55	B-X
,	B-X
62	B-X
,	B-X
66	B-X
)	B-X
risk	B-X
of	B-X
cervical	B-X
squamous	B-X
carcinoma	B-X
.	B-X
Other	B-X
lesions	B-X
reported	B-X
to	B-X
be	B-X
HPV-associated	B-X
are	B-X
:	B-X
papillomas	B-X
,	B-X
dysplasia	B-X
and	B-X
carcinomas	B-X
in	B-X
the	B-X
nasal	B-X
cavity	B-X
(	B-X
HPV	B-X
6	B-X
,	B-X
11	B-X
,	B-X
57	B-X
)	B-X
;	B-X
squamous	B-X
papilloma	B-X
,	B-X
condyloma	B-X
acuminatum	B-X
,	B-X
and	B-X
verruca	B-X
vulgaris	B-X
of	B-X
the	B-X
oral	B-X
cavity	B-X
(	B-X
HPV	B-X
6	B-X
,	B-X
11	B-X
)	B-X
,	B-X
oral	B-X
focal	B-X
epithelial	B-X
hyperplasia	B-X
(	B-X
HPV	B-X
13	B-X
,	B-X
32	B-X
)	B-X
;	B-X
warty	B-X
lip	B-X
lesions	B-X
(	B-X
HPV	B-X
2	B-X
)	B-X
:	B-X
and	B-X
conjunctival	B-X
papillomas	B-X
(	B-X
HPV	B-X
6	B-X
,	B-X
11	B-X
)	B-X
.	B-X

2	O
.	O
2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X

In	O
Vitro	O
Model	O
of	O
TBI	O
Established	O
by	O
Scratch	O
Injury	O
<EOS>	B-X
Traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
is	B-X
a	B-X
major	B-X
reason	B-X
of	B-X
cerebrovascular	B-X
and	B-X
neurological	B-X
damage	B-X
.	B-X
Premorbid	B-X
conditions	B-X
such	B-X
as	B-X
tobacco	B-X
smoking	B-X
(	B-X
TS	B-X
)	B-X
can	B-X
worsen	B-X
post-TBI	B-X
injuries	B-X
by	B-X
promoting	B-X
vascular	B-X
endothelial	B-X
impairments	B-X
.	B-X
Mechanical	B-X
impact-induced	B-X
primary	B-X
injury	B-X
after	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
leads	B-X
to	B-X
acute	B-X
microglial	B-X
pro-inflammatory	B-X
activation	B-X
and	B-X
consequently	B-X
mediates	B-X
neurodegeneration	B-X
,	B-X
which	B-X
is	B-X
a	B-X
major	B-X
secondary	B-X
brain	B-X
injury	B-X
mechanism	B-X
.	B-X
However	B-X
,	B-X
the	B-X
detailed	B-X
pathologic	B-X
cascades	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
elucidated	B-X
,	B-X
partially	B-X
because	B-X
of	B-X
the	B-X
pathologic	B-X
complexity	B-X
in	B-X
animal	B-X
TBI	B-X
models	B-X
.	B-X

Astrocyte	O
scratch	O
injury	O
was	O
performed	O
as	O
in	O
a	O
previous	O
report	O
[	O
7	O
]	O
.	O

Astrocytes	O
were	O
planted	O
in	O
6	O
-	O
well	O
plates	O
and	O
grown	O
to	O
confluence	O
.	O

The	O
cell	O
monolayer	O
was	O
scratched	O
with	O
a	O
sterile	O
26G	O
syringe	O
needle	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
0	O
.	O
5	O
mm	O
wide	O
gap	O
.	O

Immediately	O
after	O
scratch	O
,	O
cells	O
were	O
washed	O
twice	O
with	O
sterile	O
PBS	O
,	O
cultured	O
with	O
complete	O
culture	O
medium	O
,	O
and	O
named	O
as	O
TBI	O
group	O
.	O

Cells	O
,	O
which	O
did	O
not	O
received	O
scratch	O
,	O
were	O
used	O
as	O
blank	O
control	O
and	O
named	O
as	O
sham	O
group	O
.	O
<EOS>	B-X
As	B-X
an	B-X
alternative	B-X
to	B-X
histochemical	B-X
stains	B-X
,	B-X
different	B-X
antibodies	B-X
have	B-X
been	B-X
used	B-X
to	B-X
identify	B-X
mast	B-X
cells	B-X
in	B-X
humans	B-X
.	B-X
The	B-X
functionalization	B-X
of	B-X
decellularized	B-X
scaffolds	B-X
is	B-X
still	B-X
challenging	B-X
because	B-X
of	B-X
the	B-X
recellularization-related	B-X
limitations	B-X
,	B-X
including	B-X
the	B-X
finding	B-X
of	B-X
the	B-X
most	B-X
optimal	B-X
kind	B-X
of	B-X
cell	B-X
(	B-X
s	B-X
)	B-X
and	B-X
the	B-X
best	B-X
way	B-X
to	B-X
control	B-X
their	B-X
distribution	B-X
within	B-X
the	B-X
scaffolds	B-X
to	B-X
generate	B-X
native	B-X
mimicking	B-X
tissues	B-X
.	B-X
Dogmatic	B-X
conceptions	B-X
of	B-X
OHC	B-X
performance	B-X
have	B-X
been	B-X
challenged	B-X
by	B-X
decades	B-X
of	B-X
biophysical	B-X
interrogations	B-X
that	B-X
must	B-X
be	B-X
influential	B-X
on	B-X
hearing	B-X
,	B-X
but	B-X
which	B-X
have	B-X
received	B-X
little	B-X
attention	B-X
by	B-X
cochlear	B-X
modelers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
discuss	B-X
the	B-X
recent	B-X
literature	B-X
and	B-X
propose	B-X
that	B-X
the	B-X
autophagic	B-X
machinery	B-X
and	B-X
the	B-X
ciliary	B-X
proteins	B-X
are	B-X
functionally	B-X
strictly	B-X
related	B-X
to	B-X
control	B-X
both	B-X
autophagy	B-X
and	B-X
ciliogenesis	B-X
.	B-X

2	O
.	O
3	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Cell	O
Death	O
Measurement	O
by	O
CCK	O
-	O
8	O
Assay	O
<EOS>	B-X
Cell	B-X
proliferation	B-X
was	B-X
detected	B-X
through	B-X
CCK-8	B-X
and	B-X
BrdU	B-X
incorporation	B-X
assays	B-X
,	B-X
and	B-X
ROS	B-X
level	B-X
was	B-X
measured	B-X
with	B-X
the	B-X
DCFDA	B-X
assay	B-X
.	B-X
ADM	B-X
also	B-X
dose-dependently	B-X
ameliorated	B-X
LPS-induced	B-X
pyroptosis	B-X
by	B-X
reversing	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
NLRP3	B-X
,	B-X
ASC	B-X
,	B-X
caspase-1	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-18	B-X
,	B-X
GSDMD	B-X
,	B-X
caspase-3	B-X
,	B-X
caspase-7	B-X
,	B-X
TUNEL-positive	B-X
and	B-X
PI	B-X
and	B-X
active	B-X
caspase-1	B-X
double-stained	B-X
positive	B-X
rate	B-X
,	B-X
DNA	B-X
fragmentation	B-X
and	B-X
LDH	B-X
concentration	B-X
,	B-X
which	B-X
could	B-X
be	B-X
rescued	B-X
via	B-X
co-incubation	B-X
with	B-X
3-MA	B-X
.	B-X
CCK-8	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
cell	B-X
viability	B-X
.	B-X
Exosomes	B-X
Derived	B-X
From	B-X
Natural	B-X
Killer	B-X
Cells	B-X
Exert	B-X
Therapeutic	B-X
Effect	B-X
in	B-X
Melanoma	B-X
.	B-X

1	O
x	O
103	O
/	O
well	O
cells	O
were	O
seeded	O
to	O
96	O
-	O
well	O
culture	O
plates	O
and	O
cultivated	O
for	O
24	O
h	O
to	O
adhere	O
.	O

Then	O
the	O
cell	O
was	O
scrated	O
as	O
mentioned	O
above	O
.	O
<EOS>	B-X
Human	B-X
cardiac	B-X
drug	B-X
discovery	B-X
and	B-X
disease	B-X
modeling	B-X
face	B-X
challenges	B-X
in	B-X
recapitulating	B-X
cellular	B-X
complexity	B-X
and	B-X
animal-to-human	B-X
translation	B-X
due	B-X
to	B-X
the	B-X
limitations	B-X
of	B-X
conventional	B-X
2D	B-X
cell	B-X
culture	B-X
and	B-X
animal	B-X
models	B-X
.	B-X
The	B-X
development	B-X
of	B-X
human	B-X
cardiac	B-X
organoid	B-X
technologies	B-X
could	B-X
help	B-X
in	B-X
stimulating	B-X
and	B-X
maintaining	B-X
differentiated	B-X
cell	B-X
functions	B-X
for	B-X
extended	B-X
periods	B-X
of	B-X
time	B-X
.	B-X
By	B-X
closely	B-X
mimicking	B-X
in	B-X
vivo	B-X
organ	B-X
functions	B-X
in	B-X
vitro	B-X
they	B-X
could	B-X
thereby	B-X
help	B-X
in	B-X
overcoming	B-X
the	B-X
obstacles	B-X
mentioned	B-X
above	B-X
.	B-X
Through	B-X
the	B-X
construction	B-X
of	B-X
human	B-X
cardiac	B-X
organoids	B-X
from	B-X
pluripotent	B-X
stem	B-X
cell-derived	B-X
cells	B-X
,	B-X
derived	B-X
from	B-X
patients	B-X
with	B-X
specific	B-X
known	B-X
genotypes	B-X
and	B-X
phenotypes	B-X
,	B-X
more	B-X
complex	B-X
and	B-X
robust	B-X
in	B-X
vitro	B-X
tools	B-X
have	B-X
recently	B-X
become	B-X
available	B-X
for	B-X
disease	B-X
modeling	B-X
.	B-X

Astrocyte	O
cell	O
death	O
was	O
assessed	O
by	O
cell	O
counting	O
kit	O
-	O
8	O
(	O
CCK	O
-	O
8	O
)	O
(	O
Dojindo	O
,	O
Japan	O
)	O
assay	O
24	O
h	O
after	O
scratch	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
10	O
muL	O
CCK	O
-	O
8	O
was	O
added	O
into	O
every	O
well	O
and	O
incubated	O
for	O
1	O
h	O
.	O

Then	O
OD	O
value	O
was	O
read	O
at	O
450	O
nm	O
using	O
a	O
Bio	O
-	O
Rad	O
ELISA	O
microplate	O
reader	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
CA	O
,	O
USA	O
)	O
.	O

All	O
measurements	O
were	O
performed	O
in	O
sextuplicate	O
.	O

Results	O
were	O
expressed	O
as	O
mean	O
of	O
OD	O
value	O
at	O
450	O
nm	O
+	O
/	O
-	O
SD	O
.	O

2	O
.	O
4	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
The	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
a	B-X
well-established	B-X
method	B-X
to	B-X
detect	B-X
formation	B-X
of	B-X
complexes	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
and	B-X
to	B-X
determine	B-X
,	B-X
among	B-X
other	B-X
parameters	B-X
,	B-X
equilibrium	B-X
constants	B-X
for	B-X
the	B-X
interaction	B-X
.	B-X
Interactions	B-X
between	B-X
proteins	B-X
and	B-X
nucleic	B-X
acids	B-X
are	B-X
frequently	B-X
analyzed	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
.	B-X
The	B-X
current	B-X
study	B-X
utilizes	B-X
recent	B-X
advances	B-X
in	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
technology	B-X
to	B-X
develop	B-X
a	B-X
new	B-X
EMSA	B-X
protocol	B-X
that	B-X
is	B-X
simpler	B-X
and	B-X
faster	B-X
than	B-X
traditional	B-X
polyacrylamide	B-X
methods	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
demonstrate	B-X
that	B-X
EMSAs	B-X
performed	B-X
using	B-X
agarose	B-X
gels	B-X
can	B-X
be	B-X
run	B-X
at	B-X
high	B-X
voltages	B-X
(	B-X
≥20	B-X
V/cm	B-X
)	B-X
with	B-X
0.5	B-X
×	B-X
TB	B-X
(	B-X
Tris-borate	B-X
)	B-X
buffer	B-X
,	B-X
allowing	B-X
for	B-X
short	B-X
run	B-X
times	B-X
while	B-X
simultaneously	B-X
yielding	B-X
high	B-X
band	B-X
resolution	B-X
.	B-X

Monolayers	O
of	O
astrocytes	O
were	O
washed	O
with	O
PBS	O
and	O
harvested	O
by	O
scraping	O
into	O
cold	O
PBS	O
.	O

The	O
cell	O
pellet	O
obtained	O
by	O
centrifugation	O
was	O
resuspended	O
in	O
buffer	O
containing	O
10	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
1	O
mM	O
EGTA	O
,	O
1	O
.	O
0	O
mM	O
DTT	O
,	O
and	O
0	O
.	O
5	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
.	O

Then	O
10	O
%	O
Nonidet	O
P	O
-	O
40	O
was	O
added	O
and	O
vortexed	O
briefly	O
,	O
and	O
the	O
nuclei	O
were	O
pelleted	O
by	O
centrifugation	O
.	O

The	O
nuclear	O
proteins	O
were	O
extracted	O
with	O
buffer	O
containing	O
20	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
9	O
)	O
,	O
0	O
.	O
4	O
mM	O
NaCl	O
,	O
1	O
.	O
0	O
mM	O
EDTA	O
,	O
1	O
.	O
0	O
mM	O
EGTA	O
,	O
1	O
.	O
0	O
mM	O
DTT	O
,	O
and	O
1	O
.	O
0	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
at	O
14000	O
rpm	O
,	O
and	O
the	O
supernatant	O
containing	O
the	O
nuclear	O
proteins	O
was	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
a	O
bicinchoninic	O
acid	O
assay	O
kit	O
with	O
bovine	O
serum	O
albumin	O
as	O
the	O
standard	O
(	O
Pierce	O
Biochemicals	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

EMSA	O
was	O
performed	O
using	O
gel	O
shift	O
assay	O
system	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Consensus	O
oligonucleotide	O
probe	O
(	O
5	O
'	O
-	O
AGTTGAGGGGACTTTCCCAGGG	O
-	O
3	O
'	O
)	O
was	O
end	O
-	O
labeled	O
by	O
T4	O
-	O
polynucleotide	O
kinase	O
using	O
[	O
gamma	O
-	O
32P	O
]	O
-	O
ATP	O
(	O
Free	O
Biotech	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Nuclear	O
protein	O
(	O
20	O
mug	O
)	O
was	O
preincubated	O
in	O
20	O
muL	O
binding	O
buffer	O
containing	O
10	O
mM	O
Tris	O
-	O
HCl	O
(	O
PH	O
7	O
.	O
5	O
)	O
,	O
1	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
mM	O
NaCl	O
,	O
4	O
%	O
glycerol	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
and	O
2	O
mug	O
poly	O
dI	O
-	O
dC	O
for	O
20	O
minutes	O
on	O
ice	O
.	O

After	O
addition	O
of	O
the	O
1	O
muL	O
32P	O
-	O
labled	O
oligonucleotide	O
probe	O
,	O
the	O
incubation	O
was	O
continued	O
for	O
20	O
minutes	O
on	O
ice	O
.	O

The	O
DNA	O
-	O
protein	O
complexes	O
were	O
separated	O
by	O
electrophoresis	O
on	O
4	O
%	O
nondenaturing	O
polyacrylamide	O
gel	O
in	O
0	O
.	O
5	O
x	O
TBE	O
buffer	O
(	O
tris	O
-	O
borate	O
-	O
EDTA	O
)	O
at	O
390	O
V	O
for	O
1	O
hour	O
at	O
4degreesC	O
.	O

After	O
electrophoresis	O
,	O
the	O
gel	O
was	O
dried	O
and	O
exposed	O
to	O
X	O
-	O
ray	O
film	O
(	O
Fuji	O
Hyperfilm	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Levels	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
were	O
quantified	O
by	O
software	O
ImageJ	O
.	O

2	O
.	O
5	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Atomic	B-X
models	B-X
for	B-X
the	B-X
polypeptide	B-X
backbones	B-X
of	B-X
myohemerythrin	B-X
and	B-X
hemerythrin	B-X
.	B-X

RT	O
-	O
PCR	O
<EOS>	B-X
RT-PCR	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
test	B-X
for	B-X
genetic	B-X
diseases	B-X
and	B-X
to	B-X
characterize	B-X
gene	B-X
expression	B-X
in	B-X
various	B-X
tissue	B-X
types	B-X
,	B-X
cell	B-X
types	B-X
,	B-X
and	B-X
over	B-X
developmental	B-X
time	B-X
courses	B-X
.	B-X
RT-PCR	B-X
is	B-X
also	B-X
commonly	B-X
used	B-X
to	B-X
clone	B-X
cDNAs	B-X
for	B-X
further	B-X
use	B-X
with	B-X
other	B-X
molecular	B-X
biology	B-X
techniques	B-X
(	B-X
e.g.	B-X
,	B-X
see	B-X
Oligo	B-X
(	B-X
dT	B-X
)	B-X
-primed	B-X
RT-PCR	B-X
isolation	B-X
of	B-X
polyadenylated	B-X
RNA	B-X
degradation	B-X
intermediates	B-X
and	B-X
Circularized	B-X
RT-PCR	B-X
(	B-X
cRT-PCR	B-X
)	B-X
:	B-X
analysis	B-X
of	B-X
RNA	B-X
5	B-X
'	B-X
ends	B-X
,	B-X
3	B-X
'	B-X
ends	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tails	B-X
)	B-X
.	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
uses	B-X
fluorescent	B-X
reporter	B-X
molecules	B-X
to	B-X
monitor	B-X
the	B-X
production	B-X
of	B-X
amplification	B-X
products	B-X
during	B-X
each	B-X
cycle	B-X
of	B-X
the	B-X
PCR	B-X
reaction	B-X
.	B-X
Its	B-X
simplicity	B-X
,	B-X
specificity	B-X
and	B-X
sensitivity	B-X
,	B-X
together	B-X
with	B-X
its	B-X
potential	B-X
for	B-X
high	B-X
throughput	B-X
and	B-X
the	B-X
ongoing	B-X
introduction	B-X
of	B-X
new	B-X
chemistries	B-X
,	B-X
more	B-X
reliable	B-X
instrumentation	B-X
and	B-X
improved	B-X
protocols	B-X
,	B-X
has	B-X
made	B-X
real-time	B-X
RT-PCR	B-X
the	B-X
benchmark	B-X
technology	B-X
for	B-X
the	B-X
detection	B-X
and/or	B-X
comparison	B-X
of	B-X
RNA	B-X
levels	B-X
.	B-X

Total	O
RNA	O
was	O
isolated	O
with	O
Trizol	O
(	O
Invitrogen	O
,	O
CA	O
,	O
USA	O
)	O
,	O
and	O
single	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
2	O
mug	O
of	O
total	O
RNA	O
with	O
BU	O
-	O
Script	O
RT	O
-	O
Kit	O
(	O
Biunique	O
,	O
Jiangsu	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
cDNA	O
was	O
stored	O
in	O
-	O
20degreesC	O
.	O

Reverse	O
transcription	O
was	O
conducted	O
with	O
GoTaq	O
Green	O
Master	O
Mix	O
(	O
Promega	O
,	O
WI	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Table	O
1	O
shows	O
the	O
primers	O
and	O
PCR	O
parameters	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
important	B-X
parameters	B-X
to	B-X
consider	B-X
is	B-X
the	B-X
choice	B-X
of	B-X
which	B-X
polymerase	B-X
to	B-X
use	B-X
in	B-X
PCR	B-X
.	B-X
As	B-X
demonstrated	B-X
by	B-X
the	B-X
data	B-X
in	B-X
Tables	B-X
2	B-X
and	B-X
3	B-X
,	B-X
high-fidelity	B-X
DNA	B-X
amplification	B-X
will	B-X
be	B-X
best	B-X
achieved	B-X
by	B-X
using	B-X
a	B-X
polymerase	B-X
with	B-X
an	B-X
active	B-X
3	B-X
'	B-X
--	B-X
>	B-X
5	B-X
'	B-X
proofreading	B-X
exonuclease	B-X
activity	B-X
(	B-X
Fig	B-X
.	B-X
1E	B-X
)	B-X
.	B-X
1A	B-X
,	B-X
B	B-X
)	B-X
,	B-X
any	B-X
type	B-X
of	B-X
deoxynucleoside	B-X
triphosphate	B-X
pool	B-X
imbalance	B-X
should	B-X
be	B-X
avoided	B-X
.	B-X
1D	B-X
)	B-X
can	B-X
be	B-X
minimized	B-X
by	B-X
reactions	B-X
using	B-X
short	B-X
synthesis	B-X
times	B-X
,	B-X
low	B-X
dNTP	B-X
concentrations	B-X
,	B-X
and	B-X
low	B-X
enzyme	B-X
concentrations	B-X
.	B-X
To	B-X
perform	B-X
high-fidelity	B-X
PCR	B-X
with	B-X
Taq	B-X
polymerase	B-X
,	B-X
reactions	B-X
should	B-X
contain	B-X
a	B-X
low	B-X
MgCl2	B-X
concentration	B-X
,	B-X
not	B-X
in	B-X
large	B-X
excess	B-X
over	B-X
the	B-X
total	B-X
concentration	B-X
of	B-X
dNTP	B-X
substrates	B-X
,	B-X
and	B-X
be	B-X
buffered	B-X
to	B-X
approximately	B-X
pH	B-X
6	B-X
(	B-X
70	B-X
degrees	B-X
C	B-X
)	B-X
using	B-X
Bis-Tris	B-X
Propane	B-X
or	B-X
PIPES	B-X
(	B-X
Table	B-X
2	B-X
)	B-X
.	B-X
These	B-X
buffers	B-X
have	B-X
a	B-X
pKa	B-X
between	B-X
pH	B-X
6	B-X
and	B-X
pH	B-X
7	B-X
and	B-X
a	B-X
small	B-X
temperature	B-X
coefficient	B-X
(	B-X
delta	B-X
pKa/degree	B-X
C	B-X
)	B-X
,	B-X
allowing	B-X
the	B-X
pH	B-X
to	B-X
be	B-X
maintained	B-X
stably	B-X
throughout	B-X
the	B-X
PCR	B-X
cycle	B-X
.	B-X

PCR	O
products	O
were	O
detected	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O
<EOS>	B-X
The	B-X
method	B-X
presented	B-X
here	B-X
allows	B-X
efficient	B-X
discrimination	B-X
of	B-X
SNPs	B-X
by	B-X
allele-specific	B-X
PCR	B-X
in	B-X
a	B-X
single	B-X
reaction	B-X
with	B-X
standard	B-X
PCR	B-X
conditions	B-X
.	B-X
A	B-X
common	B-X
reverse	B-X
primer	B-X
and	B-X
two	B-X
forward	B-X
allele-specific	B-X
primers	B-X
with	B-X
different	B-X
tails	B-X
amplify	B-X
two	B-X
allele-specific	B-X
PCR	B-X
products	B-X
of	B-X
different	B-X
lengths	B-X
,	B-X
which	B-X
are	B-X
further	B-X
separated	B-X
by	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
.	B-X
PCR	B-X
specificity	B-X
is	B-X
improved	B-X
by	B-X
the	B-X
introduction	B-X
of	B-X
a	B-X
destabilizing	B-X
mismatch	B-X
within	B-X
the	B-X
30	B-X
end	B-X
of	B-X
the	B-X
allele-specific	B-X
primers	B-X
.	B-X
This	B-X
is	B-X
a	B-X
simple	B-X
and	B-X
inexpensive	B-X
method	B-X
for	B-X
SNP	B-X
detection	B-X
that	B-X
does	B-X
not	B-X
require	B-X
PCR	B-X
optimization	B-X
.	B-X

The	O
intensity	O
of	O
the	O
bands	O
was	O
analyzed	O
by	O
ImageJ	O
program	O
.	O

The	O
level	O
of	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
an	O
internal	O
standard	O
.	O
<EOS>	B-X
AMPK	B-X
is	B-X
regulated	B-X
by	B-X
phosphorylation	B-X
and	B-X
dephosphorylation	B-X
as	B-X
a	B-X
result	B-X
of	B-X
changing	B-X
AMP/ATP	B-X
levels	B-X
and	B-X
by	B-X
removal	B-X
of	B-X
inhibitory	B-X
ubiquitin	B-X
residues	B-X
by	B-X
USP10	B-X
.	B-X
The	B-X
appropriate	B-X
choice	B-X
of	B-X
an	B-X
internal	B-X
standard	B-X
is	B-X
critical	B-X
for	B-X
quantitative	B-X
RNA	B-X
analyses	B-X
.	B-X
As	B-X
housekeeping	B-X
genes	B-X
,	B-X
GAPDH	B-X
,	B-X
beta-actin	B-X
,	B-X
cyclophilin	B-X
,	B-X
and	B-X
28S	B-X
rRNA	B-X
are	B-X
commonly	B-X
employed	B-X
as	B-X
RNA	B-X
internal	B-X
standards	B-X
with	B-X
the	B-X
assumption	B-X
that	B-X
their	B-X
expression	B-X
levels	B-X
remain	B-X
relatively	B-X
constant	B-X
in	B-X
different	B-X
experimental	B-X
conditions	B-X
.	B-X
We	B-X
tested	B-X
this	B-X
assumption	B-X
under	B-X
hypoxia	B-X
(	B-X
1	B-X
%	B-X
O2	B-X
,	B-X
24	B-X
hours	B-X
)	B-X
compared	B-X
to	B-X
normoxia	B-X
(	B-X
20	B-X
%	B-X
O2	B-X
,	B-X
24	B-X
hours	B-X
)	B-X
and	B-X
compared	B-X
RNA	B-X
levels	B-X
of	B-X
these	B-X
4	B-X
housekeeping	B-X
genes	B-X
head	B-X
to	B-X
head	B-X
using	B-X
ribonuclease	B-X
protection	B-X
assays	B-X
.	B-X
Four	B-X
biologically	B-X
diverse	B-X
cell	B-X
lines	B-X
with	B-X
respect	B-X
to	B-X
clonal	B-X
origin	B-X
,	B-X
neoplastic	B-X
transformation	B-X
,	B-X
and	B-X
growth	B-X
rates	B-X
were	B-X
used	B-X
in	B-X
the	B-X
comparison	B-X
.	B-X
Expression	B-X
levels	B-X
of	B-X
28S	B-X
rRNA	B-X
were	B-X
constant	B-X
,	B-X
independent	B-X
of	B-X
O2	B-X
tension	B-X
,	B-X
but	B-X
levels	B-X
of	B-X
GAPDH	B-X
,	B-X
beta-actin	B-X
,	B-X
and	B-X
cyclophilin	B-X
varied	B-X
widely	B-X
with	B-X
hypoxia	B-X
.	B-X
Increased	B-X
GAPDH	B-X
transcription	B-X
in	B-X
hypoxia	B-X
was	B-X
correlated	B-X
in	B-X
the	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
upregulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
Hypoxia	B-X
Inducible	B-X
Factor-1alpha	B-X
protein	B-X
levels	B-X
in	B-X
identical	B-X
experimental	B-X
conditions	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
28S	B-X
rRNA	B-X
is	B-X
a	B-X
reliable	B-X
internal	B-X
control	B-X
for	B-X
comparative	B-X
analyses	B-X
of	B-X
transcription	B-X
under	B-X
hypoxia	B-X
;	B-X
GAPDH	B-X
appears	B-X
particularly	B-X
unfavorable	B-X
for	B-X
this	B-X
purpose	B-X
either	B-X
in	B-X
hypoxia	B-X
or	B-X
other	B-X
experimental	B-X
conditions	B-X
that	B-X
upregulate	B-X
HIF-1alpha	B-X
.	B-X

2	O
.	O
6	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Studies	B-X
of	B-X
oxygen	B-X
binding	B-X
energy	B-X
to	B-X
hemoglobin	B-X
molecule	B-X
.	B-X

Western	O
Blot	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
involves	B-X
the	B-X
separation	B-X
of	B-X
proteins	B-X
by	B-X
gel	B-X
electrophoresis	B-X
,	B-X
their	B-X
blotting	B-X
or	B-X
transfer	B-X
to	B-X
a	B-X
membrane	B-X
,	B-X
and	B-X
selective	B-X
immunodetection	B-X
of	B-X
an	B-X
immobilized	B-X
antigen	B-X
.	B-X

To	O
obtain	O
total	O
protein	O
lysates	O
,	O
cells	O
were	O
homogenized	O
in	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP40	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
EGTA	O
,	O
1	O
mM	O
Na3VO4	O
,	O
20	O
mM	O
NaF	O
,	O
0	O
.	O
5	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
,	O
and	O
protease	O
inhibitor	O
cocktail	O
in	O
PBS	O
pH	O
7	O
.	O
4	O
)	O
and	O
centrifuged	O
at	O
12	O
,	O
000	O
g	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Protein	O
concentrations	O
were	O
estimated	O
by	O
Coomassie	O
Plus	O
Protein	O
Assay	O
Reagent	O
(	O
Pierce	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Fifty	O
micrograms	O
of	O
the	O
resulting	O
cytosolic	O
protein	O
extracts	O
were	O
heat	O
-	O
denatured	O
in	O
Laemmli	O
sample	O
loading	O
buffer	O
,	O
separated	O
by	O
10	O
%	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
electroblotted	O
onto	O
a	O
nitrocellulose	O
membrane	O
.	O

For	O
immunoblotting	O
,	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
nonfat	O
dry	O
milk	O
in	O
saline	O
buffer	O
overnight	O
at	O
4degreesC	O
,	O
and	O
the	O
following	O
antibodies	O
were	O
used	O
:	O
anti	O
-	O
beta	O
-	O
actin	O
(	O
sc	O
-	O
130657	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
,	O
43	O
kDa	O
)	O
and	O
anti	O
-	O
matrix	O
metallopeptidase	O
9	O
(	O
MMP9	B-Protein
)	O
(	O
sc	O
-	O
6841	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
CA	O
,	O
USA	O
,	O
92	O
kDa	O
)	O
.	O

Each	O
primary	O
antibody	O
was	O
diluted	O
appropriately	O
in	O
blocking	O
buffer	O
and	O
then	O
added	O
to	O
the	O
blots	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

The	O
blots	O
were	O
washed	O
three	O
times	O
in	O
the	O
washing	O
buffer	O
and	O
covered	O
with	O
the	O
horseradish	O
peroxidase	O
-	O
linked	O
secondary	O
antibody	O
at	O
a	O
1	O
:	O
2000	O
dilution	O
for	O
1	O
h	O
.	O

Blots	O
were	O
incubated	O
with	O
enhanced	O
chemiluminescence	O
(	O
ECL	O
)	O
detection	O
system	O
(	O
Amersham	O
Biosciences	O
,	O
Bucks	O
,	O
UK	O
)	O
and	O
exposed	O
to	O
radiographic	O
film	O
(	O
Fuji	O
Hyperfilm	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

ImageJ	O
was	O
used	O
to	O
analyze	O
the	O
intensity	O
of	O
the	O
blots	O
.	O

The	O
level	O
of	O
beta	O
-	O
actin	O
was	O
used	O
as	O
internal	O
standard	O
.	O
<EOS>	B-X
AMPK	B-X
is	B-X
regulated	B-X
by	B-X
phosphorylation	B-X
and	B-X
dephosphorylation	B-X
as	B-X
a	B-X
result	B-X
of	B-X
changing	B-X
AMP/ATP	B-X
levels	B-X
and	B-X
by	B-X
removal	B-X
of	B-X
inhibitory	B-X
ubiquitin	B-X
residues	B-X
by	B-X
USP10	B-X
.	B-X
The	B-X
appropriate	B-X
choice	B-X
of	B-X
an	B-X
internal	B-X
standard	B-X
is	B-X
critical	B-X
for	B-X
quantitative	B-X
RNA	B-X
analyses	B-X
.	B-X
As	B-X
housekeeping	B-X
genes	B-X
,	B-X
GAPDH	B-X
,	B-X
beta-actin	B-X
,	B-X
cyclophilin	B-X
,	B-X
and	B-X
28S	B-X
rRNA	B-X
are	B-X
commonly	B-X
employed	B-X
as	B-X
RNA	B-X
internal	B-X
standards	B-X
with	B-X
the	B-X
assumption	B-X
that	B-X
their	B-X
expression	B-X
levels	B-X
remain	B-X
relatively	B-X
constant	B-X
in	B-X
different	B-X
experimental	B-X
conditions	B-X
.	B-X
We	B-X
tested	B-X
this	B-X
assumption	B-X
under	B-X
hypoxia	B-X
(	B-X
1	B-X
%	B-X
O2	B-X
,	B-X
24	B-X
hours	B-X
)	B-X
compared	B-X
to	B-X
normoxia	B-X
(	B-X
20	B-X
%	B-X
O2	B-X
,	B-X
24	B-X
hours	B-X
)	B-X
and	B-X
compared	B-X
RNA	B-X
levels	B-X
of	B-X
these	B-X
4	B-X
housekeeping	B-X
genes	B-X
head	B-X
to	B-X
head	B-X
using	B-X
ribonuclease	B-X
protection	B-X
assays	B-X
.	B-X
Four	B-X
biologically	B-X
diverse	B-X
cell	B-X
lines	B-X
with	B-X
respect	B-X
to	B-X
clonal	B-X
origin	B-X
,	B-X
neoplastic	B-X
transformation	B-X
,	B-X
and	B-X
growth	B-X
rates	B-X
were	B-X
used	B-X
in	B-X
the	B-X
comparison	B-X
.	B-X
Expression	B-X
levels	B-X
of	B-X
28S	B-X
rRNA	B-X
were	B-X
constant	B-X
,	B-X
independent	B-X
of	B-X
O2	B-X
tension	B-X
,	B-X
but	B-X
levels	B-X
of	B-X
GAPDH	B-X
,	B-X
beta-actin	B-X
,	B-X
and	B-X
cyclophilin	B-X
varied	B-X
widely	B-X
with	B-X
hypoxia	B-X
.	B-X
Increased	B-X
GAPDH	B-X
transcription	B-X
in	B-X
hypoxia	B-X
was	B-X
correlated	B-X
in	B-X
the	B-X
cancer	B-X
cell	B-X
lines	B-X
with	B-X
upregulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
Hypoxia	B-X
Inducible	B-X
Factor-1alpha	B-X
protein	B-X
levels	B-X
in	B-X
identical	B-X
experimental	B-X
conditions	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
28S	B-X
rRNA	B-X
is	B-X
a	B-X
reliable	B-X
internal	B-X
control	B-X
for	B-X
comparative	B-X
analyses	B-X
of	B-X
transcription	B-X
under	B-X
hypoxia	B-X
;	B-X
GAPDH	B-X
appears	B-X
particularly	B-X
unfavorable	B-X
for	B-X
this	B-X
purpose	B-X
either	B-X
in	B-X
hypoxia	B-X
or	B-X
other	B-X
experimental	B-X
conditions	B-X
that	B-X
upregulate	B-X
HIF-1alpha	B-X
.	B-X

2	O
.	O
7	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Maturation	B-X
of	B-X
the	B-X
adrenal	B-X
medulla	B-X
--	B-X
IV	B-X
.	B-X
Effects	B-X
of	B-X
morphine	B-X
.	B-X

Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O
<EOS>	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
specific	B-X
and	B-X
straightforward	B-X
assays	B-X
for	B-X
detecting	B-X
biomolecules	B-X
in	B-X
research	B-X
and	B-X
clinics	B-X
.	B-X
With	B-X
advances	B-X
in	B-X
analytical	B-X
methods	B-X
,	B-X
ELISA	B-X
assay	B-X
has	B-X
been	B-X
constantly	B-X
optimized	B-X
to	B-X
improve	B-X
its	B-X
sensitivity	B-X
,	B-X
and	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
are	B-X
now	B-X
available	B-X
to	B-X
detect	B-X
various	B-X
biomarkers	B-X
.	B-X
This	B-X
chapter	B-X
provides	B-X
an	B-X
overall	B-X
summary	B-X
of	B-X
the	B-X
basic	B-X
principle	B-X
of	B-X
ELISA	B-X
,	B-X
discusses	B-X
different	B-X
components	B-X
of	B-X
ELISA	B-X
assay	B-X
,	B-X
and	B-X
clearly	B-X
outline	B-X
protocols	B-X
for	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
assays	B-X
,	B-X
including	B-X
direct	B-X
,	B-X
indirect	B-X
,	B-X
sandwich	B-X
,	B-X
competitive	B-X
,	B-X
and	B-X
nanoparticle-based	B-X
ELISA	B-X
.	B-X
This	B-X
brief	B-X
note	B-X
addresses	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
invention	B-X
of	B-X
the	B-X
enzyme	B-X
immunoassay	B-X
(	B-X
EIA	B-X
)	B-X
and	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
EIA/ELISA	B-X
is	B-X
reflected	B-X
in	B-X
the	B-X
overwhelmingly	B-X
large	B-X
number	B-X
of	B-X
times	B-X
it	B-X
has	B-X
appeared	B-X
as	B-X
a	B-X
keyword	B-X
in	B-X
the	B-X
literature	B-X
since	B-X
the	B-X
1970s	B-X
.	B-X

Cells	O
of	O
four	O
groups	O
were	O
homogenized	O
as	O
mentioned	O
above	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
above-mentioned	B-X
markers	B-X
-	B-X
which	B-X
have	B-X
become	B-X
a	B-X
routine	B-X
practice	B-X
in	B-X
recent	B-X
years	B-X
,	B-X
there	B-X
are	B-X
many	B-X
efforts	B-X
to	B-X
include	B-X
the	B-X
molecular	B-X
characteristics	B-X
of	B-X
tumors	B-X
both	B-X
in	B-X
tumor	B-X
classification	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
prediction	B-X
of	B-X
results	B-X
of	B-X
cancer	B-X
treatment	B-X
.	B-X
Using	B-X
this	B-X
approach	B-X
,	B-X
four	B-X
basic	B-X
subgroups	B-X
of	B-X
breast	B-X
cancer	B-X
have	B-X
been	B-X
identified	B-X
-	B-X
luminal	B-X
,	B-X
basal-like	B-X
,	B-X
HER-2	B-X
enriched	B-X
and	B-X
normal	B-X
gland-like	B-X
.	B-X
Over	B-X
the	B-X
course	B-X
of	B-X
time	B-X
,	B-X
the	B-X
number	B-X
of	B-X
molecular	B-X
categories	B-X
has	B-X
expanded	B-X
-	B-X
originally	B-X
a	B-X
homogenous	B-X
group	B-X
of	B-X
luminal	B-X
cancers	B-X
has	B-X
been	B-X
subclassified	B-X
into	B-X
the	B-X
luminal	B-X
A	B-X
,	B-X
B	B-X
and	B-X
C.	B-X
Also	B-X
within	B-X
basal-like	B-X
carcinomas	B-X
additional	B-X
subgroups	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
The	B-X
findings	B-X
that	B-X
more	B-X
proteins	B-X
became	B-X
insoluble	B-X
during	B-X
development	B-X
mentioned	B-X
above	B-X
also	B-X
supports	B-X
such	B-X
an	B-X
interpretation	B-X
.	B-X
Experiments	B-X
with	B-X
absorbed	B-X
antisera	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
to	B-X
four	B-X
antigens	B-X
were	B-X
present	B-X
exclusively	B-X
in	B-X
one	B-X
of	B-X
the	B-X
two	B-X
soluble	B-X
fractions	B-X
.	B-X
Three	B-X
groups	B-X
of	B-X
antigens	B-X
differing	B-X
in	B-X
regard	B-X
to	B-X
their	B-X
metabolic	B-X
activities	B-X
were	B-X
distinguished	B-X
.	B-X

The	O
supernatant	O
was	O
collected	O
,	O
and	O
total	O
protein	O
was	O
determined	O
by	O
Coomassie	O
Plus	O
Protein	O
Assay	O
Reagent	O
(	O
Pierce	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Levels	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
,	O
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
protein	O
were	O
quantified	O
using	O
ELISA	O
kits	O
specific	O
for	O
mouse	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bender	O
MedSystems	O
Inc	O
.	O
CA	O
,	O
USA	O
)	O
.	O

Briefly	O
,	O
prepared	O
the	O
standard	O
and	O
created	O
the	O
standard	O
dilution	O
for	O
building	O
standard	O
curve	O
.	O

Then	O
samples	O
and	O
biotinconjugate	O
were	O
added	O
to	O
microwell	O
strips	O
.	O

After	O
incubated	O
for	O
2	O
h	O
at	O
room	O
temperature	O
,	O
the	O
microwell	O
strips	O
were	O
washed	O
3	O
times	O
with	O
wash	O
buffer	O
,	O
and	O
streptavidin	O
-	O
HRP	O
were	O
added	O
to	O
all	O
wells	O
.	O

After	O
incubated	O
for	O
1	O
h	O
,	O
microwell	O
strips	O
were	O
washed	O
3	O
times	O
followed	O
by	O
adding	O
TMB	O
substrate	O
.	O

After	O
incubated	O
for	O
about	O
10	O
-	O
30	O
min	O
,	O
the	O
stop	O
solution	O
was	O
added	O
.	O
<EOS>	B-X
For	B-X
the	B-X
test	B-X
method	B-X
,	B-X
ochratoxin	B-X
A	B-X
is	B-X
extracted	B-X
from	B-X
ground	B-X
samples	B-X
with	B-X
70	B-X
%	B-X
methanol	B-X
and	B-X
sample	B-X
extracts	B-X
plus	B-X
conjugate	B-X
are	B-X
mixed	B-X
and	B-X
then	B-X
added	B-X
to	B-X
the	B-X
antibody-coated	B-X
microwells	B-X
.	B-X
After	B-X
10	B-X
min	B-X
incubation	B-X
at	B-X
room	B-X
temperature	B-X
,	B-X
the	B-X
plate	B-X
is	B-X
washed	B-X
and	B-X
enzyme	B-X
substrate	B-X
is	B-X
added	B-X
and	B-X
allowed	B-X
to	B-X
incubate	B-X
for	B-X
an	B-X
additional	B-X
5	B-X
min	B-X
.	B-X
Stop	B-X
solution	B-X
is	B-X
then	B-X
added	B-X
and	B-X
the	B-X
intensity	B-X
of	B-X
the	B-X
resulting	B-X
yellow	B-X
color	B-X
is	B-X
measured	B-X
optically	B-X
with	B-X
a	B-X
microplate	B-X
reader	B-X
at	B-X
450	B-X
nm	B-X
.	B-X
Comparison	B-X
of	B-X
the	B-X
method	B-X
to	B-X
HPLC	B-X
,	B-X
ability	B-X
to	B-X
detect	B-X
individual	B-X
ochratoxins	B-X
,	B-X
and	B-X
ruggedness	B-X
of	B-X
the	B-X
test	B-X
kits	B-X
determined	B-X
this	B-X
test	B-X
to	B-X
be	B-X
rugged	B-X
from	B-X
18	B-X
to	B-X
30	B-X
degrees	B-X
C	B-X
,	B-X
sensitive	B-X
,	B-X
accurate	B-X
,	B-X
precise	B-X
and	B-X
effective	B-X
comparable	B-X
to	B-X
HPLC	B-X
for	B-X
measuring	B-X
ochratoxin	B-X
A	B-X
ranging	B-X
from	B-X
2	B-X
to	B-X
40	B-X
ppb	B-X
in	B-X
several	B-X
commodities	B-X
.	B-X

The	O
colour	O
intensity	O
was	O
measured	O
at	O
450	O
nm	O
using	O
a	O
Bio	O
-	O
Rad	O
ELISA	O
microplate	O
reader	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
concentration	O
of	O
protein	O
was	O
determined	O
according	O
to	O
the	O
standard	O
curve	O
and	O
expressed	O
as	O
pg	O
/	O
mg	O
of	O
total	O
protein	O
.	O

2	O
.	O
8	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Comparison	B-X
between	B-X
procaine	B-X
and	B-X
isocarboxazid	B-X
metabolism	B-X
in	B-X
vitro	B-X
by	B-X
a	B-X
liver	B-X
microsomal	B-X
amidase-esterase	B-X
.	B-X

Gelatine	O
Zymography	O
<EOS>	B-X
Zymography	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
for	B-X
the	B-X
assay	B-X
of	B-X
different	B-X
hydrolases	B-X
that	B-X
act	B-X
upon	B-X
any	B-X
biological	B-X
macromolecule	B-X
.	B-X
Zymography	B-X
is	B-X
a	B-X
method	B-X
of	B-X
electrophoretic	B-X
separation	B-X
of	B-X
proteases	B-X
under	B-X
non-reducing	B-X
conditions	B-X
in	B-X
a	B-X
polyacrylamide	B-X
gel	B-X
containing	B-X
substrate	B-X
.	B-X
Zymography	B-X
assay	B-X
is	B-X
a	B-X
semiquantitative	B-X
technique	B-X
,	B-X
very	B-X
sensitive	B-X
,	B-X
and	B-X
commonly	B-X
used	B-X
to	B-X
determine	B-X
metalloproteinase	B-X
levels	B-X
in	B-X
different	B-X
types	B-X
of	B-X
biological	B-X
samples	B-X
,	B-X
including	B-X
tissues	B-X
,	B-X
cells	B-X
,	B-X
and	B-X
extracts	B-X
of	B-X
protein	B-X
.	B-X
Zymography	B-X
is	B-X
exquisitely	B-X
sensitive	B-X
but	B-X
offers	B-X
no	B-X
loading	B-X
control	B-X
to	B-X
ensure	B-X
equal	B-X
sample	B-X
loading	B-X
.	B-X

Cells	O
of	O
four	O
groups	O
were	O
homogenized	O
in	O
lysis	O
buffer	O
containing	O
50	O
mM	O
Tris	O
-	O
HCl	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
CaCl2	O
,	O
0	O
.	O
2	O
mM	O
NaN3	O
,	O
and	O
0	O
.	O
01	O
%	O
Triton	O
.	O

Soluble	O
extracts	O
were	O
separated	O
by	O
centrifugation	O
and	O
stored	O
at	O
-	O
20degreesC	O
.	O

Gelatin	O
zymography	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Genmed	O
Scientifics	O
Inc	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Briefly	O
,	O
40	O
mug	O
cytosolic	O
protein	O
extracts	O
were	O
separated	O
by	O
electrophoresis	O
.	O

Then	O
the	O
proteins	O
were	O
renatured	O
by	O
incubation	O
in	O
2	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
and	O
then	O
incubated	O
in	O
substrate	O
buffer	O
for	O
40	O
h	O
at	O
37degreesC	O
to	O
enable	O
the	O
MMP9	B-Protein
to	O
cleave	O
the	O
gelatin	O
.	O

After	O
rinsing	O
in	O
water	O
,	O
each	O
gel	O
was	O
stained	O
with	O
Coomassie	O
blue	O
for	O
1	O
h	O
and	O
destained	O
in	O
50	O
%	O
methanol	O
.	O

Proteolytic	O
activities	O
were	O
showed	O
by	O
clear	O
bands	O
in	O
blue	O
gel	O
which	O
indicates	O
the	O
lysis	O
of	O
the	O
substrate	O
.	O

Quantification	O
of	O
MMP9	B-Protein
band	O
density	O
was	O
performed	O
with	O
image	O
analysis	O
program	O
ImageJ	O
.	O

2	O
.	O
9	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Radiochemical	B-X
assay	B-X
of	B-X
glutathione	B-X
S-epoxide	B-X
transferase	B-X
and	B-X
its	B-X
enhancement	B-X
by	B-X
phenobarbital	B-X
in	B-X
rat	B-X
liver	B-X
in	B-X
vivo	B-X
.	B-X

Statistical	O
Analysis	O

Data	O
were	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
and	O
evaluated	O
by	O
ANOVA	O
and	O
LSD	O
multiple	O
comparison	O
test	O
.	O

P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
to	O
be	O
significant	O
.	O

All	O
analyses	O
were	O
performed	O
by	O
using	O
SPSS	O
18	O
.	O
0	O
software	O
.	O

3	O
.	O
1	O
.	O
<EOS>	B-X
Formate	B-X
assay	B-X
in	B-X
body	B-X
fluids	B-X
:	B-X
application	B-X
in	B-X
methanol	B-X
poisoning	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Depletion	O
of	O
Nrf2	O
Aggravated	O
the	O
Cell	O
Death	O
in	O
Astrocytes	O
after	O
Scratch	O
Injury	O

Cell	O
death	O
was	O
detected	O
by	O
microscope	O
and	O
CCK	O
-	O
8	O
analysis	O
at	O
24	O
h	O
after	O
scratch	O
.	O

The	O
detachment	O
from	O
culture	O
plate	O
,	O
cell	O
lost	O
,	O
and	O
cytoplasmic	O
process	O
distortion	O
were	O
mostly	O
observed	O
in	O
both	O
sides	O
of	O
scratch	O
line	O
in	O
group	O
KO	O
TBI	O
.	O

CCK	O
-	O
8	O
assay	O
also	O
showed	O
lower	O
OD	O
value	O
of	O
group	O
KO	O
TBI	O
(	O
0	O
.	O
38	O
+	O
/	O
-	O
0	O
.	O
064	O
)	O
than	O
that	O
of	O
group	O
WT	O
TBI	O
(	O
0	O
.	O
98	O
+	O
/	O
-	O
0	O
.	O
098	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
which	O
also	O
suggested	O
more	O
cell	O
death	O
in	O
group	O
KO	O
TBI	O
(	O
Figure	O
1	O
)	O
.	O

There	O
was	O
no	O
difference	O
between	O
two	O
sham	O
-	O
operated	O
groups	O
.	O
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
evaluate	B-X
safety	B-X
and	B-X
blood	B-X
pressure	B-X
response	B-X
after	B-X
renal	B-X
denervation	B-X
or	B-X
sham	B-X
control	B-X
in	B-X
patients	B-X
with	B-X
uncontrolled	B-X
hypertension	B-X
on	B-X
antihypertensive	B-X
medications	B-X
with	B-X
drug	B-X
adherence	B-X
testing	B-X
.	B-X
Adults	B-X
with	B-X
resistant	B-X
hypertension	B-X
(	B-X
seated	B-X
office	B-X
blood	B-X
pressure	B-X
≥150/90	B-X
mmHg	B-X
and	B-X
24-hour	B-X
ambulatory	B-X
systolic	B-X
blood	B-X
pressure	B-X
≥140	B-X
mmHg	B-X
)	B-X
with	B-X
suitable	B-X
renal	B-X
artery	B-X
anatomy	B-X
were	B-X
randomized	B-X
to	B-X
ultrasound	B-X
renal	B-X
denervation	B-X
or	B-X
a	B-X
sham	B-X
procedure	B-X
.	B-X
A	B-X
total	B-X
of	B-X
143	B-X
patients	B-X
were	B-X
included	B-X
(	B-X
72	B-X
renal	B-X
denervation	B-X
,	B-X
71	B-X
sham	B-X
control	B-X
)	B-X
.	B-X
Reduction	B-X
from	B-X
baseline	B-X
in	B-X
24-hour	B-X
ambulatory	B-X
systolic	B-X
blood	B-X
pressure	B-X
at	B-X
3	B-X
months	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
the	B-X
renal	B-X
denervation	B-X
(	B-X
-6.6	B-X
mmHg	B-X
)	B-X
and	B-X
sham	B-X
control	B-X
(	B-X
-6.5	B-X
mmHg	B-X
)	B-X
groups	B-X
(	B-X
difference	B-X
:	B-X
-0.1	B-X
,	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
-5.5	B-X
,	B-X
5.3	B-X
;	B-X
p	B-X
=	B-X
0.971	B-X
)	B-X
.	B-X
Reductions	B-X
from	B-X
baseline	B-X
in	B-X
home	B-X
and	B-X
office	B-X
systolic	B-X
blood	B-X
pressure	B-X
(	B-X
differences	B-X
:	B-X
-1.8	B-X
mmHg	B-X
[	B-X
p	B-X
=	B-X
0.488	B-X
]	B-X
and	B-X
-2.0	B-X
mmHg	B-X
[	B-X
p	B-X
=	B-X
0.511	B-X
]	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
and	B-X
medication	B-X
load	B-X
,	B-X
did	B-X
not	B-X
differ	B-X
significantly	B-X
between	B-X
the	B-X
two	B-X
groups	B-X
.	B-X
This	B-X
study	B-X
did	B-X
not	B-X
show	B-X
a	B-X
significant	B-X
difference	B-X
in	B-X
ambulatory	B-X
blood	B-X
pressure	B-X
reductions	B-X
between	B-X
renal	B-X
denervation	B-X
and	B-X
a	B-X
sham	B-X
procedure	B-X
in	B-X
treated	B-X
patients	B-X
with	B-X
resistant	B-X
hypertension	B-X
.	B-X
Although	B-X
blood	B-X
pressure	B-X
reduction	B-X
after	B-X
renal	B-X
denervation	B-X
was	B-X
similar	B-X
to	B-X
other	B-X
sham-controlled	B-X
studies	B-X
,	B-X
the	B-X
sham	B-X
group	B-X
in	B-X
this	B-X
study	B-X
showed	B-X
much	B-X
greater	B-X
reduction	B-X
.	B-X
This	B-X
unexpected	B-X
blood	B-X
pressure	B-X
reduction	B-X
in	B-X
the	B-X
sham	B-X
control	B-X
group	B-X
highlights	B-X
study	B-X
design	B-X
issues	B-X
that	B-X
will	B-X
be	B-X
addressed	B-X
in	B-X
a	B-X
new	B-X
trial	B-X
.	B-X

3	O
.	O
2	O
.	O
<EOS>	B-X
Delineation	B-X
of	B-X
the	B-X
intimate	B-X
details	B-X
of	B-X
the	B-X
backbone	B-X
conformation	B-X
of	B-X
pyridine	B-X
nucleotide	B-X
coenzymes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Disruption	O
of	O
Nrf2	O
Enhanced	O
Upregulation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
Binding	O
Activity	O
after	O
Scratch	O
Injury	O

It	O
has	O
been	O
reported	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
in	O
brain	O
after	O
TBI	O
[	O
2	O
]	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
revealed	B-X
that	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammation	B-X
are	B-X
the	B-X
main	B-X
contributors	B-X
to	B-X
secondary	B-X
injury	B-X
after	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
In	B-X
an	B-X
earlier	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
lutein/zeaxanthin	B-X
isomers	B-X
(	B-X
L/Zi	B-X
)	B-X
exert	B-X
antioxidative	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
by	B-X
activating	B-X
the	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
and	B-X
nuclear	B-X
factor-erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
pathways	B-X
.	B-X
However	B-X
,	B-X
its	B-X
precise	B-X
role	B-X
and	B-X
underlying	B-X
mechanisms	B-X
were	B-X
largely	B-X
unknown	B-X
after	B-X
TBI	B-X
.	B-X
This	B-X
study	B-X
was	B-X
conducted	B-X
to	B-X
investigate	B-X
the	B-X
potential	B-X
mechanism	B-X
of	B-X
L/Zi	B-X
isomers	B-X
in	B-X
a	B-X
TBI	B-X
model	B-X
induced	B-X
by	B-X
a	B-X
cold	B-X
injury	B-X
model	B-X
in	B-X
mice	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
L/Zi	B-X
,	B-X
male	B-X
C57BL/6j	B-X
mice-induced	B-X
brain	B-X
injury	B-X
using	B-X
the	B-X
cold	B-X
trauma	B-X
model	B-X
was	B-X
allocated	B-X
into	B-X
two	B-X
groups	B-X
(	B-X
n	B-X
=	B-X
7	B-X
)	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TBI	B-X
+	B-X
vehicle	B-X
group	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TBI	B-X
+	B-X
L/Zi	B-X
group	B-X
(	B-X
20	B-X
mg/kg	B-X
BW	B-X
)	B-X
.	B-X
Brain	B-X
samples	B-X
were	B-X
collected	B-X
24	B-X
h	B-X
later	B-X
for	B-X
analyses	B-X
.	B-X
L/Zi	B-X
given	B-X
immediately	B-X
after	B-X
the	B-X
injury	B-X
decreased	B-X
infarct	B-X
volume	B-X
and	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
permeability	B-X
;	B-X
L/Zi	B-X
treatment	B-X
also	B-X
significantly	B-X
reduced	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
including	B-X
interleukin1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
,	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
and	B-X
NF-κB	B-X
levels	B-X
and	B-X
increased	B-X
growth-associated	B-X
protein	B-X
43	B-X
(	B-X
GAP-43	B-X
)	B-X
,	B-X
neural	B-X
cell	B-X
adhesion	B-X
molecule	B-X
(	B-X
NCAM	B-X
)	B-X
,	B-X
brain-derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
,	B-X
and	B-X
Nrf2	B-X
levels	B-X
compared	B-X
with	B-X
vehicle	B-X
control	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
L/Zi	B-X
improves	B-X
mitochondrial	B-X
function	B-X
in	B-X
TBI	B-X
models	B-X
,	B-X
possibly	B-X
decreasing	B-X
inflammation	B-X
and	B-X
activating	B-X
the	B-X
Nrf2	B-X
pathway	B-X
.	B-X

Here	O
,	O
we	O
studied	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
of	O
astrocytes	O
from	O
Nrf2	O
WT	O
or	O
KO	O
mice	O
by	O
EMSA	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
Primary	B-X
cultured	B-X
astrocytes	B-X
were	B-X
scratched	B-X
to	B-X
mimic	B-X
the	B-X
traumatic	B-X
injury	B-X
in	B-X
vitro	B-X
.	B-X
Then	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
was	B-X
evaluated	B-X
by	B-X
EMSA	B-X
.	B-X
The	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
MMP9	B-X
were	B-X
also	B-X
evaluated	B-X
.	B-X
Gelatin	B-X
zymography	B-X
was	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
activity	B-X
of	B-X
MMP9	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
mentioned	B-X
above	B-X
were	B-X
upregulated	B-X
at	B-X
24	B-X
h	B-X
after	B-X
scratch	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
MMP9	B-X
were	B-X
also	B-X
elevated	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

Scratch	O
injury	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
astrocytes	O
of	O
both	O
genotypes	O
,	O
while	O
higher	O
NF	O
-	O
kappaB	O
activity	O
was	O
observed	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
2	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
173	O
versus	O
2	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
072	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
2	O
)	O
.	O

3	O
.	O
3	O
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Expression	O
of	O
Proinflammatory	O
Cytokines	O
Was	O
Elevated	O
in	O
Nrf2	O
Knockout	O
Astrocytes	O
after	O
Scratch	O
Injury	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
proved	B-X
that	B-X
Nrf2	B-X
depletion	B-X
enhances	B-X
inflammatory	B-X
process	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
the	B-X
brain	B-X
after	B-X
TBI	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
relationship	B-X
between	B-X
Nrf2	B-X
and	B-X
NF-κB	B-X
in	B-X
astrocytes	B-X
after	B-X
TBI	B-X
.	B-X
Hence	B-X
,	B-X
we	B-X
used	B-X
primary	B-X
cultured	B-X
astrocytes	B-X
from	B-X
either	B-X
Nrf2	B-X
wildtype	B-X
or	B-X
knockout	B-X
mice	B-X
to	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
Nrf2	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
a	B-X
model	B-X
of	B-X
TBI	B-X
in	B-X
vitro	B-X
.	B-X
And	B-X
such	B-X
tendency	B-X
was	B-X
much	B-X
more	B-X
prominent	B-X
in	B-X
Nrf2	B-X
KO	B-X
astrocytes	B-X
than	B-X
that	B-X
in	B-X
WT	B-X
astrocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
Nrf2	B-X
may	B-X
induce	B-X
more	B-X
aggressive	B-X
inflammation	B-X
through	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
downstream	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
astrocytes	B-X
.	B-X

As	O
we	O
all	O
know	O
,	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
are	O
regulated	O
by	O
NF	O
-	O
kappaB	O
and	O
reflect	O
the	O
endogenous	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

It	O
has	O
been	O
revealed	O
that	O
these	O
proinflammatory	O
cytokines	O
are	O
increased	O
after	O
TBI	O
in	O
animals	O
[	O
2	O
,	O
8	O
]	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
revealed	B-X
that	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammation	B-X
are	B-X
the	B-X
main	B-X
contributors	B-X
to	B-X
secondary	B-X
injury	B-X
after	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
In	B-X
an	B-X
earlier	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
lutein/zeaxanthin	B-X
isomers	B-X
(	B-X
L/Zi	B-X
)	B-X
exert	B-X
antioxidative	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
by	B-X
activating	B-X
the	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
and	B-X
nuclear	B-X
factor-erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
pathways	B-X
.	B-X
However	B-X
,	B-X
its	B-X
precise	B-X
role	B-X
and	B-X
underlying	B-X
mechanisms	B-X
were	B-X
largely	B-X
unknown	B-X
after	B-X
TBI	B-X
.	B-X
This	B-X
study	B-X
was	B-X
conducted	B-X
to	B-X
investigate	B-X
the	B-X
potential	B-X
mechanism	B-X
of	B-X
L/Zi	B-X
isomers	B-X
in	B-X
a	B-X
TBI	B-X
model	B-X
induced	B-X
by	B-X
a	B-X
cold	B-X
injury	B-X
model	B-X
in	B-X
mice	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
L/Zi	B-X
,	B-X
male	B-X
C57BL/6j	B-X
mice-induced	B-X
brain	B-X
injury	B-X
using	B-X
the	B-X
cold	B-X
trauma	B-X
model	B-X
was	B-X
allocated	B-X
into	B-X
two	B-X
groups	B-X
(	B-X
n	B-X
=	B-X
7	B-X
)	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TBI	B-X
+	B-X
vehicle	B-X
group	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TBI	B-X
+	B-X
L/Zi	B-X
group	B-X
(	B-X
20	B-X
mg/kg	B-X
BW	B-X
)	B-X
.	B-X
Brain	B-X
samples	B-X
were	B-X
collected	B-X
24	B-X
h	B-X
later	B-X
for	B-X
analyses	B-X
.	B-X
L/Zi	B-X
given	B-X
immediately	B-X
after	B-X
the	B-X
injury	B-X
decreased	B-X
infarct	B-X
volume	B-X
and	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
permeability	B-X
;	B-X
L/Zi	B-X
treatment	B-X
also	B-X
significantly	B-X
reduced	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
including	B-X
interleukin1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
,	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
and	B-X
NF-κB	B-X
levels	B-X
and	B-X
increased	B-X
growth-associated	B-X
protein	B-X
43	B-X
(	B-X
GAP-43	B-X
)	B-X
,	B-X
neural	B-X
cell	B-X
adhesion	B-X
molecule	B-X
(	B-X
NCAM	B-X
)	B-X
,	B-X
brain-derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
,	B-X
and	B-X
Nrf2	B-X
levels	B-X
compared	B-X
with	B-X
vehicle	B-X
control	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
L/Zi	B-X
improves	B-X
mitochondrial	B-X
function	B-X
in	B-X
TBI	B-X
models	B-X
,	B-X
possibly	B-X
decreasing	B-X
inflammation	B-X
and	B-X
activating	B-X
the	B-X
Nrf2	B-X
pathway	B-X
.	B-X

And	O
our	O
previous	O
study	O
has	O
proved	O
that	O
higher	O
levels	O
of	O
such	O
proinflammatory	O
cytokines	O
were	O
observed	O
in	O
the	O
brain	O
of	O
Nrf2	O
-	O
deficient	O
mice	O
after	O
TBI	O
[	O
5	O
]	O
.	O

But	O
it	O
is	O
still	O
ambiguous	O
about	O
the	O
relationship	O
between	O
these	O
cytokines	O
and	O
Nrf2	O
in	O
astrocytes	O
after	O
TBI	O
.	O

Here	O
,	O
we	O
tested	O
the	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
cultured	O
astrocytes	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
by	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

It	O
was	O
shown	O
that	O
the	O
mRNA	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
increased	O
after	O
scratch	O
in	O
both	O
WT	O
and	O
KO	O
astrocytes	O
when	O
compared	O
with	O
their	O
sham	O
counterparts	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
mRNA	O
levels	O
of	O
these	O
cytokines	O
in	O
group	O
KO	O
TBI	O
were	O
much	O
higher	O
than	O
those	O
in	O
group	O
WT	O
TBI	O
(	O
1	O
.	O
66	O
+	O
/	O
-	O
0	O
.	O
085	O
versus	O
1	O
.	O
39	O
+	O
/	O
-	O
0	O
.	O
110	O
for	O
TNF	O
-	O
alpha	O
,	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
064	O
versus	O
0	O
.	O
73	O
+	O
/	O
-	O
0	O
.	O
088	O
for	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
1	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
102	O
versus	O
0	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
073	O
for	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figures	O
3	O
(	O
a	O
)	O
-	O
3	O
(	O
d	O
)	O
)	O
.	O

The	O
results	O
of	O
ELISA	O
revealed	O
that	O
the	O
protein	O
level	O
of	O
TNF	O
-	O
alpha	O
was	O
upregulated	O
after	O
scratch	O
injury	O
in	O
WT	O
and	O
KO	O
astrocytes	O
when	O
compared	O
with	O
their	O
sham	O
counterparts	O
.	O

And	O
it	O
was	O
also	O
higher	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
3	O
.	O
67	O
+	O
/	O
-	O
0	O
.	O
156	O
versus	O
2	O
.	O
31	O
+	O
/	O
-	O
0	O
.	O
087	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
a	O
)	O
)	O
.	O

Similar	O
tendency	O
was	O
observed	O
in	O
protein	O
level	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O
<EOS>	B-X
Compared	B-X
with	B-X
normal	B-X
lesions	B-X
,	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
acyl-CoA	B-X
synthetase	B-X
long-chain	B-X
family	B-X
member	B-X
4	B-X
(	B-X
ACSL4	B-X
)	B-X
,	B-X
prostaglandin-endoperoxide	B-X
synthase	B-X
2	B-X
(	B-X
PTGS2	B-X
)	B-X
,	B-X
and	B-X
transferrin	B-X
receptor	B-X
(	B-X
TFRC	B-X
)	B-X
were	B-X
highly	B-X
expressed	B-X
in	B-X
psoriatic	B-X
lesions	B-X
,	B-X
with	B-X
decreased	B-X
levels	B-X
of	B-X
glutathione	B-X
peroxidase	B-X
4	B-X
(	B-X
GPX4	B-X
)	B-X
,	B-X
ferritin	B-X
light	B-X
chain	B-X
(	B-X
FTL	B-X
)	B-X
,	B-X
and	B-X
ferritin	B-X
heavy	B-X
chain	B-X
1	B-X
(	B-X
FTH1	B-X
)	B-X
.	B-X
The	B-X
protein	B-X
levels	B-X
of	B-X
ACSL4	B-X
and	B-X
GPX4	B-X
were	B-X
consistent	B-X
with	B-X
their	B-X
mRNA	B-X
levels	B-X
.	B-X
A	B-X
similar	B-X
tendency	B-X
of	B-X
ferroptosis	B-X
was	B-X
also	B-X
observed	B-X
in	B-X
erastin-treated	B-X
human	B-X
primary	B-X
keratinocytes	B-X
and	B-X
the	B-X
Imiquimod	B-X
(	B-X
IMQ	B-X
)	B-X
-induced	B-X
model	B-X
of	B-X
psoriasis	B-X
.	B-X
There	B-X
was	B-X
a	B-X
high	B-X
correlation	B-X
between	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
lipid	B-X
oxidation	B-X
and	B-X
the	B-X
Th22/Th17	B-X
response	B-X
in	B-X
keratinocytes	B-X
at	B-X
a	B-X
single-cell	B-X
level	B-X
.	B-X
Additionally	B-X
,	B-X
Fer-1	B-X
blocked	B-X
inflammatory	B-X
responses	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
reducing	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
including	B-X
TNF-α	B-X
,	B-X
IL-6	B-X
,	B-X
IL-1α	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-17	B-X
,	B-X
IL-22	B-X
,	B-X
and	B-X
IL-23	B-X
.	B-X

For	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
it	O
was	O
36	O
.	O
07	O
+	O
/	O
-	O
0	O
.	O
786	O
for	O
group	O
KO	O
TBI	O
while	O
25	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
536	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

For	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
it	O
was	O
190	O
.	O
75	O
+	O
/	O
-	O
6	O
.	O
339	O
for	O
group	O
KO	O
TBI	O
while	O
154	O
.	O
50	O
+	O
/	O
-	O
5	O
.	O
348	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

3	O
.	O
4	O
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Expression	O
and	O
Activity	O
of	O
MMP9	B-Protein
Were	O
Greatly	O
Enhanced	O
in	O
Nrf2	O
Knockout	O
Astrocytes	O
after	O
Scratch	O
Injury	O

MMP9	B-Protein
is	O
an	O
important	O
gelatinase	O
to	O
induce	O
or	O
aggravate	O
the	O
inflammation	O
process	O
.	O
<EOS>	B-X
The	B-X
prolonged	B-X
and	B-X
usually	B-X
clinically	B-X
silent	B-X
progression	B-X
of	B-X
atherosclerosis	B-X
involves	B-X
periods	B-X
of	B-X
smouldering	B-X
inflammation	B-X
,	B-X
punctuated	B-X
by	B-X
episodes	B-X
of	B-X
acute	B-X
activation	B-X
that	B-X
may	B-X
arise	B-X
from	B-X
inflammatory	B-X
mediators	B-X
released	B-X
from	B-X
sites	B-X
of	B-X
extravascular	B-X
injury	B-X
or	B-X
infection	B-X
or	B-X
from	B-X
subclinical	B-X
disruptions	B-X
of	B-X
the	B-X
plaque	B-X
.	B-X
Inflammatory	B-X
mediators	B-X
participate	B-X
in	B-X
both	B-X
processes	B-X
.	B-X
Incorporation	B-X
of	B-X
the	B-X
thrombi	B-X
can	B-X
promote	B-X
plaque	B-X
healing	B-X
and	B-X
progressive	B-X
intimal	B-X
thickening	B-X
that	B-X
can	B-X
aggravate	B-X
stenosis	B-X
and	B-X
further	B-X
limit	B-X
downstream	B-X
blood	B-X
flow	B-X
.	B-X
Inflammatory	B-X
mediators	B-X
regulate	B-X
many	B-X
aspects	B-X
of	B-X
both	B-X
plaque	B-X
disruption	B-X
and	B-X
healing	B-X
process	B-X
.	B-X
Thus	B-X
,	B-X
inflammatory	B-X
processes	B-X
contribute	B-X
to	B-X
all	B-X
phases	B-X
of	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
atherosclerotic	B-X
plaques	B-X
,	B-X
and	B-X
represent	B-X
ripe	B-X
targets	B-X
for	B-X
mitigating	B-X
the	B-X
disease	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
elevated	O
the	O
mRNA	O
,	O
protein	O
levels	O
,	O
and	O
activity	O
of	O
MMP9	B-Protein
in	O
astrocytes	O
at	O
24	O
h	O
after	O
scratch	O
injury	O
by	O
RT	O
-	O
PCR	O
,	O
western	O
blot	O
,	O
and	O
gelatine	O
zymography	O
.	O

Expression	O
of	O
MMP9	B-Protein
was	O
elevated	O
after	O
scratch	O
injury	O
in	O
WT	O
and	O
KO	O
astrocytes	O
as	O
compared	O
with	O
their	O
sham	O
counterparts	O
.	O

The	O
mRNA	O
level	O
of	O
MMP9	B-Protein
was	O
higher	O
in	O
group	O
KO	O
TBI	O
than	O
in	O
group	O
WT	O
TBI	O
(	O
1	O
.	O
36	O
+	O
/	O
-	O
0	O
.	O
090	O
versus	O
1	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
068	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figures	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
e	O
)	O
)	O
.	O

Significant	O
difference	O
was	O
also	O
discovered	O
in	O
MMP9	B-Protein
protein	O
level	O
by	O
western	O
blot	O
,	O
as	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
076	O
for	O
group	O
KO	O
TBI	O
and	O
1	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
048	O
for	O
group	O
WT	O
TBI	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Gelatine	O
zymography	O
revealed	O
higher	O
MMP9	B-Protein
activity	O
in	O
group	O
KO	O
TBI	O
than	O
that	O
in	O
group	O
WT	O
TBI	O
too	O
(	O
101	O
.	O
76	O
+	O
/	O
-	O
6	O
.	O
343	O
versus	O
76	O
.	O
32	O
+	O
/	O
-	O
3	O
.	O
388	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
6	O
)	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
scratch	O
injury	O
induced	O
the	O
upregulation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
overexpression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
in	O
cultured	O
astrocytes	O
.	O

Also	O
we	O
revealed	O
that	O
scratch	O
injury	O
induced	O
higher	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
enhanced	O
expression	O
of	O
proinflammatory	O
cytokines	O
in	O
Nrf2	O
knockout	O
cultured	O
astrocytes	O
than	O
those	O
in	O
wildtype	O
astrocytes	O
for	O
the	O
first	O
time	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
in	O
brain	O
and	O
spinal	O
cord	O
after	O
traumatic	O
injury	O
[	O
2	O
,	O
9	O
]	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
response	B-X
following	B-X
spinal	B-X
cord	B-X
injury	B-X
(	B-X
SCI	B-X
)	B-X
involves	B-X
the	B-X
activation	B-X
of	B-X
resident	B-X
microglia	B-X
and	B-X
the	B-X
infiltration	B-X
of	B-X
macrophages	B-X
.	B-X
Activated	B-X
microglia/macrophages	B-X
have	B-X
either	B-X
detrimental	B-X
or	B-X
beneficial	B-X
effects	B-X
on	B-X
neural	B-X
regeneration	B-X
based	B-X
on	B-X
their	B-X
functional	B-X
polarized	B-X
M1/M2	B-X
subsets	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
or	B-X
AR-deficiency	B-X
(	B-X
KO	B-X
)	B-X
mice	B-X
were	B-X
subjected	B-X
to	B-X
SCI	B-X
by	B-X
a	B-X
spinal	B-X
crush	B-X
injury	B-X
model	B-X
.	B-X
AR	B-X
KO	B-X
mice	B-X
showed	B-X
better	B-X
locomotor	B-X
recovery	B-X
and	B-X
smaller	B-X
injury	B-X
lesion	B-X
areas	B-X
after	B-X
spinal	B-X
cord	B-X
crushing	B-X
compared	B-X
with	B-X
WT	B-X
mice	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
first	B-X
demonstrated	B-X
that	B-X
AR	B-X
deficiency	B-X
repressed	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
in	B-X
vitro	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
autophagy	B-X
.	B-X
AR	B-X
deficiency	B-X
caused	B-X
4-hydroxy-2-	B-X
(	B-X
E	B-X
)	B-X
-nonenal	B-X
(	B-X
4-HNE	B-X
)	B-X
accumulation	B-X
in	B-X
LPS-induced	B-X
macrophages	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
exogenous	B-X
addition	B-X
of	B-X
low	B-X
concentrations	B-X
of	B-X
4-HNE	B-X
in	B-X
LPS-induced	B-X
macrophages	B-X
had	B-X
the	B-X
effect	B-X
of	B-X
promoting	B-X
further	B-X
activation	B-X
of	B-X
NF-κB	B-X
pathway	B-X
,	B-X
whereas	B-X
high	B-X
concentrations	B-X
of	B-X
4-HNE	B-X
had	B-X
inhibitory	B-X
effects	B-X
.	B-X

As	O
a	O
transcript	O
factor	O
,	O
NF	O
-	O
kappaB	O
binds	O
with	O
DNA	O
once	O
it	O
was	O
activated	O
and	O
induces	O
transcription	O
of	O
MMP9	B-Protein
and	O
a	O
battery	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
in	O
brain	O
tissues	O
after	O
TBI	O
[	O
3	O
,	O
10	O
,	O
11	O
]	O
.	O

Our	O
results	O
also	O
revealed	O
that	O
scratch	O
injury	O
induced	O
elevation	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
overexpression	O
of	O
MMP9	B-Protein
,	O
and	O
proinflammatory	O
mediators	O
mentioned	O
above	O
in	O
cultured	O
astrocytes	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
there	O
is	O
an	O
autoregulatory	O
loop	O
among	O
these	O
proinflammatory	O
mediators	O
.	O
<EOS>	B-X
Our	B-X
findings	B-X
suggest	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
that	B-X
enables	B-X
the	B-X
sustained	B-X
induction	B-X
of	B-X
miR-21	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
proinflammatory	B-X
responses	B-X
of	B-X
vascular	B-X
endothelium	B-X
under	B-X
OSS	B-X
.	B-X
In	B-X
turn	B-X
,	B-X
NF-kappaB	B-X
regulates	B-X
the	B-X
transcription	B-X
of	B-X
many	B-X
inflammatory	B-X
mediators	B-X
,	B-X
including	B-X
cytokines	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
intrathecal	B-X
injection	B-X
of	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus-1	B-X
(	B-X
HIV-1	B-X
)	B-X
envelope	B-X
glycoprotein	B-X
,	B-X
gp120	B-X
,	B-X
induces	B-X
mechanical	B-X
allodynia	B-X
via	B-X
the	B-X
release	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
.	B-X
To	B-X
reveal	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
we	B-X
assessed	B-X
inhibitory	B-X
factor	B-X
kappaBalpha	B-X
(	B-X
IkappaBalpha	B-X
)	B-X
mRNA	B-X
expression	B-X
by	B-X
in	B-X
situ	B-X
hybridization	B-X
,	B-X
as	B-X
NF-kappaB	B-X
activation	B-X
up-regulates	B-X
IkappaBalpha	B-X
gene	B-X
expression	B-X
as	B-X
part	B-X
of	B-X
an	B-X
autoregulatory	B-X
feedback	B-X
loop	B-X
.	B-X
Moreover	B-X
,	B-X
IkappaBalpha	B-X
mRNA	B-X
expression	B-X
positively	B-X
correlated	B-X
with	B-X
proinflammatory	B-X
cytokine	B-X
protein	B-X
levels	B-X
in	B-X
lumbosacral	B-X
cerebrospinal	B-X
fluid	B-X
.	B-X

For	O
example	O
,	O
TNF	O
-	O
alpha	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
are	O
potent	O
stimulators	O
for	O
MMP9	B-Protein
in	O
astrocytes	O
[	O
12	O
,	O
13	O
]	O
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
induces	O
overexpression	O
of	O
MMP9	B-Protein
in	O
human	O
colon	O
carcinoma	O
cells	O
[	O
14	O
]	O
,	O
and	O
TNF	O
-	O
alpha	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
also	O
can	O
induce	O
activation	O
of	O
NF	O
-	O
kappaB	O
[	O
15	O
,	O
16	O
]	O
.	O

This	O
autoregulatory	O
loop	O
extremely	O
aggravates	O
the	O
damaging	O
effect	O
of	O
inflammation	O
and	O
induces	O
secondary	O
injury	O
to	O
brain	O
.	O

It	O
is	O
a	O
good	O
choice	O
for	O
targeting	O
on	O
an	O
upstream	O
factor	O
to	O
prevent	O
such	O
autoregulatory	O
loop	O
after	O
TBI	O
.	O

Nrf2	O
-	O
ARE	O
pathway	O
has	O
been	O
proved	O
to	O
be	O
the	O
key	O
regulator	O
in	O
reducing	O
oxidative	O
stress	O
,	O
inflammatory	O
damage	O
,	O
and	O
accumulation	O
of	O
toxic	O
metabolites	O
,	O
which	O
are	O
all	O
involved	O
in	O
TBI	O
.	O
<EOS>	B-X
Secondary	B-X
brain	B-X
injury	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
the	B-X
outcome	B-X
of	B-X
patients	B-X
suffering	B-X
from	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
Previous	B-X
studies	B-X
focused	B-X
on	B-X
one	B-X
of	B-X
these	B-X
mechanisms	B-X
have	B-X
been	B-X
proved	B-X
to	B-X
be	B-X
ineffective	B-X
in	B-X
clinical	B-X
practice	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
target	B-X
,	B-X
which	B-X
can	B-X
interrupt	B-X
multi-mechanisms	B-X
underlying	B-X
TBI	B-X
,	B-X
is	B-X
desirable	B-X
.	B-X
Nrf2-ARE	B-X
pathway	B-X
has	B-X
been	B-X
proved	B-X
to	B-X
be	B-X
the	B-X
key	B-X
regulator	B-X
in	B-X
reducing	B-X
oxidative	B-X
stress	B-X
,	B-X
inflammatory	B-X
damage	B-X
and	B-X
accumulation	B-X
of	B-X
toxic	B-X
metabolites	B-X
,	B-X
which	B-X
are	B-X
all	B-X
involved	B-X
in	B-X
TBI	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
Nrf2-ARE	B-X
pathway	B-X
is	B-X
activated	B-X
after	B-X
TBI	B-X
has	B-X
not	B-X
been	B-X
studied	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
nuclear	B-X
Nrf2	B-X
protein	B-X
level	B-X
was	B-X
detected	B-X
by	B-X
Western	B-X
blot	B-X
,	B-X
and	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
heme	B-X
oxygenase-1	B-X
(	B-X
HO-1	B-X
)	B-X
and	B-X
NAD	B-X
(	B-X
P	B-X
)	B-X
H	B-X
:	B-X
quinone	B-X
oxidoreductase-1	B-X
(	B-X
NQO1	B-X
)	B-X
,	B-X
two	B-X
Nrf2-regulated	B-X
gene	B-X
products	B-X
,	B-X
were	B-X
determined	B-X
using	B-X
reverse-transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
24h	B-X
after	B-X
TBI	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
also	B-X
localized	B-X
the	B-X
expression	B-X
of	B-X
Nrf2	B-X
and	B-X
HO-1	B-X
using	B-X
immunohistochemical	B-X
study	B-X
.	B-X
After	B-X
TBI	B-X
,	B-X
the	B-X
nuclear	B-X
Nrf2	B-X
protein	B-X
level	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
and	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
both	B-X
HO-1	B-X
and	B-X
NQO1	B-X
were	B-X
also	B-X
up	B-X
regulated	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
Nrf2	B-X
and	B-X
HO-1	B-X
were	B-X
localized	B-X
in	B-X
the	B-X
same	B-X
types	B-X
of	B-X
cells	B-X
.	B-X
According	B-X
to	B-X
these	B-X
results	B-X
,	B-X
it	B-X
could	B-X
be	B-X
postulated	B-X
that	B-X
Nrf2-ARE	B-X
pathway	B-X
was	B-X
activated	B-X
in	B-X
brain	B-X
after	B-X
TBI	B-X
.	B-X

Our	O
previous	O
study	O
has	O
proved	O
the	O
augmentation	O
of	O
Nrf2	O
in	O
brain	O
tissue	O
after	O
TBI	O
[	O
17	O
]	O
.	O

Enhanced	O
level	O
of	O
Nrf2	O
activates	O
transcription	O
of	O
a	O
group	O
of	O
antioxidant	O
genes	O
,	O
such	O
as	O
heme	B-Protein
oxygenase	I-Protein
-	I-Protein
1	I-Protein
(	O
HO	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
(	O
NQO1	O
)	O
,	O
which	O
would	O
subsequently	O
reduce	O
the	O
damage	O
in	O
brain	O
[	O
18	O
]	O
.	O

Postinjury	O
administration	O
of	O
SFN	O
,	O
an	O
inducer	O
of	O
Nrf2	O
,	O
significantly	O
improves	O
spatial	O
memory	O
of	O
rat	O
and	O
decreases	O
the	O
immunoreactivity	O
for	O
4	O
-	O
Hydroxynonenal	O
(	O
4	O
-	O
HNE	O
)	O
,	O
a	O
marker	O
of	O
lipid	O
peroxidation	O
,	O
in	O
the	O
cortex	O
and	O
the	O
CA3	O
subfield	O
of	O
hippocampus	O
after	O
TBI	O
[	O
19	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
Nrf2	O
-	O
deficient	O
mice	O
appear	O
more	O
susceptible	O
to	O
TBI	O
.	O

Depletion	O
of	O
Nrf2	O
induces	O
higher	O
expression	O
of	O
proinflammatory	O
mediators	O
in	O
brain	O
after	O
TBI	O
[	O
20	O
]	O
.	O

Here	O
,	O
our	O
results	O
revealed	O
that	O
overexpression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
after	O
scratch	O
injury	O
was	O
more	O
aggravated	O
in	O
cultured	O
Nrf2	O
knockout	O
astrocytes	O
than	O
in	O
wildtype	O
astrocyetes	O
for	O
the	O
first	O
time	O
,	O
and	O
overexpression	O
of	O
these	O
proinflammatory	O
mediators	O
led	O
to	O
more	O
astrocytes	O
deaths	O
.	O

Data	O
obtained	O
from	O
animal	O
studies	O
suggest	O
the	O
possibility	O
that	O
antioxidant	O
effect	O
of	O
Nrf2	O
may	O
be	O
achieved	O
by	O
suppression	O
of	O
proinflammatory	O
pathways	O
which	O
are	O
mediated	O
by	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Administration	O
of	O
SFN	O
is	O
found	O
to	O
be	O
able	O
to	O
inhibit	O
IKK	O
/	O
IkappaB	O
phosphorylation	O
and	O
p65	B-Protein
NF	O
-	O
kappaB	O
subunit	O
nuclear	O
translocation	O
,	O
consequently	O
alleviating	O
NF	O
-	O
kappaB	O
signaling	O
[	O
21	O
]	O
.	O

And	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
could	O
be	O
attenuated	O
by	O
diverse	O
Nrf2	O
activators	O
,	O
such	O
as	O
SFN	O
and	O
curcumin	O
(	O
CUR	O
)	O
[	O
22	O
]	O
.	O

Furthermore	O
,	O
our	O
previous	O
studies	O
indicate	O
that	O
depletion	O
of	O
Nrf2	O
induces	O
augmentation	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
inflammatory	O
response	O
in	O
lung	O
,	O
brain	O
,	O
and	O
intestine	O
after	O
TBI	O
[	O
4	O
,	O
5	O
,	O
23	O
]	O
.	O

Results	O
from	O
this	O
study	O
further	O
confirmed	O
such	O
relationship	O
existed	O
in	O
cultured	O
astrocytes	O
after	O
scratch	O
injury	O
.	O

Enhanced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
also	O
discovered	O
in	O
lung	O
,	O
macrophages	O
,	O
and	O
mouse	O
embryonic	O
fibroblasts	O
of	O
Nrf2	O
-	O
deficient	O
mice	O
after	O
experimental	O
sepsis	O
[	O
24	O
]	O
.	O

Interestingly	O
,	O
it	O
is	O
reported	O
that	O
NF	O
-	O
kappaB	O
can	O
inhibit	O
Nrf2	O
at	O
transcriptional	O
level	O
.	O
<EOS>	B-X
In	B-X
the	B-X
2-h	B-X
iE-DAP	B-X
group	B-X
,	B-X
when	B-X
levels	B-X
of	B-X
inflammation	B-X
peaked	B-X
,	B-X
iE-DAP	B-X
treatment	B-X
increased	B-X
both	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
NOD1	B-X
,	B-X
inhibitor	B-X
of	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NFKBIA	B-X
,	B-X
IκB	B-X
)	B-X
,	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
subunit	B-X
p65	B-X
(	B-X
RELA	B-X
,	B-X
NF-κB	B-X
p65	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
IL6	B-X
and	B-X
IL8	B-X
and	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
in	B-X
cell	B-X
culture	B-X
supernatants	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
8	B-X
mM	B-X
GLN	B-X
pretreatment	B-X
inhibited	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
inflammatory-related	B-X
factors	B-X
by	B-X
suppressing	B-X
the	B-X
NOD1/NF-κB	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
8-h	B-X
iE-DAP	B-X
group	B-X
,	B-X
iE-DAP	B-X
treatment	B-X
decreased	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
extracellular	B-X
regulated	B-X
kinase	B-X
(	B-X
Erk	B-X
,	B-X
ERK	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-associated	B-X
factor2	B-X
(	B-X
NFE2L2	B-X
,	B-X
Nrf2	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
superoxide	B-X
dismutase	B-X
1	B-X
(	B-X
SOD1	B-X
)	B-X
,	B-X
catalase	B-X
(	B-X
CAT	B-X
)	B-X
,	B-X
coenzyme	B-X
II	B-X
oxidoreductase	B-X
1	B-X
(	B-X
NQO1	B-X
)	B-X
,	B-X
and	B-X
heme	B-X
oxygenase	B-X
1	B-X
(	B-X
HMOX1	B-X
,	B-X
HO1	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
iE-DAP	B-X
treatment	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
malondialdehyde	B-X
in	B-X
BMEC	B-X
when	B-X
oxidative	B-X
stress	B-X
levels	B-X
peaked	B-X
.	B-X
Interestingly	B-X
,	B-X
4	B-X
mM	B-X
GLN	B-X
pretreatment	B-X
induced	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
antioxidative	B-X
stress-related	B-X
factors	B-X
and	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
in	B-X
BMEC	B-X
by	B-X
promoting	B-X
the	B-X
ERK/Nrf2	B-X
pathway	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
showing	B-X
that	B-X
GLN	B-X
protects	B-X
against	B-X
iE-DAP-induced	B-X
inflammation	B-X
and	B-X
oxidative	B-X
stress	B-X
via	B-X
the	B-X
NOD1/NF-κB	B-X
and	B-X
ERK/Nrf2	B-X
pathways	B-X
in	B-X
BMEC	B-X
.	B-X

NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
repressed	O
the	O
Nrf2	O
-	O
ARE	O
pathway	O
at	O
transcriptional	O
level	O
by	O
competitive	O
interaction	O
with	O
the	O
CH1	O
-	O
KIX	O
domain	O
of	O
CBP	O
or	O
local	O
histone	O
hypoacetylation	O
[	O
25	O
]	O
.	O
<EOS>	B-X
The	B-X
luteinizing	B-X
hormone	B-X
receptor	B-X
(	B-X
LHR	B-X
)	B-X
transcription	B-X
is	B-X
subject	B-X
to	B-X
an	B-X
epigenetic	B-X
regulatory	B-X
mode	B-X
whereby	B-X
the	B-X
proximal	B-X
Sp1	B-X
site	B-X
acts	B-X
as	B-X
an	B-X
anchor	B-X
to	B-X
recruit	B-X
histone	B-X
deacetylases	B-X
(	B-X
HDAC	B-X
)	B-X
1/2	B-X
and	B-X
the	B-X
Sin3A	B-X
co-repressor	B-X
complex	B-X
.	B-X
This	B-X
results	B-X
in	B-X
promoter-localized	B-X
histone	B-X
hypo-acetylation	B-X
that	B-X
contributes	B-X
to	B-X
the	B-X
silencing	B-X
of	B-X
LHR	B-X
transcriptional	B-X
expression	B-X
.	B-X
Chromatin	B-X
changes	B-X
resulting	B-X
from	B-X
site-specific	B-X
acetylation	B-X
and	B-X
methylation	B-X
of	B-X
histones	B-X
regulate	B-X
LHR	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
HDAC	B-X
inhibitor	B-X
TSA-induced	B-X
cell-specific	B-X
phosphatase	B-X
release	B-X
from	B-X
the	B-X
promoter	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
an	B-X
'on	B-X
'	B-X
mechanism	B-X
for	B-X
Sp1	B-X
phosphorylation	B-X
by	B-X
phosphatidylinositol	B-X
3-kinase/protein	B-X
kinase	B-X
Czeta	B-X
(	B-X
PI3K/PKCzeta	B-X
)	B-X
at	B-X
Ser641	B-X
,	B-X
leading	B-X
to	B-X
p107	B-X
repressor	B-X
derecruitment	B-X
and	B-X
LHR	B-X
transcriptional	B-X
activation	B-X
.	B-X
Maximal	B-X
derepression	B-X
of	B-X
the	B-X
LHR	B-X
gene	B-X
is	B-X
dependent	B-X
on	B-X
complete	B-X
DNA	B-X
demethylation	B-X
of	B-X
the	B-X
promoter	B-X
in	B-X
conjunction	B-X
with	B-X
histone	B-X
hyperacetylation	B-X
and	B-X
release	B-X
of	B-X
repressors	B-X
(	B-X
p107	B-X
and	B-X
HDAC/Sin3A	B-X
)	B-X
.	B-X
Independently	B-X
,	B-X
the	B-X
PKC-alpha/Erk	B-X
pathway	B-X
,	B-X
participates	B-X
in	B-X
LHR	B-X
gene	B-X
expression	B-X
through	B-X
induction	B-X
of	B-X
Sp1	B-X
phosphorylation	B-X
at	B-X
Ser	B-X
site	B-X
(	B-X
s	B-X
)	B-X
other	B-X
than	B-X
Ser641	B-X
.	B-X
This	B-X
causes	B-X
dissociation	B-X
of	B-X
the	B-X
HDAC1/mSin3A	B-X
from	B-X
the	B-X
promoter	B-X
,	B-X
recruitment	B-X
of	B-X
TFIIB	B-X
and	B-X
Pol	B-X
II	B-X
,	B-X
and	B-X
transcriptional	B-X
activation	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
LHR	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
complex	B-X
and	B-X
diverse	B-X
networks	B-X
,	B-X
in	B-X
which	B-X
coordination	B-X
and	B-X
interactions	B-X
between	B-X
these	B-X
regulatory	B-X
effectors	B-X
are	B-X
crucial	B-X
for	B-X
silencing/activation	B-X
of	B-X
LHR	B-X
expression	B-X
.	B-X

All	O
these	O
findings	O
indicate	O
the	O
potential	O
complicate	O
crosstalk	O
between	O
NF	O
-	O
kappaB	O
and	O
Nrf2	O
,	O
which	O
may	O
be	O
regulated	O
by	O
the	O
upstream	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPKs	O
)	O
pathway	O
[	O
26	O
]	O
.	O

It	O
has	O
been	O
confirmed	O
that	O
Nrf2	O
is	O
mainly	O
detected	O
in	O
nucleus	O
of	O
astrocytes	O
after	O
TBI	O
[	O
18	O
]	O
.	O

In	O
view	O
of	O
the	O
fact	O
that	O
Nrf2	O
is	O
a	O
transcription	O
factor	O
which	O
should	O
take	O
function	O
mainly	O
in	O
nucleus	O
,	O
it	O
can	O
be	O
reasoned	O
that	O
astrocytes	O
may	O
be	O
one	O
kind	O
of	O
respondent	O
cells	O
in	O
activation	O
of	O
Nrf2	O
-	O
ARE	O
pathway	O
after	O
TBI	O
.	O

Previous	O
study	O
identified	O
the	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
cultured	O
astrocytes	O
after	O
treatment	O
with	O
LPS	O
or	O
oxyhemoglobin	O
[	O
27	O
,	O
28	O
]	O
.	O
<EOS>	B-X
In	B-X
1970	B-X
,	B-X
Perutz	B-X
tried	B-X
to	B-X
put	B-X
the	B-X
allosteric	B-X
mechanism	B-X
of	B-X
hemoglobin	B-X
,	B-X
proposed	B-X
by	B-X
Monod	B-X
,	B-X
Wyman	B-X
and	B-X
Changeux	B-X
in	B-X
1965	B-X
,	B-X
on	B-X
a	B-X
stereochemical	B-X
basis	B-X
.	B-X
The	B-X
equilibrium	B-X
was	B-X
thought	B-X
to	B-X
be	B-X
governed	B-X
primarily	B-X
by	B-X
the	B-X
positions	B-X
of	B-X
the	B-X
iron	B-X
atoms	B-X
relative	B-X
to	B-X
the	B-X
porphyrin	B-X
:	B-X
out-of-plane	B-X
in	B-X
five-coordinated	B-X
,	B-X
high-spin	B-X
deoxyhemoglobin	B-X
,	B-X
and	B-X
in-plane	B-X
in	B-X
six-coordinated	B-X
,	B-X
low-spin	B-X
oxyhemoglobin	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
potential	B-X
effect	B-X
of	B-X
CD24	B-X
in	B-X
astrocytes	B-X
on	B-X
neuron	B-X
growth	B-X
in	B-X
the	B-X
hippocampus	B-X
,	B-X
we	B-X
used	B-X
a	B-X
Transwell	B-X
co-culture	B-X
system	B-X
of	B-X
hippocampal	B-X
astrocytes	B-X
and	B-X
neurons	B-X
,	B-X
and	B-X
oxyhemoglobin	B-X
(	B-X
OxyHb	B-X
)	B-X
was	B-X
added	B-X
to	B-X
the	B-X
culture	B-X
medium	B-X
to	B-X
mimic	B-X
SAH	B-X
in	B-X
vitro	B-X
.	B-X
A	B-X
specific	B-X
lentivirus	B-X
was	B-X
used	B-X
to	B-X
knock	B-X
down	B-X
CD24	B-X
expression	B-X
in	B-X
astrocytes	B-X
,	B-X
which	B-X
was	B-X
verified	B-X
by	B-X
western	B-X
blot	B-X
,	B-X
quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
,	B-X
and	B-X
immunofluorescent	B-X
staining	B-X
.	B-X
We	B-X
first	B-X
determined	B-X
the	B-X
augmented	B-X
expression	B-X
level	B-X
of	B-X
CD24	B-X
in	B-X
hippocampal	B-X
astrocytes	B-X
after	B-X
SAH	B-X
.	B-X
A	B-X
similar	B-X
result	B-X
was	B-X
observed	B-X
in	B-X
cultured	B-X
astrocytes	B-X
exposed	B-X
to	B-X
OxyHb	B-X
,	B-X
and	B-X
a	B-X
corresponding	B-X
change	B-X
in	B-X
SHP2/ERK	B-X
was	B-X
also	B-X
noticed	B-X
.	B-X
CD24	B-X
in	B-X
astrocytes	B-X
was	B-X
then	B-X
downregulated	B-X
by	B-X
the	B-X
lentivirus	B-X
,	B-X
which	B-X
led	B-X
to	B-X
the	B-X
impairment	B-X
of	B-X
axons	B-X
and	B-X
dendrites	B-X
on	B-X
the	B-X
co-cultured	B-X
neurons	B-X
.	B-X
Aggravated	B-X
neuronal	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
CD24	B-X
downregulation	B-X
in	B-X
astrocytes	B-X
,	B-X
which	B-X
might	B-X
be	B-X
a	B-X
result	B-X
of	B-X
a	B-X
lower	B-X
level	B-X
of	B-X
brain	B-X
derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
knock-down	B-X
of	B-X
CD24	B-X
in	B-X
astrocytes	B-X
suppressed	B-X
hippocampal	B-X
neuron	B-X
growth	B-X
,	B-X
in	B-X
which	B-X
the	B-X
SHP2-ERK	B-X
signaling	B-X
pathway	B-X
and	B-X
BNDF	B-X
were	B-X
possibly	B-X
involved	B-X
.	B-X

Another	O
study	O
revealed	O
that	O
after	O
middle	O
cerebral	O
artery	O
occlusion	O
,	O
MMP9	B-Protein
-	O
positive	O
astrocytes	O
were	O
observed	O
in	O
brain	O
tissues	O
by	O
immunohistochemistry	O
[	O
29	O
]	O
.	O

Those	O
results	O
indicate	O
the	O
role	O
of	O
astrocytes	O
in	O
inflammatory	O
process	O
after	O
brain	O
injury	O
.	O
<EOS>	B-X
Inflammation	B-X
in	B-X
the	B-X
brain	B-X
is	B-X
a	B-X
double-edged	B-X
process	B-X
that	B-X
may	B-X
be	B-X
beneficial	B-X
in	B-X
promoting	B-X
homeostasis	B-X
and	B-X
repair	B-X
,	B-X
but	B-X
can	B-X
also	B-X
result	B-X
in	B-X
tissue	B-X
injury	B-X
through	B-X
the	B-X
damaging	B-X
potential	B-X
of	B-X
inflammatory	B-X
mediators	B-X
.	B-X
Thus	B-X
,	B-X
control	B-X
mechanisms	B-X
that	B-X
minimize	B-X
the	B-X
extent	B-X
of	B-X
the	B-X
inflammatory	B-X
reaction	B-X
are	B-X
necessary	B-X
in	B-X
order	B-X
to	B-X
help	B-X
preserve	B-X
brain	B-X
architecture	B-X
and	B-X
restore	B-X
function	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
neurotrophic	B-X
factors	B-X
such	B-X
as	B-X
nerve	B-X
growth	B-X
factor	B-X
(	B-X
NGF	B-X
)	B-X
is	B-X
increased	B-X
after	B-X
brain	B-X
injury	B-X
,	B-X
in	B-X
part	B-X
mediated	B-X
by	B-X
effects	B-X
on	B-X
astrocytes	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
and	B-X
cytokines	B-X
produced	B-X
by	B-X
immune	B-X
cells	B-X
.	B-X
Multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
and	B-X
the	B-X
disease	B-X
model	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
are	B-X
neurodegenerative	B-X
disorders	B-X
whereby	B-X
chronic	B-X
destruction	B-X
of	B-X
the	B-X
brain	B-X
parenchyma	B-X
results	B-X
from	B-X
an	B-X
autoaggressive	B-X
,	B-X
immune-mediated	B-X
inflammatory	B-X
process	B-X
and	B-X
insufficient	B-X
tissue	B-X
regeneration	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
evidence	B-X
indicating	B-X
that	B-X
the	B-X
increased	B-X
production	B-X
of	B-X
NGF	B-X
and	B-X
other	B-X
trophic	B-X
factors	B-X
in	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
during	B-X
these	B-X
diseases	B-X
can	B-X
suppress	B-X
inflammation	B-X
by	B-X
switching	B-X
the	B-X
immune	B-X
response	B-X
to	B-X
an	B-X
anti-inflammatory	B-X
,	B-X
suppressive	B-X
mode	B-X
in	B-X
a	B-X
brain-specific	B-X
environment	B-X
.	B-X
Thus	B-X
,	B-X
trophic	B-X
factors	B-X
networks	B-X
in	B-X
the	B-X
adult	B-X
CNS	B-X
not	B-X
only	B-X
protects	B-X
axons	B-X
and	B-X
myelin	B-X
but	B-X
appear	B-X
to	B-X
also	B-X
actively	B-X
contribute	B-X
to	B-X
the	B-X
maintenance	B-X
of	B-X
the	B-X
brain	B-X
immune	B-X
privilege	B-X
.	B-X
These	B-X
agents	B-X
may	B-X
represent	B-X
good	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
in	B-X
MS	B-X
and	B-X
other	B-X
chronic	B-X
CNS	B-X
inflammatory	B-X
diseases	B-X
.	B-X

But	O
till	O
now	O
,	O
there	O
is	O
no	O
study	O
focused	O
on	O
the	O
relationship	O
among	O
astrocytes	O
,	O
Nrf2	O
,	O
and	O
proinflammatory	O
mediators	O
after	O
TBI	O
.	O

Our	O
results	O
demonstrated	O
the	O
upregulated	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
in	O
Nrf2	O
knockout	O
astrocytes	O
after	O
scratch	O
injury	O
for	O
the	O
first	O
time	O
.	O

In	O
conclusion	O
,	O
depletion	O
of	O
Nrf2	O
induced	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
MMP9	B-Protein
resulting	O
in	O
more	O
cell	O
deaths	O
in	O
astrocytes	O
after	O
scratch	O
injury	O
.	O

These	O
results	O
suggest	O
that	O
Nrf2	O
may	O
be	O
an	O
important	O
target	O
for	O
anti	O
-	O
inflammatory	O
therapy	O
after	O
TBI	O
.	O

Regulation	O
ofMycobacterium	O
tuberculosis	O
-	O
Dependent	O
HIV	O
-	O
1	O
Transcription	O
Reveals	O
a	O
New	O
Role	O
for	O
NFAT5	B-Protein
in	O
the	O
Toll	O
-	O
Like	O
Receptor	O
Pathway	O

Tuberculosis	O
(	O
TB	O
)	O
disease	O
in	O
HIV	O
co	O
-	O
infected	O
patients	O
contributes	O
to	O
increased	O
mortality	O
by	O
activating	O
innate	O
and	O
adaptive	O
immune	O
signaling	O
cascades	O
that	O
stimulate	O
HIV	O
-	O
1	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
viral	O
load	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
silencing	O
of	O
the	O
expression	O
of	O
the	O
transcription	O
factor	O
nuclear	B-Protein
factor	I-Protein
of	I-Protein
activated	I-Protein
T	I-Protein
cells	I-Protein
5	I-Protein
(	O
NFAT5	B-Protein
)	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
inhibits	O
Mycobacterium	O
tuberculosis	O
(	O
MTb	O
)	O
-	O
stimulated	O
HIV	O
-	O
1	O
replication	O
in	O
co	O
-	O
infected	O
macrophages	O
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

We	O
show	O
that	O
NFAT5	B-Protein
gene	O
and	O
protein	O
expression	O
are	O
strongly	O
induced	O
by	O
MTb	O
,	O
which	O
is	O
a	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
ligand	O
,	O
and	O
that	O
an	O
intact	O
NFAT5	O
binding	O
site	O
in	O
the	O
viral	O
promoter	O
of	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
subtype	O
B	O
and	O
subtype	O
C	O
molecular	O
clones	O
is	O
required	O
for	O
efficent	O
induction	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
MTb	O
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

Furthermore	O
,	O
silencing	O
by	O
RNAi	O
of	O
key	O
components	O
of	O
the	O
TLR	O
pathway	O
in	O
human	O
monocytes	O
,	O
including	O
the	O
downstream	O
signaling	O
molecules	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
significantly	O
inhibits	O
MTb	O
-	O
induced	O
NFAT5	B-Protein
gene	O
expression	O
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

Thus	O
,	O
the	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
induces	O
NFAT5	B-Protein
gene	O
and	O
protein	O
expression	O
,	O
and	O
NFAT5	B-Protein
plays	O
a	O
crucial	O
role	O
in	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
viral	O
promoter	O
.	O

These	O
findings	O
also	O
demonstrate	O
a	O
general	O
role	O
for	O
NFAT5	B-Protein
in	O
TLR	O
-	O
and	O
MTb	O
-	O
mediated	O
control	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

Mycobacterium	O
tuberculosis	O
(	O
MTb	O
)	O
,	O
the	O
causative	O
agent	O
of	O
tuberculosis	O
(	O
TB	O
)	O
,	O
is	O
the	O
most	O
common	O
co	O
-	O
infection	O
and	O
cause	O
of	O
death	O
in	O
patients	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Direct	O
engagement	O
of	O
pathogen	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
by	O
MTb	O
on	O
mononuclear	O
phagocytes	O
activates	O
signaling	O
cascades	O
that	O
directly	O
induce	O
transcription	O
from	O
the	O
proviral	O
LTR	O
(	O
reviewed	O
in	O
[	O
3	O
]	O
)	O
.	O

Furthermore	O
,	O
inflammatory	O
cytokines	O
and	O
chemokines	O
produced	O
by	O
the	O
human	O
host	O
in	O
response	O
to	O
MTb	O
infection	O
activate	O
signal	O
transduction	O
pathways	O
in	O
CD4	B-Protein
T	O
cells	O
and	O
monocytic	O
cells	O
that	O
also	O
result	O
in	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
[	O
4	O
]	O
-	O
[	O
6	O
]	O
.	O

Activation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
these	O
MTb	O
-	O
induced	O
pathways	O
ultimately	O
leads	O
to	O
higher	O
viral	O
loads	O
and	O
,	O
in	O
turn	O
,	O
expedited	O
CD4	B-Protein
T	O
cell	O
loss	O
and	O
progression	O
to	O
AIDS	O
(	O
[	O
7	O
]	O
,	O
reviewed	O
in	O
[	O
8	O
]	O
-	O
[	O
10	O
]	O
)	O
.	O

Furthermore	O
,	O
the	O
progressive	O
immune	O
compromise	O
associated	O
with	O
HIV	O
-	O
1	O
infection	O
itself	O
is	O
a	O
major	O
cause	O
of	O
latent	O
MTb	O
reactivation	O
,	O
as	O
well	O
as	O
increased	O
susceptibility	O
to	O
primary	O
TB	O
infection	O
(	O
[	O
11	O
]	O
-	O
[	O
15	O
]	O
,	O
reviewed	O
in	O
[	O
8	O
]	O
)	O
.	O

The	O
primary	O
PRR	O
on	O
monocytic	O
cells	O
triggered	O
by	O
MTb	O
infection	O
is	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
(	I-Protein
TLR	I-Protein
)	I-Protein
2	I-Protein
[	O
16	O
]	O
-	O
[	O
20	O
]	O
.	O

Engagement	O
of	O
TLR2	B-Protein
results	O
in	O
engagement	O
of	O
the	O
adaptor	O
protein	O
MyD88	B-Protein
and	O
the	O
subsequent	O
recruitment	O
of	O
several	O
kinases	O
,	O
including	O
IRAK1	B-Protein
and	O
IRAK4	B-Protein
,	O
and	O
the	O
ubiquitin	O
ligase	O
TRAF6	B-Protein
(	O
[	O
21	O
]	O
-	O
[	O
23	O
]	O
,	O
reviewed	O
in	O
[	O
10	O
]	O
,	O
[	O
24	O
]	O
)	O
.	O

TRAF6	B-Protein
activates	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
that	O
,	O
in	O
turn	O
,	O
ultimately	O
induce	O
activation	O
of	O
specific	O
transcription	O
factor	O
families	O
,	O
including	O
the	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
families	O
,	O
which	O
have	O
been	O
shown	O
to	O
associate	O
with	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
to	O
drive	O
its	O
transcription	O
(	O
[	O
22	O
]	O
,	O
[	O
25	O
]	O
-	O
[	O
27	O
]	O
,	O
reviewed	O
in	O
[	O
10	O
]	O
)	O
.	O

Notably	O
,	O
HIV	O
-	O
1	O
comprises	O
several	O
subtypes	O
,	O
and	O
the	O
LTR	O
of	O
each	O
subtype	O
is	O
unique	O
with	O
respect	O
to	O
the	O
number	O
and	O
organization	O
of	O
activator	O
binding	O
sites	O
.	O

For	O
example	O
,	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
the	O
most	O
highly	O
characterized	O
viral	O
subtype	O
and	O
the	O
primary	O
cause	O
of	O
infection	O
in	O
the	O
Americas	O
,	O
Europe	O
,	O
Japan	O
,	O
and	O
Australia	O
,	O
has	O
two	O
tandem	O
NF	O
-	O
kappaB	O
motifs	O
in	O
its	O
LTR	O
.	O

By	O
contrast	O
,	O
HIV	O
-	O
1	O
subtypes	O
C	O
and	O
E	O
,	O
which	O
have	O
spread	O
disproportionately	O
in	O
TB	O
-	O
burdened	O
sub	O
-	O
Saharan	O
Africa	O
and	O
southeast	O
Asia	O
,	O
have	O
three	O
and	O
one	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
respectively	O
[	O
1	O
]	O
,	O
[	O
28	O
]	O
-	O
[	O
30	O
]	O
.	O

We	O
previously	O
showed	O
that	O
the	O
most	O
primordial	O
member	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
,	O
NFAT5	B-Protein
(	O
also	O
known	O
as	O
TonEBP	B-Protein
)	O
,	O
binds	O
to	O
a	O
site	O
within	O
the	O
HIV	O
-	O
1	O
LTR	O
that	O
is	O
highly	O
conserved	O
across	O
all	O
HIV	O
-	O
1	O
subtypes	O
,	O
and	O
is	O
also	O
conserved	O
in	O
HIV	O
-	O
2	O
and	O
SIV	O
LTRs	O
.	O

This	O
NFAT5	O
site	O
overlaps	O
the	O
core	O
NF	O
-	O
kappaB	O
binding	O
motifs	O
in	O
the	O
LTR	O
and	O
is	O
required	O
for	O
constitutive	O
replication	O
of	O
representative	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
isolates	O
in	O
human	O
primary	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDM	O
)	O
[	O
31	O
]	O
.	O

Given	O
that	O
NFAT5	B-Protein
has	O
previously	O
been	O
shown	O
to	O
be	O
transcriptionally	O
activated	O
by	O
the	O
MAP	O
kinase	O
p38	O
,	O
which	O
is	O
downstream	O
of	O
MyD88	B-Protein
signaling	O
,	O
[	O
32	O
]	O
,	O
we	O
speculated	O
that	O
NFAT5	B-Protein
may	O
also	O
be	O
involved	O
in	O
MTb	O
-	O
induced	O
activation	O
of	O
HIV	O
-	O
1	O
replication	O
via	O
a	O
TLR	O
-	O
mediated	O
pathway	O
in	O
monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
NFAT5	B-Protein
and	O
its	O
cognate	O
binding	O
site	O
are	O
of	O
crucial	O
importance	O
for	O
efficient	O
MTb	O
-	O
induced	O
stimulation	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
human	O
MDM	O
and	O
PBMC	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
MTb	O
infection	O
increases	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
in	O
a	O
MyD88	B-Protein
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
these	O
results	O
expand	O
the	O
known	O
stimuli	O
of	O
NFAT5	B-Protein
expression	O
to	O
the	O
PRR	O
-	O
mediated	O
innate	O
immune	O
response	O
,	O
and	O
demonstrate	O
that	O
NFAT5	B-Protein
is	O
a	O
critical	O
modulator	O
of	O
MTb	O
-	O
induced	O
enhancement	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

Ethics	O
statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
This	B-X
is	B-X
a	B-X
condensed	B-X
summary	B-X
of	B-X
an	B-X
international	B-X
multisociety	B-X
statement	B-X
on	B-X
ethics	B-X
of	B-X
artificial	B-X
intelligence	B-X
(	B-X
AI	B-X
)	B-X
in	B-X
radiology	B-X
produced	B-X
by	B-X
the	B-X
ACR	B-X
,	B-X
European	B-X
Society	B-X
of	B-X
Radiology	B-X
,	B-X
RSNA	B-X
,	B-X
Society	B-X
for	B-X
Imaging	B-X
Informatics	B-X
in	B-X
Medicine	B-X
,	B-X
European	B-X
Society	B-X
of	B-X
Medical	B-X
Imaging	B-X
Informatics	B-X
,	B-X
Canadian	B-X
Association	B-X
of	B-X
Radiologists	B-X
,	B-X
and	B-X
American	B-X
Association	B-X
of	B-X
Physicists	B-X
in	B-X
Medicine	B-X
.	B-X
This	B-X
statement	B-X
highlights	B-X
our	B-X
consensus	B-X
that	B-X
ethical	B-X
use	B-X
of	B-X
AI	B-X
in	B-X
radiology	B-X
should	B-X
promote	B-X
well-being	B-X
,	B-X
minimize	B-X
harm	B-X
,	B-X
and	B-X
ensure	B-X
that	B-X
the	B-X
benefits	B-X
and	B-X
harms	B-X
are	B-X
distributed	B-X
among	B-X
stakeholders	B-X
in	B-X
a	B-X
just	B-X
manner	B-X
.	B-X

In	O
our	O
studies	O
we	O
used	O
unidentified	O
human	O
discarded	O
blood	O
cells	O
(	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
PBMC	O
)	O
,	O
which	O
we	O
obtained	O
from	O
the	O
Blood	O
Bank	O
of	O
Children	O
'	O
s	O
Hospital	O
in	O
Boston	O
.	O

Cell	O
culture	O
<EOS>	B-X
This	B-X
overview	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
to	B-X
provide	B-X
an	B-X
unmet	B-X
need	B-X
for	B-X
information	B-X
on	B-X
best	B-X
practices	B-X
in	B-X
animal	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
target	B-X
audience	B-X
primarily	B-X
consists	B-X
of	B-X
entry-level	B-X
scientists	B-X
with	B-X
minimal	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
It	B-X
also	B-X
include	B-X
scientists	B-X
,	B-X
journalists	B-X
,	B-X
and	B-X
educators	B-X
with	B-X
some	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
,	B-X
but	B-X
in	B-X
need	B-X
of	B-X
a	B-X
refresher	B-X
in	B-X
best	B-X
practices	B-X
.	B-X
The	B-X
articles	B-X
will	B-X
be	B-X
published	B-X
in	B-X
this	B-X
journal	B-X
over	B-X
a	B-X
six-month	B-X
period	B-X
and	B-X
will	B-X
emphasize	B-X
best	B-X
practices	B-X
in	B-X
:	B-X
(	B-X
1	B-X
)	B-X
media	B-X
selection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
use	B-X
and	B-X
evaluation	B-X
of	B-X
animal	B-X
serum	B-X
as	B-X
a	B-X
component	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
;	B-X
(	B-X
3	B-X
)	B-X
receipt	B-X
of	B-X
new	B-X
cells	B-X
into	B-X
the	B-X
laboratory	B-X
;	B-X
(	B-X
4	B-X
)	B-X
naming	B-X
cell	B-X
lines	B-X
;	B-X
(	B-X
5	B-X
)	B-X
authenticating	B-X
cell	B-X
line	B-X
identity	B-X
;	B-X
(	B-X
6	B-X
)	B-X
detecting	B-X
and	B-X
mitigating	B-X
risk	B-X
of	B-X
cell	B-X
culture	B-X
contamination	B-X
;	B-X
(	B-X
7	B-X
)	B-X
cryopreservation	B-X
and	B-X
thawing	B-X
of	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
8	B-X
)	B-X
storing	B-X
and	B-X
shipping	B-X
viable	B-X
cells	B-X
.	B-X

PBMC	O
from	O
normal	O
unidentified	O
donors	O
were	O
isolated	O
by	O
Ficoll	O
-	O
Hypaque	O
(	O
Pharmacia	O
Corporation	O
,	O
Peapack	O
,	O
NJ	O
)	O
density	O
gradient	O
centrifugation	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
BioWhittaker	O
,	O
Inc	O
.	O
,	O
Walkersville	O
,	O
MD	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
(	O
Gemini	O
Bio	O
-	O
Products	O
,	O
www	O
.	O
gembio	O
.	O
com	O
)	O
.	O

Human	O
monocytes	O
were	O
isolated	O
from	O
PBMC	O
preparations	O
by	O
positive	O
selection	O
with	O
CD14	B-Protein
microbeads	O
from	O
Miltenyi	O
Biotec	O
(	O
www	O
.	O
miltenyibiotec	O
.	O
com	O
)	O
as	O
described	O
by	O
the	O
manufacturer	O
,	O
and	O
were	O
cultured	O
at	O
1x106	O
cells	O
per	O
well	O
in	O
6	O
-	O
well	O
plates	O
in	O
Macrophage	O
-	O
SFM	O
medium	O
(	O
Gibco	O
,	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
supplemented	O
with	O
15	O
ng	O
/	O
ml	O
recombinant	O
human	O
MCSF	B-Protein
(	O
R	O
&	O
D	O
,	O
www	O
.	O
rndsystems	O
.	O
com	O
)	O
and	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
AB	O
serum	O
(	O
Nabi	O
,	O
Boca	O
Raton	O
,	O
FL	O
)	O
.	O

The	O
cell	O
cultures	O
were	O
incubated	O
at	O
37degreesC	O
and	O
5	O
%	O
CO2	O
for	O
5	O
days	O
,	O
after	O
which	O
supernatant	O
was	O
replaced	O
with	O
fresh	O
medium	O
lacking	O
MCSF	B-Protein
before	O
manipulation	O
.	O

More	O
than	O
95	O
%	O
of	O
the	O
adherent	O
cells	O
obtained	O
with	O
this	O
technique	O
were	O
CD14	B-Protein
+	O
macrophages	O
as	O
verified	O
by	O
flow	O
cytometry	O
.	O

THP	O
-	O
1	O
cells	O
were	O
obtained	O
from	O
ATCC	O
(	O
www	O
.	O
atcc	O
.	O
org	O
)	O
and	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
FCS	O
(	O
BioWhittaker	O
,	O
www	O
.	O
lonzabio	O
.	O
com	O
)	O
.	O

293T	O
cells	O
were	O
obtained	O
from	O
ATCC	O
(	O
www	O
.	O
atcc	O
.	O
org	O
)	O
and	O
were	O
maintained	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
(	O
Gibco	O
,	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
.	O

Viruses	O
<EOS>	B-X
Viruses	B-X
of	B-X
microbes	B-X
encompass	B-X
all	B-X
viruses	B-X
that	B-X
infect	B-X
archaea	B-X
,	B-X
bacteria	B-X
,	B-X
and	B-X
single-celled	B-X
eukaryotes	B-X
,	B-X
especially	B-X
algae	B-X
and	B-X
protozoa	B-X
[	B-X
...	B-X
]	B-X
.	B-X
Viruses	B-X
exist	B-X
wherever	B-X
life	B-X
is	B-X
found	B-X
.	B-X
Viruses	B-X
can	B-X
move	B-X
between	B-X
marine	B-X
and	B-X
terrestrial	B-X
reservoirs	B-X
,	B-X
raising	B-X
the	B-X
spectre	B-X
of	B-X
emerging	B-X
pathogens	B-X
.	B-X
Viruses	B-X
are	B-X
important	B-X
pathogens	B-X
of	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X

HIV	O
-	O
1Bal	O
,	O
HIV	O
-	O
1Lai	O
,	O
HIV	O
-	O
193TH64	O
,	O
HIV	O
-	O
192TH51	O
,	O
HIV	O
-	O
192TH53	O
,	O
HIV	O
-	O
198CH01	O
,	O
and	O
HIV	O
-	O
198IN22	O
were	O
obtained	O
from	O
The	O
Centralized	O
Facility	O
for	O
AIDS	O
Reagents	O
,	O
National	O
Institute	O
for	O
Biological	O
Standard	O
and	O
Control	O
(	O
NIBSC	O
)	O
,	O
United	O
Kingdom	O
.	O

HIV	O
-	O
1KR25	O
was	O
isolated	O
in	O
our	O
laboratory	O
as	O
described	O
before	O
[	O
33	O
]	O
.	O
<EOS>	B-X
To	B-X
describe	B-X
the	B-X
prevalence	B-X
of	B-X
HIV/AIDS	B-X
in	B-X
China	B-X
from	B-X
2004	B-X
to	B-X
2016	B-X
and	B-X
to	B-X
assess	B-X
whether	B-X
regional	B-X
and	B-X
age	B-X
differences	B-X
exist	B-X
with	B-X
HIV/AIDS	B-X
infection	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
lentivectors	B-X
(	B-X
LVs	B-X
)	B-X
derived	B-X
from	B-X
HIV-1	B-X
have	B-X
gradually	B-X
evolved	B-X
to	B-X
display	B-X
many	B-X
desirable	B-X
features	B-X
aimed	B-X
at	B-X
increasing	B-X
both	B-X
their	B-X
safety	B-X
and	B-X
their	B-X
versatility	B-X
.	B-X
This	B-X
chapter	B-X
describes	B-X
protocols	B-X
and	B-X
guidelines	B-X
,	B-X
for	B-X
production	B-X
and	B-X
titration	B-X
of	B-X
LVs	B-X
,	B-X
which	B-X
can	B-X
be	B-X
implemented	B-X
in	B-X
a	B-X
research	B-X
laboratory	B-X
setting	B-X
,	B-X
with	B-X
an	B-X
emphasis	B-X
on	B-X
standardization	B-X
in	B-X
order	B-X
to	B-X
improve	B-X
transposability	B-X
of	B-X
results	B-X
between	B-X
laboratories	B-X
.	B-X
In	B-X
the	B-X
early	B-X
19th	B-X
century	B-X
,	B-X
tropanes	B-X
were	B-X
isolated	B-X
,	B-X
characterized	B-X
,	B-X
and	B-X
synthesized	B-X
by	B-X
notable	B-X
chemical	B-X
researchers	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
which	B-X
addresses	B-X
the	B-X
developments	B-X
in	B-X
this	B-X
field	B-X
since	B-X
1994	B-X
,	B-X
the	B-X
focus	B-X
is	B-X
on	B-X
the	B-X
synthesis	B-X
of	B-X
these	B-X
compounds	B-X
,	B-X
and	B-X
several	B-X
examples	B-X
of	B-X
sophisticated	B-X
synthetic	B-X
protocols	B-X
involving	B-X
both	B-X
asymmetric	B-X
and	B-X
catalytic	B-X
approaches	B-X
are	B-X
described	B-X
.	B-X

LTR	O
plasmid	O
construction	O
and	O
reporter	O
assay	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
HIV-1	B-X
LTR	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
vector	B-X
containing	B-X
Renilla	B-X
and	B-X
Firefly	B-X
luciferase	B-X
genes	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
LTR	B-X
(	B-X
wild-type	B-X
or	B-X
mutated	B-X
version	B-X
)	B-X
and	B-X
oriented	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
allowed	B-X
them	B-X
to	B-X
be	B-X
transcribed	B-X
in	B-X
opposite	B-X
directions	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
HIV-1	B-X
LTR	B-X
acted	B-X
as	B-X
a	B-X
bidirectional	B-X
promoter	B-X
,	B-X
which	B-X
activity	B-X
was	B-X
controlled	B-X
by	B-X
NF-κB-	B-X
and	B-X
Sp1-binding	B-X
sites	B-X
in	B-X
both	B-X
orientations	B-X
.	B-X
We	B-X
next	B-X
analyzed	B-X
with	B-X
this	B-X
reporter	B-X
vector	B-X
the	B-X
bidirectional	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
HTLV-1	B-X
LTR	B-X
and	B-X
showed	B-X
that	B-X
this	B-X
LTR	B-X
also	B-X
possessed	B-X
a	B-X
bidirectional	B-X
transcriptional	B-X
activity	B-X
.	B-X
We	B-X
also	B-X
cloned	B-X
into	B-X
this	B-X
plasmid	B-X
the	B-X
MLV	B-X
LTR	B-X
and	B-X
found	B-X
that	B-X
the	B-X
LTR	B-X
of	B-X
a	B-X
simple	B-X
retrovirus	B-X
also	B-X
possessed	B-X
bidirectional	B-X
transcriptional	B-X
activity	B-X
.	B-X
This	B-X
reporter	B-X
vector	B-X
represents	B-X
a	B-X
powerful	B-X
tool	B-X
to	B-X
analyze	B-X
the	B-X
bidirectional	B-X
transcriptional	B-X
activity	B-X
of	B-X
retrovirus	B-X
LTRs	B-X
.	B-X

LTR	O
reporter	O
plasmids	O
were	O
constructed	O
by	O
inserting	O
nucleotides	O
-	O
208	O
to	O
+	O
64	O
relative	O
to	O
the	O
transcriptional	O
initiation	O
site	O
of	O
HIV	O
-	O
1Lai	O
,	O
HIV	O
-	O
1Bal	O
(	O
B	O
subtype	O
)	O
,	O
HIV	O
-	O
198IN17	O
,	O
HIV	O
-	O
198IN22	O
,	O
HIV	O
-	O
198CH01	O
,	O
HIV	O
-	O
1CM9	O
(	O
C	O
subtype	O
)	O
,	O
HIV	O
-	O
193TH64	O
,	O
HIV	O
-	O
192TH53	O
,	O
HIV	O
-	O
192TH51	O
,	O
and	O
HIV	O
-	O
1KR25	O
(	O
E	O
subtype	O
)	O
into	O
the	O
reporter	O
vector	O
pGL3	O
(	O
Promega	O
BioSciences	O
,	O
www	O
.	O
promega	O
.	O
com	O
)	O
using	O
Xho	O
I	O
and	O
Hind	O
III	O
restriction	O
enzyme	O
sites	O
.	O

Sequences	O
were	O
aligned	O
and	O
analyzed	O
with	O
CLUSTAL	O
W	O
(	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
clustalw	O
/	O
)	O
.	O

The	O
HIV	O
-	O
1Lai	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
(	O
N5	O
-	O
Mut	O
)	O
reporter	O
plasmid	O
was	O
created	O
by	O
standard	O
PCR	O
-	O
based	O
mutagenesis	O
methods	O
[	O
34	O
]	O
.	O

THP	O
-	O
1	O
cells	O
(	O
0	O
.	O
8x106	O
/	O
ml	O
)	O
were	O
transfected	O
with	O
0	O
.	O
3	O
microg	O
/	O
ml	O
LTR	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
mutated	O
reporter	O
plasmids	O
in	O
combination	O
with	O
0	O
.	O
03	O
microg	O
/	O
ml	O
Renilla	O
luciferase	B-Protein
(	O
pRL	O
-	O
TK	O
)	O
control	O
vector	O
using	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
;	O
www	O
.	O
qiagen	O
.	O
com	O
)	O
.	O

Cells	O
were	O
incubated	O
at	O
37degreesC	O
for	O
16	O
hours	O
after	O
which	O
they	O
were	O
stimulated	O
with	O
10	O
microg	O
/	O
ml	O
MTb	O
CDC1551	O
lysate	O
or	O
left	O
unstimulated	O
for	O
8	O
hours	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
human	B-X
orbital	B-X
fibroblast	B-X
(	B-X
OF	B-X
)	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
proinflammatory	B-X
stimuli	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
and	B-X
cyclosporin	B-X
A	B-X
(	B-X
CSA	B-X
)	B-X
on	B-X
cytokine-stimulated	B-X
OF	B-X
IL-6	B-X
gene	B-X
expression	B-X
.	B-X
Four	B-X
hours	B-X
after	B-X
induction	B-X
of	B-X
acute	B-X
bilateral	B-X
hind	B-X
joint	B-X
arthritis	B-X
by	B-X
single	B-X
intraarticular	B-X
injection	B-X
of	B-X
urate	B-X
crystals	B-X
,	B-X
the	B-X
knees	B-X
of	B-X
14	B-X
anesthetized	B-X
rabbits	B-X
were	B-X
fixed	B-X
at	B-X
90	B-X
degrees	B-X
between	B-X
femur	B-X
and	B-X
tibia	B-X
.	B-X
TENS	B-X
was	B-X
supplied	B-X
from	B-X
an	B-X
electrical	B-X
stimulator	B-X
to	B-X
the	B-X
left	B-X
knee	B-X
joint	B-X
while	B-X
the	B-X
other	B-X
joint	B-X
was	B-X
unstimulated	B-X
as	B-X
a	B-X
control	B-X
.	B-X
Readings	B-X
were	B-X
carried	B-X
out	B-X
at	B-X
10-min	B-X
intervals	B-X
three	B-X
times	B-X
before	B-X
and	B-X
four	B-X
times	B-X
after	B-X
5	B-X
min	B-X
of	B-X
TENS	B-X
.	B-X
A	B-X
significant	B-X
increase	B-X
in	B-X
IA	B-X
temperature	B-X
from	B-X
mean	B-X
36.2C	B-X
to	B-X
36.6C	B-X
and	B-X
significant	B-X
reduction	B-X
of	B-X
IA	B-X
pressure	B-X
(	B-X
mean	B-X
decrease	B-X
of	B-X
0.8	B-X
mmHg	B-X
,	B-X
from	B-X
2.5	B-X
mmHg	B-X
to	B-X
1.7	B-X
mmHg	B-X
)	B-X
were	B-X
found	B-X
in	B-X
the	B-X
stimulated	B-X
joints	B-X
,	B-X
which	B-X
also	B-X
showed	B-X
a	B-X
reduction	B-X
of	B-X
synovial	B-X
fluid	B-X
volume	B-X
and	B-X
total	B-X
leukocyte	B-X
count	B-X
in	B-X
comparison	B-X
to	B-X
the	B-X
controls	B-X
.	B-X
While	B-X
the	B-X
nonstimulated	B-X
synovial	B-X
membrane	B-X
showed	B-X
massive	B-X
leukocytic	B-X
infiltration	B-X
with	B-X
neutrophilic	B-X
exudate	B-X
and	B-X
fibrin	B-X
clot	B-X
in	B-X
the	B-X
intraarticular	B-X
cavity	B-X
,	B-X
the	B-X
stimulated	B-X
synovial	B-X
membrane	B-X
demonstrated	B-X
moderate	B-X
homogeneous	B-X
leukocytic	B-X
infiltration	B-X
through	B-X
all	B-X
layers	B-X
,	B-X
with	B-X
absence	B-X
of	B-X
inflammatory	B-X
exudate	B-X
in	B-X
the	B-X
intraarticular	B-X
cavity	B-X
.	B-X

Reporter	B-Protein
gene	I-Protein
expression	O
was	O
quantitated	O
by	O
dual	O
-	O
luciferase	B-Protein
reporter	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Promega	O
;	O
www	O
.	O
promega	O
.	O
com	O
)	O
.	O

Quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
<EOS>	B-X
We	B-X
used	B-X
DNase	B-X
I	B-X
sequencing	B-X
to	B-X
measure	B-X
chromatin	B-X
accessibility	B-X
in	B-X
70	B-X
Yoruba	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
,	B-X
for	B-X
which	B-X
genome-wide	B-X
genotypes	B-X
and	B-X
estimates	B-X
of	B-X
gene	B-X
expression	B-X
levels	B-X
are	B-X
also	B-X
available	B-X
.	B-X
We	B-X
obtained	B-X
a	B-X
total	B-X
of	B-X
2.7	B-X
billion	B-X
uniquely	B-X
mapped	B-X
DNase	B-X
I-sequencing	B-X
(	B-X
DNase-seq	B-X
)	B-X
reads	B-X
,	B-X
which	B-X
allowed	B-X
us	B-X
to	B-X
produce	B-X
genome-wide	B-X
maps	B-X
of	B-X
chromatin	B-X
accessibility	B-X
for	B-X
each	B-X
individual	B-X
.	B-X
We	B-X
identified	B-X
8,902	B-X
locations	B-X
at	B-X
which	B-X
the	B-X
DNase-seq	B-X
read	B-X
depth	B-X
correlated	B-X
significantly	B-X
with	B-X
genotype	B-X
at	B-X
a	B-X
nearby	B-X
single	B-X
nucleotide	B-X
polymorphism	B-X
or	B-X
insertion/deletion	B-X
(	B-X
false	B-X
discovery	B-X
rate	B-X
=	B-X
10	B-X
%	B-X
)	B-X
.	B-X
We	B-X
call	B-X
such	B-X
variants	B-X
'DNase	B-X
I	B-X
sensitivity	B-X
quantitative	B-X
trait	B-X
loci	B-X
'	B-X
(	B-X
dsQTLs	B-X
)	B-X
.	B-X

Recombinant	O
NFAT5	B-Protein
(	O
amino	O
acids	O
175	O
-	O
471	O
)	O
with	O
an	O
N	O
-	O
terminal	O
6x	O
His	O
tag	O
was	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
cells	O
(	O
Stratagene	O
;	O
www	O
.	O
stratagene	O
.	O
com	O
)	O
and	O
purified	O
under	O
native	O
conditions	O
using	O
Ni	O
-	O
NTA	O
agarose	O
(	O
Qiagen	O
)	O
.	O

Recombinant	O
p50	B-Protein
and	O
p65	B-Protein
were	O
purchased	O
(	O
Active	O
Motif	O
,	O
www	O
.	O
activemotif	O
.	O
com	O
)	O
.	O

Quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
was	O
performed	O
as	O
previously	O
described	O
[	O
31	O
]	O
.	O
<EOS>	B-X
Analysis	B-X
of	B-X
results	B-X
of	B-X
quantitative	B-X
DNase	B-X
I	B-X
footprint	B-X
titrations	B-X
performed	B-X
on	B-X
the	B-X
wild-type	B-X
biotin	B-X
operator	B-X
template	B-X
indicate	B-X
that	B-X
binding	B-X
is	B-X
well	B-X
described	B-X
by	B-X
a	B-X
cooperative	B-X
mechanism	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
to	B-X
further	B-X
dissect	B-X
the	B-X
energetics	B-X
of	B-X
assembly	B-X
of	B-X
the	B-X
biotin	B-X
repressor-biotin	B-X
operator	B-X
complex	B-X
,	B-X
measurements	B-X
of	B-X
binding	B-X
of	B-X
BirA	B-X
to	B-X
four	B-X
bioO	B-X
variants	B-X
designed	B-X
to	B-X
reduce	B-X
the	B-X
valency	B-X
of	B-X
repressor	B-X
binding	B-X
from	B-X
2	B-X
to	B-X
1	B-X
have	B-X
been	B-X
performed	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
cooperative	B-X
binding	B-X
mechanism	B-X
,	B-X
the	B-X
cooperative	B-X
free	B-X
energy	B-X
associated	B-X
with	B-X
the	B-X
biotin	B-X
repressor-biotin	B-X
operator	B-X
interaction	B-X
is	B-X
significantly	B-X
more	B-X
favorable	B-X
than	B-X
the	B-X
previously	B-X
estimated	B-X
-2	B-X
kcal/mol	B-X
.	B-X

HIV	O
-	O
1	O
infectious	O
molecular	O
clones	O
<EOS>	B-X
Currently	B-X
,	B-X
HIV-1	B-X
CRF63_02A6	B-X
is	B-X
the	B-X
prevalent	B-X
genetic	B-X
variant	B-X
of	B-X
the	B-X
HIV-infected	B-X
subjects	B-X
in	B-X
the	B-X
major	B-X
part	B-X
of	B-X
the	B-X
Siberian	B-X
Federal	B-X
District	B-X
(	B-X
Russia	B-X
)	B-X
.	B-X
The	B-X
HIV-1	B-X
CRF63_02A6	B-X
R5-tropic	B-X
pT11.17	B-X
and	B-X
X4-tropic	B-X
pMtBs.18	B-X
infectious	B-X
molecular	B-X
clones	B-X
(	B-X
IMCs	B-X
)	B-X
were	B-X
constructed	B-X
using	B-X
the	B-X
virus	B-X
isolates	B-X
recovered	B-X
in	B-X
2015	B-X
and	B-X
2017	B-X
of	B-X
male	B-X
HIV-infected	B-X
Russian	B-X
residents	B-X
(	B-X
from	B-X
Tomsk	B-X
and	B-X
Novosibirsk	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Near	B-X
full-length	B-X
proviral	B-X
HIV-1	B-X
sequences	B-X
(	B-X
9,644	B-X
and	B-X
9,748	B-X
bp	B-X
)	B-X
were	B-X
subcloned	B-X
in	B-X
pBluescript	B-X
II	B-X
KS	B-X
(	B-X
-	B-X
)	B-X
.	B-X
The	B-X
CRF63_02A6	B-X
IMC	B-X
virions	B-X
were	B-X
obtained	B-X
by	B-X
transfecting	B-X
HEK293T	B-X
cells	B-X
with	B-X
the	B-X
constructed	B-X
plasmids	B-X
and	B-X
demonstrated	B-X
a	B-X
stable	B-X
growth	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cell	B-X
culture	B-X
(	B-X
p24	B-X
concentration	B-X
increased	B-X
>	B-X
1,000-fold	B-X
and	B-X
the	B-X
virus	B-X
protein	B-X
accumulation	B-X
in	B-X
culture	B-X
liquid	B-X
exceeded	B-X
100,000	B-X
pg/mL	B-X
)	B-X
.	B-X
The	B-X
obtained	B-X
HIV-1	B-X
CRF63_02A6	B-X
IMCs	B-X
may	B-X
be	B-X
useful	B-X
in	B-X
basic	B-X
and	B-X
applied	B-X
research	B-X
.	B-X

The	O
plasmid	O
encoding	O
the	O
full	O
-	O
length	O
infectious	O
molecular	O
clone	O
of	O
HIV	O
-	O
1Lai	O
was	O
obtained	O
from	O
the	O
NIH	O
AIDS	O
Reagent	O
and	O
Reference	O
Program	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
infectious	O
molecular	O
clone	O
was	O
constructed	O
by	O
replacing	O
the	O
envelope	O
(	O
env	O
)	O
gp160	B-Protein
amino	O
acids	O
103	O
-	O
717	O
of	O
the	O
HIV	O
-	O
1Lai	O
(	O
B	O
subtype	O
that	O
utilizes	O
CXCR4	B-Protein
)	O
molecular	O
clone	O
with	O
the	O
corresponding	O
region	O
of	O
HIV	O
-	O
1Bal	O
(	O
B	O
subtype	O
that	O
utilizes	O
CCR5	B-Protein
)	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
chimeric	O
virus	O
uses	O
CCR5	O
as	O
a	O
secondary	O
receptor	O
.	O

The	O
infectious	O
molecular	O
clone	O
of	O
HIV	O
-	O
198IN22	O
was	O
constructed	O
using	O
DNA	O
extracted	O
from	O
PBMC	O
that	O
were	O
infected	O
with	O
a	O
primary	O
isolate	O
of	O
HIV	O
-	O
198IN22	O
.	O

HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
and	O
HIV	O
-	O
198IN22	O
mutant	O
viruses	O
were	O
constructed	O
by	O
introducing	O
point	O
mutations	O
using	O
standard	O
PCR	O
-	O
based	O
mutagenesis	O
methods	O
.	O

siRNA	O
transfection	O
of	O
MDM	O
<EOS>	B-X
The	B-X
small-molecule	B-X
inhibitor	B-X
of	B-X
murine	B-X
double	B-X
minute	B-X
(	B-X
MDM-2	B-X
)	B-X
,	B-X
Nutlin-3	B-X
,	B-X
induced	B-X
variable	B-X
apoptosis	B-X
in	B-X
primary	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
blasts	B-X
and	B-X
promoted	B-X
myeloid	B-X
maturation	B-X
of	B-X
surviving	B-X
cells	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
analysis	B-X
of	B-X
CD11b	B-X
and	B-X
CD14	B-X
surface	B-X
antigens	B-X
and	B-X
by	B-X
morphologic	B-X
examination	B-X
.	B-X
Human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X
were	B-X
exposed	B-X
to	B-X
H3N2	B-X
X31	B-X
influenza	B-X
virus	B-X
,	B-X
M37	B-X
respiratory	B-X
syncytial	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
or	B-X
UV-irradiated	B-X
virus	B-X
.	B-X
No	B-X
infection	B-X
of	B-X
MDM	B-X
was	B-X
seen	B-X
upon	B-X
exposure	B-X
to	B-X
UV-irradiated	B-X
virus	B-X
but	B-X
incubation	B-X
with	B-X
live	B-X
X31	B-X
or	B-X
M37	B-X
resulted	B-X
in	B-X
significant	B-X
levels	B-X
of	B-X
viral	B-X
detection	B-X
by	B-X
flow	B-X
cytometry	B-X
or	B-X
RT-PCR	B-X
respectively	B-X
.	B-X
Infection	B-X
resulted	B-X
in	B-X
significantly	B-X
diminished	B-X
uptake	B-X
of	B-X
S.	B-X
pneumoniae	B-X
by	B-X
MDM	B-X
and	B-X
significantly	B-X
decreased	B-X
expression	B-X
of	B-X
CD36	B-X
at	B-X
both	B-X
the	B-X
cell	B-X
surface	B-X
and	B-X
mRNA	B-X
level	B-X
.	B-X
Concurrently	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
IFNβ	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
infection	B-X
and	B-X
we	B-X
observed	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
bacterial	B-X
phagocytosis	B-X
(	B-X
p	B-X
=	B-X
0.031	B-X
)	B-X
and	B-X
CD36	B-X
gene	B-X
expression	B-X
(	B-X
p	B-X
=	B-X
0.031	B-X
)	B-X
by	B-X
MDM	B-X
cultured	B-X
for	B-X
24	B-X
h	B-X
in	B-X
50IU/ml	B-X
IFNβ	B-X
.	B-X
Knockdown	B-X
of	B-X
CD36	B-X
by	B-X
siRNA	B-X
resulted	B-X
in	B-X
decreased	B-X
phagocytosis	B-X
,	B-X
but	B-X
this	B-X
was	B-X
mimicked	B-X
by	B-X
transfection	B-X
reagent	B-X
alone	B-X
.	B-X
When	B-X
MDM	B-X
were	B-X
incubated	B-X
with	B-X
CD36	B-X
blocking	B-X
antibodies	B-X
no	B-X
effect	B-X
on	B-X
phagocytic	B-X
ability	B-X
was	B-X
observed	B-X
.	B-X

An	O
siRNA	O
was	O
constructed	O
(	O
Ambion	O
Inc	O
.	O
,	O
www	O
.	O
ambion	O
.	O
com	O
)	O
to	O
target	O
a	O
sequence	O
unique	O
to	O
the	O
NFAT5	B-Protein
transcript	O
:	O
5	O
'	O
-	O
CAACATGCCTGGAATTCAA	O
-	O
3	O
'	O
(	O
nt	O
335	O
to	O
353	O
)	O
[	O
31	O
]	O
.	O

As	O
described	O
,	O
a	O
control	O
for	O
non	O
-	O
specific	O
siRNA	O
effects	O
,	O
we	O
used	O
an	O
siRNA	O
targeting	O
the	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
,	O
5	O
'	O
-	O
GGCTACGTCCAGGAGCGCACC	O
-	O
3	O
'	O
.	O

MDM	O
were	O
transfected	O
in	O
6	O
-	O
well	O
plates	O
using	O
1	O
microM	O
of	O
the	O
indicated	O
siRNA	O
in	O
siPORT	O
NeoFX	O
transfection	O
reagent	O
(	O
Ambion	O
Inc	O
.	O
,	O
www	O
.	O
ambion	O
.	O
com	O
)	O
,	O
prepared	O
as	O
recommended	O
by	O
the	O
manufacturer	O
,	O
in	O
a	O
final	O
volume	O
of	O
750	O
microl	O
in	O
Macrophage	O
-	O
SFM	O
medium	O
plus	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
AB	O
serum	O
.	O

The	O
cultures	O
were	O
left	O
at	O
37degreesC	O
overnight	O
after	O
which	O
cells	O
were	O
washed	O
and	O
incubated	O
in	O
fresh	O
medium	O
.	O

MDM	O
were	O
transfected	O
two	O
times	O
for	O
efficient	O
knock	O
down	O
of	O
NFAT5	B-Protein
expression	O
before	O
infection	O
experiments	O
were	O
performed	O
[	O
31	O
]	O
.	O

Stable	O
THP	O
-	O
1	O
cells	O
expressing	O
shRNA	B-Protein
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
macrophage	B-X
polarization	B-X
on	B-X
the	B-X
response	B-X
of	B-X
inflammatory	B-X
breast	B-X
cancer	B-X
(	B-X
IBC	B-X
)	B-X
cells	B-X
to	B-X
radiation	B-X
and	B-X
whether	B-X
modulation	B-X
of	B-X
macrophage	B-X
plasticity	B-X
can	B-X
alter	B-X
radiation	B-X
response	B-X
.	B-X
Toll-like	B-X
receptor	B-X
10	B-X
(	B-X
TLR10	B-X
)	B-X
is	B-X
the	B-X
only	B-X
orphan	B-X
receptor	B-X
whose	B-X
natural	B-X
ligand	B-X
and	B-X
function	B-X
are	B-X
unknown	B-X
among	B-X
the	B-X
10	B-X
human	B-X
TLRs	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
to	B-X
test	B-X
whether	B-X
TLR10	B-X
recognizes	B-X
some	B-X
known	B-X
TLR	B-X
ligands	B-X
,	B-X
we	B-X
established	B-X
a	B-X
stable	B-X
TLR10	B-X
knockdown	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
using	B-X
TLR10	B-X
short	B-X
hairpin	B-X
RNA	B-X
lentiviral	B-X
particle	B-X
and	B-X
puromycin	B-X
selection	B-X
.	B-X
Among	B-X
60	B-X
TLR10	B-X
knockdown	B-X
clones	B-X
that	B-X
were	B-X
derived	B-X
from	B-X
each	B-X
single	B-X
transduced	B-X
cell	B-X
,	B-X
six	B-X
clones	B-X
were	B-X
randomly	B-X
selected	B-X
,	B-X
and	B-X
then	B-X
one	B-X
of	B-X
those	B-X
clones	B-X
,	B-X
named	B-X
E7	B-X
,	B-X
was	B-X
chosen	B-X
for	B-X
the	B-X
functional	B-X
study	B-X
.	B-X
E7	B-X
exhibited	B-X
approximately	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
TLR10	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
TLRs	B-X
,	B-X
only	B-X
the	B-X
expression	B-X
of	B-X
TLR10	B-X
changed	B-X
significantly	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Additionally	B-X
,	B-X
phorbol	B-X
12-myristate	B-X
13-acetate-induced	B-X
macrophage	B-X
differentiation	B-X
of	B-X
TLR10	B-X
knockdown	B-X
cells	B-X
was	B-X
not	B-X
affected	B-X
in	B-X
the	B-X
knockdown	B-X
cells	B-X
.	B-X
When	B-X
exposed	B-X
to	B-X
TLR	B-X
ligands	B-X
,	B-X
such	B-X
as	B-X
synthetic	B-X
diacylated	B-X
lipoprotein	B-X
(	B-X
FSL-1	B-X
)	B-X
,	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
and	B-X
flagellin	B-X
,	B-X
significant	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokine	B-X
gene	B-X
expression	B-X
including	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
,	B-X
Interleukin-1	B-X
beta	B-X
(	B-X
IL-1β	B-X
)	B-X
,	B-X
Tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-α	B-X
)	B-X
and	B-X
Chemokine	B-X
(	B-X
C-C	B-X
Motif	B-X
)	B-X
Ligand	B-X
20	B-X
(	B-X
CCL20	B-X
)	B-X
expression	B-X
,	B-X
was	B-X
found	B-X
in	B-X
the	B-X
control	B-X
THP-1	B-X
cells	B-X
,	B-X
whereas	B-X
the	B-X
TLR10	B-X
knockdown	B-X
cells	B-X
exhibited	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
IL-8	B-X
,	B-X
IL-1β	B-X
,	B-X
and	B-X
CCL20	B-X
.	B-X
TNF-α	B-X
was	B-X
the	B-X
only	B-X
cytokine	B-X
for	B-X
which	B-X
the	B-X
expression	B-X
did	B-X
not	B-X
decrease	B-X
in	B-X
the	B-X
TLR10	B-X
knockdown	B-X
cells	B-X
from	B-X
that	B-X
measured	B-X
in	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
Analysis	B-X
of	B-X
putative	B-X
binding	B-X
sites	B-X
for	B-X
transcription	B-X
factors	B-X
using	B-X
a	B-X
binding-site-prediction	B-X
program	B-X
revealed	B-X
that	B-X
the	B-X
TNF-α	B-X
promoter	B-X
does	B-X
not	B-X
have	B-X
putative	B-X
binding	B-X
sites	B-X
for	B-X
AP-1	B-X
or	B-X
c-Jun	B-X
,	B-X
comprising	B-X
a	B-X
major	B-X
transcription	B-X
factor	B-X
along	B-X
with	B-X
NF-κB	B-X
for	B-X
TLR	B-X
signaling	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
TLR10	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
FSL-1	B-X
,	B-X
LPS	B-X
,	B-X
and	B-X
flagellin	B-X
and	B-X
TLR-ligand-induced	B-X
expression	B-X
of	B-X
TNF-α	B-X
does	B-X
not	B-X
depend	B-X
on	B-X
TLR10	B-X
.	B-X

The	O
lentiviral	O
plasmid	O
pLKO	O
.	O
1	O
expressing	O
shRNA	B-Protein
targeting	O
human	O
MyD88	B-Protein
was	O
purchased	O
from	O
Open	O
Biosystems	O
(	O
www	O
.	O
openbiosystems	O
.	O
com	O
)	O
and	O
was	O
validated	O
in	O
our	O
laboratory	O
.	O

shRNA	O
targeting	O
human	O
IRAK1	B-Protein
(	O
forward	O
primer	O
5	O
'	O
-	O
CCGGAGCAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGCTGCTCCTTTTTG	O
-	O
3	O
'	O
,	O
reverse	O
primer	O
5	O
'	O
-	O
AATTCAAAAAGGAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGACAGCTGCT	O
-	O
3	O
'	O
mRNA	O
(	O
IRAK1	B-Protein
mRNA	O
target	O
sequence	O
is	O
underlined	O
)	O
and	O
human	O
TRAF6	B-Protein
(	O
forward	O
primer	O
5	O
'	O
-	O
CCGGAGAAACCTGTTGTGATTCGTCTCATAAATCACAACAGGTTTCTCCTTTTTG	O
-	O
3	O
'	O
,	O
reverse	O
primer	O
5	O
'	O
-	O
AATTCAAAAAGGAGAAACCTGTTGTGATTTATGAGACGAATCACAACAGGTTTCT	O
-	O
3	O
'	O
(	O
TRAF6	B-Protein
mRNA	O
target	O
sequence	O
is	O
underlined	O
)	O
were	O
designed	O
in	O
our	O
laboratory	O
and	O
were	O
cloned	O
into	O
the	O
pLKO	O
.	O
1	O
plasmid	O
.	O

Lentiviruses	O
encoding	O
shRNA	O
sequences	O
were	O
generated	O
by	O
transfecting	O
the	O
packaging	O
cell	O
line	O
HEK	O
-	O
293T	O
with	O
the	O
shRNA	O
-	O
encoding	O
pLKO	O
.	O
1	O
plasmids	O
in	O
combination	O
with	O
the	O
packaging	O
plasmid	O
psPAX2	O
and	O
the	O
envelope	O
plasmid	O
pMD2	O
.	O
G	O
using	O
Effectene	O
transfection	O
reagent	O
(	O
Qiagen	O
,	O
www	O
.	O
qiagen	O
.	O
com	O
)	O
.	O

Supernatants	O
were	O
collected	O
48	O
hours	O
post	O
-	O
transfection	O
,	O
clarified	O
by	O
centrifugation	O
,	O
and	O
stored	O
at	O
-	O
80degreesC	O
.	O

THP	O
-	O
1	O
cells	O
were	O
transduced	O
with	O
the	O
lentiviral	O
particles	O
by	O
culturing	O
the	O
cells	O
with	O
supernatants	O
from	O
the	O
virus	O
-	O
producing	O
cells	O
in	O
the	O
presence	O
of	O
8	O
microg	O
/	O
ml	O
polybrene	O
(	O
Millipore	O
,	O
www	O
.	O
millipore	O
.	O
com	O
)	O
and	O
spinoculation	O
for	O
two	O
hours	O
at	O
2000	O
RPM	O
.	O

Successfully	O
transduced	O
cells	O
were	O
selected	O
and	O
expanded	O
by	O
treatment	O
with	O
0	O
.	O
8	O
microg	O
/	O
ml	O
puromycin	O
.	O

MTb	O
culture	O
<EOS>	B-X
This	B-X
study	B-X
evaluated	B-X
Xpert	B-X
Mycobacterium	B-X
Tuberculosis	B-X
(	B-X
MTB	B-X
)	B-X
/Rifampicin	B-X
(	B-X
RIF	B-X
)	B-X
Ultra	B-X
(	B-X
Ultra	B-X
)	B-X
and	B-X
mycobacterial	B-X
cultures	B-X
in	B-X
routine	B-X
clinical	B-X
care	B-X
at	B-X
a	B-X
tertiary	B-X
paediatric	B-X
hospital	B-X
.	B-X
This	B-X
review	B-X
briefly	B-X
describes	B-X
the	B-X
phenomenon	B-X
of	B-X
Mtb	B-X
dormancy	B-X
and	B-X
its	B-X
role	B-X
in	B-X
the	B-X
context	B-X
of	B-X
tuberculosis	B-X
as	B-X
a	B-X
persistent	B-X
bacterial	B-X
infection	B-X
;	B-X
then	B-X
the	B-X
article	B-X
characterizes	B-X
in	B-X
details	B-X
the	B-X
in	B-X
vitro	B-X
methods	B-X
used	B-X
for	B-X
modeling	B-X
the	B-X
Mtb	B-X
dormancy	B-X
in	B-X
bacterial	B-X
cultures	B-X
.	B-X
However	B-X
,	B-X
high	B-X
mycobacterial	B-X
culture	B-X
contamination	B-X
rates	B-X
and	B-X
Xpert	B-X
MTB/RIF	B-X
Ultra	B-X
test	B-X
error	B-X
rates	B-X
on	B-X
stool	B-X
samples	B-X
have	B-X
limited	B-X
its	B-X
use	B-X
.	B-X
We	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
OM-S	B-X
on	B-X
Mtb	B-X
diagnostic	B-X
yield	B-X
from	B-X
stool	B-X
using	B-X
smear	B-X
microscopy	B-X
,	B-X
Xpert	B-X
MTB/RIF	B-X
Ultra	B-X
,	B-X
and	B-X
culture	B-X
among	B-X
presumptive	B-X
TB	B-X
patients	B-X
.	B-X

The	O
MTb	O
clinical	O
strain	O
CDC1551	O
was	O
prepared	O
by	O
adding	O
100	O
microl	O
of	O
frozen	O
bacteria	O
stock	O
into	O
10	O
ml	O
of	O
Middlebrook	O
7H9	O
medium	O
(	O
Difco	O
BD	O
,	O
www	O
.	O
bd	O
.	O
com	O
)	O
supplemented	O
with	O
albumin	O
dextrose	O
complex	O
(	O
ADC	O
)	O
and	O
0	O
.	O
05	O
%	O
Tween	O
80	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
www	O
.	O
sigmaaldrich	O
.	O
com	O
)	O
.	O

The	O
cultures	O
were	O
grown	O
to	O
an	O
OD650	O
of	O
0	O
.	O
4	O
at	O
37degreesC	O
to	O
ensure	O
that	O
they	O
were	O
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

Bacteria	O
were	O
then	O
plated	O
,	O
washed	O
with	O
PBS	O
,	O
resuspended	O
in	O
PBS	O
,	O
and	O
passed	O
through	O
a	O
5	O
microm	O
filter	O
to	O
ensure	O
that	O
the	O
bacteria	O
were	O
in	O
a	O
single	O
cell	O
suspension	O
.	O

Bacterial	O
cell	O
numbers	O
were	O
determined	O
by	O
measurement	O
of	O
OD650	O
before	O
further	O
dilution	O
with	O
RPMI	O
1640	O
medium	O
for	O
cell	O
infection	O
studies	O
at	O
10	O
:	O
1	O
PBMC	O
:	O
bacilli	O
or	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
and	O
THP	O
-	O
1	O
:	O
bacilli	O
.	O

Colony	O
-	O
forming	O
unit	O
(	O
CFU	O
)	O
analysis	O
was	O
performed	O
and	O
on	O
days	O
4	O
and	O
7	O
the	O
average	O
CFU	O
counts	O
were	O
6x103	O
and	O
5x104	O
,	O
respectively	O
,	O
confirming	O
that	O
mycobacteria	O
levels	O
increased	O
over	O
the	O
course	O
of	O
infection	O
of	O
primary	O
MDM	O
.	O

Western	O
blot	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X
In	B-X
the	B-X
past	B-X
,	B-X
western	B-X
blotting	B-X
was	B-X
used	B-X
simply	B-X
to	B-X
detect	B-X
a	B-X
specific	B-X
target	B-X
protein	B-X
in	B-X
a	B-X
complex	B-X
mixture	B-X
,	B-X
but	B-X
now	B-X
journal	B-X
editors	B-X
and	B-X
reviewers	B-X
are	B-X
requesting	B-X
the	B-X
quantitative	B-X
interpretation	B-X
of	B-X
western	B-X
blot	B-X
data	B-X
in	B-X
terms	B-X
of	B-X
fold	B-X
changes	B-X
in	B-X
protein	B-X
expression	B-X
between	B-X
samples	B-X
.	B-X
The	B-X
calculations	B-X
are	B-X
based	B-X
on	B-X
the	B-X
differential	B-X
densitometry	B-X
of	B-X
the	B-X
associated	B-X
chemiluminescent	B-X
and/or	B-X
fluorescent	B-X
signals	B-X
from	B-X
the	B-X
blots	B-X
and	B-X
this	B-X
now	B-X
requires	B-X
a	B-X
fundamental	B-X
shift	B-X
in	B-X
the	B-X
experimental	B-X
methodology	B-X
,	B-X
acquisition	B-X
,	B-X
and	B-X
interpretation	B-X
of	B-X
the	B-X
data	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
published	B-X
an	B-X
updated	B-X
approach	B-X
to	B-X
produce	B-X
quantitative	B-X
densitometric	B-X
data	B-X
from	B-X
western	B-X
blots	B-X
(	B-X
Taylor	B-X
et	B-X
al.	B-X
,	B-X
2013	B-X
)	B-X
and	B-X
here	B-X
we	B-X
summarize	B-X
the	B-X
complete	B-X
western	B-X
blot	B-X
workflow	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
sample	B-X
preparation	B-X
and	B-X
data	B-X
analysis	B-X
for	B-X
quantitative	B-X
western	B-X
blotting	B-X
.	B-X

Whole	O
cell	O
extracts	O
were	O
collected	O
with	O
lysis	O
buffer	O
containing	O
150	O
mM	O
NaCl	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
,	O
1	O
%	O
Triton	O
,	O
10	O
%	O
glycerol	O
,	O
and	O
1	O
tablet	O
of	O
Complete	O
EDTA	O
-	O
free	O
Protease	O
Inhibitor	O
Cocktail	O
(	O
Roche	O
)	O
per	O
25	O
ml	O
of	O
buffer	O
.	O

Extracts	O
were	O
boiled	O
for	O
5	O
min	O
in	O
1x	O
Laemmli	O
sample	O
buffer	O
with	O
5	O
%	O
v	O
/	O
v	O
2	O
-	O
mercaptoethanol	O
and	O
proteins	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
.	O

The	O
gel	O
was	O
transferred	O
to	O
a	O
nitrocellulose	O
Trans	O
-	O
Blot	O
Transfer	O
Membrane	O
(	O
BioRad	O
)	O
.	O

The	O
blot	O
was	O
then	O
blocked	O
for	O
1	O
h	O
at	O
37degreesC	O
in	O
a	O
solution	O
of	O
4	O
%	O
BSA	B-Protein
(	O
Sigma	O
)	O
and	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
(	O
BioRad	O
)	O
in	O
a	O
buffer	O
containing	O
50	O
mM	O
Tris	O
and	O
150	O
mM	O
NaCl	O
at	O
pH	O
7	O
.	O
6	O
(	O
BSA	O
/	O
TBST	O
)	O
.	O

Primary	O
incubation	O
was	O
carried	O
out	O
with	O
a1	O
:	O
200	O
dilution	O
of	O
rabbit	O
anti	O
-	O
NFAT5	O
antibody	O
(	O
H	O
-	O
300	O
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
and	O
a	O
1	O
:	O
500	O
dilution	O
of	O
goat	O
anti	O
-	O
Lamin	O
-	O
B1	O
antibody	O
(	O
sc	O
-	O
6217	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
in	O
BSA	B-Protein
/	O
TBST	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

The	O
blot	O
was	O
washed	O
3x5	O
min	O
in	O
TBST	O
and	O
incubated	O
in	O
1	O
:	O
6000	O
donkey	O
anti	O
-	O
goat	O
-	O
HRP	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
or	O
goat	O
anti	O
-	O
rabbit	O
-	O
HRP	O
(	O
BioRad	O
)	O
as	O
appropriate	O
for	O
1	O
h	O
.	O

The	O
blot	O
was	O
again	O
washed	O
3x5	O
min	O
in	O
TBST	O
and	O
developed	O
with	O
SuperSignal	O
West	O
Pico	O
Chemiluminescent	O
Reagent	O
(	O
Pierce	O
)	O
.	O

Quantitative	O
PCR	O
<EOS>	B-X
Real-time	B-X
quantitative	B-X
PCR	B-X
allows	B-X
the	B-X
sensitive	B-X
,	B-X
specific	B-X
and	B-X
reproducible	B-X
quantitation	B-X
of	B-X
nucleic	B-X
acids	B-X
.	B-X
Since	B-X
its	B-X
introduction	B-X
,	B-X
real-time	B-X
quantitative	B-X
PCR	B-X
has	B-X
revolutionized	B-X
the	B-X
field	B-X
of	B-X
molecular	B-X
diagnostics	B-X
and	B-X
the	B-X
technique	B-X
is	B-X
being	B-X
used	B-X
in	B-X
a	B-X
rapidly	B-X
expanding	B-X
number	B-X
of	B-X
applications	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
the	B-X
basic	B-X
principles	B-X
of	B-X
real-time	B-X
PCR	B-X
and	B-X
describes	B-X
the	B-X
various	B-X
chemistries	B-X
available	B-X
:	B-X
the	B-X
double-stranded	B-X
DNA-intercalating	B-X
agent	B-X
SYBR	B-X
Green	B-X
1	B-X
,	B-X
hydrolysis	B-X
probes	B-X
,	B-X
dual	B-X
hybridization	B-X
probes	B-X
,	B-X
molecular	B-X
beacons	B-X
and	B-X
scorpion	B-X
probes	B-X
.	B-X
Quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
a	B-X
routinely	B-X
used	B-X
method	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantitation	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
real	B-X
time	B-X
.	B-X
Multiplex	B-X
qPCR	B-X
requires	B-X
the	B-X
use	B-X
of	B-X
probe-based	B-X
assays	B-X
,	B-X
in	B-X
which	B-X
each	B-X
probe	B-X
is	B-X
labeled	B-X
with	B-X
a	B-X
unique	B-X
fluorescent	B-X
dye	B-X
,	B-X
resulting	B-X
in	B-X
different	B-X
observed	B-X
colors	B-X
for	B-X
each	B-X
assay	B-X
.	B-X

The	O
mRNA	O
expression	O
levels	O
were	O
determined	O
by	O
SYBR	O
Green	O
-	O
based	O
real	O
-	O
time	O
PCR	O
(	O
Applied	O
Biosystems	O
,	O
www	O
.	O
appliedbiosystems	O
.	O
com	O
)	O
.	O

The	O
reaction	O
conditions	O
were	O
95degreesC	O
for	O
10	O
min	O
followed	O
by	O
40	O
cycles	O
of	O
95degreesC	O
for	O
15	O
sec	O
and	O
60degreesC	O
for	O
1	O
min	O
.	O

The	O
results	O
were	O
normalized	O
using	O
beta	B-Protein
-	I-Protein
actin	I-Protein
mRNA	O
as	O
an	O
internal	O
control	O
and	O
expressed	O
as	O
relative	O
values	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
magnitude	B-X
of	B-X
the	B-X
relative	B-X
SC	B-X
,	B-X
citrate	B-X
synthase	B-X
activity	B-X
,	B-X
UCP2	B-X
and	B-X
UCP3	B-X
mRNA	B-X
levels	B-X
and	B-X
muscle	B-X
fibre	B-X
composition	B-X
in	B-X
both	B-X
endurance-trained	B-X
and	B-X
recreationally	B-X
active	B-X
subjects	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
overexpression	B-X
of	B-X
hMTH	B-X
in	B-X
unaffected	B-X
(	B-X
normal	B-X
)	B-X
surrogate	B-X
tissue	B-X
is	B-X
associated	B-X
with	B-X
risk	B-X
of	B-X
prostate	B-X
cancer	B-X
in	B-X
a	B-X
pilot	B-X
study	B-X
of	B-X
51	B-X
patients	B-X
with	B-X
diagnosed	B-X
prostate	B-X
cancer	B-X
and	B-X
50	B-X
age-	B-X
and	B-X
ethnicity-matched	B-X
controls	B-X
.	B-X
We	B-X
performed	B-X
the	B-X
real-time	B-X
reverse	B-X
transcription-polymerase	B-X
chain	B-X
reaction	B-X
assay	B-X
to	B-X
evaluate	B-X
the	B-X
relative	B-X
mRNA	B-X
expression	B-X
of	B-X
three	B-X
oxidative-damage-repair	B-X
genes	B-X
,	B-X
human	B-X
MutM	B-X
homolog	B-X
(	B-X
hMMH	B-X
)	B-X
,	B-X
hMTH	B-X
,	B-X
and	B-X
human	B-X
MutY	B-X
homolog	B-X
(	B-X
hMYH	B-X
)	B-X
,	B-X
with	B-X
beta-actin	B-X
and	B-X
human	B-X
O	B-X
(	B-X
6	B-X
)	B-X
-methylguanine	B-X
DNA	B-X
methyltransferase	B-X
(	B-X
hMGMT	B-X
)	B-X
as	B-X
the	B-X
internal	B-X
controls	B-X
.	B-X
The	B-X
relative	B-X
gene	B-X
expression	B-X
levels	B-X
of	B-X
hMMH	B-X
and	B-X
hMTH	B-X
were	B-X
borderline	B-X
higher	B-X
in	B-X
the	B-X
cases	B-X
than	B-X
in	B-X
controls	B-X
(	B-X
15.3	B-X
%	B-X
and	B-X
28.8	B-X
%	B-X
higher	B-X
,	B-X
respectively	B-X
;	B-X
P	B-X
=	B-X
0.046	B-X
and	B-X
P	B-X
=	B-X
0.035	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
whereas	B-X
no	B-X
increase	B-X
was	B-X
observed	B-X
for	B-X
hMYH	B-X
and	B-X
hMGMT	B-X
.	B-X
With	B-X
the	B-X
median	B-X
of	B-X
the	B-X
controls	B-X
'	B-X
values	B-X
as	B-X
the	B-X
cutoff	B-X
point	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
a	B-X
high	B-X
expression	B-X
level	B-X
of	B-X
hMTH	B-X
,	B-X
but	B-X
not	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
significantly	B-X
increased	B-X
risk	B-X
of	B-X
prostate	B-X
cancer	B-X
(	B-X
odds	B-X
ratio	B-X
=	B-X
2.62	B-X
;	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
=	B-X
1.13-6.75	B-X
)	B-X
after	B-X
adjustment	B-X
for	B-X
age	B-X
and	B-X
ethnicity	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
increased	B-X
expression	B-X
of	B-X
hMTH	B-X
in	B-X
peripheral	B-X
lymphocytes	B-X
may	B-X
be	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
prostate	B-X
cancer	B-X
and	B-X
support	B-X
our	B-X
priori	B-X
hypothesis	B-X
.	B-X

Statistical	O
analysis	O

Where	O
applicable	O
,	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
.	O

Comparison	O
between	O
two	O
groups	O
was	O
performed	O
using	O
the	O
paired	O
Student	O
t	O
-	O
Test	O
with	O
the	O
aid	O
of	O
Microsoft	O
Excel	O
software	O
.	O

p	O
<	O
=	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
ultrasound	B-X
characteristics	B-X
of	B-X
ipsilateral	B-X
axillary	B-X
lymph	B-X
nodes	B-X
after	B-X
two	B-X
doses	B-X
of	B-X
four	B-X
different	B-X
COVID-19	B-X
vaccination	B-X
protocols	B-X
,	B-X
to	B-X
determine	B-X
whether	B-X
these	B-X
parameters	B-X
differed	B-X
with	B-X
age	B-X
,	B-X
and	B-X
to	B-X
describe	B-X
how	B-X
they	B-X
changed	B-X
on	B-X
follow-up	B-X
imaging	B-X
.	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
side	B-X
effects	B-X
of	B-X
application	B-X
of	B-X
the	B-X
Pfizer	B-X
BioNTech	B-X
vaccine	B-X
on	B-X
the	B-X
workers	B-X
at	B-X
a	B-X
Mexican	B-X
hospital	B-X
.	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
has	B-X
evolved	B-X
rapidly	B-X
,	B-X
leading	B-X
to	B-X
viral	B-X
lineages	B-X
characterized	B-X
by	B-X
multiple	B-X
mutations	B-X
in	B-X
the	B-X
spike	B-X
protein	B-X
,	B-X
which	B-X
could	B-X
potentially	B-X
confer	B-X
to	B-X
the	B-X
virus	B-X
the	B-X
ability	B-X
to	B-X
avoid	B-X
the	B-X
vaccine-induced	B-X
immune	B-X
response	B-X
,	B-X
making	B-X
the	B-X
vaccines	B-X
less	B-X
effective	B-X
or	B-X
ineffective	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
initially	B-X
evaluated	B-X
the	B-X
neutralization	B-X
capabilities	B-X
in	B-X
vitro	B-X
by	B-X
serum	B-X
neutralization	B-X
(	B-X
SN	B-X
)	B-X
of	B-X
six	B-X
serum	B-X
samples	B-X
collected	B-X
from	B-X
recipients	B-X
of	B-X
the	B-X
BNT162b2	B-X
vaccine	B-X
against	B-X
11	B-X
SARS-CoV-2	B-X
isolates	B-X
belonging	B-X
to	B-X
the	B-X
major	B-X
SARS-CoV-2	B-X
lineages	B-X
that	B-X
had	B-X
been	B-X
circulating	B-X
in	B-X
Italy	B-X
.	B-X
Then	B-X
,	B-X
we	B-X
considered	B-X
30	B-X
additional	B-X
serum	B-X
samples	B-X
by	B-X
SN	B-X
assay	B-X
against	B-X
the	B-X
dominant	B-X
B.1.617.2	B-X
(	B-X
Delta	B-X
)	B-X
variant	B-X
.	B-X
In	B-X
the	B-X
first	B-X
analysis	B-X
,	B-X
significant	B-X
differences	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
reference	B-X
strain	B-X
(	B-X

MTb	O
increases	O
HIV	O
-	O
1	O
LTR	O
activity	O
of	O
HIV	O
-	O
1	O
subtypes	O
B	O
,	O
C	O
,	O
and	O
E	O

To	O
compare	O
the	O
functional	O
impact	O
of	O
MTb	O
stimulation	O
on	O
subtype	O
-	O
specific	O
HIV	O
-	O
1	O
LTR	O
activity	O
,	O
we	O
first	O
constructed	O
reporter	O
plasmids	O
containing	O
viral	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
LTRs	O
(	O
-	O
208	O
to	O
+	O
64	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
linked	O
to	O
the	O
firefly	O
luciferase	B-Protein
reporter	O
gene	O
.	O

After	O
transfection	O
of	O
the	O
monocytic	O
THP	O
-	O
1	O
cell	O
line	O
with	O
these	O
plasmids	O
,	O
cells	O
were	O
stimulated	O
with	O
an	O
irradiated	O
whole	O
cell	O
lysate	O
of	O
MTb	O
(	O
H37Rv	O
)	O
.	O

We	O
note	O
that	O
MTb	O
lysate	O
induces	O
inflammatory	O
responses	O
in	O
monocytes	O
that	O
resemble	O
those	O
induced	O
in	O
response	O
to	O
live	O
MTb	O
(	O
see	O
for	O
example	O
,	O
[	O
35	O
]	O
-	O
[	O
37	O
]	O
)	O
.	O

Upon	O
stimulation	O
,	O
the	O
B	O
,	O
C	O
,	O
and	O
E	O
LTR	O
-	O
driven	O
reporters	O
demonstrated	O
a	O
significant	O
enhancement	O
in	O
luciferase	B-Protein
activity	O
(	O
Figure	O
1A	O
)	O
and	O
the	O
magnitude	O
of	O
this	O
effect	O
was	O
subtype	O
-	O
specific	O
.	O

Subtype	O
C	O
LTRs	O
displayed	O
the	O
strongest	O
activity	O
,	O
while	O
the	O
LTRs	O
from	O
subtype	O
E	O
isolates	O
consistently	O
showed	O
the	O
weakest	O
activity	O
(	O
Figure	O
1A	O
)	O
,	O
consistent	O
with	O
previous	O
studies	O
demonstrating	O
subtype	O
-	O
specific	O
LTR	O
activity	O
that	O
used	O
TNF	B-Protein
as	O
a	O
stimulus	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

Specific	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
impairs	O
LTR	O
-	O
driven	O
transcription	O
in	O
THP	O
-	O
1	O
cells	O
in	O
response	O
to	O
MTb	O
stimulation	O

Although	O
the	O
transcription	O
factor	O
NFAT5	B-Protein
binds	O
to	O
a	O
core	O
NF	O
-	O
kappaB	O
binding	O
motif	O
in	O
the	O
HIV	O
-	O
1	O
LTR	O
enhancer	O
region	O
of	O
subtype	O
B	O
,	O
when	O
two	O
thymines	O
(	O
TT	O
)	O
are	O
changed	O
to	O
cytosines	O
(	O
CC	O
)	O
in	O
the	O
proximal	O
NF	O
-	O
kappaB	O
binding	O
motif	O
(	O
named	O
N5	O
-	O
Mut	O
)	O
(	O
bottom	O
of	O
Figure	O
1B	O
)	O
,	O
the	O
binding	O
of	O
NFAT5	B-Protein
can	O
be	O
disrupted	O
while	O
leaving	O
binding	O
of	O
NF	O
-	O
kappaB	O
unperturbed	O
[	O
31	O
]	O
.	O

We	O
examined	O
the	O
requirement	O
of	O
NFAT5	B-Protein
for	O
MTb	O
-	O
induced	O
LTR	O
activity	O
by	O
transfecting	O
a	O
wild	O
-	O
type	O
and	O
NFAT5	O
mutant	O
LTR	O
reporter	O
construct	O
into	O
THP	O
-	O
1	O
cells	O
,	O
followed	O
by	O
stimulation	O
with	O
an	O
MTb	O
lysate	O
.	O

As	O
shown	O
in	O
Figure	O
1B	O
,	O
in	O
the	O
absence	O
of	O
MTb	O
lysate	O
stimulation	O
the	O
activity	O
of	O
the	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
LTR	O
was	O
significantly	O
reduced	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
LTR	O
.	O

When	O
the	O
NFAT5	O
binding	O
site	O
-	O
mutant	O
LTR	O
was	O
examined	O
in	O
THP	O
-	O
1	O
cells	O
stimulated	O
with	O
the	O
MTb	O
lysate	O
,	O
its	O
activity	O
was	O
reduced	O
to	O
an	O
even	O
more	O
significant	O
extent	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

To	O
determine	O
whether	O
MTb	O
lysate	O
stimulation	O
directly	O
enhances	O
NFAT5	B-Protein
expression	O
in	O
THP	O
-	O
1	O
cells	O
,	O
we	O
stimulated	O
cells	O
for	O
8	O
or	O
24	O
hours	O
or	O
left	O
them	O
unstimulated	O
and	O
examined	O
NFAT5	B-Protein
protein	O
levels	O
by	O
western	O
blot	O
.	O
<EOS>	B-X
To	B-X
compare	B-X
the	B-X
efficacy	B-X
of	B-X
methylprednisolone	B-X
administered	B-X
for	B-X
24	B-X
hours	B-X
with	B-X
methyprednisolone	B-X
administered	B-X
for	B-X
48	B-X
hours	B-X
or	B-X
tirilazad	B-X
mesylate	B-X
administered	B-X
for	B-X
48	B-X
hours	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
spinal	B-X
cord	B-X
injury	B-X
.	B-X
National	B-X
guidelines	B-X
generally	B-X
recommend	B-X
24	B-X
hours	B-X
or	B-X
less	B-X
of	B-X
surgical	B-X
antibiotic	B-X
prophylaxis	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
effect	B-X
relugolix	B-X
and	B-X
elagolix	B-X
have	B-X
on	B-X
the	B-X
production	B-X
of	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
proteins	B-X
in	B-X
human	B-X
leiomyoma	B-X
cells	B-X
.	B-X
Leukocyte	B-X
recruitment	B-X
to	B-X
CSF	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
peak	B-X
around	B-X
24	B-X
hours	B-X
after	B-X
prolonged	B-X
seizures	B-X
in	B-X
animal	B-X
studies	B-X
,	B-X
suggesting	B-X
that	B-X
CSF	B-X
pleocytosis	B-X
within	B-X
the	B-X
first	B-X
24	B-X
hours	B-X
of	B-X
SE	B-X
onset	B-X
may	B-X
be	B-X
due	B-X
to	B-X
underlying	B-X
causes	B-X
.	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
assess	B-X
if	B-X
SE	B-X
is	B-X
associated	B-X
with	B-X
CSF	B-X
pleocytosis	B-X
,	B-X
independent	B-X
of	B-X
other	B-X
causes	B-X
within	B-X
the	B-X
first	B-X
24	B-X
hours	B-X
of	B-X
onset	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
1C	O
,	O
we	O
found	O
that	O
NFAT5	B-Protein
protein	O
levels	O
steadily	O
increased	O
in	O
response	O
to	O
MTb	O
lysate	O
stimulation	O
,	O
revealing	O
that	O
TLR	O
engagement	O
by	O
MTb	O
results	O
in	O
enhanced	O
levels	O
of	O
NFAT5	B-Protein
,	O
consistent	O
with	O
its	O
playing	O
a	O
role	O
in	O
MTb	O
-	O
induced	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
.	O

MTb	O
increases	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
human	O
MDM	O

Given	O
that	O
macrophages	O
,	O
which	O
are	O
the	O
primary	O
target	O
of	O
MTb	O
infection	O
,	O
are	O
also	O
a	O
major	O
reservoir	O
of	O
HIV	O
-	O
1	O
as	O
infection	O
progresses	O
[	O
40	O
]	O
,	O
we	O
next	O
investigated	O
whether	O
MTb	O
is	O
able	O
to	O
directly	O
enhance	O
NFAT5	B-Protein
mRNA	O
expression	O
in	O
primary	O
human	O
MDM	O
.	O

We	O
prepared	O
MDM	O
from	O
five	O
normal	O
donors	O
,	O
stimulated	O
the	O
cells	O
with	O
the	O
MTb	O
lysate	O
or	O
left	O
them	O
unstimulated	O
,	O
and	O
measured	O
NFAT5	B-Protein
gene	O
expression	O
levels	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
at	O
24	O
and	O
48	O
hours	O
.	O

We	O
also	O
investigated	O
whether	O
HIV	O
-	O
1	O
infection	O
is	O
capable	O
of	O
inducing	O
NFAT5	B-Protein
mRNA	O
synthesis	O
by	O
infecting	O
MDM	O
with	O
live	O
or	O
heat	O
-	O
inactivated	O
R5	O
-	O
tropic	O
representatives	O
of	O
subtype	O
B	O
(	O
HIV	O
-	O
1Bal	O
)	O
,	O
C	O
(	O
HIV	O
-	O
198IN22	O
)	O
,	O
or	O
E	O
(	O
HIV	O
-	O
192TH64	O
)	O
.	O
<EOS>	B-X
Combination	B-X
antiretroviral	B-X
therapy	B-X
(	B-X
ART	B-X
)	B-X
has	B-X
significantly	B-X
reduced	B-X
the	B-X
morbidity	B-X
and	B-X
mortality	B-X
resulting	B-X
from	B-X
HIV	B-X
infection	B-X
.	B-X
ART	B-X
is	B-X
,	B-X
however	B-X
,	B-X
unable	B-X
to	B-X
eradicate	B-X
HIV	B-X
,	B-X
which	B-X
persists	B-X
latently	B-X
in	B-X
several	B-X
cell	B-X
types	B-X
and	B-X
tissues	B-X
.	B-X
Conversely	B-X
,	B-X
it	B-X
is	B-X
widely	B-X
accepted	B-X
that	B-X
drug	B-X
resistance	B-X
mutations	B-X
(	B-X
DRMs	B-X
)	B-X
do	B-X
not	B-X
appear	B-X
during	B-X
ART	B-X
in	B-X
patients	B-X
with	B-X
suppressed	B-X
viral	B-X
loads	B-X
.	B-X
Studies	B-X
based	B-X
on	B-X
sequence	B-X
clustering	B-X
have	B-X
in	B-X
fact	B-X
indicated	B-X
that	B-X
,	B-X
at	B-X
least	B-X
in	B-X
developed	B-X
countries	B-X
,	B-X
HIV-infected	B-X
ART-naive	B-X
patients	B-X
are	B-X
the	B-X
major	B-X
source	B-X
of	B-X
drug-resistant	B-X
viruses	B-X
.	B-X
Analysis	B-X
of	B-X
longitudinally	B-X
sampled	B-X
sequences	B-X
have	B-X
also	B-X
shown	B-X
that	B-X
DRMs	B-X
have	B-X
variable	B-X
fitness	B-X
costs	B-X
,	B-X
which	B-X
are	B-X
strongly	B-X
influenced	B-X
by	B-X
the	B-X
viral	B-X
genetic	B-X
background	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
2A	O
,	O
stimulation	O
with	O
MTb	O
lysate	O
significantly	O
increased	O
NFAT5	B-Protein
mRNA	O
levels	O
at	O
24	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
48	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
hours	O
,	O
whereas	O
infection	O
with	O
viable	O
or	O
heat	O
-	O
inactivated	O
HIV	O
-	O
1	O
isolates	O
did	O
not	O
increase	O
NFAT5	B-Protein
mRNA	O
levels	O
(	O
Figure	O
2A	O
)	O
.	O

Thus	O
,	O
MTb	O
specifically	O
enhances	O
NFAT5	B-Protein
mRNA	O
expression	O
in	O
human	O
MDM	O
,	O
and	O
this	O
response	O
continues	O
to	O
increase	O
for	O
at	O
least	O
48	O
hours	O
post	O
-	O
stimulation	O
(	O
Figure	O
2A	O
)	O
.	O

RNAi	O
directed	O
against	O
NFAT5	B-Protein
inhibits	O
replication	O
of	O
subtype	O
B	O
HIV	O
-	O
1	O

To	O
extend	O
the	O
results	O
we	O
obtained	O
in	O
the	O
reporter	O
assays	O
to	O
a	O
physiological	O
TB	O
/	O
HIV	O
co	O
-	O
infection	O
model	O
,	O
we	O
next	O
tested	O
the	O
effect	O
of	O
siRNA	O
-	O
mediated	O
ablation	O
of	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
MDM	O
co	O
-	O
infected	O
with	O
a	O
subtype	O
B	O
HIV	O
-	O
1Lai	O
infectious	O
molecular	O
clone	O
and	O
a	O
clinical	O
isolate	O
of	O
MTb	O
.	O

To	O
perform	O
this	O
experiment	O
,	O
we	O
first	O
constructed	O
an	O
HIV	O
-	O
1Lai	O
clone	O
bearing	O
the	O
CCR5	B-Protein
-	O
tropic	O
envelope	O
region	O
of	O
HIV	O
-	O
1Bal	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
)	O
so	O
that	O
it	O
would	O
efficiently	O
infect	O
primary	O
MDM	O
.	O

We	O
used	O
this	O
approach	O
to	O
ensure	O
that	O
our	O
analysis	O
of	O
the	O
roles	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
in	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
could	O
be	O
interpreted	O
in	O
the	O
proper	O
context	O
of	O
previous	O
research	O
findings	O
that	O
examined	O
LTR	O
regulation	O
in	O
the	O
context	O
of	O
full	O
-	O
length	O
viral	O
replication	O
[	O
41	O
]	O
-	O
[	O
46	O
]	O
.	O

The	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	B-Protein
infectious	O
clone	O
is	O
isogenic	O
for	O
the	O
entire	O
sequence	O
of	O
the	O
parental	O
HIV	O
-	O
1Lai	O
infectious	O
clone	O
except	O
for	O
the	O
substitution	O
of	O
the	O
HIV	O
-	O
1Bal	O
envelope	B-Protein
co	O
-	O
receptor	O
binding	O
region	O
in	O
place	O
of	O
the	O
HIV	O
-	O
1Lai	O
envelope	B-Protein
co	O
-	O
receptor	O
binding	O
region	O
.	O

We	O
note	O
that	O
we	O
confirmed	O
that	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	B-Protein
grew	O
in	O
PBMC	O
at	O
a	O
similar	O
rate	O
to	O
wild	O
-	O
type	O
HIV	O
-	O
1Bal	O
,	O
indicating	O
proper	O
co	O
-	O
receptor	O
engagement	O
and	O
internalization	O
of	O
this	O
infectious	O
clone	O
(	O
data	O
not	O
shown	O
)	O
.	O

Next	O
,	O
we	O
knocked	O
down	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
MDM	O
using	O
an	O
siRNA	O
that	O
suppresses	O
both	O
NFAT5	B-Protein
mRNA	O
and	O
NFAT5	B-Protein
protein	O
levels	O
[	O
31	O
]	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
transfection	O
of	O
the	O
siRNA	O
specific	O
for	O
NFAT5	B-Protein
reduces	O
NFAT5	B-Protein
mRNA	O
levels	O
in	O
both	O
MTb	O
-	O
uninfected	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
and	O
MTb	O
-	O
infected	O
(	O
p	O
=	O
0	O
.	O
021	O
)	O
MDM	O
as	O
compared	O
to	O
transfection	O
of	O
control	O
GFP	B-Protein
siRNA	O
into	O
MTb	O
-	O
uninfected	O
or	O
-	O
infected	O
MDM	O
(	O
Figure	O
2B	O
)	O
.	O

We	O
note	O
that	O
although	O
siRNA	O
normally	O
is	O
effective	O
for	O
48	O
-	O
72	O
hours	O
in	O
cell	O
lines	O
that	O
divide	O
rapidly	O
,	O
in	O
human	O
MDM	O
,	O
which	O
are	O
non	O
-	O
dividing	O
cells	O
,	O
siRNA	O
to	O
host	O
factors	O
remains	O
detectable	O
and	O
functional	O
up	O
to	O
at	O
least	O
15	O
days	O
post	O
-	O
transfection	O
[	O
47	O
]	O
.	O

MDM	O
in	O
which	O
NFAT5	B-Protein
expression	O
had	O
been	O
inhibited	O
with	O
NFAT5	B-Protein
siRNA	O
or	O
that	O
were	O
transfected	O
with	O
control	O
GFP	B-Protein
siRNA	O
were	O
then	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
.	O

After	O
overnight	O
virus	O
infection	O
,	O
the	O
cells	O
were	O
then	O
co	O
-	O
infected	O
with	O
the	O
MTb	O
clinical	O
strain	O
CDC1551	O
.	O

Free	O
virus	O
levels	O
were	O
then	O
measured	O
in	O
culture	O
supernatants	O
from	O
MDM	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
or	O
GFP	B-Protein
control	O
siRNA	O
at	O
days	O
6	O
,	O
9	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
to	O
measure	O
the	O
impact	O
of	O
NFAT5	B-Protein
inhibition	O
on	O
MTb	O
-	O
induced	O
HIV	O
replication	O
.	O

As	O
shown	O
in	O
Figure	O
2C	O
,	O
HIV	O
-	O
1	O
replication	O
was	O
suppressed	O
at	O
days	O
6	O
and	O
9	O
post	O
-	O
infection	O
in	O
the	O
NFAT5	B-Protein
siRNA	O
-	O
treated	O
cells	O
as	O
compared	O
to	O
cells	O
treated	O
with	O
control	O
siRNA	O
,	O
and	O
it	O
was	O
significantly	O
inhibited	O
by	O
day	O
12	O
post	O
-	O
infection	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Figure	O
2C	O
)	O
.	O

Thus	O
,	O
knock	O
down	O
of	O
NFAT5	B-Protein
expression	O
significantly	O
impairs	O
HIV	O
-	O
1	O
subtype	O
B	O
replication	O
in	O
MDM	O
co	O
-	O
infected	O
with	O
MTb	O
.	O

NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
can	O
be	O
specifically	O
disrupted	O

To	O
demonstrate	O
that	O
the	O
impact	O
of	O
NFAT5	B-Protein
silencing	O
on	O
MTb	O
-	O
induced	O
viral	O
replication	O
was	O
a	O
direct	O
effect	O
due	O
to	O
modulation	O
of	O
recruitment	O
of	O
NFAT5	B-Protein
to	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
not	O
due	O
to	O
secondary	O
,	O
NFAT5	B-Protein
-	O
regulated	O
effects	O
,	O
we	O
set	O
out	O
to	O
disrupt	O
NFAT5	B-Protein
binding	O
to	O
the	O
viral	O
LTR	O
in	O
the	O
context	O
of	O
HIV	O
-	O
1	O
/	O
MTb	O
co	O
-	O
infection	O
.	O

This	O
series	O
of	O
experiments	O
also	O
allowed	O
us	O
to	O
dissect	O
the	O
relative	O
importance	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
.	O

To	O
perform	O
these	O
experiments	O
,	O
we	O
constructed	O
a	O
panel	O
of	O
infectious	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
molecular	O
clones	O
where	O
either	O
the	O
NFAT5	O
site	O
was	O
specifically	O
disrupted	O
or	O
the	O
two	O
NF	O
-	O
kappaB	O
binding	O
sites	O
were	O
either	O
individually	O
or	O
dually	O
disrupted	O
(	O
Figure	O
3A	O
)	O
.	O
<EOS>	B-X
The	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
has	B-X
evolved	B-X
to	B-X
coordinate	B-X
its	B-X
replication	B-X
with	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
host	B-X
CD4T	B-X
cell	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
T-cell	B-X
activation	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
become	B-X
the	B-X
best-studied	B-X
examples	B-X
.	B-X
The	B-X
past	B-X
several	B-X
years	B-X
have	B-X
revealed	B-X
compelling	B-X
evidence	B-X
that	B-X
another	B-X
transcription	B-X
factor	B-X
family	B-X
involved	B-X
in	B-X
T-cell	B-X
activation	B-X
,	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
,	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
HIV-1	B-X
.	B-X
Major	B-X
advances	B-X
have	B-X
been	B-X
made	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
HIV-1	B-X
with	B-X
this	B-X
intriguing	B-X
transcription	B-X
factor	B-X
.	B-X
The	B-X
duplicated	B-X
NF-kappaB	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
HIV-1	B-X
enhancer	B-X
surprisingly	B-X
also	B-X
bind	B-X
NFAT	B-X
proteins	B-X
and	B-X
appear	B-X
to	B-X
be	B-X
the	B-X
most	B-X
important	B-X
targets	B-X
for	B-X
NFAT	B-X
transactivation	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
NFAT1	B-X
bound	B-X
to	B-X
one	B-X
of	B-X
these	B-X
duplicated	B-X
sites	B-X
was	B-X
solved	B-X
recently	B-X
.	B-X
Interestingly	B-X
,	B-X
it	B-X
showed	B-X
that	B-X
NFAT1	B-X
binds	B-X
to	B-X
this	B-X
site	B-X
as	B-X
a	B-X
homodimer	B-X
and	B-X
occupies	B-X
the	B-X
core	B-X
of	B-X
the	B-X
NF-kappaB	B-X
site	B-X
,	B-X
suggesting	B-X
mutually	B-X
exclusive	B-X
binding	B-X
and	B-X
alternate	B-X
transactivation	B-X
by	B-X
these	B-X
two	B-X
factors	B-X
.	B-X
NFAT	B-X
also	B-X
regulates	B-X
HIV-1	B-X
infection	B-X
indirectly	B-X
,	B-X
as	B-X
it	B-X
can	B-X
relieve	B-X
a	B-X
block	B-X
to	B-X
reverse	B-X
transcription	B-X
in	B-X
quiescent	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
turn	B-X
,	B-X
HIV-1	B-X
,	B-X
and	B-X
particularly	B-X
its	B-X
Tat	B-X
and	B-X
Nef	B-X
gene	B-X
products	B-X
,	B-X
can	B-X
upregulate	B-X
NFAT	B-X
expression	B-X
and	B-X
activity	B-X
.	B-X
This	B-X
reciprocal	B-X
regulation	B-X
between	B-X
virus	B-X
and	B-X
transcription	B-X
factor	B-X
potentially	B-X
creates	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
,	B-X
which	B-X
may	B-X
facilitate	B-X
the	B-X
establishment	B-X
of	B-X
early	B-X
HIV-1	B-X
infection	B-X
and	B-X
,	B-X
later	B-X
,	B-X
the	B-X
transition	B-X
from	B-X
latent	B-X
to	B-X
productive	B-X
infection	B-X
.	B-X
The	B-X
immunosuppressive	B-X
drug	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
inhibits	B-X
NFAT	B-X
activity	B-X
and	B-X
thus	B-X
represents	B-X
a	B-X
potential	B-X
treatment	B-X
for	B-X
HIV-1	B-X
infection	B-X
.	B-X
Recent	B-X
small-scale	B-X
clinical	B-X
trials	B-X
have	B-X
yielded	B-X
optimistic	B-X
results	B-X
,	B-X
suggesting	B-X
roles	B-X
for	B-X
CsA	B-X
after	B-X
organ	B-X
transplantation	B-X
in	B-X
HIV-1+	B-X
individuals	B-X
and	B-X
as	B-X
adjunct	B-X
treatment	B-X
in	B-X
stable	B-X
early	B-X
HIV-1	B-X
infection	B-X
.	B-X

Specifically	O
,	O
we	O
constructed	O
a	O
clone	O
in	O
which	O
the	O
NFAT5	O
binding	O
site	O
was	O
mutated	O
(	O
named	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
)	O
by	O
changing	O
the	O
CC	O
dinucleotide	O
to	O
TT	O
in	O
the	O
core	O
NFAT5	O
binding	O
site	O
and	O
introduced	O
substitution	O
mutations	O
into	O
the	O
NF	O
-	O
kappaB	O
/	O
NFAT5	O
shared	O
binding	O
element	O
that	O
we	O
predicted	O
would	O
disrupt	O
NF	O
-	O
kappaB	O
binding	O
but	O
preserve	O
NFAT5	B-Protein
binding	O
.	O

Specifically	O
,	O
we	O
mutated	O
two	O
guanines	O
(	O
GG	O
)	O
in	O
the	O
kappaB	O
I	O
site	O
and	O
changed	O
them	O
to	O
thymine	O
and	O
adenine	O
(	O
TA	O
)	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
mut	O
)	O
and	O
also	O
introduced	O
the	O
same	O
GG	O
to	O
TA	O
change	O
in	O
the	O
second	O
,	O
more	O
distal	O
NF	O
-	O
kappaB	O
site	O
(	O
kappaB	O
II	O
)	O
in	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
)	O
.	O

We	O
also	O
created	O
a	O
double	O
NF	O
-	O
kappaB	O
site	O
mutant	O
virus	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
in	O
order	O
to	O
test	O
the	O
impact	O
of	O
complete	O
disruption	O
of	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
on	O
MTb	O
regulation	O
.	O

To	O
determine	O
the	O
specificity	O
of	O
these	O
substitutions	O
upon	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
LTR	O
,	O
we	O
performed	O
a	O
quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
analysis	O
using	O
the	O
wild	O
-	O
type	O
LTR	O
or	O
mutant	O
LTRs	O
in	O
combination	O
with	O
increasing	O
concentrations	O
of	O
recombinant	O
NFAT5	B-Protein
or	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
proteins	O
.	O
<EOS>	B-X
The	B-X
pleiotropic	B-X
consequences	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
kappa	B-X
light	B-X
polypeptide	B-X
gene	B-X
enhancer	B-X
in	B-X
B-cells	B-X
(	B-X
NF-κB	B-X
)	B-X
pathway	B-X
activation	B-X
result	B-X
from	B-X
the	B-X
combinatorial	B-X
effects	B-X
of	B-X
the	B-X
five	B-X
subunits	B-X
that	B-X
form	B-X
the	B-X
homo-	B-X
and	B-X
heterodimeric	B-X
NF-κB	B-X
complexes	B-X
.	B-X
Although	B-X
biochemical	B-X
and	B-X
gene	B-X
knockout	B-X
studies	B-X
have	B-X
demonstrated	B-X
overlapping	B-X
and	B-X
distinct	B-X
functions	B-X
for	B-X
these	B-X
proteins	B-X
,	B-X
much	B-X
is	B-X
still	B-X
not	B-X
known	B-X
about	B-X
the	B-X
mechanisms	B-X
determining	B-X
context-dependent	B-X
functions	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
different	B-X
dimer	B-X
complexes	B-X
and	B-X
transcriptional	B-X
control	B-X
in	B-X
response	B-X
to	B-X
diverse	B-X
stimuli	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
recent	B-X
results	B-X
that	B-X
reveal	B-X
that	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
kappa	B-X
light	B-X
polypeptide	B-X
gene	B-X
enhancer	B-X
in	B-X
B-cells	B-X
1	B-X
(	B-X
NFKB1	B-X
)	B-X
(	B-X
p105/p50	B-X
)	B-X
subunit	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
NF-κB	B-X
activity	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
effects	B-X
are	B-X
not	B-X
restricted	B-X
to	B-X
being	B-X
a	B-X
dimer	B-X
partner	B-X
for	B-X
other	B-X
NF-κB	B-X
subunits	B-X
.	B-X
Rather	B-X
p50	B-X
homodimers	B-X
have	B-X
a	B-X
critical	B-X
role	B-X
as	B-X
suppressors	B-X
of	B-X
the	B-X
NF-κB	B-X
response	B-X
,	B-X
while	B-X
the	B-X
p105	B-X
precursor	B-X
has	B-X
a	B-X
variety	B-X
of	B-X
NF-κB-independent	B-X
functions	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
Nfkb1	B-X
function	B-X
can	B-X
be	B-X
seen	B-X
in	B-X
mouse	B-X
models	B-X
,	B-X
where	B-X
Nfkb1	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
display	B-X
increased	B-X
inflammation	B-X
and	B-X
susceptibility	B-X
to	B-X
certain	B-X
forms	B-X
of	B-X
DNA	B-X
damage	B-X
,	B-X
leading	B-X
to	B-X
cancer	B-X
,	B-X
and	B-X
a	B-X
rapid	B-X
ageing	B-X
phenotype	B-X
.	B-X
In	B-X
humans	B-X
,	B-X
low	B-X
expression	B-X
of	B-X
Kip1	B-X
ubiquitination-promoting	B-X
complex	B-X
1	B-X
(	B-X
KPC1	B-X
)	B-X
,	B-X
a	B-X
ubiquitin	B-X
ligase	B-X
required	B-X
for	B-X
p105	B-X
to	B-X
p50	B-X
processing	B-X
,	B-X
was	B-X
shown	B-X
to	B-X
correlate	B-X
with	B-X
a	B-X
reduction	B-X
in	B-X
p50	B-X
and	B-X
glioblastoma	B-X
incidence	B-X
.	B-X
Therefore	B-X
,	B-X
while	B-X
the	B-X
majority	B-X
of	B-X
research	B-X
in	B-X
this	B-X
field	B-X
has	B-X
focused	B-X
on	B-X
the	B-X
upstream	B-X
signalling	B-X
pathways	B-X
leading	B-X
to	B-X
NF-κB	B-X
activation	B-X
or	B-X
the	B-X
function	B-X
of	B-X
other	B-X
NF-κB	B-X
subunits	B-X
,	B-X
such	B-X
as	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
NFKB1	B-X
,	B-X
potentially	B-X
revealing	B-X
new	B-X
strategies	B-X
for	B-X
targeting	B-X
this	B-X
pathway	B-X
in	B-X
inflammatory	B-X
diseases	B-X
and	B-X
cancer	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
3B	O
,	O
the	O
N5	O
-	O
Mut	O
LTR	O
could	O
not	O
bind	O
NFAT5	B-Protein
(	O
compare	O
lanes	O
12	O
-	O
15	O
and	O
lanes	O
17	O
-	O
20	O
)	O
,	O
but	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
was	O
not	O
impaired	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
with	O
lanes	O
7	O
-	O
10	O
)	O
.	O

By	O
contrast	O
,	O
changing	O
the	O
GG	O
dinucleotide	O
to	O
TA	O
in	O
either	O
NF	O
-	O
kappaB	O
binding	O
motif	O
,	O
as	O
predicted	O
,	O
inhibited	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
at	O
each	O
site	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
with	O
lanes	O
7	O
-	O
10	O
and	O
lanes	O
12	O
-	O
15	O
of	O
Figure	O
3C	O
)	O
.	O

As	O
expected	O
,	O
mutation	O
of	O
both	O
NF	O
-	O
kappaB	O
sites	O
(	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
resulted	O
in	O
abrogation	O
of	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
LTR	O
.	O

However	O
,	O
recombinant	O
NFAT5	B-Protein
binding	O
to	O
the	O
single	O
and	O
the	O
double	O
NF	O
-	O
kappaB	O
mutant	O
LTRs	O
was	O
not	O
impaired	O
and	O
indeed	O
appeared	O
enhanced	O
(	O
compare	O
lanes	O
2	O
-	O
5	O
to	O
lanes	O
7	O
-	O
20	O
of	O
Figure	O
3D	O
)	O
.	O

Thus	O
,	O
binding	O
of	O
NFAT5	B-Protein
or	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
to	O
their	O
respective	O
motifs	O
can	O
be	O
specifically	O
disrupted	O
within	O
an	O
overlapping	O
or	O
shared	O
binding	O
site	O
.	O
<EOS>	B-X
The	B-X
structures	B-X
have	B-X
been	B-X
solved	B-X
for	B-X
editing	B-X
complexes	B-X
between	B-X
KF	B-X
and	B-X
single-stranded	B-X
DNA	B-X
and	B-X
for	B-X
duplex	B-X
DNA	B-X
with	B-X
a	B-X
3	B-X
'	B-X
overhanging	B-X
single	B-X
strand	B-X
,	B-X
but	B-X
not	B-X
for	B-X
a	B-X
complex	B-X
containing	B-X
duplex	B-X
DNA	B-X
at	B-X
the	B-X
polymerase	B-X
active-site	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
the	B-X
co-crystal	B-X
structure	B-X
of	B-X
Taq	B-X
polymerase	B-X
with	B-X
a	B-X
blunt-ended	B-X
duplex	B-X
DNA	B-X
bound	B-X
to	B-X
the	B-X
polymerase	B-X
active-site	B-X
cleft	B-X
;	B-X
the	B-X
DNA	B-X
neither	B-X
bends	B-X
nor	B-X
goes	B-X
through	B-X
the	B-X
large	B-X
polymerase	B-X
cleft	B-X
,	B-X
and	B-X
the	B-X
structural	B-X
form	B-X
of	B-X
the	B-X
bound	B-X
DNA	B-X
is	B-X
between	B-X
the	B-X
B	B-X
and	B-X
A	B-X
forms	B-X
.	B-X
Part	B-X
of	B-X
the	B-X
DNA	B-X
bound	B-X
to	B-X
the	B-X
polymerase	B-X
site	B-X
shares	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
with	B-X
DNA	B-X
bound	B-X
to	B-X
the	B-X
exonuclease	B-X
site	B-X
,	B-X
but	B-X
they	B-X
are	B-X
translated	B-X
relative	B-X
to	B-X
each	B-X
other	B-X
by	B-X
several	B-X
angstroms	B-X
along	B-X
their	B-X
helix	B-X
axes	B-X
.	B-X
Transcription	B-X
factors	B-X
are	B-X
defined	B-X
by	B-X
their	B-X
sequence-specific	B-X
binding	B-X
to	B-X
DNA	B-X
and	B-X
by	B-X
their	B-X
selective	B-X
impacts	B-X
on	B-X
gene	B-X
expression	B-X
,	B-X
depending	B-X
on	B-X
specific	B-X
binding	B-X
sites	B-X
.	B-X
The	B-X
factor	B-X
binding	B-X
motifs	B-X
in	B-X
the	B-X
DNA	B-X
should	B-X
thus	B-X
represent	B-X
a	B-X
blueprint	B-X
of	B-X
regulatory	B-X
logic	B-X
,	B-X
suggesting	B-X
that	B-X
transcription	B-X
factor	B-X
binding	B-X
patterns	B-X
on	B-X
the	B-X
genome	B-X
(	B-X
e.g.	B-X
,	B-X
measured	B-X
by	B-X
ChIP-seq	B-X
)	B-X
should	B-X
indicate	B-X
which	B-X
target	B-X
genes	B-X
the	B-X
factors	B-X
are	B-X
directly	B-X
controlling	B-X
.	B-X
However	B-X
,	B-X
although	B-X
genetic	B-X
data	B-X
confirm	B-X
high	B-X
impacts	B-X
of	B-X
transcription	B-X
factor	B-X
perturbation	B-X
in	B-X
embryology	B-X
,	B-X
transcription	B-X
factors	B-X
bind	B-X
to	B-X
far	B-X
more	B-X
sites	B-X
than	B-X
the	B-X
number	B-X
of	B-X
genes	B-X
they	B-X
dynamically	B-X
regulate	B-X
,	B-X
when	B-X
measured	B-X
by	B-X
direct	B-X
perturbation	B-X
in	B-X
a	B-X
given	B-X
cell	B-X
type	B-X
.	B-X
Also	B-X
,	B-X
deletion	B-X
of	B-X
carefully	B-X
chosen	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
often	B-X
gives	B-X
disappointingly	B-X
weak	B-X
results	B-X
.	B-X

NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
binding	O
play	O
independent	O
activating	O
roles	O
in	O
MTb	O
-	O
mediated	O
induction	O
of	O
HIV	O
-	O
1	O
replication	O

We	O
next	O
examined	O
the	O
functional	O
impact	O
of	O
specifically	O
disrupting	O
NF	O
-	O
kappaB	O
or	O
NFAT5	B-Protein
binding	O
on	O
regulation	O
of	O
HIV	O
-	O
1	O
replication	O
by	O
infecting	O
bulk	O
PBMC	O
from	O
four	O
normal	O
donors	O
with	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
molecular	O
clones	O
.	O

After	O
overnight	O
infection	O
,	O
cells	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
or	O
mock	O
-	O
infected	O
and	O
free	O
virus	O
levels	O
were	O
detected	O
by	O
measuring	O
p24	B-Protein
levels	O
in	O
culture	O
supernatants	O
at	O
days	O
4	O
,	O
7	O
,	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
.	O

Replication	O
of	O
each	O
mutant	O
virus	O
was	O
reduced	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
in	O
mock	O
-	O
and	O
MTb	O
-	O
co	O
-	O
infected	O
cells	O
at	O
all	O
timepoints	O
examined	O
(	O
Figures	O
4A	O
-	O
4B	O
)	O
.	O

As	O
depicted	O
in	O
the	O
histograms	O
displayed	O
in	O
Figure	O
4C	O
,	O
at	O
day	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
in	O
MTb	O
-	O
co	O
-	O
infected	O
cells	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
levels	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
4C	O
)	O
.	O

In	O
the	O
absence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
p24	B-Protein
levels	O
were	O
also	O
significantly	O
lower	O
in	O
the	O
PBMC	O
cultures	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
,	O
but	O
not	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
in	O
comparison	O
to	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
4C	O
)	O
.	O

None	O
of	O
the	O
mutations	O
completely	O
abolished	O
viral	O
induction	O
by	O
MTb	O
co	O
-	O
infection	O
.	O

However	O
,	O
the	O
replication	O
of	O
each	O
mutant	O
virus	O
was	O
impaired	O
to	O
a	O
more	O
significant	O
extent	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
consistent	O
with	O
important	O
roles	O
for	O
both	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
in	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
.	O

To	O
specifically	O
examine	O
the	O
functional	O
impact	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
site	O
usage	O
in	O
MDM	O
,	O
which	O
are	O
efficiently	O
infected	O
by	O
both	O
pathogens	O
,	O
we	O
next	O
isolated	O
MDM	O
from	O
four	O
normal	O
donors	O
and	O
infected	O
these	O
cells	O
with	O
1000	O
TCID50	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
or	O
with	O
the	O
mutant	O
viral	O
clones	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
.	O

After	O
overnight	O
incubation	O
,	O
cell	O
cultures	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
or	O
left	O
infected	O
with	O
virus	O
alone	O
.	O
<EOS>	B-X
Myocarditis	B-X
is	B-X
defined	B-X
as	B-X
inflammation	B-X
of	B-X
the	B-X
myocardium	B-X
accompanied	B-X
by	B-X
myocellular	B-X
necrosis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
use	B-X
of	B-X
corticosteroids	B-X
as	B-X
immunosuppressives	B-X
for	B-X
this	B-X
condition	B-X
remains	B-X
controversial	B-X
.	B-X
GBS	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
an	B-X
autoimmune	B-X
disease	B-X
triggered	B-X
by	B-X
a	B-X
preceding	B-X
bacterial	B-X
or	B-X
viral	B-X
infection	B-X
.	B-X
Campylobacter	B-X
jejuni	B-X
,	B-X
cytomegalovirus	B-X
,	B-X
Epstein-Barr	B-X
virus	B-X
and	B-X
Mycoplasma	B-X
pneumoniae	B-X
are	B-X
commonly	B-X
identified	B-X
antecedent	B-X
pathogens	B-X
.	B-X
In	B-X
the	B-X
acute	B-X
motor	B-X
axonal	B-X
neuropathy	B-X
(	B-X
AMAN	B-X
)	B-X
form	B-X
of	B-X
GBS	B-X
,	B-X
the	B-X
infecting	B-X
organisms	B-X
probably	B-X
share	B-X
homologous	B-X
epitopes	B-X
to	B-X
a	B-X
component	B-X
of	B-X
the	B-X
peripheral	B-X
nerves	B-X
(	B-X
molecular	B-X
mimicry	B-X
)	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
the	B-X
immune	B-X
responses	B-X
cross-react	B-X
with	B-X
the	B-X
nerves	B-X
causing	B-X
axonal	B-X
degeneration	B-X
;	B-X
the	B-X
target	B-X
molecules	B-X
in	B-X
AMAN	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
gangliosides	B-X
GM1	B-X
,	B-X
GM1b	B-X
,	B-X
GD1a	B-X
and	B-X
GalNAc-GD1a	B-X
expressed	B-X
on	B-X
the	B-X
motor	B-X
axolemma	B-X
.	B-X
In	B-X
the	B-X
acute	B-X
inflammatory	B-X
demyelinating	B-X
polyneuropathy	B-X
(	B-X
AIDP	B-X
)	B-X
form	B-X
,	B-X
immune	B-X
system	B-X
reactions	B-X
against	B-X
target	B-X
epitopes	B-X
in	B-X
Schwann	B-X
cells	B-X
or	B-X
myelin	B-X
result	B-X
in	B-X
demyelination	B-X
;	B-X
however	B-X
,	B-X
the	B-X
exact	B-X
target	B-X
molecules	B-X
in	B-X
the	B-X
case	B-X
of	B-X
AIDP	B-X
have	B-X
not	B-X
yet	B-X
been	B-X
identified	B-X
.	B-X
AIDP	B-X
is	B-X
by	B-X
far	B-X
the	B-X
most	B-X
common	B-X
form	B-X
of	B-X
GBS	B-X
in	B-X
Europe	B-X
and	B-X
North	B-X
America	B-X
,	B-X
whereas	B-X
AMAN	B-X
occurs	B-X
more	B-X
frequently	B-X
in	B-X
east	B-X
Asia	B-X
(	B-X
China	B-X
and	B-X
Japan	B-X
)	B-X
.	B-X
The	B-X
prognosis	B-X
of	B-X
GBS	B-X
is	B-X
generally	B-X
favourable	B-X
,	B-X
but	B-X
it	B-X
is	B-X
a	B-X
serious	B-X
disease	B-X
with	B-X
a	B-X
mortality	B-X
of	B-X
approximately	B-X
10	B-X
%	B-X
and	B-X
approximately	B-X
20	B-X
%	B-X
of	B-X
patients	B-X
are	B-X
left	B-X
with	B-X
severe	B-X
disability	B-X
.	B-X
Treatment	B-X
of	B-X
GBS	B-X
is	B-X
subdivided	B-X
into	B-X
:	B-X
(	B-X
i	B-X
)	B-X
the	B-X
management	B-X
of	B-X
severely	B-X
paralysed	B-X
patients	B-X
with	B-X
intensive	B-X
care	B-X
and	B-X
ventilatory	B-X
support	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
specific	B-X
immunomodulating	B-X
treatments	B-X
that	B-X
shorten	B-X
the	B-X
progressive	B-X
course	B-X
of	B-X
GBS	B-X
,	B-X
presumably	B-X
by	B-X
limiting	B-X
nerve	B-X
damage	B-X
.	B-X
The	B-X
predominant	B-X
mechanisms	B-X
by	B-X
which	B-X
IVIg	B-X
therapy	B-X
exerts	B-X
its	B-X
action	B-X
appear	B-X
to	B-X
be	B-X
a	B-X
combined	B-X
effect	B-X
of	B-X
complement	B-X
inactivation	B-X
,	B-X
neutralisation	B-X
of	B-X
idiotypic	B-X
antibodies	B-X
,	B-X
cytokine	B-X
inhibition	B-X
and	B-X
saturation	B-X
of	B-X
Fc	B-X
receptors	B-X
on	B-X
macrophages	B-X
.	B-X
Corticosteroids	B-X
alone	B-X
do	B-X
not	B-X
alter	B-X
the	B-X
outcome	B-X
of	B-X
GBS	B-X
.	B-X

Supernatants	O
were	O
collected	O
at	O
days	O
4	O
,	O
7	O
,	O
and	O
12	O
post	O
-	O
HIV	O
-	O
1	O
infection	O
and	O
virus	O
replication	O
was	O
measured	O
.	O

As	O
shown	O
in	O
Figures	O
5A	O
and	O
5C	O
,	O
in	O
the	O
absence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
replication	O
of	O
mutant	O
viral	O
molecular	O
clones	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
as	O
well	O
as	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
significantly	O
reduced	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
virus	O
(	O
Figures	O
5A	O
-	O
5C	O
)	O
.	O

When	O
the	O
cultures	O
were	O
co	O
-	O
infected	O
with	O
MTb	O
,	O
p24	B-Protein
levels	O
increased	O
when	O
the	O
cells	O
were	O
infected	O
with	O
either	O
the	O
wild	O
-	O
type	O
or	O
,	O
to	O
lower	O
levels	O
,	O
with	O
the	O
kappaB	O
-	O
I	O
mutant	O
virus	O
(	O
Figure	O
5B	O
)	O
.	O

However	O
,	O
p24	B-Protein
levels	O
were	O
significantly	O
inhibited	O
in	O
cells	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
5D	O
)	O
.	O

Moreover	O
,	O
p24	B-Protein
levels	O
were	O
significantly	O
lower	O
at	O
day	O
12	O
in	O
cultures	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
as	O
compared	O
to	O
infection	O
of	O
cells	O
with	O
wild	O
-	O
type	O
virus	O
(	O
Figure	O
5D	O
)	O
.	O

Notably	O
,	O
although	O
replication	O
of	O
the	O
mutant	O
virus	O
with	O
the	O
single	O
,	O
proximal	O
NF	O
-	O
kappaB	O
binding	O
site	O
mutation	O
in	O
the	O
shared	O
NFAT5	O
/	O
NF	O
-	O
kappaB	O
element	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
)	O
was	O
diminished	O
,	O
this	O
was	O
not	O
significant	O
at	O
day	O
12	O
(	O
Figures	O
5B	O
-	O
5D	O
)	O
.	O

We	O
note	O
that	O
overall	O
p24	B-Protein
levels	O
were	O
noticeably	O
lower	O
in	O
the	O
cultures	O
co	O
-	O
infected	O
with	O
MTb	O
compared	O
with	O
those	O
infected	O
with	O
HIV	O
-	O
1	O
alone	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
observations	O
showing	O
that	O
MTb	O
infection	O
of	O
human	O
primary	O
macrophage	O
cultures	O
ex	O
vivo	O
suppresses	O
HIV	O
-	O
1	O
infection	O
due	O
to	O
chemokine	O
synthesis	O
and	O
the	O
enhanced	O
expression	O
of	O
cellular	O
inhibitory	O
factors	O
[	O
48	O
]	O
-	O
[	O
50	O
]	O
.	O

Given	O
that	O
NF	O
-	O
kappaB	O
is	O
efficiently	O
activated	O
in	O
primary	O
MDM	O
in	O
response	O
to	O
TLR	O
agonists	O
[	O
51	O
]	O
and	O
as	O
we	O
have	O
shown	O
in	O
Figure	O
2	O
,	O
NFAT5	B-Protein
gene	O
expression	O
is	O
also	O
induced	O
by	O
TLR	O
agonists	O
,	O
MDM	O
are	O
a	O
suitable	O
experimental	O
system	O
to	O
analyze	O
the	O
effect	O
of	O
NF	O
-	O
kappaB	O
versus	O
NFAT5	O
binding	O
site	O
mutations	O
on	O
virus	O
replication	O
in	O
isolated	O
MDM	O
in	O
the	O
absence	O
or	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O
<EOS>	B-X
Although	B-X
hypotheses	B-X
suggest	B-X
HIV-1	B-X
disrupts	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
Mtb	B-X
)	B-X
granuloma	B-X
function	B-X
,	B-X
few	B-X
studies	B-X
have	B-X
examined	B-X
this	B-X
directly	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
what	B-X
evidence	B-X
exists	B-X
about	B-X
the	B-X
effect	B-X
HIV-1	B-X
co-infection	B-X
has	B-X
upon	B-X
Mtb	B-X
granulomas	B-X
.	B-X
A	B-X
systematic	B-X
search	B-X
of	B-X
PubMed	B-X
,	B-X
Web	B-X
of	B-X
Science	B-X
,	B-X
and	B-X
Medline	B-X
up	B-X
to	B-X
20	B-X
March	B-X
2015	B-X
was	B-X
conducted	B-X
,	B-X
to	B-X
identify	B-X
studies	B-X
comparing	B-X
Mtb-infected	B-X
tissue	B-X
from	B-X
HIV-1	B-X
infected	B-X
and	B-X
uninfected	B-X
persons	B-X
,	B-X
or	B-X
HIV-1	B-X
infected	B-X
persons	B-X
with	B-X
stratified	B-X
peripheral	B-X
CD4	B-X
T	B-X
cell	B-X
(	B-X
pCD4	B-X
)	B-X
counts	B-X
.	B-X
We	B-X
summarized	B-X
findings	B-X
that	B-X
focused	B-X
on	B-X
how	B-X
HIV-1	B-X
changes	B-X
granuloma	B-X
formation	B-X
,	B-X
bacterial	B-X
presence	B-X
,	B-X
cellular	B-X
composition	B-X
,	B-X
and	B-X
cytokine	B-X
production	B-X
.	B-X
Nineteen	B-X
studies	B-X
with	B-X
a	B-X
combined	B-X
sample	B-X
size	B-X
of	B-X
899	B-X
persons	B-X
were	B-X
included	B-X
.	B-X
Although	B-X
studies	B-X
frequently	B-X
were	B-X
limited	B-X
by	B-X
variable	B-X
or	B-X
inadequately	B-X
described	B-X
definitions	B-X
of	B-X
outcomes	B-X
and	B-X
analytical	B-X
methods	B-X
,	B-X
HIV-1	B-X
was	B-X
found	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
increased	B-X
bacillary	B-X
load	B-X
within	B-X
Mtb-infected	B-X
tissue	B-X
.	B-X
Reductions	B-X
in	B-X
pCD4	B-X
counts	B-X
within	B-X
co-infected	B-X
persons	B-X
associated	B-X
with	B-X
both	B-X
poorer	B-X
granuloma	B-X
formation	B-X
and	B-X
higher	B-X
bacterial	B-X
load	B-X
.	B-X
The	B-X
high	B-X
degree	B-X
of	B-X
heterogeneity	B-X
among	B-X
studies	B-X
combined	B-X
with	B-X
experimental	B-X
limitations	B-X
made	B-X
it	B-X
difficult	B-X
to	B-X
conclusively	B-X
support	B-X
previously	B-X
published	B-X
and	B-X
prevalent	B-X
hypotheses	B-X
about	B-X
HIV-1/Mtb	B-X
co-infection	B-X
granulomas	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
validity	B-X
of	B-X
these	B-X
hypotheses	B-X
we	B-X
have	B-X
described	B-X
areas	B-X
that	B-X
can	B-X
be	B-X
improved	B-X
in	B-X
future	B-X
studies	B-X
in	B-X
order	B-X
to	B-X
clarify	B-X
the	B-X
influence	B-X
HIV-1	B-X
co-infection	B-X
has	B-X
upon	B-X
the	B-X
Mtb	B-X
granuloma	B-X
.	B-X

Taken	O
together	O
,	O
the	O
results	O
from	O
PBMC	O
and	O
MDM	O
co	O
-	O
infection	O
experiments	O
demonstrate	O
that	O
the	O
conserved	O
NFAT5	O
binding	O
site	O
plays	O
as	O
important	O
a	O
transcriptional	O
role	O
in	O
LTR	O
regulation	O
by	O
MTb	O
as	O
do	O
the	O
NF	O
-	O
kappaB	O
sites	O
.	O

NFAT5	B-Protein
is	O
important	O
for	O
enhancement	O
of	O
HIV	O
-	O
1	O
subtype	O
C	O
replication	O
in	O
response	O
to	O
MTb	O
infection	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
the	O
subtype	O
C	O
LTR	O
was	O
the	O
most	O
active	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
subtypes	O
in	O
the	O
reporter	O
assays	O
.	O

Subtype	O
C	O
LTRs	O
generally	O
have	O
three	O
functional	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
LTRs	O
,	O
and	O
subtype	O
C	O
is	O
the	O
predominant	O
viral	O
subtype	O
in	O
the	O
African	O
and	O
Asian	O
HIV	O
-	O
1	O
epidemics	O
where	O
MTb	O
co	O
-	O
infection	O
is	O
extremely	O
common	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
28	O
]	O
,	O
[	O
52	O
]	O
.	O

We	O
thus	O
next	O
extended	O
our	O
analysis	O
of	O
the	O
role	O
of	O
NFAT5	B-Protein
in	O
MTb	O
/	O
HIV	O
-	O
1	O
co	O
-	O
infection	O
to	O
a	O
subtype	O
C	O
isolate	O
.	O

We	O
first	O
constructed	O
an	O
infectious	O
molecular	O
clone	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
C	O
primary	O
isolate	O
HIV	O
-	O
198IN22	O
,	O
which	O
has	O
two	O
NFAT5	O
binding	O
sites	O
in	O
its	O
LTR	O
and	O
three	O
NF	O
-	O
kappaB	O
sites	O
(	O
Figure	O
6A	O
)	O
.	O

We	O
disrupted	O
the	O
two	O
NFAT5	O
binding	O
sites	O
by	O
changing	O
the	O
TT	O
of	O
each	O
site	O
to	O
CC	O
to	O
create	O
a	O
mutant	O
virus	O
that	O
we	O
named	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
.	O

Bulk	O
PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
overnight	O
with	O
1000	O
TCID50	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
or	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
and	O
the	O
cultures	O
were	O
then	O
co	O
-	O
infected	O
with	O
MTb	O
CDC1551	O
or	O
left	O
infected	O
with	O
virus	O
alone	O
.	O
<EOS>	B-X
Myocarditis	B-X
is	B-X
defined	B-X
as	B-X
inflammation	B-X
of	B-X
the	B-X
myocardium	B-X
accompanied	B-X
by	B-X
myocellular	B-X
necrosis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
use	B-X
of	B-X
corticosteroids	B-X
as	B-X
immunosuppressives	B-X
for	B-X
this	B-X
condition	B-X
remains	B-X
controversial	B-X
.	B-X
To	B-X
analyze	B-X
the	B-X
clinical	B-X
presentation	B-X
and	B-X
outcomes	B-X
of	B-X
myocarditis	B-X
after	B-X
administration	B-X
of	B-X
the	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
vaccine	B-X
.	B-X
Nine	B-X
case	B-X
series	B-X
and	B-X
15	B-X
case	B-X
reports	B-X
(	B-X
74	B-X
patients	B-X
)	B-X
of	B-X
myocarditis	B-X
after	B-X
administration	B-X
of	B-X
the	B-X
BNT162b2	B-X
or	B-X
mRNA-1273	B-X
vaccine	B-X
were	B-X
reviewed	B-X
from	B-X
PubMed	B-X
,	B-X
Scopus	B-X
,	B-X
Embase	B-X
,	B-X
and	B-X
Web	B-X
of	B-X
Science	B-X
.	B-X
We	B-X
analyzed	B-X
clinical	B-X
manifestations	B-X
,	B-X
diagnostic	B-X
findings	B-X
,	B-X
and	B-X
outcomes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
pooled	B-X
analysis	B-X
and	B-X
investigated	B-X
risk	B-X
factors	B-X
leading	B-X
to	B-X
admission	B-X
to	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
recovery	B-X
with	B-X
conservative	B-X
care	B-X
.	B-X
Patients	B-X
who	B-X
received	B-X
the	B-X
BNT162b2	B-X
(	B-X
n	B-X
=	B-X
58	B-X
,	B-X
78.4	B-X
%	B-X
)	B-X
vaccine	B-X
presented	B-X
fewer	B-X
systemic	B-X
symptoms	B-X
and	B-X
left	B-X
ventricular	B-X
dysfunction	B-X
than	B-X
mRNA-1273	B-X
recipients	B-X
.	B-X
The	B-X
clinical	B-X
course	B-X
of	B-X
all	B-X
patients	B-X
was	B-X
favorable	B-X
without	B-X
mortality	B-X
,	B-X
and	B-X
one-third	B-X
of	B-X
patients	B-X
resolved	B-X
with	B-X
conservative	B-X
care	B-X
alone	B-X
.	B-X
Risk	B-X
factor	B-X
analyses	B-X
revealed	B-X
that	B-X
patients	B-X
with	B-X
gastrointestinal	B-X
symptoms	B-X
required	B-X
intensive	B-X
care	B-X
(	B-X
odds	B-X
ratio	B-X
:	B-X
20.3	B-X
,	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
1.90-217	B-X
,	B-X
p	B-X
=	B-X
0.013	B-X
)	B-X
.	B-X
However	B-X
,	B-X
patients	B-X
with	B-X
gastrointestinal	B-X
symptoms	B-X
received	B-X
more	B-X
intensive	B-X
care	B-X
,	B-X
and	B-X
a	B-X
significant	B-X
proportion	B-X
of	B-X
patients	B-X
recovered	B-X
with	B-X
conservative	B-X
management	B-X
.	B-X

At	O
day	O
11	O
post	O
-	O
viral	O
infection	O
,	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
replication	O
was	O
greater	O
,	O
but	O
not	O
significantly	O
so	O
,	O
as	O
compared	O
to	O
replication	O
of	O
HIV	O
-	O
198IN22	O
NFAT5	O
-	O
Mut	O
(	O
Figure	O
6B	O
)	O
.	O

However	O
,	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
wild	O
-	O
type	O
HIV	O
-	O
198IN22	O
replication	O
was	O
significantly	O
increased	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
at	O
day	O
11	O
over	O
HIV	O
-	O
198IN22	O
NFAT5	O
-	O
Mut	O
replication	O
(	O
Figure	O
6C	O
)	O
,	O
indicating	O
that	O
the	O
absence	O
of	O
NFAT5	O
binding	O
sites	O
was	O
particularly	O
detrimental	O
to	O
virus	O
replication	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Thus	O
,	O
even	O
when	O
three	O
functional	O
NF	O
-	O
kappaB	O
binding	O
sites	O
are	O
present	O
in	O
the	O
LTR	O
,	O
as	O
in	O
the	O
HIV	O
-	O
1	O
subtype	O
C	O
infectious	O
clone	O
studied	O
here	O
,	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
impairs	O
virus	O
replication	O
in	O
response	O
to	O
MTb	O
co	O
-	O
infection	O
.	O

MTb	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
via	O
the	O
MyD88	B-Protein
-	O
dependent	O
signaling	O
cascade	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

To	O
begin	O
to	O
decipher	O
the	O
cellular	O
mechanisms	O
underlying	O
NFAT5	B-Protein
-	O
dependent	O
,	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
,	O
we	O
next	O
investigated	O
the	O
requirement	O
for	O
specific	O
signaling	O
molecules	O
in	O
the	O
TLR	O
pathway	O
that	O
are	O
required	O
for	O
MTb	O
stimulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
.	O

We	O
began	O
by	O
examining	O
the	O
requirement	O
of	O
TLR2	B-Protein
ligation	O
in	O
enhancing	O
NFAT5	B-Protein
mRNA	O
levels	O
.	O

When	O
THP	O
-	O
1	O
cells	O
were	O
treated	O
with	O
the	O
TLR2	B-Protein
-	O
specific	O
agonist	O
Pam3Cys	O
for	O
16	O
hours	O
,	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
significantly	O
increased	O
in	O
Pam3Cys	O
-	O
stimulated	O
cells	O
as	O
compared	O
to	O
mock	O
-	O
stimulated	O
control	O
cells	O
(	O
Figure	O
7A	O
)	O
.	O

As	O
a	O
positive	O
control	O
for	O
this	O
experiment	O
we	O
also	O
infected	O
THP	O
-	O
1	O
cells	O
with	O
CDC1551	O
(	O
Figure	O
7A	O
)	O
.	O

Notably	O
,	O
MTb	O
infection	O
enhanced	O
NFAT5	B-Protein
mRNA	O
levels	O
to	O
a	O
greater	O
extent	O
than	O
Pam3Cys	O
stimulation	O
,	O
suggesting	O
that	O
additional	O
PRRs	O
may	O
be	O
triggered	O
during	O
actual	O
MTb	O
infection	O
,	O
augmenting	O
its	O
stimulatory	O
effect	O
on	O
NFAT5	B-Protein
gene	O
expression	O
(	O
Figure	O
7A	O
)	O
.	O

The	O
adaptor	O
molecule	O
MyD88	B-Protein
transmits	O
signals	O
upon	O
TLR2	B-Protein
ligation	O
(	O
reviewed	O
in	O
[	O
53	O
]	O
)	O
.	O

To	O
confirm	O
that	O
this	O
protein	O
and	O
,	O
therefore	O
,	O
that	O
this	O
TLR	O
-	O
dependent	O
pathway	O
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
,	O
we	O
constructed	O
a	O
THP	O
-	O
1	O
cell	O
line	O
that	O
constitutively	O
expresses	O
a	O
lentivirally	O
-	O
delivered	O
short	B-Protein
hairpin	I-Protein
(	I-Protein
sh	I-Protein
)	I-Protein
RNA	I-Protein
targeting	O
MyD88	B-Protein
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
demonstrated	O
that	O
MyD88	B-Protein
mRNA	O
levels	O
in	O
these	O
cells	O
were	O
constitutively	O
and	O
significantly	O
reduced	O
in	O
comparison	O
to	O
control	O
THP	O
-	O
1	O
cells	O
transduced	O
with	O
a	O
lentivirus	O
expressing	O
control	O
GFP	B-Protein
shRNA	I-Protein
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
MyD88	B-Protein
knockdown	O
THP	O
-	O
1	O
cells	O
were	O
then	O
infected	O
with	O
MTb	O
(	O
CDC1551	O
)	O
and	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
examined	O
.	O

Since	O
TNF	B-Protein
is	O
a	O
MyD88	B-Protein
-	O
dependent	O
gene	O
[	O
21	O
]	O
,	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
,	O
as	O
a	O
positive	O
control	O
we	O
measured	O
TNF	B-Protein
mRNA	O
levels	O
.	O

For	O
a	O
negative	O
control	O
,	O
we	O
measured	O
mRNA	O
levels	O
of	O
the	O
MyD88	B-Protein
-	O
independent	O
gene	O
CD86	B-Protein
[	O
55	O
]	O
,	O
[	O
56	O
]	O
.	O

As	O
shown	O
in	O
Figure	O
7B	O
,	O
knockdown	O
of	O
MyD88	B-Protein
specifically	O
inhibited	O
MTb	O
-	O
induced	O
NFAT5	B-Protein
and	O
TNF	B-Protein
mRNA	O
levels	O
and	O
had	O
no	O
impact	O
on	O
CD86	B-Protein
mRNA	O
levels	O
.	O

Thus	O
,	O
MTb	O
regulation	O
of	O
NFAT5	B-Protein
is	O
dependent	O
upon	O
MyD88	B-Protein
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

To	O
futher	O
dissect	O
the	O
pathway	O
mediating	O
MTb	O
upregulation	O
of	O
NFAT5	B-Protein
transcription	O
,	O
we	O
also	O
constructed	O
THP	O
-	O
1	O
cells	O
transduced	O
with	O
lentivirally	O
-	O
delivered	O
shRNAs	O
targeting	O
IRAK1	B-Protein
or	O
TRAF6	B-Protein
,	O
two	O
signaling	O
molecules	O
downstream	O
of	O
MyD88	B-Protein
.	O
<EOS>	B-X
Myeloid	B-X
differentiation	B-X
factor	B-X
88	B-X
(	B-X
MyD88	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
6	B-X
(	B-X
TRAF6	B-X
)	B-X
are	B-X
two	B-X
key	B-X
adaptor	B-X
molecules	B-X
in	B-X
Toll-like	B-X
receptor	B-X
signal	B-X
transduction	B-X
that	B-X
triggers	B-X
downstream	B-X
cascades	B-X
involved	B-X
in	B-X
innate	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
reported	B-X
the	B-X
isolation	B-X
and	B-X
characterization	B-X
the	B-X
full-length	B-X
cDNAs	B-X
of	B-X
MyD88	B-X
and	B-X
TRAF6	B-X
from	B-X
sea	B-X
cucumber	B-X
Apostichopus	B-X
japonicus	B-X
(	B-X
denoted	B-X
as	B-X
AjMyD88	B-X
and	B-X
AjTRAF6	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Both	B-X
of	B-X
two	B-X
factors	B-X
shared	B-X
a	B-X
remarkable	B-X
high	B-X
degree	B-X
of	B-X
structural	B-X
conservation	B-X
with	B-X
their	B-X
mammalian	B-X
and	B-X
Drosophila	B-X
orthologs	B-X
,	B-X
such	B-X
as	B-X
a	B-X
typical	B-X
death	B-X
domain	B-X
(	B-X
DD	B-X
)	B-X
and	B-X
a	B-X
conservative	B-X
Toll/IL-1R	B-X
(	B-X
TIR	B-X
)	B-X
domain	B-X
for	B-X
the	B-X
deduced	B-X
amino	B-X
acid	B-X
of	B-X
AjMyD88	B-X
,	B-X
a	B-X
zinc	B-X
finger	B-X
of	B-X
RING-type	B-X
,	B-X
two	B-X
zinc	B-X
fingers	B-X
of	B-X
TRAF-type	B-X
,	B-X
a	B-X
coiled-coil	B-X
region	B-X
,	B-X
and	B-X
a	B-X
MATH	B-X
domain	B-X
for	B-X
that	B-X
of	B-X
AjTRAF6	B-X
.	B-X
Constitutive	B-X
expression	B-X
patterns	B-X
were	B-X
also	B-X
observed	B-X
in	B-X
the	B-X
two	B-X
genes	B-X
with	B-X
different	B-X
expression	B-X
levels	B-X
.	B-X
AjMyD88	B-X
mRNA	B-X
transcripts	B-X
were	B-X
higher	B-X
expressed	B-X
in	B-X
intestine	B-X
and	B-X
respiratory	B-X
trees	B-X
,	B-X
and	B-X
AjTRAF6	B-X
were	B-X
abundant	B-X
in	B-X
coelomocytes	B-X
and	B-X
tentacle	B-X
.	B-X
During	B-X
Vibrio	B-X
splendidus	B-X
challenge	B-X
experiment	B-X
,	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
two	B-X
genes	B-X
were	B-X
increased	B-X
significantly	B-X
with	B-X
larger	B-X
amplitude	B-X
and	B-X
longer	B-X
duration	B-X
in	B-X
AjTRAF6	B-X
.	B-X
The	B-X
peak	B-X
expression	B-X
levels	B-X
were	B-X
detected	B-X
at	B-X
6	B-X
h	B-X
for	B-X
AjMyD88	B-X
with	B-X
1.80-fold	B-X
increase	B-X
,	B-X
and	B-X
at	B-X
24	B-X
h	B-X
for	B-X
AjTRAF6	B-X
with	B-X
2.73-fold	B-X
increase	B-X
compared	B-X
with	B-X
that	B-X
in	B-X
the	B-X
control	B-X
group	B-X
.	B-X
All	B-X
these	B-X
results	B-X
suggested	B-X
that	B-X
AjMyD88	B-X
and	B-X
AjTRAF6	B-X
might	B-X
be	B-X
involved	B-X
into	B-X
immune	B-X
response	B-X
toward	B-X
V.	B-X
splendidus	B-X
challenge	B-X
.	B-X

As	O
shown	O
in	O
Figures	O
7C	O
and	O
7D	O
,	O
knockdown	O
of	O
both	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
significantly	O
inhibited	O
MTb	O
induced	O
NFAT5	B-Protein
mRNA	O
levels	O
.	O

As	O
expected	O
,	O
MTb	O
-	O
induced	O
TNF	B-Protein
gene	O
expression	O
was	O
also	O
significantly	O
reduced	O
(	O
Figures	O
7C	O
-	O
7D	O
)	O
,	O
consistent	O
with	O
a	O
role	O
for	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
in	O
TNF	B-Protein
gene	O
expression	O
secondary	O
to	O
MTb	O
infection	O
as	O
previously	O
reported	O
.	O

Although	O
CD86	B-Protein
gene	O
expression	O
did	O
not	O
depend	O
on	O
MyD88	B-Protein
(	O
Figure	O
7B	O
)	O
,	O
abrogation	O
of	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
gene	O
expression	O
significantly	O
reduced	O
CD86	B-Protein
mRNA	O
levels	O
,	O
indicating	O
that	O
CD86	B-Protein
expression	O
is	O
IRAK1	B-Protein
-	O
and	O
TRAF6	B-Protein
-	O
dependent	O
,	O
but	O
MyD88	B-Protein
-	O
independent	O
in	O
MTb	O
-	O
infected	O
monocytes	O
(	O
Figures	O
7C	O
-	O
7D	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
clearly	O
demonstrate	O
that	O
MTb	O
upregulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
MyD88	B-Protein
and	O
the	O
MyD88	B-Protein
-	O
associated	O
adaptor	O
molecules	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
.	O

The	O
transcription	O
factor	O
NFAT5	B-Protein
is	O
the	O
most	O
evolutionarily	O
divergent	O
member	O
of	O
the	O
Rel	O
family	O
of	O
NFAT	O
proteins	O
[	O
57	O
]	O
.	O

Unlike	O
the	O
other	O
NFAT	O
proteins	O
(	O
NFATp	B-Protein
,	O
NFATc	B-Protein
,	O
NFAT3	B-Protein
,	O
and	O
NFAT4	B-Protein
)	O
,	O
NFAT5	B-Protein
binds	O
DNA	O
as	O
an	O
obligate	O
dimer	O
in	O
a	O
fashion	O
resembling	O
NF	O
-	O
kappaB	O
proteins	O
[	O
58	O
]	O
,	O
is	O
calcineurin	B-Protein
independent	O
,	O
and	O
does	O
not	O
cooperate	O
with	O
the	O
basic	O
region	O
-	O
leucine	O
zipper	O
proteins	O
Fos	B-Protein
and	O
Jun	B-Protein
in	O
gene	O
activation	O
(	O
[	O
59	O
]	O
,	O
[	O
60	O
]	O
,	O
reviewed	O
in	O
[	O
61	O
]	O
-	O
[	O
63	O
]	O
)	O
.	O

To	O
date	O
,	O
osmotic	O
stress	O
,	O
integrin	O
activation	O
,	O
and	O
T	O
cell	O
-	O
stimulation	O
have	O
been	O
shown	O
to	O
regulate	O
NFAT5	B-Protein
activity	O
[	O
59	O
]	O
,	O
[	O
64	O
]	O
,	O
[	O
65	O
]	O
.	O

Based	O
on	O
our	O
demonstration	O
here	O
that	O
the	O
host	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
induces	O
MyD88	B-Protein
-	O
dependent	O
upregulation	O
of	O
NFAT5	B-Protein
gene	O
expression	O
,	O
we	O
have	O
expanded	O
this	O
list	O
to	O
include	O
MTb	O
as	O
an	O
additional	O
stimulus	O
.	O

We	O
have	O
linked	O
this	O
observation	O
to	O
MTb	O
-	O
stimulated	O
HIV	O
-	O
1	O
gene	O
expression	O
by	O
showing	O
that	O
MTb	O
enhances	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
subtypes	O
B	O
and	O
C	O
via	O
a	O
direct	O
interaction	O
between	O
NFAT5	B-Protein
and	O
the	O
viral	O
promoter	O
.	O

Thus	O
,	O
HIV	O
-	O
1	O
has	O
co	O
-	O
opted	O
NFAT5	B-Protein
,	O
which	O
is	O
induced	O
as	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
TB	O
,	O
for	O
enhanced	O
viral	O
transcription	O
/	O
replication	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
after	O
MTb	O
engagement	O
of	O
PRRs	O
[	O
20	O
]	O
,	O
[	O
66	O
]	O
.	O

Multiple	O
studies	O
of	O
HIV	O
-	O
1	O
activation	O
have	O
shown	O
that	O
initial	O
recruitment	O
of	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
to	O
the	O
HIV	O
-	O
1	O
proviral	O
enhancer	O
region	O
is	O
crucial	O
for	O
HIV	O
gene	O
transcription	O
(	O
reviewed	O
in	O
[	O
67	O
]	O
,	O
[	O
68	O
]	O
)	O
.	O

Upon	O
interaction	O
with	O
the	O
viral	O
LTR	O
,	O
NF	O
-	O
kappaB	O
rapidly	O
induces	O
hyperacetylation	O
of	O
histones	O
associated	O
with	O
nucleosome	O
1	O
(	O
nuc	O
-	O
1	O
)	O
at	O
the	O
HIV	O
-	O
1	O
transcription	O
start	O
site	O
,	O
resulting	O
in	O
recruitment	O
of	O
the	O
pTEFb	O
complex	O
,	O
which	O
is	O
required	O
for	O
RNA	O
pol	O
II	O
processivity	O
(	O
[	O
69	O
]	O
,	O
reviewed	O
in	O
[	O
68	O
]	O
,	O
[	O
70	O
]	O
)	O
.	O

In	O
this	O
report	O
we	O
directly	O
examined	O
the	O
relative	O
roles	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
in	O
HIV	O
-	O
1	O
replication	O
under	O
conditions	O
of	O
activation	O
by	O
MTb	O
co	O
-	O
infection	O
,	O
when	O
NF	O
-	O
kappaB	O
levels	O
in	O
the	O
nucleus	O
are	O
elevated	O
.	O

We	O
found	O
that	O
specific	O
disruption	O
of	O
the	O
NFAT5	O
binding	O
site	O
(	O
s	O
)	O
in	O
R5	O
-	O
tropic	O
subtype	O
B	O
or	O
subtype	O
C	O
infectious	O
molecular	O
clones	O
significantly	O
reduced	O
virus	O
replication	O
in	O
PBMC	O
or	O
MDM	O
co	O
-	O
infected	O
with	O
a	O
clinical	O
isolate	O
of	O
MTb	O
.	O
<EOS>	B-X
Heterosexual	B-X
transmission	B-X
of	B-X
HIV-1	B-X
is	B-X
characterized	B-X
by	B-X
a	B-X
genetic	B-X
bottleneck	B-X
that	B-X
selects	B-X
a	B-X
single	B-X
viral	B-X
variant	B-X
,	B-X
the	B-X
transmitted/founder	B-X
(	B-X
TF	B-X
)	B-X
,	B-X
during	B-X
most	B-X
transmission	B-X
events	B-X
.	B-X
To	B-X
assess	B-X
viral	B-X
characteristics	B-X
influencing	B-X
HIV-1	B-X
transmission	B-X
,	B-X
we	B-X
sequenced	B-X
167	B-X
near	B-X
full-length	B-X
viral	B-X
genomes	B-X
and	B-X
generated	B-X
40	B-X
infectious	B-X
molecular	B-X
clones	B-X
(	B-X
IMC	B-X
)	B-X
including	B-X
TF	B-X
variants	B-X
and	B-X
multiple	B-X
non-transmitted	B-X
(	B-X
NT	B-X
)	B-X
HIV-1	B-X
subtype	B-X
C	B-X
variants	B-X
from	B-X
six	B-X
linked	B-X
heterosexual	B-X
transmission	B-X
pairs	B-X
near	B-X
the	B-X
time	B-X
of	B-X
transmission	B-X
.	B-X
Consensus-like	B-X
genomes	B-X
sensitive	B-X
to	B-X
donor	B-X
antibodies	B-X
were	B-X
selected	B-X
for	B-X
during	B-X
transmission	B-X
in	B-X
these	B-X
six	B-X
transmission	B-X
pairs	B-X
.	B-X
However	B-X
,	B-X
TF	B-X
variants	B-X
did	B-X
not	B-X
demonstrate	B-X
increased	B-X
viral	B-X
fitness	B-X
in	B-X
terms	B-X
of	B-X
particle	B-X
infectivity	B-X
or	B-X
viral	B-X
replicative	B-X
capacity	B-X
in	B-X
activated	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
and	B-X
monocyte-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
MDDC	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
resistance	B-X
of	B-X
the	B-X
TF	B-X
variant	B-X
to	B-X
the	B-X
antiviral	B-X
effects	B-X
of	B-X
interferon-α	B-X
(	B-X
IFN-α	B-X
)	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
from	B-X
that	B-X
of	B-X
non-transmitted	B-X
variants	B-X
from	B-X
the	B-X
same	B-X
transmission	B-X
pair	B-X
.	B-X
Thus	B-X
neither	B-X
in	B-X
vitro	B-X
viral	B-X
replicative	B-X
capacity	B-X
nor	B-X
IFN-α	B-X
resistance	B-X
discriminated	B-X
the	B-X
transmission	B-X
potential	B-X
of	B-X
viruses	B-X
in	B-X
the	B-X
quasispecies	B-X
of	B-X
these	B-X
chronically	B-X
infected	B-X
individuals	B-X
.	B-X

Thus	O
,	O
NF	O
-	O
kappaB	O
binding	O
to	O
the	O
viral	O
LTR	O
is	O
not	O
sufficient	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
under	O
conditions	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Reciprocally	O
,	O
an	O
intact	O
NFAT5	O
site	O
could	O
not	O
compensate	O
for	O
disruption	O
of	O
the	O
two	O
NF	O
-	O
kappaB	O
sites	O
.	O

Thus	O
,	O
both	O
factors	O
are	O
required	O
for	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

Intriguingly	O
,	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
,	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
II	O
consistently	O
resulted	O
in	O
greater	O
suppression	O
of	O
virus	O
replication	O
than	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
I	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
synthetic	O
reporter	O
assays	O
have	O
previously	O
shown	O
that	O
these	O
two	O
sites	O
have	O
distinct	O
roles	O
in	O
driving	O
transcription	O
.	O

The	O
downstream	O
NF	O
-	O
kappaB	O
site	O
I	O
binding	O
site	O
,	O
which	O
is	O
directly	O
upstream	O
of	O
three	O
highly	O
conserved	O
Sp	O
binding	O
sites	O
,	O
appears	O
to	O
enhance	O
Sp	O
protein	O
recruitment	O
to	O
the	O
LTR	O
[	O
71	O
]	O
-	O
[	O
73	O
]	O
.	O

Because	O
NF	O
-	O
kappaB	O
site	O
I	O
overlaps	O
the	O
NFAT5	O
binding	O
site	O
,	O
it	O
is	O
possible	O
that	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
to	O
this	O
site	O
is	O
mitigated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
increased	O
NFAT5	B-Protein
binding	O
to	O
the	O
mutated	O
site	O
.	O

This	O
hypothesis	O
is	O
consistent	O
with	O
our	O
quantitative	O
DNase	B-Protein
I	I-Protein
footprinting	O
analysis	O
that	O
shows	O
that	O
specific	O
disruption	O
of	O
NF	O
-	O
kappaB	O
site	O
I	O
results	O
in	O
enhanced	O
binding	O
of	O
NFAT5	B-Protein
to	O
the	O
LTR	O
.	O

HIV	O
-	O
1	O
subtype	O
C	O
now	O
makes	O
up	O
greater	O
than	O
50	O
%	O
of	O
all	O
HIV	O
-	O
1	O
infections	O
worldwide	O
,	O
and	O
its	O
prevalence	O
is	O
especially	O
high	O
in	O
regions	O
of	O
endemic	O
TB	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
28	O
]	O
,	O
[	O
52	O
]	O
,	O
Most	O
HIV	O
-	O
1	O
subtype	O
C	O
isolates	O
possess	O
three	O
NF	O
-	O
kappaB	O
binding	O
sites	O
in	O
the	O
LTR	O
[	O
30	O
]	O
.	O

Our	O
analysis	O
of	O
MTb	O
whole	O
lysate	O
-	O
stimulated	O
,	O
LTR	O
-	O
driven	O
reporter	O
gene	O
expression	O
from	O
representative	O
B	O
,	O
C	O
,	O
and	O
E	O
LTRs	O
showed	O
that	O
LTRs	O
derived	O
from	O
subtype	O
C	O
isolates	O
were	O
superior	O
in	O
driving	O
reporter	O
gene	O
expression	O
as	O
compared	O
to	O
LTRs	O
derived	O
from	O
subtype	O
B	O
or	O
E	O
isolates	O
.	O
<EOS>	B-X
The	B-X
house-dust	B-X
mites	B-X
,	B-X
Dermatophagoides	B-X
farinae	B-X
,	B-X
D.	B-X
pheronyssinus	B-X
and	B-X
Euroglyphus	B-X
maynei	B-X
are	B-X
cosmopolitan	B-X
inhabitants	B-X
of	B-X
the	B-X
homes	B-X
of	B-X
humans	B-X
worldwide	B-X
.	B-X
This	B-X
review	B-X
briefly	B-X
summarizes	B-X
the	B-X
progress	B-X
made	B-X
in	B-X
isolating	B-X
and	B-X
characterizing	B-X
mite-derived	B-X
antigens	B-X
and	B-X
allergens	B-X
,	B-X
the	B-X
relationship	B-X
between	B-X
antigens	B-X
isolated	B-X
in	B-X
different	B-X
laboratories	B-X
,	B-X
and	B-X
the	B-X
patients	B-X
'	B-X
reactivity	B-X
to	B-X
these	B-X
allergens	B-X
.	B-X
A	B-X
brief	B-X
summary	B-X
of	B-X
the	B-X
allergic	B-X
reaction	B-X
and	B-X
the	B-X
role	B-X
of	B-X
IgE	B-X
are	B-X
provided	B-X
as	B-X
background	B-X
.	B-X
Escherichia	B-X
coli	B-X
has	B-X
been	B-X
widely	B-X
used	B-X
for	B-X
the	B-X
production	B-X
of	B-X
recombinant	B-X
proteins	B-X
.	B-X
To	B-X
improve	B-X
protein	B-X
production	B-X
yields	B-X
in	B-X
E.	B-X
coli	B-X
,	B-X
directed	B-X
engineering	B-X
approaches	B-X
have	B-X
been	B-X
commonly	B-X
used	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
only	B-X
few	B-X
reported	B-X
examples	B-X
of	B-X
the	B-X
isolation	B-X
of	B-X
E.	B-X
coli	B-X
protein	B-X
production	B-X
strains	B-X
using	B-X
evolutionary	B-X
approaches	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
first	B-X
give	B-X
an	B-X
introduction	B-X
to	B-X
bacterial	B-X
evolution	B-X
and	B-X
mutagenesis	B-X
to	B-X
set	B-X
the	B-X
stage	B-X
for	B-X
discussing	B-X
how	B-X
so	B-X
far	B-X
selection-	B-X
and	B-X
screening-based	B-X
approaches	B-X
have	B-X
been	B-X
used	B-X
to	B-X
isolate	B-X
E.	B-X
coli	B-X
protein	B-X
production	B-X
strains	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
discuss	B-X
how	B-X
evolutionary	B-X
approaches	B-X
may	B-X
be	B-X
used	B-X
in	B-X
the	B-X
future	B-X
to	B-X
isolate	B-X
E.	B-X
coli	B-X
strains	B-X
with	B-X
improved	B-X
protein	B-X
production	B-X
characteristics	B-X
.	B-X

Other	O
studies	O
have	O
found	O
that	O
,	O
in	O
response	O
to	O
TNF	B-Protein
,	O
subtype	O
C	O
LTRs	O
drive	O
reporter	O
gene	O
transcription	O
more	O
strongly	O
than	O
other	O
subtype	O
LTRs	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
.	O

In	O
the	O
co	O
-	O
infection	O
model	O
utilized	O
in	O
this	O
report	O
,	O
in	O
which	O
clinical	O
isolates	O
of	O
both	O
MTb	O
and	O
HIV	O
-	O
1	O
subtype	O
C	O
were	O
used	O
to	O
infect	O
freshly	O
prepared	O
human	O
peripheral	O
blood	O
cells	O
,	O
we	O
found	O
that	O
specific	O
disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
LTR	O
significantly	O
impaired	O
viral	O
replication	O
during	O
MTb	O
co	O
-	O
infection	O
,	O
indicating	O
that	O
even	O
the	O
presence	O
of	O
three	O
intact	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
which	O
is	O
typical	O
for	O
HIV	O
-	O
1	O
subtype	O
C	O
isolates	O
[	O
30	O
]	O
,	O
cannot	O
compensate	O
for	O
loss	O
of	O
NFAT5	B-Protein
recruitment	O
to	O
the	O
viral	O
LTR	O
in	O
the	O
context	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

Given	O
that	O
the	O
NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
motifs	O
overlap	O
,	O
how	O
do	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
function	O
at	O
this	O
overlapping	O
or	O
shared	O
site	O
in	O
the	O
LTR	O
to	O
drive	O
viral	O
transcription	O
in	O
response	O
to	O
MTb	O
infection	O
?	O

Because	O
NFAT5	B-Protein
expression	O
continues	O
to	O
rise	O
for	O
at	O
least	O
48	O
hours	O
post	O
-	O
MTb	O
infection	O
(	O
Figure	O
2A	O
)	O
,	O
one	O
possibility	O
is	O
that	O
the	O
host	O
factors	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
associate	O
with	O
the	O
LTR	O
at	O
different	O
stages	O
after	O
viral	O
activation	O
.	O

While	O
NF	O
-	O
kappaB	O
presence	O
in	O
the	O
nucleus	O
declines	O
in	O
the	O
hours	O
post	O
MTb	O
infection	O
[	O
74	O
]	O
,	O
[	O
75	O
]	O
,	O
NFAT5	B-Protein
levels	O
escalate	O
.	O

Thus	O
,	O
NFAT5	B-Protein
,	O
which	O
is	O
pivotal	O
for	O
HIV	O
-	O
1	O
transcription	O
in	O
unstimulated	O
cells	O
[	O
31	O
]	O
,	O
may	O
,	O
after	O
Mtb	O
infection	O
,	O
perpetuate	O
viral	O
transcriptional	O
initiation	O
begun	O
by	O
NF	O
-	O
kappaB	O
and	O
,	O
with	O
Tat	B-Protein
levels	O
also	O
elevated	O
,	O
promote	O
high	O
levels	O
of	O
sustained	O
HIV	O
-	O
1	O
transcription	O
.	O

Indeed	O
,	O
in	O
response	O
to	O
hypertonic	O
stress	O
,	O
NFAT5	B-Protein
binds	O
to	O
the	O
aldose	B-Protein
reductase	I-Protein
(	O
AR	B-Protein
)	O
promoter	O
and	O
induces	O
rapid	O
hyperacetylation	O
of	O
histones	O
H3	O
and	O
H4	O
[	O
76	O
]	O
.	O

Furthermore	O
,	O
hypertonic	O
stress	O
of	O
mouse	O
renal	O
collecting	O
duct	O
epithelial	O
cells	O
results	O
in	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
complex	O
formation	O
at	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
promoters	O
[	O
77	O
]	O
.	O

Thus	O
,	O
there	O
are	O
precedents	O
for	O
imagining	O
that	O
NFAT5	B-Protein
could	O
function	O
at	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
inducing	O
histone	O
remodeling	O
in	O
a	O
manner	O
similar	O
to	O
NF	O
-	O
kappaB	O
(	O
[	O
69	O
]	O
,	O
reviewed	O
in	O
[	O
68	O
]	O
,	O
[	O
70	O
]	O
)	O
or	O
by	O
directly	O
interacting	O
with	O
NF	O
-	O
kappaB	O
in	O
a	O
cooperative	O
manner	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
demonstrated	O
that	O
NFAT5	B-Protein
is	O
required	O
for	O
the	O
replication	O
of	O
R5	O
-	O
tropic	O
subtype	O
B	O
and	O
subtype	O
C	O
HIV	O
-	O
1	O
isolates	O
in	O
response	O
to	O
MTb	O
-	O
co	O
-	O
infection	O
of	O
human	O
PBMC	O
and	O
MDM	O
.	O

Functional	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
interaction	O
with	O
the	O
viral	O
LTR	O
is	O
also	O
required	O
,	O
but	O
fully	O
intact	O
NF	O
-	O
kappaB	O
binding	O
elements	O
are	O
unable	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
NFAT5	B-Protein
recruitment	O
to	O
the	O
viral	O
promoter	O
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
that	O
MTb	O
infection	O
or	O
stimulation	O
with	O
the	O
TLR2	B-Protein
ligand	O
PAM3Cys	O
,	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O
<EOS>	B-X
SIRT3	B-X
deficiency	B-X
enhanced	B-X
inflammatory	B-X
responses	B-X
and	B-X
mitochondrial	B-X
dysfunction	B-X
,	B-X
leading	B-X
to	B-X
defective	B-X
host	B-X
defense	B-X
and	B-X
pathological	B-X
inflammation	B-X
during	B-X
mycobacterial	B-X
infection	B-X
.	B-X
Antibody-mediated	B-X
depletion	B-X
of	B-X
polymorphonuclear	B-X
neutrophils	B-X
significantly	B-X
increased	B-X
protection	B-X
against	B-X
mycobacterial	B-X
infection	B-X
in	B-X
In	B-X
order	B-X
to	B-X
mount	B-X
an	B-X
appropriate	B-X
immune	B-X
response	B-X
to	B-X
infection	B-X
,	B-X
the	B-X
macrophage	B-X
must	B-X
alter	B-X
its	B-X
metabolism	B-X
by	B-X
increasing	B-X
aerobic	B-X
glycolysis	B-X
and	B-X
concomitantly	B-X
decreasing	B-X
oxidative	B-X
phosphorylation	B-X
;	B-X
a	B-X
process	B-X
known	B-X
as	B-X
the	B-X
Warburg	B-X
effect	B-X
.	B-X
Irg1	B-X
is	B-X
an	B-X
enzyme	B-X
that	B-X
generates	B-X
itaconate	B-X
,	B-X
a	B-X
metabolite	B-X
that	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
inflammatory	B-X
responses	B-X
.	B-X

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
MTb	O
stimulation	O
of	O
NFAT5	B-Protein
depends	O
on	O
TLR	O
pathway	O
signaling	O
molecules	O
,	O
including	O
MyD88	B-Protein
,	O
IRAK1	B-Protein
,	O
and	O
TRAF6	B-Protein
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
disease	B-X
in	B-X
HIV	B-X
co-infected	B-X
patients	B-X
contributes	B-X
to	B-X
increased	B-X
mortality	B-X
by	B-X
activating	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
signaling	B-X
cascades	B-X
that	B-X
stimulate	B-X
HIV-1	B-X
replication	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
viral	B-X
load	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
silencing	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
by	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
inhibits	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTb	B-X
)	B-X
-stimulated	B-X
HIV-1	B-X
replication	B-X
in	B-X
co-infected	B-X
macrophages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
are	B-X
strongly	B-X
induced	B-X
by	B-X
MTb	B-X
,	B-X
which	B-X
is	B-X
a	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
ligand	B-X
,	B-X
and	B-X
that	B-X
an	B-X
intact	B-X
NFAT5	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
viral	B-X
promoter	B-X
of	B-X
R5-tropic	B-X
HIV-1	B-X
subtype	B-X
B	B-X
and	B-X
subtype	B-X
C	B-X
molecular	B-X
clones	B-X
is	B-X
required	B-X
for	B-X
efficent	B-X
induction	B-X
of	B-X
HIV-1	B-X
replication	B-X
by	B-X
MTb	B-X
.	B-X
Furthermore	B-X
,	B-X
silencing	B-X
by	B-X
RNAi	B-X
of	B-X
key	B-X
components	B-X
of	B-X
the	B-X
TLR	B-X
pathway	B-X
in	B-X
human	B-X
monocytes	B-X
,	B-X
including	B-X
the	B-X
downstream	B-X
signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
and	B-X
TRAF6	B-X
,	B-X
significantly	B-X
inhibits	B-X
MTb-induced	B-X
NFAT5	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
MTb	B-X
infection	B-X
induces	B-X
NFAT5	B-X
gene	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
and	B-X
NFAT5	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
MTb	B-X
regulation	B-X
of	B-X
HIV-1	B-X
replication	B-X
via	B-X
a	B-X
direct	B-X
interaction	B-X
with	B-X
the	B-X
viral	B-X
promoter	B-X
.	B-X
These	B-X
findings	B-X
also	B-X
demonstrate	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NFAT5	B-X
in	B-X
TLR-	B-X
and	B-X
MTb-mediated	B-X
control	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

Taken	O
together	O
,	O
the	O
findings	O
presented	O
here	O
enhance	O
the	O
general	O
understanding	O
of	O
the	O
innate	O
immune	O
response	O
to	O
MTb	O
infection	O
by	O
showing	O
that	O
NFAT5	B-Protein
is	O
a	O
major	O
mediator	O
of	O
TLR	O
-	O
dependent	O
gene	O
expression	O
;	O
its	O
importance	O
for	O
gene	O
regulation	O
is	O
likely	O
applicable	O
to	O
other	O
MTb	O
-	O
and	O
TLR	O
-	O
regulated	O
genes	O
.	O

Moreover	O
,	O
these	O
data	O
provide	O
molecular	O
insights	O
into	O
MTb	O
regulation	O
of	O
HIV	O
-	O
1	O
transcription	O
,	O
thereby	O
elucidating	O
several	O
new	O
targets	O
for	O
therapeutic	O
interventions	O
aimed	O
at	O
controlling	O
TB	O
/	O
HIV	O
-	O
1	O
co	O
-	O
infection	O
.	O

NFAT5	B-Protein
interaction	O
with	O
the	O
LTR	O
is	O
important	O
for	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
transcription	O
.	O

(	O
A	O
)	O
MTb	O
stimulation	O
increases	O
activity	O
of	O
LTRs	O
derived	O
from	O
HIV	O
-	O
1	O
subtypes	O
B	O
,	O
C	O
,	O
and	O
E	O
.	O

HIV	O
-	O
1	O
LTRs	O
(	O
-	O
208	O
to	O
+	O
64	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
from	O
representative	O
subtype	O
B	O
,	O
C	O
,	O
and	O
E	O
viral	O
isolates	O
were	O
cloned	O
into	O
plasmid	O
pGL3	O
.	O

THP	O
-	O
1	O
cells	O
(	O
0	O
.	O
8x106	O
/	O
ml	O
)	O
were	O
transfected	O
with	O
each	O
reporter	O
plasmid	O
(	O
0	O
.	O
3	O
microg	O
/	O
ml	O
)	O
plus	O
the	O
Renilla	O
luciferase	B-Protein
control	O
plasmid	O
pRL	O
-	O
TK	O
(	O
0	O
.	O
03	O
microg	O
/	O
ml	O
)	O
and	O
incubated	O
at	O
37degreesC	O
for	O
16	O
hours	O
.	O

Cells	O
were	O
then	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
hours	O
before	O
termination	O
of	O
the	O
cultures	O
.	O
<EOS>	B-X
Affected	B-X
patients	B-X
have	B-X
fever	B-X
,	B-X
chills	B-X
,	B-X
and	B-X
infections	B-X
;	B-X
severe	B-X
infections	B-X
left	B-X
untreated	B-X
can	B-X
result	B-X
in	B-X
death	B-X
.	B-X
If	B-X
left	B-X
untreated	B-X
,	B-X
liver	B-X
fibrosis	B-X
can	B-X
progress	B-X
to	B-X
liver	B-X
cirrhosis	B-X
,	B-X
hepatocellular	B-X
carcinoma	B-X
and	B-X
eventually	B-X
,	B-X
liver	B-X
failure	B-X
.	B-X
If	B-X
left	B-X
untreated	B-X
it	B-X
rapidly	B-X
progresses	B-X
and	B-X
compromises	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
This	B-X
article	B-X
is	B-X
part	B-X
of	B-X
a	B-X
Special	B-X
Issue	B-X
entitled	B-X
:	B-X
Stem	B-X
Cells	B-X
and	B-X
Their	B-X
Applications	B-X
to	B-X
Human	B-X
Diseases	B-X
edited	B-X
by	B-X
Hemachandra	B-X
Reddy	B-X
.	B-X

In	O
the	O
histogram	O
,	O
open	O
bars	O
represent	O
individual	O
LTR	O
activities	O
in	O
untreated	O
cells	O
.	O

Light	O
grey	O
bars	O
represent	O
mean	O
values	O
of	O
LTR	O
activities	O
from	O
each	O
subtype	O
in	O
untreated	O
cells	O
.	O

Black	O
bars	O
represent	O
individual	O
LTR	O
activities	O
in	O
MTb	O
lysate	O
-	O
treated	O
cells	O
,	O
and	O
dark	O
grey	O
bars	O
represent	O
mean	O
values	O
of	O
LTR	O
activities	O
from	O
each	O
subtype	O
in	O
cells	O
treated	O
with	O
MTb	O
lysate	O
.	O

LTR	O
transcriptional	O
activity	O
for	O
all	O
of	O
the	O
representative	O
LTRs	O
tested	O
was	O
significantly	O
increased	O
in	O
cultures	O
treated	O
with	O
MTb	O
lysate	O
in	O
comparison	O
to	O
untreated	O
cultures	O
.	O

Results	O
are	O
from	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
as	O
compared	O
to	O
unstimulated	O
cultures	O
)	O
.	O

(	O
B	O
)	O
Specific	O
disruption	O
of	O
the	O
NFAT5	O
binding	O
site	O
significantly	O
reduces	O
LTR	O
-	O
reporter	O
gene	O
activity	O
in	O
monocytic	O
cells	O
in	O
response	O
to	O
MTb	O
lysate	O
treatment	O
.	O

THP	O
-	O
1	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
expression	O
vectors	O
encoding	O
nucleotides	O
208	O
to	O
+	O
64	O
of	O
the	O
wild	O
-	O
type	O
HIV	O
-	O
1Lai	O
LTR	O
and	O
an	O
HIV	O
-	O
1Lai	O
LTR	O
containing	O
the	O
NFAT5	O
binding	O
site	O
mutations	O
(	O
N5	O
-	O
Mut	O
)	O
.	O

After	O
16	O
hours	O
,	O
the	O
cells	O
were	O
left	O
untreated	O
or	O
exposed	O
to	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
hours	O
at	O
37degreesC	O
.	O
<EOS>	B-X
Nine	B-X
patients	B-X
with	B-X
untreated	B-X
essential	B-X
hypertension	B-X
(	B-X
mean	B-X
casual	B-X
blood	B-X
pressure	B-X
173/109	B-X
+/-	B-X
14/7	B-X
mm	B-X
Hg	B-X
)	B-X
(	B-X
+/-	B-X
SD	B-X
)	B-X
were	B-X
studied	B-X
in	B-X
the	B-X
control	B-X
state	B-X
and	B-X
after	B-X
16	B-X
weeks	B-X
of	B-X
treatment	B-X
with	B-X
nifedipine	B-X
,	B-X
10	B-X
mg	B-X
orally	B-X
every	B-X
8	B-X
hours	B-X
.	B-X
Direct	B-X
arterial	B-X
blood	B-X
pressure	B-X
monitored	B-X
continuously	B-X
over	B-X
24	B-X
hours	B-X
showed	B-X
that	B-X
nifedipine	B-X
significantly	B-X
reduced	B-X
systolic	B-X
and	B-X
diastolic	B-X
blood	B-X
pressure	B-X
throughout	B-X
the	B-X
day	B-X
and	B-X
the	B-X
night	B-X
.	B-X
Successful	B-X
control	B-X
of	B-X
blood	B-X
pressure	B-X
with	B-X
nifedipine	B-X
led	B-X
to	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
left	B-X
ventricular	B-X
mass	B-X
index	B-X
.	B-X
In	B-X
a	B-X
clinically	B-X
applicable	B-X
cat	B-X
stroke	B-X
model	B-X
,	B-X
16	B-X
purpose-bred	B-X
adult	B-X
animals	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
beneficial	B-X
effects	B-X
of	B-X
two	B-X
treatment	B-X
regimens	B-X
:	B-X
isovolemic	B-X
hemodilution	B-X
with	B-X
either	B-X
a	B-X
perfluorocarbon	B-X
emulsion	B-X
or	B-X
dextran	B-X
40	B-X
(	B-X
a	B-X
glucose	B-X
polymer	B-X
)	B-X
.	B-X
Animals	B-X
that	B-X
received	B-X
these	B-X
treatment	B-X
regimens	B-X
were	B-X
then	B-X
compared	B-X
with	B-X
a	B-X
control	B-X
group	B-X
of	B-X
untreated	B-X
animals	B-X
.	B-X
Focal	B-X
cerebral	B-X
infarctions	B-X
were	B-X
produced	B-X
by	B-X
transorbital	B-X
ligation	B-X
of	B-X
the	B-X
left	B-X
middle	B-X
cerebral	B-X
artery	B-X
.	B-X
The	B-X
randomly	B-X
allocated	B-X
treatment	B-X
arms	B-X
of	B-X
the	B-X
study	B-X
were	B-X
instituted	B-X
3	B-X
hours	B-X
after	B-X
ligation	B-X
of	B-X
the	B-X
middle	B-X
cerebral	B-X
artery	B-X
,	B-X
thereby	B-X
simulating	B-X
a	B-X
human	B-X
clinical	B-X
situation	B-X
.	B-X

Disruption	O
of	O
NFAT5	B-Protein
binding	O
to	O
the	O
enhancer	O
region	O
significantly	O
suppressed	O
LTR	O
-	O
driven	O
reporter	O
gene	O
expression	O
in	O
comparison	O
to	O
the	O
wild	O
-	O
type	O
LTR	O
when	O
cells	O
were	O
treated	O
with	O
MTb	O
lysate	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

LTR	O
activity	O
was	O
also	O
suppressed	O
in	O
the	O
untreated	O
cells	O
but	O
to	O
a	O
lesser	O
extent	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Results	O
are	O
from	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
and	O
adjusted	O
to	O
Renilla	O
luciferase	B-Protein
control	O
expression	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Nucleotide	O
sequences	O
representing	O
the	O
wild	O
-	O
type	O
and	O
NFAT5	O
binding	O
site	O
-	O
mutated	O
HIV	O
-	O
1Lai	O
LTRs	O
are	O
shown	O
at	O
the	O
bottom	O
of	O
the	O
figure	O
.	O

(	O
C	O
)	O
MTb	O
lysate	O
increases	O
NFAT5	B-Protein
protein	O
levels	O
in	O
monocytic	O
cells	O
.	O

THP	O
-	O
1	O
cells	O
were	O
left	O
untreated	O
(	O
control	O
)	O
or	O
exposed	O
to	O
10	O
microg	O
/	O
ml	O
MTb	O
lysate	O
for	O
8	O
or	O
24	O
hours	O
at	O
37degreesC	O
.	O
<EOS>	B-X
Aberrant	B-X
lipid	B-X
accumulation	B-X
in	B-X
both	B-X
endothelial	B-X
cells	B-X
and	B-X
macrophage	B-X
foam	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
atherogenic	B-X
inflammation	B-X
in	B-X
the	B-X
atherosclerotic	B-X
lesions	B-X
,	B-X
if	B-X
left	B-X
untreated	B-X
,	B-X
eventually	B-X
lead	B-X
to	B-X
plaque	B-X
rupture	B-X
and	B-X
arterial	B-X
damage	B-X
,	B-X
causing	B-X
devastating	B-X
consequences	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
explore	B-X
a	B-X
dual	B-X
cell	B-X
therapy	B-X
modality	B-X
by	B-X
designing	B-X
a	B-X
dual-targeting	B-X
core-shell	B-X
nanoplatform	B-X
to	B-X
deliver	B-X
siRNA	B-X
against	B-X
lectin-like	B-X
oxidized	B-X
low-density	B-X
lipoprotein	B-X
receptor-1	B-X
(	B-X
LOX-1	B-X
siRNA	B-X
)	B-X
and	B-X
atorvastatin	B-X
(	B-X
AT	B-X
)	B-X
to	B-X
control	B-X
lipid	B-X
trafficking	B-X
to	B-X
and	B-X
from	B-X
endothelial	B-X
cells	B-X
and	B-X
macrophages	B-X
in	B-X
the	B-X
atherosclerotic	B-X
lesions	B-X
selectively	B-X
and	B-X
sequentially	B-X
.	B-X
Following	B-X
a	B-X
12-week	B-X
biweekly	B-X
dosing	B-X
regimen	B-X
,	B-X
the	B-X
core-shell	B-X
nanoparticles	B-X
coated	B-X
with	B-X
high	B-X
molecular	B-X
weight	B-X
HA	B-X
(	B-X
200	B-X
kDa	B-X
)	B-X
exhibited	B-X
the	B-X
most	B-X
potent	B-X
anti-atherosclerotic	B-X
activities	B-X
as	B-X
evidenced	B-X
by	B-X
39	B-X
%	B-X
plaque	B-X
size	B-X
reduction	B-X
,	B-X
63	B-X
%	B-X
decrease	B-X
in	B-X
lipid	B-X
accumulation	B-X
,	B-X
68	B-X
%	B-X
reduction	B-X
in	B-X
CD68	B-X
The	B-X
growing	B-X
drug	B-X
resistance	B-X
(	B-X
DR	B-X
)	B-X
raises	B-X
major	B-X
concerns	B-X
for	B-X
the	B-X
control	B-X
of	B-X
visceral	B-X
leishmaniasis	B-X
(	B-X
VL	B-X
)	B-X
,	B-X
a	B-X
neglected	B-X
disease	B-X
lethal	B-X
in	B-X
95	B-X
percent	B-X
of	B-X
the	B-X
cases	B-X
if	B-X
left	B-X
untreated	B-X
.	B-X
In	B-X
this	B-X
academic/industrial	B-X
collaboration	B-X
,	B-X
130	B-X
compounds	B-X
from	B-X
the	B-X
GSK	B-X
``	B-X
Leishbox	B-X
''	B-X
were	B-X
screened	B-X
against	B-X
one	B-X
SSG-sensitive	B-X
and	B-X
one	B-X
SSG-resistant	B-X
strain	B-X
of	B-X
L.	B-X
donovani	B-X
recently	B-X
isolated	B-X
from	B-X
ISC	B-X
patients	B-X
,	B-X
using	B-X
an	B-X
intracellular	B-X
assay	B-X
of	B-X
L.	B-X
donovani-infected	B-X
THP1-derived	B-X
macrophages	B-X
.	B-X

Whole	O
cell	O
extracts	O
were	O
collected	O
and	O
analyzed	O
by	O
western	O
blot	O
with	O
anti	O
-	O
NFAT5	O
antibody	O
.	O

An	O
antibody	O
directed	O
against	O
Lamin	B-Protein
-	I-Protein
B1	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

The	O
histogram	O
shows	O
densitometric	O
analysis	O
of	O
the	O
NFAT5	B-Protein
bands	O
from	O
the	O
western	O
blot	O
autoradiograph	O
displayed	O
and	O
values	O
represent	O
mean	O
band	O
intensities	O
at	O
0	O
,	O
8	O
,	O
and	O
24	O
hours	O
post	O
-	O
stimulation	O
with	O
MTb	O
lysate	O
.	O

MTb	O
induces	O
NFAT5	B-Protein
gene	O
expression	O
and	O
knockdown	O
of	O
NFAT5	B-Protein
impairs	O
HIV	O
-	O
1	O
replication	O
during	O
MTb	O
co	O
-	O
infection	O
.	O

(	O
A	O
)	O
MTb	O
but	O
not	O
HIV	O
-	O
1	O
increases	O
NFAT5	B-Protein
mRNA	O
synthesis	O
in	O
human	O
macrophages	O
.	O
<EOS>	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
caused	B-X
by	B-X
the	B-X
bacterial	B-X
pathogen	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
Mtb	B-X
)	B-X
remains	B-X
one	B-X
of	B-X
the	B-X
deadliest	B-X
infectious	B-X
diseases	B-X
with	B-X
over	B-X
a	B-X
billion	B-X
deaths	B-X
in	B-X
the	B-X
past	B-X
200	B-X
years	B-X
(	B-X
Paulson	B-X
2013	B-X
)	B-X
.	B-X
TB	B-X
causes	B-X
more	B-X
deaths	B-X
worldwide	B-X
than	B-X
any	B-X
other	B-X
single	B-X
infectious	B-X
agent	B-X
,	B-X
with	B-X
10.4	B-X
million	B-X
new	B-X
cases	B-X
and	B-X
close	B-X
to	B-X
1.7	B-X
million	B-X
deaths	B-X
in	B-X
2017	B-X
.	B-X
Mtb	B-X
needs	B-X
to	B-X
replicate	B-X
within	B-X
human	B-X
cells	B-X
to	B-X
disseminate	B-X
to	B-X
other	B-X
individuals	B-X
and	B-X
cause	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarise	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
complex	B-X
host	B-X
cell-pathogen	B-X
interactions	B-X
in	B-X
TB	B-X
and	B-X
review	B-X
the	B-X
cellular	B-X
mechanisms	B-X
operating	B-X
at	B-X
the	B-X
interface	B-X
between	B-X
Mtb	B-X
and	B-X
the	B-X
human	B-X
host	B-X
cell	B-X
,	B-X
highlighting	B-X
the	B-X
technical	B-X
and	B-X
methodological	B-X
challenges	B-X
to	B-X
investigating	B-X
the	B-X
cell	B-X
biology	B-X
of	B-X
human	B-X
host	B-X
cell-Mtb	B-X
interactions	B-X
.	B-X

MDM	O
were	O
isolated	O
from	O
PBMC	O
obtained	O
from	O
four	O
normal	O
donors	O
.	O

The	O
cells	O
were	O
incubated	O
for	O
24	O
or	O
48	O
hours	O
with	O
heat	O
-	O
inactivated	O
or	O
live	O
R5	O
-	O
tropic	O
HIV	O
-	O
1	O
subtype	O
B	O
,	O
C	O
,	O
or	O
E	O
isolates	O
,	O
live	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
,	O
or	O
left	O
untreated	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
a	B-X
sealed	B-X
polyurethane	B-X
wound	B-X
chamber	B-X
has	B-X
allowed	B-X
us	B-X
to	B-X
perform	B-X
studies	B-X
evaluating	B-X
the	B-X
effects	B-X
of	B-X
growth	B-X
factors	B-X
,	B-X
transplanted	B-X
cells	B-X
,	B-X
and	B-X
other	B-X
bioactive	B-X
substances	B-X
on	B-X
wound	B-X
healing	B-X
.	B-X
The	B-X
wet	B-X
environment	B-X
is	B-X
also	B-X
paramount	B-X
for	B-X
the	B-X
survival	B-X
and	B-X
proliferation	B-X
of	B-X
transplanted	B-X
cells	B-X
or	B-X
tissue	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
studies	B-X
of	B-X
porcine	B-X
and	B-X
human	B-X
wounds	B-X
.	B-X
Cholesterol	B-X
content	B-X
of	B-X
cells	B-X
must	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
very	B-X
tight	B-X
limits	B-X
,	B-X
too	B-X
much	B-X
or	B-X
too	B-X
little	B-X
cholesterol	B-X
in	B-X
a	B-X
cell	B-X
results	B-X
in	B-X
disruption	B-X
of	B-X
cellular	B-X
membranes	B-X
,	B-X
apoptosis	B-X
and	B-X
necrosis	B-X
.	B-X
Cells	B-X
can	B-X
source	B-X
cholesterol	B-X
from	B-X
intracellular	B-X
synthesis	B-X
and	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
,	B-X
both	B-X
sources	B-X
are	B-X
sufficient	B-X
to	B-X
fully	B-X
satisfy	B-X
cells	B-X
'	B-X
requirements	B-X
for	B-X
cholesterol	B-X
.	B-X
Excessive	B-X
cholesterol	B-X
is	B-X
more	B-X
common	B-X
problem	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
hepatocytes	B-X
and	B-X
to	B-X
some	B-X
degree	B-X
adrenocortical	B-X
cells	B-X
,	B-X
cells	B-X
are	B-X
unable	B-X
to	B-X
degrade	B-X
cholesterol	B-X
.	B-X
Cells	B-X
have	B-X
two	B-X
options	B-X
to	B-X
reduce	B-X
their	B-X
cholesterol	B-X
content	B-X
:	B-X
to	B-X
convert	B-X
cholesterol	B-X
into	B-X
cholesteryl	B-X
esters	B-X
,	B-X
an	B-X
option	B-X
with	B-X
limited	B-X
capacity	B-X
as	B-X
overloading	B-X
cells	B-X
with	B-X
cholesteryl	B-X
esters	B-X
is	B-X
also	B-X
toxic	B-X
,	B-X
and	B-X
cholesterol	B-X
efflux	B-X
,	B-X
an	B-X
option	B-X
with	B-X
potentially	B-X
unlimited	B-X
capacity	B-X
.	B-X
Cholesterol	B-X
efflux	B-X
is	B-X
a	B-X
specific	B-X
process	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
number	B-X
of	B-X
intracellular	B-X
transporters	B-X
,	B-X
such	B-X
as	B-X
ATP	B-X
binding	B-X
cassette	B-X
transporter	B-X
proteins	B-X
A1	B-X
(	B-X
ABCA1	B-X
)	B-X
and	B-X
G1	B-X
(	B-X
ABCG1	B-X
)	B-X
and	B-X
scavenger	B-X
receptor	B-X
type	B-X
B1	B-X
.	B-X
The	B-X
cholesterol	B-X
efflux	B-X
assay	B-X
is	B-X
designed	B-X
to	B-X
quantitate	B-X
the	B-X
rate	B-X
of	B-X
cholesterol	B-X
efflux	B-X
from	B-X
cultured	B-X
cells	B-X
.	B-X
It	B-X
measures	B-X
the	B-X
capacity	B-X
of	B-X
cells	B-X
to	B-X
maintain	B-X
cholesterol	B-X
efflux	B-X
and/or	B-X
the	B-X
capacity	B-X
of	B-X
plasma	B-X
acceptors	B-X
to	B-X
accept	B-X
cholesterol	B-X
released	B-X
from	B-X
cells	B-X
.	B-X
Step	B-X
1	B-X
:	B-X
labelling	B-X
cellular	B-X
cholesterol	B-X
by	B-X
adding	B-X
labelled	B-X
cholesterol	B-X
to	B-X
serum-containing	B-X
medium	B-X
and	B-X
incubating	B-X
with	B-X
cells	B-X
for	B-X
24-48	B-X
h.	B-X
This	B-X
step	B-X
may	B-X
be	B-X
combined	B-X
with	B-X
loading	B-X
of	B-X
cells	B-X
with	B-X
cholesterol	B-X
.	B-X
Step	B-X
2	B-X
:	B-X
incubation	B-X
of	B-X
cells	B-X
in	B-X
serum-free	B-X
medium	B-X
to	B-X
equilibrate	B-X
labelled	B-X
cholesterol	B-X
among	B-X
all	B-X
intracellular	B-X
cholesterol	B-X
pools	B-X
.	B-X
Step	B-X
3	B-X
:	B-X
incubation	B-X
of	B-X
cells	B-X
with	B-X
extracellular	B-X
acceptor	B-X
and	B-X
quantitation	B-X
of	B-X
movement	B-X
of	B-X
labelled	B-X
cholesterol	B-X
from	B-X
cells	B-X
to	B-X
the	B-X
acceptor	B-X
.	B-X
The	B-X
assay	B-X
delivers	B-X
the	B-X
following	B-X
information	B-X
:	B-X
(	B-X
i	B-X
)	B-X
how	B-X
a	B-X
particular	B-X
treatment	B-X
(	B-X
a	B-X
mutation	B-X
,	B-X
a	B-X
knock-down	B-X
,	B-X
an	B-X
overexpression	B-X
or	B-X
a	B-X
treatment	B-X
)	B-X
affects	B-X
the	B-X
capacity	B-X
of	B-X
cell	B-X
to	B-X
efflux	B-X
cholesterol	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
how	B-X
the	B-X
capacity	B-X
of	B-X
plasma	B-X
acceptors	B-X
to	B-X
accept	B-X
cholesterol	B-X
is	B-X
affected	B-X
by	B-X
a	B-X
disease	B-X
or	B-X
a	B-X
treatment	B-X
.	B-X

Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
of	O
NFAT5	B-Protein
mRNA	O
expression	O
levels	O
revealed	O
that	O
the	O
low	O
,	O
constitutively	O
present	O
level	O
of	O
NFAT5	B-Protein
mRNA	O
expressed	O
in	O
untreated	O
cells	O
was	O
not	O
affected	O
by	O
exposure	O
to	O
live	O
or	O
inactivated	O
HIV	O
-	O
1	O
,	O
but	O
was	O
significantly	O
increased	O
at	O
both	O
24	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
48	O
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
hours	O
following	O
infection	O
with	O
MTb	O
.	O

(	O
B	O
)	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
effectively	O
suppresses	O
NFAT5	B-Protein
expression	O
in	O
MDM	O
in	O
both	O
the	O
absence	O
and	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

MDM	O
(	O
1x106	O
cells	O
/	O
well	O
in	O
a	O
6	O
-	O
well	O
plate	O
)	O
from	O
four	O
normal	O
donors	O
were	O
transfected	O
with	O
siRNA	O
specific	O
for	O
NFAT5	B-Protein
or	O
,	O
as	O
a	O
control	O
,	O
GFP	B-Protein
,	O
and	O
were	O
then	O
infected	O
with	O
MTb	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
or	O
left	O
uninfected	O
.	O
<EOS>	B-X
People	B-X
with	B-X
diabetes	B-X
are	B-X
at	B-X
high	B-X
risk	B-X
for	B-X
developing	B-X
foot	B-X
ulcers	B-X
,	B-X
which	B-X
often	B-X
become	B-X
infected	B-X
.	B-X
These	B-X
wounds	B-X
,	B-X
especially	B-X
when	B-X
infected	B-X
,	B-X
cause	B-X
substantial	B-X
morbidity	B-X
.	B-X
Topical	B-X
antimicrobial	B-X
therapy	B-X
has	B-X
been	B-X
used	B-X
on	B-X
diabetic	B-X
foot	B-X
ulcers	B-X
,	B-X
either	B-X
as	B-X
a	B-X
treatment	B-X
for	B-X
clinically	B-X
infected	B-X
wounds	B-X
,	B-X
or	B-X
to	B-X
prevent	B-X
infection	B-X
in	B-X
clinically	B-X
uninfected	B-X
wounds	B-X
.	B-X
HCV	B-X
,	B-X
left	B-X
untreated	B-X
,	B-X
worsens	B-X
patient	B-X
and	B-X
graft	B-X
survival	B-X
after	B-X
kidney	B-X
transplantation	B-X
through	B-X
multiple	B-X
mechanisms	B-X
.	B-X
Limited	B-X
data	B-X
suggest	B-X
that	B-X
current	B-X
HCV	B-X
treatment	B-X
improves	B-X
outcomes	B-X
of	B-X
infected	B-X
kidney	B-X
transplant	B-X
patients	B-X
.	B-X
Along	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
successfully	B-X
treat	B-X
HCV	B-X
,	B-X
the	B-X
increased	B-X
HCV	B-X
prevalence	B-X
among	B-X
donors	B-X
has	B-X
led	B-X
to	B-X
transplantation	B-X
of	B-X
kidneys	B-X
from	B-X
HCV-viremic	B-X
donors	B-X
into	B-X
uninfected	B-X
recipients	B-X
.	B-X

In	O
the	O
cells	O
transfected	O
with	O
control	O
siRNA	O
,	O
MTb	O
infection	O
significantly	O
increased	O
NFAT5	B-Protein
expression	O
in	O
comparison	O
to	O
uninfected	O
cells	O
(	O
open	O
bars	O
)	O
.	O

When	O
MDM	O
were	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
,	O
both	O
constitutively	O
expressed	O
(	O
p	O
=	O
0	O
.	O
048	O
)	O
and	O
MTb	O
-	O
induced	O
(	O
p	O
=	O
0	O
.	O
021	O
)	O
NFAT5	B-Protein
mRNA	O
were	O
significantly	O
suppressed	O
(	O
grey	O
bars	O
)	O
.	O

(	O
C	O
)	O
HIV	O
-	O
1	O
subtype	O
B	O
replication	O
is	O
significantly	O
suppressed	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
when	O
NFAT5	B-Protein
expression	O
is	O
abrogated	O
in	O
human	O
MDM	O
.	O

MDM	O
from	O
four	O
normal	O
donors	O
were	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
and	O
control	O
siRNAs	O
as	O
described	O
in	O
2B	O
.	O

Cells	O
were	O
then	O
infected	O
with	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
followed	O
by	O
co	O
-	O
infection	O
with	O
MTb	O
CDC1551	O
.	O

Virus	O
replication	O
was	O
measured	O
at	O
days	O
6	O
,	O
9	O
,	O
and	O
12	O
post	O
-	O
infection	O
.	O
<EOS>	B-X
Severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
coronavirus	B-X
which	B-X
caused	B-X
a	B-X
global	B-X
respiratory	B-X
disease	B-X
pandemic	B-X
beginning	B-X
in	B-X
December	B-X
2019	B-X
.	B-X
Understanding	B-X
the	B-X
pathogenesis	B-X
of	B-X
infection	B-X
and	B-X
the	B-X
immune	B-X
responses	B-X
in	B-X
a	B-X
SARS-CoV-2-infected	B-X
animal	B-X
model	B-X
is	B-X
urgently	B-X
needed	B-X
for	B-X
vaccine	B-X
development	B-X
.	B-X
Chimeric	B-X
urokinase	B-X
type	B-X
plasminogen	B-X
activator	B-X
(	B-X
uPA	B-X
)	B-X
/severely	B-X
severe	B-X
combined	B-X
immunodeficiency	B-X
(	B-X
SCID	B-X
)	B-X
mice	B-X
reconstituted	B-X
with	B-X
humanized	B-X
livers	B-X
are	B-X
useful	B-X
for	B-X
studying	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
infection	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
an	B-X
adaptive	B-X
immune	B-X
response	B-X
.	B-X
However	B-X
,	B-X
the	B-X
detailed	B-X
characterization	B-X
of	B-X
HBV	B-X
infection	B-X
kinetics	B-X
necessary	B-X
to	B-X
enable	B-X
in-depth	B-X
mechanistic	B-X
studies	B-X
in	B-X
this	B-X
in	B-X
vivo	B-X
HBV	B-X
infection	B-X
model	B-X
is	B-X
lacking	B-X
.	B-X
To	B-X
characterize	B-X
HBV	B-X
kinetics	B-X
post-inoculation	B-X
(	B-X
p.i	B-X
.	B-X
)	B-X
Serum	B-X
HBV	B-X
DNA	B-X
was	B-X
frequently	B-X
measured	B-X
from	B-X
1	B-X
minute	B-X
to	B-X
63	B-X
days	B-X
p.i	B-X
.	B-X
Total	B-X
intrahepatic	B-X
HBV	B-X
DNA	B-X
,	B-X
HBV	B-X
covalently	B-X
closed	B-X
circular	B-X
DNA	B-X
(	B-X
cccDNA	B-X
)	B-X
,	B-X
and	B-X
HBV	B-X
RNA	B-X
was	B-X
measured	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
mice	B-X
at	B-X
2	B-X
,	B-X
4	B-X
,	B-X
6	B-X
,	B-X
10	B-X
,	B-X
and	B-X
13	B-X
weeks	B-X
p.i	B-X
.	B-X

At	O
day	O
12	O
,	O
virus	O
replication	O
was	O
significantly	O
reduced	O
in	O
cells	O
transfected	O
with	O
NFAT5	B-Protein
-	O
specific	O
siRNA	O
in	O
comparison	O
to	O
cells	O
transfected	O
with	O
control	O
siRNA	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
monitored	O
the	O
morphology	O
of	O
cells	O
within	O
the	O
infected	O
cultures	O
and	O
did	O
not	O
observe	O
noticeable	O
macrophage	O
necrosis	O
even	O
at	O
the	O
final	O
timepoint	O
of	O
viral	O
harvest	O
.	O
<EOS>	B-X
Neutrophil-mediated	B-X
processes	B-X
,	B-X
characteristic	B-X
for	B-X
both	B-X
inflammatory	B-X
and	B-X
infectious	B-X
processes	B-X
,	B-X
can	B-X
be	B-X
targeted	B-X
in	B-X
situ	B-X
by	B-X
radiolabeled	B-X
leukocytes	B-X
,	B-X
antibodies	B-X
or	B-X
fragments	B-X
,	B-X
or	B-X
even	B-X
by	B-X
cytokines	B-X
and	B-X
(	B-X
18	B-X
)	B-X
F-fluorodeoxyglucose	B-X
.	B-X
It	B-X
is	B-X
believed	B-X
that	B-X
P.	B-X
insidiosum	B-X
's	B-X
zoospores	B-X
,	B-X
its	B-X
infected	B-X
form	B-X
,	B-X
play	B-X
major	B-X
role	B-X
in	B-X
pathogenesis	B-X
.	B-X
It	B-X
was	B-X
previously	B-X
believed	B-X
that	B-X
surgery	B-X
with	B-X
negative	B-X
surgical	B-X
margins	B-X
was	B-X
the	B-X
essential	B-X
to	B-X
survive	B-X
in	B-X
vascular	B-X
pythiosis	B-X
;	B-X
however	B-X
,	B-X
it	B-X
was	B-X
recently	B-X
found	B-X
that	B-X
patients	B-X
could	B-X
have	B-X
residual	B-X
disease	B-X
despite	B-X
documented	B-X
negative	B-X
surgical	B-X
margins	B-X
as	B-X
infected	B-X
clot	B-X
may	B-X
be	B-X
dislodged	B-X
to	B-X
proximal	B-X
arterial	B-X
sites	B-X
prior	B-X
to	B-X
surgery	B-X
.	B-X
A	B-X
significant	B-X
decrease	B-X
in	B-X
BG	B-X
levels	B-X
within	B-X
2	B-X
weeks	B-X
after	B-X
surgery	B-X
is	B-X
indicative	B-X
of	B-X
the	B-X
absence	B-X
of	B-X
residual	B-X
infection	B-X
.	B-X
Itraconazole	B-X
plus	B-X
terbinafine	B-X
have	B-X
generally	B-X
been	B-X
used	B-X
in	B-X
P.	B-X
insidiosum-infected	B-X
patients	B-X
;	B-X
however	B-X
,	B-X
antibacterial	B-X
agents	B-X
,	B-X
including	B-X
azithromycin	B-X
and	B-X
linezolid	B-X
,	B-X
have	B-X
also	B-X
been	B-X
used	B-X
with	B-X
favorable	B-X
outcomes	B-X
in	B-X
ocular	B-X
disease	B-X
.	B-X

Specific	O
disruption	O
of	O
NFAT5	O
or	O
NF	O
-	O
kappaB	O
binding	O
sites	O
in	O
the	O
LTR	O
of	O
HIV	O
-	O
1	O
subtype	O
B	O
.	O
<EOS>	B-X
Mechanistically	B-X
,	B-X
NLRC3	B-X
inhibits	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
p65	B-X
binding	B-X
to	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
5	B-X
(	B-X
NFAT5	B-X
)	B-X
,	B-X
which	B-X
further	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
glycolytic	B-X
genes	B-X
and	B-X
proinflammatory	B-X
cytokines	B-X
of	B-X
immunosuppressive	B-X
macrophages	B-X
.	B-X
This	B-X
is	B-X
achieved	B-X
by	B-X
decreasing	B-X
NF-κB	B-X
activation-co-induced	B-X
by	B-X
TNF-receptor-associated	B-X
factor	B-X
6	B-X
(	B-X
TRAF6	B-X
)	B-X
or	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
-and	B-X
decreasing	B-X
transcriptional	B-X
co-activator	B-X
p300	B-X
activity	B-X
by	B-X
inducing	B-X
NLRC3	B-X
sequestration	B-X
of	B-X
mTOR	B-X
and	B-X
p300	B-X
.	B-X
Genetic	B-X
inhibition	B-X
of	B-X
NLRC3	B-X
disrupted	B-X
the	B-X
NLRC3-mTOR-p300	B-X
complex	B-X
and	B-X
enhanced	B-X
NF-κB	B-X
binding	B-X
to	B-X
the	B-X
NFAT5	B-X
promoter	B-X
in	B-X
concert	B-X
with	B-X
p300	B-X
.	B-X
Helminth	B-X
infections	B-X
as	B-X
well	B-X
as	B-X
structural	B-X
alternations	B-X
in	B-X
the	B-X
long-terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
regions	B-X
of	B-X
HIV-1	B-X
are	B-X
known	B-X
to	B-X
contribute	B-X
to	B-X
elevated	B-X
HIV	B-X
RNA	B-X
level	B-X
and	B-X
enhance	B-X
HIV-1	B-X
diseases	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
the	B-X
impact	B-X
of	B-X
helminths	B-X
infections	B-X
on	B-X
the	B-X
occurrences	B-X
of	B-X
triple	B-X
NF-κB	B-X
and	B-X
genetic	B-X
variability	B-X
in	B-X
LTR	B-X
region	B-X
of	B-X
HIV-1C	B-X
isolates	B-X
is	B-X
not	B-X
known	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
examine	B-X
the	B-X
presence	B-X
of	B-X
genetic	B-X
variability	B-X
in	B-X
the	B-X
LTR	B-X
region	B-X
of	B-X
HIV-1C	B-X
isolates	B-X
during	B-X
chronic	B-X
HIV-helminth	B-X
co-infection	B-X
.	B-X

(	O
A	O
)	O
Mutations	O
introduced	O
into	O
a	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
infectious	O
molecular	O
clone	O
.	O

NF	O
-	O
kappaB	O
and	O
NFAT5	O
binding	O
site	O
mutations	O
were	O
introduced	O
into	O
the	O
LTR	O
of	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
wild	O
type	O
(	O
WT	O
)	O
infectious	O
molecular	O
clone	O
.	O

The	O
NF	O
-	O
kappaB	O
binding	O
site	O
mutants	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
)	O
,	O
and	O
NFAT5	O
binding	O
site	O
mutant	O
(	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
)	O
are	O
shown	O
along	O
with	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
sequence	O
.	O

Mutations	O
were	O
introduced	O
into	O
the	O
3	O
'	O
LTR	O
of	O
the	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
proviral	O
sequence	O
.	O

(	O
B	O
)	O
Specific	O
mutation	O
of	O
the	O
NFAT5	O
binding	O
site	O
abolishes	O
NFAT5	B-Protein
binding	O
to	O
the	O
viral	O
LTR	O
but	O
does	O
not	O
affect	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
to	O
the	O
overlapping	O
NF	O
-	O
kappaB	O
binding	O
site	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
using	O
HIV	O
-	O
1	O
LTR	O
fragments	O
(	O
-	O
262	O
to	O
+	O
4	O
nt	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
(	O
25	O
ng	O
,	O
100	O
ng	O
,	O
and	O
500	O
ng	O
)	O
,	O
or	O
NFAT5	B-Protein
(	O
10	O
ng	O
,	O
50	O
ng	O
,	O
and	O
250	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
NF	O
-	O
kappaB	O
and	O
NFAT5	B-Protein
are	O
indicated	O
with	O
a	O
bars	O
.	O

(	O
C	O
)	O
Specific	O
disruption	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
NF	O
-	O
kappaB	O
binding	O
sites	O
effectively	O
abrogates	O
recombinant	O
p50	B-Protein
/	O
p65	B-Protein
binding	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
of	O
nucleotides	O
-	O
262	O
to	O
+	O
4	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
(	O
25	O
ng	O
,	O
100	O
ng	O
,	O
and	O
500	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
recombinant	O
NF	O
-	O
kappaB	O
are	O
indicated	O
with	O
a	O
bars	O
.	O

(	O
D	O
)	O
Specific	O
disruption	O
of	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
NF	O
-	O
kappaB	O
binding	O
site	O
does	O
not	O
inhibit	O
but	O
enhances	O
NFAT5	B-Protein
binding	O
to	O
this	O
region	O
.	O

Quantitative	O
DNaseI	B-Protein
footprinting	O
analysis	O
is	O
shown	O
of	O
nucleotides	O
-	O
262	O
to	O
+	O
4	O
from	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
and	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
and	O
increasing	O
concentrations	O
of	O
recombinant	O
NFAT5	B-Protein
(	O
10	O
ng	O
,	O
50	O
ng	O
,	O
and	O
250	O
ng	O
)	O
.	O

The	O
regions	O
that	O
are	O
protected	O
from	O
DNase	B-Protein
I	I-Protein
cleavage	O
by	O
the	O
binding	O
of	O
recombinant	O
NFAT5	B-Protein
are	O
indicated	O
with	O
a	O
bars	O
.	O

MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
PBMC	O
depends	O
on	O
binding	O
of	O
NFAT5	B-Protein
and	O
NF	O
-	O
kappaB	O
to	O
the	O
LTR	O
.	O

Specific	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
or	O
NFAT5	O
binding	O
sites	O
in	O
the	O
HIV	O
-	O
1	O
subtype	O
B	O
LTR	O
inhibits	O
R5	O
-	O
tropic	O
virus	O
replication	O
in	O
human	O
PBMC	O
after	O
co	O
-	O
infection	O
with	O
MTb	O
.	O
<EOS>	B-X
SD	B-X
results	B-X
from	B-X
Malassezia	B-X
hydrolysation	B-X
of	B-X
free	B-X
fatty	B-X
acids	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
by	B-X
the	B-X
way	B-X
of	B-X
pattern	B-X
recognition	B-X
receptors	B-X
,	B-X
inflammasome	B-X
,	B-X
IL-1β	B-X
and	B-X
NF-kB	B-X
.	B-X
M.	B-X
restricta	B-X
and	B-X
M.	B-X
globosa	B-X
are	B-X
likely	B-X
the	B-X
most	B-X
virulent	B-X
subspecies	B-X
,	B-X
producing	B-X
large	B-X
quantities	B-X
of	B-X
irritating	B-X
oleic	B-X
acids	B-X
,	B-X
leading	B-X
to	B-X
IL-8	B-X
and	B-X
IL-17	B-X
activation	B-X
.	B-X
IL-17	B-X
and	B-X
IL-4	B-X
might	B-X
play	B-X
a	B-X
big	B-X
role	B-X
in	B-X
pathogenesis	B-X
,	B-X
but	B-X
this	B-X
needs	B-X
to	B-X
be	B-X
further	B-X
studied	B-X
using	B-X
novel	B-X
biologics	B-X
.	B-X
No	B-X
clear	B-X
genetic	B-X
predisposition	B-X
has	B-X
been	B-X
established	B-X
;	B-X
however	B-X
,	B-X
recent	B-X
studies	B-X
implicated	B-X
certain	B-X
increased-risk	B-X
human	B-X
leucocyte	B-X
antigen	B-X
(	B-X
HLA	B-X
)	B-X
alleles	B-X
,	B-X
such	B-X
as	B-X
A	B-X
*	B-X
32	B-X
,	B-X
DQB1	B-X
*	B-X
05	B-X
and	B-X
DRB1	B-X
*	B-X
01	B-X
as	B-X
well	B-X
as	B-X
possible	B-X
associations	B-X
with	B-X
psoriasis	B-X
and	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
through	B-X
the	B-X
LCE3	B-X
gene	B-X
cluster	B-X
while	B-X
SD	B-X
,	B-X
and	B-X
SD-like	B-X
syndromes	B-X
,	B-X
shares	B-X
genetic	B-X
mutations	B-X
that	B-X
appear	B-X
to	B-X
impair	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
to	B-X
restrict	B-X
Malassezia	B-X
growth	B-X
,	B-X
partially	B-X
due	B-X
to	B-X
complement	B-X
system	B-X
dysfunction	B-X
.	B-X
In	B-X
HIV	B-X
,	B-X
SD	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
secondary	B-X
to	B-X
a	B-X
combination	B-X
of	B-X
immune	B-X
dysregulation	B-X
and	B-X
disruption	B-X
in	B-X
skin	B-X
microbiota	B-X
with	B-X
unhindered	B-X
Malassezia	B-X
proliferation	B-X
.	B-X
In	B-X
Parkinson	B-X
's	B-X
disease	B-X
,	B-X
SD	B-X
is	B-X
most	B-X
likely	B-X
secondary	B-X
to	B-X
parasympathetic	B-X
hyperactivity	B-X
with	B-X
increased	B-X
sebum	B-X
production	B-X
as	B-X
well	B-X
as	B-X
facial	B-X
immobility	B-X
which	B-X
leads	B-X
to	B-X
sebum	B-X
accumulation	B-X
.	B-X

PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
or	O
the	O
mutants	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
and	O
either	O
;	O
(	O
A	O
)	O
left	O
untreated	O
,	O
or	O
(	O
B	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
isolate	O
CDC1551	O
(	O
10	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
.	O

Viral	O
p24	B-Protein
levels	O
in	O
culture	O
supernatants	O
were	O
measured	O
at	O
days	O
4	O
,	O
7	O
and	O
12	O
post	O
-	O
infection	O
.	O

(	O
C	O
)	O
Histograms	O
show	O
viral	O
p24	B-Protein
levels	O
at	O
day	O
12	O
in	O
the	O
MTb	O
uninfected	O
(	O
grey	O
bars	O
)	O
and	O
MTb	O
co	O
-	O
infected	O
(	O
black	O
bars	O
)	O
PBMC	O
cultures	O
.	O

Replication	O
of	O
the	O
mutant	O
viruses	O
was	O
compared	O
to	O
wild	O
-	O
type	O
virus	O
replication	O
under	O
the	O
same	O
experimental	O
conditions	O
(	O
without	O
and	O
with	O
MTb	O
co	O
-	O
infection	O
,	O
respectively	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
to	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
Env	O
-	O
WT	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

Disruption	O
of	O
NF	O
-	O
kappaB	O
or	O
NFAT5	O
sites	O
in	O
the	O
LTR	O
inhibits	O
MTb	O
-	O
induced	O
HIV	O
-	O
1	O
replication	O
in	O
MDM	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
innate	B-X
immunity	B-X
and	B-X
energy	B-X
metabolism	B-X
are	B-X
connected	B-X
together	B-X
through	B-X
an	B-X
antagonistic	B-X
crosstalk	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
signaling	B-X
pathways	B-X
.	B-X
NF-κB	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
defense	B-X
while	B-X
SIRT1	B-X
regulates	B-X
the	B-X
oxidative	B-X
respiration	B-X
and	B-X
cellular	B-X
survival	B-X
.	B-X
However	B-X
,	B-X
NF-κB	B-X
signaling	B-X
can	B-X
stimulate	B-X
glycolytic	B-X
energy	B-X
flux	B-X
during	B-X
acute	B-X
inflammation	B-X
,	B-X
whereas	B-X
SIRT1	B-X
activation	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
and	B-X
enhances	B-X
oxidative	B-X
metabolism	B-X
and	B-X
the	B-X
resolution	B-X
of	B-X
inflammation	B-X
.	B-X
SIRT1	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
directly	B-X
by	B-X
deacetylating	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
complex	B-X
.	B-X
SIRT1	B-X
stimulates	B-X
oxidative	B-X
energy	B-X
production	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
AMPK	B-X
,	B-X
PPARα	B-X
and	B-X
PGC-1α	B-X
and	B-X
simultaneously	B-X
,	B-X
these	B-X
factors	B-X
inhibit	B-X
NF-κB	B-X
signaling	B-X
and	B-X
suppress	B-X
inflammation	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
NF-κB	B-X
signaling	B-X
down-regulates	B-X
SIRT1	B-X
activity	B-X
through	B-X
the	B-X
expression	B-X
of	B-X
miR-34a	B-X
,	B-X
IFNγ	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
SIRT1	B-X
disrupts	B-X
oxidative	B-X
energy	B-X
metabolism	B-X
and	B-X
stimulates	B-X
the	B-X
NF-κB-induced	B-X
inflammatory	B-X
responses	B-X
present	B-X
in	B-X
many	B-X
chronic	B-X
metabolic	B-X
and	B-X
age-related	B-X
diseases	B-X
.	B-X
We	B-X
will	B-X
examine	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
antagonistic	B-X
signaling	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
and	B-X
describe	B-X
how	B-X
this	B-X
crosstalk	B-X
controls	B-X
inflammatory	B-X
process	B-X
and	B-X
energy	B-X
metabolism	B-X
.	B-X

MDM	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
or	O
the	O
mutants	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
II	O
-	O
Mut	O
,	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
kappaB	O
I	O
+	O
II	O
-	O
Mut	O
,	O
or	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
N5	O
-	O
Mut	O
,	O
and	O
were	O
either	O
(	O
A	O
)	O
left	O
infected	O
with	O
virus	O
alone	O
or	O
(	O
B	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
CDC1551	O
(	O
1	O
:	O
1	O
MDM	O
:	O
bacilli	O
)	O
.	O

Viral	O
p24	B-Protein
levels	O
in	O
the	O
culture	O
supernatants	O
were	O
measured	O
at	O
days	O
4	O
,	O
7	O
and	O
12	O
post	O
-	O
infection	O
.	O

Presentation	O
of	O
viral	O
p24	B-Protein
levels	O
at	O
day	O
12	O
in	O
cultures	O
infected	O
with	O
(	O
C	O
)	O
HIV	O
-	O
1	O
alone	O
or	O
(	O
D	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
are	O
shown	O
as	O
histograms	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
to	O
HIV	O
-	O
1Lai	O
/	O
Bal	O
-	O
env	B-Protein
-	O
WT	O
)	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

Disruption	O
of	O
the	O
NFAT5	O
site	O
in	O
HIV	O
-	O
1	O
subtype	O
C	O
significantly	O
impairs	O
MTb	O
-	O
induced	O
viral	O
replication	O
.	O

(	O
A	O
)	O
Mutation	O
of	O
the	O
NFAT5	O
binding	O
site	O
in	O
an	O
HIV	O
-	O
1	O
subtype	O
C	O
infectious	O
molecular	O
clone	O
.	O

NFAT5	O
binding	O
site	O
mutations	O
were	O
introduced	O
into	O
the	O
LTR	O
of	O
subtype	O
C	O
HIV	O
-	O
198IN22	O
-	O
WT	O
.	O

The	O
NFAT5	O
binding	O
site	O
mutant	O
(	O
HIV	O
-	O
198IN22	O
N5	O
-	O
Mut	O
)	O
LTR	O
sequence	O
is	O
shown	O
alongside	O
that	O
of	O
HIV	O
-	O
198IN22	O
-	O
WT	O
.	O

The	O
HIV	O
-	O
198IN22	O
isolate	O
analyzed	O
here	O
contains	O
three	O
NF	O
-	O
kappaB	O
and	O
two	O
NFAT5	O
binding	O
sites	O
.	O

The	O
unique	O
3	O
'	O
terminal	O
adenine	O
,	O
which	O
is	O
important	O
for	O
NFAT5	B-Protein
binding	O
to	O
its	O
site	O
,	O
is	O
shown	O
in	O
blocks	O
.	O

Mutations	O
were	O
introduced	O
into	O
the	O
3	O
'	O
LTR	O
of	O
the	O
HIV	O
-	O
198IN22	O
-	O
WT	O
proviral	O
sequence	O
.	O

PBMC	O
from	O
four	O
normal	O
donors	O
were	O
infected	O
with	O
1000	O
TCID50	O
of	O
HIV	O
-	O
198IN22	O
-	O
WT	O
or	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
.	O

Cells	O
were	O
then	O
(	O
B	O
)	O
left	O
infected	O
with	O
virus	O
alone	O
or	O
(	O
C	O
)	O
co	O
-	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
10	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
.	O

Culture	O
supernatants	O
were	O
collected	O
at	O
days	O
3	O
,	O
7	O
and	O
11	O
post	O
-	O
infection	O
and	O
viral	O
p24	B-Protein
levels	O
were	O
measured	O
.	O

Replication	O
of	O
HIV	O
-	O
198IN22	O
-	O
N5	O
-	O
Mut	O
was	O
significantly	O
reduced	O
at	O
day	O
11	O
post	O
-	O
infection	O
in	O
comparison	O
to	O
HIV	O
-	O
198IN22	O
-	O
WT	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
presence	O
of	O
MTb	O
co	O
-	O
infection	O
.	O

The	O
MyD88	B-Protein
-	O
mediated	O
signaling	O
cascade	O
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
expression	O
in	O
human	O
monocytes	O
.	O

(	O
A	O
)	O
Engagement	O
of	O
TLR2	B-Protein
significantly	O
enhances	O
NFAT5	B-Protein
mRNA	O
synthesis	O
in	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
were	O
incubated	O
with	O
the	O
TLR2	B-Protein
-	O
specific	O
ligand	O
Pam3Cys	O
(	O
5	O
microg	O
/	O
ml	O
)	O
,	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
,	O
or	O
left	O
untreated	O
.	O
<EOS>	B-X
Alcoholic	B-X
ketoacidosis	B-X
is	B-X
a	B-X
relatively	B-X
rare	B-X
condition	B-X
,	B-X
which	B-X
may	B-X
have	B-X
a	B-X
lethal	B-X
outcome	B-X
if	B-X
left	B-X
untreated	B-X
.	B-X
One	B-X
of	B-X
the	B-X
complications	B-X
is	B-X
foot	B-X
ulceration	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
amputation	B-X
if	B-X
left	B-X
untreated	B-X
.	B-X
The	B-X
incidence	B-X
of	B-X
leishmaniasis	B-X
is	B-X
reported	B-X
to	B-X
be	B-X
up	B-X
to	B-X
1	B-X
million	B-X
per	B-X
year	B-X
.	B-X
Our	B-X
study	B-X
identified	B-X
a	B-X
total	B-X
of	B-X
57	B-X
published	B-X
articles	B-X
as	B-X
describing	B-X
cases	B-X
of	B-X
OL	B-X
involving	B-X
:	B-X
adnexa	B-X
(	B-X
n	B-X
=	B-X
26	B-X
)	B-X
,	B-X
orbit	B-X
(	B-X
n	B-X
=	B-X
1	B-X
)	B-X
,	B-X
retina	B-X
(	B-X
n	B-X
=	B-X
7	B-X
)	B-X
,	B-X
uvea	B-X
(	B-X
n	B-X
=	B-X
18	B-X
)	B-X
and	B-X
cornea	B-X
(	B-X
n	B-X
=	B-X
6	B-X
)	B-X
.	B-X
Though	B-X
well	B-X
described	B-X
and	B-X
easily	B-X
treated	B-X
,	B-X
palpebral	B-X
leishmaniasis	B-X
is	B-X
often	B-X
misdiagnosed	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
chronic	B-X
issues	B-X
if	B-X
untreated	B-X
.	B-X
Corneal	B-X
involvement	B-X
in	B-X
most	B-X
geographic	B-X
areas	B-X
generally	B-X
follows	B-X
an	B-X
aggressive	B-X
course	B-X
,	B-X
most	B-X
often	B-X
ending	B-X
in	B-X
corneal	B-X
perforation	B-X
if	B-X
left	B-X
untreated	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
though	B-X
ocular	B-X
involvement	B-X
in	B-X
Leishmaniasis	B-X
is	B-X
rare	B-X
,	B-X
severe	B-X
sight-threatening	B-X
consequences	B-X
follow	B-X
if	B-X
left	B-X
untreated	B-X
.	B-X

After	O
16	O
hours	O
,	O
NFAT5	B-Protein
mRNA	O
levels	O
were	O
measured	O
.	O

NFAT5	B-Protein
mRNA	O
expression	O
was	O
significantly	O
increased	O
when	O
the	O
cells	O
were	O
incubated	O
with	O
Pam3Cys	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
or	O
infected	O
with	O
MTb	O
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

(	O
B	O
)	O
MyD88	B-Protein
is	O
important	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
that	O
constitutively	O
express	O
lentivirally	O
-	O
delivered	O
shRNA	O
targeting	O
MyD88	B-Protein
or	O
control	O
shRNA	O
targeting	O
GFP	B-Protein
were	O
constructed	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O
<EOS>	B-X
Controlling	B-X
the	B-X
expression	B-X
or	B-X
activity	B-X
of	B-X
specific	B-X
genes	B-X
through	B-X
the	B-X
myocardial	B-X
delivery	B-X
of	B-X
genetic	B-X
materials	B-X
in	B-X
murine	B-X
models	B-X
permits	B-X
the	B-X
investigation	B-X
of	B-X
gene	B-X
functions	B-X
.	B-X
Here	B-X
,	B-X
a	B-X
detailed	B-X
procedure	B-X
to	B-X
construct	B-X
,	B-X
package	B-X
,	B-X
and	B-X
purify	B-X
the	B-X
rAAV9	B-X
vectors	B-X
is	B-X
described	B-X
.	B-X
Subcutaneous	B-X
injection	B-X
of	B-X
rAAV9	B-X
into	B-X
neonatal	B-X
pups	B-X
results	B-X
in	B-X
robust	B-X
expression	B-X
or	B-X
efficient	B-X
knockdown	B-X
of	B-X
the	B-X
gene	B-X
(	B-X
s	B-X
)	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
mouse	B-X
heart	B-X
,	B-X
but	B-X
not	B-X
in	B-X
the	B-X
liver	B-X
and	B-X
other	B-X
tissues	B-X
.	B-X
Using	B-X
the	B-X
cardiac-specific	B-X
TnnT2	B-X
promoter	B-X
,	B-X
high	B-X
expression	B-X
of	B-X
GFP	B-X
gene	B-X
in	B-X
the	B-X
heart	B-X
was	B-X
obtained	B-X
.	B-X
Additionally	B-X
,	B-X
target	B-X
mRNA	B-X
was	B-X
inhibited	B-X
in	B-X
the	B-X
heart	B-X
when	B-X
a	B-X
rAAV9-U6-shRNA	B-X
was	B-X
utilized	B-X
.	B-X

Cells	O
were	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
(	O
1	O
:	O
1	O
cells	O
:	O
bacilli	O
)	O
or	O
left	O
uninfected	O
for	O
16	O
hours	O
at	O
37degreesC	O
,	O
and	O
RNA	O
was	O
analyzed	O
.	O
<EOS>	B-X
Dynamic	B-X
,	B-X
cholesterol-dense	B-X
regions	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
known	B-X
as	B-X
lipid	B-X
rafts	B-X
(	B-X
LR	B-X
)	B-X
,	B-X
have	B-X
been	B-X
observed	B-X
to	B-X
develop	B-X
during	B-X
and	B-X
may	B-X
be	B-X
directly	B-X
involved	B-X
in	B-X
infection	B-X
of	B-X
host	B-X
cells	B-X
by	B-X
various	B-X
pathogens	B-X
.	B-X
This	B-X
study	B-X
focuses	B-X
on	B-X
LR	B-X
aggregation	B-X
induced	B-X
in	B-X
alveolar	B-X
epithelial	B-X
cells	B-X
during	B-X
infection	B-X
with	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
Mtb	B-X
)	B-X
bacilli	B-X
.	B-X
We	B-X
report	B-X
dose-	B-X
and	B-X
time-dependent	B-X
increases	B-X
in	B-X
LR	B-X
aggregation	B-X
after	B-X
infection	B-X
with	B-X
three	B-X
different	B-X
strains	B-X
at	B-X
multiplicities	B-X
of	B-X
infection	B-X
of	B-X
1	B-X
,	B-X
10	B-X
and	B-X
100	B-X
from	B-X
2-24	B-X
hr	B-X
post	B-X
infection	B-X
(	B-X
hpi	B-X
)	B-X
.	B-X
Specific	B-X
strain-dependent	B-X
variations	B-X
were	B-X
noted	B-X
among	B-X
H37Rv	B-X
,	B-X
HN878	B-X
and	B-X
CDC1551	B-X
with	B-X
H37Rv	B-X
producing	B-X
the	B-X
most	B-X
significant	B-X
increase	B-X
from	B-X
15	B-X
aggregates	B-X
per	B-X
cell	B-X
(	B-X
APC	B-X
)	B-X
to	B-X
27	B-X
APC	B-X
at	B-X
MOI	B-X
100	B-X
during	B-X
the	B-X
24	B-X
hour	B-X
infection	B-X
period	B-X
.	B-X
Treatment	B-X
of	B-X
epithelial	B-X
cells	B-X
with	B-X
Culture	B-X
Filtrate	B-X
Protein	B-X
,	B-X
Total	B-X
Lipids	B-X
and	B-X
gamma-irradiated	B-X
whole	B-X
cells	B-X
from	B-X
each	B-X
strain	B-X
failed	B-X
to	B-X
induce	B-X
the	B-X
level	B-X
of	B-X
LR	B-X
aggregation	B-X
observed	B-X
during	B-X
infection	B-X
with	B-X
any	B-X
of	B-X
the	B-X
live	B-X
strains	B-X
.	B-X
However	B-X
,	B-X
filtered	B-X
supernatants	B-X
from	B-X
infected	B-X
epithelial	B-X
cells	B-X
did	B-X
produce	B-X
comparable	B-X
LR	B-X
aggregation	B-X
,	B-X
suggesting	B-X
a	B-X
secreted	B-X
mycobacterial	B-X
product	B-X
produced	B-X
during	B-X
infection	B-X
of	B-X
host	B-X
cells	B-X
is	B-X
responsible	B-X
for	B-X
LR	B-X
aggregation	B-X
.	B-X
Disruption	B-X
of	B-X
lipid	B-X
raft	B-X
formation	B-X
prior	B-X
to	B-X
infection	B-X
indicates	B-X
that	B-X
Mtb	B-X
bacilli	B-X
utilize	B-X
LR	B-X
aggregates	B-X
for	B-X
internalization	B-X
and	B-X
survival	B-X
in	B-X
epithelial	B-X
cells	B-X
.	B-X
Treatment	B-X
of	B-X
host	B-X
cells	B-X
with	B-X
the	B-X
LR-disruption	B-X
agent	B-X
Filipin	B-X
III	B-X
produced	B-X
a	B-X
nearly	B-X
22	B-X
%	B-X
reduction	B-X
in	B-X
viable	B-X
bacteria	B-X
for	B-X
strains	B-X
H37Rv	B-X
and	B-X
HN878	B-X
,	B-X
and	B-X
a	B-X
7	B-X
%	B-X
reduction	B-X
for	B-X
strain	B-X
CDC1551	B-X
after	B-X
6	B-X
hpi	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
evidence	B-X
for	B-X
significant	B-X
mycobacterial-induced	B-X
changes	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
of	B-X
alveolar	B-X
epithelial	B-X
cells	B-X
and	B-X
that	B-X
Mtb	B-X
strains	B-X
vary	B-X
in	B-X
their	B-X
ability	B-X
to	B-X
facilitate	B-X
aggregation	B-X
and	B-X
utilization	B-X
of	B-X
LR	B-X
.	B-X

NFAT5	B-Protein
mRNA	O
levels	O
were	O
significantly	O
inhibited	O
in	O
the	O
cells	O
transduced	O
with	O
MyD88	B-Protein
-	O
specific	O
shRNA	O
(	O
black	O
bars	O
)	O
compared	O
with	O
the	O
cells	O
transduced	O
with	O
control	O
shRNA	O
(	O
open	O
bars	O
)	O
in	O
both	O
,	O
the	O
absence	O
or	O
presence	O
of	O
MTb	O
infection	O
.	O
<EOS>	B-X
The	B-X
clinical	B-X
manifestations	B-X
of	B-X
miliary	B-X
TB	B-X
are	B-X
protean	B-X
and	B-X
nonspecific	B-X
.	B-X
Fundus	B-X
examination	B-X
for	B-X
detecting	B-X
choroid	B-X
tubercles	B-X
offers	B-X
a	B-X
valuable	B-X
clinical	B-X
clue	B-X
for	B-X
early	B-X
diagnosis	B-X
,	B-X
as	B-X
their	B-X
presence	B-X
is	B-X
pathognomonic	B-X
of	B-X
miliary	B-X
TB	B-X
.	B-X
Miliary	B-X
TB	B-X
is	B-X
uniformly	B-X
fatal	B-X
if	B-X
untreated	B-X
;	B-X
therefore	B-X
,	B-X
early	B-X
initiation	B-X
of	B-X
specific	B-X
anti-TB	B-X
treatment	B-X
can	B-X
be	B-X
lifesaving	B-X
.	B-X
Resistance-related	B-X
mutations	B-X
could	B-X
also	B-X
exert	B-X
certain	B-X
fitness	B-X
cost	B-X
to	B-X
the	B-X
drug-resistant	B-X
MTB	B-X
strains	B-X
and	B-X
growth	B-X
fitness	B-X
could	B-X
be	B-X
restored	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
compensatory	B-X
mutations	B-X
.	B-X

TNF	B-Protein
and	O
CD86	B-Protein
mRNAs	O
,	O
the	O
expression	O
of	O
which	O
are	O
MyD88	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
,	O
respectively	O
,	O
during	O
MTb	O
infection	O
,	O
were	O
measured	O
as	O
controls	O
.	O

(	O
C	O
,	O
D	O
)	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
are	O
required	O
for	O
MTb	O
induction	O
of	O
NFAT5	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

THP	O
-	O
1	O
cells	O
that	O
constitutively	O
express	O
lentivirally	O
-	O
delivered	O
IRAK1	B-Protein
-	O
or	O
TRAF6	B-Protein
-	O
specific	O
shRNA	O
were	O
constructed	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

THP	O
-	O
1	O
cells	O
expressing	O
control	O
shRNA	B-Protein
were	O
used	O
as	O
described	O
in	O
7B	O
.	O

Cells	O
were	O
infected	O
with	O
MTb	O
strain	O
CDC1551	O
or	O
left	O
uninfected	O
for	O
16	O
hours	O
at	O
37degreesC	O
,	O
and	O
RNA	O
was	O
analyzed	O
.	O
<EOS>	B-X
TB	B-X
spheroids	B-X
exhibit	B-X
higher	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
factor	B-X
TNFα	B-X
and	B-X
growth	B-X
factors	B-X
G-CSF	B-X
and	B-X
VEGF	B-X
when	B-X
compared	B-X
to	B-X
non-infected	B-X
control	B-X
.	B-X
TB	B-X
spheroids	B-X
infected	B-X
with	B-X
strains	B-X
of	B-X
differential	B-X
virulence	B-X
,	B-X
Using	B-X
a	B-X
rabbit	B-X
model	B-X
of	B-X
pulmonary	B-X
TB	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
infection	B-X
with	B-X
the	B-X
Mtb	B-X
clinical	B-X
isolate	B-X
HN878	B-X
(	B-X
a	B-X
hyper-virulent	B-X
W-Beijing	B-X
lineage	B-X
strain	B-X
)	B-X
leads	B-X
to	B-X
progressive	B-X
cavitary	B-X
disease	B-X
similar	B-X
to	B-X
what	B-X
is	B-X
seen	B-X
in	B-X
humans	B-X
with	B-X
active	B-X
TB	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
infection	B-X
with	B-X
Mtb	B-X
CDC1551	B-X
(	B-X
a	B-X
hyper-immunogenic	B-X
clinical	B-X
isolate	B-X
)	B-X
is	B-X
efficiently	B-X
controlled	B-X
in	B-X
rabbit	B-X
lungs	B-X
,	B-X
with	B-X
establishment	B-X
of	B-X
LTBI	B-X
,	B-X
which	B-X
can	B-X
be	B-X
reactivated	B-X
upon	B-X
treatment	B-X
with	B-X
immune-suppressive	B-X
drugs	B-X
.	B-X

NFAT5	B-Protein
expression	O
was	O
significantly	O
inhibited	O
in	O
the	O
MTb	O
-	O
infected	O
cells	O
expressing	O
either	O
IRAK1	B-Protein
(	O
C	O
)	O
or	O
TRAF6	B-Protein
(	O
D	O
)	O
shRNA	O
(	O
black	O
bars	O
)	O
compared	O
to	O
cells	O
expressing	O
control	O
shRNA	B-Protein
(	O
open	O
bars	O
)	O
.	O

TNF	B-Protein
and	O
CD86	B-Protein
mRNAs	O
,	O
both	O
of	O
which	O
require	O
IRAK1	B-Protein
and	O
TRAF6	B-Protein
to	O
be	O
induced	O
by	O
PRR	O
activation	O
,	O
were	O
measured	O
as	O
controls	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
<EOS>	B-X
Safety	B-X
surveillance	B-X
of	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
is	B-X
critical	B-X
to	B-X
ensure	B-X
safety	B-X
,	B-X
maintain	B-X
trust	B-X
,	B-X
and	B-X
inform	B-X
policy	B-X
.	B-X
Concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
a	B-X
potential	B-X
surge	B-X
of	B-X
COVID-19	B-X
in	B-X
pregnancy	B-X
,	B-X
secondary	B-X
to	B-X
the	B-X
rising	B-X
numbers	B-X
of	B-X
COVID-19	B-X
in	B-X
the	B-X
community	B-X
,	B-X
easing	B-X
of	B-X
societal	B-X
restrictions	B-X
,	B-X
and	B-X
vaccine	B-X
hesitancy	B-X
.	B-X
Although	B-X
COVID-19	B-X
vaccination	B-X
is	B-X
now	B-X
offered	B-X
to	B-X
all	B-X
pregnant	B-X
women	B-X
in	B-X
the	B-X
United	B-X
Kingdom	B-X
;	B-X
limited	B-X
data	B-X
exist	B-X
on	B-X
its	B-X
uptake	B-X
and	B-X
safety	B-X
.	B-X
Data	B-X
about	B-X
the	B-X
safety	B-X
of	B-X
vaccines	B-X
against	B-X
SARS-CoV-2	B-X
during	B-X
pregnancy	B-X
are	B-X
limited	B-X
.	B-X

Deficiency	O
of	O
C	B-Protein
-	I-Protein
C	I-Protein
Chemokine	I-Protein
Receptor	I-Protein
5	I-Protein
Suppresses	O
Tumor	O
DevelopmentviaInactivation	O
of	O
NF	O
-	O
?	O
B	O
and	O
Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
Melanoma	O
Model	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

To	O
evaluate	O
the	O
relevance	O
of	O
C	B-Protein
-	I-Protein
C	I-Protein
chemokine	I-Protein
receptor	I-Protein
type	I-Protein
5	I-Protein
(	O
CCR5	B-Protein
)	O
expression	O
and	O
tumor	O
development	O
,	O
we	O
compared	O
melanoma	O
growth	O
in	O
CCR5	B-Protein
knockout	O
(	O
CCR5	B-Protein
-	O
/	O
-	O
)	O
mice	O
and	O
wild	O
type	O
(	O
CCR5	B-Protein
+	O
/	O
+	O
)	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

CCR5	B-Protein
-	O
/	O
-	O
mice	O
showed	O
reduced	O
tumor	O
volume	O
,	O
tumor	O
weight	O
,	O
and	O
increased	O
survival	O
rate	O
when	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

We	O
investigated	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
since	O
it	O
is	O
an	O
implicated	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
genes	O
involving	O
cell	O
growth	O
,	O
apoptosis	O
,	O
and	O
tumor	O
growth	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor	B-X
kappa-B	B-X
(	B-X
NF-κB	B-X
)	B-X
proteins	B-X
,	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
found	B-X
virtually	B-X
in	B-X
all	B-X
cells	B-X
,	B-X
are	B-X
known	B-X
to	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
a	B-X
number	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
NF-κB	B-X
to	B-X
target	B-X
a	B-X
large	B-X
number	B-X
of	B-X
genes	B-X
that	B-X
regulate	B-X
cell	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
apoptosis	B-X
,	B-X
provides	B-X
clues	B-X
toward	B-X
its	B-X
deregulation	B-X
during	B-X
the	B-X
process	B-X
of	B-X
tumorigenesis	B-X
,	B-X
metastatic	B-X
progression	B-X
,	B-X
and	B-X
therapeutic	B-X
resistance	B-X
of	B-X
tumors	B-X
.	B-X
The	B-X
actin	B-X
crosslinking	B-X
protein	B-X
α-actinin-4	B-X
(	B-X
ACTN4	B-X
)	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
contributor	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
cancer	B-X
.	B-X
This	B-X
has	B-X
largely	B-X
been	B-X
attributed	B-X
to	B-X
its	B-X
role	B-X
in	B-X
regulating	B-X
cytoskeleton	B-X
organization	B-X
and	B-X
its	B-X
involvement	B-X
in	B-X
transcriptional	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
ACTN4	B-X
bound	B-X
to	B-X
RIPK1	B-X
and	B-X
cellular	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
protein	B-X
1	B-X
(	B-X
cIAP1	B-X
)	B-X
with	B-X
its	B-X
actin-binding	B-X
domain	B-X
at	B-X
the	B-X
N-terminus	B-X
and	B-X
the	B-X
CaM-like	B-X
domain	B-X
at	B-X
the	B-X
C-terminus	B-X
,	B-X
respectively	B-X
.	B-X
This	B-X
facilitated	B-X
the	B-X
physical	B-X
association	B-X
between	B-X
RIPK1	B-X
and	B-X
cIAP1	B-X
and	B-X
was	B-X
critical	B-X
for	B-X
stabilization	B-X
of	B-X
RIPK1	B-X
that	B-X
in	B-X
turn	B-X
activated	B-X
NF-κB	B-X
.	B-X
Functional	B-X
investigations	B-X
showed	B-X
that	B-X
silencing	B-X
of	B-X
ACTN4	B-X
suppressed	B-X
melanoma	B-X
cell	B-X
proliferation	B-X
and	B-X
retarded	B-X
melanoma	B-X
xenograft	B-X
growth	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
overexpression	B-X
of	B-X
ACTN4	B-X
promoted	B-X
melanocyte	B-X
and	B-X
melanoma	B-X
cell	B-X
proliferation	B-X
and	B-X
moreover	B-X
,	B-X
prompted	B-X
melanocyte	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
ACTN4	B-X
was	B-X
transcriptionally	B-X
activated	B-X
by	B-X
NF-κB	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
ACTN4	B-X
as	B-X
an	B-X
oncogenic	B-X
regulator	B-X
through	B-X
driving	B-X
a	B-X
feedforward	B-X
signaling	B-X
axis	B-X
of	B-X
ACTN4-RIPK1-NF-κB	B-X
,	B-X
with	B-X
potential	B-X
implications	B-X
for	B-X
targeting	B-X
ACTN4	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
melanoma	B-X
.	B-X

Significant	O
inhibition	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
translocation	O
of	O
p50	B-Protein
and	O
p65	B-Protein
into	O
the	O
nucleus	O
through	O
the	O
inhibition	O
of	O
phosphorylation	O
of	O
IkappaB	O
was	O
found	O
in	O
the	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

NF	O
-	O
kappaB	O
target	O
apoptotic	O
protein	O
expression	O
,	O
such	O
as	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
PARP	O
,	O
and	O
Bax	O
,	O
was	O
elevated	O
,	O
whereas	O
the	O
survival	O
protein	O
expression	O
levels	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
,	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
,	O
was	O
decreased	O
in	O
the	O
melanoma	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

Interestingly	O
,	O
we	O
found	O
that	O
the	O
level	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
a	O
tumor	O
growth	O
suppressive	O
cytokine	O
,	O
was	O
significantly	O
elevated	O
in	O
tumor	O
tissue	O
and	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
the	O
level	O
in	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Moreover	O
,	O
infiltration	O
of	O
CD8	O
+	O
cytotoxic	O
T	O
cell	O
and	O
CD57	O
+	O
natural	O
killer	O
cells	O
was	O
significantly	O
increased	O
in	O
melanoma	O
tumor	O
and	O
spleen	O
tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
that	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

Therefore	O
,	O
these	O
results	O
showed	O
that	O
CCR5	B-Protein
deficiency	O
caused	O
apoptotic	O
cell	O
death	O
of	O
melanoma	O
through	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
and	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

Chemokines	O
are	O
small	O
soluble	O
molecules	O
that	O
are	O
best	O
known	O
for	O
their	O
potent	O
ability	O
to	O
induce	O
cancer	O
cell	O
growth	O
by	O
inflammation	O
.	O

Many	O
types	O
of	O
cancer	O
cells	O
express	O
chemokines	O
and	O
chemokine	O
receptors	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Chemokines	B-X
govern	B-X
leukocyte	B-X
migration	B-X
by	B-X
attracting	B-X
cells	B-X
that	B-X
express	B-X
their	B-X
cognate	B-X
ligands	B-X
.	B-X
Many	B-X
cancer	B-X
types	B-X
show	B-X
altered	B-X
chemokine	B-X
secretion	B-X
profiles	B-X
,	B-X
favoring	B-X
the	B-X
recruitment	B-X
of	B-X
pro-tumorigenic	B-X
immune	B-X
cells	B-X
and	B-X
preventing	B-X
the	B-X
accumulation	B-X
of	B-X
anti-tumorigenic	B-X
effector	B-X
cells	B-X
.	B-X
This	B-X
can	B-X
ultimately	B-X
result	B-X
in	B-X
cancer	B-X
immune	B-X
evasion	B-X
.	B-X
The	B-X
manipulation	B-X
of	B-X
chemokine	B-X
and	B-X
chemokine-receptor	B-X
signaling	B-X
can	B-X
reshape	B-X
the	B-X
immunological	B-X
phenotypes	B-X
within	B-X
the	B-X
tumor	B-X
microenvironment	B-X
in	B-X
order	B-X
to	B-X
increase	B-X
the	B-X
therapeutic	B-X
efficacy	B-X
of	B-X
cancer	B-X
immunotherapy	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
the	B-X
three	B-X
chemokine-chemokine	B-X
receptor	B-X
axes	B-X
,	B-X
CXCR1/2-CXCL1-3/5-8	B-X
,	B-X
CXCR3-CXCL9/10/11	B-X
,	B-X
and	B-X
CXCR4-CXCL12	B-X
and	B-X
their	B-X
role	B-X
on	B-X
pro-tumorigenic	B-X
immune	B-X
cells	B-X
and	B-X
anti-tumorigenic	B-X
effector	B-X
cells	B-X
in	B-X
solid	B-X
tumors	B-X
.	B-X

The	O
accumulated	O
evidence	O
indicates	O
that	O
the	O
chemokine	B-Protein
(	I-Protein
C	I-Protein
-	I-Protein
C	I-Protein
motif	I-Protein
)	I-Protein
ligand	I-Protein
5	I-Protein
(	O
CCL5	B-Protein
)	O
and	O
C	B-Protein
-	I-Protein
C	I-Protein
chemokine	I-Protein
receptor	I-Protein
(	O
CCR5	B-Protein
)	O
,	O
which	O
are	O
potent	O
chemotactic	O
factors	O
for	O
inflammatory	O
cells	O
,	O
may	O
be	O
significantly	O
involved	O
in	O
the	O
proliferation	O
and	O
metastasis	O
of	O
several	O
cancers	O
.	O

Intermediate	O
and	O
strong	O
CCR5	B-Protein
expression	O
is	O
significantly	O
associated	O
with	O
nonmetastatic	O
development	O
of	O
colorectal	O
cancer	O
[	O
2	O
]	O
,	O
melanoma	O
[	O
3	O
]	O
,	O
hepatoma	O
[	O
4	O
]	O
,	O
glioblastoma	O
,	O
Hodgkin	O
lymphoma	O
[	O
5	O
]	O
,	O
as	O
well	O
as	O
oral	O
and	O
prostate	O
cancer	O
cells	O
[	O
6	O
]	O
.	O

Local	O
production	O
of	O
the	O
CCL5	B-Protein
is	O
also	O
important	O
in	O
the	O
progression	O
of	O
breast	O
cancer	O
[	O
7	O
]	O
,	O
and	O
also	O
correlates	O
with	O
poor	O
prognosis	O
[	O
8	O
]	O
.	O

Meanwhile	O
,	O
CCR5	B-Protein
disruption	O
has	O
been	O
demonstrated	O
to	O
inhibit	O
experimental	O
tumor	O
growth	O
and	O
metastasis	O
of	O
pancreatic	O
cancer	O
[	O
9	O
]	O
.	O

In	O
addition	O
,	O
host	O
absence	O
of	O
CCR5	B-Protein
potentiates	O
the	O
delay	O
of	O
tumor	O
growth	O
[	O
10	O
]	O
,	O
and	O
CCR5	B-Protein
inhibitors	O
prevented	O
cancer	O
cell	O
growth	O
,	O
such	O
as	O
prostate	O
cancer	O
[	O
11	O
]	O
,	O
breast	O
cancer	O
,	O
hepatoma	O
cells	O
[	O
4	O
]	O
,	O
and	O
lung	O
cancer	O
[	O
12	O
]	O
.	O

These	O
data	O
suggest	O
that	O
the	O
deficiency	O
of	O
inflammatory	O
chemokine	O
receptor	O
CCR5	B-Protein
may	O
function	O
as	O
a	O
suppressive	O
receptor	O
in	O
cancer	O
progression	O
.	O

However	O
,	O
more	O
studies	O
are	O
required	O
to	O
describe	O
how	O
CCR5	B-Protein
deficiency	O
acts	O
in	O
the	O
inhibition	O
of	O
tumor	O
development	O
.	O

Interleukin	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
(	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
,	O
a	O
member	O
of	O
the	O
IL	O
-	O
1	O
family	O
,	O
is	O
a	O
naturally	O
occurring	O
cytokine	B-Protein
that	O
competitively	O
blocks	O
the	O
IL	O
-	O
1	O
receptor	O
[	O
13	O
]	O
.	O
<EOS>	B-X
IL-1ra	B-X
is	B-X
the	B-X
first	B-X
described	B-X
naturally	B-X
occurring	B-X
receptor	B-X
antagonist	B-X
of	B-X
any	B-X
cytokine	B-X
or	B-X
hormone-like	B-X
molecule	B-X
.	B-X
IL-1ra	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IL-1	B-X
family	B-X
by	B-X
three	B-X
criteria	B-X
:	B-X
amino	B-X
acid	B-X
sequence	B-X
homology	B-X
of	B-X
26	B-X
to	B-X
30	B-X
%	B-X
to	B-X
IL-1	B-X
beta	B-X
and	B-X
19	B-X
%	B-X
to	B-X
IL-1	B-X
alpha	B-X
;	B-X
similarities	B-X
in	B-X
gene	B-X
structure	B-X
;	B-X
and	B-X
common	B-X
gene	B-X
localization	B-X
to	B-X
human	B-X
chromosome	B-X
2q14	B-X
.	B-X
Two	B-X
structural	B-X
variants	B-X
of	B-X
IL-1ra	B-X
exist	B-X
:	B-X
sIL-1ra	B-X
,	B-X
a	B-X
secretory	B-X
molecule	B-X
produced	B-X
by	B-X
monocytes	B-X
,	B-X
macrophages	B-X
,	B-X
neutrophils	B-X
,	B-X
fibroblasts	B-X
,	B-X
and	B-X
other	B-X
cells	B-X
;	B-X
and	B-X
icIL-1ra	B-X
,	B-X
an	B-X
intracellular	B-X
molecule	B-X
produced	B-X
by	B-X
keratinocytes	B-X
and	B-X
other	B-X
epithelial	B-X
cells	B-X
,	B-X
macrophages	B-X
,	B-X
and	B-X
fibroblasts	B-X
.	B-X
IL-1ra	B-X
production	B-X
by	B-X
monocytes	B-X
,	B-X
macrophages	B-X
,	B-X
and	B-X
neutrophils	B-X
may	B-X
be	B-X
regulated	B-X
in	B-X
a	B-X
differential	B-X
fashion	B-X
with	B-X
IL-1	B-X
beta	B-X
.	B-X
Human	B-X
IL-1ra	B-X
binds	B-X
to	B-X
both	B-X
human	B-X
IL-1RIs	B-X
and	B-X
IL-1RIIs	B-X
on	B-X
cell	B-X
surfaces	B-X
,	B-X
although	B-X
with	B-X
100-fold	B-X
greater	B-X
avidity	B-X
to	B-X
IL-1RIs	B-X
.	B-X
IL-1ra	B-X
may	B-X
bind	B-X
preferentially	B-X
to	B-X
soluble	B-X
IL-1RIs	B-X
and	B-X
not	B-X
at	B-X
all	B-X
to	B-X
soluble	B-X
IL-1RIIs	B-X
.	B-X
IL-1ra	B-X
competitively	B-X
inhibits	B-X
binding	B-X
of	B-X
both	B-X
IL-1	B-X
alpha	B-X
and	B-X
IL-1	B-X
beta	B-X
to	B-X
cell	B-X
surface	B-X
receptors	B-X
without	B-X
inducing	B-X
any	B-X
discernible	B-X
intracellular	B-X
responses	B-X
.	B-X
All	B-X
three	B-X
forms	B-X
of	B-X
IL-1	B-X
may	B-X
bind	B-X
to	B-X
IL-1	B-X
receptors	B-X
in	B-X
a	B-X
similar	B-X
fashion	B-X
but	B-X
IL-1ra	B-X
may	B-X
lack	B-X
the	B-X
secondary	B-X
interactions	B-X
necessary	B-X
to	B-X
trigger	B-X
cell	B-X
responses	B-X
.	B-X
A	B-X
100-fold	B-X
or	B-X
greater	B-X
excess	B-X
of	B-X
IL-1ra	B-X
over	B-X
IL-1	B-X
may	B-X
be	B-X
necessary	B-X
to	B-X
inhibit	B-X
biological	B-X
responses	B-X
to	B-X
IL-1	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
roles	B-X
of	B-X
sIL-1ra	B-X
and	B-X
icIL-1ra	B-X
in	B-X
normal	B-X
physiology	B-X
or	B-X
in	B-X
host	B-X
defense	B-X
mechanisms	B-X
remain	B-X
unclear	B-X
.	B-X
The	B-X
administration	B-X
of	B-X
IL-1ra	B-X
blocks	B-X
the	B-X
effects	B-X
of	B-X
IL-1	B-X
in	B-X
some	B-X
animal	B-X
models	B-X
of	B-X
septic	B-X
shock	B-X
,	B-X
inflammatory	B-X
arthritis	B-X
,	B-X
graft-versus-host	B-X
disease	B-X
,	B-X
and	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
.	B-X
The	B-X
preliminary	B-X
results	B-X
of	B-X
clinical	B-X
trials	B-X
in	B-X
humans	B-X
indicate	B-X
possible	B-X
efficacy	B-X
of	B-X
IL-1ra	B-X
in	B-X
sepsis	B-X
syndrome	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
and	B-X
GVHD	B-X
.	B-X

Because	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
has	O
been	O
shown	O
to	O
inhibit	O
tumor	O
progression	O
by	O
promoting	O
antitumor	O
immune	O
responses	O
and	O
by	O
enhancing	O
the	O
activity	O
of	O
chemotherapy	O
,	O
numerous	O
studies	O
have	O
examined	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
block	O
tumor	O
progression	O
.	O

IL	B-Protein
-	I-Protein
1Ra	I-Protein
expression	O
was	O
reduced	O
in	O
prostate	O
[	O
14	O
]	O
,	O
breast	O
[	O
15	O
]	O
,	O
and	O
skin	O
cancer	O
[	O
16	O
]	O
.	O

It	O
was	O
also	O
reported	O
that	O
endogenous	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
deficient	O
mice	O
developed	O
aggressive	O
tumors	O
following	O
exposure	O
to	O
carcinogens	O
[	O
17	O
]	O
.	O

Meanwhile	O
,	O
proliferation	O
of	O
the	O
melanoma	O
cells	O
that	O
were	O
transduced	O
with	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
gene	O
was	O
reduced	O
and	O
inhibited	O
melanoma	O
development	O
[	O
18	O
]	O
.	O

IL	O
-	O
1R	O
blockade	O
also	O
reduced	O
hepatic	O
tumor	O
growth	O
[	O
19	O
]	O
.	O

Moreover	O
,	O
it	O
has	O
also	O
been	O
reported	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
reduces	O
fibrosarcoma	O
development	O
[	O
20	O
]	O
,	O
B16	O
melanoma	O
growth	O
and	O
metastasis	O
[	O
21	O
]	O
,	O
colon	O
adenocarcinoma	O
growth	O
[	O
22	O
]	O
,	O
and	O
skin	O
cancer	O
development	O
[	O
23	O
]	O
.	O

IL	O
-	O
1	O
knockout	O
mice	O
injected	O
with	O
melanoma	O
failed	O
to	O
develop	O
solid	O
tumors	O
[	O
24	O
]	O
.	O

It	O
was	O
also	O
found	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
combined	O
with	O
temozolomide	O
and	O
docetaxel	O
chemotherapy	O
,	O
demonstrated	O
more	O
significant	O
antitumor	O
activity	O
against	O
B16	O
melanoma	O
cells	O
in	O
vivo	O
[	O
25	O
]	O
.	O

These	O
data	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
important	O
as	O
a	O
tumor	O
growth	O
suppressing	O
cytokine	B-Protein
.	O

NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
suppression	O
of	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
induction	O
of	O
cell	O
proliferation	O
and	O
inflammation	O
,	O
and	O
is	O
closely	O
associated	O
with	O
cancer	O
development	O
[	O
26	O
]	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
described	O
in	O
a	O
great	O
number	O
of	O
cancers	O
including	O
colon	O
cancers	O
,	O
prostate	O
cancers	O
and	O
melanoma	O
[	O
27	O
]	O
,	O
and	O
was	O
found	O
to	O
up	O
-	O
regulate	O
anti	O
-	O
apoptotic	O
genes	O
and	O
/	O
or	O
down	O
regulate	O
apoptotic	O
gene	O
expression	O
[	O
28	O
]	O
.	O
<EOS>	B-X
Long	B-X
non-coding	B-X
RNA	B-X
(	B-X
lncRNA	B-X
)	B-X
RMRP	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
glioma	B-X
progression	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
lncRNAs	B-X
and	B-X
mRNAs	B-X
were	B-X
measured	B-X
by	B-X
RT-qPCR	B-X
assay	B-X
.	B-X
Protein	B-X
levels	B-X
of	B-X
genes	B-X
were	B-X
detected	B-X
by	B-X
western	B-X
blot	B-X
and	B-X
immunofluorescence	B-X
assays	B-X
.	B-X
Cell	B-X
apoptotic	B-X
pattern	B-X
was	B-X
estimated	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
RMRP	B-X
reduced	B-X
ZNRF3	B-X
expression	B-X
and	B-X
mRNA	B-X
stability	B-X
by	B-X
IGF2BP3	B-X
.	B-X
RMRP	B-X
knockdown	B-X
inhibited	B-X
β-catenin	B-X
expression	B-X
by	B-X
up-regulating	B-X
ZNRF3	B-X
.	B-X
β-catenin	B-X
promoted	B-X
RMRP	B-X
expression	B-X
by	B-X
TCF4	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
RMRP/ZNRF3	B-X
axis	B-X
and	B-X
Wnt/β-catenin	B-X
signaling	B-X
formed	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
to	B-X
regulate	B-X
TMZ	B-X
resistance	B-X
in	B-X
glioma	B-X
.	B-X
The	B-X
sustained	B-X
activation	B-X
of	B-X
Wnt/β-catenin	B-X
signaling	B-X
by	B-X
RMRP	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
better	B-X
management	B-X
of	B-X
cancers	B-X
.	B-X

Although	O
NF	O
-	O
kappaB	O
promotes	O
tumor	O
growth	O
,	O
it	O
is	O
required	O
for	O
the	O
immune	O
system	O
to	O
function	O
normally	O
[	O
29	O
]	O
.	O
<EOS>	B-X
Ing4	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
growth	B-X
(	B-X
ING	B-X
)	B-X
family	B-X
of	B-X
chromatin-modifying	B-X
proteins	B-X
.	B-X
Biochemical	B-X
experiments	B-X
indicate	B-X
that	B-X
Ing4	B-X
is	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
HB01-JADE-hEAF6	B-X
histone	B-X
acetyltransferase	B-X
complex	B-X
responsible	B-X
for	B-X
most	B-X
nucleosomal	B-X
histone	B-X
H4	B-X
acetylation	B-X
in	B-X
eukaryotes	B-X
,	B-X
and	B-X
transfection	B-X
studies	B-X
suggest	B-X
that	B-X
Ing4	B-X
may	B-X
regulate	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
DNA	B-X
repair	B-X
,	B-X
apoptosis	B-X
,	B-X
cell-cycle	B-X
regulation	B-X
,	B-X
metastasis	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
tumor	B-X
suppression	B-X
.	B-X
However	B-X
,	B-X
in	B-X
vivo	B-X
evidence	B-X
for	B-X
a	B-X
physiological	B-X
role	B-X
for	B-X
Ing4	B-X
in	B-X
cell-growth	B-X
regulation	B-X
is	B-X
lacking	B-X
.	B-X
We	B-X
have	B-X
generated	B-X
Ing4-deficient	B-X
mice	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
Ing4	B-X
in	B-X
development	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
in	B-X
NF-kappaB	B-X
signaling	B-X
.	B-X
Ing4-null	B-X
mice	B-X
develop	B-X
normally	B-X
and	B-X
are	B-X
viable	B-X
.	B-X
Although	B-X
mice	B-X
deficient	B-X
for	B-X
Ing4	B-X
fail	B-X
to	B-X
form	B-X
spontaneous	B-X
tumors	B-X
,	B-X
they	B-X
are	B-X
hypersensitive	B-X
to	B-X
LPS	B-X
treatment	B-X
and	B-X
display	B-X
elevated	B-X
cytokine	B-X
responses	B-X
.	B-X
Macrophages	B-X
isolated	B-X
from	B-X
Ing4-null	B-X
mice	B-X
have	B-X
increased	B-X
levels	B-X
of	B-X
nuclear	B-X
p65/RelA	B-X
protein	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
RelA	B-X
binding	B-X
to	B-X
NF-kappaB	B-X
target	B-X
promoters	B-X
and	B-X
up-regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
.	B-X
However	B-X
,	B-X
increased	B-X
promoter	B-X
occupancy	B-X
by	B-X
RelA	B-X
in	B-X
LPS-stimulated	B-X
,	B-X
Ing4-null	B-X
cells	B-X
does	B-X
not	B-X
always	B-X
correlate	B-X
with	B-X
increased	B-X
NF-kappaB	B-X
target-gene	B-X
expression	B-X
,	B-X
as	B-X
RelA	B-X
activation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
cytokine	B-X
promoters	B-X
also	B-X
requires	B-X
Ing4	B-X
for	B-X
proper	B-X
histone	B-X
H4	B-X
acetylation	B-X
.	B-X
Furthermore	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
IkappaB	B-X
alpha	B-X
promoter	B-X
by	B-X
RelA	B-X
is	B-X
also	B-X
Ing4-dependent	B-X
,	B-X
and	B-X
LPS-stimulated	B-X
,	B-X
Ing4-null	B-X
cells	B-X
have	B-X
reduced	B-X
levels	B-X
of	B-X
IkappaB	B-X
alpha	B-X
promoter	B-X
H4	B-X
acetylation	B-X
and	B-X
IkappaB	B-X
gene	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
Ing4	B-X
negatively	B-X
regulates	B-X
the	B-X
cytokine-mediated	B-X
inflammatory	B-X
response	B-X
in	B-X
mice	B-X
by	B-X
facilitating	B-X
NF-kappaB	B-X
activation	B-X
of	B-X
IkappaB	B-X
promoters	B-X
,	B-X
thereby	B-X
suppressing	B-X
nuclear	B-X
RelA	B-X
levels	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
select	B-X
NF-kappaB	B-X
target	B-X
cytokines	B-X
.	B-X

Studies	O
on	O
c	B-Protein
-	I-Protein
Rel	I-Protein
-	O
deficient	O
mice	O
demonstrated	O
that	O
c	B-Protein
-	I-Protein
Rel	I-Protein
is	O
essential	O
for	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
3	I-Protein
,	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
and	O
IFNgamma	O
expression	O
in	O
T	O
lymphocytes	O
[	O
30	O
]	O
.	O

C	O
-	O
Rel	O
-	O
deficient	O
mice	O
also	O
have	O
a	O
tissue	O
-	O
specific	O
deficiency	O
of	O
various	O
cytokines	O
and	O
growth	O
factors	O
in	O
T	O
cells	O
and	O
macrophages	O
affecting	O
both	O
innate	O
and	O
humoral	O
immune	O
responses	O
in	O
the	O
host	O
[	O
31	O
]	O
.	O

Therefore	O
,	O
NF	O
-	O
kappaB	O
can	O
be	O
specially	O
targeted	O
to	O
prevent	O
cancer	O
cell	O
growth	O
by	O
(	O
1	O
)	O
directly	O
affecting	O
apoptotic	O
cancer	O
cell	O
death	O
,	O
(	O
2	O
)	O
stimulating	O
tumor	O
killing	O
lymphocytes	O
infiltration	O
or	O
(	O
3	O
)	O
increasing	O
the	O
production	O
of	O
tumor	O
killing	O
lymphokines	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
is	O
important	O
in	O
the	O
regulation	O
of	O
CCR	O
-	O
mediated	O
tumor	O
growth	O
and	O
metastasis	O
.	O

It	O
was	O
reported	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
by	O
dehydroxymethyl	O
-	O
epoxyquinomicin	O
(	O
DHMEQ	O
)	O
induces	O
cell	O
death	O
of	O
primary	O
effusion	O
lymphoma	O
by	O
inhibition	O
of	O
CCR5	B-Protein
expression	O
[	O
32	O
]	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
also	O
increases	O
CCL5	B-Protein
-	O
mediated	O
oral	O
cancer	O
motility	O
(	O
5	O
)	O
and	O
lung	O
metastasis	O
[	O
33	O
]	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
could	O
be	O
involved	O
in	O
CCR5	B-Protein
mediated	O
tumor	O
development	O
.	O

NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoter	O
region	O
of	O
proinflammatory	O
cytokine	O
genes	O
,	O
such	O
as	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
and	O
KC	B-Protein
[	O
34	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
a	O
negative	O
regulator	O
of	O
the	O
inflammatory	O
response	O
.	O

Several	O
studies	O
have	O
demonstrated	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
abrogate	O
the	O
proinflammatory	O
effects	O
of	O
IL	O
-	O
1	O
.	O
<EOS>	B-X
Adiponectin	B-X
is	B-X
an	B-X
adipokine	B-X
that	B-X
exerts	B-X
anti-inflammatory	B-X
and	B-X
anti-atherogenic	B-X
effects	B-X
during	B-X
macrophage	B-X
transformation	B-X
into	B-X
foam	B-X
cells	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
the	B-X
signaling	B-X
pathways	B-X
of	B-X
adiponectin	B-X
involved	B-X
in	B-X
macrophage	B-X
foam	B-X
cell	B-X
transformation	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
roles	B-X
of	B-X
two	B-X
adiponectin	B-X
receptors	B-X
(	B-X
AdipoR1	B-X
and	B-X
AdipoR2	B-X
)	B-X
and	B-X
their	B-X
downstream	B-X
adaptor	B-X
protein	B-X
,	B-X
phosphotyrosine	B-X
interaction	B-X
,	B-X
PH	B-X
domain	B-X
and	B-X
leucine	B-X
zipper	B-X
containing	B-X
1	B-X
(	B-X
APPL1	B-X
)	B-X
in	B-X
mediating	B-X
adiponectin	B-X
action	B-X
on	B-X
foam	B-X
cell	B-X
transformation	B-X
.	B-X

Smith	O
et	O
al	O
.	O
suggested	O
that	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
gene	O
expression	O
is	O
a	O
complex	O
event	O
involving	O
the	O
interactions	O
of	O
three	O
different	O
transcription	O
factors	O
;	O
NF	O
-	O
kappaB	O
/	O
PU	B-Protein
.	I-Protein
1	I-Protein
/	O
GA	O
-	O
binding	O
protein	O
binding	O
site	O
[	O
35	O
]	O
.	O

Nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p65	B-Protein
)	O
was	O
significantly	O
enhanced	O
and	O
prolonged	O
in	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
-	O
deficient	O
mice	O
,	O
compared	O
to	O
that	O
in	O
wild	O
type	O
mice	O
[	O
36	O
]	O
.	O
<EOS>	B-X
Although	B-X
enhanced	B-X
expression	B-X
of	B-X
IL-1	B-X
family	B-X
proteins	B-X
,	B-X
including	B-X
IL-1alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
and	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
IL-1ra	B-X
)	B-X
during	B-X
wound	B-X
healing	B-X
has	B-X
been	B-X
observed	B-X
,	B-X
the	B-X
pathophysiological	B-X
roles	B-X
of	B-X
these	B-X
factors	B-X
,	B-X
particularly	B-X
IL-1ra	B-X
,	B-X
still	B-X
remain	B-X
elusive	B-X
.	B-X
We	B-X
explored	B-X
skin	B-X
wound-healing	B-X
processes	B-X
in	B-X
IL-1ra-deficient	B-X
mice	B-X
.	B-X
Compared	B-X
to	B-X
wild-type	B-X
(	B-X
WT	B-X
)	B-X
mice	B-X
,	B-X
IL-1ra-deficient	B-X
mice	B-X
exhibited	B-X
impaired	B-X
wound	B-X
healing	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
attenuated	B-X
collagen	B-X
deposition	B-X
and	B-X
delayed	B-X
neovascularization	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neutrophil	B-X
recruitment	B-X
was	B-X
significantly	B-X
exaggerated	B-X
,	B-X
with	B-X
the	B-X
augmented	B-X
expression	B-X
of	B-X
IL-1s	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
CXC	B-X
chemokines	B-X
,	B-X
MIP-2	B-X
and	B-X
KC	B-X
,	B-X
in	B-X
IL-1ra-deficient	B-X
mice	B-X
compared	B-X
with	B-X
WT	B-X
mice	B-X
.	B-X
Because	B-X
the	B-X
transcription	B-X
of	B-X
these	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
CXC	B-X
chemokines	B-X
requires	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
a	B-X
major	B-X
target	B-X
of	B-X
IL-1-	B-X
and	B-X
TNF-alpha-mediated	B-X
signal	B-X
pathway	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
activation	B-X
states	B-X
of	B-X
NF-kappaB	B-X
.	B-X
Nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
was	B-X
significantly	B-X
enhanced	B-X
and	B-X
prolonged	B-X
in	B-X
IL-1ra-deficient	B-X
mice	B-X
,	B-X
compared	B-X
to	B-X
that	B-X
in	B-X
WT	B-X
mice	B-X
.	B-X
The	B-X
cross-talk	B-X
between	B-X
NF-kappaB	B-X
and	B-X
TGF-beta-mediated	B-X
signals	B-X
has	B-X
been	B-X
proposed	B-X
based	B-X
on	B-X
in	B-X
vitro	B-X
observations	B-X
.	B-X
Indeed	B-X
,	B-X
compared	B-X
to	B-X
WT	B-X
mice	B-X
,	B-X
the	B-X
amounts	B-X
of	B-X
total	B-X
and	B-X
phosphorylated	B-X
Smad2	B-X
and	B-X
Smad3	B-X
were	B-X
decreased	B-X
with	B-X
a	B-X
reciprocal	B-X
increase	B-X
in	B-X
the	B-X
amount	B-X
of	B-X
Smad7	B-X
in	B-X
skin	B-X
wound	B-X
sites	B-X
of	B-X
IL-1ra-deficient	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
gene	B-X
expression	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
,	B-X
a	B-X
target	B-X
gene	B-X
of	B-X
TGF-beta1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
IL-1ra-deficient	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
IL-1ra	B-X
may	B-X
suppress	B-X
TGF-beta-mediated	B-X
signaling	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
crucial	B-X
for	B-X
collagen	B-X
deposition	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor-mediated	B-X
neovascularization	B-X
in	B-X
wound	B-X
healing	B-X
.	B-X

Intracellular	B-Protein
IL	I-Protein
-	I-Protein
1Ra	I-Protein
(	O
icIL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
was	O
found	O
to	O
inhibit	O
IL	O
-	O
1	O
by	O
blocking	O
NF	O
-	O
kappaB	O
signal	O
transduction	O
pathways	O
in	O
inflammatory	O
responses	O
[	O
37	O
]	O
.	O

Because	O
IL	O
-	O
1	O
has	O
been	O
shown	O
to	O
be	O
an	O
inducer	O
of	O
NF	O
-	O
kappaB	O
activation	O
[	O
38	O
]	O
,	O
we	O
hypothesized	O
that	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
play	O
an	O
important	O
role	O
in	O
the	O
autocrine	O
activation	O
of	O
transcription	O
factors	O
NF	O
-	O
kappaB	O
or	O
vice	O
versa	O
.	O
<EOS>	B-X
2015	B-X
;	B-X
90	B-X
(	B-X
3	B-X
Suppl	B-X
1	B-X
)	B-X
:	B-X
S235-8	B-X
.	B-X
Image	B-X
2	B-X
was	B-X
switched	B-X
for	B-X
image	B-X
3	B-X
and	B-X
vice-versa	B-X
.	B-X
They	B-X
share	B-X
similar	B-X
trigger	B-X
factors	B-X
and	B-X
have	B-X
been	B-X
observed	B-X
to	B-X
coexist	B-X
in	B-X
individuals	B-X
.	B-X
In	B-X
this	B-X
research	B-X
article	B-X
,	B-X
the	B-X
absorption	B-X
data	B-X
for	B-X
10	B-X
medications	B-X
that	B-X
can	B-X
be	B-X
used	B-X
as	B-X
an	B-X
oral	B-X
medication	B-X
or	B-X
a	B-X
transdermal	B-X
patch	B-X
were	B-X
compiled	B-X
,	B-X
and	B-X
from	B-X
the	B-X
collected	B-X
data	B-X
,	B-X
the	B-X
interindividual	B-X
variance	B-X
was	B-X
calculated	B-X
for	B-X
topical	B-X
and	B-X
oral	B-X
absorption	B-X
as	B-X
an	B-X
overall	B-X
average	B-X
and	B-X
by	B-X
drug	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
there	B-X
is	B-X
considerable	B-X
interindividual	B-X
variation	B-X
in	B-X
topical	B-X
and	B-X
oral	B-X
absorption	B-X
for	B-X
the	B-X
10	B-X
medications	B-X
investigated	B-X
.	B-X
Yet	B-X
,	B-X
surprisingly	B-X
,	B-X
the	B-X
calculated	B-X
overall	B-X
mean	B-X
and	B-X
median	B-X
coefficient	B-X
of	B-X
variation	B-X
(	B-X
CV	B-X
)	B-X
for	B-X
topical	B-X
and	B-X
oral	B-X
absorption	B-X
were	B-X
comparable	B-X
(	B-X
within	B-X
10	B-X
%	B-X
of	B-X
each	B-X
other	B-X
)	B-X
.	B-X
In	B-X
a	B-X
drug-by-drug	B-X
comparison	B-X
,	B-X
certain	B-X
medications	B-X
demonstrated	B-X
considerably	B-X
more	B-X
variation	B-X
when	B-X
absorbed	B-X
orally	B-X
versus	B-X
topically	B-X
and	B-X
vice	B-X
versa	B-X
.	B-X
It	B-X
is	B-X
unclear	B-X
why	B-X
certain	B-X
drugs	B-X
had	B-X
less	B-X
variation	B-X
in	B-X
absorption	B-X
when	B-X
delivered	B-X
topically	B-X
versus	B-X
orally	B-X
(	B-X
or	B-X
vice	B-X
versa	B-X
)	B-X
.	B-X
However	B-X
,	B-X
patterns	B-X
in	B-X
drug	B-X
molecular	B-X
weight	B-X
(	B-X
MW	B-X
)	B-X
or	B-X
octanol	B-X
partition	B-X
coefficient	B-X
(	B-X
log	B-X
K	B-X
(	B-X
OCT	B-X
)	B-X
)	B-X
could	B-X
not	B-X
totally	B-X
explain	B-X
these	B-X
findings	B-X
.	B-X
In	B-X
our	B-X
analysis	B-X
,	B-X
the	B-X
previously	B-X
reported	B-X
correlation	B-X
between	B-X
MW	B-X
or	B-X
log	B-X
K	B-X
(	B-X
OCT	B-X
)	B-X
and	B-X
interindividual	B-X
variation	B-X
in	B-X
absorption	B-X
could	B-X
only	B-X
be	B-X
replicated	B-X
when	B-X
plotting	B-X
the	B-X
topical	B-X
absorption	B-X
CV	B-X
and	B-X
MW	B-X
.	B-X
What	B-X
became	B-X
clear	B-X
from	B-X
our	B-X
analysis	B-X
is	B-X
that	B-X
the	B-X
drug	B-X
itself	B-X
is	B-X
an	B-X
important	B-X
variable	B-X
when	B-X
considering	B-X
which	B-X
route	B-X
of	B-X
delivery	B-X
(	B-X
oral	B-X
or	B-X
topical	B-X
)	B-X
will	B-X
provide	B-X
the	B-X
least	B-X
amount	B-X
of	B-X
interindividual	B-X
variation	B-X
.	B-X

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
roles	O
of	O
NF	O
-	O
kappaB	O
and	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
chemokine	B-Protein
receptor	I-Protein
CCR5	B-Protein
-	O
mediated	O
suppression	O
of	O
tumor	O
development	O
.	O

Inhibition	O
of	O
Tumor	O
Development	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
mechanisms	B-X
of	B-X
CCR5	B-X
upregulation	B-X
and	B-X
increased	B-X
immunosuppressive	B-X
function	B-X
of	B-X
CCR5	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
CCR2	B-X
and	B-X
CCR5	B-X
were	B-X
induced	B-X
in	B-X
PDAC	B-X
following	B-X
treatment	B-X
with	B-X
anti-PD-1	B-X
antibody	B-X
(	B-X
αPD-1	B-X
)	B-X
;	B-X
thus	B-X
,	B-X
we	B-X
examined	B-X
PDAC	B-X
vaccine	B-X
or	B-X
radiation	B-X
therapy	B-X
(	B-X
RT	B-X
)	B-X
as	B-X
T	B-X
cell	B-X
priming	B-X
mechanisms	B-X
together	B-X
with	B-X
BMS-687681	B-X
,	B-X
a	B-X
dual	B-X
antagonist	B-X
of	B-X
CCR2	B-X
and	B-X
CCR5	B-X
(	B-X
CCR2/5i	B-X
)	B-X
,	B-X
in	B-X
combination	B-X
with	B-X
αPD-1	B-X
as	B-X
new	B-X
treatment	B-X
strategies	B-X
.	B-X
Hepatic	B-X
stellate	B-X
cells	B-X
(	B-X
HSC	B-X
)	B-X
seem	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
fibrogenic	B-X
response	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
an	B-X
autocrine	B-X
loop	B-X
involving	B-X
the	B-X
chemokine	B-X
receptor	B-X
,	B-X
CCR5	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
CCR5	B-X
in	B-X
HCC	B-X
remains	B-X
poorly	B-X
understood	B-X
.	B-X
Since	B-X
this	B-X
receptor	B-X
is	B-X
also	B-X
one	B-X
of	B-X
the	B-X
main	B-X
ports	B-X
of	B-X
entry	B-X
for	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
,	B-X
several	B-X
CCR5	B-X
inhibitors	B-X
are	B-X
being	B-X
used	B-X
in	B-X
the	B-X
clinic	B-X
to	B-X
reduce	B-X
viral	B-X
load	B-X
.	B-X
Clinical	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
demonstrate	B-X
the	B-X
efficacy	B-X
of	B-X
this	B-X
drug	B-X
,	B-X
or	B-X
other	B-X
CCR5	B-X
inhibitors	B-X
,	B-X
in	B-X
patients	B-X
with	B-X
high	B-X
risk	B-X
of	B-X
developing	B-X
HCC	B-X
.	B-X

The	O
effect	O
of	O
CCR5	B-Protein
in	O
tumor	O
development	O
was	O
investigated	O
using	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
Papillomavirus-like	B-X
particle	B-X
(	B-X
VLP	B-X
)	B-X
-based	B-X
subunit	B-X
vaccines	B-X
have	B-X
undergone	B-X
rapid	B-X
development	B-X
over	B-X
the	B-X
past	B-X
8	B-X
years	B-X
.	B-X
Three	B-X
types	B-X
are	B-X
being	B-X
investigated	B-X
.	B-X
Preliminary	B-X
results	B-X
have	B-X
been	B-X
encouraging	B-X
in	B-X
that	B-X
systemic	B-X
immunization	B-X
with	B-X
the	B-X
L1	B-X
VLPs	B-X
induced	B-X
high	B-X
serum	B-X
titers	B-X
of	B-X
neutralizing	B-X
antibodies	B-X
without	B-X
substantial	B-X
adverse	B-X
effects	B-X
.	B-X
Studies	B-X
in	B-X
mice	B-X
indicate	B-X
that	B-X
these	B-X
vaccines	B-X
generate	B-X
potent	B-X
antitumor	B-X
cytotoxic	B-X
lymphocyte	B-X
(	B-X
CTL	B-X
)	B-X
responses	B-X
while	B-X
retaining	B-X
the	B-X
ability	B-X
to	B-X
induce	B-X
high-titer	B-X
neutralizing	B-X
antibodies	B-X
.	B-X
In	B-X
a	B-X
recent	B-X
proof	B-X
of	B-X
concept	B-X
study	B-X
,	B-X
a	B-X
peptide	B-X
from	B-X
an	B-X
external	B-X
loop	B-X
of	B-X
mouse	B-X
CCR5	B-X
protein	B-X
was	B-X
inserted	B-X
into	B-X
a	B-X
neutralizing	B-X
epitope	B-X
of	B-X
L1	B-X
.	B-X
In	B-X
mice	B-X
,	B-X
the	B-X
particles	B-X
generated	B-X
by	B-X
this	B-X
chimeric	B-X
L1	B-X
were	B-X
able	B-X
to	B-X
induce	B-X
high	B-X
titers	B-X
of	B-X
CCR5	B-X
antibodies	B-X
that	B-X
specifically	B-X
recognized	B-X
the	B-X
surface	B-X
of	B-X
CCR5-transfected	B-X
cells	B-X
and	B-X
blocked	B-X
in	B-X
vitro	B-X
infection	B-X
of	B-X
an	B-X
M-tropic	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
strain	B-X
.	B-X

B16	O
-	O
F0	O
melanoma	O
cells	O
were	O
inoculated	O
subcutaneously	O
into	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
.	O

Tumor	O
growth	O
was	O
monitored	O
for	O
31	O
days	O
.	O
<EOS>	B-X
To	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
FGFR	B-X
)	B-X
gene	B-X
alterations	B-X
and	B-X
the	B-X
pharmacology	B-X
,	B-X
clinical	B-X
effectiveness	B-X
,	B-X
dosage	B-X
and	B-X
administration	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
place	B-X
in	B-X
therapy	B-X
of	B-X
erdafitinib	B-X
in	B-X
bladder	B-X
cancer	B-X
.	B-X
Although	B-X
the	B-X
MCS	B-X
contained	B-X
a	B-X
lower	B-X
percentage	B-X
(	B-X
~32.5	B-X
%	B-X
)	B-X
of	B-X
pores	B-X
suitable	B-X
for	B-X
cell	B-X
ingrowth	B-X
(	B-X
113-357	B-X
μm	B-X
in	B-X
diameter	B-X
)	B-X
than	B-X
the	B-X
UCS	B-X
(	B-X
~70	B-X
%	B-X
)	B-X
,	B-X
the	B-X
number	B-X
of	B-X
human-osteoblast-like	B-X
MG-63	B-X
cells	B-X
on	B-X
days	B-X
1	B-X
,	B-X
3	B-X
and	B-X
7	B-X
after	B-X
seeding	B-X
was	B-X
higher	B-X
on	B-X
MCS	B-X
than	B-X
on	B-X
UCS	B-X
,	B-X
and	B-X
the	B-X
cells	B-X
penetrated	B-X
deeper	B-X
into	B-X
the	B-X
MCS	B-X
.	B-X
The	B-X
cell	B-X
growth	B-X
in	B-X
extracts	B-X
prepared	B-X
by	B-X
eluting	B-X
the	B-X
scaffolds	B-X
for	B-X
7	B-X
days	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
medium	B-X
was	B-X
also	B-X
markedly	B-X
higher	B-X
in	B-X
the	B-X
MCS	B-X
extracts	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
real-time	B-X
monitoring	B-X
in	B-X
the	B-X
sensory	B-X
xCELLigence	B-X
system	B-X
for	B-X
7	B-X
days	B-X
.	B-X
Tumor	B-X
protease-activated	B-X
theranostic	B-X
nanoparticles	B-X
for	B-X
MRI-guided	B-X
glioblastoma	B-X
therapy	B-X
.	B-X

Tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
CCL3	B-X
might	B-X
stimulate	B-X
cancer	B-X
progression	B-X
by	B-X
promoting	B-X
leukocyte	B-X
accumulation	B-X
,	B-X
angiogenesis	B-X
and	B-X
tumour	B-X
growth	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
CCL3	B-X
and	B-X
its	B-X
receptors	B-X
CCR1	B-X
and	B-X
CCR5	B-X
was	B-X
demonstrated	B-X
in	B-X
oral	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
OSCC	B-X
)	B-X
,	B-X
but	B-X
their	B-X
role	B-X
was	B-X
not	B-X
defined	B-X
.	B-X
We	B-X
detected	B-X
a	B-X
strong	B-X
WWP2	B-X
expression	B-X
in	B-X
tumor	B-X
tissues	B-X
of	B-X
the	B-X
People	B-X
's	B-X
Hospital	B-X
of	B-X
Lishui	B-X
,	B-X
and	B-X
the	B-X
survival	B-X
rate	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
patients	B-X
with	B-X
lower	B-X
WWP2-expressing	B-X
tumors	B-X
.	B-X
WWP2	B-X
small	B-X
hairpin	B-X
RNA	B-X
(	B-X
shRNA	B-X
)	B-X
lentivirus	B-X
stably	B-X
infected	B-X
cells	B-X
(	B-X
shWWP2	B-X
)	B-X
,	B-X
Huh7	B-X
,	B-X
showed	B-X
slower	B-X
growth	B-X
speed	B-X
compared	B-X
with	B-X
scramble	B-X
control-infected	B-X
cells	B-X
in	B-X
a	B-X
xenograft	B-X
mouse	B-X
model	B-X
.	B-X
WWP2	B-X
also	B-X
regulated	B-X
MMP-9	B-X
,	B-X
caspase-9	B-X
,	B-X
CXCR3	B-X
,	B-X
and	B-X
CCR5	B-X
expression	B-X
in	B-X
liver	B-X
cancer	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
knockdown	B-X
of	B-X
CXCR3	B-X
and	B-X
CCR5	B-X
significantly	B-X
inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
adhesion	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
migration	B-X
in	B-X
Huh7	B-X
and	B-X
BEL-7404	B-X
cells	B-X
.	B-X

The	O
tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
reduced	O
to	O
19	O
.	O
1	O
%	O
,	O
whereas	O
the	O
tumor	O
growth	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
was	O
only	O
reduced	O
to	O
24	O
.	O
3	O
%	O
,	O
in	O
both	O
tumor	O
weight	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
and	O
tumor	O
volume	O
,	O
respectively	O
(	O
Figure	O
1A	O
and	O
1C	O
)	O
.	O

These	O
results	O
correlated	O
with	O
mice	O
survival	O
rates	O
.	O
<EOS>	B-X
Hypoxia-induced	B-X
lncRNA-AC020978	B-X
promotes	B-X
proliferation	B-X
and	B-X
glycolytic	B-X
metabolism	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
by	B-X
regulating	B-X
PKM2/HIF-1α	B-X
axis	B-X
.	B-X
Cancer-associated	B-X
fibroblasts	B-X
(	B-X
CAFs	B-X
)	B-X
are	B-X
tumor-promoting	B-X
and	B-X
correlate	B-X
with	B-X
poor	B-X
survival	B-X
in	B-X
many	B-X
cancers	B-X
,	B-X
which	B-X
has	B-X
led	B-X
to	B-X
their	B-X
emergence	B-X
as	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X
CD47	B-X
expression	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
progression-free	B-X
survival	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
macrophage	B-X
infiltration	B-X
in	B-X
ovarian	B-X
cancer	B-X
tissues	B-X
.	B-X
Long	B-X
non-coding	B-X
RNA	B-X
H19	B-X
was	B-X
demonstrated	B-X
to	B-X
be	B-X
significantly	B-X
correlated	B-X
with	B-X
tumor	B-X
metastasis	B-X
.	B-X

There	O
was	O
a	O
significant	O
difference	O
in	O
survival	O
rates	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
75	O
%	O
of	O
starting	O
time	O
)	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
15	O
%	O
)	O
at	O
the	O
end	O
of	O
the	O
experiment	O
(	O
Figure	O
1D	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
survival	O
rates	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
75	O
%	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
survived	O
while	O
only	O
15	O
%	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
survived	O
.	O

Subcutaneous	O
tumors	O
were	O
harvested	O
from	O
the	O
sacrificed	O
mice	O
31	O
days	O
after	O
inoculation	O
.	O

The	O
immunohistochemical	O
analysis	O
of	O
tumor	O
sections	O
,	O
stained	O
with	O
H	O
&	O
E	O
and	O
for	O
proliferation	O
antigen	O
PCNA	O
,	O
revealed	O
greater	O
inhibition	O
of	O
tumor	O
cell	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

The	O
histologic	O
findings	O
after	O
H	O
&	O
E	O
staining	O
indicated	O
that	O
the	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
but	O
not	O
those	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
,	O
contained	O
large	O
areas	O
of	O
necrosis	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
evidence	B-X
that	B-X
Helicobacter	B-X
pylori	B-X
eradication	B-X
reduces	B-X
the	B-X
development	B-X
of	B-X
gastric	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
such	B-X
as	B-X
peptic	B-X
ulcer	B-X
,	B-X
eradication	B-X
therapy	B-X
has	B-X
prevailed	B-X
.	B-X
However	B-X
,	B-X
gastric	B-X
cancer	B-X
can	B-X
develop	B-X
even	B-X
after	B-X
successful	B-X
eradication	B-X
.	B-X
Despite	B-X
the	B-X
large	B-X
number	B-X
of	B-X
gastric	B-X
bypasses	B-X
performed	B-X
for	B-X
morbid	B-X
obesity	B-X
,	B-X
very	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
endoscopic	B-X
and	B-X
histologic	B-X
aspects	B-X
of	B-X
the	B-X
gastric	B-X
pouch	B-X
and	B-X
the	B-X
Roux-limb	B-X
late	B-X
after	B-X
surgery	B-X
.	B-X
We	B-X
performed	B-X
prospective	B-X
routine	B-X
endoscopic	B-X
and	B-X
histologic	B-X
studies	B-X
of	B-X
the	B-X
pouch	B-X
and	B-X
Roux-limb	B-X
2	B-X
years	B-X
after	B-X
gastric	B-X
bypass	B-X
.	B-X

PCNA	O
reactive	O
cells	O
were	O
significantly	O
reduced	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
1E	O
)	O
.	O

Decrease	O
of	O
NF	O
-	O
kappaB	O
Activity	O
in	O
Tumor	O
Tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
plays	O
a	O
critical	O
role	O
in	O
cancer	O
cell	O
survival	O
,	O
especially	O
melanoma	O
cancer	O
cells	O
and	O
in	O
CCR5	B-Protein
expression	O
.	O

To	O
evaluate	O
whether	O
the	O
tumor	O
inhibition	O
was	O
related	O
with	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
melanoma	O
,	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
determined	O
by	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
in	O
melanoma	O
tissue	O
.	O

The	O
constitutively	O
activated	O
DNA	O
binding	O
activity	O
was	O
reduced	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tumor	O
tissue	O
(	O
Figure	O
2A	O
)	O
.	O

Moreover	O
,	O
the	O
translocation	O
of	O
p50	B-Protein
and	O
p	O
-	O
p65	B-Protein
into	O
the	O
nucleus	O
through	O
the	O
inhibition	O
of	O
phosphorylation	O
of	O
IkappaB	O
was	O
also	O
prevented	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
2B	O
)	O
.	O

Immunofluorescence	O
analysis	O
also	O
confirmed	O
that	O
the	O
intensity	O
of	O
nuclear	O
staining	O
for	O
p50	B-Protein
had	O
decreased	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
2C	O
)	O
.	O

Induction	O
of	O
Apoptotic	O
Cell	O
Death	O
and	O
Inhibition	O
of	O
the	O
Expression	O
of	O
Anti	O
-	O
apoptotic	O
Proteins	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

To	O
see	O
whether	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
results	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
and	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
apoptotic	O
cell	O
death	O
regulatory	O
protein	O
,	O
the	O
levels	O
of	O
apoptotic	O
cell	O
death	O
and	O
expression	O
of	O
apoptotic	O
cell	O
death	O
regulatory	O
proteins	O
were	O
assessed	O
.	O

Apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
sections	O
were	O
evaluated	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
that	O
were	O
inoculated	O
with	O
melanoma	O
cells	O
.	O

TUNEL	O
staining	O
revealed	O
a	O
higher	O
frequency	O
of	O
apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
that	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
3A	O
)	O
.	O

Immunohistochemical	O
and	O
immunofluorescence	O
showed	O
that	O
high	O
levels	O
of	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
were	O
found	O
more	O
frequently	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
3B	O
and	O
3C	O
)	O
.	O

Consistent	O
with	O
the	O
immunohistochemical	O
data	O
,	O
Western	O
blot	O
analysis	O
of	O
tumor	O
proteins	O
showed	O
greater	O
increased	O
levels	O
of	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
caspase	O
-	O
9	O
,	O
cleaved	O
PARP	O
and	O
Bax	O
,	O
whereas	O
the	O
levels	O
of	O
Bcl	O
-	O
2	O
and	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
were	O
significantly	O
decreased	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tissues	O
(	O
Figure	O
3D	O
)	O
.	O

Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
Tumor	O
and	O
Spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

To	O
investigate	O
the	O
difference	O
in	O
the	O
cytokine	O
levels	O
between	O
the	O
tumor	O
and	O
spleen	O
tissues	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
we	O
conducted	O
a	O
cytokine	O
array	O
assay	O
using	O
a	O
Mouse	O
Proteome	O
Array	O
(	O
Figure	O
4A	O
)	O
.	O

Among	O
40	O
tested	O
cytokines	O
,	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
MIG	B-Protein
,	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
increased	O
about	O
686	O
,	O
9	O
and	O
25	O
-	O
fold	O
respectively	O
,	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Using	O
this	O
technique	O
,	O
no	O
other	O
cytokines	O
were	O
found	O
to	O
be	O
different	O
between	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
4B	O
)	O
.	O

Similar	O
altered	O
cytokine	O
levels	O
were	O
found	O
in	O
the	O
spleens	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
4C	O
)	O
.	O

Since	O
the	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
level	O
was	O
the	O
most	O
significantly	O
elevated	O
,	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumor	O
and	O
spleen	O
tissues	O
was	O
analyzed	O
by	O
immunofluorescence	O
and	O
western	O
blotting	O
.	O

The	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
was	O
upregulated	O
in	O
tumor	O
and	O
spleen	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
Figure	O
4D	O
-	O
G	O
)	O
.	O

Induction	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
Cell	O
Infiltration	O
into	O
Tumor	O
and	O
Spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
Mice	O

To	O
investigate	O
whether	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
is	O
related	O
to	O
tumor	O
-	O
specific	O
immune	O
responses	O
,	O
we	O
analyzed	O
the	O
distribution	O
patterns	O
of	O
CD8	O
+	O
cytotoxic	O
T	O
cell	O
and	O
CD57	O
+	O
Natural	O
Killer	O
cells	O
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

By	O
staining	O
the	O
tumor	O
sections	O
from	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
we	O
found	O
that	O
there	O
was	O
a	O
significant	O
influx	O
of	O
CD8	O
+	O
cells	O
into	O
the	O
tumor	O
,	O
as	O
well	O
as	O
an	O
increase	O
in	O
the	O
number	O
of	O
infiltrating	O
NK	O
cells	O
(	O
Figure	O
5A	O
)	O
.	O

CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
were	O
spread	O
diffusely	O
throughout	O
the	O
entire	O
sections	O
.	O

To	O
further	O
investigate	O
the	O
differences	O
in	O
the	O
numbers	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
between	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
in	O
immunity	O
-	O
related	O
organ	O
,	O
we	O
also	O
analyzed	O
the	O
CD8	O
and	O
CD57	O
reactive	O
cell	O
number	O
in	O
spleen	O
tissues	O
.	O

The	O
number	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
CD57	O
+	O
NK	O
cells	O
were	O
higher	O
in	O
the	O
spleen	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
than	O
in	O
the	O
spleen	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5B	O
)	O
.	O

These	O
data	O
suggest	O
that	O
by	O
promoting	O
the	O
infiltration	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
cells	O
,	O
which	O
are	O
potent	O
cytotoxic	O
effectors	O
for	O
tumors	O
,	O
could	O
play	O
a	O
role	O
in	O
an	O
anti	O
-	O
tumor	O
effect	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

To	O
analyze	O
the	O
cell	O
phenotype	O
change	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
by	O
inoculation	O
of	O
the	O
melanoma	O
cell	O
,	O
lymphocytes	O
were	O
isolated	O
from	O
the	O
tumor	O
and	O
spleen	O
tissues	O
.	O

The	O
B	O
,	O
CD3	O
T	O
,	O
CD4	B-Protein
T	O
,	O
CD	O
8	O
T	O
and	O
NK	O
cell	O
portion	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
tumor	O
tissue	O
were	O
7	O
.	O
2	O
%	O
,	O
48	O
.	O
2	O
%	O
,	O
16	O
.	O
9	O
%	O
,	O
32	O
.	O
1	O
%	O
and	O
7	O
.	O
8	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
2	O
.	O
9	O
%	O
,	O
11	O
.	O
1	O
%	O
,	O
2	O
.	O
3	O
%	O
,	O
0	O
.	O
6	O
%	O
and	O
3	O
.	O
1	O
%	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5C	O
)	O
.	O

The	O
lymphocytes	O
that	O
infiltrated	O
the	O
tumor	O
tissue	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
also	O
had	O
higher	O
levels	O
of	O
CD19	B-Protein
,	O
CD3	O
,	O
CD4	B-Protein
,	O
CD8	O
and	O
CD57	O
when	O
compared	O
to	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

The	O
B	O
,	O
CD3	O
T	O
,	O
CD4	B-Protein
T	O
,	O
CD	O
8	O
T	O
and	O
NK	O
cell	O
portion	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
spleen	O
were	O
61	O
.	O
3	O
%	O
,	O
33	O
.	O
4	O
%	O
,	O
17	O
.	O
6	O
%	O
,	O
9	O
.	O
2	O
%	O
and	O
0	O
.	O
6	O
%	O
,	O
respectively	O
compared	O
to	O
38	O
.	O
3	O
%	O
,	O
5	O
.	O
9	O
%	O
,	O
4	O
.	O
0	O
%	O
,	O
1	O
.	O
0	O
%	O
and	O
3	O
.	O
9	O
%	O
of	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
Figure	O
5D	O
)	O
.	O

These	O
data	O
suggest	O
that	O
by	O
promoting	O
the	O
infiltration	O
of	O
CD8	O
T	O
cells	O
and	O
NK	O
cells	O
,	O
which	O
are	O
potent	O
cytotoxic	O
effectors	O
for	O
tumors	O
,	O
could	O
play	O
a	O
role	O
in	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
tumor	O
weight	O
and	O
volume	O
were	O
much	O
smaller	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
to	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
inoculated	O
with	O
B16	O
melanoma	O
cells	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
.	O

The	O
tumor	O
growth	O
inhibition	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
was	O
associated	O
with	O
the	O
inhibition	O
of	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
and	O
elevation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
tumor	O
tissue	O
.	O

This	O
anti	O
-	O
tumor	O
activity	O
was	O
also	O
associated	O
with	O
decreased	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
anti	O
-	O
apoptotic	O
,	O
cell	O
proliferative	O
,	O
and	O
tumor	O
promoting	O
genes	O
(	O
Bcl	O
-	O
2	O
and	O
C	B-Protein
-	I-Protein
IAP1	I-Protein
)	O
but	O
with	O
increased	O
expression	O
of	O
their	O
target	O
apoptotic	O
genes	O
;	O
cleaved	O
caspase	O
-	O
3	O
and	O
9	O
,	O
and	O
Bax	O
(	O
Figure	O
3A	O
-	O
D	O
)	O
.	O

In	O
the	O
tumor	O
and	O
the	O
spleen	O
,	O
the	O
number	O
of	O
cytotoxic	O
CD8	O
+	O
T	O
cells	O
,	O
CD57	O
+	O
natural	O
killer	O
cells	O
,	O
and	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
were	O
increased	O
(	O
Figure	O
4	O
and	O
5	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
melanoma	O
growth	O
was	O
inhibited	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
and	O
that	O
the	O
elevation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
accompanied	O
with	O
decreased	O
NF	O
-	O
kappaB	O
,	O
is	O
significant	O
in	O
the	O
inhibition	O
of	O
melanoma	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

NF	O
-	O
kappaB	O
regulates	O
the	O
expression	O
of	O
over	O
200	O
genes	O
that	O
control	O
the	O
immune	O
system	O
,	O
cancer	O
cell	O
growth	O
and	O
inflammation	O
[	O
39	O
]	O
.	O
<EOS>	B-X
Nuclear	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
initially	B-X
discovered	B-X
as	B-X
a	B-X
factor	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
B	B-X
cells	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
enhancer	B-X
of	B-X
the	B-X
kappa	B-X
light	B-X
chain	B-X
of	B-X
immunoglobulin	B-X
,	B-X
has	B-X
since	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
expressed	B-X
ubiquitously	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
all	B-X
cell	B-X
types	B-X
,	B-X
conserved	B-X
from	B-X
Drosophila	B-X
to	B-X
man	B-X
.	B-X
It	B-X
translocates	B-X
to	B-X
the	B-X
nucleus	B-X
only	B-X
when	B-X
activated	B-X
,	B-X
where	B-X
it	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
over	B-X
200	B-X
genes	B-X
that	B-X
control	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
growth	B-X
,	B-X
and	B-X
inflammation	B-X
.	B-X
The	B-X
dysregulation	B-X
of	B-X
NF-kappaB	B-X
can	B-X
mediate	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
diseases	B-X
including	B-X
cancer	B-X
.	B-X
Whether	B-X
NF-kappaB	B-X
activation	B-X
is	B-X
beneficial	B-X
or	B-X
harmful	B-X
for	B-X
cancer	B-X
is	B-X
controversial	B-X
.	B-X
The	B-X
development	B-X
of	B-X
novel	B-X
therapeutics	B-X
targeting	B-X
NF-kappaB	B-X
requires	B-X
full	B-X
understanding	B-X
of	B-X
its	B-X
role	B-X
in	B-X
pathology	B-X
and	B-X
physiology	B-X
.	B-X
The	B-X
current	B-X
review	B-X
is	B-X
an	B-X
attempt	B-X
to	B-X
describe	B-X
two	B-X
sides	B-X
of	B-X
the	B-X
NF-kappaB	B-X
coin	B-X
;	B-X
viz	B-X
,	B-X
as	B-X
a	B-X
friend	B-X
and	B-X
as	B-X
a	B-X
foe	B-X
.	B-X

Because	O
of	O
its	O
abilities	O
to	O
induce	O
the	O
expression	O
of	O
a	O
large	O
array	O
of	O
inflammatory	O
mediators	O
and	O
its	O
roles	O
as	O
core	O
transcription	O
factors	O
in	O
diverse	O
immune	O
responses	O
,	O
NF	O
-	O
kappaB	O
has	O
been	O
recognized	O
as	O
a	O
major	O
factor	O
responsible	O
for	O
cytokine	O
-	O
associated	O
cancer	O
development	O
or	O
anti	O
-	O
tumor	O
immunity	O
.	O
<EOS>	B-X
Trained	B-X
innate	B-X
immunity	B-X
,	B-X
induced	B-X
via	B-X
modulation	B-X
of	B-X
mature	B-X
myeloid	B-X
cells	B-X
or	B-X
their	B-X
bone	B-X
marrow	B-X
progenitors	B-X
,	B-X
mediates	B-X
sustained	B-X
increased	B-X
responsiveness	B-X
to	B-X
secondary	B-X
challenges	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
anti-tumor	B-X
immunity	B-X
can	B-X
be	B-X
enhanced	B-X
through	B-X
induction	B-X
of	B-X
trained	B-X
immunity	B-X
.	B-X
Pre-treatment	B-X
of	B-X
mice	B-X
with	B-X
β-glucan	B-X
,	B-X
a	B-X
fungal-derived	B-X
prototypical	B-X
agonist	B-X
of	B-X
trained	B-X
immunity	B-X
,	B-X
resulted	B-X
in	B-X
diminished	B-X
tumor	B-X
growth	B-X
.	B-X
The	B-X
anti-tumor	B-X
effect	B-X
of	B-X
β-glucan-induced	B-X
trained	B-X
immunity	B-X
was	B-X
associated	B-X
with	B-X
transcriptomic	B-X
and	B-X
epigenetic	B-X
rewiring	B-X
of	B-X
granulopoiesis	B-X
and	B-X
neutrophil	B-X
reprogramming	B-X
toward	B-X
an	B-X
anti-tumor	B-X
phenotype	B-X
;	B-X
this	B-X
process	B-X
required	B-X
type	B-X
I	B-X
interferon	B-X
signaling	B-X
irrespective	B-X
of	B-X
adaptive	B-X
immunity	B-X
in	B-X
the	B-X
host	B-X
.	B-X
Adoptive	B-X
transfer	B-X
of	B-X
neutrophils	B-X
from	B-X
β-glucan-trained	B-X
mice	B-X
to	B-X
naive	B-X
recipients	B-X
suppressed	B-X
tumor	B-X
growth	B-X
in	B-X
the	B-X
latter	B-X
in	B-X
a	B-X
ROS-dependent	B-X
manner	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
anti-tumor	B-X
effect	B-X
of	B-X
β-glucan-induced	B-X
trained	B-X
granulopoiesis	B-X
was	B-X
transmissible	B-X
by	B-X
bone	B-X
marrow	B-X
transplantation	B-X
to	B-X
recipient	B-X
naive	B-X
mice	B-X
.	B-X
Our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
and	B-X
therapeutically	B-X
relevant	B-X
anti-tumor	B-X
facet	B-X
of	B-X
trained	B-X
immunity	B-X
involving	B-X
appropriate	B-X
rewiring	B-X
of	B-X
granulopoiesis	B-X
.	B-X

In	O
the	O
melanoma	O
tumor	O
tissues	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
target	O
cell	O
death	O
genes	O
(	O
Bax	O
,	O
caspase	O
-	O
3	O
and	O
9	O
)	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
,	O
were	O
significantly	O
inhibited	O
,	O
but	O
the	O
expression	O
of	O
cell	O
death	O
inhibitory	O
NF	O
-	O
kappaB	O
target	O
genes	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
and	O
cIAP	O
were	O
enhanced	O
.	O

In	O
addition	O
,	O
CCR5	B-Protein
-	O
/	O
-	O
prevented	O
the	O
phosphorylation	O
of	O
IkappaB	O
,	O
accompanied	O
with	O
the	O
inhibition	O
of	O
the	O
p50	B-Protein
and	O
p65	B-Protein
translocation	O
into	O
the	O
nucleus	O
(	O
Figure	O
2A	O
-	O
C	O
)	O
.	O

Many	O
tumors	O
,	O
including	O
melanoma	O
,	O
have	O
increased	O
levels	O
of	O
NF	O
-	O
kappaB	O
[	O
40	O
]	O
,	O
which	O
is	O
likely	O
acting	O
as	O
a	O
survival	O
factor	O
for	O
melanoma	O
growth	O
.	O

Thus	O
,	O
the	O
inhibitions	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
the	O
expression	O
of	O
target	O
genes	O
are	O
critical	O
in	O
the	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Although	O
the	O
mechanism	O
is	O
not	O
clear	O
as	O
to	O
how	O
CCR5	B-Protein
-	O
/	O
-	O
downregulates	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
noteworthy	O
that	O
NF	O
-	O
kappaB	O
is	O
activated	O
or	O
inactivated	O
by	O
many	O
cytokines	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
β	B-X
(	B-X
TGF-β	B-X
)	B-X
signaling	B-X
pathway	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
many	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
differentiation	B-X
,	B-X
apoptosis	B-X
,	B-X
migration	B-X
,	B-X
as	B-X
well	B-X
as	B-X
cancer	B-X
initiation	B-X
and	B-X
progression	B-X
.	B-X
SMAD4	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
the	B-X
central	B-X
mediator	B-X
of	B-X
TGF-β	B-X
signaling	B-X
,	B-X
is	B-X
specifically	B-X
inactivated	B-X
in	B-X
over	B-X
half	B-X
of	B-X
pancreatic	B-X
duct	B-X
adenocarcinoma	B-X
,	B-X
and	B-X
varying	B-X
degrees	B-X
in	B-X
many	B-X
other	B-X
types	B-X
of	B-X
cancers	B-X
.	B-X
In	B-X
other	B-X
cases	B-X
,	B-X
such	B-X
as	B-X
skin	B-X
cancer	B-X
,	B-X
loss	B-X
of	B-X
SMAD4	B-X
plays	B-X
an	B-X
important	B-X
initiating	B-X
role	B-X
by	B-X
disrupting	B-X
DNA	B-X
damage	B-X
response	B-X
and	B-X
repair	B-X
mechanisms	B-X
and	B-X
enhance	B-X
genomic	B-X
instability	B-X
,	B-X
suggesting	B-X
its	B-X
distinct	B-X
roles	B-X
in	B-X
different	B-X
types	B-X
of	B-X
tumors	B-X
.	B-X
Many	B-X
clinical	B-X
trials	B-X
have	B-X
been	B-X
carried	B-X
out	B-X
while	B-X
using	B-X
molecular	B-X
targeted	B-X
drugs	B-X
in	B-X
advanced	B-X
HCC	B-X
with	B-X
many	B-X
more	B-X
in	B-X
progress	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
insight	B-X
of	B-X
various	B-X
molecular	B-X
mechanisms	B-X
,	B-X
leading	B-X
to	B-X
HCC	B-X
development	B-X
and	B-X
progression	B-X
,	B-X
and	B-X
also	B-X
the	B-X
range	B-X
of	B-X
experimental	B-X
therapeutics	B-X
for	B-X
patients	B-X
with	B-X
advanced	B-X
HCC	B-X
.	B-X

Numerous	O
studies	O
showed	O
that	O
cytokine	O
affect	O
tumor	O
growth	O
by	O
regulating	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
A	B-X
profound	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
underpinnings	B-X
of	B-X
gastric	B-X
cancer	B-X
has	B-X
lagged	B-X
compared	B-X
to	B-X
several	B-X
other	B-X
tumors	B-X
with	B-X
similar	B-X
incidence	B-X
and	B-X
morbidity	B-X
rates	B-X
,	B-X
owing	B-X
to	B-X
our	B-X
limited	B-X
knowledge	B-X
of	B-X
the	B-X
role	B-X
of	B-X
carcinogens	B-X
in	B-X
this	B-X
malignancy	B-X
.	B-X
The	B-X
International	B-X
Agency	B-X
for	B-X
Research	B-X
on	B-X
Cancer	B-X
(	B-X
IARC	B-X
)	B-X
has	B-X
classified	B-X
gastric	B-X
carcinogenic	B-X
agents	B-X
into	B-X
four	B-X
groups	B-X
based	B-X
on	B-X
scientific	B-X
evidence	B-X
from	B-X
human	B-X
and	B-X
experimental	B-X
animal	B-X
studies	B-X
.	B-X
Zinc	B-X
is	B-X
essential	B-X
for	B-X
numerous	B-X
biochemical	B-X
pathways	B-X
in	B-X
the	B-X
body	B-X
and	B-X
is	B-X
known	B-X
to	B-X
significantly	B-X
affect	B-X
the	B-X
skeleton	B-X
.	B-X
We	B-X
recently	B-X
characterized	B-X
several	B-X
pharmacological	B-X
and	B-X
nutritional	B-X
factors	B-X
that	B-X
are	B-X
likewise	B-X
endowed	B-X
with	B-X
the	B-X
capacity	B-X
to	B-X
promote	B-X
bone	B-X
formation	B-X
and	B-X
suppress	B-X
bone	B-X
resorption	B-X
and	B-X
demonstrated	B-X
that	B-X
a	B-X
common	B-X
centralized	B-X
mechanism	B-X
for	B-X
achieving	B-X
such	B-X
actions	B-X
is	B-X
through	B-X
suppression	B-X
of	B-X
NF-κB	B-X
activation	B-X
.	B-X
NF-κB	B-X
is	B-X
a	B-X
pathway	B-X
required	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
but	B-X
suppresses	B-X
osteoblast	B-X
differentiation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
actions	B-X
of	B-X
zinc	B-X
on	B-X
NF-κB	B-X
activation	B-X
in	B-X
osteoclast	B-X
and	B-X
osteoblast	B-X
precursors	B-X
in	B-X
vitro	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
zinc	B-X
suppressed	B-X
osteoclast	B-X
differentiation	B-X
and	B-X
promoted	B-X
osteoblast	B-X
mineralization	B-X
and	B-X
did	B-X
indeed	B-X
act	B-X
as	B-X
a	B-X
potent	B-X
NF-κB	B-X
activation	B-X
antagonist	B-X
in	B-X
both	B-X
osteoclast	B-X
and	B-X
osteoblast	B-X
precursors	B-X
.	B-X
Importantly	B-X
,	B-X
zinc	B-X
antagonized	B-X
NF-κB	B-X
activation	B-X
driven	B-X
by	B-X
TNFα	B-X
,	B-X
a	B-X
potent	B-X
inflammatory	B-X
mediator	B-X
or	B-X
bone	B-X
resorption	B-X
and	B-X
suppressor	B-X
of	B-X
bone	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
Zinc	B-X
further	B-X
alleviated	B-X
the	B-X
suppressive	B-X
effect	B-X
of	B-X
TNFα	B-X
on	B-X
Smad	B-X
activation	B-X
induced	B-X
by	B-X
TGFβ	B-X
and	B-X
BMP2	B-X
,	B-X
cytokines	B-X
that	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
osteoblast	B-X
commitment	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
recruitment	B-X
to	B-X
sites	B-X
of	B-X
bone	B-X
remodeling	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
reveal	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
a	B-X
major	B-X
mechanism	B-X
by	B-X
which	B-X
zinc	B-X
promotes	B-X
osteoblastogenesis	B-X
and	B-X
suppresses	B-X
osteoclastogenesis	B-X
may	B-X
center	B-X
on	B-X
the	B-X
antagonism	B-X
of	B-X
NF-κB	B-X
activation	B-X
.	B-X

Inflammatory	O
cytokines	O
,	O
including	O
IL	O
-	O
1	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	O
-	O
8	O
,	O
activate	O
NF	O
-	O
kappaB	O
pathways	O
in	O
tumor	O
cells	O
[	O
41	O
]	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
revealed	B-X
that	B-X
quercetin	B-X
could	B-X
suppress	B-X
the	B-X
expression	B-X
of	B-X
matrix	B-X
metalloprotease-9	B-X
(	B-X
MMP-9	B-X
)	B-X
and	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
(	B-X
ICAM-1	B-X
)	B-X
to	B-X
achieve	B-X
anti-inflammatory	B-X
effects	B-X
in	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
-stimulated	B-X
human	B-X
retinal	B-X
pigment	B-X
epithelial	B-X
(	B-X
ARPE-19	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
present	B-X
study	B-X
explored	B-X
whether	B-X
quercetin	B-X
can	B-X
inhibit	B-X
the	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
-induced	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
in	B-X
ARPE-19	B-X
cells	B-X
.	B-X
Prior	B-X
to	B-X
stimulation	B-X
by	B-X
IL-1β	B-X
,	B-X
ARPE-19	B-X
cells	B-X
were	B-X
pretreated	B-X
with	B-X
quercetin	B-X
at	B-X
various	B-X
concentrations	B-X
(	B-X
2.5-20	B-X
µM	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
quercetin	B-X
could	B-X
dose-dependently	B-X
decrease	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
ICAM-1	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
and	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
.	B-X
It	B-X
also	B-X
attenuated	B-X
the	B-X
adherence	B-X
of	B-X
the	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
to	B-X
IL-1β-stimulated	B-X
ARPE-19	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
demonstrated	B-X
that	B-X
quercetin	B-X
inhibited	B-X
signaling	B-X
pathways	B-X
related	B-X
to	B-X
the	B-X
inflammatory	B-X
process	B-X
,	B-X
including	B-X
phosphorylation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
(	B-X
MAPKs	B-X
)	B-X
,	B-X
inhibitor	B-X
of	B-X
nuclear	B-X
factor	B-X
κ-B	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
α/β	B-X
,	B-X
c-Jun	B-X
,	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
,	B-X
activating	B-X
transcription	B-X
factor	B-X
2	B-X
(	B-X
ATF2	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
p65	B-X
,	B-X
and	B-X
blocked	B-X
the	B-X
translocation	B-X
of	B-X
NF-κB	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
Furthermore	B-X
,	B-X
MAPK	B-X
inhibitors	B-X
including	B-X
an	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
1/2	B-X
inhibitor	B-X
(	B-X
U0126	B-X
)	B-X
,	B-X
a	B-X
p38	B-X
inhibitor	B-X
(	B-X
SB202190	B-X
)	B-X
and	B-X
a	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
inhibitor	B-X
(	B-X
SP600125	B-X
)	B-X
decreased	B-X
the	B-X
expression	B-X
of	B-X
soluble	B-X
ICAM-1	B-X
(	B-X
sICAM-1	B-X
)	B-X
,	B-X
but	B-X
not	B-X
ICAM-1	B-X
.	B-X
U0126	B-X
and	B-X
SB202190	B-X
could	B-X
inhibit	B-X
the	B-X
expression	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
and	B-X
MCP-1	B-X
,	B-X
but	B-X
SP600125	B-X
could	B-X
not	B-X
.	B-X
An	B-X
NF-κB	B-X
inhibitor	B-X
(	B-X
Bay	B-X
11-7082	B-X
)	B-X
also	B-X
reduced	B-X
the	B-X
expression	B-X
of	B-X
ICAM-1	B-X
,	B-X
sICAM-1	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
and	B-X
MCP-1	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
provide	B-X
evidence	B-X
that	B-X
quercetin	B-X
protects	B-X
ARPE-19	B-X
cells	B-X
from	B-X
the	B-X
IL-1β-stimulated	B-X
increase	B-X
in	B-X
ICAM-1	B-X
,	B-X
sICAM-1	B-X
,	B-X
IL-6	B-X
,	B-X
IL-8	B-X
and	B-X
MCP-1	B-X
production	B-X
by	B-X
blocking	B-X
the	B-X
activation	B-X
of	B-X
MAPK	B-X
and	B-X
NF-κB	B-X
signaling	B-X
pathways	B-X
to	B-X
ameliorate	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X

The	O
interleukin	B-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
is	O
well	O
known	O
as	O
an	O
anti	O
-	O
tumor	O
factor	O
as	O
well	O
as	O
an	O
anti	O
-	O
inflammatory	O
factor	O
[	O
42	O
]	O
,	O
[	O
43	O
]	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibits	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
both	O
in	O
vitro	O
[	O
44	O
]	O
and	O
in	O
vivo	O
[	O
45	O
]	O
.	O
<EOS>	B-X
The	B-X
exact	B-X
in	B-X
vivo	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
rituximab	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
,	B-X
although	B-X
antibody-dependent	B-X
cell-mediated	B-X
cytotoxicity	B-X
(	B-X
ADCC	B-X
)	B-X
,	B-X
complement-dependent	B-X
cytotoxicity	B-X
(	B-X
CDC	B-X
)	B-X
,	B-X
and	B-X
apoptosis	B-X
have	B-X
been	B-X
suggested	B-X
.	B-X
ARL	B-X
(	B-X
acquired	B-X
immunodeficiency	B-X
syndrome	B-X
(	B-X
AIDS	B-X
)	B-X
-related	B-X
lymphoma	B-X
)	B-X
and	B-X
non-ARL	B-X
cell	B-X
lines	B-X
have	B-X
been	B-X
examined	B-X
as	B-X
in	B-X
vitro	B-X
model	B-X
systems	B-X
.	B-X
In	B-X
ARL	B-X
,	B-X
rituximab	B-X
diminishes	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
p38MAPK	B-X
signaling	B-X
pathway	B-X
resulting	B-X
in	B-X
inhibition	B-X
of	B-X
the	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-10/IL-10R	B-X
autocrine/paracrine	B-X
cytokine	B-X
autoregulatory	B-X
loop	B-X
leading	B-X
to	B-X
the	B-X
inhibition	B-X
of	B-X
constitutive	B-X
STAT-3	B-X
activity	B-X
and	B-X
subsequent	B-X
downregulation	B-X
of	B-X
Bcl-2	B-X
expression	B-X
leading	B-X
to	B-X
chemosensitization	B-X
.	B-X
Through	B-X
physical	B-X
association	B-X
with	B-X
Raf-1	B-X
and	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
RKIP	B-X
negatively	B-X
regulates	B-X
two	B-X
major	B-X
survival	B-X
pathways	B-X
,	B-X
namely	B-X
,	B-X
the	B-X
extracellular	B-X
signal-regulated	B-X
kinase1/2	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
the	B-X
NF-kappa	B-X
B	B-X
pathways	B-X
,	B-X
respectively	B-X
.	B-X
Downmodulation	B-X
of	B-X
the	B-X
ERK1/2	B-X
and	B-X
NF-kappa	B-X
B	B-X
pathways	B-X
inhibits	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
transcription	B-X
factors	B-X
,	B-X
respectively	B-X
,	B-X
both	B-X
of	B-X
which	B-X
lead	B-X
to	B-X
the	B-X
downregulation	B-X
of	B-X
Bcl-	B-X
(	B-X
xL	B-X
)	B-X
(	B-X
Bcl-2	B-X
related	B-X
gene	B-X
(	B-X
long	B-X
alternatively	B-X
spliced	B-X
variant	B-X
of	B-X
Bcl-x	B-X
gene	B-X
)	B-X
)	B-X
transcription	B-X
and	B-X
expression	B-X
and	B-X
sensitization	B-X
to	B-X
drug-induced	B-X
apoptosis	B-X
.	B-X

Inhibition	O
of	O
NF	O
-	O
kappaB	O
by	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
contributes	O
to	O
the	O
anti	O
-	O
tumor	O
effects	O
through	O
the	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
apoptosis	O
in	O
Colon26	O
-	O
bearing	O
mice	O
[	O
43	O
]	O
.	O

Similarly	O
,	O
several	O
studies	O
have	O
demonstrated	O
the	O
ability	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
to	O
abrogate	O
the	O
proinflammatory	O
effects	O
of	O
IL	O
-	O
1	O
[	O
46	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
IL	O
-	O
1	O
induces	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
several	O
cancers	O
,	O
and	O
increases	O
cell	O
cycle	O
progression	O
,	O
and	O
the	O
suppression	O
of	O
apoptotic	O
cell	O
death	O
leading	O
to	O
tumor	O
promotion	O
.	O

The	O
results	O
of	O
various	O
studies	O
over	O
the	O
past	O
10	O
years	O
indicate	O
that	O
the	O
major	O
function	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
is	O
to	O
regulate	O
the	O
pleiotropic	O
effects	O
of	O
IL	O
-	O
1	O
by	O
competitively	O
blocking	O
its	O
functions	O
[	O
47	O
]	O
.	O

The	O
ability	O
of	O
IL	O
-	O
1	O
to	O
induce	O
its	O
own	O
antagonist	O
is	O
of	O
interest	O
in	O
understanding	O
the	O
regulation	O
and	O
dysregulation	O
of	O
IL	O
-	O
1	O
signaling	O
in	O
normal	O
and	O
diseased	O
tissue	O
.	O

Up	O
-	O
regulation	O
of	O
the	O
receptor	O
antagonist	O
represents	O
a	O
mechanism	O
for	O
turning	O
off	O
IL	O
-	O
1	O
signaling	O
and	O
creating	O
a	O
temporary	O
state	O
of	O
refractoriness	O
.	O

The	O
elevated	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
,	O
without	O
any	O
change	O
of	O
IL	O
-	O
1	O
in	O
tumors	O
,	O
suggests	O
that	O
the	O
IL	O
-	O
1	O
-	O
signaling	O
system	O
may	O
be	O
dysregulated	O
by	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumors	O
.	O

IL	O
-	O
1Ra	O
has	O
been	O
shown	O
to	O
inhibit	O
tumor	O
progression	O
in	O
prostate	O
,	O
breast	O
,	O
and	O
skin	O
cancer	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

Intracellular	B-Protein
IL	I-Protein
-	I-Protein
1Ra	I-Protein
(	O
icIL	B-Protein
-	I-Protein
1Ra	I-Protein
)	O
inhibits	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
IL	O
-	O
8	O
production	O
in	O
Caco	O
-	O
2	O
cells	O
by	O
blocking	O
NF	O
-	O
kappaB	O
pathways	O
[	O
37	O
]	O
.	O

We	O
found	O
that	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
were	O
significantly	O
elevated	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
inoculated	O
with	O
B16	O
melanoma	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
be	O
critically	O
involved	O
in	O
the	O
tumor	O
growth	O
inhibition	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
through	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
present	O
study	O
.	O

CCR5	B-Protein
increases	O
tumor	O
growth	O
in	O
a	O
local	O
model	O
and	O
inhibits	O
the	O
efficacy	O
of	O
a	O
dendrite	O
cell	O
vaccine	O
in	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
compared	O
with	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
[	O
10	O
]	O
.	O

Cheng	O
J	O
and	O
Sung	O
RS	O
examined	O
the	O
effect	O
of	O
CCR5	B-Protein
on	O
the	O
immune	O
response	O
to	O
adenovirus	O
vectors	O
and	O
graft	O
function	O
in	O
an	O
islet	O
transplant	O
model	O
.	O

They	O
found	O
that	O
CCR5	B-Protein
absence	O
does	O
not	O
prevent	O
the	O
local	O
immune	O
response	O
to	O
adenovirus	O
transduction	O
[	O
48	O
]	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
CCR5	B-X
and	B-X
its	B-X
cognate	B-X
ligands	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
COVID-19	B-X
pathogenesis	B-X
,	B-X
consequently	B-X
therapeutics	B-X
directed	B-X
against	B-X
CCR5	B-X
are	B-X
being	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
explored	B-X
the	B-X
role	B-X
of	B-X
CCR5	B-X
and	B-X
its	B-X
ligands	B-X
across	B-X
the	B-X
immunologic	B-X
spectrum	B-X
of	B-X
COVID-19	B-X
.	B-X
We	B-X
assessed	B-X
the	B-X
plasma	B-X
and	B-X
isolated	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
from	B-X
29	B-X
healthy	B-X
controls	B-X
,	B-X
26	B-X
Mild-Moderate	B-X
COVID-19	B-X
individuals	B-X
,	B-X
48	B-X
Severe	B-X
COVID-19	B-X
individuals	B-X
,	B-X
and	B-X
121	B-X
individuals	B-X
with	B-X
post-acute	B-X
sequelae	B-X
of	B-X
COVID-19	B-X
(	B-X
PASC	B-X
)	B-X
symptoms	B-X
.	B-X
B-cells	B-X
were	B-X
significantly	B-X
elevated	B-X
compared	B-X
to	B-X
healthy	B-X
control	B-X
individuals	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
as	B-X
was	B-X
the	B-X
CD14+	B-X
,	B-X
CD16+	B-X
,	B-X
CCR5+	B-X
monocytic	B-X
subset	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
While	B-X
PASC	B-X
patients	B-X
are	B-X
characterized	B-X
by	B-X
a	B-X
profile	B-X
able	B-X
to	B-X
induce	B-X
the	B-X
activation	B-X
of	B-X
effector	B-X
T	B-X
cells	B-X
with	B-X
pro-inflammatory	B-X
properties	B-X
and	B-X
the	B-X
capacity	B-X
of	B-X
generating	B-X
an	B-X
effective	B-X
immune	B-X
response	B-X
to	B-X
eliminate	B-X
the	B-X
virus	B-X
but	B-X
without	B-X
the	B-X
proper	B-X
recruitment	B-X
signals	B-X
to	B-X
attract	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X

Additionally	O
,	O
Tan	O
MC	O
et	O
al	O
.	O
suggested	O
that	O
disruption	O
of	O
CCR5	B-Protein
/	O
CCL5	B-Protein
signaling	O
,	O
either	O
by	O
reducing	O
CCL5	B-Protein
production	O
by	O
tumor	O
cells	O
or	O
by	O
systemic	O
administration	O
of	O
a	O
CCR5	B-Protein
inhibitor	O
(	O
TAK	O
-	O
779	O
)	O
,	O
reduced	O
Treg	O
(	O
regulatory	O
T	O
cells	O
)	O
migration	O
to	O
tumors	O
so	O
that	O
tumors	O
are	O
smaller	O
in	O
control	O
mice	O
[	O
9	O
]	O
.	O
<EOS>	B-X
Tumors	B-X
evade	B-X
immune	B-X
destruction	B-X
by	B-X
actively	B-X
inducing	B-X
immune	B-X
tolerance	B-X
through	B-X
the	B-X
recruitment	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
described	B-X
increased	B-X
prevalence	B-X
of	B-X
these	B-X
cells	B-X
in	B-X
pancreatic	B-X
adenocarcinoma	B-X
,	B-X
but	B-X
it	B-X
remains	B-X
unclear	B-X
what	B-X
mechanisms	B-X
are	B-X
involved	B-X
in	B-X
recruiting	B-X
Tregs	B-X
into	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
postulated	B-X
that	B-X
chemokines	B-X
might	B-X
direct	B-X
Treg	B-X
homing	B-X
to	B-X
tumor	B-X
.	B-X
We	B-X
show	B-X
,	B-X
in	B-X
both	B-X
human	B-X
pancreatic	B-X
adenocarcinoma	B-X
and	B-X
a	B-X
murine	B-X
pancreatic	B-X
tumor	B-X
model	B-X
(	B-X
Pan02	B-X
)	B-X
,	B-X
that	B-X
tumor	B-X
cells	B-X
produce	B-X
increased	B-X
levels	B-X
of	B-X
ligands	B-X
for	B-X
the	B-X
CCR5	B-X
chemokine	B-X
receptor	B-X
and	B-X
,	B-X
reciprocally	B-X
,	B-X
that	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
,	B-X
compared	B-X
with	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
-	B-X
)	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
preferentially	B-X
express	B-X
CCR5	B-X
.	B-X
When	B-X
CCR5/CCL5	B-X
signaling	B-X
is	B-X
disrupted	B-X
,	B-X
either	B-X
by	B-X
reducing	B-X
CCL5	B-X
production	B-X
by	B-X
tumor	B-X
cells	B-X
or	B-X
by	B-X
systemic	B-X
administration	B-X
of	B-X
a	B-X
CCR5	B-X
inhibitor	B-X
(	B-X
N	B-X
,	B-X
N-dimethyl-N-	B-X
{	B-X
{	B-X
4-	B-X
{	B-X
[	B-X
2-	B-X
(	B-X
4-methylphenyl	B-X
)	B-X
-6,7-dihydro-5H-benzocyclohepten-8-yl	B-X
]	B-X
carbonyl	B-X
}	B-X
amino	B-X
}	B-X
}	B-X
benzyl	B-X
]	B-X
-N	B-X
,	B-X
N-dimethyl-N-	B-X
{	B-X
{	B-X
{	B-X
4-	B-X
{	B-X
{	B-X
{	B-X
[	B-X
2-	B-X
(	B-X
4-methylphenyl	B-X
)	B-X
-6,7-dihydro-5H-benzocycloheptan-8-yl	B-X
]	B-X
carbonyl	B-X
}	B-X
amino	B-X
}	B-X
}	B-X
benzyl	B-X
}	B-X
}	B-X
}	B-X
tetrahydro-2H-pyran-4-aminiumchloride	B-X
;	B-X
TAK-779	B-X
)	B-X
,	B-X
Treg	B-X
migration	B-X
to	B-X
tumors	B-X
is	B-X
reduced	B-X
and	B-X
tumors	B-X
are	B-X
smaller	B-X
than	B-X
in	B-X
control	B-X
mice	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
study	B-X
demonstrates	B-X
the	B-X
importance	B-X
of	B-X
Tregs	B-X
in	B-X
immune	B-X
evasion	B-X
by	B-X
tumors	B-X
,	B-X
how	B-X
blockade	B-X
of	B-X
Treg	B-X
migration	B-X
might	B-X
inhibit	B-X
tumor	B-X
growth	B-X
,	B-X
and	B-X
,	B-X
specifically	B-X
in	B-X
pancreatic	B-X
adenocarcinoma	B-X
,	B-X
the	B-X
role	B-X
of	B-X
CCR5	B-X
in	B-X
the	B-X
homing	B-X
of	B-X
tumor-associated	B-X
Tregs	B-X
.	B-X
Selective	B-X
targeting	B-X
of	B-X
CCR5/CCL5	B-X
signaling	B-X
may	B-X
represent	B-X
a	B-X
novel	B-X
immunomodulatory	B-X
strategy	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
.	B-X

These	O
data	O
support	O
the	O
important	O
premise	O
that	O
inhibition	O
of	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
could	O
be	O
related	O
with	O
the	O
inhibition	O
of	O
immune	O
escape	O
.	O

Similar	O
to	O
this	O
finding	O
,	O
we	O
found	O
that	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
injected	O
with	O
melanoma	O
cells	O
apparently	O
have	O
a	O
lower	O
number	O
of	O
cytotoxic	O
T	O
cells	O
(	O
CD8	O
+	O
positive	O
T	O
Lymphocytes	O
cells	O
)	O
and	O
natural	O
killer	O
cells	O
(	O
CD57	O
positive	O
NK	O
cells	O
)	O
,	O
as	O
well	O
as	O
dendrite	O
cells	O
,	O
in	O
spleen	O
tissues	O
compared	O
to	O
those	O
without	O
melanoma	O
cells	O
.	O

But	O
the	O
lymphocytes	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
did	O
not	O
decrease	O
when	O
injected	O
with	O
melanoma	O
cells	O
.	O
<EOS>	B-X
To	B-X
explore	B-X
the	B-X
underlying	B-X
immune	B-X
regulators	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
microenvironment	B-X
in	B-X
glioma	B-X
and	B-X
find	B-X
that	B-X
tumor-infiltrating	B-X
T	B-X
cells	B-X
are	B-X
mainly	B-X
confined	B-X
to	B-X
the	B-X
perivascular	B-X
cuffs	B-X
and	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
CCR5	B-X
,	B-X
CXCR3	B-X
,	B-X
and	B-X
programmed	B-X
cell	B-X
death	B-X
protein	B-X
1	B-X
(	B-X
PD-1	B-X
)	B-X
.	B-X
Combined	B-X
analysis	B-X
of	B-X
T	B-X
cell	B-X
clustering	B-X
with	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
clone	B-X
expansion	B-X
shows	B-X
that	B-X
potential	B-X
tumor-killing	B-X
T	B-X
cells	B-X
are	B-X
mainly	B-X
categorized	B-X
into	B-X
pre-exhausted/exhausted	B-X
and	B-X
effector	B-X
CD8	B-X
The	B-X
ability	B-X
to	B-X
engineer	B-X
primary	B-X
human	B-X
B	B-X
cells	B-X
to	B-X
differentiate	B-X
into	B-X
long-lived	B-X
plasma	B-X
cells	B-X
and	B-X
secrete	B-X
a	B-X
de	B-X
novo	B-X
protein	B-X
may	B-X
allow	B-X
the	B-X
creation	B-X
of	B-X
novel	B-X
plasma	B-X
cell	B-X
therapies	B-X
for	B-X
protein	B-X
deficiency	B-X
diseases	B-X
and	B-X
other	B-X
clinical	B-X
applications	B-X
.	B-X
We	B-X
initially	B-X
developed	B-X
methods	B-X
for	B-X
efficient	B-X
genome	B-X
editing	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
isolated	B-X
from	B-X
peripheral	B-X
blood	B-X
.	B-X
By	B-X
delivering	B-X
CRISPR/CRISPR-associated	B-X
protein	B-X
9	B-X
(	B-X
Cas9	B-X
)	B-X
ribonucleoprotein	B-X
(	B-X
RNP	B-X
)	B-X
complexes	B-X
under	B-X
conditions	B-X
of	B-X
rapid	B-X
B	B-X
cell	B-X
expansion	B-X
,	B-X
we	B-X
achieved	B-X
site-specific	B-X
gene	B-X
disruption	B-X
at	B-X
multiple	B-X
loci	B-X
in	B-X
primary	B-X
human	B-X
B	B-X
cells	B-X
(	B-X
with	B-X
editing	B-X
rates	B-X
of	B-X
up	B-X
to	B-X
94	B-X
%	B-X
)	B-X
.	B-X
This	B-X
method	B-X
enabled	B-X
us	B-X
to	B-X
engineer	B-X
plasma	B-X
cells	B-X
to	B-X
secrete	B-X
factor	B-X
IX	B-X
(	B-X
FIX	B-X
)	B-X
or	B-X
B	B-X
cell	B-X
activating	B-X
factor	B-X
(	B-X
BAFF	B-X
)	B-X
at	B-X
high	B-X
levels	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
introduction	B-X
of	B-X
BAFF	B-X
into	B-X
plasma	B-X
cells	B-X
promotes	B-X
their	B-X
engraftment	B-X
into	B-X
immunodeficient	B-X
mice	B-X
.	B-X
Our	B-X
results	B-X
highlight	B-X
the	B-X
utility	B-X
of	B-X
genome	B-X
editing	B-X
in	B-X
studying	B-X
human	B-X
B	B-X
cell	B-X
biology	B-X
and	B-X
demonstrate	B-X
a	B-X
novel	B-X
strategy	B-X
for	B-X
modifying	B-X
human	B-X
plasma	B-X
cells	B-X
to	B-X
secrete	B-X
therapeutic	B-X
proteins	B-X
.	B-X

These	O
differences	O
of	O
the	O
immune	O
response	O
between	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
involving	O
tumor	O
immune	O
tolerance	O
,	O
may	O
be	O
connected	O
with	O
the	O
inhibition	O
of	O
cancer	O
progression	O
.	O

Taken	O
together	O
,	O
in	O
the	O
cytokine	O
array	O
experiment	O
,	O
the	O
level	O
of	O
MIP	B-Protein
-	I-Protein
1alpha	I-Protein
(	O
which	O
has	O
a	O
potent	O
activity	O
of	O
T	O
cell	O
and	O
B	O
cell	O
migration	O
)	O
was	O
increased	O
in	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
compared	O
with	O
those	O
in	O
the	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

Thus	O
,	O
relatively	O
increased	O
tumor	O
associated	O
cytotoxic	O
lymphocytes	O
could	O
play	O
an	O
important	O
role	O
in	O
inhibiting	O
the	O
tumor	O
growth	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
could	O
modulate	O
subcellular	O
localization	O
of	O
NK	O
cells	O
and	O
pathogenesis	O
[	O
49	O
]	O
.	O
<EOS>	B-X
Deregulation	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
signalling	B-X
is	B-X
common	B-X
in	B-X
cancers	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
tumourigenesis	B-X
.	B-X
Constitutive	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
extranodal	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
-cell	B-X
lymphoma	B-X
,	B-X
nasal	B-X
type	B-X
(	B-X
ENKL	B-X
)	B-X
is	B-X
known	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
aberrant	B-X
nuclear	B-X
translocation	B-X
of	B-X
BCL10	B-X
.	B-X
Here	B-X
we	B-X
investigated	B-X
the	B-X
mechanisms	B-X
leading	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
BCL10	B-X
nuclear	B-X
localization	B-X
in	B-X
ENKLs	B-X
.	B-X
Given	B-X
that	B-X
ENKLs	B-X
are	B-X
dependent	B-X
on	B-X
T-cell-derived	B-X
interleukin-2	B-X
(	B-X
IL2	B-X
)	B-X
for	B-X
cytotoxicity	B-X
and	B-X
proliferation	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IL2	B-X
modulates	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
BCL10	B-X
subcellular	B-X
localization	B-X
in	B-X
ENKLs	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
IL2-activated	B-X
NK	B-X
lymphoma	B-X
cells	B-X
were	B-X
found	B-X
to	B-X
induce	B-X
NF-kappaB	B-X
activation	B-X
via	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
,	B-X
leading	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
entry	B-X
of	B-X
G	B-X
(	B-X
2	B-X
)	B-X
/M	B-X
phase	B-X
and	B-X
concomitant	B-X
transcription	B-X
of	B-X
NF-kappaB-responsive	B-X
genes	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
BCL10	B-X
,	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
NF-kappaB	B-X
signalling	B-X
,	B-X
participates	B-X
in	B-X
the	B-X
cytokine	B-X
receptor-induced	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
Knockdown	B-X
of	B-X
BCL10	B-X
expression	B-X
resulted	B-X
in	B-X
deficient	B-X
NF-kappaB	B-X
signalling	B-X
,	B-X
whereas	B-X
Akt	B-X
activation	B-X
was	B-X
unaffected	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
BCL10	B-X
plays	B-X
a	B-X
role	B-X
downstream	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
IL2-triggered	B-X
NF-kappaB	B-X
signalling	B-X
pathway	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
IL2	B-X
to	B-X
NK	B-X
cells	B-X
led	B-X
to	B-X
aberrant	B-X
nuclear	B-X
translocation	B-X
of	B-X
BCL10	B-X
,	B-X
which	B-X
is	B-X
a	B-X
pathological	B-X
feature	B-X
of	B-X
ENKLs	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
BCL10	B-X
in	B-X
the	B-X
cytokine	B-X
receptor-induced	B-X
NF-kappaB	B-X
signalling	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
essential	B-X
for	B-X
NK	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
revealed	B-X
the	B-X
underlying	B-X
mechanism	B-X
that	B-X
controls	B-X
BCL10	B-X
nuclear	B-X
translocation	B-X
in	B-X
NK	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
provide	B-X
insight	B-X
into	B-X
a	B-X
molecular	B-X
network	B-X
within	B-X
the	B-X
NF-kappaB	B-X
signalling	B-X
pathway	B-X
that	B-X
promotes	B-X
the	B-X
pathogenesis	B-X
of	B-X
NK	B-X
cell	B-X
lymphomas	B-X
.	B-X

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
prevented	O
NK	O
cell	O
depletion	O
,	O
and	O
thus	O
increased	O
anti	O
-	O
tumor	O
activity	O
by	O
decreasing	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
[	O
50	O
]	O
.	O

Thus	O
,	O
the	O
decreased	O
NF	O
-	O
kappaB	O
and	O
elevated	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
also	O
be	O
associated	O
in	O
the	O
infiltration	O
of	O
cytotoxic	O
lymphocytes	O
into	O
tumor	O
,	O
resulting	O
in	O
tumor	O
growth	O
inhibition	O
.	O

In	O
contrast	O
,	O
IL	O
-	O
23	O
,	O
a	O
tumor	O
growth	O
promoting	O
cytokine	O
,	O
increased	O
NF	O
-	O
kappaB	O
and	O
immune	O
cell	O
infiltration	O
in	O
oral	O
tumor	O
[	O
51	O
]	O
.	O

These	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
could	O
be	O
involved	O
in	O
the	O
cytokine	O
mediated	O
anti	O
-	O
tumor	O
activities	O
of	O
immune	O
cells	O
.	O
<EOS>	B-X
Purpose	B-X
The	B-X
combretastatins	B-X
(	B-X
CAs	B-X
)	B-X
are	B-X
known	B-X
to	B-X
exhibit	B-X
anti-tumour	B-X
activity	B-X
but	B-X
the	B-X
underlying	B-X
mechanism	B-X
remains	B-X
to	B-X
be	B-X
fully	B-X
elucidated	B-X
.	B-X
Inflammation	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
altering	B-X
the	B-X
function	B-X
of	B-X
cancer	B-X
cells	B-X
and	B-X
evasion	B-X
of	B-X
cell	B-X
death	B-X
and	B-X
increased	B-X
proliferation	B-X
are	B-X
characteristics	B-X
of	B-X
transformed	B-X
malignancies	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
proteins	B-X
involved	B-X
in	B-X
these	B-X
pathways	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
which	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
tumour	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF-α	B-X
)	B-X
,	B-X
a	B-X
pro-inflammatory	B-X
cytokine	B-X
released	B-X
by	B-X
both	B-X
malignant	B-X
and	B-X
immune	B-X
cells	B-X
within	B-X
the	B-X
tumour	B-X
microenvironment	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
combretastatin	B-X
A-4	B-X
(	B-X
CA-4	B-X
)	B-X
and	B-X
its	B-X
novel	B-X
,	B-X
cis-restricted	B-X
analogue	B-X
CA-432	B-X
to	B-X
target	B-X
the	B-X
NF-κB	B-X
signalling	B-X
pathway	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Modulation	B-X
of	B-X
the	B-X
NF-κB	B-X
signalling	B-X
pathway	B-X
was	B-X
determined	B-X
through	B-X
western	B-X
blotting	B-X
and	B-X
through	B-X
assessment	B-X
of	B-X
NF-κB	B-X
reporter	B-X
gene	B-X
activity	B-X
.	B-X
Results	B-X
CA-4	B-X
and	B-X
CA-432	B-X
reduced	B-X
cell	B-X
viability	B-X
and	B-X
induced	B-X
apoptosis	B-X
in	B-X
DND-41	B-X
and	B-X
Jurkat	B-X
T	B-X
cells	B-X
and	B-X
sensitised	B-X
the	B-X
cells	B-X
to	B-X
TNF-α-induced	B-X
apoptosis	B-X
through	B-X
inhibition	B-X
of	B-X
the	B-X
NF-κB	B-X
signalling	B-X
pathway	B-X
.	B-X
Suppression	B-X
of	B-X
the	B-X
NF-κB	B-X
pathway	B-X
downregulated	B-X
NF-κB-dependent	B-X
gene	B-X
products	B-X
involved	B-X
in	B-X
cell	B-X
survival	B-X
(	B-X
IAPs	B-X
,	B-X
Bcl-2	B-X
and	B-X
Mcl-1	B-X
)	B-X
,	B-X
proliferation	B-X
(	B-X
cyclin	B-X
D1	B-X
)	B-X
and	B-X
inflammation	B-X
(	B-X
COX-2	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
both	B-X
CA-4	B-X
and	B-X
CA-432	B-X
inhibited	B-X
TNF-α-induced	B-X
NF-κB	B-X
activation	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
IκBα	B-X
degradation	B-X
and	B-X
p65	B-X
nuclear	B-X
translocation	B-X
and	B-X
decreased	B-X
NF-κB	B-X
reporter	B-X
gene	B-X
activity	B-X
.	B-X
Conclusions	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
anti-cancer	B-X
properties	B-X
of	B-X
comebretastatins	B-X
may	B-X
be	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
targeting	B-X
the	B-X
NF-κB	B-X
pathway	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
CA	B-X
compounds	B-X
and	B-X
a	B-X
potential	B-X
application	B-X
of	B-X
combretastatins	B-X
for	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
cancers	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
abnormal	B-X
NF-κB	B-X
activation	B-X
.	B-X

It	O
is	O
also	O
noteworthy	O
that	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
inhibited	O
melanoma	O
tumor	O
growth	O
by	O
increasing	O
the	O
number	O
of	O
myeloid	O
suppressor	O
cells	O
in	O
tumor	O
[	O
25	O
]	O
.	O

The	O
3	O
-	O
methylcholatrene	O
-	O
induced	O
tumor	O
incidence	O
was	O
reduced	O
in	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
knockout	O
mice	O
,	O
but	O
increased	O
in	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
mice	O
with	O
concomitant	O
maturation	O
of	O
NK	O
cells	O
and	O
anti	O
-	O
tumor	O
immunity	O
[	O
52	O
]	O
.	O

These	O
data	O
indicate	O
that	O
the	O
decrease	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
thus	O
increase	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
could	O
be	O
significant	O
in	O
tumor	O
growth	O
inhibition	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Our	O
data	O
thus	O
show	O
significant	O
clinical	O
implications	O
of	O
CCR5	B-Protein
,	O
because	O
CCR5	B-Protein
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
and	O
it	O
is	O
amenable	O
to	O
use	O
as	O
a	O
small	O
molecule	O
for	O
the	O
inhibition	O
of	O
CCR5	B-Protein
.	O

Several	O
such	O
compounds	O
have	O
already	O
been	O
shown	O
to	O
be	O
safe	O
in	O
clinical	O
trials	O
for	O
use	O
in	O
certain	O
diseases	O
such	O
as	O
HIV	O
[	O
53	O
]	O
.	O

Thus	O
,	O
we	O
believe	O
CCR5	B-Protein
is	O
a	O
cancer	O
target	O
that	O
warrants	O
continued	O
investigation	O
.	O

In	O
summary	O
,	O
this	O
study	O
showed	O
that	O
melanoma	O
cells	O
growth	O
was	O
inhibited	O
via	O
modulation	O
of	O
NF	O
-	O
kappaB	O
/	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
pathways	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Ethics	O
Statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
Statement	B-X
is	B-X
to	B-X
increase	B-X
awareness	B-X
of	B-X
all	B-X
stakeholders	B-X
of	B-X
science	B-X
communication	B-X
of	B-X
the	B-X
emerging	B-X
ethical	B-X
issues	B-X
in	B-X
journal	B-X
editing	B-X
and	B-X
publishing	B-X
and	B-X
initiate	B-X
a	B-X
campaign	B-X
of	B-X
upgrading	B-X
and	B-X
enforcing	B-X
related	B-X
journal	B-X
instructions	B-X
.	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
related	B-X
to	B-X
caring	B-X
theory	B-X
,	B-X
the	B-X
concepts	B-X
of	B-X
moral	B-X
accountability	B-X
and	B-X
integrity	B-X
,	B-X
and	B-X
the	B-X
documents	B-X
that	B-X
speak	B-X
of	B-X
these	B-X
values	B-X
and	B-X
concepts	B-X
in	B-X
professional	B-X
practice	B-X
(	B-X
eg	B-X
,	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
,	B-X
Nursing	B-X
's	B-X
Social	B-X
Policy	B-X
Statement	B-X
)	B-X
are	B-X
presented	B-X
in	B-X
this	B-X
article	B-X
.	B-X

All	O
experiments	O
were	O
approved	O
and	O
carried	O
out	O
according	O
to	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Animals	O
[	O
Animal	O
Care	O
Committee	O
of	O
Chungbuk	O
National	O
University	O
,	O
Korea	O
(	O
CBNUA	O
-	O
045	O
-	O
0902	O
-	O
01	O
)	O
]	O
.	O

Animals	O
<EOS>	B-X
Lifting	B-X
the	B-X
veil	B-X
on	B-X
the	B-X
oldest-known	B-X
animals	B-X
.	B-X
EXPERIMENTS	B-X
on	B-X
animals	B-X
.	B-X
Veterinary	B-X
Medical	B-X
Ethics	B-X
.	B-X
News	B-X
&	B-X
Views	B-X
.	B-X

The	O
CCR5	B-Protein
wild	O
type	O
(	O
CCR5	B-Protein
+	O
/	O
+	O
)	O
and	O
CCR5	B-Protein
knockout	O
(	O
CCR5	B-Protein
-	O
/	O
-	O
)	O
mice	O
were	O
purchased	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
04609	O
USA	O
)	O
.	O

The	O
mice	O
were	O
housed	O
and	O
bred	O
under	O
specific	O
pathogen	O
free	O
conditions	O
at	O
the	O
Laboratory	O
Animal	O
Research	O
Center	O
of	O
Chungbuk	O
National	O
University	O
,	O
Korea	O
.	O

The	O
mice	O
(	O
n	O
=	O
4	O
/	O
cage	O
)	O
were	O
maintained	O
in	O
a	O
room	O
with	O
a	O
constant	O
temperature	O
of	O
22	O
+	O
/	O
-	O
1degreesC	O
,	O
relative	O
humidity	O
of	O
55	O
+	O
/	O
-	O
10	O
%	O
,	O
and	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
,	O
and	O
fed	O
standard	O
rodent	O
chow	O
(	O
Samyang	O
,	O
Korea	O
)	O
and	O
purified	O
tap	O
water	O
ad	O
libitum	O
.	O

The	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
n	O
=	O
20	O
)	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
,	O
that	O
were	O
used	O
,	O
had	O
matched	O
ages	O
(	O
10	O
-	O
11	O
weeks	O
old	O
)	O
and	O
weights	O
(	O
16	O
-	O
19	O
g	O
)	O
.	O

Control	O
mice	O
(	O
B6129PF2	O
/	O
J	O
)	O
were	O
F2	O
hybrid	O
mice	O
from	O
the	O
C57BL	O
/	O
6J	O
-	O
AW	O
-	O
J	O
and	O
129P3	O
/	O
J	O
parental	O
strains	O
.	O

CCR5	B-Protein
mice	O
(	O
B6	O
,	O
129P2	O
-	O
Ccr5tm1Kuz	O
/	O
J	O
)	O
have	O
the	O
entire	O
coding	O
region	O
of	O
the	O
CCR5	B-Protein
gene	O
deleted	O
from	O
the	O
parental	O
strains	O
,	O
B6	O
;	O
129P2	O
-	O
Ccr5tm1kuz	O
and	O
B6	O
;	O
129P2	O
-	O
Cmkbr5tm1Kuz	O
.	O

Tumor	O
Inoculation	O
and	O
Tumor	O
Monitoring	O
<EOS>	B-X
Tumor-associated	B-X
macrophages	B-X
(	B-X
TAMs	B-X
)	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
promoting	B-X
tumor	B-X
growth	B-X
and	B-X
development	B-X
.	B-X
Monitoring	B-X
circulating	B-X
tumor	B-X
DNA	B-X
(	B-X
ctDNA	B-X
)	B-X
and	B-X
circulating	B-X
tumor	B-X
cells	B-X
(	B-X
CTCs	B-X
)	B-X
,	B-X
known	B-X
as	B-X
liquid	B-X
biopsies	B-X
,	B-X
continue	B-X
to	B-X
be	B-X
developed	B-X
as	B-X
diagnostic	B-X
and	B-X
prognostic	B-X
markers	B-X
for	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cancer	B-X
indications	B-X
,	B-X
mainly	B-X
due	B-X
to	B-X
their	B-X
minimally	B-X
invasive	B-X
nature	B-X
and	B-X
ability	B-X
to	B-X
offer	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
phenotypic	B-X
and	B-X
genetic	B-X
information	B-X
.	B-X
Monitoring	B-X
the	B-X
impact	B-X
of	B-X
prophylactic	B-X
HPV	B-X
vaccines	B-X
will	B-X
be	B-X
useful	B-X
for	B-X
understanding	B-X
the	B-X
population	B-X
level	B-X
impact	B-X
of	B-X
vaccination	B-X
.	B-X

B16	O
melanoma	O
cells	O
were	O
injected	O
subcutaneously	O
[	O
5x105	O
tumor	O
cells	O
in	O
0	O
.	O
1	O
ml	O
Phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
/	O
animal	O
]	O
using	O
a	O
27	O
G	O
needle	O
into	O
the	O
right	O
-	O
lower	O
flanks	O
of	O
the	O
carrier	O
mice	O
as	O
previously	O
described	O
[	O
54	O
]	O
.	O

The	O
body	O
weights	O
and	O
tumor	O
volumes	O
of	O
the	O
animals	O
were	O
monitored	O
twice	O
weekly	O
.	O

The	O
tumor	O
volumes	O
were	O
measured	O
with	O
Vernier	O
calipers	O
and	O
calculated	O
using	O
the	O
following	O
formula	O
:	O
(	O
AxB2	O
)	O
/	O
2	O
,	O
where	O
A	O
is	O
the	O
larger	O
and	O
B	O
is	O
the	O
smaller	O
of	O
the	O
two	O
dimensions	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
the	O
animals	O
were	O
sacrificed	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
melatonin	B-X
on	B-X
CCH-induced	B-X
AD	B-X
pathology	B-X
,	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
,	B-X
and	B-X
synaptic	B-X
plasticity	B-X
,	B-X
all	B-X
of	B-X
which	B-X
are	B-X
correlated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
oxidative	B-X
stress	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
cognitive	B-X
impairment	B-X
.	B-X
At	B-X
the	B-X
end	B-X
of	B-X
the	B-X
experiment	B-X
,	B-X
all	B-X
rats	B-X
were	B-X
assessed	B-X
for	B-X
memory	B-X
impairment	B-X
by	B-X
using	B-X
the	B-X
Morris	B-X
water	B-X
maze	B-X
test	B-X
.	B-X
Subsequently	B-X
,	B-X
rats	B-X
were	B-X
sacrificed	B-X
,	B-X
and	B-X
brains	B-X
were	B-X
removed	B-X
to	B-X
determine	B-X
the	B-X
levels	B-X
of	B-X
beta-amyloid	B-X
(	B-X
Aβ	B-X
)	B-X
,	B-X
malondialdehyde	B-X
(	B-X
MDA	B-X
)	B-X
;	B-X
the	B-X
acetylcholinesterase	B-X
(	B-X
AChE	B-X
)	B-X
activity	B-X
;	B-X
subjected	B-X
to	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
dUTP	B-X
nick	B-X
end	B-X
labeling	B-X
(	B-X
TUNEL	B-X
)	B-X
;	B-X
and	B-X
subjected	B-X
to	B-X
western	B-X
blotting	B-X
of	B-X
proteins	B-X
related	B-X
to	B-X
memory	B-X
,	B-X
AD	B-X
pathology	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
ER	B-X
stress	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
Study	B-X
of	B-X
the	B-X
Effect	B-X
of	B-X
Photobiomodulation	B-X
on	B-X
a	B-X
Skin	B-X
Repair	B-X
Model	B-X
in	B-X
SKH-1	B-X
Mice	B-X
.	B-X

The	O
tumors	O
were	O
separated	O
from	O
the	O
surrounding	O
muscles	O
and	O
dermis	O
.	O
<EOS>	B-X
The	B-X
scrotal	B-X
mass	B-X
and	B-X
surrounding	B-X
skin	B-X
were	B-X
surgically	B-X
resected	B-X
using	B-X
a	B-X
vertical	B-X
elliptical	B-X
incision	B-X
and	B-X
sent	B-X
for	B-X
histopathology	B-X
.	B-X
The	B-X
epidermis	B-X
was	B-X
normal	B-X
with	B-X
a	B-X
prominent	B-X
proliferation	B-X
of	B-X
intertwined	B-X
smooth	B-X
muscle	B-X
fibers	B-X
with	B-X
interlacing	B-X
collagen	B-X
bundles	B-X
in	B-X
the	B-X
dermis	B-X
.	B-X
The	B-X
histologic	B-X
and	B-X
immunochemical	B-X
characteristics	B-X
of	B-X
benign	B-X
vascular	B-X
tumors	B-X
excised	B-X
from	B-X
the	B-X
skin	B-X
of	B-X
seven	B-X
young	B-X
horses	B-X
were	B-X
evaluated	B-X
.	B-X
Six	B-X
tumors	B-X
occurred	B-X
on	B-X
the	B-X
extremities	B-X
,	B-X
and	B-X
one	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
lip	B-X
.	B-X
Histologically	B-X
,	B-X
most	B-X
tumors	B-X
consisted	B-X
of	B-X
cellular	B-X
nodules	B-X
of	B-X
varying	B-X
compactness	B-X
with	B-X
few	B-X
to	B-X
many	B-X
blood-filled	B-X
lumina	B-X
.	B-X
Nodular	B-X
growth	B-X
separated	B-X
preexisting	B-X
adnexa	B-X
and	B-X
subcutaneous	B-X
collagen	B-X
.	B-X
Some	B-X
tumors	B-X
contained	B-X
or	B-X
consisted	B-X
predominantly	B-X
of	B-X
loosely	B-X
packed	B-X
arrays	B-X
of	B-X
ramifying	B-X
,	B-X
veins	B-X
,	B-X
and	B-X
capillaries	B-X
separated	B-X
by	B-X
collagen	B-X
within	B-X
the	B-X
dermis	B-X
and	B-X
subcutis	B-X
.	B-X
Within	B-X
areas	B-X
of	B-X
nodular	B-X
growth	B-X
,	B-X
multilayered	B-X
vascular	B-X
walls	B-X
were	B-X
encircled	B-X
by	B-X
reticulin	B-X
strands	B-X
that	B-X
surrounded	B-X
the	B-X
endothelium	B-X
and	B-X
adjacent	B-X
pericytes	B-X
and	B-X
also	B-X
separated	B-X
nonperivascular	B-X
cells	B-X
in	B-X
the	B-X
mass	B-X
.	B-X
Immunohistochemical	B-X
staining	B-X
of	B-X
factor-VIII-related	B-X
antigen	B-X
and	B-X
labeling	B-X
by	B-X
Ulex	B-X
europeus-1	B-X
lectin	B-X
was	B-X
restricted	B-X
to	B-X
an	B-X
innermost	B-X
layer	B-X
of	B-X
cells	B-X
surrounding	B-X
vascular	B-X
spaces	B-X
,	B-X
confirming	B-X
their	B-X
vascular	B-X
endothelial	B-X
origin	B-X
.	B-X

Western	O
Blotting	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
used	B-X
techniques	B-X
in	B-X
molecular	B-X
biology	B-X
and	B-X
proteomics	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
important	B-X
procedure	B-X
for	B-X
the	B-X
immunodetection	B-X
of	B-X
proteins	B-X
,	B-X
particularly	B-X
proteins	B-X
that	B-X
are	B-X
of	B-X
low	B-X
abundance	B-X
.	B-X
Western	B-X
blotting	B-X
(	B-X
protein	B-X
blotting	B-X
or	B-X
immunoblotting	B-X
)	B-X
is	B-X
a	B-X
powerful	B-X
and	B-X
important	B-X
procedure	B-X
for	B-X
the	B-X
immunodetection	B-X
of	B-X
proteins	B-X
post-electrophoresis	B-X
,	B-X
particularly	B-X
proteins	B-X
that	B-X
are	B-X
of	B-X
low	B-X
abundance	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X

Tumor	O
tissues	O
were	O
homogenized	O
with	O
protein	O
extraction	O
solution	O
(	O
PRO	O
-	O
PREPTM	O
,	O
Intron	O
Biotechnology	O
,	O
Seoul	O
,	O
Korea	O
)	O
,	O
and	O
lysed	O
by	O
60	O
min	O
incubation	O
on	O
ice	O
.	O

The	O
tissue	O
lysate	O
centrifuged	O
at	O
15	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

Equal	O
amounts	O
of	O
proteins	O
(	O
40	O
microg	O
)	O
were	O
separated	O
on	O
a	O
SDS	O
/	O
12	O
%	O
-	O
polyacrylamide	O
gel	O
,	O
and	O
then	O
transferred	O
to	O
a	O
polyvinylidene	O
difluoride	O
(	O
PVDF	O
)	O
membrane	O
(	O
GE	O
Water	O
and	O
Process	O
technologies	O
,	O
Trevose	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Blots	O
were	O
blocked	O
for	O
1	O
h	O
at	O
room	O
temperature	O
with	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
non	O
-	O
fat	O
dried	O
milk	O
in	O
Tris	O
-	O
Buffered	O
Saline	O
Tween	O
-	O
20	O
[	O
TBST	O
:	O
10	O
mM	O
Tris	O
(	O
pH	O
8	O
.	O
0	O
)	O
and	O
150	O
mM	O
NaCl	O
solution	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
]	O
.	O

After	O
a	O
short	O
washing	O
in	O
TBST	O
,	O
the	O
membranes	O
were	O
immunoblotted	O
with	O
the	O
following	O
primary	O
antibodies	O
:	O
mouse	O
monoclonal	O
antibodies	O
directed	O
against	O
p65	B-Protein
and	O
p50	B-Protein
(	O
1	O
:	O
500	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
rabbit	O
polyclonal	O
antibodies	O
directed	O
against	O
Bax	O
and	O
PARP	O
(	O
1	O
:	O
500	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
and	O
against	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
9	O
,	O
Bcl	O
-	O
2	O
and	O
c	B-Protein
-	I-Protein
IAP	I-Protein
-	I-Protein
1	I-Protein
(	O
1	O
:	O
1000	O
dilutions	O
;	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
MA	O
)	O
.	O

The	O
blots	O
were	O
incubated	O
with	O
the	O
respective	O
horseradish	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	O
or	O
anti	O
-	O
mouse	O
IgG	O
(	O
1	O
:	O
4000	O
dilutions	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
use	B-X
a	B-X
P.	B-X
heterotremus	B-X
cDNA	B-X
library	B-X
to	B-X
create	B-X
a	B-X
recombinant	B-X
version	B-X
of	B-X
this	B-X
antigen	B-X
for	B-X
use	B-X
in	B-X
immunodiagnosis	B-X
of	B-X
paragonimiasis	B-X
.	B-X
An	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
has	B-X
been	B-X
developed	B-X
to	B-X
detect	B-X
antibodies	B-X
against	B-X
surface	B-X
components	B-X
of	B-X
rat	B-X
islet	B-X
and	B-X
spleen	B-X
lymphocytes	B-X
.	B-X
Live	B-X
islet	B-X
tumor	B-X
RIN5	B-X
AH	B-X
cells	B-X
expressing	B-X
characteristic	B-X
ganglioside	B-X
target	B-X
antigens	B-X
or	B-X
rat	B-X
spleen	B-X
cells	B-X
were	B-X
immobilized	B-X
onto	B-X
wells	B-X
of	B-X
microtiter	B-X
polystyrene	B-X
plates	B-X
precoated	B-X
with	B-X
poly-l-lysine	B-X
and	B-X
then	B-X
incubated	B-X
with	B-X
test	B-X
or	B-X
normal	B-X
rat	B-X
sera	B-X
.	B-X
Cell	B-X
surface-bound	B-X
antibodies	B-X
were	B-X
quantitated	B-X
after	B-X
reaction	B-X
with	B-X
horseradish	B-X
peroxidase-conjugated	B-X
rabbit	B-X
anti-rat	B-X
Ig	B-X
.	B-X
With	B-X
this	B-X
assay	B-X
,	B-X
46	B-X
%	B-X
(	B-X
6/13	B-X
)	B-X
of	B-X
sera	B-X
from	B-X
diabetes-prone	B-X
BB	B-X
rats	B-X
and	B-X
100	B-X
%	B-X
(	B-X
8/8	B-X
)	B-X
of	B-X
sera	B-X
from	B-X
rats	B-X
treated	B-X
with	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant/streptozotocin	B-X
(	B-X
CFA/STZ	B-X
)	B-X
prior	B-X
to	B-X
immunization	B-X
with	B-X
RIN	B-X
cells	B-X
had	B-X
islet	B-X
cell	B-X
surface	B-X
antibodies	B-X
:	B-X
54	B-X
%	B-X
(	B-X
7/13	B-X
)	B-X
and	B-X
75	B-X
%	B-X
(	B-X
6/8	B-X
)	B-X
,	B-X
respectively	B-X
,	B-X
were	B-X
positive	B-X
for	B-X
lymphocyte	B-X
antibodies	B-X
(	B-X
defined	B-X
as	B-X
the	B-X
HRP	B-X
anti-rat	B-X
Ig	B-X
binding	B-X
exceeding	B-X
the	B-X
mean	B-X
+	B-X
2SD	B-X
of	B-X
control	B-X
group	B-X
values	B-X
)	B-X
.	B-X
SDS	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
followed	B-X
by	B-X
immunoblotting	B-X
analysis	B-X
suggested	B-X
that	B-X
the	B-X
islet	B-X
cell	B-X
antibodies	B-X
in	B-X
sera	B-X
from	B-X
the	B-X
BB	B-X
and	B-X
CFA/STZ	B-X
rats	B-X
recognized	B-X
RIN-cell	B-X
components	B-X
that	B-X
were	B-X
different	B-X
in	B-X
their	B-X
molecular	B-X
weights	B-X
.	B-X
These	B-X
antigens	B-X
were	B-X
not	B-X
detectable	B-X
on	B-X
spleen	B-X
cells	B-X
indicating	B-X
that	B-X
the	B-X
ELISA	B-X
described	B-X
can	B-X
be	B-X
used	B-X
to	B-X
quantitate	B-X
levels	B-X
of	B-X
islet	B-X
cell	B-X
specific	B-X
antibodies	B-X
which	B-X
possibly	B-X
reflect	B-X
beta	B-X
cell	B-X
damage	B-X
with	B-X
progression	B-X
to	B-X
islet	B-X
degeneration	B-X
in	B-X
the	B-X
rat	B-X
.	B-X

Immunoreactive	O
proteins	O
were	O
detected	O
with	O
the	O
ECL	O
detection	O
system	O
.	O
<EOS>	B-X
A	B-X
quenching-typed	B-X
electrochemiluminescence	B-X
(	B-X
ECL	B-X
)	B-X
immunosensing	B-X
method	B-X
was	B-X
proposed	B-X
for	B-X
protein	B-X
detection	B-X
by	B-X
the	B-X
redox	B-X
reaction	B-X
of	B-X
tungsten-based	B-X
polyoxometalate	B-X
nanoclusters	B-X
(	B-X
W-POM	B-X
NCs	B-X
)	B-X
with	B-X
free	B-X
radical	B-X
(	B-X
O	B-X
This	B-X
work	B-X
presents	B-X
a	B-X
novel	B-X
signal	B-X
amplification	B-X
strategy	B-X
for	B-X
electrochemiluminescence	B-X
(	B-X
ECL	B-X
)	B-X
biosensor	B-X
based	B-X
on	B-X
liposome-assisted	B-X
chemical	B-X
redox	B-X
cycling	B-X
for	B-X
in	B-X
situ	B-X
formation	B-X
of	B-X
Au	B-X
nanoparticles	B-X
(	B-X
Au	B-X
NPs	B-X
)	B-X
on	B-X
TiO	B-X
Proteins	B-X
participating	B-X
in	B-X
vesicular	B-X
docking	B-X
and	B-X
fusion	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
Such	B-X
proteins	B-X
appear	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
molecular	B-X
regulation	B-X
of	B-X
exocytosis	B-X
also	B-X
in	B-X
non-neuronal	B-X
cells	B-X
.	B-X
The	B-X
enterochromaffin-like	B-X
(	B-X
ECL	B-X
)	B-X
cells	B-X
of	B-X
the	B-X
gastric	B-X
acid-secreting	B-X
(	B-X
oxyntic	B-X
)	B-X
mucosa	B-X
secrete	B-X
histamine	B-X
and	B-X
chromogranin	B-X
A-derived	B-X
peptides	B-X
,	B-X
such	B-X
as	B-X
pancreastatin	B-X
.	B-X
Using	B-X
immunohistochemistry	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
whether	B-X
the	B-X
ECL	B-X
cells	B-X
of	B-X
the	B-X
rat	B-X
stomach	B-X
,	B-X
identified	B-X
with	B-X
antibodies	B-X
to	B-X
histidine	B-X
decarboxylase	B-X
(	B-X
HDC	B-X
,	B-X
the	B-X
histamine-forming	B-X
enzyme	B-X
)	B-X
,	B-X
express	B-X
the	B-X
same	B-X
exocytotic	B-X
proteins	B-X
as	B-X
neurons	B-X
.	B-X
The	B-X
ECL	B-X
cells	B-X
displayed	B-X
immunoreactivity	B-X
for	B-X
synaptophysin	B-X
,	B-X
synaptotagmin	B-X
III	B-X
,	B-X
vesicle-associated	B-X
membrane	B-X
protein-2	B-X
(	B-X
VAMP-2	B-X
)	B-X
,	B-X
cysteine	B-X
string	B-X
protein	B-X
(	B-X
CSP	B-X
)	B-X
,	B-X
vesicular	B-X
monoamine	B-X
transporter-2	B-X
(	B-X
VMAT-2	B-X
)	B-X
,	B-X
synaptosomal-associated	B-X
protein	B-X
of	B-X
25	B-X
kDa	B-X
(	B-X
SNAP-25	B-X
)	B-X
,	B-X
syntaxin	B-X
,	B-X
and	B-X
Munc-18	B-X
,	B-X
but	B-X
not	B-X
for	B-X
synaptotagmin	B-X
I/II	B-X
and	B-X
VAMP-1	B-X
.	B-X
Synaptophysin	B-X
and	B-X
VMAT-2	B-X
could	B-X
be	B-X
detected	B-X
not	B-X
only	B-X
in	B-X
the	B-X
ECL	B-X
cells	B-X
,	B-X
but	B-X
also	B-X
in	B-X
a	B-X
population	B-X
of	B-X
HDC-negative	B-X
cells	B-X
.	B-X
The	B-X
demonstration	B-X
of	B-X
synaptotagmin	B-X
III	B-X
in	B-X
only	B-X
a	B-X
limited	B-X
number	B-X
of	B-X
ECL	B-X
cells	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
subpopulation	B-X
of	B-X
ECL	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
several	B-X
exocytotic	B-X
proteins	B-X
,	B-X
previously	B-X
identified	B-X
in	B-X
neurons	B-X
,	B-X
are	B-X
present	B-X
in	B-X
rat	B-X
stomach	B-X
ECL	B-X
cells	B-X
.	B-X
Hence	B-X
,	B-X
proteins	B-X
engaged	B-X
in	B-X
vesicular	B-X
docking	B-X
and	B-X
in	B-X
the	B-X
fusion	B-X
of	B-X
granule/vesicle	B-X
membrane	B-X
with	B-X
plasma	B-X
membrane	B-X
seem	B-X
to	B-X
exist	B-X
in	B-X
both	B-X
neurons	B-X
and	B-X
endocrine	B-X
cells	B-X
.	B-X

Immunohistochemistry	O
<EOS>	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
for	B-X
tissue-based	B-X
diagnostics	B-X
and	B-X
biomarker	B-X
detection	B-X
with	B-X
broad	B-X
worldwide	B-X
adoption	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
in	B-X
many	B-X
veterinary	B-X
laboratories	B-X
for	B-X
diagnostic	B-X
and	B-X
research	B-X
purposes	B-X
.	B-X
Next-Generation	B-X
Pathology	B-X
by	B-X
Multiplexed	B-X
Immunohistochemistry	B-X
.	B-X

All	O
specimens	O
were	O
fixed	O
in	O
formalin	O
and	O
embedded	O
in	O
paraffin	O
for	O
examination	O
.	O
<EOS>	B-X
In	B-X
situ	B-X
analysis	B-X
of	B-X
biomarkers	B-X
is	B-X
highly	B-X
desirable	B-X
in	B-X
molecular	B-X
pathology	B-X
because	B-X
it	B-X
allows	B-X
the	B-X
examination	B-X
of	B-X
biomarker	B-X
status	B-X
within	B-X
the	B-X
histopathological	B-X
context	B-X
of	B-X
clinical	B-X
specimens	B-X
.	B-X
RNAscope	B-X
is	B-X
compatible	B-X
with	B-X
routine	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
tissue	B-X
specimens	B-X
and	B-X
can	B-X
use	B-X
either	B-X
conventional	B-X
chromogenic	B-X
dyes	B-X
for	B-X
bright-field	B-X
microscopy	B-X
or	B-X
fluorescent	B-X
dyes	B-X
for	B-X
multiplex	B-X
analysis	B-X
.	B-X
Microvascular	B-X
invasion	B-X
(	B-X
MVI	B-X
)	B-X
,	B-X
a	B-X
major	B-X
risk	B-X
factor	B-X
for	B-X
tumor	B-X
recurrence	B-X
after	B-X
surgery	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
,	B-X
is	B-X
only	B-X
detectable	B-X
by	B-X
microscopic	B-X
examination	B-X
of	B-X
the	B-X
surgical	B-X
specimen	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
define	B-X
a	B-X
transcriptomic	B-X
signature	B-X
associated	B-X
with	B-X
MVI	B-X
in	B-X
HCC	B-X
than	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
formalin-fixed	B-X
paraffin-embedded	B-X
(	B-X
FFPE	B-X
)	B-X
biopsies	B-X
for	B-X
use	B-X
in	B-X
clinical	B-X
practice	B-X
.	B-X

Sections	O
(	O
4	O
microm	O
thick	O
)	O
were	O
stained	O
with	O
H	O
&	O
E	O
and	O
analyzed	O
by	O
immunohistochemistry	O
.	O

The	O
paraffin	O
-	O
embedded	O
sections	O
were	O
deparaffinized	O
and	O
rehydrated	O
,	O
washed	O
in	O
distilled	O
water	O
,	O
and	O
then	O
subjected	O
to	O
heat	O
-	O
mediated	O
antigen	O
retrieval	O
.	O

Endogenous	O
peroxidase	O
activity	O
was	O
quenched	O
by	O
incubation	O
in	O
3	O
%	O
hydrogen	O
peroxide	O
in	O
methanol	O
for	O
15	O
min	O
,	O
followed	O
by	O
clearing	O
in	O
PBS	O
for	O
5	O
min	O
.	O

The	O
sections	O
were	O
blocked	O
for	O
30	O
min	O
with	O
3	O
%	O
normal	O
horse	O
serum	O
diluted	O
in	O
PBS	O
,	O
blotted	O
,	O
and	O
incubated	O
with	O
primary	O
mouse	O
anti	O
-	O
mouse	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
,	O
1	O
:	O
200	O
dilution	O
)	O
monoclonal	O
antibodies	O
in	O
blocking	O
serum	O
for	O
4	O
h	O
at	O
room	O
temperature	O
.	O

Thereafter	O
,	O
the	O
slides	O
were	O
washed	O
three	O
times	O
for	O
5	O
min	O
each	O
in	O
PBS	O
and	O
incubated	O
with	O
biotinylated	O
anti	O
-	O
mouse	O
and	O
anti	O
-	O
rabbit	O
antibodies	O
for	O
2	O
h	O
.	O

The	O
slides	O
were	O
washed	O
in	O
PBS	O
,	O
followed	O
by	O
the	O
addition	O
of	O
the	O
avidin	O
biotin	O
peroxidase	O
complex	O
(	O
ABC	O
kit	O
;	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
slides	O
were	O
washed	O
and	O
the	O
peroxidase	O
reaction	O
was	O
developed	O
with	O
diaminobenzidine	O
(	O
DAB	O
)	O
and	O
peroxide	O
,	O
followed	O
by	O
counterstaining	O
with	O
hematoxylin	O
,	O
mounting	O
in	O
aqua	O
-	O
mount	O
,	O
and	O
evaluation	O
under	O
a	O
light	O
microscope	O
(	O
magnificationx200	O
;	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

A	O
negative	O
control	O
was	O
included	O
in	O
all	O
experiments	O
by	O
omitting	O
the	O
primary	O
antibody	O
.	O

For	O
the	O
detection	O
of	O
apoptotic	O
cell	O
death	O
in	O
the	O
tumor	O
tissues	O
,	O
the	O
paraffin	O
-	O
embedded	O
sections	O
were	O
incubated	O
in	O
a	O
mixture	O
of	O
the	O
labeling	O
solution	O
(	O
540	O
microl	O
)	O
and	O
enzyme	O
solution	O
(	O
60	O
microl	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
,	O
and	O
then	O
washed	O
three	O
times	O
in	O
0	O
.	O
1	O
M	O
PBS	O
for	O
5	O
min	O
each	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Next	O
,	O
the	O
sections	O
were	O
incubated	O
with	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
for	O
15	O
min	O
at	O
37degreesC	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
rinsed	O
,	O
mounted	O
on	O
slides	O
,	O
and	O
cover	O
-	O
slipped	O
for	O
fluorescence	O
microscopy	O
(	O
DAS	O
microscope	O
)	O
.	O

Immunofluorescence	O
<EOS>	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
is	B-X
an	B-X
important	B-X
immunochemical	B-X
technique	B-X
that	B-X
allows	B-X
for	B-X
detection	B-X
and	B-X
localization	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
antigens	B-X
in	B-X
different	B-X
types	B-X
of	B-X
tissues	B-X
of	B-X
various	B-X
cell	B-X
preparations	B-X
.	B-X
Immunofluorescence	B-X
techniques	B-X
.	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
studies	B-X
have	B-X
now	B-X
become	B-X
an	B-X
invaluable	B-X
supplement	B-X
to	B-X
clinical	B-X
and	B-X
histological	B-X
examination	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
dermatological	B-X
diseases	B-X
.	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
on	B-X
tissue	B-X
sections	B-X
allows	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
protein	B-X
species	B-X
subcellular	B-X
localization	B-X
.	B-X

Sections	O
were	O
treated	O
with	O
10	O
%	O
bovine	O
serum	O
albumin	O
in	O
PBS	O
for	O
1	O
h	O
at	O
room	O
temperature	O
,	O
incubated	O
overnight	O
at	O
4degreesC	O
with	O
p50	B-Protein
(	O
1	O
:	O
250	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
p65	B-Protein
(	O
1	O
:	O
250	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
Bax	O
(	O
1	O
:	O
200	O
dilution	O
)	O
,	O
cleaved	O
caspase	O
-	O
3	O
(	O
1	O
:	O
100	O
)	O
,	O
CD8	O
(	O
1	O
:	O
10	O
)	O
,	O
CD57	O
(	O
1	O
:	O
50	O
)	O
and	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
(	O
1	O
:	O
500	O
)	O
antibodies	O
,	O
followed	O
by	O
incubation	O
in	O
anti	O
-	O
mouse	O
IgG	O
conjugated	O
with	O
Alexa	O
488	O
(	O
1	O
:	O
100	O
dilution	O
,	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
and	O
anti	O
-	O
rabbit	O
IgG	O
conjugated	O
with	O
Alexa	O
568	O
(	O
1	O
:	O
100	O
dilution	O
,	O
Molecular	O
Probes	O
)	O
for	O
40	O
min	O
at	O
room	O
temperature	O
.	O

Finally	O
,	O
the	O
sections	O
were	O
rinsed	O
,	O
mounted	O
on	O
slides	O
,	O
and	O
cover	O
-	O
slipped	O
for	O
fluorescence	O
microscopy	O
and	O
photography	O
using	O
ApoTome	O
microscopy	O
(	O
Carl	O
Zeiss	O
,	O
Thornwood	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Gel	O
Electromobility	O
Shift	O
Assay	O
<EOS>	B-X
Electromobility	B-X
shift	B-X
assays	B-X
were	B-X
developed	B-X
in	B-X
native	B-X
capillary	B-X
gels	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
used	B-X
for	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
in	B-X
the	B-X
second	B-X
dimension	B-X
.	B-X
Electromobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
provide	B-X
a	B-X
way	B-X
to	B-X
study	B-X
proteinnucleic	B-X
acid	B-X
interactions	B-X
.	B-X
Electromobility	B-X
gel	B-X
shift	B-X
assay	B-X
was	B-X
carried	B-X
out	B-X
by	B-X
the	B-X
incubation	B-X
of	B-X
nuclear	B-X
proteins	B-X
from	B-X
cultured	B-X
human	B-X
mononuclear	B-X
cells	B-X
with	B-X
oligonucleotides	B-X
representing	B-X
the	B-X
alternate	B-X
-174	B-X
alleles	B-X
.	B-X
Electromobility	B-X
shift	B-X
assays	B-X
using	B-X
hepatic	B-X
nuclear	B-X
extracts	B-X
from	B-X
these	B-X
neonates	B-X
and	B-X
the	B-X
GH	B-X
response	B-X
element	B-X
from	B-X
the	B-X
serine	B-X
protease	B-X
inhibitor	B-X
2.1	B-X
promoter	B-X
showed	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
5	B-X
(	B-X
Stat5	B-X
)	B-X
binding	B-X
in	B-X
response	B-X
to	B-X
GH	B-X
in	B-X
extracts	B-X
from	B-X
d-7	B-X
rats	B-X
only	B-X
.	B-X

A	O
gel	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

The	O
tumor	O
tissues	O
were	O
briefly	O
homogenized	O
in	O
200	O
microl	O
of	O
solution	O
A	O
(	O
10	O
mM	O
HEPES	O
[	O
pH	O
7	O
.	O
9	O
]	O
,	O
1	O
.	O
5	O
mM	O
MgCl2	O
,	O
10	O
mM	O
KCl	O
,	O
0	O
.	O
5	O
mM	O
dithiothreitol	O
,	O
0	O
.	O
2	O
mM	O
phenylmethylsulfonylfluoride	O
)	O
,	O
vortexed	O
vigorously	O
,	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
,	O
and	O
then	O
centrifuged	O
at	O
15000	O
rpm	O
for	O
15	O
min	O
.	O

The	O
pelleted	O
nuclei	O
were	O
resuspended	O
in	O
solution	O
C	O
(	O
solution	O
A	O
supplemented	O
with	O
420	O
mM	O
NaCl	O
and	O
20	O
%	O
glycerol	O
)	O
,	O
and	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
.	O

The	O
resuspended	O
pellet	O
was	O
centrifuged	O
at	O
15000	O
rpm	O
for	O
15	O
min	O
,	O
and	O
the	O
resulting	O
nuclear	O
extracts	O
supernatant	O
were	O
collected	O
in	O
a	O
chilled	O
Eppendorf	O
tube	O
.	O

Consensus	O
oligonucleotides	O
were	O
end	O
-	O
labeled	O
using	O
T4	O
polynucleotide	O
kinase	O
and	O
[	O
P32	O
]	O
-	O
ATP	O
for	O
10	O
min	O
at	O
37degreesC	O
.	O

The	O
gel	O
shift	O
reactions	O
were	O
assembled	O
and	O
incubated	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
1	O
ml	O
of	O
gel	O
loading	O
buffer	O
was	O
added	O
to	O
each	O
reaction	O
and	O
loaded	O
onto	O
a	O
6	O
%	O
non	O
-	O
denaturating	O
gel	O
.	O

The	O
gel	O
was	O
subjected	O
to	O
electrophoresis	O
until	O
the	O
dye	O
was	O
four	O
-	O
fifths	O
of	O
the	O
way	O
down	O
the	O
gel	O
.	O

The	O
gel	O
was	O
dried	O
for	O
1	O
h	O
at	O
80degreesC	O
and	O
exposed	O
to	O
film	O
overnight	O
at	O
-	O
70degreesC	O
.	O

Flow	O
Cytometric	O
Analysis	O
<EOS>	B-X
Flow	B-X
cytometric	B-X
DNA	B-X
analysis	B-X
,	B-X
including	B-X
principles	B-X
,	B-X
techniques	B-X
,	B-X
and	B-X
applications	B-X
,	B-X
is	B-X
reviewed	B-X
.	B-X
Flow	B-X
cytometry	B-X
,	B-X
a	B-X
relatively	B-X
recently	B-X
developed	B-X
technology	B-X
,	B-X
is	B-X
being	B-X
increasingly	B-X
used	B-X
in	B-X
the	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
benign	B-X
and	B-X
malignant	B-X
diseases	B-X
.	B-X
Flow	B-X
cytometric	B-X
DNA	B-X
analysis	B-X
offers	B-X
a	B-X
quick	B-X
,	B-X
reliable	B-X
method	B-X
of	B-X
analyzing	B-X
cellular	B-X
DNA	B-X
content	B-X
capable	B-X
of	B-X
identifying	B-X
cell	B-X
populations	B-X
with	B-X
abnormalities	B-X
in	B-X
total	B-X
DNA	B-X
content	B-X
.	B-X
Flow	B-X
cytometric	B-X
analysis	B-X
thus	B-X
allows	B-X
the	B-X
pathologist	B-X
to	B-X
more	B-X
effectively	B-X
diagnose	B-X
,	B-X
predict	B-X
prognosis	B-X
,	B-X
and	B-X
monitor	B-X
disease	B-X
progression	B-X
.	B-X

Lymphocytes	O
were	O
obtained	O
from	O
tumor	O
and	O
spleen	O
tissues	O
for	O
phenotype	O
analysis	O
.	O
<EOS>	B-X
Non-lymphoid	B-X
tissues	B-X
(	B-X
NLTs	B-X
)	B-X
harbor	B-X
a	B-X
pool	B-X
of	B-X
adaptive	B-X
immune	B-X
cells	B-X
with	B-X
largely	B-X
unexplored	B-X
phenotype	B-X
and	B-X
development	B-X
.	B-X
AID	B-X
deficiency	B-X
caused	B-X
a	B-X
complete	B-X
defect	B-X
in	B-X
class	B-X
switching	B-X
and	B-X
showed	B-X
a	B-X
hyper-IgM	B-X
phenotype	B-X
with	B-X
enlarged	B-X
germinal	B-X
centers	B-X
containing	B-X
strongly	B-X
activated	B-X
B	B-X
cells	B-X
before	B-X
or	B-X
after	B-X
immunization	B-X
.	B-X
AID-/-	B-X
spleen	B-X
cells	B-X
stimulated	B-X
in	B-X
vitro	B-X
with	B-X
LPS	B-X
and	B-X
cytokines	B-X
failed	B-X
to	B-X
undergo	B-X
class	B-X
switch	B-X
recombination	B-X
although	B-X
they	B-X
expressed	B-X
germline	B-X
transcripts	B-X
.	B-X
A	B-X
prototypical	B-X
vagus	B-X
nerve	B-X
circuit	B-X
,	B-X
the	B-X
inflammatory	B-X
reflex	B-X
,	B-X
inhibits	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
production	B-X
in	B-X
spleen	B-X
by	B-X
a	B-X
mechanism	B-X
requiring	B-X
acetylcholine	B-X
signaling	B-X
through	B-X
the	B-X
α7	B-X
nicotinic	B-X
acetylcholine	B-X
receptor	B-X
expressed	B-X
on	B-X
cytokine-producing	B-X
macrophages	B-X
.	B-X
Nerve	B-X
fibers	B-X
in	B-X
spleen	B-X
lack	B-X
the	B-X
enzymatic	B-X
machinery	B-X
necessary	B-X
for	B-X
acetylcholine	B-X
production	B-X
;	B-X
therefore	B-X
,	B-X
how	B-X
does	B-X
this	B-X
neural	B-X
circuit	B-X
terminate	B-X
in	B-X
cholinergic	B-X
signaling	B-X
?	B-X
We	B-X
identified	B-X
an	B-X
acetylcholine-producing	B-X
,	B-X
memory	B-X
phenotype	B-X
T	B-X
cell	B-X
population	B-X
in	B-X
mice	B-X
that	B-X
is	B-X
integral	B-X
to	B-X
the	B-X
inflammatory	B-X
reflex	B-X
.	B-X

Spleen	O
and	O
tumor	O
lymphocytes	O
were	O
isolated	O
from	O
fresh	O
spleen	O
and	O
tumor	O
biopsies	O
obtained	O
from	O
three	O
mice	O
per	O
group	O
.	O

Spleen	O
and	O
tumor	O
biopsies	O
were	O
briefly	O
homogenized	O
mechanically	O
in	O
PBS	O
,	O
filtered	O
(	O
100	O
microm	O
cell	O
strainer	O
;	O
BD	O
PharMingen	O
)	O
and	O
then	O
placed	O
in	O
lysis	O
buffer	O
(	O
ACK	O
lysing	O
buffer	O
,	O
LONZA	O
)	O
to	O
remove	O
red	O
blood	O
cells	O
.	O

One	O
million	O
splenocytes	O
were	O
washed	O
once	O
in	O
PBS	O
containing	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
and	O
re	O
-	O
suspended	O
in	O
100	O
microl	O
of	O
PBS	O
/	O
BSA	O
buffer	O
.	O

Meanwhile	O
,	O
one	O
million	O
cells	O
obtained	O
from	O
tumor	O
tissues	O
were	O
placed	O
in	O
RPMI	O
medium	O
,	O
incubated	O
to	O
obtain	O
suspension	O
cell	O
for	O
1hour	O
at	O
37degreesC	O
,	O
centrifuged	O
(	O
1200	O
rpm	O
,	O
3	O
min	O
)	O
and	O
then	O
washed	O
in	O
PBS	O
.	O

Next	O
,	O
the	O
lymphocytes	O
were	O
incubated	O
with	O
various	O
conjugated	O
monoclonal	O
antibodies	O
,	O
including	O
CD4	B-Protein
-	O
APC	O
,	O
CD8	O
-	O
FITC	O
and	O
CD19	B-Protein
-	O
PE	O
for	O
20min	O
at	O
4degreesC	O
,	O
washed	O
twice	O
in	O
PBS	O
,	O
and	O
re	O
-	O
suspended	O
in	O
400	O
microl	O
of	O
PBS	O
.	O

A	O
flow	O
cytometric	O
analysis	O
was	O
performed	O
on	O
a	O
FACSAria	O
flow	O
cytometry	O
(	O
BD	O
Biosciences	O
)	O
,	O
and	O
the	O
data	O
were	O
analyzed	O
using	O
the	O
WinMDI	O
statistical	O
software	O
(	O
Scripps	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Forward	O
and	O
side	O
scatter	O
parameters	O
were	O
used	O
to	O
gate	O
on	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
light-scatter	B-X
characteristics	B-X
of	B-X
lymphocytes	B-X
are	B-X
commonly	B-X
used	B-X
to	B-X
gate	B-X
lymphocytes	B-X
for	B-X
further	B-X
analysis	B-X
in	B-X
a	B-X
lysed	B-X
whole-blood	B-X
assay	B-X
.	B-X
Because	B-X
lymphocytes	B-X
can	B-X
be	B-X
identified	B-X
by	B-X
antigens	B-X
that	B-X
they	B-X
possess	B-X
,	B-X
a	B-X
light-scatter	B-X
gate	B-X
can	B-X
be	B-X
validated	B-X
by	B-X
measuring	B-X
parameters	B-X
other	B-X
than	B-X
light	B-X
scatter	B-X
.	B-X
When	B-X
a	B-X
specimen	B-X
possesses	B-X
poor	B-X
light	B-X
scatter	B-X
(	B-X
usually	B-X
from	B-X
contaminating	B-X
nonlymphocytes	B-X
within	B-X
the	B-X
light-scatter	B-X
gate	B-X
for	B-X
lymphocytes	B-X
)	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
gate	B-X
and	B-X
,	B-X
thus	B-X
,	B-X
the	B-X
analyses	B-X
of	B-X
lymphocyte	B-X
subsets	B-X
can	B-X
be	B-X
compromised	B-X
.	B-X
We	B-X
present	B-X
data	B-X
to	B-X
demonstrate	B-X
the	B-X
use	B-X
of	B-X
CD45	B-X
fluorescence	B-X
combined	B-X
with	B-X
side	B-X
scatter	B-X
(	B-X
SSC	B-X
)	B-X
for	B-X
analyzing	B-X
lysed	B-X
whole-blood	B-X
specimens	B-X
.	B-X
When	B-X
we	B-X
compared	B-X
CD45/SSC	B-X
to	B-X
light	B-X
scatter	B-X
(	B-X
forward	B-X
and	B-X
side	B-X
scatter	B-X
)	B-X
for	B-X
validating	B-X
a	B-X
lymphocyte	B-X
gate	B-X
,	B-X
both	B-X
methods	B-X
performed	B-X
similarly	B-X
in	B-X
recovering	B-X
as	B-X
many	B-X
lymphocytes	B-X
as	B-X
possible	B-X
in	B-X
the	B-X
gate	B-X
(	B-X
lymphocyte	B-X
recovery	B-X
)	B-X
;	B-X
however	B-X
,	B-X
the	B-X
CD45/SSC	B-X
gate	B-X
had	B-X
fewer	B-X
contaminants	B-X
within	B-X
the	B-X
gate	B-X
(	B-X
lymphocyte	B-X
purity	B-X
)	B-X
.	B-X
Replicate	B-X
CD3	B-X
values	B-X
from	B-X
the	B-X
CD45/SSC	B-X
gate	B-X
were	B-X
less	B-X
variable	B-X
than	B-X
those	B-X
from	B-X
the	B-X
light-scatter	B-X
gate	B-X
,	B-X
confirming	B-X
that	B-X
most	B-X
of	B-X
the	B-X
variability	B-X
in	B-X
a	B-X
light-scatter	B-X
gate	B-X
is	B-X
due	B-X
to	B-X
nonlymphocyte	B-X
contaminants	B-X
in	B-X
the	B-X
gate	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
lymphocytes	B-X
be	B-X
gated	B-X
using	B-X
CD45	B-X
fluorescence	B-X
as	B-X
well	B-X
as	B-X
side-scattering	B-X
properties	B-X
and	B-X
that	B-X
CD3	B-X
also	B-X
be	B-X
included	B-X
in	B-X
each	B-X
data	B-X
analysis	B-X
tube	B-X
for	B-X
quality	B-X
control	B-X
.	B-X

Protein	O
Immuno	O
-	O
arrays	O
<EOS>	B-X
Nonetheless	B-X
,	B-X
cost-	B-X
and	B-X
time-effective	B-X
,	B-X
high-throughput	B-X
targeted	B-X
phospho-proteomics	B-X
at	B-X
a	B-X
preclinical	B-X
stage	B-X
still	B-X
relies	B-X
on	B-X
ad	B-X
hoc	B-X
microarray	B-X
platforms	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Reverse-Phase	B-X
Protein	B-X
microArrays	B-X
(	B-X
RPPA	B-X
)	B-X
.	B-X
Immuno-MALDI-TOF-MS	B-X
in	B-X
the	B-X
Clinic	B-X
.	B-X
Reliable	B-X
on-chip	B-X
immuno-MALDI-TOF	B-X
MS	B-X
for	B-X
multiple	B-X
biomarkers	B-X
requires	B-X
successful	B-X
adaptation	B-X
of	B-X
antibody	B-X
array	B-X
biochips	B-X
,	B-X
which	B-X
also	B-X
must	B-X
accommodate	B-X
consistent	B-X
reaction	B-X
conditions	B-X
on	B-X
antibody	B-X
arrays	B-X
during	B-X
immuno-capture	B-X
and	B-X
MS	B-X
analysis	B-X
.	B-X
Hydrophilic	B-X
gold	B-X
arrays	B-X
surrounded	B-X
by	B-X
super-hydrophobic	B-X
surfaces	B-X
were	B-X
formed	B-X
on	B-X
a	B-X
gold	B-X
patterned	B-X
biochip	B-X
via	B-X
spontaneous	B-X
chemical	B-X
or	B-X
protein	B-X
layer	B-X
deposition	B-X
.	B-X

The	O
tumor	O
and	O
spleen	O
tissues	O
were	O
excised	O
and	O
homogenized	O
in	O
PBS	O
with	O
protease	O
inhibitor	O
cocktail	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
USA	O
)	O
and	O
Triton	O
X	O
-	O
100	O
(	O
final	O
concentration	O
1	O
%	O
)	O
.	O

The	O
samples	O
were	O
frozen	O
at	O
-	O
70degreesC	O
,	O
thawed	O
,	O
and	O
centrifuged	O
at	O
10	O
,	O
000xg	O
for	O
5	O
min	O
to	O
remove	O
cellular	O
debris	O
.	O

The	O
tissue	O
lysates	O
were	O
performed	O
protein	O
assay	O
in	O
the	O
same	O
way	O
as	O
for	O
western	O
blotting	O
.	O

4	O
.	O
5	O
mg	O
of	O
proteins	O
,	O
collected	O
from	O
three	O
samples	O
per	O
group	O
,	O
were	O
used	O
for	O
Mouse	O
cytokine	O
array	O
as	O
the	O
protocol	O
provided	O
by	O
supplier	O
(	O
Proteome	O
Profiler	O
(	O
TM	O
)	O
,	O
#	O
ARY006	O
,	O
R	O
&	O
D	O
Systems	O
,	O
USA	O
)	O
.	O

Statistical	O
Analysis	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
GraphPad	O
Prism	O
4	O
ver	O
.	O

4	O
.	O
03	O
software	O
(	O
GraphPad	O
Software	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O
<EOS>	B-X
Dizziness	B-X
is	B-X
a	B-X
common	B-X
complaint	B-X
presented	B-X
in	B-X
the	B-X
emergency	B-X
department	B-X
(	B-X
ED	B-X
)	B-X
.	B-X
Although	B-X
TMTS	B-X
is	B-X
typically	B-X
ascribed	B-X
to	B-X
high-income	B-X
countries	B-X
and	B-X
TLTL	B-X
to	B-X
low-income	B-X
and	B-X
middle-income	B-X
ones	B-X
,	B-X
social	B-X
and	B-X
health	B-X
inequities	B-X
mean	B-X
these	B-X
extremes	B-X
coexist	B-X
in	B-X
many	B-X
countries	B-X
.	B-X
Data	B-X
were	B-X
collected	B-X
from	B-X
8am	B-X
to	B-X
7pm	B-X
from	B-X
a	B-X
period	B-X
that	B-X
spanned	B-X
a	B-X
total	B-X
of	B-X
40	B-X
week-day	B-X
on	B-X
calls	B-X
.	B-X
The	B-X
total	B-X
number	B-X
of	B-X
bleeps	B-X
was	B-X
491	B-X
,	B-X
the	B-X
mean	B-X
(	B-X
SD	B-X
)	B-X
bleep	B-X
count/day	B-X
irrespective	B-X
of	B-X
treatment	B-X
was	B-X
12.3	B-X
(	B-X
4.6	B-X
)	B-X
.	B-X
The	B-X
mean	B-X
(	B-X
SD	B-X
)	B-X
bleep	B-X
count	B-X
was	B-X
11.45	B-X
(	B-X
4.15	B-X
)	B-X
for	B-X
the	B-X
control	B-X
group	B-X
and	B-X
13.1	B-X
(	B-X
4.9	B-X
)	B-X
for	B-X
the	B-X
quiet	B-X
(	B-X
treatment	B-X
)	B-X
group	B-X
.	B-X
Welch	B-X
's	B-X
independent-sample	B-X
t	B-X
test	B-X
identified	B-X
no	B-X
significant	B-X
difference	B-X
in	B-X
the	B-X
mean	B-X
number	B-X
of	B-X
bleeps	B-X
encountered	B-X
between	B-X
groups	B-X
.	B-X
Moreover	B-X
,	B-X
ANOVA	B-X
identified	B-X
no	B-X
significant	B-X
difference	B-X
in	B-X
the	B-X
mean	B-X
number	B-X
of	B-X
bleeps	B-X
between	B-X
days	B-X
(	B-X
F	B-X
(	B-X
4,35	B-X
)	B-X
=0.086	B-X
,	B-X
p=0.986	B-X
)	B-X
.	B-X

Difference	O
between	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
were	O
compared	O
using	O
t	O
test	O
.	O
<EOS>	B-X
In	B-X
an	B-X
earlier	B-X
report	B-X
,	B-X
we	B-X
provided	B-X
evidence	B-X
that	B-X
expression	B-X
of	B-X
CCR5	B-X
by	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
renders	B-X
them	B-X
permissive	B-X
for	B-X
vaccinia	B-X
virus	B-X
(	B-X
VACV	B-X
)	B-X
replication	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
wild-type	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
and	B-X
CCR5	B-X
null	B-X
mice	B-X
were	B-X
challenged	B-X
with	B-X
VACV	B-X
by	B-X
intranasal	B-X
inoculation	B-X
.	B-X
In	B-X
time	B-X
course	B-X
studies	B-X
using	B-X
different	B-X
infective	B-X
doses	B-X
of	B-X
VACV	B-X
,	B-X
we	B-X
identified	B-X
viral	B-X
replication	B-X
in	B-X
the	B-X
lungs	B-X
of	B-X
both	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
and	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
yet	B-X
there	B-X
were	B-X
diminished	B-X
viral	B-X
loads	B-X
in	B-X
the	B-X
spleens	B-X
and	B-X
brains	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
with	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
association	B-X
with	B-X
VACV	B-X
infection	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
for	B-X
CD4+	B-X
and	B-X
CD8+	B-X
T-cell	B-X
as	B-X
well	B-X
as	B-X
CD11c+	B-X
and	B-X
F4/80+	B-X
cell	B-X
infiltration	B-X
into	B-X
the	B-X
lungs	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
but	B-X
not	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
the	B-X
CCR5-expressing	B-X
T	B-X
cells	B-X
harbor	B-X
virus	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
this	B-X
CCR5	B-X
dependence	B-X
is	B-X
VACV	B-X
specific	B-X
,	B-X
since	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
are	B-X
as	B-X
susceptible	B-X
to	B-X
intranasal	B-X
influenza	B-X
virus	B-X
(	B-X
A/WSN/33	B-X
)	B-X
infection	B-X
as	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
final	B-X
series	B-X
of	B-X
experiments	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
adoptive	B-X
transfer	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
bone	B-X
marrow	B-X
leukocytes	B-X
into	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
restores	B-X
VACV	B-X
permissiveness	B-X
,	B-X
with	B-X
evidence	B-X
of	B-X
lung	B-X
and	B-X
spleen	B-X
infection	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
suggest	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
CCR5	B-X
in	B-X
VACV	B-X
dissemination	B-X
in	B-X
vivo	B-X
.	B-X

A	O
value	O
of	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
conducted	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
COVID-19	B-X
vaccine	B-X
influence	B-X
on	B-X
unilateral	B-X
axillary	B-X
lymph	B-X
nodes	B-X
,	B-X
comparing	B-X
nodal	B-X
basal	B-X
features	B-X
with	B-X
their	B-X
characteristics	B-X
after	B-X
the	B-X
first	B-X
and	B-X
second	B-X
vaccination	B-X
dose	B-X
.	B-X
To	B-X
assess	B-X
ultrasound	B-X
characteristics	B-X
of	B-X
ipsilateral	B-X
axillary	B-X
lymph	B-X
nodes	B-X
after	B-X
two	B-X
doses	B-X
of	B-X
four	B-X
different	B-X
COVID-19	B-X
vaccination	B-X
protocols	B-X
,	B-X
to	B-X
determine	B-X
whether	B-X
these	B-X
parameters	B-X
differed	B-X
with	B-X
age	B-X
,	B-X
and	B-X
to	B-X
describe	B-X
how	B-X
they	B-X
changed	B-X
on	B-X
follow-up	B-X
imaging	B-X
.	B-X

Survival	O
data	O
were	O
presented	O
by	O
Kaplan	O
-	O
Meier	O
survival	O
estimates	O
and	O
compared	O
and	O
calculated	O
by	O
Log	O
-	O
rank	O
(	O
Mantel	O
-	O
Cox	O
)	O
Test	O
in	O
GraphPad	O
Prism	O
.	O

Inhibition	O
of	O
tumor	O
development	O
in	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
In	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
ALD	B-X
,	B-X
liver	B-X
injury	B-X
(	B-X
alanine	B-X
aminotransferase	B-X
[	B-X
ALT	B-X
]	B-X
)	B-X
and	B-X
steatosis	B-X
were	B-X
prevented	B-X
by	B-X
CVC	B-X
whether	B-X
administered	B-X
as	B-X
``	B-X
prevention	B-X
''	B-X
throughout	B-X
the	B-X
alcohol	B-X
feeding	B-X
or	B-X
as	B-X
``	B-X
treatment	B-X
''	B-X
started	B-X
after	B-X
the	B-X
development	B-X
of	B-X
ALD	B-X
.	B-X
We	B-X
found	B-X
that	B-X
prevention	B-X
and	B-X
treatment	B-X
with	B-X
CVC	B-X
reversed	B-X
alcohol-related	B-X
increases	B-X
in	B-X
liver	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
CCL2	B-X
.	B-X
Recruitment	B-X
of	B-X
MDSC	B-X
to	B-X
the	B-X
tumor	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
chemokines	B-X
and	B-X
chemokine	B-X
receptors	B-X
,	B-X
in	B-X
particular	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
(	B-X
CCR	B-X
)	B-X
5	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
mechanisms	B-X
of	B-X
CCR5	B-X
upregulation	B-X
and	B-X
increased	B-X
immunosuppressive	B-X
function	B-X
of	B-X
CCR5	B-X

A	O
-	O
C	O
,	O
Tumor	O
images	O
,	O
volumes	O
,	O
and	O
weights	O
.	O

B16	O
melanoma	O
cells	O
(	O
5x105	O
cells	O
/	O
mouse	O
)	O
were	O
inoculated	O
s	O
.	O
c	O
.	O
into	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
(	O
n	O
=	O
20	O
)	O
.	O

Tumor	O
volumes	O
were	O
measured	O
every	O
day	O
and	O
tumor	O
weights	O
were	O
measured	O
at	O
study	O
termination	O
(	O
Day	O
31	O
)	O
.	O
<EOS>	B-X
To	B-X
study	B-X
the	B-X
anti-tumor	B-X
effects	B-X
of	B-X
the	B-X
extracts	B-X
from	B-X
Huangqi	B-X
(	B-X
Radix	B-X
Astragali	B-X
Mongolici	B-X
)	B-X
and	B-X
Ezhu	B-X
(	B-X
Rhizoma	B-X
Curcumae	B-X
Phaeocaulis	B-X
)	B-X
on	B-X
the	B-X
growth	B-X
of	B-X
Lewis	B-X
lung	B-X
carcinoma	B-X
(	B-X
LLC	B-X
)	B-X
in	B-X
a	B-X
xenograft	B-X
mouse	B-X
model	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
possible	B-X
underlying	B-X
mechanism	B-X
.	B-X

The	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
had	O
a	O
significant	O
reduction	O
in	O
tumor	O
growth	O
and	O
volume	O
as	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O

The	O
results	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O
<EOS>	B-X
By	B-X
using	B-X
Baboon	B-X
envelope	B-X
pseudotyped	B-X
lentiviral	B-X
vectors	B-X
(	B-X
BaEV-LVs	B-X
)	B-X
encoding	B-X
eGFP	B-X
,	B-X
we	B-X
obtained	B-X
a	B-X
transduction	B-X
rate	B-X
of	B-X
23.0	B-X
±	B-X
6.6	B-X
%	B-X
(	B-X
mean	B-X
±	B-X
SD	B-X
)	B-X
in	B-X
freshly-isolated	B-X
human	B-X
NK-cells	B-X
(	B-X
FI-NK	B-X
)	B-X
and	B-X
83.4	B-X
±	B-X
10.1	B-X
%	B-X
(	B-X
mean	B-X
±	B-X
SD	B-X
)	B-X
in	B-X
NK-cells	B-X
obtained	B-X
from	B-X
the	B-X
NK-cell	B-X
Activation	B-X
and	B-X
Expansion	B-X
System	B-X
(	B-X
NKAES	B-X
)	B-X
,	B-X
with	B-X
a	B-X
sustained	B-X
transgene	B-X
expression	B-X
for	B-X
at	B-X
least	B-X
21	B-X
days	B-X
.	B-X
The	B-X
interaction	B-X
between	B-X
laminin-511/α6β1	B-X
integrin	B-X
and	B-X
E-cadherin	B-X
,	B-X
an	B-X
intercellular	B-X
adhesion	B-X
molecule	B-X
,	B-X
results	B-X
in	B-X
protection	B-X
against	B-X
apoptosis	B-X
through	B-X
the	B-X
proto-oncogene	B-X
tyrosine-protein	B-X
kinase	B-X
Fyn	B-X
(	B-X
Fyn	B-X
)	B-X
-RhoA-ROCK	B-X
signaling	B-X
pathway	B-X
and	B-X
the	B-X
Ras	B-X
homolog	B-X
gene	B-X
family	B-X
member	B-X
A	B-X
(	B-X
RhoA	B-X
)	B-X
/Rho	B-X
kinase	B-X
(	B-X
ROCK	B-X
)	B-X
signaling	B-X
pathway	B-X
(	B-X
the	B-X
major	B-X
pathway	B-X
for	B-X
cell	B-X
death	B-X
)	B-X
.	B-X
There	B-X
are	B-X
no	B-X
general	B-X
recommendations	B-X
on	B-X
how	B-X
changes	B-X
in	B-X
outcome	B-X
measure	B-X
(	B-X
effect	B-X
size	B-X
)	B-X
should	B-X
be	B-X
expressed	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
data	B-X
from	B-X
a	B-X
recently	B-X
published	B-X
study	B-X
to	B-X
express	B-X
change	B-X
as	B-X
:	B-X
a	B-X
)	B-X
the	B-X
mean	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
individual	B-X
baseline	B-X
,	B-X
b	B-X
)	B-X
the	B-X
median	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
individual	B-X
baseline	B-X
,	B-X
c	B-X
)	B-X
the	B-X
mean	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
SD	B-X
of	B-X
baseline	B-X
and	B-X
d	B-X
)	B-X
the	B-X
median	B-X
of	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
SD	B-X
of	B-X
baseline	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
correlations	B-X
between	B-X
different	B-X
ways	B-X
of	B-X
expressing	B-X
effect	B-X
sizes	B-X
were	B-X
poor	B-X
and	B-X
the	B-X
perceived	B-X
relative	B-X
magnitudes	B-X
of	B-X
various	B-X
effects	B-X
depended	B-X
on	B-X
how	B-X
they	B-X
were	B-X
expressed	B-X
.	B-X
Organisations	B-X
aiming	B-X
at	B-X
consensus	B-X
ought	B-X
to	B-X
recommend	B-X
the	B-X
way	B-X
in	B-X
which	B-X
change	B-X
ought	B-X
to	B-X
be	B-X
expressed	B-X
.	B-X

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

D	O
,	O
The	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
demonstrated	O
significantly	O
higher	O
survival	O
rates	O
compared	O
to	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
by	O
Log	O
-	O
rank	O
Test	O
)	O
.	O

E	O
.	O
<EOS>	B-X
Electronic	B-X
cigarette	B-X
(	B-X
e-cigarette	B-X
)	B-X
use	B-X
has	B-X
increased	B-X
substantially	B-X
in	B-X
recent	B-X
years	B-X
.	B-X
E-cigarettes	B-X
may	B-X
lead	B-X
to	B-X
initiation	B-X
of	B-X
nicotine	B-X
use	B-X
in	B-X
adult	B-X
and	B-X
youth	B-X
non-smokers	B-X
,	B-X
re-initiation	B-X
of	B-X
nicotine	B-X
dependence	B-X
in	B-X
ex-smokers	B-X
or	B-X
increased	B-X
severity	B-X
of	B-X
nicotine	B-X
dependence	B-X
in	B-X
dual-users	B-X
of	B-X
cigarettes	B-X
and	B-X
e-cigarettes	B-X
.	B-X
Hepatitis	B-X
E	B-X
was	B-X
identified	B-X
as	B-X
an	B-X
epidemic	B-X
of	B-X
non-A	B-X
,	B-X
non-B	B-X
hepatitis	B-X
from	B-X
Kashmir	B-X
,	B-X
India	B-X
in	B-X
1978	B-X
.	B-X
Hepatitis	B-X
E	B-X
virus	B-X
(	B-X
HEV	B-X
)	B-X
,	B-X
the	B-X
etiological	B-X
agent	B-X
is	B-X
the	B-X
sole	B-X
member	B-X
of	B-X
family	B-X
Hepeviridae	B-X
.	B-X
Hepatitis	B-X
E	B-X
is	B-X
a	B-X
disease	B-X
with	B-X
a	B-X
major	B-X
global	B-X
impact	B-X
and	B-X
has	B-X
two	B-X
distinct	B-X
epidemiological	B-X
patterns	B-X
.	B-X
Hepatitis	B-X
E	B-X
is	B-X
an	B-X
imperative	B-X
health	B-X
issue	B-X
in	B-X
developing	B-X
nations	B-X
,	B-X
transmitted	B-X
through	B-X
sullied	B-X
water	B-X
and	B-X
happens	B-X
most	B-X
every	B-X
now	B-X
in	B-X
young	B-X
adults	B-X
.	B-X
Autochthonous	B-X
hepatitis	B-X
E	B-X
is	B-X
increasingly	B-X
recognized	B-X
in	B-X
developed	B-X
countries	B-X
.	B-X
HEV	B-X
infections	B-X
in	B-X
humans	B-X
occur	B-X
by	B-X
eating	B-X
the	B-X
undercooked	B-X
game	B-X
flesh	B-X
,	B-X
raw	B-X
liver	B-X
from	B-X
supermarkets	B-X
and	B-X
Figatelli	B-X
sausages	B-X
.	B-X
Blood	B-X
transfusion-associated	B-X
HEV	B-X
infections	B-X
occur	B-X
in	B-X
many	B-X
countries	B-X
and	B-X
screening	B-X
of	B-X
donors	B-X
for	B-X
HEV	B-X
RNA	B-X
is	B-X
under	B-X
consideration	B-X
.	B-X
Hepatitis	B-X
E	B-X
causes	B-X
a	B-X
number	B-X
of	B-X
extrahepatic	B-X
diseases	B-X
,	B-X
including	B-X
a	B-X
wide	B-X
spectrum	B-X
of	B-X
neurological	B-X
syndromes	B-X
.	B-X
HEV	B-X
genotype	B-X
3	B-X
causes	B-X
prolonged	B-X
viremia	B-X
,	B-X
chronic	B-X
hepatitis	B-X
,	B-X
liver	B-X
fibrosis	B-X
and	B-X
cirrhosis	B-X
in	B-X
organ	B-X
transplant	B-X
patients	B-X
.	B-X
Hepatitis	B-X
E	B-X
vaccine	B-X
-239	B-X
,	B-X
marketed	B-X
in	B-X
China	B-X
,	B-X
has	B-X
shown	B-X
high	B-X
efficacy	B-X
with	B-X
sustained	B-X
protection	B-X
for	B-X
over	B-X
four	B-X
years	B-X
.	B-X

Tumor	O
sections	O
were	O
analyzed	O
by	O
H	O
&	O
E	O
stain	O
and	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
by	O
immunohistochemistry	O
.	O
<EOS>	B-X
Integrated	B-X
microbiome	B-X
and	B-X
metabolome	B-X
analysis	B-X
reveals	B-X
a	B-X
novel	B-X
interplay	B-X
between	B-X
commensal	B-X
bacteria	B-X
and	B-X
metabolites	B-X
in	B-X
colorectal	B-X
cancer	B-X
.	B-X
High-grade	B-X
glioma	B-X
(	B-X
HGG	B-X
)	B-X
is	B-X
a	B-X
fatal	B-X
human	B-X
cancer	B-X
.	B-X
The	B-X
genes	B-X
analyzed	B-X
include	B-X
E-cadherin	B-X
,	B-X
Based	B-X
on	B-X
the	B-X
profile	B-X
of	B-X
genetic	B-X
alterations	B-X
occurring	B-X
in	B-X
tumor	B-X
samples	B-X
from	B-X
selected	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
patients	B-X
,	B-X
2	B-X
recent	B-X
whole-exome	B-X
sequencing	B-X
studies	B-X
proposed	B-X
partially	B-X
overlapping	B-X
classification	B-X
systems	B-X
.	B-X
Bernoulli	B-X
mixture-model	B-X
clustering	B-X
was	B-X
applied	B-X
and	B-X
the	B-X
resulting	B-X
subtypes	B-X
analyzed	B-X
in	B-X
relation	B-X
to	B-X
their	B-X
clinical	B-X
characteristics	B-X
and	B-X
outcomes	B-X
.	B-X
Five	B-X
molecular	B-X
subtypes	B-X
were	B-X
resolved	B-X
,	B-X
termed	B-X
MYD88	B-X
,	B-X
BCL2	B-X
,	B-X
SOCS1/SGK1	B-X
,	B-X
TET2/SGK1	B-X
,	B-X
and	B-X
NOTCH2	B-X
,	B-X
along	B-X
with	B-X
an	B-X
unclassified	B-X
group	B-X
.	B-X
The	B-X
subtypes	B-X
characterized	B-X
by	B-X
genetic	B-X
alterations	B-X
of	B-X
BCL2	B-X
,	B-X
NOTCH2	B-X
,	B-X
and	B-X
MYD88	B-X
recapitulated	B-X
recent	B-X
studies	B-X
showing	B-X
good	B-X
,	B-X
intermediate	B-X
,	B-X
and	B-X
poor	B-X
prognosis	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
SOCS1/SGK1	B-X
subtype	B-X
showed	B-X
biological	B-X
overlap	B-X
with	B-X
primary	B-X
mediastinal	B-X
B-cell	B-X
lymphoma	B-X
and	B-X
conferred	B-X
excellent	B-X
prognosis	B-X
.	B-X
Although	B-X
not	B-X
identified	B-X
as	B-X
a	B-X
distinct	B-X
cluster	B-X
,	B-X
NOTCH1	B-X
mutation	B-X
was	B-X
associated	B-X
with	B-X
poor	B-X
prognosis	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
TP53	B-X
mutation	B-X
varied	B-X
with	B-X
genomic	B-X
subtypes	B-X
,	B-X
conferring	B-X
no	B-X
effect	B-X
in	B-X
the	B-X
NOTCH2	B-X
subtype	B-X
and	B-X
poor	B-X
prognosis	B-X
in	B-X
the	B-X
MYD88	B-X
subtype	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
both	B-X
good	B-X
and	B-X
poor	B-X
risk	B-X
subtypes	B-X
in	B-X
patients	B-X
treated	B-X
with	B-X
R-CHOP	B-X
(	B-X
rituximab	B-X
,	B-X
cyclophosphamide	B-X
,	B-X
doxorubicin	B-X
,	B-X
vincristine	B-X
,	B-X
and	B-X
prednisone	B-X
)	B-X
clearly	B-X
show	B-X
the	B-X
clinical	B-X
value	B-X
of	B-X
the	B-X
approach	B-X
,	B-X
confirming	B-X
the	B-X
need	B-X
for	B-X
a	B-X
consensus	B-X
classification	B-X
.	B-X

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Scale	O
bar	O
indicates	O
50	O
m	O
.	O
<EOS>	B-X
The	B-X
monoliths	B-X
'	B-X
porosity	B-X
(	B-X
77-49	B-X
%	B-X
)	B-X
,	B-X
mesopore	B-X
size	B-X
(	B-X
6.2-5.2	B-X
nm	B-X
)	B-X
,	B-X
pore	B-X
volume	B-X
(	B-X
0.50-0.22	B-X
g	B-X
cm	B-X
Stepwise	B-X
ASD	B-X
fabrication	B-X
process	B-X
(	B-X
a	B-X
)	B-X
3D	B-X
computer	B-X
model	B-X
of	B-X
ASD	B-X
was	B-X
generated	B-X
by	B-X
using	B-X
Rhinoceros	B-X
5.0	B-X
software	B-X
(	B-X
b	B-X
)	B-X
3D	B-X
blue	B-X
wax	B-X
model	B-X
of	B-X
ASD	B-X
(	B-X
c	B-X
)	B-X
Silicon	B-X
was	B-X
prepared	B-X
by	B-X
mixing	B-X
the	B-X
solutions	B-X
(	B-X
as	B-X
per	B-X
manufacturer	B-X
instruction	B-X
)	B-X
(	B-X
d	B-X
)	B-X
Blue	B-X
wax	B-X
model	B-X
of	B-X
ASD	B-X
was	B-X
immersed	B-X
into	B-X
liquid	B-X
Silicon	B-X
(	B-X
e	B-X
)	B-X
ASD	B-X
model	B-X
was	B-X
put	B-X
into	B-X
the	B-X
oven	B-X
for	B-X
3	B-X
hours	B-X
at	B-X
50	B-X
°C	B-X
.	B-X
(	B-X
f	B-X
)	B-X
Blue	B-X
wax	B-X
started	B-X
melting	B-X
from	B-X
the	B-X
ASD	B-X
model	B-X
(	B-X
g	B-X
)	B-X
ASD	B-X
model	B-X
was	B-X
built	B-X
from	B-X
pure	B-X
silicon	B-X
(	B-X
h	B-X
)	B-X
Two	B-X
access	B-X
lines	B-X
were	B-X
linked	B-X
to	B-X
the	B-X
ASD	B-X
device	B-X
,	B-X
which	B-X
was	B-X
connected	B-X
with	B-X
an	B-X
implantable	B-X
catheter	B-X
(	B-X
Port-a-cath	B-X
)	B-X
,	B-X
scale	B-X
bar	B-X
100	B-X
µm	B-X
.	B-X
These	B-X
included	B-X
control	B-X
morning	B-X
(	B-X
M	B-X
,	B-X
07:30	B-X
h	B-X
)	B-X
and	B-X
evening	B-X
(	B-X
E	B-X
,	B-X
17:30	B-X
h	B-X
)	B-X
sessions	B-X
(	B-X
5-min	B-X
standardized	B-X
warm-up	B-X
at	B-X
150	B-X
W	B-X
,	B-X
on	B-X
a	B-X
cycle	B-X
ergometer	B-X
)	B-X
,	B-X
and	B-X
one	B-X
further	B-X
session	B-X
consisting	B-X
of	B-X
an	B-X
extended	B-X
active	B-X
warm-up	B-X
morning	B-X
trial	B-X
(	B-X
M	B-X

Decrease	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
tumor	O
tissue	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

A	O
,	O
The	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
was	O
determined	O
in	O
the	O
nuclear	O
extracts	O
of	O
the	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
and	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
tumor	O
tissues	O
by	O
EMSA	O
described	O
in	O
material	O
and	O
methods	O
.	O

B	O
,	O
Expression	O
of	O
p50	B-Protein
and	O
p65	B-Protein
phosphorylation	O
in	O
nuclear	O
extracts	O
(	O
NE	O
)	O
,	O
and	O
IkappaB	O
and	O
IkappaB	O
phosphorylation	O
in	O
the	O
cytosol	O
(	O
CE	O
)	O
determined	O
by	O
Western	O
blotting	O
.	O

C	O
,	O
Immunolfluorescence	O
analysis	O
of	O
p50	B-Protein
confirmed	O
that	O
the	O
intensities	O
of	O
nuclear	O
staining	O
for	O
p50	B-Protein
were	O
decreased	O
in	O
the	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

Induction	O
of	O
apoptotic	O
cell	O
death	O
in	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
,	O
Apoptotic	O
cells	O
in	O
tumor	O
sections	O
were	O
examined	O
by	O
fluorescence	O
microscopy	O
after	O
DAPI	O
and	O
TUNEL	O
staining	O
as	O
described	O
in	O
material	O
and	O
methods	O
.	O

The	O
apoptotic	O
index	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
TUNEL	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
chemokine	B-X
receptor	B-X
,	B-X
CCR5	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
CNS	B-X
host	B-X
defense	B-X
during	B-X
WNV	B-X
infection	B-X
,	B-X
regional	B-X
effects	B-X
of	B-X
its	B-X
activity	B-X
within	B-X
the	B-X
infected	B-X
brain	B-X
have	B-X
not	B-X
been	B-X
defined	B-X
.	B-X
Mainly	B-X
responsible	B-X
for	B-X
new	B-X
infections	B-X
are	B-X
variants	B-X
only	B-X
using	B-X
CCR5	B-X
for	B-X
cell	B-X
entry	B-X
,	B-X
whereas	B-X
CXCR4-using	B-X
variants	B-X
can	B-X
become	B-X
dominant	B-X
in	B-X
later	B-X
infection	B-X
stages	B-X
.	B-X

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

B	O
and	O
C	O
,	O
Apoptotic	O
protein	O
(	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
)	O
in	O
tumor	O
sections	O
were	O
detected	O
by	O
immunofluorescence	O
assay	O
.	O

The	O
reactive	O
cell	O
number	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
Specific	O
antibody	O
(	O
cleaved	O
caspase	O
-	O
3	O
and	O
Bax	O
)	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
chemokine	B-X
receptor	B-X
,	B-X
CCR5	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
CNS	B-X
host	B-X
defense	B-X
during	B-X
WNV	B-X
infection	B-X
,	B-X
regional	B-X
effects	B-X
of	B-X
its	B-X
activity	B-X
within	B-X
the	B-X
infected	B-X
brain	B-X
have	B-X
not	B-X
been	B-X
defined	B-X
.	B-X
Mainly	B-X
responsible	B-X
for	B-X
new	B-X
infections	B-X
are	B-X
variants	B-X
only	B-X
using	B-X
CCR5	B-X
for	B-X
cell	B-X
entry	B-X
,	B-X
whereas	B-X
CXCR4-using	B-X
variants	B-X
can	B-X
become	B-X
dominant	B-X
in	B-X
later	B-X
infection	B-X
stages	B-X
.	B-X

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

D	O
,	O
The	O
expression	O
of	O
apoptotic	O
proteins	O
was	O
detected	O
by	O
Western	O
blotting	O
using	O
specific	O
antibodies	O
;	O
cleaved	O
caspase	O
-	O
3	O
,	O
cleaved	O
caspase	O
-	O
9	O
,	O
cleaved	O
PARP	O
,	O
Bax	O
,	O
Bcl	O
-	O
2	O
and	O
c	B-Protein
-	I-Protein
IAP1	I-Protein
in	O
the	O
tumor	O
tissues	O
.	O
<EOS>	B-X
Human	B-X
HspB1	B-X
(	B-X
also	B-X
denoted	B-X
Hsp27	B-X
)	B-X
is	B-X
an	B-X
oligomeric	B-X
anti-apoptotic	B-X
protein	B-X
that	B-X
has	B-X
tumorigenic	B-X
and	B-X
metastatic	B-X
roles	B-X
.	B-X
To	B-X
approach	B-X
the	B-X
structural	B-X
organizations	B-X
of	B-X
HspB1	B-X
that	B-X
are	B-X
active	B-X
in	B-X
response	B-X
to	B-X
apoptosis	B-X
inducers	B-X
acting	B-X
through	B-X
different	B-X
pathways	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
the	B-X
relative	B-X
protective	B-X
efficiency	B-X
induced	B-X
by	B-X
this	B-X
protein	B-X
as	B-X
well	B-X
its	B-X
localization	B-X
,	B-X
oligomerization	B-X
and	B-X
phosphorylation	B-X
.	B-X
HeLa	B-X
cells	B-X
,	B-X
that	B-X
constitutively	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
HspB1	B-X
were	B-X
treated	B-X
with	B-X
either	B-X
etoposide	B-X
,	B-X
Fas	B-X
agonist	B-X
antibody	B-X
,	B-X
staurosporine	B-X
or	B-X
cytochalasin	B-X
D.	B-X
Variability	B-X
in	B-X
HspB1	B-X
efficiency	B-X
to	B-X
interfere	B-X
with	B-X
the	B-X
different	B-X
apoptotic	B-X
transduction	B-X
pathways	B-X
induced	B-X
by	B-X
these	B-X
agents	B-X
were	B-X
detected	B-X
.	B-X
Moreover	B-X
,	B-X
inducer-specific	B-X
dynamic	B-X
changes	B-X
in	B-X
HspB1	B-X
localization	B-X
,	B-X
native	B-X
size	B-X
and	B-X
phosphorylation	B-X
were	B-X
observed	B-X
,	B-X
that	B-X
differed	B-X
from	B-X
those	B-X
observed	B-X
after	B-X
heat	B-X
shock	B-X
.	B-X
Etoposide	B-X
and	B-X
Fas	B-X
treatments	B-X
gradually	B-X
shifted	B-X
HspB1	B-X
towards	B-X
large	B-X
but	B-X
differently	B-X
phosphorylated	B-X
oligomeric	B-X
structures	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
staurosporine	B-X
and	B-X
cytochalasin	B-X
D	B-X
induced	B-X
the	B-X
rapid	B-X
but	B-X
transient	B-X
formation	B-X
of	B-X
small	B-X
oligomers	B-X
before	B-X
large	B-X
structures	B-X
were	B-X
formed	B-X
.	B-X
These	B-X
events	B-X
correlated	B-X
with	B-X
inducer-specific	B-X
phosphorylations	B-X
of	B-X
HspB1	B-X
.	B-X
Of	B-X
interest	B-X
,	B-X
the	B-X
formation	B-X
of	B-X
small	B-X
oligomers	B-X
in	B-X
response	B-X
to	B-X
staurosporine	B-X
and	B-X
cytochalasin	B-X
D	B-X
was	B-X
time	B-X
correlated	B-X
with	B-X
the	B-X
rapid	B-X
disruption	B-X
of	B-X
F-actin	B-X
.	B-X
The	B-X
subsequent	B-X
,	B-X
or	B-X
gradual	B-X
in	B-X
the	B-X
case	B-X
of	B-X
etoposide	B-X
and	B-X
Fas	B-X
,	B-X
formation	B-X
of	B-X
large	B-X
oligomeric	B-X
structures	B-X
was	B-X
a	B-X
later	B-X
event	B-X
concomitant	B-X
with	B-X
the	B-X
early	B-X
phase	B-X
of	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
observations	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
HspB1	B-X
has	B-X
the	B-X
ability	B-X
,	B-X
through	B-X
specific	B-X
changes	B-X
in	B-X
its	B-X
structural	B-X
organization	B-X
,	B-X
to	B-X
adapt	B-X
and	B-X
interfere	B-X
at	B-X
several	B-X
levels	B-X
with	B-X
challenges	B-X
triggered	B-X
by	B-X
different	B-X
signal	B-X
transduction	B-X
pathways	B-X
upstream	B-X
of	B-X
the	B-X
execution	B-X
phase	B-X
of	B-X
apoptosis	B-X
.	B-X

The	O
beta	B-Protein
-	I-Protein
actin	I-Protein
protein	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O
<EOS>	B-X
Organisms	B-X
from	B-X
all	B-X
domains	B-X
of	B-X
life	B-X
depend	B-X
on	B-X
filaments	B-X
of	B-X
the	B-X
protein	B-X
actin	B-X
to	B-X
provide	B-X
structure	B-X
and	B-X
to	B-X
support	B-X
internal	B-X
movements	B-X
.	B-X
Many	B-X
eukaryotic	B-X
cells	B-X
use	B-X
forces	B-X
produced	B-X
by	B-X
actin	B-X
polymerization	B-X
for	B-X
their	B-X
motility	B-X
,	B-X
and	B-X
myosin	B-X
motor	B-X
proteins	B-X
use	B-X
ATP	B-X
hydrolysis	B-X
to	B-X
produce	B-X
force	B-X
on	B-X
actin	B-X
filaments	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
properties	B-X
of	B-X
actin	B-X
and	B-X
shows	B-X
how	B-X
dozens	B-X
of	B-X
proteins	B-X
control	B-X
both	B-X
the	B-X
assembly	B-X
and	B-X
disassembly	B-X
of	B-X
actin	B-X
filaments	B-X
.	B-X
These	B-X
players	B-X
catalyze	B-X
nucleotide	B-X
exchange	B-X
on	B-X
actin	B-X
monomers	B-X
,	B-X
initiate	B-X
polymerization	B-X
,	B-X
promote	B-X
phosphate	B-X
dissociation	B-X
,	B-X
cap	B-X
the	B-X
ends	B-X
of	B-X
polymers	B-X
,	B-X
cross-link	B-X
filaments	B-X
to	B-X
each	B-X
other	B-X
and	B-X
other	B-X
cellular	B-X
components	B-X
,	B-X
and	B-X
sever	B-X
filaments	B-X
.	B-X

Each	O
band	O
is	O
representative	O
of	O
three	O
independent	O
experimental	O
results	O
.	O
<EOS>	B-X
The	B-X
present	B-X
work	B-X
describes	B-X
a	B-X
3D	B-X
finite	B-X
element	B-X
model	B-X
of	B-X
the	B-X
Drosophila	B-X
embryo	B-X
designed	B-X
to	B-X
simulate	B-X
three	B-X
morphogenetic	B-X
movements	B-X
during	B-X
early	B-X
gastrulation	B-X
:	B-X
ventral	B-X
furrow	B-X
invagination	B-X
,	B-X
cephalic	B-X
furrow	B-X
formation	B-X
and	B-X
germ	B-X
band	B-X
extension	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
parametric	B-X
description	B-X
of	B-X
the	B-X
biological	B-X
structure	B-X
in	B-X
a	B-X
special	B-X
curvilinear	B-X
system	B-X
provides	B-X
mesh-independent	B-X
endogenous	B-X
strains	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
number	B-X
of	B-X
active	B-X
strains	B-X
responsible	B-X
for	B-X
the	B-X
morphogenetic	B-X
events	B-X
can	B-X
be	B-X
less	B-X
than	B-X
that	B-X
deduced	B-X
from	B-X
direct	B-X
experimental	B-X
observations	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
estimation	B-X
of	B-X
the	B-X
non-local	B-X
pressures	B-X
induced	B-X
during	B-X
morphogenetic	B-X
movements	B-X
is	B-X
in	B-X
good	B-X
agreement	B-X
with	B-X
the	B-X
experimental	B-X
data	B-X
.	B-X

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
three	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Upregulation	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
the	O
tumor	O
and	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
To	B-X
evaluate	B-X
the	B-X
relevance	B-X
of	B-X
C-C	B-X
chemokine	B-X
receptor	B-X
type	B-X
5	B-X
(	B-X
CCR5	B-X
)	B-X
expression	B-X
and	B-X
tumor	B-X
development	B-X
,	B-X
we	B-X
compared	B-X
melanoma	B-X
growth	B-X
in	B-X
CCR5	B-X
knockout	B-X
(	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
mice	B-X
and	B-X
wild	B-X
type	B-X
(	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
)	B-X
mice	B-X
.	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
showed	B-X
reduced	B-X
tumor	B-X
volume	B-X
,	B-X
tumor	B-X
weight	B-X
,	B-X
and	B-X
increased	B-X
survival	B-X
rate	B-X
when	B-X
compared	B-X
to	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
since	B-X
it	B-X
is	B-X
an	B-X
implicated	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
genes	B-X
involving	B-X
cell	B-X
growth	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
tumor	B-X
growth	B-X
.	B-X
Significant	B-X
inhibition	B-X
of	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-κB	B-X
,	B-X
and	B-X
translocation	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
phosphorylation	B-X
of	B-X
IκB	B-X
was	B-X
found	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
NF-κB	B-X
target	B-X
apoptotic	B-X
protein	B-X
expression	B-X
,	B-X
such	B-X
as	B-X
cleaved	B-X
caspase-3	B-X
,	B-X
cleaved	B-X
PARP	B-X
,	B-X
and	B-X
Bax	B-X
,	B-X
was	B-X
elevated	B-X
,	B-X
whereas	B-X
the	B-X
survival	B-X
protein	B-X
expression	B-X
levels	B-X
,	B-X
such	B-X
as	B-X
Bcl-2	B-X
,	B-X
C-IAP1	B-X
,	B-X
was	B-X
decreased	B-X
in	B-X
the	B-X
melanoma	B-X
tissues	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
level	B-X
of	B-X
IL-1Ra	B-X
,	B-X
a	B-X
tumor	B-X
growth	B-X
suppressive	B-X
cytokine	B-X
,	B-X
was	B-X
significantly	B-X
elevated	B-X
in	B-X
tumor	B-X
tissue	B-X
and	B-X
spleen	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
the	B-X
level	B-X
in	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Moreover	B-X
,	B-X
infiltration	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cytotoxic	B-X
T	B-X
cell	B-X
and	B-X
CD57	B-X
(	B-X
+	B-X
)	B-X
natural	B-X
killer	B-X
cells	B-X
was	B-X
significantly	B-X
increased	B-X
in	B-X
melanoma	B-X
tumor	B-X
and	B-X
spleen	B-X
tissue	B-X
of	B-X
CCR5	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
CCR5	B-X
(	B-X
+/+	B-X
)	B-X
mice	B-X
.	B-X
Therefore	B-X
,	B-X
these	B-X
results	B-X
showed	B-X
that	B-X
CCR5	B-X
deficiency	B-X
caused	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
melanoma	B-X
through	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
and	B-X
upregulation	B-X
of	B-X
IL-1Ra	B-X
.	B-X

A	O
,	O
Figure	O
4A	O
indicates	O
mouse	O
cytokine	O
array	O
panel	O
coordinates	O
.	O

Nitrocellulose	O
membranes	O
contain	O
40	O
different	O
anti	O
-	O
cytokine	O
antibodies	O
printed	O
in	O
duplicate	O
.	O

B	O
,	O
Mouse	O
cytokine	O
array	O
panel	O
indicate	O
the	O
cytokine	O
expression	O
difference	O
in	O
tumor	O
tissues	O
of	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
especially	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O

Representative	O
blot	O
from	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
Could	B-X
the	B-X
follicle	B-X
proteome	B-X
be	B-X
mapped	B-X
by	B-X
identifying	B-X
specific	B-X
proteins	B-X
that	B-X
are	B-X
common	B-X
or	B-X
differ	B-X
between	B-X
three	B-X
developmental	B-X
stages	B-X
from	B-X
the	B-X
secondary	B-X
follicle	B-X
(	B-X
SF	B-X
)	B-X
to	B-X
the	B-X
antrum-like	B-X
stage	B-X
?	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
measure	B-X
the	B-X
levels	B-X
of	B-X
three	B-X
circulating	B-X
ECM	B-X
related	B-X
proteins	B-X
(	B-X
COL11A1	B-X
,	B-X
COL10A1	B-X
and	B-X
SPARC	B-X
)	B-X
in	B-X
plasma	B-X
samples	B-X
of	B-X
lung	B-X
cancer	B-X
patients	B-X
and	B-X
in	B-X
healthy	B-X
heavy-smokers	B-X
controls	B-X
and	B-X
test	B-X
whether	B-X
such	B-X
measurements	B-X
have	B-X
diagnostic	B-X
or	B-X
prognostic	B-X
value	B-X
.	B-X
Histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitors	B-X
have	B-X
shown	B-X
significant	B-X
anti-proliferative	B-X
and	B-X
apoptotic	B-X
properties	B-X
on	B-X
various	B-X
cancer	B-X
cells	B-X
,	B-X
including	B-X
prostate	B-X
cancer	B-X
,	B-X
and	B-X
are	B-X
therefore	B-X
being	B-X
evaluated	B-X
as	B-X
treatment	B-X
modalities	B-X
.	B-X
However	B-X
,	B-X
the	B-X
specific	B-X
effect	B-X
of	B-X
HDAC	B-X
inhibitors	B-X
on	B-X
androgen-sensitive	B-X
and	B-X
androgen-independent	B-X
cell	B-X
lines	B-X
have	B-X
not	B-X
been	B-X
thoroughly	B-X
studied	B-X
which	B-X
we	B-X
hypothesized	B-X
could	B-X
be	B-X
different	B-X
.	B-X
We	B-X
therefore	B-X
assessed	B-X
whether	B-X
three	B-X
structurally	B-X
unrelated	B-X
HDAC	B-X
inhibitors	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
,	B-X
depsipeptide	B-X
(	B-X
FR901228	B-X
)	B-X
,	B-X
and	B-X
sodium	B-X
butyrate	B-X
,	B-X
affect	B-X
cell	B-X
death	B-X
in	B-X
the	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
LNCaP	B-X
,	B-X
DU-145	B-X
,	B-X
and	B-X
PC-3	B-X
.	B-X

Positive	O
controls	O
show	O
the	O
manufacturer	O
'	O
s	O
internal	O
positive	O
control	O
samples	O
on	O
the	O
membrane	O
.	O
<EOS>	B-X
The	B-X
outer	B-X
surface	B-X
protein	B-X
C	B-X
(	B-X
OspC	B-X
)	B-X
and	B-X
the	B-X
internal	B-X
14-kDa	B-X
flagellin	B-X
fragment	B-X
of	B-X
strain	B-X
GeHo	B-X
of	B-X
Borrelia	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
were	B-X
expressed	B-X
as	B-X
recombinant	B-X
proteins	B-X
in	B-X
Escherichia	B-X
coli	B-X
and	B-X
were	B-X
purified	B-X
for	B-X
use	B-X
in	B-X
an	B-X
immunoglobulin	B-X
M	B-X
(	B-X
IgM	B-X
)	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
OspC-14-kDa	B-X
antigen	B-X
ELISA	B-X
)	B-X
.	B-X
According	B-X
to	B-X
the	B-X
manufacturer	B-X
's	B-X
information	B-X
,	B-X
the	B-X
cell	B-X
extract	B-X
contains	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
other	B-X
antigens	B-X
,	B-X
the	B-X
following	B-X
diagnostically	B-X
relevant	B-X
antigens	B-X
:	B-X
the	B-X
100-kDa	B-X
(	B-X
synonyms	B-X
,	B-X
93-	B-X
and	B-X
83-kDa	B-X
antigens	B-X
)	B-X
,	B-X
41-kDa	B-X
,	B-X
OspA	B-X
,	B-X
OspC	B-X
,	B-X
and	B-X
17-kDa	B-X
antigens	B-X
.	B-X
The	B-X
specificity	B-X
was	B-X
adjusted	B-X
to	B-X
95	B-X
%	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
data	B-X
for	B-X
154	B-X
healthy	B-X
controls	B-X
.	B-X
On	B-X
testing	B-X
of	B-X
104	B-X
serum	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
erythema	B-X
migrans	B-X
(	B-X
EM	B-X
)	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
recombinant	B-X
ELISA	B-X
(	B-X
46	B-X
%	B-X
)	B-X
for	B-X
IgM	B-X
antibodies	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
commercial	B-X
ELISA	B-X
(	B-X
45	B-X
%	B-X
)	B-X
.	B-X
However	B-X
,	B-X
when	B-X
42	B-X
serum	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
polyclonal	B-X
B-cell	B-X
stimulation	B-X
due	B-X
to	B-X
an	B-X
Epstein-Barr	B-X
virus	B-X
infection	B-X
were	B-X
tested	B-X
,	B-X
false-positive	B-X
reactions	B-X
were	B-X
significantly	B-X
less	B-X
frequent	B-X
in	B-X
the	B-X
recombinant	B-X
ELISA	B-X
(	B-X
10	B-X
%	B-X
)	B-X
than	B-X
in	B-X
the	B-X
whole-cell-extract	B-X
ELISA	B-X
(	B-X
23	B-X
%	B-X
)	B-X
.	B-X
However	B-X
,	B-X
when	B-X
the	B-X
reactions	B-X
of	B-X
serum	B-X
specimens	B-X
from	B-X
controls	B-X
and	B-X
EM	B-X
patients	B-X
with	B-X
OspC	B-X
from	B-X
representative	B-X
strains	B-X
of	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
(	B-X
strain	B-X
GeHo	B-X
)	B-X
and	B-X
B.	B-X
afzelii	B-X
(	B-X
strain	B-X
PKo	B-X
)	B-X
were	B-X
compared	B-X
in	B-X
an	B-X
ELISA	B-X
,	B-X
almost	B-X
no	B-X
differences	B-X
in	B-X
specificity	B-X
and	B-X
sensitivity	B-X
were	B-X
seen	B-X
.	B-X

C	O
,	O
Protein	O
immune	O
-	O
arrays	O
were	O
performed	O
using	O
Mouse	O
cytokine	O
array	O
in	O
spleen	O
tissues	O
.	O
<EOS>	B-X
Japanese	B-X
encephalitis	B-X
(	B-X
JE	B-X
)	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
neurotropic	B-X
flavivirus	B-X
that	B-X
causes	B-X
CNS	B-X
damage	B-X
that	B-X
leads	B-X
to	B-X
death	B-X
in	B-X
acute	B-X
cases	B-X
or	B-X
permanent	B-X
neuropsychiatric	B-X
sequel	B-X
in	B-X
survivors	B-X
.	B-X
The	B-X
course	B-X
of	B-X
infection	B-X
of	B-X
this	B-X
virus	B-X
is	B-X
not	B-X
well	B-X
defined	B-X
though	B-X
it	B-X
is	B-X
clear	B-X
that	B-X
it	B-X
evades	B-X
the	B-X
host	B-X
's	B-X
innate	B-X
immune	B-X
response	B-X
in	B-X
the	B-X
periphery	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
time-dependent	B-X
changes	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
lymph	B-X
node	B-X
,	B-X
apart	B-X
from	B-X
the	B-X
CNS	B-X
that	B-X
are	B-X
infected	B-X
by	B-X
the	B-X
Japanese	B-X
encephalitis	B-X
virus	B-X
(	B-X
JEV	B-X
)	B-X
.	B-X
Levels	B-X
of	B-X
IL-12	B-X
and	B-X
MCP-1	B-X
in	B-X
the	B-X
organs	B-X
were	B-X
estimated	B-X
by	B-X
cytometric	B-X
bead	B-X
array	B-X
,	B-X
and	B-X
immunohistochemical	B-X
studies	B-X
were	B-X
performed	B-X
on	B-X
cryosections	B-X
of	B-X
tissue	B-X
to	B-X
detect	B-X
CD3-	B-X
or	B-X
CD11b-positive	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
JEV	B-X
antigen	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
T	B-X
cell-activating	B-X
cytokine	B-X
IL-12	B-X
and	B-X
MCP-1	B-X
levels	B-X
were	B-X
significantly	B-X
elevated	B-X
in	B-X
JEV-infected	B-X
tissue	B-X
samples	B-X
in	B-X
a	B-X
time-dependent	B-X
manner	B-X
.	B-X
Corresponding	B-X
to	B-X
this	B-X
increase	B-X
was	B-X
the	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
CD3-	B-X
and	B-X
CD11b-positive	B-X
cells	B-X
in	B-X
the	B-X
tissues	B-X
of	B-X
infected	B-X
animals	B-X
.	B-X
Minocycline	B-X
treatment	B-X
also	B-X
resulted	B-X
in	B-X
the	B-X
gradual	B-X
decrease	B-X
in	B-X
the	B-X
number	B-X
of	B-X
CD11b	B-X
(	B-X
but	B-X
not	B-X
CD3	B-X
)	B-X
positive	B-X
cells	B-X
in	B-X
the	B-X
lymph	B-X
node	B-X
and	B-X
spleen	B-X
,	B-X
even	B-X
though	B-X
the	B-X
virus	B-X
persisted	B-X
in	B-X
these	B-X
organs	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
structural	B-X
changes	B-X
in	B-X
the	B-X
spleen	B-X
following	B-X
minocycline	B-X
treatment	B-X
.	B-X

There	O
were	O
differences	O
in	O
cytokines	O
between	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
and	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
,	O
especially	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
.	O

Representative	O
blot	O
from	O
three	O
independent	O
experiments	O
is	O
shown	O
.	O
<EOS>	B-X
Could	B-X
the	B-X
follicle	B-X
proteome	B-X
be	B-X
mapped	B-X
by	B-X
identifying	B-X
specific	B-X
proteins	B-X
that	B-X
are	B-X
common	B-X
or	B-X
differ	B-X
between	B-X
three	B-X
developmental	B-X
stages	B-X
from	B-X
the	B-X
secondary	B-X
follicle	B-X
(	B-X
SF	B-X
)	B-X
to	B-X
the	B-X
antrum-like	B-X
stage	B-X
?	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
measure	B-X
the	B-X
levels	B-X
of	B-X
three	B-X
circulating	B-X
ECM	B-X
related	B-X
proteins	B-X
(	B-X
COL11A1	B-X
,	B-X
COL10A1	B-X
and	B-X
SPARC	B-X
)	B-X
in	B-X
plasma	B-X
samples	B-X
of	B-X
lung	B-X
cancer	B-X
patients	B-X
and	B-X
in	B-X
healthy	B-X
heavy-smokers	B-X
controls	B-X
and	B-X
test	B-X
whether	B-X
such	B-X
measurements	B-X
have	B-X
diagnostic	B-X
or	B-X
prognostic	B-X
value	B-X
.	B-X
Histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
inhibitors	B-X
have	B-X
shown	B-X
significant	B-X
anti-proliferative	B-X
and	B-X
apoptotic	B-X
properties	B-X
on	B-X
various	B-X
cancer	B-X
cells	B-X
,	B-X
including	B-X
prostate	B-X
cancer	B-X
,	B-X
and	B-X
are	B-X
therefore	B-X
being	B-X
evaluated	B-X
as	B-X
treatment	B-X
modalities	B-X
.	B-X
However	B-X
,	B-X
the	B-X
specific	B-X
effect	B-X
of	B-X
HDAC	B-X
inhibitors	B-X
on	B-X
androgen-sensitive	B-X
and	B-X
androgen-independent	B-X
cell	B-X
lines	B-X
have	B-X
not	B-X
been	B-X
thoroughly	B-X
studied	B-X
which	B-X
we	B-X
hypothesized	B-X
could	B-X
be	B-X
different	B-X
.	B-X
We	B-X
therefore	B-X
assessed	B-X
whether	B-X
three	B-X
structurally	B-X
unrelated	B-X
HDAC	B-X
inhibitors	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
,	B-X
depsipeptide	B-X
(	B-X
FR901228	B-X
)	B-X
,	B-X
and	B-X
sodium	B-X
butyrate	B-X
,	B-X
affect	B-X
cell	B-X
death	B-X
in	B-X
the	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
LNCaP	B-X
,	B-X
DU-145	B-X
,	B-X
and	B-X
PC-3	B-X
.	B-X

Positive	O
controls	O
show	O
the	O
manufacturer	O
'	O
s	O
internal	O
positive	O
control	O
samples	O
on	O
the	O
membrane	O
.	O
<EOS>	B-X
The	B-X
outer	B-X
surface	B-X
protein	B-X
C	B-X
(	B-X
OspC	B-X
)	B-X
and	B-X
the	B-X
internal	B-X
14-kDa	B-X
flagellin	B-X
fragment	B-X
of	B-X
strain	B-X
GeHo	B-X
of	B-X
Borrelia	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
were	B-X
expressed	B-X
as	B-X
recombinant	B-X
proteins	B-X
in	B-X
Escherichia	B-X
coli	B-X
and	B-X
were	B-X
purified	B-X
for	B-X
use	B-X
in	B-X
an	B-X
immunoglobulin	B-X
M	B-X
(	B-X
IgM	B-X
)	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
OspC-14-kDa	B-X
antigen	B-X
ELISA	B-X
)	B-X
.	B-X
According	B-X
to	B-X
the	B-X
manufacturer	B-X
's	B-X
information	B-X
,	B-X
the	B-X
cell	B-X
extract	B-X
contains	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
other	B-X
antigens	B-X
,	B-X
the	B-X
following	B-X
diagnostically	B-X
relevant	B-X
antigens	B-X
:	B-X
the	B-X
100-kDa	B-X
(	B-X
synonyms	B-X
,	B-X
93-	B-X
and	B-X
83-kDa	B-X
antigens	B-X
)	B-X
,	B-X
41-kDa	B-X
,	B-X
OspA	B-X
,	B-X
OspC	B-X
,	B-X
and	B-X
17-kDa	B-X
antigens	B-X
.	B-X
The	B-X
specificity	B-X
was	B-X
adjusted	B-X
to	B-X
95	B-X
%	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
data	B-X
for	B-X
154	B-X
healthy	B-X
controls	B-X
.	B-X
On	B-X
testing	B-X
of	B-X
104	B-X
serum	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
erythema	B-X
migrans	B-X
(	B-X
EM	B-X
)	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
recombinant	B-X
ELISA	B-X
(	B-X
46	B-X
%	B-X
)	B-X
for	B-X
IgM	B-X
antibodies	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
commercial	B-X
ELISA	B-X
(	B-X
45	B-X
%	B-X
)	B-X
.	B-X
However	B-X
,	B-X
when	B-X
42	B-X
serum	B-X
samples	B-X
from	B-X
patients	B-X
with	B-X
polyclonal	B-X
B-cell	B-X
stimulation	B-X
due	B-X
to	B-X
an	B-X
Epstein-Barr	B-X
virus	B-X
infection	B-X
were	B-X
tested	B-X
,	B-X
false-positive	B-X
reactions	B-X
were	B-X
significantly	B-X
less	B-X
frequent	B-X
in	B-X
the	B-X
recombinant	B-X
ELISA	B-X
(	B-X
10	B-X
%	B-X
)	B-X
than	B-X
in	B-X
the	B-X
whole-cell-extract	B-X
ELISA	B-X
(	B-X
23	B-X
%	B-X
)	B-X
.	B-X
However	B-X
,	B-X
when	B-X
the	B-X
reactions	B-X
of	B-X
serum	B-X
specimens	B-X
from	B-X
controls	B-X
and	B-X
EM	B-X
patients	B-X
with	B-X
OspC	B-X
from	B-X
representative	B-X
strains	B-X
of	B-X
B.	B-X
burgdorferi	B-X
sensu	B-X
stricto	B-X
(	B-X
strain	B-X
GeHo	B-X
)	B-X
and	B-X
B.	B-X
afzelii	B-X
(	B-X
strain	B-X
PKo	B-X
)	B-X
were	B-X
compared	B-X
in	B-X
an	B-X
ELISA	B-X
,	B-X
almost	B-X
no	B-X
differences	B-X
in	B-X
specificity	B-X
and	B-X
sensitivity	B-X
were	B-X
seen	B-X
.	B-X

D	O
and	O
E	O
,	O
Immunolfluorescence	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
expression	O
levels	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

The	O
reactive	O
cell	O
number	O
was	O
determined	O
as	O
the	O
number	O
of	O
DAPI	O
-	O
stained	O
,	O
IL	O
-	O
1Ra	O
antibody	O
-	O
positive	O
cells	O
that	O
were	O
counted	O
.	O

Values	O
are	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

*	O
indicates	O
statistically	O
significant	O
differences	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
chemokine	B-X
receptor	B-X
,	B-X
CCR5	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
CNS	B-X
host	B-X
defense	B-X
during	B-X
WNV	B-X
infection	B-X
,	B-X
regional	B-X
effects	B-X
of	B-X
its	B-X
activity	B-X
within	B-X
the	B-X
infected	B-X
brain	B-X
have	B-X
not	B-X
been	B-X
defined	B-X
.	B-X
Mainly	B-X
responsible	B-X
for	B-X
new	B-X
infections	B-X
are	B-X
variants	B-X
only	B-X
using	B-X
CCR5	B-X
for	B-X
cell	B-X
entry	B-X
,	B-X
whereas	B-X
CXCR4-using	B-X
variants	B-X
can	B-X
become	B-X
dominant	B-X
in	B-X
later	B-X
infection	B-X
stages	B-X
.	B-X

Scale	O
bar	O
indicates	O
50	O
microm	O
.	O

F	O
and	O
G	O
,	O
Expression	O
of	O
IL	B-Protein
-	I-Protein
1Ra	I-Protein
was	O
analyzed	O
by	O
western	O
blotting	O
in	O
tumor	O
and	O
spleen	O
tissues	O
.	O

Each	O
band	O
is	O
representative	O
of	O
three	O
independent	O
experimental	O
results	O
.	O
<EOS>	B-X
The	B-X
present	B-X
work	B-X
describes	B-X
a	B-X
3D	B-X
finite	B-X
element	B-X
model	B-X
of	B-X
the	B-X
Drosophila	B-X
embryo	B-X
designed	B-X
to	B-X
simulate	B-X
three	B-X
morphogenetic	B-X
movements	B-X
during	B-X
early	B-X
gastrulation	B-X
:	B-X
ventral	B-X
furrow	B-X
invagination	B-X
,	B-X
cephalic	B-X
furrow	B-X
formation	B-X
and	B-X
germ	B-X
band	B-X
extension	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
parametric	B-X
description	B-X
of	B-X
the	B-X
biological	B-X
structure	B-X
in	B-X
a	B-X
special	B-X
curvilinear	B-X
system	B-X
provides	B-X
mesh-independent	B-X
endogenous	B-X
strains	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
number	B-X
of	B-X
active	B-X
strains	B-X
responsible	B-X
for	B-X
the	B-X
morphogenetic	B-X
events	B-X
can	B-X
be	B-X
less	B-X
than	B-X
that	B-X
deduced	B-X
from	B-X
direct	B-X
experimental	B-X
observations	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
estimation	B-X
of	B-X
the	B-X
non-local	B-X
pressures	B-X
induced	B-X
during	B-X
morphogenetic	B-X
movements	B-X
is	B-X
in	B-X
good	B-X
agreement	B-X
with	B-X
the	B-X
experimental	B-X
data	B-X
.	B-X

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
three	O
experimental	O
animals	O
.	O

*	O
indicates	O
significant	O
difference	O
from	O
CCR5	B-Protein
+	O
/	O
+	O
mice	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Induction	O
of	O
the	O
infiltration	O
of	O
CD8	O
+	O
T	O
cells	O
and	O
NK	O
cells	O
into	O
tumor	O
,	O
and	O
increase	O
in	O
spleen	O
of	O
CCR5	B-Protein
-	O
/	O
-	O
mice	O
.	O

A	O
and	O
B	O
,	O
Immunolfluorescence	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
expression	O
levels	O
of	O
CD8	O
(	O
CD8	O
+	O
cytotoxic	O
T	O
-	O
cell	O
surface	O
marker	O
)	O
and	O
CD57	O
(	O
NK	O
cell	O
marker	O
)	O
in	O
tumor	O
and	O
spleen	O
sections	O
.	O

The	O
images	O
shown	O
are	O
representative	O
of	O
three	O
separate	O
experiments	O
performed	O
in	O
triplicate	O
.	O

Scale	O
bars	O
indicate	O
50	O
microm	O
(	O
A	O
)	O
and	O
100	O
microm	O
(	O
B	O
)	O
.	O

C	O
and	O
D	O
,	O
Analysis	O
of	O
lymphocyte	O
phenotypes	O
.	O

The	O
tumor	O
and	O
spleen	O
tissues	O
were	O
separated	O
at	O
study	O
termination	O
(	O
Day	O
31	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
was	O
performed	O
using	O
FACSAria	O
flow	O
cytometry	O
,	O
and	O
represent	O
data	O
were	O
shown	O
.	O

Data	O
are	O
means	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
of	O
four	O
experimental	O
animals	O
.	O

Akt	O
Regulates	O
TNFalpha	B-Protein
Synthesis	O
Downstream	O
of	O
RIP1	B-Protein
Kinase	O
Activation	O
during	O
Necroptosis	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Necroptosis	O
is	O
a	O
regulated	O
form	O
of	O
necrotic	O
cell	O
death	O
that	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
diseases	O
including	O
intestinal	O
inflammation	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
.	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
signaling	O
mechanisms	O
controlled	O
by	O
the	O
necroptosis	O
mediator	O
receptor	B-Protein
interacting	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
RIP1	B-Protein
)	O
kinase	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

We	O
show	O
that	O
Akt	O
kinase	O
activity	O
is	O
critical	O
for	O
necroptosis	O
in	O
L929	O
cells	O
and	O
plays	O
a	O
key	O
role	O
in	O
TNFalpha	B-Protein
production	O
.	O

During	O
necroptosis	O
,	O
Akt	O
is	O
activated	O
in	O
a	O
RIP1	B-Protein
dependent	O
fashion	O
through	O
its	O
phosphorylation	O
on	O
Thr308	O
.	O

In	O
L929	O
cells	O
,	O
this	O
activation	O
requires	O
independent	O
signaling	O
inputs	O
from	O
both	O
growth	O
factors	O
and	O
RIP1	B-Protein
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X

Akt	O
controls	O
necroptosis	O
through	O
downstream	O
targeting	O
of	O
mammalian	O
Target	O
of	O
Rapamycin	O
complex	O
1	O
(	O
mTORC1	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Akt	O
activity	O
,	O
mediated	O
in	O
part	O
through	O
mTORC1	O
,	O
links	O
RIP1	B-Protein
to	O
JNK	O
activation	O
and	O
autocrine	O
production	O
of	O
TNFalpha	B-Protein
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

In	O
other	O
cell	O
types	O
,	O
such	O
as	O
mouse	O
lung	O
fibroblasts	O
and	O
macrophages	O
,	O
Akt	O
exhibited	O
control	O
over	O
necroptosis	O
-	O
associated	O
TNFalpha	B-Protein
production	O
without	O
contributing	O
to	O
cell	O
death	O
.	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Overall	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
mechanism	O
of	O
necroptosis	O
and	O
the	O
role	O
of	O
Akt	O
kinase	O
in	O
both	O
cell	O
death	O
and	O
inflammatory	O
regulation	O
.	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Necroptosis	O
is	O
a	O
form	O
of	O
regulated	O
cell	O
death	O
that	O
displays	O
all	O
the	O
major	O
hallmarks	O
of	O
necrosis	O
[	O
1	O
]	O
.	O

A	O
growing	O
number	O
of	O
studies	O
have	O
implicated	O
necroptosis	O
in	O
a	O
wide	O
range	O
of	O
animal	O
models	O
of	O
human	O
disease	O
,	O
including	O
brain	O
,	O
heart	O
and	O
retinal	O
ischemia	O
-	O
reperfusion	O
injury	O
,	O
acute	O
pancreatitis	O
,	O
brain	O
trauma	O
,	O
retinal	O
detachment	O
,	O
and	O
Huntington	O
'	O
s	O
disease	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

Importantly	O
,	O
several	O
recent	O
studies	O
have	O
linked	O
necroptosis	O
to	O
models	O
of	O
inflammation	O
including	O
intestinal	O
inflammation	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

The	O
discovery	O
of	O
a	O
regulated	O
form	O
of	O
necrotic	O
death	O
could	O
uncover	O
molecular	O
targets	O
amenable	O
to	O
pharmacological	O
intervention	O
for	O
the	O
treatment	O
of	O
various	O
conditions	O
.	O

A	O
complex	O
consisting	O
of	O
two	O
related	O
Ser	O
/	O
Thr	O
kinases	O
,	O
RIP1	B-Protein
and	O
RIP3	B-Protein
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
initiation	O
of	O
necroptosis	O
in	O
multiple	O
systems	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

A	O
recent	O
genome	O
wide	O
siRNA	O
screen	O
for	O
mediators	O
of	O
necroptosis	O
induced	O
by	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
in	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
,	O
revealed	O
a	O
broad	O
and	O
diverse	O
cellular	O
network	O
of	O
432	O
genes	O
that	O
may	O
regulate	O
this	O
process	O
[	O
10	O
]	O
.	O

These	O
data	O
provided	O
important	O
confirmation	O
of	O
the	O
highly	O
regulated	O
nature	O
of	O
necroptosis	O
and	O
revealed	O
the	O
first	O
insight	O
into	O
the	O
full	O
repertoire	O
of	O
mediators	O
of	O
this	O
form	O
of	O
cell	O
death	O
.	O

However	O
,	O
the	O
specific	O
signaling	O
pathways	O
activated	O
during	O
necroptosis	O
and	O
their	O
connections	O
to	O
RIP1	B-Protein
and	O
RIP3	B-Protein
remain	O
poorly	O
understood	O
.	O

Several	O
recent	O
studies	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
have	O
suggested	O
that	O
JNK	O
kinase	O
activation	O
plays	O
an	O
important	O
role	O
during	O
necroptosis	O
in	O
L929	O
cells	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
.	O

For	O
example	O
,	O
the	O
transcription	O
factor	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
a	O
key	O
cellular	O
target	O
of	O
JNK	O
activity	O
,	O
was	O
one	O
of	O
the	O
hits	O
in	O
the	O
genome	O
wide	O
siRNA	O
screen	O
[	O
10	O
]	O
.	O

Activation	O
of	O
JNK	O
in	O
L929	O
cells	O
has	O
been	O
linked	O
to	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
activation	O
of	O
oxidative	O
stress	O
and	O
induction	O
of	O
autophagy	O
,	O
all	O
of	O
which	O
contribute	O
to	O
necroptosis	O
.	O

Importantly	O
,	O
RIP1	B-Protein
kinase	O
dependent	O
activation	O
of	O
JNK	O
and	O
TNFalpha	B-Protein
production	O
has	O
recently	O
been	O
described	O
to	O
be	O
independent	O
of	O
its	O
role	O
in	O
necroptosis	O
[	O
15	O
]	O
.	O

Curiously	O
,	O
Akt	O
kinase	O
,	O
a	O
key	O
pro	O
-	O
survival	O
molecule	O
and	O
a	O
well	O
-	O
established	O
inhibitor	O
of	O
apoptotic	O
cell	O
death	O
,	O
has	O
also	O
recently	O
been	O
linked	O
to	O
necroptosis	O
in	O
L929	O
cells	O
[	O
16	O
]	O
,	O
where	O
insulin	B-Protein
-	O
dependent	O
activation	O
of	O
Akt	O
was	O
suggested	O
to	O
promote	O
necroptosis	O
by	O
suppressing	O
autophagy	O
.	O

This	O
conclusion	O
was	O
unexpected	O
,	O
since	O
several	O
reports	O
from	O
different	O
groups	O
,	O
including	O
ours	O
,	O
have	O
established	O
that	O
autophagy	O
promotes	O
,	O
rather	O
than	O
suppresses	O
,	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
in	O
L929	O
cells	O
[	O
11	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
17	O
]	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
Akt	O
controls	O
more	O
general	O
mechanisms	O
that	O
contribute	O
to	O
the	O
execution	O
of	O
necroptosis	O
.	O

Furthermore	O
,	O
the	O
key	O
question	O
of	O
whether	O
insulin	B-Protein
-	O
dependent	O
Akt	O
activity	O
solely	O
provides	O
an	O
environment	O
conducive	O
for	O
necroptosis	O
or	O
if	O
Akt	O
activation	O
is	O
an	O
intrinsic	O
component	O
of	O
necroptosis	O
signaling	O
that	O
is	O
linked	O
to	O
RIP1	B-Protein
kinase	O
has	O
not	O
been	O
explored	O
.	O

In	O
this	O
study	O
,	O
we	O
expanded	O
these	O
observations	O
to	O
delineate	O
the	O
specific	O
contributions	O
and	O
molecular	O
ordering	O
of	O
the	O
Akt	O
and	O
JNK	O
pathways	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
during	O
necroptosis	O
.	O

Our	O
data	O
reveal	O
that	O
Akt	O
is	O
activated	O
through	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
Thr308	O
phosphorylation	O
during	O
necroptosis	O
in	O
multiple	O
cell	O
types	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
downstream	O
Akt	O
signaling	O
through	O
mTORC1	O
and	O
S6	B-Protein
contributes	O
to	O
the	O
activation	O
of	O
necroptosis	O
and	O
TNFalpha	B-Protein
production	O
.	O

We	O
found	O
that	O
the	O
Akt	O
pathway	O
serves	O
as	O
a	O
critical	O
link	O
between	O
RIP1	B-Protein
kinase	O
and	O
JNK	O
activation	O
in	O
L929	O
cells	O
.	O

Further	O
data	O
suggested	O
that	O
in	O
multiple	O
other	O
cell	O
types	O
including	O
FADD	B-Protein
deficient	O
Jurkat	O
cells	O
,	O
RAW	O
and	O
J774	O
.	O
1	O
macrophage	O
cell	O
lines	O
,	O
and	O
mouse	O
lung	O
fibroblasts	O
Akt	O
provides	O
a	O
key	O
link	O
to	O
TNFalpha	B-Protein
production	O
,	O
but	O
is	O
dispensible	O
for	O
cell	O
death	O
per	O
se	O
.	O

Overall	O
,	O
our	O
results	O
reveal	O
a	O
specific	O
and	O
novel	O
role	O
for	O
the	O
Akt	O
pathway	O
in	O
regulated	O
necrosis	O
and	O
necrosis	O
-	O
associated	O
inflammatory	O
signaling	O
.	O
<EOS>	B-X
Periodontitis	B-X
and	B-X
orthodontic	B-X
treatment	B-X
can	B-X
lead	B-X
to	B-X
inflammatory	B-X
root	B-X
resorption	B-X
(	B-X
IRR	B-X
)	B-X
through	B-X
an	B-X
unclear	B-X
mechanism	B-X
.	B-X
Chemerin	B-X
,	B-X
a	B-X
novel	B-X
chemoattractant	B-X
protein	B-X
,	B-X
is	B-X
closely	B-X
associated	B-X
with	B-X
inflammation	B-X
,	B-X
affects	B-X
osteoblast	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
,	B-X
and	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
IRR	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
explore	B-X
possible	B-X
roles	B-X
of	B-X
the	B-X
chemerin/ChemR23	B-X
interaction	B-X
in	B-X
cementoblast	B-X
function	B-X
and	B-X
IRR	B-X
and	B-X
reveal	B-X
a	B-X
new	B-X
IRR	B-X
therapeutic	B-X
target	B-X
.	B-X

Basic	B-Protein
Fibroblast	I-Protein
Growth	I-Protein
Factor	I-Protein
Promotes	O
Necroptosis	O
in	O
L929	O
Cells	O

It	O
has	O
been	O
established	O
that	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
undergo	O
necroptotic	O
cell	O
death	O
following	O
stimulation	O
with	O
TNFalpha	B-Protein
[	O
10	O
]	O
,	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
caspase	B-Protein
-	I-Protein
8	I-Protein
activity	O
alone	O
,	O
either	O
through	O
siRNA	O
knockdown	O
or	O
by	O
using	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
,	O
zVAD	O
.	O
fmk	O
,	O
is	O
sufficient	O
to	O
trigger	O
necroptosis	O
in	O
these	O
cells	O
[	O
10	O
]	O
,	O
[	O
14	O
]	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor-related	B-X
apoptosis-induced	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
its	B-X
lethality	B-X
to	B-X
precancerous	B-X
and	B-X
cancerous	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
many	B-X
kinds	B-X
of	B-X
tumor	B-X
cells	B-X
,	B-X
including	B-X
most	B-X
glioma	B-X
cells	B-X
,	B-X
tend	B-X
to	B-X
evade	B-X
TRAIL-induced	B-X
apoptosis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
and	B-X
role	B-X
of	B-X
celastrol	B-X
in	B-X
the	B-X
sensitization	B-X
of	B-X
glioma	B-X
cells	B-X
remain	B-X
to	B-X
be	B-X
elucidated	B-X
.	B-X
Small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
-mediated	B-X
transcriptional	B-X
knockdown	B-X
of	B-X
urokinase	B-X
plasminogen	B-X
activator	B-X
receptor	B-X
(	B-X
uPAR	B-X
)	B-X
and	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
,	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
,	B-X
inhibits	B-X
uPAR	B-X
and/or	B-X
MMP-9	B-X
expression	B-X
and	B-X
induces	B-X
apoptosis	B-X
in	B-X
the	B-X
human	B-X
glioblastoma	B-X
xenograft	B-X
cell	B-X
lines	B-X
4910	B-X
and	B-X
5310.	B-X
siRNA	B-X
against	B-X
uPAR	B-X
(	B-X
pU-Si	B-X
)	B-X
,	B-X
MMP-9	B-X
(	B-X
pM-Si	B-X
)	B-X
,	B-X
or	B-X
both	B-X
(	B-X
pUM-Si	B-X
)	B-X
induced	B-X
apoptosis	B-X
and	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
cleavage	B-X
of	B-X
caspase-8	B-X
,	B-X
caspase-3	B-X
,	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
Fas	B-X
siRNA	B-X
against	B-X
the	B-X
Fas	B-X
death	B-X
receptor	B-X
blocked	B-X
apoptosis	B-X
induced	B-X
by	B-X
pU-Si	B-X
,	B-X
pM-Si	B-X
,	B-X
or	B-X
pUM-Si	B-X
,	B-X
thereby	B-X
indicating	B-X
the	B-X
role	B-X
for	B-X
Fas	B-X
signaling	B-X
in	B-X
pU-Si-	B-X
,	B-X
pM-Si-	B-X
,	B-X
or	B-X
pUM-Si-mediated	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
human	B-X
glioma	B-X
xenograft	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
transcriptional	B-X
inactivation	B-X
of	B-X
uPAR	B-X
and/or	B-X
MMP-9	B-X
enhanced	B-X
localization	B-X
of	B-X
Fas	B-X
death	B-X
receptor	B-X
,	B-X
Fas-associated	B-X
death	B-X
domain-containing	B-X
protein	B-X
,	B-X
and	B-X
procaspase-8	B-X
into	B-X
lipid	B-X
rafts	B-X
.	B-X
Additionally	B-X
,	B-X
disruption	B-X
of	B-X
lipid	B-X
rafts	B-X
with	B-X
methyl	B-X
β	B-X
cyclodextrin	B-X
prevented	B-X
Fas	B-X
clustering	B-X
and	B-X
pU-Si-	B-X
,	B-X
pM-Si-	B-X
,	B-X
or	B-X
pUM-Si-induced	B-X
apoptosis	B-X
,	B-X
which	B-X
is	B-X
indicative	B-X
of	B-X
coclustering	B-X
of	B-X
Fas	B-X
death	B-X
receptor	B-X
into	B-X
lipid	B-X
rafts	B-X
in	B-X
the	B-X
glioblastoma	B-X
xenograft	B-X
cell	B-X
lines	B-X
4910	B-X
and	B-X
5310	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
the	B-X
crucial	B-X
role	B-X
of	B-X
the	B-X
clusters	B-X
of	B-X
apoptotic	B-X
signaling	B-X
molecule-enriched	B-X
rafts	B-X
in	B-X
programmed	B-X
cell	B-X
death	B-X
,	B-X
acting	B-X
as	B-X
concentrators	B-X
of	B-X
death	B-X
receptors	B-X
and	B-X
downstream	B-X
signaling	B-X
molecules	B-X
,	B-X
and	B-X
as	B-X
the	B-X
linchpin	B-X
from	B-X
which	B-X
a	B-X
potent	B-X
death	B-X
signal	B-X
is	B-X
launched	B-X
in	B-X
uPAR-	B-X
and/or	B-X
MMP-9-downregulated	B-X
cells	B-X
.	B-X

Interestingly	O
,	O
while	O
necroptosis	O
was	O
initially	O
identified	O
as	O
a	O
back	O
-	O
up	O
form	O
of	O
cell	O
death	O
triggered	O
by	O
pro	O
-	O
apoptotic	O
stimuli	O
in	O
the	O
presence	O
of	O
apoptosis	O
inhibitors	O
[	O
17	O
]	O
,	O
recent	O
analysis	O
of	O
physiological	O
cell	O
death	O
during	O
mouse	O
development	O
has	O
suggested	O
that	O
the	O
loss	O
of	O
apoptotic	O
regulators	O
,	O
such	O
as	O
caspase	B-Protein
-	I-Protein
8	I-Protein
and	O
FADD	B-Protein
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
,	O
leads	O
to	O
robust	O
induction	O
of	O
necroptosis	O
and	O
death	O
of	O
E10	O
.	O
5	O
embryos	O
even	O
though	O
apoptosis	O
is	O
not	O
normally	O
induced	O
in	O
wild	O
type	O
embryos	O
.	O

These	O
data	O
are	O
reminiscent	O
of	O
the	O
observations	O
in	O
L929	O
cells	O
where	O
the	O
loss	O
of	O
caspase	O
activity	O
in	O
healthy	O
cells	O
is	O
sufficient	O
to	O
trigger	O
necroptosis	O
and	O
prompted	O
us	O
to	O
explore	O
the	O
extrinsic	O
or	O
intrinsic	O
cellular	O
factors	O
that	O
promote	O
necroptosis	O
once	O
caspase	B-Protein
-	I-Protein
8	I-Protein
activity	O
,	O
which	O
cleaves	O
and	O
inactivates	O
RIP1	B-Protein
kinase	O
and	O
the	O
RIP1	B-Protein
deubiquitinase	I-Protein
CYLD	B-Protein
[	O
21	O
]	O
,	O
[	O
22	O
]	O
,	O
is	O
removed	O
in	O
L929	O
cells	O
.	O

Consistent	O
with	O
a	O
previous	O
report	O
[	O
16	O
]	O
,	O
we	O
found	O
that	O
serum	O
starvation	O
of	O
L929	O
cells	O
prevented	O
necroptosis	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

The	O
addition	O
of	O
growth	O
factors	O
,	O
such	O
as	O
bFGF	B-Protein
,	O
restored	O
zVAD	O
.	O
fmk	O
induced	O
death	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Interestingly	O
,	O
this	O
does	O
not	O
reflect	O
a	O
generic	O
requirement	O
for	O
growth	O
factor	O
signaling	O
,	O
as	O
only	O
some	O
growth	O
factors	O
(	O
bFGF	B-Protein
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
not	O
EGF	B-Protein
and	O
PDGF	O
)	O
promoted	O
death	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Furthermore	O
,	O
growth	O
factor	O
-	O
dependent	O
necroptosis	O
required	O
the	O
inhibition	O
of	O
caspase	O
activity	O
,	O
as	O
bFGF	B-Protein
alone	O
did	O
not	O
induce	O
cell	O
death	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

In	O
contrast	O
,	O
TNFalpha	B-Protein
triggered	O
necroptosis	O
equally	O
efficiently	O
in	O
the	O
absence	O
of	O
serum	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
suggesting	O
that	O
either	O
growth	O
factors	O
and	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
are	O
required	O
for	O
necroptotic	O
death	O
in	O
L929	O
cells	O
.	O
<EOS>	B-X
MLKL	B-X
(	B-X
mixed	B-X
lineage	B-X
kinase	B-X
domain	B-X
like	B-X
pseudokinase	B-X
)	B-X
is	B-X
a	B-X
well-known	B-X
core	B-X
component	B-X
of	B-X
necrosome	B-X
that	B-X
executes	B-X
necroptotic	B-X
cell	B-X
death	B-X
upon	B-X
phosphorylation	B-X
by	B-X
RIPK3	B-X
(	B-X
receptor	B-X
interacting	B-X
serine/threonine	B-X
kinase	B-X
3	B-X
)	B-X
.	B-X
Using	B-X
mouse	B-X
Neuro-2a	B-X
and	B-X
L929	B-X
as	B-X
well	B-X
as	B-X
human	B-X
HEK293	B-X
and	B-X
HT29	B-X
cells	B-X
,	B-X
we	B-X
show	B-X
here	B-X
that	B-X
MLKL	B-X
is	B-X
phosphorylated	B-X
in	B-X
response	B-X
to	B-X
serum	B-X
and	B-X
amino	B-X
acid	B-X
deprivation	B-X
from	B-X
the	B-X
culture	B-X
medium	B-X
,	B-X
in	B-X
a	B-X
manner	B-X
that	B-X
depends	B-X
on	B-X
CAMK2/CaMKII	B-X
(	B-X
calcium/calmodulin	B-X
dependent	B-X
protein	B-X
kinase	B-X
II	B-X
)	B-X
but	B-X
not	B-X
RIPK3	B-X
.	B-X
These	B-X
changes	B-X
were	B-X
prevented	B-X
by	B-X
disrupting	B-X
either	B-X
MLKL	B-X
or	B-X
CAMK2	B-X
by	B-X
pharmacology	B-X
and	B-X
genetic	B-X
manipulations	B-X
.	B-X
Moreover	B-X
,	B-X
disrupting	B-X
MLKL	B-X
or	B-X
CAMK2	B-X
also	B-X
inhibited	B-X
the	B-X
incorporation	B-X
of	B-X
LC3-II	B-X
into	B-X
autolysosomes	B-X
,	B-X
demonstrating	B-X
a	B-X
role	B-X
of	B-X
the	B-X
CAMK2-MLKL	B-X
pathway	B-X
in	B-X
facilitating	B-X
autophagic	B-X
flux	B-X
during	B-X
short-term	B-X
starvation	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
necroptosis	B-X
which	B-X
suppressed	B-X
autophagic	B-X
flux	B-X
.	B-X
Furthermore	B-X
,	B-X
unlike	B-X
the	B-X
necroptotic	B-X
pathway	B-X
,	B-X
the	B-X
starvation-evoked	B-X
CAMK2-mediated	B-X
MLKL	B-X
phosphorylation	B-X
protected	B-X
cells	B-X
from	B-X
starvation-induced	B-X
death	B-X
.	B-X
This	B-X
novel	B-X
function	B-X
is	B-X
independent	B-X
of	B-X
RIPK3	B-X
and	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
necroptosis	B-X
,	B-X
implicating	B-X
new	B-X
roles	B-X
for	B-X
this	B-X
pseudokinase	B-X
in	B-X
cell	B-X
survival	B-X
,	B-X
signaling	B-X
and	B-X
metabolism	B-X
.	B-X

Previously	O
we	O
described	O
the	O
development	O
of	O
7	O
-	O
Cl	O
-	O
O	O
-	O
Nec	O
-	O
1	O
(	O
Nec	O
-	O
1	O
)	O
as	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
RIP1	B-Protein
kinase	O
and	O
necroptosis	O
(	O
Fig	O
.	O
S1A	O
)	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

Recently	O
,	O
its	O
selectivity	O
has	O
been	O
further	O
validated	O
against	O
a	O
panel	O
of	O
more	O
than	O
400	O
human	O
kinases	O
[	O
15	O
]	O
.	O

This	O
inhibitor	O
efficiently	O
blocked	O
growth	O
factor	O
/	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
serum	O
free	O
conditions	O
in	O
L929	O
cells	O
and	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
-	O
induced	O
necroptosis	O
under	O
full	O
serum	O
conditions	O
(	O
Fig	O
.	O
1B	O
,	O
S1B	O
)	O
.	O

To	O
further	O
validate	O
the	O
role	O
of	O
RIP1	B-Protein
,	O
we	O
used	O
an	O
inactive	O
analog	O
,	O
7	O
-	O
Cl	O
-	O
O	O
-	O
Nec	O
-	O
1i	O
(	O
Nec	O
-	O
1i	O
)	O
(	O
Fig	O
.	O
S1A	O
)	O
,	O
which	O
contains	O
an	O
extra	O
N	O
-	O
methyl	O
group	O
that	O
leads	O
to	O
almost	O
complete	O
loss	O
of	O
RIP1	B-Protein
kinase	O
inhibitory	O
activity	O
in	O
vitro	O
[	O
23	O
]	O
.	O

Nec	O
-	O
1i	O
was	O
unable	O
to	O
protect	O
L929	O
cell	O
death	O
under	O
serum	O
condtions	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
S1B	O
)	O
or	O
serum	O
free	O
conditions	O
treated	O
with	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S1C	O
)	O
.	O

This	O
confirms	O
that	O
RIP1	B-Protein
kinase	O
is	O
responsible	O
for	O
necroptosis	O
in	O
L929	O
cells	O
under	O
both	O
serum	O
and	O
serum	O
free	O
conditions	O
.	O

We	O
next	O
examined	O
whether	O
bFGF	B-Protein
contributes	O
to	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
normal	O
serum	O
conditions	O
(	O
10	O
%	O
FBS	O
)	O
.	O

We	O
used	O
two	O
bFGF	B-Protein
receptor	I-Protein
tyrosine	I-Protein
kinase	I-Protein
inhibitors	O
(	O
PD173074	O
and	O
PD166866	O
)	O
,	O
and	O
determined	O
that	O
inhibition	O
of	O
bFGF	B-Protein
signaling	O
strongly	O
inhibited	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
under	O
normal	O
serum	O
conditions	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

In	O
contrast	O
,	O
neither	O
bFGF	B-Protein
receptor	I-Protein
inhibitor	O
was	O
able	O
to	O
attenuate	O
TNFalpha	B-Protein
-	O
induced	O
necroptosis	O
(	O
Fig	O
.	O
1D	O
)	O
,	O
consistent	O
with	O
growth	O
factors	O
being	O
dispensable	O
for	O
this	O
pathway	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
the	O
induction	O
of	O
necroptosis	O
by	O
zVAD	O
.	O
fmk	O
is	O
promoted	O
by	O
bFGF	B-Protein
under	O
both	O
serum	O
and	O
serum	O
free	O
conditions	O
.	O

The	O
induction	O
of	O
necroptosis	O
,	O
however	O
,	O
is	O
not	O
a	O
simple	O
consequence	O
of	O
growth	O
factor	O
signaling	O
since	O
not	O
all	O
growth	O
factors	O
allowed	O
death	O
to	O
occur	O
.	O
<EOS>	B-X
Since	B-X
it	B-X
is	B-X
a	B-X
general	B-X
characteristic	B-X
of	B-X
cancers	B-X
to	B-X
resist	B-X
apoptosis	B-X
,	B-X
induction	B-X
of	B-X
non-apoptotic	B-X
regulated	B-X
cell	B-X
death	B-X
(	B-X
RCD	B-X
)	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
new	B-X
cancer	B-X
treatment	B-X
strategy	B-X
.	B-X
Specifically	B-X
,	B-X
autophagy	B-X
,	B-X
ferroptosis	B-X
,	B-X
pyroptosis	B-X
,	B-X
and	B-X
necroptosis	B-X
exhibit	B-X
synergistic	B-X
antitumor	B-X
immune	B-X
responses	B-X
while	B-X
possibly	B-X
exerting	B-X
inhibitory	B-X
effects	B-X
on	B-X
antitumor	B-X
immune	B-X
responses	B-X
.	B-X
Thus	B-X
,	B-X
targeted	B-X
therapies	B-X
(	B-X
inducers	B-X
or	B-X
inhibitors	B-X
)	B-X
against	B-X
autophagy	B-X
,	B-X
ferroptosis	B-X
,	B-X
pyroptosis	B-X
,	B-X
and	B-X
necroptosis	B-X
in	B-X
combination	B-X
with	B-X
immunotherapy	B-X
may	B-X
exert	B-X
potent	B-X
antitumor	B-X
activity	B-X
,	B-X
even	B-X
in	B-X
tumors	B-X
resistant	B-X
to	B-X
ICIs	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
multilevel	B-X
relationship	B-X
between	B-X
antitumor	B-X
immunity	B-X
and	B-X
non-apoptotic	B-X
RCD	B-X
,	B-X
including	B-X
autophagy	B-X
,	B-X
ferroptosis	B-X
,	B-X
pyroptosis	B-X
,	B-X
and	B-X
necroptosis	B-X
,	B-X
and	B-X
the	B-X
potential	B-X
targeting	B-X
application	B-X
of	B-X
non-apoptotic	B-X
RCD	B-X
to	B-X
improve	B-X
the	B-X
efficacy	B-X
of	B-X
immunotherapy	B-X
in	B-X
malignancy	B-X
.	B-X

Instead	O
,	O
specific	O
signaling	O
events	O
mediated	O
by	O
particular	O
growth	O
factors	O
appear	O
to	O
contribute	O
to	O
necroptotic	O
death	O
.	O

RIP1	B-Protein
Kinase	O
-	O
dependent	O
Activation	O
of	O
Akt	O
Contributes	O
to	O
Necroptosis	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Given	O
our	O
observation	O
that	O
growth	O
factors	O
are	O
important	O
for	O
zVAD	O
.	O
fmk	O
induced	O
death	O
,	O
we	O
examined	O
the	O
contribution	O
of	O
several	O
pathways	O
,	O
including	O
MAPK	O
pathways	O
and	O
Akt	O
,	O
which	O
are	O
known	O
to	O
be	O
activated	O
following	O
growth	O
factor	O
receptor	O
activation	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Inhibition	O
of	O
Akt	O
(	O
Akt	O
inhibitor	O
VIII	O
)	O
strongly	O
protected	O
the	O
cells	O
from	O
growth	O
factor	O
-	O
sensitive	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
[	O
16	O
]	O
as	O
well	O
as	O
cell	O
death	O
triggered	O
by	O
bFGF	B-Protein
or	O
IGF	B-Protein
-	I-Protein
1	I-Protein
/	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Inhibition	O
of	O
Akt	O
also	O
protected	O
the	O
cells	O
from	O
growth	O
-	O
factor	O
insensitive	O
death	O
by	O
caused	O
by	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
2A	O
)	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
the	O
JNK	O
inhibitor	O
SP600125	O
protected	O
the	O
cells	O
from	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
2A	O
,	O
B	O
and	O
Fig	O
.	O
S2A	O
)	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
two	O
other	O
MAPKs	O
,	O
p38	O
and	O
ERK	O
,	O
previously	O
reported	O
not	O
to	O
be	O
activated	O
during	O
necroptosis	O
[	O
14	O
]	O
,	O
did	O
not	O
protect	O
from	O
either	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Next	O
,	O
we	O
used	O
two	O
approaches	O
to	O
further	O
validate	O
the	O
role	O
of	O
Akt	O
in	O
necroptotic	O
cell	O
death	O
.	O

First	O
,	O
two	O
additional	O
Akt	O
inhibitors	O
,	O
a	O
highly	O
specific	O
,	O
allosteric	O
kinase	O
inhibitor	O
MK	O
-	O
2206	O
[	O
25	O
]	O
and	O
triciribine	O
(	O
TCN	O
)	O
[	O
26	O
]	O
,	O
which	O
blocks	O
membrane	O
translocation	O
of	O
Akt	O
,	O
both	O
attenuated	O
cell	O
death	O
(	O
Fig	O
.	O
S2B	O
)	O
.	O

Secondly	O
,	O
simultaneous	O
knockdown	O
of	O
Akt	O
isoforms	O
Akt1	B-Protein
and	O
Akt2	B-Protein
using	O
siRNAs	O
protected	O
cells	O
from	O
necroptosis	O
induced	O
by	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
(	O
Fig	O
.	O
2C	O
)	O
.	O

No	O
expression	O
of	O
Akt3	B-Protein
was	O
seen	O
in	O
L929	O
cells	O
(	O
Fig	O
.	O
S2C	O
)	O
and	O
,	O
consistently	O
,	O
Akt3	B-Protein
siRNA	I-Protein
had	O
no	O
additional	O
effect	O
on	O
necroptosis	O
.	O

Our	O
results	O
confirmed	O
that	O
Akt	O
plays	O
a	O
key	O
role	O
in	O
necroptosis	O
induced	O
by	O
multiple	O
stimuli	O
in	O
L929	O
cells	O
.	O

To	O
understand	O
the	O
activation	O
of	O
Akt	O
and	O
JNK	O
under	O
necroptotic	O
conditions	O
,	O
we	O
examined	O
the	O
changes	O
in	O
Akt	O
and	O
JNK	O
phosphorylation	O
at	O
9	O
hrs	O
post	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
stimulation	O
.	O

This	O
time	O
point	O
was	O
chosen	O
because	O
it	O
reflects	O
the	O
early	O
stage	O
of	O
cell	O
death	O
in	O
our	O
system	O
(	O
Fig	O
.	O
S3A	O
,	O
B	O
)	O
.	O

Following	O
stimulation	O
with	O
either	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
we	O
observed	O
a	O
robust	O
increase	O
in	O
Akt	O
phosphorylation	O
at	O
a	O
known	O
major	O
activation	O
site	O
,	O
Thr308	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
<EOS>	B-X
Neospora	B-X
caninum	B-X
is	B-X
an	B-X
intracellular	B-X
parasite	B-X
that	B-X
causes	B-X
neosporosis	B-X
in	B-X
cattle	B-X
.	B-X
Bovine	B-X
neosporosis	B-X
is	B-X
considered	B-X
a	B-X
major	B-X
cause	B-X
of	B-X
bovine	B-X
abortion	B-X
worldwide	B-X
.	B-X
Our	B-X
previous	B-X
study	B-X
revealed	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
in	B-X
N.	B-X
caninum-infected	B-X
murine	B-X
macrophages	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
inflammasome	B-X
activity	B-X
in	B-X
N.	B-X
caninum-infected	B-X
bovine	B-X
cells	B-X
is	B-X
unknown	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
a	B-X
bovine	B-X
peritoneal	B-X
macrophage	B-X
cell	B-X
line	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
inflammasome	B-X
activation	B-X
in	B-X
regulating	B-X
intracellular	B-X
N.	B-X
caninum	B-X
replication	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
inflammasome	B-X
mediated	B-X
activation	B-X
of	B-X
caspase-1	B-X
occurs	B-X
in	B-X
N.	B-X
caninum-infected	B-X
bovine	B-X
macrophages	B-X
,	B-X
and	B-X
caspase-1-dependent	B-X
cell	B-X
death	B-X
was	B-X
considered	B-X
to	B-X
be	B-X
induced	B-X
in	B-X
N.	B-X
caninum-infected	B-X
bovine	B-X
macrophages	B-X
because	B-X
N.	B-X
caninum	B-X
induced	B-X
cell	B-X
death	B-X
decreased	B-X
following	B-X
pretreatment	B-X
with	B-X
zVAD-fmk	B-X
and	B-X
VX765	B-X
.	B-X
Meanwhile	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
caspase-1	B-X
in	B-X
N.	B-X
caninum-infected	B-X
bovine	B-X
macrophages	B-X
led	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
more	B-X
parasites	B-X
in	B-X
the	B-X
parasitophorous	B-X
vacuole	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
inflammasome	B-X
activation	B-X
induced	B-X
by	B-X
ATP	B-X
treatment	B-X
in	B-X
N.	B-X
caninum-infected	B-X
bovine	B-X
macrophages	B-X
contributed	B-X
to	B-X
the	B-X
clearance	B-X
of	B-X
N.	B-X
caninum	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
pyroptotic	B-X
cell	B-X
supernatant	B-X
collected	B-X
from	B-X
ATP-stimulated	B-X
bovine	B-X
macrophages	B-X
also	B-X
impaired	B-X
the	B-X
ability	B-X
of	B-X
this	B-X
parasite	B-X
to	B-X
infect	B-X
new	B-X
cells	B-X
.	B-X

Interestingly	O
,	O
we	O
did	O
not	O
observe	O
concomitant	O
phosphorylation	O
changes	O
in	O
the	O
second	O
major	O
activation	O
site	O
of	O
Akt	O
,	O
Ser473	O
.	O
<EOS>	B-X
Interestingly	B-X
,	B-X
recent	B-X
evidence	B-X
has	B-X
suggested	B-X
that	B-X
the	B-X
formation	B-X
of	B-X
double	B-X
strand	B-X
breaks	B-X
(	B-X
DSBs	B-X
)	B-X
in	B-X
DNA	B-X
,	B-X
the	B-X
most	B-X
toxic	B-X
form	B-X
of	B-X
damage	B-X
,	B-X
is	B-X
a	B-X
physiological	B-X
process	B-X
that	B-X
modifies	B-X
gene	B-X
expression	B-X
during	B-X
normal	B-X
brain	B-X
activity	B-X
.	B-X
Interestingly	B-X
,	B-X
neurodegenerative	B-X
diseases	B-X
such	B-X
as	B-X
Alzheimer	B-X
's	B-X
disease	B-X
,	B-X
amyotrophic	B-X
lateral	B-X
sclerosis	B-X
,	B-X
frontotemporal	B-X
dementia	B-X
,	B-X
and	B-X
Huntington	B-X
's	B-X
disease	B-X
,	B-X
manifest	B-X
by	B-X
a	B-X
decline	B-X
in	B-X
cognitive	B-X
functions	B-X
,	B-X
which	B-X
are	B-X
governed	B-X
by	B-X
plasticity	B-X
.	B-X
Alzheimer	B-X
's	B-X
Disease	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
a	B-X
severe	B-X
neurodegenerative	B-X
disorder	B-X
that	B-X
includes	B-X
the	B-X
occurrence	B-X
of	B-X
behavioral	B-X
disorders	B-X
as	B-X
well	B-X
as	B-X
memory	B-X
and	B-X
cognitive	B-X
impairment	B-X
as	B-X
major	B-X
symptoms	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
and	B-X
according	B-X
to	B-X
with	B-X
our	B-X
neuroimmunomodulation	B-X
theory	B-X
,	B-X
microglial	B-X
activation	B-X
modifies	B-X
the	B-X
cross-talks	B-X
between	B-X
microglia	B-X
and	B-X
neurons	B-X
.	B-X
We	B-X
postulated	B-X
that	B-X
glial	B-X
activation	B-X
triggered	B-X
by	B-X
``	B-X
damage	B-X
signals	B-X
''	B-X
activates	B-X
a	B-X
pathological	B-X
molecular	B-X
cascade	B-X
that	B-X
finally	B-X
leads	B-X
to	B-X
hyperphosphorylation	B-X
and	B-X
oligomerization	B-X
of	B-X
the	B-X
tau	B-X
protein	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
modifications	B-X
correlate	B-X
with	B-X
the	B-X
gradual	B-X
cognitive	B-X
impairment	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
AD	B-X
.	B-X
Microglial	B-X
activation	B-X
is	B-X
determined	B-X
by	B-X
the	B-X
nature	B-X
and	B-X
strength	B-X
of	B-X
the	B-X
stimulus	B-X
.	B-X
In	B-X
the	B-X
AD	B-X
,	B-X
a	B-X
continuous	B-X
activation	B-X
state	B-X
of	B-X
microglia	B-X
appears	B-X
to	B-X
generate	B-X
neuronal	B-X
injury	B-X
and	B-X
neurodegeneration	B-X
,	B-X
producing	B-X
the	B-X
outflow	B-X
of	B-X
pathological	B-X
tau	B-X
from	B-X
the	B-X
inner	B-X
of	B-X
neurons	B-X
to	B-X
the	B-X
extraneuronal	B-X
space	B-X
.	B-X
Released	B-X
tau	B-X
,	B-X
together	B-X
with	B-X
the	B-X
contribution	B-X
of	B-X
ApoE4	B-X
protein	B-X
,	B-X
would	B-X
then	B-X
produce	B-X
reactivation	B-X
of	B-X
microglia	B-X
,	B-X
thus	B-X
inducing	B-X
a	B-X
positive	B-X
feedback	B-X
that	B-X
stimulates	B-X
the	B-X
vicious	B-X
cycle	B-X
in	B-X
neurodegeneration	B-X
.	B-X

We	O
also	O
observed	O
an	O
increase	O
in	O
the	O
phosphorylation	O
of	O
both	O
the	O
p46	B-Protein
and	O
p54	B-Protein
isoforms	O
of	O
JNK	O
and	O
its	O
major	O
substrate	O
c	B-Protein
-	I-Protein
Jun	I-Protein
(	O
Fig	O
.	O
3A	O
)	O
.	O

These	O
data	O
indicate	O
that	O
both	O
Akt	O
and	O
JNK	O
are	O
activated	O
under	O
necroptotic	O
conditions	O
.	O

The	O
RIP1	B-Protein
kinase	O
inhibitor	O
,	O
Nec	O
-	O
1	O
,	O
completely	O
prevented	O
the	O
increase	O
in	O
Thr308	O
Akt	B-Protein
phosphorylation	O
,	O
while	O
Nec	O
-	O
1i	O
did	O
not	O
(	O
Fig	O
.	O
3A	O
,	O
Fig	O
.	O
S1D	O
)	O
.	O

Similarly	O
,	O
Nec	O
-	O
1	O
prevented	O
the	O
induction	O
of	O
JNK	O
phosphorylation	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
and	O
substantially	O
reduced	O
this	O
change	O
after	O
TNFalpha	B-Protein
addition	O
.	O

We	O
observed	O
some	O
changes	O
in	O
total	O
protein	O
levels	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
following	O
necroptotic	O
stimulation	O
.	O

Some	O
of	O
these	O
changes	O
,	O
e	O
.	O
g	O
.	O
zVAD	O
.	O
fmk	O
-	O
induced	O
increase	O
in	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
were	O
also	O
attenuated	O
by	O
Nec	O
-	O
1	O
.	O

Importantly	O
,	O
Nec	O
-	O
1	O
did	O
not	O
alter	O
the	O
basal	O
phosphorylation	O
levels	O
of	O
either	O
Akt	O
or	O
JNK	O
(	O
Fig	O
.	O
3A	O
)	O
.	O
<EOS>	B-X
Additionally	B-X
,	B-X
the	B-X
intercellular	B-X
levels	B-X
of	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
were	B-X
lower	B-X
in	B-X
HaCaT	B-X
cells	B-X
treated	B-X
with	B-X
CNT	B-X
than	B-X
in	B-X
control	B-X
HaCaT	B-X
cells	B-X
,	B-X
and	B-X
typical	B-X
necroptosis-associated	B-X
characteristics	B-X
were	B-X
observed	B-X
by	B-X
electron	B-X
microscopy	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
CNT	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
HaCaT	B-X
cells	B-X
,	B-X
CNT-treated	B-X
HaCaT	B-X
cells	B-X
produced	B-X
more	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
,	B-X
but	B-X
this	B-X
effect	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidants	B-X
N-acetyl-cysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
diphenyleneiodonium	B-X
chloride	B-X
(	B-X
DPI	B-X
)	B-X
,	B-X
and	B-X
apocynin	B-X
and	B-X
the	B-X
necroptosis	B-X
inhibitor	B-X
Nec-1	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
CNT	B-X
ameliorated	B-X
skin	B-X
lesions	B-X
and	B-X
inflammation	B-X
in	B-X
imiquimod	B-X
(	B-X
IMQ	B-X
)	B-X
-	B-X
and	B-X
12-O-tetradecanoyl-phorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
psoriasis-like	B-X
mouse	B-X
models	B-X
.	B-X
Necroptosis	B-X
reportedly	B-X
activates	B-X
and	B-X
induces	B-X
neuronal	B-X
death	B-X
in	B-X
patients	B-X
with	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
;	B-X
however	B-X
,	B-X
the	B-X
main	B-X
mediators	B-X
and	B-X
mechanisms	B-X
underlying	B-X
necroptosis	B-X
induction	B-X
in	B-X
AD	B-X
remain	B-X
elusive	B-X
.	B-X

This	O
established	O
that	O
Akt	O
Thr308	O
and	O
JNK	O
phosphorylation	O
during	O
necroptosis	O
is	O
RIP1	B-Protein
dependent	O
.	O

Interestingly	O
,	O
we	O
discovered	O
that	O
the	O
phosphorylation	O
of	O
Akt	O
Thr308	O
,	O
JNK	O
and	O
Jun	O
are	O
late	O
events	O
following	O
zVAD	O
.	O
fmk	O
stimulation	O
(	O
Fig	O
.	O
3B	O
)	O
that	O
coincide	O
with	O
the	O
onset	O
of	O
necroptosis	O
at	O
6	O
hr	O
post	O
-	O
stimulation	O
(	O
Fig	O
.	O
S3A	O
)	O
.	O

To	O
better	O
understand	O
the	O
contributions	O
of	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
to	O
necroptotic	O
regulation	O
of	O
Akt	O
,	O
we	O
next	O
analyzed	O
the	O
time	O
course	O
of	O
these	O
phosphorylation	O
changes	O
under	O
serum	O
free	O
conditions	O
.	O

We	O
found	O
that	O
the	O
addition	O
of	O
bFGF	B-Protein
alone	O
or	O
in	O
combination	O
with	O
zVAD	O
.	O
fmk	O
led	O
to	O
a	O
substantial	O
rapid	O
and	O
transient	O
increase	O
in	O
both	O
Thr308	O
and	O
Ser473	O
phosphorylation	O
of	O
Akt	O
as	O
well	O
as	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
at	O
15	O
minutes	O
,	O
reflecting	O
the	O
expected	O
response	O
to	O
growth	O
factor	O
stimulation	O
(	O
Fig	O
.	O
3C	O
)	O
.	O
<EOS>	B-X
Ulcerative	B-X
colitis	B-X
(	B-X
UC	B-X
)	B-X
is	B-X
a	B-X
chronic	B-X
,	B-X
relapsing	B-X
inflammatory	B-X
disorder	B-X
of	B-X
the	B-X
colonic	B-X
mucosa	B-X
followed	B-X
by	B-X
poor	B-X
quality	B-X
of	B-X
healing	B-X
and	B-X
recurring	B-X
lesions	B-X
.	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
that	B-X
the	B-X
poor	B-X
healing	B-X
and	B-X
chronic	B-X
inflammation	B-X
in	B-X
colon	B-X
of	B-X
UC	B-X
could	B-X
be	B-X
the	B-X
result	B-X
of	B-X
microvascular	B-X
dysfunction	B-X
and	B-X
endothelial	B-X
barrier	B-X
defect	B-X
,	B-X
resulting	B-X
in	B-X
sustained	B-X
tissue	B-X
hypoperfusion	B-X
and	B-X
ischemia	B-X
in	B-X
the	B-X
colon	B-X
.	B-X
Long	B-X
before	B-X
angiogenesis	B-X
became	B-X
a	B-X
popular	B-X
research	B-X
topic	B-X
,	B-X
our	B-X
laboratory	B-X
was	B-X
the	B-X
first	B-X
to	B-X
postulate	B-X
that	B-X
stimulation	B-X
of	B-X
angiogenesis	B-X
alone	B-X
might	B-X
be	B-X
sufficient	B-X
to	B-X
accelerate	B-X
ulcer	B-X
healing	B-X
in	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
.	B-X
Our	B-X
earlier	B-X
studies	B-X
demonstrated	B-X
that	B-X
therapy	B-X
with	B-X
genes	B-X
or	B-X
peptides	B-X
of	B-X
angiogenic	B-X
growth	B-X
factors	B-X
,	B-X
e.g.	B-X
,	B-X
bFGF	B-X
,	B-X
PDGF	B-X
and	B-X
VEGF	B-X
significantly	B-X
accelerated	B-X
healing	B-X
of	B-X
experimental	B-X
duodenal	B-X
ulcers	B-X
(	B-X
DU	B-X
)	B-X
,	B-X
while	B-X
blockade	B-X
of	B-X
these	B-X
angiogenic	B-X
factors	B-X
resulted	B-X
in	B-X
impaired	B-X
healing	B-X
of	B-X
DU	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
the	B-X
angiogenesis	B-X
in	B-X
DU	B-X
,	B-X
increasing	B-X
evidences	B-X
from	B-X
us	B-X
and	B-X
others	B-X
indicate	B-X
that	B-X
angiogenesis	B-X
plays	B-X
a	B-X
pathogenic	B-X
role	B-X
in	B-X
UC	B-X
,	B-X
e.g.	B-X
,	B-X
VEGF	B-X
induces	B-X
an	B-X
abnormal	B-X
``	B-X
pathologic	B-X
''	B-X
angiogenesis	B-X
which	B-X
interferes	B-X
with	B-X
UC	B-X
healing	B-X
.	B-X
Recently	B-X
,	B-X
another	B-X
angiogenic	B-X
factor	B-X
,	B-X
placental	B-X
growth	B-X
factor	B-X
(	B-X
PlGF	B-X
)	B-X
,	B-X
has	B-X
also	B-X
been	B-X
suggested	B-X
to	B-X
be	B-X
a	B-X
marker	B-X
of	B-X
pathologic	B-X
angiogenesis	B-X
and	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
pathogenesis	B-X
of	B-X
UC	B-X
.	B-X
Although	B-X
inhibition	B-X
of	B-X
pathologic	B-X
angiogenesis	B-X
by	B-X
,	B-X
e.g.	B-X
,	B-X
anti-VEGF	B-X
or	B-X
-PlGF	B-X
,	B-X
was	B-X
demonstrated	B-X
to	B-X
be	B-X
a	B-X
new	B-X
approach	B-X
to	B-X
attenuate	B-X
UC	B-X
development	B-X
,	B-X
additional	B-X
data	B-X
of	B-X
our	B-X
and	B-X
others	B-X
showed	B-X
that	B-X
stimulating	B-X
angiogenesis	B-X
by	B-X
administration	B-X
of	B-X
PDGF	B-X
or	B-X
bFGF	B-X
significantly	B-X
accelerated	B-X
healing	B-X
of	B-X
UC	B-X
.	B-X
Also	B-X
,	B-X
activation	B-X
of	B-X
Rac1	B-X
,	B-X
a	B-X
small	B-X
GTPase	B-X
,	B-X
markedly	B-X
improved	B-X
VEGF-induced	B-X
neovessel	B-X
architecture	B-X
defect	B-X
and	B-X
reduced	B-X
vascular	B-X
permeability	B-X
(	B-X
VP	B-X
)	B-X
in	B-X
an	B-X
angiogenic	B-X
model	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
seems	B-X
that	B-X
both	B-X
angiogenic	B-X
and	B-X
anti-angiogenic	B-X
therapies	B-X
may	B-X
be	B-X
used	B-X
in	B-X
various	B-X
stages	B-X
of	B-X
UC	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
increased	B-X
VP	B-X
in	B-X
colonic	B-X
mucosa	B-X
is	B-X
an	B-X
early	B-X
and	B-X
essential	B-X
element	B-X
in	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
UC	B-X
.	B-X
The	B-X
increased	B-X
VP	B-X
is	B-X
initiated	B-X
by	B-X
early	B-X
release	B-X
of	B-X
histamine	B-X
and	B-X
maintained/aggravated	B-X
by	B-X
VEGF	B-X
,	B-X
leading	B-X
to	B-X
perivascular	B-X
edema	B-X
,	B-X
vascular	B-X
stasis	B-X
,	B-X
hypoxia	B-X
,	B-X
inflammatory	B-X
cell	B-X
infiltration	B-X
,	B-X
and	B-X
colonic	B-X
erosions/ulcers	B-X
.	B-X
Inhibition	B-X
of	B-X
increased	B-X
VP	B-X
prevents	B-X
or	B-X
reduces	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
UC	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
novel	B-X
pharmacologic	B-X
approaches	B-X
to	B-X
prevent	B-X
UC	B-X
,	B-X
differential	B-X
actions	B-X
of	B-X
angiogenic	B-X
growth	B-X
factors	B-X
in	B-X
UC	B-X
pathogenesis	B-X
and	B-X
blocking	B-X
the	B-X
early	B-X
increase	B-X
in	B-X
VP	B-X
in	B-X
UC	B-X
development	B-X
,	B-X
these	B-X
new	B-X
findings	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
angiogenesis	B-X
in	B-X
UC	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
development	B-X
of	B-X
VP-related	B-X
drugs	B-X
to	B-X
accelerate	B-X
the	B-X
healing	B-X
of	B-X
UC	B-X
.	B-X

Significantly	O
,	O
the	O
combination	O
of	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
,	O
but	O
not	O
bFGF	B-Protein
alone	O
,	O
also	O
caused	O
a	O
robust	O
,	O
second	O
,	O
delayed	O
increase	O
in	O
the	O
phosphorylation	O
of	O
Thr308	O
,	O
but	O
not	O
Ser473	O
,	O
of	O
Akt	O
as	O
well	O
as	O
a	O
delayed	O
increase	O
in	O
the	O
phosphorylation	O
of	O
JNK	O
and	O
Jun	O
.	O
<EOS>	B-X
Caspase	B-X
inhibitors	B-X
blocked	B-X
VEGF-	B-X
or	B-X
bFGF-induced	B-X
HUVEC	B-X
angiogenesis	B-X
on	B-X
2-	B-X
or	B-X
3-D	B-X
collagen	B-X
gels	B-X
,	B-X
respectively	B-X
,	B-X
confirming	B-X
that	B-X
apoptosis	B-X
was	B-X
not	B-X
the	B-X
result	B-X
of	B-X
nonspecific	B-X
cell	B-X
death	B-X
after	B-X
seeding	B-X
on	B-X
the	B-X
matrix	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
combined	B-X
use	B-X
of	B-X
trophic	B-X
factors	B-X
and	B-X
caspase	B-X
inhibitors	B-X
increases	B-X
brain	B-X
resistance	B-X
to	B-X
ischaemia	B-X
in	B-X
mice	B-X
.	B-X
Intracerebroventricular	B-X
administration	B-X
of	B-X
bFGF	B-X
(	B-X
>	B-X
10	B-X
ng	B-X
)	B-X
30	B-X
min	B-X
after	B-X
MCA	B-X
occlusion	B-X
decreased	B-X
infarct	B-X
size	B-X
and	B-X
neurological	B-X
deficit	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
following	B-X
2	B-X
h	B-X
ischemia	B-X
and	B-X
reperfusion	B-X
(	B-X
20	B-X
h	B-X
)	B-X
.	B-X
Combined	B-X
administration	B-X
of	B-X
the	B-X
subthreshold	B-X
doses	B-X
of	B-X
bFGF	B-X
(	B-X
3	B-X
ng	B-X
)	B-X
and	B-X
caspase	B-X
inhibitors	B-X
(	B-X
z-VAD.FMK	B-X
,	B-X
27	B-X
ng	B-X
or	B-X
z-DEVD.FMK	B-X
,	B-X
80	B-X
mg	B-X
)	B-X
reduced	B-X
infarct	B-X
volume	B-X
by	B-X
60	B-X
%	B-X
,	B-X
and	B-X
reduced	B-X
neurological	B-X
deficit	B-X
.	B-X
Treatment	B-X
with	B-X
a	B-X
subthreshold	B-X
dose	B-X
of	B-X
bFGF	B-X
(	B-X
3	B-X
ng	B-X
)	B-X
extended	B-X
the	B-X
therapeutic	B-X
window	B-X
for	B-X
z-DEVD.FMK	B-X
(	B-X
480	B-X
ng	B-X
)	B-X
from	B-X
1	B-X
to	B-X
3	B-X
h	B-X
after	B-X
reperfusion	B-X
.	B-X
Caspase-3	B-X
activity	B-X
in	B-X
the	B-X
ischaemic	B-X
brain	B-X
was	B-X
increased	B-X
30	B-X
min	B-X
and	B-X
2	B-X
h	B-X
after	B-X
reperfusion	B-X
but	B-X
,	B-X
was	B-X
significantly	B-X
reduced	B-X
in	B-X
bFGF-treated	B-X
animals	B-X
by	B-X
29	B-X
and	B-X
16	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
Caspase-3	B-X
activity	B-X
was	B-X
not	B-X
reduced	B-X
by	B-X
a	B-X
direct	B-X
bFGF	B-X
effect	B-X
because	B-X
addition	B-X
of	B-X
bFGF	B-X
(	B-X
10	B-X
nM	B-X
-	B-X
2	B-X
microM	B-X
)	B-X
did	B-X
not	B-X
decrease	B-X
recombinant	B-X
caspase-3	B-X
activity	B-X
,	B-X
in	B-X
vitro	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
combining	B-X
caspase	B-X
inhibitors	B-X
and	B-X
bFGF	B-X
lengthens	B-X
the	B-X
treatment	B-X
window	B-X
for	B-X
the	B-X
second	B-X
treatment	B-X
,	B-X
plus	B-X
lowers	B-X
the	B-X
dosage	B-X
requirements	B-X
for	B-X
neuroprotection	B-X
.	B-X
These	B-X
findings	B-X
are	B-X
important	B-X
because	B-X
low	B-X
doses	B-X
of	B-X
caspase	B-X
inhibitors	B-X
or	B-X
bFGF	B-X
reduce	B-X
the	B-X
possibility	B-X
of	B-X
side	B-X
effects	B-X
plus	B-X
extend	B-X
the	B-X
short	B-X
treatment	B-X
window	B-X
for	B-X
ischaemic	B-X
stroke	B-X
.	B-X

Furthermore	O
,	O
Nec	O
-	O
1	O
had	O
no	O
significant	O
effect	O
on	O
the	O
early	O
increase	O
in	O
both	O
Akt	O
and	O
JNK	O
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
triggered	O
by	O
both	O
bFGF	B-Protein
and	O
bFGF	B-Protein
/	O
zVAD	O
,	O
while	O
Nec	O
-	O
1	O
,	O
but	O
not	O
its	O
inactive	O
analog	O
Nec	O
-	O
1i	O
(	O
Fig	O
.	O
S1E	O
)	O
,	O
efficiently	O
blocked	O
the	O
bFGF	B-Protein
/	O
zVAD	O
increase	O
at	O
6	O
-	O
9	O
hr	O
(	O
Fig	O
.	O
3D	O
)	O
,	O
suggesting	O
that	O
only	O
the	O
delayed	O
activation	O
of	O
Akt	O
and	O
JNK	O
is	O
specific	O
for	O
necroptosis	O
and	O
dependent	O
on	O
RIP1	B-Protein
kinase	O
activity	O
.	O

Similarly	O
,	O
IGF	O
/	O
zVAD	O
,	O
which	O
also	O
promoted	O
cell	O
death	O
under	O
serum	O
free	O
conditions	O
,	O
produced	O
a	O
delayed	O
increase	O
in	O
Thr308	O
phosphorylation	O
on	O
Akt	O
,	O
while	O
IGF	O
alone	O
caused	O
solely	O
an	O
early	O
,	O
transient	O
increase	O
in	O
phosphorylation	O
(	O
Fig	O
.	O
S3C	O
)	O
.	O

We	O
confirmed	O
the	O
kinetics	O
of	O
the	O
Akt	O
Thr308	O
and	O
Ser473	O
phosphorylation	O
changes	O
using	O
a	O
quantitative	O
ELISA	O
assay	O
,	O
which	O
also	O
showed	O
a	O
robust	O
delayed	O
necroptosis	O
-	O
specific	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S3D	O
,	O
E	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
observed	O
delayed	O
increases	O
in	O
Akt	O
and	O
JNK	O
phosphorylation	O
,	O
preceding	O
the	O
onset	O
of	O
cell	O
death	O
,	O
represent	O
specific	O
consequences	O
of	O
necroptotic	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
.	O

TNFalpha	B-Protein
Induces	O
Delayed	O
Akt	O
Thr308	O
Phosphorylation	O
and	O
Necroptosis	O
Independent	O
of	O
Growth	O
Factor	O
Stimulation	O

Consistent	O
with	O
TNFalpha	B-Protein
inducing	O
necroptosis	O
independently	O
of	O
growth	O
factors	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
FGFR	O
inhibitors	O
did	O
not	O
attenuate	O
TNFalpha	B-Protein
-	O
induced	O
changes	O
in	O
Akt	O
or	O
JNK	O
phosphorylation	O
,	O
while	O
efficiently	O
preventing	O
these	O
changes	O
in	O
response	O
to	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S4A	O
)	O
.	O

Furthermore	O
,	O
addition	O
of	O
TNFalpha	B-Protein
led	O
to	O
comparable	O
late	O
activation	O
of	O
Akt	O
p308	O
signal	O
under	O
both	O
normal	O
and	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
S4B	O
,	O
C	O
)	O
,	O
indicating	O
that	O
TNFalpha	B-Protein
signaling	O
to	O
Akt	O
Thr308	O
is	O
growth	O
factor	O
-	O
independent	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
JNK	O
by	O
TNFalpha	B-Protein
followed	O
different	O
kinetics	O
from	O
zVAD	O
.	O
fmk	O
-	O
induced	O
changes	O
.	O

TNFalpha	B-Protein
treatment	O
caused	O
an	O
early	O
and	O
robust	O
increase	O
in	O
the	O
phosphorylation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
.	O

Nec	O
-	O
1	O
did	O
not	O
affect	O
this	O
early	O
increase	O
,	O
however	O
,	O
it	O
reduced	O
levels	O
of	O
pJNK	O
/	O
Jun	O
at	O
the	O
late	O
,	O
9	O
hr	O
time	O
point	O
(	O
Fig	O
.	O
S4B	O
,	O
C	O
)	O
.	O
<EOS>	B-X
Necrostatin-1	B-X
(	B-X
Nec-1	B-X
)	B-X
is	B-X
a	B-X
RIP1-targeted	B-X
inhibitor	B-X
of	B-X
necroptosis	B-X
,	B-X
a	B-X
form	B-X
of	B-X
programmed	B-X
cell	B-X
death	B-X
discovered	B-X
and	B-X
investigated	B-X
in	B-X
recent	B-X
years	B-X
.	B-X
However	B-X
,	B-X
the	B-X
potential	B-X
of	B-X
Nec-1	B-X
in	B-X
diseases	B-X
has	B-X
not	B-X
received	B-X
much	B-X
attention	B-X
.	B-X
Nec-1	B-X
is	B-X
able	B-X
to	B-X
inhibit	B-X
necroptosis	B-X
signaling	B-X
pathway	B-X
and	B-X
thus	B-X
ameliorate	B-X
necroptotic	B-X
cell	B-X
death	B-X
in	B-X
disease	B-X
development	B-X
.	B-X
Recent	B-X
research	B-X
findings	B-X
indicate	B-X
that	B-X
Nec-1	B-X
could	B-X
be	B-X
applied	B-X
in	B-X
several	B-X
types	B-X
of	B-X
diseases	B-X
to	B-X
alleviate	B-X
disease	B-X
development	B-X
or	B-X
improve	B-X
prognosis	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
predict	B-X
that	B-X
Nec-1	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
protect	B-X
against	B-X
the	B-X
complications	B-X
of	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
.	B-X
This	B-X
review	B-X
summarized	B-X
the	B-X
effect	B-X
of	B-X
Nec-1	B-X
in	B-X
disease	B-X
models	B-X
and	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanism	B-X
,	B-X
providing	B-X
research	B-X
evidence	B-X
for	B-X
its	B-X
future	B-X
application	B-X
.	B-X

This	O
again	O
separated	O
early	O
RIP1	B-Protein
-	O
independent	O
changes	O
,	O
which	O
likely	O
reflect	O
the	O
ability	O
of	O
additional	O
upstream	O
kinases	O
,	O
such	O
as	O
Ask1	B-Protein
to	O
activate	O
JNK	O
[	O
27	O
]	O
,	O
from	O
the	O
late	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
necroptotic	O
signaling	O
.	O

Late	O
Increase	O
in	O
Akt	O
Thr308	O
Phosphorylation	O
Contributes	O
to	O
the	O
Induction	O
of	O
Necroptotic	O
Cell	O
Death	O

We	O
next	O
investigated	O
if	O
the	O
delayed	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
functionally	O
contributes	O
to	O
the	O
execution	O
of	O
necroptotic	O
cell	O
death	O
.	O

Firstly	O
,	O
PDGF	O
/	O
zVAD	O
.	O
fmk	O
,	O
which	O
cannot	O
induce	O
necroptosis	O
(	O
Fig	O
.	O
2A	O
)	O
,	O
triggered	O
only	O
the	O
initial	O
,	O
rapid	O
Akt	O
and	O
JNK	O
phosphorylation	O
changes	O
and	O
not	O
the	O
delayed	O
activation	O
(	O
Fig	O
.	O
4A	O
)	O
,	O
indicating	O
that	O
late	O
,	O
rather	O
than	O
early	O
Akt	O
phosphorylation	O
correlates	O
with	O
necroptosis	O
.	O

Secondly	O
,	O
we	O
saw	O
that	O
the	O
ability	O
of	O
the	O
Akt	O
inhibitor	O
to	O
protect	O
cells	O
from	O
necroptosis	O
rapidly	O
declined	O
after	O
6	O
hrs	O
of	O
stimulation	O
with	O
zVAD	O
.	O
fmk	O
,	O
TNFalpha	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
and	O
no	O
protection	O
was	O
observed	O
when	O
the	O
inhibitor	O
was	O
added	O
at	O
9	O
hrs	O
(	O
Fig	O
.	O
4B	O
,	O
C	O
)	O
.	O

This	O
time	O
frame	O
coincides	O
with	O
the	O
timing	O
of	O
the	O
secondary	O
Akt	O
Thr308	O
phosphorylation	O
.	O

Finally	O
,	O
we	O
terminated	O
the	O
bFGF	B-Protein
signal	O
one	O
hour	O
after	O
addition	O
of	O
bFGF	B-Protein
by	O
the	O
addition	O
of	O
PD173074	O
.	O

This	O
allowed	O
us	O
to	O
retain	O
early	O
Akt	O
activation	O
,	O
but	O
to	O
suppress	O
the	O
secondary	O
increase	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

Both	O
pre	O
-	O
addition	O
and	O
delayed	O
addition	O
of	O
PD173074	O
fully	O
prevented	O
necroptosis	O
(	O
Fig	O
.	O
4E	O
)	O
.	O

Overall	O
,	O
these	O
data	O
,	O
while	O
correlative	O
,	O
indicate	O
that	O
early	O
Akt	O
activation	O
is	O
insufficient	O
to	O
promote	O
necroptosis	O
and	O
are	O
strongly	O
supportive	O
of	O
an	O
important	O
role	O
for	O
the	O
delayed	O
activation	O
of	O
Akt	O
in	O
the	O
induction	O
of	O
necroptotic	O
cell	O
death	O
.	O

The	O
Akt	O
Signaling	O
Pathway	O
Contributes	O
to	O
the	O
Regulation	O
of	O
Necroptosis	O

We	O
next	O
determined	O
whether	O
the	O
necroptosis	O
-	O
associated	O
increase	O
in	O
Thr308	O
phosphorylation	O
results	O
in	O
an	O
increase	O
in	O
Akt	O
kinase	O
activity	O
.	O

Under	O
necroptotic	O
conditions	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
phosphorylation	O
of	O
multiple	O
known	O
Akt	O
substrates	O
(	O
Forkhead	O
box	O
class	O
O	O
(	O
FoxO	O
)	O
proteins	O
,	O
GSK	O
-	O
3	O
kinases	O
and	O
mouse	O
double	B-Protein
minute	I-Protein
2	I-Protein
(	O
MDM2	B-Protein
)	O
)	O
as	O
well	O
as	O
downstream	O
molecules	O
(	O
p70	B-Protein
ribosomal	I-Protein
protein	I-Protein
S6	I-Protein
Kinase	I-Protein
(	O
p70S6K	B-Protein
)	O
,	O
S6	B-Protein
)	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

In	O
some	O
cases	O
(	O
FoxO1	B-Protein
,	O
FoxO4	B-Protein
,	O
MDM2	B-Protein
)	O
,	O
a	O
robust	O
increase	O
was	O
observed	O
.	O

In	O
other	O
cases	O
(	O
FoxO3a	B-Protein
,	O
GSK	B-Protein
-	I-Protein
3alpha	I-Protein
/	O
beta	B-Protein
,	O
p70S6K	B-Protein
and	O
its	O
substrate	O
S6	B-Protein
)	O
,	O
the	O
changes	O
were	O
less	O
pronounced	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

The	O
timing	O
of	O
the	O
phosphorylation	O
changes	O
paralleled	O
the	O
increase	O
in	O
Akt	O
phosphorylation	O
(	O
Fig	O
.	O
5B	O
,	O
S5A	O
,	O
B	O
)	O
.	O

In	O
the	O
case	O
of	O
pFoxO1	B-Protein
we	O
occasionally	O
observed	O
a	O
shift	O
in	O
migration	O
rather	O
than	O
an	O
increase	O
in	O
band	O
intensity	O
(	O
e	O
.	O
g	O
.	O
comparing	O
Fig	O
.	O
5A	O
and	O
B	O
)	O
,	O
suggesting	O
that	O
phosphorylation	O
events	O
in	O
addition	O
to	O
Thr24	O
take	O
place	O
during	O
necroptosis	O
.	O

Notably	O
,	O
in	O
all	O
cases	O
the	O
necroptosis	O
-	O
associated	O
increases	O
in	O
Akt	O
substrates	O
were	O
abrogated	O
by	O
Nec	O
-	O
1	O
(	O
Fig	O
.	O
5A	O
,	O
Fig	O
.	O
S5A	O
,	O
B	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggested	O
that	O
a	O
significant	O
part	O
of	O
the	O
"	O
canonical	O
"	O
Akt	O
signaling	O
network	O
is	O
activated	O
at	O
the	O
onset	O
of	O
necroptotic	O
cell	O
death	O
in	O
a	O
RIP1	B-Protein
dependent	O
fashion	O
.	O

Akt	O
kinase	O
is	O
considered	O
to	O
be	O
a	O
pro	O
-	O
survival	O
protein	O
that	O
inhibits	O
apoptosis	O
through	O
the	O
control	O
of	O
multiple	O
effectors	O
including	O
mTORC1	O
,	O
GSK	O
-	O
3	O
and	O
others	O
[	O
28	O
]	O
.	O

An	O
important	O
question	O
is	O
whether	O
these	O
same	O
molecules	O
reverse	O
their	O
pro	O
-	O
survival	O
roles	O
during	O
necroptosis	O
.	O

We	O
found	O
that	O
inhibition	O
of	O
mTORC1	O
by	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
the	O
mTOR	O
co	O
-	O
factor	O
Raptor	B-Protein
[	O
29	O
]	O
,	O
protected	O
cells	O
from	O
necroptosis	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Similarly	O
,	O
the	O
direct	O
mTOR	O
kinase	O
inhibitor	O
Torin1	O
[	O
30	O
]	O
and	O
the	O
dual	O
PI3K	O
/	O
mTOR	O
inhibitor	O
PI	O
-	O
103	O
[	O
31	O
]	O
also	O
efficiently	O
inhibited	O
necroptosis	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Knockdown	O
of	O
mTOR	O
using	O
siRNA	O
further	O
validated	O
the	O
small	O
-	O
molecule	O
inhibitor	O
data	O
indicating	O
a	O
role	O
for	O
mTOR	O
in	O
necroptosis	O
by	O
protecting	O
cells	O
from	O
both	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
induced	O
death	O
(	O
Fig	O
.	O
5D	O
)	O
.	O

mTORC1	O
regulates	O
translation	O
through	O
activation	O
of	O
p70S6	B-Protein
kinase	I-Protein
and	O
,	O
subsequently	O
,	O
ribosomal	O
protein	O
S6	B-Protein
[	O
32	O
]	O
.	O
<EOS>	B-X
Growth	B-X
factors	B-X
and	B-X
nutrients	B-X
,	B-X
such	B-X
as	B-X
amino	B-X
acids	B-X
and	B-X
glucose	B-X
,	B-X
regulate	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
signaling	B-X
and	B-X
subsequent	B-X
translational	B-X
control	B-X
in	B-X
a	B-X
coordinated	B-X
manner	B-X
.	B-X
Brain-derived	B-X
neurotrophic	B-X
factor	B-X
(	B-X
BDNF	B-X
)	B-X
,	B-X
the	B-X
most	B-X
prominent	B-X
neurotrophic	B-X
factor	B-X
in	B-X
the	B-X
brain	B-X
,	B-X
activates	B-X
mTORC1	B-X
and	B-X
induces	B-X
phosphorylation	B-X
of	B-X
its	B-X
target	B-X
,	B-X
p70S6	B-X
kinase	B-X
(	B-X
p70S6K	B-X
)	B-X
,	B-X
at	B-X
Thr389	B-X
in	B-X
neurons	B-X
.	B-X
BDNF	B-X
also	B-X
increases	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin-dependent	B-X
novel	B-X
protein	B-X
synthesis	B-X
in	B-X
neurons	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
BDNF-induced	B-X
p70S6K	B-X
activation	B-X
is	B-X
dependent	B-X
on	B-X
glucose	B-X
,	B-X
but	B-X
not	B-X
amino	B-X
acids	B-X
,	B-X
sufficiency	B-X
in	B-X
cultured	B-X
cortical	B-X
neurons	B-X
.	B-X
AMP-activated	B-X
protein	B-X
kinase	B-X
(	B-X
AMPK	B-X
)	B-X
is	B-X
the	B-X
molecular	B-X
background	B-X
to	B-X
this	B-X
specific	B-X
nutrient	B-X
dependency	B-X
.	B-X
Activation	B-X
of	B-X
AMPK	B-X
,	B-X
which	B-X
is	B-X
induced	B-X
by	B-X
glucose	B-X
deprivation	B-X
,	B-X
treatment	B-X
with	B-X
pharmacological	B-X
agents	B-X
such	B-X
as	B-X
2-deoxy-D-glucose	B-X
,	B-X
metformin	B-X
,	B-X
and	B-X
5-aminoimidazole-4-carboxamide	B-X
ribonucleoside	B-X
or	B-X
forced	B-X
expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
AMPKα	B-X
subunit	B-X
,	B-X
counteracts	B-X
BDNF-induced	B-X
phosphorylation	B-X
of	B-X
p70S6K	B-X
and	B-X
enhanced	B-X
protein	B-X
synthesis	B-X
in	B-X
cortical	B-X
neurons	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
AMPK	B-X
inhibits	B-X
the	B-X
effects	B-X
of	B-X
BDNF	B-X
on	B-X
mTORC1-mediated	B-X
translation	B-X
in	B-X
neurons	B-X
.	B-X

Notably	O
,	O
a	O
genome	O
-	O
wide	O
siRNA	O
screen	O
[	O
10	O
]	O
suggested	O
an	O
important	O
role	O
for	O
protein	O
translation	O
in	O
necroptosis	O
.	O

Consistently	O
,	O
we	O
found	O
that	O
the	O
small	O
molecule	O
inhibitor	O
of	O
p70S6K	B-Protein
PF	O
-	O
4708671	O
[	O
33	O
]	O
attenuated	O
necroptosis	O
at	O
the	O
concentrations	O
required	O
to	O
block	O
S6	B-Protein
phosphorylation	O
(	O
Fig	O
.	O
S5C	O
,	O
D	O
)	O
.	O

Partial	O
siRNA	O
knockdown	O
of	O
S6	B-Protein
protein	O
attenuated	O
necroptosis	O
as	O
well	O
(	O
Fig	O
.	O
S5E	O
)	O
,	O
suggesting	O
that	O
translational	O
control	O
by	O
p70S6K	B-Protein
/	O
S6	B-Protein
may	O
play	O
a	O
role	O
in	O
necroptosis	O
.	O

Overall	O
,	O
while	O
the	O
full	O
repertoire	O
of	O
Akt	O
targets	O
during	O
necroptosis	O
remains	O
to	O
be	O
fully	O
explored	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
the	O
activity	O
of	O
an	O
anti	O
-	O
apoptotic	O
branch	O
of	O
Akt	O
signaling	O
can	O
promote	O
necroptosis	O
.	O

RIP1	B-Protein
kinase	O
,	O
Akt	O
,	O
mTORC1	O
and	O
JNK	O
control	O
the	O
upregulation	O
of	O
TNFalpha	B-Protein
accompanying	O
necroptosis	O
.	O

Hitomi	O
et	O
al	O
.	O
<EOS>	B-X
Letter	B-X
to	B-X
Hitomi	B-X
Tomohara-Ichishima	B-X
et	B-X
al	B-X
.	B-X
Necrosis	B-X
is	B-X
often	B-X
viewed	B-X
as	B-X
an	B-X
accidental	B-X
and	B-X
unregulated	B-X
cellular	B-X
event	B-X
.	B-X
Hitomi	B-X
et	B-X
al	B-X
.	B-X
(	B-X
2008	B-X
)	B-X
now	B-X
describe	B-X
an	B-X
extensive	B-X
network	B-X
of	B-X
genes	B-X
that	B-X
mediate	B-X
a	B-X
form	B-X
of	B-X
programmed	B-X
necrosis	B-X
called	B-X
necroptosis	B-X
.	B-X

[	O
10	O
]	O
have	O
recently	O
reported	O
that	O
the	O
induction	O
of	O
necroptosis	O
by	O
zVAD	O
.	O
fmk	O
in	O
L929	O
cells	O
is	O
associated	O
with	O
increased	O
synthesis	O
of	O
TNFalpha	B-Protein
,	O
which	O
potentiates	O
cell	O
death	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
Akt	O
and	O
its	O
effectors	O
contribute	O
to	O
TNFalpha	B-Protein
synthesis	O
.	O

Consistent	O
with	O
a	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
TNFalpha	B-Protein
protein	O
(	O
Fig	O
.	O
S6A	O
,	O
B	O
)	O
,	O
we	O
found	O
that	O
TNFalpha	B-Protein
mRNA	O
levels	O
increased	O
during	O
necroptosis	O
in	O
L929	O
cells	O
in	O
a	O
RIP1	B-Protein
(	O
Fig	O
.	O

S6C	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
suggested	B-X
that	B-X
the	B-X
exoprotein-deficient	B-X
phenotype	B-X
of	B-X
a	B-X
Delta	B-X
1058	B-X
:	B-X
:Tn551	B-X
insertion/deletion	B-X
mutant	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
S6C	B-X
was	B-X
not	B-X
owing	B-X
to	B-X
the	B-X
insertion/deletion	B-X
event	B-X
,	B-X
but	B-X
instead	B-X
was	B-X
owing	B-X
to	B-X
the	B-X
inherent	B-X
instability	B-X
of	B-X
the	B-X
agrC	B-X
gene	B-X
during	B-X
transduction	B-X
of	B-X
the	B-X
Delta	B-X
1058	B-X
:	B-X
:Tn551	B-X
region	B-X
into	B-X
S6C	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
following	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
S6C	B-X
as	B-X
a	B-X
potential	B-X
source	B-X
of	B-X
exoprotein-deficient	B-X
mutants	B-X
that	B-X
would	B-X
account	B-X
for	B-X
their	B-X
appearance	B-X
after	B-X
transposition	B-X
and	B-X
transduction	B-X
.	B-X
Four	B-X
stable	B-X
variants	B-X
of	B-X
S6C	B-X
were	B-X
isolated	B-X
that	B-X
differed	B-X
in	B-X
their	B-X
hemolysin	B-X
and	B-X
catalase	B-X
activities	B-X
.	B-X
When	B-X
the	B-X
original	B-X
Delta	B-X
1058	B-X
:	B-X
:Tn551	B-X
mutation	B-X
was	B-X
transduced	B-X
into	B-X
the	B-X
hemolytic	B-X
,	B-X
catalase-positive	B-X
variant	B-X
of	B-X
S6C	B-X
,	B-X
none	B-X
of	B-X
the	B-X
transductants	B-X
exhibited	B-X
an	B-X
exoprotein-deficient	B-X
phenotype	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
while	B-X
the	B-X
exoprotein-deficient	B-X
phenotype	B-X
of	B-X
the	B-X
S6C	B-X
variant	B-X
is	B-X
most	B-X
likely	B-X
due	B-X
to	B-X
mutations	B-X
in	B-X
the	B-X
agr	B-X
regulatory	B-X
system	B-X
,	B-X
these	B-X
mutations	B-X
are	B-X
not	B-X
caused	B-X
by	B-X
the	B-X
transduction	B-X
of	B-X
the	B-X
Delta	B-X
1058	B-X
:	B-X
:Tn551	B-X
region	B-X
into	B-X
S6C	B-X
,	B-X
but	B-X
instead	B-X
already	B-X
exist	B-X
in	B-X
an	B-X
exoprotein-deficient	B-X
variant	B-X
of	B-X
S6C	B-X
.	B-X

Under	O
serum	O
free	O
conditions	O
,	O
bFGF	B-Protein
alone	O
triggered	O
some	O
induction	O
of	O
TNFalpha	B-Protein
mRNA	O
,	O
while	O
its	O
combination	O
with	O
zVAD	O
.	O
fmk	O
(	O
but	O
not	O
zVAD	O
.	O
fmk	O
alone	O
)	O
caused	O
a	O
pronounced	O
further	O
increase	O
(	O
Fig	O
.	O
6A	O
)	O
.	O

Conversely	O
,	O
PDGF	O
caused	O
a	O
modest	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
,	O
which	O
was	O
not	O
further	O
increased	O
in	O
the	O
presence	O
of	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
demonstrating	O
that	O
activation	O
of	O
necroptosis	O
is	O
specifically	O
accompanied	O
by	O
a	O
marked	O
increase	O
in	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
.	O

Further	O
analysis	O
suggested	O
that	O
both	O
Akt	O
and	O
mTORC1	O
contribute	O
to	O
the	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
during	O
necroptosis	O
as	O
both	O
small	O
-	O
molecule	O
inhibition	O
and	O
siRNA	O
knockdown	O
of	O
Akt	O
and	O
mTOR	O
reduced	O
TNFalpha	B-Protein
mRNA	O
levels	O
in	O
necroptotic	O
cells	O
(	O
Fig	O
.	O
6B	O
,	O
C	O
,	O
D	O
)	O
.	O

Notably	O
,	O
RIP1	B-Protein
and	O
Akt	O
inhibitors	O
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
TNFalpha	B-Protein
mRNA	O
in	O
control	O
cells	O
or	O
in	O
the	O
cells	O
stimulated	O
with	O
bFGF	B-Protein
alone	O
(	O
Fig	O
.	O
6A	O
,	O
B	O
,	O
Fig	O
.	O
S6C	O
)	O
,	O
suggesting	O
that	O
these	O
kinases	O
specifically	O
mediate	O
necroptosis	O
-	O
dependent	O
increase	O
in	O
TNFalpha	B-Protein
synthesis	O
.	O

Akt	O
and	O
mTORC1	O
Control	O
the	O
Activation	O
of	O
JNK	O
during	O
Necroptosis	O
<EOS>	B-X
Necroptosis	B-X
is	B-X
a	B-X
regulated	B-X
form	B-X
of	B-X
necrotic	B-X
cell	B-X
death	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
diseases	B-X
including	B-X
intestinal	B-X
inflammation	B-X
and	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

JNK	O
is	O
a	O
well	O
-	O
established	O
regulator	O
of	O
TNFalpha	B-Protein
synthesis	O
in	O
a	O
variety	O
of	O
systems	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
34	O
]	O
.	O

Therefore	O
,	O
the	O
ability	O
of	O
Akt	O
and	O
mTORC1	O
inhibitors	O
to	O
block	O
the	O
increase	O
in	O
TNFalpha	B-Protein
mRNA	O
lead	O
us	O
to	O
examine	O
their	O
role	O
in	O
the	O
activation	O
of	O
JNK	O
during	O
necroptosis	O
.	O

Knockdown	O
of	O
Akt	O
isoforms	O
Akt1	B-Protein
and	O
Akt2	B-Protein
or	O
inhibition	O
of	O
Akt	O
prominently	O
suppressed	O
the	O
necroptosis	O
dependent	O
increase	O
in	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
6E	O
,	O
S6D	O
,	O
E	O
)	O
suggesting	O
that	O
Akt	O
may	O
provide	O
a	O
link	O
between	O
RIP1	B-Protein
and	O
JNK	O
activation	O
.	O
<EOS>	B-X
LY3023414	B-X
is	B-X
a	B-X
novel	B-X
oral	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
dual	B-X
inhibitor	B-X
designed	B-X
for	B-X
advanced	B-X
cancers	B-X
,	B-X
for	B-X
which	B-X
a	B-X
phase	B-X
II	B-X
clinical	B-X
study	B-X
was	B-X
completed	B-X
in	B-X
March	B-X
2020	B-X
;	B-X
however	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
its	B-X
effect	B-X
on	B-X
bone	B-X
modelling/remodelling	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
function	B-X
of	B-X
LY3023414	B-X
in	B-X
bone	B-X
modelling/remodelling	B-X
.	B-X
The	B-X
RTK/PI3K/AKT	B-X
pathway	B-X
plays	B-X
key	B-X
roles	B-X
in	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
many	B-X
cancers	B-X
,	B-X
including	B-X
GBM	B-X
.	B-X
As	B-X
a	B-X
regulatory	B-X
molecule	B-X
and	B-X
a	B-X
potential	B-X
drug	B-X
target	B-X
,	B-X
the	B-X
oncogenic	B-X
role	B-X
of	B-X
AKT	B-X
has	B-X
been	B-X
substantially	B-X
studied	B-X
.	B-X
Three	B-X
isoforms	B-X
of	B-X
AKT	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
including	B-X
AKT1	B-X
,	B-X
AKT2	B-X
and	B-X
AKT3	B-X
,	B-X
but	B-X
their	B-X
individual	B-X
functions	B-X
in	B-X
GBM	B-X
remain	B-X
controversial	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
is	B-X
not	B-X
known	B-X
if	B-X
there	B-X
are	B-X
more	B-X
AKT	B-X
alternative	B-X
splicing	B-X
variants	B-X
.	B-X

Importantly	O
,	O
inhibition	O
of	O
Akt	O
only	O
inhibited	O
the	O
delayed	O
,	O
but	O
not	O
the	O
early	O
,	O
increase	O
in	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
induced	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
S6F	O
)	O
.	O
<EOS>	B-X
Cervical	B-X
cancer	B-X
(	B-X
CC	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
major	B-X
causes	B-X
of	B-X
death	B-X
of	B-X
women	B-X
throughout	B-X
the	B-X
world	B-X
is	B-X
primarily	B-X
caused	B-X
due	B-X
to	B-X
Human	B-X
Papilloma	B-X
Virus	B-X
(	B-X
HPV	B-X
)	B-X
16	B-X
and	B-X
18	B-X
.	B-X
The	B-X
early	B-X
region	B-X
(	B-X
E	B-X
)	B-X
oncoproteins	B-X
of	B-X
HPV	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
etiopathogenesis	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
progression	B-X
of	B-X
cancer	B-X
.	B-X
The	B-X
present	B-X
article	B-X
comprehensively	B-X
discussed	B-X
the	B-X
structural	B-X
organization	B-X
and	B-X
biological	B-X
functions	B-X
of	B-X
all	B-X
E	B-X
proteins	B-X
of	B-X
HPV	B-X
and	B-X
their	B-X
contribution	B-X
to	B-X
progression	B-X
of	B-X
CC	B-X
with	B-X
an	B-X
intent	B-X
to	B-X
decipher	B-X
the	B-X
pathological	B-X
hallmarks	B-X
and	B-X
their	B-X
relationship	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
role	B-X
of	B-X
E	B-X
proteins	B-X
in	B-X
reference	B-X
to	B-X
therapeutics	B-X
will	B-X
also	B-X
be	B-X
presented	B-X
.	B-X

Knockdown	O
of	O
mTOR	O
,	O
rapamycin	O
and	O
the	O
p70S6K	B-Protein
inhibitor	O
PF	O
-	O
4708671	O
also	O
attenuated	O
the	O
necroptosis	O
-	O
associated	O
increase	O
in	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
6F	O
,	O
S6E	O
,	O
G	O
,	O
Fig	O
.	O
S5D	O
)	O
.	O

Overall	O
,	O
these	O
data	O
suggested	O
that	O
the	O
Akt	O
-	O
mTORC1	O
-	O
S6K	B-Protein
axis	O
,	O
acting	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
is	O
required	O
for	O
the	O
increase	O
in	O
JNK	O
activity	O
during	O
necroptosis	O
in	O
L929	O
cells	O
.	O

PI3	O
-	O
kinase	O
and	O
PDK1	B-Protein
Mediate	O
the	O
Increase	O
in	O
Akt	O
Thr308	O
Phosphorylation	O
Under	O
Necroptotic	O
Conditions	O

Typical	O
regulation	O
of	O
Akt	O
by	O
growth	O
factors	O
involves	O
its	O
recruitment	O
to	O
the	O
plasma	O
membrane	O
,	O
which	O
is	O
mediated	O
by	O
the	O
binding	O
of	O
the	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
of	O
Akt	O
to	O
the	O
product	O
of	O
PI3K	O
,	O
phosphatidylinositol	O
-	O
3	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
PIP3	O
)	O
.	O

In	O
the	O
membrane	O
,	O
Akt	O
is	O
phosphorylated	O
on	O
Thr308	O
and	O
Ser473	O
by	O
3	B-Protein
-	I-Protein
phosphoinositide	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
-	I-Protein
1	I-Protein
(	O
PDK1	B-Protein
)	O
and	O
mTORC2	O
(	O
or	O
DNA	O
-	O
PK	O
)	O
,	O
respectively	O
[	O
35	O
]	O
.	O

Since	O
our	O
results	O
showed	O
that	O
only	O
Thr308	O
Akt	O
phosphorylation	O
is	O
increased	O
during	O
necroptosis	O
,	O
we	O
next	O
examined	O
whether	O
it	O
is	O
still	O
dependent	O
on	O
PI3K	O
and	O
PDK1	B-Protein
.	O

Inhibition	O
of	O
PI3K	O
and	O
PDK1	B-Protein
using	O
the	O
specific	O
inhibitors	O
LY249002	O
and	O
BX912	O
[	O
36	O
]	O
resulted	O
in	O
the	O
efficient	O
inhibition	O
of	O
cell	O
death	O
and	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S7A	O
-	O
D	O
)	O
.	O

Likewise	O
,	O
siRNA	O
knockdown	O
of	O
PDK1	B-Protein
protected	O
cells	O
from	O
death	O
and	O
inhibited	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
S7E	O
,	O
F	O
)	O
Therefore	O
,	O
PI3K	O
and	O
PDK1	B-Protein
activity	O
is	O
still	O
required	O
for	O
non	O
-	O
canonical	O
Akt	O
activation	O
during	O
necroptosis	O
.	O

Expression	O
of	O
Constitutively	O
Active	O
Akt	O
,	O
Rescues	O
Necroptosis	O
Under	O
Serum	O
Free	O
Conditions	O

We	O
used	O
L929	O
cells	O
stably	O
expressing	O
constitutively	O
active	O
wild	O
type	O
Akt1	B-Protein
(	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
)	O
or	O
the	O
catalytically	O
inactive	O
mutant	O
K179M	B-Protein
in	O
order	O
to	O
further	O
understand	O
the	O
contribution	O
of	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
to	O
Akt	O
activation	O
during	O
necroptosis	O
.	O

Constitutively	O
active	O
Akt1	B-Protein
(	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
)	O
was	O
generated	O
as	O
previously	O
described	O
[	O
37	O
]	O
by	O
the	O
addition	O
of	O
a	O
myristoylation	O
signal	O
which	O
provides	O
constitutive	O
localization	O
to	O
the	O
plasma	O
membrane	O
and	O
by	O
the	O
deletion	O
of	O
the	O
auto	O
-	O
inhibitory	O
PH	O
domain	O
(	O
Fig	O
.	O
7A	O
)	O
resulting	O
in	O
an	O
Akt	O
that	O
is	O
active	O
under	O
serum	O
free	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
cells	O
expressing	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
were	O
viable	O
,	O
grew	O
in	O
a	O
manner	O
indistinguishable	O
from	O
the	O
empty	O
vector	O
control	O
cells	O
,	O
and	O
were	O
not	O
triggered	O
to	O
induce	O
necroptosis	O
by	O
serum	O
starvation	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

This	O
indicates	O
that	O
active	O
Akt	O
alone	O
is	O
not	O
sufficient	O
to	O
induce	O
necroptotic	O
cell	O
death	O
.	O
<EOS>	B-X
The	B-X
mitogen-activated	B-X
protein	B-X
kinase/extracellular	B-X
signal-regulated	B-X
(	B-X
MAPK/ERK	B-X
)	B-X
pathway	B-X
is	B-X
activated	B-X
by	B-X
upstream	B-X
genomic	B-X
events	B-X
and/or	B-X
activation	B-X
of	B-X
multiple	B-X
signaling	B-X
events	B-X
in	B-X
which	B-X
information	B-X
coalesces	B-X
at	B-X
this	B-X
important	B-X
nodal	B-X
pathway	B-X
point	B-X
.	B-X
Recent	B-X
evidence	B-X
indicates	B-X
that	B-X
the	B-X
MAPK/ERK	B-X
signaling	B-X
node	B-X
can	B-X
function	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
as	B-X
well	B-X
as	B-X
the	B-X
more	B-X
common	B-X
pro-oncogenic	B-X
signal	B-X
.	B-X
Currently	B-X
approved	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
melanoma	B-X
,	B-X
inhibitors	B-X
of	B-X
BRAF	B-X
kinase	B-X
are	B-X
being	B-X
studied	B-X
alone	B-X
and	B-X
in	B-X
combination	B-X
with	B-X
inhibitors	B-X
of	B-X
the	B-X
MAPK	B-X
and	B-X
other	B-X
pathways	B-X
to	B-X
optimize	B-X
the	B-X
treatment	B-X
of	B-X
many	B-X
tumor	B-X
types	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
studies	B-X
have	B-X
been	B-X
dedicated	B-X
to	B-X
understanding	B-X
the	B-X
'terpenoid	B-X
induced	B-X
autophagy	B-X
'	B-X
phenomenon	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
nine	B-X
of	B-X
the	B-X
most	B-X
studied	B-X
terpenoids	B-X
and	B-X
on	B-X
their	B-X
cell	B-X
death	B-X
and	B-X
autophagic	B-X
activity	B-X
.	B-X
These	B-X
terpenoids	B-X
alone	B-X
demonstrate	B-X
the	B-X
complexity	B-X
by	B-X
which	B-X
these	B-X
secondary	B-X
metabolites	B-X
induce	B-X
autophagy	B-X
via	B-X
complex	B-X
signaling	B-X
pathways	B-X
such	B-X
as	B-X
MAPK/ERK/JNK	B-X
,	B-X
PI3K/AKT/mTOR	B-X
,	B-X
AMPK	B-X
,	B-X
NF-kB	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
Moreover	B-X
,	B-X
induction	B-X
of	B-X
autophagy	B-X
can	B-X
be	B-X
either	B-X
destructive	B-X
or	B-X
protective	B-X
in	B-X
tumor	B-X
cells	B-X
.	B-X

Under	O
serum	O
free	O
conditions	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
but	O
not	O
the	O
K179M	B-Protein
mutant	O
,	O
fully	O
restored	O
zVAD	O
.	O
fmk	O
-	O
induced	O
necroptosis	O
(	O
Fig	O
.	O
7A	O
,	O
B	O
)	O
.	O

Nec	O
-	O
1	O
prevented	O
both	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
dependent	O
cell	O
death	O
and	O
the	O
necroptosis	O
-	O
specific	O
delayed	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
(	O
Fig	O
.	O
7B	O
,	O
C	O
)	O
.	O

Myr	O
-	O
Akt	O
also	O
allowed	O
other	O
zVAD	O
.	O
fmk	O
-	O
dependent	O
events	O
,	O
including	O
activation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
(	O
Fig	O
.	O
7C	O
)	O
and	O
upregulation	O
of	O
TNFalpha	B-Protein
mRNA	O
(	O
Fig	O
.	O
7D	O
)	O
to	O
occur	O
under	O
serum	O
free	O
conditions	O
,	O
confirming	O
an	O
important	O
role	O
for	O
Akt	O
at	O
the	O
apex	O
of	O
necroptotic	O
signaling	O
.	O

These	O
data	O
demonstrated	O
that	O
the	O
presence	O
of	O
active	O
and	O
membrane	O
localized	O
Akt	O
is	O
sufficient	O
to	O
uncouple	O
Akt	O
activation	O
during	O
necroptosis	O
from	O
growth	O
factor	O
signaling	O
.	O

RIP1	B-Protein
kinase	O
was	O
still	O
able	O
to	O
regulate	O
Akt	O
activation	O
during	O
necroptosis	O
,	O
suggesting	O
that	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
provide	O
two	O
independent	O
inputs	O
required	O
for	O
Akt	O
changes	O
during	O
necroptosis	O
.	O

RIP1	B-Protein
kinase	O
-	O
dependent	O
Thr308	O
phosphorylation	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
during	O
necroptosis	O
increased	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
activity	O
as	O
it	O
did	O
with	O
endogenous	O
Akt	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Phosphorylation	O
of	O
many	O
previously	O
described	O
Akt	O
substrates	O
was	O
increased	O
upon	O
the	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
but	O
not	O
the	O
K179M	B-Protein
mutant	O
,	O
confirming	O
that	O
these	O
molecules	O
are	O
Akt	O
substrates	O
in	O
L929	O
cells	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

The	O
effect	O
of	O
zVAD	O
.	O
fmk	O
on	O
their	O
phosphorylation	O
varied	O
,	O
likely	O
due	O
to	O
the	O
increased	O
basal	O
activity	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
.	O

Some	O
substrates	O
,	O
including	O
p70S6K	B-Protein
,	O
S6	B-Protein
,	O
GSK	O
-	O
3	O
and	O
FoxO4	B-Protein
,	O
were	O
fully	O
phosphorylated	O
even	O
in	O
the	O
absence	O
of	O
zVAD	O
.	O
fmk	O
.	O

On	O
the	O
other	O
hand	O
,	O
phosphorylation	O
of	O
FoxO1	B-Protein
and	O
MDM2	B-Protein
was	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
zVAD	O
.	O
fmk	O
,	O
indicating	O
that	O
necroptotic	O
Thr308	O
phosphorylation	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
still	O
promoted	O
its	O
activity	O
.	O

Under	O
serum	O
free	O
conditions	O
all	O
zVAD	O
.	O
fmk	O
-	O
induced	O
downstream	O
events	O
(	O
cell	O
death	O
,	O
JNK	O
activation	O
,	O
TNFalpha	B-Protein
production	O
)	O
were	O
dependent	O
on	O
the	O
over	O
expressed	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
.	O

This	O
allowed	O
us	O
to	O
examine	O
the	O
effects	O
of	O
other	O
Akt	O
mutations	O
on	O
necroptosis	O
.	O

First	O
,	O
we	O
found	O
that	O
membrane	O
localization	O
of	O
Akt	O
is	O
required	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanism	B-X
by	B-X
which	B-X
SHIP2	B-X
negatively	B-X
regulates	B-X
insulin-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
,	B-X
a	B-X
key	B-X
downstream	B-X
molecule	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
important	B-X
for	B-X
the	B-X
biological	B-X
action	B-X
of	B-X
insulin	B-X
.	B-X
Overexpression	B-X
of	B-X
wild-type	B-X
SHIP2	B-X
(	B-X
WT-SHIP2	B-X
)	B-X
inhibited	B-X
insulin-induced	B-X
phosphorylation	B-X
of	B-X
Akt	B-X
at	B-X
both	B-X
Thr	B-X
(	B-X
308	B-X
)	B-X
and	B-X
Ser	B-X
(	B-X
473	B-X
)	B-X
in	B-X
Rat1	B-X
fibroblasts	B-X
expressing	B-X
insulin	B-X
receptors	B-X
.	B-X
However	B-X
,	B-X
on	B-X
addition	B-X
of	B-X
a	B-X
myristoylation	B-X
signal	B-X
,	B-X
WT-SHIP2	B-X
,	B-X
R/Q-SHIP2	B-X
,	B-X
and	B-X
Y/F-SHIP2	B-X
all	B-X
efficiently	B-X
inhibited	B-X
insulin-induced	B-X
Akt	B-X
phosphorylation	B-X
at	B-X
both	B-X
residues	B-X
,	B-X
whereas	B-X
a	B-X
5'-phosphatase-defective	B-X
mutant	B-X
SHIP2	B-X
(	B-X
deltaIP-SHIP2	B-X
)	B-X
with	B-X
the	B-X
myristoylation	B-X
signal	B-X
did	B-X
not	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
degree	B-X
of	B-X
inhibition	B-X
of	B-X
Akt	B-X
phosphorylation	B-X
by	B-X
R/Q-SHIP2	B-X
and	B-X
Y/F-SHIP2	B-X
is	B-X
well	B-X
correlated	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
their	B-X
association	B-X
with	B-X
Shc	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
inhibitory	B-X
effect	B-X
on	B-X
insulin-induced	B-X
Akt	B-X
phosphorylation	B-X
by	B-X
WT-SHIP2	B-X
was	B-X
decreased	B-X
in	B-X
antisense-Shc	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
SHIP2	B-X
with	B-X
its	B-X
5'-phosphatase	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
negative	B-X
regulation	B-X
of	B-X
insulin-induced	B-X
Akt	B-X
phosphorylation	B-X
and	B-X
that	B-X
the	B-X
localization	B-X
is	B-X
regulated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
the	B-X
association	B-X
of	B-X
SHIP2	B-X
with	B-X
Shc	B-X
in	B-X
Rat1	B-X
fibroblasts	B-X
.	B-X

Full	O
length	O
Akt	O
or	O
a	O
mutant	O
lacking	O
both	O
the	O
PH	O
domain	O
and	O
the	O
Myr	O
tag	O
did	O
not	O
support	O
the	O
activation	O
of	O
cell	O
death	O
or	O
increased	O
Thr308	O
phosphorylation	O
following	O
zVAD	O
.	O
fmk	O
addition	O
under	O
serum	O
free	O
conditions	O
(	O
Fig	O
.	O
S8A	O
,	O
B	O
)	O
.	O
<EOS>	B-X
Two	B-X
weeks	B-X
of	B-X
globular	B-X
adiponectin	B-X
(	B-X
gAcrp30	B-X
)	B-X
treatment	B-X
reduced	B-X
fasting	B-X
plasma	B-X
glucose	B-X
,	B-X
triglyceride	B-X
(	B-X
TAG	B-X
)	B-X
,	B-X
and	B-X
insulin	B-X
concentrations	B-X
and	B-X
reversed	B-X
whole-body	B-X
insulin	B-X
resistance	B-X
,	B-X
which	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
both	B-X
improved	B-X
insulin-mediated	B-X
suppression	B-X
of	B-X
endogenous	B-X
glucose	B-X
production	B-X
and	B-X
increased	B-X
insulin-stimulated	B-X
glucose	B-X
uptake	B-X
in	B-X
muscle	B-X
and	B-X
adipose	B-X
tissues	B-X
.	B-X
Reductions	B-X
of	B-X
PM	B-X
DAG	B-X
content	B-X
in	B-X
liver	B-X
and	B-X
skeletal	B-X
muscle	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
PKCε	B-X
translocation	B-X
in	B-X
liver	B-X
and	B-X
reduced	B-X
PKCθ	B-X
and	B-X
PKCε	B-X
translocation	B-X
in	B-X
skeletal	B-X
muscle	B-X
resulting	B-X
in	B-X
increased	B-X
insulin-stimulated	B-X
insulin	B-X
receptor	B-X
tyrosine1162	B-X
phosphorylation	B-X
,	B-X
IRS-1/IRS-2-associated	B-X
PI3-kinase	B-X
activity	B-X
,	B-X
and	B-X
Akt-serine	B-X
phosphorylation	B-X
.	B-X
Both	B-X
gAcrp30	B-X
and	B-X
full-length	B-X
adiponectin	B-X
(	B-X
Acrp30	B-X
)	B-X
treatment	B-X
increased	B-X
eNOS/AMPK	B-X
activation	B-X
in	B-X
muscle	B-X
and	B-X
muscle	B-X
fatty	B-X
acid	B-X
oxidation	B-X
.	B-X
gAcrp30	B-X
and	B-X
Acrp30	B-X
infusions	B-X
also	B-X
increased	B-X
TAG	B-X
uptake	B-X
in	B-X
epididymal	B-X
white	B-X
adipose	B-X
tissue	B-X
(	B-X
eWAT	B-X
)	B-X
,	B-X
which	B-X
could	B-X
be	B-X
attributed	B-X
to	B-X
increased	B-X
lipoprotein	B-X
lipase	B-X
(	B-X
LPL	B-X
)	B-X
activity	B-X
.	B-X

Second	O
,	O
we	O
found	O
a	O
specific	O
and	O
critical	O
role	O
for	O
Thr308	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
the	O
necroptotic	O
functions	O
of	O
Akt	O
.	O

It	O
has	O
been	O
reported	O
that	O
Ala	O
mutations	O
at	O
Thr308	O
and	O
Ser473	O
cause	O
a	O
reduction	O
in	O
the	O
catalytic	O
activity	O
of	O
Akt	B-Protein
,	O
while	O
Asp	O
mutants	O
increase	O
activity	O
[	O
38	O
]	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Ala	O
and	O
Asp	O
mutants	O
at	O
both	O
sites	O
during	O
necroptosis	O
.	O

In	O
our	O
hands	O
,	O
both	O
Asp	O
mutants	O
displayed	O
activity	O
comparable	O
to	O
wild	O
type	O
Akt	O
,	O
while	O
both	O
Ala	O
mutants	O
displayed	O
comparable	O
decreases	O
in	O
activity	O
(	O
Fig	O
.	O
S8C	O
)	O
.	O

Despite	O
similar	O
catalytic	O
activities	O
,	O
Thr308	O
and	O
Ser473	O
mutants	O
displayed	O
major	O
differences	O
in	O
their	O
ability	O
to	O
promote	O
necroptotic	O
changes	O
(	O
Fig	O
.	O
7E	O
,	O
F	O
,	O
G	O
)	O
.	O

As	O
expected	O
,	O
the	O
S473D	B-Protein
mutant	I-Protein
,	O
which	O
was	O
phosphorylated	O
on	O
Thr308	O
after	O
the	O
addition	O
of	O
zVAD	O
,	O
displayed	O
only	O
slightly	O
reduced	O
activity	O
,	O
while	O
S473A	B-Protein
was	O
significantly	O
less	O
active	O
in	O
all	O
aspects	O
of	O
necroptosis	O
.	O

S473A	B-Protein
was	O
unable	O
to	O
be	O
efficiently	O
phosphorylated	O
on	O
Thr308	O
possibly	O
due	O
to	O
the	O
inability	O
of	O
the	O
Ala	O
mutated	O
473	O
site	O
to	O
be	O
phosphorylated	O
and	O
provide	O
a	O
docking	O
site	O
for	O
PDK1	B-Protein
to	O
phosphorylate	O
Thr308	O
[	O
39	O
]	O
.	O

Strikingly	O
,	O
both	O
Ala	O
and	O
Asp	O
mutants	O
of	O
Thr308	O
were	O
significantly	O
less	O
active	O
in	O
promoting	O
cell	O
death	O
,	O
phosphorylation	O
of	O
JNK	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
TNFalpha	B-Protein
mRNA	O
.	O

This	O
suggests	O
that	O
T308D	B-Protein
,	O
in	O
spite	O
of	O
being	O
an	O
active	O
Akt	O
construct	O
,	O
may	O
not	O
be	O
a	O
perfect	O
mimic	O
of	O
phosphorylation	O
and	O
this	O
mutant	O
form	O
of	O
the	O
kinase	O
may	O
not	O
have	O
sufficient	O
activity	O
to	O
phosphorylate	O
the	O
entire	O
repertoire	O
of	O
substrates	O
in	O
the	O
cells	O
.	O

When	O
tested	O
,	O
T308D	B-Protein
did	O
not	O
support	O
the	O
downstream	O
phosphorylation	O
of	O
several	O
substrates	O
that	O
were	O
phosphorylated	O
by	O
the	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
construct	O
in	O
the	O
presence	O
of	O
zVAD	O
including	O
FoxO1	B-Protein
,	O
Foxo4	B-Protein
,	O
MDM2	B-Protein
,	O
and	O
p70S6K	B-Protein
(	O
Fig	O
.	O
S8D	O
)	O
.	O
<EOS>	B-X
Protein	B-X
kinase	B-X
B	B-X
(	B-X
PKB	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
Akt	B-X
or	B-X
RAC-PK	B-X
,	B-X
is	B-X
a	B-X
serine/threonine	B-X
kinase	B-X
that	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
growth	B-X
factors	B-X
via	B-X
phosphatidylinositol	B-X
3-kinase	B-X
.	B-X
A	B-X
clear	B-X
inhibitory	B-X
effect	B-X
of	B-X
PKCzeta	B-X
was	B-X
found	B-X
on	B-X
the	B-X
constitutively	B-X
active	B-X
double	B-X
PKB	B-X
mutant	B-X
(	B-X
T308D/S473D	B-X
)	B-X
.	B-X

Our	O
model	O
,	O
based	O
on	O
these	O
results	O
,	O
is	O
that	O
necroptosis	O
-	O
specific	O
Thr308	O
phosphorylation	O
provides	O
a	O
critical	O
link	O
between	O
necroptotic	O
machinery	O
and	O
Akt	O
kinase	O
,	O
allowing	O
Akt	O
to	O
phosphorylate	O
substrates	O
during	O
necroptosis	O
,	O
promote	O
TNFalpha	B-Protein
synthesis	O
,	O
JNK	O
activation	O
and	O
eventual	O
cell	O
death	O
.	O

Akt	O
Controls	O
TNFalpha	B-Protein
Production	O
in	O
Other	O
Cell	O
Types	O
<EOS>	B-X
The	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
immunomodulatory	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
the	B-X
active	B-X
compounds	B-X
of	B-X
S.	B-X
baicalensis	B-X
include	B-X
downregulation	B-X
of	B-X
toll-like	B-X
receptors	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
Nrf2	B-X
and	B-X
PPAR	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
the	B-X
nuclear	B-X
thioredoxin	B-X
system	B-X
and	B-X
inflammation-associated	B-X
pathways	B-X
such	B-X
as	B-X
those	B-X
of	B-X
MAPK	B-X
,	B-X
Akt	B-X
,	B-X
NFκB	B-X
,	B-X
and	B-X
JAK-STAT	B-X
.	B-X
The	B-X
non-cancerous	B-X
functions	B-X
of	B-X
Akt	B-X
in	B-X
the	B-X
airway	B-X
are	B-X
understudied	B-X
.	B-X
In	B-X
some	B-X
tissues	B-X
,	B-X
Akt	B-X
phosphorylates	B-X
and	B-X
activates	B-X
endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
to	B-X
produce	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
that	B-X
has	B-X
anti-inflammatory	B-X
effects	B-X
.	B-X
Akt	B-X
also	B-X
stimulates	B-X
the	B-X
nuclear	B-X
factor	B-X
erythroid	B-X
2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf-2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
transcribes	B-X
antioxidant	B-X
genes	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
Akt/eNOS	B-X
pathway	B-X
,	B-X
which	B-X
also	B-X
activates	B-X
Nrf-2	B-X
,	B-X
may	B-X
have	B-X
protective	B-X
effects	B-X
in	B-X
human	B-X
airway	B-X
cells	B-X
against	B-X
injury	B-X
.	B-X

After	O
establishing	O
the	O
role	O
of	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
signaling	O
to	O
Akt	O
in	O
L929	O
cells	O
,	O
we	O
sought	O
to	O
expand	O
our	O
study	O
to	O
other	O
cell	O
types	O
that	O
are	O
known	O
to	O
undergo	O
necroptotic	O
cell	O
death	O
.	O

Fas	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
with	I-Protein
death	I-Protein
domain	I-Protein
(	O
FADD	B-Protein
)	O
-	O
deficient	O
Jurkat	O
T	O
lymphocytes	O
and	O
the	O
macrophage	O
cell	O
lines	O
(	O
J774A	O
.	O
1	O
and	O
RAW264	O
.	O
7	O
)	O
are	O
other	O
models	O
of	O
necroptosis	O
,	O
which	O
can	O
be	O
induced	O
by	O
stimulation	O
with	O
TNFalpha	B-Protein
or	O
zVAD	O
.	O
fmk	O
,	O
respectively	O
[	O
17	O
]	O
.	O
<EOS>	B-X
AKI	B-X
is	B-X
histologically	B-X
characterized	B-X
by	B-X
necrotic	B-X
cell	B-X
death	B-X
and	B-X
inflammation	B-X
.	B-X
We	B-X
explored	B-X
the	B-X
relative	B-X
contributions	B-X
of	B-X
ferroptosis	B-X
and	B-X
necroptosis	B-X
to	B-X
folic	B-X
acid	B-X
(	B-X
FA	B-X
)	B-X
-induced	B-X
AKI	B-X
in	B-X
mice	B-X
.	B-X
FA-AKI	B-X
in	B-X
mice	B-X
associates	B-X
with	B-X
lipid	B-X
peroxidation	B-X
and	B-X
downregulation	B-X
of	B-X
glutathione	B-X
metabolism	B-X
proteins	B-X
,	B-X
features	B-X
that	B-X
are	B-X
typical	B-X
of	B-X
ferroptotic	B-X
cell	B-X
death	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ferrostatin-1	B-X
(	B-X
Fer-1	B-X
)	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
ferroptosis	B-X
,	B-X
preserved	B-X
renal	B-X
function	B-X
and	B-X
decreased	B-X
histologic	B-X
injury	B-X
,	B-X
oxidative	B-X
stress	B-X
,	B-X
and	B-X
tubular	B-X
cell	B-X
death	B-X
in	B-X
this	B-X
model	B-X
.	B-X
With	B-X
respect	B-X
to	B-X
the	B-X
immunogenicity	B-X
of	B-X
ferroptosis	B-X
,	B-X
Fer-1	B-X
prevented	B-X
the	B-X
upregulation	B-X
of	B-X
IL-33	B-X
,	B-X
an	B-X
alarmin	B-X
linked	B-X
to	B-X
necroptosis	B-X
,	B-X
and	B-X
other	B-X
chemokines	B-X
and	B-X
cytokines	B-X
and	B-X
prevented	B-X
macrophage	B-X
infiltration	B-X
and	B-X
Klotho	B-X
downregulation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
pancaspase	B-X
inhibitor	B-X
zVAD-fmk	B-X
did	B-X
not	B-X
protect	B-X
against	B-X
FA-AKI	B-X
.	B-X
Additionally	B-X
,	B-X
although	B-X
FA-AKI	B-X
resulted	B-X
in	B-X
increased	B-X
protein	B-X
expression	B-X
of	B-X
the	B-X
necroptosis	B-X
mediators	B-X
receptor-interacting	B-X
protein	B-X
kinase	B-X
3	B-X
(	B-X
RIPK3	B-X
)	B-X
and	B-X
mixed	B-X
lineage	B-X
domain-like	B-X
protein	B-X
(	B-X
MLKL	B-X
)	B-X
,	B-X
targeting	B-X
necroptosis	B-X
with	B-X
the	B-X
RIPK1	B-X
inhibitor	B-X
necrostatin-1	B-X
or	B-X
genetic	B-X
deficiency	B-X
of	B-X
RIPK3	B-X
or	B-X
MLKL	B-X
did	B-X
not	B-X
preserve	B-X
renal	B-X
function	B-X
.	B-X
However	B-X
,	B-X
RIPK3	B-X
knockout	B-X
mice	B-X
with	B-X
AKI	B-X
had	B-X
less	B-X
inflammation	B-X
than	B-X
their	B-X
wild-type	B-X
counterparts	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
associated	B-X
with	B-X
higher	B-X
IL-10	B-X
concentration	B-X
and	B-X
regulatory	B-X
T	B-X
cell-to-leukocyte	B-X
ratio	B-X
in	B-X
RIPK3	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
ferroptosis	B-X
is	B-X
the	B-X
primary	B-X
cause	B-X
of	B-X
FA-AKI	B-X
and	B-X
that	B-X
immunogenicity	B-X
secondary	B-X
to	B-X
ferroptosis	B-X
may	B-X
further	B-X
worsen	B-X
the	B-X
damage	B-X
,	B-X
although	B-X
necroptosis-related	B-X
proteins	B-X
may	B-X
have	B-X
additional	B-X
roles	B-X
in	B-X
AKI	B-X
.	B-X

Similar	O
to	O
L929	O
cells	O
,	O
a	O
RIP1	B-Protein
kinase	O
dependent	O
increase	O
in	O
the	O
phosphorylation	O
of	O
Thr308	O
on	O
Akt	O
occurred	O
during	O
necroptosis	O
(	O
Fig	O
.	O
8B	O
,	O
D	O
,	O
F	O
)	O
in	O
these	O
cell	O
types	O
.	O

Furthermore	O
,	O
TNFalpha	B-Protein
mRNA	O
levels	O
were	O
increased	O
in	O
each	O
of	O
these	O
cell	O
types	O
during	O
necroptosis	O
and	O
efficiently	O
inhibited	O
by	O
both	O
RIP1	B-Protein
and	O
Akt	O
inhibitors	O
(	O
Fig	O
.	O
8A	O
,	O
C	O
,	O
E	O
)	O
.	O

However	O
,	O
inhibition	O
of	O
Akt	O
did	O
not	O
protect	O
these	O
cells	O
from	O
death	O
(	O
Fig	O
.	O
S9A	O
,	O
B	O
,	O
C	O
)	O
.	O
<EOS>	B-X
WTD	B-X
Attenuating	B-X
Rheumatoid	B-X
Arthritis	B-X
Chemoresistance	B-X
is	B-X
the	B-X
primary	B-X
reason	B-X
for	B-X
the	B-X
poor	B-X
prognosis	B-X
of	B-X
patients	B-X
with	B-X
ovarian	B-X
cancer	B-X
,	B-X
and	B-X
the	B-X
search	B-X
for	B-X
a	B-X
novel	B-X
drug	B-X
treatment	B-X
or	B-X
adjuvant	B-X
chemotherapy	B-X
drug	B-X
is	B-X
an	B-X
urgent	B-X
need	B-X
.	B-X
α-Cyperone	B-X
,	B-X
one	B-X
of	B-X
the	B-X
main	B-X
ingredients	B-X
of	B-X
Cyperus	B-X
rotundus	B-X
oil	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
possess	B-X
anti-inflammatory	B-X
activity	B-X
in	B-X
activated	B-X
macrophages	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
α-cyperone	B-X
markedly	B-X
decreased	B-X
the	B-X
production	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNF-α	B-X
)	B-X
,	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
and	B-X
interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
in	B-X
LPS-induced	B-X
BV-2	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
α-cyperone	B-X
inhibited	B-X
NF-κB	B-X
activation	B-X
and	B-X
enhanced	B-X
heme	B-X
oxygenase-1	B-X
(	B-X
HO-1	B-X
)	B-X
,	B-X
nuclear	B-X
factor-E2-related	B-X
factor	B-X
2	B-X
(	B-X
Nrf2	B-X
)	B-X
and	B-X
Akt	B-X
expression	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
α-cyperone	B-X
could	B-X
upregulate	B-X
HO-1	B-X
expression	B-X
and	B-X
enhance	B-X
nuclear	B-X
translocation	B-X
of	B-X
Nrf2	B-X
via	B-X
activating	B-X
the	B-X
Akt	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
Akt	B-X
,	B-X
Nrf2	B-X
or	B-X
HO-1	B-X
attenuated	B-X
LPS-induced	B-X
expression	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
BV-2	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
toxicities	B-X
of	B-X
conditioned	B-X
medium	B-X
from	B-X
activated	B-X
microglia	B-X
toward	B-X
dopaminergic	B-X
neuronal	B-X
SH-SY5Y	B-X
cells	B-X
and	B-X
hippocampal	B-X
neuronal	B-X
HT22	B-X
cells	B-X
were	B-X
significantly	B-X
inhibited	B-X
by	B-X
pretreatment	B-X
with	B-X
α-cyperone	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
α-cyperone	B-X
exerts	B-X
neuroprotective	B-X
effects	B-X
by	B-X
inhibiting	B-X
the	B-X
production	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
in	B-X
BV-2	B-X
cells	B-X
through	B-X
activating	B-X
Akt/Nrf2/HO-1	B-X
and	B-X
suppressing	B-X
the	B-X
NF-κB	B-X
pathway	B-X
.	B-X

These	O
results	O
indicate	O
that	O
regulation	O
of	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
necroptosis	O
-	O
associated	O
inflammatory	O
signaling	O
may	O
be	O
a	O
more	O
important	O
function	O
of	O
Akt	O
pathway	O
activation	O
by	O
RIP1	B-Protein
kinase	O
in	O
multiple	O
cell	O
types	O
compared	O
to	O
its	O
contribution	O
to	O
cell	O
death	O
.	O

We	O
next	O
chose	O
to	O
look	O
at	O
the	O
role	O
of	O
Akt	O
in	O
necroptosis	O
in	O
mouse	O
lung	O
fibroblasts	O
.	O

Lung	O
fibroblasts	O
selected	O
to	O
survive	O
after	O
deletion	O
of	O
all	O
three	O
Akt	O
isoforms	O
[	O
40	O
]	O
were	O
resistant	O
to	O
cell	O
death	O
induced	O
by	O
the	O
addition	O
of	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
.	O

Expression	O
of	O
catalytically	O
active	O
Akt	O
(	O
Myr	O
-	O
Akt	O
)	O
in	O
these	O
cells	O
restored	O
TNFalpha	B-Protein
mRNA	O
production	O
in	O
response	O
to	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
8G	O
)	O
without	O
re	O
-	O
establishing	O
cell	O
death	O
(	O
Fig	O
.	O
S9D	O
)	O
.	O

Consistent	O
with	O
our	O
earlier	O
Akt	O
knockdown	O
data	O
,	O
lung	O
fibroblasts	O
expressing	O
endogenous	O
Akt1	B-Protein
or	O
Akt2	B-Protein
were	O
phosphorylated	O
on	O
Thr308	O
in	O
response	O
to	O
TNFalpha	B-Protein
and	O
zVAD	O
.	O
fmk	O
(	O
Fig	O
.	O
S9E	O
)	O
and	O
in	O
both	O
cases	O
robust	O
RIP1	B-Protein
-	O
dependent	O
TNFalpha	B-Protein
mRNA	O
upregulation	O
occurred	O
under	O
necroptotic	O
conditions	O
(	O
Fig	O
.	O
8H	O
)	O
.	O

These	O
data	O
further	O
support	O
the	O
notion	O
that	O
Akt	O
activity	O
is	O
critical	O
for	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
even	O
in	O
the	O
absence	O
of	O
necroptotic	O
cell	O
death	O
,	O
indicating	O
an	O
unexpected	O
differentiation	O
between	O
Akt	O
-	O
mediated	O
inflammatory	O
signaling	O
under	O
necroptotic	O
conditions	O
and	O
cell	O
death	O
per	O
se	O
.	O

Model	O
of	O
RIP1	B-Protein
,	O
Akt	O
and	O
JNK	O
Dependent	O
Signaling	O
in	O
Necroptotic	O
L929	O
Cells	O

In	O
this	O
study	O
we	O
investigated	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
signaling	O
pathways	O
using	O
mouse	O
fibrosarcoma	O
L929	O
cells	O
that	O
die	O
by	O
necroptosis	O
when	O
treated	O
with	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
Akt	O
kinase	O
is	O
specifically	O
engaged	O
in	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
which	O
leads	O
to	O
a	O
selective	O
increase	O
in	O
its	O
phosphorylation	O
on	O
Thr308	O
,	O
but	O
not	O
Ser473	O
.	O

According	O
to	O
our	O
model	O
(	O
Fig	O
.	O
9	O
)	O
,	O
necroptosis	O
-	O
associated	O
phosphorylation	O
of	O
Akt	O
requires	O
two	O
distinct	O
signals	O
.	O

The	O
first	O
input	O
,	O
which	O
is	O
induced	O
by	O
growth	O
factors	O
,	O
leads	O
to	O
the	O
plasma	O
membrane	O
localization	O
of	O
Akt	O
.	O

Expression	O
of	O
a	O
constitutively	O
membrane	O
-	O
targeted	O
Akt	O
construct	O
,	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
,	O
overcomes	O
the	O
requirement	O
for	O
growth	O
factors	O
.	O

At	O
the	O
same	O
time	O
,	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
alone	O
is	O
not	O
sufficient	O
for	O
the	O
induction	O
of	O
necroptosis	O
.	O

A	O
second	O
,	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
input	O
is	O
required	O
for	O
Thr308	O
phosphorylation	O
of	O
Akt	O
in	O
response	O
to	O
caspase	O
inhibition	O
and	O
is	O
essential	O
for	O
the	O
propagation	O
of	O
the	O
necroptotic	O
signal	O
.	O

Using	O
Akt	O
inhibitors	O
,	O
knockdown	O
of	O
Akt	O
isoforms	O
,	O
and	O
the	O
expression	O
of	O
Akt	O
mutants	O
,	O
we	O
showed	O
that	O
necroptotic	O
activation	O
of	O
Akt	O
is	O
indispensable	O
for	O
this	O
form	O
of	O
cell	O
death	O
in	O
L929	O
cells	O
.	O

We	O
also	O
investigated	O
downstream	O
Akt	O
-	O
dependent	O
pathways	O
that	O
contribute	O
to	O
necroptosis	O
.	O

First	O
,	O
we	O
demonstrated	O
that	O
selective	O
necroptotic	O
phosphorylation	O
of	O
Thr308	O
of	O
Akt	O
is	O
sufficient	O
to	O
increase	O
its	O
activity	O
towards	O
a	O
number	O
of	O
known	O
substrates	O
and	O
Akt	O
effector	O
pathways	O
such	O
as	O
the	O
mTORC1	O
pathway	O
,	O
which	O
,	O
in	O
turn	O
,	O
contributes	O
to	O
cell	O
death	O
.	O

Second	O
,	O
our	O
data	O
suggested	O
that	O
Akt	O
activation	O
provides	O
a	O
pivotal	O
link	O
connecting	O
RIP1	B-Protein
kinase	O
to	O
known	O
downstream	O
signaling	O
and	O
execution	O
events	O
in	O
necroptotic	O
L929	O
cells	O
,	O
namely	O
,	O
JNK	O
activation	O
and	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
,	O
a	O
critical	O
event	O
in	O
necroptosis	O
in	O
L929	O
cells	O
[	O
15	O
]	O
.	O

In	O
order	O
to	O
further	O
test	O
our	O
model	O
,	O
we	O
examined	O
Akt	O
phosphorylation	O
after	O
inhibition	O
of	O
a	O
downstream	O
kinase	O
in	O
the	O
pathway	O
,	O
JNK	O
.	O

However	O
,	O
we	O
found	O
that	O
SP600125	O
,	O
which	O
protected	O
L929	O
cells	O
from	O
death	O
and	O
inhibited	O
TNFalpha	B-Protein
production	O
(	O
Fig	O
.	O
2A	O
,	O
B	O
S2A	O
S10A	O
)	O
,	O
inhibited	O
both	O
basal	O
and	O
post	O
-	O
treatment	O
phosphorylation	O
levels	O
of	O
Akt	O
at	O
both	O
Ser473	O
and	O
Thr308	O
(	O
Fig	O
.	O
S10B	O
)	O
.	O

It	O
has	O
been	O
published	O
that	O
SP600125	O
is	O
a	O
somewhat	O
non	O
-	O
specific	O
inhibitor	O
that	O
may	O
inhibit	O
the	O
p110delta	B-Protein
subunit	I-Protein
of	O
PI3K	O
[	O
41	O
]	O
and	O
PDK1	B-Protein
[	O
42	O
]	O
.	O

Both	O
of	O
these	O
off	O
-	O
target	O
effects	O
could	O
inhibit	O
basal	O
Akt	O
phosphorylation	O
levels	O
,	O
precluding	O
the	O
use	O
of	O
SP600125	O
in	O
this	O
system	O
.	O

Therefore	O
,	O
to	O
examine	O
the	O
role	O
of	O
JNK	O
,	O
we	O
switched	O
to	O
a	O
more	O
specific	O
JNK	O
inhibitor	O
,	O
JNK	O
inhibitor	O
VIII	O
[	O
43	O
]	O
,	O
and	O
siRNAs	O
against	O
JNK1	B-Protein
and	O
JNK2	B-Protein
(	O
Fig	O
.	O
S10B	O
-	O
G	O
)	O
.	O

As	O
expected	O
,	O
specific	O
inhibition	O
or	O
knockdown	O
of	O
JNK1	B-Protein
/	O
2	B-Protein
allowed	O
phosphorylation	O
of	O
Akt	O
on	O
Thr308	O
while	O
inhibiting	O
the	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
at	O
Ser63	O
(	O
Fig	O
.	O
S10B	O
,	O
E	O
)	O
,	O
agreeing	O
with	O
our	O
model	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
the	B-X
frontal	B-X
lobe	B-X
is	B-X
critical	B-X
to	B-X
acquisition	B-X
,	B-X
execution	B-X
,	B-X
and	B-X
control	B-X
of	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
functions	B-X
,	B-X
from	B-X
basic	B-X
motor	B-X
response	B-X
to	B-X
complex	B-X
decision-making	B-X
.	B-X
These	B-X
functions	B-X
are	B-X
influenced	B-X
by	B-X
contingency-based	B-X
(	B-X
e.g.	B-X
,	B-X
reward	B-X
and	B-X
response-cost/punishment	B-X
)	B-X
feedback	B-X
that	B-X
is	B-X
mediated	B-X
through	B-X
the	B-X
adaptive	B-X
integration	B-X
of	B-X
fronto-subcortical	B-X
neural	B-X
circuitry	B-X
.	B-X
The	B-X
frontal	B-X
lobe	B-X
manages	B-X
incoming	B-X
information	B-X
and	B-X
chooses	B-X
the	B-X
appropriate	B-X
action	B-X
based	B-X
on	B-X
one	B-X
's	B-X
goals	B-X
in	B-X
a	B-X
particular	B-X
context	B-X
.	B-X
This	B-X
aspect	B-X
of	B-X
frontal	B-X
function	B-X
,	B-X
while	B-X
only	B-X
one	B-X
component	B-X
,	B-X
is	B-X
crucial	B-X
to	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
approach	B-X
and	B-X
avoidance	B-X
behavior	B-X
central	B-X
to	B-X
all	B-X
human	B-X
(	B-X
and	B-X
animal	B-X
)	B-X
behavior	B-X
.	B-X
Furthermore	B-X
,	B-X
disruptions	B-X
in	B-X
fronto-subcortical	B-X
circuitry	B-X
governing	B-X
motivated	B-X
behavior	B-X
appear	B-X
to	B-X
contribute	B-X
to	B-X
a	B-X
range	B-X
of	B-X
developmental	B-X
disorders	B-X
,	B-X
including	B-X
attention-deficit/hyperactivity	B-X
disorder	B-X
(	B-X
ADHD	B-X
)	B-X
,	B-X
and	B-X
confer	B-X
vulnerability	B-X
for	B-X
psychopathology	B-X
more	B-X
broadly	B-X
.	B-X
The	B-X
particular	B-X
deficits	B-X
that	B-X
manifest	B-X
in	B-X
altered	B-X
behavior	B-X
depend	B-X
upon	B-X
the	B-X
specific	B-X
circuitry	B-X
that	B-X
is	B-X
compromised	B-X
due	B-X
to	B-X
the	B-X
functional	B-X
specificity	B-X
of	B-X
distinct	B-X
regions	B-X
of	B-X
the	B-X
frontal	B-X
lobe	B-X
and	B-X
its	B-X
interconnections	B-X
with	B-X
subcortical	B-X
structures	B-X
.	B-X
Neurobiologic	B-X
models	B-X
of	B-X
motivated	B-X
behavior	B-X
provide	B-X
a	B-X
valuable	B-X
framework	B-X
for	B-X
characterizing	B-X
developmental	B-X
disorders	B-X
from	B-X
a	B-X
transdiagnostic	B-X
dimensional	B-X
systems	B-X
perspective	B-X
.	B-X
Improved	B-X
characterization	B-X
of	B-X
approach	B-X
and	B-X
avoidance	B-X
motivation	B-X
across	B-X
neurodevelopmental	B-X
disorders	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
inform	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
interventions	B-X
and	B-X
personalized	B-X
medicine	B-X
.	B-X

It	O
did	O
not	O
,	O
however	O
,	O
lead	O
to	O
a	O
reduction	O
in	O
TNFalpha	B-Protein
production	O
or	O
cell	O
death	O
(	O
Fig	O
.	O
S10C	O
,	O
D	O
,	O
F	O
,	O
G	O
)	O
,	O
suggesting	O
that	O
earlier	O
data	O
with	O
SP600125	O
protection	O
(	O
Fig	O
.	O
2	O
)	O
could	O
reflect	O
off	O
-	O
target	O
effects	O
of	O
this	O
molecule	O
,	O
rather	O
than	O
JNK	O
inhibition	O
.	O

Previous	O
reports	O
also	O
suggested	O
a	O
critical	O
role	O
for	O
c	B-Protein
-	I-Protein
Jun	I-Protein
in	O
necroptosis	O
and	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
and	O
we	O
confirmed	O
these	O
conclusions	O
using	O
c	B-Protein
-	I-Protein
Jun	I-Protein
siRNA	O
knockdown	O
(	O
Fig	O
.	O
S10H	O
-	O
J	O
)	O
.	O

Notably	O
,	O
in	O
this	O
case	O
,	O
Thr308	O
phosphorylation	O
was	O
reduced	O
after	O
the	O
induction	O
of	O
necroptosis	O
.	O

Thus	O
,	O
autocrine	O
TNFalpha	B-Protein
production	O
,	O
dependent	O
on	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
may	O
create	O
a	O
feedback	O
loop	O
that	O
contributes	O
to	O
the	O
delayed	O
activation	O
of	O
Akt	O
.	O

It	O
is	O
also	O
important	O
to	O
note	O
that	O
we	O
observed	O
an	O
overall	O
increase	O
in	O
the	O
protein	O
level	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
after	O
treatment	O
of	O
L929	O
cells	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
,	O
which	O
was	O
both	O
Akt	O
and	O
mTOR	O
-	O
dependent	O
(	O
Fig	O
.	O
6E	O
,	O
F	O
)	O
.	O

These	O
new	O
data	O
led	O
us	O
to	O
an	O
unexpected	O
,	O
but	O
important	O
conclusion	O
that	O
c	B-Protein
-	I-Protein
Jun	I-Protein
is	O
critical	O
for	O
necroptosis	O
,	O
while	O
JNK	O
activity	O
may	O
serve	O
as	O
a	O
useful	O
marker	O
of	O
pathway	O
activation	O
,	O
but	O
may	O
be	O
either	O
redundant	O
(	O
e	O
.	O
g	O
.	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
on	O
a	O
site	O
other	O
than	O
Ser63	O
may	O
occur	O
[	O
44	O
]	O
)	O
or	O
dispensable	O
functionally	O
.	O
<EOS>	B-X
Genome-wide	B-X
mutagenesis	B-X
studies	B-X
indicate	B-X
that	B-X
up	B-X
to	B-X
about	B-X
90	B-X
%	B-X
of	B-X
genes	B-X
in	B-X
bacteria	B-X
and	B-X
80	B-X
%	B-X
in	B-X
eukaryotes	B-X
can	B-X
be	B-X
inactivated	B-X
individually	B-X
leaving	B-X
an	B-X
organism	B-X
viable	B-X
,	B-X
often	B-X
seemingly	B-X
unaffected	B-X
.	B-X
Several	B-X
strategies	B-X
are	B-X
used	B-X
to	B-X
learn	B-X
what	B-X
these	B-X
apparently	B-X
dispensable	B-X
genes	B-X
contribute	B-X
to	B-X
fitness	B-X
.	B-X
Assays	B-X
of	B-X
growth	B-X
under	B-X
hundreds	B-X
of	B-X
physical	B-X
and	B-X
chemical	B-X
stresses	B-X
are	B-X
among	B-X
the	B-X
most	B-X
effective	B-X
experimental	B-X
approaches	B-X
.	B-X
Comparative	B-X
studies	B-X
of	B-X
genomic	B-X
DNA	B-X
sequences	B-X
continue	B-X
to	B-X
be	B-X
valuable	B-X
in	B-X
discriminating	B-X
between	B-X
the	B-X
core	B-X
bacterial	B-X
genome	B-X
and	B-X
the	B-X
more	B-X
variable	B-X
niche-specific	B-X
genes	B-X
.	B-X
The	B-X
concept	B-X
of	B-X
the	B-X
core	B-X
genome	B-X
appears	B-X
currently	B-X
unfeasible	B-X
for	B-X
eukaryotes	B-X
but	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
understanding	B-X
why	B-X
they	B-X
contain	B-X
numerous	B-X
gene	B-X
duplicates	B-X
.	B-X

In	O
addition	O
,	O
researchers	O
need	O
to	O
use	O
caution	O
when	O
using	O
SP600125	O
due	O
to	O
potantial	O
off	O
-	O
target	O
effects	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
Akt	O
kinase	O
is	O
specifically	O
engaged	O
in	O
the	O
signaling	O
downstream	O
from	O
RIP1	B-Protein
kinase	O
,	O
which	O
exerts	O
its	O
activity	O
through	O
promoting	O
a	O
selective	O
increase	O
in	O
Akt	O
phosphorylation	O
on	O
Thr308	O
.	O

This	O
provides	O
a	O
link	O
connecting	O
RIP1	B-Protein
kinase	O
to	O
downstream	O
signaling	O
and	O
execution	O
events	O
during	O
necroptosis	O
in	O
L929	O
cells	O
,	O
including	O
JNK	O
activation	O
,	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
eventual	O
cell	O
death	O
.	O

According	O
to	O
our	O
model	O
,	O
phosphorylation	O
of	O
Akt	O
requires	O
two	O
distinct	O
signals	O
.	O

The	O
first	O
input	O
,	O
which	O
is	O
induced	O
by	O
growth	O
factors	O
,	O
leads	O
to	O
the	O
plasma	O
membrane	O
localization	O
of	O
Akt	O
.	O

Expression	O
of	O
constitutively	O
active	O
membrane	O
-	O
targeted	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
overcomes	O
this	O
requirement	O
.	O

At	O
the	O
same	O
time	O
,	O
expression	O
of	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
is	O
not	O
sufficient	O
for	O
the	O
induction	O
of	O
necroptosis	O
or	O
efficient	O
activation	O
of	O
JNK	O
and	O
TNFalpha	B-Protein
synthesis	O
.	O
<EOS>	B-X
Using	B-X
TAK779	B-X
to	B-X
block	B-X
CXCL13/CXCR5	B-X
axis	B-X
significantly	B-X
attenuated	B-X
these	B-X
inflammatory	B-X
damages	B-X
and	B-X
efficiently	B-X
improved	B-X
bladder	B-X
function	B-X
(	B-X
significant	B-X
reduction	B-X
in	B-X
micturition	B-X
frequency	B-X
,	B-X
significant	B-X
prolongation	B-X
of	B-X
inter-contraction	B-X
interval	B-X
)	B-X
.	B-X
Further	B-X
investigation	B-X
showed	B-X
that	B-X
inhibiton	B-X
of	B-X
JNK	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
the	B-X
bioinformatics	B-X
analysis-indicated	B-X
downstream	B-X
signaling	B-X
of	B-X
CXCL13/CXCR5	B-X
axis	B-X
,	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
TAK779	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
CXCL13/CXCR5	B-X
axis	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
IC/BPS	B-X
and	B-X
EAC	B-X
.	B-X
Blocking	B-X
CXCL13/CXCR5	B-X
axis	B-X
activation	B-X
by	B-X
TAK-779	B-X
reduces	B-X
bladder	B-X
inflammation	B-X
and	B-X
improves	B-X
bladder	B-X
function	B-X
in	B-X
EAC	B-X
mice	B-X
.	B-X

A	O
second	O
,	O
RIP1	B-Protein
kinase	O
-	O
dependent	O
input	O
is	O
required	O
for	O
Thr308	O
phosphorylation	O
of	O
Akt	O
,	O
which	O
in	O
turn	O
is	O
required	O
for	O
necroptotic	O
signaling	O
.	O

Necroptotic	O
phosphorylation	O
of	O
Thr308	O
of	O
Akt	O
is	O
sufficient	O
to	O
increase	O
its	O
activity	O
towards	O
a	O
number	O
of	O
known	O
substrates	O
in	O
L929	O
cells	O
and	O
our	O
data	O
reveal	O
that	O
the	O
Akt	O
effector	O
pathway	O
downstream	O
of	O
mTORC1	O
contributes	O
to	O
necroptosis	O
,	O
thereby	O
identifying	O
a	O
new	O
mediator	O
of	O
this	O
form	O
of	O
cell	O
death	O
.	O

Our	O
results	O
raise	O
some	O
important	O
mechanistic	O
questions	O
relevant	O
to	O
the	O
specific	O
regulation	O
of	O
Akt	O
during	O
necroptosis	O
.	O

First	O
,	O
what	O
is	O
the	O
mechanism	O
of	O
the	O
RIP1	B-Protein
-	O
dependent	O
increase	O
in	O
Akt	O
Thr308	O
phosphorylation	O
?	O

One	O
possibility	O
is	O
that	O
RIP1	B-Protein
kinase	O
inhibits	O
a	O
phosphatase	O
that	O
targets	O
Thr308	O
.	O

To	O
our	O
knowledge	O
,	O
PP2A	O
is	O
the	O
only	O
enzyme	O
established	O
to	O
specifically	O
dephosphorylate	O
this	O
residue	O
[	O
45	O
]	O
.	O

However	O
,	O
we	O
did	O
not	O
observe	O
any	O
effect	O
of	O
the	O
PP2A	O
inhibitor	O
,	O
okadaic	O
acid	O
,	O
on	O
Thr308	O
phosphorylation	O
or	O
activation	O
of	O
necroptosis	O
in	O
L929	O
cells	O
.	O
<EOS>	B-X
IFN-induced	B-X
necroptosis	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
cells	B-X
deficient	B-X
in	B-X
receptor-interacting	B-X
protein	B-X
kinase	B-X
1	B-X
(	B-X
RIPK1	B-X
)	B-X
,	B-X
Fas-associated	B-X
protein	B-X
with	B-X
death	B-X
domain	B-X
(	B-X
FADD	B-X
)	B-X
,	B-X
or	B-X
caspase-8	B-X
,	B-X
but	B-X
the	B-X
mechanism	B-X
is	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
DNA-dependent	B-X
activator	B-X
of	B-X
IFN	B-X
regulatory	B-X
factors	B-X
(	B-X
ZBP1	B-X
,	B-X
also	B-X
known	B-X
as	B-X
DAI	B-X
)	B-X
is	B-X
required	B-X
for	B-X
both	B-X
type	B-X
I	B-X
(	B-X
β	B-X
)	B-X
and	B-X
type	B-X
II	B-X
(	B-X
γ	B-X
)	B-X
IFN-induced	B-X
necroptosis	B-X
.	B-X
We	B-X
show	B-X
that	B-X
L929	B-X
fibroblast	B-X
cells	B-X
became	B-X
susceptible	B-X
to	B-X
IFN-induced	B-X
necroptosis	B-X
when	B-X
RIPK1	B-X
,	B-X
FADD	B-X
,	B-X
or	B-X
Caspase-8	B-X
was	B-X
genetically	B-X
deleted	B-X
,	B-X
confirming	B-X
the	B-X
antinecroptotic	B-X
role	B-X
of	B-X
these	B-X
proteins	B-X
in	B-X
IFN	B-X
signaling	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
pronecroptotic	B-X
signal	B-X
from	B-X
IFN	B-X
stimulation	B-X
depends	B-X
on	B-X
new	B-X
protein	B-X
synthesis	B-X
and	B-X
identified	B-X
ZBP1	B-X
,	B-X
an	B-X
IFN-stimulated	B-X
gene	B-X
(	B-X
ISG	B-X
)	B-X
product	B-X
,	B-X
as	B-X
the	B-X
de	B-X
novo	B-X
synthesized	B-X
protein	B-X
that	B-X
triggers	B-X
necroptosis	B-X
in	B-X
IFN-stimulated	B-X
cells	B-X
.	B-X
The	B-X
N-terminal	B-X
domain	B-X
(	B-X
ND	B-X
)	B-X
of	B-X
ZBP1	B-X
is	B-X
important	B-X
for	B-X
ZBP1-ZBP1	B-X
homointeraction	B-X
,	B-X
and	B-X
its	B-X
RHIM	B-X
domain	B-X
in	B-X
the	B-X
C-terminal	B-X
region	B-X
interacts	B-X
with	B-X
RIPK3	B-X
to	B-X
initiate	B-X
RIPK3-dependent	B-X
necroptosis	B-X
.	B-X
The	B-X
antinecroptotic	B-X
function	B-X
of	B-X
RIPK1	B-X
,	B-X
FADD	B-X
,	B-X
and	B-X
caspase-8	B-X
in	B-X
IFN-treated	B-X
cells	B-X
is	B-X
most	B-X
likely	B-X
executed	B-X
by	B-X
caspase-8-mediated	B-X
cleavage	B-X
of	B-X
RIPK3	B-X
,	B-X
since	B-X
the	B-X
inhibitory	B-X
effect	B-X
on	B-X
necroptosis	B-X
was	B-X
eliminated	B-X
when	B-X
the	B-X
caspase-8	B-X
cleavage	B-X
site	B-X
in	B-X
RIPK3	B-X
was	B-X
mutated	B-X
.	B-X
ZBP1-mediated	B-X
necroptosis	B-X
in	B-X
IFN-treated	B-X
cells	B-X
is	B-X
likely	B-X
physiologically	B-X
relevant	B-X
,	B-X
as	B-X
ZBP1	B-X
KO	B-X
mice	B-X
were	B-X
significantly	B-X
protected	B-X
against	B-X
acute	B-X
systemic	B-X
inflammatory	B-X
response	B-X
syndrome	B-X
(	B-X
SIRS	B-X
)	B-X
induced	B-X
by	B-X
TNF	B-X
+	B-X
IFN-γ	B-X
.	B-X

Another	O
possibility	O
is	O
that	O
the	O
increase	O
in	O
Thr308	O
results	O
from	O
RIP1	B-Protein
kinase	O
targeting	O
PDK1	B-Protein
,	O
Akt	O
or	O
scaffolding	O
factors	O
that	O
bring	O
these	O
two	O
kinases	O
together	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
we	B-X
identified	B-X
two	B-X
new	B-X
sites	B-X
which	B-X
together	B-X
with	B-X
the	B-X
previously	B-X
identified	B-X
conserved	B-X
tyrosine	B-X
constitute	B-X
three	B-X
discontinuous	B-X
Sef	B-X
regions	B-X
each	B-X
indispensable	B-X
for	B-X
Sef	B-X
binding	B-X
to	B-X
RelA	B-X
:	B-X
p50	B-X
and	B-X
inhibiting	B-X
its	B-X
cytokine	B-X
induced	B-X
transcriptional	B-X
activation	B-X
.	B-X
Contrary	B-X
to	B-X
IκBα	B-X
,	B-X
endogenous	B-X
Sef	B-X
is	B-X
not	B-X
degraded	B-X
upon	B-X
cytokine-stimulation	B-X
,	B-X
and	B-X
its	B-X
targeting	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
markedly	B-X
enhances	B-X
cytokine-induced	B-X
NF-κB	B-X
nuclear	B-X
translocation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
Sef	B-X
as	B-X
the	B-X
first	B-X
scaffold	B-X
that	B-X
brings	B-X
together	B-X
the	B-X
components	B-X
of	B-X
NF-κB/RelA	B-X
:	B-X
p50	B-X
signaling-module	B-X
.	B-X
Sef	B-X
scaffolding	B-X
function	B-X
explains	B-X
the	B-X
basis	B-X
for	B-X
Sef	B-X
specificity	B-X
towards	B-X
inhibiting	B-X
inflammatory	B-X
cytokine-induction	B-X
of	B-X
NF-κB/RelA	B-X
:	B-X
p50	B-X
.	B-X

Interestingly	O
,	O
we	O
observed	O
phosphorylation	O
of	O
Akt	O
by	O
recombinant	O
RIP1	B-Protein
kinase	O
in	O
vitro	O
on	O
Thr146	O
,	O
195	O
/	O
197	O
,	O
and	O
435	O
and	O
Ser381	O
residues	O
.	O

Furthermore	O
,	O
mutating	O
these	O
residues	O
to	O
Ala	O
in	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
leads	O
to	O
the	O
loss	O
of	O
its	O
ability	O
to	O
promote	O
necroptosis	O
.	O

However	O
,	O
we	O
were	O
not	O
able	O
to	O
confirm	O
phosphorylation	O
of	O
these	O
residues	O
on	O
endogenous	O
Akt	O
in	O
L929	O
cells	O
using	O
either	O
mass	O
spectrometry	O
or	O
western	O
blotting	O
with	O
a	O
phospho	O
-	O
specific	O
antibody	O
raised	O
against	O
Thr435	O
peptide	O
,	O
suggesting	O
that	O
direct	O
phosphorylation	O
of	O
Akt	O
by	O
RIP1	B-Protein
likely	O
represents	O
an	O
in	O
vitro	O
artifact	O
and	O
does	O
not	O
reflect	O
endogenous	O
regulation	O
.	O

Second	O
,	O
what	O
are	O
the	O
key	O
substrates	O
of	O
Akt	O
that	O
promote	O
necrotic	O
death	O
and	O
TNFalpha	B-Protein
synthesis	O
?	O

On	O
the	O
one	O
hand	O
,	O
our	O
data	O
suggest	O
new	O
roles	O
for	O
Akt	O
effector	O
pathways	O
mediated	O
by	O
mTORC1	O
in	O
necroptotic	O
control	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
have	O
observed	O
only	O
modest	O
changes	O
in	O
mTORC1	O
activity	O
under	O
necroptotic	O
conditions	O
,	O
suggesting	O
that	O
additional	O
Akt	O
substrates	O
are	O
likely	O
to	O
be	O
involved	O
.	O

This	O
warrants	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
roles	O
of	O
additional	O
Akt	O
substrates	O
in	O
necroptotic	O
death	O
,	O
since	O
no	O
such	O
connections	O
have	O
been	O
established	O
.	O

Similarly	O
,	O
the	O
mechanisms	O
connecting	O
mTORC1	O
to	O
JNK	O
remain	O
to	O
be	O
elucidated	O
.	O

While	O
there	O
are	O
some	O
recent	O
examples	O
of	O
mTORC1	O
-	O
dependent	O
regulation	O
of	O
JNK	O
,	O
e	O
.	O
g	O
.	O
following	O
ER	O
stress	O
[	O
46	O
]	O
,	O
the	O
exact	O
mechanisms	O
during	O
necroptosis	O
remain	O
to	O
be	O
established	O
.	O

Given	O
the	O
activation	O
of	O
JNK	O
by	O
TNFalpha	B-Protein
and	O
the	O
importance	O
of	O
mTORC1	O
-	O
dependent	O
translational	O
control	O
in	O
necroptosis	O
,	O
one	O
possibility	O
is	O
that	O
mTORC1	O
contributes	O
to	O
the	O
translation	O
of	O
TNFalpha	B-Protein
and	O
forms	O
a	O
positive	O
feed	O
forward	O
loop	O
with	O
JNK	O
.	O

Akt	O
'	O
s	O
role	O
as	O
a	O
key	O
inhibitor	O
of	O
apoptosis	O
is	O
well	O
documented	O
,	O
however	O
,	O
evidence	O
of	O
its	O
contribution	O
as	O
a	O
mediator	O
of	O
cell	O
death	O
under	O
various	O
circumstances	O
has	O
begun	O
to	O
emerge	O
as	O
well	O
[	O
45	O
]	O
,	O
[	O
47	O
]	O
.	O

Our	O
data	O
demonstrates	O
a	O
new	O
mode	O
of	O
necrosis	O
-	O
specific	O
regulation	O
of	O
Akt	O
by	O
RIP1	B-Protein
kinase	O
.	O

Importantly	O
,	O
while	O
it	O
is	O
possible	O
that	O
necroptosis	O
-	O
specific	O
targets	O
of	O
Akt	O
exist	O
,	O
this	O
regulation	O
clearly	O
involves	O
a	O
number	O
of	O
well	O
established	O
Akt	O
targets	O
including	O
mTORC1	O
,	O
and	O
potentially	O
,	O
GSK	O
-	O
3	O
,	O
FoxO1	B-Protein
/	O
4	B-Protein
,	O
and	O
MDM2	B-Protein
.	O

Therefore	O
,	O
it	O
may	O
no	O
longer	O
be	O
safe	O
to	O
assume	O
that	O
activation	O
of	O
Akt	O
universally	O
reflects	O
pro	O
-	O
survival	O
signaling	O
nor	O
that	O
its	O
inhibition	O
will	O
lead	O
to	O
more	O
cell	O
death	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
rather	O
than	O
serving	O
a	O
universally	O
pro	O
-	O
survival	O
role	O
,	O
the	O
Akt	O
pathway	O
may	O
function	O
to	O
promote	O
cell	O
fates	O
alternative	O
to	O
apoptosis	O
,	O
ranging	O
from	O
survival	O
to	O
non	O
-	O
apoptotic	O
cell	O
death	O
.	O

The	O
final	O
decision	O
between	O
survival	O
and	O
death	O
may	O
depend	O
on	O
additional	O
,	O
Akt	O
-	O
independent	O
inputs	O
,	O
such	O
as	O
the	O
status	O
of	O
RIP1	B-Protein
kinase	O
,	O
expression	O
of	O
particular	O
oncogenic	O
factors	O
[	O
45	O
]	O
or	O
excessive	O
metabolic	O
stress	O
[	O
47	O
]	O
.	O
<EOS>	B-X
Oxidative	B-X
stress	B-X
(	B-X
OS	B-X
)	B-X
,	B-X
defined	B-X
as	B-X
disturbances	B-X
in	B-X
the	B-X
pro-/antioxidant	B-X
balance	B-X
,	B-X
is	B-X
harmful	B-X
to	B-X
cells	B-X
due	B-X
to	B-X
the	B-X
excessive	B-X
generation	B-X
of	B-X
highly	B-X
reactive	B-X
oxygen	B-X
(	B-X
ROS	B-X
)	B-X
and	B-X
nitrogen	B-X
(	B-X
RNS	B-X
)	B-X
species	B-X
.	B-X
However	B-X
,	B-X
an	B-X
excessive	B-X
amount	B-X
of	B-X
ROS	B-X
and	B-X
RNS	B-X
results	B-X
in	B-X
the	B-X
oxidation	B-X
of	B-X
biological	B-X
molecules	B-X
such	B-X
as	B-X
lipids	B-X
,	B-X
proteins	B-X
,	B-X
and	B-X
DNA	B-X
.	B-X
Oxidative	B-X
stress	B-X
has	B-X
been	B-X
reported	B-X
in	B-X
kidney	B-X
disease	B-X
,	B-X
due	B-X
to	B-X
both	B-X
antioxidant	B-X
depletions	B-X
as	B-X
well	B-X
as	B-X
increased	B-X
ROS	B-X
production	B-X
.	B-X
The	B-X
kidney	B-X
is	B-X
a	B-X
highly	B-X
metabolic	B-X
organ	B-X
,	B-X
rich	B-X
in	B-X
oxidation	B-X
reactions	B-X
in	B-X
mitochondria	B-X
,	B-X
which	B-X
makes	B-X
it	B-X
vulnerable	B-X
to	B-X
damage	B-X
caused	B-X
by	B-X
OS	B-X
,	B-X
and	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
OS	B-X
can	B-X
accelerate	B-X
kidney	B-X
disease	B-X
progression	B-X
.	B-X
We	B-X
also	B-X
discuss	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
various	B-X
antioxidants	B-X
and	B-X
pharmacological	B-X
agents	B-X
,	B-X
which	B-X
may	B-X
represent	B-X
potential	B-X
therapeutic	B-X
targets	B-X
to	B-X
reduce	B-X
OS	B-X
in	B-X
both	B-X
pediatric	B-X
and	B-X
adult	B-X
CKD	B-X
patients	B-X
.	B-X

Another	O
mechanism	O
that	O
should	O
be	O
considered	O
in	O
conjunction	O
with	O
the	O
regulation	O
of	O
cell	O
death	O
by	O
Akt	O
is	O
autophagy	O
.	O

Akt	O
activation	O
leads	O
to	O
the	O
inhibition	O
of	O
autophagy	O
through	O
activation	O
of	O
mTOR	O
[	O
48	O
]	O
.	O

The	O
role	O
of	O
autophagy	O
in	O
cell	O
death	O
in	O
general	O
is	O
very	O
complex	O
and	O
it	O
can	O
both	O
promote	O
and	O
inhibit	O
necroptosis	O
in	O
various	O
situations	O
.	O

Several	O
studies	O
suggested	O
that	O
activation	O
of	O
autophagy	O
promotes	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
in	O
L929	O
cells	O
[	O
11	O
]	O
,	O
[	O
14	O
]	O
.	O

Others	O
,	O
including	O
ourselves	O
in	O
unpublished	O
data	O
,	O
have	O
found	O
that	O
inihibition	O
of	O
autophagy	O
promotes	O
necroptosis	O
by	O
TNFalpha	B-Protein
[	O
49	O
]	O
.	O

This	O
suggests	O
that	O
the	O
inhibition	O
of	O
autophagy	O
by	O
Akt	O
or	O
mTOR	O
in	O
our	O
system	O
may	O
contribute	O
to	O
necroptosis	O
induced	O
by	O
TNFalpha	B-Protein
,	O
however	O
,	O
it	O
is	O
more	O
difficult	O
to	O
reconcile	O
with	O
the	O
positive	O
role	O
of	O
these	O
proteins	O
in	O
zVAD	O
-	O
induced	O
death	O
.	O
<EOS>	B-X
Emerging	B-X
evidence	B-X
shows	B-X
that	B-X
lipophagy	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
lipid	B-X
droplets	B-X
accumulation	B-X
.	B-X
Here	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
models	B-X
,	B-X
we	B-X
found	B-X
that	B-X
exercise	B-X
and	B-X
dietary	B-X
intervention	B-X
reduced	B-X
lipid	B-X
droplets	B-X
formation	B-X
,	B-X
decreased	B-X
hepatic	B-X
triglyceride	B-X
in	B-X
the	B-X
liver	B-X
induced	B-X
by	B-X
high-fat	B-X
diet	B-X
.	B-X
Exercise	B-X
and	B-X
dietary	B-X
intervention	B-X
enhanced	B-X
the	B-X
lipophagy	B-X
by	B-X
activating	B-X
AMPK/ULK1	B-X
and	B-X
inhibiting	B-X
Akt/mTOR/ULK1	B-X
pathways	B-X
respectively	B-X
.	B-X
Sustained	B-X
macroautophagy/autophagy	B-X
favors	B-X
the	B-X
differentiation	B-X
of	B-X
fibroblasts	B-X
into	B-X
myofibroblasts	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
evaluate	B-X
the	B-X
relationship	B-X
between	B-X
senescence	B-X
and	B-X
myofibroblast	B-X
differentiation	B-X
in	B-X
the	B-X
context	B-X
of	B-X
sustained	B-X
autophagy	B-X
.	B-X

Clearly	O
,	O
further	O
identification	O
of	O
the	O
factors	O
differentiating	O
between	O
pro	O
-	O
death	O
and	O
pro	O
-	O
survival	O
autophagy	O
in	O
mammalian	O
cells	O
is	O
required	O
to	O
better	O
understand	O
its	O
role	O
in	O
the	O
regulation	O
necroptosis	O
by	O
Akt	O
pathway	O
.	O

Importantly	O
,	O
our	O
data	O
revealed	O
that	O
RIP1	B-Protein
kinase	O
signaling	O
to	O
Akt	O
is	O
a	O
general	O
feature	O
of	O
necroptotic	O
signaling	O
that	O
is	O
observed	O
in	O
multiple	O
cell	O
types	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
significance	O
of	O
this	O
connection	O
varies	O
in	O
a	O
cell	O
type	O
specific	O
fashion	O
.	O

Importantly	O
,	O
in	O
mouse	O
lung	O
fibroblasts	O
,	O
FADD	B-Protein
-	O
deficient	O
Jurkat	O
cells	O
,	O
and	O
macrophages	O
,	O
Akt	O
signaling	O
contributed	O
more	O
prominently	O
to	O
an	O
increase	O
in	O
TNFalpha	B-Protein
synthesis	O
,	O
rather	O
than	O
cell	O
death	O
per	O
se	O
,	O
unlike	O
its	O
role	O
in	O
L929	O
cells	O
.	O

A	O
recent	O
study	O
[	O
15	O
]	O
has	O
demonstrated	O
that	O
,	O
in	O
addition	O
to	O
its	O
role	O
in	O
necroptosis	O
,	O
RIP1	B-Protein
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
production	O
of	O
TNFalpha	B-Protein
.	O

These	O
data	O
emphasize	O
the	O
emerging	O
complexity	O
of	O
necroptotic	O
signaling	O
mechanisms	O
and	O
highlight	O
the	O
major	O
contribution	O
of	O
Akt	O
to	O
increased	O
inflammatory	O
signaling	O
,	O
specifically	O
accompanying	O
this	O
form	O
of	O
regulated	O
necrosis	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
10	O
]	O
.	O

Robust	O
inflammation	O
is	O
one	O
of	O
the	O
most	O
important	O
consequences	O
of	O
necrotic	O
cell	O
death	O
as	O
well	O
as	O
its	O
regulated	O
subtype	O
,	O
necroptosis	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
1	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
50	O
]	O
,	O
[	O
51	O
]	O
.	O

Our	O
results	O
highlight	O
an	O
important	O
notion	O
that	O
inflammation	O
not	O
only	O
passively	O
accompanies	O
necroptosis	O
in	O
a	O
variety	O
of	O
cellular	O
systems	O
by	O
the	O
virtue	O
of	O
rapid	O
loss	O
of	O
plasma	O
membrane	O
integrity	O
characteristic	O
for	O
necrotic	O
cell	O
death	O
,	O
but	O
also	O
that	O
it	O
is	O
an	O
intrinsic	O
and	O
regulated	O
component	O
of	O
necroptosis	O
due	O
to	O
the	O
specific	O
activation	O
of	O
TNFalpha	B-Protein
synthesis	O
by	O
RIP1	B-Protein
/	O
Akt	O
kinases	O
.	O
<EOS>	B-X
As	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
COVID-19	B-X
continues	B-X
to	B-X
evolve	B-X
,	B-X
a	B-X
synthesis	B-X
of	B-X
the	B-X
literature	B-X
on	B-X
the	B-X
neurological	B-X
impact	B-X
of	B-X
this	B-X
novel	B-X
virus	B-X
may	B-X
help	B-X
inform	B-X
clinical	B-X
management	B-X
and	B-X
highlight	B-X
potentially	B-X
important	B-X
avenues	B-X
of	B-X
investigation	B-X
.	B-X
Additionally	B-X
,	B-X
studies	B-X
have	B-X
demonstrated	B-X
an	B-X
increase	B-X
in	B-X
cytokine	B-X
serum	B-X
levels	B-X
as	B-X
a	B-X
result	B-X
of	B-X
SARS-CoV	B-X
infection	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
notion	B-X
that	B-X
cytokine	B-X
overproduction	B-X
and	B-X
toxicity	B-X
may	B-X
be	B-X
a	B-X
relevant	B-X
potential	B-X
mechanism	B-X
of	B-X
neurologic	B-X
injury	B-X
,	B-X
paralleling	B-X
a	B-X
known	B-X
pathway	B-X
of	B-X
pulmonary	B-X
injury	B-X
.	B-X
We	B-X
also	B-X
discuss	B-X
evidence	B-X
that	B-X
suggests	B-X
that	B-X
SARS-CoV-2	B-X
may	B-X
be	B-X
a	B-X
vasculotropic	B-X
and	B-X
neurotropic	B-X
virus	B-X
.	B-X
Fibroblasts	B-X
are	B-X
important	B-X
cells	B-X
for	B-X
the	B-X
support	B-X
of	B-X
homeostatic	B-X
tissue	B-X
function	B-X
.	B-X
In	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis	B-X
and	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
fibroblasts	B-X
take	B-X
on	B-X
different	B-X
roles	B-X
(	B-X
a	B-X
)	B-X
as	B-X
inflammatory	B-X
cells	B-X
themselves	B-X
and	B-X
(	B-X
b	B-X
)	B-X
in	B-X
recruiting	B-X
leukocytes	B-X
,	B-X
driving	B-X
angiogenesis	B-X
,	B-X
and	B-X
enabling	B-X
chronic	B-X
inflammation	B-X
in	B-X
tissues	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
single-cell	B-X
profiling	B-X
techniques	B-X
have	B-X
transformed	B-X
the	B-X
ability	B-X
to	B-X
examine	B-X
fibroblast	B-X
states	B-X
and	B-X
populations	B-X
in	B-X
inflamed	B-X
tissues	B-X
,	B-X
providing	B-X
evidence	B-X
of	B-X
previously	B-X
underappreciated	B-X
heterogeneity	B-X
and	B-X
disease-associated	B-X
fibroblast	B-X
populations	B-X
.	B-X
These	B-X
studies	B-X
challenge	B-X
the	B-X
preconceived	B-X
notion	B-X
that	B-X
fibroblasts	B-X
are	B-X
homogeneous	B-X
and	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
fibroblasts	B-X
in	B-X
inflammatory	B-X
pathology	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
new	B-X
molecular	B-X
insights	B-X
into	B-X
the	B-X
mechanisms	B-X
of	B-X
fibroblast	B-X
activation	B-X
reveal	B-X
powerful	B-X
cell-intrinsic	B-X
amplification	B-X
loops	B-X
that	B-X
synergize	B-X
with	B-X
primary	B-X
fibroblast	B-X
stimuli	B-X
to	B-X
result	B-X
in	B-X
striking	B-X
responses	B-X
.	B-X
We	B-X
highlight	B-X
new	B-X
approaches	B-X
to	B-X
,	B-X
and	B-X
applications	B-X
of	B-X
,	B-X
single-cell	B-X
profiling	B-X
techniques	B-X
and	B-X
what	B-X
they	B-X
teach	B-X
us	B-X
about	B-X
fibroblast	B-X
biology	B-X
.	B-X

Therefore	O
,	O
this	O
pathway	O
may	O
represent	O
a	O
new	O
molecular	O
target	O
for	O
the	O
inhibition	O
of	O
pathologic	O
inflammatory	O
signaling	O
.	O
<EOS>	B-X
Immune	B-X
checkpoint	B-X
inhibitors	B-X
(	B-X
ICI	B-X
)	B-X
revolutionized	B-X
the	B-X
field	B-X
of	B-X
immuno-oncology	B-X
and	B-X
opened	B-X
new	B-X
avenues	B-X
towards	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
assets	B-X
to	B-X
achieve	B-X
durable	B-X
immune	B-X
control	B-X
of	B-X
cancer	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
tumor	B-X
immune	B-X
evasion	B-X
mechanisms	B-X
represents	B-X
a	B-X
challenge	B-X
for	B-X
the	B-X
development	B-X
of	B-X
efficient	B-X
treatment	B-X
options	B-X
.	B-X
Therefore	B-X
,	B-X
combination	B-X
therapies	B-X
are	B-X
taking	B-X
the	B-X
center	B-X
of	B-X
the	B-X
stage	B-X
in	B-X
immuno-oncology	B-X
.	B-X
Such	B-X
combination	B-X
therapies	B-X
should	B-X
boost	B-X
anti-tumor	B-X
immune	B-X
responses	B-X
and/or	B-X
target	B-X
tumor	B-X
immune	B-X
escape	B-X
mechanisms	B-X
,	B-X
especially	B-X
those	B-X
created	B-X
by	B-X
major	B-X
players	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
such	B-X
as	B-X
tumor-associated	B-X
macrophages	B-X
(	B-X
TAM	B-X
)	B-X
.	B-X
Natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
were	B-X
recently	B-X
positioned	B-X
at	B-X
the	B-X
forefront	B-X
of	B-X
many	B-X
immunotherapy	B-X
strategies	B-X
,	B-X
and	B-X
several	B-X
new	B-X
approaches	B-X
are	B-X
being	B-X
designed	B-X
to	B-X
fully	B-X
exploit	B-X
NK	B-X
cell	B-X
antitumor	B-X
potential	B-X
.	B-X
MICA	B-X
and	B-X
MICB	B-X
are	B-X
poorly	B-X
expressed	B-X
on	B-X
normal	B-X
cells	B-X
but	B-X
become	B-X
upregulated	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
damaged	B-X
,	B-X
transformed	B-X
or	B-X
infected	B-X
cells	B-X
as	B-X
a	B-X
result	B-X
of	B-X
post-transcriptional	B-X
or	B-X
post-translational	B-X
mechanisms	B-X
and	B-X
intracellular	B-X
pathways	B-X
.	B-X
Although	B-X
immunotherapeutic	B-X
approaches	B-X
that	B-X
target	B-X
the	B-X
NKG2D-NKG2DL	B-X
axis	B-X
are	B-X
under	B-X
investigation	B-X
,	B-X
several	B-X
tumor	B-X
immune	B-X
escape	B-X
mechanisms	B-X
account	B-X
for	B-X
reduced	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
NKG2DL	B-X
and	B-X
contribute	B-X
to	B-X
tumor	B-X
immune	B-X
escape	B-X
.	B-X
Also	B-X
,	B-X
NKG2DL	B-X
polymorphism	B-X
determines	B-X
functional	B-X
NKG2D-dependent	B-X
responses	B-X
,	B-X
thus	B-X
representing	B-X
an	B-X
additional	B-X
challenge	B-X
for	B-X
leveraging	B-X
NKG2DL	B-X
in	B-X
immuno-oncology	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
strategies	B-X
to	B-X
boost	B-X
MICA/B	B-X
expression	B-X
and/or	B-X
inhibit	B-X
their	B-X
shedding	B-X
and	B-X
propose	B-X
that	B-X
combination	B-X
strategies	B-X
that	B-X
target	B-X
MICA/B	B-X
with	B-X
antibodies	B-X
and	B-X
strategies	B-X
aimed	B-X
at	B-X
promoting	B-X
their	B-X
upregulation	B-X
on	B-X
tumor	B-X
cells	B-X
or	B-X
at	B-X
reprograming	B-X
TAM	B-X
into	B-X
pro-inflammatory	B-X
macrophages	B-X
and	B-X
remodeling	B-X
of	B-X
the	B-X
TME	B-X
,	B-X
emerge	B-X
as	B-X
frontrunners	B-X
in	B-X
immuno-oncology	B-X
because	B-X
they	B-X
may	B-X
unleash	B-X
the	B-X
antitumor	B-X
effector	B-X
functions	B-X
of	B-X
NK	B-X
cells	B-X
and	B-X
cytotoxic	B-X
CD8	B-X
T	B-X
cells	B-X
(	B-X
CTL	B-X
)	B-X
.	B-X

Initial	O
in	O
vivo	O
data	O
appears	O
to	O
support	O
this	O
notion	O
.	O
<EOS>	B-X
Recent	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
data	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
brief	B-X
periods	B-X
of	B-X
mechanical	B-X
compression	B-X
elicit	B-X
rapid	B-X
vasodilatation	B-X
.	B-X
TF	B-X
mediated	B-X
initiation	B-X
of	B-X
coagulation	B-X
appears	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
normal	B-X
hemostasis	B-X
and	B-X
probably	B-X
pathologic	B-X
thrombosis	B-X
as	B-X
well	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
LACI	B-X
appears	B-X
to	B-X
help	B-X
explain	B-X
the	B-X
clinical	B-X
need	B-X
for	B-X
both	B-X
``	B-X
extrinsic	B-X
''	B-X
and	B-X
``	B-X
intrinsic	B-X
''	B-X
coagulation	B-X
pathways	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
data	B-X
to	B-X
the	B-X
present	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
notion	B-X
that	B-X
,	B-X
in	B-X
normal	B-X
hemostasis	B-X
at	B-X
least	B-X
,	B-X
TF	B-X
is	B-X
responsible	B-X
for	B-X
an	B-X
initial	B-X
burst	B-X
of	B-X
factor	B-X
Xa	B-X
generation	B-X
which	B-X
provides	B-X
sufficient	B-X
thrombin	B-X
to	B-X
induce	B-X
the	B-X
aggregation	B-X
of	B-X
platelets	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
critical	B-X
coagulation	B-X
cofactors	B-X
factor	B-X
V	B-X
and	B-X
factor	B-X
VIII	B-X
.	B-X
Ultimate	B-X
and	B-X
persistent	B-X
hemostasis	B-X
,	B-X
however	B-X
,	B-X
appears	B-X
to	B-X
require	B-X
the	B-X
continued	B-X
production	B-X
of	B-X
additional	B-X
factor	B-X
Xa	B-X
through	B-X
the	B-X
action	B-X
of	B-X
factor	B-X
IXa	B-X
and	B-X
factor	B-X
VIII	B-X
.	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
this	B-X
factor	B-X
XIa	B-X
is	B-X
generated	B-X
in	B-X
vivo	B-X
,	B-X
however	B-X
,	B-X
has	B-X
not	B-X
been	B-X
determined	B-X
.	B-X
We	B-X
stress	B-X
that	B-X
the	B-X
predicted	B-X
in	B-X
vivo	B-X
role	B-X
of	B-X
LACI	B-X
is	B-X
simply	B-X
that	B-X
--	B-X
a	B-X
prediction	B-X
based	B-X
on	B-X
its	B-X
known	B-X
in	B-X
vitro	B-X
properties	B-X
.	B-X

Two	O
recent	O
papers	O
showed	O
that	O
the	O
loss	O
of	O
control	O
over	O
RIP1	B-Protein
/	O
RIP3	B-Protein
kinase	O
activities	O
by	O
FADD	B-Protein
and	O
caspase	B-Protein
-	I-Protein
8	I-Protein
in	O
epithelial	O
cells	O
unleashes	O
a	O
feed	O
forward	O
cycle	O
of	O
necroptosis	O
and	O
TNFalpha	B-Protein
production	O
,	O
resulting	O
in	O
the	O
development	O
of	O
intestinal	O
inflammation	O
in	O
mice	O
and	O
,	O
possibly	O
,	O
in	O
patients	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
.	O

This	O
increased	O
production	O
of	O
TNFalpha	B-Protein
during	O
necroptosis	O
may	O
also	O
be	O
important	O
for	O
acute	O
necrotizing	O
diseases	O
,	O
such	O
as	O
necrotizing	O
pancreatitis	O
and	O
acute	O
bacterial	O
infections	O
,	O
where	O
hyper	O
-	O
acute	O
inflammation	O
accompanying	O
necrotic	O
cell	O
death	O
is	O
the	O
primary	O
cause	O
of	O
multiple	O
organ	O
failure	O
and	O
patient	O
death	O
.	O

Along	O
these	O
lines	O
,	O
another	O
recent	O
paper	O
by	O
Duprez	O
et	O
al	O
.	O
has	O
shown	O
that	O
RIP1	B-Protein
and	O
RIP3	B-Protein
mediate	O
the	O
cellular	O
damage	O
introduced	O
by	O
TNF	O
-	O
induced	O
SIRS	O
[	O
6	O
]	O
.	O

The	O
role	O
of	O
RIP1	B-Protein
kinase	O
in	O
acute	O
and	O
chronic	O
inflammatory	O
diseases	O
warrants	O
further	O
investigation	O
,	O
as	O
efficient	O
and	O
specific	O
RIP1	B-Protein
kinase	O
inhibitors	O
may	O
offer	O
therapeutic	O
benefit	O
for	O
treating	O
these	O
conditions	O
.	O

Reagents	O
and	O
Chemicals	O
<EOS>	B-X
Recent	B-X
Uses	B-X
of	B-X
Reagents	B-X
with	B-X
a	B-X
wider	B-X
span	B-X
might	B-X
be	B-X
of	B-X
interest	B-X
.	B-X
Phenolphthalein	B-X
.	B-X
ortho-toluidine	B-X
.	B-X

Necrostatin	O
analogs	O
were	O
synthesized	O
as	O
previously	O
described	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
following	O
reagents	O
and	O
final	O
concentrations	O
(	O
unless	O
otherwise	O
specified	O
in	O
the	O
text	O
/	O
figures	O
)	O
were	O
used	O
in	O
the	O
experiments	O
:	O
Akt	O
inhibitor	O
VIII	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
MK	O
-	O
2206	O
(	O
10	O
microM	O
,	O
Selleck	O
Chem	O
)	O
,	O
Triciribine	O
(	O
100	O
microM	O
,	O
National	O
Cancer	O
Institute	O
)	O
,	O
SP600125	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
JNK	O
inhibitor	O
VIII	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
UO126	O
(	O
10	O
mM	O
,	O
Cayman	O
Chem	O
)	O
,	O
PD169316	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
LiCl	O
(	O
10	O
mM	O
,	O
Sigma	O
)	O
,	O
SB216763	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
BX912	O
(	O
10	O
microM	O
,	O
Axon	O
Med	O
Chem	O
)	O
,	O
PF	O
-	O
4706871	O
(	O
Sigma	O
)	O
,	O
rapamycin	O
(	O
100	O
nM	O
,	O
Santa	O
Cruz	O
)	O
,	O
PI	O
-	O
103	O
(	O
10	O
microM	O
,	O
Calbiochem	O
)	O
,	O
Torin	O
-	O
1	O
(	O
500	O
nM	O
,	O
gift	O
of	O
Dr	O
.	O
Nathanael	O
Grey	O
(	O
Harvard	O
Medical	O
School	O
)	O
,	O
LY249002	O
(	O
10	O
microM	O
,	O
Cell	O
Signaling	O
)	O
,	O
PD173074	O
(	O
2	O
microM	O
,	O
Cayman	O
Chem	O
)	O
,	O
PD166866	O
(	O
20	O
microM	O
,	O
Calbiochem	O
)	O
,	O
4EGI	O
-	O
1	O
(	O
50	O
microM	O
,	O
Calbiochem	O
)	O
.	O

Pan	O
-	O
caspase	O
inhibitor	O
zVAD	O
.	O
fmk	O
(	O
20	O
-	O
30	O
microM	O
)	O
was	O
purchased	O
from	O
Bachem	O
.	O

Human	O
and	O
mouse	O
TNFalpha	B-Protein
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
human	O
bFGF	B-Protein
(	O
25	O
ng	O
/	O
ml	O
)	O
,	O
EGF	B-Protein
(	O
50	O
ng	O
/	O
ml	O
)	O
,	O
PDGF	O
-	O
BB	O
(	O
20	O
ng	O
/	O
ml	O
)	O
,	O
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
(	O
50	O
ng	O
/	O
ml	O
)	O
were	O
from	O
Cell	O
Sciences	O
or	O
Peprotech	O
.	O
<EOS>	B-X
Plasma	B-X
IL-17A	B-X
detection	B-X
in	B-X
Langerhans	B-X
Cell	B-X
Histiocytosis	B-X
(	B-X
LCH	B-X
)	B-X
is	B-X
currently	B-X
a	B-X
source	B-X
of	B-X
debate	B-X
.	B-X
Indeed	B-X
,	B-X
500-P07G	B-X
(	B-X
PeproTech	B-X
)	B-X
and	B-X
41802	B-X
(	B-X
R	B-X
&	B-X
D	B-X
Systems	B-X
)	B-X
anti-IL-17A	B-X
antibodies	B-X
have	B-X
been	B-X
suspected	B-X
to	B-X
recognize	B-X
nonspecific	B-X
proteins	B-X
.	B-X
To	B-X
resolve	B-X
this	B-X
discrepancy	B-X
,	B-X
we	B-X
set	B-X
up	B-X
two	B-X
new	B-X
ELISAs	B-X
by	B-X
using	B-X
41802	B-X
or	B-X
neutralizing	B-X
eBio64CAP17	B-X
(	B-X
eBioscience	B-X
)	B-X
capture	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
we	B-X
compared	B-X
to	B-X
the	B-X
commercial	B-X
PeproTech	B-X
ELISA	B-X
kit	B-X
.	B-X
The	B-X
three	B-X
ELISAs	B-X
,	B-X
called	B-X
E_500-P07G	B-X
,	B-X
E_41802	B-X
and	B-X
E_eBio64CAP17	B-X
,	B-X
differ	B-X
in	B-X
their	B-X
anti-IL-17A	B-X
capture	B-X
antibodies	B-X
:	B-X
either	B-X
polyclonal	B-X
,	B-X
monoclonal	B-X
or	B-X
neutralizing	B-X
monoclonal	B-X
antibodies	B-X
,	B-X
respectively	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
these	B-X
ELISAs	B-X
had	B-X
a	B-X
similar	B-X
capacity	B-X
to	B-X
specifically	B-X
detect	B-X
recombinant	B-X
or	B-X
native	B-X
human	B-X
IL-17A	B-X
.	B-X
However	B-X
,	B-X
a	B-X
significantly	B-X
lower	B-X
plasma	B-X
IL-17A	B-X
detection	B-X
was	B-X
obtained	B-X
with	B-X
E_41802	B-X
compared	B-X
to	B-X
the	B-X
two	B-X
other	B-X
ELISAs	B-X
.	B-X
Both	B-X
E_500-P07G	B-X
and	B-X
E_eBio64CAP17	B-X
showed	B-X
similar	B-X
results	B-X
.	B-X
Consequently	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
use	B-X
of	B-X
E_500-P07G	B-X
and	B-X
E_eBio64CAP17	B-X
may	B-X
ensure	B-X
more	B-X
accurate	B-X
and	B-X
reliable	B-X
results	B-X
in	B-X
the	B-X
context	B-X
of	B-X
LCH	B-X
studies	B-X
.	B-X
The	B-X
highest	B-X
plasma	B-X
IL-17A	B-X
levels	B-X
in	B-X
LCH	B-X
patients	B-X
compared	B-X
to	B-X
controls	B-X
detected	B-X
by	B-X
both	B-X
E_500-P07G	B-X
and	B-X
E_eBio64CAP17	B-X
ELISAs	B-X
led	B-X
us	B-X
to	B-X
propose	B-X
these	B-X
latter	B-X
as	B-X
reference	B-X
techniques	B-X
to	B-X
investigate	B-X
IL-17A	B-X
as	B-X
a	B-X
potential	B-X
new	B-X
biomarker	B-X
in	B-X
LCH.•The	B-X
customization	B-X
of	B-X
a	B-X
new	B-X
E_eBio64CAP17	B-X
ELISA	B-X
is	B-X
suitable	B-X
to	B-X
detect	B-X
human	B-X
IL-17A.•E_eBio64CAP17	B-X
ELISA	B-X
protocol	B-X
differs	B-X
only	B-X
in	B-X
the	B-X
anti-IL-17A	B-X
capture	B-X
antibody	B-X
compared	B-X
to	B-X
the	B-X
commercial	B-X
E_500-P07G	B-X
PeproTech	B-X
kit.•Data	B-X
generated	B-X
using	B-X
the	B-X
E_eBio64CAP17	B-X
ELISA	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
PeproTech	B-X
kit	B-X
.	B-X

All	O
other	O
reagents	O
were	O
from	O
Sigma	O
.	O
<EOS>	B-X
Sigma	B-X
metrics	B-X
provide	B-X
an	B-X
objective	B-X
and	B-X
quantitative	B-X
methodology	B-X
for	B-X
analytical	B-X
quality	B-X
evaluation	B-X
of	B-X
clinical	B-X
laboratory	B-X
.	B-X
Sigma	B-X
receptors	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
a	B-X
myriad	B-X
of	B-X
cellular	B-X
functions	B-X
,	B-X
biological	B-X
processes	B-X
and	B-X
diseases	B-X
.	B-X
Sigma	B-X
receptors	B-X
have	B-X
recently	B-X
been	B-X
a	B-X
target	B-X
of	B-X
drug	B-X
development	B-X
related	B-X
to	B-X
psychiatric	B-X
and	B-X
neurological	B-X
disorders	B-X
.	B-X
Sigma	B-X
ligands	B-X
have	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
modulate	B-X
endothelial	B-X
cell	B-X
proliferation	B-X
and	B-X
can	B-X
control	B-X
angiogenesis	B-X
which	B-X
makes	B-X
them	B-X
a	B-X
promising	B-X
target	B-X
for	B-X
oncology	B-X
applications	B-X
.	B-X

DNA	O
<EOS>	B-X
The	B-X
widespread	B-X
circular	B-X
form	B-X
of	B-X
DNA	B-X
molecules	B-X
inside	B-X
cells	B-X
creates	B-X
very	B-X
serious	B-X
topological	B-X
problems	B-X
during	B-X
replication	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
helical	B-X
structure	B-X
of	B-X
the	B-X
double	B-X
helix	B-X
the	B-X
parental	B-X
strands	B-X
of	B-X
circular	B-X
DNA	B-X
form	B-X
a	B-X
link	B-X
of	B-X
very	B-X
high	B-X
order	B-X
,	B-X
and	B-X
yet	B-X
they	B-X
have	B-X
to	B-X
be	B-X
unlinked	B-X
before	B-X
the	B-X
cell	B-X
division	B-X
.	B-X
DNA	B-X
topoisomerases	B-X
,	B-X
the	B-X
enzymes	B-X
that	B-X
catalyze	B-X
passing	B-X
of	B-X
one	B-X
DNA	B-X
segment	B-X
through	B-X
another	B-X
,	B-X
solve	B-X
this	B-X
problem	B-X
in	B-X
principle	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
very	B-X
difficult	B-X
to	B-X
remove	B-X
all	B-X
entanglements	B-X
between	B-X
the	B-X
replicated	B-X
DNA	B-X
molecules	B-X
due	B-X
to	B-X
huge	B-X
length	B-X
of	B-X
DNA	B-X
comparing	B-X
to	B-X
the	B-X
cell	B-X
size	B-X
.	B-X
One	B-X
strategy	B-X
that	B-X
nature	B-X
uses	B-X
to	B-X
overcome	B-X
this	B-X
problem	B-X
is	B-X
to	B-X
create	B-X
the	B-X
topoisomerases	B-X
that	B-X
can	B-X
dramatically	B-X
reduce	B-X
the	B-X
fraction	B-X
of	B-X
linked	B-X
circular	B-X
DNA	B-X
molecules	B-X
relative	B-X
to	B-X
the	B-X
corresponding	B-X
fraction	B-X
at	B-X
thermodynamic	B-X
equilibrium	B-X
.	B-X
This	B-X
striking	B-X
property	B-X
of	B-X
the	B-X
enzymes	B-X
means	B-X
that	B-X
the	B-X
enzymes	B-X
that	B-X
interact	B-X
with	B-X
DNA	B-X
only	B-X
locally	B-X
can	B-X
access	B-X
their	B-X
topology	B-X
,	B-X
a	B-X
global	B-X
property	B-X
of	B-X
circular	B-X
DNA	B-X
molecules	B-X
.	B-X

Cloning	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein
,	O
containing	O
c	O
-	O
terminal	O
FLAG	O
tag	O
,	O
has	O
been	O
described	O
[	O
52	O
]	O
.	O

Myr	B-Protein
-	I-Protein
Akt1	I-Protein
-	I-Protein
FLAG	I-Protein
was	O
amplified	O
by	O
PCR	O
and	O
subcloned	O
into	O
the	O
BglII	O
and	O
EcoRI	O
sites	O
of	O
pMSCV	O
-	O
puro	O
retroviral	O
vector	O
(	O
Invitrogen	O
)	O
.	O

Mutant	O
versions	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein
were	O
generated	O
using	O
the	O
same	O
strategy	O
.	O

Antibodies	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
Structure	B-X
of	B-X
antibodies	B-X
.	B-X
Antibodies	B-X
can	B-X
also	B-X
be	B-X
modified	B-X
to	B-X
deliver	B-X
toxic	B-X
or	B-X
modulatory	B-X
payloads	B-X
(	B-X
small	B-X
molecules	B-X
,	B-X
radionuclides	B-X
and	B-X
enzymes	B-X
)	B-X
and	B-X
engineered	B-X
to	B-X
bind	B-X
multiple	B-X
epitopes	B-X
(	B-X
bispecifics	B-X
)	B-X
or	B-X
even	B-X
to	B-X
have	B-X
novel	B-X
catalytic	B-X
activity	B-X
(	B-X
abzymes	B-X
)	B-X
.	B-X

The	O
following	O
antibodies	O
were	O
used	O
:	O
phospho	O
-	O
Akt	O
(	O
Thr308	O
)	O
(	O
clone	O
C31E5E	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
Akt	O
(	O
Ser473	O
)	O
(	O
clone	O
D9E	O
)	O
XP	O
rabbit	O
mAb	O
,	O
Akt	O
(	O
pan	O
)	O
(	O
clone	O
C67E7	O
)	O
rabbit	O
mAb	O
,	O
Akt1	O
(	O
clone	O
C73H10	O
)	O
rabbit	O
mAb	O
,	O
Akt2	O
(	O
clone	O
D6G4	O
)	O
rabbit	O
mAb	O
,	O
Akt3	O
(	O
clone	O
62A8	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
JNK	O
(	O
Thr183	O
/	O
Tyr185	O
)	O
(	O
81E11	O
)	O
rabbit	O
mAb	O
,	O
SAPK	O
/	O
JNK	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
c	O
-	O
Jun	O
(	O
Ser63	O
)	O
II	O
rabbit	O
pAb	O
,	O
c	O
-	O
Jun	O
(	O
60A8	O
)	O
rabbit	O
mAb	O
,	O
alpha	O
-	O
tubulin	O
(	O
clone	O
DM1A	O
)	O
mouse	O
mAb	O
,	O
phospho	O
-	O
FoxO1	O
(	O
Thr24	O
)	O
/	O
FoxO3a	O
(	O
Thr32	O
)	O
rabbit	O
pAb	O
,	O
FoxO1	O
(	O
L27	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
FoxO4	O
(	O
Ser193	O
)	O
rabbit	O
pAb	O
,	O
FoxO4	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
MDM2	O
(	O
Ser166	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
GSK	O
-	O
3alpha	O
/	O
beta	O
(	O
Ser21	O
/	O
9	O
)	O
rabbit	O
pAb	O
,	O
phospho	O
-	O
p70	O
S6	O
Kinase	O
(	O
Thr389	O
)	O
(	O
clone	O
108D2	O
)	O
rabbit	O
mAb	O
,	O
phospho	O
-	O
S6	O
Ribosomal	O
Protein	O
(	O
Ser235	O
/	O
236	O
)	O
(	O
clone	O
D57	O
.	O
2	O
.	O
2E	O
)	O
XP	O
rabbit	O
mAb	O
,	O
S6	O
Ribosomal	O
Protein	O
(	O
clone	O
54D2	O
)	O
mouse	O
mAb	O
,	O
phospho	O
-	O
4E	O
-	O
BP1	O
(	O
Thr37	O
/	O
46	O
)	O
rabbit	O
pAb	O
,	O
mTOR	O
(	O
clone	O
7C10	O
)	O
rabbit	O
mAb	O
,	O
PDK1	O
rabbit	O
pAb	O
(	O
all	O
Cell	O
Signaling	O
)	O
,	O
MDM2	O
rabbit	O
pAb	O
(	O
Bioworlde	O
)	O
.	O

QPCR	O
Primers	O
<EOS>	B-X
Primers	B-X
are	B-X
critical	B-X
components	B-X
of	B-X
any	B-X
PCR	B-X
assay	B-X
,	B-X
as	B-X
they	B-X
are	B-X
the	B-X
main	B-X
determinants	B-X
of	B-X
its	B-X
specificity	B-X
,	B-X
sensitivity	B-X
,	B-X
and	B-X
robustness	B-X
.	B-X

Mouse	O
TNFalpha	B-Protein
:	O
forward	O
5	O
'	O
-	O
CCCTCACACTCAGATCATCTTCT	O
-	O
3	O
'	O
,	O
reverse	O
5	O
'	O
-	O
GCTACGACGTGGGCTACAG	O
-	O
3	O
'	O
;	O
mouse	O
18S	B-Protein
:	O
forward	O
5	O
-	O
'	O
ATAACAGGTCTGTGATGCCCTTAG	O
-	O
3	O
,	O
reverse	O
5	O
'	O
-	O
CTAAACCATCCAATCGGTAGTAGC	O
-	O
3	O
'	O
;	O
human	O
TNFalpha	B-Protein
:	O
forward	O
5	O
'	O
-	O
ATGAGCACTGAAAGCATGATCC	O
-	O
3	O
'	O
,	O
human	O
TNFalpha	B-Protein
:	O
reverse	O
5	O
'	O
-	O
GAGGGCTGATTAGAGAGAGGTC	O
-	O
3	O
'	O
;	O
human	O
18S	B-Protein
:	O
forward	O
5	O
'	O
-	O
CAGCCACCCGAGATTGAGCA	O
-	O
3	O
,	O
human	O
18S	B-Protein
:	O
reverse	O
5	O
'	O
-	O
TAGTAGCGACGGGCGGTGTG	O
-	O
3	O
'	O
.	O
<EOS>	B-X
Mouse	B-X
DCs	B-X
were	B-X
treated	B-X
with	B-X
LPS	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
rapamycin	B-X
(	B-X
100	B-X
nM	B-X
)	B-X
.	B-X
ROS	B-X
production	B-X
was	B-X
determined	B-X
from	B-X
2',7'-dichlorodihydrofluorescein	B-X
diacetate	B-X
(	B-X
DCFDA	B-X
)	B-X
fluorescence	B-X
,	B-X
cytosolic	B-X
pH	B-X
(	B-X
pH	B-X
(	B-X
i	B-X
)	B-X
)	B-X
from	B-X
2',7'-bis-	B-X
(	B-X
2-carboxyethyl	B-X
)	B-X
-5-	B-X
(	B-X
and-6	B-X
)	B-X
-carboxyfluorescein	B-X
(	B-X
BCECF	B-X
)	B-X
fluorescence	B-X
,	B-X
NHE	B-X
activity	B-X
from	B-X
the	B-X
Na	B-X
(	B-X
+	B-X
)	B-X
-dependent	B-X
realkalinization	B-X
following	B-X
an	B-X
ammonium	B-X
pulse	B-X
,	B-X
cell	B-X
volume	B-X
from	B-X
forward	B-X
scatter	B-X
in	B-X
FACS	B-X
analysis	B-X
,	B-X
and	B-X
TNF-α	B-X
production	B-X
utilizing	B-X
ELISA	B-X
.	B-X
LPS	B-X
stimulated	B-X
NHE	B-X
activity	B-X
,	B-X
enhanced	B-X
forward	B-X
scatter	B-X
,	B-X
increased	B-X
ROS	B-X
formation	B-X
,	B-X
and	B-X
triggered	B-X
TNF-α	B-X
release	B-X
,	B-X
effects	B-X
all	B-X
blunted	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
rapamycin	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
rapamycin	B-X
on	B-X
TNF-α	B-X
release	B-X
was	B-X
also	B-X
mimicked	B-X
by	B-X
the	B-X
antioxidant	B-X
ROS	B-X
scavenger	B-X
Tempol	B-X
(	B-X
30	B-X
μM	B-X
)	B-X
and	B-X
partially	B-X
reversed	B-X
by	B-X
additional	B-X
application	B-X
of	B-X
tert-butylhydroperoxide	B-X
(	B-X
10	B-X
μM	B-X
)	B-X
.	B-X

Cell	O
Lines	O
<EOS>	B-X
HeLa	B-X
cell	B-X
lines	B-X
.	B-X
Cell	B-X
lines	B-X
are	B-X
widely	B-X
used	B-X
in	B-X
biomedical	B-X
research	B-X
.	B-X
Cell	B-X
adhesion	B-X
,	B-X
as	B-X
dynamic	B-X
interactions	B-X
between	B-X
cell-cell	B-X
and	B-X
cell-matrix	B-X
,	B-X
has	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
cancer	B-X
cell	B-X
migration	B-X
.	B-X
An	B-X
Effect	B-X
of	B-X
Culture	B-X
Media	B-X
on	B-X
Epithelial	B-X
Differentiation	B-X
Markers	B-X
in	B-X
Breast	B-X
Cancer	B-X
Cell	B-X
Lines	B-X
MCF7	B-X
,	B-X
MDA-MB-436	B-X
and	B-X
SkBr3	B-X
.	B-X

L929	O
and	O
FADD	B-Protein
-	O
deficient	O
Jurkat	O
cells	O
were	O
obtained	O
from	O
ATCC	O
.	O

Lung	O
fibroblasts	O
were	O
a	O
generous	O
gift	O
of	O
Dr	O
.	O
Philip	O
Tsichlis	O
(	O
Tufts	O
University	O
)	O
[	O
53	O
]	O
.	O

J774A	O
.	O
1	O
(	O
ATCC	O
)	O
cells	O
and	O
RAW264	O
.	O
7	O
(	O
ATCC	O
)	O
cells	O
were	O
generous	O
gifts	O
of	O
Junying	O
Yuan	O
(	O
Harvard	O
University	O
)	O
and	O
Alexander	O
Poltorak	O
(	O
Tufts	O
University	O
)	O
,	O
respectively	O
.	O

Cells	O
were	O
maintained	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
mixture	O
(	O
Invitrogen	O
)	O
.	O

The	O
mouse	O
lung	O
fibroblast	O
media	O
was	O
additionally	O
supplemented	O
with	O
L	O
-	O
glutamine	O
,	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
and	O
sodium	O
pyruvate	O
.	O

Jurkat	O
cells	O
were	O
maintained	O
in	O
RPMI1640	O
,	O
supplemented	O
with	O
10	O
%	O
FetalPlex	O
(	O
Gemini	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
.	O

Cell	O
Viability	O
Experiments	O
<EOS>	B-X
Cell	B-X
viability	B-X
is	B-X
defined	B-X
as	B-X
the	B-X
number	B-X
of	B-X
healthy	B-X
cells	B-X
in	B-X
a	B-X
sample	B-X
and	B-X
proliferation	B-X
of	B-X
cells	B-X
is	B-X
a	B-X
vital	B-X
indicator	B-X
for	B-X
understanding	B-X
the	B-X
mechanisms	B-X
in	B-X
action	B-X
of	B-X
certain	B-X
genes	B-X
,	B-X
proteins	B-X
and	B-X
pathways	B-X
involved	B-X
cell	B-X
survival	B-X
or	B-X
death	B-X
after	B-X
exposing	B-X
to	B-X
toxic	B-X
agents	B-X
.	B-X
Cell	B-X
cytotoxicity	B-X
and	B-X
proliferation	B-X
assays	B-X
are	B-X
generally	B-X
used	B-X
for	B-X
drug	B-X
screening	B-X
to	B-X
detect	B-X
whether	B-X
the	B-X
test	B-X
molecules	B-X
have	B-X
effects	B-X
on	B-X
cell	B-X
proliferation	B-X
or	B-X
display	B-X
direct	B-X
cytotoxic	B-X
effects	B-X
.	B-X
Cell	B-X
viability	B-X
of	B-X
H9c2	B-X
cells	B-X
was	B-X
detected	B-X
by	B-X
MTT	B-X
assay	B-X
.	B-X
Cell	B-X
apoptosis	B-X
was	B-X
detected	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X

Cells	O
were	O
seeded	O
into	O
white	O
clear	O
bottom	O
96	O
well	O
plates	O
at	O
the	O
density	O
of	O
1x104	O
cells	O
/	O
well	O
and	O
treated	O
as	O
described	O
for	O
western	O
blot	O
experiments	O
.	O

Cell	O
viability	O
was	O
determined	O
using	O
CellTiter	O
-	O
Glo	O
Cell	O
Viability	O
Assay	O
(	O
Promega	O
)	O
.	O
<EOS>	B-X
However	B-X
,	B-X
since	B-X
the	B-X
inception	B-X
of	B-X
3D	B-X
systems	B-X
,	B-X
few	B-X
methods	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
successfully	B-X
analyze	B-X
cell	B-X
viability	B-X
quantitatively	B-X
within	B-X
hydrogel	B-X
constructs	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
describe	B-X
and	B-X
compare	B-X
commercially	B-X
available	B-X
viability	B-X
assays	B-X
developed	B-X
for	B-X
two-dimensional	B-X
(	B-X
2D	B-X
)	B-X
applications	B-X
for	B-X
use	B-X
in	B-X
3D	B-X
constructs	B-X
composed	B-X
of	B-X
organic	B-X
,	B-X
synthetic	B-X
,	B-X
or	B-X
hybrid	B-X
hydrogel	B-X
formulations	B-X
.	B-X
We	B-X
utilized	B-X
Promega	B-X
's	B-X
CellTiter-Glo	B-X
The	B-X
assay	B-X
,	B-X
ApoLive-Glo	B-X
(	B-X
Promega	B-X
)	B-X
,	B-X
measures	B-X
viability	B-X
of	B-X
drug-treated	B-X
,	B-X
reverse-transfected	B-X
cells	B-X
via	B-X
the	B-X
fluorescent	B-X
CellTiter-Fluor	B-X
reagent	B-X
,	B-X
which	B-X
includes	B-X
a	B-X
substrate	B-X
that	B-X
is	B-X
cleaved	B-X
by	B-X
a	B-X
live	B-X
cell	B-X
protease	B-X
.	B-X
ApoLive-Glo	B-X
also	B-X
quantitates	B-X
cell	B-X
death	B-X
by	B-X
the	B-X
amount	B-X
of	B-X
cleaved	B-X
caspases	B-X
3	B-X
and	B-X
7	B-X
using	B-X
a	B-X
luminescent	B-X
Caspase-Glo	B-X
3/7	B-X
caspase	B-X
activation	B-X
assay	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
a	B-X
high-content	B-X
imaging	B-X
protocol	B-X
involving	B-X
4',6-diamidino-2-phenylindole-stained	B-X
nuclei	B-X
is	B-X
used	B-X
as	B-X
a	B-X
cost-effective	B-X
way	B-X
to	B-X
quantitate	B-X
viability	B-X
of	B-X
vehicle-treated	B-X
control	B-X
cells	B-X
.	B-X
A	B-X
screen	B-X
using	B-X
these	B-X
assays	B-X
will	B-X
identify	B-X
gene	B-X
targets	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
viability	B-X
irrespective	B-X
of	B-X
drug	B-X
treatment	B-X
and	B-X
gene	B-X
targets	B-X
that	B-X
cause	B-X
a	B-X
synergistic	B-X
enhancement	B-X
of	B-X
cell	B-X
death	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
drug	B-X
.	B-X

Experiments	O
were	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
.	O
<EOS>	B-X
2B	B-X
appeared	B-X
to	B-X
have	B-X
been	B-X
duplicated	B-X
,	B-X
such	B-X
that	B-X
the	B-X
same	B-X
data	B-X
were	B-X
shown	B-X
to	B-X
represent	B-X
experiments	B-X
that	B-X
were	B-X
meant	B-X
to	B-X
have	B-X
been	B-X
performed	B-X
under	B-X
different	B-X
experimental	B-X
conditions	B-X
.	B-X
No	B-X
significant	B-X
differences	B-X
were	B-X
observed	B-X
between	B-X
the	B-X
duplicates	B-X
in	B-X
any	B-X
of	B-X
the	B-X
experiments	B-X
performed	B-X
.	B-X
Until	B-X
I	B-X
provided	B-X
video	B-X
,	B-X
my	B-X
claim	B-X
that	B-X
the	B-X
butterflies	B-X
duplicate	B-X
natural	B-X
post-alighting	B-X
host-assessment	B-X
behavior	B-X
when	B-X
placed	B-X
on	B-X
hosts	B-X
by	B-X
hand	B-X
was	B-X
not	B-X
credible	B-X
,	B-X
and	B-X
the	B-X
preference-testing	B-X
technique	B-X
that	B-X
I	B-X
had	B-X
developed	B-X
elicited	B-X
skepticism	B-X
,	B-X
anger	B-X
,	B-X
and	B-X
derision	B-X
.	B-X
A	B-X
literature	B-X
search	B-X
was	B-X
conducted	B-X
independently	B-X
and	B-X
in	B-X
duplicate	B-X
in	B-X
the	B-X
PubMed	B-X
and	B-X
LILACS	B-X
databases	B-X
.	B-X
The	B-X
methodological	B-X
quality	B-X
of	B-X
studies	B-X
was	B-X
assessed	B-X
independently	B-X
and	B-X
in	B-X
duplicate	B-X
by	B-X
using	B-X
the	B-X
AMSTAR	B-X
checklist	B-X
;	B-X
the	B-X
quality	B-X
was	B-X
scored	B-X
as	B-X
low	B-X
,	B-X
moderate	B-X
,	B-X
or	B-X
high	B-X
.	B-X
For	B-X
determining	B-X
the	B-X
need	B-X
for	B-X
additional	B-X
investigations	B-X
in	B-X
animals	B-X
and	B-X
in	B-X
order	B-X
to	B-X
provide	B-X
good	B-X
data	B-X
for	B-X
potential	B-X
application	B-X
in	B-X
human	B-X
,	B-X
such	B-X
reviews	B-X
should	B-X
be	B-X
based	B-X
on	B-X
animal	B-X
experiments	B-X
performed	B-X
according	B-X
to	B-X
sound	B-X
methodological	B-X
principles	B-X
.	B-X

Viability	O
of	O
the	O
control	O
untreated	O
cells	O
was	O
set	O
as	O
100	O
%	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
newly	B-X
developed	B-X
silicon	B-X
oxide	B-X
coatings	B-X
on	B-X
the	B-X
growth	B-X
of	B-X
endothelial	B-X
cells	B-X
was	B-X
therefore	B-X
the	B-X
goal	B-X
of	B-X
this	B-X
work	B-X
in	B-X
a	B-X
cell	B-X
culture	B-X
study	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
epoxy	B-X
resin-based	B-X
root	B-X
canal	B-X
filling	B-X
material	B-X
AH	B-X
Plus	B-X
,	B-X
the	B-X
compounds	B-X
paste	B-X
A	B-X
and	B-X
paste	B-X
B	B-X
were	B-X
tested	B-X
for	B-X
cytotoxicity	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
micronuclei	B-X
in	B-X
V79	B-X
cells	B-X
.	B-X
AH	B-X
Plus	B-X
was	B-X
tested	B-X
immediately	B-X
after	B-X
mixing	B-X
and	B-X
after	B-X
a	B-X
setting	B-X
time	B-X
of	B-X
24	B-X
h.	B-X
The	B-X
materials	B-X
were	B-X
eluted	B-X
in	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
and	B-X
physiologic	B-X
saline	B-X
for	B-X
24	B-X
h.	B-X
DMSO	B-X
eluates	B-X
of	B-X
the	B-X
mixed	B-X
material	B-X
,	B-X
paste	B-X
A	B-X
and	B-X
paste	B-X
B	B-X
clearly	B-X
reduced	B-X
the	B-X
viability	B-X
of	B-X
V79	B-X
cells	B-X
,	B-X
but	B-X
eluates	B-X
prepared	B-X
with	B-X
physiological	B-X
saline	B-X
were	B-X
at	B-X
least	B-X
10-100-fold	B-X
less	B-X
toxic	B-X
.	B-X
Likewise	B-X
,	B-X
freshly	B-X
mixed	B-X
AH	B-X
Plus	B-X
was	B-X
mutagenic	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
in	B-X
V79	B-X
cells	B-X
after	B-X
elution	B-X
in	B-X
dimethyl	B-X
sulfoxide	B-X
only	B-X
.	B-X
The	B-X
numbers	B-X
of	B-X
micronuclei	B-X
were	B-X
about	B-X
7-fold	B-X
higher	B-X
in	B-X
treated	B-X
cell	B-X
cultures	B-X
compared	B-X
with	B-X
untreated	B-X
controls	B-X
.	B-X
No	B-X
mutagenicity	B-X
was	B-X
observed	B-X
with	B-X
DMSO	B-X
and	B-X
physiological	B-X
saline	B-X
eluates	B-X
of	B-X
mixed	B-X
AH	B-X
Plus	B-X
set	B-X
for	B-X
24	B-X
h.	B-X
DMSO	B-X
eluates	B-X
of	B-X
paste	B-X
A	B-X
induced	B-X
effects	B-X
similar	B-X
to	B-X
the	B-X
freshly	B-X
mixed	B-X
AH	B-X
Plus	B-X
,	B-X
and	B-X
paste	B-X
B	B-X
was	B-X
not	B-X
effective	B-X
.	B-X

Relative	O
viability	O
of	O
cells	O
,	O
induced	O
to	O
undergo	O
necroptosis	O
and	O
treated	O
with	O
the	O
compound	O
relative	O
to	O
the	O
control	O
compound	O
-	O
treated	O
cells	O
,	O
was	O
determined	O
and	O
plotted	O
to	O
exclude	O
the	O
possible	O
effects	O
of	O
non	O
-	O
specific	O
toxicity	O
of	O
the	O
small	O
molecules	O
.	O

siRNA	O
Knockdown	O
<EOS>	B-X
The	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
is	B-X
based	B-X
on	B-X
post-transcriptional	B-X
gene	B-X
silencing	B-X
.	B-X
siRNA	B-X
molecules	B-X
are	B-X
usually	B-X
specific	B-X
and	B-X
efficient	B-X
in	B-X
the	B-X
knockdown	B-X
of	B-X
disease-related	B-X
genes	B-X
.	B-X
Therefore	B-X
,	B-X
siRNAs	B-X
require	B-X
a	B-X
carrier	B-X
for	B-X
their	B-X
protection	B-X
and	B-X
efficient	B-X
delivery	B-X
into	B-X
target	B-X
cells	B-X
.	B-X
The	B-X
current	B-X
review	B-X
highlights	B-X
the	B-X
siRNA-based	B-X
mechanism	B-X
of	B-X
action	B-X
,	B-X
challanges	B-X
,	B-X
and	B-X
recent	B-X
advances	B-X
in	B-X
clinical	B-X
applications	B-X
.	B-X

siRNAs	O
were	O
purchased	O
from	O
Dharmacon	O
.	O

Mouse	O
ribosomal	O
S6	O
protein	O
(	O
L	O
-	O
040893	O
-	O
00	O
and	O
L	O
-	O
045791	O
-	O
00	O
)	O
,	O
mouse	O
Akt1	B-Protein
(	O
L	O
-	O
040709	O
-	O
00	O
)	O
,	O
mouse	O
Akt2	B-Protein
(	O
L	O
-	O
040782	O
-	O
00	O
)	O
,	O
mouse	O
Akt3	B-Protein
(	O
L	O
-	O
040891	O
-	O
00	O
)	O
,	O
mouse	O
mTOR	O
(	O
L	O
-	O
065427	O
-	O
00	O
)	O
,	O
mouse	O
PDK1	B-Protein
(	O
L	O
-	O
040658	O
-	O
00	O
)	O
,	O
non	O
-	O
coding	O
control	O
(	O
D	O
-	O
001810	O
-	O
10	O
-	O
05	O
)	O
,	O
mouse	O
Mapk8	B-Protein
(	O
J	O
-	O
040128	O
-	O
05	O
)	O
,	O
mouse	O
Mapk9	B-Protein
(	O
J	O
-	O
040134	O
-	O
05	O
)	O
,	O
mouse	O
Jun	O
(	O
L	O
-	O
043776	O
-	O
00	O
)	O
.	O

siRNA	O
were	O
transfected	O
using	O
RNAiMAX	O
reagent	O
(	O
Invitrogen	O
)	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

After	O
72	O
hr	O
,	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
(	O
RNA	O
or	O
Western	O
blot	O
)	O
or	O
24	O
hr	O
(	O
cell	O
viability	O
)	O
.	O
<EOS>	B-X
Our	B-X
objective	B-X
was	B-X
to	B-X
examine	B-X
whether	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
could	B-X
aggravate	B-X
high	B-X
glucose-	B-X
(	B-X
HG-	B-X
)	B-X
and	B-X
hypoxia/reoxygenation-	B-X
(	B-X
H/R-	B-X
)	B-X
induced	B-X
injury	B-X
by	B-X
upregulating	B-X
ROS	B-X
production	B-X
to	B-X
activate	B-X
NLRP3	B-X
inflammasome-mediated	B-X
pyroptosis	B-X
in	B-X
H9C2	B-X
cardiomyocytes	B-X
.	B-X
H9C2	B-X
cardiomyocytes	B-X
were	B-X
exposed	B-X
to	B-X
HG	B-X
(	B-X
30	B-X
mM	B-X
)	B-X
condition	B-X
with	B-X
or	B-X
without	B-X
LPS	B-X
,	B-X
along	B-X
with	B-X
caspase-1	B-X
inhibitor	B-X
(	B-X
Ac-YVAD-CMK	B-X
)	B-X
,	B-X
inflammasome	B-X
inhibitor	B-X
(	B-X
BAY11-7082	B-X
)	B-X
,	B-X
ROS	B-X
scavenger	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
or	B-X
not	B-X
for	B-X
24	B-X
h	B-X
,	B-X
then	B-X
subjected	B-X
to	B-X
4	B-X
h	B-X
of	B-X
hypoxia	B-X
followed	B-X
by	B-X
2	B-X
h	B-X
of	B-X
reoxygenation	B-X
(	B-X
H/R	B-X
)	B-X
.	B-X
The	B-X
cell	B-X
viability	B-X
,	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
release	B-X
,	B-X
caspase-1	B-X
activity	B-X
,	B-X
and	B-X
intracellular	B-X
ROS	B-X
production	B-X
were	B-X
detected	B-X
by	B-X
using	B-X
assay	B-X
kits	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
gimeracil	B-X
enhances	B-X
the	B-X
efficacy	B-X
of	B-X
radiotherapy	B-X
through	B-X
the	B-X
suppression	B-X
of	B-X
homologous	B-X
recombination	B-X
(	B-X
HR	B-X
)	B-X
in	B-X
DNA	B-X
double	B-X
strand	B-X
repair	B-X
.	B-X

Western	O
Blot	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
involves	B-X
the	B-X
separation	B-X
of	B-X
proteins	B-X
by	B-X
gel	B-X
electrophoresis	B-X
,	B-X
their	B-X
blotting	B-X
or	B-X
transfer	B-X
to	B-X
a	B-X
membrane	B-X
,	B-X
and	B-X
selective	B-X
immunodetection	B-X
of	B-X
an	B-X
immobilized	B-X
antigen	B-X
.	B-X

For	O
Western	O
blot	O
,	O
4x105	O
adherent	O
cells	O
(	O
1x106	O
Jurkat	O
cells	O
)	O
were	O
seeded	O
into	O
35	O
mm2	O
dishes	O
.	O

After	O
24	O
-	O
48	O
hr	O
,	O
cells	O
were	O
stimulated	O
with	O
30	O
microM	O
zVAD	O
.	O
fmk	O
or	O
10	O
ng	O
/	O
ml	O
mouse	O
TNFalpha	B-Protein
.	O

For	O
treatments	O
under	O
serum	O
free	O
conditions	O
,	O
cells	O
were	O
serum	O
starved	O
for	O
24	O
hr	O
prior	O
to	O
the	O
addition	O
of	O
growth	O
factors	O
,	O
20	O
microM	O
zVAD	O
.	O
fmk	O
or	O
10	O
ng	O
/	O
ml	O
mouse	O
TNFalpha	B-Protein
.	O

Cells	O
were	O
harvested	O
in	O
1xRIPA	O
buffer	O
(	O
Cell	O
Signaling	O
)	O
supplemented	O
with	O
50	O
microg	O
/	O
ml	O
phenylmethanesulfonylfluoride	O
.	O

After	O
brief	O
sonication	O
,	O
cell	O
lysates	O
were	O
spun	O
down	O
for	O
15	O
min	O
at	O
14	O
,	O
000xrpm	O
.	O

Protein	O
concentrations	O
were	O
measured	O
using	O
the	O
Pierce	O
660	O
nm	O
Assay	O
Reagent	O
(	O
Pierce	O
)	O
.	O

Equal	O
amounts	O
of	O
proteins	O
were	O
boiled	O
for	O
5	O
min	O
at	O
95degreesC	O
.	O

Western	O
blotting	O
was	O
performed	O
according	O
to	O
standard	O
protocols	O
.	O
<EOS>	B-X
Myostatin	B-X
propeptide	B-X
is	B-X
prohibited	B-X
according	B-X
to	B-X
chapter	B-X
S4	B-X
of	B-X
the	B-X
``	B-X
WADA	B-X
2022	B-X
List	B-X
of	B-X
Prohibited	B-X
Substances	B-X
and	B-X
Methods	B-X
.	B-X
''	B-X
The	B-X
developed	B-X
detection	B-X
method	B-X
for	B-X
serum	B-X
is	B-X
based	B-X
on	B-X
immunoprecipitation	B-X
(	B-X
IP	B-X
)	B-X
followed	B-X
by	B-X
SDS-PAGE	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
All	B-X
of	B-X
them	B-X
were	B-X
well	B-X
suited	B-X
for	B-X
either	B-X
IP	B-X
or	B-X
immunoblotting	B-X
.	B-X
Furthermore	B-X
,	B-X
practically	B-X
all	B-X
currently	B-X
available	B-X
myostatin	B-X
propeptide	B-X
standards	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X

Briefly	O
,	O
SDS	O
-	O
PAGE	O
gels	O
were	O
transferred	O
to	O
PVDF	O
membrane	O
,	O
blocked	O
in	O
3	O
%	O
milk	O
or	O
5	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
TBST	O
buffer	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Primary	O
antibodies	O
were	O
incubated	O
in	O
5	O
%	O
BSA	O
/	O
TBST	O
overnight	O
at	O
4degreesC	O
.	O

Secondary	O
antibodies	O
were	O
incubated	O
in	O
TBST	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Luminata	O
(	O
Millipore	O
)	O
ECL	O
reagents	O
were	O
used	O
to	O
develop	O
the	O
signals	O
.	O

In	O
some	O
cases	O
,	O
membranes	O
were	O
stripped	O
using	O
OneMinute	O
stripping	O
buffer	O
(	O
GM	O
Biosciences	O
)	O
and	O
reprobed	O
with	O
new	O
antibodies	O
.	O

qRT	O
-	O
PCR	O
<EOS>	B-X
qRT-PCR	B-X
(	B-X
real-time	B-X
reverse	B-X
transcription-PCR	B-X
)	B-X
has	B-X
become	B-X
the	B-X
benchmark	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantification	B-X
of	B-X
RNA	B-X
targets	B-X
and	B-X
is	B-X
being	B-X
utilized	B-X
increasingly	B-X
in	B-X
novel	B-X
clinical	B-X
diagnostic	B-X
assays	B-X
.	B-X
qRT-PCR	B-X
assays	B-X
are	B-X
most	B-X
established	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
viral	B-X
load	B-X
and	B-X
therapy	B-X
monitoring	B-X
,	B-X
and	B-X
the	B-X
development	B-X
of	B-X
SARS	B-X
(	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
)	B-X
-associated	B-X
coronavirus	B-X
qRT-PCR	B-X
assays	B-X
provide	B-X
a	B-X
textbook	B-X
example	B-X
of	B-X
the	B-X
value	B-X
of	B-X
this	B-X
technology	B-X
for	B-X
clinical	B-X
diagnostics	B-X
.	B-X
The	B-X
widespread	B-X
use	B-X
of	B-X
qRT-PCR	B-X
assays	B-X
for	B-X
diagnosis	B-X
and	B-X
the	B-X
detection	B-X
of	B-X
disease-specific	B-X
prognostic	B-X
markers	B-X
in	B-X
leukaemia	B-X
patients	B-X
provide	B-X
further	B-X
examples	B-X
of	B-X
their	B-X
usefulness	B-X
.	B-X
This	B-X
is	B-X
because	B-X
of	B-X
conceptual	B-X
reservations	B-X
as	B-X
well	B-X
as	B-X
technical	B-X
limitations	B-X
that	B-X
can	B-X
interfere	B-X
with	B-X
the	B-X
diagnostic	B-X
specificity	B-X
of	B-X
qRT-PCR	B-X
assays	B-X
.	B-X
Therefore	B-X
,	B-X
although	B-X
it	B-X
is	B-X
evident	B-X
that	B-X
qRT-PCR	B-X
assay	B-X
has	B-X
become	B-X
a	B-X
useful	B-X
and	B-X
important	B-X
technology	B-X
in	B-X
the	B-X
clinical	B-X
diagnostic	B-X
laboratory	B-X
,	B-X
it	B-X
must	B-X
be	B-X
used	B-X
appropriately	B-X
and	B-X
it	B-X
is	B-X
essential	B-X
to	B-X
be	B-X
aware	B-X
of	B-X
its	B-X
limitations	B-X
if	B-X
it	B-X
is	B-X
to	B-X
fulfil	B-X
its	B-X
potential	B-X
.	B-X

Cells	O
were	O
treated	O
as	O
described	O
for	O
Western	O
blots	O
.	O
<EOS>	B-X
Most	B-X
C.	B-X
trachomatis	B-X
infections	B-X
remain	B-X
asymptomatic	B-X
(	B-X
>	B-X
50	B-X
%	B-X
)	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
untreated	B-X
,	B-X
leading	B-X
to	B-X
severe	B-X
reproductive	B-X
complications	B-X
in	B-X
both	B-X
women	B-X
and	B-X
men	B-X
,	B-X
like	B-X
infertility	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
described	B-X
the	B-X
application	B-X
of	B-X
In-Cell	B-X
Western	B-X
assay	B-X
(	B-X
ICW	B-X
)	B-X
via	B-X
Odyssey	B-X
CLx	B-X
as	B-X
a	B-X
fast	B-X
,	B-X
more	B-X
accessible	B-X
,	B-X
and	B-X
high-throughput	B-X
platform	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
C.	B-X
trachomatis	B-X
and	B-X
the	B-X
screening	B-X
of	B-X
anti-chlamydial	B-X
drugs	B-X
.	B-X
Electrotransfer	B-X
is	B-X
an	B-X
active	B-X
technique	B-X
used	B-X
in	B-X
Western	B-X
blots	B-X
and	B-X
other	B-X
gel-based	B-X
immunoassays	B-X
that	B-X
overcomes	B-X
limitations	B-X
of	B-X
size	B-X
exclusion	B-X
(	B-X
increasing	B-X
the	B-X
total	B-X
probe	B-X
mass	B-X
delivered	B-X
into	B-X
gel	B-X
)	B-X
and	B-X
expedites	B-X
probe	B-X
delivery	B-X
,	B-X
even	B-X
in	B-X
millimeter-thick	B-X
slab	B-X
gels	B-X
.	B-X
We	B-X
describe	B-X
grafting	B-X
nanoporous	B-X
membranes	B-X
to	B-X
thin-polyacrylamide-gel	B-X
layers	B-X
via	B-X
silanization	B-X
,	B-X
characterize	B-X
the	B-X
electrical	B-X
conductivity	B-X
of	B-X
silane-treated	B-X
nanoporous	B-X
membranes	B-X
,	B-X
and	B-X
report	B-X
the	B-X
dependence	B-X
of	B-X
in-gel	B-X
immunoprobe	B-X
concentration	B-X
on	B-X
transfer	B-X
duration	B-X
for	B-X
passive	B-X
diffusion	B-X
and	B-X
active	B-X
electrotransfer	B-X
.	B-X

Total	O
RNA	O
was	O
isolated	O
using	O
ZR	O
Miniprep	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O
<EOS>	B-X
DNA	B-X
extraction	B-X
was	B-X
performed	B-X
using	B-X
the	B-X
ZR	B-X
Fecal	B-X
DNA	B-X
MiniPrep™	B-X
kit	B-X
(	B-X
Zymo	B-X
Research	B-X
)	B-X
.	B-X
was	B-X
accomplished	B-X
using	B-X
nested	B-X
PCR	B-X
targeting	B-X
the	B-X
18S	B-X
RNA	B-X
gene	B-X
and	B-X
sequencing	B-X
of	B-X
amplified	B-X
fragments	B-X
.	B-X

1	O
microg	O
of	O
RNA	O
was	O
converted	O
to	O
cDNA	O
using	O
random	O
primers	O
(	O
M	O
-	O
MuLV	O
cDNA	O
kit	O
,	O
New	O
England	O
Biolabs	O
)	O
.	O

1	O
microL	O
of	O
cDNA	O
was	O
used	O
with	O
500	O
pM	O
primers	O
in	O
qPCR	O
reactions	O
.	O

Reactions	O
were	O
performs	O
using	O
SYBRGreen	O
2xMaster	O
mix	O
(	O
SABiosciences	O
)	O
in	O
a	O
LightCycler480	O
(	O
Roche	O
)	O
.	O

Stable	O
Infection	O
of	O
Myr	B-Protein
-	I-Protein
Akt1	I-Protein

To	O
generate	O
MSCV	O
retroviruses	O
,	O
HEK293FT	O
cells	O
(	O
Invitrogen	O
)	O
were	O
transfected	O
with	O
2	O
microg	O
of	O
viral	O
DNA	O
and	O
1	O
microg	O
of	O
gal	O
/	O
pol	O
and	O
VSV	O
-	O
G	O
accessory	O
plasmids	O
in	O
6	O
well	O
plates	O
using	O
GenJet	O
transfection	O
reagent	O
(	O
Signagen	O
Labs	O
)	O
.	O

Virus	O
-	O
containing	O
media	O
was	O
collected	O
72	O
hr	O
later	O
,	O
filtered	O
through	O
0	O
.	O
45	O
microm	O
filter	O
and	O
applied	O
to	O
L929	O
cells	O
with	O
8	O
microg	O
/	O
ml	O
polybrene	O
.	O

Cells	O
were	O
selected	O
and	O
maintained	O
in	O
10	O
microg	O
/	O
ml	O
puromycin	O
.	O

ELISAOne	O
Assay	O
<EOS>	B-X
Cell-based	B-X
screening	B-X
.	B-X
The	B-X
first	B-X
method	B-X
,	B-X
the	B-X
``	B-X
Macroscopic	B-X
Twitching	B-X
Assay	B-X
,	B-X
''	B-X
can	B-X
be	B-X
used	B-X
to	B-X
determine	B-X
if	B-X
a	B-X
strain	B-X
is	B-X
capable	B-X
of	B-X
twitching	B-X
motility	B-X
mediated	B-X
interstitial	B-X
colony	B-X
expansion	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
quantitatively	B-X
assess	B-X
the	B-X
influence	B-X
of	B-X
mutation	B-X
or	B-X
environmental	B-X
signals	B-X
on	B-X
this	B-X
process	B-X
.	B-X
The	B-X
second	B-X
method	B-X
,	B-X
the	B-X
``	B-X
Microscopic	B-X
Twitching	B-X
Assay	B-X
,	B-X
''	B-X
can	B-X
be	B-X
used	B-X
for	B-X
detailed	B-X
interrogation	B-X
of	B-X
the	B-X
movements	B-X
of	B-X
individual	B-X
cells	B-X
or	B-X
small	B-X
groups	B-X
of	B-X
bacteria	B-X
during	B-X
twitching	B-X
motility	B-X
mediated	B-X
colony	B-X
expansion	B-X
.	B-X
Microbiological	B-X
assay	B-X
of	B-X
ethambutol	B-X
.	B-X

ELISAOne	O
assays	O
(	O
TGRBio	O
,	O
Hindmarsh	O
,	O
Australia	O
)	O
were	O
performed	O
according	O
to	O
manufacturer	O
'	O
s	O
protocol	O
with	O
the	O
following	O
modifications	O
.	O

Cell	O
lysates	O
were	O
prepared	O
in	O
RIPA	O
buffer	O
as	O
described	O
for	O
Western	O
blots	O
.	O

Five	O
microliters	O
of	O
samples	O
were	O
diluted	O
in	O
45	O
microL	O
of	O
ELISAOne	O
lysis	O
buffer	O
prior	O
to	O
analysis	O
.	O

Primary	O
antibodies	O
to	O
phopsho	O
-	O
Thr308	O
and	O
phopsho	O
-	O
Ser473	O
were	O
incubated	O
with	O
the	O
samples	O
for	O
2	O
hr	O
at	O
room	O
temperature	O
.	O

Primary	O
antibody	O
to	O
pan	O
-	O
Akt	O
was	O
incubated	O
overnight	O
at	O
4degreesC	O
.	O

Signals	O
for	O
phospho	O
-	O
antibodies	O
were	O
normalized	O
based	O
on	O
pan	O
-	O
Akt	O
values	O
.	O
<EOS>	B-X
Because	B-X
cellular	B-X
phosphorylation	B-X
cascades	B-X
are	B-X
complex	B-X
multidirectional	B-X
pathways	B-X
,	B-X
the	B-X
behavior	B-X
of	B-X
a	B-X
drug	B-X
in	B-X
a	B-X
biochemical	B-X
enzyme	B-X
assay	B-X
may	B-X
not	B-X
accurately	B-X
reflect	B-X
its	B-X
performance	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
whole	B-X
cell	B-X
.	B-X
Following	B-X
stimulation	B-X
,	B-X
protein	B-X
phosphorylation	B-X
was	B-X
detected	B-X
immunohistochemically	B-X
by	B-X
simultaneous	B-X
staining	B-X
with	B-X
two	B-X
primary	B-X
antibodies	B-X
:	B-X
a	B-X
phospho-specific	B-X
primary	B-X
and	B-X
normalization	B-X
antibody	B-X
that	B-X
recognized	B-X
either	B-X
the	B-X
target	B-X
protein	B-X
regardless	B-X
of	B-X
phosphorylation	B-X
status	B-X
(	B-X
pan	B-X
protein	B-X
)	B-X
or	B-X
a	B-X
housekeeping	B-X
protein	B-X
.	B-X
Secondary	B-X
antibodies	B-X
labeled	B-X
with	B-X
two	B-X
spectrally	B-X
distinct	B-X
near-infrared	B-X
dyes	B-X
were	B-X
used	B-X
for	B-X
visualization	B-X
.	B-X
The	B-X
near-infrared	B-X
cytoblot	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
phosphorylation	B-X
of	B-X
EGFR	B-X
,	B-X
Akt	B-X
,	B-X
Stat3	B-X
,	B-X
MEK	B-X
1	B-X
,	B-X
and	B-X
ERK1/2	B-X
.	B-X
This	B-X
assay	B-X
format	B-X
was	B-X
also	B-X
able	B-X
to	B-X
simultaneously	B-X
assess	B-X
the	B-X
phosphorylation	B-X
of	B-X
multiple	B-X
signaling	B-X
proteins	B-X
in	B-X
response	B-X
to	B-X
known	B-X
kinase	B-X
inhibitors	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
the	B-X
receptor	B-X
and	B-X
its	B-X
effectors	B-X
show	B-X
different	B-X
IC50	B-X
values	B-X
for	B-X
the	B-X
same	B-X
inhibitory	B-X
drug	B-X
could	B-X
be	B-X
important	B-X
for	B-X
target	B-X
selection	B-X
in	B-X
drug	B-X
development	B-X
.	B-X

TNFalpha	B-Protein
ELISA	O
<EOS>	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
methods	B-X
of	B-X
cell	B-X
viability	B-X
assay	B-X
,	B-X
ELISA	B-X
assay	B-X
,	B-X
RT-PCR	B-X
,	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
for	B-X
estimating	B-X
LPS-induced	B-X
TNF-α	B-X
protein	B-X
expressions	B-X
are	B-X
described	B-X
in	B-X
detail	B-X
.	B-X
Although	B-X
human	B-X
myocardial	B-X
TNFalpha	B-X
levels	B-X
are	B-X
increased	B-X
during	B-X
the	B-X
ischemia	B-X
associated	B-X
with	B-X
chonic	B-X
heart	B-X
failure	B-X
,	B-X
it	B-X
remains	B-X
unknown	B-X
whether	B-X
an	B-X
acute	B-X
global	B-X
ischemic	B-X
insult	B-X
further	B-X
increases	B-X
TNFalpha	B-X
expression	B-X
in	B-X
human	B-X
cardiac	B-X
myocytes	B-X
.	B-X
To	B-X
study	B-X
this	B-X
,	B-X
biopsies	B-X
of	B-X
human	B-X
myocardium	B-X
were	B-X
obtained	B-X
before	B-X
and	B-X
after	B-X
cardiopulmonary	B-X
bypass	B-X
(	B-X
in	B-X
vivo	B-X
acute	B-X
global	B-X
ischemia	B-X
)	B-X
,	B-X
and	B-X
myocardial	B-X
TNFalpha	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
ELISA	B-X
and	B-X
cytotoxicity	B-X
assay	B-X
(	B-X
WEHI-164	B-X
clone	B-X
13	B-X
cell	B-X
line	B-X
)	B-X
.	B-X
TNFalpha	B-X
was	B-X
immunolocalized	B-X
by	B-X
immunohistochemistry	B-X
.	B-X
Results	B-X
indicate	B-X
that	B-X
cardiopulmonary	B-X
bypass	B-X
induces	B-X
an	B-X
increase	B-X
in	B-X
human	B-X
myocardial	B-X
TNFalpha	B-X
by	B-X
both	B-X
ELISA	B-X
and	B-X
cytotoxicity	B-X
assays	B-X
.	B-X
Immunolocalization	B-X
revealed	B-X
that	B-X
prior	B-X
to	B-X
cardiopulmonary	B-X
bypass	B-X
TNFalpha	B-X
was	B-X
located	B-X
predominantly	B-X
in	B-X
the	B-X
myocardial	B-X
interstitial	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
following	B-X
bypass	B-X
,	B-X
increased	B-X
TNFalpha	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
cardiocytes	B-X
themselves	B-X
.	B-X
Locally-produced	B-X
myocardial	B-X
TNFalpha	B-X
may	B-X
be	B-X
an	B-X
important	B-X
contributor	B-X
to	B-X
myocardial	B-X
functional	B-X
depression	B-X
and	B-X
injury	B-X
following	B-X
acute	B-X
ischemia	B-X
.	B-X
Targeted	B-X
anti-TNFalpha	B-X
therapy	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cardiac	B-X
ischemic	B-X
injury	B-X
may	B-X
further	B-X
elucidate	B-X
its	B-X
clinical	B-X
relevance	B-X
.	B-X

Mouse	O
TNFalpha	B-Protein
Quantikine	O
ELISA	O
assays	O
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
performed	O
according	O
to	O
manufacturer	O
'	O
s	O
descriptions	O
.	O

Cell	O
lysates	O
were	O
prepared	O
from	O
3x106	O
cells	O
plated	O
and	O
treated	O
in	O
a	O
10	O
cm2	O
dish	O
.	O

In	O
vitro	O
Akt	O
Kinase	O
Assay	O
<EOS>	B-X
The	B-X
study	B-X
aimed	B-X
to	B-X
explore	B-X
the	B-X
anti-cancer	B-X
role	B-X
of	B-X
marmesin	B-X
using	B-X
EC	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
also	B-X
inhibited	B-X
the	B-X
levels	B-X
of	B-X
phospho	B-X
(	B-X
p	B-X
)	B-X
-phosphatidylinositol	B-X
3-kinase	B-X
and	B-X
p-Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
present	B-X
study	B-X
exhibited	B-X
the	B-X
positive	B-X
role	B-X
of	B-X
geraniin	B-X
in	B-X
inhibiting	B-X
proliferation	B-X
and	B-X
inducing	B-X
apoptosis	B-X
through	B-X
suppression	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase/Akt	B-X
pathway	B-X
in	B-X
colorectal	B-X
cancer	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
,	B-X
which	B-X
might	B-X
provide	B-X
new	B-X
insights	B-X
in	B-X
searching	B-X
for	B-X
new	B-X
drug	B-X
candidates	B-X
of	B-X
anticolorectal	B-X
cancer	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
microRNA-126	B-X
(	B-X
miR-126	B-X
)	B-X
inhibits	B-X
SLK	B-X
cell	B-X
proliferation	B-X
,	B-X
inhibits	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
induces	B-X
cell	B-X
apoptosis	B-X
,	B-X
and	B-X
reduces	B-X
cell	B-X
invasiveness	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
miR-126	B-X
negatively	B-X
regulated	B-X
AKT1	B-X
expression	B-X
but	B-X
no	B-X
regulation	B-X
of	B-X
PTEN	B-X
expression	B-X
was	B-X
evident	B-X
.	B-X

Akt	O
kinase	O
activity	O
was	O
measured	O
using	O
the	O
Akt	O
kinase	O
assay	O
kit	O
(	O
nonradioactive	O
)	O
from	O
Cell	O
Signaling	O
Technology	O
.	O

In	O
brief	O
,	O
Myr	B-Protein
-	I-Protein
Akt	I-Protein
was	O
immunoprecipitated	O
from	O
L929	O
cells	O
using	O
anti	O
-	O
FLAG	O
M2	O
magnetic	O
beads	O
(	O
Sigma	O
)	O
.	O

The	O
in	O
vitro	O
assay	O
was	O
performed	O
in	O
the	O
presence	O
of	O
a	O
GSK	O
fusion	O
protein	O
substrate	O
.	O

Phosphorylation	O
of	O
the	O
GSK	O
fusion	O
protein	O
was	O
visualized	O
by	O
western	O
blot	O
.	O

bFGF	B-Protein
and	O
IGF	B-Protein
-	I-Protein
1	I-Protein
promote	O
necroptosis	O
in	O
concert	O
with	O
zVAD	O
.	O
fmk	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
TNFalpha	B-Protein
or	O
zVAD	O
.	O
fmk	O
under	O
normal	O
serum	O
(	O
10	O
%	O
FBS	O
)	O
or	O
serum	O
free	O
conditions	O
.	O
<EOS>	B-X
Measurements	B-X
of	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
synthesized	B-X
by	B-X
trophoblast	B-X
cells	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
of	B-X
pregnancy	B-X
monitoring	B-X
.	B-X
In	B-X
urine	B-X
and	B-X
serum	B-X
of	B-X
both	B-X
pregnant	B-X
women	B-X
and	B-X
tumors	B-X
patients	B-X
a	B-X
fifteen	B-X
various	B-X
forms	B-X
of	B-X
hCG	B-X
,	B-X
such	B-X
as	B-X
:	B-X
regular	B-X
hCG	B-X
,	B-X
hyperglycosylated	B-X
hCG	B-X
and	B-X
predominant	B-X
hyperglycosylated	B-X
hCG	B-X
free	B-X
β	B-X
,	B-X
were	B-X
identified	B-X
.	B-X
To	B-X
better	B-X
study	B-X
microglia	B-X
and	B-X
the	B-X
properties	B-X
that	B-X
distinguish	B-X
them	B-X
from	B-X
other	B-X
tissue	B-X
macrophage	B-X
populations	B-X
,	B-X
we	B-X
have	B-X
optimized	B-X
serum-free	B-X
culture	B-X
conditions	B-X
to	B-X
permit	B-X
robust	B-X
survival	B-X
of	B-X
highly	B-X
ramified	B-X
adult	B-X
microglia	B-X
under	B-X
defined-medium	B-X
conditions	B-X
.	B-X
Using	B-X
microglial	B-X
cultures	B-X
that	B-X
have	B-X
never	B-X
been	B-X
exposed	B-X
to	B-X
serum	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
dramatic	B-X
and	B-X
lasting	B-X
change	B-X
in	B-X
phagocytic	B-X
capacity	B-X
after	B-X
serum	B-X
exposure	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
find	B-X
that	B-X
mature	B-X
microglia	B-X
rapidly	B-X
lose	B-X
signature	B-X
gene	B-X
expression	B-X
after	B-X
isolation	B-X
,	B-X
and	B-X
that	B-X
this	B-X
loss	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
engrafting	B-X
cells	B-X
back	B-X
into	B-X
an	B-X
intact	B-X
CNS	B-X
environment	B-X
.	B-X

Cell	O
viability	O
was	O
determined	O
after	O
24	O
hr	O
using	O
the	O
CellTiter	O
-	O
Glo	O
Viability	O
assay	O
.	O

The	O
concentrations	O
of	O
all	O
necroptosis	O
-	O
inducing	O
agents	O
are	O
listed	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
or	O
indicated	O
in	O
the	O
figures	O
.	O
<EOS>	B-X
Many	B-X
example	B-X
figures	B-X
are	B-X
supplied	B-X
to	B-X
give	B-X
the	B-X
reader	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
author	B-X
believes	B-X
compensation	B-X
should	B-X
be	B-X
handled	B-X
.	B-X
Counting	B-X
mitotic	B-X
figures	B-X
(	B-X
MF	B-X
)	B-X
in	B-X
hematoxylin	B-X
and	B-X
eosin-stained	B-X
histologic	B-X
sections	B-X
is	B-X
an	B-X
integral	B-X
part	B-X
of	B-X
the	B-X
diagnostic	B-X
pathologist	B-X
's	B-X
tumor	B-X
evaluation	B-X
.	B-X
(	B-X
2002	B-X
)	B-X
,	B-X
Figures	B-X
2	B-X
,	B-X
3	B-X
and	B-X
6	B-X
contain	B-X
northern	B-X
or	B-X
western	B-X
blot	B-X
images	B-X
comprising	B-X
spliced	B-X
lanes	B-X
that	B-X
were	B-X
not	B-X
indicated	B-X
in	B-X
the	B-X
original	B-X
Figures	B-X
,	B-X
and	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
editors	B-X
,	B-X
we	B-X
have	B-X
decided	B-X
to	B-X
replace	B-X
these	B-X
figures	B-X
with	B-X
updated	B-X
versions	B-X
in	B-X
which	B-X
the	B-X
spliced	B-X
lanes	B-X
are	B-X
now	B-X
clearly	B-X
indicated	B-X
by	B-X
white	B-X
vertical	B-X
bars	B-X
.	B-X
While	B-X
correcting	B-X
these	B-X
figures	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
one	B-X
panel	B-X
of	B-X
Figure	B-X
2c	B-X
was	B-X
also	B-X
incorrect	B-X
and	B-X
this	B-X
has	B-X
been	B-X
replaced	B-X
with	B-X
the	B-X
correct	B-X
panel	B-X
.	B-X

(	O
B	O
)	O
Cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
,	O
the	O
indicated	O
growth	O
factors	O
,	O
and	O
Nec	O
-	O
1	O
under	O
serum	O
free	O
conditions	O
for	O
24	O
hrs	O
followed	O
by	O
measurement	O
of	O
cell	O
viability	O
.	O

(	O
C	O
)	O
Cells	O
under	O
serum	O
free	O
conditions	O
were	O
treated	O
with	O
FGF	O
,	O
zVAD	O
.	O
fmk	O
,	O
or	O
both	O
for	O
24	O
hrs	O
followed	O
by	O
viability	O
assay	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
toxicity	B-X
of	B-X
Afriplex	B-X
TM	B-X
GRT	B-X
in	B-X
HepG2/C3A	B-X
cells	B-X
and	B-X
Sprague	B-X
Dawley	B-X
rats	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
biodegradable	B-X
,	B-X
and	B-X
biocompatible	B-X
nanocarrier	B-X
``	B-X
polybutylcyanoacrylate	B-X
''	B-X
(	B-X
PBCA	B-X
)	B-X
loaded	B-X
with	B-X
strontium	B-X
was	B-X
constructed	B-X
and	B-X
its	B-X
ability	B-X
to	B-X
promote	B-X
bone	B-X
formation	B-X
was	B-X
assessed	B-X
.	B-X
In	B-X
the	B-X
present	B-X
investigation	B-X
cytotoxicity	B-X
and	B-X
radiosensitizing	B-X
activity	B-X
of	B-X
2,4-dinitrobenzyl	B-X
,	B-X
2,4-dinitrobenzoyl	B-X
,	B-X
and	B-X
2,4-dinitrophenacetyl	B-X
derivatives	B-X
of	B-X
5-fluorouracil	B-X
which	B-X
was	B-X
assumed	B-X
to	B-X
release	B-X
cytotoxic	B-X
active	B-X
quinone	B-X
methidide	B-X
and	B-X
5-fluorouracil	B-X
under	B-X
hypoxic	B-X
conditions	B-X
on	B-X
HT-29	B-X
cell	B-X
line	B-X
under	B-X
both	B-X
aerobic	B-X
and	B-X
hypoxic	B-X
conditions	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
solar	B-X
disinfection	B-X
on	B-X
the	B-X
viability	B-X
of	B-X
intestinal	B-X
protozoa	B-X
Giardia	B-X
lamblia	B-X
,	B-X
Microsporidia	B-X
sp.	B-X
,	B-X
Cryptosporidium	B-X
parvum	B-X
,	B-X
Cyclospora	B-X
cyatenensis	B-X
and	B-X
Entamoeba	B-X
histolytica	B-X
in	B-X
drinking	B-X
water	B-X
was	B-X
studied	B-X
as	B-X
compared	B-X
to	B-X
chlorine	B-X
disinfection	B-X
.	B-X
Chlorinated	B-X
water	B-X
samples	B-X
were	B-X
prepared	B-X
at	B-X
concentration	B-X
of	B-X
4	B-X
ppm	B-X
,	B-X
and	B-X
the	B-X
parasites	B-X
were	B-X
incubated	B-X
overnight	B-X
at	B-X
room	B-X
temperature	B-X
with	B-X
the	B-X
treated	B-X
water	B-X
.	B-X
Sun	B-X
treatment	B-X
was	B-X
applied	B-X
for	B-X
2	B-X
exposures	B-X
(	B-X
6	B-X
&	B-X
24	B-X
hrs	B-X
)	B-X
,	B-X
in	B-X
summer	B-X
and	B-X
winter	B-X
.	B-X
Sun	B-X
treated	B-X
water	B-X
samples	B-X
were	B-X
put	B-X
in	B-X
tubes	B-X
and	B-X
exposed	B-X
to	B-X
sun	B-X
.	B-X
Parasites	B-X
viability	B-X
was	B-X
assessed	B-X
by	B-X
viability	B-X
assay	B-X
using	B-X
trypan	B-X
blue	B-X
stain	B-X
(	B-X
0.4	B-X
%	B-X
)	B-X
,	B-X
and	B-X
bioassay	B-X
infectivity	B-X
tests	B-X
in	B-X
experimentally	B-X
laboratory	B-X
bred	B-X
mice	B-X
.	B-X
Results	B-X
proved	B-X
that	B-X
all	B-X
parasites	B-X
'	B-X
viability	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
chlorine	B-X
,	B-X
following	B-X
solar	B-X
disinfection	B-X
treatment	B-X
,	B-X
parasites	B-X
became	B-X
dark	B-X
blue	B-X
in	B-X
colour	B-X
and	B-X
deformed	B-X
by	B-X
trypan	B-X
blue	B-X
stain	B-X
.	B-X
Bioassay	B-X
infectivity	B-X
test	B-X
showed	B-X
a	B-X
statistically	B-X
significant	B-X
reduction	B-X
in	B-X
mean	B-X
number	B-X
of	B-X
all	B-X
parasites	B-X
in	B-X
intestinal	B-X
sections	B-X
compared	B-X
to	B-X
controls	B-X
.	B-X
The	B-X
best	B-X
results	B-X
were	B-X
tubes	B-X
exposure	B-X
to	B-X
sun	B-X
for	B-X
24	B-X
hrs	B-X
in	B-X
summer	B-X
,	B-X
where	B-X
G.	B-X
lamblia	B-X
,	B-X
C.	B-X
parvum	B-X
and	B-X
C.	B-X
cyatenensis	B-X
were	B-X
inactivated	B-X
or	B-X
absence	B-X
in	B-X
intestinal	B-X
sections	B-X
.	B-X
No	B-X
statistically	B-X
significant	B-X
difference	B-X
was	B-X
between	B-X
the	B-X
use	B-X
of	B-X
plastic	B-X
and	B-X
glass	B-X
tubes	B-X
,	B-X
either	B-X
in	B-X
chlorine	B-X
or	B-X
sun	B-X
treated	B-X
parasites	B-X
.	B-X

(	O
D	O
)	O
Cell	O
death	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
under	O
full	O
serum	O
condition	O
in	O
the	O
presence	O
of	O
2	O
microM	O
PD173074	O
and	O
20	O
microM	O
PD166866	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

Akt	O
contributes	O
to	O
necroptosis	O
induced	O
by	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
necroptosis	B-X
in	B-X
myocardial	B-X
injury	B-X
has	B-X
not	B-X
been	B-X
fully	B-X
characterized	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
roles	B-X
of	B-X
mitochondrial	B-X
permeability	B-X
transition	B-X
pore	B-X
(	B-X
mPTP	B-X
)	B-X
and	B-X
autophagy	B-X
in	B-X
necroptosis	B-X
of	B-X
cardiomyocytes	B-X
.	B-X

(	O
A	O
,	O
B	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
full	O
serum	O
,	O
A	O
)	O
or	O
growth	O
factors	O
/	O
zVAD	O
.	O
fmk	O
(	O
serum	O
free	O
,	O
B	O
)	O
in	O
the	O
presence	O
of	O
inhibitors	O
of	O
Akt	O
(	O
Akt	O
inhibitor	O
VIII	O
)	O
,	O
JNK	O
(	O
SP600125	O
)	O
,	O
p38	O
(	O
PD169316	O
)	O
,	O
and	O
Erk	O
(	O
UO126	O
)	O
.	O

Cell	O
viability	O
was	O
determined	O
after	O
24	O
hrs	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
analyze	B-X
cell	B-X
viability	B-X
and	B-X
gene	B-X
expression	B-X
interleukin	B-X
6	B-X
and	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
after	B-X
continuous	B-X
ultrasound	B-X
therapy	B-X
of	B-X
1	B-X
and	B-X
3	B-X
MHz	B-X
in	B-X
L929	B-X
fibroblast	B-X
cells	B-X
.	B-X
Mouse	B-X
striatal	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
various	B-X
concentrations	B-X
of	B-X
ketamine	B-X
(	B-X
10	B-X
μM	B-X
,	B-X
100	B-X
μM	B-X
,	B-X
1	B-X
mM	B-X
)	B-X
or	B-X
DMEM	B-X
for	B-X
9-72	B-X
hrs	B-X
.	B-X
Cell	B-X
viability	B-X
was	B-X
assessed	B-X
using	B-X
the	B-X
MTT	B-X
assay	B-X
,	B-X
and	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
of	B-X
ER	B-X
stress	B-X
markers	B-X
were	B-X
evaluated	B-X
using	B-X
RT-qPCR	B-X
.	B-X
MTT	B-X
results	B-X
revealed	B-X
that	B-X
1	B-X
mM	B-X
ketamine	B-X
decreased	B-X
cell	B-X
viability	B-X
in	B-X
striatal	B-X
cells	B-X
after	B-X
24	B-X
h	B-X
of	B-X
treatment	B-X
.	B-X

(	O
C	O
)	O
L929	O
cells	O
transfected	O
with	O
Akt1	B-Protein
,	O
Akt2	B-Protein
,	O
and	O
Akt3	B-Protein
siRNAs	I-Protein
for	O
72	O
hrs	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hrs	O
.	O
<EOS>	B-X
Because	B-X
low-grade	B-X
inflammation	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
coronary	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
,	B-X
and	B-X
pro-inflammatory	B-X
cytokines	B-X
govern	B-X
inflammatory	B-X
cascades	B-X
,	B-X
this	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
associations	B-X
of	B-X
several	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
CHD	B-X
risk	B-X
in	B-X
a	B-X
new	B-X
prospective	B-X
study	B-X
,	B-X
including	B-X
meta-analysis	B-X
of	B-X
prospective	B-X
studies	B-X
.	B-X
Cytokines	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
lymphomas	B-X
via	B-X
an	B-X
autocrine	B-X
or	B-X
a	B-X
paracrine	B-X
mechanism	B-X
,	B-X
or	B-X
both	B-X
.	B-X
Determination	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
cytokines	B-X
on	B-X
the	B-X
growth	B-X
or	B-X
differentiation	B-X
of	B-X
lymphoma	B-X
cells	B-X
is	B-X
often	B-X
complicated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
more	B-X
than	B-X
one	B-X
cytokine	B-X
is	B-X
responsible	B-X
,	B-X
and	B-X
by	B-X
the	B-X
failure	B-X
of	B-X
anti-cytokine	B-X
antibodies	B-X
or	B-X
antisense	B-X
oligonucleotides	B-X
to	B-X
block	B-X
the	B-X
proliferation	B-X
in	B-X
vitro	B-X
of	B-X
lymphoma	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
IL-6	B-X
and/or	B-X
IL-9	B-X
may	B-X
play	B-X
a	B-X
prominent	B-X
role	B-X
in	B-X
the	B-X
tumor	B-X
cell	B-X
proliferation	B-X
of	B-X
Hodgkin	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
,	B-X
anaplastic	B-X
large-cell	B-X
lymphoma	B-X
,	B-X
or	B-X
immunoblastic	B-X
lymphoma	B-X
.	B-X
IL-6	B-X
may	B-X
also	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
plasmacytoid	B-X
differentiation	B-X
of	B-X
lymphoma	B-X
cells	B-X
in	B-X
polymorphic	B-X
immunocytoma	B-X
.	B-X
The	B-X
malignant	B-X
(	B-X
H-RS	B-X
)	B-X
cells	B-X
of	B-X
HD	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
express	B-X
IL-1	B-X
,	B-X
IL-5	B-X
,	B-X
IL-6	B-X
,	B-X
IL-9	B-X
,	B-X
TNF-alpha	B-X
,	B-X
M-CSF	B-X
,	B-X
TGF-beta	B-X
,	B-X
and	B-X
CD80	B-X
,	B-X
and	B-X
,	B-X
less	B-X
frequently	B-X
,	B-X
IL-4	B-X
and	B-X
G-CSF	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
H-RS	B-X
cells	B-X
,	B-X
most	B-X
non-HD	B-X
lymphoma	B-X
cells	B-X
do	B-X
not	B-X
produce	B-X
cytokines	B-X
in	B-X
excess	B-X
amounts	B-X
and	B-X
reveal	B-X
only	B-X
a	B-X
minimal	B-X
cellular	B-X
reaction	B-X
.	B-X

Cell	O
viability	O
and	O
Akt	O
expression	O
levels	O
were	O
determined	O
after	O
24	O
hrs	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

RIP1	B-Protein
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
Akt	O
and	O
JNK	O
during	O
necroptosis	O
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
assay	B-X
with	B-X
Annexin	B-X
V-FITC	B-X
and	B-X
PI	B-X
demonstrated	B-X
that	B-X
emodin	B-X
induces	B-X
necroptosis	B-X
,	B-X
but	B-X
not	B-X
apoptosis	B-X
,	B-X
in	B-X
renal	B-X
cancer	B-X
cells	B-X
.	B-X
Meanwhile	B-X
,	B-X
the	B-X
phosphorylation	B-X
levels	B-X
of	B-X
RIP1	B-X
and	B-X
MLKL	B-X
,	B-X
the	B-X
key	B-X
necroptosis-related	B-X
proteins	B-X
,	B-X
were	B-X
significantly	B-X
increased	B-X
.	B-X
To	B-X
explore	B-X
how	B-X
emodin	B-X
inhibits	B-X
kidney	B-X
tumor	B-X
growth	B-X
,	B-X
we	B-X
tested	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
levels	B-X
and	B-X
found	B-X
that	B-X
the	B-X
levels	B-X
of	B-X
ROS	B-X
increased	B-X
upon	B-X
emodin	B-X
treatment	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
Further	B-X
studies	B-X
demonstrated	B-X
that	B-X
emodin	B-X
induces	B-X
necroptosis	B-X
through	B-X
ROS-mediated	B-X
activation	B-X
of	B-X
JNK	B-X
signaling	B-X
pathway	B-X
and	B-X
also	B-X
inhibits	B-X
glycolysis	B-X
by	B-X
downregulation	B-X
of	B-X
GLUT1	B-X
through	B-X
ROS-mediated	B-X
inactivation	B-X
of	B-X
the	B-X
PI3K/AKT	B-X
signaling	B-X
pathway	B-X
.	B-X
Our	B-X
findings	B-X
revealed	B-X
the	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
emodin	B-X
suppresses	B-X
renal	B-X
cancer	B-X
cell	B-X
growth	B-X
and	B-X
will	B-X
help	B-X
develop	B-X
novel	B-X
therapeutic	B-X
approaches	B-X
for	B-X
patients	B-X
with	B-X
JNK-	B-X
or	B-X
PI3K/AKT-dysregulated	B-X
renal	B-X
cancer	B-X
.	B-X

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
,	O
followed	O
by	O
western	O
blotting	O
with	O
indicated	O
antibodies	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
necroptosis-caspase-independent	B-X
programmed	B-X
necrotic	B-X
cell	B-X
death-can	B-X
be	B-X
induced	B-X
by	B-X
treatment	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
the	B-X
L929	B-X
murine	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
caspase	B-X
inhibitor	B-X
.	B-X
Although	B-X
it	B-X
was	B-X
reported	B-X
that	B-X
necrostatin-1-a	B-X
specific	B-X
inhibitor	B-X
of	B-X
necroptosis-inhibited	B-X
TNF-induced	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
,	B-X
it	B-X
has	B-X
not	B-X
been	B-X
elucidated	B-X
whether	B-X
the	B-X
cells	B-X
eventually	B-X
die	B-X
by	B-X
apoptosis	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
necrostatin-1	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
induction	B-X
of	B-X
apoptosis	B-X
was	B-X
demonstrated	B-X
in	B-X
TNF-treated	B-X
L929	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
necrostatin-1	B-X
.	B-X
Co-treatment	B-X
with	B-X
cycloheximide	B-X
expedited	B-X
apoptosis	B-X
induction	B-X
in	B-X
necrostatin-1/TNF-treated	B-X
L929	B-X
cells	B-X
:	B-X
typical	B-X
apoptotic	B-X
morphological	B-X
changes	B-X
,	B-X
including	B-X
membrane	B-X
blebbing	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
,	B-X
induction	B-X
of	B-X
caspase-3	B-X
activity	B-X
,	B-X
proteolytic	B-X
activation	B-X
of	B-X
caspases-3	B-X
,	B-X
-8	B-X
,	B-X
and	B-X
-9	B-X
,	B-X
and	B-X
cleavage	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
(	B-X
a	B-X
well-known	B-X
substrate	B-X
of	B-X
caspase-3	B-X
)	B-X
were	B-X
observed	B-X
.	B-X
Moreover	B-X
,	B-X
co-treatment	B-X
with	B-X
Z-VAD-fmk	B-X
(	B-X
a	B-X
pan-caspase	B-X
inhibitor	B-X
)	B-X
inhibited	B-X
apoptosis	B-X
by	B-X
completely	B-X
inhibiting	B-X
caspases	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
shift	B-X
from	B-X
apoptosis	B-X
to	B-X
necroptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
apoptosis	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
TNF-treated	B-X
L929	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
are	B-X
protected	B-X
from	B-X
necroptosis	B-X
,	B-X
and	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
partial	B-X
activation	B-X
of	B-X
caspase-8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
caspase	B-X
inhibitor	B-X
preferential	B-X
to	B-X
caspase-3	B-X
suppresses	B-X
both	B-X
apoptosis	B-X
and	B-X
necroptosis	B-X
.	B-X

(	O
B	O
,	O
C	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
(	O
B	O
)	O
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
(	O
serum	O
free	O
conditions	O
,	O
C	O
)	O
and	O
samples	O
were	O
collected	O
at	O
the	O
indicated	O
time	O
points	O
for	O
western	O
blot	O
.	O

(	O
D	O
)	O
Nec	O
-	O
1	O
was	O
added	O
to	O
the	O
cells	O
stimulated	O
with	O
bFGF	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
(	O
serum	O
free	O
conditions	O
)	O
for	O
15	O
min	O
or	O
9	O
hr	O
followed	O
by	O
western	O
blot	O
with	O
the	O
indicated	O
antibodies	O
.	O
<EOS>	B-X
P001	B-X
-	B-X
Sepsis	B-X
impairs	B-X
the	B-X
capillary	B-X
response	B-X
within	B-X
hypoxic	B-X
capillaries	B-X
and	B-X
decreases	B-X
erythrocyte	B-X
oxygen-dependent	B-X
ATP	B-X
efflux	B-X
R.	B-X
M.	B-X
Bateman	B-X
,	B-X
M.	B-X
D.	B-X
Sharpe	B-X
,	B-X
J.	B-X
E.	B-X
Jagger	B-X
,	B-X
C.	B-X
G.	B-X
Ellis	B-X
P002	B-X
-	B-X
Lower	B-X
serum	B-X
immunoglobulin	B-X
G2	B-X
level	B-X
does	B-X
not	B-X
predispose	B-X
to	B-X
severe	B-X
flu	B-X
.	B-X
J.	B-X
Solé-Violán	B-X
,	B-X
M.	B-X
López-Rodríguez	B-X
,	B-X
E.	B-X
Herrera-Ramos	B-X
,	B-X
J.	B-X
Ruíz-Hernández	B-X
,	B-X
L.	B-X
Borderías	B-X
,	B-X
J.	B-X
Horcajada	B-X
,	B-X
N.	B-X
González-Quevedo	B-X
,	B-X
O.	B-X
Rajas	B-X
,	B-X
M.	B-X
Briones	B-X
,	B-X
F.	B-X
Rodríguez	B-X
de	B-X
Castro	B-X
,	B-X
C.	B-X
Rodríguez	B-X
Gallego	B-X
P003	B-X
-	B-X
Brain	B-X
protective	B-X
effects	B-X
of	B-X
intravenous	B-X
immunoglobulin	B-X
through	B-X
inhibition	B-X
of	B-X
complement	B-X
activation	B-X
and	B-X
apoptosis	B-X
in	B-X
a	B-X
rat	B-X
model	B-X
of	B-X
sepsis	B-X
F.	B-X
Esen	B-X
,	B-X
G.	B-X
Orhun	B-X
,	B-X
P.	B-X
Ergin	B-X
Ozcan	B-X
,	B-X
E.	B-X
Senturk	B-X
,	B-X
C.	B-X
Ugur	B-X
Yilmaz	B-X
,	B-X
N.	B-X
Orhan	B-X
,	B-X
N.	B-X
Arican	B-X
,	B-X
M.	B-X
Kaya	B-X
,	B-X
M.	B-X
Kucukerden	B-X
,	B-X
M.	B-X
Giris	B-X
,	B-X
U.	B-X
Akcan	B-X
,	B-X
S.	B-X
Bilgic	B-X
Gazioglu	B-X
,	B-X
E.	B-X
Tuzun	B-X
P004	B-X
-	B-X
Adenosine	B-X
a1	B-X
receptor	B-X
dysfunction	B-X
is	B-X
associated	B-X
with	B-X
leukopenia	B-X
:	B-X
A	B-X
possible	B-X
mechanism	B-X
for	B-X
sepsis-induced	B-X
leukopenia	B-X
R.	B-X
Riff	B-X
,	B-X
O.	B-X
Naamani	B-X
,	B-X
A.	B-X
Douvdevani	B-X
P005	B-X
-	B-X
Analysis	B-X
of	B-X
neutrophil	B-X
by	B-X
hyper	B-X
spectral	B-X
imaging	B-X
-	B-X
A	B-X
preliminary	B-X
report	B-X
R.	B-X
Takegawa	B-X
,	B-X
H.	B-X
Yoshida	B-X
,	B-X
T.	B-X
Hirose	B-X
,	B-X
N.	B-X
Yamamoto	B-X
,	B-X
H.	B-X
Hagiya	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
Y.	B-X
Akeda	B-X
,	B-X
O.	B-X
Tasaki	B-X
,	B-X
K.	B-X
Tomono	B-X
,	B-X
T.	B-X
Shimazu	B-X
P006	B-X
-	B-X
Chemiluminescent	B-X
intensity	B-X
assessed	B-X
by	B-X
eaa	B-X
predicts	B-X
the	B-X
incidence	B-X
of	B-X
postoperative	B-X
infectious	B-X
complications	B-X
following	B-X
gastrointestinal	B-X
surgery	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Kubo	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
T.	B-X
Ikeda	B-X
P007	B-X
-	B-X
Serial	B-X
change	B-X
of	B-X
c1	B-X
inhibitor	B-X
in	B-X
patients	B-X
with	B-X
sepsis	B-X
–	B-X
A	B-X
prospective	B-X
observational	B-X
study	B-X
T.	B-X
Hirose	B-X
,	B-X
H.	B-X
Ogura	B-X
,	B-X
H.	B-X
Takahashi	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
J.	B-X
Kang	B-X
,	B-X
Y.	B-X
Nakamura	B-X
,	B-X
T.	B-X
Kojima	B-X
,	B-X
T.	B-X
Shimazu	B-X
P008	B-X
-	B-X
Comparison	B-X
of	B-X
bacteremia	B-X
and	B-X
sepsis	B-X
on	B-X
sepsis	B-X
related	B-X
biomarkers	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
Y.	B-X
Izutani	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
S.	B-X
Ono	B-X
P009	B-X
-	B-X
The	B-X
changes	B-X
of	B-X
procalcitonin	B-X
levels	B-X
in	B-X
critical	B-X
patients	B-X
with	B-X
abdominal	B-X
septic	B-X
shock	B-X
during	B-X
blood	B-X
purification	B-X
T.	B-X
Taniguchi	B-X
,	B-X
M.	B-X
O	B-X
P010	B-X
-	B-X
Validation	B-X
of	B-X
a	B-X
new	B-X
sensitive	B-X
point	B-X
of	B-X
care	B-X
device	B-X
for	B-X
rapid	B-X
measurement	B-X
of	B-X
procalcitonin	B-X
C.	B-X
Dinter	B-X
,	B-X
J.	B-X
Lotz	B-X
,	B-X
B.	B-X
Eilers	B-X
,	B-X
C.	B-X
Wissmann	B-X
,	B-X
R.	B-X
Lott	B-X
P011	B-X
-	B-X
Infection	B-X
biomarkers	B-X
in	B-X
primary	B-X
care	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
tract	B-X
infections	B-X
–	B-X
Comparison	B-X
of	B-X
procalcitonin	B-X
and	B-X
C-reactive	B-X
protein	B-X
M.	B-X
M.	B-X
Meili	B-X
,	B-X
P.	B-X
S.	B-X
Schuetz	B-X
P012	B-X
-	B-X
Do	B-X
we	B-X
need	B-X
a	B-X
lower	B-X
procalcitonin	B-X
cut	B-X
off	B-X
?	B-X
H.	B-X
Hawa	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
Aburageila	B-X
,	B-X
N.	B-X
Salahuddin	B-X
P013	B-X
-	B-X
The	B-X
predictive	B-X
role	B-X
of	B-X
C-reactive	B-X
protein	B-X
and	B-X
procalcitonin	B-X
biomarkers	B-X
in	B-X
central	B-X
nervous	B-X
system	B-X
infections	B-X
with	B-X
extensively	B-X
drug	B-X
resistant	B-X
bacteria	B-X
V.	B-X
Chantziara	B-X
,	B-X
S.	B-X
Georgiou	B-X
,	B-X
A.	B-X
Tsimogianni	B-X
,	B-X
P.	B-X
Alexandropoulos	B-X
,	B-X
A.	B-X
Vassi	B-X
,	B-X
F.	B-X
Lagiou	B-X
,	B-X
M.	B-X
Valta	B-X
,	B-X
G.	B-X
Micha	B-X
,	B-X
E.	B-X
Chinou	B-X
,	B-X
G.	B-X
Michaloudis	B-X
P014	B-X
-	B-X
Changes	B-X
in	B-X
endotoxin	B-X
activity	B-X
assay	B-X
and	B-X
procalcitonin	B-X
levels	B-X
after	B-X
direct	B-X
hemoperfusion	B-X
with	B-X
polymyxin-b	B-X
immobilized	B-X
fiber	B-X
A.	B-X
Kodaira	B-X
,	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
S.	B-X
Suda	B-X
,	B-X
Y.	B-X
Izutani	B-X
,	B-X
H.	B-X
Imaizumi	B-X
P015	B-X
-	B-X
Diagnostic	B-X
usefullness	B-X
of	B-X
combination	B-X
biomarkers	B-X
on	B-X
ICU	B-X
admission	B-X
M.	B-X
V.	B-X
De	B-X
la	B-X
Torre-Prados	B-X
,	B-X
A.	B-X
Garcia-De	B-X
la	B-X
Torre	B-X
,	B-X
A.	B-X
Enguix-Armada	B-X
,	B-X
A.	B-X
Puerto-Morlan	B-X
,	B-X
V.	B-X
Perez-Valero	B-X
,	B-X
A.	B-X
Garcia-Alcantara	B-X
P016	B-X
-	B-X
Platelet	B-X
function	B-X
analysis	B-X
utilising	B-X
the	B-X
PFA-100	B-X
does	B-X
not	B-X
predict	B-X
infection	B-X
,	B-X
bacteraemia	B-X
,	B-X
sepsis	B-X
or	B-X
outcome	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
N.	B-X
Bolton	B-X
,	B-X
J.	B-X
Dudziak	B-X
,	B-X
S.	B-X
Bonney	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
P.	B-X
Nee	B-X
P017	B-X
-	B-X
Extracellular	B-X
histone	B-X
H3	B-X
levels	B-X
are	B-X
inversely	B-X
correlated	B-X
with	B-X
antithrombin	B-X
levels	B-X
and	B-X
platelet	B-X
counts	B-X
and	B-X
are	B-X
associated	B-X
with	B-X
mortality	B-X
in	B-X
sepsis	B-X
patients	B-X
G.	B-X
Nicolaes	B-X
,	B-X
M.	B-X
Wiewel	B-X
,	B-X
M.	B-X
Schultz	B-X
,	B-X
K.	B-X
Wildhagen	B-X
,	B-X
J.	B-X
Horn	B-X
,	B-X
R.	B-X
Schrijver	B-X
,	B-X
T.	B-X
Van	B-X
der	B-X
Poll	B-X
,	B-X
C.	B-X
Reutelingsperger	B-X
P018	B-X
-	B-X
Il-8	B-X
:	B-X
is	B-X
this	B-X
a	B-X
more	B-X
reliable	B-X
biomarker	B-X
for	B-X
sepsis	B-X
severity	B-X
than	B-X
CRP	B-X
,	B-X
Procalcitonin	B-X
,	B-X
E-selectin	B-X
,	B-X
IL-6	B-X
and	B-X
TNF-	B-X
[	B-X
alpha	B-X
]	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P019	B-X
-	B-X
Relation	B-X
between	B-X
adrenomedullin	B-X
and	B-X
short-term	B-X
outcome	B-X
in	B-X
ICU	B-X
patients	B-X
:	B-X
Results	B-X
from	B-X
the	B-X
frog	B-X
ICU	B-X
study	B-X
E.	B-X
G.	B-X
Gayat	B-X
,	B-X
J	B-X
.	B-X
Struck	B-X
,	B-X
A.	B-X
Cariou	B-X
,	B-X
N.	B-X
Deye	B-X
,	B-X
B.	B-X
Guidet	B-X
,	B-X
S.	B-X
Jabert	B-X
,	B-X
J.	B-X
Launay	B-X
,	B-X
M.	B-X
Legrand	B-X
,	B-X
M.	B-X
Léone	B-X
,	B-X
M.	B-X
Resche-Rigon	B-X
,	B-X
E.	B-X
Vicaut	B-X
,	B-X
A.	B-X
Vieillard-Baron	B-X
,	B-X
A.	B-X
Mebazaa	B-X
P020	B-X
-	B-X
Impact	B-X
of	B-X
disease	B-X
severity	B-X
assessment	B-X
on	B-X
performance	B-X
of	B-X
heparin-binding	B-X
protein	B-X
for	B-X
the	B-X
prediction	B-X
of	B-X
septic	B-X
shock	B-X
R.	B-X
Arnold	B-X
,	B-X
M.	B-X
Capan	B-X
,	B-X
A.	B-X
Linder	B-X
,	B-X
P.	B-X
Akesson	B-X
P021	B-X
-	B-X
Kinetics	B-X
and	B-X
prognostic	B-X
value	B-X
of	B-X
presepsin	B-X
(	B-X
sCD14	B-X
)	B-X
in	B-X
septic	B-X
patients	B-X
.	B-X
A	B-X
pilot	B-X
study	B-X
M.	B-X
Popescu	B-X
,	B-X
D.	B-X
Tomescu	B-X
P022	B-X
-	B-X
Comparison	B-X
of	B-X
CD64	B-X
levels	B-X
performed	B-X
by	B-X
the	B-X
facs	B-X
and	B-X
accellix	B-X
systems	B-X
C.	B-X
L.	B-X
Sprung	B-X
,	B-X
R.	B-X
Calderon	B-X
Morales	B-X
,	B-X
G.	B-X
Munteanu	B-X
,	B-X
E.	B-X
Orenbuch-Harroch	B-X
,	B-X
P.	B-X
Levin	B-X
,	B-X
H.	B-X
Kasdan	B-X
,	B-X
A.	B-X
Reiter	B-X
,	B-X
T.	B-X
Volker	B-X
,	B-X
Y.	B-X
Himmel	B-X
,	B-X
Y.	B-X
Cohen	B-X
,	B-X
J.	B-X
Meissonnier	B-X
P023	B-X
-	B-X
Diagnosing	B-X
sepsis	B-X
in	B-X
5	B-X
minutes	B-X
:	B-X
Nanofluidic	B-X
technology	B-X
study	B-X
with	B-X
pancreatic-stone	B-X
protein	B-X
(	B-X
PSP/	B-X
reg	B-X
)	B-X
L.	B-X
Girard	B-X
,	B-X
F.	B-X
Rebeaud	B-X
P024	B-X
-	B-X
How	B-X
nanotechnology-based	B-X
approaches	B-X
could	B-X
contribute	B-X
to	B-X
sepsis	B-X
prevention	B-X
,	B-X
diagnosis	B-X
and	B-X
treatment	B-X
I.	B-X
Herrmann	B-X
P025	B-X
-	B-X
Il7r	B-X
transcriptional	B-X
expression	B-X
analysis	B-X
during	B-X
septic	B-X
shock	B-X
B.	B-X
Delwarde	B-X
,	B-X
E.	B-X
Peronnet	B-X
,	B-X
E.	B-X
Cerrato	B-X
,	B-X
F.	B-X
Venet	B-X
,	B-X
A.	B-X
Lepape	B-X
,	B-X
T.	B-X
Rimmelé	B-X
,	B-X
G.	B-X
Monneret	B-X
,	B-X
J.	B-X
Textoris	B-X
P026	B-X
-	B-X
Disbalance	B-X
of	B-X
microbial	B-X
metabolites	B-X
of	B-X
aromatic	B-X
acids	B-X
affects	B-X
the	B-X
severity	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
N.	B-X
Beloborodova	B-X
,	B-X
V.	B-X
Moroz	B-X
,	B-X
A.	B-X
Osipov	B-X
,	B-X
A.	B-X
Bedova	B-X
,	B-X
Y.	B-X
Sarshor	B-X
,	B-X
A.	B-X
Pautova	B-X
,	B-X
A.	B-X
Sergeev	B-X
,	B-X
E.	B-X
Chernevskaya	B-X
P027	B-X
-	B-X
Copeptin	B-X
predicts	B-X
10-year	B-X
all-cause	B-X
mortality	B-X
in	B-X
community	B-X
patients	B-X
J.	B-X
Odermatt	B-X
,	B-X
R.	B-X
Bolliger	B-X
,	B-X
L.	B-X
Hersberger	B-X
,	B-X
M.	B-X
Ottiger	B-X
,	B-X
M.	B-X
Christ-Crain	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P028	B-X
-	B-X
Identification	B-X
of	B-X
differential	B-X
proteomic	B-X
response	B-X
in	B-X
septic	B-X
patients	B-X
secondary	B-X
to	B-X
community	B-X
and	B-X
hospital	B-X
acquired	B-X
pneumonia	B-X
N.	B-X
K.	B-X
Sharma	B-X
,	B-X
A.	B-X
K.	B-X
Tashima	B-X
,	B-X
M.	B-X
K.	B-X
Brunialti	B-X
,	B-X
F.	B-X
R.	B-X
Machado	B-X
,	B-X
M.	B-X
Assuncao	B-X
,	B-X
O.	B-X
Rigato	B-X
,	B-X
R.	B-X
Salomao	B-X
P029	B-X
-	B-X
Monocyte	B-X
HLA-DR	B-X
expression	B-X
in	B-X
community-acquired	B-X
bacteremic	B-X
sepsis	B-X
-	B-X
dynamics	B-X
associated	B-X
to	B-X
aetiology	B-X
and	B-X
prediction	B-X
of	B-X
secondary	B-X
sepsis	B-X
S.	B-X
C.	B-X
Cajander	B-X
,	B-X
G.	B-X
Rasmussen	B-X
,	B-X
E.	B-X
Tina	B-X
,	B-X
B.	B-X
Söderquist	B-X
,	B-X
J.	B-X
Källman	B-X
,	B-X
K.	B-X
Strålin	B-X
P030	B-X
-	B-X
Soluble	B-X
B-	B-X
and	B-X
T-lymphocyte	B-X
attenuator	B-X
:	B-X
A	B-X
possible	B-X
prognostic	B-X
marker	B-X
in	B-X
sepsis	B-X
A.	B-X
L.	B-X
Lange	B-X
,	B-X
J.	B-X
S.	B-X
Sundén-Cullberg	B-X
,	B-X
A.	B-X
M.	B-X
Magnuson	B-X
,	B-X
O.	B-X
H.	B-X
Hultgren	B-X
P031	B-X
-	B-X
Fractal	B-X
dimension	B-X
:	B-X
A	B-X
new	B-X
biomarker	B-X
for	B-X
quantifying	B-X
clot	B-X
microstructure	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
G.	B-X
Davies	B-X
,	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P032	B-X
-	B-X
Comparison	B-X
between	B-X
the	B-X
new	B-X
biomarker	B-X
for	B-X
coagulation	B-X
,	B-X
clot	B-X
microstructure	B-X
(	B-X
Df	B-X
)	B-X
with	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
in	B-X
patients	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P033	B-X
-	B-X
Changes	B-X
in	B-X
fibrinolysis	B-X
across	B-X
the	B-X
sepsis	B-X
spectrum	B-X
:	B-X
The	B-X
use	B-X
of	B-X
rotational	B-X
thromboelastometry	B-X
(	B-X
ROTEM	B-X
)	B-X
lysis	B-X
index	B-X
(	B-X
LI60	B-X
)	B-X
and	B-X
D-Dimer	B-X
concentration	B-X
S.	B-X
Pillai	B-X
,	B-X
G.	B-X
Davies	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
R.	B-X
Aubrey	B-X
,	B-X
K.	B-X
Morris	B-X
,	B-X
P.	B-X
Williams	B-X
,	B-X
P.	B-X
Evans	B-X
P034	B-X
-	B-X
The	B-X
intensive	B-X
care	B-X
infection	B-X
score	B-X
–	B-X
a	B-X
promising	B-X
marker	B-X
for	B-X
the	B-X
prediction	B-X
of	B-X
infection	B-X
and	B-X
its	B-X
severity	B-X
.	B-X
C.	B-X
Mcgrath	B-X
,	B-X
E.	B-X
Nsutebu	B-X
P038	B-X
-	B-X
Prehospital	B-X
transport	B-X
of	B-X
acute	B-X
septic	B-X
patients	B-X
P.	B-X
Bank	B-X
Pedersen	B-X
,	B-X
D.	B-X
Pilsgaard	B-X
Henriksen	B-X
,	B-X
S.	B-X
Mikkelsen	B-X
,	B-X
A.	B-X
Touborg	B-X
Lassen	B-X
P039	B-X
-	B-X
Vasodilatory	B-X
plant	B-X
extracts	B-X
gel	B-X
as	B-X
an	B-X
alternative	B-X
treatment	B-X
for	B-X
fever	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P040	B-X
-	B-X
Host	B-X
response	B-X
and	B-X
outcome	B-X
of	B-X
hypothermic	B-X
sepsis	B-X
M.	B-X
A.	B-X
Wiewel	B-X
,	B-X
M.	B-X
B.	B-X
Harmon	B-X
,	B-X
L.	B-X
A	B-X
.	B-X
Van	B-X
Vught	B-X
,	B-X
B.	B-X
P.	B-X
Scicluna	B-X
,	B-X
A.	B-X
J.	B-X
Hoogendijk	B-X
,	B-X
J.	B-X
Horn	B-X
,	B-X
A.	B-X
H.	B-X
Zwinderman	B-X
,	B-X
O.	B-X
L.	B-X
Cremer	B-X
,	B-X
M.	B-X
J.	B-X
Bonten	B-X
,	B-X
M.	B-X
J.	B-X
Schultz	B-X
,	B-X
T.	B-X
Van	B-X
der	B-X
Poll	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
,	B-X
W.	B-X
J.	B-X
Wiersinga	B-X
P041	B-X
-	B-X
Septic	B-X
shock	B-X
alert	B-X
over	B-X
SIRS	B-X
criteria	B-X
has	B-X
an	B-X
impact	B-X
on	B-X
outcome	B-X
but	B-X
needs	B-X
to	B-X
be	B-X
revised	B-X
G.	B-X
Eren	B-X
,	B-X
Y	B-X
Tekdos	B-X
,	B-X
M.	B-X
Dogan	B-X
,	B-X
O.	B-X
Acicbe	B-X
,	B-X
E.	B-X
Kaya	B-X
,	B-X
O.	B-X
Hergunsel	B-X
P042	B-X
-	B-X
Association	B-X
between	B-X
previous	B-X
prescription	B-X
of	B-X
βblockers	B-X
and	B-X
mortality	B-X
rate	B-X
among	B-X
septic	B-X
patients	B-X
:	B-X
A	B-X
retrospective	B-X
observational	B-X
study	B-X
S.	B-X
Alsolamy	B-X
,	B-X
G.	B-X
Ghamdi	B-X
,	B-X
L.	B-X
Alswaidan	B-X
,	B-X
S.	B-X
Alharbi	B-X
,	B-X
F.	B-X
Alenezi	B-X
,	B-X
Y.	B-X
Arabi	B-X
P043	B-X
-	B-X
Recognition	B-X
and	B-X
treatment	B-X
of	B-X
sepsis	B-X
on	B-X
labour	B-X
ward–	B-X
teaching	B-X
&	B-X
information	B-X
resources	B-X
can	B-X
improve	B-X
knowledge	B-X
J.	B-X
Heaton	B-X
,	B-X
A.	B-X
Boyce	B-X
,	B-X
L.	B-X
Nolan	B-X
,	B-X
J.	B-X
Johnston	B-X
,	B-X
A.	B-X
Dukoff-Gordon	B-X
,	B-X
A.	B-X
T.	B-X
Mann	B-X
Ben	B-X
Yehudah	B-X
P045	B-X
-	B-X
Organ	B-X
dysfunction	B-X
in	B-X
severe	B-X
sepsis	B-X
patients	B-X
identified	B-X
in	B-X
administrative	B-X
data	B-X
in	B-X
Germany	B-X
,	B-X
2007-2013	B-X
C.	B-X
Fleischmann	B-X
,	B-X
D.	B-X
Thomas-Rueddel	B-X
,	B-X
C.	B-X
Haas	B-X
,	B-X
U.	B-X
Dennler	B-X
,	B-X
K.	B-X
Reinhart	B-X
P046	B-X
-	B-X
A	B-X
comparison	B-X
of	B-X
residents	B-X
’	B-X
knowledge	B-X
regarding	B-X
;	B-X
the	B-X
Surviving	B-X
Sepsis	B-X
Campaign	B-X
2012	B-X
guideline	B-X
O.	B-X
Suntornlohanakul	B-X
,	B-X
B.	B-X
Khwannimit	B-X
P047	B-X
-	B-X
Effectiveness	B-X
of	B-X
a	B-X
septic	B-X
shock	B-X
bundle	B-X
to	B-X
improve	B-X
outcomes	B-X
in	B-X
the	B-X
ICU	B-X
F.	B-X
Breckenridge	B-X
,	B-X
A.	B-X
Puxty	B-X
P048	B-X
-	B-X
Dose	B-X
of	B-X
norepinephrine	B-X
in	B-X
the	B-X
first	B-X
24	B-X
hours	B-X
as	B-X
a	B-X
parameter	B-X
evaluating	B-X
the	B-X
effectiveness	B-X
of	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
P.	B-X
Szturz	B-X
,	B-X
P.	B-X
Folwarzcny	B-X
,	B-X
J.	B-X
Svancara	B-X
,	B-X
R.	B-X
Kula	B-X
,	B-X
P.	B-X
Sevcik	B-X
P049	B-X
-	B-X
Norepinephrine	B-X
or	B-X
vasopressin	B-X
+	B-X
norepinephrine	B-X
in	B-X
septic	B-X
shock	B-X
.	B-X
A	B-X
retrospective	B-X
series	B-X
of	B-X
39	B-X
patients	B-X
L.	B-X
Caneva	B-X
,	B-X
A.	B-X
Casazza	B-X
,	B-X
E.	B-X
Bellazzi	B-X
,	B-X
S.	B-X
Marra	B-X
,	B-X
L.	B-X
Pagani	B-X
,	B-X
M.	B-X
Vetere	B-X
,	B-X
R.	B-X
Vanzino	B-X
,	B-X
D.	B-X
Ciprandi	B-X
,	B-X
R.	B-X
Preda	B-X
,	B-X
R.	B-X
Boschi	B-X
,	B-X
L.	B-X
Carnevale	B-X
P050	B-X
-	B-X
Methylene	B-X
blue	B-X
effectiveness	B-X
as	B-X
contributory	B-X
treatment	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
V.	B-X
Lopez	B-X
,	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
A.	B-X
Escalante	B-X
,	B-X
J.	B-X
Gongora	B-X
,	B-X
M.	B-X
Cetina	B-X
P051	B-X
-	B-X
Coagulation	B-X
disorders	B-X
in	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
DIC	B-X
evaluated	B-X
with	B-X
thromboelastometry	B-X
.	B-X
A	B-X
case-control	B-X
pilot	B-X
study	B-X
E.	B-X
Scarlatescu	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
G.	B-X
Droc	B-X
,	B-X
S.	B-X
Arama	B-X
P054	B-X
-	B-X
Thromboelastometry	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
disseminated	B-X
intravascular	B-X
coagulation	B-X
M.	B-X
Müller	B-X
,	B-X
M.	B-X
Straat	B-X
,	B-X
S.	B-X
S.	B-X
Zeerleder	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
P055	B-X
-	B-X
Cessation	B-X
of	B-X
a	B-X
preexisting	B-X
chronic	B-X
antiplatelet	B-X
therapy	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
mortality	B-X
rates	B-X
in	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
C.	B-X
F.	B-X
Fuchs	B-X
,	B-X
C.	B-X
S.	B-X
Scheer	B-X
,	B-X
S.	B-X
W.	B-X
Wauschkuhn	B-X
,	B-X
M.	B-X
V.	B-X
Vollmer	B-X
,	B-X
K.	B-X
M.	B-X
Meissner	B-X
,	B-X
S.	B-X
K.	B-X
Kuhn	B-X
,	B-X
K.	B-X
H.	B-X
Hahnenkamp	B-X
,	B-X
S.	B-X
R.	B-X
Rehberg	B-X
,	B-X
M.	B-X
G.	B-X
Gründling	B-X
P056	B-X
-	B-X
Neutrophil	B-X
Extracellular	B-X
Traps	B-X
(	B-X
NETs	B-X
)	B-X
production	B-X
under	B-X
hypoxic	B-X
condition	B-X
N.	B-X
Yamamoto	B-X
,	B-X
M.	B-X
Ojima	B-X
,	B-X
S.	B-X
Hamaguchi	B-X
,	B-X
T.	B-X
Hirose	B-X
,	B-X
Y.	B-X
Akeda	B-X
,	B-X
R.	B-X
Takegawa	B-X
,	B-X
O.	B-X
Tasaki	B-X
,	B-X
T.	B-X
Shimazu	B-X
,	B-X
K.	B-X
Tomono	B-X
P057	B-X
-	B-X
Impact	B-X
of	B-X
ultraviolet	B-X
air	B-X
sterilizer	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
room	B-X
,	B-X
and	B-X
clinical	B-X
outcomes	B-X
of	B-X
patients	B-X
E.	B-X
Gómez-Sánchez	B-X
,	B-X
M.	B-X
Heredia-Rodríguez	B-X
,	B-X
E.	B-X
Álvarez-Fuente	B-X
,	B-X
M.	B-X
Lorenzo-López	B-X
,	B-X
E.	B-X
Gómez-Pesquera	B-X
,	B-X
M.	B-X
Aragón-Camino	B-X
,	B-X
P.	B-X
Liu-Zhu	B-X
,	B-X
A.	B-X
Sánchez-López	B-X
,	B-X
A.	B-X
Hernández-Lozano	B-X
,	B-X
M.	B-X
T.	B-X
Peláez-Jareño	B-X
,	B-X
E.	B-X
Tamayo	B-X
P058	B-X
-	B-X
Focus	B-X
of	B-X
infection	B-X
in	B-X
severe	B-X
sepsis	B-X
-	B-X
comparison	B-X
of	B-X
administrative	B-X
data	B-X
and	B-X
prospective	B-X
cohorts	B-X
from	B-X
Germany	B-X
D.	B-X
O.	B-X
Thomas-Rüddel	B-X
,	B-X
C.	B-X
Fleischmann	B-X
,	B-X
C.	B-X
Haas	B-X
,	B-X
U.	B-X
Dennler	B-X
,	B-X
K.	B-X
Reinhart	B-X
P059	B-X
-	B-X
“	B-X
Zero	B-X
CLABSI	B-X
”	B-X
–	B-X
can	B-X
we	B-X
get	B-X
there	B-X
?	B-X
Obstacles	B-X
on	B-X
the	B-X
4	B-X
year	B-X
journey	B-X
and	B-X
our	B-X
strategies	B-X
to	B-X
overcome	B-X
them	B-X
–	B-X
experience	B-X
from	B-X
an	B-X
Indian	B-X
ICU	B-X
V.	B-X
Adora	B-X
,	B-X
A.	B-X
Kar	B-X
,	B-X
A.	B-X
Chakraborty	B-X
,	B-X
S.	B-X
Roy	B-X
,	B-X
A.	B-X
Bandyopadhyay	B-X
,	B-X
M.	B-X
Das	B-X
P060	B-X
-	B-X
Novel	B-X
molecular	B-X
techniques	B-X
to	B-X
identify	B-X
central	B-X
venous	B-X
catheter	B-X
(	B-X
CVC	B-X
)	B-X
associated	B-X
blood	B-X
stream	B-X
infections	B-X
(	B-X
BSIs	B-X
)	B-X
T.	B-X
Mann	B-X
Ben	B-X
Yehudah	B-X
,	B-X
G.	B-X
Ben	B-X
Yehudah	B-X
,	B-X
M.	B-X
Salim	B-X
,	B-X
N.	B-X
Kumar	B-X
,	B-X
L.	B-X
Arabi	B-X
,	B-X
T.	B-X
Burger	B-X
,	B-X
P.	B-X
Lephart	B-X
,	B-X
E.	B-X
Toth-martin	B-X
P061	B-X
-	B-X
Zero	B-X
clabsi	B-X
”	B-X
–	B-X
can	B-X
we	B-X
get	B-X
there	B-X
?	B-X
monobacteremia	B-X
in	B-X
surgical	B-X
and	B-X
medical	B-X
intensive	B-X
care	B-X
units	B-X
at	B-X
university	B-X
hospital	B-X
in	B-X
Lithuania	B-X
D.	B-X
Adukauskiene	B-X
,	B-X
D.	B-X
Valanciene	B-X
P067	B-X
-	B-X
Group	B-X
A	B-X
and	B-X
group	B-X
B	B-X
streptococcal	B-X
infections	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
–	B-X
our	B-X
experience	B-X
in	B-X
a	B-X
tertiary	B-X
centre	B-X
G.	B-X
Bose	B-X
,	B-X
V.	B-X
Lostarakos	B-X
,	B-X
B.	B-X
Carr	B-X
P068	B-X
-	B-X
Improved	B-X
detection	B-X
of	B-X
spontaneous	B-X
bacterial	B-X
peritonitis	B-X
by	B-X
uritop	B-X
+	B-X
tm	B-X
strip	B-X
test	B-X
and	B-X
inoculation	B-X
of	B-X
blood	B-X
culture	B-X
bottles	B-X
with	B-X
ascitic	B-X
fluid	B-X
S.	B-X
Khedher	B-X
,	B-X
A.	B-X
Maaoui	B-X
,	B-X
A.	B-X
Ezzamouri	B-X
,	B-X
M.	B-X
Salem	B-X
P069	B-X
-	B-X
Increased	B-X
risk	B-X
of	B-X
cellulitis	B-X
in	B-X
patients	B-X
with	B-X
congestive	B-X
heart	B-X
failure	B-X
:	B-X
a	B-X
population	B-X
based	B-X
cohort	B-X
study	B-X
J.	B-X
Chen	B-X
P070	B-X
-	B-X
Outcomes	B-X
of	B-X
severe	B-X
cellulitis	B-X
and	B-X
necrotizing	B-X
fasciitis	B-X
in	B-X
the	B-X
critically	B-X
ill	B-X
D.	B-X
R.	B-X
Cranendonk	B-X
,	B-X
L.	B-X
A	B-X
.	B-X
Van	B-X
Vught	B-X
,	B-X
M.	B-X
A.	B-X
Wiewel	B-X
,	B-X
O.	B-X
L.	B-X
Cremer	B-X
,	B-X
J.	B-X
Horn	B-X
,	B-X
M.	B-X
J.	B-X
Bonten	B-X
,	B-X
M.	B-X
J.	B-X
Schultz	B-X
,	B-X
T.	B-X
Van	B-X
der	B-X
Poll	B-X
,	B-X
W.	B-X
J.	B-X
Wiersinga	B-X
P071	B-X
-	B-X
Botulism	B-X
outbreak	B-X
associated	B-X
with	B-X
people	B-X
who	B-X
inject	B-X
drugs	B-X
(	B-X
PWIDs	B-X
)	B-X
in	B-X
Scotland	B-X
.	B-X
Van	B-X
Oers	B-X
,	B-X
A.	B-X
Harts	B-X
,	B-X
E.	B-X
Nieuwkoop	B-X
,	B-X
P.	B-X
Vos	B-X
P077	B-X
-	B-X
Epidemiology	B-X
and	B-X
risk	B-X
factors	B-X
of	B-X
ICU	B-X
acquired	B-X
infections	B-X
caused	B-X
by	B-X
multidrug-resistant	B-X
gram	B-X
negative	B-X
bacilli	B-X
Y.	B-X
Boussarsar	B-X
,	B-X
F.	B-X
Boutouta	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
I.	B-X
Mezghani	B-X
,	B-X
S.	B-X
Koubaji	B-X
,	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.	B-X
S.	B-X
Mebazaa	B-X
P078	B-X
-	B-X
Improving	B-X
outcomes	B-X
of	B-X
severe	B-X
infections	B-X
by	B-X
multidrug-resistant	B-X
pathogens	B-X
with	B-X
polyclonal	B-X
IgM-enriched	B-X
immunoglobulins	B-X
E.	B-X
Giamarellos-Bourboulis	B-X
,	B-X
N.	B-X
Tziolos	B-X
,	B-X
C.	B-X
Routsi	B-X
,	B-X
C.	B-X
Katsenos	B-X
,	B-X
I.	B-X
Tsangaris	B-X
,	B-X
I.	B-X
Pneumatikos	B-X
,	B-X
G.	B-X
Vlachogiannis	B-X
,	B-X
V.	B-X
Theodorou	B-X
,	B-X
A.	B-X
Prekates	B-X
,	B-X
E.	B-X
Antypa	B-X
,	B-X
V.	B-X
Koulouras	B-X
,	B-X
N.	B-X
Kapravelos	B-X
,	B-X
C.	B-X
Gogos	B-X
,	B-X
E.	B-X
Antoniadou	B-X
,	B-X
K.	B-X
Mandragos	B-X
,	B-X
A.	B-X
Armaganidis	B-X
P079	B-X
-	B-X
Must	B-X
change	B-X
the	B-X
medical	B-X
practice	B-X
in	B-X
ICU	B-X
?	B-X
A.	B-X
R.	B-X
Robles	B-X
Caballero	B-X
,	B-X
B.	B-X
Civantos	B-X
,	B-X
J.	B-X
C.	B-X
Figueira	B-X
,	B-X
J.	B-X
López	B-X
P080	B-X
-	B-X
Mediterranean	B-X
spotted	B-X
fever	B-X
in	B-X
an	B-X
infectious	B-X
diseases	B-X
intensive	B-X
care	B-X
unit	B-X
A.	B-X
Silva-Pinto	B-X
,	B-X
F.	B-X
Ceia	B-X
,	B-X
A.	B-X
Sarmento	B-X
,	B-X
L.	B-X
Santos	B-X
P081	B-X
-	B-X
Clinical	B-X
features	B-X
and	B-X
outcomes	B-X
of	B-X
patients	B-X
with	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
requiring	B-X
admission	B-X
to	B-X
a	B-X
saudi	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
A	B-X
retrospective	B-X
analysis	B-X
of	B-X
31	B-X
cases	B-X
G.	B-X
Almekhlafi	B-X
,	B-X
Y.	B-X
Sakr	B-X
P082	B-X
-	B-X
The	B-X
ICU	B-X
response	B-X
to	B-X
a	B-X
hospital	B-X
outbreak	B-X
of	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
infection	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
S.	B-X
Baharoon	B-X
,	B-X
A.	B-X
Aldawood	B-X
,	B-X
A.	B-X
Matroud	B-X
,	B-X
J.	B-X
Alchin	B-X
,	B-X
S.	B-X
Al	B-X
Johani	B-X
,	B-X
H.	B-X
Balkhy	B-X
,	B-X
Y.	B-X
Arabi	B-X
P083	B-X
-	B-X
Middle	B-X
East	B-X
respiratory	B-X
syndrome	B-X
:	B-X
Surveillance	B-X
data	B-X
analysis	B-X
S.	B-X
Alsolamy	B-X
,	B-X
S.	B-X
Y.	B-X
Yousif	B-X
,	B-X
B.	B-X
O.	B-X
Alotabi	B-X
,	B-X
A.	B-X
S.	B-X
Alsaawi	B-X
P085	B-X
-	B-X
Use	B-X
of	B-X
Taqman	B-X
array	B-X
card	B-X
molecular	B-X
diagnostics	B-X
in	B-X
severe	B-X
pneumonia	B-X
:	B-X
A	B-X
case	B-X
series	B-X
J.	B-X
Ang	B-X
,	B-X
MD	B-X
Curran	B-X
,	B-X
D.	B-X
Enoch	B-X
,	B-X
V.	B-X
Navapurkar	B-X
,	B-X
A.	B-X
Conway	B-X
Morris	B-X
P086	B-X
-	B-X
‘	B-X
BUNS	B-X
’	B-X
:	B-X
An	B-X
investigation	B-X
protocol	B-X
improves	B-X
the	B-X
ICU	B-X
management	B-X
of	B-X
pneumonia	B-X
R.	B-X
Sharvill	B-X
,	B-X
J.	B-X
Astin	B-X
P087	B-X
-	B-X
Pneumonia	B-X
in	B-X
patients	B-X
following	B-X
secondary	B-X
peritonitis	B-X
:	B-X
epidemiological	B-X
features	B-X
and	B-X
impact	B-X
on	B-X
mortality	B-X
M.	B-X
Heredia-Rodríguez	B-X
,	B-X
E.	B-X
Gómez-Sánchez	B-X
,	B-X
M.	B-X
T.	B-X
Peláez-Jareño	B-X
,	B-X
E.	B-X
Gómez-Pesquera	B-X
,	B-X
M.	B-X
Lorenzo-López	B-X
,	B-X
P.	B-X
Liu-Zhu	B-X
,	B-X
M.	B-X
Aragón-Camino	B-X
,	B-X
A.	B-X
Hernández-Lozano	B-X
,	B-X
A.	B-X
Sánchez-López	B-X
,	B-X
E.	B-X
Álvarez-Fuente	B-X
,	B-X
E.	B-X
Tamayo	B-X
P088	B-X
-	B-X
The	B-X
use	B-X
of	B-X
the	B-X
“	B-X
CURB-65	B-X
score	B-X
”	B-X
by	B-X
emergency	B-X
room	B-X
clinicians	B-X
in	B-X
a	B-X
large	B-X
teaching	B-X
hospital	B-X
J.	B-X
Patel	B-X
,	B-X
C.	B-X
Kruger	B-X
P089	B-X
-	B-X
Incidence	B-X
of	B-X
community	B-X
acquired	B-X
pneumonia	B-X
with	B-X
viral	B-X
infection	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
in	B-X
the	B-X
medical	B-X
intensive	B-X
care	B-X
unit	B-X
J.	B-X
O	B-X
’	B-X
Neal	B-X
,	B-X
H.	B-X
Rhodes	B-X
,	B-X
J.	B-X
Jancik	B-X
P090	B-X
-	B-X
The	B-X
SAATELLITE	B-X
Study	B-X
:	B-X
Prevention	B-X
of	B-X
S	B-X
aureus	B-X
Nosocomial	B-X
Pneumonia	B-X
(	B-X
NP	B-X
)	B-X
with	B-X
MEDI4893	B-X
,	B-X
a	B-X
Human	B-X
Monoclonal	B-X
Antibody	B-X
(	B-X
mAb	B-X
)	B-X
Against	B-X
S	B-X
aureus	B-X
B.	B-X
François	B-X
,	B-X
P.	B-X
F.	B-X
Laterre	B-X
,	B-X
P.	B-X
Eggimann	B-X
,	B-X
A.	B-X
Torres	B-X
,	B-X
M.	B-X
Sánchez	B-X
,	B-X
P.	B-X
F.	B-X
Dequin	B-X
,	B-X
G.	B-X
L.	B-X
Bassi	B-X
,	B-X
J.	B-X
Chastre	B-X
,	B-X
H.	B-X
S.	B-X
Jafri	B-X
P091	B-X
-	B-X
Risk	B-X
factors	B-X
and	B-X
microbiological	B-X
profile	B-X
for	B-X
nosocomial	B-X
infections	B-X
in	B-X
trauma	B-X
patients	B-X
M.	B-X
Ben	B-X
Romdhane	B-X
,	B-X
Z.	B-X
Douira	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
M.	B-X
Bousselmi	B-X
,	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
Y.	B-X
Boussarsar	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.S	B-X
.	B-X
Mebazaa	B-X
P092	B-X
-	B-X
Correlation	B-X
between	B-X
percentages	B-X
of	B-X
ventilated	B-X
patients	B-X
developed	B-X
vap	B-X
and	B-X
use	B-X
of	B-X
antimicrobial	B-X
agents	B-X
in	B-X
ICU	B-X
patients	B-X
.	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P093	B-X
-	B-X
A	B-X
comparison	B-X
of	B-X
two	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
surveillance	B-X
techniques	B-X
T.	B-X
H.	B-X
Craven	B-X
,	B-X
G.	B-X
Wojcik	B-X
,	B-X
K.	B-X
Kefala	B-X
,	B-X
J.	B-X
McCoubrey	B-X
,	B-X
J.	B-X
Reilly	B-X
,	B-X
R.	B-X
Paterson	B-X
,	B-X
D.	B-X
Inverarity	B-X
,	B-X
I.	B-X
Laurenson	B-X
,	B-X
T.	B-X
S.	B-X
Walsh	B-X
P094	B-X
-	B-X
Lung	B-X
ultrasound	B-X
before	B-X
and	B-X
after	B-X
fiberbronchoscopy	B-X
-	B-X
modifications	B-X
may	B-X
improve	B-X
ventilator-associated	B-X
pneumonia	B-X
diagnosis	B-X
S.	B-X
Mongodi	B-X
,	B-X
B.	B-X
Bouhemad	B-X
,	B-X
A.	B-X
Orlando	B-X
,	B-X
A.	B-X
Stella	B-X
,	B-X
G.	B-X
Via	B-X
,	B-X
G.	B-X
Iotti	B-X
,	B-X
A.	B-X
Braschi	B-X
,	B-X
F.	B-X
Mojoli	B-X
P095	B-X
-	B-X
Comparing	B-X
the	B-X
accuracy	B-X
of	B-X
predictors	B-X
of	B-X
mortality	B-X
in	B-X
ventilator-associated	B-X
pneumonia	B-X
M.	B-X
Haliloglu	B-X
,	B-X
B.	B-X
Bilgili	B-X
,	B-X
U.	B-X
Kasapoglu	B-X
,	B-X
I.	B-X
Sayan	B-X
,	B-X
M.	B-X
Süzer	B-X
Aslan	B-X
,	B-X
A.	B-X
Yalcın	B-X
,	B-X
I.	B-X
Cinel	B-X
P096	B-X
-	B-X
Impact	B-X
of	B-X
pRBCs	B-X
transfusion	B-X
on	B-X
percentage	B-X
of	B-X
ventilated	B-X
patients	B-X
developed	B-X
VAP	B-X
in	B-X
ICU	B-X
patients	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P097	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
a	B-X
series	B-X
of	B-X
interventions	B-X
on	B-X
the	B-X
rate	B-X
of	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
in	B-X
a	B-X
large	B-X
teaching	B-X
hospital	B-X
H.	B-X
E.	B-X
Ellis	B-X
,	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
D.	B-X
Miller	B-X
,	B-X
A	B-X
Temple	B-X
P098	B-X
-	B-X
The	B-X
EVADE	B-X
study	B-X
:	B-X
Prevention	B-X
of	B-X
Nosocomial	B-X
Pneumonia	B-X
(	B-X
NP	B-X
)	B-X
caused	B-X
by	B-X
P	B-X
aeruginosa	B-X
with	B-X
MEDI3902	B-X
,	B-X
a	B-X
Novel	B-X
Bispecific	B-X
Monoclonal	B-X
Antibody	B-X
,	B-X
against	B-X
P	B-X
aeruginosa	B-X
virulence	B-X
factors	B-X
J.	B-X
Chastre	B-X
,	B-X
B.	B-X
François	B-X
,	B-X
A.	B-X
Torres	B-X
,	B-X
C.	B-X
E.	B-X
Luyt	B-X
,	B-X
M.	B-X
Sánchez	B-X
,	B-X
M.	B-X
Singer	B-X
,	B-X
H.	B-X
S.	B-X
Jafri	B-X
P099	B-X
-	B-X
Short-term	B-X
inhaled	B-X
colistin	B-X
adjunctive	B-X
therapy	B-X
for	B-X
ventilator-associated	B-X
pneumonia	B-X
Y.	B-X
Nassar	B-X
,	B-X
M.	B-X
S.	B-X
Ayad	B-X
P100	B-X
-	B-X
Effect	B-X
of	B-X
aerosolised	B-X
colistin	B-X
on	B-X
weaning	B-X
from	B-X
mechanical	B-X
ventilation	B-X
A.	B-X
Trifi	B-X
,	B-X
S.	B-X
Abdellatif	B-X
,	B-X
F.	B-X
Daly	B-X
,	B-X
R.	B-X
Nasri	B-X
,	B-X
S.	B-X
Ben	B-X
Lakhal	B-X
P101	B-X
-	B-X
Septic	B-X
shock	B-X
is	B-X
an	B-X
independent	B-X
risk	B-X
factor	B-X
for	B-X
colistin-induced	B-X
severe	B-X
acute	B-X
kidney	B-X
injury	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
study	B-X
B.	B-X
Bilgili	B-X
,	B-X
M.	B-X
Haliloglu	B-X
,	B-X
F.	B-X
Gul	B-X
,	B-X
I.	B-X
Cinel	B-X
P102	B-X
-	B-X
Nosocomial	B-X
pneumonia	B-X
-	B-X
emphasis	B-X
on	B-X
inhaled	B-X
tobramycin	B-X
A.	B-X
Kuzovlev	B-X
,	B-X
A.	B-X
Shabanov	B-X
,	B-X
S.	B-X
Polovnikov	B-X
,	B-X
V.	B-X
Moroz	B-X
P103	B-X
-	B-X
In	B-X
vitro	B-X
evaluation	B-X
of	B-X
amikacin	B-X
inhale	B-X
and	B-X
commercial	B-X
nebulizers	B-X
in	B-X
a	B-X
mechanical	B-X
ventilator	B-X
N.	B-X
Kadrichu	B-X
,	B-X
T.	B-X
Dang	B-X
,	B-X
K.	B-X
Corkery	B-X
,	B-X
P.	B-X
Challoner	B-X
P104	B-X
-	B-X
The	B-X
effects	B-X
of	B-X
nebulized	B-X
amikacin/fosfomycin	B-X
and	B-X
systemic	B-X
meropenem	B-X
on	B-X
severe	B-X
amikacin-resistant	B-X
meropenem-susceptible	B-X
P.aeruginosa	B-X
pneumonia	B-X
G.	B-X
Li	B-X
Bassi	B-X
,	B-X
E.	B-X
Aguilera	B-X
,	B-X
C.	B-X
Chiurazzi	B-X
,	B-X
C.	B-X
Travierso	B-X
,	B-X
A.	B-X
Motos	B-X
,	B-X
L.	B-X
Fernandez	B-X
,	B-X
R.	B-X
Amaro	B-X
,	B-X
T.	B-X
Senussi	B-X
,	B-X
F.	B-X
Idone	B-X
,	B-X
J.	B-X
Bobi	B-X
,	B-X
M.	B-X
Rigol	B-X
,	B-X
A.	B-X
Torres	B-X
P105	B-X
-	B-X
Optimization	B-X
of	B-X
gentamicin	B-X
peak	B-X
concentrations	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
C.	B-X
J.	B-X
Hodiamont	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
,	B-X
J.	B-X
M.	B-X
Janssen	B-X
,	B-X
C.	B-X
S.	B-X
Bouman	B-X
,	B-X
R.	B-X
A.	B-X
Mathôt	B-X
,	B-X
M.	B-X
D.	B-X
De	B-X
Jong	B-X
,	B-X
R.	B-X
M.	B-X
Van	B-X
Hest	B-X
P106	B-X
-	B-X
Systematic	B-X
review	B-X
of	B-X
cefepime	B-X
induced	B-X
neurotoxicity	B-X
L.	B-X
Payne	B-X
,	B-X
G.	B-X
L.	B-X
Fraser	B-X
P107	B-X
-	B-X
Unasyn®	B-X
causes	B-X
QT	B-X
prolongation	B-X
during	B-X
treatment	B-X
of	B-X
intensive	B-X
care	B-X
patients	B-X
B.	B-X
Tudor	B-X
,	B-X
M.	B-X
Lahner	B-X
,	B-X
G.	B-X
Roth	B-X
,	B-X
C.	B-X
Krenn	B-X
P108	B-X
-	B-X
Comparative	B-X
study	B-X
between	B-X
teicoplanin	B-X
and	B-X
vancomycin	B-X
in	B-X
methicillin-resistant	B-X
staphylococcus	B-X
aureus	B-X
(	B-X
mrsa	B-X
)	B-X
infectious	B-X
of	B-X
toxicological	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ticu	B-X
)	B-X
patients	B-X
–	B-X
Tehran	B-X
,	B-X
Iran	B-X
H.	B-X
Talaie	B-X
P109	B-X
-	B-X
Phage	B-X
therapy	B-X
against	B-X
antimicrobial	B-X
resistance	B-X
,	B-X
design	B-X
of	B-X
the	B-X
first	B-X
clinical	B-X
study	B-X
phagoburn	B-X
P.	B-X
Jault	B-X
,	B-X
J.	B-X
Gabard	B-X
,	B-X
T.	B-X
Leclerc	B-X
,	B-X
S.	B-X
Jennes	B-X
,	B-X
Y.	B-X
Que	B-X
,	B-X
A.	B-X
Rousseau	B-X
,	B-X
F.	B-X
Ravat	B-X
P110	B-X
-	B-X
Antibiotic	B-X
dosing	B-X
errors	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
or	B-X
septic	B-X
shock	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
A.	B-X
Eissa	B-X
,	B-X
S.	B-X
Al-Harbi	B-X
,	B-X
T.	B-X
Aldabbagh	B-X
,	B-X
R.	B-X
Khan	B-X
,	B-X
Y.	B-X
Arabi	B-X
P111	B-X
-	B-X
Does	B-X
empiric	B-X
antifungal	B-X
therapy	B-X
improve	B-X
survival	B-X
in	B-X
septic	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
(	B-X
immunocompromised	B-X
excluded	B-X
)	B-X
A.	B-X
Trifi	B-X
,	B-X
S.	B-X
Abdellatif	B-X
,	B-X
F.	B-X
Daly	B-X
,	B-X
R.	B-X
Nasri	B-X
,	B-X
S.	B-X
Ben	B-X
Lakhal	B-X
P112	B-X
-	B-X
Neurocysticercosis-Qatar	B-X
experience	B-X
F.	B-X
Paramba	B-X
,	B-X
N.	B-X
Purayil	B-X
,	B-X
V.	B-X
Naushad	B-X
,	B-X
O.	B-X
Mohammad	B-X
,	B-X
V.	B-X
Negi	B-X
,	B-X
P.	B-X
Chandra	B-X
P113	B-X
-	B-X
Early	B-X
indicators	B-X
in	B-X
acute	B-X
haemorrhagic	B-X
shock	B-X
A.	B-X
Kleinsasser	B-X
P114	B-X
-	B-X
Filtering	B-X
of	B-X
red	B-X
blood	B-X
cells	B-X
reduces	B-X
the	B-X
inflammatory	B-X
response	B-X
of	B-X
pulmonary	B-X
cells	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
model	B-X
of	B-X
mechanical	B-X
ventilation	B-X
M.	B-X
R.	B-X
Witrz	B-X
,	B-X
J.	B-X
F.	B-X
Buchner-Doeven	B-X
,	B-X
A.	B-X
M.	B-X
Tuip-de	B-X
Boer	B-X
,	B-X
J.	B-X
C.	B-X
Goslings	B-X
,	B-X
N.	B-X
P.	B-X
Juffermans	B-X
P115	B-X
-	B-X
Microparticles	B-X
from	B-X
red	B-X
blood	B-X
cell	B-X
transfusion	B-X
induce	B-X
a	B-X
pro-coagulant	B-X
and	B-X
pro-inflammatory	B-X
endothelial	B-X
cell	B-X
response	B-X
M.	B-X
Van	B-X
Hezel	B-X
,	B-X
M.	B-X
Straat	B-X
,	B-X
A	B-X
Boing	B-X
,	B-X
R	B-X
Van	B-X
Bruggen	B-X
,	B-X
N	B-X
Juffermans	B-X
P116	B-X
-	B-X
The	B-X
contribution	B-X
of	B-X
cytokines	B-X
on	B-X
thrombosis	B-X
development	B-X
during	B-X
hospitalization	B-X
in	B-X
ICU	B-X
D.	B-X
Markopoulou	B-X
,	B-X
K.	B-X
Venetsanou	B-X
,	B-X
V.	B-X
Kaldis	B-X
,	B-X
D.	B-X
Koutete	B-X
,	B-X
D.	B-X
Chroni	B-X
,	B-X
I.	B-X
Alamanos	B-X
P117	B-X
-	B-X
Prophylactic	B-X
enoxaparin	B-X
dosing	B-X
and	B-X
adjustment	B-X
through	B-X
anti-xa	B-X
monitoring	B-X
in	B-X
an	B-X
inpatient	B-X
burn	B-X
unit	B-X
L.	B-X
Koch	B-X
,	B-X
J.	B-X
Jancik	B-X
,	B-X
H.	B-X
Rhodes	B-X
,	B-X
E.	B-X
Walter	B-X
P118	B-X
-	B-X
Determination	B-X
of	B-X
optimal	B-X
cut-off	B-X
values	B-X
of	B-X
haemoglobin	B-X
,	B-X
platelet	B-X
count	B-X
and	B-X
fibrinogen	B-X
at	B-X
24	B-X
hours	B-X
after	B-X
injury	B-X
associated	B-X
with	B-X
mortality	B-X
in	B-X
trauma	B-X
patients	B-X
K.	B-X
Maekawa	B-X
,	B-X
M.	B-X
Hayakawa	B-X
,	B-X
S.	B-X
Kushimoto	B-X
,	B-X
A.	B-X
Shiraishi	B-X
,	B-X
H.	B-X
Kato	B-X
,	B-X
J.	B-X
Sasaki	B-X
,	B-X
H.	B-X
Ogura	B-X
,	B-X
T.	B-X
Matauoka	B-X
,	B-X
T.	B-X
Uejima	B-X
,	B-X
N.	B-X
Morimura	B-X
,	B-X
H.	B-X
Ishikura	B-X
,	B-X
A.	B-X
Hagiwara	B-X
,	B-X
M.	B-X
Takeda	B-X
P119	B-X
-	B-X
Trauma-induced	B-X
coagulopathy	B-X
-	B-X
prothrombin	B-X
complex	B-X
concentrate	B-X
vs	B-X
fresh	B-X
frozen	B-X
plasma	B-X
O.	B-X
Tarabrin	B-X
,	B-X
S.	B-X
Shcherbakow	B-X
,	B-X
D.	B-X
Gavrychenko	B-X
,	B-X
G.	B-X
Mazurenko	B-X
,	B-X
V.	B-X
Ivanova	B-X
,	B-X
O.	B-X
Chystikov	B-X
P120	B-X
-	B-X
First	B-X
study	B-X
to	B-X
prove	B-X
the	B-X
superiority	B-X
of	B-X
prothrombin	B-X
complex	B-X
concentrates	B-X
on	B-X
mortality	B-X
rate	B-X
over	B-X
fresh	B-X
frozen	B-X
plasma	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
bleeding	B-X
C.	B-X
Plourde	B-X
,	B-X
J.	B-X
Lessard	B-X
,	B-X
J.	B-X
Chauny	B-X
,	B-X
R.	B-X
Daoust	B-X
P121	B-X
-	B-X
Prothrombin	B-X
complex	B-X
concentrate	B-X
vs	B-X
fresh	B-X
frozen	B-X
plasma	B-X
in	B-X
obstetric	B-X
massive	B-X
bleeding	B-X
S.	B-X
Shcherbakow	B-X
,	B-X
O.	B-X
Tarabrin	B-X
,	B-X
D.	B-X
Gavrychenko	B-X
,	B-X
G.	B-X
Mazurenko	B-X
,	B-X
O.	B-X
Chystikov	B-X
P122	B-X
-	B-X
Impact	B-X
of	B-X
FFP	B-X
transfusion	B-X
on	B-X
VAP	B-X
in	B-X
ICU	B-X
patients	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P123	B-X
-	B-X
Preoperative	B-X
platelet	B-X
function	B-X
test	B-X
and	B-X
the	B-X
thrombin	B-X
generation	B-X
assay	B-X
are	B-X
predictive	B-X
for	B-X
blood	B-X
loss	B-X
after	B-X
cardiac	B-X
surgery	B-X
L.	B-X
Kropman	B-X
,	B-X
L.	B-X
In	B-X
het	B-X
Panhuis	B-X
,	B-X
J.	B-X
Konings	B-X
,	B-X
D.	B-X
Huskens	B-X
,	B-X
E.	B-X
Schurgers	B-X
,	B-X
M.	B-X
Roest	B-X
,	B-X
B	B-X
.	B-X
De	B-X
Laat	B-X
,	B-X
M.	B-X
Lance	B-X
P124	B-X
-	B-X
Rotational	B-X
thromboelastometry	B-X
versus	B-X
standard	B-X
coagulation	B-X
tests	B-X
before	B-X
surgical	B-X
interventions	B-X
M.	B-X
Durila	B-X
,	B-X
P.	B-X
Lukas	B-X
,	B-X
M.	B-X
Astraverkhava	B-X
,	B-X
J.	B-X
Jonas	B-X
P125	B-X
-	B-X
Correction	B-X
of	B-X
impaired	B-X
clot	B-X
quality	B-X
and	B-X
stability	B-X
by	B-X
fibrinogen	B-X
and	B-X
activated	B-X
prothrombin	B-X
complex	B-X
concentrate	B-X
in	B-X
a	B-X
model	B-X
of	B-X
severe	B-X
thrombocytopenia	B-X
I.	B-X
Budnik	B-X
,	B-X
B.	B-X
Shenkman	B-X
P126	B-X
-	B-X
Assessment	B-X
of	B-X
point-of-care	B-X
prothrombin	B-X
time	B-X
analyzer	B-X
as	B-X
a	B-X
monitor	B-X
after	B-X
cardiopulmonary	B-X
bypass	B-X
H.	B-X
Hayami	B-X
,	B-X
Y.	B-X
Koide	B-X
,	B-X
T.	B-X
Goto	B-X
P127	B-X
-	B-X
Disseminated	B-X
intravascular	B-X
coagulation	B-X
(	B-X
dic	B-X
)	B-X
is	B-X
underdiagnosed	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
do	B-X
we	B-X
need	B-X
d-dimer	B-X
measurements	B-X
?	B-X
R.	B-X
Iqbal	B-X
,	B-X
Y.	B-X
Alhamdi	B-X
,	B-X
N.	B-X
Venugopal	B-X
,	B-X
S.	B-X
Abrams	B-X
,	B-X
C.	B-X
Downey	B-X
,	B-X
C.	B-X
H.	B-X
Toh	B-X
,	B-X
I.	B-X
D.	B-X
Welters	B-X
P128	B-X
-	B-X
Validity	B-X
of	B-X
the	B-X
age-adjusted	B-X
d-dimer	B-X
cutoff	B-X
in	B-X
patients	B-X
with	B-X
COPD	B-X
B.	B-X
Bombay	B-X
,	B-X
J.	B-X
M.	B-X
Chauny	B-X
,	B-X
R.	B-X
D.	B-X
Daoust	B-X
,	B-X
J.	B-X
L.	B-X
Lessard	B-X
,	B-X
M.	B-X
M.	B-X
Marquis	B-X
,	B-X
J.	B-X
P.	B-X
Paquet	B-X
P129	B-X
-	B-X
A	B-X
scoping	B-X
review	B-X
of	B-X
strategies	B-X
for	B-X
prevention	B-X
and	B-X
management	B-X
of	B-X
bleeding	B-X
following	B-X
paediatric	B-X
cardiopulmonary	B-X
bypass	B-X
surgery	B-X
K.	B-X
Siemens	B-X
,	B-X
D.	B-X
Sangaran	B-X
,	B-X
B.	B-X
J	B-X
.	B-X
A.	B-X
Murdoch	B-X
,	B-X
S.	B-X
M.	B-X
Tibby	B-X
P130	B-X
-	B-X
Nadir	B-X
hemoglobulin	B-X
during	B-X
cardiopulmonary	B-X
bypass	B-X
:	B-X
impact	B-X
on	B-X
postoperative	B-X
morbidity	B-X
and	B-X
mortality	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
D.	B-X
Moisidou	B-X
,	B-X
E.	B-X
Dalampini	B-X
,	B-X
M.	B-X
Nastou	B-X
,	B-X
E.	B-X
Vasilarou	B-X
,	B-X
V.	B-X
Kalaizi	B-X
,	B-X
H.	B-X
Chatzikostenoglou	B-X
,	B-X
G.	B-X
Drossos	B-X
P131	B-X
-	B-X
Red	B-X
blood	B-X
cell	B-X
transfusion	B-X
do	B-X
not	B-X
influence	B-X
the	B-X
prognostic	B-X
value	B-X
of	B-X
RDW	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
S.	B-X
Spadaro	B-X
,	B-X
A.	B-X
Fogagnolo	B-X
,	B-X
T.	B-X
Fiore	B-X
,	B-X
A.	B-X
Schiavi	B-X
,	B-X
V.	B-X
Fontana	B-X
,	B-X
F.	B-X
Taccone	B-X
,	B-X
C.	B-X
Volta	B-X
P132	B-X
-	B-X
Reasons	B-X
for	B-X
admission	B-X
in	B-X
the	B-X
paediatric	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
the	B-X
need	B-X
for	B-X
blood	B-X
and	B-X
blood	B-X
products	B-X
transfusions	B-X
E.	B-X
Chochliourou	B-X
,	B-X
E.	B-X
Volakli	B-X
,	B-X
A.	B-X
Violaki	B-X
,	B-X
E.	B-X
Samkinidou	B-X
,	B-X
G.	B-X
Evlavis	B-X
,	B-X
V.	B-X
Panagiotidou	B-X
,	B-X
M.	B-X
Sdougka	B-X
P133	B-X
-	B-X
The	B-X
implementation	B-X
of	B-X
a	B-X
massive	B-X
haemorrhage	B-X
protocol	B-X
(	B-X
mhp	B-X
)	B-X
for	B-X
the	B-X
management	B-X
of	B-X
major	B-X
trauma	B-X
:	B-X
a	B-X
ten	B-X
year	B-X
,	B-X
single-centre	B-X
study	B-X
R.	B-X
Mothukuri	B-X
,	B-X
C.	B-X
Battle	B-X
,	B-X
K.	B-X
Guy	B-X
,	B-X
G.	B-X
Mills	B-X
,	B-X
P.	B-X
Evans	B-X
P134	B-X
-	B-X
An	B-X
integrated	B-X
major	B-X
haemorrhage	B-X
protocol	B-X
for	B-X
pre-hospital	B-X
and	B-X
retrieval	B-X
medical	B-X
teams	B-X
J.	B-X
Wijesuriya	B-X
,	B-X
S.	B-X
Keogh	B-X
P135	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
transfusion	B-X
thresholds	B-X
on	B-X
mortality	B-X
and	B-X
cardiovascular	B-X
events	B-X
in	B-X
patients	B-X
with	B-X
cardiovascular	B-X
disease	B-X
(	B-X
non-cardiac	B-X
surgery	B-X
)	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
A.	B-X
Docherty	B-X
,	B-X
R.	B-X
O	B-X
’	B-X
Donnell	B-X
,	B-X
S.	B-X
Brunskill	B-X
,	B-X
M.	B-X
Trivella	B-X
,	B-X
C.	B-X
Doree	B-X
,	B-X
L.	B-X
Holst	B-X
,	B-X
M.	B-X
Parker	B-X
,	B-X
M.	B-X
Gregersen	B-X
,	B-X
J.	B-X
Almeida	B-X
,	B-X
T.	B-X
Walsh	B-X
,	B-X
S.	B-X
Stanworth	B-X
P136	B-X
-	B-X
The	B-X
relationship	B-X
between	B-X
poor	B-X
pre-operative	B-X
immune	B-X
status	B-X
and	B-X
outcome	B-X
from	B-X
cardiac	B-X
surgery	B-X
is	B-X
specific	B-X
to	B-X
the	B-X
peri-operative	B-X
antigenic	B-X
threat	B-X
S.	B-X
Moravcova	B-X
,	B-X
J.	B-X
Mansell	B-X
,	B-X
A.	B-X
Rogers	B-X
,	B-X
R.	B-X
A.	B-X
Smith	B-X
,	B-X
C.	B-X
Hamilton-Davies	B-X
P137	B-X
-	B-X
Impact	B-X
of	B-X
simple	B-X
clinical	B-X
practice	B-X
guidelines	B-X
for	B-X
reducing	B-X
post-operative	B-X
atrial	B-X
fibrillation	B-X
after	B-X
cardiac	B-X
surgery	B-X
.	B-X
A.	B-X
Omar	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
O.	B-X
Bilala	B-X
,	B-X
A.	B-X
Kindawi	B-X
,	B-X
H.	B-X
Ewila	B-X
P138	B-X
-	B-X
Dexamethasone	B-X
administration	B-X
during	B-X
cardiopulmonary	B-X
bypass	B-X
has	B-X
no	B-X
beneficial	B-X
effects	B-X
on	B-X
elective	B-X
postoperative	B-X
cardiac	B-X
surgery	B-X
patients	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
D.	B-X
Moisidou	B-X
,	B-X
M.	B-X
Nastou	B-X
,	B-X
E.	B-X
Dalampini	B-X
,	B-X
A.	B-X
Malamas	B-X
,	B-X
E.	B-X
Vasilarou	B-X
,	B-X
G.	B-X
Drossos	B-X
P139	B-X
-	B-X
Intra-aortic	B-X
balloon	B-X
counterpulsation	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
(	B-X
IABCS	B-X
)	B-X
:	B-X
preliminary	B-X
results	B-X
G.	B-X
Ferreira	B-X
,	B-X
J.	B-X
Caldas	B-X
,	B-X
J.	B-X
Fukushima	B-X
,	B-X
E.	B-X
A.	B-X
Osawa	B-X
,	B-X
E.	B-X
Arita	B-X
,	B-X
L.	B-X
Camara	B-X
,	B-X
S.	B-X
Zeferino	B-X
,	B-X
J.	B-X
Jardim	B-X
,	B-X
F.	B-X
Gaioto	B-X
,	B-X
L.	B-X
Dallan	B-X
,	B-X
F.	B-X
B.	B-X
Jatene	B-X
,	B-X
R.	B-X
Kalil	B-X
Filho	B-X
,	B-X
.F	B-X
Galas	B-X
,	B-X
L.	B-X
A.	B-X
Hajjar	B-X
P140	B-X
-	B-X
Effects	B-X
of	B-X
low-dose	B-X
atrial	B-X
natriuretic	B-X
peptide	B-X
infusion	B-X
on	B-X
cardiac	B-X
surgery-associated	B-X
acute	B-X
kidney	B-X
injury	B-X
C.	B-X
Mitaka	B-X
,	B-X
T.	B-X
Ohnuma	B-X
,	B-X
T.	B-X
Murayama	B-X
,	B-X
F.	B-X
Kunimoto	B-X
,	B-X
M.	B-X
Nagashima	B-X
,	B-X
T.	B-X
Takei	B-X
,	B-X
M.	B-X
Tomita	B-X
P141	B-X
-	B-X
Acute	B-X
kidney	B-X
injury	B-X
influence	B-X
on	B-X
high	B-X
sensitive	B-X
troponin	B-X
measurements	B-X
after	B-X
cardiac	B-X
surgery	B-X
A.	B-X
Omar	B-X
,	B-X
K.	B-X
Mahmoud	B-X
,	B-X
S.	B-X
Hanoura	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
P.	B-X
Sivadasan	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
Y.	B-X
Shouman	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P142	B-X
-	B-X
Complex	B-X
evaluation	B-X
of	B-X
endothelial	B-X
dysfunction	B-X
markers	B-X
for	B-X
prognosis	B-X
of	B-X
outcomes	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
I.	B-X
Mandel	B-X
,	B-X
S.	B-X
Mikheev	B-X
,	B-X
I.	B-X
Suhodolo	B-X
,	B-X
V.	B-X
Kiselev	B-X
,	B-X
Y.	B-X
Svirko	B-X
,	B-X
Y.	B-X
Podoksenov	B-X
P143	B-X
-	B-X
New-onset	B-X
atrial	B-X
fibrillation	B-X
in	B-X
intensive	B-X
care	B-X
:	B-X
incidence	B-X
,	B-X
management	B-X
and	B-X
outcome	B-X
S.	B-X
A.	B-X
Jenkins	B-X
,	B-X
R.	B-X
Griffin	B-X
P144	B-X
-	B-X
One	B-X
single	B-X
spot	B-X
measurement	B-X
of	B-X
the	B-X
sublingual	B-X
microcirculation	B-X
during	B-X
acute	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
pig	B-X
model	B-X
of	B-X
shock	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
A.	B-X
Lima	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
C.	B-X
Ince	B-X
P145	B-X
-	B-X
Assessment	B-X
of	B-X
levosimendan	B-X
as	B-X
a	B-X
therapeutic	B-X
option	B-X
to	B-X
recruit	B-X
the	B-X
microcirculation	B-X
in	B-X
cardiogenic	B-X
shock	B-X
–	B-X
initial	B-X
experience	B-X
in	B-X
cardiac	B-X
ICU	B-X
A.	B-X
Taha	B-X
,	B-X
A.	B-X
Shafie	B-X
,	B-X
M.	B-X
Mostafa	B-X
,	B-X
N.	B-X
Syed	B-X
,	B-X
H.	B-X
Hon	B-X
P146	B-X
-	B-X
Terlipressin	B-X
vs.	B-X
norepinephrine	B-X
in	B-X
the	B-X
Potential	B-X
Multiorgan	B-X
Donor	B-X
(	B-X
PMD	B-X
)	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
,	B-X
G.	B-X
Castellano	B-X
P147	B-X
-	B-X
Echocardiography	B-X
in	B-X
the	B-X
potential	B-X
heart	B-X
donor	B-X
exposed	B-X
to	B-X
substitution	B-X
hormonotherapy	B-X
F.	B-X
Righetti	B-X
,	B-X
E.	B-X
Colombaroli	B-X
P148	B-X
-	B-X
Machine	B-X
learning	B-X
can	B-X
reduce	B-X
rate	B-X
of	B-X
monitor	B-X
alarms	B-X
M.	B-X
Hravnak	B-X
,	B-X
L.	B-X
C.	B-X
Chen	B-X
,	B-X
A.	B-X
D.	B-X
Dubrawski	B-X
,	B-X
G.	B-X
C.	B-X
Clermont	B-X
,	B-X
M.	B-X
R.	B-X
Pinsky	B-X
P149	B-X
-	B-X
Peripherally	B-X
inserted	B-X
central	B-X
catheters	B-X
placed	B-X
in	B-X
the	B-X
ICU	B-X
S.	B-X
Gonzalez	B-X
,	B-X
D.	B-X
Macias	B-X
,	B-X
J.	B-X
Acosta	B-X
,	B-X
P.	B-X
Jimenez	B-X
,	B-X
A.	B-X
Loza	B-X
,	B-X
A.	B-X
Lesmes	B-X
,	B-X
F.	B-X
Lucena	B-X
,	B-X
C.	B-X
Leon	B-X
P150	B-X
-	B-X
Recordings	B-X
of	B-X
abnormal	B-X
central	B-X
venous	B-X
pressure	B-X
waveform	B-X
morphology	B-X
during	B-X
an	B-X
episode	B-X
of	B-X
pulmonary	B-X
hypertension	B-X
in	B-X
a	B-X
porcine	B-X
shock	B-X
model	B-X
M.	B-X
S.	B-X
Tovar	B-X
Doncel	B-X
,	B-X
C.	B-X
Ince	B-X
,	B-X
C.	B-X
Aldecoa	B-X
,	B-X
A.	B-X
Lima	B-X
P151	B-X
-	B-X
Ultrasound	B-X
guided	B-X
central	B-X
venous	B-X
access	B-X
technique	B-X
among	B-X
French	B-X
intensivists	B-X
M.	B-X
Bastide	B-X
,	B-X
J.	B-X
Richecoeur	B-X
,	B-X
E.	B-X
Frenoy	B-X
,	B-X
C.	B-X
Lemaire	B-X
,	B-X
B.	B-X
Sauneuf	B-X
,	B-X
F.	B-X
Tamion	B-X
,	B-X
S.	B-X
Nseir	B-X
,	B-X
D.	B-X
Du	B-X
Cheyron	B-X
,	B-X
H.	B-X
Dupont	B-X
,	B-X
J.	B-X
Maizel	B-X
P152	B-X
-	B-X
Predictive	B-X
ability	B-X
of	B-X
the	B-X
Pv-aCO2	B-X
gap	B-X
in	B-X
patients	B-X
with	B-X
shock	B-X
M.	B-X
Shaban	B-X
,	B-X
R.	B-X
Kolko	B-X
,	B-X
N.	B-X
Salahuddin	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
AbuRageila	B-X
,	B-X
A.	B-X
AlHussain	B-X
P153	B-X
-	B-X
Comparison	B-X
of	B-X
echocardiography	B-X
and	B-X
pulmonary	B-X
artery	B-X
catheter	B-X
measurements	B-X
of	B-X
hemodynamic	B-X
parameters	B-X
in	B-X
critical	B-X
ill	B-X
patients	B-X
P.	B-X
Mercado	B-X
,	B-X
J.	B-X
Maizel	B-X
,	B-X
L.	B-X
Kontar	B-X
,	B-X
D.	B-X
Titeca	B-X
,	B-X
F.	B-X
Brazier	B-X
,	B-X
A.	B-X
Riviere	B-X
,	B-X
M.	B-X
Joris	B-X
,	B-X
T.	B-X
Soupison	B-X
,	B-X
B	B-X
.	B-X
De	B-X
Cagny	B-X
,	B-X
M.	B-X
Slama	B-X
P154	B-X
-	B-X
The	B-X
volume	B-X
clamp	B-X
method	B-X
for	B-X
noninvasive	B-X
cardiac	B-X
output	B-X
measurement	B-X
in	B-X
postoperative	B-X
cardiothoracic	B-X
surgery	B-X
patients	B-X
:	B-X
a	B-X
comparison	B-X
with	B-X
intermittent	B-X
pulmonary	B-X
artery	B-X
thermodilution	B-X
J.	B-X
Wagner	B-X
,	B-X
A.	B-X
Körner	B-X
,	B-X
M.	B-X
Kubik	B-X
,	B-X
S.	B-X
Kluge	B-X
,	B-X
D.	B-X
Reuter	B-X
,	B-X
B.	B-X
Saugel	B-X
P155	B-X
-	B-X
Hemodynamic	B-X
monitoring	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
(	B-X
SS	B-X
)	B-X
–	B-X
CPCCO	B-X
(	B-X
continuous	B-X
pulse	B-X
contour	B-X
cardiac	B-X
output	B-X
)	B-X
vs.	B-X
TEE	B-X
(	B-X
transesophageal	B-X
echocardiography	B-X
)	B-X
E.	B-X
Colombaroli	B-X
,	B-X
F.	B-X
Righetti	B-X
,	B-X
G.	B-X
Castellano	B-X
P156	B-X
-	B-X
Cardiac	B-X
output	B-X
measurement	B-X
with	B-X
transthoracic	B-X
echocardiography	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
a	B-X
pragmatic	B-X
clinical	B-X
study	B-X
T.	B-X
Tran	B-X
,	B-X
D.	B-X
De	B-X
Bels	B-X
,	B-X
A.	B-X
Cudia	B-X
,	B-X
M.	B-X
Strachinaru	B-X
,	B-X
P.	B-X
Ghottignies	B-X
,	B-X
J.	B-X
Devriendt	B-X
,	B-X
C.	B-X
Pierrakos	B-X
P157	B-X
-	B-X
Left	B-X
ventricular	B-X
outflow	B-X
tract	B-X
velocity	B-X
time	B-X
integral	B-X
correlates	B-X
with	B-X
stroke	B-X
volume	B-X
index	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
Ó.	B-X
Martínez	B-X
González	B-X
,	B-X
R.	B-X
Blancas	B-X
,	B-X
J.	B-X
Luján	B-X
,	B-X
D.	B-X
Ballesteros	B-X
,	B-X
C.	B-X
Martínez	B-X
Díaz	B-X
,	B-X
A.	B-X
Núñez	B-X
,	B-X
C.	B-X
Martín	B-X
Parra	B-X
,	B-X
B.	B-X
López	B-X
Matamala	B-X
,	B-X
M.	B-X
Alonso	B-X
Fernández	B-X
,	B-X
M.	B-X
Chana	B-X
P158	B-X
-	B-X
Transpulmonary	B-X
thermodilution	B-X
(	B-X
TPTD	B-X
)	B-X
derived	B-X
from	B-X
femoral	B-X
vs.	B-X
jugular	B-X
central	B-X
venous	B-X
catheter	B-X
:	B-X
validation	B-X
of	B-X
a	B-X
previously	B-X
published	B-X
correction	B-X
formula	B-X
and	B-X
a	B-X
proprietary	B-X
correction	B-X
formula	B-X
for	B-X
global	B-X
end-diastolic	B-X
volume	B-X
index	B-X
(	B-X
GEDVI	B-X
)	B-X
W.	B-X
Huber	B-X
,	B-X
M.	B-X
Eckmann	B-X
,	B-X
F.	B-X
Elkmann	B-X
,	B-X
A.	B-X
Gruber	B-X
,	B-X
I.	B-X
Klein	B-X
,	B-X
R.	B-X
M.	B-X
Schmid	B-X
,	B-X
T.	B-X
Lahmer	B-X
P160	B-X
-	B-X
Dynamic	B-X
arterial	B-X
elastance	B-X
calculated	B-X
with	B-X
lidcoplus	B-X
monitor	B-X
does	B-X
not	B-X
predict	B-X
changes	B-X
in	B-X
arterial	B-X
pressure	B-X
after	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
postsurgical	B-X
patients	B-X
D.	B-X
Bastoni	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
L.	B-X
Toscani	B-X
,	B-X
L.	B-X
Pigozzi	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P159	B-X
-	B-X
Venous	B-X
return	B-X
driving	B-X
pressure	B-X
and	B-X
resistance	B-X
in	B-X
acute	B-X
blood	B-X
volume	B-X
changes	B-X
P.	B-X
W.	B-X
Moller	B-X
,	B-X
S.	B-X
Sondergaard	B-X
,	B-X
S.	B-X
M.	B-X
Jakob	B-X
,	B-X
J.	B-X
Takala	B-X
,	B-X
D.	B-X
Berger	B-X
P160	B-X
-	B-X
Dynamic	B-X
arterial	B-X
elastance	B-X
calculated	B-X
with	B-X
lidcoplus	B-X
monitor	B-X
does	B-X
not	B-X
predict	B-X
changes	B-X
in	B-X
arterial	B-X
pressure	B-X
after	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
postsurgical	B-X
patients	B-X
D.	B-X
Bastoni	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
L.	B-X
Toscani	B-X
,	B-X
L.	B-X
Pigozzi	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P161	B-X
-	B-X
Analysis	B-X
of	B-X
duration	B-X
of	B-X
post-operative	B-X
goal-directed	B-X
therapy	B-X
protocol	B-X
C.	B-X
Ostrowska	B-X
,	B-X
H.	B-X
Aya	B-X
,	B-X
A.	B-X
Abbas	B-X
,	B-X
J.	B-X
Mellinghoff	B-X
,	B-X
C.	B-X
Ryan	B-X
,	B-X
D.	B-X
Dawson	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
M.	B-X
Cecconi	B-X
P162	B-X
-	B-X
Hemodynamic	B-X
optimization	B-X
–	B-X
back	B-X
to	B-X
square	B-X
one	B-X
?	B-X
Wall	B-X
,	B-X
E.	B-X
Nyberg	B-X
,	B-X
R.	B-X
Zeng	B-X
,	B-X
C.	B-X
Svensen	B-X
,	B-X
J.	B-X
Mårtensson	B-X
,	B-X
E.	B-X
Joelsson-Alm	B-X
P163	B-X
-	B-X
Effectiveness	B-X
of	B-X
fluid	B-X
thoracic	B-X
content	B-X
measurement	B-X
by	B-X
bioimpedance	B-X
guiding	B-X
intravascular	B-X
volume	B-X
optimization	B-X
in	B-X
patients	B-X
with	B-X
septic	B-X
shock	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
V.	B-X
Lopez	B-X
,	B-X
M.	B-X
Cetina	B-X
P164	B-X
-	B-X
A	B-X
systematic	B-X
review	B-X
on	B-X
the	B-X
role	B-X
of	B-X
internal	B-X
jugular	B-X
vein	B-X
ultrasound	B-X
measurements	B-X
in	B-X
assessment	B-X
of	B-X
volume	B-X
status	B-X
in	B-X
critical	B-X
shock	B-X
patients	B-X
N.	B-X
Parenti	B-X
,	B-X
C.	B-X
Palazzi	B-X
,	B-X
L.	B-X
A.	B-X
Amidei	B-X
,	B-X
F.	B-X
B.	B-X
Borrelli	B-X
,	B-X
S.	B-X
C.	B-X
Campanale	B-X
,	B-X
F.	B-X
T.	B-X
Tagliazucchi	B-X
,	B-X
G.	B-X
S.	B-X
Sedoni	B-X
,	B-X
D.	B-X
L.	B-X
Lucchesi	B-X
,	B-X
E.	B-X
C.	B-X
Carella	B-X
,	B-X
A.	B-X
L	B-X
Luciani	B-X
P165	B-X
-	B-X
Importance	B-X
of	B-X
recognizing	B-X
dehydration	B-X
in	B-X
medical	B-X
Intensive	B-X
Care	B-X
Unit	B-X
M.	B-X
Mackovic	B-X
,	B-X
N.	B-X
Maric	B-X
,	B-X
M.	B-X
Bakula	B-X
P166	B-X
-	B-X
Effect	B-X
of	B-X
volume	B-X
for	B-X
a	B-X
fluid	B-X
challenge	B-X
in	B-X
septic	B-X
patients	B-X
H.	B-X
Aya	B-X
,	B-X
A.	B-X
Rhodes	B-X
,	B-X
R.	B-X
M.	B-X
Grounds	B-X
,	B-X
N.	B-X
Fletcher	B-X
,	B-X
M.	B-X
Cecconi	B-X
P167	B-X
-	B-X
Fluid	B-X
bolus	B-X
practices	B-X
in	B-X
a	B-X
large	B-X
Australian	B-X
intensive	B-X
care	B-X
unit	B-X
B.	B-X
Avard	B-X
,	B-X
P.	B-X
Zhang	B-X
P168	B-X
-	B-X
Liberal	B-X
late	B-X
fluid	B-X
management	B-X
is	B-X
associated	B-X
with	B-X
longer	B-X
ventilation	B-X
duration	B-X
and	B-X
worst	B-X
outcome	B-X
in	B-X
severe	B-X
trauma	B-X
patients	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
of	B-X
294	B-X
patients	B-X
M.	B-X
Mezidi	B-X
,	B-X
J.	B-X
Charbit	B-X
,	B-X
M.	B-X
Ould-Chikh	B-X
,	B-X
P.	B-X
Deras	B-X
,	B-X
C.	B-X
Maury	B-X
,	B-X
O.	B-X
Martinez	B-X
,	B-X
X.	B-X
Capdevila	B-X
P169	B-X
-	B-X
Association	B-X
of	B-X
fluids	B-X
and	B-X
outcomes	B-X
in	B-X
emergency	B-X
department	B-X
patients	B-X
hospitalized	B-X
with	B-X
community-acquired	B-X
pneumonia	B-X
P.	B-X
Hou	B-X
,	B-X
W.	B-X
Z.	B-X
Linde-Zwirble	B-X
,	B-X
I.	B-X
D.	B-X
Douglas	B-X
,	B-X
N.	B-X
S.	B-X
Shapiro	B-X
P170	B-X
-	B-X
Association	B-X
of	B-X
positive	B-X
fluid	B-X
balance	B-X
with	B-X
poor	B-X
outcome	B-X
in	B-X
medicosurgical	B-X
ICU	B-X
patients	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
I.	B-X
Mezghani	B-X
,	B-X
Y.	B-X
Ben	B-X
Aicha	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
B.	B-X
Laribi	B-X
,	B-X
B.	B-X
Jeribi	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.	B-X
S.	B-X
Mebazaa	B-X
P171	B-X
-	B-X
Impact	B-X
of	B-X
fluid	B-X
balance	B-X
to	B-X
organ	B-X
dysfunction	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
C.	B-X
Pereira	B-X
,	B-X
R.	B-X
Marinho	B-X
,	B-X
R.	B-X
Antunes	B-X
,	B-X
A.	B-X
Marinho	B-X
P172	B-X
-	B-X
Volume	B-X
bolus	B-X
in	B-X
ICU	B-X
patients	B-X
:	B-X
do	B-X
we	B-X
need	B-X
to	B-X
balance	B-X
our	B-X
crystalloids	B-X
?	B-X
M.	B-X
Crivits	B-X
,	B-X
M.	B-X
Raes	B-X
,	B-X
J.	B-X
Decruyenaere	B-X
,	B-X
E.	B-X
Hoste	B-X
P173	B-X
-	B-X
The	B-X
use	B-X
of	B-X
6	B-X
%	B-X
HES	B-X
solution	B-X
do	B-X
not	B-X
reduce	B-X
total	B-X
fluid	B-X
requirement	B-X
in	B-X
the	B-X
therapy	B-X
of	B-X
patients	B-X
with	B-X
burn	B-X
shock	B-X
V.	B-X
Bagin	B-X
,	B-X
V.	B-X
Rudnov	B-X
,	B-X
A.	B-X
Savitsky	B-X
,	B-X
M.	B-X
Astafyeva	B-X
,	B-X
I.	B-X
Korobko	B-X
,	B-X
V.	B-X
Vein	B-X
P174	B-X
-	B-X
Electron	B-X
microscopic	B-X
assessment	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
septic	B-X
sheep	B-X
resuscitated	B-X
with	B-X
crystalloids	B-X
or	B-X
different	B-X
colloids	B-X
T.	B-X
Kampmeier	B-X
,	B-X
P.	B-X
Arnemann	B-X
,	B-X
M.	B-X
Hessler	B-X
,	B-X
A.	B-X
Wald	B-X
,	B-X
K.	B-X
Bockbreder	B-X
,	B-X
A.	B-X
Morelli	B-X
,	B-X
H.	B-X
Van	B-X
Aken	B-X
,	B-X
S.	B-X
Rehberg	B-X
,	B-X
C.	B-X
Ertmer	B-X
P175	B-X
-	B-X
Alterations	B-X
of	B-X
conjunctival	B-X
microcirculation	B-X
in	B-X
a	B-X
sheep	B-X
model	B-X
of	B-X
haemorrhagic	B-X
shock	B-X
and	B-X
resuscitation	B-X
with	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
balanced	B-X
tetrastarch	B-X
P.	B-X
Arnemann	B-X
,	B-X
M.	B-X
Hessler	B-X
,	B-X
T.	B-X
Kampmeier	B-X
,	B-X
S.	B-X
Rehberg	B-X
,	B-X
H.	B-X
Van	B-X
Aken	B-X
,	B-X
C.	B-X
Ince	B-X
,	B-X
C.	B-X
Ertmer	B-X
P176	B-X
-	B-X
A	B-X
single	B-X
centre	B-X
nested	B-X
pilot	B-X
study	B-X
investigating	B-X
the	B-X
effect	B-X
of	B-X
using	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
Plasma-Lyte	B-X
148	B-X
®	B-X
as	B-X
crystalloid	B-X
fluid	B-X
therapy	B-X
on	B-X
gastrointestinal	B-X
feeding	B-X
intolerance	B-X
in	B-X
mechanically	B-X
ventilated	B-X
patients	B-X
receiving	B-X
nasogastric	B-X
enteral	B-X
nutrition	B-X
S.	B-X
Reddy	B-X
,	B-X
M.	B-X
Bailey	B-X
,	B-X
R.	B-X
Beasley	B-X
,	B-X
R.	B-X
Bellomo	B-X
,	B-X
D.	B-X
Mackle	B-X
,	B-X
A.	B-X
Psirides	B-X
,	B-X
P.	B-X
Young	B-X
P177	B-X
-	B-X
A	B-X
single	B-X
centre	B-X
nested	B-X
pilot	B-X
study	B-X
investigating	B-X
the	B-X
effect	B-X
on	B-X
post-operative	B-X
bleeding	B-X
of	B-X
using	B-X
0.9	B-X
%	B-X
saline	B-X
or	B-X
Plasma-Lyte®	B-X
148	B-X
as	B-X
crystalloid	B-X
fluid	B-X
therapy	B-X
in	B-X
adults	B-X
in	B-X
ICU	B-X
after	B-X
heart	B-X
surgery	B-X
S.	B-X
Reddy	B-X
,	B-X
M.	B-X
Bailey	B-X
,	B-X
R.	B-X
Beasley	B-X
,	B-X
R.	B-X
Bellomo	B-X
,	B-X
D.	B-X
Mackle	B-X
,	B-X
P.	B-X
Young	B-X
P178	B-X
-	B-X
Extreme	B-X
hypernatremia	B-X
and	B-X
sepsis	B-X
in	B-X
a	B-X
patient	B-X
with	B-X
Huntington	B-X
’	B-X
s	B-X
dementia	B-X
:	B-X
a	B-X
conundrum	B-X
in	B-X
fluid	B-X
management	B-X
H.	B-X
Venkatesh	B-X
,	B-X
S.	B-X
Ramachandran	B-X
,	B-X
A.	B-X
Basu	B-X
,	B-X
H.	B-X
Nair	B-X
P179	B-X
-	B-X
Diagnosis	B-X
and	B-X
management	B-X
of	B-X
severe	B-X
hypernatraemia	B-X
in	B-X
the	B-X
critical	B-X
care	B-X
setting	B-X
S.	B-X
Egan	B-X
,	B-X
J.	B-X
Bates	B-X
P180	B-X
-	B-X
Correlation	B-X
between	B-X
arterial	B-X
blood	B-X
gas	B-X
and	B-X
electrolyte	B-X
disturbances	B-X
during	B-X
hospitalization	B-X
and	B-X
outcome	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
S.	B-X
Oliveira	B-X
,	B-X
N.	B-X
R.	B-X
Rangel	B-X
Neto	B-X
,	B-X
F.	B-X
Q.	B-X
Reis	B-X
P181	B-X
-	B-X
Missing	B-X
the	B-X
“	B-X
I	B-X
”	B-X
in	B-X
MUDPILES	B-X
–	B-X
a	B-X
rare	B-X
cause	B-X
of	B-X
high	B-X
anion	B-X
gap	B-X
metabolic	B-X
acidosis	B-X
(	B-X
HAGMA	B-X
)	B-X
C.	B-X
P.	B-X
Lee	B-X
,	B-X
X.	B-X
L.	B-X
Lin	B-X
,	B-X
C.	B-X
Choong	B-X
,	B-X
K.	B-X
M.	B-X
Eu	B-X
,	B-X
W.	B-X
Y.	B-X
Sim	B-X
,	B-X
K.	B-X
S.	B-X
Tee	B-X
,	B-X
J.	B-X
Pau	B-X
,	B-X
J.	B-X
Abisheganaden	B-X
P182	B-X
-	B-X
Plasma	B-X
NGAL	B-X
and	B-X
urinary	B-X
output	B-X
:	B-X
potential	B-X
parameters	B-X
for	B-X
early	B-X
initiation	B-X
of	B-X
renal	B-X
replacement	B-X
therapy	B-X
K.	B-X
Maas	B-X
,	B-X
H.	B-X
De	B-X
Geus	B-X
P183	B-X
-	B-X
Renal	B-X
replacement	B-X
therapy	B-X
for	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
an	B-X
intermittent	B-X
continuity	B-X
E.	B-X
Lafuente	B-X
,	B-X
R.	B-X
Marinho	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
R.	B-X
Antunes	B-X
,	B-X
A.	B-X
Marinho	B-X
P184	B-X
-	B-X
A	B-X
survey	B-X
of	B-X
practices	B-X
related	B-X
to	B-X
renal	B-X
replacement	B-X
therapy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
in	B-X
the	B-X
north	B-X
of	B-X
England	B-X
.	B-X
T.	B-X
E.	B-X
Doris	B-X
,	B-X
D.	B-X
Monkhouse	B-X
,	B-X
T.	B-X
Shipley	B-X
,	B-X
S.	B-X
Kardasz	B-X
,	B-X
I	B-X
Gonzalez	B-X
P185	B-X
-	B-X
High	B-X
initiation	B-X
creatinine	B-X
associated	B-X
with	B-X
lower	B-X
28-day	B-X
mortality	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
necessitating	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Stads	B-X
,	B-X
A.	B-X
J.	B-X
Groeneveld	B-X
P186	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
Karnofsky	B-X
performance	B-X
scale	B-X
on	B-X
outcomes	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
patients	B-X
receiving	B-X
renal	B-X
replacement	B-X
therapy	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
I.	B-X
Elsayed	B-X
,	B-X
N.	B-X
Ward	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
A.	B-X
Raithatha	B-X
P187	B-X
-	B-X
Severe	B-X
hypophosphatemia	B-X
during	B-X
citrate-anticoagulated	B-X
CRRT	B-X
A.	B-X
Steuber	B-X
,	B-X
C.	B-X
Pelletier	B-X
,	B-X
S.	B-X
Schroeder	B-X
,	B-X
E.	B-X
Michael	B-X
,	B-X
T.	B-X
Slowinski	B-X
,	B-X
D.	B-X
Kindgen-Milles	B-X
P188	B-X
-	B-X
Citrate	B-X
regional	B-X
anticoagulation	B-X
for	B-X
post	B-X
dilution	B-X
continuous	B-X
renal	B-X
replacement	B-X
therapy	B-X
S.	B-X
Ghabina	B-X
P189	B-X
-	B-X
Citrate	B-X
18	B-X
mmol/l	B-X
improves	B-X
anticoagulation	B-X
during	B-X
RRT	B-X
with	B-X
adsorbing	B-X
filters	B-X
F.	B-X
Turani	B-X
,	B-X
A.	B-X
Belli	B-X
,	B-X
S.	B-X
Busatti	B-X
,	B-X
G.	B-X
Barettin	B-X
,	B-X
F.	B-X
Candidi	B-X
,	B-X
F.	B-X
Gargano	B-X
,	B-X
R.	B-X
Barchetta	B-X
,	B-X
M.	B-X
Falco	B-X
P190	B-X
-	B-X
Calcium	B-X
gluconate	B-X
instead	B-X
of	B-X
calcium	B-X
chloride	B-X
in	B-X
citrate-anticoagulated	B-X
CVVHD	B-X
O.	B-X
Demirkiran	B-X
,	B-X
M.	B-X
Kosuk	B-X
,	B-X
S.	B-X
Bozbay	B-X
P191	B-X
-	B-X
Enhanced	B-X
clearance	B-X
of	B-X
interleukin-6	B-X
with	B-X
continuous	B-X
veno-venous	B-X
haemodialysis	B-X
(	B-X
CVVHD	B-X
)	B-X
using	B-X
Ultraflux	B-X
EMiC2	B-X
vs.	B-X
Ultraflux	B-X
AV1000S	B-X
V.	B-X
Weber	B-X
,	B-X
J.	B-X
Hartmann	B-X
,	B-X
S.	B-X
Harm	B-X
,	B-X
I.	B-X
Linsberger	B-X
,	B-X
T.	B-X
Eichhorn	B-X
,	B-X
G.	B-X
Valicek	B-X
,	B-X
G.	B-X
Miestinger	B-X
,	B-X
C.	B-X
Hoermann	B-X
P192	B-X
-	B-X
Removal	B-X
of	B-X
bilirubin	B-X
with	B-X
a	B-X
new	B-X
adsorbent	B-X
system	B-X
:	B-X
in	B-X
vitro	B-X
kinetics	B-X
S.	B-X
Faenza	B-X
,	B-X
D.	B-X
Ricci	B-X
,	B-X
E.	B-X
Mancini	B-X
,	B-X
C.	B-X
Gemelli	B-X
,	B-X
A.	B-X
Cuoghi	B-X
,	B-X
S.	B-X
Magnani	B-X
,	B-X
M.	B-X
Atti	B-X
P193	B-X
-	B-X
Case	B-X
series	B-X
of	B-X
patients	B-X
with	B-X
severe	B-X
sepsis	B-X
and	B-X
septic	B-X
shock	B-X
treated	B-X
with	B-X
a	B-X
new	B-X
extracorporeal	B-X
sorbent	B-X
T.	B-X
Laddomada	B-X
,	B-X
A.	B-X
Doronzio	B-X
,	B-X
B.	B-X
Balicco	B-X
P194	B-X
-	B-X
In	B-X
vitro	B-X
adsorption	B-X
of	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
inflammatory	B-X
mediators	B-X
with	B-X
CytoSorb®	B-X
hemoadsorbent	B-X
polymer	B-X
beads	B-X
M.	B-X
C.	B-X
Gruda	B-X
,	B-X
P.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
V.	B-X
P.	B-X
Dan	B-X
,	B-X
T.	B-X
Guliashvili	B-X
,	B-X
A.	B-X
Scheirer	B-X
,	B-X
T.	B-X
D.	B-X
Golobish	B-X
,	B-X
V.	B-X
J.	B-X
Capponi	B-X
,	B-X
P.	B-X
P.	B-X
Chan	B-X
P195	B-X
-	B-X
Observations	B-X
in	B-X
early	B-X
vs.	B-X
late	B-X
use	B-X
of	B-X
cytosorb	B-X
therapy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
K.	B-X
Kogelmann	B-X
,	B-X
M.	B-X
Drüner	B-X
,	B-X
D.	B-X
Jarczak	B-X
P196	B-X
-	B-X
Oxiris	B-X
membrane	B-X
decreases	B-X
endotoxin	B-X
during	B-X
rrt	B-X
in	B-X
septic	B-X
patients	B-X
with	B-X
basal	B-X
EAA	B-X
>	B-X
0,6	B-X
F.	B-X
Turani	B-X
,	B-X
A	B-X
.	B-X
B.	B-X
Belli	B-X
,	B-X
S.	B-X
M.	B-X
Martni	B-X
,	B-X
V.	B-X
C.	B-X
Cotticelli	B-X
,	B-X
F.	B-X
Mounajergi	B-X
,	B-X
R.	B-X
Barchetta	B-X
P197	B-X
-	B-X
An	B-X
observational	B-X
prospective	B-X
study	B-X
on	B-X
the	B-X
onset	B-X
of	B-X
augmented	B-X
renal	B-X
clearance	B-X
:	B-X
the	B-X
first	B-X
report	B-X
S.	B-X
Morimoto	B-X
,	B-X
H.	B-X
Ishikura	B-X
P198	B-X
-	B-X
An	B-X
ultrasound-	B-X
guided	B-X
algorithm	B-X
for	B-X
the	B-X
management	B-X
of	B-X
oliguria	B-X
in	B-X
severe	B-X
sepsis	B-X
I.	B-X
Hussain	B-X
,	B-X
N.	B-X
Salahuddin	B-X
,	B-X
A.	B-X
Nadeem	B-X
,	B-X
K.	B-X
Ghorab	B-X
,	B-X
K.	B-X
Maghrabi	B-X
P199	B-X
-	B-X
Ultrasound	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
(	B-X
aki	B-X
)	B-X
.	B-X
First	B-X
findings	B-X
of	B-X
farius	B-X
,	B-X
an	B-X
education-programme	B-X
in	B-X
structural	B-X
ultrasonography	B-X
S.	B-X
K.	B-X
Kloesel	B-X
,	B-X
C.	B-X
Goldfuss	B-X
,	B-X
A.	B-X
Stieglitz	B-X
,	B-X
A.	B-X
S.	B-X
Stieglitz	B-X
,	B-X
L.	B-X
Krstevska	B-X
,	B-X
G.	B-X
Albuszies	B-X
P200	B-X
-	B-X
Effectiveness	B-X
of	B-X
renal	B-X
angina	B-X
index	B-X
score	B-X
predicting	B-X
acute	B-X
kidney	B-X
injury	B-X
on	B-X
critically	B-X
ill	B-X
patients	B-X
M.	B-X
Aguilar	B-X
Arzapalo	B-X
,	B-X
L.	B-X
Barradas	B-X
,	B-X
V.	B-X
Lopez	B-X
,	B-X
A.	B-X
Escalante	B-X
,	B-X
G.	B-X
Jimmy	B-X
,	B-X
M.	B-X
Cetina	B-X
P201	B-X
-	B-X
Time	B-X
length	B-X
below	B-X
blood	B-X
pressure	B-X
thresholds	B-X
and	B-X
progression	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
sepsis	B-X
:	B-X
a	B-X
retrospective	B-X
,	B-X
exploratory	B-X
cohort	B-X
study	B-X
J.	B-X
Izawa	B-X
,	B-X
T.	B-X
Iwami	B-X
,	B-X
S.	B-X
Uchino	B-X
,	B-X
M.	B-X
Takinami	B-X
,	B-X
T.	B-X
Kitamura	B-X
,	B-X
T.	B-X
Kawamura	B-X
P202	B-X
-	B-X
Anaemia	B-X
does	B-X
not	B-X
affect	B-X
renal	B-X
recovery	B-X
in	B-X
acute	B-X
kidney	B-X
injury	B-X
J.	B-X
G.	B-X
Powell-Tuck	B-X
,	B-X
S.	B-X
Crichton	B-X
,	B-X
M.	B-X
Raimundo	B-X
,	B-X
L.	B-X
Camporota	B-X
,	B-X
D.	B-X
Wyncoll	B-X
,	B-X
M.	B-X
Ostermann	B-X
P203	B-X
-	B-X
Estimated	B-X
glomerular	B-X
filtration	B-X
rate	B-X
based	B-X
on	B-X
serum	B-X
creatinine	B-X
:	B-X
actual	B-X
practice	B-X
in	B-X
Dutch	B-X
ICU	B-X
’	B-X
s	B-X
A.	B-X
Hana	B-X
,	B-X
H.	B-X
R.	B-X
De	B-X
Geus	B-X
P204	B-X
-	B-X
Comparison	B-X
of	B-X
estimated	B-X
glomerular	B-X
filtration	B-X
rate	B-X
calculated	B-X
by	B-X
mdrd	B-X
,	B-X
ckd-epi-serum-creatinine	B-X
and	B-X
ckd-epi-cystatin-c	B-X
in	B-X
adult	B-X
critically	B-X
ill	B-X
patients	B-X
H.	B-X
R.	B-X
De	B-X
Geus	B-X
,	B-X
A.	B-X
Hana	B-X
P205	B-X
-	B-X
Early	B-X
diagnosis	B-X
of	B-X
septic	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
medical	B-X
critical	B-X
care	B-X
patients	B-X
with	B-X
a	B-X
urine	B-X
cell	B-X
cycle	B-X
arrest	B-X
marker	B-X
:	B-X
insulin	B-X
like	B-X
growth	B-X
factor	B-X
binding	B-X
protein-7	B-X
(	B-X
IGFBP-7	B-X
)	B-X
M.	B-X
Aydogdu	B-X
,	B-X
N.	B-X
Boyaci	B-X
,	B-X
S.	B-X
Yuksel	B-X
,	B-X
G.	B-X
Gursel	B-X
,	B-X
A	B-X
.	B-X
B.	B-X
Cayci	B-X
Sivri	B-X
P206	B-X
-	B-X
Urinary	B-X
neutrophil	B-X
gelatinase-associated	B-X
lipocalin	B-X
as	B-X
early	B-X
biomarker	B-X
of	B-X
severe	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
intensive	B-X
care	B-X
J.	B-X
Meza-Márquez	B-X
,	B-X
J.	B-X
Nava-López	B-X
,	B-X
R.	B-X
Carrillo-Esper	B-X
P207	B-X
-	B-X
Shrunken	B-X
pore	B-X
syndrome	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
sharp	B-X
rise	B-X
in	B-X
mortality	B-X
in	B-X
patients	B-X
undergoing	B-X
elective	B-X
coronary	B-X
artery	B-X
bypass	B-X
grafting	B-X
A.	B-X
Dardashti	B-X
,	B-X
A.	B-X
Grubb	B-X
P208	B-X
-	B-X
The	B-X
biomarker	B-X
nephrocheck™	B-X
can	B-X
discriminate	B-X
the	B-X
septic	B-X
shock	B-X
patients	B-X
with	B-X
an	B-X
akin	B-X
1	B-X
or	B-X
2	B-X
acute	B-X
renal	B-X
failure	B-X
who	B-X
will	B-X
not	B-X
progress	B-X
toward	B-X
the	B-X
akin	B-X
3	B-X
level	B-X
J.	B-X
Maizel	B-X
,	B-X
M.	B-X
Wetzstein	B-X
,	B-X
D.	B-X
Titeca	B-X
,	B-X
L.	B-X
Kontar	B-X
,	B-X
F.	B-X
Brazier	B-X
,	B-X
B	B-X
.	B-X
De	B-X
Cagny	B-X
,	B-X
A.	B-X
Riviere	B-X
,	B-X
T.	B-X
Soupison	B-X
,	B-X
M.	B-X
Joris	B-X
,	B-X
M.	B-X
Slama	B-X
P209	B-X
-	B-X
A	B-X
worldwide	B-X
multicentre	B-X
evaluation	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
septic	B-X
and	B-X
non-septic	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
the	B-X
intensive	B-X
care	B-X
over	B-X
nations	B-X
(	B-X
icon	B-X
)	B-X
audit	B-X
E.	B-X
Peters	B-X
,	B-X
H.	B-X
Njimi	B-X
,	B-X
P.	B-X
Pickkers	B-X
,	B-X
J.	B-X
L.	B-X
Vincent	B-X
P210	B-X
-	B-X
Does	B-X
enhanced	B-X
recovery	B-X
after	B-X
surgery	B-X
reduce	B-X
the	B-X
incidence	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
in	B-X
those	B-X
undergoing	B-X
major	B-X
gynae-oncological	B-X
surgery	B-X
?	B-X
M.	B-X
Waraich	B-X
,	B-X
J.	B-X
Doyle	B-X
,	B-X
T.	B-X
Samuels	B-X
,	B-X
L.	B-X
Forni	B-X
P211	B-X
-	B-X
Identification	B-X
of	B-X
risk	B-X
factors	B-X
for	B-X
the	B-X
development	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
lower	B-X
limb	B-X
arthroplasty	B-X
N.	B-X
Desai	B-X
,	B-X
R.	B-X
Baumber	B-X
,	B-X
P.	B-X
Gunning	B-X
,	B-X
A	B-X
.	B-X
Sell	B-X
P212	B-X
-	B-X
Incidences	B-X
and	B-X
associations	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
major	B-X
trauma	B-X
S.	B-X
Lin	B-X
,	B-X
H.	B-X
Torrence	B-X
,	B-X
M.	B-X
O	B-X
’	B-X
Dwyer	B-X
,	B-X
C.	B-X
Kirwan	B-X
,	B-X
J.	B-X
Prowle	B-X
P213	B-X
-	B-X
Acute	B-X
kidney	B-X
injury	B-X
of	B-X
major	B-X
trauma	B-X
patients	B-X
T	B-X
Kim	B-X
P214	B-X
-	B-X
Trajectory	B-X
of	B-X
serum	B-X
creatinine	B-X
after	B-X
major	B-X
surgery	B-X
and	B-X
the	B-X
diagnosis	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
M.	B-X
E.	B-X
O	B-X
’	B-X
Connor	B-X
,	B-X
R.	B-X
W.	B-X
Hewson	B-X
,	B-X
C.	B-X
J.	B-X
Kirwan	B-X
,	B-X
R.	B-X
M.	B-X
Pearse	B-X
,	B-X
J.	B-X
Prowle	B-X
P215	B-X
-	B-X
Epidemiology	B-X
of	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
cardiac	B-X
surgery	B-X
.	B-X
A	B-X
single	B-X
center	B-X
retrospective	B-X
study	B-X
S.	B-X
Hanoura	B-X
,	B-X
A.	B-X
Omar	B-X
,	B-X
H.	B-X
Othamn	B-X
,	B-X
S.	B-X
Sudarsanan	B-X
,	B-X
M.	B-X
Allam	B-X
,	B-X
M.	B-X
Maksoud	B-X
,	B-X
R.	B-X
Singh	B-X
,	B-X
A.	B-X
Al	B-X
Khulaifi	B-X
P216	B-X
-	B-X
Post-operative	B-X
acute	B-X
kidney	B-X
injury	B-X
after	B-X
major	B-X
non-cardiac	B-X
surgery	B-X
and	B-X
its	B-X
association	B-X
with	B-X
death	B-X
in	B-X
the	B-X
following	B-X
year	B-X
M.	B-X
E.	B-X
O	B-X
’	B-X
Connor	B-X
,	B-X
R.	B-X
W.	B-X
Hewson	B-X
,	B-X
C.	B-X
J.	B-X
Kirwan	B-X
,	B-X
R.	B-X
M.	B-X
Pearse	B-X
,	B-X
J.	B-X
Prowle	B-X
P217	B-X
-	B-X
Factors	B-X
affecting	B-X
acute	B-X
renal	B-X
failure	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
and	B-X
effect	B-X
of	B-X
these	B-X
factors	B-X
on	B-X
mortality	B-X
O.	B-X
Uzundere	B-X
,	B-X
D.	B-X
Memis	B-X
,	B-X
M.	B-X
Ýnal	B-X
,	B-X
A.	B-X
,	B-X
N.	B-X
Turan	B-X
P218	B-X
-	B-X
Results	B-X
of	B-X
the	B-X
live	B-X
kidney	B-X
transplantations	B-X
according	B-X
to	B-X
national	B-X
data	B-X
of	B-X
turkish	B-X
organ	B-X
and	B-X
tissue	B-X
information	B-X
system	B-X
M.	B-X
A.	B-X
Aydin	B-X
,	B-X
H.	B-X
Basar	B-X
,	B-X
I.	B-X
Sencan	B-X
,	B-X
A.	B-X
Kapuagasi	B-X
,	B-X
M.	B-X
Ozturk	B-X
,	B-X
Z.	B-X
Uzundurukan	B-X
,	B-X
D.	B-X
Gokmen	B-X
,	B-X
A.	B-X
Ozcan	B-X
,	B-X
C.	B-X
Kaymak	B-X
P219	B-X
-	B-X
Anaesthesia	B-X
procedure	B-X
and	B-X
intensive	B-X
therapy	B-X
in	B-X
patients	B-X
with	B-X
neck	B-X
phlegmon	B-X
V.	B-X
A.	B-X
Artemenko	B-X
,	B-X
A.	B-X
Budnyuk	B-X
P220	B-X
-	B-X
Nasal	B-X
high	B-X
flow	B-X
oygen	B-X
for	B-X
acute	B-X
respiratory	B-X
failure	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
R.	B-X
Pugh	B-X
,	B-X
S.	B-X
Bhandari	B-X
P221	B-X
-	B-X
Setting	B-X
optimal	B-X
flow	B-X
rate	B-X
during	B-X
high	B-X
flow	B-X
nasal	B-X
cannula	B-X
support	B-X
:	B-X
preliminary	B-X
results	B-X
T.	B-X
Mauri	B-X
,	B-X
C.	B-X
Turrini	B-X
,	B-X
T.	B-X
Langer	B-X
,	B-X
P.	B-X
Taccone	B-X
,	B-X
C.	B-X
A.	B-X
Volta	B-X
,	B-X
C.	B-X
Marenghi	B-X
,	B-X
L.	B-X
Gattinoni	B-X
,	B-X
A.	B-X
Pesenti	B-X
P222	B-X
-	B-X
Dose	B-X
to	B-X
dose	B-X
consistency	B-X
across	B-X
two	B-X
different	B-X
gas	B-X
flow	B-X
rates	B-X
using	B-X
cystic	B-X
fibrosis	B-X
and	B-X
normal	B-X
adult	B-X
breathing	B-X
profiles	B-X
during	B-X
nasal	B-X
high	B-X
flow	B-X
oxygen	B-X
therapy	B-X
L.	B-X
Sweeney	B-X
,	B-X
A	B-X
.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P223	B-X
-	B-X
Final	B-X
results	B-X
of	B-X
an	B-X
evaluation	B-X
of	B-X
airway	B-X
medix	B-X
closed	B-X
suction	B-X
system	B-X
compared	B-X
to	B-X
a	B-X
standard	B-X
closed	B-X
suction	B-X
system	B-X
M.	B-X
Pfeffer	B-X
,	B-X
J.	B-X
T.	B-X
Thomas	B-X
,	B-X
G.	B-X
B.	B-X
Bregman	B-X
,	B-X
G.	B-X
K.	B-X
Karp	B-X
,	B-X
E.	B-X
K.	B-X
Kishinevsky	B-X
,	B-X
D.	B-X
S.	B-X
Stavi	B-X
,	B-X
N.	B-X
A.	B-X
Adi	B-X
P224	B-X
-	B-X
Different	B-X
cuff	B-X
materials	B-X
and	B-X
different	B-X
leak	B-X
tests	B-X
-	B-X
one	B-X
size	B-X
does	B-X
not	B-X
fit	B-X
all	B-X
T.	B-X
Poropat	B-X
,	B-X
R.	B-X
Knafelj	B-X
P225	B-X
-	B-X
Observational	B-X
study	B-X
on	B-X
the	B-X
value	B-X
of	B-X
the	B-X
cuff-leak	B-X
test	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
upper	B-X
airway	B-X
obstruction	B-X
after	B-X
extubation	B-X
E.	B-X
Llopart	B-X
,	B-X
M.	B-X
Batlle	B-X
,	B-X
C.	B-X
De	B-X
Haro	B-X
,	B-X
J.	B-X
Mesquida	B-X
,	B-X
A.	B-X
Artigas	B-X
P226	B-X
-	B-X
A	B-X
device	B-X
for	B-X
emergency	B-X
transtracheal	B-X
lung	B-X
ventilation	B-X
D.	B-X
Pavlovic	B-X
,	B-X
L.	B-X
Lewerentz	B-X
,	B-X
A.	B-X
Spassov	B-X
,	B-X
R.	B-X
Schneider	B-X
P227	B-X
-	B-X
Long-term	B-X
outcome	B-X
and	B-X
health-related	B-X
quality	B-X
of	B-X
life	B-X
in	B-X
patients	B-X
discharged	B-X
from	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
with	B-X
a	B-X
tracheostomy	B-X
and	B-X
with	B-X
or	B-X
without	B-X
prolonged	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
De	B-X
Smet	B-X
,	B-X
S.	B-X
De	B-X
Raedt	B-X
,	B-X
E.	B-X
Derom	B-X
,	B-X
P	B-X
Depuydt	B-X
,	B-X
S.	B-X
Oeyen	B-X
,	B-X
D.	B-X
Benoit	B-X
,	B-X
J.	B-X
Decruyenaere	B-X
P228	B-X
-	B-X
Ultrasound-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
versus	B-X
bronchoscopy-guided	B-X
percutaneous	B-X
dilational	B-X
tracheostomy	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
(	B-X
trachus	B-X
)	B-X
:	B-X
a	B-X
randomized	B-X
clinical	B-X
trial	B-X
A.	B-X
Gobatto	B-X
,	B-X
B.	B-X
Bese	B-X
,	B-X
P.	B-X
Tierno	B-X
,	B-X
L.	B-X
Melro	B-X
,	B-X
P.	B-X
Mendes	B-X
,	B-X
F.	B-X
Cadamuro	B-X
,	B-X
M.	B-X
Park	B-X
,	B-X
L.	B-X
M.	B-X
Malbouisson	B-X
P229	B-X
-	B-X
Is	B-X
it	B-X
safe	B-X
to	B-X
discharge	B-X
patients	B-X
with	B-X
tracheostomy	B-X
from	B-X
the	B-X
ICU	B-X
to	B-X
the	B-X
ward	B-X
?	B-X
B.	B-X
C.	B-X
Civanto	B-X
,	B-X
J.	B-X
L.	B-X
Lopez	B-X
,	B-X
A.	B-X
Robles	B-X
,	B-X
J.	B-X
Figueira	B-X
,	B-X
S.	B-X
Yus	B-X
,	B-X
A.	B-X
Garcia	B-X
P230	B-X
-	B-X
The	B-X
application	B-X
of	B-X
tracheostomy	B-X
in	B-X
children	B-X
in	B-X
ICU	B-X
A.	B-X
Oglinda	B-X
,	B-X
G.	B-X
Ciobanu	B-X
,	B-X
C.	B-X
Oglinda	B-X
,	B-X
L.	B-X
Schirca	B-X
,	B-X
T.	B-X
Sertinean	B-X
,	B-X
V.	B-X
Lupu	B-X
P231	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
passive	B-X
humidifiers	B-X
on	B-X
aerosol	B-X
drug	B-X
delivery	B-X
during	B-X
mechanical	B-X
ventilation	B-X
P.	B-X
Kelly	B-X
,	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P232	B-X
-	B-X
Evaluation	B-X
of	B-X
vibrating	B-X
mesh	B-X
and	B-X
jet	B-X
nebuliser	B-X
performance	B-X
at	B-X
two	B-X
different	B-X
attachment	B-X
setups	B-X
in	B-X
line	B-X
with	B-X
a	B-X
humidifier	B-X
nebuliser	B-X
system	B-X
A.	B-X
O	B-X
’	B-X
Sullivan	B-X
,	B-X
P.	B-X
Kelly	B-X
,	B-X
L.	B-X
Sweeney	B-X
,	B-X
E.	B-X
Mukeria	B-X
,	B-X
M.	B-X
Wolny	B-X
,	B-X
R.	B-X
MacLoughlin	B-X
P233	B-X
-	B-X
Psv-niv	B-X
versus	B-X
cpap	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
acute	B-X
cardiogenic	B-X
pulmonary	B-X
edema	B-X
A.	B-X
Pagano	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
G.	B-X
Vison	B-X
,	B-X
L.	B-X
Saldamarco	B-X
,	B-X
T.	B-X
Russo	B-X
,	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Paladino	B-X
P234	B-X
-	B-X
Noninvasive	B-X
ventilation	B-X
in	B-X
patients	B-X
with	B-X
haematologic	B-X
malignancy	B-X
:	B-X
a	B-X
retrospective	B-X
review	B-X
C.	B-X
Bell	B-X
,	B-X
J.	B-X
Liu	B-X
,	B-X
J.	B-X
Debacker	B-X
,	B-X
C.	B-X
Lee	B-X
,	B-X
E.	B-X
Tamberg	B-X
,	B-X
V.	B-X
Campbell	B-X
,	B-X
S.	B-X
Mehta	B-X
P235	B-X
-	B-X
Use	B-X
of	B-X
non-invasive	B-X
ventilation	B-X
in	B-X
infectious	B-X
diseases	B-X
besides	B-X
classical	B-X
indications	B-X
A.	B-X
Silva-Pinto	B-X
,	B-X
A.	B-X
Sarmento	B-X
,	B-X
L.	B-X
Santos	B-X
P236	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
fragility	B-X
on	B-X
noninvasive	B-X
mechanical	B-X
ventilation	B-X
application	B-X
and	B-X
results	B-X
in	B-X
the	B-X
ICU	B-X
Ý.	B-X
Kara	B-X
,	B-X
F.	B-X
Yýldýrým	B-X
,	B-X
A.	B-X
Zerman	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
N.	B-X
Boyacý	B-X
,	B-X
B.	B-X
Basarýk	B-X
Aydogan	B-X
,	B-X
Ü.	B-X
Gaygýsýz	B-X
,	B-X
K.	B-X
Gönderen	B-X
,	B-X
G.	B-X
Arýk	B-X
,	B-X
M.	B-X
Turkoglu	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Aygencel	B-X
,	B-X
Z.	B-X
Ülger	B-X
,	B-X
G.	B-X
Gursel	B-X
P237	B-X
-	B-X
Effects	B-X
of	B-X
metabolic	B-X
alkalosis	B-X
on	B-X
noninvasive	B-X
ventilation	B-X
success	B-X
and	B-X
ICU	B-X
outcome	B-X
in	B-X
patients	B-X
with	B-X
hypercapnic	B-X
respiratory	B-X
failure	B-X
N.	B-X
Boyacý	B-X
,	B-X
Z.	B-X
Isýkdogan	B-X
,	B-X
Ö.	B-X
Özdedeoglu	B-X
,	B-X
Z.	B-X
Güllü	B-X
,	B-X
M.	B-X
Badoglu	B-X
,	B-X
U.	B-X
Gaygýsýz	B-X
,	B-X
M.	B-X
Aydogdu	B-X
,	B-X
G.	B-X
Gursel	B-X
P238	B-X
-	B-X
Asynchrony	B-X
index	B-X
and	B-X
breathing	B-X
patterns	B-X
of	B-X
acute	B-X
exacerbation	B-X
copd	B-X
patients	B-X
assisted	B-X
with	B-X
noninvasive	B-X
pressure	B-X
support	B-X
ventilation	B-X
and	B-X
neurally	B-X
adjusted	B-X
ventilatory	B-X
assist	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
C.	B-X
Sittipunt	B-X
P239	B-X
-	B-X
High	B-X
frequency	B-X
jet	B-X
ventilation	B-X
for	B-X
severe	B-X
acute	B-X
hypoxemia	B-X
A.	B-X
Eden	B-X
,	B-X
Y.	B-X
Kokhanovsky	B-X
,	B-X
S.	B-X
Bursztein	B-X
–	B-X
De	B-X
Myttenaere	B-X
,	B-X
R.	B-X
Pizov	B-X
P240	B-X
-	B-X
HFOV	B-X
revisited	B-X
:	B-X
a	B-X
7	B-X
year	B-X
retrospective	B-X
analysis	B-X
of	B-X
patients	B-X
receiving	B-X
HFOV	B-X
who	B-X
met	B-X
oscillate	B-X
trial	B-X
entry	B-X
criteria	B-X
L.	B-X
Neilans	B-X
,	B-X
N.	B-X
MacIntyre	B-X
P241	B-X
-	B-X
Implementation	B-X
of	B-X
a	B-X
goal-directed	B-X
mechanical	B-X
ventilation	B-X
order	B-X
set	B-X
driven	B-X
by	B-X
respiratory	B-X
therapists	B-X
can	B-X
improve	B-X
compliance	B-X
with	B-X
best	B-X
practices	B-X
for	B-X
mechanical	B-X
ventilation	B-X
M.	B-X
Radosevich	B-X
,	B-X
B.	B-X
Wanta	B-X
,	B-X
V.	B-X
Weber	B-X
,	B-X
T.	B-X
Meyer	B-X
,	B-X
N.	B-X
Smischney	B-X
,	B-X
D.	B-X
Brown	B-X
,	B-X
D.	B-X
Diedrich	B-X
P242	B-X
-	B-X
A	B-X
reduction	B-X
in	B-X
tidal	B-X
volumes	B-X
for	B-X
ventilated	B-X
patients	B-X
on	B-X
ICU	B-X
calculated	B-X
from	B-X
IBW	B-X
.	B-X
can	B-X
it	B-X
minimise	B-X
mortality	B-X
in	B-X
comparison	B-X
to	B-X
traditional	B-X
strategies	B-X
?	B-X
Fuller	B-X
,	B-X
P.	B-X
McLindon	B-X
,	B-X
K.	B-X
Sim	B-X
P243	B-X
-	B-X
Predictive	B-X
value	B-X
of	B-X
lung	B-X
aeration	B-X
scoring	B-X
using	B-X
lung	B-X
ultrasound	B-X
in	B-X
weaning	B-X
failure	B-X
M.	B-X
Shoaeir	B-X
,	B-X
K.	B-X
Noeam	B-X
,	B-X
A.	B-X
Mahrous	B-X
,	B-X
R.	B-X
Matsa	B-X
,	B-X
A.	B-X
Ali	B-X
P244	B-X
-	B-X
Conventional	B-X
versus	B-X
automated	B-X
weaning	B-X
from	B-X
mechanical	B-X
ventilation	B-X
using	B-X
SmartCare™	B-X
C.	B-X
Dridi	B-X
,	B-X
S.	B-X
Koubaji	B-X
,	B-X
S.	B-X
Kamoun	B-X
,	B-X
F.	B-X
Haddad	B-X
,	B-X
A.	B-X
Ben	B-X
Souissi	B-X
,	B-X
B.	B-X
Laribi	B-X
,	B-X
A.	B-X
Riahi	B-X
,	B-X
M.	B-X
S.	B-X
Mebazaa	B-X
P245	B-X
-	B-X
Ultrasonographic	B-X
evaluation	B-X
protocol	B-X
for	B-X
weaning	B-X
from	B-X
mechanichal	B-X
ventilation	B-X
A.	B-X
Pérez-Calatayud	B-X
,	B-X
R.	B-X
Carrillo-Esper	B-X
,	B-X
A.	B-X
Zepeda-Mendoza	B-X
,	B-X
M.	B-X
Diaz-Carrillo	B-X
,	B-X
E.	B-X
Arch-Tirado	B-X
P246	B-X
-	B-X
Diaphragm	B-X
ultrasonography	B-X
:	B-X
a	B-X
method	B-X
for	B-X
weaning	B-X
patients	B-X
from	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
Carbognin	B-X
,	B-X
L.	B-X
Pelacani	B-X
,	B-X
F.	B-X
Zannoni	B-X
,	B-X
A.	B-X
Agnoli	B-X
,	B-X
G.	B-X
Gagliardi	B-X
P247	B-X
-	B-X
Dorsal	B-X
diaphragmatic	B-X
excursion	B-X
tracks	B-X
transpulmonary	B-X
pressure	B-X
in	B-X
ventilated	B-X
ARDS	B-X
patients	B-X
:	B-X
a	B-X
potential	B-X
non-invasive	B-X
indicator	B-X
of	B-X
lung	B-X
recruitment	B-X
?	B-X
M.	B-X
Thijssen	B-X
,	B-X
L.	B-X
Janssen	B-X
,	B-X
N.	B-X
Foudraine	B-X
P249	B-X
-	B-X
Ventilation	B-X
is	B-X
a	B-X
better	B-X
assessment	B-X
of	B-X
respiratory	B-X
status	B-X
than	B-X
EtCO2	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
P250	B-X
-	B-X
Evaluation	B-X
of	B-X
the	B-X
relationship	B-X
between	B-X
non-invasive	B-X
minute	B-X
ventilation	B-X
and	B-X
end-tidal	B-X
CO2	B-X
in	B-X
patients	B-X
undergoing	B-X
general	B-X
vs	B-X
spinal	B-X
anesthesia	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P251	B-X
-	B-X
Respiratory	B-X
volume	B-X
monitoring	B-X
provides	B-X
early	B-X
warning	B-X
of	B-X
respiratory	B-X
depression	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
reduce	B-X
false	B-X
alarms	B-X
in	B-X
non-intubated	B-X
patients	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
D.	B-X
Eversole	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P252	B-X
-	B-X
P/i	B-X
index	B-X
:	B-X
a	B-X
predictive	B-X
edi-derived	B-X
weaning	B-X
index	B-X
during	B-X
nava	B-X
S.	B-X
Muttini	B-X
,	B-X
R.	B-X
Bigi	B-X
,	B-X
G.	B-X
Villani	B-X
,	B-X
N.	B-X
Patroniti	B-X
P253	B-X
-	B-X
Adequacy	B-X
of	B-X
ventilation	B-X
in	B-X
patients	B-X
receiving	B-X
opioids	B-X
in	B-X
the	B-X
post	B-X
anesthesia	B-X
care	B-X
unit	B-X
:	B-X
minute	B-X
ventilation	B-X
versus	B-X
respiratory	B-X
rate	B-X
G.	B-X
Williams	B-X
,	B-X
C.	B-X
J.	B-X
Voscopoulos	B-X
,	B-X
J.	B-X
Freeman	B-X
,	B-X
E.	B-X
George	B-X
P254	B-X
-	B-X
Comparison	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constants	B-X
measured	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
(	B-X
EIT	B-X
)	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P255	B-X
-	B-X
Electrical	B-X
impedance	B-X
tomography	B-X
:	B-X
robustness	B-X
of	B-X
a	B-X
new	B-X
pixel	B-X
wise	B-X
regional	B-X
expiratory	B-X
time	B-X
constant	B-X
calculation	B-X
A.	B-X
Waldmann	B-X
,	B-X
S.	B-X
Böhm	B-X
,	B-X
W.	B-X
Windisch	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
C.	B-X
Karagiannidis	B-X
P256	B-X
-	B-X
Validation	B-X
of	B-X
regional	B-X
and	B-X
global	B-X
expiratory	B-X
time	B-X
constant	B-X
measurement	B-X
by	B-X
electrical	B-X
impedance	B-X
tomography	B-X
in	B-X
ards	B-X
and	B-X
obstructive	B-X
pulmonary	B-X
diseases	B-X
C.	B-X
K.	B-X
Karagiannidis	B-X
,	B-X
A.	B-X
W.	B-X
Waldmann	B-X
,	B-X
S.	B-X
B.	B-X
Böhm	B-X
,	B-X
S.	B-X
Strassmann	B-X
,	B-X
W.	B-X
W.	B-X
Windisch	B-X
P257	B-X
-	B-X
Transpulmonary	B-X
pressure	B-X
in	B-X
a	B-X
model	B-X
with	B-X
elastic	B-X
recoiling	B-X
lung	B-X
and	B-X
expanding	B-X
chest	B-X
wall	B-X
P.	B-X
Persson	B-X
,	B-X
S.	B-X
Lundin	B-X
,	B-X
O.	B-X
Stenqvist	B-X
P258	B-X
-	B-X
Lactate	B-X
in	B-X
pleural	B-X
and	B-X
abdominal	B-X
effusion	B-X
G.	B-X
Porta	B-X
,	B-X
F.	B-X
Numis	B-X
,	B-X
C.	B-X
S.	B-X
Serra	B-X
,	B-X
A.	B-X
P.	B-X
Pagano	B-X
,	B-X
M.	B-X
M.	B-X
Masarone	B-X
,	B-X
L.	B-X
R.	B-X
Rinaldi	B-X
,	B-X
A	B-X
.	B-X
A.	B-X
Amelia	B-X
,	B-X
M.	B-X
F.	B-X
Fascione	B-X
,	B-X
L.	B-X
A.	B-X
Adinolfi	B-X
,	B-X
E.	B-X
R.	B-X
Ruggiero	B-X
P259	B-X
-	B-X
Outcome	B-X
of	B-X
patients	B-X
admitted	B-X
to	B-X
the	B-X
intensive	B-X
care	B-X
with	B-X
pulmonary	B-X
fibrosis	B-X
F.	B-X
Asota	B-X
,	B-X
K.	B-X
O	B-X
’	B-X
Rourke	B-X
,	B-X
S.	B-X
Ranjan	B-X
,	B-X
P.	B-X
Morgan	B-X
P260	B-X
-	B-X
Sedation	B-X
and	B-X
analgesia	B-X
practice	B-X
in	B-X
extra-corporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
ECMO	B-X
)	B-X
-treated	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
(	B-X
ARDS	B-X
)	B-X
:	B-X
a	B-X
retrospective	B-X
study	B-X
J.	B-X
W.	B-X
DeBacker	B-X
,	B-X
E.	B-X
Tamberg	B-X
,	B-X
L.	B-X
O	B-X
’	B-X
Neill	B-X
,	B-X
L.	B-X
Munshi	B-X
,	B-X
L.	B-X
Burry	B-X
,	B-X
E.	B-X
Fan	B-X
,	B-X
S.	B-X
Mehta	B-X
P261	B-X
-	B-X
Characteristics	B-X
and	B-X
outcomes	B-X
of	B-X
patients	B-X
deemed	B-X
not	B-X
eligible	B-X
when	B-X
referred	B-X
for	B-X
veno-venous	B-X
extracorporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
vv-ECMO	B-X
)	B-X
S.	B-X
Poo	B-X
,	B-X
K.	B-X
Mahendran	B-X
,	B-X
J.	B-X
Fowles	B-X
,	B-X
C.	B-X
Gerrard	B-X
,	B-X
A.	B-X
Vuylsteke	B-X
P262	B-X
-	B-X
The	B-X
SAVE	B-X
SMR	B-X
for	B-X
veno-arterial	B-X
ECMO	B-X
R.	B-X
Loveridge	B-X
,	B-X
C.	B-X
Chaddock	B-X
,	B-X
S.	B-X
Patel	B-X
,	B-X
V.	B-X
Kakar	B-X
,	B-X
C.	B-X
Willars	B-X
,	B-X
T.	B-X
Hurst	B-X
,	B-X
C.	B-X
Park	B-X
,	B-X
T.	B-X
Best	B-X
,	B-X
A.	B-X
Vercueil	B-X
,	B-X
G.	B-X
Auzinger	B-X
P263	B-X
-	B-X
A	B-X
simplified	B-X
score	B-X
to	B-X
predict	B-X
early	B-X
(	B-X
48	B-X
h	B-X
)	B-X
mortality	B-X
in	B-X
patients	B-X
being	B-X
considered	B-X
for	B-X
VA-ECMO	B-X
A.	B-X
Borgman	B-X
,	B-X
A.	B-X
G.	B-X
Proudfoot	B-X
,	B-X
E.	B-X
Grins	B-X
,	B-X
K.	B-X
E.	B-X
Emiley	B-X
,	B-X
J.	B-X
Schuitema	B-X
,	B-X
S.	B-X
J.	B-X
Fitch	B-X
,	B-X
G.	B-X
Marco	B-X
,	B-X
J.	B-X
Sturgill	B-X
,	B-X
M.	B-X
G.	B-X
Dickinson	B-X
,	B-X
M.	B-X
Strueber	B-X
,	B-X
A.	B-X
Khaghani	B-X
,	B-X
P.	B-X
Wilton	B-X
,	B-X
S.	B-X
M.	B-X
Jovinge	B-X
P264	B-X
-	B-X
Lung	B-X
function	B-X
six	B-X
months	B-X
post	B-X
extra	B-X
corporeal	B-X
membrane	B-X
oxygenation	B-X
(	B-X
ECMO	B-X
)	B-X
for	B-X
severe	B-X
acute	B-X
respiratory	B-X
failure	B-X
in	B-X
adult	B-X
survivors	B-X
C.	B-X
Sampson	B-X
,	B-X
S.	B-X
Harris-Fox	B-X
P265	B-X
-	B-X
Bicarbonate	B-X
dialysis	B-X
removes	B-X
carbon	B-X
dioxide	B-X
in	B-X
hypoventilated	B-X
rodents	B-X
.	B-X
A.	B-X
Kellum	B-X
P266	B-X
-	B-X
Procalcitonin	B-X
as	B-X
predictor	B-X
of	B-X
primary	B-X
graft	B-X
dysfunction	B-X
and	B-X
mortality	B-X
in	B-X
post-lung	B-X
transplantation	B-X
C.	B-X
Mazo	B-X
Torre	B-X
,	B-X
J.	B-X
Riera	B-X
,	B-X
S.	B-X
Ramirez	B-X
,	B-X
B.	B-X
Borgatta	B-X
,	B-X
L.	B-X
Lagunes	B-X
,	B-X
J.	B-X
Rello	B-X
P267	B-X
-	B-X
New	B-X
molecular	B-X
biomarkers	B-X
of	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
in	B-X
abdominal	B-X
sepsis	B-X
A.	B-X
K.	B-X
Kuzovlev	B-X
,	B-X
V.	B-X
Moroz	B-X
,	B-X
A.	B-X
Goloubev	B-X
,	B-X
S.	B-X
Polovnikov	B-X
,	B-X
S.	B-X
Nenchuk	B-X
P268	B-X
-	B-X
Tight	B-X
junction	B-X
’	B-X
s	B-X
proteins	B-X
claudin	B-X
-5	B-X
and	B-X
regulation	B-X
by	B-X
tnf	B-X
in	B-X
experimental	B-X
murine	B-X
lung	B-X
injury	B-X
model	B-X
of	B-X
ali/ards	B-X
V.	B-X
Karavana	B-X
,	B-X
C.	B-X
Glynos	B-X
,	B-X
A.	B-X
Asimakos	B-X
,	B-X
K.	B-X
Pappas	B-X
,	B-X
C.	B-X
Vrettou	B-X
,	B-X
M.	B-X
Magkou	B-X
,	B-X
E.	B-X
Ischaki	B-X
,	B-X
G.	B-X
Stathopoulos	B-X
,	B-X
S.	B-X
Zakynthinos	B-X
P269	B-X
-	B-X
Cell	B-X
counts	B-X
in	B-X
endobronchial	B-X
aspirate	B-X
to	B-X
assess	B-X
airway	B-X
inflammation	B-X
in	B-X
ARDS	B-X
patients	B-X
:	B-X
a	B-X
pilot	B-X
study	B-X
S.	B-X
Spadaro	B-X
,	B-X
I.	B-X
Kozhevnikova	B-X
,	B-X
F.	B-X
Dalla	B-X
Corte	B-X
,	B-X
S.	B-X
Grasso	B-X
,	B-X
P.	B-X
Casolari	B-X
,	B-X
G.	B-X
Caramori	B-X
,	B-X
C.	B-X
Volta	B-X
P270	B-X
-	B-X
Epidemiological	B-X
and	B-X
clinical	B-X
profile	B-X
of	B-X
patients	B-X
with	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
in	B-X
the	B-X
surgical	B-X
intensive	B-X
care	B-X
unit	B-X
surgical	B-X
,	B-X
hospital	B-X
JRA	B-X
,	B-X
Antananarivo	B-X
T.	B-X
Andrianjafiarinoa	B-X
,	B-X
T.	B-X
Randriamandrato	B-X
,	B-X
T.	B-X
Rajaonera	B-X
P271	B-X
-	B-X
Effect	B-X
of	B-X
high	B-X
PEEP	B-X
after	B-X
recruitment	B-X
maneuver	B-X
on	B-X
right	B-X
ventricular	B-X
function	B-X
in	B-X
ARDS	B-X
.	B-X
Remmington	B-X
,	B-X
A.	B-X
Fischer	B-X
,	B-X
S.	B-X
Squire	B-X
,	B-X
M.	B-X
Boichat	B-X
P274	B-X
-	B-X
Epidemiological	B-X
study	B-X
of	B-X
severe	B-X
acute	B-X
pancreatitis	B-X
in	B-X
Japan	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
etiology	B-X
and	B-X
the	B-X
patient	B-X
outcomes	B-X
on	B-X
1159	B-X
patients	B-X
.	B-X
Experience	B-X
in	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
R.	B-X
Marinho	B-X
,	B-X
J.	B-X
Daniel	B-X
,	B-X
H.	B-X
Miranda	B-X
,	B-X
A.	B-X
Marinho	B-X
P276	B-X
-	B-X
Accuracy	B-X
of	B-X
mortality	B-X
prediction	B-X
models	B-X
in	B-X
acute	B-X
versus	B-X
acute-on-chronic	B-X
liver	B-X
failure	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
setting	B-X
K.	B-X
Milinis	B-X
,	B-X
M.	B-X
Cooper	B-X
,	B-X
G.	B-X
R.	B-X
Williams	B-X
,	B-X
E.	B-X
McCarron	B-X
,	B-X
S.	B-X
Simants	B-X
,	B-X
I.	B-X
Patanwala	B-X
,	B-X
I.	B-X
Welters	B-X
P277	B-X
-	B-X
Risk	B-X
of	B-X
coronary	B-X
artery	B-X
disease	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
liver	B-X
disease	B-X
:	B-X
a	B-X
population	B-X
based	B-X
cohort	B-X
study	B-X
Y.	B-X
Su	B-X
P278	B-X
-	B-X
20	B-X
years	B-X
of	B-X
liver	B-X
transplantation	B-X
in	B-X
Santiago	B-X
de	B-X
Compostela	B-X
(	B-X
Spain	B-X
)	B-X
.	B-X
Experience	B-X
review	B-X
J.	B-X
Fernández	B-X
Villanueva	B-X
,	B-X
R.	B-X
Fernández	B-X
Garda	B-X
,	B-X
A.	B-X
López	B-X
Lago	B-X
,	B-X
E.	B-X
Rodríguez	B-X
Ruíz	B-X
,	B-X
R.	B-X
Hernández	B-X
Vaquero	B-X
,	B-X
S.	B-X
Tomé	B-X
Martínez	B-X
de	B-X
Rituerto	B-X
,	B-X
E.	B-X
Varo	B-X
Pérez	B-X
P279	B-X
-	B-X
Diarrhea	B-X
is	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
liver	B-X
injury	B-X
and	B-X
may	B-X
lead	B-X
to	B-X
intestinal	B-X
failure	B-X
associated	B-X
liver	B-X
disease	B-X
in	B-X
critical	B-X
illness	B-X
N.	B-X
Lefel	B-X
,	B-X
F.	B-X
Schaap	B-X
,	B-X
D.	B-X
Bergmans	B-X
,	B-X
S.	B-X
Olde	B-X
Damink	B-X
,	B-X
M.	B-X
Van	B-X
de	B-X
Poll	B-X
P280	B-X
-	B-X
Bowel	B-X
care	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
constipation	B-X
guideline	B-X
compliance	B-X
and	B-X
complications	B-X
K.	B-X
Tizard	B-X
,	B-X
C.	B-X
Lister	B-X
,	B-X
L.	B-X
Poole	B-X
P281	B-X
-	B-X
Malnutrition	B-X
assessed	B-X
by	B-X
phase	B-X
angle	B-X
determines	B-X
outcomes	B-X
in	B-X
low	B-X
risk	B-X
cardiac	B-X
surgery	B-X
patients	B-X
D.	B-X
Ringaitiene	B-X
,	B-X
D.	B-X
Gineityte	B-X
,	B-X
V.	B-X
Vicka	B-X
,	B-X
I.	B-X
Norkiene	B-X
,	B-X
J.	B-X
Sipylaite	B-X
P282	B-X
-	B-X
Preoperative	B-X
fasting	B-X
times	B-X
in	B-X
an	B-X
irish	B-X
hospital	B-X
A.	B-X
O	B-X
’	B-X
Loughlin	B-X
,	B-X
V.	B-X
Maraj	B-X
,	B-X
J.	B-X
Dowling	B-X
P283	B-X
-	B-X
Costs	B-X
and	B-X
final	B-X
outcome	B-X
of	B-X
early	B-X
x	B-X
delayed	B-X
feeding	B-X
in	B-X
a	B-X
private	B-X
Brazil	B-X
ICU	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
,	B-X
E.	B-X
B.	B-X
Dias	B-X
,	B-X
S.	B-X
L.	B-X
Fernandes	B-X
P284	B-X
-	B-X
Can	B-X
ventilator	B-X
derived	B-X
energy	B-X
expenditure	B-X
measurements	B-X
replace	B-X
indirect	B-X
calorimetry	B-X
?	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Duarte	B-X
,	B-X
S.	B-X
Castro	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P289	B-X
Protein	B-X
provision	B-X
in	B-X
an	B-X
adult	B-X
intensive	B-X
care	B-X
unit	B-X
S.	B-X
Gray	B-X
P290	B-X
-	B-X
Prevalence	B-X
and	B-X
clinical	B-X
outcomes	B-X
of	B-X
vitamin	B-X
d	B-X
deficiency	B-X
in	B-X
the	B-X
medical	B-X
critically	B-X
ill	B-X
patients	B-X
in	B-X
Songklanagarind	B-X
hospital	B-X
K.	B-X
Maipang	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
P291	B-X
-	B-X
Vitamin	B-X
d	B-X
deficiency	B-X
strongly	B-X
predicts	B-X
adverse	B-X
medical	B-X
outcome	B-X
across	B-X
different	B-X
medical	B-X
inpatient	B-X
populations	B-X
:	B-X
results	B-X
from	B-X
a	B-X
prospective	B-X
study	B-X
L.	B-X
G.	B-X
Grädel	B-X
,	B-X
P.	B-X
Schütz	B-X
P292	B-X
-	B-X
Omega-3	B-X
fatty	B-X
acids	B-X
in	B-X
patients	B-X
undergoing	B-X
cardiac	B-X
surgery	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
P.	B-X
Langlois	B-X
,	B-X
W.	B-X
Manzanares	B-X
P293	B-X
-	B-X
Can	B-X
5-hydroxytriptophan	B-X
prevent	B-X
post-traumatic	B-X
stress	B-X
disorder	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
?	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P294	B-X
-	B-X
Parenteral	B-X
selenium	B-X
in	B-X
the	B-X
critically	B-X
ill	B-X
:	B-X
an	B-X
updated	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
W.	B-X
Manzanares	B-X
,	B-X
P.	B-X
Langlois	B-X
,	B-X
M.	B-X
Lemieux	B-X
,	B-X
G.	B-X
Elke	B-X
,	B-X
F.	B-X
Bloos	B-X
,	B-X
K.	B-X
Reinhart	B-X
,	B-X
D.	B-X
Heyland	B-X
P295	B-X
-	B-X
Probiotics	B-X
in	B-X
the	B-X
critically	B-X
ill	B-X
:	B-X
an	B-X
updated	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
P.	B-X
Langlois	B-X
,	B-X
M.	B-X
Lemieux	B-X
,	B-X
I.	B-X
Aramendi	B-X
,	B-X
D.	B-X
Heyland	B-X
,	B-X
W.	B-X
Manzanares	B-X
P296	B-X
-	B-X
Diabetes	B-X
with	B-X
hyperglycemic	B-X
crisis	B-X
episodes	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
higher	B-X
risk	B-X
of	B-X
pancreatic	B-X
cancer	B-X
:	B-X
a	B-X
population-based	B-X
cohort	B-X
study	B-X
Y.	B-X
Su	B-X
P297	B-X
-	B-X
Incidence	B-X
of	B-X
hypoglycemia	B-X
in	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
depending	B-X
on	B-X
insulin	B-X
protocol	B-X
R.	B-X
Marinho	B-X
,	B-X
N.	B-X
Babo	B-X
,	B-X
A.	B-X
Marinho	B-X
P298	B-X
-	B-X
Severity	B-X
of	B-X
the	B-X
diseases	B-X
is	B-X
two-dimensionally	B-X
correlated	B-X
to	B-X
blood	B-X
glucose	B-X
,	B-X
including	B-X
blood	B-X
glucose	B-X
variability	B-X
,	B-X
especially	B-X
in	B-X
moderately	B-X
to	B-X
severely	B-X
ill	B-X
patients	B-X
with	B-X
glucose	B-X
intolerance	B-X
.	B-X
M.	B-X
Hoshino	B-X
,	B-X
Y.	B-X
Haraguchi	B-X
,	B-X
S.	B-X
Kajiwara	B-X
,	B-X
T.	B-X
Mitsuhashi	B-X
,	B-X
T.	B-X
Tsubata	B-X
,	B-X
M.	B-X
Aida	B-X
P299	B-X
-	B-X
A	B-X
study	B-X
of	B-X
glycemic	B-X
control	B-X
by	B-X
subcutaneous	B-X
glargine	B-X
injection	B-X
transition	B-X
from	B-X
continuous	B-X
regular	B-X
insulin	B-X
infusion	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
T.	B-X
Rattanapraphat	B-X
,	B-X
R.	B-X
Bhurayanontachai	B-X
,	B-X
C.	B-X
Kongkamol	B-X
,	B-X
B.	B-X
Khwannimit	B-X
P300	B-X
-	B-X
Glycemic	B-X
control	B-X
in	B-X
Portuguese	B-X
intensive	B-X
care	B-X
unit	B-X
R.	B-X
Marinho	B-X
,	B-X
M.	B-X
Santos	B-X
,	B-X
H.	B-X
Castro	B-X
,	B-X
E.	B-X
Lafuente	B-X
,	B-X
A.	B-X
Salgueiro	B-X
,	B-X
S.	B-X
Cabral	B-X
,	B-X
P.	B-X
Martins	B-X
,	B-X
J.	B-X
Moura	B-X
,	B-X
B.	B-X
Oliveira	B-X
,	B-X
M.	B-X
Melo	B-X
,	B-X
B.	B-X
Xavier	B-X
,	B-X
J.	B-X
Valente	B-X
,	B-X
C.	B-X
Magalhaes	B-X
,	B-X
P.	B-X
Casteloes	B-X
,	B-X
A.	B-X
Marinho	B-X
P301	B-X
-	B-X
Impact	B-X
of	B-X
hyperglycemia	B-X
duration	B-X
on	B-X
the	B-X
day	B-X
of	B-X
operation	B-X
on	B-X
short-term	B-X
outcome	B-X
of	B-X
cardiac	B-X
surgery	B-X
patients	B-X
D.	B-X
Moisidou	B-X
,	B-X
F.	B-X
Ampatzidou	B-X
,	B-X
C.	B-X
Koutsogiannidis	B-X
,	B-X
M.	B-X
Moschopoulou	B-X
,	B-X
G.	B-X
Drossos	B-X
P302	B-X
-	B-X
Lactate	B-X
levels	B-X
in	B-X
diabetic	B-X
ketoacidosis	B-X
patients	B-X
at	B-X
ICU	B-X
admissions	B-X
G.	B-X
Taskin	B-X
,	B-X
M.	B-X
Çakir	B-X
,	B-X
AK	B-X
Güler	B-X
,	B-X
A.	B-X
Taskin	B-X
,	B-X
N.	B-X
Öcal	B-X
,	B-X
S.	B-X
Özer	B-X
,	B-X
L.	B-X
Yamanel	B-X
P303	B-X
-	B-X
Intensive	B-X
care	B-X
implications	B-X
of	B-X
merging	B-X
heart	B-X
attack	B-X
centre	B-X
units	B-X
in	B-X
London	B-X
J.	B-X
M.	B-X
Wong	B-X
,	B-X
C.	B-X
Fitton	B-X
,	B-X
S.	B-X
Anwar	B-X
,	B-X
S.	B-X
Stacey	B-X
P304	B-X
-	B-X
Special	B-X
characteristics	B-X
of	B-X
in-hospital	B-X
cardiac	B-X
arrests	B-X
M.	B-X
Aggou	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Lolakos	B-X
,	B-X
E.	B-X
Papapostolou	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P305	B-X
-	B-X
Clinical	B-X
evaluation	B-X
of	B-X
ICU-admitted	B-X
patients	B-X
who	B-X
were	B-X
resuscitated	B-X
in	B-X
the	B-X
general	B-X
medicine	B-X
ward	B-X
S.	B-X
Suda	B-X
,	B-X
T.	B-X
Ikeda	B-X
,	B-X
S.	B-X
Ono	B-X
,	B-X
T.	B-X
Ueno	B-X
,	B-X
Y.	B-X
Izutani	B-X
P306	B-X
-	B-X
Serious	B-X
game	B-X
evaluation	B-X
of	B-X
a	B-X
one-hour	B-X
training	B-X
basic	B-X
life	B-X
support	B-X
session	B-X
for	B-X
secondary	B-X
school	B-X
students	B-X
:	B-X
new	B-X
tools	B-X
for	B-X
future	B-X
bystanders	B-X
S.	B-X
Gaudry	B-X
,	B-X
V.	B-X
Desailly	B-X
,	B-X
P.	B-X
Pasquier	B-X
,	B-X
PB	B-X
Brun	B-X
,	B-X
AT	B-X
Tesnieres	B-X
,	B-X
JD	B-X
Ricard	B-X
,	B-X
D.	B-X
Dreyfuss	B-X
,	B-X
A.	B-X
Mignon	B-X
P307	B-X
-	B-X
Public	B-X
and	B-X
clinical	B-X
staff	B-X
perceptions	B-X
and	B-X
knowledge	B-X
of	B-X
CPR	B-X
compared	B-X
to	B-X
local	B-X
and	B-X
national	B-X
data	B-X
J	B-X
.	B-X
Dean	B-X
,	B-X
A.	B-X
Stilwell	B-X
,	B-X
G.	B-X
Friedlaender	B-X
P308	B-X
Dispatcher-assisted	B-X
telephone	B-X
cardiopulmonary	B-X
resuscitation	B-X
using	B-X
a	B-X
French-language	B-X
compression-ventilation	B-X
pediatric	B-X
protocol	B-X
M.	B-X
Peters	B-X
,	B-X
S.	B-X
Stipulante	B-X
,	B-X
A.	B-X
Delfosse	B-X
,	B-X
AF	B-X
Donneau	B-X
,	B-X
A.	B-X
Ghuysen	B-X
P309	B-X
Dantrolene	B-X
versus	B-X
amiodarone	B-X
for	B-X
resuscitation	B-X
–	B-X
an	B-X
experimental	B-X
study	B-X
C.	B-X
Feldmann	B-X
,	B-X
D.	B-X
Freitag	B-X
,	B-X
W.	B-X
Dersch	B-X
,	B-X
M.	B-X
Irqsusi	B-X
,	B-X
D.	B-X
Eschbach	B-X
,	B-X
T.	B-X
Steinfeldt	B-X
,	B-X
H.	B-X
Wulf	B-X
,	B-X
T.	B-X
Wiesmann	B-X
P310	B-X
Long	B-X
term	B-X
survival	B-X
and	B-X
functional	B-X
neurological	B-X
outcome	B-X
in	B-X
comatose	B-X
survivors	B-X
undergoing	B-X
therapeutic	B-X
hypothermia	B-X
N.	B-X
Kongpolprom	B-X
,	B-X
J.	B-X
Cholkraisuwat	B-X
P311	B-X
Impact	B-X
of	B-X
kidney	B-X
disease	B-X
on	B-X
mortality	B-X
and	B-X
neurological	B-X
outcome	B-X
in	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
prospective	B-X
observational	B-X
study	B-X
S.	B-X
Beitland	B-X
,	B-X
E.	B-X
Nakstad	B-X
,	B-X
H.	B-X
Stær-Jensen	B-X
,	B-X
T.	B-X
Drægni	B-X
,	B-X
G.	B-X
Andersen	B-X
,	B-X
D.	B-X
Jacobsen	B-X
,	B-X
C.	B-X
Brunborg	B-X
,	B-X
B.	B-X
Waldum-Grevbo	B-X
,	B-X
K.	B-X
Sunde	B-X
P312	B-X
ICU	B-X
dependency	B-X
of	B-X
patients	B-X
admitted	B-X
after	B-X
primary	B-X
percutaneous	B-X
coronary	B-X
intervention	B-X
(	B-X
PPCI	B-X
)	B-X
following	B-X
out	B-X
of	B-X
the	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
K.	B-X
Hoyland	B-X
,	B-X
D.	B-X
Pandit	B-X
P313	B-X
Prognostic	B-X
indicators	B-X
and	B-X
outcome	B-X
prediction	B-X
model	B-X
for	B-X
patients	B-X
with	B-X
return	B-X
of	B-X
spontaneous	B-X
circulation	B-X
from	B-X
cardiopulmonary	B-X
arrest	B-X
:	B-X
comprehensive	B-X
registry	B-X
of	B-X
in-hospital	B-X
intensive	B-X
care	B-X
on	B-X
OHCA	B-X
survival	B-X
(	B-X
critical	B-X
)	B-X
study	B-X
in	B-X
Osaka	B-X
,	B-X
Japan	B-X
K.	B-X
Hayakawa	B-X
P314	B-X
Cerebral	B-X
oxygen	B-X
saturation	B-X
during	B-X
resuscitation	B-X
in	B-X
a	B-X
porcine	B-X
model	B-X
of	B-X
cardiac	B-X
arrest	B-X
E.	B-X
Oloktsidou	B-X
,	B-X
K.	B-X
Kotzampassi	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
L.	B-X
Loukipoudi	B-X
,	B-X
E.	B-X
Doumaki	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
P315	B-X
Presumption	B-X
of	B-X
cardiopulmonary	B-X
resuscitation	B-X
for	B-X
sustaining	B-X
cerebral	B-X
oxidation	B-X
using	B-X
regional	B-X
cerebral	B-X
saturation	B-X
of	B-X
oxygen	B-X
:	B-X
observational	B-X
cohort	B-X
study	B-X
(	B-X
press	B-X
study	B-X
)	B-X
H.	B-X
Yasuda	B-X
P316	B-X
EEG	B-X
reactivity	B-X
in	B-X
patients	B-X
after	B-X
cardiac	B-X
arrest	B-X
:	B-X
a	B-X
close	B-X
look	B-X
at	B-X
stimuli	B-X
MM	B-X
Admiraal	B-X
,	B-X
M.	B-X
Van	B-X
Assen	B-X
,	B-X
MJ	B-X
Van	B-X
Putten	B-X
,	B-X
M.	B-X
Tjepkema-Cloostermans	B-X
,	B-X
AF	B-X
Van	B-X
Rootselaar	B-X
,	B-X
J.	B-X
Horn	B-X
P317	B-X
Prognostic	B-X
value	B-X
of	B-X
neuron-specific	B-X
enolase	B-X
after	B-X
cardiac	B-X
arrest	B-X
F.	B-X
Ragusa	B-X
,	B-X
A.	B-X
Marudi	B-X
,	B-X
S.	B-X
Baroni	B-X
,	B-X
A.	B-X
Gaspari	B-X
,	B-X
E.	B-X
Bertellini	B-X
P318	B-X
Correlation	B-X
between	B-X
electroencephalographic	B-X
findings	B-X
and	B-X
serum	B-X
neuron	B-X
specific	B-X
enolase	B-X
with	B-X
outcome	B-X
of	B-X
post	B-X
cardiac	B-X
arrest	B-X
patients	B-X
A.	B-X
Taha	B-X
,	B-X
T.	B-X
Abdullah	B-X
,	B-X
S.	B-X
Abdel	B-X
Monem	B-X
P319	B-X
Introduction	B-X
of	B-X
a	B-X
targeted	B-X
temperature	B-X
management	B-X
strategy	B-X
following	B-X
cardiac	B-X
arrest	B-X
in	B-X
a	B-X
district	B-X
general	B-X
hospital	B-X
intensive	B-X
care	B-X
unit	B-X
.	B-X
S.	B-X
Alcorn	B-X
,	B-X
S.	B-X
McNeill	B-X
,	B-X
S.	B-X
Russell	B-X
P320	B-X
The	B-X
evolution	B-X
of	B-X
cerebral	B-X
oxygen	B-X
saturation	B-X
in	B-X
post-cardiac	B-X
arrest	B-X
patients	B-X
treated	B-X
with	B-X
therapeutic	B-X
hypothermia	B-X
W.	B-X
Eertmans	B-X
,	B-X
C.	B-X
Genbrugge	B-X
,	B-X
I.	B-X
Meex	B-X
,	B-X
J.	B-X
Dens	B-X
,	B-X
F.	B-X
Jans	B-X
,	B-X
C.	B-X
De	B-X
Deyne	B-X
P321	B-X
Prognostic	B-X
factors	B-X
and	B-X
neurological	B-X
outcomes	B-X
of	B-X
therapeutic	B-X
hypothermia	B-X
in	B-X
comatose	B-X
survivors	B-X
from	B-X
cardiac	B-X
arrest	B-X
:	B-X
8-year	B-X
single	B-X
center	B-X
experience	B-X
J.	B-X
Cholkraisuwat	B-X
,	B-X
N.	B-X
Kongpolprom	B-X
P322	B-X
Adherence	B-X
to	B-X
targeted	B-X
temperature	B-X
management	B-X
after	B-X
out	B-X
of	B-X
hospital	B-X
cardiac	B-X
arrest	B-X
B.	B-X
Avard	B-X
,	B-X
R.	B-X
Burns	B-X
P323	B-X
Implementation	B-X
of	B-X
a	B-X
therapeutic	B-X
hypothermia	B-X
protocol	B-X
for	B-X
comatose	B-X
survivors	B-X
of	B-X
out-of-hospital	B-X
cardiac	B-X
arrest	B-X
.	B-X
Moon	B-X
,	B-X
C.	B-X
W.	B-X
Park	B-X
,	B-X
T.	B-X
G.	B-X
Ohk	B-X
,	B-X
M.	B-X
C.	B-X
Shin	B-X
P329	B-X
Brain	B-X
death	B-X
and	B-X
admission	B-X
diagnosis	B-X
in	B-X
neurologic	B-X
intensive	B-X
care	B-X
unit	B-X
,	B-X
a	B-X
correlation	B-X
?	B-X
Esen	B-X
P331	B-X
Benefits	B-X
of	B-X
L-carnitine	B-X
in	B-X
valproic	B-X
acid	B-X
induced	B-X
encephalopathy	B-X
R.	B-X
Tincu	B-X
,	B-X
C.	B-X
Cobilinschi	B-X
,	B-X
D.	B-X
Tomescu	B-X
,	B-X
Z.	B-X
Ghiorghiu	B-X
,	B-X
R.	B-X
Macovei	B-X
P332Automatic	B-X
analysis	B-X
of	B-X
EEG	B-X
reactivity	B-X
in	B-X
comatose	B-X
patients	B-X
M.	B-X
Van	B-X
Assen	B-X
,	B-X
M.	B-X
M.	B-X
Admiraal	B-X
,	B-X
M.	B-X
J	B-X
.	B-X
Van	B-X
Putten	B-X
,	B-X
M.	B-X
Tjepkema-Cloostermans	B-X
,	B-X
A.	B-X
F.	B-X
Van	B-X
Rootselaar	B-X
,	B-X
J.	B-X
Horn	B-X
P333	B-X
Usefulness	B-X
of	B-X
common	B-X
ICU	B-X
severity	B-X
scoring	B-X
systems	B-X
in	B-X
predicting	B-X
outcome	B-X
after	B-X
spontaneous	B-X
intracerebral	B-X
hemorrhage	B-X
M.	B-X
Fallenius	B-X
,	B-X
M.	B-X
B.	B-X
Skrifvars	B-X
,	B-X
M.	B-X
Reinikainen	B-X
,	B-X
S.	B-X
Bendel	B-X
,	B-X
R.	B-X
Raj	B-X
P334	B-X
Evalution	B-X
of	B-X
patients	B-X
with	B-X
suspected	B-X
subarachnoid	B-X
haemorrhage	B-X
and	B-X
negative	B-X
ct	B-X
imaging	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
C.	B-X
Hymers	B-X
,	B-X
A.	B-X
Borowska	B-X
,	B-X
H.	B-X
Sivadhas	B-X
,	B-X
S.	B-X
Sahiba	B-X
,	B-X
S.	B-X
Perkins	B-X
P335	B-X
Timing	B-X
of	B-X
endovascular	B-X
and	B-X
surgical	B-X
treatment	B-X
for	B-X
aneurysmal	B-X
subarachnoid	B-X
haemorrhage	B-X
:	B-X
early	B-X
but	B-X
not	B-X
so	B-X
fast	B-X
.	B-X
T.	B-X
Groza	B-X
,	B-X
N.	B-X
Moreau	B-X
,	B-X
D.	B-X
Castanares-Zapatero	B-X
,	B-X
P.	B-X
Hantson	B-X
P339	B-X
-	B-X
ICU-acquired	B-X
infections	B-X
in	B-X
aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
patients	B-X
:	B-X
impact	B-X
on	B-X
ICU	B-X
and	B-X
hospital	B-X
length	B-X
of	B-X
stay	B-X
M.	B-X
Carbonara	B-X
,	B-X
F.	B-X
Ortolano	B-X
,	B-X
T.	B-X
Zoerle	B-X
,	B-X
S.	B-X
Magnoni	B-X
,	B-X
S.	B-X
Pifferi	B-X
,	B-X
V.	B-X
Conte	B-X
,	B-X
N.	B-X
Stocchetti	B-X
P340	B-X
-	B-X
Cerebral	B-X
metabolic	B-X
effects	B-X
of	B-X
normobaric	B-X
hyperoxia	B-X
during	B-X
the	B-X
acute	B-X
phase	B-X
of	B-X
aneurysmal	B-X
subarachnoid	B-X
hemorrhage	B-X
L.	B-X
Carteron	B-X
,	B-X
T.	B-X
Suys	B-X
,	B-X
C.	B-X
Patet	B-X
,	B-X
H.	B-X
Quintard	B-X
,	B-X
M.	B-X
Oddo	B-X
P341	B-X
-	B-X
Postoperative	B-X
care	B-X
for	B-X
elective	B-X
craniotomy	B-X
:	B-X
where	B-X
is	B-X
best	B-X
done	B-X
?	B-X
A.	B-X
Rubio	B-X
,	B-X
J.	B-X
Rubio	B-X
,	B-X
R.	B-X
Sierra	B-X
P342	B-X
-	B-X
5-year	B-X
follow-up	B-X
of	B-X
patients	B-X
after	B-X
transplantation	B-X
of	B-X
organs	B-X
from	B-X
donors	B-X
from	B-X
neurocritical	B-X
care	B-X
V.	B-X
Spatenkova	B-X
,	B-X
E.	B-X
Pokorna	B-X
,	B-X
P.	B-X
Suchomel	B-X
P343	B-X
-	B-X
Evaluation	B-X
of	B-X
levetiracetam	B-X
pharmacokinetics	B-X
after	B-X
severe	B-X
traumatic	B-X
brain	B-X
injury	B-X
in	B-X
neurocritical	B-X
care	B-X
patients	B-X
at	B-X
a	B-X
level	B-X
one	B-X
trauma	B-X
center	B-X
N.	B-X
Ebert	B-X
,	B-X
J.	B-X
Jancik	B-X
,	B-X
H.	B-X
Rhodes	B-X
P344	B-X
-	B-X
Model	B-X
based	B-X
time	B-X
series	B-X
cluster	B-X
analysis	B-X
to	B-X
determine	B-X
unique	B-X
patient	B-X
states	B-X
in	B-X
traumatic	B-X
brain	B-X
injury	B-X
T.	B-X
Bylinski	B-X
,	B-X
C.	B-X
Hawthorne	B-X
,	B-X
M.	B-X
Shaw	B-X
,	B-X
I.	B-X
Piper	B-X
,	B-X
J.	B-X
Kinsella	B-X
P345	B-X
-	B-X
Brain	B-X
compartment	B-X
monitoring	B-X
capabilities	B-X
from	B-X
ICP	B-X
to	B-X
BI	B-X
(	B-X
bioimpedance	B-X
)	B-X
during	B-X
HS	B-X
(	B-X
hypertonic	B-X
saline	B-X
)	B-X
administration	B-X
.	B-X
State	B-X
of	B-X
art	B-X
simulation	B-X
outcome	B-X
depending	B-X
on	B-X
brain	B-X
swelling	B-X
type	B-X
A.	B-X
K.	B-X
Kink	B-X
,	B-X
I.	B-X
R.	B-X
Rätsep	B-X
P346	B-X
-	B-X
Transfusion	B-X
of	B-X
red	B-X
blood	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
traumatic	B-X
brain	B-X
injury	B-X
admitted	B-X
to	B-X
Canadian	B-X
trauma	B-X
health	B-X
centers	B-X
:	B-X
a	B-X
multicenter	B-X
cohort	B-X
study	B-X
A.	B-X
Boutin	B-X
,	B-X
L.	B-X
Moore	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
S.	B-X
English	B-X
,	B-X
L.	B-X
McIntyre	B-X
,	B-X
J.	B-X
Lacroix	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
P.	B-X
Lessard-Bonaventure	B-X
,	B-X
A.	B-X
F.	B-X
Turgeon	B-X
P347	B-X
-	B-X
Hemoglobin	B-X
thresholds	B-X
and	B-X
red	B-X
blood	B-X
cell	B-X
transfusions	B-X
in	B-X
adult	B-X
patients	B-X
with	B-X
moderate	B-X
or	B-X
severe	B-X
traumatic	B-X
brain	B-X
injury	B-X
:	B-X
a	B-X
retrospective	B-X
cohort	B-X
study	B-X
A.	B-X
Boutin	B-X
,	B-X
L.	B-X
Moore	B-X
,	B-X
R.	B-X
Green	B-X
,	B-X
P.	B-X
Lessard-Bonaventure	B-X
,	B-X
M.	B-X
Erdogan	B-X
,	B-X
M.	B-X
Butler	B-X
,	B-X
F.	B-X
Lauzier	B-X
,	B-X
M.	B-X
Chasse	B-X
,	B-X
S.	B-X
English	B-X
,	B-X
L.	B-X
McIntyre	B-X
,	B-X
R.	B-X
Zarychanski	B-X
,	B-X
J.	B-X
Lacroix	B-X
,	B-X
D.	B-X
Griesdale	B-X
,	B-X
P.	B-X
Desjardins	B-X
,	B-X
D.	B-X
A.	B-X
Fergusson	B-X
,	B-X
A.	B-X
F.	B-X
Turgeon	B-X
P348	B-X
-	B-X
Characteristics	B-X
of	B-X
patients	B-X
with	B-X
gunshot	B-X
wounds	B-X
to	B-X
the	B-X
head	B-X
-	B-X
an	B-X
observational	B-X
Brazilian	B-X
study	B-X
B.	B-X
Goncalves	B-X
,	B-X
B.	B-X
Vidal	B-X
,	B-X
C.	B-X
Valdez	B-X
,	B-X
A.	B-X
C.	B-X
Rodrigues	B-X
,	B-X
L.	B-X
Miguez	B-X
,	B-X
G.	B-X
Moralez	B-X
P349	B-X
-	B-X
Base	B-X
excess	B-X
as	B-X
predictor	B-X
for	B-X
ICU	B-X
admission	B-X
and	B-X
the	B-X
injury	B-X
severity	B-X
in	B-X
blunt	B-X
trauma	B-X
patients	B-X
T.	B-X
Hong	B-X
P350	B-X
-	B-X
Enhancement	B-X
of	B-X
usual	B-X
emergency	B-X
department	B-X
care	B-X
with	B-X
proadrenomedullin	B-X
to	B-X
improve	B-X
outcome	B-X
prediction	B-X
-	B-X
Results	B-X
from	B-X
the	B-X
multi-national	B-X
,	B-X
prospective	B-X
,	B-X
observational	B-X
TRIAGE	B-X
study	B-X
A.	B-X
Kutz	B-X
,	B-X
P.	B-X
Hausfater	B-X
,	B-X
D.	B-X
Amin	B-X
,	B-X
T.	B-X
Struja	B-X
,	B-X
S.	B-X
Haubitz	B-X
,	B-X
A.	B-X
Huber	B-X
,	B-X
B.	B-X
Mueller	B-X
,	B-X
P.	B-X
Schuetz	B-X
P351	B-X
-	B-X
Developing	B-X
an	B-X
innovative	B-X
emergency	B-X
medicine	B-X
point-of-care	B-X
simulation	B-X
programme	B-X
T.	B-X
Brown	B-X
,	B-X
J.	B-X
Collinson	B-X
,	B-X
C.	B-X
Pritchett	B-X
,	B-X
T.	B-X
Slade	B-X
P352	B-X
-	B-X
The	B-X
InSim	B-X
program	B-X
:	B-X
an	B-X
in	B-X
situ	B-X
simulation	B-X
program	B-X
for	B-X
junior	B-X
trainees	B-X
in	B-X
intensive	B-X
care	B-X
M.	B-X
Le	B-X
Guen	B-X
,	B-X
S.	B-X
Hellings	B-X
,	B-X
R.	B-X
Ramsaran	B-X
P353	B-X
-	B-X
Impact	B-X
of	B-X
excessive	B-X
and	B-X
inappropriate	B-X
troponin	B-X
testing	B-X
in	B-X
the	B-X
emergency	B-X
setting	B-X
how	B-X
good	B-X
are	B-X
we	B-X
A.	B-X
Alsheikhly	B-X
P354	B-X
-	B-X
The	B-X
development	B-X
of	B-X
time	B-X
tracking	B-X
monitor	B-X
at	B-X
emergency	B-X
department	B-X
T.	B-X
Abe	B-X
P355	B-X
-	B-X
Role	B-X
of	B-X
focussed	B-X
echocardiography	B-X
in	B-X
emergency	B-X
assessment	B-X
of	B-X
syncope	B-X
L.	B-X
Kanapeckaite	B-X
,	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
R.	B-X
Bahl	B-X
P356	B-X
-	B-X
Insertion	B-X
of	B-X
an	B-X
open-ended	B-X
14-gauge	B-X
catheter	B-X
through	B-X
the	B-X
chest	B-X
wall	B-X
causes	B-X
a	B-X
significant	B-X
pneumothorax	B-X
in	B-X
a	B-X
self-ventilating	B-X
swine	B-X
model	B-X
M.	B-X
Q	B-X
Russell	B-X
,	B-X
K.	B-X
J	B-X
.	B-X
Real	B-X
,	B-X
M.	B-X
Abu-Habsa	B-X
,	B-X
R.	B-X
M.	B-X
Lyon	B-X
,	B-X
N.	B-X
P.	B-X
Oveland	B-X
P357	B-X
-	B-X
Ez-io®	B-X
intraosseous	B-X
access	B-X
teaching	B-X
in	B-X
the	B-X
workplace	B-X
using	B-X
a	B-X
mobile	B-X
‘	B-X
tea	B-X
trolley	B-X
’	B-X
training	B-X
method	B-X
J.	B-X
Penketh	B-X
,	B-X
M.	B-X
Mcdonald	B-X
,	B-X
F.	B-X
Kelly	B-X
P358	B-X
-	B-X
Black	B-X
widow	B-X
envenomation	B-X
in	B-X
Saudi	B-X
Arabia	B-X
:	B-X
a	B-X
prospective	B-X
observational	B-X
case	B-X
series	B-X
M.	B-X
Alfafi	B-X
,	B-X
S.	B-X
Alsolamy	B-X
,	B-X
W.	B-X
Almutairi	B-X
,	B-X
B.	B-X
Alotaibi	B-X
P359	B-X
-	B-X
Mechanical	B-X
ventilation	B-X
in	B-X
patients	B-X
with	B-X
overdose	B-X
not	B-X
yet	B-X
intubated	B-X
on	B-X
icu	B-X
admission	B-X
A.	B-X
E.	B-X
Van	B-X
den	B-X
Berg	B-X
,	B-X
Y.	B-X
Schriel	B-X
,	B-X
L.	B-X
Dawson	B-X
,	B-X
I	B-X
.	B-X
A.	B-X
Meynaar	B-X
P360	B-X
-	B-X
Central	B-X
nervous	B-X
system	B-X
depressants	B-X
poisoning	B-X
and	B-X
ventilator	B-X
associated	B-X
pneumonia	B-X
:	B-X
an	B-X
underrated	B-X
risk	B-X
factor	B-X
in	B-X
toxicological	B-X
intensive	B-X
care	B-X
unit	B-X
H.	B-X
Talaie	B-X
P361	B-X
-	B-X
Acute	B-X
barium	B-X
intoxication	B-X
treated	B-X
with	B-X
hemodiafiltration	B-X
D.	B-X
Silva	B-X
,	B-X
S.	B-X
Fernandes	B-X
,	B-X
J.	B-X
Gouveia	B-X
,	B-X
J.	B-X
Santos	B-X
Silva	B-X
P362	B-X
-	B-X
Major	B-X
trauma	B-X
presenting	B-X
to	B-X
the	B-X
emergency	B-X
department	B-X
.	B-X
the	B-X
spectrum	B-X
of	B-X
cycling	B-X
injuries	B-X
in	B-X
Ireland	B-X
J.	B-X
Foley	B-X
,	B-X
A.	B-X
Kaskovagheorgescu	B-X
,	B-X
D.	B-X
Evoy	B-X
,	B-X
J.	B-X
Cronin	B-X
,	B-X
J.	B-X
Ryan	B-X
P363	B-X
-	B-X
Burns	B-X
from	B-X
French	B-X
military	B-X
operations	B-X
:	B-X
a	B-X
14-year	B-X
retrospective	B-X
observational	B-X
analysis	B-X
.	B-X
O.	B-X
Howarth	B-X
,	B-X
K.	B-X
Davenport	B-X
,	B-X
P.	B-X
Jeanrenaud	B-X
,	B-X
S.	B-X
Raftery	B-X
P365	B-X
-	B-X
Clasification	B-X
of	B-X
pain	B-X
and	B-X
its	B-X
treatment	B-X
and	B-X
an	B-X
intensive	B-X
care	B-X
rehabiliation	B-X
clinic	B-X
P.	B-X
MacTavish	B-X
,	B-X
H.	B-X
Devine	B-X
,	B-X
J.	B-X
McPeake	B-X
,	B-X
M.	B-X
Daniel	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
T.	B-X
Quasim	B-X
P366	B-X
-	B-X
Pain	B-X
management	B-X
adequacy	B-X
in	B-X
critical	B-X
care	B-X
areas	B-X
,	B-X
the	B-X
process	B-X
and	B-X
the	B-X
barriers	B-X
perceived	B-X
by	B-X
critical	B-X
care	B-X
nurses	B-X
S.	B-X
Alrabiee	B-X
,	B-X
A.	B-X
Alrashid	B-X
,	B-X
S.	B-X
Alsolamy	B-X
P367	B-X
-	B-X
Pain	B-X
assessment	B-X
in	B-X
critically	B-X
ill	B-X
adult	B-X
patients	B-X
:	B-X
validation	B-X
of	B-X
the	B-X
Turkish	B-X
version	B-X
of	B-X
the	B-X
critical-care	B-X
pain	B-X
observation	B-X
tool	B-X
O.	B-X
Gundogan	B-X
,	B-X
C.	B-X
Bor	B-X
,	B-X
E.	B-X
Akýn	B-X
Korhan	B-X
,	B-X
K.	B-X
Demirag	B-X
,	B-X
M.	B-X
Uyar	B-X
P368	B-X
-	B-X
An	B-X
audit	B-X
of	B-X
pain	B-X
and	B-X
sedation	B-X
assessments	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
recommendations	B-X
for	B-X
clinical	B-X
practice	B-X
F.	B-X
Frame	B-X
,	B-X
C.	B-X
Ashton	B-X
,	B-X
L.	B-X
Bergstrom	B-X
Niska	B-X
P369	B-X
-	B-X
Impact	B-X
of	B-X
pharmaceutical	B-X
care	B-X
on	B-X
treatment	B-X
of	B-X
pain	B-X
and	B-X
agitation	B-X
in	B-X
medical	B-X
intensive	B-X
care	B-X
unit	B-X
P.	B-X
Dilokpattanamongkol	B-X
,	B-X
T.	B-X
Suansanae	B-X
,	B-X
C.	B-X
Suthisisang	B-X
,	B-X
S.	B-X
Morakul	B-X
,	B-X
C.	B-X
Karnjanarachata	B-X
,	B-X
V.	B-X
Tangsujaritvijit	B-X
P370	B-X
-	B-X
Agitation	B-X
in	B-X
trauma	B-X
ICU	B-X
,	B-X
prevention	B-X
and	B-X
outcome	B-X
S.	B-X
Mahmood	B-X
,	B-X
H.	B-X
Al	B-X
Thani	B-X
,	B-X
A.	B-X
Almenyar	B-X
P371	B-X
Correlation	B-X
between	B-X
percentages	B-X
of	B-X
ventilated	B-X
patients	B-X
developed	B-X
vap	B-X
and	B-X
use	B-X
of	B-X
sedative	B-X
agents	B-X
in	B-X
icu	B-X
patients	B-X
.	B-X
A.	B-X
Vakalos	B-X
,	B-X
V.	B-X
Avramidis	B-X
P372	B-X
-	B-X
Improving	B-X
recording	B-X
of	B-X
sedation	B-X
events	B-X
in	B-X
the	B-X
Emergency	B-X
Department	B-X
:	B-X
The	B-X
implementation	B-X
of	B-X
the	B-X
SIVA	B-X
International	B-X
Taskforce	B-X
adverse	B-X
event	B-X
reporting	B-X
tool	B-X
for	B-X
procedural	B-X
sedation	B-X
R.	B-X
Sharvill	B-X
,	B-X
J.	B-X
Penketh	B-X
P373	B-X
-	B-X
Impact	B-X
of	B-X
sedative	B-X
drug	B-X
use	B-X
on	B-X
the	B-X
length	B-X
of	B-X
mechanical	B-X
ventilation	B-X
S.	B-X
E.	B-X
Morton	B-X
,	B-X
Y.	B-X
S.	B-X
Chiew	B-X
,	B-X
C.	B-X
Pretty	B-X
,	B-X
J.	B-X
G.	B-X
Chase	B-X
,	B-X
G.	B-X
M.	B-X
Shaw	B-X
P374	B-X
-	B-X
Co-administration	B-X
of	B-X
nitric	B-X
oxide	B-X
and	B-X
sevoflurane	B-X
using	B-X
anaconda	B-X
R.	B-X
Knafelj	B-X
,	B-X
P.	B-X
Kordis	B-X
P375	B-X
-	B-X
A	B-X
retrospective	B-X
study	B-X
of	B-X
the	B-X
use	B-X
of	B-X
Dexmedetomidine	B-X
in	B-X
an	B-X
oncological	B-X
critical	B-X
care	B-X
setting	B-X
S.	B-X
Patel	B-X
,	B-X
V.	B-X
Grover	B-X
P376	B-X
-	B-X
Dexmedetomidine	B-X
and	B-X
posttraumatic	B-X
stress	B-X
disorder	B-X
incidence	B-X
in	B-X
alcohol	B-X
withdrawal	B-X
icu	B-X
patients	B-X
I.	B-X
Kuchyn	B-X
,	B-X
K.	B-X
Bielka	B-X
P377	B-X
-	B-X
Hemodynamic	B-X
effects	B-X
of	B-X
dexmedetomidine	B-X
in	B-X
a	B-X
porcine	B-X
model	B-X
of	B-X
septic	B-X
shock	B-X
Z.	B-X
Aidoni	B-X
,	B-X
V.	B-X
Grosomanidis	B-X
,	B-X
K.	B-X
Kotzampassi	B-X
,	B-X
G.	B-X
Stavrou	B-X
,	B-X
B.	B-X
Fyntanidou	B-X
,	B-X
S.	B-X
Patsatzakis	B-X
,	B-X
C.	B-X
Skourtis	B-X
P378	B-X
-	B-X
Ketamine	B-X
for	B-X
analgosedation	B-X
in	B-X
severe	B-X
hypoxic	B-X
respiratory	B-X
failure	B-X
S.	B-X
D.	B-X
Lee	B-X
,	B-X
K.	B-X
Williams	B-X
,	B-X
I.	B-X
D.	B-X
Weltes	B-X
P379	B-X
-	B-X
Madness	B-X
from	B-X
the	B-X
moon	B-X
?	B-X
lunar	B-X
cycle	B-X
and	B-X
the	B-X
incidence	B-X
of	B-X
delirium	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
S.	B-X
Berhane	B-X
,	B-X
C.	B-X
Arrowsmith	B-X
,	B-X
C.	B-X
Peters	B-X
,	B-X
S.	B-X
Robert	B-X
P380	B-X
-	B-X
Impaired	B-X
dynamic	B-X
cerebral	B-X
autoregulation	B-X
after	B-X
coronary	B-X
artery	B-X
bypass	B-X
grafting	B-X
and	B-X
association	B-X
with	B-X
postoperative	B-X
delirium	B-X
J.	B-X
Caldas	B-X
,	B-X
R.	B-X
B.	B-X
Panerai	B-X
,	B-X
T.	B-X
G.	B-X
Robinson	B-X
,	B-X
L.	B-X
Camara	B-X
,	B-X
G.	B-X
Ferreira	B-X
,	B-X
E.	B-X
Borg-Seng-Shu	B-X
,	B-X
M.	B-X
De	B-X
Lima	B-X
Oliveira	B-X
,	B-X
N.	B-X
C.	B-X
Mian	B-X
,	B-X
L.	B-X
Santos	B-X
,	B-X
R.	B-X
Nogueira	B-X
,	B-X
S.	B-X
P.	B-X
Zeferino	B-X
,	B-X
M.	B-X
Jacobsen	B-X
Teixeira	B-X
,	B-X
F.	B-X
Galas	B-X
,	B-X
L.	B-X
A.	B-X
Hajjar	B-X
P381	B-X
-	B-X
Risk	B-X
factors	B-X
predicting	B-X
prolonged	B-X
intensive	B-X
care	B-X
unit	B-X
length	B-X
of	B-X
stay	B-X
after	B-X
major	B-X
elective	B-X
surgery	B-X
.	B-X
P.	B-X
Wacharasint	B-X
,	B-X
P.	B-X
Fuengfoo	B-X
,	B-X
N.	B-X
Sukcharoen	B-X
,	B-X
R.	B-X
Rangsin	B-X
P386	B-X
-	B-X
The	B-X
national	B-X
early	B-X
warning	B-X
score	B-X
(	B-X
news	B-X
)	B-X
reliably	B-X
improves	B-X
adverse	B-X
clinical	B-X
outcome	B-X
prediction	B-X
in	B-X
community-acquired	B-X
pneumonia	B-X
-	B-X
results	B-X
from	B-X
a	B-X
6	B-X
year	B-X
follow-up	B-X
D.	B-X
Sbiti-Rohr	B-X
,	B-X
P.	B-X
Schuetz	B-X
P387	B-X
-	B-X
Clinical	B-X
usefulness	B-X
of	B-X
the	B-X
charlson¡¯s	B-X
weighted	B-X
index	B-X
of	B-X
comorbidities	B-X
_as	B-X
prognostic	B-X
factor	B-X
in	B-X
patients	B-X
with	B-X
prolonged	B-X
acute	B-X
mechanical	B-X
ventilation	B-X
H.	B-X
Na	B-X
,	B-X
S.	B-X
Song	B-X
,	B-X
S.	B-X
Lee	B-X
,	B-X
E.	B-X
Jeong	B-X
,	B-X
K.	B-X
Lee	B-X
P388	B-X
-	B-X
Comparison	B-X
of	B-X
mortality	B-X
prediction	B-X
scoring	B-X
systems	B-X
in	B-X
patients	B-X
with	B-X
cirrhosis	B-X
admitted	B-X
to	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
M.	B-X
Cooper	B-X
,	B-X
K.	B-X
Milinis	B-X
,	B-X
G.	B-X
Williams	B-X
,	B-X
E.	B-X
McCarron	B-X
,	B-X
S.	B-X
Simants	B-X
,	B-X
I.	B-X
Patanwala	B-X
,	B-X
I.	B-X
D.	B-X
Welters	B-X
P389	B-X
-	B-X
Impact	B-X
of	B-X
admission	B-X
source	B-X
and	B-X
time	B-X
of	B-X
admission	B-X
on	B-X
outcome	B-X
of	B-X
pediatric	B-X
intensive	B-X
care	B-X
patients	B-X
:	B-X
retrospective	B-X
15	B-X
years	B-X
study	B-X
E.	B-X
Zoumpelouli	B-X
,	B-X
EA	B-X
Volakli	B-X
,	B-X
V.	B-X
Chrysohoidou	B-X
,	B-X
S.	B-X
Georgiou	B-X
,	B-X
K.	B-X
Charisopoulou	B-X
,	B-X
E.	B-X
Kotzapanagiotou	B-X
,	B-X
V.	B-X
Panagiotidou	B-X
,	B-X
K.	B-X
Manavidou	B-X
,	B-X
Z.	B-X
Stathi	B-X
,	B-X
M.	B-X
Sdougka	B-X
P390	B-X
-	B-X
Heart	B-X
rate	B-X
variability	B-X
and	B-X
outcomes	B-X
prediction	B-X
in	B-X
critical	B-X
illness	B-X
N.	B-X
Salahuddin	B-X
,	B-X
B.	B-X
AlGhamdi	B-X
,	B-X
Q.	B-X
Marashly	B-X
,	B-X
K.	B-X
Zaza	B-X
,	B-X
M.	B-X
Sharshir	B-X
,	B-X
M.	B-X
Khurshid	B-X
,	B-X
Z.	B-X
Ali	B-X
,	B-X
M.	B-X
Malgapo	B-X
,	B-X
M.	B-X
Jamil	B-X
,	B-X
A.	B-X
Shafquat	B-X
,	B-X
M.	B-X
Shoukri	B-X
,	B-X
M.	B-X
Hijazi	B-X
P391	B-X
-	B-X
The	B-X
incidence	B-X
and	B-X
outcome	B-X
of	B-X
hyperlactatemia	B-X
in	B-X
the	B-X
post	B-X
anaesthesia	B-X
care	B-X
unit	B-X
T.	B-X
Abe	B-X
,	B-X
S.	B-X
Uchino	B-X
,	B-X
M.	B-X
Takinami	B-X
P392	B-X
-	B-X
Correlation	B-X
between	B-X
arterial	B-X
blood	B-X
gas	B-X
disturbances	B-X
and	B-X
arterial	B-X
lactate	B-X
levels	B-X
during	B-X
hospitalization	B-X
and	B-X
outcome	B-X
in	B-X
critically	B-X
septic	B-X
patients	B-X
N.	B-X
R.	B-X
Rangel	B-X
Neto	B-X
,	B-X
S.	B-X
Oliveira	B-X
,	B-X
F.	B-X
Q.	B-X
Reis	B-X
,	B-X
F.	B-X
A.	B-X
Rocha	B-X
P393	B-X
-	B-X
External	B-X
validation	B-X
of	B-X
saps	B-X
3	B-X
and	B-X
mpm	B-X
iii	B-X
scores	B-X
in	B-X
48,816	B-X
patients	B-X
from	B-X
72	B-X
brazilian	B-X
icus	B-X
G.	B-X
Moralez	B-X
,	B-X
K.	B-X
Ebecken	B-X
,	B-X
L.	B-X
S.	B-X
Rabello	B-X
,	B-X
M.	B-X
F.	B-X
Lima	B-X
,	B-X
R.	B-X
Hatum	B-X
,	B-X
F.	B-X
V.	B-X
De	B-X
Marco	B-X
,	B-X
A.	B-X
Alves	B-X
,	B-X
J.	B-X
E.	B-X
Pinto	B-X
,	B-X
M.	B-X
Godoy	B-X
,	B-X
P.	B-X
E.	B-X
Brasil	B-X
,	B-X
F.	B-X
A.	B-X
Bozza	B-X
,	B-X
J.	B-X
I.	B-X
Salluh	B-X
,	B-X
M.	B-X
Soares	B-X
P394	B-X
-	B-X
The	B-X
frailty	B-X
penalty	B-X
:	B-X
pre-admission	B-X
functional	B-X
status	B-X
confounds	B-X
mortality	B-X
prediction	B-X
models	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
J.	B-X
Krinsley	B-X
,	B-X
G.	B-X
Kang	B-X
P395	B-X
-	B-X
‘	B-X
sooner	B-X
rather	B-X
than	B-X
later	B-X
”	B-X
:	B-X
how	B-X
delayed	B-X
discharge	B-X
from	B-X
critical	B-X
care	B-X
leads	B-X
to	B-X
increased	B-X
out	B-X
of	B-X
hours	B-X
discharges	B-X
and	B-X
subsequent	B-X
increase	B-X
in	B-X
in-hospital	B-X
mortality	B-X
.	B-X
J.	B-X
Perry	B-X
,	B-X
H.	B-X
Hines	B-X
P396	B-X
-	B-X
Identifying	B-X
poor	B-X
outcome	B-X
patient	B-X
groups	B-X
in	B-X
a	B-X
resource-constrained	B-X
critical	B-X
care	B-X
unit	B-X
K.	B-X
M.	B-X
Wilkinson	B-X
,	B-X
C.	B-X
Tordoff	B-X
,	B-X
B.	B-X
Sloan	B-X
,	B-X
M.	B-X
C.	B-X
Bellamy	B-X
P397	B-X
-	B-X
Effects	B-X
of	B-X
icu	B-X
weekend	B-X
admission	B-X
and	B-X
discharge	B-X
on	B-X
mortality	B-X
.	B-X
E.	B-X
Moreira	B-X
,	B-X
F.	B-X
Verga	B-X
,	B-X
M.	B-X
Barbato	B-X
,	B-X
G.	B-X
Burghi	B-X
P398	B-X
-	B-X
Organizational	B-X
factors	B-X
,	B-X
outcomes	B-X
and	B-X
resource	B-X
use	B-X
in	B-X
9,946	B-X
cancer	B-X
patients	B-X
admitted	B-X
to	B-X
70	B-X
ICUs	B-X
M	B-X
Soares	B-X
,	B-X
U.	B-X
V.	B-X
Silva	B-X
,	B-X
L.	B-X
C.	B-X
Azevedo	B-X
,	B-X
A.	B-X
P.	B-X
Torelly	B-X
,	B-X
J.	B-X
M.	B-X
Kahn	B-X
,	B-X
D.	B-X
C.	B-X
Angus	B-X
,	B-X
M.	B-X
F.	B-X
Knibel	B-X
,	B-X
P.	B-X
E.	B-X
Brasil	B-X
,	B-X
F.	B-X
A.	B-X
Bozza	B-X
,	B-X
J.	B-X
I.	B-X
Salluh	B-X
P399	B-X
-	B-X
Evaluation	B-X
of	B-X
oncological	B-X
critically	B-X
ill	B-X
patients	B-X
,	B-X
severity	B-X
score	B-X
and	B-X
outcome	B-X
compared	B-X
to	B-X
not	B-X
oncological	B-X
in	B-X
a	B-X
particular	B-X
hospital	B-X
cti	B-X
.	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
P400	B-X
-	B-X
Outcomes	B-X
of	B-X
patients	B-X
admitted	B-X
to	B-X
a	B-X
large	B-X
uk	B-X
critical	B-X
care	B-X
department	B-X
with	B-X
palliative	B-X
oncological	B-X
diagnoses	B-X
R.	B-X
Marshall	B-X
,	B-X
T.	B-X
Gilpin	B-X
,	B-X
A.	B-X
Tridente	B-X
,	B-X
A.	B-X
Raithatha	B-X
P401	B-X
-	B-X
Predictors	B-X
of	B-X
mortality	B-X
in	B-X
febrile	B-X
neutropenic	B-X
patients	B-X
with	B-X
haematological	B-X
malignancies	B-X
admitted	B-X
to	B-X
an	B-X
intensive	B-X
care	B-X
unit	B-X
of	B-X
a	B-X
cancer	B-X
center	B-X
D.	B-X
Mota	B-X
,	B-X
B.	B-X
Loureiro	B-X
,	B-X
J.	B-X
Dias	B-X
,	B-X
O.	B-X
Afonso	B-X
,	B-X
F.	B-X
Coelho	B-X
,	B-X
A.	B-X
Martins	B-X
,	B-X
F.	B-X
Faria	B-X
P402	B-X
-	B-X
Patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
requiring	B-X
invasive	B-X
mechanical	B-X
ventilation	B-X
:	B-X
characteristics	B-X
and	B-X
predictors	B-X
of	B-X
mortality	B-X
H.	B-X
Al-Dorzi	B-X
,	B-X
H.	B-X
Al	B-X
Orainni	B-X
,	B-X
F.	B-X
AlEid	B-X
,	B-X
H.	B-X
Tlaygeh	B-X
,	B-X
A.	B-X
Itani	B-X
,	B-X
A.	B-X
Hejazi	B-X
,	B-X
Y.	B-X
Arabi	B-X
P403	B-X
-	B-X
Patient-important	B-X
outcomes	B-X
in	B-X
randomized	B-X
controlled	B-X
trials	B-X
in	B-X
critically	B-X
ill	B-X
patients	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
S.	B-X
Gaudry	B-X
,	B-X
J.	B-X
Messika	B-X
,	B-X
J.	B-X
D.	B-X
Ricard	B-X
,	B-X
S.	B-X
Guillo	B-X
,	B-X
B.	B-X
Pasquet	B-X
,	B-X
E.	B-X
Dubief	B-X
,	B-X
D.	B-X
Dreyfuss	B-X
,	B-X
F.	B-X
Tubach	B-X
P404	B-X
-	B-X
Alopecia	B-X
in	B-X
survivors	B-X
of	B-X
critical	B-X
illness	B-X
:	B-X
a	B-X
qualitative	B-X
study	B-X
C	B-X
.	B-X
Battle	B-X
,	B-X
K.	B-X
James	B-X
,	B-X
P.	B-X
Temblett	B-X
P405	B-X
-	B-X
The	B-X
impact	B-X
of	B-X
mental	B-X
health	B-X
on	B-X
icu	B-X
admission	B-X
L.	B-X
Davies	B-X
,	B-X
C.	B-X
Battle	B-X
,	B-X
C.	B-X
Lynch	B-X
P406	B-X
-	B-X
Cognitive	B-X
impairment	B-X
5	B-X
years	B-X
after	B-X
ICU	B-X
discharge	B-X
S.	B-X
Pereira	B-X
,	B-X
S.	B-X
Cavaco	B-X
,	B-X
J.	B-X
Fernandes	B-X
,	B-X
I.	B-X
Moreira	B-X
,	B-X
E.	B-X
Almeida	B-X
,	B-X
F.	B-X
Seabra	B-X
Pereira	B-X
,	B-X
M.	B-X
Malheiro	B-X
,	B-X
F.	B-X
Cardoso	B-X
,	B-X
I.	B-X
Aragão	B-X
,	B-X
T.	B-X
Cardoso	B-X
P407	B-X
-	B-X
Apache	B-X
ii	B-X
versus	B-X
apache	B-X
iv	B-X
for	B-X
octagenerians	B-X
in	B-X
medical	B-X
icu	B-X
M.	B-X
Fister	B-X
,	B-X
R.	B-X
Knafelj	B-X
P408	B-X
-	B-X
Outcomes	B-X
of	B-X
octagenarians	B-X
in	B-X
an	B-X
indian	B-X
icu	B-X
P.	B-X
Muraray	B-X
Govind	B-X
,	B-X
N.	B-X
Brahmananda	B-X
Reddy	B-X
,	B-X
R.	B-X
Pratheema	B-X
,	B-X
E.	B-X
D.	B-X
Arul	B-X
,	B-X
J.	B-X
Devachandran	B-X
P409	B-X
-	B-X
Mortality	B-X
and	B-X
outcomes	B-X
in	B-X
elderly	B-X
patients	B-X
80	B-X
years	B-X
of	B-X
age	B-X
or	B-X
older	B-X
admitted	B-X
to	B-X
the	B-X
icu	B-X
M.	B-X
B.	B-X
Velasco	B-X
,	B-X
D.	B-X
M.	B-X
Dalcomune	B-X
P410	B-X
-	B-X
Octagenerians	B-X
in	B-X
medical	B-X
icu	B-X
-	B-X
adding	B-X
days	B-X
to	B-X
life	B-X
or	B-X
life	B-X
to	B-X
days	B-X
?	B-X
R.	B-X
Knafelj	B-X
,	B-X
M.	B-X
Fister	B-X
P411	B-X
-	B-X
The	B-X
very	B-X
elderly	B-X
admitted	B-X
to	B-X
intensive	B-X
care	B-X
unit	B-X
:	B-X
outcomes	B-X
and	B-X
economic	B-X
evaluation	B-X
N.	B-X
Chin-Yee	B-X
,	B-X
G.	B-X
D	B-X
’	B-X
Egidio	B-X
,	B-X
K.	B-X
Thavorn	B-X
,	B-X
D.	B-X
Heyland	B-X
,	B-X
K.	B-X
Kyeremanteng	B-X
P412	B-X
-	B-X
The	B-X
very	B-X
elderly	B-X
in	B-X
intensive	B-X
care	B-X
:	B-X
relationship	B-X
between	B-X
acuity	B-X
of	B-X
illness	B-X
and	B-X
long-term	B-X
mortality	B-X
A.	B-X
G.	B-X
Murchison	B-X
,	B-X
K.	B-X
Swalwell	B-X
,	B-X
J.	B-X
Mandeville	B-X
,	B-X
D.	B-X
Stott	B-X
P413	B-X
-	B-X
Acquired	B-X
weakness	B-X
in	B-X
an	B-X
oncological	B-X
intensive	B-X
care	B-X
unit	B-X
I.	B-X
Guerreiro	B-X
P414	B-X
-	B-X
Musculoskeletal	B-X
problems	B-X
in	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ICU	B-X
)	B-X
patients	B-X
post-discharge	B-X
H.	B-X
Devine	B-X
,	B-X
P.	B-X
MacTavish	B-X
,	B-X
J.	B-X
McPeake	B-X
,	B-X
T.	B-X
Quasim	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
M.	B-X
Daniel	B-X
P415	B-X
-	B-X
Premorbid	B-X
obesity	B-X
,	B-X
but	B-X
not	B-X
nutrition	B-X
,	B-X
prevents	B-X
critical	B-X
illness-induced	B-X
muscle	B-X
wasting	B-X
and	B-X
weakness	B-X
C.	B-X
Goossens	B-X
M.	B-X
B.	B-X
Marques	B-X
,	B-X
S.	B-X
Derde	B-X
,	B-X
S.	B-X
Vander	B-X
Perre	B-X
,	B-X
T.	B-X
Dufour	B-X
,	B-X
S.	B-X
E.	B-X
Thiessen	B-X
,	B-X
F.	B-X
Güiza	B-X
,	B-X
T.	B-X
Janssens	B-X
,	B-X
G.	B-X
Hermans	B-X
,	B-X
I.	B-X
Vanhorebeek	B-X
,	B-X
K.	B-X
De	B-X
Bock	B-X
,	B-X
G.	B-X
Van	B-X
den	B-X
Berghe	B-X
,	B-X
L.	B-X
Langouche	B-X
P416	B-X
-	B-X
Physical	B-X
outcome	B-X
measures	B-X
for	B-X
critical	B-X
care	B-X
patients	B-X
following	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
icu	B-X
)	B-X
discharge	B-X
H.	B-X
Devine	B-X
,	B-X
P.	B-X
MacTavish	B-X
,	B-X
T.	B-X
Quasim	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
M.	B-X
Daniel	B-X
,	B-X
J.	B-X
McPeake	B-X
P417	B-X
-	B-X
Improving	B-X
active	B-X
mobilisation	B-X
in	B-X
a	B-X
general	B-X
intensive	B-X
care	B-X
unit	B-X
B	B-X
.	B-X
Miles	B-X
,	B-X
S.	B-X
Madden	B-X
,	B-X
H.	B-X
Devine	B-X
P418	B-X
-	B-X
Mobilization	B-X
in	B-X
patients	B-X
on	B-X
vasoactive	B-X
drugs	B-X
use	B-X
–	B-X
a	B-X
pilot	B-X
study	B-X
.	B-X
M.	B-X
Weiler	B-X
,	B-X
P.	B-X
Marques	B-X
,	B-X
C.	B-X
Rodrigues	B-X
,	B-X
M.	B-X
Boeira	B-X
,	B-X
K.	B-X
Brenner	B-X
,	B-X
C.	B-X
Leães	B-X
,	B-X
A.	B-X
Machado	B-X
,	B-X
R.	B-X
Townsend	B-X
,	B-X
J.	B-X
Andrade	B-X
P419	B-X
-	B-X
Pharmacy	B-X
intervention	B-X
at	B-X
an	B-X
intensive	B-X
care	B-X
rehabilitation	B-X
clinic	B-X
P.	B-X
MacTavish	B-X
,	B-X
J.	B-X
McPeake	B-X
,	B-X
H.	B-X
Devine	B-X
,	B-X
J.	B-X
Kinsella	B-X
,	B-X
M.	B-X
Daniel	B-X
,	B-X
R.	B-X
Kishore	B-X
,	B-X
C.	B-X
Fenlon	B-X
,	B-X
T.	B-X
Quasim	B-X
P420	B-X
-	B-X
Interactive	B-X
gaming	B-X
is	B-X
feasible	B-X
and	B-X
potentially	B-X
increases	B-X
icu	B-X
patients	B-X
’	B-X
motivation	B-X
to	B-X
be	B-X
engaged	B-X
in	B-X
rehabilitation	B-X
programs	B-X
T.	B-X
Fiks	B-X
,	B-X
A.	B-X
Ruijter	B-X
,	B-X
M.	B-X
Te	B-X
Raa	B-X
,	B-X
P.	B-X
Spronk	B-X
P421	B-X
-	B-X
Simulation-based	B-X
design	B-X
of	B-X
a	B-X
robust	B-X
stopping	B-X
rule	B-X
to	B-X
ensure	B-X
patient	B-X
safety	B-X
Y.	B-X
S.	B-X
Chiew	B-X
,	B-X
P.	B-X
Docherty	B-X
,	B-X
J.	B-X
Dickson	B-X
,	B-X
E.	B-X
Moltchanova	B-X
,	B-X
C.	B-X
Scarrot	B-X
,	B-X
C.	B-X
Pretty	B-X
,	B-X
G.	B-X
M.	B-X
Shaw	B-X
,	B-X
J.	B-X
G.	B-X
Chase	B-X
P422	B-X
-	B-X
Are	B-X
daily	B-X
blood	B-X
tests	B-X
on	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
necessary	B-X
?	B-X
Bor	B-X
,	B-X
E.	B-X
Akin	B-X
Korhan	B-X
,	B-X
K.	B-X
Demirag	B-X
,	B-X
M.	B-X
Uyar	B-X
P425	B-X
-	B-X
Intensivist/patient	B-X
ratios	B-X
in	B-X
closed	B-X
ICUs	B-X
in	B-X
Alexandria	B-X
,	B-X
Egypt	B-X
;	B-X
an	B-X
overview	B-X
M.	B-X
Shirazy	B-X
,	B-X
A.	B-X
Fayed	B-X
P426	B-X
-	B-X
Eicu	B-X
(	B-X
electronic	B-X
intensive	B-X
care	B-X
unit	B-X
)	B-X
:	B-X
impact	B-X
on	B-X
ALOS	B-X
(	B-X
average	B-X
length	B-X
of	B-X
stay	B-X
)	B-X
in	B-X
a	B-X
developing	B-X
country	B-X
like	B-X
India	B-X
S.	B-X
Gupta	B-X
,	B-X
A.	B-X
Kaushal	B-X
,	B-X
S.	B-X
Dewan	B-X
,	B-X
A.	B-X
Varma	B-X
P427	B-X
-	B-X
Predicting	B-X
deterioration	B-X
in	B-X
general	B-X
ward	B-X
using	B-X
early	B-X
deterioration	B-X
indicator	B-X
E.	B-X
Ghosh	B-X
,	B-X
L.	B-X
Yang	B-X
,	B-X
L.	B-X
Eshelman	B-X
,	B-X
B.	B-X
Lord	B-X
,	B-X
E.	B-X
Carlson	B-X
P428	B-X
-	B-X
High	B-X
impact	B-X
enhanced	B-X
critical	B-X
care	B-X
outreach	B-X
-	B-X
the	B-X
imobile	B-X
service	B-X
:	B-X
making	B-X
a	B-X
difference	B-X
E.	B-X
Helme	B-X
,	B-X
R.	B-X
Broderick	B-X
,	B-X
S.	B-X
Hadfield	B-X
,	B-X
R.	B-X
Loveridge	B-X
P429	B-X
-	B-X
Impact	B-X
of	B-X
bed	B-X
availability	B-X
and	B-X
cognitive	B-X
load	B-X
on	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
ICU	B-X
)	B-X
bed	B-X
allocation	B-X
:	B-X
a	B-X
vignette-based	B-X
trial	B-X
J.	B-X
Ramos	B-X
,	B-X
D.	B-X
Forte	B-X
P430	B-X
-	B-X
Characteristics	B-X
of	B-X
critically	B-X
ill	B-X
patients	B-X
admitted	B-X
through	B-X
the	B-X
emergency	B-X
department	B-X
F.	B-X
Yang	B-X
,	B-X
P.	B-X
Hou	B-X
P431	B-X
-	B-X
Admission	B-X
to	B-X
critical	B-X
care	B-X
:	B-X
the	B-X
quantification	B-X
of	B-X
functional	B-X
reserve	B-X
J.	B-X
Dudziak	B-X
,	B-X
J.	B-X
Feeney	B-X
,	B-X
K.	B-X
Wilkinson	B-X
,	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
K.	B-X
Shuker	B-X
,	B-X
M.	B-X
Faulds	B-X
,	B-X
A.	B-X
Raithatha	B-X
,	B-X
D.	B-X
Bryden	B-X
,	B-X
L.	B-X
England	B-X
,	B-X
N.	B-X
Bolton	B-X
,	B-X
A.	B-X
Tridente	B-X
P432	B-X
-	B-X
Admission	B-X
to	B-X
critical	B-X
care	B-X
:	B-X
the	B-X
importance	B-X
of	B-X
frailty	B-X
K.	B-X
Bauchmuller	B-X
,	B-X
K	B-X
Shuker	B-X
,	B-X
A	B-X
Tridente	B-X
,	B-X
M	B-X
Faulds	B-X
,	B-X
A	B-X
Matheson	B-X
,	B-X
J.	B-X
Gaynor	B-X
,	B-X
D	B-X
Bryden	B-X
,	B-X
S	B-X
South	B-X
Yorkshire	B-X
Hospitals	B-X
Research	B-X
Collaboration	B-X
P433	B-X
-	B-X
Development	B-X
of	B-X
an	B-X
instrument	B-X
to	B-X
aid	B-X
triage	B-X
decisions	B-X
for	B-X
intensive	B-X
care	B-X
unit	B-X
admission	B-X
J.	B-X
Ramos	B-X
,	B-X
B.	B-X
Peroni	B-X
,	B-X
R.	B-X
Daglius-Dias	B-X
,	B-X
L.	B-X
Miranda	B-X
,	B-X
C.	B-X
Cohen	B-X
,	B-X
C.	B-X
Carvalho	B-X
,	B-X
I	B-X
.	B-X
Velasco	B-X
,	B-X
D.	B-X
Forte	B-X
P434	B-X
-	B-X
Using	B-X
selective	B-X
serotonin	B-X
re-uptake	B-X
inhibitors	B-X
and	B-X
serotonin-norepinephrine	B-X
re-uptake	B-X
inhibitors	B-X
in	B-X
critical	B-X
care	B-X
:	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
evidence	B-X
for	B-X
benefit	B-X
or	B-X
harm	B-X
J.	B-X
M.	B-X
Kelly	B-X
,	B-X
A.	B-X
Neill	B-X
,	B-X
G.	B-X
Rubenfeld	B-X
,	B-X
N.	B-X
Masson	B-X
,	B-X
A.	B-X
Min	B-X
P435	B-X
-	B-X
Measuring	B-X
adaptive	B-X
coping	B-X
of	B-X
hospitalized	B-X
patients	B-X
with	B-X
a	B-X
severe	B-X
medical	B-X
condition	B-X
:	B-X
the	B-X
sickness	B-X
insight	B-X
in	B-X
coping	B-X
questionnaire	B-X
(	B-X
sicq	B-X
)	B-X
E.	B-X
Boezeman	B-X
,	B-X
J.	B-X
Hofhuis	B-X
,	B-X
A.	B-X
Hovingh	B-X
,	B-X
R.	B-X
De	B-X
Vries	B-X
,	B-X
P.	B-X
Spronk	B-X
P436	B-X
-	B-X
Results	B-X
of	B-X
a	B-X
national	B-X
survey	B-X
regarding	B-X
intensive	B-X
care	B-X
medicine	B-X
training	B-X
G.	B-X
Cabral-Campello	B-X
,	B-X
I.	B-X
Aragão	B-X
,	B-X
T.	B-X
Cardoso	B-X
P437	B-X
-	B-X
Work	B-X
engagement	B-X
among	B-X
healthcare	B-X
professionals	B-X
in	B-X
the	B-X
intensive	B-X
care	B-X
unit	B-X
M.	B-X
Van	B-X
Mol	B-X
,	B-X
M.	B-X
Nijkamp	B-X
,	B-X
E	B-X
.	B-X
P.	B-X
Ostrowski	B-X
,	B-X
A.	B-X
Omar	B-X
P439	B-X
-	B-X
Icu	B-X
patients	B-X
suffer	B-X
from	B-X
circadian	B-X
rhythm	B-X
desynchronisation	B-X
K.	B-X
Kiss	B-X
,	B-X
B.	B-X
Köves	B-X
,	B-X
V.	B-X
Csernus	B-X
,	B-X
Z.	B-X
Molnár	B-X
P440	B-X
-	B-X
Noise	B-X
reduction	B-X
in	B-X
the	B-X
ICU	B-X
:	B-X
feasible	B-X
?	B-X
Van	B-X
Assche	B-X
,	B-X
L.	B-X
Jamaer	B-X
,	B-X
J.	B-X
Dubois	B-X
P441	B-X
-	B-X
Accidental	B-X
removal	B-X
of	B-X
invasive	B-X
devices	B-X
in	B-X
the	B-X
critical	B-X
patient	B-X
into	B-X
the	B-X
bed-washing	B-X
.	B-X
V.	B-X
Medo	B-X
,	B-X
R.	B-X
Galvez	B-X
,	B-X
J.	B-X
P.	B-X
Miranda	B-X
P442	B-X
-	B-X
Deprivation	B-X
of	B-X
liberty	B-X
safeguards	B-X
(	B-X
dols	B-X
)	B-X
:	B-X
audit	B-X
of	B-X
compliance	B-X
in	B-X
a	B-X
of	B-X
a	B-X
16-bed	B-X
specialist	B-X
cancer	B-X
critical	B-X
care	B-X
unit	B-X
.	B-X
A.	B-X
Fernandez	B-X
,	B-X
C.	B-X
McBride	B-X
P448	B-X
-	B-X
End	B-X
of	B-X
life	B-X
who	B-X
may	B-X
decide	B-X
E.	B-X
Koonthalloor	B-X
,	B-X
C.	B-X
Walsh	B-X
P449	B-X
-	B-X
Correctly	B-X
diagnosing	B-X
death	B-X
A.	B-X
Webber	B-X
,	B-X
M.	B-X
Ashe	B-X
,	B-X
K.	B-X
Smith	B-X
,	B-X
P.	B-X
Jeanrenaud	B-X
P450	B-X
-	B-X
Skin	B-X
procurement	B-X
performed	B-X
by	B-X
intensive	B-X
care	B-X
physicians	B-X
:	B-X
yes	B-X
,	B-X
we	B-X
can	B-X
.	B-X
A.	B-X
Marudi	B-X
,	B-X
S.	B-X
Baroni	B-X
,	B-X
F.	B-X
Ragusa	B-X
,	B-X
E.	B-X
Bertellini	B-X
P451	B-X
-	B-X
Death	B-X
analysis	B-X
in	B-X
pediatric	B-X
intensive	B-X
care	B-X
patients	B-X
E.	B-X
A.	B-X
Volakli	B-X
,	B-X
E.	B-X
Chochliourou	B-X
,	B-X
M.	B-X
Dimitriadou	B-X
,	B-X
A.	B-X
Violaki	B-X
,	B-X
P.	B-X
Mantzafleri	B-X
,	B-X
E.	B-X
Samkinidou	B-X
,	B-X
O.	B-X
Vrani	B-X
,	B-X
A.	B-X
Arbouti	B-X
,	B-X
T.	B-X
Varsami	B-X
,	B-X
M.	B-X
Sdougka	B-X
P452	B-X
-	B-X
The	B-X
potential	B-X
impact	B-X
of	B-X
euthanasia	B-X
on	B-X
organ	B-X
donation	B-X
:	B-X
analysis	B-X
of	B-X
data	B-X
from	B-X
belgium	B-X
J	B-X
.	B-X
B.	B-X
Nyamaizi	B-X
,	B-X
C.	B-X
Dalrymple	B-X
,	B-X
A.	B-X
Molokhia	B-X
,	B-X
A.	B-X
Dobru	B-X
P457	B-X
-	B-X
A	B-X
simple	B-X
alternative	B-X
to	B-X
the	B-X
family	B-X
satisfaction	B-X
survey	B-X
(	B-X
fs-icu	B-X
)	B-X
E.	B-X
Marrinan	B-X
,	B-X
A.	B-X
Ankuli	B-X
,	B-X
A.	B-X
Molokhia	B-X
P458	B-X
-	B-X
A	B-X
study	B-X
to	B-X
explore	B-X
the	B-X
experiences	B-X
of	B-X
patient	B-X
and	B-X
family	B-X
volunteers	B-X
in	B-X
a	B-X
critical	B-X
care	B-X
environment	B-X
:	B-X
a	B-X
phenomenological	B-X
analysis	B-X
J.	B-X
McPeake	B-X
,	B-X
R.	B-X
Struthers	B-X
,	B-X
R.	B-X
Crawford	B-X
,	B-X
H.	B-X
Devine	B-X
,	B-X
P.	B-X
Mactavish	B-X
,	B-X
T.	B-X
Quasim	B-X
P459	B-X
-	B-X
Prevalence	B-X
and	B-X
risk	B-X
factors	B-X
of	B-X
anxiety	B-X
and	B-X
depression	B-X
in	B-X
relatives	B-X
of	B-X
burn	B-X
patients	B-X
.	B-X
P.	B-X
Morelli	B-X
,	B-X
M.	B-X
Degiovanangelo	B-X
,	B-X
F.	B-X
Lemos	B-X
,	B-X
V.	B-X
MArtinez	B-X
,	B-X
F.	B-X
Verga	B-X
,	B-X
J.	B-X
Cabrera	B-X
,	B-X
G.	B-X
Burghi	B-X
P460	B-X
-	B-X
Guidance	B-X
of	B-X
visiting	B-X
children	B-X
at	B-X
an	B-X
adult	B-X
intensive	B-X
care	B-X
unit	B-X
(	B-X
icu	B-X
)	B-X
A.	B-X
Rutten	B-X
,	B-X
S.	B-X
Van	B-X
Ieperen	B-X
,	B-X
S.	B-X
De	B-X
Geer	B-X
,	B-X
M.	B-X
Van	B-X
Vugt	B-X
,	B-X
E.	B-X
Der	B-X
Kinderen	B-X
P461	B-X
-	B-X
Visiting	B-X
policies	B-X
in	B-X
Italian	B-X
pediatric	B-X
ICUs	B-X
:	B-X
an	B-X
update	B-X
A.	B-X
Giannini	B-X
,	B-X
G	B-X
Miccinesi	B-X
,	B-X
T	B-X
Marchesi	B-X
,	B-X
E	B-X
Prandi	B-X

Late	O
Thr308	O
phosphorylation	O
of	O
Akt	O
contributes	O
to	O
necroptosis	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
bFGF	B-Protein
or	O
PDGF	O
,	O
with	O
or	O
without	O
Nec	O
-	O
1	O
,	O
for	O
the	O
indicated	O
periods	O
of	O
time	O
.	O
<EOS>	B-X
Platelet-derived	B-X
growth	B-X
factors	B-X
(	B-X
PDGFs	B-X
)	B-X
were	B-X
discovered	B-X
more	B-X
than	B-X
two	B-X
decades	B-X
ago	B-X
.	B-X
Today	B-X
the	B-X
PDGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
consists	B-X
of	B-X
five	B-X
different	B-X
disulphide-linked	B-X
dimers	B-X
built	B-X
up	B-X
of	B-X
four	B-X
different	B-X
polypeptide	B-X
chains	B-X
encoded	B-X
by	B-X
four	B-X
different	B-X
genes	B-X
.	B-X
These	B-X
isoforms	B-X
,	B-X
PDGF-AA	B-X
,	B-X
PDGF-AB	B-X
,	B-X
PDGF-BB	B-X
,	B-X
PDGF-CC	B-X
and	B-X
PDGF-DD	B-X
,	B-X
act	B-X
via	B-X
two	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
,	B-X
PDGF	B-X
receptors	B-X
alpha	B-X
and	B-X
beta	B-X
.	B-X
The	B-X
classic	B-X
PDGFs	B-X
,	B-X
PDGF-A	B-X
and	B-X
PDGF-B	B-X
,	B-X
undergo	B-X
intracellular	B-X
activation	B-X
during	B-X
transport	B-X
in	B-X
the	B-X
exocytic	B-X
pathway	B-X
for	B-X
subsequent	B-X
secretion	B-X
,	B-X
while	B-X
the	B-X
novel	B-X
PDGFs	B-X
,	B-X
PDGF-C	B-X
and	B-X
PDGF-D	B-X
,	B-X
are	B-X
secreted	B-X
as	B-X
latent	B-X
factors	B-X
that	B-X
require	B-X
activation	B-X
by	B-X
extracellular	B-X
proteases	B-X
.	B-X
The	B-X
classical	B-X
PDGF	B-X
polypeptide	B-X
chains	B-X
,	B-X
PDGF-A	B-X
and	B-X
PDGF-B	B-X
,	B-X
are	B-X
well	B-X
studied	B-X
and	B-X
they	B-X
regulate	B-X
several	B-X
physiological	B-X
and	B-X
pathophysiological	B-X
processes	B-X
,	B-X
mainly	B-X
using	B-X
cells	B-X
of	B-X
mesenchymal	B-X
or	B-X
neuroectodermal	B-X
origin	B-X
as	B-X
their	B-X
targets	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
two	B-X
additional	B-X
ligands	B-X
for	B-X
the	B-X
two	B-X
PDGF	B-X
receptors	B-X
suggests	B-X
that	B-X
PDGF-mediated	B-X
cellular	B-X
signaling	B-X
is	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
thought	B-X
.	B-X

(	O
B	O
,	O
C	O
)	O
L929	O
cells	O
were	O
stimulated	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
(	O
B	O
)	O
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
C	O
)	O
.	O
<EOS>	B-X
Increased	B-X
osteoclast	B-X
(	B-X
OC	B-X
)	B-X
differentiation	B-X
and	B-X
activity	B-X
is	B-X
the	B-X
critical	B-X
event	B-X
that	B-X
results	B-X
in	B-X
bone	B-X
loss	B-X
and	B-X
joint	B-X
destruction	B-X
in	B-X
common	B-X
pathological	B-X
bone	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
osteoporosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
RANKL	B-X
and	B-X
its	B-X
decoy	B-X
receptor	B-X
,	B-X
osteoprotegerin	B-X
(	B-X
OPG	B-X
)	B-X
,	B-X
control	B-X
OC	B-X
differentiation	B-X
and	B-X
activity	B-X
.	B-X
TNFα	B-X
can	B-X
induce	B-X
OC	B-X
differentiation	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
the	B-X
RANKL/RANK	B-X
system	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
factors	B-X
that	B-X
negatively	B-X
and	B-X
positively	B-X
regulate	B-X
TNFα	B-X
induction	B-X
of	B-X
OC	B-X
formation	B-X
,	B-X
and	B-X
the	B-X
mechanisms	B-X
involved	B-X
to	B-X
inform	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anti-resorptive	B-X
agents	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
bone	B-X
conditions	B-X
with	B-X
enhanced	B-X
OC	B-X
formation	B-X
.	B-X
Similar	B-X
to	B-X
,	B-X
and	B-X
being	B-X
independent	B-X
of	B-X
,	B-X
RANKL	B-X
,	B-X
TNFα	B-X
recruits	B-X
TNF	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
to	B-X
sequentially	B-X
activate	B-X
transcriptional	B-X
factors	B-X
NF-κB	B-X
p50	B-X
and	B-X
p52	B-X
,	B-X
followed	B-X
by	B-X
c-Fos	B-X
,	B-X
and	B-X
then	B-X
NFATc1	B-X
to	B-X
induce	B-X
OC	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
induction	B-X
of	B-X
OC	B-X
formation	B-X
by	B-X
TNFα	B-X
alone	B-X
is	B-X
very	B-X
limited	B-X
,	B-X
since	B-X
it	B-X
also	B-X
induces	B-X
many	B-X
inhibitory	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
TRAF3	B-X
,	B-X
p100	B-X
,	B-X
IRF8	B-X
,	B-X
and	B-X
RBP-j	B-X
.	B-X
TNFα	B-X
induction	B-X
of	B-X
OC	B-X
differentiation	B-X
is	B-X
,	B-X
however	B-X
,	B-X
versatile	B-X
,	B-X
and	B-X
Interleukin-1	B-X
or	B-X
TGFβ1	B-X
can	B-X
enhance	B-X
TNFα-induced	B-X
OC	B-X
formation	B-X
through	B-X
a	B-X
mechanism	B-X
which	B-X
is	B-X
independent	B-X
of	B-X
RANKL	B-X
,	B-X
TRAF6	B-X
,	B-X
and/or	B-X
NF-κB	B-X
.	B-X
However	B-X
,	B-X
TNFα	B-X
polarized	B-X
macrophages	B-X
also	B-X
produce	B-X
anabolic	B-X
factors	B-X
,	B-X
including	B-X
insulin	B-X
such	B-X
as	B-X
6	B-X
peptide	B-X
and	B-X
Jagged1	B-X
,	B-X
to	B-X
slow	B-X
down	B-X
bone	B-X
loss	B-X
in	B-X
the	B-X
pathological	B-X
conditions	B-X
.	B-X

Akt	O
inh	O
.	O
<EOS>	B-X
The	B-X
NO	B-X
production	B-X
stimulated	B-X
by	B-X
GW7647	B-X
was	B-X
suppressed	B-X
by	B-X
inhibitors	B-X
of	B-X
PI3K	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
Akt	B-X
(	B-X
AKT	B-X
1/2	B-X
Kinase	B-X
Inhibitor	B-X
,	B-X
AKT-inh	B-X
)	B-X
,	B-X
although	B-X
it	B-X
was	B-X
also	B-X
suppressed	B-X
by	B-X
the	B-X
inhibitors	B-X
of	B-X
PPARα	B-X
(	B-X
GW6471	B-X
)	B-X
and	B-X
NOS1	B-X
(	B-X
N-PLA	B-X
)	B-X
.	B-X
GW7647	B-X
enhanced	B-X
the	B-X
ACh	B-X
(	B-X
acetylcholine	B-X
)	B-X
-stimulated	B-X
exocytosis	B-X
(	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-regulated	B-X
exocytosis	B-X
)	B-X
mediated	B-X
via	B-X
NO	B-X
,	B-X
which	B-X
was	B-X
abolished	B-X
by	B-X
GW6471	B-X
,	B-X
N-PLA	B-X
,	B-X
wortmannin	B-X
,	B-X
and	B-X
AKT-inh	B-X
.	B-X
The	B-X
Western	B-X
blotting	B-X
revealed	B-X
that	B-X
GW7647	B-X
phosphorylates	B-X
NOS1	B-X
via	B-X
phosphorylation	B-X
of	B-X
PI3K/Akt	B-X
in	B-X
antral	B-X
mucous	B-X
cells	B-X
.	B-X
The	B-X
immunofluorescence	B-X
examinations	B-X
demonstrated	B-X
that	B-X
PPARα	B-X
existing	B-X
with	B-X
NOS1	B-X
co-localizes	B-X
with	B-X
PI3K	B-X
and	B-X
Akt	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
antral	B-X
mucous	B-X
cells	B-X
.	B-X
ACh	B-X
alone	B-X
and	B-X
AACOCF3	B-X
,	B-X
an	B-X
analogue	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
,	B-X
induced	B-X
the	B-X
NOS1	B-X
phosphorylation	B-X
via	B-X
PI3K/Akt	B-X
to	B-X
produce	B-X
NO	B-X
,	B-X
which	B-X
was	B-X
inhibited	B-X
by	B-X
GW6471	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
PPARα	B-X
activates	B-X
NOS1	B-X
via	B-X
PI3K/Akt	B-X
phosphorylation	B-X
to	B-X
produce	B-X
NO	B-X
in	B-X
antral	B-X
mucous	B-X
cells	B-X
during	B-X
ACh	B-X
stimulation	B-X
.	B-X

VIII	O
was	O
added	O
15	O
min	O
before	O
necroptotic	O
stimulation	O
(	O
Pre	O
)	O
or	O
at	O
indicated	O
times	O
after	O
stimulation	O
.	O
<EOS>	B-X
Previously	B-X
made	B-X
experiments	B-X
has	B-X
shown	B-X
that	B-X
these	B-X
cells	B-X
in	B-X
small	B-X
numbers	B-X
form	B-X
in	B-X
specific	B-X
circumstances	B-X
after	B-X
anticancer	B-X
treatment	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
timing	B-X
of	B-X
acid-induced	B-X
increase	B-X
in	B-X
saliva	B-X
secretion	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
possibility	B-X
of	B-X
parasympathetic	B-X
reinnervation	B-X
of	B-X
transplanted	B-X
submandibular	B-X
glands	B-X
(	B-X
SMGs	B-X
)	B-X
.	B-X
Citric	B-X
acid	B-X
stimulation-induced	B-X
changes	B-X
in	B-X
secretion	B-X
of	B-X
transplanted	B-X
SMGs	B-X
were	B-X
evaluated	B-X
in	B-X
27	B-X
patients	B-X
who	B-X
underwent	B-X
SMG	B-X
transplantation	B-X
for	B-X
keratoconjunctivitis	B-X
sicca	B-X
(	B-X
KCS	B-X
)	B-X
;	B-X
(	B-X
99m	B-X
)	B-X
Tc	B-X
scintigraphy	B-X
and	B-X
Schirmer	B-X
tests	B-X
were	B-X
done	B-X
at	B-X
1	B-X
,	B-X
3	B-X
,	B-X
6	B-X
,	B-X
and	B-X
9	B-X
months	B-X
after	B-X
transplantation	B-X
.	B-X
Schirmer	B-X
tests	B-X
showed	B-X
significantly	B-X
increased	B-X
secretion	B-X
of	B-X
the	B-X
transplanted	B-X
SMGs	B-X
after	B-X
acid	B-X
stimulation	B-X
at	B-X
6	B-X
and	B-X
9	B-X
months	B-X
,	B-X
but	B-X
not	B-X
at	B-X
1	B-X
and	B-X
3	B-X
months	B-X
.	B-X
On	B-X
(	B-X
99m	B-X
)	B-X
Tc	B-X
scintigraphy	B-X
,	B-X
no	B-X
decline	B-X
was	B-X
detected	B-X
on	B-X
the	B-X
dynamic	B-X
time-activity	B-X
curve	B-X
after	B-X
acid	B-X
stimulation	B-X
at	B-X
1	B-X
and	B-X
3	B-X
months	B-X
,	B-X
but	B-X
a	B-X
decline	B-X
was	B-X
detected	B-X
in	B-X
nine	B-X
glands	B-X
at	B-X
6	B-X
months	B-X
and	B-X
in	B-X
19	B-X
glands	B-X
at	B-X
9	B-X
months	B-X
.	B-X

Viability	O
was	O
measured	O
24	O
hr	O
after	O
activation	O
of	O
necroptosis	O
.	O

(	O
D	O
)	O
L929	O
cells	O
were	O
stimulated	O
with	O
bFGF	B-Protein
/	O
zVAD	O
under	O
serum	O
free	O
conditions	O
.	O

PD173074	O
was	O
added	O
15	O
min	O
before	O
or	O
1	O
hr	O
after	O
FGF	O
/	O
zVAD	O
.	O
<EOS>	B-X
The	B-X
pyridopyrimidinones	B-X
are	B-X
a	B-X
potent	B-X
class	B-X
of	B-X
inhibitors	B-X
of	B-X
c-Abl	B-X
kinase	B-X
and	B-X
Bcr-Abl	B-X
kinase	B-X
,	B-X
the	B-X
causative	B-X
fusion	B-X
protein	B-X
in	B-X
chronic	B-X
myelogenous	B-X
leukemia	B-X
and	B-X
Src	B-X
family	B-X
kinases	B-X
.	B-X
A	B-X
novel	B-X
method	B-X
for	B-X
routine	B-X
,	B-X
high-yield	B-X
no-carrier-added	B-X
synthesis	B-X
of	B-X
[	B-X
(	B-X
124	B-X
)	B-X
I	B-X
]	B-X
-	B-X
,	B-X
[	B-X
(	B-X
125	B-X
)	B-X
I	B-X
]	B-X
-	B-X
and	B-X
[	B-X
(	B-X
131	B-X
)	B-X
I	B-X
]	B-X
-6-	B-X
(	B-X
2,6-dichlorophenyl	B-X
)	B-X
-2-	B-X
(	B-X
4-iodophenylamino	B-X
)	B-X
-8-methyl-8H-pyrido	B-X
[	B-X
2,3-d	B-X
]	B-X
pyrimidin-7-one	B-X
has	B-X
been	B-X
developed	B-X
.	B-X
The	B-X
4'-trimethylstannyl-	B-X
or	B-X
4'-tri-n-butylstannyl-pyridopyrimidinone	B-X
precursors	B-X
were	B-X
prepared	B-X
from	B-X
the	B-X
aryl	B-X
bromide	B-X
via	B-X
a	B-X
palladium-mediated	B-X
coupling	B-X
with	B-X
hexaalkylditin	B-X
(	B-X
dioxane/microwave	B-X
irradiation/10	B-X
min	B-X
at	B-X
160	B-X
degrees	B-X
C	B-X
)	B-X
.	B-X
The	B-X
radioiodination	B-X
of	B-X
4'-stannylpyridopyrimidinones	B-X
was	B-X
found	B-X
to	B-X
optimally	B-X
occur	B-X
via	B-X
an	B-X
iododestannylation	B-X
with	B-X
Na	B-X
(	B-X
124	B-X
)	B-X
I	B-X
,	B-X
Na	B-X
(	B-X
125	B-X
)	B-X
I	B-X
or	B-X
Na	B-X
(	B-X
131	B-X
)	B-X
I	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
oxidant	B-X
[	B-X
30	B-X
%	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/HOAc	B-X
(	B-X
1:3	B-X
)	B-X
/10	B-X
min	B-X
]	B-X
in	B-X
79-87	B-X
%	B-X
radiochemical	B-X
yield	B-X
with	B-X
>	B-X
99	B-X
%	B-X
radiochemical	B-X
purity	B-X
.	B-X
The	B-X
total	B-X
radiosynthesis	B-X
time	B-X
was	B-X
30	B-X
min	B-X
.	B-X
Cell	B-X
proliferation	B-X
of	B-X
K562	B-X
and	B-X
A431	B-X
cells	B-X
was	B-X
inhibited	B-X
with	B-X
an	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
2.0	B-X
and	B-X
20	B-X
nM	B-X
,	B-X
respectively	B-X
.	B-X
Rapid	B-X
cellular	B-X
uptake	B-X
and	B-X
equilibrium	B-X
were	B-X
observed	B-X
within	B-X
10-15	B-X
min	B-X
using	B-X
[	B-X
(	B-X
131	B-X
)	B-X
I	B-X
]	B-X
-4-iodophenylpyridopyrimidinone	B-X
6c	B-X
in	B-X
K562	B-X
and	B-X
A431	B-X
cells	B-X
and	B-X
demonstrated	B-X
a	B-X
2.8-fold	B-X
uptake	B-X
selectivity	B-X
for	B-X
the	B-X
Bcr-Abl-expressing	B-X
K562	B-X
cells	B-X
at	B-X
60	B-X
min	B-X
.	B-X

Samples	O
for	O
western	O
blot	O
were	O
collected	O
at	O
15	O
min	O
and	O
9	O
hr	O
time	O
points	O
.	O

(	O
E	O
)	O
Cells	O
were	O
pretreated	O
with	O
PD173074	O
or	O
it	O
was	O
added	O
1	O
hr	O
after	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
,	O
followed	O
by	O
viability	O
assessment	O
at	O
24	O
hr	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

mTORC1	O
contributes	O
to	O
the	O
regulation	O
of	O
necroptosis	O
.	O

(	O
A	O
)	O
L929	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
and	O
harvested	O
for	O
western	O
blot	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
shown	B-X
that	B-X
necroptosis-caspase-independent	B-X
programmed	B-X
necrotic	B-X
cell	B-X
death-can	B-X
be	B-X
induced	B-X
by	B-X
treatment	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
in	B-X
the	B-X
L929	B-X
murine	B-X
fibrosarcoma	B-X
cell	B-X
line	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
caspase	B-X
inhibitor	B-X
.	B-X
Although	B-X
it	B-X
was	B-X
reported	B-X
that	B-X
necrostatin-1-a	B-X
specific	B-X
inhibitor	B-X
of	B-X
necroptosis-inhibited	B-X
TNF-induced	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
,	B-X
it	B-X
has	B-X
not	B-X
been	B-X
elucidated	B-X
whether	B-X
the	B-X
cells	B-X
eventually	B-X
die	B-X
by	B-X
apoptosis	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
necrostatin-1	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
induction	B-X
of	B-X
apoptosis	B-X
was	B-X
demonstrated	B-X
in	B-X
TNF-treated	B-X
L929	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
necrostatin-1	B-X
.	B-X
Co-treatment	B-X
with	B-X
cycloheximide	B-X
expedited	B-X
apoptosis	B-X
induction	B-X
in	B-X
necrostatin-1/TNF-treated	B-X
L929	B-X
cells	B-X
:	B-X
typical	B-X
apoptotic	B-X
morphological	B-X
changes	B-X
,	B-X
including	B-X
membrane	B-X
blebbing	B-X
and	B-X
nuclear	B-X
fragmentation	B-X
,	B-X
induction	B-X
of	B-X
caspase-3	B-X
activity	B-X
,	B-X
proteolytic	B-X
activation	B-X
of	B-X
caspases-3	B-X
,	B-X
-8	B-X
,	B-X
and	B-X
-9	B-X
,	B-X
and	B-X
cleavage	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
(	B-X
PARP	B-X
)	B-X
(	B-X
a	B-X
well-known	B-X
substrate	B-X
of	B-X
caspase-3	B-X
)	B-X
were	B-X
observed	B-X
.	B-X
Moreover	B-X
,	B-X
co-treatment	B-X
with	B-X
Z-VAD-fmk	B-X
(	B-X
a	B-X
pan-caspase	B-X
inhibitor	B-X
)	B-X
inhibited	B-X
apoptosis	B-X
by	B-X
completely	B-X
inhibiting	B-X
caspases	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
shift	B-X
from	B-X
apoptosis	B-X
to	B-X
necroptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
apoptosis	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
TNF-treated	B-X
L929	B-X
cells	B-X
when	B-X
the	B-X
cells	B-X
are	B-X
protected	B-X
from	B-X
necroptosis	B-X
,	B-X
and	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
partial	B-X
activation	B-X
of	B-X
caspase-8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
caspase	B-X
inhibitor	B-X
preferential	B-X
to	B-X
caspase-3	B-X
suppresses	B-X
both	B-X
apoptosis	B-X
and	B-X
necroptosis	B-X
.	B-X

(	O
B	O
)	O
Cell	O
under	O
serum	O
free	O
condition	O
were	O
treated	O
with	O
bFGF	B-Protein
or	O
bFGF	B-Protein
/	O
zVAD	O
.	O
fmk	O
for	O
the	O
indicated	O
amounts	O
of	O
time	O
,	O
followed	O
by	O
western	O
blotting	O
using	O
the	O
indicated	O
antibodies	O
.	O

(	O
C	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
in	O
L929	O
cell	O
in	O
the	O
presence	O
of	O
inhibitors	O
of	O
Akt	O
(	O
Akt	O
inh	O
.	O
VIII	O
)	O
and	O
mTOR	O
(	O
rapamycin	O
,	O
Torin	O
-	O
1	O
and	O
PI	O
-	O
103	O
)	O
.	O

(	O
D	O
)	O
L929	O
cells	O
with	O
mTOR	O
siRNA	O
knockdown	O
were	O
harvested	O
for	O
western	O
blot	O
or	O
treated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
24	O
hrs	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
adjuvant	B-X
,	B-X
tumor	B-X
cells	B-X
dying	B-X
in	B-X
response	B-X
to	B-X
anthracyclins	B-X
can	B-X
elicit	B-X
an	B-X
effective	B-X
antitumor	B-X
immune	B-X
response	B-X
that	B-X
suppresses	B-X
the	B-X
growth	B-X
of	B-X
inoculated	B-X
tumors	B-X
or	B-X
leads	B-X
to	B-X
the	B-X
regression	B-X
of	B-X
established	B-X
neoplasia	B-X
.	B-X
Caspase	B-X
inhibition	B-X
by	B-X
Z-VAD-fmk	B-X
or	B-X
transfection	B-X
with	B-X
the	B-X
baculovirus	B-X
inhibitor	B-X
p35	B-X
did	B-X
not	B-X
inhibit	B-X
doxorubicin	B-X
(	B-X
DX	B-X
)	B-X
-induced	B-X
cell	B-X
death	B-X
,	B-X
yet	B-X
suppressed	B-X
the	B-X
immunogenicity	B-X
of	B-X
dying	B-X
tumor	B-X
cells	B-X
in	B-X
several	B-X
rodent	B-X
models	B-X
of	B-X
neoplasia	B-X
.	B-X
Depletion	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
or	B-X
CD8+T	B-X
cells	B-X
abolished	B-X
the	B-X
immune	B-X
response	B-X
against	B-X
DX-treated	B-X
apoptotic	B-X
tumor	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
Caspase	B-X
inhibition	B-X
suppressed	B-X
the	B-X
capacity	B-X
of	B-X
DX-killed	B-X
cells	B-X
to	B-X
be	B-X
phagocytosed	B-X
by	B-X
DCs	B-X
,	B-X
yet	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
their	B-X
capacity	B-X
to	B-X
elicit	B-X
DC	B-X
maturation	B-X
.	B-X

Cell	O
viability	O
was	O
determined	O
24	O
hr	O
after	O
activation	O
of	O
necroptosis	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

Akt	O
and	O
mTORC1	O
control	O
autocrine	O
TNFalpha	B-Protein
synthesis	O
and	O
JNK	O
activation	O
during	O
necroptosis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

(	O
A	O
)	O
Cells	O
were	O
treated	O
under	O
serum	O
free	O
conditions	O
with	O
bFGF	B-Protein
or	O
PDGF	O
with	O
or	O
without	O
zVAD	O
.	O
fmk	O
for	O
9	O
hr	O
,	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
mTNFalpha	B-Protein
.	O
<EOS>	B-X
Platelet-derived	B-X
growth	B-X
factors	B-X
(	B-X
PDGFs	B-X
)	B-X
were	B-X
discovered	B-X
more	B-X
than	B-X
two	B-X
decades	B-X
ago	B-X
.	B-X
Today	B-X
the	B-X
PDGF	B-X
family	B-X
of	B-X
growth	B-X
factors	B-X
consists	B-X
of	B-X
five	B-X
different	B-X
disulphide-linked	B-X
dimers	B-X
built	B-X
up	B-X
of	B-X
four	B-X
different	B-X
polypeptide	B-X
chains	B-X
encoded	B-X
by	B-X
four	B-X
different	B-X
genes	B-X
.	B-X
These	B-X
isoforms	B-X
,	B-X
PDGF-AA	B-X
,	B-X
PDGF-AB	B-X
,	B-X
PDGF-BB	B-X
,	B-X
PDGF-CC	B-X
and	B-X
PDGF-DD	B-X
,	B-X
act	B-X
via	B-X
two	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
,	B-X
PDGF	B-X
receptors	B-X
alpha	B-X
and	B-X
beta	B-X
.	B-X
The	B-X
classic	B-X
PDGFs	B-X
,	B-X
PDGF-A	B-X
and	B-X
PDGF-B	B-X
,	B-X
undergo	B-X
intracellular	B-X
activation	B-X
during	B-X
transport	B-X
in	B-X
the	B-X
exocytic	B-X
pathway	B-X
for	B-X
subsequent	B-X
secretion	B-X
,	B-X
while	B-X
the	B-X
novel	B-X
PDGFs	B-X
,	B-X
PDGF-C	B-X
and	B-X
PDGF-D	B-X
,	B-X
are	B-X
secreted	B-X
as	B-X
latent	B-X
factors	B-X
that	B-X
require	B-X
activation	B-X
by	B-X
extracellular	B-X
proteases	B-X
.	B-X
The	B-X
classical	B-X
PDGF	B-X
polypeptide	B-X
chains	B-X
,	B-X
PDGF-A	B-X
and	B-X
PDGF-B	B-X
,	B-X
are	B-X
well	B-X
studied	B-X
and	B-X
they	B-X
regulate	B-X
several	B-X
physiological	B-X
and	B-X
pathophysiological	B-X
processes	B-X
,	B-X
mainly	B-X
using	B-X
cells	B-X
of	B-X
mesenchymal	B-X
or	B-X
neuroectodermal	B-X
origin	B-X
as	B-X
their	B-X
targets	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
two	B-X
additional	B-X
ligands	B-X
for	B-X
the	B-X
two	B-X
PDGF	B-X
receptors	B-X
suggests	B-X
that	B-X
PDGF-mediated	B-X
cellular	B-X
signaling	B-X
is	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
thought	B-X
.	B-X

Data	O
was	O
normalized	O
to	O
mouse	O
18S	B-Protein
RNA	O
.	O
<EOS>	B-X
The	B-X
U14	B-X
RNA	B-X
of	B-X
Saccharomyces	B-X
cerevisiae	B-X
is	B-X
a	B-X
small	B-X
nucleolar	B-X
RNA	B-X
(	B-X
snoRNA	B-X
)	B-X
required	B-X
for	B-X
normal	B-X
production	B-X
of	B-X
18S	B-X
rRNA	B-X
.	B-X
Depletion	B-X
of	B-X
U14	B-X
results	B-X
in	B-X
impaired	B-X
processing	B-X
of	B-X
pre-rRNA	B-X
,	B-X
deficiency	B-X
in	B-X
18S-containing	B-X
intermediates	B-X
and	B-X
marked	B-X
under-accumulation	B-X
of	B-X
mature	B-X
18S	B-X
RNA	B-X
.	B-X
Special	B-X
attention	B-X
was	B-X
directed	B-X
at	B-X
assessing	B-X
the	B-X
importance	B-X
of	B-X
sequence	B-X
elements	B-X
conserved	B-X
between	B-X
yeast	B-X
and	B-X
mouse	B-X
U14	B-X
as	B-X
well	B-X
as	B-X
other	B-X
snoRNA	B-X
species	B-X
.	B-X
These	B-X
regions	B-X
include	B-X
bases	B-X
in	B-X
:	B-X
(	B-X
i	B-X
)	B-X
the	B-X
5'-proximal	B-X
box	B-X
C	B-X
region	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
3'-distal	B-X
box	B-X
D	B-X
region	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
a	B-X
13	B-X
base	B-X
domain	B-X
complementary	B-X
to	B-X
18S	B-X
rRNA	B-X
.	B-X
Point	B-X
and	B-X
multi-base	B-X
substitution	B-X
mutations	B-X
in	B-X
the	B-X
snoRNA	B-X
conserved	B-X
box	B-X
C	B-X
and	B-X
box	B-X
D	B-X
regions	B-X
prevent	B-X
U14	B-X
accumulation	B-X
.	B-X
Mutations	B-X
in	B-X
the	B-X
essential	B-X
18S	B-X
related	B-X
domain	B-X
do	B-X
not	B-X
effect	B-X
U14	B-X
levels	B-X
,	B-X
but	B-X
do	B-X
disrupt	B-X
synthesis	B-X
of	B-X
18S	B-X
RNA	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
region	B-X
is	B-X
required	B-X
for	B-X
function	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
box	B-X
C	B-X
and	B-X
box	B-X
D	B-X
regions	B-X
influence	B-X
U14	B-X
expression	B-X
or	B-X
stability	B-X
and	B-X
that	B-X
U14	B-X
function	B-X
might	B-X
involve	B-X
direct	B-X
interaction	B-X
with	B-X
18S	B-X
RNA	B-X
.	B-X

(	O
B	O
)	O
Necroptosis	O
was	O
induced	O
by	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
in	O
cells	O
treated	O
with	O
Nec	O
-	O
1	O
,	O
rapamycin	O
(	O
rapa	O
)	O
,	O
or	O
Akt	O
inh	O
.	O
<EOS>	B-X
Cholesterol	B-X
7alpha-hydroxylase	B-X
(	B-X
CYP7A1	B-X
)	B-X
is	B-X
the	B-X
rate	B-X
limiting	B-X
enzyme	B-X
of	B-X
the	B-X
bile	B-X
acid	B-X
biosynthetic	B-X
pathway	B-X
to	B-X
convert	B-X
cholesterol	B-X
to	B-X
bile	B-X
acids	B-X
,	B-X
which	B-X
is	B-X
a	B-X
major	B-X
output	B-X
pathway	B-X
for	B-X
cholesterol	B-X
catabolism	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
potential	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
microRNA-185	B-X
(	B-X
miR-185	B-X
)	B-X
in	B-X
cholesterol	B-X
and	B-X
bile	B-X
acid	B-X
homeostasis	B-X
.	B-X
A	B-X
PPARα	B-X
(	B-X
peroxisome	B-X
proliferation	B-X
activation	B-X
receptor	B-X
α	B-X
)	B-X
agonist	B-X
(	B-X
GW7647	B-X
)	B-X
activates	B-X
nitric	B-X
oxide	B-X
synthase	B-X
1	B-X
(	B-X
NOS1	B-X
)	B-X
to	B-X
produce	B-X
NO	B-X
leading	B-X
to	B-X
cGMP	B-X
accumulation	B-X
in	B-X
antral	B-X
mucous	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
how	B-X
PPARα	B-X
activates	B-X
NOS1	B-X
.	B-X
The	B-X
NO	B-X
production	B-X
stimulated	B-X
by	B-X
GW7647	B-X
was	B-X
suppressed	B-X
by	B-X
inhibitors	B-X
of	B-X
PI3K	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
Akt	B-X
(	B-X
AKT	B-X
1/2	B-X
Kinase	B-X
Inhibitor	B-X
,	B-X
AKT-inh	B-X
)	B-X
,	B-X
although	B-X
it	B-X
was	B-X
also	B-X
suppressed	B-X
by	B-X
the	B-X
inhibitors	B-X
of	B-X
PPARα	B-X
(	B-X
GW6471	B-X
)	B-X
and	B-X
NOS1	B-X
(	B-X
N-PLA	B-X
)	B-X
.	B-X
GW7647	B-X
enhanced	B-X
the	B-X
ACh	B-X
(	B-X
acetylcholine	B-X
)	B-X
-stimulated	B-X
exocytosis	B-X
(	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-regulated	B-X
exocytosis	B-X
)	B-X
mediated	B-X
via	B-X
NO	B-X
,	B-X
which	B-X
was	B-X
abolished	B-X
by	B-X
GW6471	B-X
,	B-X
N-PLA	B-X
,	B-X
wortmannin	B-X
,	B-X
and	B-X
AKT-inh	B-X
.	B-X
The	B-X
Western	B-X
blotting	B-X
revealed	B-X
that	B-X
GW7647	B-X
phosphorylates	B-X
NOS1	B-X
via	B-X
phosphorylation	B-X
of	B-X
PI3K/Akt	B-X
in	B-X
antral	B-X
mucous	B-X
cells	B-X
.	B-X
The	B-X
immunofluorescence	B-X
examinations	B-X
demonstrated	B-X
that	B-X
PPARα	B-X
existing	B-X
with	B-X
NOS1	B-X
co-localizes	B-X
with	B-X
PI3K	B-X
and	B-X
Akt	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
antral	B-X
mucous	B-X
cells	B-X
.	B-X
ACh	B-X
alone	B-X
and	B-X
AACOCF3	B-X
,	B-X
an	B-X
analogue	B-X
of	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
,	B-X
induced	B-X
the	B-X
NOS1	B-X
phosphorylation	B-X
via	B-X
PI3K/Akt	B-X
to	B-X
produce	B-X
NO	B-X
,	B-X
which	B-X
was	B-X
inhibited	B-X
by	B-X
GW6471	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
PPARα	B-X
activates	B-X
NOS1	B-X
via	B-X
PI3K/Akt	B-X
phosphorylation	B-X
to	B-X
produce	B-X
NO	B-X
in	B-X
antral	B-X
mucous	B-X
cells	B-X
during	B-X
ACh	B-X
stimulation	B-X
.	B-X

VIII	O
inh	O
.	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
.	O

(	O
C	O
-	O
F	O
)	O
L929	O
cells	O
with	O
siRNA	O
knockdown	O
of	O
Akt	O
isoforms	O
(	O
C	O
,	O
E	O
)	O
or	O
mTOR	O
(	O
D	O
,	O
F	O
)	O
were	O
stimulated	O
with	O
zVAD	O
.	O
fmk	O
or	O
TNFalpha	B-Protein
for	O
9	O
hr	O
,	O
followed	O
by	O
qRT	O
-	O
PCR	O
analysis	O
of	O
mTNFalpha	B-Protein
(	O
C	O
,	O
D	O
)	O
or	O
western	O
blot	O
(	O
E	O
,	O
F	O
)	O
.	O
<EOS>	B-X
Cell	B-X
adhesion	B-X
molecules	B-X
(	B-X
CADMs	B-X
)	B-X
comprise	B-X
of	B-X
a	B-X
protein	B-X
family	B-X
whose	B-X
functions	B-X
include	B-X
maintenance	B-X
of	B-X
cell	B-X
polarity	B-X
and	B-X
tumor	B-X
suppression	B-X
.	B-X
Hypo-expression	B-X
of	B-X
CADM2	B-X
gene	B-X
expression	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
several	B-X
cancers	B-X
including	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
and	B-X
mechanisms	B-X
of	B-X
CADM2	B-X
in	B-X
HCC	B-X
remain	B-X
unclear	B-X
.	B-X

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

Over	O
expression	O
of	O
constitutively	O
active	O
Akt	O
restores	O
necroptosis	O
under	O
serum	O
free	O
conditions	O
.	O

(	O
A	O
,	O
B	O
)	O
L929	O
cells	O
were	O
stably	O
infected	O
with	O
empty	O
MSCV	O
retrovirus	O
or	O
viruses	O
encoding	O
Myr	O
-	O
Akt	O
or	O
the	O
catalytically	O
inactive	O
Myr	O
-	O
Akt	O
K179M	O
.	O
<EOS>	B-X
Akt	B-X
is	B-X
a	B-X
major	B-X
activator	B-X
of	B-X
the	B-X
endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
enzyme	B-X
,	B-X
but	B-X
its	B-X
potential	B-X
role	B-X
in	B-X
intrahepatic	B-X
resistance	B-X
in	B-X
cirrhosis	B-X
is	B-X
unknown	B-X
.	B-X
For	B-X
this	B-X
reason	B-X
the	B-X
aims	B-X
of	B-X
the	B-X
present	B-X
study	B-X
were	B-X
to	B-X
determine	B-X
whether	B-X
there	B-X
is	B-X
an	B-X
impaired	B-X
Akt	B-X
activation	B-X
in	B-X
cirrhotic	B-X
livers	B-X
and	B-X
how	B-X
this	B-X
phenomenon	B-X
relates	B-X
to	B-X
the	B-X
decrease	B-X
in	B-X
NO	B-X
production	B-X
associated	B-X
with	B-X
portal	B-X
hypertension	B-X
.	B-X
One	B-X
accessory	B-X
protein	B-X
,	B-X
the	B-X
HIV-1	B-X
viral	B-X
infectivity	B-X
factor	B-X
(	B-X
Vif	B-X
)	B-X
,	B-X
is	B-X
known	B-X
to	B-X
promote	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
of	B-X
the	B-X
antiviral	B-X
restriction	B-X
factor	B-X
apolipoprotein	B-X
B	B-X
mRNA-editing	B-X
enzyme-catalytic	B-X
polypeptide-like	B-X
3G	B-X
(	B-X
APOBEC3G	B-X
)	B-X
,	B-X
a	B-X
cytosine	B-X
deaminase	B-X
that	B-X
leads	B-X
to	B-X
hypermutations	B-X
in	B-X
the	B-X
viral	B-X
DNA	B-X
and	B-X
subsequent	B-X
aberrant	B-X
viral	B-X
replication	B-X
.	B-X
Because	B-X
the	B-X
HIV-1	B-X
Vif	B-X
protein	B-X
contains	B-X
the	B-X
putative	B-X
AKT	B-X
phosphorylation	B-X
motif	B-X
RMRINT	B-X
,	B-X
here	B-X
we	B-X
investigated	B-X
whether	B-X
AKT	B-X
directly	B-X
phosphorylates	B-X
HIV-1	B-X
Vif	B-X
to	B-X
regulate	B-X
its	B-X
function	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
constitutively	B-X
active	B-X
AKT	B-X
(	B-X
Myr-AKT	B-X
)	B-X
reduced	B-X
K48-ubiquitination	B-X
of	B-X
Vif	B-X
to	B-X
promote	B-X
its	B-X
stability	B-X
.	B-X
Finally	B-X
,	B-X
inhibition	B-X
of	B-X
AKT	B-X
function	B-X
restored	B-X
APOBEC3G	B-X
levels	B-X
,	B-X
which	B-X
subsequently	B-X
reduced	B-X
HIV-1	B-X
infectivity	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
results	B-X
establish	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
HIV-1	B-X
Vif	B-X
stabilization	B-X
through	B-X
AKT-mediated	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
20	B-X
,	B-X
which	B-X
reduces	B-X
APOBEC3G	B-X
levels	B-X
and	B-X
potentiates	B-X
HIV-1	B-X
infectivity	B-X
.	B-X

Necroptosis	O
was	O
induced	O
by	O
the	O
addition	O
of	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
(	O
A	O
)	O
or	O
serum	O
or	O
serum	O
free	O
conditions	O
with	O
Nec	O
-	O
1	O
(	O
B	O
)	O
.	O
<EOS>	B-X
The	B-X
paper	B-X
presents	B-X
the	B-X
dynamic	B-X
association	B-X
of	B-X
several	B-X
gradients	B-X
of	B-X
separation	B-X
with	B-X
electrophoresis	B-X
and	B-X
the	B-X
laboratory	B-X
implementation	B-X
of	B-X
a	B-X
prototype	B-X
device	B-X
for	B-X
dynamic	B-X
electrochromatography	B-X
in	B-X
a	B-X
centrifugal	B-X
and	B-X
electromagnetic	B-X
gradient	B-X
(	B-X
DECGOE	B-X
)	B-X
,	B-X
based	B-X
on	B-X
patent	B-X
PL171643	B-X
.	B-X
The	B-X
object	B-X
of	B-X
the	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
separation	B-X
capacity	B-X
and	B-X
repeatability	B-X
of	B-X
the	B-X
location	B-X
of	B-X
edge	B-X
parameters	B-X
(	B-X
xx	B-X
(	B-X
1	B-X
)	B-X
,	B-X
yy	B-X
(	B-X
1	B-X
)	B-X
,	B-X
d	B-X
)	B-X
of	B-X
the	B-X
contours	B-X
of	B-X
a	B-X
proteinogram	B-X
fraction	B-X
for	B-X
conventional	B-X
electrophoresis	B-X
(	B-X
EF	B-X
)	B-X
,	B-X
radial	B-X
SR-DECGOE	B-X
separation	B-X
and	B-X
three	B-X
variants	B-X
of	B-X
radial-transverse	B-X
SR-SPM	B-X
,	B-X
SR-SPE	B-X
,	B-X
SRSPRRM	B-X
distribution	B-X
as	B-X
well	B-X
as	B-X
the	B-X
reproducibility	B-X
of	B-X
the	B-X
following	B-X
prototype	B-X
parameters	B-X
:	B-X
PV	B-X
(	B-X
1	B-X
)	B-X
,	B-X
PV	B-X
(	B-X
2	B-X
)	B-X
,	B-X
PV	B-X
(	B-X
3	B-X
)	B-X
[	B-X
V	B-X
]	B-X
potentials	B-X
,	B-X
PV	B-X
(	B-X
3	B-X
)	B-X
[	B-X
F	B-X
]	B-X
frequency	B-X
,	B-X
ω	B-X
(	B-X
1	B-X
)	B-X
and	B-X
ω	B-X
(	B-X
2	B-X
)	B-X
rotational	B-X
speed	B-X
,	B-X
MC	B-X
mixer	B-X
chamber	B-X
buffer	B-X
[	B-X
pH	B-X
]	B-X
and	B-X
volume	B-X
[	B-X
ml	B-X
]	B-X
,	B-X
and	B-X
B	B-X
[	B-X
T	B-X
]	B-X
magnetic	B-X
induction	B-X
.	B-X
Human	B-X
blood	B-X
serum	B-X
was	B-X
used	B-X
in	B-X
the	B-X
study	B-X
,	B-X
50	B-X
samples	B-X
for	B-X
each	B-X
separation	B-X
type	B-X
.	B-X
Chromogranin	B-X
B	B-X
(	B-X
CgB	B-X
)	B-X
is	B-X
an	B-X
acidic	B-X
protein	B-X
of	B-X
the	B-X
granin	B-X
family	B-X
,	B-X
which	B-X
can	B-X
be	B-X
used	B-X
to	B-X
detect	B-X
the	B-X
tumours	B-X
of	B-X
neuroendocrine	B-X
nature	B-X
.	B-X
Analysis	B-X
of	B-X
levels	B-X
and	B-X
evaluation	B-X
of	B-X
the	B-X
diagnostic	B-X
efficiency	B-X
of	B-X
CgB	B-X
in	B-X
the	B-X
blood	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
NETs	B-X
of	B-X
various	B-X
localizations	B-X
.	B-X
Patients	B-X
with	B-X
NETs	B-X
(	B-X
n=121	B-X
)	B-X
without	B-X
specific	B-X
treatment	B-X
were	B-X
examined	B-X
.	B-X
In	B-X
the	B-X
study	B-X
were	B-X
presented	B-X
next	B-X
localizations	B-X
:	B-X
74	B-X
-	B-X
pancreas	B-X
,	B-X
20	B-X
-	B-X
stomach	B-X
,	B-X
12	B-X
-	B-X
large	B-X
intestine	B-X
,	B-X
15	B-X
-	B-X
other	B-X
localizations	B-X
(	B-X
lungs	B-X
,	B-X
mammary	B-X
gland	B-X
,	B-X
prostate	B-X
gland	B-X
,	B-X
NETs	B-X
with	B-X
unidentified	B-X
primary	B-X
)	B-X
.	B-X
The	B-X
determination	B-X
of	B-X
CgB	B-X
in	B-X
blood	B-X
serum	B-X
was	B-X
performed	B-X
with	B-X
ELISA	B-X
method	B-X
on	B-X
BEP	B-X
2000	B-X
analyzer	B-X
using	B-X
a	B-X
standardized	B-X
test	B-X
system	B-X
Human	B-X
Chromogranin	B-X
B	B-X
(	B-X
USCN	B-X
,	B-X
China	B-X
)	B-X
.	B-X
CgB	B-X
levels	B-X
in	B-X
common	B-X
NET	B-X
group	B-X
(	B-X
median	B-X
18.9	B-X
ng/mL	B-X
)	B-X
were	B-X
statistically	B-X
significantly	B-X
higher	B-X
than	B-X
in	B-X
the	B-X
control	B-X
group	B-X
(	B-X
8.8	B-X
ng/mL	B-X
)	B-X
.	B-X
The	B-X
highest	B-X
median	B-X
was	B-X
obtained	B-X
in	B-X
group	B-X
of	B-X
intestinal	B-X
NETs	B-X
(	B-X
21.2	B-X
ng/ml	B-X
)	B-X
,	B-X
which	B-X
exceeded	B-X
the	B-X
median	B-X
of	B-X
the	B-X
control	B-X
group	B-X
by	B-X
more	B-X
than	B-X
2.4	B-X
times	B-X
.	B-X
According	B-X
to	B-X
cut-off	B-X
level	B-X
of	B-X
CgB	B-X
-	B-X
15.8	B-X
ng/ml	B-X
,	B-X
the	B-X
diagnostic	B-X
sensitivity	B-X
was	B-X
69.4	B-X
%	B-X
,	B-X
with	B-X
a	B-X
specificity	B-X
of	B-X
96.3	B-X
%	B-X
.	B-X
The	B-X
highest	B-X
diagnostic	B-X
sensitivity	B-X
was	B-X
in	B-X
the	B-X
group	B-X
of	B-X
the	B-X
intestinal	B-X
NETs	B-X
(	B-X
75.0	B-X
%	B-X
)	B-X
and	B-X
pancreas	B-X
(	B-X
71.2	B-X
%	B-X
)	B-X
.	B-X
The	B-X
study	B-X
showed	B-X
the	B-X
significance	B-X
of	B-X
CgB	B-X
as	B-X
a	B-X
potential	B-X
biochemical	B-X
marker	B-X
of	B-X
NETs	B-X
with	B-X
various	B-X
localizations	B-X
,	B-X
alternative	B-X
to	B-X
CgA	B-X
.	B-X

Viability	O
assays	O
were	O
performed	O
after	O
24	O
hr	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
IPC	B-X
on	B-X
the	B-X
rat	B-X
renal	B-X
ischemia-reperfusion	B-X
injury	B-X
(	B-X
IRI	B-X
)	B-X
via	B-X
miR-376c-3p/HIF-1α/VEGF	B-X
axis	B-X
.	B-X
Sex	B-X
diagnosis	B-X
was	B-X
done	B-X
by	B-X
PCR	B-X
amplification	B-X
of	B-X
ZFX/ZFY	B-X
and	B-X
SRY	B-X
sequences	B-X
after	B-X
PEP-PCR	B-X
while	B-X
PrP	B-X
genotype	B-X
determination	B-X
was	B-X
performed	B-X
after	B-X
specific	B-X
pre-amplification	B-X
of	B-X
specific	B-X
target	B-X
including	B-X
codons	B-X
136	B-X
,	B-X
154	B-X
and	B-X
171	B-X
.	B-X
Blastocysts	B-X
and	B-X
expanded	B-X
blastocysts	B-X
were	B-X
biopsied	B-X
immediately	B-X
after	B-X
collection	B-X
whereas	B-X
compacted	B-X
morulae	B-X
were	B-X
biopsied	B-X
after	B-X
24	B-X
hr	B-X
of	B-X
in	B-X
vitro	B-X
culture	B-X
.	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
to	B-X
evaluate	B-X
the	B-X
cytotoxicity	B-X
of	B-X
four	B-X
calcium	B-X
silicate-based	B-X
endodontic	B-X
cements	B-X
at	B-X
different	B-X
storage	B-X
times	B-X
after	B-X
mixing	B-X
.	B-X

(	O
C	O
)	O
Myr	O
-	O
Akt	O
and	O
Myr	O
-	O
Akt	O
K179M	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
/	O
or	O
Nec	O
-	O
1	O
under	O
serum	O
free	O
conditions	O
for	O
9	O
hr	O
,	O
followed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

Endogenous	O
Akt	O
(	O
~	O
)	O
and	O
Myr	O
-	O
Akt	O
(	O
*	O
)	O
bands	O
are	O
indicated	O
.	O

(	O
D	O
)	O
L929	O
cells	O
,	O
stably	O
infected	O
with	O
Myr	O
-	O
Akt	O
and	O
Myr	O
-	O
Akt	O
K179KM	O
,	O
were	O
stimulated	O
with	O
zVAD	O
.	O
fmk	O
for	O
9	O
hr	O
under	O
serum	O
free	O
conditions	O
.	O

TNFalpha	B-Protein
mRNA	O
levels	O
were	O
determined	O
by	O
qRT	O
-	O
PCR	O
and	O
normalized	O
using	O
mouse	O
18S	B-Protein
RNA	O
.	O

(	O
E	O
-	O
G	O
)	O
L929	O
cells	O
expressing	O
Myr	O
-	O
Akt	O
and	O
Ala	O
and	O
Asp	O
mutants	O
of	O
Thr308	O
and	O
Ser473	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
under	O
serum	O
free	O
conditions	O
,	O
followed	O
by	O
viability	O
assay	O
at	O
24	O
hr	O
(	O
E	O
)	O
,	O
western	O
blot	O
at	O
9	O
hr	O
(	O
F	O
)	O
,	O
or	O
evaluation	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hrs	O
(	O
G	O
)	O
.	O

In	O
all	O
graphs	O
,	O
average	O
+	O
/	O
-	O
SD	O
was	O
plotted	O
.	O
<EOS>	B-X
However	B-X
,	B-X
it	B-X
can	B-X
vary	B-X
greatly	B-X
based	B-X
on	B-X
the	B-X
x-ray	B-X
beam	B-X
angle	B-X
,	B-X
which	B-X
can	B-X
lead	B-X
to	B-X
multiple	B-X
radiographs	B-X
causing	B-X
excessive	B-X
radiation	B-X
exposure	B-X
,	B-X
cost	B-X
,	B-X
and	B-X
discomfort	B-X
for	B-X
the	B-X
acutely	B-X
injured	B-X
child	B-X
.	B-X
The	B-X
maximal	B-X
neuromuscular	B-X
responses	B-X
were	B-X
plotted	B-X
on	B-X
a	B-X
log-probit	B-X
paper	B-X
.	B-X
The	B-X
maximal	B-X
response	B-X
following	B-X
this	B-X
second	B-X
dose	B-X
was	B-X
then	B-X
plotted	B-X
.	B-X
The	B-X
mean	B-X
maximal	B-X
response	B-X
following	B-X
the	B-X
second	B-X
atracurium	B-X
dose	B-X
was	B-X
95.5	B-X
%	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
92.6-97.4	B-X
%	B-X
)	B-X
NMB	B-X
.	B-X
The	B-X
average	B-X
ED50	B-X
and	B-X
ED95	B-X
determined	B-X
by	B-X
the	B-X
two-dose	B-X
and	B-X
the	B-X
single-dose	B-X
techniques	B-X
were	B-X
nearly	B-X
identical	B-X
[	B-X
160	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
126-201	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
164	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
150-179	B-X
micrograms/kg	B-X
)	B-X
and	B-X
302	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
251-363	B-X
micrograms/kg	B-X
)	B-X
vs.	B-X
336	B-X
micrograms/kg	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
274-411	B-X
micrograms/kg	B-X
)	B-X
respectively	B-X
]	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
slopes	B-X
of	B-X
the	B-X
curves	B-X
were	B-X
similar	B-X
[	B-X
6.2	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
5.2-7.2	B-X
)	B-X
vs.	B-X
5.4	B-X
(	B-X
SD	B-X
range	B-X
,	B-X
4.5-6.4	B-X
)	B-X
probit/log	B-X
]	B-X
.	B-X

Akt	O
signaling	O
contributes	O
to	O
autocrine	O
TNFalpha	B-Protein
production	O
in	O
multiple	O
cell	O
types	O
.	O

FADD	B-Protein
deficient	O
Jurkat	O
cells	O
were	O
treated	O
with	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
(	O
A	O
)	O
human	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
and	O
normalized	O
using	O
human	O
18S	B-Protein
RNA	O
or	O
(	O
B	O
)	O
western	O
blot	O
at	O
9	O
hr	O
.	O
<EOS>	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
antitumoral	B-X
activity	B-X
of	B-X
a	B-X
novel	B-X
proteolysis-targeting	B-X
chimera	B-X
(	B-X
PROTAC	B-X
)	B-X
compound	B-X
against	B-X
CDK9	B-X
.	B-X
Breast	B-X
cancer	B-X
cell	B-X
lines	B-X
from	B-X
different	B-X
subtypes	B-X
were	B-X
used	B-X
.	B-X
Transcriptomic	B-X
mapping	B-X
of	B-X
CDKs	B-X
in	B-X
breast	B-X
cancer	B-X
demonstrated	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CDK9	B-X
predicted	B-X
a	B-X
detrimental	B-X
outcome	B-X
in	B-X
basal-like	B-X
tumors	B-X
(	B-X
HR	B-X
=	B-X
1.51	B-X
,	B-X
CI	B-X
=	B-X
1.08-2.11	B-X
,	B-X
Emerging	B-X
evidence	B-X
shows	B-X
that	B-X
microRNAs	B-X
(	B-X
miRs	B-X
)	B-X
are	B-X
critical	B-X
in	B-X
the	B-X
development	B-X
of	B-X
pathological	B-X
processes	B-X
underlying	B-X
cardiovascular	B-X
diseases	B-X
by	B-X
regulating	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
and	B-X
autophagy	B-X
.	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
miR‑103a‑3p	B-X
in	B-X
cardiomyocyte	B-X
injury	B-X
through	B-X
autophagy	B-X
and	B-X
apoptosis	B-X
.	B-X
H9c2	B-X
cells	B-X
were	B-X
cultured	B-X
under	B-X
hypoxia	B-X
and	B-X
reoxygenation	B-X
(	B-X
H/R	B-X
)	B-X
conditions	B-X
and	B-X
were	B-X
used	B-X
to	B-X
mimic	B-X
cells	B-X
under	B-X
ischemia	B-X
.	B-X
The	B-X
transfection	B-X
of	B-X
cells	B-X
with	B-X
miR‑103a‑3p	B-X
(	B-X
mimics	B-X
and	B-X
inhibitors	B-X
)	B-X
was	B-X
performed	B-X
to	B-X
examine	B-X
its	B-X
function	B-X
in	B-X
cardiomyocytes	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
miR‑103a‑3p	B-X
were	B-X
evaluated	B-X
by	B-X
reverse	B-X
transcription‑quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
analysis	B-X
.	B-X
Cell	B-X
viability	B-X
was	B-X
determined	B-X
using	B-X
an	B-X
MTT	B-X
assay	B-X
,	B-X
and	B-X
the	B-X
lactate	B-X
dehydrogenase	B-X
assay	B-X
(	B-X
LDH	B-X
)	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
cell	B-X
injury	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
B‑cell	B-X
lymphoma	B-X
2	B-X
(	B-X
Bcl‑2	B-X
)	B-X
,	B-X
Bcl‑2‑associated	B-X
X	B-X
protein	B-X
,	B-X
Beclin‑1	B-X
,	B-X
autophagy‑related	B-X
5	B-X
(	B-X
Atg5	B-X
)	B-X
,	B-X
cleaved	B-X
caspase‑3	B-X
and	B-X
cleaved	B-X
caspase‑9	B-X
were	B-X
detected	B-X
using	B-X
western	B-X
blotting	B-X
.	B-X
The	B-X
target	B-X
gene	B-X
of	B-X
miR‑103a‑3p	B-X
was	B-X
identified	B-X
using	B-X
dual‑luciferase	B-X
reporter	B-X
assays	B-X
.	B-X
The	B-X
results	B-X
revealed	B-X
that	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
miR‑103a‑3p	B-X
were	B-X
significantly	B-X
downregulated	B-X
in	B-X
cardiomyocytes	B-X
under	B-X
H/R	B-X
conditions	B-X
.	B-X
Following	B-X
transfection	B-X
of	B-X
the	B-X
cells	B-X
with	B-X
miR‑103a‑3p	B-X
inhibitors	B-X
,	B-X
cell	B-X
injury	B-X
was	B-X
increased	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
LDH	B-X
and	B-X
MTT	B-X
assays	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
apoptotic	B-X
proteins	B-X
were	B-X
consistent	B-X
with	B-X
the	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
LDH	B-X
and	B-X
cell	B-X
viability	B-X
assays	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
autophagy	B-X
was	B-X
increased	B-X
in	B-X
cells	B-X
under	B-X
H/R	B-X
conditions	B-X
and	B-X
cells	B-X
with	B-X
miR‑103a‑3p	B-X
inhibitor	B-X
transfection	B-X
,	B-X
whereas	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
miR‑103a‑3p	B-X
mimics	B-X
.	B-X

RAW	O
264	O
.	O
7	O
or	O
J774A	O
.	O
1	O
cells	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
(	O
100	O
uM	O
or	O
50	O
uM	O
respectively	O
)	O
followed	O
by	O
(	O
C	O
,	O
E	O
)	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
or	O
(	O
D	O
,	O
F	O
)	O
western	O
blot	O
at	O
9	O
hr	O
.	O

(	O
G	O
)	O
Akt	O
null	O
mouse	O
lung	O
fibroblasts	O
expressing	O
Myr	O
-	O
Akt	O
or	O
K179M	O
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hr	O
.	O

(	O
H	O
)	O
Mouse	O
lung	O
fibroblasts	O
expressing	O
only	O
endogenous	O
Akt1	B-Protein
or	O
Akt2	B-Protein
were	O
treated	O
with	O
zVAD	O
.	O
fmk	O
and	O
TNFalpha	B-Protein
followed	O
by	O
measurement	O
of	O
TNFalpha	B-Protein
mRNA	O
levels	O
by	O
qRT	O
-	O
PCR	O
at	O
9	O
hr	O
.	O

Model	O
of	O
RIP1	B-Protein
,	O
Akt	O
and	O
JNK	O
dependent	O
signaling	O
in	O
necroptotic	O
L929	O
cells	O
.	O

Akt	O
phosphorylation	O
at	O
Thr308	O
during	O
necroptosis	O
requires	O
inputs	O
from	O
both	O
growth	O
factors	O
and	O
RIP1	B-Protein
kinase	O
.	O
<EOS>	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
signaling	B-X
mechanisms	B-X
controlled	B-X
by	B-X
the	B-X
necroptosis	B-X
mediator	B-X
receptor	B-X
interacting	B-X
protein-1	B-X
(	B-X
RIP1	B-X
)	B-X
kinase	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Akt	B-X
kinase	B-X
activity	B-X
is	B-X
critical	B-X
for	B-X
necroptosis	B-X
in	B-X
L929	B-X
cells	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
TNFα	B-X
production	B-X
.	B-X
During	B-X
necroptosis	B-X
,	B-X
Akt	B-X
is	B-X
activated	B-X
in	B-X
a	B-X
RIP1	B-X
dependent	B-X
fashion	B-X
through	B-X
its	B-X
phosphorylation	B-X
on	B-X
Thr308	B-X
.	B-X
In	B-X
L929	B-X
cells	B-X
,	B-X
this	B-X
activation	B-X
requires	B-X
independent	B-X
signaling	B-X
inputs	B-X
from	B-X
both	B-X
growth	B-X
factors	B-X
and	B-X
RIP1	B-X
.	B-X
Akt	B-X
controls	B-X
necroptosis	B-X
through	B-X
downstream	B-X
targeting	B-X
of	B-X
mammalian	B-X
Target	B-X
of	B-X
Rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
.	B-X
Akt	B-X
activity	B-X
,	B-X
mediated	B-X
in	B-X
part	B-X
through	B-X
mTORC1	B-X
,	B-X
links	B-X
RIP1	B-X
to	B-X
JNK	B-X
activation	B-X
and	B-X
autocrine	B-X
production	B-X
of	B-X
TNFα	B-X
.	B-X
In	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
such	B-X
as	B-X
mouse	B-X
lung	B-X
fibroblasts	B-X
and	B-X
macrophages	B-X
,	B-X
Akt	B-X
exhibited	B-X
control	B-X
over	B-X
necroptosis-associated	B-X
TNFα	B-X
production	B-X
without	B-X
contributing	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
necroptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
Akt	B-X
kinase	B-X
in	B-X
both	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
regulation	B-X
.	B-X

Downstream	O
from	O
Akt	O
,	O
JNK	O
activation	O
leads	O
to	O
TNFalpha	B-Protein
synthesis	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Celecoxib	B-X
potently	B-X
inhibited	B-X
TNFalpha-induced	B-X
transcriptional	B-X
activity	B-X
and	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
;	B-X
however	B-X
,	B-X
Celecoxib	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
TNFalpha-induced	B-X
IKK	B-X
activation	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
and	B-X
IkappaBbeta	B-X
,	B-X
suggesting	B-X
that	B-X
it	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
via	B-X
suppressing	B-X
downstream	B-X
of	B-X
IKK	B-X
activation	B-X
and	B-X
IkappaBs	B-X
degradation	B-X
.	B-X
Interestingly	B-X
,	B-X
it	B-X
was	B-X
also	B-X
found	B-X
that	B-X
Celecoxib	B-X
abrogated	B-X
TNFalpha-induced	B-X
nuclear	B-X
accumulation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
p65	B-X
subunit	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
TNFalpha-induced	B-X
expression	B-X
of	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
CXCL1/KC	B-X
and	B-X
CCL2/MCP-1	B-X
,	B-X
was	B-X
clearly	B-X
inhibited	B-X
by	B-X
Celecoxib	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
Celecoxib	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
TNFalpha-induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-jun	B-X
and	B-X
activation	B-X
of	B-X
ERK	B-X
,	B-X
JNK	B-X
,	B-X
p38	B-X
and	B-X
Akt	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
Celecoxib	B-X
specifically	B-X
inhibits	B-X
TNFalpha-induced	B-X
NF-kappaB	B-X
activation	B-X
at	B-X
the	B-X
level	B-X
of	B-X
its	B-X
nuclear	B-X
translocation	B-X
.	B-X
This	B-X
negative	B-X
regulation	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
Celecoxib	B-X
might	B-X
be	B-X
an	B-X
important	B-X
mechanism	B-X
leading	B-X
to	B-X
its	B-X
anti-inflammatory	B-X
activity	B-X
.	B-X

Activation	O
of	O
Akt	O
during	O
necroptosis	O
also	O
leads	O
the	O
phosphorylation	O
of	O
several	O
known	O
Akt	O
substrates	O
,	O
such	O
as	O
mTOR	O
,	O
which	O
contribute	O
to	O
the	O
execution	O
of	O
necroptotic	O
death	O
in	O
L929	O
cells	O
.	O

Tumor	O
Suppressor	O
WWOX	B-Protein
and	O
p53	B-Protein
Alterations	O
and	O
Drug	O
Resistance	O
in	O
Glioblastomas	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Tumor	O
suppressor	O
p53	B-Protein
are	O
frequently	O
mutated	O
in	O
glioblastomas	O
(	O
GBMs	O
)	O
and	O
appears	O
to	O
contribute	O
,	O
in	O
part	O
,	O
to	O
resistance	O
to	O
temozolomide	O
(	O
TMZ	O
)	O
and	O
therapeutic	O
drugs	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

WW	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
oxidoreductase	I-Protein
WWOX	B-Protein
(	O
FOR	B-Protein
or	O
WOX1	B-Protein
)	O
is	O
a	O
proapoptotic	O
protein	O
and	O
is	O
considered	O
as	O
a	O
tumor	O
suppressor	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Loss	O
of	O
WWOX	B-Protein
gene	O
expression	O
is	O
frequently	O
seen	O
in	O
malignant	O
cancer	O
cells	O
due	O
to	O
promoter	O
hypermethylation	O
,	O
genetic	O
alterations	O
,	O
and	O
translational	O
blockade	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Intriguingly	O
,	O
ectopic	O
expression	O
of	O
wild	O
type	O
WWOX	B-Protein
preferentially	O
induces	O
apoptosis	O
in	O
human	O
glioblastoma	O
cells	O
harboring	O
mutant	O
p53	B-Protein
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

WWOX	B-Protein
is	O
known	O
to	O
physically	O
bind	O
and	O
stabilize	O
wild	O
type	O
p53	B-Protein
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Here	O
,	O
we	O
provide	O
an	O
overview	O
for	O
the	O
updated	O
knowledge	O
in	O
p53	B-Protein
and	O
WWOX	B-Protein
,	O
and	O
postulate	O
potential	O
scenarios	O
that	O
wild	O
type	O
and	O
mutant	O
p53	B-Protein
,	O
or	O
isoforms	O
,	O
modulate	O
the	O
apoptotic	O
function	O
of	O
WWOX	B-Protein
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

We	O
propose	O
that	O
triggering	O
WWOX	B-Protein
activation	O
by	O
therapeutic	O
drugs	O
under	O
p53	B-Protein
functional	O
deficiency	O
is	O
needed	O
to	O
overcome	O
TMZ	O
resistance	O
and	O
induce	O
GBM	O
cell	O
death	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Glioblastoma	O
multiforme	O
afflicts	O
12	O
,	O
500	O
new	O
patients	O
in	O
the	O
U	O
.	O
S	O
.	O
annually	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Stupp	O
et	O
al	O
.	O
,	O
2009	O
;	O
Silber	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
is	O
highly	O
lethal	O
,	O
and	O
the	O
average	O
survival	O
expectancy	O
is	O
14	O
.	O
6	O
months	O
,	O
and	O
the	O
overall	O
5	O
-	O
year	O
survival	O
rate	O
for	O
GBM	O
is	O
only	O
9	O
.	O
8	O
%	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Stupp	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

High	O
levels	O
of	O
resistance	O
to	O
current	O
therapeutic	O
modalities	O
and	O
cancer	O
relapse	O
are	O
frequently	O
seen	O
in	O
patients	O
(	O
Haar	O
et	O
al	O
.	O
,	O
2012	O
;	O
Happold	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

The	O
current	O
standard	O
therapy	O
for	O
GBM	O
mainly	O
includes	O
maximum	O
debulking	O
surgery	O
,	O
radiation	O
,	O
and	O
treatment	O
with	O
the	O
monofunctional	O
alkylating	O
agent	O
temozolomide	O
(	O
TMZ	O
)	O
(	O
Friedman	O
et	O
al	O
.	O
,	O
2000	O
;	O
Nishikawa	O
,	O
2010	O
)	O
.	O

Multiple	O
mechanisms	O
are	O
involved	O
in	O
the	O
TMZ	O
resistance	O
,	O
which	O
may	O
include	O
cancer	O
stem	O
cells	O
,	O
microRNAs	O
,	O
drug	O
efflux	O
,	O
DNA	O
damage	O
repair	O
,	O
tumor	O
cells	O
under	O
hypoxia	O
,	O
histone	O
deacetylation	O
,	O
epithelial	O
-	O
mesenchymal	O
transition	O
,	O
STAT3	O
kinase	O
,	O
and	O
many	O
others	O
(	O
Haar	O
et	O
al	O
.	O
,	O
2012	O
;	O
Happold	O
et	O
al	O
.	O
,	O
2012	O
;	O
Johannessen	O
and	O
Bjerkvig	O
,	O
2012	O
;	O
Kitange	O
et	O
al	O
.	O
,	O
2012	O
;	O
Kohsaka	O
et	O
al	O
.	O
,	O
2012	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Temozolomide	O
induces	O
generation	O
of	O
DNA	O
lesions	O
,	O
including	O
O6	O
-	O
methylguanine	O
,	O
N3	O
-	O
methyladenine	O
,	O
and	O
N7	O
-	O
methylguanine	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

The	O
O6	O
-	O
methylguanine	O
lesion	O
is	O
known	O
to	O
trigger	O
autophagy	O
,	O
rather	O
than	O
apoptosis	O
,	O
to	O
cause	O
cell	O
death	O
(	O
Kanzawa	O
et	O
al	O
.	O
,	O
2003	O
)	O
.	O

Also	O
,	O
inhibition	O
of	O
antiapoptotic	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
by	O
a	O
pan	O
-	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
inhibitor	O
(	O
-	O
)	O
-	O
gossypol	O
leads	O
to	O
autophagic	O
death	O
in	O
gliomas	O
and	O
enhances	O
the	O
action	O
of	O
TMZ	O
(	O
Voss	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

However	O
,	O
a	O
recent	O
study	O
demonstrated	O
that	O
TMZ	O
-	O
induced	O
autophagy	O
is	O
pro	O
-	O
survival	O
,	O
and	O
may	O
block	O
the	O
eventual	O
apoptosis	O
in	O
GBM	O
cells	O
(	O
Knizhnik	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

Also	O
,	O
MAPO2	B-Protein
(	O
C1orf201	B-Protein
)	O
gene	O
participates	O
in	O
the	O
O6	O
-	O
methylguanine	O
lesion	O
-	O
induced	O
apoptosis	O
(	O
Fujikane	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

MAPO2	B-Protein
gene	O
encodes	O
a	O
novel	O
37	O
-	O
kDa	O
protein	O
.	O

It	O
is	O
not	O
determined	O
whether	O
this	O
gene	O
is	O
involved	O
in	O
autophagy	O
.	O

The	O
O6	O
-	O
methylguanine	O
lesion	O
is	O
a	O
substrate	O
for	O
direct	O
repair	O
by	O
O6	B-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	I-Protein
(	O
MGMT	B-Protein
)	O
(	O
Pollack	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hegi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Fukushima	O
et	O
al	O
.	O
,	O
2009	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Without	O
MGMT	B-Protein
repair	O
,	O
O6	O
-	O
methylguanine	O
initiates	O
activation	O
of	O
mismatch	O
repair	O
-	O
deficient	O
(	O
MMR	O
)	O
proteins	O
or	O
Rad3	O
-	O
related	O
protein	O
kinase	O
that	O
ultimately	O
leads	O
to	O
apoptotic	O
cell	O
death	O
(	O
Caporali	O
et	O
al	O
.	O
,	O
2004	O
;	O
Wang	O
and	O
Edelmann	O
,	O
2006	O
;	O
Roos	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
<EOS>	B-X
Temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
is	B-X
active	B-X
against	B-X
glioblastomas	B-X
(	B-X
GBM	B-X
)	B-X
in	B-X
which	B-X
the	B-X
O6-methylguanine-DNA	B-X
methyltransferase	B-X
(	B-X
MGMT	B-X
)	B-X
gene	B-X
is	B-X
silenced	B-X
.	B-X
However	B-X
,	B-X
even	B-X
in	B-X
responsive	B-X
cases	B-X
,	B-X
its	B-X
beneficial	B-X
effect	B-X
is	B-X
undermined	B-X
by	B-X
the	B-X
emergence	B-X
of	B-X
drug	B-X
resistance	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
tested	B-X
whether	B-X
inhibition	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase-1	B-X
and	B-X
-2	B-X
(	B-X
PARP	B-X
)	B-X
enhanced	B-X
the	B-X
effectiveness	B-X
of	B-X
TMZ	B-X
.	B-X

High	O
expression	O
of	O
MGMT	B-Protein
or	O
loss	O
of	O
MMR	O
contributes	O
significantly	O
to	O
TMZ	O
resistance	O
in	O
many	O
clinical	O
cases	O
(	O
Pollack	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hegi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Sarkaria	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
<EOS>	B-X
Gliomas	B-X
are	B-X
the	B-X
most	B-X
common	B-X
malignant	B-X
primary	B-X
brain	B-X
tumors	B-X
,	B-X
of	B-X
which	B-X
glioblastoma	B-X
is	B-X
the	B-X
most	B-X
malignant	B-X
form	B-X
(	B-X
WHO	B-X
grade	B-X
IV	B-X
)	B-X
,	B-X
and	B-X
notorious	B-X
for	B-X
treatment	B-X
resistance	B-X
.	B-X
Over	B-X
the	B-X
last	B-X
decade	B-X
mutations	B-X
in	B-X
epigenetic	B-X
regulator	B-X
genes	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
key	B-X
drivers	B-X
of	B-X
subtypes	B-X
of	B-X
gliomas	B-X
with	B-X
distinct	B-X
clinical	B-X
features	B-X
.	B-X
Most	B-X
characteristic	B-X
are	B-X
mutations	B-X
in	B-X
IDH1	B-X
or	B-X
IDH2	B-X
in	B-X
lower	B-X
grade	B-X
gliomas	B-X
,	B-X
and	B-X
histone	B-X
3	B-X
mutations	B-X
in	B-X
pediatric	B-X
high	B-X
grade	B-X
gliomas	B-X
that	B-X
are	B-X
also	B-X
associated	B-X
with	B-X
characteristic	B-X
DNA	B-X
methylation	B-X
patterns	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
adult	B-X
glioblastoma	B-X
patients	B-X
epigenetic	B-X
silencing	B-X
of	B-X
the	B-X
DNA	B-X
repair	B-X
gene	B-X
MGMT	B-X
by	B-X
promoter	B-X
methylation	B-X
is	B-X
predictive	B-X
for	B-X
benefit	B-X
from	B-X
alkylating	B-X
agent	B-X
therapy	B-X
.	B-X
These	B-X
epigenetic	B-X
alterations	B-X
are	B-X
used	B-X
as	B-X
biomarkers	B-X
and	B-X
play	B-X
a	B-X
central	B-X
role	B-X
for	B-X
classification	B-X
of	B-X
gliomas	B-X
(	B-X
WHO	B-X
2016	B-X
)	B-X
and	B-X
treatment	B-X
decisions	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
pivotal	B-X
role	B-X
of	B-X
epigenetic	B-X
alterations	B-X
in	B-X
the	B-X
etiology	B-X
and	B-X
biology	B-X
of	B-X
gliomas	B-X
.	B-X
We	B-X
summarize	B-X
the	B-X
complex	B-X
interactions	B-X
between	B-X
``	B-X
driver	B-X
''	B-X
mutations	B-X
,	B-X
DNA	B-X
methylation	B-X
,	B-X
histone	B-X
post-translational	B-X
modifications	B-X
,	B-X
and	B-X
overall	B-X
chromatin	B-X
organization	B-X
,	B-X
and	B-X
how	B-X
they	B-X
inform	B-X
current	B-X
efforts	B-X
of	B-X
testing	B-X
epigenetic	B-X
compounds	B-X
and	B-X
combinations	B-X
in	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
.	B-X

The	O
initiation	O
of	O
apoptotic	O
signaling	O
fails	O
in	O
the	O
absence	O
of	O
the	O
MMR	O
system	O
.	O

Sensitivity	O
to	O
TMZ	O
is	O
significantly	O
associated	O
with	O
the	O
methylation	O
status	O
of	O
MGMT	B-Protein
gene	O
promoter	O
in	O
cells	O
committed	O
to	O
differentiation	O
(	O
Villalva	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

An	O
increase	O
in	O
MGMT	B-Protein
gene	O
promoter	O
methylation	O
,	O
which	O
blocks	O
MGMT	B-Protein
protein	O
expression	O
,	O
prolongs	O
cancer	O
patient	O
survival	O
.	O

Intriguingly	O
,	O
overexpressed	O
microRNA	B-Protein
-	I-Protein
21	I-Protein
reduces	O
Bax	B-Protein
/	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
ratio	O
and	O
caspase	B-Protein
-	I-Protein
3	I-Protein
activity	O
,	O
thereby	O
blocking	O
TMZ	O
-	O
induced	O
apoptosis	O
(	O
Shi	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

MicroRNA	B-Protein
-	I-Protein
21	I-Protein
is	O
considered	O
as	O
a	O
pro	O
-	O
survival	O
factor	O
for	O
cancer	O
cells	O
(	O
Li	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Integrins	O
play	O
a	O
role	O
in	O
the	O
resistance	O
of	O
advanced	O
cancers	O
to	O
radiotherapy	O
and	O
chemotherapy	O
.	O
<EOS>	B-X
Integrins	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
resistance	B-X
of	B-X
advanced	B-X
cancers	B-X
to	B-X
radiotherapy	B-X
and	B-X
chemotherapy	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
negative	B-X
cross-talk	B-X
between	B-X
α5β1	B-X
integrin	B-X
and	B-X
p53	B-X
supports	B-X
glioma	B-X
resistance	B-X
to	B-X
temozolomide	B-X
,	B-X
providing	B-X
preclinical	B-X
proof-of-concept	B-X
that	B-X
α5β1	B-X
integrin	B-X
represents	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
high-grade	B-X
brain	B-X
tumors	B-X
.	B-X

alpha5beta1	O
integrin	O
negatively	O
regulates	O
p53	B-Protein
signaling	O
,	O
and	O
the	O
event	O
induces	O
glioma	O
cell	O
resistance	O
to	O
TMZ	O
(	O
Janouskova	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

alpha5beta1	O
integrin	O
is	O
considered	O
as	O
a	O
therapeutic	O
target	O
for	O
high	O
-	O
grade	O
brain	O
tumors	O
.	O
<EOS>	B-X
The	B-X
Wnt/beta	B-X
catenin	B-X
pathway	B-X
has	B-X
been	B-X
highlighted	B-X
as	B-X
an	B-X
important	B-X
player	B-X
of	B-X
brain	B-X
tumors	B-X
aggressiveness	B-X
and	B-X
resistance	B-X
to	B-X
therapies	B-X
.	B-X
Crosstalks	B-X
between	B-X
integrins	B-X
and	B-X
beta-catenin	B-X
pathways	B-X
have	B-X
been	B-X
suggested	B-X
in	B-X
several	B-X
tumor	B-X
tissues	B-X
.	B-X
As	B-X
we	B-X
demonstrated	B-X
earlier	B-X
that	B-X
α5β1	B-X
integrin	B-X
may	B-X
be	B-X
considered	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
in	B-X
high	B-X
grade	B-X
glioma	B-X
through	B-X
its	B-X
contribution	B-X
to	B-X
glioma	B-X
cell	B-X
migration	B-X
and	B-X
resistance	B-X
to	B-X
chemotherapy	B-X
,	B-X
we	B-X
addressed	B-X
here	B-X
the	B-X
potential	B-X
relationship	B-X
between	B-X
α5β1	B-X
integrin	B-X
and	B-X
beta-catenin	B-X
activation	B-X
in	B-X
glioma	B-X
cells	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
overexpression	B-X
and	B-X
activation	B-X
by	B-X
fibronectin	B-X
of	B-X
α5β1	B-X
integrin	B-X
allowed	B-X
the	B-X
transactivation	B-X
of	B-X
beta-catenin	B-X
gene	B-X
targets	B-X
included	B-X
in	B-X
an	B-X
EMT-like	B-X
program	B-X
that	B-X
induced	B-X
an	B-X
increase	B-X
in	B-X
cell	B-X
migration	B-X
.	B-X
Hampering	B-X
of	B-X
beta	B-X
catenin	B-X
activation	B-X
and	B-X
cell	B-X
migration	B-X
could	B-X
be	B-X
similarly	B-X
achieved	B-X
by	B-X
a	B-X
specific	B-X
integrin	B-X
antagonist	B-X
.	B-X
In	B-X
addition	B-X
we	B-X
showed	B-X
that	B-X
α5β1	B-X
integrin/AKT	B-X
axis	B-X
is	B-X
mainly	B-X
involved	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
However	B-X
,	B-X
blockade	B-X
of	B-X
beta-catenin	B-X
by	B-X
XAV939	B-X
(	B-X
tankyrase	B-X
inhibitor	B-X
leading	B-X
to	B-X
beta-catenin	B-X
degradation	B-X
)	B-X
did	B-X
not	B-X
synergize	B-X
with	B-X
p53	B-X
activation	B-X
aiming	B-X
to	B-X
cell	B-X
apoptosis	B-X
as	B-X
was	B-X
the	B-X
case	B-X
with	B-X
integrin	B-X
antagonists	B-X
.	B-X
We	B-X
therefore	B-X
propose	B-X
a	B-X
dual	B-X
implication	B-X
of	B-X
α5β1	B-X
integrin/AKT	B-X
axis	B-X
in	B-X
glioma	B-X
cell	B-X
resistance	B-X
to	B-X
therapies	B-X
and	B-X
migration	B-X
each	B-X
supported	B-X
by	B-X
different	B-X
signaling	B-X
pathways	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
suggest	B-X
that	B-X
α5β1	B-X
integrin	B-X
may	B-X
be	B-X
added	B-X
to	B-X
the	B-X
growing	B-X
list	B-X
of	B-X
beta-catenin	B-X
modulators	B-X
and	B-X
provide	B-X
new	B-X
evidences	B-X
to	B-X
assign	B-X
this	B-X
integrin	B-X
as	B-X
a	B-X
valuable	B-X
target	B-X
to	B-X
fight	B-X
high	B-X
grade	B-X
glioma	B-X
.	B-X

The	O
base	O
excision	O
repair	O
enzyme	O
alkylpurine	O
-	O
DNA	O
-	O
N	O
-	O
glycosylase	O
(	O
APNG	O
)	O
,	O
which	O
repairs	O
the	O
cytotoxic	O
lesions	O
N3	O
-	O
methyladenine	O
and	O
N7	O
-	O
methylguanine	O
,	O
also	O
participates	O
in	O
the	O
TMZ	O
resistance	O
(	O
Agnihotri	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Upregulation	O
of	O
mitochondrial	O
respiratory	O
chain	O
coupling	O
to	O
suppress	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
regulated	O
by	O
cytochrome	O
c	O
oxidase	O
contributes	O
in	O
part	O
to	O
TMZ	O
resistance	O
in	O
gliomas	O
(	O
Oliva	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Reversal	O
of	O
TMZ	O
resistance	O
may	O
be	O
achieved	O
by	O
MGMT	B-Protein
pseudosubstrates	O
,	O
O6	O
-	O
benzylguanine	O
and	O
lomeguatrib	O
to	O
sensitize	O
tumors	O
to	O
TMZ	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Methoxyamine	O
-	O
blocker	O
of	O
base	O
excision	O
repair	O
contributes	O
significantly	O
to	O
TMZ	O
cytotoxicity	O
particularly	O
when	O
O6	O
-	O
methylguanine	O
adducts	O
are	O
repaired	O
or	O
tolerated	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
;	O
Zhang	O
et	O
al	O
.	O
,	O
2012b	O
)	O
.	O

Dual	O
targeting	O
of	O
base	O
excision	O
repair	O
and	O
NAD	O
(	O
+	O
)	O
biosynthesis	O
may	O
reverse	O
TMZ	O
resistance	O
in	O
patients	O
with	O
resistant	O
and	O
recurrent	O
GBM	O
(	O
Goellner	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Interferon	B-Protein
-	I-Protein
beta	I-Protein
(	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
)	O
,	O
levetiracetam	O
(	O
LEV	O
)	O
,	O
resveratrol	O
,	O
and	O
valproic	O
acid	O
(	O
VAP	O
)	O
increase	O
the	O
sensitivity	O
of	O
TMZ	O
through	O
MGMT	B-Protein
-	O
dependent	O
or	O
-	O
independent	O
mechanisms	O
(	O
Nakada	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
<EOS>	B-X
MLS128	B-X
is	B-X
an	B-X
anti-carbohydrate	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
that	B-X
binds	B-X
three	B-X
or	B-X
two	B-X
consecutive	B-X
Tn-antigens	B-X
.	B-X
One	B-X
possible	B-X
mechanism	B-X
of	B-X
MLS128	B-X
's	B-X
inhibition	B-X
of	B-X
growth	B-X
may	B-X
be	B-X
via	B-X
insulin-like	B-X
growth	B-X
factor-I	B-X
receptor	B-X
(	B-X
IGF-IR	B-X
)	B-X
down-regulation	B-X
(	B-X
Morita	B-X
et	B-X
al	B-X
.	B-X
The	B-X
current	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
colon	B-X
cancer	B-X
cells	B-X
and	B-X
its	B-X
possible	B-X
interaction	B-X
with	B-X
MLS128-induced	B-X
inhibition	B-X
of	B-X
cell	B-X
growth	B-X
in	B-X
LS180	B-X
,	B-X
LS174T	B-X
,	B-X
and	B-X
HT29	B-X
human	B-X
colon	B-X
cancer	B-X
cells	B-X
treated	B-X
with	B-X
MLS128	B-X
or	B-X
anti-IGF-IR	B-X
1H7	B-X
.	B-X
Their	B-X
growth	B-X
was	B-X
in	B-X
part	B-X
IGF-I	B-X
dependent	B-X
,	B-X
but	B-X
inhibition	B-X
by	B-X
MLS128	B-X
was	B-X
independent	B-X
of	B-X
IGF-IR	B-X
signaling	B-X
.	B-X
All	B-X
of	B-X
the	B-X
colon	B-X
cancer	B-X
cell	B-X
lines	B-X
expressed	B-X
an	B-X
110kDa	B-X
GP	B-X
for	B-X
MLS128	B-X
binding	B-X
,	B-X
but	B-X
MCF-7	B-X
cells	B-X
expressed	B-X
MLS128-detectable	B-X
bands	B-X
with	B-X
higher	B-X
molecular	B-X
masses	B-X
.	B-X
MLS128	B-X
treatments	B-X
resulted	B-X
in	B-X
partial	B-X
disappearance	B-X
of	B-X
the	B-X
110kDa	B-X
band	B-X
but	B-X
did	B-X
not	B-X
affect	B-X
IGF-IR	B-X
levels	B-X
.	B-X
Western	B-X
blotting	B-X
analyses	B-X
of	B-X
colon	B-X
and	B-X
breast	B-X
cancer	B-X
cell	B-X
lysates	B-X
revealed	B-X
that	B-X
colon	B-X
and	B-X
breast	B-X
cancer	B-X
cells	B-X
differed	B-X
significantly	B-X
in	B-X
patterns	B-X
of	B-X
expression	B-X
of	B-X
growth-related	B-X
molecules	B-X
while	B-X
colon	B-X
cancer	B-X
cells	B-X
were	B-X
similar	B-X
but	B-X
distinctive	B-X
.	B-X
Inhibition	B-X
of	B-X
growth	B-X
by	B-X
MLS128	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
affect	B-X
IGF-IR	B-X
signaling	B-X
and	B-X
instead	B-X
only	B-X
affected	B-X
other	B-X
growth	B-X
signaling	B-X
pathways	B-X
.	B-X

Resveratrol	O
,	O
a	O
natural	O
polyphenol	O
,	O
reverses	O
TMZ	O
resistance	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
(	O
Huang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

STAT3	B-Protein
inhibitor	O
or	O
STAT3	B-Protein
knockdown	O
potentiates	O
TMZ	O
efficacy	O
in	O
resistant	O
GBM	O
cell	O
lines	O
(	O
Kohsaka	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O
<EOS>	B-X
As	B-X
a	B-X
point	B-X
of	B-X
convergence	B-X
for	B-X
numerous	B-X
oncogenic	B-X
signaling	B-X
pathways	B-X
,	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
is	B-X
central	B-X
in	B-X
regulating	B-X
the	B-X
anti-tumor	B-X
immune	B-X
response	B-X
.	B-X
STAT3	B-X
is	B-X
broadly	B-X
hyperactivated	B-X
both	B-X
in	B-X
cancer	B-X
and	B-X
non-cancerous	B-X
cells	B-X
within	B-X
the	B-X
tumor	B-X
ecosystem	B-X
and	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
inhibiting	B-X
the	B-X
expression	B-X
of	B-X
crucial	B-X
immune	B-X
activation	B-X
regulators	B-X
and	B-X
promoting	B-X
the	B-X
production	B-X
of	B-X
immunosuppressive	B-X
factors	B-X
.	B-X
Therefore	B-X
,	B-X
targeting	B-X
the	B-X
STAT3	B-X
signaling	B-X
pathway	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
promising	B-X
therapeutic	B-X
strategy	B-X
for	B-X
numerous	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
outline	B-X
the	B-X
importance	B-X
of	B-X
STAT3	B-X
signaling	B-X
pathway	B-X
in	B-X
tumorigenesis	B-X
and	B-X
its	B-X
immune	B-X
regulation	B-X
,	B-X
and	B-X
highlight	B-X
the	B-X
current	B-X
status	B-X
for	B-X
the	B-X
development	B-X
of	B-X
STAT3-targeting	B-X
therapeutic	B-X
approaches	B-X
.	B-X
We	B-X
also	B-X
summarize	B-X
and	B-X
discuss	B-X
recent	B-X
advances	B-X
in	B-X
STAT3-based	B-X
combination	B-X
immunotherapy	B-X
in	B-X
detail	B-X
.	B-X
These	B-X
endeavors	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
translational	B-X
application	B-X
of	B-X
STAT3	B-X
in	B-X
cancer	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
promotion	B-X
of	B-X
more	B-X
effective	B-X
treatments	B-X
toward	B-X
malignancies	B-X
.	B-X

Intratumoral	O
hypoxia	O
is	O
common	O
in	O
GBMs	O
and	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
TMZ	O
resistance	O
.	O

Induced	O
hyperoxia	O
can	O
be	O
utilized	O
to	O
reverse	O
TMZ	O
resistance	O
in	O
GBMs	O
(	O
Sun	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Cancer	O
stem	O
cells	O
are	O
probably	O
the	O
key	O
to	O
failure	O
in	O
TMZ	O
treatment	O
.	O

The	O
concept	O
of	O
cancer	O
stem	O
cell	O
survival	O
from	O
treatment	O
with	O
TMZ	O
and	O
other	O
chemotherapeutic	O
drugs	O
has	O
been	O
more	O
complicated	O
than	O
previously	O
thought	O
(	O
Beier	O
et	O
al	O
.	O
,	O
2011	O
;	O
Chen	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

CD133	B-Protein
-	O
positive	O
cancer	O
stem	O
cells	O
are	O
expressed	O
in	O
both	O
normal	O
stem	O
cells	O
and	O
cancer	O
stem	O
cells	O
(	O
Donovan	O
and	O
Pilkington	O
,	O
2012	O
)	O
.	O

However	O
,	O
the	O
role	O
of	O
CD133	B-Protein
as	O
a	O
marker	O
for	O
glioma	O
cancer	O
stem	O
cells	O
relative	O
to	O
its	O
biological	O
function	O
has	O
yet	O
to	O
be	O
established	O
.	O

Recently	O
,	O
tumor	O
suppressors	O
p53	B-Protein
and	O
WWOX	B-Protein
were	O
shown	O
to	O
regulate	O
the	O
apoptosis	O
of	O
glioblastoma	O
cells	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

WW	B-Protein
domain	I-Protein
-	I-Protein
containing	I-Protein
oxidoreductase	I-Protein
,	O
known	O
as	O
WWOX	B-Protein
,	O
FOR	B-Protein
,	O
or	O
WOX1	B-Protein
,	O
is	O
encoded	O
by	O
human	O
or	O
mouse	O
WWOX	B-Protein
/	O
Wwox	B-Protein
gene	O
.	O
<EOS>	B-X
Risk	B-X
for	B-X
late-onset	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
LOAD	B-X
)	B-X
,	B-X
the	B-X
most	B-X
prevalent	B-X
dementia	B-X
,	B-X
is	B-X
partially	B-X
driven	B-X
by	B-X
genetics	B-X
.	B-X
We	B-X
confirm	B-X
20	B-X
previous	B-X
LOAD	B-X
risk	B-X
loci	B-X
and	B-X
identify	B-X
five	B-X
new	B-X
genome-wide	B-X
loci	B-X
(	B-X
IQCK	B-X
,	B-X
ACE	B-X
,	B-X
ADAM10	B-X
,	B-X
ADAMTS1	B-X
,	B-X
and	B-X
WWOX	B-X
)	B-X
,	B-X
two	B-X
of	B-X
which	B-X
(	B-X
ADAM10	B-X
,	B-X
ACE	B-X
)	B-X
were	B-X
identified	B-X
in	B-X
a	B-X
recent	B-X
genome-wide	B-X
association	B-X
(	B-X
GWAS	B-X
)	B-X
-by-familial-proxy	B-X
of	B-X
Alzheimer	B-X
's	B-X
or	B-X
dementia	B-X
.	B-X
Fine-mapping	B-X
of	B-X
the	B-X
human	B-X
leukocyte	B-X
antigen	B-X
(	B-X
HLA	B-X
)	B-X
region	B-X
confirms	B-X
the	B-X
neurological	B-X
and	B-X
immune-mediated	B-X
disease	B-X
haplotype	B-X
HLA-DR15	B-X
as	B-X
a	B-X
risk	B-X
factor	B-X
for	B-X
LOAD	B-X
.	B-X
Pathway	B-X
analysis	B-X
implicates	B-X
immunity	B-X
,	B-X
lipid	B-X
metabolism	B-X
,	B-X
tau	B-X
binding	B-X
proteins	B-X
,	B-X
and	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
metabolism	B-X
,	B-X
showing	B-X
that	B-X
genetic	B-X
variants	B-X
affecting	B-X
APP	B-X
and	B-X
Aβ	B-X
processing	B-X
are	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
early-onset	B-X
autosomal	B-X
dominant	B-X
Alzheimer	B-X
's	B-X
disease	B-X
but	B-X
also	B-X
with	B-X
LOAD	B-X
.	B-X
Analyses	B-X
of	B-X
risk	B-X
genes	B-X
and	B-X
pathways	B-X
show	B-X
enrichment	B-X
for	B-X
rare	B-X
variants	B-X
(	B-X
P	B-X
=	B-X
1.32	B-X
×	B-X
10	B-X

This	O
gene	O
is	O
located	O
in	O
chromosome	O
16q23	O
.	O
3	O
-	O
24	O
.	O
1	O
,	O
an	O
area	O
known	O
as	O
the	O
common	O
fragile	O
site	O
FRA16D	O
.	O

The	O
full	O
-	O
length	O
WWOX	B-Protein
protein	O
is	O
composed	O
of	O
two	O
N	O
-	O
terminal	O
WW	O
domains	O
,	O
a	O
C	O
-	O
terminal	O
short	O
-	O
chain	O
alcohol	O
dehydrogenase	O
/	O
reductase	O
(	O
SDR	O
)	O
domain	O
,	O
and	O
a	O
proapoptotic	O
C	O
-	O
terminal	O
tail	O
D3	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2007	O
,	O
2010	O
;	O
Aqeilan	O
et	O
al	O
.	O
,	O
2004	O
,	O
2007	O
;	O
Hong	O
et	O
al	O
.	O
,	O
2007	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
(	O
Figure	O
1	O
)	O
.	O

WWOX	B-Protein
may	O
act	O
as	O
an	O
alternative	O
receptor	O
for	O
sex	O
steroid	O
hormones	O
,	O
since	O
its	O
SDR	O
domain	O
possesses	O
an	O
NSYK	O
motif	O
capable	O
of	O
interacting	O
with	O
androgen	O
and	O
estrogen	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005a	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Expression	O
of	O
WWOX	B-Protein
is	O
either	O
altered	O
or	O
lost	O
from	O
epigenetic	O
modification	O
in	O
multiple	O
malignant	O
cancers	O
,	O
such	O
as	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
(	O
Donati	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
hematopoietic	O
malignancies	O
(	O
Ishii	O
and	O
Furukawa	O
,	O
2004	O
)	O
,	O
gastric	O
carcinoma	O
(	O
Aqeilan	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
pancreatic	O
carcinoma	O
(	O
Kuroki	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
breast	O
carcinoma	O
(	O
Guler	O
et	O
al	O
.	O
,	O
2004	O
;	O
Aqeilan	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
and	O
glioblastoma	O
multiforme	O
(	O
Kosla	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Restoration	O
of	O
WWOX	B-Protein
gene	O
prevents	O
the	O
growth	O
of	O
lung	O
cancer	O
(	O
Fabbri	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
pancreatic	O
cancer	O
(	O
Nakayama	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
and	O
prostate	O
cancer	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

The	O
first	O
WW	O
domain	O
of	O
WWOX	B-Protein
may	O
interact	O
with	O
proteins	O
possessing	O
a	O
PPxY	O
motif	O
(	O
s	O
)	O
such	O
as	O
AP	B-Protein
-	I-Protein
2gamma	I-Protein
,	O
p73	B-Protein
,	O
ErbB4	B-Protein
,	O
Ezrin	B-Protein
,	O
SIMPLE	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
RUNX4	B-Protein
,	O
and	O
many	O
others	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
;	O
Figure	O
1	O
)	O
.	O

Transiently	O
overexpressed	O
WWOX	B-Protein
binds	O
transcription	O
factors	O
AP	B-Protein
-	I-Protein
2	I-Protein
,	O
p73	B-Protein
,	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
and	O
block	O
their	O
nuclear	O
relocation	O
in	O
vitro	O
,	O
which	O
suppresses	O
cancer	O
cell	O
survival	O
(	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
stark	O
contrast	O
,	O
Wwox	B-Protein
co	O
-	O
migrates	O
with	O
proapoptotic	O
and	O
pro	O
-	O
survival	O
transcription	O
factors	O
to	O
the	O
nuclei	O
of	O
neurons	O
upon	O
sciatic	O
nerve	O
axotomy	O
in	O
rats	O
(	O
Li	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

No	O
blocking	O
of	O
translocation	O
of	O
transcription	O
factors	O
to	O
the	O
nuclei	O
by	O
Wwox	B-Protein
was	O
observed	O
.	O

Under	O
stress	O
conditions	O
,	O
WWOX	B-Protein
is	O
activated	O
via	O
phosphorylation	O
at	O
Tyr33	O
,	O
and	O
binds	O
proteins	O
independently	O
of	O
the	O
PPxY	O
motif	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2003	O
,	O
2005a	O
,	O
b	O
,	O
2007	O
,	O
2010	O
)	O
.	O

Activated	O
WWOX	B-Protein
physically	O
interacts	O
with	O
serine	O
46	O
-	O
phosphorylated	O
p53	B-Protein
(	O
Figure	O
1	O
)	O
,	O
which	O
stabilizes	O
p53	B-Protein
and	O
its	O
apoptotic	O
function	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

Also	O
,	O
WWOX	B-Protein
binds	O
Disheveled	O
proteins	O
(	O
Dvl	O
)	O
,	O
which	O
are	O
key	O
components	O
in	O
Wnt	O
/	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
signaling	O
pathway	O
(	O
Figure	O
1	O
)	O
.	O

No	O
PPxY	O
motif	O
is	O
in	O
Dvl	O
.	O
<EOS>	B-X
Its	B-X
levels	B-X
are	B-X
controlled	B-X
by	B-X
ubiquitylation	B-X
,	B-X
mediated	B-X
by	B-X
various	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
including	B-X
NEDD4	B-X
family	B-X
members	B-X
that	B-X
bind	B-X
to	B-X
a	B-X
conserved	B-X
PPxY	B-X
motif	B-X
in	B-X
Dishevelled	B-X
(	B-X
mammalian	B-X
Dvl1-3	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Dvl2	B-X
binds	B-X
to	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
WWP2	B-X
and	B-X
unlocks	B-X
its	B-X
ligase	B-X
activity	B-X
from	B-X
autoinhibition	B-X
.	B-X
This	B-X
disinhibition	B-X
of	B-X
WWP2	B-X
depends	B-X
on	B-X
several	B-X
features	B-X
of	B-X
Dvl2	B-X
including	B-X
its	B-X
PPxY	B-X
motif	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
its	B-X
DEP	B-X
domain	B-X
,	B-X
but	B-X
crucially	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
Dvl2	B-X
to	B-X
polymerize	B-X
,	B-X
indicating	B-X
that	B-X
WWP2	B-X
is	B-X
activated	B-X
in	B-X
Wnt	B-X
signalosomes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Notch	B-X
intracellular	B-X
domains	B-X
are	B-X
substrates	B-X
for	B-X
Dvl-activated	B-X
WWP2	B-X
and	B-X
their	B-X
transcriptional	B-X
activity	B-X
is	B-X
consequently	B-X
reduced	B-X
,	B-X
providing	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
cross-talk	B-X
between	B-X
Wnt	B-X
and	B-X
Notch	B-X
signalling	B-X
.	B-X

Transiently	O
overexpressed	O
WWOX	B-Protein
sequesters	O
Dvl	B-Protein
-	I-Protein
2	I-Protein
in	O
the	O
cytoplasm	O
and	O
thereby	O
blocks	O
Dvl	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
TCF	O
transcriptional	O
activity	O
(	O
Bouteille	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Overexpressed	O
WWOX	B-Protein
induces	O
apoptosis	O
and	O
inhibits	O
proliferation	O
of	O
human	O
hepatic	O
carcinoma	O
cells	O
(	O
Hu	O
et	O
al	O
.	O
,	O
2012	O
)	O
and	O
many	O
cancer	O
cell	O
types	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
,	O
2010	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

WWOX	B-Protein
enhances	O
the	O
cytotoxic	O
function	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
by	O
down	O
-	O
regulating	O
apoptosis	O
inhibitor	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
and	O
up	O
-	O
regulating	O
apoptotic	O
p53	B-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

Also	O
,	O
WWOX	B-Protein
mediates	O
cell	O
death	O
synergistically	O
with	O
p53	B-Protein
.	O
<EOS>	B-X
Transient	B-X
activation	B-X
of	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
promotes	B-X
cell	B-X
survival	B-X
,	B-X
whereas	B-X
persistent	B-X
JNK	B-X
activation	B-X
induces	B-X
apoptosis	B-X
.	B-X
Bovine	B-X
testicular	B-X
hyaluronidase	B-X
PH-20	B-X
activates	B-X
JNK1	B-X
and	B-X
protects	B-X
L929	B-X
fibroblasts	B-X
from	B-X
staurosporine-mediated	B-X
cell	B-X
death	B-X
.	B-X
PH-20	B-X
also	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
p53-interacting	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
(	B-X
WOX1	B-X
,	B-X
also	B-X
known	B-X
as	B-X
WWOX	B-X
or	B-X
FOR	B-X
)	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
WOX1	B-X
enhances	B-X
the	B-X
cytotoxic	B-X
function	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
mediates	B-X
apoptosis	B-X
synergistically	B-X
with	B-X
p53	B-X
.	B-X
Here	B-X
it	B-X
is	B-X
demonstrated	B-X
that	B-X
ectopic	B-X
JNK1	B-X
inhibited	B-X
WOX1-mediated	B-X
apoptosis	B-X
of	B-X
L929	B-X
fibroblasts	B-X
,	B-X
monocytic	B-X
U937	B-X
cells	B-X
,	B-X
and	B-X
other	B-X
cell	B-X
types	B-X
.	B-X
Also	B-X
,	B-X
JNK1	B-X
blocked	B-X
WOX1	B-X
prevention	B-X
of	B-X
cell	B-X
cycle	B-X
progression	B-X
.	B-X
By	B-X
stimulating	B-X
cells	B-X
with	B-X
anisomycin	B-X
or	B-X
UV	B-X
light	B-X
,	B-X
JNK1	B-X
became	B-X
activated	B-X
,	B-X
and	B-X
WOX1	B-X
was	B-X
phosphorylated	B-X
at	B-X
Tyr	B-X
(	B-X
33	B-X
)	B-X
.	B-X
Alteration	B-X
of	B-X
Tyr	B-X
(	B-X
33	B-X
)	B-X
to	B-X
Arg	B-X
(	B-X
33	B-X
)	B-X
in	B-X
WOX1	B-X
abrogated	B-X
its	B-X
binding	B-X
interaction	B-X
with	B-X
JNK1	B-X
and	B-X
its	B-X
activity	B-X
in	B-X
mediating	B-X
cell	B-X
death	B-X
,	B-X
indicating	B-X
that	B-X
Tyr	B-X
(	B-X
33	B-X
)	B-X
phosphorylation	B-X
is	B-X
needed	B-X
to	B-X
activate	B-X
WOX1	B-X
.	B-X
A	B-X
dominant	B-X
negative	B-X
WOX1	B-X
was	B-X
developed	B-X
and	B-X
shown	B-X
to	B-X
block	B-X
p53-mediated	B-X
apoptosis	B-X
and	B-X
anisomycin-mediated	B-X
WOX1	B-X
phosphorylation	B-X
but	B-X
could	B-X
not	B-X
inhibit	B-X
JNK1	B-X
activation	B-X
.	B-X
This	B-X
mutant	B-X
protein	B-X
bound	B-X
p53	B-X
but	B-X
could	B-X
not	B-X
interact	B-X
with	B-X
JNK1	B-X
,	B-X
as	B-X
determined	B-X
in	B-X
yeast	B-X
two-hybrid	B-X
analysis	B-X
.	B-X

Upon	O
exposure	O
to	O
chemicals	O
or	O
environmental	O
stress	O
,	O
such	O
as	O
UV	O
irradiation	O
and	O
chemotherapeutic	O
drugs	O
,	O
WWOX	B-Protein
undergoes	O
phosphorylation	O
in	O
Tyr33	O
and	O
probably	O
others	O
sites	O
,	O
followed	O
by	O
relocating	O
to	O
mitochondria	O
or	O
nuclei	O
for	O
inducing	O
apoptosis	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
,	O
2010	O
)	O
.	O
<EOS>	B-X
The	B-X
use	B-X
of	B-X
nanotechnology	B-X
in	B-X
medicine	B-X
and	B-X
more	B-X
specifically	B-X
drug	B-X
delivery	B-X
is	B-X
set	B-X
to	B-X
spread	B-X
rapidly	B-X
.	B-X
Currently	B-X
many	B-X
substances	B-X
are	B-X
under	B-X
investigation	B-X
for	B-X
drug	B-X
delivery	B-X
and	B-X
more	B-X
specifically	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X
Interestingly	B-X
pharmaceutical	B-X
sciences	B-X
are	B-X
using	B-X
nanoparticles	B-X
to	B-X
reduce	B-X
toxicity	B-X
and	B-X
side	B-X
effects	B-X
of	B-X
drugs	B-X
and	B-X
up	B-X
to	B-X
recently	B-X
did	B-X
not	B-X
realize	B-X
that	B-X
carrier	B-X
systems	B-X
themselves	B-X
may	B-X
impose	B-X
risks	B-X
to	B-X
the	B-X
patient	B-X
.	B-X
The	B-X
kind	B-X
of	B-X
hazards	B-X
that	B-X
are	B-X
introduced	B-X
by	B-X
using	B-X
nanoparticles	B-X
for	B-X
drug	B-X
delivery	B-X
are	B-X
beyond	B-X
that	B-X
posed	B-X
by	B-X
conventional	B-X
hazards	B-X
imposed	B-X
by	B-X
chemicals	B-X
in	B-X
classical	B-X
delivery	B-X
matrices	B-X
.	B-X
For	B-X
nanoparticles	B-X
the	B-X
knowledge	B-X
on	B-X
particle	B-X
toxicity	B-X
as	B-X
obtained	B-X
in	B-X
inhalation	B-X
toxicity	B-X
shows	B-X
the	B-X
way	B-X
how	B-X
to	B-X
investigate	B-X
the	B-X
potential	B-X
hazards	B-X
of	B-X
nanoparticles	B-X
.	B-X
The	B-X
toxicology	B-X
of	B-X
particulate	B-X
matter	B-X
differs	B-X
from	B-X
toxicology	B-X
of	B-X
substances	B-X
as	B-X
the	B-X
composing	B-X
chemical	B-X
(	B-X
s	B-X
)	B-X
may	B-X
or	B-X
may	B-X
not	B-X
be	B-X
soluble	B-X
in	B-X
biological	B-X
matrices	B-X
,	B-X
thus	B-X
influencing	B-X
greatly	B-X
the	B-X
potential	B-X
exposure	B-X
of	B-X
various	B-X
internal	B-X
organs	B-X
.	B-X
This	B-X
may	B-X
vary	B-X
from	B-X
a	B-X
rather	B-X
high	B-X
local	B-X
exposure	B-X
in	B-X
the	B-X
lungs	B-X
and	B-X
a	B-X
low	B-X
or	B-X
neglectable	B-X
exposure	B-X
for	B-X
other	B-X
organ	B-X
systems	B-X
after	B-X
inhalation	B-X
.	B-X
However	B-X
,	B-X
absorbed	B-X
species	B-X
may	B-X
also	B-X
influence	B-X
the	B-X
potential	B-X
toxicity	B-X
of	B-X
the	B-X
inhaled	B-X
particles	B-X
.	B-X
For	B-X
nanoparticles	B-X
the	B-X
situation	B-X
is	B-X
different	B-X
as	B-X
their	B-X
size	B-X
opens	B-X
the	B-X
potential	B-X
for	B-X
crossing	B-X
the	B-X
various	B-X
biological	B-X
barriers	B-X
within	B-X
the	B-X
body	B-X
.	B-X
From	B-X
a	B-X
positive	B-X
viewpoint	B-X
,	B-X
especially	B-X
the	B-X
potential	B-X
to	B-X
cross	B-X
the	B-X
blood	B-X
brain	B-X
barrier	B-X
may	B-X
open	B-X
new	B-X
ways	B-X
for	B-X
drug	B-X
delivery	B-X
into	B-X
the	B-X
brain	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
nanosize	B-X
also	B-X
allows	B-X
for	B-X
access	B-X
into	B-X
the	B-X
cell	B-X
and	B-X
various	B-X
cellular	B-X
compartments	B-X
including	B-X
the	B-X
nucleus	B-X
.	B-X
A	B-X
multitude	B-X
of	B-X
substances	B-X
are	B-X
currently	B-X
under	B-X
investigation	B-X
for	B-X
the	B-X
preparation	B-X
of	B-X
nanoparticles	B-X
for	B-X
drug	B-X
delivery	B-X
,	B-X
varying	B-X
from	B-X
biological	B-X
substances	B-X
like	B-X
albumin	B-X
,	B-X
gelatine	B-X
and	B-X
phospholipids	B-X
for	B-X
liposomes	B-X
,	B-X
and	B-X
more	B-X
substances	B-X
of	B-X
a	B-X
chemical	B-X
nature	B-X
like	B-X
various	B-X
polymers	B-X
and	B-X
solid	B-X
metal	B-X
containing	B-X
nanoparticles	B-X
.	B-X
It	B-X
is	B-X
obvious	B-X
that	B-X
the	B-X
potential	B-X
interaction	B-X
with	B-X
tissues	B-X
and	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
potential	B-X
toxicity	B-X
,	B-X
greatly	B-X
depends	B-X
on	B-X
the	B-X
actual	B-X
composition	B-X
of	B-X
the	B-X
nanoparticle	B-X
formulation	B-X
.	B-X
Besides	B-X
the	B-X
potential	B-X
beneficial	B-X
use	B-X
also	B-X
attention	B-X
is	B-X
drawn	B-X
to	B-X
the	B-X
questions	B-X
how	B-X
we	B-X
should	B-X
proceed	B-X
with	B-X
the	B-X
safety	B-X
evaluation	B-X
of	B-X
the	B-X
nanoparticle	B-X
formulations	B-X
for	B-X
drug	B-X
delivery	B-X
.	B-X
For	B-X
such	B-X
testing	B-X
the	B-X
lessons	B-X
learned	B-X
from	B-X
particle	B-X
toxicity	B-X
as	B-X
applied	B-X
in	B-X
inhalation	B-X
toxicology	B-X
may	B-X
be	B-X
of	B-X
use	B-X
.	B-X
Although	B-X
for	B-X
pharmaceutical	B-X
use	B-X
the	B-X
current	B-X
requirements	B-X
seem	B-X
to	B-X
be	B-X
adequate	B-X
to	B-X
detect	B-X
most	B-X
of	B-X
the	B-X
adverse	B-X
effects	B-X
of	B-X
nanoparticle	B-X
formulations	B-X
,	B-X
it	B-X
can	B-X
not	B-X
be	B-X
expected	B-X
that	B-X
all	B-X
aspects	B-X
of	B-X
nanoparticle	B-X
toxicology	B-X
will	B-X
be	B-X
detected	B-X
.	B-X
So	B-X
,	B-X
probably	B-X
additional	B-X
more	B-X
specific	B-X
testing	B-X
would	B-X
be	B-X
needed	B-X
.	B-X

WWOX	B-Protein
binds	O
MEK	O
in	O
Jurkat	O
T	O
cells	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
dissociates	O
the	O
MEK	O
/	O
WWOX	O
complex	O
and	O
induces	O
WWOX	B-Protein
to	O
translocate	O
to	O
the	O
mitochondria	O
to	O
induce	O
apoptosis	O
,	O
whereas	O
MEK	O
relocates	O
to	O
the	O
lipid	O
raft	O
.	O

Inhibition	O
of	O
MEK	O
activity	O
increases	O
TMZ	O
-	O
induced	O
suppression	O
of	O
cancer	O
cell	O
growth	O
(	O
Holt	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Ectopic	O
expression	O
of	O
WWOX	B-Protein
in	O
A549	O
cells	O
induces	O
procaspase	B-Protein
-	I-Protein
3	I-Protein
and	O
procaspase	B-Protein
-	I-Protein
9	I-Protein
activation	O
and	O
induces	O
cytochrome	O
C	O
releasing	O
from	O
the	O
mitochondria	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
2012a	O
)	O
.	O

Complement	O
C1q	O
induces	O
ectopic	O
WWOX	B-Protein
phosphorylation	O
in	O
Try33	O
and	O
leads	O
to	O
cell	O
apoptosis	O
independently	O
of	O
the	O
classical	O
complement	O
activation	O
pathway	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

A	O
portion	O
of	O
WWOX	B-Protein
is	O
anchored	O
in	O
the	O
membrane	O
/	O
cytoskeleton	O
area	O
via	O
binding	O
with	O
hyaluronidase	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
(	O
Hsu	O
et	O
al	O
.	O
,	O
2009	O
)	O
and	O
Phospho	O
-	O
Ezrin	B-Protein
(	O
Jin	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta1	I-Protein
binds	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
as	O
a	O
cognate	O
receptor	O
to	O
signal	O
the	O
formation	O
of	O
the	O
WWOX	O
/	O
Hyal	O
-	O
2	O
/	O
Smad4	O
complex	O
to	O
relocate	O
to	O
the	O
nucleus	O
for	O
enhancing	O
the	O
SMAD	O
-	O
driven	O
promoter	O
activity	O
(	O
Hsu	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

Activated	O
p53	B-Protein
mediates	O
apoptosis	O
,	O
cell	O
cycle	O
arrest	O
,	O
senescence	O
,	O
DNA	O
repair	O
,	O
or	O
metabolism	O
(	O
Lane	O
and	O
Levine	O
,	O
2010	O
)	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
transcription	B-X
factor	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
cellular	B-X
responses	B-X
to	B-X
stress	B-X
.	B-X
Its	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
DNA	B-X
damage	B-X
leads	B-X
to	B-X
cell	B-X
growth	B-X
arrest	B-X
,	B-X
allowing	B-X
for	B-X
DNA	B-X
repair	B-X
,	B-X
or	B-X
directs	B-X
cellular	B-X
senescence	B-X
or	B-X
apoptosis	B-X
,	B-X
thereby	B-X
maintaining	B-X
genome	B-X
integrity	B-X
.	B-X
Senescence	B-X
is	B-X
a	B-X
permanent	B-X
cell-cycle	B-X
arrest	B-X
that	B-X
has	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
aging	B-X
,	B-X
and	B-X
it	B-X
also	B-X
represents	B-X
a	B-X
robust	B-X
physiological	B-X
antitumor	B-X
response	B-X
,	B-X
which	B-X
counteracts	B-X
oncogenic	B-X
insults	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
senescent	B-X
cells	B-X
can	B-X
also	B-X
negatively	B-X
impact	B-X
the	B-X
surrounding	B-X
tissue	B-X
microenvironment	B-X
and	B-X
the	B-X
neighboring	B-X
cells	B-X
by	B-X
secreting	B-X
pro-inflammatory	B-X
cytokines	B-X
,	B-X
ultimately	B-X
triggering	B-X
tissue	B-X
dysfunction	B-X
and/or	B-X
unfavorable	B-X
outcomes	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
characteristics	B-X
of	B-X
senescence	B-X
and	B-X
on	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
contribution	B-X
of	B-X
p53	B-X
to	B-X
cellular	B-X
senescence	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
also	B-X
discuss	B-X
the	B-X
p53-mediated	B-X
regulation	B-X
of	B-X
several	B-X
pathophysiological	B-X
microenvironments	B-X
that	B-X
could	B-X
be	B-X
associated	B-X
with	B-X
senescence	B-X
and	B-X
its	B-X
development	B-X
.	B-X

The	O
primary	O
structures	O
of	O
p53	B-Protein
and	O
its	O
isoforms	O
are	O
depicted	O
(	O
Figure	O
2	O
)	O
.	O

p53	B-Protein
induces	O
cell	O
cycle	O
arrest	O
by	O
transactivating	O
genes	O
such	O
as	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	B-Protein
,	O
or	O
microRNA	O
miR34	B-Protein
.	O
<EOS>	B-X
In	B-X
just	B-X
over	B-X
two	B-X
decades	B-X
since	B-X
the	B-X
discovery	B-X
of	B-X
the	B-X
first	B-X
microRNA	B-X
(	B-X
miRNA	B-X
)	B-X
,	B-X
the	B-X
field	B-X
of	B-X
miRNA	B-X
biology	B-X
has	B-X
expanded	B-X
considerably	B-X
.	B-X
Functional	B-X
studies	B-X
have	B-X
confirmed	B-X
that	B-X
miRNA	B-X
dysregulation	B-X
is	B-X
causal	B-X
in	B-X
many	B-X
cases	B-X
of	B-X
cancer	B-X
,	B-X
with	B-X
miRNAs	B-X
acting	B-X
as	B-X
tumour	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
(	B-X
oncomiRs	B-X
)	B-X
,	B-X
and	B-X
miRNA	B-X
mimics	B-X
and	B-X
molecules	B-X
targeted	B-X
at	B-X
miRNAs	B-X
(	B-X
antimiRs	B-X
)	B-X
have	B-X
shown	B-X
promise	B-X
in	B-X
preclinical	B-X
development	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
to	B-X
explore	B-X
how	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
skin	B-X
functioning	B-X
and	B-X
aging	B-X
.	B-X
Recent	B-X
evidence	B-X
has	B-X
suggested	B-X
that	B-X
miRNAs	B-X
regulate	B-X
all	B-X
aspects	B-X
of	B-X
cutaneous	B-X
biogenesis	B-X
,	B-X
functionality	B-X
,	B-X
and	B-X
aging	B-X
.	B-X
These	B-X
miRNAs	B-X
affected	B-X
cell	B-X
proliferation	B-X
pathways	B-X
via	B-X
targeting	B-X
the	B-X
p63	B-X
and	B-X
Sirtuin	B-X
1	B-X
mRNAs	B-X
.	B-X
Notably	B-X
,	B-X
miR-181a	B-X
was	B-X
also	B-X
implicated	B-X
in	B-X
skin	B-X
immunosenescence	B-X
,	B-X
represented	B-X
by	B-X
the	B-X
Langerhans	B-X
cells	B-X
.	B-X
Dermal	B-X
fibroblasts	B-X
also	B-X
expressed	B-X
increased	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
biomarkers	B-X
of	B-X
aging	B-X
that	B-X
affect	B-X
telomere	B-X
maintenance	B-X
and	B-X
all	B-X
phases	B-X
of	B-X
the	B-X
cellular	B-X
life	B-X
cycle	B-X
,	B-X
such	B-X
as	B-X
let-7	B-X
,	B-X
miR-23a-3p	B-X
,	B-X
34a-5p	B-X
,	B-X
miR-125a	B-X
,	B-X
miR-181a-5p	B-X
,	B-X
and	B-X
miR-221/222-3p	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
the	B-X
miR-34	B-X
family	B-X
,	B-X
stimulated	B-X
by	B-X
ultraviolet	B-X
B	B-X
irradiation	B-X
,	B-X
deteriorates	B-X
collagen	B-X
in	B-X
the	B-X
extracellular	B-X
matrix	B-X
due	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
matrix	B-X
metalloproteinases	B-X
and	B-X
thereby	B-X
potentiates	B-X
wrinkle	B-X
formation	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
pro-aging	B-X
effects	B-X
of	B-X
miRNAs	B-X
,	B-X
the	B-X
plausible	B-X
antiaging	B-X
activity	B-X
of	B-X
miR-146a	B-X
that	B-X
antagonized	B-X
the	B-X
UVA-induced	B-X
inhibition	B-X
of	B-X
proliferation	B-X
and	B-X
suppressed	B-X
aging-related	B-X
genes	B-X
(	B-X
e.g.	B-X
,	B-X

p53	B-Protein
induces	O
apoptosis	O
by	O
transactivating	O
proapoptotic	O
genes	O
such	O
as	O
BAX	B-Protein
,	O
PUMA	B-Protein
,	O
SCOTIN	B-Protein
,	O
and	O
FAS	B-Protein
,	O
and	O
inhibiting	O
the	O
antiapoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
2	I-Protein
(	O
Lane	O
and	O
Levine	O
,	O
2010	O
)	O
.	O

p53	B-Protein
triggers	O
pro	O
-	O
survival	O
or	O
cell	O
death	O
response	O
,	O
depending	O
upon	O
cell	O
types	O
,	O
the	O
intensity	O
of	O
the	O
stress	O
signal	O
,	O
and	O
the	O
extent	O
of	O
cellular	O
damage	O
(	O
Menendez	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
<EOS>	B-X
Apoptosis	B-X
or	B-X
programmed	B-X
cell	B-X
death	B-X
is	B-X
a	B-X
key	B-X
function	B-X
in	B-X
regulating	B-X
skin	B-X
development	B-X
,	B-X
homeostasis	B-X
and	B-X
tumorigenesis	B-X
.	B-X
The	B-X
epidermis	B-X
is	B-X
exposed	B-X
to	B-X
various	B-X
external	B-X
stimuli	B-X
and	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
is	B-X
UV	B-X
radiation	B-X
.	B-X
The	B-X
UVA	B-X
and	B-X
UVB	B-X
spectra	B-X
differ	B-X
in	B-X
their	B-X
biological	B-X
effects	B-X
and	B-X
in	B-X
their	B-X
depth	B-X
of	B-X
penetration	B-X
through	B-X
the	B-X
skin	B-X
layers	B-X
.	B-X
UVB	B-X
rays	B-X
are	B-X
absorbed	B-X
directly	B-X
by	B-X
DNA	B-X
which	B-X
results	B-X
in	B-X
its	B-X
damage	B-X
.	B-X
UVA	B-X
can	B-X
also	B-X
cause	B-X
DNA	B-X
damage	B-X
but	B-X
primarily	B-X
by	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
By	B-X
eliminating	B-X
photodamaged	B-X
cells	B-X
,	B-X
apoptosis	B-X
has	B-X
an	B-X
important	B-X
function	B-X
in	B-X
the	B-X
prevention	B-X
of	B-X
epidermal	B-X
carcinogenesis	B-X
.	B-X
These	B-X
include	B-X
:	B-X
1.	B-X
activation	B-X
of	B-X
the	B-X
tumour	B-X
suppressor	B-X
gene	B-X
p53	B-X
;	B-X
2.	B-X
triggering	B-X
of	B-X
cell	B-X
death	B-X
receptors	B-X
directly	B-X
by	B-X
UV	B-X
or	B-X
by	B-X
autocrine	B-X
release	B-X
of	B-X
death	B-X
ligands	B-X
;	B-X
3.	B-X
mitochondrial	B-X
damage	B-X
and	B-X
cytochrome	B-X
C	B-X
release	B-X
.	B-X
The	B-X
extrinsic	B-X
pathway	B-X
through	B-X
death	B-X
receptors	B-X
such	B-X
as	B-X
fibroblast-associated	B-X
,	B-X
tumour	B-X
necrosis	B-X
factor	B-X
receptor	B-X
and	B-X
TNF	B-X
related	B-X
apoptosis	B-X
inducing	B-X
ligand	B-X
receptor	B-X
activate	B-X
caspase	B-X
cascade	B-X
.	B-X
The	B-X
intrinsic	B-X
or	B-X
mitochondrial	B-X
pathway	B-X
of	B-X
apoptosis	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
Bcl-2	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
,	B-X
Bcl-xl	B-X
,	B-X
Bcl-w	B-X
)	B-X
and	B-X
the	B-X
pro-apoptotic	B-X
(	B-X
Bax	B-X
,	B-X
Bak	B-X
,	B-X
Bid	B-X
)	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
the	B-X
pro-apoptotic	B-X
and	B-X
anti-apoptotic	B-X
proteins	B-X
determines	B-X
cell	B-X
survival	B-X
or	B-X
death	B-X
.	B-X

Also	O
,	O
p53	B-Protein
plays	O
a	O
role	O
in	O
controlling	O
cell	O
motility	O
via	O
regulating	O
the	O
expression	O
of	O
smooth	B-Protein
muscle	I-Protein
alpha	I-Protein
-	I-Protein
actin	I-Protein
(	O
Comer	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
collagens	B-Protein
IIalpha1	I-Protein
and	O
VIalpha1	B-Protein
(	O
Sun	O
et	O
al	O
.	O
,	O
1999	O
)	O
,	O
and	O
many	O
others	O
.	O

At	O
least	O
nine	O
isoforms	O
of	O
p53	B-Protein
have	O
been	O
identified	O
due	O
to	O
alternative	O
mRNA	O
splicing	O
,	O
multiple	O
gene	O
promoters	O
,	O
and	O
alternative	O
initiation	O
sites	O
of	O
translation	O
(	O
Ghosh	O
et	O
al	O
.	O
,	O
2004	O
;	O
Ray	O
et	O
al	O
.	O
,	O
2006	O
;	O
Figure	O
2	O
)	O
.	O

In	O
cancers	O
,	O
aberrant	O
expression	O
of	O
p53	B-Protein
isoforms	O
occurs	O
frequently	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
;	O
Bourdon	O
,	O
2007	O
)	O
.	O

Full	O
-	O
length	O
p53	B-Protein
,	O
delta133p53	B-Protein
,	O
and	O
p53beta	B-Protein
are	O
localized	O
mainly	O
in	O
the	O
nucleus	O
,	O
and	O
only	O
few	O
of	O
them	O
are	O
in	O
cytoplasm	O
.	O

p53gamma	B-Protein
and	O
delta133p53beta	B-Protein
are	O
localized	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O

delta133p53gamma	B-Protein
is	O
localized	O
in	O
the	O
cytoplasm	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Co	O
-	O
transfection	O
of	O
p53	B-Protein
and	O
p53beta	B-Protein
increases	O
p53	B-Protein
-	O
mediated	O
apoptosis	O
,	O
whereas	O
co	O
-	O
expression	O
of	O
p53	B-Protein
with	O
delta133p53	B-Protein
suppresses	O
p53	B-Protein
-	O
mediated	O
apoptosis	O
(	O
Bourdon	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

delta133p53	B-Protein
differentially	O
regulates	O
gene	O
expression	O
in	O
p53	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
manners	O
(	O
Aoubala	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Co	O
-	O
expression	O
of	O
delta133p53beta	B-Protein
or	O
delta133p53gamma	B-Protein
with	O
p53	B-Protein
does	O
not	O
affect	O
p53	B-Protein
transcriptional	O
activity	O
on	O
p21	B-Protein
and	O
Bax	B-Protein
promoters	O
,	O
as	O
well	O
as	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
activities	B-X
are	B-X
due	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
form	B-X
oligomers	B-X
that	B-X
bind	B-X
to	B-X
specific	B-X
DNA	B-X
sequences	B-X
and	B-X
activate	B-X
transcription	B-X
.	B-X
Since	B-X
some	B-X
mutant	B-X
p53	B-X
proteins	B-X
and	B-X
ΔNp73	B-X
isoforms	B-X
form	B-X
heterocomplexes	B-X
with	B-X
TAp73	B-X
,	B-X
we	B-X
asked	B-X
whether	B-X
p53	B-X
isoforms	B-X
can	B-X
do	B-X
the	B-X
same	B-X
and	B-X
potentially	B-X
act	B-X
as	B-X
dominant-negative	B-X
inhibitors	B-X
of	B-X
TAp73	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
already	B-X
been	B-X
found	B-X
that	B-X
some	B-X
isoforms	B-X
form	B-X
complex	B-X
with	B-X
wtp53	B-X
and	B-X
some	B-X
of	B-X
them	B-X
inhibit	B-X
p53	B-X
tumor-suppressor	B-X
functions	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
complex	B-X
formation	B-X
and	B-X
co-immunoprecipitation	B-X
assays	B-X
show	B-X
that	B-X
all	B-X
six	B-X
p53	B-X
isoforms	B-X
examined	B-X
can	B-X
form	B-X
complexes	B-X
with	B-X
TAp73β	B-X
,	B-X
whereas	B-X
only	B-X
Δ133p53α/β/γ	B-X
isoforms	B-X
form	B-X
complex	B-X
with	B-X
TAp73α	B-X
.	B-X
All	B-X
p53	B-X
isoforms	B-X
counteract	B-X
TAp73β	B-X
transactivation	B-X
function	B-X
but	B-X
with	B-X
different	B-X
efficiency	B-X
and	B-X
in	B-X
a	B-X
promoter-dependent	B-X
manner	B-X
.	B-X
Furthermore	B-X
,	B-X
apoptotic	B-X
activity	B-X
of	B-X
TAp73β	B-X
was	B-X
augmented	B-X
by	B-X
coexpression	B-X
of	B-X
p53β	B-X
,	B-X
whereas	B-X
Δ133p53α	B-X
and	B-X
β	B-X
inhibit	B-X
its	B-X
apoptotic	B-X
activity	B-X
most	B-X
efficiently	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
half-life	B-X
of	B-X
different	B-X
p53	B-X
isoforms	B-X
:	B-X
p53γ	B-X
isoform	B-X
has	B-X
the	B-X
shortest	B-X
half-life	B-X
,	B-X
whereas	B-X
Δ133p53γ	B-X
has	B-X
the	B-X
longest	B-X
half-life	B-X
.	B-X
However	B-X
,	B-X
only	B-X
three	B-X
isoforms	B-X
(	B-X
Δ133p53α	B-X
,	B-X
Δ133p53β	B-X
and	B-X
Δ40p53α	B-X
)	B-X
stabilize	B-X
TAp73β	B-X
.	B-X
We	B-X
are	B-X
convinced	B-X
that	B-X
defining	B-X
the	B-X
interactions	B-X
between	B-X
p53/p73	B-X
would	B-X
give	B-X
a	B-X
new	B-X
insight	B-X
into	B-X
how	B-X
the	B-X
p53	B-X
isoforms	B-X
modulate	B-X
the	B-X
p73	B-X
functions	B-X
in	B-X
tumorigenesis	B-X
.	B-X

p53	B-Protein
mutants	O
are	O
considered	O
as	O
unfavorable	O
factors	O
for	O
the	O
effectiveness	O
in	O
radiotherapy	O
and	O
TMZ	O
treatment	O
in	O
glioma	O
cells	O
(	O
Gjerset	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hirose	O
et	O
al	O
.	O
,	O
2001	O
;	O
Squatrito	O
et	O
al	O
.	O
,	O
2010	O
;	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Loss	O
of	O
functional	O
p53	B-Protein
confers	O
sensitivity	O
to	O
TMZ	O
in	O
glioma	O
cells	O
,	O
whereas	O
wild	O
type	O
p53	B-Protein
increases	O
the	O
TMZ	O
resistance	O
(	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

p53	B-Protein
mutants	O
reduce	O
TMZ	O
sensitivity	O
in	O
gliomas	O
(	O
Blough	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Altered	O
WWOX	B-Protein
expression	O
is	O
shown	O
in	O
GBMs	O
,	O
in	O
which	O
downregulation	O
of	O
WWOX	B-Protein
is	O
associated	O
with	O
loss	O
of	O
heterozygosity	O
and	O
promoter	O
methylation	O
(	O
Kosla	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
overexpressed	O
WWOX	B-Protein
induces	O
apoptosis	O
of	O
glioblastoma	O
U373	O
-	O
MG	O
cells	O
harboring	O
mutant	O
p53	B-Protein
by	O
causing	O
hypoploidy	O
and	O
DNA	O
fragmentation	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

However	O
,	O
ectopic	O
WWOX	B-Protein
has	O
no	O
effect	O
with	O
U87	O
-	O
MG	O
expressing	O
wild	O
type	O
p53	B-Protein
.	O

Unlike	O
TMZ	O
,	O
WWOX	B-Protein
induces	O
apoptosis	O
of	O
U373	O
-	O
MG	O
cells	O
via	O
a	O
mitochondria	O
-	O
independent	O
and	O
caspase	B-Protein
-	I-Protein
3	I-Protein
-	O
independent	O
pathway	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

While	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
the	O
survival	O
of	O
human	O
glioblastoma	O
cells	O
depends	O
upon	O
interactions	O
between	O
the	O
gain	O
-	O
of	O
-	O
function	O
of	O
p53	B-Protein
mutants	O
and	O
WWOX	B-Protein
.	O

Activated	O
WWOX	B-Protein
binds	O
wild	O
type	O
p53	B-Protein
with	O
Ser46	O
phosphorylation	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

UV	O
irradiation	O
enhances	O
the	O
binding	O
interactions	O
.	O
<EOS>	B-X
Instead	B-X
UV	B-X
crosslinking	B-X
modifies	B-X
aromatic	B-X
side	B-X
chains	B-X
.	B-X
Here	B-X
we	B-X
elucidate	B-X
the	B-X
impact	B-X
that	B-X
EDC	B-X
,	B-X
in	B-X
combination	B-X
with	B-X
UV	B-X
,	B-X
exerts	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
integrin-binding	B-X
motifs	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
CCAAT	B-X
box-binding	B-X
protein	B-X
,	B-X
NF-Y	B-X
,	B-X
mediates	B-X
MDR1	B-X
activation	B-X
by	B-X
the	B-X
histone	B-X
deacetylase	B-X
inhibitors	B-X
,	B-X
trichostatin	B-X
A	B-X
and	B-X
sodium	B-X
butyrate	B-X
,	B-X
through	B-X
the	B-X
recruitment	B-X
of	B-X
the	B-X
co-activator	B-X
,	B-X
P/CAF	B-X
.	B-X
We	B-X
show	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
MDR1	B-X
promoter	B-X
by	B-X
UV	B-X
irradiation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
the	B-X
CCAAT	B-X
box	B-X
(	B-X
-82	B-X
to	B-X
-73	B-X
)	B-X
as	B-X
well	B-X
as	B-X
on	B-X
a	B-X
proximal	B-X
GC	B-X
element	B-X
(	B-X
-56	B-X
to	B-X
-42	B-X
)	B-X
.	B-X
Gel	B-X
shift	B-X
and	B-X
supershift	B-X
analyses	B-X
with	B-X
nuclear	B-X
extracts	B-X
prepared	B-X
from	B-X
human	B-X
KB-3-1	B-X
cells	B-X
identified	B-X
NF-Y	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interacting	B-X
with	B-X
the	B-X
CCAAT	B-X
box	B-X
,	B-X
while	B-X
Sp1	B-X
was	B-X
the	B-X
predominant	B-X
factor	B-X
binding	B-X
to	B-X
the	B-X
GC	B-X
element	B-X
.	B-X
Mutations	B-X
that	B-X
abrogated	B-X
binding	B-X
of	B-X
either	B-X
of	B-X
these	B-X
factors	B-X
reduced	B-X
or	B-X
abolished	B-X
activation	B-X
by	B-X
ultraviolet	B-X
irradiation	B-X
;	B-X
moreover	B-X
,	B-X
co-expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
NF-Y	B-X
protein	B-X
(	B-X
NF-YA29	B-X
)	B-X
reduced	B-X
UV-activated	B-X
transcription	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
mutation	B-X
that	B-X
abolished	B-X
activation	B-X
of	B-X
MDR1	B-X
by	B-X
UV-irradiation	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
YB-1	B-X
binding	B-X
and	B-X
co-transfection	B-X
of	B-X
a	B-X
YB-1	B-X
expression	B-X
plasmid	B-X
had	B-X
a	B-X
repressive	B-X
effect	B-X
on	B-X
UV-inducible	B-X
transcription	B-X
.	B-X

Despite	O
the	O
presence	O
of	O
Ser46	O
in	O
delta40p53	B-Protein
,	O
binding	O
of	O
this	O
protein	O
with	O
WWOX	B-Protein
remains	O
to	O
be	O
determined	O
.	O

We	O
postulate	O
that	O
in	O
GBM	O
cells	O
,	O
both	O
wild	O
type	O
p53	B-Protein
and	O
ectopic	O
WWOX	B-Protein
proteins	O
appear	O
to	O
have	O
a	O
functional	O
antagonism	O
,	O
thereby	O
nullifying	O
each	O
other	O
'	O
s	O
function	O
in	O
inducing	O
apoptosis	O
(	O
Figure	O
2	O
)	O
.	O

Mutant	O
p53	B-Protein
proteins	O
cannot	O
bind	O
ectopic	O
WWOX	B-Protein
in	O
GBM	O
cells	O
,	O
and	O
WWOX	B-Protein
is	O
able	O
to	O
induce	O
apoptosis	O
.	O

Whether	O
WWOX	B-Protein
causes	O
apoptosis	O
in	O
GBM	O
expressing	O
p53	B-Protein
isoforms	O
is	O
unknown	O
and	O
remains	O
to	O
be	O
established	O
.	O

Whether	O
WWOX	B-Protein
affects	O
TMZ	O
sensitivity	O
has	O
never	O
been	O
determined	O
.	O

Binding	O
proteins	O
for	O
WWOX	B-Protein
and	O
/	O
or	O
p53	B-Protein
are	O
likely	O
to	O
affect	O
apoptosis	O
and	O
TMZ	O
sensitivity	O
in	O
GBM	O
cells	O
.	O
<EOS>	B-X
We	B-X
confirm	B-X
20	B-X
previous	B-X
LOAD	B-X
risk	B-X
loci	B-X
and	B-X
identify	B-X
five	B-X
new	B-X
genome-wide	B-X
loci	B-X
(	B-X
IQCK	B-X
,	B-X
ACE	B-X
,	B-X
ADAM10	B-X
,	B-X
ADAMTS1	B-X
,	B-X
and	B-X
WWOX	B-X
)	B-X
,	B-X
two	B-X
of	B-X
which	B-X
(	B-X
ADAM10	B-X
,	B-X
ACE	B-X
)	B-X
were	B-X
identified	B-X
in	B-X
a	B-X
recent	B-X
genome-wide	B-X
association	B-X
(	B-X
GWAS	B-X
)	B-X
-by-familial-proxy	B-X
of	B-X
Alzheimer	B-X
's	B-X
or	B-X
dementia	B-X
.	B-X
Pathway	B-X
analysis	B-X
implicates	B-X
immunity	B-X
,	B-X
lipid	B-X
metabolism	B-X
,	B-X
tau	B-X
binding	B-X
proteins	B-X
,	B-X
and	B-X
amyloid	B-X
precursor	B-X
protein	B-X
(	B-X
APP	B-X
)	B-X
metabolism	B-X
,	B-X
showing	B-X
that	B-X
genetic	B-X
variants	B-X
affecting	B-X
APP	B-X
and	B-X
Aβ	B-X
processing	B-X
are	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
early-onset	B-X
autosomal	B-X
dominant	B-X
Alzheimer	B-X
's	B-X
disease	B-X
but	B-X
also	B-X
with	B-X
LOAD	B-X
.	B-X
Several	B-X
genes	B-X
'	B-X
mutations	B-X
were	B-X
incorporated	B-X
in	B-X
this	B-X
review	B-X
including	B-X
AFG3L2	B-X
,	B-X
ASPM	B-X
,	B-X
ATN1	B-X
,	B-X
ATP1A2	B-X
,	B-X
BMP5	B-X
,	B-X
CCDC88A	B-X
,	B-X
C12orf57	B-X
,	B-X
DNAJA1	B-X
,	B-X
EML1	B-X
,	B-X
ERLIN2	B-X
,	B-X
FRRS1L	B-X
,	B-X
GABRG3	B-X
,	B-X
NRXN3	B-X
,	B-X
MDH1	B-X
,	B-X
KCNJ10	B-X
,	B-X
KCNMA1	B-X
,	B-X
KCNT1	B-X
,	B-X
KIAA0226	B-X
,	B-X
OPHN1	B-X
,	B-X
PCCA	B-X
,	B-X
PCCB	B-X
,	B-X
PEX	B-X
,	B-X
PGAP2	B-X
,	B-X
PI4K2A	B-X
,	B-X
PODXL	B-X
,	B-X
PRICKLE1	B-X
,	B-X
PNKP	B-X
,	B-X
RELN	B-X
,	B-X
SCN2A	B-X
,	B-X
SCN1B	B-X
,	B-X
SLC2A1	B-X
,	B-X
SLC19A3	B-X
,	B-X
SLC25	B-X
,	B-X
SIAH1	B-X
,	B-X
SYNJ1	B-X
,	B-X
SZT2	B-X
,	B-X
TBCK	B-X
,	B-X
TMX2	B-X
,	B-X
TSC1	B-X
,	B-X
TSC2	B-X
,	B-X
TSEN	B-X
,	B-X
WDR45B	B-X
,	B-X
WWOX	B-X
,	B-X
UBR	B-X
,	B-X
UGDH	B-X
,	B-X
and	B-X
YIF1B	B-X
.	B-X
For	B-X
each	B-X
of	B-X
these	B-X
genes	B-X
,	B-X
we	B-X
tried	B-X
to	B-X
explain	B-X
a	B-X
little	B-X
about	B-X
the	B-X
gene	B-X
associated	B-X
proteins	B-X
and	B-X
their	B-X
roles	B-X
in	B-X
epilepsy	B-X
development	B-X
.	B-X

WWOX	B-Protein
binds	O
MEK	O
,	O
and	O
that	O
PMA	O
dissociates	O
this	O
complex	O
for	O
causing	O
apoptosis	O
of	O
T	O
leukemia	O
cells	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Thus	O
,	O
appropriate	O
chemicals	O
,	O
which	O
break	O
apart	O
the	O
WWOX	O
/	O
MEK	O
complex	O
,	O
are	O
expected	O
to	O
cause	O
GBM	O
cell	O
death	O
.	O

Preliminary	O
studies	O
from	O
our	O
screening	O
of	O
chemicals	O
have	O
selected	O
certain	O
small	O
molecules	O
that	O
induce	O
apoptosis	O
of	O
many	O
types	O
of	O
cancer	O
cells	O
(	O
Lu	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Indeed	O
,	O
specific	O
inhibition	O
of	O
MEK	O
by	O
selumetinib	O
enhances	O
TMZ	O
-	O
induced	O
cancer	O
cell	O
death	O
in	O
vivo	O
(	O
Holt	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Serum	O
factors	O
can	O
be	O
utilized	O
for	O
blocking	O
cancer	O
growth	O
.	O
<EOS>	B-X
Snail	B-X
knockdown	B-X
in	B-X
mouse	B-X
ovarian	B-X
cancer	B-X
cells	B-X
suppresses	B-X
tumor	B-X
growth	B-X
in	B-X
immunocompetent	B-X
mice	B-X
,	B-X
associated	B-X
with	B-X
an	B-X
increase	B-X
of	B-X
CD8	B-X
Patients	B-X
with	B-X
chronic	B-X
renal	B-X
disease	B-X
have	B-X
elevated	B-X
serum	B-X
phosphate	B-X
levels	B-X
,	B-X
elevated	B-X
fibroblast-like	B-X
growth	B-X
factor	B-X
23	B-X
(	B-X
FGF-23	B-X
)	B-X
,	B-X
and	B-X
declining	B-X
vitamin	B-X
D	B-X
status	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
biochemistry	B-X
and	B-X
pathophysiology	B-X
of	B-X
CYP24A1	B-X
and	B-X
the	B-X
utility	B-X
of	B-X
blocking	B-X
this	B-X
enzyme	B-X
with	B-X
CYP24A1	B-X
inhibitors	B-X
in	B-X
chronic	B-X
kidney	B-X
disease	B-X
(	B-X
CKD	B-X
)	B-X
patients	B-X
.	B-X
HK-2	B-X
cell	B-X
growth	B-X
is	B-X
epidermal	B-X
growth	B-X
factor	B-X
dependent	B-X
and	B-X
the	B-X
cells	B-X
retain	B-X
a	B-X
phenotype	B-X
indicative	B-X
of	B-X
well-differentiated	B-X
PTCs	B-X
(	B-X
positive	B-X
for	B-X
alkaline	B-X
phosphatase	B-X
,	B-X
gamma	B-X
glutamyltranspeptidase	B-X
,	B-X
leucine	B-X
aminopeptidase	B-X
,	B-X
acid	B-X
phosphatase	B-X
,	B-X
cytokeratin	B-X
,	B-X
alpha	B-X
3	B-X
beta	B-X
1	B-X
integrin	B-X
,	B-X
fibronectin	B-X
;	B-X
negative	B-X
for	B-X
factor	B-X
VIII-related	B-X
antigen	B-X
,	B-X
6.19	B-X
antigen	B-X
and	B-X
CALLA	B-X
endopeptidase	B-X
)	B-X
.	B-X

For	O
example	O
,	O
serum	O
complement	O
C1q	O
induces	O
apoptosis	O
of	O
prostate	O
cancer	O
and	O
neuroblastomas	O
cells	O
without	O
participation	O
of	O
downstream	O
proteins	O
in	O
the	O
classical	O
activation	O
pathway	O
(	O
Hong	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

In	O
this	O
event	O
,	O
ectopic	O
WWOX	B-Protein
is	O
activated	O
for	O
inducing	O
apoptosis	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
WWOX	B-X
physically	B-X
binds	B-X
p53	B-X
and	B-X
TIAF1	B-X
and	B-X
together	B-X
induces	B-X
apoptosis	B-X
and	B-X
tumor	B-X
suppression	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
molecular	B-X
action	B-X
,	B-X
here	B-X
we	B-X
investigated	B-X
the	B-X
formation	B-X
of	B-X
WWOX/TIAF1/p53	B-X
triad	B-X
and	B-X
its	B-X
regulation	B-X
of	B-X
cancer	B-X
cell	B-X
migration	B-X
,	B-X
anchorage-independent	B-X
growth	B-X
,	B-X
SMAD	B-X
promoter	B-X
activation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
potential	B-X
role	B-X
in	B-X
neurodegeneration	B-X
.	B-X

Failure	O
of	O
ectopic	O
WWOX	B-Protein
in	O
inducing	O
apoptosis	O
of	O
glioma	O
cells	O
possessing	O
wild	O
type	O
p53	B-Protein
is	O
unusual	O
(	O
Chiang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
most	O
cases	O
,	O
we	O
have	O
shown	O
that	O
p53	B-Protein
functionally	O
interacts	O
with	O
WWOX	B-Protein
,	O
and	O
both	O
proteins	O
induce	O
apoptosis	O
in	O
a	O
synergistic	O
manner	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2001	O
,	O
2003	O
,	O
2005a	O
,	O
b	O
,	O
2007	O
,	O
2010	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

A	O
likely	O
scenario	O
is	O
that	O
p53	B-Protein
-	O
binding	O
proteins	O
,	O
which	O
are	O
present	O
in	O
GBMs	O
,	O
may	O
interfere	O
with	O
the	O
apoptotic	O
function	O
of	O
WWOX	B-Protein
and	O
p53	B-Protein
.	O

Functional	O
antagonism	O
among	O
tumor	O
suppressors	O
has	O
never	O
been	O
documented	O
in	O
the	O
literature	O
.	O

However	O
,	O
it	O
is	O
not	O
surprising	O
to	O
find	O
that	O
many	O
tumor	O
suppressor	O
proteins	O
,	O
e	O
.	O
g	O
.	O
,	O
p53	B-Protein
,	O
WWOX	B-Protein
,	O
Smad4	B-Protein
,	O
PTEN	B-Protein
,	O
PP2A	O
,	O
and	O
etc	O
.	O
,	O
are	O
significantly	O
upregulated	O
during	O
the	O
early	O
stage	O
of	O
cancer	O
progression	O
(	O
Lai	O
et	O
al	O
.	O
,	O
2005	O
;	O
Chang	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Do	O
these	O
proteins	O
act	O
synergistically	O
in	O
blocking	O
cancer	O
progression	O
but	O
lose	O
control	O
eventually	O
?	O

Or	O
,	O
do	O
they	O
counteract	O
each	O
other	O
'	O
s	O
function	O
,	O
thus	O
allowing	O
cancer	O
growth	O
?	O

Whether	O
endogenous	O
WWOX	B-Protein
counteracts	O
with	O
the	O
function	O
of	O
endogenous	O
p53	B-Protein
is	O
unknown	O
and	O
remains	O
to	O
be	O
established	O
.	O

One	O
of	O
the	O
unique	O
characteristics	O
for	O
malignant	O
gliomas	O
is	O
their	O
diffuse	O
infiltration	O
into	O
distant	O
brain	O
tissue	O
.	O

Signal	O
pathways	O
,	O
involving	O
PI3K	O
,	O
Akt	B-Protein
,	O
mTOR	B-Protein
,	O
NF	O
-	O
kappaB	O
,	O
and	O
autophagy	O
,	O
are	O
believed	O
to	O
confer	O
these	O
migrating	O
cells	O
resistant	O
to	O
apoptotic	O
death	O
(	O
Lefranc	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Glioma	O
cells	O
possess	O
CD44	B-Protein
as	O
a	O
receptor	O
for	O
interacting	O
with	O
brain	O
matrix	O
hyaluronan	O
(	O
Murai	O
et	O
al	O
.	O
,	O
2004	O
;	O
Yoshida	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
and	O
secrete	O
hyaluronidases	O
and	O
metalloproteinases	O
to	O
facilitate	O
their	O
migration	O
(	O
Delpech	O
et	O
al	O
.	O
,	O
2002	O
;	O
Junker	O
et	O
al	O
.	O
,	O
2003	O
;	O
Hagemann	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Also	O
,	O
lack	O
of	O
WWOX	B-Protein
expression	O
is	O
expected	O
to	O
enhance	O
cell	O
migration	O
.	O

For	O
example	O
,	O
loss	O
of	O
WWOX	B-Protein
facilitates	O
migration	O
of	O
ovarian	O
cancer	O
and	O
osteosarcoma	O
cells	O
(	O
Gourley	O
et	O
al	O
.	O
,	O
2009	O
;	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Ectopic	O
expression	O
of	O
TIAF1	B-Protein
(	O
TGF	O
-	O
beta	O
-	O
induced	O
antiapoptotic	O
factor	O
)	O
,	O
p53	B-Protein
,	O
and	O
WWOX	B-Protein
suppresses	O
anchorage	O
-	O
independent	O
growth	O
and	O
cell	O
migration	O
and	O
causes	O
apoptosis	O
in	O
cancer	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

We	O
believe	O
that	O
glioma	O
cells	O
,	O
with	O
stem	O
cell	O
-	O
like	O
properties	O
,	O
migrate	O
individually	O
rather	O
than	O
collectively	O
.	O

This	O
assumption	O
is	O
based	O
upon	O
our	O
observations	O
that	O
mouse	O
Wwox	B-Protein
gene	O
knockout	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
embryonic	O
fibroblasts	O
)	O
migrate	O
individually	O
and	O
aggressively	O
.	O

In	O
contrast	O
,	O
wild	O
type	O
cells	O
migrate	O
collectively	O
(	O
Chou	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

While	O
a	O
portion	O
of	O
WWOX	B-Protein
is	O
anchored	O
on	O
the	O
cell	O
membrane	O
/	O
cytoskeleton	O
,	O
WWOX	B-Protein
-	O
negative	O
cells	O
lose	O
recognition	O
by	O
parental	O
WWOX	B-Protein
-	O
positive	O
cells	O
,	O
and	O
this	O
increases	O
the	O
mobility	O
of	O
WWOX	B-Protein
-	O
negative	O
cells	O
to	O
move	O
away	O
from	O
the	O
WWOX	B-Protein
-	O
positive	O
cells	O
.	O

Conceivably	O
,	O
WWOX	B-Protein
-	O
negative	O
glioma	O
cells	O
migrate	O
individually	O
and	O
turn	O
away	O
from	O
WWOX	B-Protein
-	O
expressing	O
brain	O
cells	O
to	O
low	O
WWOX	B-Protein
expression	O
areas	O
.	O

Apparently	O
,	O
the	O
migratory	O
behavior	O
of	O
WWOX	B-Protein
-	O
negative	O
glioma	O
cells	O
may	O
account	O
for	O
the	O
diffuse	O
invasion	O
into	O
distant	O
brain	O
tissue	O
(	O
Chou	O
et	O
al	O
.	O
,	O
unpublished	O
)	O
.	O

Metabolic	O
alterations	O
have	O
been	O
shown	O
in	O
Wwox	B-Protein
knockout	O
mice	O
,	O
including	O
postnatal	O
lethality	O
,	O
bone	O
metabolism	O
defects	O
,	O
ataxia	O
,	O
steroidogenesis	O
,	O
and	O
generation	O
of	O
osteosarcomas	O
(	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

In	O
a	O
Drosophila	O
model	O
,	O
Wwox	B-Protein
is	O
shown	O
to	O
participate	O
in	O
pathways	O
involving	O
aerobic	O
metabolism	O
and	O
oxidative	O
stress	O
for	O
generation	O
of	O
ROS	O
(	O
O	O
'	O
Keefe	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

Under	O
UV	O
stress	O
,	O
functional	O
Wwox	B-Protein
gene	O
expression	O
induces	O
ROS	O
production	O
in	O
Drosophila	O
.	O

Cancer	O
cells	O
are	O
known	O
to	O
overly	O
utilize	O
glycolysis	O
for	O
growth	O
advantage	O
-	O
the	O
so	O
-	O
called	O
Warburg	O
(	O
Moncada	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Conceivably	O
,	O
WWOX	B-Protein
is	O
likely	O
to	O
override	O
glucose	O
consumption	O
in	O
cancer	O
cells	O
and	O
exerts	O
generation	O
of	O
ROS	O
to	O
curb	O
the	O
cancer	O
cell	O
growth	O
and	O
invasion	O
.	O

In	O
summary	O
,	O
in	O
this	O
perspective	O
article	O
we	O
have	O
discussed	O
the	O
potential	O
role	O
of	O
tumor	O
suppressors	O
p53	B-Protein
and	O
WWOX	B-Protein
in	O
regulating	O
TMZ	O
sensitivity	O
in	O
GBM	O
cells	O
.	O

We	O
have	O
shown	O
the	O
role	O
of	O
WWOX	B-Protein
in	O
controlling	O
cell	O
migration	O
and	O
metabolic	O
alterations	O
,	O
and	O
discussed	O
the	O
effects	O
of	O
WWOX	B-Protein
deficiency	O
and	O
TMZ	O
resistance	O
in	O
cancer	O
cells	O
.	O

Ming	O
-	O
Fu	O
Chiang	O
and	O
Chun	O
-	O
I	O
Sze	O
wrote	O
the	O
sections	O
dealing	O
with	O
TMZ	O
;	O
Pei	O
-	O
Yi	O
Chou	O
wrote	O
the	O
review	O
sections	O
for	O
p53	B-Protein
and	O
WWOX	B-Protein
and	O
designed	O
graphs	O
;	O
Wan	O
-	O
Jen	O
Wang	O
managed	O
citations	O
;	O
Nan	O
-	O
Shan	O
Chang	O
conceived	O
ideas	O
,	O
wrote	O
and	O
thoroughly	O
revised	O
the	O
manuscript	O
,	O
and	O
discussed	O
with	O
coauthors	O
.	O

The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
<EOS>	B-X
The	B-X
research	B-X
in	B-X
this	B-X
article	B-X
aims	B-X
to	B-X
explore	B-X
how	B-X
to	B-X
use	B-X
health	B-X
and	B-X
medical	B-X
resources	B-X
fairly	B-X
and	B-X
effectively	B-X
to	B-X
allocate	B-X
health	B-X
resources	B-X
in	B-X
different	B-X
fields	B-X
,	B-X
populations	B-X
and	B-X
projects	B-X
,	B-X
in	B-X
order	B-X
to	B-X
achieve	B-X
the	B-X
maximization	B-X
of	B-X
social	B-X
and	B-X
economic	B-X
benefits	B-X
of	B-X
health	B-X
and	B-X
medical	B-X
resources	B-X
.	B-X
In	B-X
the	B-X
study	B-X
of	B-X
the	B-X
distribution	B-X
and	B-X
equity	B-X
of	B-X
public	B-X
health	B-X
and	B-X
medical	B-X
resources	B-X
,	B-X
we	B-X
comprehensively	B-X
apply	B-X
Gini	B-X
coefficient	B-X
,	B-X
Theil	B-X
index	B-X
,	B-X
Lorentz	B-X
curve	B-X
and	B-X
difference	B-X
index	B-X
,	B-X
based	B-X
on	B-X
the	B-X
theory	B-X
of	B-X
health	B-X
resource	B-X
allocation	B-X
and	B-X
the	B-X
theory	B-X
of	B-X
health	B-X
equity	B-X
,	B-X
the	B-X
province	B-X
's	B-X
health	B-X
service	B-X
resources	B-X
have	B-X
been	B-X
researched	B-X
and	B-X
evaluated	B-X
,	B-X
combined	B-X
with	B-X
regional	B-X
health	B-X
planning	B-X
theories	B-X
and	B-X
public	B-X
health	B-X
theories	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
scientific	B-X
methods	B-X
were	B-X
used	B-X
to	B-X
analyze	B-X
community	B-X
health	B-X
service	B-X
resources	B-X
at	B-X
all	B-X
levels	B-X
across	B-X
the	B-X
country	B-X
.	B-X
The	B-X
research	B-X
in	B-X
this	B-X
paper	B-X
found	B-X
that	B-X
from	B-X
2016	B-X
to	B-X
2020	B-X
,	B-X
the	B-X
Gini	B-X
coefficient	B-X
of	B-X
the	B-X
province	B-X
's	B-X
health	B-X
institutions	B-X
according	B-X
to	B-X
population	B-X
distribution	B-X
has	B-X
been	B-X
fluctuating	B-X
between	B-X
0.14	B-X
and	B-X
0.17	B-X
.	B-X
Editorial	B-X
:	B-X
Discounting	B-X
Models	B-X
in	B-X
Behavioral	B-X
Health	B-X
Economics	B-X
and	B-X
Quantitative	B-X
Health	B-X
Psychology	B-X
.	B-X

Schematic	O
diagrams	O
of	O
WWOX	B-Protein
structure	O
and	O
its	O
role	O
in	O
signaling	O
.	O

WWOX	B-Protein
contains	O
two	O
N	O
-	O
terminal	O
WW	O
domains	O
,	O
a	O
C	O
-	O
terminal	O
short	O
-	O
chain	O
alcohol	O
dehydrogenase	O
/	O
reductase	O
(	O
SDR	O
)	O
domain	O
,	O
and	O
a	O
D3	O
region	O
.	O

A	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
is	O
in	O
between	O
the	O
WW	O
domains	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2003	O
,	O
2007	O
;	O
Del	O
Mare	O
et	O
al	O
.	O
,	O
2011	O
;	O
Salah	O
et	O
al	O
.	O
,	O
2012	O
;	O
Su	O
et	O
al	O
.	O
,	O
2012	O
;	O
reviews	O
)	O
.	O

The	O
SDR	O
domain	O
possesses	O
a	O
mitochondria	O
-	O
binding	O
region	O
.	O

There	O
are	O
two	O
conserved	O
tyrosine	O
phosphorylation	O
sites	O
,	O
Tyr33	O
and	O
Tyr287	O
.	O

Other	O
phosphorylation	O
sites	O
predicted	O
by	O
NetPhos	O
2	O
.	O
0	O
Server	O
are	O
Tyr6	O
,	O
Thr12	O
,	O
Ser14	O
,	O
Tyr61	O
,	O
Tyr293	O
,	O
and	O
Thr3B3	O
,	O
respectively	O
.	O

Upon	O
stress	O
stimulation	O
,	O
WWOX	B-Protein
is	O
phosphorylated	O
in	O
Tyr33	O
and	O
binds	O
p53	B-Protein
.	O

The	O
WWOX	O
/	O
p53	O
complex	O
then	O
translocates	O
to	O
mitochondria	O
or	O
nucleus	O
to	O
induce	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
concept	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
as	B-X
an	B-X
essential	B-X
part	B-X
of	B-X
the	B-X
development	B-X
and	B-X
life	B-X
of	B-X
complex	B-X
organisms	B-X
has	B-X
been	B-X
devised	B-X
in	B-X
different	B-X
situations	B-X
and	B-X
tested	B-X
from	B-X
various	B-X
angles	B-X
.	B-X
This	B-X
review	B-X
article	B-X
discusses	B-X
the	B-X
morphological	B-X
changes	B-X
during	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
In	B-X
cells	B-X
undergoing	B-X
apoptosis	B-X
,	B-X
an	B-X
intracellular	B-X
signalling	B-X
pathway	B-X
operates	B-X
cell	B-X
autonomously	B-X
to	B-X
implement	B-X
the	B-X
death	B-X
and	B-X
disposal	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
The	B-X
similarity	B-X
of	B-X
the	B-X
biochemical	B-X
events	B-X
during	B-X
apoptosis	B-X
in	B-X
different	B-X
situations	B-X
is	B-X
reflected	B-X
by	B-X
a	B-X
high	B-X
uniformity	B-X
of	B-X
morphological	B-X
changes	B-X
in	B-X
many	B-X
situations	B-X
of	B-X
naturally	B-X
occurring	B-X
or	B-X
experimentally	B-X
induced	B-X
cell	B-X
death	B-X
.	B-X
The	B-X
unifying	B-X
concept	B-X
of	B-X
apoptosis	B-X
has	B-X
been	B-X
derived	B-X
from	B-X
the	B-X
observation	B-X
of	B-X
this	B-X
morphological	B-X
consistency	B-X
of	B-X
dying	B-X
cells	B-X
almost	B-X
30	B-X
years	B-X
ago	B-X
.	B-X

WWOX	B-Protein
also	O
binds	O
PPxY	O
motif	O
-	O
containing	O
transcription	O
factors	O
,	O
such	O
as	O
RUNX2	B-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
ERBB4	B-Protein
,	O
via	O
its	O
first	O
WW	O
domain	O
,	O
and	O
the	O
binding	O
blocks	O
the	O
activity	O
of	O
these	O
proteins	O
by	O
retaining	O
them	O
in	O
the	O
cytoplasm	O
.	O

WWOX	B-Protein
binds	O
Tau	B-Protein
via	O
its	O
SDR	O
domain	O
.	O
<EOS>	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
(	B-X
WWOX	B-X
)	B-X
is	B-X
known	B-X
as	B-X
one	B-X
of	B-X
the	B-X
risk	B-X
factors	B-X
for	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
,	B-X
a	B-X
neurodegenerative	B-X
disease	B-X
.	B-X
WWOX	B-X
binds	B-X
Tau	B-X
via	B-X
its	B-X
C-terminal	B-X
SDR	B-X
domain	B-X
and	B-X
interacts	B-X
with	B-X
Tau	B-X
phosphorylating	B-X
enzymes	B-X
ERK	B-X
,	B-X
JNK	B-X
,	B-X
and	B-X
GSK-3β	B-X
,	B-X
and	B-X
thereby	B-X
limits	B-X
AD	B-X
progression	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
in	B-X
newborns	B-X
leads	B-X
to	B-X
severe	B-X
neural	B-X
diseases	B-X
and	B-X
early	B-X
death	B-X
.	B-X
Gradual	B-X
loss	B-X
of	B-X
WWOX	B-X
protein	B-X
in	B-X
the	B-X
hippocampus	B-X
and	B-X
cortex	B-X
starting	B-X
from	B-X
middle	B-X
age	B-X
may	B-X
slowly	B-X
induce	B-X
aggregation	B-X
of	B-X
a	B-X
protein	B-X
cascade	B-X
that	B-X
ultimately	B-X
causes	B-X
accumulation	B-X
of	B-X
extracellular	B-X
amyloid	B-X
beta	B-X
plaques	B-X
and	B-X
intracellular	B-X
tau	B-X
tangles	B-X
,	B-X
along	B-X
with	B-X
reduction	B-X
in	B-X
inhibitory	B-X
GABAergic	B-X
interneurons	B-X
,	B-X
in	B-X
AD	B-X
patients	B-X
over	B-X
70	B-X
years	B-X
old	B-X
.	B-X
Age-related	B-X
increases	B-X
in	B-X
pS14-WWOX	B-X
accumulation	B-X
in	B-X
the	B-X
brain	B-X
promotes	B-X
neuronal	B-X
degeneration	B-X
.	B-X
Intriguingly	B-X
,	B-X
tumor	B-X
suppressors	B-X
p53	B-X
and	B-X
WWOX	B-X
may	B-X
counteract	B-X
each	B-X
other	B-X
in	B-X
vivo	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
upregulation	B-X
of	B-X
AD-related	B-X
protein	B-X
aggregation	B-X
in	B-X
the	B-X
brain	B-X
and	B-X
lung	B-X
.	B-X
WWOX	B-X
has	B-X
numerous	B-X
binding	B-X
proteins	B-X
.	B-X
We	B-X
reported	B-X
that	B-X
the	B-X
stronger	B-X
the	B-X
binding	B-X
between	B-X
WWOX	B-X
and	B-X
its	B-X
partners	B-X
,	B-X
the	B-X
better	B-X
the	B-X
suppression	B-X
of	B-X
cancer	B-X
growth	B-X
and	B-X
reduction	B-X
in	B-X
inflammation	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
stronger	B-X
complex	B-X
formation	B-X
between	B-X
WWOX	B-X
and	B-X
partners	B-X
may	B-X
provide	B-X
a	B-X
better	B-X
blockade	B-X
of	B-X
AD	B-X
progression	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
describe	B-X
whether	B-X
and	B-X
how	B-X
WWOX	B-X
and	B-X
partner	B-X
proteins	B-X
control	B-X
inflammatory	B-X
response	B-X
and	B-X
protein	B-X
aggregation	B-X
and	B-X
thereby	B-X
limit	B-X
AD	B-X
progression	B-X
.	B-X

WWOX	B-Protein
participates	O
in	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signal	O
pathway	O
by	O
binding	O
Dvl	O
and	O
inhibiting	O
its	O
nuclear	O
import	O
.	O

Phorbol	O
ester	O
stimulates	O
the	O
dissociation	O
of	O
MEK	O
/	O
WWOX	O
complex	O
in	O
Jurkat	O
T	O
cell	O
,	O
and	O
the	O
released	O
WWOX	B-Protein
translocates	O
to	O
the	O
mitochondria	O
for	O
causing	O
cell	O
death	O
.	O

WWOX	B-Protein
is	O
recruited	O
to	O
the	O
membrane	O
area	O
by	O
association	O
with	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
and	O
phospho	O
-	O
Ezrin	B-Protein
.	O

Hyal	B-Protein
-	I-Protein
2	I-Protein
is	O
an	O
alternative	O
receptor	O
for	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
.	O

In	O
response	O
to	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
,	O
WWOX	B-Protein
binds	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
and	O
forms	O
a	O
complex	O
,	O
followed	O
by	O
relocating	O
to	O
the	O
nucleus	O
and	O
enhancing	O
the	O
SMAD	O
-	O
driven	O
promoter	O
activity	O
.	O

Ack1	B-Protein
,	O
activated	B-Protein
Cdc42	I-Protein
-	I-Protein
associated	I-Protein
kinase	I-Protein
1	I-Protein
;	O
Hyal	B-Protein
-	I-Protein
2	I-Protein
,	O
hyaluronoglucosaminidase	B-Protein
2	I-Protein
;	O
CKI	O
,	O
casein	O
kinase	O
;	O
GSK	O
,	O
glycogen	O
synthase	O
kinase	O
;	O
PKA	O
,	O
protein	O
kinase	O
A	O
.	O
<EOS>	B-X
Activated	B-X
Cdc42-associated	B-X
kinase	B-X
1	B-X
(	B-X
ACK1/TNK2	B-X
)	B-X
is	B-X
a	B-X
nonreceptor	B-X
tyrosine	B-X
kinase	B-X
with	B-X
a	B-X
unique	B-X
structure	B-X
.	B-X
It	B-X
not	B-X
only	B-X
can	B-X
act	B-X
as	B-X
an	B-X
activated	B-X
transmembrane	B-X
effector	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
(	B-X
RTKs	B-X
)	B-X
to	B-X
transmit	B-X
various	B-X
RTK	B-X
signals	B-X
but	B-X
also	B-X
can	B-X
play	B-X
a	B-X
corresponding	B-X
role	B-X
in	B-X
epigenetic	B-X
regulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ACK1	B-X
is	B-X
a	B-X
carcinogenic	B-X
factor	B-X
.	B-X
Blockage	B-X
of	B-X
ACK1	B-X
has	B-X
been	B-X
proven	B-X
to	B-X
be	B-X
able	B-X
to	B-X
inhibit	B-X
cancer	B-X
cell	B-X
survival	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
and	B-X
radiation	B-X
resistance	B-X
.	B-X
Thus	B-X
,	B-X
ACK1	B-X
is	B-X
a	B-X
promising	B-X
potential	B-X
antitumor	B-X
target	B-X
.	B-X
To	B-X
date	B-X
,	B-X
despite	B-X
many	B-X
efforts	B-X
to	B-X
develop	B-X
ACK1	B-X
inhibitors	B-X
,	B-X
no	B-X
specific	B-X
small	B-X
molecule	B-X
inhibitors	B-X
have	B-X
entered	B-X
clinical	B-X
trials	B-X
.	B-X
This	B-X
Perspective	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
structural	B-X
features	B-X
,	B-X
biological	B-X
functions	B-X
,	B-X
and	B-X
association	B-X
with	B-X
diseases	B-X
of	B-X
ACK1	B-X
and	B-X

p53	B-Protein
and	O
WWOX	B-Protein
in	O
GBM	O
cell	O
apoptosis	O
.	O
<EOS>	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

(	O
A	O
)	O
Full	O
-	O
length	O
p53	B-Protein
possesses	O
two	O
N	O
-	O
terminal	O
transactivation	O
acidic	O
domains	O
,	O
a	O
proline	O
-	O
rich	O
domain	O
,	O
a	O
central	O
DNA	O
-	O
binding	O
region	O
,	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
,	O
containing	O
a	O
nuclear	O
localization	O
signal	O
,	O
an	O
oligomerization	O
domain	O
,	O
and	O
a	O
basic	O
region	O
.	O

N	O
-	O
terminal	O
deletion	O
mutants	O
of	O
p53	B-Protein
are	O
also	O
shown	O
.	O
<EOS>	B-X
TP53INP2/DOR	B-X
(	B-X
tumor	B-X
protein	B-X
p53-inducible	B-X
nuclear	B-X
protein	B-X
2	B-X
)	B-X
contributes	B-X
to	B-X
mammalian	B-X
macroautophagy/autophagy	B-X
by	B-X
carrying	B-X
nuclear	B-X
deacetylated	B-X
MAP1LC3/LC3	B-X
to	B-X
the	B-X
cytoplasm	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
TP53INP2	B-X
further	B-X
functions	B-X
in	B-X
autophagosome	B-X
biogenesis	B-X
by	B-X
promoting	B-X
LC3B-ATG7	B-X
interaction	B-X
.	B-X
Cytoplasmic	B-X
expression	B-X
of	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
TP53INP2	B-X
,	B-X
which	B-X
includes	B-X
the	B-X
LC3-interacting	B-X
region	B-X
,	B-X
effectively	B-X
triggered	B-X
LC3B-PE	B-X
production	B-X
and	B-X
autophagosome	B-X
formation	B-X
.	B-X
In	B-X
the	B-X
cytoplasm	B-X
,	B-X
TP53INP2	B-X
colocalized	B-X
to	B-X
early	B-X
autophagic	B-X
membrane	B-X
structures	B-X
containing	B-X
ATG14	B-X
,	B-X
ZFYVE1/DFCP1	B-X
or	B-X
WIPI2	B-X
.	B-X

(	O
B	O
)	O
Three	O
likely	O
scenarios	O
are	O
proposed	O
for	O
WWOX	B-Protein
and	O
p53	B-Protein
to	O
regulate	O
GBM	O
cell	O
death	O
.	O

First	O
,	O
ectopic	O
WWOX	B-Protein
fails	O
to	O
induce	O
apoptosis	O
of	O
GBM	O
cells	O
expressing	O
endogenous	O
wild	O
type	O
p53	B-Protein
.	O

It	O
appears	O
that	O
ectopic	O
WWOX	B-Protein
binds	O
and	O
functionally	O
antagonizes	O
p53	B-Protein
,	O
and	O
both	O
proteins	O
nullify	O
each	O
other	O
'	O
s	O
function	O
in	O
inducing	O
apoptosis	O
.	O

Second	O
,	O
no	O
physical	O
interactions	O
between	O
mutant	O
p53	B-Protein
proteins	O
and	O
WWOX	B-Protein
are	O
expected	O
in	O
GBM	O
cells	O
.	O

Thus	O
,	O
ectopic	O
WWOX	B-Protein
induce	O
apoptosis	O
in	O
mutant	O
p53	B-Protein
-	O
expressing	O
cells	O
.	O
<EOS>	B-X
Human	B-X
WWOX	B-X
gene	B-X
encoding	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
,	B-X
named	B-X
WWOX	B-X
,	B-X
FOR	B-X
,	B-X
or	B-X
WOX1	B-X
,	B-X
has	B-X
been	B-X
studied	B-X
in	B-X
various	B-X
types	B-X
of	B-X
cancer	B-X
cells	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
tumor	B-X
suppressor	B-X
with	B-X
pro-apoptotic	B-X
properties	B-X
.	B-X
Mutation	B-X
or	B-X
gain-of-function	B-X
of	B-X
p53	B-X
in	B-X
glioma	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
resistance	B-X
to	B-X
radiation	B-X
therapy	B-X
and	B-X
poor	B-X
prognosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
overexpressed	B-X
WOX1	B-X
to	B-X
examine	B-X
the	B-X
pro-apoptotic	B-X
activity	B-X
against	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
Tumor	B-X
suppressor	B-X
p53	B-X
are	B-X
frequently	B-X
mutated	B-X
in	B-X
glioblastomas	B-X
(	B-X
GBMs	B-X
)	B-X
and	B-X
appears	B-X
to	B-X
contribute	B-X
,	B-X
in	B-X
part	B-X
,	B-X
to	B-X
resistance	B-X
to	B-X
temozolomide	B-X
(	B-X
TMZ	B-X
)	B-X
and	B-X
therapeutic	B-X
drugs	B-X
.	B-X
WW	B-X
domain-containing	B-X
oxidoreductase	B-X
WWOX	B-X
(	B-X
FOR	B-X
or	B-X
WOX1	B-X
)	B-X
is	B-X
a	B-X
proapoptotic	B-X
protein	B-X
and	B-X
is	B-X
considered	B-X
as	B-X
a	B-X
tumor	B-X
suppressor	B-X
.	B-X
Loss	B-X
of	B-X
WWOX	B-X
gene	B-X
expression	B-X
is	B-X
frequently	B-X
seen	B-X
in	B-X
malignant	B-X
cancer	B-X
cells	B-X
due	B-X
to	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
genetic	B-X
alterations	B-X
,	B-X
and	B-X
translational	B-X
blockade	B-X
.	B-X
Intriguingly	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
WWOX	B-X
preferentially	B-X
induces	B-X
apoptosis	B-X
in	B-X
human	B-X
glioblastoma	B-X
cells	B-X
harboring	B-X
mutant	B-X
p53	B-X
.	B-X
WWOX	B-X
is	B-X
known	B-X
to	B-X
physically	B-X
bind	B-X
and	B-X
stabilize	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
updated	B-X
knowledge	B-X
in	B-X
p53	B-X
and	B-X
WWOX	B-X
,	B-X
and	B-X
postulate	B-X
potential	B-X
scenarios	B-X
that	B-X
wild	B-X
type	B-X
and	B-X
mutant	B-X
p53	B-X
,	B-X
or	B-X
isoforms	B-X
,	B-X
modulate	B-X
the	B-X
apoptotic	B-X
function	B-X
of	B-X
WWOX	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
triggering	B-X
WWOX	B-X
activation	B-X
by	B-X
therapeutic	B-X
drugs	B-X
under	B-X
p53	B-X
functional	B-X
deficiency	B-X
is	B-X
needed	B-X
to	B-X
overcome	B-X
TMZ	B-X
resistance	B-X
and	B-X
induce	B-X
GBM	B-X
cell	B-X
death	B-X
.	B-X

Finally	O
,	O
whether	O
WWOX	B-Protein
binds	O
p53	B-Protein
isoforms	O
is	O
unknown	O
.	O

Also	O
,	O
whether	O
ectopic	O
WWOX	B-Protein
induction	O
of	O
apoptosis	O
in	O
GBM	O
cells	O
expressing	O
p53	B-Protein
isoforms	O
remains	O
to	O
be	O
established	O
.	O

TAD	O
,	O
transactivation	O
domain	O
;	O
PrD	O
,	O
proline	O
domain	O
;	O
NLS	O
,	O
nuclear	O
localization	O
signal	O
;	O
OD	O
,	O
oligomerization	O
domain	O
;	O
BR	O
,	O
basic	O
region	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
in	B-X
acute	B-X
leukaemias	B-X
,	B-X
EZH2	B-X
has	B-X
additional	B-X
noncanonical	B-X
functions	B-X
by	B-X
binding	B-X
cMyc	B-X
at	B-X
non-PRC2	B-X
targets	B-X
and	B-X
uses	B-X
a	B-X
hidden	B-X
transactivation	B-X
domain	B-X
(	B-X
TAD	B-X
)	B-X
for	B-X
(	B-X
co	B-X
)	B-X
activator	B-X
recruitment	B-X
and	B-X
gene	B-X
activation	B-X
.	B-X
Both	B-X
canonical	B-X
(	B-X
EZH2-PRC2	B-X
)	B-X
and	B-X
noncanonical	B-X
(	B-X
EZH2-TAD-cMyc-coactivators	B-X
)	B-X
activities	B-X
of	B-X
EZH2	B-X
promote	B-X
oncogenesis	B-X
,	B-X
which	B-X
explains	B-X
the	B-X
slow	B-X
and	B-X
ineffective	B-X
antitumour	B-X
effect	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
catalytic	B-X
function	B-X
of	B-X
EZH2	B-X
.	B-X
HOTTIP	B-X
lncRNA	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
driven	B-X
by	B-X
MLL	B-X
rearrangements	B-X
or	B-X
NPM1	B-X
mutations	B-X
to	B-X
mediate	B-X
HOXA	B-X
topologically	B-X
associated	B-X
domain	B-X
(	B-X
TAD	B-X
)	B-X
formation	B-X
and	B-X
drive	B-X
aberrant	B-X
transcription	B-X
.	B-X
HOTTIP-mediated	B-X
R-loops	B-X
reinforce	B-X
the	B-X
CTCF	B-X
boundary	B-X
and	B-X
facilitate	B-X
formation	B-X
of	B-X
TADs	B-X
to	B-X
drive	B-X
gene	B-X
transcription	B-X
.	B-X
Either	B-X
deleting	B-X
CBS	B-X
or	B-X
targeting	B-X
RNase	B-X
H	B-X
to	B-X
eliminate	B-X
R-loops	B-X
in	B-X
the	B-X
boundary	B-X
CBS	B-X
of	B-X
β-catenin	B-X
TAD	B-X
impaired	B-X
CTCF	B-X
boundary	B-X
activity	B-X
,	B-X
inhibited	B-X
promoter/enhancer	B-X
interactions	B-X
,	B-X
reduced	B-X
β-catenin	B-X
target	B-X
expression	B-X
,	B-X
and	B-X
mitigated	B-X
leukemogenesis	B-X
in	B-X
xenograft	B-X
mouse	B-X
models	B-X
with	B-X
aberrant	B-X
HOTTIP	B-X
expression	B-X
.	B-X
Thus	B-X
,	B-X
HOTTIP-mediated	B-X
R-loop	B-X
formation	B-X
directly	B-X
reinforces	B-X
CTCF	B-X
chromatin	B-X
boundary	B-X
activity	B-X
and	B-X
TAD	B-X
integrity	B-X
to	B-X
drive	B-X
oncogene	B-X
transcription	B-X
and	B-X
leukemia	B-X
development	B-X
.	B-X

The	O
Transcription	O
Factor	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Mediates	O
Constitutive	O
and	O
LPS	O
-	O
Inducible	O
Transcription	O
of	O
Murine	O
SerpinB2	B-Protein
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

SerpinB2	B-Protein
or	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
type	I-Protein
2	I-Protein
(	O
PAI	B-Protein
-	I-Protein
2	I-Protein
)	O
is	O
highly	O
induced	O
in	O
macrophages	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
and	O
is	O
linked	O
to	O
the	O
modulation	O
of	O
innate	O
immunity	O
,	O
macrophage	O
survival	O
,	O
and	O
inhibition	O
of	O
plasminogen	O
activators	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
SerpinB2	B-X
,	B-X
a	B-X
regulator	B-X
of	B-X
inflammatory	B-X
processes	B-X
,	B-X
has	B-X
been	B-X
described	B-X
in	B-X
the	B-X
context	B-X
of	B-X
macrophage	B-X
activation	B-X
and	B-X
cellular	B-X
senescence	B-X
.	B-X
Given	B-X
that	B-X
mechanisms	B-X
for	B-X
these	B-X
processes	B-X
interact	B-X
and	B-X
can	B-X
shape	B-X
kidney	B-X
disease	B-X
,	B-X
it	B-X
seems	B-X
plausible	B-X
that	B-X
SerpinB2	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
renal	B-X
aging	B-X
,	B-X
injury	B-X
,	B-X
and	B-X
repair	B-X
.	B-X
Although	B-X
some	B-X
of	B-X
the	B-X
key	B-X
genes	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
are	B-X
known	B-X
,	B-X
no	B-X
previous	B-X
study	B-X
has	B-X
compared	B-X
the	B-X
``	B-X
coagulome	B-X
''	B-X
,	B-X
i.e.	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
coagulation/fibrinolysis	B-X
genes	B-X
,	B-X
across	B-X
different	B-X
primary	B-X
tumor	B-X
types	B-X
.	B-X
Interleukin	B-X
11	B-X
(	B-X
IL11	B-X
)	B-X
is	B-X
upregulated	B-X
in	B-X
inflammatory	B-X
conditions	B-X
,	B-X
where	B-X
it	B-X
is	B-X
mostly	B-X
believed	B-X
to	B-X
have	B-X
anti-inflammatory	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
assessed	B-X
whether	B-X
IL11	B-X
is	B-X
pro-	B-X
or	B-X
anti-inflammatory	B-X
in	B-X
fibroblasts	B-X
.	B-X
Primary	B-X
cultures	B-X
of	B-X
human	B-X
kidney	B-X
,	B-X
lung	B-X
or	B-X
skin	B-X
fibroblasts	B-X
were	B-X
stimulated	B-X
with	B-X
IL11	B-X
that	B-X
resulted	B-X
in	B-X
the	B-X
transient	B-X
phosphorylation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
and	B-X
the	B-X
sustained	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
protein	B-X
kinases	B-X
(	B-X
ERK	B-X
)	B-X
.	B-X
RNA	B-X
sequencing	B-X
over	B-X
a	B-X
time	B-X
course	B-X
of	B-X
IL11	B-X
stimulation	B-X
revealed	B-X
a	B-X
robust	B-X
but	B-X
short-lived	B-X
transcriptional	B-X
response	B-X
that	B-X
was	B-X
enriched	B-X
for	B-X
gene	B-X
set	B-X
hallmarks	B-X
of	B-X
inflammation	B-X
and	B-X
characterized	B-X
by	B-X
the	B-X
upregulation	B-X
of	B-X

Lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
a	O
potent	O
bacterial	O
endotoxin	O
,	O
can	O
induce	O
SerpinB2	B-Protein
expression	O
via	O
the	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
(	O
TLR4	B-Protein
)	O
by	O
~	O
1000	O
-	O
fold	O
over	O
a	O
period	O
of	O
24	O
hrs	O
in	O
murine	O
macrophages	O
.	O

To	O
map	O
the	O
LPS	O
-	O
regulated	O
SerpinB2	B-Protein
promoter	O
regions	O
,	O
we	O
transfected	O
reporter	O
constructs	O
driven	O
by	O
the	O
~	O
5	O
kb	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
and	O
several	O
deletion	O
mutants	O
into	O
murine	O
macrophages	O
.	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
murine	B-X
5	B-X
'	B-X
flanking	B-X
sequence	B-X
with	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
human	B-X
gene	B-X
for	B-X
homologous	B-X
functional	B-X
regulatory	B-X
elements	B-X
and	B-X
identified	B-X
several	B-X
regulatory	B-X
cis-acting	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
SERPINB2	B-X
promoter	B-X
conserved	B-X
in	B-X
the	B-X
mouse	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

In	O
addition	O
,	O
we	O
compared	O
the	O
DNA	O
sequence	O
of	O
the	O
murine	O
5	O
'	O
flanking	O
sequence	O
with	O
the	O
sequence	O
of	O
the	O
human	O
gene	O
for	O
homologous	O
functional	O
regulatory	O
elements	O
and	O
identified	O
several	O
regulatory	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
conserved	O
in	O
the	O
mouse	O
.	O
<EOS>	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
murine	B-X
5	B-X
'	B-X
flanking	B-X
sequence	B-X
with	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
human	B-X
gene	B-X
for	B-X
homologous	B-X
functional	B-X
regulatory	B-X
elements	B-X
and	B-X
identified	B-X
several	B-X
regulatory	B-X
cis-acting	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
SERPINB2	B-X
promoter	B-X
conserved	B-X
in	B-X
the	B-X
mouse	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X

Mutation	O
analyses	O
revealed	O
that	O
a	O
CCAAT	O
enhancer	O
binding	O
(	O
C	O
/	O
EBP	O
)	O
element	O
,	O
a	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
two	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
response	O
elements	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
are	O
essential	O
for	O
optimal	O
LPS	O
-	O
inducibility	O
.	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
murine	B-X
5	B-X
'	B-X
flanking	B-X
sequence	B-X
with	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
human	B-X
gene	B-X
for	B-X
homologous	B-X
functional	B-X
regulatory	B-X
elements	B-X
and	B-X
identified	B-X
several	B-X
regulatory	B-X
cis-acting	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
SERPINB2	B-X
promoter	B-X
conserved	B-X
in	B-X
the	B-X
mouse	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

Electrophoretic	O
mobility	O
shift	O
(	O
EMSA	O
)	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
demonstrated	O
that	O
LPS	O
induces	O
the	O
formation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
containing	O
complexes	O
with	O
the	O
SerpinB2	B-Protein
promoter	O
.	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
murine	B-X
5	B-X
'	B-X
flanking	B-X
sequence	B-X
with	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
human	B-X
gene	B-X
for	B-X
homologous	B-X
functional	B-X
regulatory	B-X
elements	B-X
and	B-X
identified	B-X
several	B-X
regulatory	B-X
cis-acting	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
SERPINB2	B-X
promoter	B-X
conserved	B-X
in	B-X
the	B-X
mouse	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

Importantly	O
,	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
expression	O
was	O
severely	O
abrogated	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
primary	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
peritoneal	O
macrophages	O
.	O

Together	O
,	O
these	O
data	O
provide	O
new	O
insight	O
into	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
dependent	O
regulation	O
of	O
inflammation	O
-	O
associated	O
SerpinB2	B-Protein
expression	O
.	O

The	O
inflammatory	O
response	O
is	O
a	O
double	O
-	O
edged	O
sword	O
.	O
<EOS>	B-X
The	B-X
response	B-X
of	B-X
immune	B-X
cells	B-X
in	B-X
cardiac	B-X
injury	B-X
is	B-X
divided	B-X
into	B-X
three	B-X
continuous	B-X
phases	B-X
:	B-X
inflammation	B-X
,	B-X
proliferation	B-X
and	B-X
maturation	B-X
.	B-X
The	B-X
kinetics	B-X
of	B-X
the	B-X
inflammatory	B-X
and	B-X
proliferation	B-X
phases	B-X
directly	B-X
influence	B-X
the	B-X
tissue	B-X
repair	B-X
.	B-X
Meanwhile	B-X
,	B-X
NK	B-X
cells	B-X
prevent	B-X
the	B-X
maturation	B-X
and	B-X
transport	B-X
of	B-X
inflammatory	B-X
cells	B-X
.	B-X
Type	B-X
1	B-X
macrophages	B-X
trigger	B-X
the	B-X
cardioprotective	B-X
responses	B-X
and	B-X
promote	B-X
tissue	B-X
fibrosis	B-X
in	B-X
the	B-X
early	B-X
stage	B-X
.	B-X
Circulating	B-X
macrophages	B-X
and	B-X
neutrophils	B-X
firstly	B-X
lead	B-X
to	B-X
chronic	B-X
inflammation	B-X
by	B-X
secreting	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
and	B-X
then	B-X
release	B-X
anti-inflammatory	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
,	B-X
which	B-X
regulate	B-X
cardiac	B-X
remodeling	B-X
.	B-X
CMs	B-X
protectors	B-X
,	B-X
Treg	B-X
cells	B-X
,	B-X
inhibit	B-X
reduce	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
then	B-X
directly	B-X
trigger	B-X
the	B-X
regeneration	B-X
of	B-X
local	B-X
progenitor	B-X
cell	B-X
via	B-X
IL-10	B-X
.	B-X

Properly	O
orchestrated	O
,	O
it	O
results	O
in	O
the	O
clearing	O
of	O
foreign	O
molecules	O
and	O
invading	O
pathogens	O
from	O
the	O
body	O
.	O

Uncontrolled	O
,	O
it	O
may	O
lead	O
to	O
organ	O
damage	O
,	O
sepsis	O
,	O
and	O
even	O
cancer	O
[	O
1	O
]	O
-	O
[	O
3	O
]	O
.	O

Many	O
of	O
the	O
pathological	O
manifestations	O
of	O
the	O
inflammatory	O
response	O
are	O
mediated	O
by	O
cytokines	O
and	O
other	O
inducible	O
gene	O
products	O
expressed	O
by	O
macrophages	O
upon	O
exposure	O
to	O
the	O
gram	O
-	O
negative	O
bacterial	O
cell	O
wall	O
component	O
LPS	O
.	O

As	O
macrophages	O
are	O
key	O
effectors	O
of	O
pathogen	O
-	O
induced	O
innate	O
immune	O
responses	O
,	O
their	O
survival	O
is	O
critical	O
for	O
initial	O
pathogen	O
neutralization	O
and	O
subsequent	O
development	O
of	O
adaptive	O
immune	O
responses	O
.	O

One	O
of	O
the	O
most	O
LPS	O
-	O
inducible	O
macrophage	O
gene	O
products	O
known	O
is	O
the	O
ovalbumin	O
-	O
like	O
serine	O
protease	O
inhibitor	O
(	O
ov	O
-	O
serpin	O
)	O
SerpinB2	B-Protein
,	O
a	O
widely	O
recognized	O
macrophage	O
survival	O
factor	O
[	O
4	O
]	O
;	O
[	O
5	O
]	O
.	O

SerpinB2	B-Protein
was	O
first	O
identified	O
as	O
an	O
inhibitor	O
of	O
urokinase	B-Protein
-	I-Protein
type	I-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
uPA	B-Protein
)	O
[	O
6	O
]	O
-	O
[	O
8	O
]	O
,	O
a	O
serine	O
protease	O
involved	O
in	O
the	O
degradation	O
and	O
turnover	O
of	O
the	O
extracellular	O
matrix	O
through	O
the	O
activation	O
of	O
plasminogen	B-Protein
[	O
7	O
]	O
;	O
[	O
9	O
]	O
.	O

Such	O
function	O
requires	O
SerpinB2	B-Protein
to	O
be	O
secreted	O
from	O
the	O
cell	O
yet	O
SerpinB2	B-Protein
exists	O
primarily	O
as	O
a	O
nonglycosylated	O
intracellular	O
protein	O
[	O
10	O
]	O
.	O

Over	O
the	O
past	O
decade	O
,	O
intracellular	O
roles	O
for	O
SerpinB2	B-Protein
in	O
cell	O
survival	O
[	O
11	O
]	O
-	O
[	O
17	O
]	O
,	O
proliferation	O
and	O
differentiation	O
[	O
18	O
]	O
-	O
[	O
21	O
]	O
,	O
signal	O
transduction	O
[	O
15	O
]	O
;	O
[	O
22	O
]	O
;	O
[	O
23	O
]	O
and	O
innate	O
immunity	O
[	O
24	O
]	O
-	O
[	O
28	O
]	O
,	O
have	O
been	O
described	O
.	O

The	O
SerpinB2	B-Protein
gene	O
is	O
highly	O
regulated	O
in	O
a	O
cell	O
type	O
specific	O
manner	O
analogous	O
to	O
that	O
of	O
cytokines	O
and	O
oncogenes	O
[	O
29	O
]	O
;	O
[	O
30	O
]	O
.	O

It	O
is	O
one	O
of	O
the	O
most	O
responsive	O
genes	O
known	O
[	O
31	O
]	O
,	O
and	O
can	O
be	O
induced	O
over	O
1000	O
-	O
fold	O
by	O
LPS	O
[	O
31	O
]	O
-	O
[	O
32	O
]	O
,	O
and	O
is	O
up	O
-	O
regulated	O
by	O
a	O
range	O
of	O
inflammatory	O
mediators	O
[	O
9	O
]	O
.	O

LPS	O
activates	O
immune	O
responses	O
through	O
multiple	O
signalling	O
pathways	O
.	O
<EOS>	B-X
Monitoring	B-X
of	B-X
the	B-X
cytosolic	B-X
compartment	B-X
by	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
for	B-X
pathogen-encoded	B-X
products	B-X
or	B-X
pathogen	B-X
activities	B-X
often	B-X
enables	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
caspases	B-X
.	B-X
In	B-X
most	B-X
cases	B-X
,	B-X
the	B-X
cytosolic	B-X
surveillance	B-X
pathways	B-X
are	B-X
coupled	B-X
to	B-X
activation	B-X
of	B-X
caspase-1	B-X
via	B-X
canonical	B-X
inflammasome	B-X
complexes	B-X
.	B-X
A	B-X
related	B-X
set	B-X
of	B-X
caspases	B-X
,	B-X
caspase-11	B-X
in	B-X
rodents	B-X
and	B-X
caspase-4	B-X
and	B-X
caspase-5	B-X
in	B-X
humans	B-X
,	B-X
monitors	B-X
the	B-X
cytosol	B-X
for	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Direct	B-X
activation	B-X
of	B-X
caspase-11	B-X
,	B-X
caspase-4	B-X
and	B-X
caspase-5	B-X
by	B-X
intracellular	B-X
LPS	B-X
elicits	B-X
the	B-X
lytic	B-X
cell	B-X
death	B-X
called	B-X
'pyroptosis	B-X
'	B-X
,	B-X
which	B-X
occurs	B-X
in	B-X
multiple	B-X
cell	B-X
types	B-X
.	B-X
Caspase-11-mediated	B-X
pyroptosis	B-X
in	B-X
response	B-X
to	B-X
cytosolic	B-X
LPS	B-X
is	B-X
critical	B-X
for	B-X
antibacterial	B-X
defense	B-X
and	B-X
septic	B-X
shock	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
emerging	B-X
literature	B-X
on	B-X
the	B-X
sensing	B-X
of	B-X
cytosolic	B-X
LPS	B-X
and	B-X
its	B-X
regulation	B-X
and	B-X
pathophysiological	B-X
functions	B-X
.	B-X

The	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
(	O
TLR4	B-Protein
)	O
is	O
responsible	O
for	O
the	O
recognition	O
of	O
LPS	O
and	O
other	O
microbial	O
products	O
and	O
plays	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
innate	O
immune	O
responses	O
,	O
including	O
cytokine	O
release	O
.	O

The	O
binding	O
of	O
LPS	O
to	O
TLR4	B-Protein
on	O
the	O
surface	O
of	O
macrophages	O
leads	O
to	O
the	O
recruitment	O
of	O
adaptor	O
molecules	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
,	O
generating	O
signals	O
to	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
/	O
or	O
phosphoinositide	O
3	O
(	O
PI3	O
)	O
-	O
kinase	O
pathways	O
[	O
33	O
]	O
.	O
<EOS>	B-X
These	B-X
signaling	B-X
molecules	B-X
are	B-X
difficult	B-X
to	B-X
study	B-X
because	B-X
they	B-X
are	B-X
extremely	B-X
low	B-X
abundance	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
two	B-X
of	B-X
the	B-X
lowest	B-X
abundance	B-X
phosphoinositides	B-X
,	B-X
PI	B-X
(	B-X
3,5	B-X
)	B-X
P	B-X
We	B-X
found	B-X
a	B-X
lens-specific	B-X
cytokinetic	B-X
process	B-X
that	B-X
required	B-X
PI3K-C2α	B-X
(	B-X
phosphatidylinositol-4-phosphate	B-X
3-kinase	B-X
catalytic	B-X
subunit	B-X
type	B-X
2α	B-X
)	B-X
,	B-X
its	B-X
lipid	B-X
product	B-X
PI	B-X
(	B-X
3,4	B-X
)	B-X
P	B-X
The	B-X
plasma	B-X
membrane	B-X
contains	B-X
three	B-X
phosphoinositides	B-X
:	B-X
PI	B-X
(	B-X
4	B-X
)	B-X
P	B-X
,	B-X
PI	B-X
(	B-X
4,5	B-X
)	B-X
P	B-X

In	O
studies	O
aimed	O
at	O
identifying	O
LPS	O
-	O
inducible	O
pro	O
-	O
survival	O
factors	O
downstream	O
of	O
p38	O
MAPK	O
,	O
SerpinB2	B-Protein
was	O
identified	O
as	O
a	O
factor	O
whose	O
expression	O
was	O
upregulated	O
by	O
cooperation	O
of	O
the	O
IKKbeta	B-Protein
/	O
NF	O
-	O
kappaB	O
and	O
p38	O
MAPK	O
/	O
CREB	O
pathways	O
[	O
16	O
]	O
.	O

Our	O
previously	O
published	O
data	O
indicated	O
that	O
SerpinB2	B-Protein
is	O
distinctly	O
regulated	O
from	O
other	O
LPS	O
-	O
inducible	O
genes	O
in	O
terms	O
of	O
kinetics	O
,	O
LPS	O
dose	O
response	O
and	O
sensitivity	O
to	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
co	O
-	O
stimulation	O
[	O
4	O
]	O
;	O
however	O
,	O
the	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
SerpinB2	B-Protein
promoter	O
responsible	O
for	O
LPS	O
-	O
dependent	O
transcription	O
in	O
macrophages	O
and	O
the	O
specific	O
LPS	O
-	O
responsive	O
transcription	O
factors	O
that	O
bind	O
the	O
SerpinB2	B-Protein
promoter	O
were	O
not	O
defined	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induction	O
of	O
SerpinB2	B-Protein
is	O
dependent	O
upon	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
,	O
and	O
is	O
critically	O
dependent	O
upon	O
a	O
C	O
/	O
EBP	O
binding	O
site	O
at	O
-	O
203	O
/	O
-	O
195	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
directly	O
bound	O
to	O
this	O
site	O
in	O
vivo	O
and	O
its	O
deficiency	O
abrogated	O
constitutive	O
SerpinB2	B-Protein
expression	O
and	O
SerpinB2	B-Protein
induction	O
by	O
LPS	O
.	O

Importantly	O
,	O
a	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	O
-	O
acceptor	O
site	O
was	O
found	O
to	O
negatively	O
regulate	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
provide	O
new	O
insight	O
into	O
the	O
transcriptional	O
regulation	O
of	O
the	O
SerpinB2	B-Protein
gene	O
.	O

Cell	O
Culture	O
<EOS>	B-X
Cultures	B-X
,	B-X
supposedly	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
or	B-X
mouse	B-X
,	B-X
proved	B-X
to	B-X
be	B-X
HeLa	B-X
cells	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
valuable	B-X
tools	B-X
which	B-X
is	B-X
being	B-X
applied	B-X
in	B-X
both	B-X
fundamental	B-X
and	B-X
applied	B-X
gastrointestinal	B-X
research	B-X
.	B-X
Cell	B-X
culture	B-X
-	B-X
Fact	B-X
and	B-X
fiction	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
a	B-X
well-established	B-X
standard	B-X
technique	B-X
and	B-X
a	B-X
fundamental	B-X
tool	B-X
in	B-X
biology	B-X
and	B-X
medicine	B-X
.	B-X

Murine	O
macrophage	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
ATCC	O
TIB	O
-	O
71	O
)	O
were	O
maintained	O
in	O
RPMI	O
1640	O
media	O
(	O
Gibco	O
BRL	O
)	O
,	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
(	O
Gibco	O
BRL	O
)	O
,	O
10	O
%	O
serum	O
supreme	O
(	O
BioWhittaker	O
)	O
,	O
200	O
microg	O
/	O
ml	O
penicillin	O
,	O
100	O
microg	O
/	O
ml	O
streptomycin	O
,	O
25	O
mM	O
N	O
-	O
2	O
-	O
hydroxyethylpiperazine	O
-	O
N	O
-	O
2	O
-	O
ethane	O
sulphonic	O
acid	O
(	O
HEPES	O
)	O
and	O
25	O
mM	O
sodium	O
bicarbonate	O
,	O
in	O
5	O
%	O
CO2	O
and	O
95	O
%	O
humidified	O
air	O
atmosphere	O
at	O
37degreesC	O
.	O

Wild	O
-	O
type	O
(	O
Cebpb	B-Protein
+	O
/	O
+	O
)	O
and	O
knockout	O
(	O
Cebpb	B-Protein
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
[	O
34	O
]	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
Invitrogen	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
/	O
glutamate	O
solution	O
(	O
Cellgro	O
)	O
.	O

Primary	O
peritoneal	O
macrophages	O
were	O
obtained	O
by	O
injecting	O
C57BL	O
/	O
6	O
mice	O
with	O
3	O
%	O
thioglycollate	O
broth	O
followed	O
by	O
peritoneal	O
lavage	O
3	O
-	O
5	O
days	O
later	O
,	O
and	O
maintained	O
in	O
50	O
%	O
DMEM	O
/	O
F12	O
media	O
(	O
Gibco	O
BRL	O
)	O
.	O

Precautions	O
were	O
taken	O
to	O
exclude	O
bacterial	O
lipopolysaccharide	O
contamination	O
from	O
all	O
cell	O
cultures	O
through	O
the	O
use	O
of	O
certified	O
LPS	O
-	O
free	O
serum	O
.	O

Cell	O
viability	O
was	O
determined	O
using	O
the	O
trypan	O
blue	O
(	O
Sigma	O
)	O
dye	O
exclusion	O
method	O
.	O
<EOS>	B-X
Excellent	B-X
flow	B-X
cytometric	B-X
resolution	B-X
of	B-X
the	B-X
DL	B-X
staining	B-X
cells	B-X
from	B-X
several	B-X
cell	B-X
lines	B-X
was	B-X
obtained	B-X
by	B-X
using	B-X
bivariate	B-X
(	B-X
forward	B-X
angle	B-X
light	B-X
scatter	B-X
versus	B-X
DL-fluorescence	B-X
)	B-X
analysis	B-X
.	B-X
Nearly	B-X
all	B-X
of	B-X
the	B-X
DL-staining	B-X
cells	B-X
were	B-X
propidium	B-X
iodide	B-X
and	B-X
trypan	B-X
blue	B-X
excluding	B-X
.	B-X

All	O
cultures	O
were	O
routinely	O
checked	O
to	O
exclude	O
Mycoplasma	O
infection	O
by	O
nuclear	O
staining	O
using	O
Hoechst	O
stain	O
33258	O
(	O
Sigma	O
)	O
and	O
the	O
MycoAlert	O
Detection	O
Kit	O
(	O
Lonza	O
)	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
Salmonella	O
minnesota	O
Strain	O
Re595	O
)	O
was	O
obtained	O
from	O
Sigma	O
.	O

Real	O
-	O
time	O
Quantitative	O
PCR	O
(	O
qPCR	O
)	O
<EOS>	B-X
Quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
a	B-X
routinely	B-X
used	B-X
method	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantitation	B-X
of	B-X
gene	B-X
expression	B-X
in	B-X
real	B-X
time	B-X
.	B-X
Multiplex	B-X
qPCR	B-X
requires	B-X
the	B-X
use	B-X
of	B-X
probe-based	B-X
assays	B-X
,	B-X
in	B-X
which	B-X
each	B-X
probe	B-X
is	B-X
labeled	B-X
with	B-X
a	B-X
unique	B-X
fluorescent	B-X
dye	B-X
,	B-X
resulting	B-X
in	B-X
different	B-X
observed	B-X
colors	B-X
for	B-X
each	B-X
assay	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
method	B-X
using	B-X
the	B-X
SensiFAST	B-X
and	B-X
SensiFAST	B-X
One-Step	B-X
probe	B-X
kits	B-X
which	B-X
allows	B-X
simultaneous	B-X
real-time	B-X
quantitation	B-X
of	B-X
up	B-X
to	B-X
5	B-X
amplicons	B-X
.	B-X
Real-time	B-X
quantitative	B-X
PCR	B-X
is	B-X
a	B-X
technique	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
PCR	B-X
reaction	B-X
in	B-X
real	B-X
time	B-X
.	B-X
RT-qPCR	B-X
is	B-X
broadly	B-X
classified	B-X
into	B-X
two	B-X
types	B-X
based	B-X
on	B-X
its	B-X
purpose	B-X
:	B-X
absolute	B-X
and	B-X
relative	B-X
quantification	B-X
.	B-X
A	B-X
laboratory	B-X
work	B-X
that	B-X
covers	B-X
the	B-X
basic	B-X
principles	B-X
involved	B-X
in	B-X
RT-qPCR	B-X
and	B-X
data	B-X
analysis	B-X
using	B-X
the	B-X
manual	B-X
as	B-X
well	B-X
as	B-X
the	B-X
software	B-X
methods	B-X
are	B-X
incorporated	B-X
.	B-X
The	B-X
laboratory	B-X
experiment	B-X
was	B-X
designed	B-X
to	B-X
provide	B-X
insights	B-X
on	B-X
certain	B-X
important	B-X
principles	B-X
such	B-X
as	B-X
primer	B-X
characteristics	B-X
,	B-X
PCR	B-X
efficiency	B-X
,	B-X
and	B-X
melt	B-X
curve	B-X
analysis	B-X
.	B-X
This	B-X
laboratory	B-X
exercise	B-X
provides	B-X
all	B-X
the	B-X
significant	B-X
components	B-X
of	B-X
RT-qPCR	B-X
,	B-X
which	B-X
can	B-X
be	B-X
useful	B-X
while	B-X
performing	B-X
an	B-X
experiment	B-X
in	B-X
an	B-X
undergraduate	B-X
and	B-X
graduate	B-X
laboratory	B-X
.	B-X

The	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
was	O
used	O
to	O
isolate	O
total	O
RNA	O
from	O
cells	O
.	O
<EOS>	B-X
The	B-X
efficiency	B-X
of	B-X
different	B-X
commercial	B-X
RNA	B-X
extraction	B-X
kits	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
hepatitis	B-X
A	B-X
virus	B-X
(	B-X
HAV	B-X
)	B-X
from	B-X
seeded	B-X
strawberry	B-X
samples	B-X
was	B-X
assessed	B-X
by	B-X
standard	B-X
RT-PCR	B-X
and	B-X
real	B-X
time	B-X
RT-PCR	B-X
(	B-X
RT-qPCR	B-X
)	B-X
.	B-X
The	B-X
best	B-X
results	B-X
with	B-X
standard	B-X
RT-PCR	B-X
were	B-X
achieved	B-X
with	B-X
Aurum™	B-X
Total	B-X
RNA	B-X
extraction	B-X
kit	B-X
(	B-X
BioRad	B-X
)	B-X
,	B-X
obtaining	B-X
a	B-X
detection	B-X
limit	B-X
of	B-X
5-6.25	B-X
pfu/mg	B-X
of	B-X
tissue	B-X
.	B-X
A	B-X
slightly	B-X
lower	B-X
sensitivity	B-X
was	B-X
rendered	B-X
by	B-X
the	B-X
RNeasy®	B-X
Plant	B-X
mini	B-X
kit	B-X
(	B-X
Qiagen	B-X
)	B-X
(	B-X
10-12.5	B-X
pfu/mg	B-X
tissue	B-X
)	B-X
,	B-X
while	B-X
the	B-X
Total	B-X
Quick	B-X
RNA	B-X
Cells	B-X
and	B-X
Tissues	B-X
kit	B-X
version	B-X
mini	B-X
(	B-X
Talent	B-X
)	B-X
rendered	B-X
a	B-X
detection	B-X
limit	B-X
of	B-X
50-100	B-X
pfu/mg	B-X
of	B-X
tissue	B-X
.	B-X
With	B-X
RT-qPCR	B-X
and	B-X
ten	B-X
fold	B-X
diluted	B-X
RNA	B-X
all	B-X
the	B-X
kits	B-X
showed	B-X
an	B-X
increase	B-X
of	B-X
sensitivity	B-X
,	B-X
detecting	B-X
the	B-X
kits	B-X
from	B-X
Qiagen	B-X
,	B-X
Talent	B-X
and	B-X
BioRad	B-X
down	B-X
to	B-X
0.05	B-X
pfu/mg	B-X
of	B-X
strawberry	B-X
homogenate	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
use	B-X
of	B-X
Aurum™	B-X
Total	B-X
RNA	B-X
extraction	B-X
kit	B-X
,	B-X
with	B-X
standard	B-X
RT-PCR	B-X
technique	B-X
or	B-X
RT-qPCR	B-X
,	B-X
can	B-X
not	B-X
only	B-X
be	B-X
labor	B-X
and	B-X
time	B-X
saving	B-X
but	B-X
also	B-X
helpful	B-X
to	B-X
improve	B-X
the	B-X
sensitivity	B-X
for	B-X
the	B-X
HAV	B-X
detection	B-X
from	B-X
fruits	B-X
and	B-X
to	B-X
facilitate	B-X
the	B-X
standardization	B-X
of	B-X
detection	B-X
methods	B-X
among	B-X
laboratories	B-X
.	B-X

For	O
cDNA	O
synthesis	O
,	O
1	O
microg	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
TaqMan	O
(	O
R	O
)	O
Reverse	O
Transcription	O
Reagents	O
(	O
Applied	O
Biosystems	O
)	O
.	O

qPCR	O
was	O
performed	O
using	O
TaqMan	O
(	O
R	O
)	O
Gene	O
Expression	O
20X	O
primers	O
for	O
Serpinb2	B-Protein
/	O
SerpinB2	B-Protein
(	O
Mm00440905	O
_	O
m1	O
)	O
,	O
Cebpb	B-Protein
(	O
Mm00843434	O
_	O
s1	O
)	O
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
Mm00607939	O
_	O
s1	O
)	O
(	O
Applied	O
Biosystems	O
)	O
.	O

DNA	O
Sequence	O
Analysis	O
<EOS>	B-X
Over	B-X
the	B-X
last	B-X
fifty	B-X
years	B-X
large	B-X
numbers	B-X
of	B-X
researchers	B-X
have	B-X
applied	B-X
themselves	B-X
to	B-X
the	B-X
production	B-X
of	B-X
techniques	B-X
and	B-X
technologies	B-X
to	B-X
facilitate	B-X
this	B-X
feat	B-X
,	B-X
sequencing	B-X
DNA	B-X
and	B-X
RNA	B-X
molecules	B-X
.	B-X
Recent	B-X
scientific	B-X
discoveries	B-X
that	B-X
resulted	B-X
from	B-X
the	B-X
application	B-X
of	B-X
next-generation	B-X
DNA	B-X
sequencing	B-X
technologies	B-X
highlight	B-X
the	B-X
striking	B-X
impact	B-X
of	B-X
these	B-X
massively	B-X
parallel	B-X
platforms	B-X
on	B-X
genetics	B-X
.	B-X
These	B-X
new	B-X
methods	B-X
have	B-X
expanded	B-X
previously	B-X
focused	B-X
readouts	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
DNA	B-X
preparation	B-X
protocols	B-X
to	B-X
a	B-X
genome-wide	B-X
scale	B-X
and	B-X
have	B-X
fine-tuned	B-X
their	B-X
resolution	B-X
to	B-X
single	B-X
base	B-X
precision	B-X
.	B-X
The	B-X
sequencing	B-X
of	B-X
RNA	B-X
also	B-X
has	B-X
transitioned	B-X
and	B-X
now	B-X
includes	B-X
full-length	B-X
cDNA	B-X
analyses	B-X
,	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
(	B-X
SAGE	B-X
)	B-X
-based	B-X
methods	B-X
,	B-X
and	B-X
noncoding	B-X
RNA	B-X
discovery	B-X
.	B-X
Next-generation	B-X
sequencing	B-X
has	B-X
also	B-X
enabled	B-X
novel	B-X
applications	B-X
such	B-X
as	B-X
the	B-X
sequencing	B-X
of	B-X
ancient	B-X
DNA	B-X
samples	B-X
,	B-X
and	B-X
has	B-X
substantially	B-X
widened	B-X
the	B-X
scope	B-X
of	B-X
metagenomic	B-X
analysis	B-X
of	B-X
environmentally	B-X
derived	B-X
samples	B-X
.	B-X

The	O
DNA	O
sequence	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
was	O
determined	O
by	O
sequencing	O
the	O
pUC	O
-	O
based	O
plasmids	O
pDB9406	O
,	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
,	O
in	O
addition	O
to	O
plasmids	O
prepared	O
from	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
containing	O
deletions	O
introduced	O
by	O
exonuclease	B-Protein
III	I-Protein
digestion	O
.	O

Plasmids	O
pDB9406	O
,	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
containing	O
genomic	O
DNA	O
isolated	O
from	O
a	O
lambdaFIXII	O
(	O
Stratagene	O
)	O
genomic	O
library	O
prepared	O
from	O
a	O
129	O
mouse	O
strain	O
,	O
were	O
kindly	O
provided	O
by	O
Dr	O
.	O
Dominique	O
Belin	O
,	O
University	O
of	O
Geneva	O
.	O

pDB9406	O
contains	O
a	O
4	O
.	O
4	O
kb	O
EcoRI	O
/	O
SpeI	O
genomic	O
fragment	O
spanning	O
the	O
transcription	O
initiation	O
site	O
;	O
pDB9402	O
-	O
41	O
and	O
pDB9402	O
-	O
42	O
contain	O
a	O
1	O
.	O
2	O
kb	O
EcoRI	O
genomic	O
fragment	O
,	O
located	O
immediately	O
upstream	O
of	O
the	O
pDB9406	O
EcoRI	O
fragment	O
,	O
cloned	O
in	O
opposite	O
orientations	O
.	O

Subcloned	O
inserts	O
were	O
verified	O
by	O
restriction	O
enzyme	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
4480	O
bp	O
murine	O
SerpinB2	B-Protein
gene	O
5	O
'	O
flanking	O
region	O
was	O
determined	O
using	O
the	O
ABI	O
PRISM	O
dye	O
terminator	O
cycle	O
sequencing	O
ready	O
reaction	O
kit	O
(	O
Perkin	O
-	O
Elmer	O
)	O
and	O
a	O
PE	O
373A	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
)	O
.	O

This	O
sequence	O
was	O
deposited	O
in	O
GenBank	O
/	O
EMBL	O
/	O
DDBJ	O
Data	O
Bank	O
with	O
Accession	O
No	O
.	O
<EOS>	B-X
First	B-X
case	B-X
of	B-X
human	B-X
bacteraemia	B-X
by	B-X

AF339731	O
.	O

Western	O
Blot	O
Assays	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
has	B-X
been	B-X
in	B-X
practice	B-X
for	B-X
more	B-X
than	B-X
three	B-X
decades	B-X
that	B-X
began	B-X
as	B-X
a	B-X
means	B-X
of	B-X
detecting	B-X
a	B-X
protein	B-X
target	B-X
in	B-X
a	B-X
complex	B-X
sample	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Western	B-X
blotting	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
involves	B-X
the	B-X
separation	B-X
of	B-X
proteins	B-X
by	B-X
gel	B-X
electrophoresis	B-X
,	B-X
their	B-X
blotting	B-X
or	B-X
transfer	B-X
to	B-X
a	B-X
membrane	B-X
,	B-X
and	B-X
selective	B-X
immunodetection	B-X
of	B-X
an	B-X
immobilized	B-X
antigen	B-X
.	B-X

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
RIPA	O
buffer	O
(	O
10	O
mM	O
Tris	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
)	O
,	O
proteins	O
were	O
separated	O
on	O
4	O
-	O
12	O
%	O
Bis	O
-	O
Tris	O
NuPAGE	O
gels	O
(	O
Invitrogen	O
)	O
,	O
and	O
transferred	O
to	O
PVDF	O
membranes	O
.	O

Membranes	O
were	O
subsequently	O
blocked	O
with	O
5	O
%	O
milk	O
in	O
PBS	O
-	O
T	O
(	O
1X	O
PBS	O
,	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
)	O
,	O
and	O
incubated	O
with	O
primary	O
antibodies	O
overnight	O
.	O

Affinity	O
purified	O
rabbit	O
anti	O
-	O
mouse	O
SerpinB2	O
antibodies	O
were	O
prepared	O
after	O
immunization	O
with	O
a	O
purified	O
recombinant	O
GST	B-Protein
-	I-Protein
murine	I-Protein
SerpinB2	I-Protein
fusion	I-Protein
protein	I-Protein
produced	O
in	O
E	O
.	O
coli	O
as	O
in	O
[	O
35	O
]	O
.	O

Other	O
antibodies	O
used	O
for	O
western	O
blot	O
assays	O
include	O
:	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	O
sc	O
-	O
150	O
)	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
)	O
,	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
(	O
GAPDH	B-Protein
)	O
and	O
alpha	O
/	O
beta	O
tubulin	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Inc	O
.	O
)	O
.	O

Construction	O
of	O
SerpinB2	B-Protein
Reporter	I-Protein
Gene	I-Protein
Plasmids	O

The	O
PCR	O
primers	O
DW5	O
'	O
LUC	O
,	O
containing	O
a	O
Kpn	O
I	O
restriction	O
site	O
,	O
and	O
DW3	O
'	O
LUC	O
,	O
containing	O
an	O
Xho	O
I	O
restriction	O
site	O
,	O
were	O
used	O
to	O
PCR	O
amplify	O
and	O
clone	O
the	O
SerpinB2	B-Protein
promoter	O
(	O
-	O
3261	O
to	O
+	O
92	O
)	O
from	O
pDB9406	O
into	O
the	O
Kpn	O
I	O
/	O
Xho	O
I	O
polylinker	O
restriction	O
sites	O
of	O
pGL3	O
Basic	O
(	O
Promega	O
)	O
to	O
produce	O
pGLmP	O
-	O
3261	O
.	O

The	O
EcoR	O
I	O
insert	O
of	O
pDB9402	O
-	O
42	O
was	O
sub	O
-	O
cloned	O
immediately	O
upstream	O
of	O
the	O
SerpinB2	B-Protein
promoter	O
EcoR	O
I	O
site	O
(	O
-	O
3261	O
)	O
of	O
pGLmP	O
-	O
3261	O
to	O
produce	O
pGLmP	O
-	O
4480	O
.	O

Additional	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
(	O
pGLmP	O
-	O
2751	O
,	O
pGLmP	O
-	O
2614	O
,	O
pGLmP	O
-	O
1686	O
,	O
pGLmP	O
-	O
1341	O
,	O
pGLmP	O
-	O
694	O
,	O
pGLmP	O
-	O
539	O
and	O
pGLmP	O
-	O
189	O
)	O
were	O
generated	O
by	O
digesting	O
pGLmP	O
-	O
3261	O
with	O
EcoR	B-Protein
I	I-Protein
and	O
a	O
second	O
restriction	O
enzyme	O
(	O
Sfi	B-Protein
I	I-Protein
,	O
Apa	B-Protein
I	I-Protein
,	O
BstX	B-Protein
I	I-Protein
,	O
Bsu36	B-Protein
I	I-Protein
,	O
Pac	B-Protein
I	I-Protein
,	O
Hae	B-Protein
III	I-Protein
and	O
Apo	B-Protein
I	I-Protein
respectively	O
)	O
,	O
blunt	O
ending	O
the	O
resultant	O
5	O
'	O
or	O
3	O
'	O
overhangs	O
with	O
T4	B-Protein
DNA	I-Protein
polymerase	I-Protein
(	O
NEB	O
)	O
and	O
re	O
-	O
ligating	O
the	O
vector	O
ends	O
with	O
T4	B-Protein
DNA	I-Protein
ligase	I-Protein
.	O

The	O
PCR	O
primers	O
BSPCR2	O
and	O
DW3	O
'	O
LUC	O
were	O
used	O
to	O
subclone	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
regions	O
-	O
87	O
to	O
+	O
92	O
into	O
the	O
Kpn	O
I	O
/	O
Xho	O
I	O
polylinker	O
restriction	O
sites	O
of	O
pGL3	O
Basic	O
to	O
produce	O
pGLmP	O
-	O
87	O
.	O

The	O
control	O
empty	O
vector	O
was	O
pGL3	O
Basic	O
(	O
Promega	O
)	O
.	O

Luciferase	B-Protein
reporter	I-Protein
constructs	O
containing	O
mutations	O
in	O
the	O
SerpinB2	B-Protein
promoter	O
LPS	O
-	O
responsive	O
regions	O
E	O
box	O
,	O
PU	O
.	O
1	O
,	O
Oct	O
-	O
1	O
and	O
C	O
/	O
EBP	O
(	O
pGLmP	O
-	O
539mEbox	O
,	O
pGLmP	O
-	O
539mPU	O
.	O
1	O
,	O
pGLmP	O
-	O
539mOct	O
and	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
respectively	O
)	O
were	O
generated	O
as	O
described	O
[	O
36	O
]	O
.	O

The	O
mutant	O
oligonucleotide	O
PCR	O
primer	O
sequences	O
are	O
provided	O
in	O
Fig	O
.	O

S1	O
,	O
and	O
were	O
used	O
as	O
follows	O
:	O
pGLmP	O
-	O
539mEbox	O
:	O
mPAI2mEboxa	O
and	O
mPAI2mEboxb	O
;	O
pGLmP	O
-	O
539mPU	O
.	O
1	O
:	O
mPAI2mPU	O
.	O
1a	O
and	O
mPAI2mPU	O
.	O
1b	O
;	O
pGLmP	O
-	O
539mOct	O
:	O
mPAI2mOct	O
-	O
2a	O
and	O
mPAI2mOct	O
-	O
2b	O
;	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
:	O
mPAI2mCEBPa	O
and	O
mPAI2mCEBPb	O
.	O
<EOS>	B-X
Advanced	B-X
gastric	B-X
cancer	B-X
can	B-X
respond	B-X
to	B-X
S-1	B-X
,	B-X
an	B-X
oral	B-X
fluoropyrimidine	B-X
.	B-X
We	B-X
tested	B-X
S-1	B-X
as	B-X
adjuvant	B-X
chemotherapy	B-X
in	B-X
patients	B-X
with	B-X
curatively	B-X
resected	B-X
gastric	B-X
cancer	B-X
.	B-X
Although	B-X
adjuvant	B-X
chemotherapy	B-X
with	B-X
gemcitabine	B-X
is	B-X
standard	B-X
care	B-X
for	B-X
resected	B-X
pancreatic	B-X
cancer	B-X
,	B-X
S-1	B-X
has	B-X
shown	B-X
non-inferiority	B-X
to	B-X
gemcitabine	B-X
for	B-X
advanced	B-X
disease	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
non-inferiority	B-X
of	B-X
S-1	B-X
to	B-X
gemcitabine	B-X
as	B-X
adjuvant	B-X
chemotherapy	B-X
for	B-X
pancreatic	B-X
cancer	B-X
in	B-X
terms	B-X
of	B-X
overall	B-X
survival	B-X
.	B-X

The	O
oligonucleotide	O
PCR	O
primers	O
used	O
to	O
generate	O
mutants	O
,	O
pGLmP	O
-	O
539mCRE	O
,	O
pGLmP	O
-	O
539mAP	O
-	O
1a	O
,	O
and	O
pGLmP	O
-	O
539mAP	O
-	O
1b	O
were	O
reported	O
previously	O
[	O
37	O
]	O
.	O

The	O
flanking	O
oligonucleotide	O
PCR	O
primers	O
were	O
RVprimer3	O
(	O
Promega	O
)	O
and	O
GLprimer2	O
(	O
Promega	O
)	O
.	O

pGLmP	O
-	O
539	O
was	O
used	O
as	O
the	O
template	O
in	O
each	O
case	O
.	O
<EOS>	B-X
By	B-X
virtue	B-X
of	B-X
sequencing	B-X
clonally	B-X
amplified	B-X
DNA	B-X
templates	B-X
or	B-X
single	B-X
DNA	B-X
molecules	B-X
in	B-X
a	B-X
massively	B-X
parallel	B-X
fashion	B-X
in	B-X
a	B-X
flow	B-X
cell	B-X
,	B-X
NGS	B-X
provides	B-X
both	B-X
qualitative	B-X
and	B-X
quantitative	B-X
sequence	B-X
data	B-X
.	B-X
These	B-X
concepts	B-X
are	B-X
subsequently	B-X
further	B-X
illustrated	B-X
by	B-X
showing	B-X
representative	B-X
results	B-X
from	B-X
a	B-X
case	B-X
study	B-X
using	B-X
NGS	B-X
for	B-X
targeted	B-X
resequencing	B-X
of	B-X
genes	B-X
implicated	B-X
in	B-X
hypertrophic	B-X
cardiomyopathy	B-X
.	B-X
We	B-X
studied	B-X
the	B-X
kinetics	B-X
of	B-X
nontemplated	B-X
nucleotide	B-X
addition	B-X
by	B-X
the	B-X
reverse	B-X
transcriptase	B-X
(	B-X
RT	B-X
)	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
using	B-X
model	B-X
substrates	B-X
derived	B-X
from	B-X
the	B-X
3	B-X
'	B-X
end	B-X
of	B-X
HIV-1	B-X
minus-strand	B-X
strong-stop	B-X
DNA	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
a	B-X
nontemplated	B-X
nucleotide	B-X
was	B-X
highly	B-X
dependent	B-X
on	B-X
the	B-X
nature	B-X
of	B-X
the	B-X
base	B-X
(	B-X
fastest	B-X
addition	B-X
with	B-X
dATP	B-X
)	B-X
,	B-X
type	B-X
of	B-X
nucleoside	B-X
,	B-X
and	B-X
pH	B-X
of	B-X
the	B-X
reaction	B-X
buffer	B-X
.	B-X
In	B-X
every	B-X
case	B-X
,	B-X
nontemplated	B-X
nucleotide	B-X
addition	B-X
was	B-X
much	B-X
slower	B-X
than	B-X
templated	B-X
polymerization	B-X
.	B-X
The	B-X
K	B-X
(	B-X
d	B-X
)	B-X
for	B-X
the	B-X
incoming	B-X
dNTP	B-X
with	B-X
an	B-X
RT	B-X
bound	B-X
to	B-X
a	B-X
blunt-ended	B-X
duplex	B-X
was	B-X
at	B-X
least	B-X
1000-fold	B-X
higher	B-X
than	B-X
with	B-X
a	B-X
duplex	B-X
with	B-X
a	B-X
template	B-X
overhang	B-X
.	B-X
At	B-X
concentrations	B-X
normally	B-X
found	B-X
in	B-X
vivo	B-X
,	B-X
ATP	B-X
can	B-X
compete	B-X
with	B-X
dNTPs	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
polymerase	B-X
active	B-X
site	B-X
and	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
nontemplated	B-X
nucleotide	B-X
addition	B-X
.	B-X
Although	B-X
a	B-X
stable	B-X
ternary	B-X
complex	B-X
RT/DNA/dNTP	B-X
could	B-X
be	B-X
readily	B-X
detected	B-X
by	B-X
gel	B-X
retardation	B-X
assays	B-X
if	B-X
the	B-X
DNA	B-X
had	B-X
a	B-X
template	B-X
overhang	B-X
,	B-X
stable	B-X
ternary	B-X
complexes	B-X
were	B-X
not	B-X
observed	B-X
with	B-X
a	B-X
blunt-ended	B-X
duplex	B-X
substrate	B-X
.	B-X
At	B-X
in	B-X
vivo	B-X
concentrations	B-X
of	B-X
dNTPs	B-X
(	B-X
5-10	B-X
microM	B-X
)	B-X
,	B-X
nontemplated	B-X
nucleotide	B-X
addition	B-X
occurred	B-X
,	B-X
but	B-X
it	B-X
was	B-X
very	B-X
inefficient	B-X
and	B-X
the	B-X
rate	B-X
of	B-X
nontemplated	B-X
polymerization	B-X
is	B-X
at	B-X
least	B-X
10000-fold	B-X
slower	B-X
than	B-X
the	B-X
rate	B-X
of	B-X
templated	B-X
polymerization	B-X
.	B-X
We	B-X
could	B-X
conclude	B-X
that	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
unfavorable	B-X
binding	B-X
of	B-X
the	B-X
incoming	B-X
dNTP	B-X
,	B-X
low	B-X
concentration	B-X
of	B-X
dNTPs	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
large	B-X
concentration	B-X
of	B-X
ATP	B-X
,	B-X
and	B-X
the	B-X
inability	B-X
to	B-X
form	B-X
a	B-X
stable	B-X
ternary	B-X
complex	B-X
prior	B-X
to	B-X
the	B-X
polymerization	B-X
step	B-X
collaborate	B-X
to	B-X
reduce	B-X
the	B-X
efficiency	B-X
of	B-X
nontemplated	B-X
nucleotide	B-X
addition	B-X
.	B-X

Recombinant	O
PCR	O
products	O
were	O
digested	O
with	O
EcoR	B-Protein
I	I-Protein
and	O
Xho	B-Protein
I	I-Protein
and	O
cloned	O
between	O
the	O
EcoR	O
I	O
and	O
Xho	O
I	O
restriction	O
sites	O
of	O
pGLmP	O
-	O
539	O
in	O
place	O
of	O
the	O
-	O
539	O
/	O
+	O
92	O
region	O
of	O
the	O
wild	O
-	O
type	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

Sequence	O
verified	O
constructs	O
were	O
used	O
in	O
the	O
experiments	O
.	O
<EOS>	B-X
METTL14	B-X
aggravates	B-X
endothelial	B-X
inflammation	B-X
and	B-X
atherosclerosis	B-X
by	B-X
increasing	B-X
FOXO1	B-X
N6-methyladeosine	B-X
modifications	B-X
.	B-X
Approach	B-X
and	B-X
Results	B-X
:	B-X
We	B-X
used	B-X
unbiased	B-X
single-cell	B-X
RNA	B-X
sequencing	B-X
for	B-X
the	B-X
high-throughput	B-X
evaluation	B-X
of	B-X
cell	B-X
heterogeneity	B-X
in	B-X
34	B-X
632	B-X
cells	B-X
isolated	B-X
from	B-X
6	B-X
different	B-X
human	B-X
aortic	B-X
valve	B-X
leaflets	B-X
.	B-X
Cellular	B-X
experiments	B-X
,	B-X
in	B-X
situ	B-X
localization	B-X
,	B-X
and	B-X
bulk	B-X
sequencing	B-X
were	B-X
performed	B-X
to	B-X
verify	B-X
the	B-X
differences	B-X
between	B-X
normal	B-X
,	B-X
healthy	B-X
valves	B-X
and	B-X
those	B-X
with	B-X
CAVD	B-X
.	B-X
Combining	B-X
additional	B-X
verification	B-X
experiments	B-X
with	B-X
single-cell	B-X
transcriptome	B-X
profiling	B-X
provided	B-X
evidence	B-X
of	B-X
endothelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
involved	B-X
in	B-X
lesion	B-X
thickening	B-X
of	B-X
the	B-X
aortic	B-X
valve	B-X
leaflet	B-X
.	B-X

Transient	O
Transfection	O
and	O
Luciferase	B-Protein
Assays	O
(	O
RAW264	O
.	O
7	O
Macrophages	O
)	O
<EOS>	B-X
Xerophilusin	B-X
A	B-X
(	B-X
1	B-X
)	B-X
,	B-X
xerophilusin	B-X
B	B-X
(	B-X
2	B-X
)	B-X
,	B-X
longikaurin	B-X
B	B-X
(	B-X
3	B-X
)	B-X
,	B-X
and	B-X
xerophilusin	B-X
F	B-X
(	B-X
4	B-X
)	B-X
from	B-X
Isodon	B-X
xerophylus	B-X
inhibit	B-X
LPS-induced	B-X
NO	B-X
production	B-X
in	B-X
RAW	B-X
264.7	B-X
macrophages	B-X
,	B-X
with	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
values	B-X
of	B-X
0.60	B-X
,	B-X
0.23	B-X
,	B-X
0.44	B-X
,	B-X
and	B-X
0.67	B-X
muM	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
they	B-X
all	B-X
inhibited	B-X
mRNA	B-X
production	B-X
in	B-X
these	B-X
same	B-X
cells	B-X
.	B-X
They	B-X
decreased	B-X
the	B-X
luciferase	B-X
activity	B-X
in	B-X
RAW	B-X
264.7	B-X
cells	B-X
transiently	B-X
transfected	B-X
with	B-X
the	B-X
NF-kappaB-dependent	B-X
luciferase	B-X
reporter	B-X
,	B-X
with	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
values	B-X
of	B-X
1.8	B-X
,	B-X
0.7	B-X
,	B-X
1.2	B-X
,	B-X
and	B-X
1.6	B-X
muM	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
previously	B-X
found	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
1	B-X
,	B-X
TLR3	B-X
and	B-X
TLR8	B-X
was	B-X
notably	B-X
upregulated	B-X
in	B-X
pEGFPC1/Aire	B-X
stably	B-X
transfected	B-X
RAW264.7	B-X
(	B-X
GFP-Aire/RAW	B-X
)	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
expressions	B-X
of	B-X
other	B-X
TLRs	B-X
were	B-X
not	B-X
significantly	B-X
changed	B-X
.	B-X
Small	B-X
interfering	B-X
RNA	B-X
knock-down	B-X
of	B-X
DNA-PKcs	B-X
in	B-X
these	B-X
cells	B-X
decreased	B-X
the	B-X
expression	B-X
of	B-X
TLR1	B-X
,	B-X
TLR3	B-X
and	B-X
TLR8	B-X
,	B-X
but	B-X
no	B-X
change	B-X
was	B-X
observed	B-X
in	B-X
pEGFPC1	B-X
stably	B-X
transfected	B-X
RAW264.7	B-X
(	B-X
GFP/RAW	B-X
)	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
DNA-PKcs	B-X
may	B-X
interact	B-X
with	B-X
Aire	B-X
to	B-X
promote	B-X
the	B-X
expression	B-X
of	B-X
TLRs	B-X
in	B-X
RAW264.7	B-X
cells	B-X
.	B-X

RAW	O
264	O
.	O
7	O
cells	O
(	O
2x107	O
)	O
growing	O
in	O
log	O
phase	O
were	O
transfected	O
with	O
the	O
indicated	O
luciferase	B-Protein
reporter	O
plasmid	O
(	O
20	O
microg	O
)	O
along	O
with	O
the	O
pRL	O
-	O
thymidine	B-Protein
kinase	I-Protein
(	O
TK	B-Protein
)	O
(	O
Promega	O
)	O
internal	O
control	O
reporter	O
plasmid	O
(	O
2	O
microg	O
)	O
by	O
electroporation	O
using	O
a	O
Bio	O
-	O
Rad	O
Gene	O
Pulser	O
with	O
a	O
Capacitance	O
Extender	O
(	O
0	O
.	O
25	O
kV	O
,	O
960	O
microFd	O
)	O
.	O

pGL3	O
control	O
plasmid	O
which	O
encodes	O
the	O
SV40	O
promoter	O
and	O
enhancer	O
was	O
included	O
as	O
a	O
positive	O
control	O
for	O
transfection	O
efficiency	O
,	O
and	O
as	O
an	O
internal	O
standard	O
for	O
promoter	O
and	O
enhancer	O
activities	O
.	O

Transfected	O
cells	O
were	O
transferred	O
to	O
10	O
ml	O
of	O
pre	O
-	O
warmed	O
media	O
in	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
,	O
divided	O
into	O
two	O
identical	O
cell	O
pools	O
and	O
incubated	O
16	O
hrs	O
in	O
a	O
5	O
%	O
CO2	O
and	O
95	O
%	O
humidified	O
air	O
atmosphere	O
at	O
37degreesC	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
ml	O
LPS	O
.	O

Luciferase	B-Protein
activity	O
was	O
measured	O
using	O
a	O
Dual	O
-	O
Luciferase	B-Protein
Reporter	O
Assay	O
System	O
kit	O
(	O
Promega	O
)	O
.	O
<EOS>	B-X
Canine	B-X
mast	B-X
cell	B-X
tumours	B-X
often	B-X
express	B-X
KIT	B-X
mutations	B-X
that	B-X
result	B-X
in	B-X
constitutive	B-X
activation	B-X
of	B-X
the	B-X
c-kit	B-X
receptor	B-X
and	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
more	B-X
aggressive	B-X
disease	B-X
.	B-X
Renilla	B-X
and	B-X
firefly	B-X
luciferase	B-X
activity	B-X
was	B-X
measured	B-X
using	B-X
the	B-X
Dual-GLO	B-X
(	B-X
®	B-X
)	B-X
Luciferase	B-X
Assay	B-X
(	B-X
Promega	B-X
)	B-X
.	B-X

Measurements	O
represent	O
the	O
results	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
This	B-X
work	B-X
describes	B-X
the	B-X
characterization	B-X
of	B-X
three	B-X
NIR	B-X
interfaces	B-X
intended	B-X
to	B-X
monitor	B-X
a	B-X
continuous	B-X
granulation	B-X
process	B-X
.	B-X
Five	B-X
independent	B-X
batches	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
prediction	B-X
performance	B-X
of	B-X
each	B-X
inlet	B-X
calibration	B-X
model	B-X
.	B-X
A	B-X
variographic	B-X
analysis	B-X
demonstrated	B-X
that	B-X
the	B-X
continuous	B-X
1-dimensional	B-X
motion	B-X
in	B-X
the	B-X
barrel	B-X
and	B-X
outlet	B-X
interfaces	B-X
produced	B-X
representative	B-X
measurements	B-X
of	B-X
each	B-X
batch	B-X
during	B-X
calibration	B-X
and	B-X
test	B-X
experiments	B-X
,	B-X
generating	B-X
a	B-X
low	B-X
minimum	B-X
practical	B-X
error	B-X
(	B-X
MPE	B-X
)	B-X
.	B-X
Dedicated	B-X
neural	B-X
systems	B-X
represent	B-X
the	B-X
space	B-X
surrounding	B-X
the	B-X
body	B-X
,	B-X
termed	B-X
Peripersonal	B-X
space	B-X
(	B-X
PPS	B-X
)	B-X
,	B-X
by	B-X
integrating	B-X
visual	B-X
or	B-X
auditory	B-X
stimuli	B-X
occurring	B-X
near	B-X
the	B-X
body	B-X
with	B-X
somatosensory	B-X
information	B-X
.	B-X
In	B-X
7	B-X
experiments	B-X
we	B-X
delineated	B-X
the	B-X
critical	B-X
distance	B-X
at	B-X
which	B-X
auditory	B-X
or	B-X
visual	B-X
stimuli	B-X
boosted	B-X
tactile	B-X
processing	B-X
on	B-X
the	B-X
hand	B-X
,	B-X
face	B-X
,	B-X
and	B-X
trunk	B-X
as	B-X
a	B-X
proxy	B-X
of	B-X
the	B-X
PPS	B-X
extension	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
at	B-X
least	B-X
three	B-X
body-part	B-X
specific	B-X
PPS	B-X
representations	B-X
exist	B-X
,	B-X
differing	B-X
in	B-X
extension	B-X
and	B-X
directional	B-X
tuning	B-X
.	B-X
These	B-X
distinct	B-X
PPS	B-X
representations	B-X
,	B-X
however	B-X
,	B-X
are	B-X
not	B-X
fully	B-X
independent	B-X
from	B-X
each	B-X
other	B-X
,	B-X
but	B-X
referenced	B-X
to	B-X
the	B-X
common	B-X
reference	B-X
frame	B-X
of	B-X
the	B-X
trunk	B-X
.	B-X

Promoter	O
activity	O
is	O
expressed	O
as	O
the	O
number	O
of	O
firefly	O
luciferase	B-Protein
light	O
units	O
normalized	O
either	O
to	O
pRL	O
-	O
TK	B-Protein
renilla	O
luciferase	B-Protein
light	O
units	O
or	O
to	O
cellular	O
protein	O
concentration	O
(	O
where	O
co	O
-	O
transfected	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
LPS	O
affected	O
pRL	O
-	O
TK	B-Protein
activity	O
)	O
.	O
<EOS>	B-X
Fat	B-X
metabolism	B-X
is	B-X
an	B-X
important	B-X
and	B-X
complex	B-X
biochemical	B-X
reaction	B-X
in	B-X
vivo	B-X
and	B-X
is	B-X
regulated	B-X
by	B-X
many	B-X
factors	B-X
.	B-X
The	B-X
study	B-X
cloned	B-X
the	B-X
goat	B-X
's	B-X
FGF16	B-X
gene	B-X
624	B-X
bp	B-X
long	B-X
,	B-X
including	B-X
the	B-X
complete	B-X
open	B-X
reading	B-X
frame	B-X
that	B-X
encodes	B-X
207	B-X
amino	B-X
acids	B-X
.	B-X
This	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
situation	B-X
where	B-X
FGF16	B-X
is	B-X
overexpressed	B-X
.	B-X
Furthermore	B-X
,	B-X
knockdown	B-X
of	B-X
FGF16	B-X
also	B-X
caused	B-X
down-regulated	B-X
expression	B-X
of	B-X
genes	B-X
associated	B-X
with	B-X
adipocyte	B-X
differentiation	B-X
including	B-X
CCAAT	B-X
enhancer-binding	B-X
protein	B-X
beta	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
,	B-X
fatty	B-X
acid-binding	B-X
protein-2	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
and	B-X
sterol	B-X
regulatory	B-X
element	B-X
binding	B-X
protein-1	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
but	B-X
the	B-X
preadipocyte	B-X
factor-1	B-X
was	B-X
up-regulated	B-X
.	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
the	B-X
genes	B-X
adipose	B-X
triglyceride	B-X
lipase	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
and	B-X
hormone-sensitive	B-X
lipase	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
associated	B-X
with	B-X
triglyceride	B-X
breakdown	B-X
were	B-X
highly	B-X
expressed	B-X
.	B-X
Next	B-X
,	B-X
we	B-X
locked	B-X
the	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptor-4	B-X
(	B-X
FGFR4	B-X
)	B-X
through	B-X
the	B-X
protein	B-X
interaction	B-X
network	B-X
and	B-X
interfering	B-X
with	B-X
FGF16	B-X
to	B-X
significantly	B-X
reduce	B-X
FGFR4	B-X
expression	B-X
.	B-X
Overexpression	B-X
and	B-X
interference	B-X
methods	B-X
confirmed	B-X
that	B-X
FGFR4	B-X
and	B-X
FGF16	B-X
have	B-X
the	B-X
same	B-X
promoting	B-X
function	B-X
in	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
Finally	B-X
,	B-X
using	B-X
co-transfection	B-X
technology	B-X
,	B-X
pc-FGF16	B-X
and	B-X
siRNA-FGFR4	B-X
,	B-X
siRNA2-FGF16	B-X
and	B-X
siRNA-FGFR4	B-X
were	B-X
combined	B-X
to	B-X
treat	B-X
adipocytes	B-X
separately	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
in	B-X
the	B-X
case	B-X
of	B-X
overexpression	B-X
of	B-X
FGF16	B-X
,	B-X
cell	B-X
lipid	B-X
secretion	B-X
and	B-X
triglyceride	B-X
synthesis	B-X
showed	B-X
a	B-X
trend	B-X
of	B-X
first	B-X
increase	B-X
and	B-X
then	B-X
decrease	B-X
with	B-X
increasing	B-X
interference	B-X
concentration	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
interference	B-X
with	B-X
FGF16	B-X
,	B-X
lipid	B-X
secretion	B-X
and	B-X
triglyceride	B-X
synthesis	B-X
showed	B-X
a	B-X
downward	B-X
trend	B-X
with	B-X
the	B-X
increase	B-X
of	B-X
interference	B-X
concentration	B-X
.	B-X
These	B-X
findings	B-X
illustrated	B-X
that	B-X
FGF16	B-X
mediates	B-X
adipocyte	B-X
differentiation	B-X
via	B-X
receptor	B-X
FGFR4	B-X
expression	B-X
and	B-X
contributed	B-X
to	B-X
further	B-X
study	B-X
of	B-X
the	B-X
functional	B-X
role	B-X
of	B-X
FGF16	B-X
in	B-X
goat	B-X
fat	B-X
formation	B-X
.	B-X

Protein	O
concentration	O
was	O
determined	O
using	O
the	O
Bio	O
-	O
Rad	O
protein	O
microassay	O
reagent	O
.	O

Lentiviral	O
shRNAs	O
,	O
Packaging	O
and	O
Transduction	O
<EOS>	B-X
This	B-X
included	B-X
designing	B-X
better	B-X
methods	B-X
for	B-X
the	B-X
successful	B-X
delivery	B-X
of	B-X
small	B-X
interfering	B-X
RNAs	B-X
(	B-X
siRNAs	B-X
)	B-X
and	B-X
short	B-X
hairpin	B-X
RNAs	B-X
(	B-X
shRNAs	B-X
)	B-X
into	B-X
mammalian	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
the	B-X
practicality	B-X
of	B-X
including	B-X
two	B-X
shRNAs	B-X
with	B-X
different	B-X
efficacies	B-X
of	B-X
knockdown	B-X
to	B-X
provide	B-X
an	B-X
additional	B-X
level	B-X
of	B-X
control	B-X
and	B-X
to	B-X
verify	B-X
dose	B-X
dependency	B-X
of	B-X
functional	B-X
effects	B-X
.	B-X
Lentiviral	B-X
vectors	B-X
are	B-X
often	B-X
used	B-X
to	B-X
introduce	B-X
protein	B-X
encoding	B-X
cDNAs	B-X
,	B-X
such	B-X
as	B-X
reporter	B-X
genes	B-X
,	B-X
or	B-X
for	B-X
noncoding	B-X
sequences	B-X
,	B-X
such	B-X
as	B-X
mediators	B-X
of	B-X
RNA	B-X
interference	B-X
or	B-X
genome	B-X
editing	B-X
,	B-X
including	B-X
shRNA	B-X
or	B-X
gRNA	B-X
,	B-X
respectively	B-X
.	B-X
Lentiviral	B-X
transduction	B-X
is	B-X
a	B-X
highly	B-X
efficient	B-X
DNA	B-X
delivery	B-X
method	B-X
for	B-X
RNA	B-X
interference	B-X
applications	B-X
.	B-X
Lentiviral	B-X
vectors	B-X
encoding	B-X
a	B-X
miRNA	B-X
sequence	B-X
and	B-X
emerald	B-X
green	B-X
fluorescence	B-X
protein	B-X
were	B-X
co-transfected	B-X
with	B-X
ViraPower™	B-X
,	B-X
Lenti-X™	B-X
HTX	B-X
,	B-X
MISSION	B-X
(	B-X
®	B-X
)	B-X
Lentiviral	B-X
or	B-X
Trans-Lentiviral™	B-X
packaging	B-X
mix	B-X
in	B-X
HEK-293T	B-X
or	B-X
293FT	B-X
cells	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
lines	B-X
,	B-X
the	B-X
highest	B-X
lentiviral	B-X
titer	B-X
was	B-X
obtained	B-X
with	B-X
MISSION	B-X
(	B-X
®	B-X
)	B-X
Lentiviral	B-X
packaging	B-X
mix	B-X
,	B-X
followed	B-X
by	B-X
ViraPower™	B-X
,	B-X
Lenti-X™	B-X
HTX	B-X
,	B-X
and	B-X
Trans-Lentiviral™	B-X
.	B-X
With	B-X
the	B-X
combination	B-X
of	B-X
MISSION	B-X
(	B-X
®	B-X
)	B-X
Lentiviral	B-X
packaging	B-X
mix	B-X
and	B-X
HEK-293T	B-X
cells	B-X
,	B-X
an	B-X
up	B-X
to	B-X
48.5-fold	B-X
higher	B-X
lentiviral	B-X
titer	B-X
was	B-X
reached	B-X
compared	B-X
to	B-X
other	B-X
packaging	B-X
mixes	B-X
and	B-X
producer	B-X
cell	B-X
lines	B-X
.	B-X

pLKO	O
.	O
1	O
-	O
puro	O
lentiviral	O
vectors	O
carrying	O
short	O
hairpin	O
RNAs	O
(	O
shRNA	O
)	O
specific	O
for	O
human	O
and	O
mouse	O
cebpb	B-Protein
were	O
used	O
in	O
these	O
studies	O
.	O

Because	O
the	O
human	O
and	O
mouse	O
cebpb	B-Protein
3	O
'	O
untranslated	O
regions	O
are	O
not	O
identical	O
,	O
these	O
species	O
-	O
specific	O
shRNAs	O
cannot	O
knockdown	O
expression	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
when	O
used	O
on	O
cells	O
of	O
the	O
other	O
species	O
;	O
therefore	O
we	O
used	O
the	O
human	O
CEBPB	O
shRNA	O
as	O
a	O
control	O
in	O
these	O
experiments	O
as	O
in	O
[	O
38	O
]	O
.	O
<EOS>	B-X
Mixed-lineage	B-X
leukemia	B-X
1	B-X
(	B-X
MLL1	B-X
)	B-X
,	B-X
which	B-X
exerts	B-X
its	B-X
H3K4	B-X
methyltransferase	B-X
activity	B-X
by	B-X
interacting	B-X
with	B-X
WDR5	B-X
,	B-X
ASH2L	B-X
,	B-X
and	B-X
RBBP5	B-X
,	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
regulating	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
homeostasis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
exact	B-X
role	B-X
of	B-X
MLL1-complex	B-X
in	B-X
myeloid	B-X
cells	B-X
is	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
microarray	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
core	B-X
components	B-X
of	B-X
the	B-X
Mll1-complex	B-X
,	B-X
Wdr5	B-X
,	B-X
Ash2l	B-X
,	B-X
and	B-X
Mll1	B-X
,	B-X
were	B-X
concurrently	B-X
downregulated	B-X
by	B-X
tumor-secreted	B-X
factors	B-X
as	B-X
well	B-X
as	B-X
GM-CSF	B-X
+	B-X
IL-6	B-X
during	B-X
the	B-X
accumulation	B-X
and	B-X
activation	B-X
of	B-X
murine	B-X
myeloid-derived	B-X
suppressor	B-X
cells	B-X
(	B-X
MDSCs	B-X
)	B-X
.	B-X
These	B-X
changes	B-X
were	B-X
further	B-X
validated	B-X
by	B-X
quantitative	B-X
RT-PCR	B-X
and	B-X
Western	B-X
blotting	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
WDR5	B-X
and	B-X
ASH2L	B-X
were	B-X
also	B-X
significantly	B-X
decreased	B-X
in	B-X
bone	B-X
marrow	B-X
MDSCs	B-X
of	B-X
lung	B-X
cancer	B-X
patients	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
healthy	B-X
controls	B-X
.	B-X
Functionally	B-X
,	B-X
ectopic	B-X
expression	B-X
of	B-X
Wdr5	B-X
,	B-X
Ash2l	B-X
,	B-X
and	B-X
Mll1	B-X
(	B-X
C	B-X
terminus	B-X
)	B-X
reversed	B-X
the	B-X
accumulation	B-X
and	B-X
function	B-X
of	B-X
GM-CSF	B-X
+	B-X
IL-6-induced	B-X
as	B-X
well	B-X
as	B-X
tumor-cocultured	B-X
polymorphonuclear	B-X
MDSCs	B-X
(	B-X
PMN-MDSCs	B-X
)	B-X
by	B-X
promoting	B-X
them	B-X
to	B-X
differentiate	B-X
into	B-X
mature	B-X
neutrophil-like	B-X
cells	B-X
.	B-X
Mechanistically	B-X
,	B-X
GM-CSF	B-X
+	B-X
IL-6-activated	B-X
Stat3	B-X
and	B-X
Cebpβ	B-X
synergistically	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
miR-21a	B-X
,	B-X
miR-21b	B-X
,	B-X
and	B-X
miR-181b	B-X
,	B-X
and	B-X
thus	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
Wdr5	B-X
,	B-X
Ash2l	B-X
,	B-X
and	B-X
Mll1	B-X
by	B-X
targeting	B-X
to	B-X
their	B-X
3	B-X
'	B-X
untranslated	B-X
regions	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
knockdown	B-X
of	B-X
these	B-X
microRNAs	B-X
also	B-X
suppressed	B-X
the	B-X
expansion	B-X
and	B-X
function	B-X
of	B-X
GM-CSF	B-X
+	B-X
IL-6-induced	B-X
PMN-MDSCs	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
Stat3/Cebpβ-miR-21a/b/181b-Mll1-complex	B-X
axis	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
PMN-MDSC	B-X
expansion	B-X
,	B-X
activation	B-X
,	B-X
and	B-X
differentiation	B-X
,	B-X
and	B-X
this	B-X
axis	B-X
may	B-X
provide	B-X
an	B-X
effectively	B-X
immunological	B-X
therapeutic	B-X
approach	B-X
for	B-X
patients	B-X
with	B-X
cancer	B-X
or	B-X
other	B-X
immunological	B-X
diseases	B-X
.	B-X

To	O
produce	O
lentiviral	O
particles	O
,	O
HEK	O
-	O
293T	O
cells	O
were	O
transfected	O
with	O
a	O
mixture	O
of	O
plasmids	O
:	O
each	O
shRNA	O
expression	O
plasmid	O
(	O
1	O
microg	O
)	O
,	O
pCMV	O
-	O
deltaR8	O
.	O
2dvpr	O
packaging	O
plasmid	O
(	O
0	O
.	O
75	O
microg	O
)	O
,	O
and	O
pCMV	O
-	O
VSV	O
-	O
G	O
envelope	O
plasmid	O
(	O
0	O
.	O
25	O
microg	O
)	O
using	O
Lipofectamine	O
2000	O
reagent	O
(	O
Invitrogen	O
)	O
.	O

The	O
lentiviral	O
supernatant	O
was	O
collected	O
48	O
hrs	O
after	O
transfection	O
,	O
cleared	O
by	O
centrifugation	O
at	O
2	O
,	O
000	O
g	O
for	O
10	O
mins	O
and	O
passed	O
through	O
a	O
0	O
.	O
45	O
microm	O
filter	O
.	O

The	O
target	O
cells	O
were	O
treated	O
with	O
the	O
lentiviral	O
supernatant	O
and	O
8	O
microg	O
/	O
ml	O
Polybrene	O
(	O
American	O
Bioanalytical	O
)	O
for	O
24	O
hrs	O
.	O

The	O
lentiviral	O
supernatant	O
was	O
replaced	O
with	O
fresh	O
growth	O
media	O
and	O
incubated	O
further	O
for	O
72	O
hrs	O
to	O
allow	O
for	O
effective	O
gene	O
knockdown	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
knockdown	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
IMiD	B-X
compounds	B-X
down-regulate	B-X
CCAAT/enhancer-binding	B-X
protein-β	B-X
(	B-X
C/EBPβ	B-X
)	B-X
resulting	B-X
in	B-X
abrogation	B-X
of	B-X
cell	B-X
proliferation	B-X
.	B-X
Overexpression	B-X
of	B-X
C/EBPβ	B-X
rescued	B-X
MM	B-X
cells	B-X
from	B-X
IMiD-induced	B-X
inhibition	B-X
of	B-X
proliferation	B-X
,	B-X
indicating	B-X
that	B-X
C/EBPβ	B-X
is	B-X
critical	B-X
in	B-X
mediating	B-X
antiproliferative	B-X
effects	B-X
.	B-X
IMiD-induced	B-X
decrease	B-X
of	B-X
C/EBPβ	B-X
protein	B-X
led	B-X
to	B-X
impaired	B-X
transcription	B-X
of	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF4	B-X
)	B-X
.	B-X
Down-regulation	B-X
of	B-X
IRF4	B-X
by	B-X
lenalidomide	B-X
was	B-X
confirmed	B-X
by	B-X
longitudinal	B-X
studies	B-X
of	B-X
bone	B-X
marrow	B-X
samples	B-X
from	B-X
23	B-X
patients	B-X
obtained	B-X
before	B-X
and	B-X
during	B-X
lenalidomide	B-X
treatment	B-X
using	B-X
CD138⁺/IRF4⁺	B-X
double	B-X
labeling	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
down-regulation	B-X
of	B-X
C/EBPβ	B-X
protein	B-X
,	B-X
IMiD	B-X
compounds	B-X
did	B-X
not	B-X
alter	B-X
C/EBPβ	B-X
mRNA	B-X
levels	B-X
or	B-X
protein	B-X
stability	B-X
,	B-X
suggesting	B-X
translational	B-X
regulation	B-X
of	B-X
C/EBPβ	B-X
.	B-X
We	B-X
could	B-X
demonstrate	B-X
that	B-X
C/EBPβ	B-X
protein	B-X
expression	B-X
is	B-X
under	B-X
eIF4E-translational	B-X
control	B-X
in	B-X
MM	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
eIF4E-C/EBPβ	B-X
axis	B-X
by	B-X
IMiD	B-X
compounds	B-X
was	B-X
not	B-X
observed	B-X
in	B-X
IMiD-resistant	B-X
MM	B-X
cells	B-X
.	B-X

Transient	O
Transfection	O
and	O
Luciferase	B-Protein
Assays	O
(	O
MEF	O
Cells	O
)	O
<EOS>	B-X
Induction	B-X
of	B-X
DDA3	B-X
was	B-X
found	B-X
in	B-X
adriamycin	B-X
treated	B-X
normal	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
cells	B-X
(	B-X
MEF	B-X
)	B-X
,	B-X
but	B-X
not	B-X
in	B-X
p53	B-X
knockout	B-X
(	B-X
p53	B-X
(	B-X
-/-	B-X
)	B-X
)	B-X
MEF	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
findings	B-X
,	B-X
elevated	B-X
expression	B-X
of	B-X
p73	B-X
protein	B-X
and	B-X
DDA3	B-X
mRNA	B-X
were	B-X
observed	B-X
concomitantly	B-X
in	B-X
the	B-X
p53	B-X
(	B-X
-/-	B-X
)	B-X
MEF	B-X
cells	B-X
treated	B-X
with	B-X
cisplatin	B-X
.	B-X
Gel	B-X
mobility	B-X
supershift	B-X
assays	B-X
with	B-X
antibodies	B-X
directed	B-X
against	B-X
the	B-X
MEF-2	B-X
protein	B-X
,	B-X
the	B-X
homeobox	B-X
protein	B-X
MHox	B-X
,	B-X
or	B-X
the	B-X
zinc	B-X
finger	B-X
protein	B-X
HF-1b	B-X
,	B-X
document	B-X
that	B-X
these	B-X
factors	B-X
are	B-X
not	B-X
major	B-X
components	B-X
of	B-X
the	B-X
endogenous	B-X
ANF-AT	B-X
binding	B-X
activity	B-X
in	B-X
cardiac	B-X
muscle	B-X
cells	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
the	B-X
Egr-1	B-X
gene	B-X
into	B-X
HeLa	B-X
cells	B-X
also	B-X
resulted	B-X
in	B-X
up-regulation	B-X
of	B-X
the	B-X
NDRG1	B-X
mRNA	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
induction	B-X
of	B-X
NDRG1	B-X
expression	B-X
by	B-X
hypoxia	B-X
and	B-X
deferoxamine	B-X
was	B-X
diminished	B-X
by	B-X
RNA	B-X
interference	B-X
knockdown	B-X
of	B-X
Egr-1	B-X
gene	B-X
expression	B-X
and	B-X
in	B-X
Egr-1-/-	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEF	B-X
)	B-X
compared	B-X
with	B-X
Egr-1+/-	B-X
MEFs	B-X
.	B-X

Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
(	O
1x105	O
)	O
[	O
34	O
]	O
were	O
transfected	O
with	O
the	O
indicated	O
luciferase	B-Protein
reporter	O
plasmid	O
(	O
400	O
ng	O
)	O
along	O
with	O
a	O
beta	B-Protein
-	I-Protein
actin	I-Protein
-	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	O
plasmid	O
(	O
200	O
ng	O
)	O
by	O
electroporation	O
using	O
the	O
Invitrogen	O
Neon	O
(	O
TM	O
)	O
system	O
(	O
1	O
pulse	O
,	O
1350	O
V	O
,	O
30	O
msec	O
)	O
.	O

Transfected	O
cells	O
were	O
transferred	O
to	O
pre	O
-	O
warmed	O
media	O
in	O
24	O
well	O
plates	O
and	O
incubated	O
for	O
48	O
hrs	O
prior	O
to	O
incubation	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hrs	O
where	O
indicated	O
.	O

In	O
some	O
experiments	O
,	O
plasmids	O
encoding	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
(	O
T188A	B-Protein
,	O
T217A	B-Protein
,	O
S64A	B-Protein
)	O
[	O
38	O
]	O
-	O
[	O
40	O
]	O
or	O
control	O
vector	O
were	O
co	O
-	O
transfected	O
(	O
0	O
.	O
6	O
-	O
1	O
.	O
0	O
microg	O
total	O
DNA	O
)	O
.	O
<EOS>	B-X
The	B-X
identification	B-X
of	B-X
the	B-X
cellular	B-X
factors	B-X
that	B-X
control	B-X
the	B-X
transcription	B-X
regulatory	B-X
activity	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
C	B-X
promoter	B-X
(	B-X
Cp	B-X
)	B-X
is	B-X
fundamental	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
control	B-X
virus	B-X
latent	B-X
gene	B-X
expression	B-X
.	B-X
Using	B-X
transient	B-X
transfection	B-X
of	B-X
reporter	B-X
plasmids	B-X
in	B-X
group	B-X
I	B-X
phenotype	B-X
B-lymphoid	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
-248	B-X
to	B-X
-55	B-X
region	B-X
(	B-X
-248/-55	B-X
region	B-X
)	B-X
of	B-X
Cp	B-X
contains	B-X
elements	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
oriPI-EBNA1-dependent	B-X
as	B-X
well	B-X
as	B-X
oriPI-EBNA1-independent	B-X
activation	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X
We	B-X
now	B-X
establish	B-X
the	B-X
importance	B-X
of	B-X
this	B-X
region	B-X
by	B-X
a	B-X
detailed	B-X
mutational	B-X
analysis	B-X
of	B-X
reporter	B-X
plasmids	B-X
carrying	B-X
Cp	B-X
regulatory	B-X
sequences	B-X
together	B-X
with	B-X
or	B-X
without	B-X
oriPI	B-X
.	B-X
The	B-X
reporter	B-X
plasmids	B-X
were	B-X
transfected	B-X
into	B-X
group	B-X
I	B-X
phenotype	B-X
Rael	B-X
cells	B-X
and	B-X
group	B-X
III	B-X
phenotype	B-X
cbc-Rael	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
Cp	B-X
activity	B-X
measured	B-X
was	B-X
correlated	B-X
with	B-X
the	B-X
binding	B-X
of	B-X
candidate	B-X
transcription	B-X
factors	B-X
in	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
further	B-X
assessed	B-X
in	B-X
cotransfection	B-X
experiments	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
NF-Y	B-X
transcription	B-X
factor	B-X
interacts	B-X
with	B-X
the	B-X
previously	B-X
identified	B-X
CCAAT	B-X
box	B-X
in	B-X
the	B-X
-71/-63	B-X
Cp	B-X
region	B-X
(	B-X
M.	B-X
T.	B-X
Puglielli	B-X
,	B-X
M.	B-X
Woisetschlaeger	B-X
,	B-X
and	B-X
S.	B-X
H.	B-X
Speck	B-X
,	B-X
J.	B-X
Virol	B-X
.	B-X
70:5758-5768	B-X
,	B-X
1996	B-X
)	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
members	B-X
of	B-X
the	B-X
C/EBP	B-X
transcription	B-X
factor	B-X
family	B-X
interact	B-X
with	B-X
a	B-X
C/EBP	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
-119/-112	B-X
region	B-X
of	B-X
Cp	B-X
and	B-X
that	B-X
this	B-X
interaction	B-X
is	B-X
important	B-X
for	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
central	B-X
finding	B-X
is	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
GC-rich	B-X
sequence	B-X
in	B-X
the	B-X
-99/-91	B-X
Cp	B-X
region	B-X
that	B-X
is	B-X
essential	B-X
for	B-X
oriPI-EBNA1-independent	B-X
as	B-X
well	B-X
as	B-X
oriPI-EBNA1-dependent	B-X
activity	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
overlapping	B-X
binding	B-X
sites	B-X
for	B-X
Sp1	B-X
and	B-X
Egr-1	B-X
,	B-X
and	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
Sp1	B-X
is	B-X
a	B-X
positive	B-X
and	B-X
Egr-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
Cp	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
a	B-X
reporter	B-X
plasmid	B-X
that	B-X
in	B-X
addition	B-X
to	B-X
oriPI	B-X
contains	B-X
only	B-X
the	B-X
-111/+76	B-X
region	B-X
of	B-X
Cp	B-X
still	B-X
retains	B-X
the	B-X
ability	B-X
to	B-X
be	B-X
activated	B-X
by	B-X
EBNA1	B-X
.	B-X

Luciferase	B-Protein
activity	O
was	O
determined	O
and	O
normalized	O
to	O
that	O
of	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
[	O
38	O
]	O
using	O
the	O
Luciferase	B-Protein
Assay	O
System	O
and	O
beta	B-Protein
-	I-Protein
Galactosidase	I-Protein
Enzyme	O
Assay	O
System	O
Kits	O
,	O
respectively	O
(	O
Promega	O
)	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
,	O
and	O
triplicate	O
samples	O
were	O
employed	O
for	O
each	O
sample	O
.	O

Expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutant	I-Protein
proteins	O
was	O
checked	O
for	O
equal	O
expression	O
by	O
western	O
blot	O
.	O

Electrophoretic	O
Mobility	O
Shift	O
Assays	O
<EOS>	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
analytical	B-X
chemistry	B-X
,	B-X
quantitative	B-X
bioscience	B-X
,	B-X
and	B-X
point-of-care	B-X
diagnostics	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSA	B-X
)	B-X
have	B-X
been	B-X
widely	B-X
used	B-X
to	B-X
study	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
protein-RNA	B-X
interactions	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
seem	B-X
well	B-X
suited	B-X
to	B-X
this	B-X
purpose	B-X
and	B-X
could	B-X
be	B-X
used	B-X
for	B-X
the	B-X
efficient	B-X
screening	B-X
of	B-X
patient	B-X
samples	B-X
for	B-X
sequence	B-X
alterations	B-X
,	B-X
effectively	B-X
reducing	B-X
the	B-X
number	B-X
of	B-X
samples	B-X
that	B-X
must	B-X
be	B-X
subjected	B-X
to	B-X
full	B-X
and	B-X
careful	B-X
sequencing	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSA	B-X
)	B-X
have	B-X
proven	B-X
their	B-X
usefulness	B-X
for	B-X
studying	B-X
interactions	B-X
between	B-X
biological	B-X
molecules	B-X
.	B-X

Radiolabelled	O
,	O
double	O
-	O
stranded	O
oligonucleotide	O
probes	O
for	O
gel	O
shift	O
assays	O
were	O
prepared	O
using	O
T4	B-Protein
polynucleotide	I-Protein
kinase	I-Protein
and	O
[	O
gamma	O
-	O
32P	O
]	O
-	O
ATP	O
.	O

RAW	O
264	O
.	O
7	O
nuclear	O
extracts	O
were	O
prepared	O
by	O
the	O
detergent	O
lysis	O
method	O
[	O
41	O
]	O
.	O

DNA	O
binding	O
reactions	O
(	O
25	O
microl	O
)	O
containing	O
10	O
mM	O
HEPES	O
pH	O
7	O
.	O
9	O
,	O
10	O
microg	O
/	O
ml	O
BSA	O
,	O
2	O
mM	O
DTT	O
,	O
30	O
%	O
glycerol	O
,	O
20	O
%	O
Ficoll	O
-	O
400	O
,	O
1	O
microg	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
,	O
6	O
microg	O
of	O
nuclear	O
extracts	O
and	O
10	O
,	O
000	O
to	O
20	O
,	O
000	O
cpm	O
(	O
0	O
.	O
05	O
to	O
0	O
.	O
2	O
ng	O
)	O
of	O
radiolabelled	O
probe	O
were	O
performed	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

Binding	O
reaction	O
products	O
were	O
resolved	O
by	O
electrophoresis	O
at	O
room	O
temperature	O
on	O
5	O
%	O
polyacrylamide	O
gels	O
(	O
29	O
:	O
1	O
acrylamide	O
:	O
bis	O
-	O
acrylamide	O
(	O
Bio	O
-	O
Rad	O
)	O
)	O
in	O
1x	O
TBE	O
at	O
10V	O
/	O
cm	O
.	O

For	O
supershift	O
assays	O
,	O
nuclear	O
extracts	O
were	O
pre	O
-	O
incubated	O
2	O
hrs	O
on	O
ice	O
with	O
4	O
microg	O
of	O
specific	O
C	O
/	O
EBP	O
antibody	O
.	O

Antibodies	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
:	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
alpha	O
(	O
sc	O
-	O
61	O
)	O
,	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
sc	O
-	O
150	O
)	O
,	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
delta	O
(	O
sc	O
-	O
151	O
)	O
and	O
anti	O
-	O
C	O
/	O
EBP	O
-	O
epsilon	O
(	O
sc	O
-	O
158	O
)	O
.	O

Chromatin	O
Immunoprecipitation	O
(	O
ChIP	O
)	O
Assay	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
is	B-X
an	B-X
important	B-X
technique	B-X
in	B-X
the	B-X
study	B-X
of	B-X
protein-gene	B-X
interactions	B-X
.	B-X
Using	B-X
ChIP	B-X
,	B-X
DNA-protein	B-X
interactions	B-X
are	B-X
studied	B-X
within	B-X
the	B-X
context	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Although	B-X
ChIP	B-X
is	B-X
a	B-X
very	B-X
versatile	B-X
tool	B-X
,	B-X
the	B-X
procedure	B-X
requires	B-X
the	B-X
optimization	B-X
of	B-X
reaction	B-X
conditions	B-X
.	B-X
Several	B-X
modifications	B-X
to	B-X
the	B-X
original	B-X
ChIP	B-X
technique	B-X
have	B-X
been	B-X
published	B-X
to	B-X
improve	B-X
the	B-X
success	B-X
and	B-X
to	B-X
enhance	B-X
the	B-X
utility	B-X
of	B-X
this	B-X
procedure	B-X
.	B-X
This	B-X
review	B-X
addresses	B-X
the	B-X
critical	B-X
parameters	B-X
and	B-X
the	B-X
variants	B-X
of	B-X
ChiP	B-X
as	B-X
well	B-X
as	B-X
the	B-X
different	B-X
analytical	B-X
tools	B-X
that	B-X
can	B-X
be	B-X
combined	B-X
with	B-X
ChIP	B-X
to	B-X
enable	B-X
better	B-X
understanding	B-X
of	B-X
DNA-protein	B-X
interactions	B-X
in	B-X
vivo	B-X
.	B-X

ChIP	O
assays	O
were	O
performed	O
using	O
a	O
commercially	O
available	O
Magna	O
-	O
ChIP	O
(	O
TM	O
)	O
kit	O
(	O
Millipore	O
)	O
,	O
as	O
recommended	O
by	O
the	O
manufacturer	O
,	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
after	O
crosslinking	O
the	O
chromatin	O
with	O
1	O
%	O
formaldehyde	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
neutralizing	O
with	O
glycine	O
for	O
5	O
min	O
at	O
room	O
temperature	O
,	O
cells	O
were	O
washed	O
with	O
cold	O
PBS	O
,	O
scraped	O
and	O
collected	O
on	O
ice	O
.	O

Cells	O
extracts	O
were	O
prepared	O
using	O
a	O
commercially	O
available	O
kit	O
(	O
Millipore	O
)	O
.	O

Nuclear	O
lysates	O
were	O
sonicated	O
5	O
times	O
for	O
15	O
sec	O
with	O
1	O
min	O
intervals	O
on	O
ice	O
using	O
a	O
Sonic	O
Dismembrator	O
(	O
Fisher	O
)	O
.	O

An	O
equal	O
amount	O
of	O
chromatin	O
was	O
immunoprecipitated	O
at	O
4degreesC	O
overnight	O
with	O
at	O
least	O
1	O
microg	O
of	O
the	O
following	O
antibodies	O
:	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
sc	O
-	O
150X	O
)	O
,	O
p	O
-	O
C	O
/	O
EBP	O
-	O
beta	O
(	O
T217	O
)	O
(	O
sc	O
-	O
16993X	O
)	O
,	O
normal	O
rabbit	O
IgG	O
(	O
sc	O
-	O
2027	O
)	O
(	O
Santa	O
Cruz	O
Biotechnologies	O
)	O
and	O
RNA	O
polymerase	O
II	O
(	O
Clone	O
CTD4H8	O
)	O
(	O
Millipore	O
)	O
.	O

Immunoprecipitated	O
products	O
were	O
collected	O
after	O
incubation	O
with	O
Protein	B-Protein
G	I-Protein
coated	O
magnetic	O
beads	O
(	O
Millipore	O
)	O
.	O

The	O
beads	O
were	O
washed	O
,	O
the	O
bound	O
chromatin	O
was	O
eluted	O
in	O
ChIP	O
Elution	O
Buffer	O
(	O
Millipore	O
)	O
and	O
the	O
proteins	O
were	O
digested	O
with	O
Proteinase	B-Protein
K	I-Protein
for	O
2	O
hrs	O
at	O
62degreesC	O
.	O

The	O
DNA	O
was	O
then	O
purified	O
using	O
the	O
QIAquick	O
PCR	O
Purification	O
Kit	O
(	O
Qiagen	O
)	O
.	O
<EOS>	B-X
Various	B-X
types	B-X
of	B-X
biological	B-X
samples	B-X
present	B-X
challenges	B-X
for	B-X
extraction	B-X
of	B-X
DNA	B-X
suitable	B-X
for	B-X
subsequent	B-X
molecular	B-X
analyses	B-X
.	B-X
Commonly	B-X
used	B-X
extraction	B-X
methods	B-X
,	B-X
such	B-X
as	B-X
silica	B-X
membrane	B-X
columns	B-X
and	B-X
phenol-chloroform	B-X
,	B-X
while	B-X
highly	B-X
successful	B-X
may	B-X
still	B-X
fail	B-X
to	B-X
provide	B-X
a	B-X
sufficiently	B-X
pure	B-X
DNA	B-X
extract	B-X
with	B-X
some	B-X
samples	B-X
.	B-X
Synchronous	B-X
coefficient	B-X
of	B-X
drag	B-X
alteration	B-X
(	B-X
SCODA	B-X
)	B-X
,	B-X
implemented	B-X
in	B-X
Boreal	B-X
Genomics	B-X
'	B-X
Aurora	B-X
Nucleic	B-X
Acid	B-X
Extraction	B-X
System	B-X
(	B-X
Boreal	B-X
Genomics	B-X
,	B-X
Vancouver	B-X
,	B-X
BC	B-X
)	B-X
,	B-X
is	B-X
a	B-X
new	B-X
technology	B-X
that	B-X
offers	B-X
the	B-X
potential	B-X
to	B-X
remove	B-X
inhibitors	B-X
effectively	B-X
while	B-X
simultaneously	B-X
concentrating	B-X
DNA	B-X
.	B-X
In	B-X
this	B-X
initial	B-X
study	B-X
,	B-X
SCODA	B-X
was	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
remove	B-X
various	B-X
concentrations	B-X
of	B-X
forensically	B-X
and	B-X
medically	B-X
relevant	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
inhibitors	B-X
naturally	B-X
found	B-X
in	B-X
tissue	B-X
,	B-X
hair	B-X
,	B-X
blood	B-X
,	B-X
plant	B-X
,	B-X
and	B-X
soil	B-X
samples	B-X
.	B-X
SCODA	B-X
was	B-X
used	B-X
to	B-X
purify	B-X
and	B-X
concentrate	B-X
DNA	B-X
from	B-X
intentionally	B-X
contaminated	B-X
DNA	B-X
samples	B-X
containing	B-X
known	B-X
concentrations	B-X
of	B-X
hematin	B-X
,	B-X
humic	B-X
acid	B-X
,	B-X
melanin	B-X
,	B-X
and	B-X
tannic	B-X
acid	B-X
.	B-X
The	B-X
internal	B-X
positive	B-X
control	B-X
(	B-X
IPC	B-X
)	B-X
provided	B-X
in	B-X
the	B-X
Quantifiler™	B-X
Human	B-X
DNA	B-X
Quantification	B-X
Kit	B-X
(	B-X
Life	B-X
Technologies	B-X
,	B-X
Foster	B-X
City	B-X
,	B-X
CA	B-X
)	B-X
and	B-X
short	B-X
tandem	B-X
repeat	B-X
(	B-X
STR	B-X
)	B-X
profiling	B-X
(	B-X
AmpFℓSTR®	B-X
Identifiler®	B-X
Plus	B-X
PCR	B-X
Amplification	B-X
Kit	B-X
;	B-X
Life	B-X
Technologies	B-X
,	B-X
Foster	B-X
City	B-X
,	B-X
CA	B-X
)	B-X
were	B-X
used	B-X
to	B-X
measure	B-X
inhibition	B-X
effects	B-X
and	B-X
hence	B-X
purification	B-X
.	B-X
SCODA	B-X
methodology	B-X
yielded	B-X
overall	B-X
higher	B-X
efficiency	B-X
of	B-X
purification	B-X
of	B-X
highly	B-X
contaminated	B-X
samples	B-X
compared	B-X
with	B-X
the	B-X
QIAquick®	B-X
PCR	B-X
Purification	B-X
Kit	B-X
(	B-X
Qiagen	B-X
,	B-X
Valencia	B-X
,	B-X
CA	B-X
)	B-X
.	B-X
SCODA-purified	B-X
DNA	B-X
yielded	B-X
no	B-X
cycle	B-X
shift	B-X
of	B-X
the	B-X
IPC	B-X
for	B-X
each	B-X
sample	B-X
and	B-X
yielded	B-X
greater	B-X
allele	B-X
percentage	B-X
recovery	B-X
and	B-X
relative	B-X
fluorescence	B-X
unit	B-X
values	B-X
compared	B-X
with	B-X
the	B-X
QIAquick®	B-X
purification	B-X
method	B-X
.	B-X
The	B-X
Aurora	B-X
provided	B-X
an	B-X
automated	B-X
,	B-X
minimal-step	B-X
approach	B-X
to	B-X
successfully	B-X
remove	B-X
inhibitors	B-X
and	B-X
concentrate	B-X
DNA	B-X
from	B-X
challenged	B-X
samples	B-X
.	B-X

DNA	O
was	O
amplified	O
by	O
semi	O
-	O
quantitative	O
PCR	O
or	O
by	O
qPCR	O
using	O
the	O
SYBR	O
green	O
method	O
and	O
primers	O
specific	O
for	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
:	O
forward	O
(	O
-	O
338	O
/	O
-	O
315	O
)	O
5	O
'	O
AAGACTCCCACAGATGGTGGCTGT3	O
'	O
;	O
reverse	O
(	O
-	O
5	O
/	O
+	O
19	O
)	O
5	O
'	O
TTCTTGGAAAGCTGGCACTGTGTG3	O
'	O
.	O
<EOS>	B-X
We	B-X
developed	B-X
a	B-X
real-time	B-X
PCR	B-X
method	B-X
for	B-X
specific	B-X
detection	B-X
and	B-X
semi-quantification	B-X
of	B-X
D.	B-X
suzukii	B-X
from	B-X
trap	B-X
samples	B-X
.	B-X
The	B-X
PCR	B-X
assay	B-X
did	B-X
not	B-X
amplify	B-X
DNA	B-X
from	B-X
29	B-X
other	B-X
Drosophilidae	B-X
species	B-X
tested	B-X
.	B-X
Drosophila	B-X
suzukii	B-X
was	B-X
detected	B-X
from	B-X
≥0.96	B-X
pg	B-X
target	B-X
DNA	B-X
and	B-X
from	B-X
laboratory	B-X
samples	B-X
containing	B-X
one	B-X
D.	B-X
suzukii	B-X
in	B-X
2000	B-X
other	B-X
Drosophila	B-X
spp	B-X
.	B-X
We	B-X
tested	B-X
DNA	B-X
stability	B-X
of	B-X
one	B-X
D.	B-X
suzukii	B-X
in	B-X
100	B-X
Drosophila	B-X
spp	B-X
.	B-X
flies	B-X
in	B-X
water	B-X
or	B-X
ethanol	B-X
at	B-X
20	B-X
,	B-X
25	B-X
,	B-X
or	B-X
30°C	B-X
for	B-X
1	B-X
,	B-X
4	B-X
,	B-X
or	B-X
7	B-X
d.	B-X
Only	B-X
water	B-X
at	B-X
30°C	B-X
for	B-X
7	B-X
d	B-X
fully	B-X
impaired	B-X
D.	B-X
suzukii	B-X
DNA	B-X
detectability	B-X
.	B-X
A	B-X
calibration	B-X
curve	B-X
was	B-X
established	B-X
using	B-X
samples	B-X
in	B-X
mouthwash	B-X
containing	B-X
1/1,000-100/1,000	B-X
D.	B-X
suzukii/total	B-X
Drosophila	B-X
spp	B-X
.	B-X
flies	B-X
and	B-X
incubated	B-X
at	B-X
25°C	B-X
for	B-X
7	B-X
d.	B-X
The	B-X
curve	B-X
had	B-X
a	B-X
coefficient	B-X
of	B-X
determination	B-X
(	B-X
R2	B-X
)	B-X
of	B-X
0.9279	B-X
between	B-X
D.	B-X
suzukii	B-X
numbers	B-X
from	B-X
the	B-X
PCR	B-X
and	B-X
the	B-X
true	B-X
D.	B-X
suzukii	B-X
numbers	B-X
in	B-X
samples	B-X
prepared	B-X
in	B-X
70	B-X
%	B-X
ethanol	B-X
.	B-X
Collecting	B-X
samples	B-X
in	B-X
mouthwash	B-X
is	B-X
expected	B-X
to	B-X
improve	B-X
detection	B-X
accuracy	B-X
,	B-X
and	B-X
the	B-X
qPCR	B-X
method	B-X
can	B-X
be	B-X
a	B-X
useful	B-X
tool	B-X
to	B-X
support	B-X
D.	B-X
suzukii	B-X
monitoring	B-X
and	B-X
management	B-X
.	B-X

Statistical	O
Analysis	O

Data	O
are	O
presented	O
as	O
mean	O
+	O
/	O
-	O
SEM	O
per	O
group	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
and	B-X
compare	B-X
the	B-X
micro	B-X
topographic	B-X
characteristics	B-X
of	B-X
dental	B-X
implants	B-X
submitted	B-X
to	B-X
different	B-X
surface	B-X
treatments	B-X
,	B-X
using	B-X
scanning	B-X
electron	B-X
microscopy	B-X
(	B-X
SEM	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
article	B-X
,	B-X
we	B-X
present	B-X
a	B-X
data	B-X
compilation	B-X
reflecting	B-X
recrystallized	B-X
microstructures	B-X
and	B-X
the	B-X
corresponding	B-X
mechanical	B-X
properties	B-X
of	B-X
an	B-X
equiatomic	B-X
,	B-X
single-phase	B-X
face-centered	B-X
cubic	B-X
(	B-X
FCC	B-X
)	B-X
CrFeNi	B-X
medium-entropy	B-X
alloy	B-X
(	B-X
MEA	B-X
)	B-X
.	B-X
For	B-X
the	B-X
analysis	B-X
,	B-X
interpretation	B-X
,	B-X
and	B-X
discussion	B-X
of	B-X
the	B-X
data	B-X
,	B-X
the	B-X
reader	B-X
can	B-X
refer	B-X
to	B-X
the	B-X
original	B-X
research	B-X
article	B-X
entitled	B-X
``	B-X
Effects	B-X
of	B-X
temperature	B-X
on	B-X
mechanical	B-X
properties	B-X
and	B-X
deformation	B-X
mechanisms	B-X
of	B-X
the	B-X
equiatomic	B-X
CrFeNi	B-X
medium-entropy	B-X
alloy	B-X
''	B-X
,	B-X
see	B-X
Ref	B-X
.	B-X
Five	B-X
groups	B-X
of	B-X
tree	B-X
shrews	B-X
(	B-X
n	B-X
=	B-X
7	B-X
per	B-X
group	B-X
)	B-X
were	B-X
used	B-X
.	B-X
Starting	B-X
24	B-X
days	B-X
after	B-X
normal	B-X
eye-opening	B-X
(	B-X
days	B-X
of	B-X
visual	B-X
experience	B-X
[	B-X
DVE	B-X
]	B-X
)	B-X
,	B-X
one	B-X
minus-lens	B-X
group	B-X
wore	B-X
a	B-X
monocular	B-X
-5	B-X
D	B-X
lens	B-X
for	B-X
2	B-X
days	B-X
(	B-X
LIM-2	B-X
)	B-X
,	B-X
another	B-X
minus-lens	B-X
group	B-X
achieved	B-X
stable	B-X
lens	B-X
compensation	B-X
while	B-X
wearing	B-X
a	B-X
monocular	B-X
-5	B-X
D	B-X
lens	B-X
for	B-X
11	B-X
days	B-X
(	B-X
LIM-11	B-X
)	B-X
;	B-X
a	B-X
recovery	B-X
group	B-X
also	B-X
wore	B-X
a	B-X
-5	B-X
D	B-X
lens	B-X
for	B-X
11	B-X
days	B-X
and	B-X
then	B-X
received	B-X
2	B-X
days	B-X
of	B-X
recovery	B-X
starting	B-X
at	B-X
35	B-X
DVE	B-X
(	B-X
REC-2	B-X
)	B-X
.	B-X
Two	B-X
age-matched	B-X
normal	B-X
groups	B-X
were	B-X
examined	B-X
at	B-X
26	B-X
DVE	B-X
and	B-X
37	B-X
DVE	B-X
.	B-X
Small	B-X
myopic	B-X
changes	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
treated	B-X
eyes	B-X
of	B-X
the	B-X
LIM-2	B-X
group	B-X
(	B-X
-1.0	B-X
±	B-X
0.2	B-X
D	B-X
;	B-X
mean	B-X
±	B-X
SEM	B-X
)	B-X
indicating	B-X
eyes	B-X
were	B-X
early	B-X
in	B-X
the	B-X
process	B-X
of	B-X
developing	B-X
LIM	B-X
.	B-X
The	B-X
LIM-11	B-X
group	B-X
exhibited	B-X
complete	B-X
refractive	B-X
compensation	B-X
(	B-X
-5.1	B-X
±	B-X
0.2	B-X
D	B-X
)	B-X
that	B-X
was	B-X
stable	B-X
for	B-X
five	B-X
days	B-X
.	B-X
The	B-X
REC-2	B-X
group	B-X
recovered	B-X
by	B-X
1.3	B-X
±	B-X
0.3	B-X
D	B-X
from	B-X
full	B-X
refractive	B-X
compensation	B-X
.	B-X

Results	O
were	O
analyzed	O
using	O
the	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
or	O
Student	O
'	O
s	O
t	O
test	O
where	O
relevant	O
.	O
<EOS>	B-X
Often	B-X
,	B-X
these	B-X
studies	B-X
are	B-X
excluded	B-X
from	B-X
meta-analysis	B-X
because	B-X
there	B-X
are	B-X
no	B-X
well-established	B-X
statistical	B-X
methods	B-X
to	B-X
pool	B-X
the	B-X
difference	B-X
of	B-X
medians	B-X
.	B-X
To	B-X
include	B-X
these	B-X
studies	B-X
in	B-X
meta-analysis	B-X
,	B-X
several	B-X
authors	B-X
have	B-X
recently	B-X
proposed	B-X
methods	B-X
to	B-X
estimate	B-X
the	B-X
sample	B-X
mean	B-X
and	B-X
standard	B-X
deviation	B-X
from	B-X
the	B-X
median	B-X
,	B-X
sample	B-X
size	B-X
,	B-X
and	B-X
several	B-X
commonly	B-X
reported	B-X
measures	B-X
of	B-X
spread	B-X
.	B-X
Researchers	B-X
frequently	B-X
apply	B-X
these	B-X
methods	B-X
to	B-X
estimate	B-X
the	B-X
difference	B-X
of	B-X
means	B-X
and	B-X
its	B-X
variance	B-X
for	B-X
each	B-X
primary	B-X
study	B-X
and	B-X
pool	B-X
the	B-X
difference	B-X
of	B-X
means	B-X
using	B-X
inverse	B-X
variance	B-X
weighting	B-X
.	B-X
The	B-X
data	B-X
were	B-X
statistically	B-X
analyzed	B-X
by	B-X
applying	B-X
the	B-X
z-score	B-X
robust	B-X
technique	B-X
as	B-X
recommended	B-X
by	B-X
ISO	B-X
Guide	B-X
35	B-X
.	B-X
ANOVA-PCA	B-X
and	B-X
DD-SIMCA	B-X
were	B-X
also	B-X
applied	B-X
to	B-X
evaluate	B-X
stability	B-X
and	B-X
interlaboratory	B-X
studies	B-X
results	B-X
,	B-X
respectively	B-X
.	B-X
It	B-X
has	B-X
been	B-X
demonstrated	B-X
that	B-X
multivariate	B-X
data	B-X
analysis	B-X
can	B-X
be	B-X
successfully	B-X
applied	B-X
as	B-X
an	B-X
alternative	B-X
method	B-X
to	B-X
the	B-X
recommendations	B-X
made	B-X
by	B-X
ISO	B-X
13528	B-X
and	B-X
ISO	B-X
Guide	B-X
35	B-X
with	B-X
defined	B-X
confidence	B-X
intervals	B-X
.	B-X

P	O
-	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

The	O
SerpinB2	B-Protein
Gene	O
is	O
Highly	O
Responsive	O
to	O
LPS	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

When	O
RAW264	O
.	O
7	O
macrophages	O
were	O
exposed	O
to	O
LPS	O
,	O
SerpinB2	B-Protein
mRNA	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
LPS	O
challenge	O
,	O
reaching	O
maximal	O
levels	O
at	O
24	O
hrs	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

A	O
similar	O
strong	O
induction	O
of	O
LPS	O
-	O
inducible	O
SerpinB2	B-Protein
mRNA	O
expression	O
has	O
been	O
reported	O
previously	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
[	O
4	O
]	O
;	O
[	O
32	O
]	O
.	O

LPS	O
-	O
induced	O
SerpinB2	B-Protein
expression	O
involves	O
both	O
an	O
increase	O
in	O
gene	O
transcription	O
and	O
stabilization	O
of	O
the	O
mRNA	O
[	O
5	O
]	O
;	O
[	O
29	O
]	O
;	O
[	O
42	O
]	O
-	O
[	O
44	O
]	O
.	O

SerpinB2	B-Protein
protein	O
expression	O
was	O
also	O
induced	O
as	O
has	O
been	O
reported	O
in	O
other	O
cell	O
types	O
[	O
31	O
]	O
,	O
and	O
detectable	O
after	O
8	O
hrs	O
of	O
LPS	O
treatment	O
(	O
Fig	O
.	O
1	O
)	O
.	O

The	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
Confers	O
LPS	O
Responsiveness	O

To	O
investigate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
responsive	O
to	O
LPS	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
,	O
nucleotides	O
-	O
4480	O
to	O
+	O
92	O
and	O
a	O
series	O
of	O
generated	O
deletion	O
mutants	O
of	O
the	O
5	O
'	O
flanking	O
region	O
were	O
cloned	O
upstream	O
of	O
a	O
promoter	O
-	O
less	O
firefly	O
luciferase	B-Protein
reporter	O
gene	O
(	O
pGL3	O
Basic	O
)	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

The	O
reporter	O
constructs	O
were	O
then	O
transiently	O
transfected	O
into	O
sub	O
-	O
confluent	O
RAW264	O
.	O
7	O
macrophages	O
and	O
assayed	O
for	O
luciferase	B-Protein
activity	O
in	O
the	O
presence	O
and	O
absence	O
of	O
LPS	O
or	O
PMA	O
,	O
for	O
comparison	O
.	O
<EOS>	B-X
Differentiated	B-X
macrophages	B-X
are	B-X
the	B-X
resident	B-X
tissue	B-X
phagocytes	B-X
and	B-X
sentinel	B-X
cells	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
phenotype	B-X
of	B-X
mature	B-X
tissue	B-X
macrophages	B-X
represents	B-X
the	B-X
composite	B-X
of	B-X
environmental	B-X
and	B-X
differentiation-dependent	B-X
imprinting	B-X
.	B-X
Phorbol-12-myristate-13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
(	B-X
3	B-X
)	B-X
)	B-X
are	B-X
stimuli	B-X
commonly	B-X
used	B-X
to	B-X
induce	B-X
macrophage	B-X
differentiation	B-X
in	B-X
monocytic	B-X
cell	B-X
lines	B-X
but	B-X
the	B-X
extent	B-X
of	B-X
differentiation	B-X
in	B-X
comparison	B-X
to	B-X
primary	B-X
tissue	B-X
macrophages	B-X
is	B-X
unclear	B-X
.	B-X
We	B-X
have	B-X
compared	B-X
the	B-X
phenotype	B-X
of	B-X
the	B-X
promonocytic	B-X
THP-1	B-X
cell	B-X
line	B-X
after	B-X
various	B-X
protocols	B-X
of	B-X
differentiation	B-X
utilising	B-X
VD	B-X
(	B-X
3	B-X
)	B-X
and	B-X
PMA	B-X
in	B-X
comparison	B-X
to	B-X
primary	B-X
human	B-X
monocytes	B-X
or	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDM	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
PMA	B-X
treatment	B-X
followed	B-X
by	B-X
5	B-X
days	B-X
resting	B-X
in	B-X
culture	B-X
without	B-X
PMA	B-X
(	B-X
PMAr	B-X
)	B-X
increased	B-X
cytoplasmic	B-X
to	B-X
nuclear	B-X
ratio	B-X
,	B-X
increased	B-X
mitochondrial	B-X
and	B-X
lysosomal	B-X
numbers	B-X
and	B-X
altered	B-X
differentiation-dependent	B-X
cell	B-X
surface	B-X
markers	B-X
in	B-X
a	B-X
pattern	B-X
similar	B-X
to	B-X
MDM	B-X
.	B-X
Moreover	B-X
,	B-X
PMAr	B-X
cells	B-X
showed	B-X
relative	B-X
resistance	B-X
to	B-X
apoptotic	B-X
stimuli	B-X
and	B-X
maintained	B-X
levels	B-X
of	B-X
the	B-X
differentiation-dependent	B-X
anti-apoptotic	B-X
protein	B-X
Mcl-1	B-X
similar	B-X
to	B-X
MDM	B-X
.	B-X
PMAr	B-X
cells	B-X
retained	B-X
a	B-X
high	B-X
phagocytic	B-X
capacity	B-X
for	B-X
latex	B-X
beads	B-X
,	B-X
and	B-X
expressed	B-X
a	B-X
cytokine	B-X
profile	B-X
that	B-X
resembled	B-X
MDM	B-X
in	B-X
response	B-X
to	B-X
TLR	B-X
ligands	B-X
,	B-X
in	B-X
particular	B-X
with	B-X
marked	B-X
TLR2	B-X
responses	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
MDM	B-X
and	B-X
PMAr	B-X
retained	B-X
marked	B-X
plasticity	B-X
to	B-X
stimulus-directed	B-X
polarization	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
a	B-X
modified	B-X
PMA	B-X
differentiation	B-X
protocol	B-X
can	B-X
enhance	B-X
macrophage	B-X
differentiation	B-X
of	B-X
THP-1	B-X
cells	B-X
and	B-X
identify	B-X
increased	B-X
numbers	B-X
of	B-X
mitochondria	B-X
and	B-X
lysosomes	B-X
,	B-X
resistance	B-X
to	B-X
apoptosis	B-X
and	B-X
the	B-X
potency	B-X
of	B-X
TLR2	B-X
responses	B-X
as	B-X
important	B-X
discriminators	B-X
of	B-X
the	B-X
level	B-X
of	B-X
macrophage	B-X
differentiation	B-X
for	B-X
transformed	B-X
cells	B-X
.	B-X

PMA	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
regulation	O
has	O
been	O
extensively	O
studied	O
in	O
human	O
macrophage	O
cell	O
lines	O
[	O
45	O
]	O
-	O
[	O
47	O
]	O
,	O
and	O
has	O
been	O
shown	O
to	O
occur	O
through	O
several	O
proximal	O
and	O
distal	O
AP	O
-	O
1	O
responsive	O
elements	O
[	O
30	O
]	O
;	O
[	O
37	O
]	O
;	O
[	O
47	O
]	O
-	O
[	O
51	O
]	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

2B	O
,	O
the	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
region	O
from	O
-	O
4480	O
to	O
+	O
92	O
directs	O
both	O
PMA	O
-	O
and	O
LPS	O
-	O
inducible	O
transcription	O
,	O
approximately	O
2	O
-	O
fold	O
and	O
7	O
-	O
fold	O
,	O
respectively	O
.	O

Deletion	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
from	O
-	O
1686	O
to	O
-	O
1341	O
increased	O
LPS	O
-	O
inducibility	O
to	O
approximately	O
16	O
-	O
fold	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
silencer	O
element	O
in	O
this	O
region	O
.	O

Further	O
deletion	O
beyond	O
-	O
539	O
abolished	O
the	O
LPS	O
-	O
response	O
of	O
the	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
essential	O
LPS	O
response	O
element	O
in	O
the	O
region	O
between	O
-	O
539	O
and	O
-	O
189	O
;	O
however	O
,	O
the	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
to	O
PMA	O
is	O
less	O
affected	O
by	O
this	O
deletion	O
.	O

While	O
deletion	O
of	O
the	O
SerpinB2	B-Protein
promoter	O
from	O
-	O
189	O
to	O
-	O
87	O
eliminated	O
the	O
LPS	O
response	O
and	O
marginally	O
reduced	O
the	O
PMA	O
response	O
,	O
the	O
-	O
87	O
murine	O
SerpinB2	B-Protein
promoter	O
construct	O
was	O
still	O
partially	O
responsive	O
to	O
PMA	O
,	O
indicating	O
that	O
cis	O
-	O
acting	O
elements	O
mediating	O
the	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
to	O
PMA	O
also	O
lie	O
downstream	O
of	O
nucleotide	O
-	O
87	O
.	O

Sequence	O
Conservation	O
within	O
the	O
Human	O
and	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoters	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

To	O
look	O
for	O
potential	O
cis	O
-	O
acting	O
elements	O
that	O
might	O
mediate	O
transcription	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
and	O
the	O
response	O
to	O
LPS	O
,	O
we	O
aligned	O
the	O
murine	O
and	O
human	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
.	O

We	O
reasoned	O
that	O
the	O
presence	O
of	O
evolutionarily	O
conserved	O
,	O
potential	O
transcription	O
factor	O
binding	O
sites	O
in	O
this	O
region	O
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
[	O
52	O
]	O
.	O

The	O
presence	O
of	O
several	O
repetitive	O
sequence	O
elements	O
delineated	O
five	O
broadly	O
homologous	O
regions	O
(	O
A	O
-	O
E	O
)	O
between	O
the	O
human	O
and	O
murine	O
promoters	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
proximal	O
promoter	O
(	O
Region	O
E	O
)	O
,	O
which	O
contains	O
the	O
essential	O
LPS	O
response	O
element	O
,	O
exhibited	O
the	O
greatest	O
homology	O
.	O

Further	O
analysis	O
of	O
Region	O
E	O
revealed	O
that	O
several	O
of	O
the	O
cis	O
-	O
acting	O
regulatory	O
elements	O
defined	O
in	O
the	O
human	O
SerpinB2	B-Protein
proximal	O
promoter	O
are	O
conserved	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Specifically	O
,	O
a	O
TATA	O
consensus	O
sequence	O
is	O
located	O
23	O
to	O
29bp	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
,	O
similar	O
to	O
the	O
position	O
of	O
the	O
TATA	O
box	O
of	O
the	O
human	O
SERPINB2	B-Protein
gene	O
[	O
53	O
]	O
;	O
[	O
54	O
]	O
.	O

A	O
putative	O
CCAAT	O
enhancer	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
site	O
is	O
present	O
at	O
-	O
192	O
/	O
-	O
203	O
,	O
two	O
potential	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
sites	O
are	O
found	O
at	O
nucleotides	O
-	O
88	O
/	O
-	O
94	O
and	O
-	O
100	O
/	O
-	O
106	O
,	O
and	O
a	O
putative	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
is	O
present	O
at	O
-	O
172	O
/	O
-	O
177	O
.	O

Both	O
of	O
the	O
AP	O
-	O
1	O
sites	O
are	O
identical	O
in	O
sequence	O
to	O
those	O
identified	O
in	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
,	O
and	O
the	O
CRE	O
differs	O
in	O
the	O
identity	O
of	O
a	O
single	O
central	O
nucleotide	O
[	O
37	O
]	O
;	O
[	O
55	O
]	O
.	O

A	O
consensus	O
E	O
box	O
(	O
-	O
538	O
/	O
-	O
533	O
)	O
,	O
as	O
well	O
as	O
potential	O
binding	O
sites	O
for	O
PU	B-Protein
.	I-Protein
1	I-Protein
(	O
-	O
412	O
/	O
-	O
407	O
)	O
and	O
Oct	B-Protein
-	I-Protein
1	I-Protein
(	O
-	O
296	O
/	O
-	O
288	O
)	O
were	O
also	O
identified	O
within	O
the	O
proximal	O
promoter	O
region	O
(	O
Fig	O
.	O
S2	O
)	O
.	O

Further	O
upstream	O
,	O
a	O
retinoic	O
acid	O
response	O
element	O
at	O
-	O
1349	O
/	O
-	O
1340	O
,	O
a	O
PAUSE	O
-	O
1	O
silencer	O
element	O
at	O
-	O
1540	O
/	O
-	O
1528	O
and	O
a	O
NF	O
-	O
kappaB	O
p65	O
binding	O
site	O
at	O
-	O
1342	O
/	O
-	O
1351	O
(	O
Fig	O
.	O
S2	O
)	O
are	O
also	O
well	O
conserved	O
[	O
16	O
]	O
;	O
[	O
30	O
]	O
;	O
[	O
56	O
]	O
.	O

A	O
C	O
/	O
EBP	O
,	O
CRE	O
and	O
Two	O
AP	O
-	O
1	O
Sites	O
in	O
the	O
Murine	O
SerpinB2	B-Protein
Gene	O
Proximal	O
Promoter	O
are	O
Essential	O
for	O
Optimal	O
LPS	O
-	O
inducible	O
Transcription	O

To	O
investigate	O
regulatory	O
elements	O
between	O
-	O
539	O
and	O
-	O
189	O
essential	O
for	O
LPS	O
-	O
inducible	O
transcription	O
,	O
several	O
candidate	O
binding	O
sites	O
for	O
transcription	O
factors	O
previously	O
reported	O
to	O
mediate	O
LPS	O
-	O
inducible	O
transcription	O
in	O
other	O
genes	O
[	O
57	O
]	O
were	O
targeted	O
by	O
nucleotide	O
substitution	O
designed	O
to	O
disrupt	O
transcription	O
factor	O
binding	O
to	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
gene	I-Protein
construct	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

4B	O
,	O
mutation	O
of	O
the	O
consensus	O
E	O
box	O
(	O
-	O
538	O
/	O
-	O
533	O
)	O
,	O
PU	O
.	O
1	O
(	O
-	O
412	O
/	O
-	O
407	O
)	O
,	O
or	O
the	O
variant	O
Oct	O
-	O
1	O
(	O
-	O
296	O
/	O
-	O
288	O
)	O
site	O
did	O
not	O
decrease	O
LPS	O
-	O
induced	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
C	O
/	O
EBP	O
site	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
completely	O
eliminated	O
promoter	O
activity	O
,	O
similar	O
to	O
the	O
levels	O
observed	O
for	O
the	O
-	O
189	O
SerpinB2	B-Protein
promoter	O
deletion	O
construct	O
.	O

Others	O
have	O
also	O
recently	O
implicated	O
this	O
C	O
/	O
EBP	O
site	O
in	O
LPS	O
-	O
induced	O
activation	O
of	O
the	O
SerpinB2	B-Protein
gene	O
[	O
58	O
]	O
.	O

Considering	O
the	O
conserved	O
sequence	O
and	O
position	O
of	O
the	O
CRE	O
and	O
two	O
AP	O
-	O
1	O
sites	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
and	O
their	O
demonstrated	O
involvement	O
in	O
the	O
PMA	O
-	O
responsiveness	O
of	O
the	O
human	O
SERPINB2	B-Protein
promoter	O
[	O
37	O
]	O
,	O
these	O
sites	O
were	O
also	O
mutated	O
by	O
nucleotide	O
substitution	O
to	O
investigate	O
whether	O
they	O
played	O
a	O
role	O
in	O
the	O
LPS	O
response	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
<EOS>	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X
Unenhanced	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
and	B-X
multiphasic	B-X
contrast-enhanced	B-X
CT	B-X
imaging	B-X
was	B-X
performed	B-X
in	B-X
arterial	B-X
(	B-X
Fig	B-X
2A	B-X
)	B-X
,	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
2B	B-X
)	B-X
,	B-X
and	B-X
delayed	B-X
(	B-X
3	B-X
minutes	B-X
after	B-X
injection	B-X
)	B-X
(	B-X
Fig	B-X
2C	B-X
)	B-X
phases	B-X
.	B-X
Axial	B-X
and	B-X
coronal	B-X
maximum	B-X
intensity	B-X
projection	B-X
reconstructed	B-X
CT	B-X
images	B-X
were	B-X
obtained	B-X
in	B-X
the	B-X
arterial	B-X
(	B-X
Fig	B-X
3	B-X
)	B-X
and	B-X
portal	B-X
venous	B-X
(	B-X
Fig	B-X
4	B-X
)	B-X
phases	B-X
.	B-X
The	B-X
patient	B-X
also	B-X
underwent	B-X
whole-body	B-X
iodine	B-X
131	B-X
scintigraphy	B-X
(	B-X
Fig	B-X
5	B-X
)	B-X
.	B-X

4B	O
,	O
mutation	O
of	O
the	O
CRE	O
at	O
-	O
177	O
/	O
-	O
172	O
or	O
either	O
of	O
the	O
two	O
AP	O
-	O
1	O
sites	O
at	O
-	O
106	O
/	O
-	O
100	O
and	O
-	O
94	O
/	O
-	O
88	O
,	O
completely	O
or	O
significantly	O
reduced	O
LPS	O
-	O
inducible	O
luciferase	B-Protein
activity	O
from	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

These	O
data	O
show	O
that	O
the	O
C	O
/	O
EBP	O
element	O
,	O
as	O
well	O
as	O
the	O
CRE	O
and	O
both	O
AP	O
-	O
1	O
cis	O
-	O
acting	O
elements	O
are	O
critical	O
for	O
LPS	O
-	O
inducible	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
.	O

The	O
C	O
/	O
EBP	O
Element	O
is	O
Bound	O
by	O
an	O
LPS	O
-	O
induced	O
Nuclear	O
Factor	O
from	O
RAW	O
264	O
.	O
7	O
Macrophages	O

Nuclear	O
factor	O
binding	O
to	O
the	O
putative	O
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
was	O
investigated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
using	O
nuclear	O
extracts	O
from	O
untreated	O
and	O
LPS	O
-	O
treated	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

Three	O
different	O
double	O
stranded	O
oligonucleotide	O
probes	O
were	O
used	O
for	O
EMSA	O
,	O
representing	O
(	O
1	O
)	O
the	O
putative	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
,	O
(	O
2	O
)	O
a	O
mutant	O
SerpinB2	B-Protein
element	O
containing	O
the	O
same	O
mutation	O
as	O
in	O
pGLmP	O
-	O
539mC	O
/	O
EBP	O
and	O
(	O
3	O
)	O
the	O
rat	O
albumin	B-Protein
promoter	O
distal	O
element	O
1	O
(	O
DEI	O
)	O
region	O
containing	O
a	O
high	O
affinity	O
C	O
/	O
EBP	O
binding	O
site	O
.	O

Four	O
bands	O
of	O
different	O
mobilities	O
,	O
representing	O
DNA	O
-	O
nuclear	O
protein	O
complexes	O
were	O
detected	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

Three	O
of	O
these	O
bands	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
represent	O
complexes	O
with	O
single	O
stranded	O
DNA	O
(	O
Fig	O
.	O
5A	O
)	O
while	O
the	O
uppermost	O
(	O
slowest	O
migrating	O
)	O
complex	O
was	O
induced	O
by	O
LPS	O
.	O

The	O
LPS	O
-	O
inducible	O
complex	O
was	O
not	O
detected	O
using	O
the	O
mutant	O
C	O
/	O
EBP	O
oligonucleotide	O
probe	O
and	O
could	O
be	O
abolished	O
by	O
an	O
excess	O
of	O
unlabeled	O
double	O
-	O
stranded	O
oligonucleotide	O
,	O
carrying	O
either	O
the	O
same	O
sequence	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
4	O
and	O
5	O
)	O
or	O
the	O
sequence	O
of	O
a	O
known	O
C	O
/	O
EBP	O
binding	O
site	O
from	O
the	O
rat	O
albumin	B-Protein
promoter	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
8	O
and	O
9	O
)	O
,	O
but	O
not	O
by	O
the	O
mutated	O
oligonucleotide	O
(	O
Fig	O
.	O
5B	O
,	O
lanes	O
6	O
and	O
7	O
)	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
the	O
putative	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
site	O
at	O
-	O
203	O
/	O
-	O
192	O
binds	O
a	O
LPS	O
-	O
inducible	O
complex	O
that	O
is	O
likely	O
to	O
contain	O
a	O
member	O
of	O
the	O
C	O
/	O
EBP	O
family	O
of	O
transcription	O
factors	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
a	O
LPS	O
-	O
induced	O
Nuclear	O
Factor	O
that	O
Binds	O
to	O
the	O
C	O
/	O
EBP	O
Element	O
of	O
the	O
SerpinB2	B-Protein
Proximal	O
Promoter	O

The	O
C	O
/	O
EBP	O
family	O
of	O
basic	O
leucine	O
zipper	O
transcription	O
factors	O
are	O
known	O
for	O
their	O
roles	O
in	O
cellular	O
differentiation	O
and	O
inflammation	O
[	O
59	O
]	O
.	O

Consisting	O
of	O
six	O
members	O
,	O
the	O
C	O
/	O
EBP	O
transcription	O
factors	O
can	O
homo	O
-	O
/	O
heterodimerize	O
and	O
display	O
similar	O
DNA	O
binding	O
specificities	O
[	O
60	O
]	O
.	O

Four	O
family	O
members	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
alpha	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
delta	I-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
epsilon	I-Protein
,	O
are	O
present	O
in	O
myeloid	O
cells	O
and	O
play	O
different	O
roles	O
in	O
differentiating	O
myeloid	O
cells	O
depending	O
on	O
the	O
extracellular	O
environment	O
[	O
61	O
]	O
.	O

To	O
determine	O
which	O
C	O
/	O
EBP	O
proteins	O
were	O
involved	O
in	O
the	O
formation	O
of	O
the	O
different	O
nucleo	O
-	O
protein	O
complexes	O
,	O
and	O
particularly	O
of	O
the	O
LPS	O
-	O
inducible	O
complex	O
,	O
EMSA	O
was	O
performed	O
after	O
incubating	O
the	O
nucleo	O
-	O
protein	O
complexes	O
with	O
antibodies	O
specific	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
alpha	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
delta	I-Protein
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
epsilon	I-Protein
.	O

Each	O
antibody	O
detects	O
the	O
carboxy	O
-	O
terminal	O
DNA	O
-	O
binding	O
region	O
of	O
the	O
respective	O
protein	O
,	O
so	O
that	O
pre	O
-	O
incubation	O
of	O
antibody	O
with	O
nuclear	O
extract	O
is	O
expected	O
to	O
abolish	O
DNA	O
binding	O
by	O
EMSA	O
[	O
62	O
]	O
.	O

Only	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
abolished	O
the	O
formation	O
of	O
the	O
LPS	O
-	O
inducible	O
complex	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

Taken	O
together	O
these	O
data	O
show	O
that	O
the	O
LPS	O
-	O
induced	O
complex	O
with	O
the	O
C	O
/	O
EBP	O
element	O
(	O
-	O
203	O
/	O
-	O
192	O
)	O
contains	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Mediates	O
both	O
Constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
Expression	O
in	O
MEFs	O
and	O
Inflammatory	O
Primary	O
Macrophages	O

To	O
investigate	O
the	O
importance	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
response	O
to	O
LPS	O
,	O
we	O
utilized	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
(	O
Cebpb	B-Protein
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
MEFs	O
(	O
Cebpb	B-Protein
+	O
/	O
+	O
)	O
,	O
since	O
RAW264	O
.	O
7	O
cells	O
constitutively	O
express	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

Wild	O
-	O
type	O
MEFs	O
express	O
low	O
levels	O
of	O
endogenous	O
SerpinB2	B-Protein
and	O
the	O
absence	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
attenuated	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
.	O

LPS	O
stimulated	O
an	O
increase	O
in	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
wild	O
-	O
type	O
MEFs	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
whereas	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
mRNA	O
expression	O
was	O
significantly	O
dampened	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
as	O
compared	O
to	O
wild	O
-	O
type	O
.	O

We	O
next	O
tested	O
if	O
similar	O
effects	O
could	O
be	O
seen	O
in	O
thioglycollate	O
-	O
elicited	O
inflammatory	O
macrophages	O
in	O
which	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
expression	O
was	O
knocked	O
down	O
using	O
species	O
-	O
specific	O
lentiviral	O
shRNAs	O
(	O
Fig	O
.	O
6B	O
,	O
left	O
)	O
.	O

As	O
was	O
observed	O
in	O
MEFs	O
,	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
inflammatory	O
macrophages	O
(	O
Fig	O
.	O
6B	O
,	O
right	O
)	O
.	O

These	O
data	O
show	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
critical	O
for	O
mediating	O
constitutive	O
and	O
LPS	O
-	O
inducible	O
transcription	O
of	O
endogenous	O
SerpinB2	B-Protein
mRNA	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Binds	O
the	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
in	O
vivo	O
in	O
an	O
LPS	O
-	O
inducible	O
Manner	O

We	O
investigated	O
the	O
temporal	O
dynamics	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
recruitment	O
to	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
in	O
response	O
to	O
LPS	O
in	O
vivo	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
stimulated	O
with	O
LPS	O
for	O
up	O
to	O
8	O
hrs	O
,	O
soluble	O
chromatin	O
was	O
immunoprecipitated	O
with	O
antibodies	O
against	O
DNA	O
binding	O
proteins	O
,	O
and	O
the	O
enriched	O
DNA	O
amplified	O
by	O
both	O
semi	O
-	O
quantitative	O
and	O
qPCR	O
using	O
SerpinB2	B-Protein
proximal	O
promoter	O
specific	O
primers	O
(	O
illustrated	O
in	O
fig	O
.	O
4A	O
)	O
.	O

The	O
results	O
showed	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
constitutively	O
present	O
at	O
the	O
SerpinB2	B-Protein
promoter	O
as	O
demonstrated	O
by	O
its	O
association	O
with	O
the	O
promoter	O
in	O
unstimulated	O
macrophages	O
and	O
increased	O
temporally	O
in	O
response	O
to	O
LPS	O
reaching	O
as	O
much	O
as	O
10	O
-	O
fold	O
over	O
unstimulated	O
cells	O
after	O
8	O
hrs	O
(	O
Fig	O
.	O
7	O
)	O
.	O

Since	O
changes	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylation	O
states	O
can	O
affect	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
'	O
s	O
ability	O
to	O
transactivate	O
target	O
genes	O
[	O
38	O
]	O
;	O
[	O
63	O
]	O
;	O
[	O
64	O
]	O
,	O
we	O
investigated	O
recruitment	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
of	O
the	O
T217	O
phosphorylated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
isoform	O
(	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
)	O
,	O
which	O
has	O
been	O
associated	O
with	O
cell	O
survival	O
[	O
65	O
]	O
.	O

p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
was	O
constitutively	O
bound	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
and	O
also	O
present	O
after	O
1	O
hr	O
of	O
LPS	O
stimulation	O
(	O
Fig	O
.	O
7	O
)	O
.	O

In	O
contrast	O
to	O
total	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
the	O
binding	O
affinity	O
of	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
for	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
diminished	O
with	O
LPS	O
stimulation	O
at	O
later	O
timepoints	O
(	O
4	O
and	O
8	O
hrs	O
)	O
(	O
Fig	O
.	O
7	O
)	O
.	O

These	O
data	O
show	O
an	O
inverse	O
relationship	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217	I-Protein
recruitment	O
,	O
and	O
indicate	O
that	O
T217	O
-	O
phosphorylated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
may	O
not	O
be	O
responsible	O
for	O
increased	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
promoter	O
in	O
response	O
to	O
LPS	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
Promotes	O
LPS	O
-	O
inducible	O
Murine	O
SerpinB2	B-Protein
Proximal	O
Promoter	O
Activity	O

Since	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
binds	O
to	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
an	O
LPS	O
-	O
inducible	O
manner	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
we	O
wanted	O
to	O
address	O
the	O
question	O
of	O
whether	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
an	O
essential	O
factor	O
for	O
driving	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
promoter	O
in	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

The	O
ability	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
direct	O
transcription	O
from	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
was	O
examined	O
by	O
transfection	O
of	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
construct	O
into	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

We	O
found	O
that	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
promoter	O
activity	O
was	O
significantly	O
increased	O
in	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
and	O
abrogated	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
(	O
Fig	O
.	O
8A	O
)	O
,	O
indicating	O
that	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
required	O
for	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
Serine	O
64	O
negatively	O
Regulates	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
Promoter	O
Activity	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
well	O
recognized	O
to	O
modulate	O
its	O
transactivation	O
potential	O
[	O
63	O
]	O
.	O

To	O
investigate	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylation	O
sites	O
that	O
may	O
be	O
important	O
for	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
(	O
Fig	O
.	O
8B	O
)	O
,	O
we	O
co	O
-	O
expressed	O
several	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
in	O
which	O
the	O
critical	O
threonine	O
or	O
serine	O
residue	O
was	O
mutated	O
to	O
an	O
alanine	O
,	O
along	O
with	O
the	O
pGLmP	O
-	O
539	O
murine	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

Re	O
-	O
expression	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
significantly	O
stimulated	O
SerpinB2	B-Protein
luciferase	I-Protein
reporter	I-Protein
gene	O
expression	O
in	O
the	O
presence	O
of	O
LPS	O
by	O
~	O
3	O
fold	O
(	O
Fig	O
.	O
8C	O
,	O
left	O
)	O
,	O
confirming	O
the	O
importance	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
to	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

Expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBPbetaT217A	I-Protein
,	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
did	O
not	O
significantly	O
increase	O
SerpinB2	B-Protein
promoter	O
activity	O
above	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	O
Fig	O
.	O
8C	O
,	O
right	O
)	O
;	O
confirming	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
T217	O
is	O
not	O
a	O
major	O
factor	O
in	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
promoter	O
activity	O
in	O
response	O
to	O
LPS	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
contains	O
additional	O
phosphorylation	O
sites	O
,	O
C	O
/	O
EBP	O
-	O
betaT188	O
and	O
C	O
/	O
EBP	O
-	O
betaS64	O
(	O
Fig	O
.	O
8B	O
)	O
,	O
which	O
may	O
be	O
involved	O
in	O
modulating	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
dependent	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

C	O
/	O
EBP	O
-	O
betaT188	O
is	O
implicated	O
in	O
regulating	O
DAPK1	B-Protein
,	O
an	O
IFNgamma	B-Protein
-	O
inducible	O
gene	B-Protein
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
and	O
apoptosis	O
[	O
38	O
]	O
,	O
processes	O
with	O
which	O
SerpinB2	B-Protein
has	O
also	O
been	O
associated	O
[	O
17	O
]	O
.	O

C	O
/	O
EBP	O
-	O
betaS64	O
is	O
important	O
for	O
LPS	O
-	O
induced	O
transcription	O
of	O
the	O
cytokines	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
[	O
64	O
]	O
.	O

Similarly	O
,	O
SerpinB2	B-Protein
is	O
induced	O
by	O
LPS	O
and	O
regulated	O
in	O
a	O
manner	O
similar	O
to	O
cytokines	O
[	O
29	O
]	O
.	O

Given	O
the	O
similarities	O
in	O
the	O
functional	O
significance	O
of	O
these	O
phospho	O
-	O
specific	O
isoforms	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
SerpinB2	B-Protein
,	O
we	O
investigated	O
whether	O
these	O
phospho	O
-	O
acceptor	O
sites	O
may	O
play	O
a	O
role	O
in	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT188A	I-Protein
-	O
transfected	O
MEFs	O
exhibited	O
SerpinB2	B-Protein
promoter	O
activity	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
transfected	O
MEFs	O
,	O
whereas	O
the	O
expression	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaS64A	I-Protein
potentiated	O
SerpinB2	B-Protein
promoter	O
activity	O
in	O
response	O
to	O
LPS	O
(	O
Fig	O
.	O
8C	O
,	O
right	O
)	O
.	O

These	O
data	O
suggest	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
S64	O
acts	O
to	O
negatively	O
regulate	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

Macrophages	O
are	O
key	O
mediators	O
of	O
the	O
innate	O
immune	O
response	O
,	O
and	O
consequently	O
provide	O
the	O
first	O
line	O
of	O
defense	O
against	O
pathogens	O
.	O
<EOS>	B-X
Innate	B-X
immunity	B-X
provides	B-X
the	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
by	B-X
recognizing	B-X
pathogen-associated	B-X
microbial	B-X
patterns	B-X
and	B-X
inducing	B-X
key	B-X
co-stimulatory	B-X
molecules	B-X
and	B-X
cytokines	B-X
,	B-X
which	B-X
activate	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
response	B-X
.	B-X
Innate	B-X
immune	B-X
cells	B-X
perform	B-X
phagocytosis	B-X
,	B-X
which	B-X
can	B-X
clear	B-X
pathogens	B-X
and	B-X
tissue	B-X
waste	B-X
products	B-X
but	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
tissue	B-X
injury	B-X
due	B-X
to	B-X
harmful	B-X
side	B-X
effects	B-X
of	B-X
inflammation	B-X
.	B-X
A	B-X
reconciliation	B-X
of	B-X
these	B-X
two	B-X
pathogenetic	B-X
mechanisms	B-X
is	B-X
crucial	B-X
to	B-X
future	B-X
progress	B-X
in	B-X
immune	B-X
diagnosis	B-X
and	B-X
effective	B-X
therapy	B-X
.	B-X
Finally	B-X
,	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
are	B-X
a	B-X
superior	B-X
model	B-X
system	B-X
for	B-X
investigation	B-X
of	B-X
innate	B-X
immune	B-X
dysfunction	B-X
in	B-X
Alzheimer	B-X
's	B-X
disease	B-X
.	B-X

Pro	O
-	O
inflammatory	O
stimuli	O
,	O
such	O
as	O
the	O
bacterial	O
endotoxin	O
LPS	O
,	O
stimulate	O
macrophages	O
to	O
mount	O
an	O
anti	O
-	O
pathogenic	O
response	O
which	O
involves	O
massive	O
induction	O
of	O
the	O
pro	O
-	O
survival	O
factor	O
SerpinB2	B-Protein
.	O

SerpinB2	B-Protein
is	O
transcriptionally	O
induced	O
by	O
cross	O
talk	O
between	O
the	O
IKKbeta	B-Protein
/	O
NF	O
-	O
kappaB	O
and	O
p38MAPK	O
signaling	O
modules	O
in	O
response	O
to	O
LPS	O
[	O
16	O
]	O
.	O

Here	O
we	O
report	O
that	O
SerpinB2	B-Protein
gene	O
transcription	O
in	O
response	O
to	O
LPS	O
is	O
conferred	O
by	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
and	O
is	O
greatly	O
dependent	O
upon	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

LPS	O
-	O
induced	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
shown	O
to	O
specifically	O
bind	O
the	O
C	O
/	O
EBP	O
response	O
element	O
in	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
loss	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
abrogates	O
constitutive	O
SerpinB2	B-Protein
gene	O
transcription	O
and	O
the	O
response	O
to	O
LPS	O
.	O

The	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
region	O
between	O
nucleotides	O
-	O
539	O
and	O
+	O
92	O
mediated	O
both	O
PMA	O
-	O
and	O
LPS	O
-	O
inducible	O
gene	O
transcription	O
,	O
with	O
induction	O
by	O
PMA	O
being	O
less	O
intense	O
and	O
more	O
transient	O
than	O
that	O
by	O
LPS	O
.	O

Inspection	O
of	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
sequence	O
shows	O
that	O
a	O
CRE	O
and	O
two	O
AP	O
-	O
1	O
-	O
like	O
elements	O
,	O
demonstrated	O
to	O
mediate	O
PMA	O
-	O
stimulated	O
transcription	O
of	O
the	O
human	O
SERPINB2	B-Protein
gene	O
[	O
37	O
]	O
,	O
also	O
are	O
present	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
87	O
.	O

These	O
sites	O
may	O
therefore	O
also	O
play	O
a	O
role	O
in	O
mediating	O
PMA	O
-	O
inducible	O
transcription	O
of	O
the	O
murine	O
SerpinB2	B-Protein
gene	O
.	O

In	O
contrast	O
to	O
the	O
pattern	O
of	O
incremental	O
increases	O
in	O
PMA	O
-	O
induced	O
transcriptional	O
activity	O
conferred	O
by	O
regions	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
containing	O
these	O
sites	O
,	O
most	O
of	O
the	O
LPS	O
-	O
inducible	O
response	O
is	O
dependent	O
upon	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
.	O

LPS	O
responsiveness	O
absolutely	O
required	O
the	O
C	O
/	O
EBP	O
binding	O
site	O
located	O
in	O
the	O
region	O
between	O
nucleotides	O
-	O
189	O
and	O
-	O
539	O
,	O
with	O
the	O
downstream	O
CRE	O
and	O
AP	O
-	O
1	O
-	O
like	O
elements	O
also	O
being	O
critical	O
.	O

Of	O
note	O
,	O
there	O
are	O
previous	O
reports	O
of	O
combinatorial	O
interactions	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
CRE	O
binding	O
proteins	O
(	O
CREB	O
)	O
and	O
AP	O
-	O
1	O
[	O
63	O
]	O
,	O
and	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
has	O
been	O
reported	O
to	O
physically	O
interact	O
with	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kappaB	O
to	O
promote	O
gene	O
expression	O
of	O
inflammatory	O
mediators	O
[	O
63	O
]	O
;	O
[	O
66	O
]	O
.	O

Additionally	O
,	O
CREB	O
has	O
been	O
shown	O
to	O
control	O
transcription	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
gene	O
[	O
67	O
]	O
.	O

In	O
this	O
study	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
was	O
found	O
to	O
be	O
a	O
major	O
requirement	O
for	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

In	O
a	O
previous	O
microarray	O
expression	O
profiling	O
study	O
,	O
SerpinB2	B-Protein
was	O
identified	O
as	O
gene	B-Protein
whose	O
induction	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
peritoneal	O
macrophages	O
by	O
LPS	O
and	O
IFNgamma	B-Protein
was	O
severely	O
impaired	O
compared	O
to	O
wild	O
-	O
type	O
macrophages	O
[	O
68	O
]	O
.	O

Our	O
qPCR	O
results	O
validate	O
this	O
finding	O
,	O
as	O
we	O
found	O
that	O
both	O
constitutive	O
and	O
LPS	O
-	O
inducible	O
SerpinB2	B-Protein
mRNA	O
expression	O
is	O
significantly	O
abrogated	O
in	O
C	O
/	O
EBP	O
-	O
beta	O
-	O
shRNA	O
transduced	O
peritoneal	O
macrophages	O
,	O
emphasizing	O
the	O
link	O
between	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
SerpinB2	B-Protein
gene	O
transcription	O
.	O

While	O
C	O
/	O
EBP	O
proteins	O
can	O
act	O
as	O
either	O
homodimers	O
or	O
heterodimers	O
[	O
63	O
]	O
,	O
we	O
identified	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
as	O
the	O
only	O
LPS	O
-	O
inducible	O
C	O
/	O
EBP	O
isoform	O
to	O
bind	O
the	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
response	O
element	O
,	O
suggesting	O
a	O
predominant	O
role	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
in	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
like	O
SerpinB2	B-Protein
,	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
,	O
as	O
it	O
is	O
upregulated	O
by	O
LPS	O
and	O
a	O
host	O
of	O
other	O
inflammatory	O
cytokines	O
[	O
59	O
]	O
;	O
[	O
62	O
]	O
.	O

Furthermore	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
null	O
mice	O
are	O
susceptible	O
to	O
bacterial	O
infection	O
[	O
69	O
]	O
;	O
[	O
70	O
]	O
and	O
SerpinB2	B-Protein
has	O
been	O
demonstrated	O
to	O
protect	O
from	O
bacterial	O
and	O
viral	O
-	O
induced	O
cell	O
death	O
[	O
14	O
]	O
-	O
[	O
16	O
]	O
;	O
[	O
25	O
]	O
.	O

Thus	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
by	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
consistent	O
with	O
its	O
functional	O
role	O
in	O
inflammation	O
.	O

Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
several	O
different	O
amino	O
acid	O
residues	O
has	O
been	O
shown	O
to	O
modulate	O
transactivation	O
of	O
its	O
target	O
genes	O
[	O
63	O
]	O
;	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phosphorylated	O
on	O
T217	O
has	O
been	O
reported	O
to	O
rescue	O
macrophages	O
from	O
apoptosis	O
induced	O
by	O
Bacillus	O
anthracis	O
lethal	O
toxin	O
(	O
LT	O
)	O
[	O
65	O
]	O
,	O
an	O
activity	O
that	O
has	O
also	O
been	O
attributed	O
to	O
SerpinB2	B-Protein
[	O
16	O
]	O
.	O

However	O
,	O
expression	O
of	O
a	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
site	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBPbetaT217A	I-Protein
,	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
did	O
not	O
increase	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
over	O
that	O
of	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
even	O
though	O
recruitment	O
of	O
C	O
/	O
EBP	O
-	O
betaT217	O
to	O
the	O
SerpinB2	B-Protein
promoter	O
was	O
observed	O
to	O
decrease	O
following	O
LPS	O
stimulation	O
of	O
RAW264	O
.	O
7	O
cells	O
.	O

These	O
data	O
indicate	O
that	O
the	O
T217	O
phospho	O
-	O
acceptor	O
site	O
is	O
not	O
important	O
for	O
the	O
regulation	O
of	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

Similarly	O
,	O
expression	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
site	I-Protein
mutant	I-Protein
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT188A	I-Protein
,	O
did	O
not	O
affect	O
SerpinB2	B-Protein
promoter	O
activity	O
differently	O
from	O
that	O
of	O
wild	O
-	O
type	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaS64A	I-Protein
significantly	O
enhanced	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
S64	O
negatively	O
regulates	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Since	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
S64	O
is	O
constitutively	O
phosphorylated	O
in	O
both	O
RAW264	O
.	O
7	O
cells	O
and	O
MEFs	O
[	O
73	O
]	O
,	O
it	O
is	O
likely	O
that	O
dephosphorylation	O
at	O
this	O
site	O
may	O
be	O
a	O
critical	O
event	O
during	O
LPS	O
-	O
induced	O
transcription	O
of	O
SerpinB2	B-Protein
to	O
increase	O
its	O
promoter	O
activity	O
.	O

Roy	O
and	O
colleagues	O
demonstrated	O
that	O
Mixed	B-Protein
lineage	I-Protein
kinase	I-Protein
-	I-Protein
3	I-Protein
(	O
MLK3	B-Protein
)	O
-	O
driven	O
dephosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
S64	O
was	O
important	O
for	O
IFNgamma	B-Protein
-	O
regulated	O
signaling	O
pathways	O
[	O
73	O
]	O
.	O

Our	O
data	O
suggest	O
that	O
MLK3	B-Protein
-	O
driven	O
dephosphorylation	O
of	O
S64	O
may	O
also	O
be	O
involved	O
in	O
LPS	O
-	O
signaling	O
pathways	O
.	O

In	O
recent	O
years	O
it	O
has	O
become	O
apparent	O
that	O
persistent	O
infection	O
is	O
integrally	O
linked	O
to	O
chronic	O
inflammation	O
and	O
cancer	O
,	O
and	O
immune	O
cells	O
such	O
as	O
macrophages	O
can	O
either	O
promote	O
or	O
attenuate	O
cancer	O
progression	O
[	O
2	O
]	O
;	O
[	O
74	O
]	O
-	O
[	O
76	O
]	O
.	O
<EOS>	B-X
TGFβ	B-X
signalling	B-X
has	B-X
key	B-X
roles	B-X
in	B-X
cancer	B-X
progression	B-X
:	B-X
most	B-X
carcinoma	B-X
cells	B-X
have	B-X
inactivated	B-X
their	B-X
epithelial	B-X
antiproliferative	B-X
response	B-X
and	B-X
benefit	B-X
from	B-X
increased	B-X
TGFβ	B-X
expression	B-X
and	B-X
autocrine	B-X
TGFβ	B-X
signalling	B-X
through	B-X
effects	B-X
on	B-X
gene	B-X
expression	B-X
,	B-X
release	B-X
of	B-X
immunosuppressive	B-X
cytokines	B-X
and	B-X
epithelial	B-X
plasticity	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
TGFβ	B-X
enables	B-X
cancer	B-X
cell	B-X
invasion	B-X
and	B-X
dissemination	B-X
,	B-X
stem	B-X
cell	B-X
properties	B-X
and	B-X
therapeutic	B-X
resistance	B-X
.	B-X
TGFβ	B-X
released	B-X
by	B-X
cancer	B-X
cells	B-X
,	B-X
stromal	B-X
fibroblasts	B-X
and	B-X
other	B-X
cells	B-X
in	B-X
the	B-X
tumour	B-X
microenvironment	B-X
further	B-X
promotes	B-X
cancer	B-X
progression	B-X
by	B-X
shaping	B-X
the	B-X
architecture	B-X
of	B-X
the	B-X
tumour	B-X
and	B-X
by	B-X
suppressing	B-X
the	B-X
antitumour	B-X
activities	B-X
of	B-X
immune	B-X
cells	B-X
,	B-X
thus	B-X
generating	B-X
an	B-X
immunosuppressive	B-X
environment	B-X
that	B-X
prevents	B-X
or	B-X
attenuates	B-X
the	B-X
efficacy	B-X
of	B-X
anticancer	B-X
immunotherapies	B-X
.	B-X
The	B-X
repression	B-X
of	B-X
TGFβ	B-X
signalling	B-X
is	B-X
therefore	B-X
considered	B-X
a	B-X
prerequisite	B-X
and	B-X
major	B-X
avenue	B-X
to	B-X
enhance	B-X
the	B-X
efficacy	B-X
of	B-X
current	B-X
and	B-X
forthcoming	B-X
immunotherapies	B-X
,	B-X
including	B-X
in	B-X
tumours	B-X
comprising	B-X
cancer	B-X
cells	B-X
that	B-X
are	B-X
not	B-X
TGFβ	B-X
responsive	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
introduce	B-X
the	B-X
mechanisms	B-X
underlying	B-X
TGFβ	B-X
signalling	B-X
in	B-X
tumours	B-X
and	B-X
their	B-X
microenvironment	B-X
and	B-X
discuss	B-X
approaches	B-X
to	B-X
inhibit	B-X
these	B-X
signalling	B-X
mechanisms	B-X
as	B-X
well	B-X
as	B-X
the	B-X
use	B-X
of	B-X
these	B-X
approaches	B-X
in	B-X
cancer	B-X
immunotherapies	B-X
and	B-X
their	B-X
potential	B-X
adverse	B-X
effects	B-X
.	B-X

SerpinB2	B-Protein
expression	O
has	O
been	O
associated	O
with	O
both	O
inflammation	O
and	O
cancer	O
,	O
and	O
is	O
a	O
favorable	O
or	O
unfavorable	O
prognostic	O
indicator	O
depending	O
on	O
cancer	O
type	O
[	O
77	O
]	O
.	O
<EOS>	B-X
It	B-X
has	B-X
frequently	B-X
been	B-X
shown	B-X
that	B-X
patients	B-X
with	B-X
cancer	B-X
are	B-X
one	B-X
of	B-X
the	B-X
largest	B-X
hospital	B-X
patient	B-X
groups	B-X
with	B-X
a	B-X
prevalence	B-X
for	B-X
malnutrition	B-X
.	B-X
Weight	B-X
loss	B-X
is	B-X
a	B-X
frequent	B-X
manifestation	B-X
of	B-X
malnutrition	B-X
in	B-X
patients	B-X
with	B-X
cancer	B-X
.	B-X
Several	B-X
large-scale	B-X
studies	B-X
over	B-X
the	B-X
past	B-X
35	B-X
y	B-X
have	B-X
reported	B-X
that	B-X
involuntary	B-X
weight	B-X
loss	B-X
affects	B-X
50	B-X
%	B-X
to	B-X
80	B-X
%	B-X
of	B-X
these	B-X
patients	B-X
with	B-X
the	B-X
degree	B-X
of	B-X
weight	B-X
loss	B-X
dependent	B-X
on	B-X
tumor	B-X
site	B-X
and	B-X
type	B-X
and	B-X
stage	B-X
of	B-X
disease	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
consequences	B-X
of	B-X
malnutrition	B-X
,	B-X
weight	B-X
loss	B-X
,	B-X
and	B-X
muscle	B-X
wasting	B-X
in	B-X
relation	B-X
to	B-X
chemotherapy	B-X
tolerance	B-X
,	B-X
postoperative	B-X
complications	B-X
,	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
and	B-X
survival	B-X
in	B-X
patients	B-X
with	B-X
cancer	B-X
.	B-X
The	B-X
prognostic	B-X
impact	B-X
of	B-X
weight	B-X
loss	B-X
on	B-X
overall	B-X
survival	B-X
has	B-X
long	B-X
been	B-X
recognised	B-X
with	B-X
recent	B-X
data	B-X
suggesting	B-X
losses	B-X
as	B-X
little	B-X
as	B-X
2.4	B-X
%	B-X
predicts	B-X
survival	B-X
independent	B-X
of	B-X
disease	B-X
,	B-X
site	B-X
,	B-X
stage	B-X
or	B-X
performance	B-X
score	B-X
.	B-X
Recently	B-X
the	B-X
use	B-X
of	B-X
gold-standard	B-X
methods	B-X
of	B-X
body	B-X
composition	B-X
assessment	B-X
,	B-X
including	B-X
computed	B-X
tomography	B-X
,	B-X
have	B-X
led	B-X
to	B-X
an	B-X
increased	B-X
understanding	B-X
of	B-X
the	B-X
importance	B-X
of	B-X
muscle	B-X
abnormalities	B-X
,	B-X
such	B-X
as	B-X
low	B-X
muscle	B-X
mass	B-X
(	B-X
sarcopenia	B-X
)	B-X
,	B-X
and	B-X
more	B-X
recently	B-X
low	B-X
muscle	B-X
attenuation	B-X
,	B-X
as	B-X
important	B-X
prognostic	B-X
indicators	B-X
of	B-X
unfavourable	B-X
outcomes	B-X
in	B-X
patients	B-X
with	B-X
cancer	B-X
.	B-X
Muscle	B-X
abnormalities	B-X
are	B-X
highly	B-X
prevalent	B-X
(	B-X
ranging	B-X
from	B-X
10-90	B-X
%	B-X
,	B-X
depending	B-X
on	B-X
cancer	B-X
site	B-X
and	B-X
the	B-X
diagnostic	B-X
criteria	B-X
used	B-X
)	B-X
.	B-X
Both	B-X
low	B-X
muscle	B-X
mass	B-X
and	B-X
low	B-X
muscle	B-X
attenuation	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
poorer	B-X
tolerance	B-X
to	B-X
chemotherapy	B-X
;	B-X
increased	B-X
risk	B-X
of	B-X
postoperative	B-X
complications	B-X
;	B-X
significant	B-X
deterioration	B-X
in	B-X
a	B-X
patients	B-X
'	B-X
performance	B-X
status	B-X
,	B-X
and	B-X
poorer	B-X
psychological	B-X
well-being	B-X
,	B-X
overall	B-X
quality	B-X
of	B-X
life	B-X
,	B-X
and	B-X
survival	B-X
.	B-X

The	O
presence	O
of	O
SerpinB2	B-Protein
has	O
been	O
shown	O
to	O
modulate	O
cytokine	O
profiles	O
which	O
can	O
affect	O
immune	O
cell	O
polarization	O
[	O
27	O
]	O
;	O
[	O
28	O
]	O
;	O
[	O
77	O
]	O
;	O
[	O
78	O
]	O
.	O

Interestingly	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
has	O
also	O
been	O
shown	O
to	O
modulate	O
cytokine	O
secretion	O
from	O
immune	O
cells	O
,	O
thereby	O
modifying	O
their	O
phenotype	O
[	O
27	O
]	O
;	O
[	O
79	O
]	O
-	O
[	O
81	O
]	O
.	O

Our	O
study	O
has	O
demonstrated	O
that	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
plays	O
an	O
important	O
role	O
in	O
mediating	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
transcription	O
of	O
the	O
SerpinB2	B-Protein
gene	O
,	O
which	O
may	O
have	O
implications	O
for	O
the	O
inflammatory	O
phenotype	O
of	O
infiltrating	O
immune	O
cells	O
in	O
the	O
tumor	O
microenvironment	O
.	O

In	O
summary	O
,	O
our	O
studies	O
show	O
that	O
the	O
C	O
/	O
EBP	O
site	O
(	O
-	O
203	O
/	O
-	O
195	O
)	O
in	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
is	O
necessary	O
to	O
support	O
both	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

Importantly	O
,	O
we	O
were	O
able	O
to	O
uncover	O
a	O
previously	O
unknown	O
role	O
for	O
C	O
/	O
EBP	O
-	O
betaS64	O
in	O
negatively	O
regulating	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Taken	O
together	O
these	O
data	O
provide	O
new	O
insight	O
into	O
the	O
regulation	O
of	O
inflammation	O
-	O
associated	O
SerpinB2	B-Protein
gene	O
expression	O
.	O

LPS	O
induction	O
of	O
SerpinB2	B-Protein
mRNA	O
and	O
protein	O
expression	O
in	O
murine	O
macrophage	O
cells	O
.	O

RAW264	O
.	O
7	O
macrophages	O
were	O
treated	O
for	O
the	O
indicated	O
times	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
.	O

(	O
A	O
)	O
qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
levels	O
,	O
relative	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
.	O

The	O
plot	O
is	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

(	O
B	O
)	O
Immunoblot	O
analysis	O
of	O
SerpinB2	B-Protein
protein	O
expression	O
in	O
whole	O
cell	O
lysates	O
.	O

Blot	O
was	O
reprobed	O
for	O
GAPDH	B-Protein
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Moreover	B-X
,	B-X
the	B-X
quality	B-X
of	B-X
western	B-X
blot	B-X
data	B-X
is	B-X
sometimes	B-X
challenged	B-X
due	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
effective	B-X
quality	B-X
control	B-X
tools	B-X
in	B-X
place	B-X
throughout	B-X
the	B-X
western	B-X
blotting	B-X
process	B-X
.	B-X
This	B-X
workflow	B-X
allows	B-X
researchers	B-X
:	B-X
1	B-X
)	B-X
to	B-X
run	B-X
a	B-X
gel	B-X
in	B-X
about	B-X
20-30	B-X
min	B-X
;	B-X
2	B-X
)	B-X
to	B-X
visualize	B-X
sample	B-X
separation	B-X
quality	B-X
within	B-X
5	B-X
min	B-X
after	B-X
the	B-X
gel	B-X
run	B-X
;	B-X
3	B-X
)	B-X
to	B-X
transfer	B-X
proteins	B-X
in	B-X
3-10	B-X
min	B-X
;	B-X
4	B-X
)	B-X
to	B-X
verify	B-X
transfer	B-X
efficiency	B-X
quantitatively	B-X
;	B-X
and	B-X
most	B-X
importantly	B-X
5	B-X
)	B-X
to	B-X
validate	B-X
changes	B-X
in	B-X
the	B-X
level	B-X
of	B-X
the	B-X
protein	B-X
of	B-X
interest	B-X
using	B-X
total	B-X
protein	B-X
loading	B-X
control	B-X
.	B-X
This	B-X
novel	B-X
approach	B-X
eliminates	B-X
the	B-X
need	B-X
of	B-X
stripping	B-X
and	B-X
reprobing	B-X
the	B-X
blot	B-X
for	B-X
housekeeping	B-X
proteins	B-X
such	B-X
as	B-X
β-actin	B-X
,	B-X
β-tubulin	B-X
,	B-X
GAPDH	B-X
,	B-X
etc	B-X
.	B-X

Deletion	O
reporter	O
gene	O
analysis	O
of	O
LPS	O
and	O
PMA	O
-	O
responsive	O
regions	O
in	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
and	I-Protein
5	I-Protein
'	I-Protein
deletion	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
.	O

The	O
murine	O
5	O
'	O
flanking	O
region	O
from	O
-	O
4480	O
to	O
+	O
92	O
was	O
inserted	O
upstream	O
of	O
the	O
luciferase	B-Protein
reporter	O
gene	O
and	O
5	O
'	O
deletions	O
were	O
generated	O
using	O
restriction	O
enzyme	O
sites	O
or	O
with	O
specific	O
oligonucleotide	O
PCR	O
primers	O
.	O
<EOS>	B-X
Nested	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
is	B-X
used	B-X
in	B-X
situations	B-X
in	B-X
which	B-X
it	B-X
is	B-X
necessary	B-X
to	B-X
increase	B-X
the	B-X
sensitivity	B-X
and/or	B-X
specificity	B-X
of	B-X
PCR	B-X
,	B-X
for	B-X
example	B-X
,	B-X
when	B-X
amplifying	B-X
a	B-X
particular	B-X
member	B-X
of	B-X
a	B-X
polymorphic	B-X
gene	B-X
family	B-X
or	B-X
when	B-X
amplifying	B-X
a	B-X
cDNA	B-X
copy	B-X
of	B-X
an	B-X
mRNA	B-X
present	B-X
at	B-X
very	B-X
low	B-X
abundance	B-X
in	B-X
a	B-X
clinical	B-X
specimen	B-X
containing	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
cell	B-X
types	B-X
.	B-X
Nested	B-X
PCR	B-X
usually	B-X
involves	B-X
two	B-X
sequential	B-X
amplification	B-X
reactions	B-X
,	B-X
each	B-X
of	B-X
which	B-X
uses	B-X
a	B-X
different	B-X
pair	B-X
of	B-X
primers	B-X
.	B-X
The	B-X
product	B-X
of	B-X
the	B-X
first	B-X
amplification	B-X
reaction	B-X
is	B-X
used	B-X
as	B-X
the	B-X
template	B-X
for	B-X
the	B-X
second	B-X
PCR	B-X
,	B-X
which	B-X
is	B-X
primed	B-X
by	B-X
oligonucleotides	B-X
that	B-X
are	B-X
placed	B-X
internal	B-X
to	B-X
the	B-X
first	B-X
primer	B-X
pair	B-X
.	B-X
The	B-X
use	B-X
of	B-X
two	B-X
pairs	B-X
of	B-X
oligonucleotides	B-X
allows	B-X
a	B-X
higher	B-X
number	B-X
of	B-X
cycles	B-X
to	B-X
be	B-X
performed	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
PCR	B-X
.	B-X
The	B-X
improved	B-X
specificity	B-X
of	B-X
the	B-X
reaction	B-X
derives	B-X
from	B-X
the	B-X
binding	B-X
of	B-X
two	B-X
separate	B-X
sets	B-X
of	B-X
primers	B-X
to	B-X
the	B-X
same	B-X
target	B-X
template	B-X
.	B-X
Nested	B-X
PCR	B-X
is	B-X
an	B-X
efficient	B-X
method	B-X
to	B-X
amplify	B-X
segments	B-X
of	B-X
long	B-X
templates	B-X
but	B-X
requires	B-X
knowledge	B-X
of	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
target	B-X
.	B-X

Construct	O
names	O
indicate	O
the	O
most	O
5	O
'	O
nucleotide	O
of	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
sequence	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
macrophages	O
were	O
transiently	O
transfected	O
with	O
the	O
indicated	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
and	O
control	O
plasmids	O
.	O

Cells	O
were	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
40	O
ng	O
/	O
ml	O
PMA	O
for	O
16	O
hrs	O
.	O
<EOS>	B-X
Neutrophils	B-X
are	B-X
the	B-X
most	B-X
abundant	B-X
white	B-X
blood	B-X
cell	B-X
in	B-X
blood	B-X
and	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
preventing	B-X
infections	B-X
as	B-X
part	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
system	B-X
.	B-X
Affected	B-X
patients	B-X
have	B-X
fever	B-X
,	B-X
chills	B-X
,	B-X
and	B-X
infections	B-X
;	B-X
severe	B-X
infections	B-X
left	B-X
untreated	B-X
can	B-X
result	B-X
in	B-X
death	B-X
.	B-X
Treatment	B-X
with	B-X
granulocyte	B-X
colony-stimulating	B-X
factor	B-X
can	B-X
hasten	B-X
neutrophil	B-X
recovery	B-X
.	B-X
Cumulative	B-X
data	B-X
show	B-X
that	B-X
severe	B-X
neutropenia	B-X
or	B-X
agranulocytosis	B-X
associated	B-X
with	B-X
exposure	B-X
to	B-X
nonchemotherapy	B-X
drugs	B-X
ranges	B-X
from	B-X
approximately	B-X
1.6	B-X
to	B-X
15.4	B-X
cases	B-X
per	B-X
million	B-X
population	B-X
per	B-X
year	B-X
.	B-X
Assays	B-X
used	B-X
for	B-X
detection	B-X
of	B-X
neutrophil	B-X
drug-dependent	B-X
antibodies	B-X
(	B-X
DDAbs	B-X
)	B-X
include	B-X
flow	B-X
cytometry	B-X
,	B-X
monoclonal	B-X
antibody	B-X
immobilization	B-X
of	B-X
granulocyte	B-X
antigens	B-X
,	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
,	B-X
immunoblotting	B-X
,	B-X
granulocyte	B-X
agglutination	B-X
,	B-X
and	B-X
granulocytotoxicity	B-X
.	B-X
However	B-X
,	B-X
testing	B-X
for	B-X
neutrophil	B-X
DDAbs	B-X
is	B-X
rarely	B-X
performed	B-X
owing	B-X
to	B-X
its	B-X
complexity	B-X
and	B-X
lack	B-X
of	B-X
availability	B-X
.	B-X

Shown	O
is	O
the	O
relative	O
luciferase	B-Protein
reporter	O
gene	O
activity	O
following	O
treatment	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptors	B-X
(	B-X
FGRFs	B-X
)	B-X
in	B-X
H	B-X
pylori-mediated	B-X
gastric	B-X
tumorigenesis	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
DHA	B-X
on	B-X
the	B-X
promoter	B-X
activity	B-X
of	B-X
Chac	B-X
glutathione	B-X
specific	B-X
γ‑glutamylcyclotransferase	B-X
1	B-X
(	B-X
CHAC1	B-X
)	B-X
was	B-X
evaluated	B-X
using	B-X
a	B-X
dual	B-X
luciferase	B-X
reporter	B-X
assay	B-X
.	B-X
PLC	B-X
cells	B-X
exposed	B-X
to	B-X
DHA	B-X
displayed	B-X
classic	B-X
features	B-X
of	B-X
ferroptosis	B-X
,	B-X
such	B-X
as	B-X
increased	B-X
lipid	B-X
reactive	B-X
oxygen	B-X
species	B-X
and	B-X
malondialdehyde	B-X
levels	B-X
,	B-X
an	B-X
iron	B-X
overload	B-X
,	B-X
and	B-X
decreased	B-X
activity	B-X
or	B-X
expression	B-X
of	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
,	B-X
glutathione	B-X
peroxidase	B-X
4	B-X
,	B-X
solute	B-X
carrier	B-X
family	B-X
(	B-X
SLC	B-X
)	B-X
7	B-X
member	B-X
11	B-X
and	B-X
SLC	B-X
family	B-X
3	B-X
member	B-X
2	B-X
.	B-X
The	B-X
antitumor	B-X
effects	B-X
of	B-X
DHA	B-X
in	B-X
PLC	B-X
cells	B-X
were	B-X
significantly	B-X
weakened	B-X
by	B-X
two	B-X
typical	B-X
ferroptosis	B-X
inhibitors	B-X
,	B-X
ferrostatin‑1	B-X
and	B-X
deferoxamine	B-X
mesylate	B-X
salt	B-X
,	B-X
whereas	B-X
the	B-X
antitumor	B-X
effects	B-X
were	B-X
augmented	B-X
following	B-X
iron	B-X
overload	B-X
.	B-X

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
four	O
independent	O
experiments	O
.	O

(	O
C	O
)	O
DNA	O
sequence	O
conservation	O
between	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
.	O
<EOS>	B-X
SerpinB2	B-X
or	B-X
plasminogen	B-X
activator	B-X
inhibitor	B-X
type	B-X
2	B-X
(	B-X
PAI-2	B-X
)	B-X
is	B-X
highly	B-X
induced	B-X
in	B-X
macrophages	B-X
in	B-X
response	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
and	B-X
is	B-X
linked	B-X
to	B-X
the	B-X
modulation	B-X
of	B-X
innate	B-X
immunity	B-X
,	B-X
macrophage	B-X
survival	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
plasminogen	B-X
activators	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
bacterial	B-X
endotoxin	B-X
,	B-X
can	B-X
induce	B-X
SerpinB2	B-X
expression	B-X
via	B-X
the	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
by	B-X
∼1000-fold	B-X
over	B-X
a	B-X
period	B-X
of	B-X
24	B-X
hrs	B-X
in	B-X
murine	B-X
macrophages	B-X
.	B-X
To	B-X
map	B-X
the	B-X
LPS-regulated	B-X
SerpinB2	B-X
promoter	B-X
regions	B-X
,	B-X
we	B-X
transfected	B-X
reporter	B-X
constructs	B-X
driven	B-X
by	B-X
the	B-X
∼5	B-X
kb	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
SerpinB2	B-X
gene	B-X
and	B-X
several	B-X
deletion	B-X
mutants	B-X
into	B-X
murine	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
DNA	B-X
sequence	B-X
of	B-X
the	B-X
murine	B-X
5	B-X
'	B-X
flanking	B-X
sequence	B-X
with	B-X
the	B-X
sequence	B-X
of	B-X
the	B-X
human	B-X
gene	B-X
for	B-X
homologous	B-X
functional	B-X
regulatory	B-X
elements	B-X
and	B-X
identified	B-X
several	B-X
regulatory	B-X
cis-acting	B-X
elements	B-X
in	B-X
the	B-X
human	B-X
SERPINB2	B-X
promoter	B-X
conserved	B-X
in	B-X
the	B-X
mouse	B-X
.	B-X
Mutation	B-X
analyses	B-X
revealed	B-X
that	B-X
a	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
(	B-X
C/EBP	B-X
)	B-X
element	B-X
,	B-X
a	B-X
cyclic	B-X
AMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
and	B-X
two	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
response	B-X
elements	B-X
in	B-X
the	B-X
murine	B-X
SerpinB2	B-X
proximal	B-X
promoter	B-X
are	B-X
essential	B-X
for	B-X
optimal	B-X
LPS-inducibility	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
(	B-X
EMSA	B-X
)	B-X
and	B-X
chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assays	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induces	B-X
the	B-X
formation	B-X
of	B-X
C/EBP-β	B-X
containing	B-X
complexes	B-X
with	B-X
the	B-X
SerpinB2	B-X
promoter	B-X
.	B-X
Importantly	B-X
,	B-X
both	B-X
constitutive	B-X
and	B-X
LPS-induced	B-X
SerpinB2	B-X
expression	B-X
was	B-X
severely	B-X
abrogated	B-X
in	B-X
C/EBP-β-null	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
and	B-X
primary	B-X
C/EBP-β-deficient	B-X
peritoneal	B-X
macrophages	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
new	B-X
insight	B-X
into	B-X
C/EBP-β-dependent	B-X
regulation	B-X
of	B-X
inflammation-associated	B-X
SerpinB2	B-X
expression	B-X
.	B-X

Schematic	O
representation	O
of	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
5	O
'	O
flanking	O
regions	O
with	O
regions	O
of	O
nucleotide	O
sequence	O
identity	O
indicated	O
by	O
the	O
same	O
colored	O
boxes	O
.	O

Homologous	O
regions	O
are	O
interrupted	O
by	O
repetitive	O
sequence	O
elements	O
in	O
both	O
5	O
'	O
flanking	O
regions	O
.	O
<EOS>	B-X
The	B-X
nucleotide	B-X
sequences	B-X
of	B-X
the	B-X
expressed	B-X
epsilon	B-X
gene	B-X
(	B-X
C	B-X
epsilon	B-X
1	B-X
)	B-X
and	B-X
one	B-X
(	B-X
C	B-X
epsilon	B-X
3	B-X
)	B-X
of	B-X
the	B-X
two	B-X
epsilon	B-X
pseudogenes	B-X
were	B-X
compared	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
lacks	B-X
the	B-X
three	B-X
intervening	B-X
sequences	B-X
entirely	B-X
and	B-X
has	B-X
a	B-X
31-base	B-X
A-rich	B-X
sequence	B-X
16	B-X
bases	B-X
3	B-X
'	B-X
to	B-X
the	B-X
putative	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
addition	B-X
signal	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
is	B-X
a	B-X
processed	B-X
gene	B-X
.	B-X
The	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
sequence	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
five	B-X
separate	B-X
DNA	B-X
segments	B-X
of	B-X
the	B-X
C	B-X
epsilon	B-X
1	B-X
gene	B-X
;	B-X
namely	B-X
,	B-X
a	B-X
segment	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
(	B-X
100	B-X
bases	B-X
)	B-X
and	B-X
four	B-X
exons	B-X
,	B-X
which	B-X
are	B-X
interrupted	B-X
by	B-X
a	B-X
spacer	B-X
region	B-X
or	B-X
intervening	B-X
sequences	B-X
.	B-X
Long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
-like	B-X
sequences	B-X
which	B-X
contain	B-X
TATAAA	B-X
and	B-X
AATAAA	B-X
sequences	B-X
as	B-X
well	B-X
as	B-X
terminal	B-X
inverted	B-X
repeats	B-X
are	B-X
present	B-X
in	B-X
both	B-X
5'-	B-X
and	B-X
3'-flanking	B-X
regions	B-X
.	B-X
The	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
LTR-like	B-X
sequences	B-X
do	B-X
not	B-X
,	B-X
however	B-X
,	B-X
constitute	B-X
a	B-X
direct	B-X
repeat	B-X
,	B-X
unlike	B-X
transposable	B-X
elements	B-X
of	B-X
eukaryotes	B-X
and	B-X
retroviruses	B-X
.	B-X
The	B-X
3	B-X
'	B-X
LTR-like	B-X
sequence	B-X
is	B-X
repetitive	B-X
in	B-X
the	B-X
human	B-X
genome	B-X
,	B-X
but	B-X
is	B-X
not	B-X
homologous	B-X
to	B-X
the	B-X
Alu	B-X
family	B-X
DNA	B-X
.	B-X
Models	B-X
for	B-X
the	B-X
evolutionary	B-X
origin	B-X
of	B-X
the	B-X
processed	B-X
gene	B-X
flanked	B-X
by	B-X
the	B-X
LTR-like	B-X
sequences	B-X
are	B-X
discussed	B-X
.	B-X

Alu	O
=	O
Alu	O
repeat	O
,	O
ID4	O
=	O
ID4	O
short	O
interspersed	O
nuclear	O
repeat	O
(	O
SINE	O
)	O
,	O
L1	O
=	O
L1	O
long	O
interspersed	O
nuclear	O
element	O
(	O
LINE	O
)	O
,	O
L2	O
=	O
L2	O
LINE	O
,	O
MIR	O
=	O
MIR	O
SINE	O
,	O
MLT1L	O
=	O
MLT1L	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
(	O
TATG	O
)	O
n	O
=	O
TATG	O
tetranucleotide	O
repeat	O
,	O
tis	O
=	O
transcription	O
initiation	O
site	O
.	O

Homologous	O
regions	O
are	O
interrupted	O
by	O
repetitive	O
sequence	O
elements	O
in	O
both	O
5	O
'	O
flanking	O
regions	O
.	O
<EOS>	B-X
The	B-X
nucleotide	B-X
sequences	B-X
of	B-X
the	B-X
expressed	B-X
epsilon	B-X
gene	B-X
(	B-X
C	B-X
epsilon	B-X
1	B-X
)	B-X
and	B-X
one	B-X
(	B-X
C	B-X
epsilon	B-X
3	B-X
)	B-X
of	B-X
the	B-X
two	B-X
epsilon	B-X
pseudogenes	B-X
were	B-X
compared	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
lacks	B-X
the	B-X
three	B-X
intervening	B-X
sequences	B-X
entirely	B-X
and	B-X
has	B-X
a	B-X
31-base	B-X
A-rich	B-X
sequence	B-X
16	B-X
bases	B-X
3	B-X
'	B-X
to	B-X
the	B-X
putative	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
addition	B-X
signal	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
is	B-X
a	B-X
processed	B-X
gene	B-X
.	B-X
The	B-X
C	B-X
epsilon	B-X
3	B-X
gene	B-X
sequence	B-X
is	B-X
homologous	B-X
to	B-X
the	B-X
five	B-X
separate	B-X
DNA	B-X
segments	B-X
of	B-X
the	B-X
C	B-X
epsilon	B-X
1	B-X
gene	B-X
;	B-X
namely	B-X
,	B-X
a	B-X
segment	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
(	B-X
100	B-X
bases	B-X
)	B-X
and	B-X
four	B-X
exons	B-X
,	B-X
which	B-X
are	B-X
interrupted	B-X
by	B-X
a	B-X
spacer	B-X
region	B-X
or	B-X
intervening	B-X
sequences	B-X
.	B-X
Long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
-like	B-X
sequences	B-X
which	B-X
contain	B-X
TATAAA	B-X
and	B-X
AATAAA	B-X
sequences	B-X
as	B-X
well	B-X
as	B-X
terminal	B-X
inverted	B-X
repeats	B-X
are	B-X
present	B-X
in	B-X
both	B-X
5'-	B-X
and	B-X
3'-flanking	B-X
regions	B-X
.	B-X
The	B-X
5	B-X
'	B-X
and	B-X
3	B-X
'	B-X
LTR-like	B-X
sequences	B-X
do	B-X
not	B-X
,	B-X
however	B-X
,	B-X
constitute	B-X
a	B-X
direct	B-X
repeat	B-X
,	B-X
unlike	B-X
transposable	B-X
elements	B-X
of	B-X
eukaryotes	B-X
and	B-X
retroviruses	B-X
.	B-X
The	B-X
3	B-X
'	B-X
LTR-like	B-X
sequence	B-X
is	B-X
repetitive	B-X
in	B-X
the	B-X
human	B-X
genome	B-X
,	B-X
but	B-X
is	B-X
not	B-X
homologous	B-X
to	B-X
the	B-X
Alu	B-X
family	B-X
DNA	B-X
.	B-X
Models	B-X
for	B-X
the	B-X
evolutionary	B-X
origin	B-X
of	B-X
the	B-X
processed	B-X
gene	B-X
flanked	B-X
by	B-X
the	B-X
LTR-like	B-X
sequences	B-X
are	B-X
discussed	B-X
.	B-X

Alu	O
=	O
Alu	O
repeat	O
,	O
ID4	O
=	O
ID4	O
short	O
interspersed	O
nuclear	O
repeat	O
(	O
SINE	O
)	O
,	O
L1	O
=	O
L1	O
long	O
interspersed	O
nuclear	O
element	O
(	O
LINE	O
)	O
,	O
L2	O
=	O
L2	O
LINE	O
,	O
MIR	O
=	O
MIR	O
SINE	O
,	O
MLT1L	O
=	O
MLT1L	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
(	O
TATG	O
)	O
n	O
=	O
TATG	O
tetranucleotide	O
repeat	O
,	O
tis	O
=	O
transcription	O
initiation	O
site	O
.	O

Potential	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
LPS	O
responsive	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O

-	O
563	O
/	O
-	O
1	O
.	O
<EOS>	B-X
2014	B-X
;	B-X
22:559-563	B-X
.	B-X
Original	B-X
doi	B-X
:	B-X
10.1177/1066896913506934	B-X
.	B-X
The	B-X
institute	B-X
name	B-X
``	B-X
(	B-X
1	B-X
)	B-X
National	B-X
Defense	B-X
Medical	B-X
Center	B-X
,	B-X
Taipei	B-X
,	B-X
Taiwan	B-X
''	B-X
on	B-X
page	B-X
559	B-X
was	B-X
incomplete	B-X
.	B-X
The	B-X
correct	B-X
affiliation	B-X
of	B-X
the	B-X
authors	B-X
is	B-X
1TRI-SERVICE	B-X
GENERAL	B-X
HOSPITAL	B-X
:	B-X
,	B-X
National	B-X
Defense	B-X
Medical	B-X
Center	B-X
,	B-X
Taipei	B-X
,	B-X
Taiwan	B-X
.	B-X

Mouse	O
and	O
human	O
nucleotide	O
sequences	O
were	O
aligned	O
using	O
Clustal	O
W	O
software	O
.	O

Cis	O
-	O
acting	O
elements	O
conserved	O
between	O
the	O
human	O
and	O
murine	O
SerpinB2	B-Protein
promoters	O
are	O
boxed	O
and	O
labeled	O
.	O

AP	O
-	O
1	O
=	O
activator	O
protein	O
1	O
;	O
C	O
/	O
EBP	O
=	O
CCAAT	O
enhancer	O
binding	O
protein	O
;	O
CRE	O
=	O
cAMP	O
response	O
element	O
;	O
Oct1	B-Protein
=	O
octamer	B-Protein
transcription	I-Protein
factor	I-Protein
1	I-Protein
/	O
POU2F1	B-Protein
;	O
PU	B-Protein
.	I-Protein
1	I-Protein
=	O
purine	B-Protein
box	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
ubiquitous	B-X
family	B-X
of	B-X
AP-1	B-X
dimeric	B-X
transcription	B-X
complexes	B-X
is	B-X
involved	B-X
in	B-X
virtually	B-X
all	B-X
cellular	B-X
and	B-X
physiological	B-X
functions	B-X
.	B-X
It	B-X
is	B-X
paramount	B-X
for	B-X
cells	B-X
to	B-X
reprogram	B-X
gene	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
cues	B-X
of	B-X
many	B-X
sorts	B-X
and	B-X
is	B-X
involved	B-X
in	B-X
many	B-X
tumorigenic	B-X
processes	B-X
.	B-X
How	B-X
AP-1	B-X
controls	B-X
gene	B-X
transcription	B-X
has	B-X
largely	B-X
remained	B-X
elusive	B-X
till	B-X
recently	B-X
.	B-X
The	B-X
advent	B-X
of	B-X
the	B-X
``	B-X
omics	B-X
''	B-X
technologies	B-X
permitting	B-X
genome-wide	B-X
studies	B-X
of	B-X
transcription	B-X
factors	B-X
has	B-X
however	B-X
changed	B-X
and	B-X
improved	B-X
our	B-X
view	B-X
of	B-X
AP-1	B-X
mechanistical	B-X
actions	B-X
.	B-X
If	B-X
these	B-X
studies	B-X
confirm	B-X
that	B-X
AP-1	B-X
can	B-X
sometimes	B-X
act	B-X
as	B-X
a	B-X
local	B-X
transcriptional	B-X
switch	B-X
operating	B-X
in	B-X
the	B-X
vicinity	B-X
of	B-X
transcription	B-X
start	B-X
sites	B-X
(	B-X
TSS	B-X
)	B-X
,	B-X
they	B-X
strikingly	B-X
indicate	B-X
that	B-X
AP-1	B-X
principally	B-X
operates	B-X
as	B-X
a	B-X
remote	B-X
command	B-X
binding	B-X
to	B-X
distal	B-X
enhancers	B-X
,	B-X
placing	B-X
chromatin	B-X
architecture	B-X
dynamics	B-X
at	B-X
the	B-X
heart	B-X
of	B-X
its	B-X
transcriptional	B-X
actions	B-X
.	B-X
They	B-X
also	B-X
unveil	B-X
novel	B-X
constraints	B-X
operating	B-X
on	B-X
AP-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
novel	B-X
mechanisms	B-X
used	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
via	B-X
transcription-pioneering-	B-X
,	B-X
chromatin-remodeling-	B-X
and	B-X
chromatin	B-X
accessibility	B-X
maintenance	B-X
effects	B-X
.	B-X

The	O
putative	O
transcription	O
initiation	O
site	O
(	O
tis	O
)	O
is	O
indicated	O
and	O
exon	O
1	O
is	O
presented	O
in	O
uppercase	O
.	O

The	O
location	O
of	O
the	O
5	O
'	O
ends	O
of	O
the	O
-	O
539	O
,	O
-	O
189	O
and	O
-	O
87	O
reporter	O
constructs	O
are	O
also	O
shown	O
.	O

Identification	O
of	O
cis	O
-	O
acting	O
elements	O
required	O
for	O
the	O
LPS	O
-	O
responsiveness	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
.	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
-	O
539	O
/	O
+	O
92	O
region	O
of	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
with	O
the	O
location	O
of	O
candidate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
indicated	O
with	O
boxes	O
.	O

The	O
location	O
of	O
the	O
5	O
'	O
ends	O
of	O
the	O
-	O
539	O
,	O
-	O
189	O
and	O
-	O
87	O
reporter	O
constructs	O
is	O
also	O
shown	O
.	O

Positions	O
of	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
-	O
specific	O
primers	O
,	O
338	O
/	O
-	O
315	O
and	O
-	O
5	O
/	O
+	O
19	O
used	O
in	O
ChIP	O
assays	O
are	O
indicated	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
macrophages	O
were	O
transiently	O
transfected	O
with	O
the	O
indicated	O
murine	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
constructs	O
and	O
either	O
left	O
untreated	O
or	O
treated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
for	O
16	O
hrs	O
.	O

The	O
results	O
show	O
relative	O
luciferase	B-Protein
activity	O
following	O
LPS	O
treatment	O
and	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
4	O
-	O
7	O
independent	O
experiments	O
.	O

The	O
LPS	O
-	O
inducible	O
nuclear	O
factor	O
binding	O
the	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
C	O
/	O
EBP	O
site	O
contains	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

(	O
A	O
)	O
EMSA	O
with	O
nuclear	O
extracts	O
from	O
untreated	O
(	O
UN	O
)	O
and	O
10	O
hr	O
LPS	O
treated	O
(	O
LPS	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
incubated	O
with	O
either	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
-	O
212	O
/	O
-	O
185	O
probe	O
containing	O
an	O
intact	O
(	O
SerpinB2	B-Protein
C	O
/	O
EBP	O
)	O
or	O
mutated	O
(	O
mutant	O
C	O
/	O
EBP	O
)	O
C	O
/	O
EBP	O
site	O
or	O
with	O
the	O
rat	O
albumin	B-Protein
promoter	O
DEI	O
region	O
C	O
/	O
EBP	O
(	O
rat	O
albumin	B-Protein
C	O
/	O
EBP	O
)	O
probe	O
.	O

(	O
B	O
)	O
Cold	O
competition	O
EMSAs	O
performed	O
with	O
the	O
radiolabelled	O
murine	O
SerpinB2	B-Protein
promoter	O
-	O
212	O
/	O
-	O
185	O
probe	O
and	O
a	O
100	O
-	O
fold	O
molar	O
excess	O
of	O
each	O
of	O
the	O
double	O
stranded	O
oligonucleotides	O
described	O
in	O
(	O
A	O
)	O
demonstrate	O
the	O
specificity	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
.	O

(	O
C	O
)	O
Supershift	O
assays	O
were	O
performed	O
with	O
the	O
-	O
212	O
/	O
-	O
185	O
probe	O
by	O
after	O
preincubation	O
with	O
the	O
indicated	O
specific	O
C	O
/	O
EBP	O
antibody	O
.	O

The	O
LPS	O
-	O
inducible	O
complex	O
is	O
indicated	O
with	O
an	O
arrowhead	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
essential	O
for	O
constitutive	O
and	O
LPS	O
-	O
induced	O
SerpinB2	B-Protein
mRNA	O
expression	O
.	O

(	O
A	O
)	O
Endogenous	O
SerpinB2	B-Protein
mRNA	O
expression	O
is	O
abrogated	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
compared	O
to	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
in	O
the	O
absence	O
and	O
presence	O
of	O
LPS	O
.	O

qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
untreated	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
,	O
and	O
after	O
simulation	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
the	O
indicated	O
times	O
.	O

(	O
B	O
)	O
Endogenous	O
SerpinB2	B-Protein
expression	O
is	O
abrogated	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
-	O
deficient	O
inflammatory	O
macrophages	O
.	O

Thioglycollate	O
-	O
elicited	O
peritoneal	O
macrophages	O
(	O
TG	O
macs	O
)	O
were	O
infected	O
with	O
human	O
and	O
murine	O
specific	O
lentiviral	O
shRNAs	O
.	O

Human	O
CEBPB	O
shRNA	O
serves	O
as	O
the	O
non	O
-	O
silencing	O
control	O
since	O
it	O
does	O
not	O
target	O
the	O
murine	O
Cebpb	B-Protein
sequence	O
[	O
38	O
]	O
.	O

Lentiviral	O
transduced	O
macrophages	O
were	O
stimulated	O
with	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
4	O
hrs	O
.	O

Left	O
:	O
Western	O
blot	O
analysis	O
shows	O
effective	O
knockdown	O
of	O
endogenous	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
following	O
infection	O
with	O
murine	O
Cebpb	O
shRNA	O
and	O
not	O
human	O
CEBPB	O
shRNA	O
.	O

Right	O
:	O
qPCR	O
analysis	O
of	O
murine	O
SerpinB2	B-Protein
mRNA	O
expression	O
in	O
the	O
lentiviral	O
transduced	O
peritoneal	O
macrophages	O
.	O

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
two	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
.	O
<EOS>	B-X
Albumin	B-X
is	B-X
an	B-X
important	B-X
tool	B-X
in	B-X
the	B-X
management	B-X
of	B-X
patients	B-X
with	B-X
cirrhosis	B-X
,	B-X
since	B-X
it	B-X
decreases	B-X
for	B-X
less	B-X
than	B-X
half	B-X
the	B-X
risk	B-X
for	B-X
post-paracentesis	B-X
cardiocirculatory	B-X
dysfunction	B-X
and	B-X
mortality	B-X
associated	B-X
with	B-X
spontaneous	B-X
bacterial	B-X
infection	B-X
,	B-X
as	B-X
well	B-X
as	B-X
,	B-X
it	B-X
triplicates	B-X
the	B-X
response	B-X
to	B-X
terlipressin	B-X
in	B-X
patients	B-X
with	B-X
hepatorenal	B-X
syndrome	B-X
.	B-X
MD	B-X
simulation	B-X
of	B-X
the	B-X
best	B-X
interacting	B-X
complexes	B-X
was	B-X
performed	B-X
using	B-X
GROMACS	B-X
2018.3	B-X
(	B-X
in	B-X
duplicate	B-X
)	B-X
and	B-X
Desmond	B-X
program	B-X
version	B-X
2.0	B-X
(	B-X
academic	B-X
version	B-X
)	B-X
(	B-X
in	B-X
triplicate	B-X
)	B-X
to	B-X
study	B-X
the	B-X
stabile	B-X
interaction	B-X
of	B-X
protein-ligand	B-X
complexes	B-X
.	B-X
Recently	B-X
unsealed	B-X
court	B-X
documents	B-X
involving	B-X
Purdue	B-X
Pharma	B-X
show	B-X
that	B-X
state-based	B-X
triplicate	B-X
prescription	B-X
programs	B-X
posed	B-X
a	B-X
major	B-X
obstacle	B-X
to	B-X
sales	B-X
of	B-X
OxyContin	B-X
and	B-X
suggest	B-X
that	B-X
less	B-X
marketing	B-X
was	B-X
targeted	B-X
to	B-X
states	B-X
with	B-X
these	B-X
programs	B-X
.	B-X
We	B-X
find	B-X
that	B-X
OxyContin	B-X
distribution	B-X
was	B-X
more	B-X
than	B-X
50	B-X
%	B-X
lower	B-X
in	B-X
``	B-X
triplicate	B-X
states	B-X
''	B-X
in	B-X
the	B-X
years	B-X
after	B-X
the	B-X
drug	B-X
's	B-X
launch	B-X
.	B-X
Although	B-X
triplicate	B-X
states	B-X
had	B-X
higher	B-X
rates	B-X
of	B-X
overdose	B-X
deaths	B-X
prior	B-X
to	B-X
1996	B-X
,	B-X
this	B-X
relationship	B-X
flipped	B-X
shortly	B-X
after	B-X
the	B-X
launch	B-X
and	B-X
triplicate	B-X
states	B-X
saw	B-X
substantially	B-X
slower	B-X
growth	B-X
in	B-X
overdose	B-X
deaths	B-X
,	B-X
continuing	B-X
even	B-X
20	B-X
years	B-X
after	B-X
OxyContin	B-X
's	B-X
introduction	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
the	B-X
introduction	B-X
and	B-X
marketing	B-X
of	B-X
OxyContin	B-X
explain	B-X
a	B-X
substantial	B-X
share	B-X
of	B-X
overdose	B-X
deaths	B-X
over	B-X
the	B-X
past	B-X
two	B-X
decades	B-X
.	B-X

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
two	O
-	O
way	O
ANOVA	O
)	O
.	O

Differential	O
recruitment	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
and	O
C	O
/	O
EBP	O
-	O
betaT217	O
to	O
the	O
murine	O
SerpinB2	B-Protein
promoter	O
in	O
vivo	O
.	O

Transcription	O
factor	O
occupancy	O
on	O
the	O
SerpinB2	B-Protein
proximal	O
promoter	O
in	O
vivo	O
was	O
determined	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O

RAW264	O
.	O
7	O
macrophages	O
were	O
treated	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
for	O
the	O
indicated	O
times	O
and	O
chromatin	O
immunoprecipitation	O
performed	O
using	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
.	O
<EOS>	B-X
Caffeine	B-X
is	B-X
a	B-X
white	B-X
crystalline	B-X
xanthine	B-X
alkaloid	B-X
found	B-X
in	B-X
the	B-X
seeds	B-X
of	B-X
coffee	B-X
plants	B-X
and	B-X
leaves	B-X
of	B-X
the	B-X
tea	B-X
bush	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
evaluated	B-X
whether	B-X
caffeine	B-X
exerts	B-X
anti-inflammatory	B-X
effects	B-X
on	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-induced	B-X
inflammation	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
RAW264.7	B-X
cells	B-X
were	B-X
treated	B-X
with	B-X
various	B-X
concentrations	B-X
of	B-X
caffeine	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
LPS	B-X
.	B-X
Caffeine	B-X
decreased	B-X
the	B-X
LPS-induced	B-X
inflammatory	B-X
mediator	B-X
,	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
.	B-X
Caffeine	B-X
treatment	B-X
also	B-X
reduced	B-X
the	B-X
expression	B-X
of	B-X
pro-inflammatory	B-X
genes	B-X
,	B-X
including	B-X
inducible	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
iNOS	B-X
)	B-X
,	B-X
cyclooxygenase-2	B-X
(	B-X
COX-2	B-X
)	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-3	B-X
,	B-X
IL-6	B-X
and	B-X
IL-12	B-X
,	B-X
and	B-X
decreased	B-X
both	B-X
IL-6	B-X
secretion	B-X
and	B-X
phosphorylated	B-X
p38MAPK	B-X
expression	B-X
in	B-X
LPS-treated	B-X
RAW264.7	B-X
cells	B-X
.	B-X
Caffeine	B-X
inhibited	B-X
nuclear	B-X
translocation	B-X
of	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
via	B-X
IκBα	B-X
phosphorylation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
caffeine	B-X
inhibited	B-X
LPS-induced	B-X
NO	B-X
production	B-X
in	B-X
zebrafish	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
caffeine	B-X
may	B-X
suppress	B-X
LPS-induced	B-X
inflammatory	B-X
responses	B-X
in	B-X
RAW264.7	B-X
cells	B-X
by	B-X
regulating	B-X
NF-κB	B-X
activation	B-X
and	B-X
MAPK	B-X
phosphorylation	B-X
.	B-X

Soluble	O
chromatin	O
(	O
600	O
-	O
700	O
ng	O
)	O
was	O
immunoprecipitated	O
with	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
,	O
RNA	O
Polymerase	O
II	O
(	O
RNAPII	O
)	O
,	O
or	O
a	O
rabbit	O
IgG	O
(	O
rIgG	O
)	O
control	O
.	O
<EOS>	B-X
This	B-X
paper	B-X
describes	B-X
a	B-X
controlled	B-X
way	B-X
to	B-X
immobilize	B-X
gold	B-X
nanoparticles	B-X
on	B-X
planar	B-X
gold	B-X
surfaces	B-X
and	B-X
the	B-X
use	B-X
of	B-X
the	B-X
resulting	B-X
3D	B-X
platform	B-X
to	B-X
build	B-X
up	B-X
a	B-X
3D	B-X
biosensor	B-X
.	B-X
The	B-X
surface	B-X
was	B-X
first	B-X
functionalized	B-X
by	B-X
grafting	B-X
hexanedithiol	B-X
,	B-X
this	B-X
molecule	B-X
has	B-X
2	B-X
thiol	B-X
end	B-X
groups	B-X
,	B-X
which	B-X
enables	B-X
its	B-X
chemical	B-X
grafting	B-X
to	B-X
planar	B-X
gold	B-X
while	B-X
retaining	B-X
a	B-X
free	B-X
thiol	B-X
group	B-X
to	B-X
attach	B-X
nanoparticles	B-X
.	B-X
This	B-X
step	B-X
was	B-X
optimized	B-X
by	B-X
varying	B-X
experimental	B-X
parameters	B-X
such	B-X
as	B-X
solvent	B-X
,	B-X
temperature	B-X
and	B-X
immersion	B-X
time	B-X
.	B-X
The	B-X
grafting	B-X
was	B-X
monitored	B-X
by	B-X
polarization	B-X
modulation	B-X
infrared	B-X
reflection	B-X
absorption	B-X
spectroscopy	B-X
(	B-X
PM-IRRAS	B-X
)	B-X
and	B-X
X-ray	B-X
photoelectron	B-X
spectroscopy	B-X
(	B-X
XPS	B-X
)	B-X
.	B-X
The	B-X
high	B-X
resolution	B-X
XPS	B-X
sulfur	B-X
peak	B-X
made	B-X
clear	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
contributions	B-X
,	B-X
S	B-X
bound	B-X
to	B-X
gold	B-X
and	B-X
free	B-X
S	B-X
,	B-X
thus	B-X
led	B-X
us	B-X
to	B-X
determine	B-X
the	B-X
optimal	B-X
conditions	B-X
to	B-X
graft	B-X
hexanedithiol	B-X
in	B-X
an	B-X
extended	B-X
conformation	B-X
.	B-X
15	B-X
nm	B-X
spherical	B-X
gold	B-X
nanoparticles	B-X
were	B-X
then	B-X
immobilized	B-X
on	B-X
the	B-X
resulting	B-X
surface	B-X
and	B-X
their	B-X
presence	B-X
was	B-X
evidenced	B-X
by	B-X
surface	B-X
enhanced	B-X
Raman	B-X
spectroscopy	B-X
(	B-X
SERS	B-X
)	B-X
and	B-X
atomic	B-X
force	B-X
microscopy	B-X
(	B-X
AFM	B-X
)	B-X
.	B-X
The	B-X
resulting	B-X
gold	B-X
layer	B-X
was	B-X
used	B-X
to	B-X
build	B-X
up	B-X
a	B-X
3D	B-X
biosensor	B-X
by	B-X
grafting	B-X
protein	B-X
A	B-X
(	B-X
PrA	B-X
)	B-X
,	B-X
rabbit	B-X
immunoglobulin	B-X
(	B-X
rIgG	B-X
)	B-X
,	B-X
and	B-X
bovine	B-X
serum	B-X
albumin	B-X
(	B-X
BSA	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Each	B-X
step	B-X
was	B-X
characterized	B-X
by	B-X
PM-IRRAS	B-X
then	B-X
compared	B-X
to	B-X
the	B-X
results	B-X
on	B-X
planar	B-X
gold	B-X
surface	B-X
.	B-X
Despite	B-X
the	B-X
small	B-X
size	B-X
of	B-X
particles	B-X
and	B-X
their	B-X
rather	B-X
low	B-X
density	B-X
on	B-X
the	B-X
planar	B-X
surface	B-X
,	B-X
the	B-X
amount	B-X
of	B-X
immobilized	B-X
proteins	B-X
,	B-X
starting	B-X
from	B-X
PrA	B-X
,	B-X
was	B-X
almost	B-X
doubled	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
rIgG	B-X
fixed	B-X
on	B-X
the	B-X
3D	B-X
layer	B-X
was	B-X
also	B-X
significantly	B-X
increased	B-X
(	B-X
approximately	B-X
4	B-X
times	B-X
higher	B-X
than	B-X
on	B-X
planar	B-X
surfaces	B-X
)	B-X
,	B-X
however	B-X
accompanied	B-X
by	B-X
a	B-X
slight	B-X
decrease	B-X
of	B-X
their	B-X
accessibility	B-X
,	B-X
checked	B-X
by	B-X
assaying	B-X
the	B-X
recognition	B-X
of	B-X
a	B-X
secondary	B-X
IgG	B-X
.	B-X
This	B-X
work	B-X
demonstrates	B-X
the	B-X
feasibility	B-X
and	B-X
interest	B-X
of	B-X
building	B-X
arrays	B-X
of	B-X
nanoparticles	B-X
to	B-X
immobilize	B-X
molecular	B-X
receptors	B-X
;	B-X
it	B-X
also	B-X
shows	B-X
that	B-X
controlling	B-X
the	B-X
conditions	B-X
of	B-X
elaboration	B-X
of	B-X
the	B-X
biosensor	B-X
at	B-X
each	B-X
step	B-X
is	B-X
determining	B-X
for	B-X
optimizing	B-X
the	B-X
number	B-X
of	B-X
molecular	B-X
receptors	B-X
.	B-X

(	O
A	O
)	O
Typical	O
PCR	O
pattern	O
obtained	O
in	O
ChIP	O
assays	O
using	O
murine	O
SerpinB2	B-Protein
proximal	O
promoter	O
-	O
specific	O
primers	O
,	O
338	O
/	O
-	O
315	O
and	O
-	O
5	O
/	O
+	O
19	O
,	O
as	O
diagrammed	O
in	O
top	O
.	O

Recruitment	O
of	O
RNAPII	O
to	O
the	O
SerpinB2	B-Protein
promoter	O
suggests	O
active	O
transcription	O
following	O
LPS	O
stimulation	O
.	O

Minimal	O
background	O
was	O
detected	O
using	O
the	O
rabbit	O
IgG	O
control	O
,	O
indicative	O
of	O
the	O
specificity	O
of	O
the	O
ChIP	O
reaction	O
.	O

(	O
B	O
)	O
qPCR	O
analysis	O
of	O
chromatin	O
immunoprecipitated	O
with	O
antibodies	O
against	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
,	O
p	B-Protein
-	I-Protein
C	I-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
(	I-Protein
T217	I-Protein
)	I-Protein
,	O
and	O
the	O
rIgG	O
control	O
.	O

The	O
data	O
are	O
represented	O
relative	O
to	O
rIgG	B-Protein
signal	O
using	O
the	O
2	O
-	O
deltadeltaCt	O
method	O
.	O

C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
is	O
necessary	O
for	O
SerpinB2	B-Protein
proximal	O
promoter	O
activity	O
.	O

(	O
A	O
)	O
The	O
SerpinB2	B-Protein
proximal	O
promoter	O
is	O
significantly	O
activated	O
in	O
LPS	O
-	O
stimulated	O
Cebpb	B-Protein
+	O
/	O
+	O
MEFs	O
and	O
not	O
in	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
.	O

Murine	O
SerpinB2	B-Protein
gene	O
promoter	O
activity	O
measured	O
in	O
Cebpb	B-Protein
+	O
/	O
+	O
and	O
Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
expressing	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
(	O
100	O
ng	O
/	O
mL	O
)	O
.	O

Cells	O
were	O
co	O
-	O
transfected	O
with	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
and	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	I-Protein
plasmids	O
,	O
and	O
luciferase	B-Protein
units	O
normalized	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
.	O

(	O
B	O
)	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
gene	O
schematic	O
depicting	O
gene	O
structure	O
and	O
phospho	O
-	O
acceptor	O
sites	O
.	O

(	O
C	O
)	O
Phosphorylation	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
at	O
Serine	O
64	O
negatively	O
regulates	O
LPS	O
-	O
stimulated	O
SerpinB2	B-Protein
promoter	O
activity	O
.	O

Cebpb	B-Protein
-	O
/	O
-	O
MEFs	O
were	O
co	O
-	O
transfected	O
with	O
expression	O
plasmids	O
encoding	O
wild	O
-	O
type	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
or	O
the	O
indicated	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
,	O
along	O
with	O
the	O
pGLmP	O
-	O
539	O
SerpinB2	B-Protein
promoter	I-Protein
-	I-Protein
luciferase	I-Protein
reporter	I-Protein
and	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
reporter	I-Protein
plasmids	O
,	O
and	O
stimulated	O
with	O
LPS	O
for	O
4	O
hrs	O
.	O

Luciferase	B-Protein
activity	O
was	O
quantified	O
and	O
normalized	O
to	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
activity	O
.	O
<EOS>	B-X
After	B-X
the	B-X
injection	B-X
of	B-X
the	B-X
E.	B-X
coli	B-X
beta-galactosidase	B-X
reporter	B-X
gene	B-X
in	B-X
pRSVLac-Z	B-X
,	B-X
foreign	B-X
gene	B-X
expression	B-X
was	B-X
localized	B-X
to	B-X
both	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
myofibers	B-X
.	B-X
Luciferase	B-X
activity	B-X
persisted	B-X
for	B-X
at	B-X
least	B-X
4	B-X
months	B-X
after	B-X
injection	B-X
.	B-X

The	O
western	O
blot	O
(	O
below	O
the	O
graphs	O
)	O
confirms	O
the	O
expression	O
of	O
the	O
respective	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
phospho	I-Protein
-	I-Protein
acceptor	I-Protein
mutants	I-Protein
.	O

The	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
betaT217A	I-Protein
-	O
transfected	O
MEFs	O
express	O
both	O
the	O
38	O
kDa	O
and	O
35	O
kDa	O
isoforms	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
-	I-Protein
beta	I-Protein
.	O

The	O
results	O
represent	O
the	O
mean	O
and	O
SEM	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
one	O
-	O
way	O
ANOVA	O
)	O
.	O

